PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	GWALTNEY, JM; PHILLIPS, CD; MILLER, RD; RIKER, DK				GWALTNEY, JM; PHILLIPS, CD; MILLER, RD; RIKER, DK			COMPUTED TOMOGRAPHIC STUDY OF THE COMMON COLD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FREQUENCY; INFECTIONS; VOLUNTEERS	Background. Colds are common, but the abnormalities they produce in the nasal passages and sinus cavities have not been well defined. Methods. We studied healthy adult volunteers with self-diagnosed colds of 48 to 96 hours' duration and obtained the following data: information on symptoms, computed tomographic (CT) studies of the nasal passages and sinuses, mucosal-transport times, measures of nasal-airway resistance, and viral-culture studies. Thirty-one subjects (mean age, 24 years) had complete evaluations, including CT scans, which were read without knowledge of the clinical data. An additional 79 subjects underwent the same evaluations, except the CT scans. Results. Of the 31 subjects with CT scans, 24 (77 percent) had occlusion of the ethmoid infundibulum; 27 (87 percent) had abnormalities of one or both maxillary-sinus cavities; 20 (65 percent) had abnormalities of the ethmoid sinuses; 10 (32 percent) had abnormalities of the frontal sinuses; and 12 (39 percent) had abnormalities of the sphenoid sinuses. Infraorbital air cells were present in 14 subjects (45 percent), and pneumatization of the middle turbinate (concha bullosa) was noted in 11 subjects (35 percent). Also common were engorged turbinates (in 7 subjects) and thickening of the walls of the nasal passages (in 13). After two weeks, the CT studies were repeated in 14 subjects, none of whom received antibiotics. In 11 of these subjects (79 percent) the abnormalities of the infundibula and sinuses had cleared or markedly improved. Nasal-airway resistance was abnormal in 29 (94 percent) and mucosal transport in 19 (61 percent) of the 31 subjects who had CT scans. Rhinovirus was detected in nasal secretions from 24 (27 percent) of 90 subjects. Conclusions. The common cold is associated with frequent and variable anatomical involvement of the upper airways, including occlusion and abnormalities in the sinus cavities.	UNIV VIRGINIA,HLTH SCI CTR,DEPT RADIOL,CHARLOTTESVILLE,VA 22908; PROCTER & GAMBLE CO,CINCINNATI,OH 45239	University of Virginia; Procter & Gamble	GWALTNEY, JM (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,DEPT INTERNAL MED,CHARLOTTESVILLE,VA 22908, USA.		Riker, Donald/AAR-8380-2020					BOLGER WE, 1991, LARYNGOSCOPE, V101, P56; CALHOUN KH, 1991, OTOLARYNG HEAD NECK, V104, P480, DOI 10.1177/019459989110400409; Clark S, 1989, AM J RHINOL, P11; CONNELL JT, 1982, ANN ALLERGY, V49, P179; CONNELL JT, 1987, AM J RHINOL, V1, P87; DINGLE JH, 1964, ILLNESS HOME STUDY 2, P347; DOYLE W J, 1987, Rhinology (Utrecht), V25, P167; DUCHATEAU GSMJE, 1985, LARYNGOSCOPE, V95, P854; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; Fox J.P., 1980, VIRUSES FAMILIES SUR; Gwaltney J.M., 1989, DIAGNOSTIC PROCEDURE, P579; GWALTNEY JM, 1966, NEW ENGL J MED, V275, P1261, DOI 10.1056/NEJM196612082752301; HENDLEY JO, 1972, J INFECT DIS, V125, P243, DOI 10.1093/infdis/125.3.243; JACKSON GG, 1958, ARCH INTERN MED, V101, P267, DOI 10.1001/archinte.1958.00260140099015; MONTO AS, 1987, J INFECT DIS, V156, P43, DOI 10.1093/infdis/156.1.43; PUCHELLE E, 1981, ACTA OTO-LARYNGOL, V91, P297, DOI 10.3109/00016488109138511; WALD ER, 1991, PEDIATRICS, V87, P129	17	449	467	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 6	1994	330	1					25	30		10.1056/NEJM199401063300105	http://dx.doi.org/10.1056/NEJM199401063300105			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP649	8259141				2022-12-28	WOS:A1994MP64900005
J	TOPOL, EJ; CALIFF, RM				TOPOL, EJ; CALIFF, RM			SCORECARD CARDIOVASCULAR MEDICINE - ITS IMPACT AND FUTURE-DIRECTIONS	ANNALS OF INTERNAL MEDICINE			English	Note							CORONARY-ARTERY DISEASE; EXPERIENCE; DEATH	Public release of operator-specific data for cardiovascular procedures has set a new precedent, introducing the ''scorecard'' era. Justification exists for public disclosure, but the mechanics of appropriate data release are complex from a clinical, statistical, and logistic standpoint. Scorecard medicine may appropriately promote regionalization of medical centers and consolidation of services, but unless the process is directed effectively, it may impair the development of new treatments because of a more restrictive clinical practice environment. We propose revamping our current system to facilitate rapid and accurate access to outcome data in the local practice environment so that improvement in practice occurs on a voluntary basis rather than in response to punitive restrictions. A rational plan needs to be developed for dealing with high-risk patients, perhaps through compensation in regression models used to calculate expected outcomes, and for the start-up of novice physicians. Special provisions are needed to promote clinical research. Before procedures are done, it would be ideal to provide a full disclosure informed consent, whereby the physician reports operator-specific data and the patient's decision-making process is facilitated. Overall, appropriate implementation of scorecards could ultimately lead to a substantial improvement in the quality of U.S. cardiovascular medicine.	DUKE UNIV, DURHAM, NC 27706 USA	Duke University	TOPOL, EJ (corresponding author), CLEVELAND CLIN FDN, DEPT CARDIOL, DESK F25, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.			Topol, Eric/0000-0002-1478-4729				[Anonymous], 1992, CORONARY ARTERY BYPA; ARNOT R, 1992, BEST MED CHOOSE TOP, P468; BERWICK DM, 1990, JAMA-J AM MED ASSOC, V263, P247, DOI 10.1001/jama.263.2.247; BYER MJ, 1992, NY TIMES        0321, pA23; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; HANNAN EL, 1992, JAMA-J AM MED ASSOC, V268, P3092, DOI 10.1001/jama.268.21.3092; KIRKLIN JW, 1989, CIRCULATION, V79, P81; LAFFEL GL, 1992, NEW ENGL J MED, V327, P1220, DOI 10.1056/NEJM199210223271707; LEE KL, 1980, CIRCULATION, V61, P508, DOI 10.1161/01.CIR.61.3.508; NIGHTINGALE F, 1863, NOTES NURSING ENLARG; OBERMAN L, 1992, AM MED NEWS     1228, P42; OBERMAN L, 1992, AM MED NEWS     1228, P1; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; PRYOR DB, 1985, MED CARE, V23, P623, DOI 10.1097/00005650-198505000-00020; RITCHIE JL, 1992, CIRCULATION S1, V86, P1011; RYAN TJ, 1990, CIRCULATION, V81, P2041; TOPOL EJ, 1993, CIRCULATION, V87, P1489, DOI 10.1161/01.CIR.87.5.1489; TOPOL EJ, 1991, CIRCULATION, V83, P689, DOI 10.1161/01.CIR.83.2.689; WILLIAMS SV, 1991, JAMA-J AM MED ASSOC, V266, P810, DOI 10.1001/jama.266.6.810; Winslow R, 1991, WALL STREET J, pB1; ZINMAN D, 1991, NEWSDAY         1218, P34; ZINMAN D, 1992, AM MED NEWS     1208, P7; ZINMAN D, 1992, AM MED NEWS     1208, P113; 1991, ACC SURVEY; 1988, J AM COLL CARD, V12, P529; 1989, J AM COLL CARD, V17, P543; 1992, PRIME TIME LIVE TRAN, V248; 1987, 01002 US DEP HLTH HU	30	105	105	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1994	120	1					65	70		10.7326/0003-4819-120-1-199401010-00011	http://dx.doi.org/10.7326/0003-4819-120-1-199401010-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP280	8250458				2022-12-28	WOS:A1994MP28000011
J	BROWN, HA; GUTOWSKI, S; MOOMAW, CR; SLAUGHTER, C; STERNWEIS, PC				BROWN, HA; GUTOWSKI, S; MOOMAW, CR; SLAUGHTER, C; STERNWEIS, PC			ADP-RIBOSYLATION FACTOR, A SMALL GTP-DEPENDENT REGULATORY PROTEIN, STIMULATES PHOSPHOLIPASE-D ACTIVITY	CELL			English	Article							BINDING PROTEINS; CHOLERA-TOXIN; ADENYLATE-CYCLASE; PHOSPHATIDYLCHOLINE HYDROLYSIS; HL-60 GRANULOCYTES; FACTOR ARF; KINASE-C; ACTIVATION; PURIFICATION; NEUTROPHILS	The hydrolysis of phosphatidylcholine by phospholipase D (PLD) results in the production of phosphatidic acid and choline. An assay that uses an exogenous substrate was developed to measure this activity in membranes and solubilized preparations from HL60 cells. A cytosolic factor markedly enhanced PLD activity in membranes and was essential for GTPgammaS-dependent stimulation of an enriched preparation of PLD. The factor was purified to homogeneity from bovine brain cytosol and identified as a member of the ADP-Ribosylation Factor (ARF) subfamily of small G proteins. Subsequently, recombinant myristoylated ARF1 was found to be a better activator of PLD activity than was the nonmyristoylated form. ARF proteins have been implicated recently as factors for regulation of intracellular vesicle traffic. The current finding suggests that PLD activity plays a prominent role in the action of ARF and that ARF may be a key component in the generation of second messengers via phospholipase D.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	BROWN, HA (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA.				NIGMS NIH HHS [GM31954] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031954] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTHES JC, 1989, BIOCHEM BIOPH RES CO, V163, P657, DOI 10.1016/0006-291X(89)92187-6; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; COCKCROFT S, 1984, BIOCHIM BIOPHYS ACTA, V795, P37, DOI 10.1016/0005-2760(84)90102-4; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; EXTON JH, 1990, J BIOL CHEM, V265, P1; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HANAHAN DJ, 1948, J BIOL CHEM, V172, P191; Heller M, 1978, Adv Lipid Res, V16, P267; KAHN RA, 1992, FASEB J, V6, P2512, DOI 10.1096/fasebj.6.8.1592203; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1991, METHOD ENZYMOL, V195, P233; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; MARTIN TW, 1989, J BIOL CHEM, V264, P8847; MARTINSON EA, 1989, J BIOL CHEM, V264, P14748; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PAI JK, 1988, J BIOL CHEM, V263, P12472; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SAITO M, 1975, ARCH BIOCHEM BIOPHYS, V169, P318, DOI 10.1016/0003-9861(75)90346-X; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHLEIFER LS, 1982, J BIOL CHEM, V257, P20; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; SIMMONDS AC, 1985, BIOCHIM BIOPHYS ACTA, V813, P331, DOI 10.1016/0005-2736(85)90249-4; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STERNWEIS PC, 1990, RECEPTOR EFFECTOR CO, P1; TAKI T, 1979, J BIOL CHEM, V254, P9761; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TSAI SC, 1991, J BIOL CHEM, V266, P23053; WANG P, 1991, J BIOL CHEM, V266, P14877; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	50	865	878	2	34	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 17	1993	75	6					1137	1144		10.1016/0092-8674(93)90323-I	http://dx.doi.org/10.1016/0092-8674(93)90323-I			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	8261513				2022-12-28	WOS:A1993MM89300012
J	ARRIAGADA, R; LECHEVALIER, T; PIGNON, JP; RIVIERE, A; MONNET, I; CHOMY, P; TUCHAIS, C; TARAYRE, M; RUFFIE, P				ARRIAGADA, R; LECHEVALIER, T; PIGNON, JP; RIVIERE, A; MONNET, I; CHOMY, P; TUCHAIS, C; TARAYRE, M; RUFFIE, P			INITIAL CHEMOTHERAPEUTIC DOSES AND SURVIVAL IN PATIENTS WITH LIMITED SMALL-CELL LUNG-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BREAST-CANCER; CARCINOMA; INTENSITY; CYCLOPHOSPHAMIDE; METAANALYSIS; CISPLATIN; TRIALS; MODELS	Background. Moderate increases in the initial doses of certain chemotherapeutic drugs, such as cisplatin and cyclophosphamide, may prolong overall survival in patients with limited small-cell lung cancer. Methods. We conducted a prospective study of 105 patients with limited small-cell lung cancer. The patients were randomly assigned to receive higher or lower initial doses of cisplatin (100 or 80 mg per square meter of body-surface area) and cyclophosphamide (300 or 225 mg per square meter daily for four days); all patients received the same doses of doxorubicin and etoposide. The first course of chemotherapy was followed by five additional courses and by three courses of radiotherapy. All patients received the lower doses of cisplatin and cyclophosphamide and the same doses of doxorubicin and etoposide from the second through the sixth cycle of chemotherapy. Results. The median follow-up was 33 months. The two-year survival rate for the 55 patients who received the higher doses of chemotherapy was 43 percent, as compared with 26 percent for the 50 patients who received the lower doses (P = 0.02). The rates of complete response at six months were 67 percent in the higher-dose group and 54 percent in the lower-dose group (P = 0.16). Disease-free survival at two years was 28 percent in the higher-dose group, as compared with 8 percent in the lower-dose group (P = 0.02). Side effects from treatment were not increased in the higher-dose group. Conclusions. Higher initial doses of cyclophosphamide and cisplatin improve disease-free and overall survival in patients with limited small-cell lung cancer.	CTR HOSP INTERCOMMUNAL CRETEIL, F-94010 CRETEIL, FRANCE; CTR FRANCOIS BACLESSE, CAEN, FRANCE; CTR PAUL PAPIN, ANGERS, FRANCE; FDN BERGONIE, F-33076 BORDEAUX, FRANCE	Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; UNICANCER; Centre Francois Baclesse; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); UNICANCER; Institut Bergonie	ARRIAGADA, R (corresponding author), INST GUSTAVE ROUSSY, RUE CAMILLE DESMOULINS, F-94805 VILLEJUIF, FRANCE.			PIGNON, Jean-Pierre/0000-0003-2047-1582				ANTMAN KH, 1993, ANN ONCOL, V4, pS29, DOI 10.1093/annonc/4.suppl_1.S29; ARRIAGADA R, 1989, B CANCER, V76, P605; ARRIAGADA R, 1992, J CLIN ONCOL, V10, P447, DOI 10.1200/JCO.1992.10.3.447; BUDMAN DR, 1992, P AN M AM SOC CLIN, V11, P51; COLDMAN AJ, 1988, MATH BIOSCI, V92, P97, DOI 10.1016/0025-5564(88)90007-7; COPPIN CML, 1987, SEMIN ONCOL, V14, P34; COX DR, 1972, J R STAT SOC B, V34, P187; DETHE H, 1986, 5TH P ANN M ESTRO BA, P319; DEVATHAIRE F, 1993, LUNG CANCER, V8, P301; DINWOODIE WR, 1981, P AM ASSOC CANC RES, V22, P505; FIGUEREDO AT, 1985, J CLIN ONCOL, V3, P54, DOI 10.1200/JCO.1985.3.1.54; FREI E, 1980, AM J MED, V69, P585, DOI 10.1016/0002-9343(80)90472-6; GRALLA RJ, 1981, ANN INTERN MED, V95, P414, DOI 10.7326/0003-4819-95-4-414; GREEN SJ, 1987, J CLIN ONCOL, V5, P1477, DOI 10.1200/JCO.1987.5.9.1477; HENDERSON IC, 1988, J CLIN ONCOL, V6, P1501, DOI 10.1200/JCO.1988.6.9.1501; HRYNIUK W, 1986, J CLIN ONCOL, V4, P1162, DOI 10.1200/JCO.1986.4.8.1162; IHDE D, 1991, LUNG CANCER S, V7, P135; IHDE DC, 1992, NEW ENGL J MED, V327, P1434; JOHNSON DH, 1987, J CLIN ONCOL, V5, P1731, DOI 10.1200/JCO.1987.5.11.1731; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAYE SB, 1992, LANCET, V340, P329, DOI 10.1016/0140-6736(92)91404-V; KLASA RJ, 1991, J CLIN ONCOL, V9, P499, DOI 10.1200/JCO.1991.9.3.499; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MEHTA C, 1982, P AM ASSOC CANC RES, V23, P155; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PIGNON JP, 1992, NEW ENGL J MED, V327, P1618, DOI 10.1056/NEJM199212033272302; SCHNIPPER LE, 1986, NEW ENGL J MED, V314, P1423; Spiessl B, 1989, TNM ATLAS ILLUSTRATE; TUBIANA M, 1985, CANCER, V55, P2131, DOI 10.1002/1097-0142(19850501)55:9+<2131::AID-CNCR2820551416>3.0.CO;2-Q; Whitehead J., 1983, DESIGN ANAL SEQUENTI; WHITEHEAD J, 1989, PEST 2 0 OPERATING M; 1979, WHO OFFSET PUBLICATI, V48, P319	32	227	231	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 16	1993	329	25					1848	1852		10.1056/NEJM199312163292504	http://dx.doi.org/10.1056/NEJM199312163292504			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML588	8247036				2022-12-28	WOS:A1993ML58800004
J	COHEN, D; CHUMAKOV, I; WEISSENBACH, J				COHEN, D; CHUMAKOV, I; WEISSENBACH, J			A 1ST-GENERATION PHYSICAL MAP OF THE HUMAN GENOME	NATURE			English	Article							YEAST ARTIFICIAL CHROMOSOMES; HUMAN Y-CHROMOSOME; DNA; STRATEGY; CLONES; LIBRARY; ELEGANS; VECTORS	SETS of ordered overlapping cloned genomic DNA fragments that span each of the human chromosomes are urgently needed for identification of human disease genes. Such a physical map also provides unique material to study the structure and function of the genome. We have therefore exhaustively analysed the CEPH yeast artificial chromosome (YAC) library, which contains 33,000 clones, whose insert size was individually determined. These YACs have an average length of 0.9 megabases and cover the equivalent of 10 haploid genomes. Several mapping techniques were combined to provide multiple sources of structural information for most of these clones. Finally, the library was screened with more than 2,000 genetic markers quasiuniformly distributed over 90% of the genome. These results should allow the scientific community to construct detailed maps of all human chromosomes. Moreover, we propose a data analysis strategy that produces a first-generation integrated map covering most of the human genome.	GENETHON,F-91002 EVRY,FRANCE; INST PASTEUR,CNRS,URA 1445,F-75014 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	COHEN, D (corresponding author), FDN JEAN DAUSSET,CEPH,27 RUE JULIETTE DODU,F-75010 PARIS,FRANCE.							BARILLOT E, 1991, P NATL ACAD SCI USA, V88, P3917, DOI 10.1073/pnas.88.9.3917; BELLANNECHANTELOT C, 1992, CELL, V70, P1059, DOI 10.1016/0092-8674(92)90254-A; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; DEJONG PJ, 1989, CYTOGENET CELL GENET, V51, P985; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; GREEN ED, 1991, GENOMICS, V11, P658, DOI 10.1016/0888-7543(91)90073-N; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; MULLIVOR RA, 1991, AM J HUM GENET S, V49, P370; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; RIED T, 1992, P NATL ACAD SCI USA, V89, P1388, DOI 10.1073/pnas.89.4.1388; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; VANOMMEN GJ, 1993, HUGO B; VOLLRATH D, 1992, SCIENCE, V258, P52, DOI 10.1126/science.1439769; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	19	476	500	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 16	1993	366	6456					698	701		10.1038/366698a0	http://dx.doi.org/10.1038/366698a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM265	8259213				2022-12-28	WOS:A1993MM26500073
J	BALDWIN, EP; HAJISEYEDJAVADI, O; BAASE, WA; MATTHEWS, BW				BALDWIN, EP; HAJISEYEDJAVADI, O; BAASE, WA; MATTHEWS, BW			THE ROLE OF BACKBONE FLEXIBILITY IN THE ACCOMMODATION OF VARIANTS THAT REPACK THE CORE OF T4-LYSOZYME	SCIENCE			English	Article							ACID SIDE-CHAINS; PROTEIN STRUCTURES; T4 LYSOZYME; PACKING ARRANGEMENTS; HYDROPHOBIC CORE; SEQUENCES; STABILITY; CONFORMATION; REFINEMENT; MUTATIONS	To understand better how the packing of side chains within the core influences protein structure and stability, the crystal structures were determined for eight variants of T4 lysozyme, each of which contains three to five substitutions at adjacent interior sites. Concerted main-chain and side-chain displacements, with movements of helical segments as large as 0.8 angstrom, were observed. In contrast, the angular conformations of the mutated side chains tended to remain unchanged, with torsion angles within 20-degrees of those in the wild-type structure. These observations suggest that not only the rotation of side chains but also movements of the main chain must be considered in the evaluation of which amino acid sequences are compatible with a given protein fold.	UNIV OREGON, HOWARD HUGHES MED INST, INST MOLEC BIOL, EUGENE, OR 97403 USA; UNIV OREGON, DEPT PHYS, EUGENE, OR 97403 USA	Howard Hughes Medical Institute; University of Oregon; University of Oregon				Baldwin, Enoch/0000-0002-1472-0944	NIGMS NIH HHS [GM12989, GM21967] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM012989, R01GM021967] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN EP, 1993, TECHNIQUES PROTEIN C, V4, P499; BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; CHANDRASEKARAN R, 1970, INT J PROT RES, V2, P223; DAOPIN S, 1991, J MOL BIOL, V221, P647, DOI 10.1016/0022-2836(91)80079-A; DESMET J, 1992, NATURE, V356, P539, DOI 10.1038/356539a0; DUNBRACK RL, 1993, J MOL BIOL, V230, P543, DOI 10.1006/jmbi.1993.1170; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; ERIKSSON AE, 1993, J MOL BIOL, V229, P747, DOI 10.1006/jmbi.1993.1077; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HURLEY JH, 1992, J MOL BIOL, V224, P1143, DOI 10.1016/0022-2836(92)90475-Y; JANIN J, 1978, J MOL BIOL, V125, P357, DOI 10.1016/0022-2836(78)90408-4; KELLIS JT, 1988, NATURE, V333, P784, DOI 10.1038/333784a0; LEE C, 1991, J MOL BIOL, V217, P373, DOI 10.1016/0022-2836(91)90550-P; LESK AM, 1980, J MOL BIOL, V136, P225, DOI 10.1016/0022-2836(80)90373-3; LESK AM, 1986, PHILOS T R SOC A, V317, P345, DOI 10.1098/rsta.1986.0044; LIM WA, 1992, BIOCHEMISTRY-US, V31, P4324, DOI 10.1021/bi00132a025; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LIM WA, IN PRESS P NATL ACAD; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MATSUMURA M, 1989, SCIENCE, V243, P792, DOI 10.1126/science.2916125; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; POTEETE AR, 1991, BIOCHEMISTRY-US, V30, P1425, DOI 10.1021/bi00219a037; RENNELL D, 1985, VIROLOGY, V143, P280, DOI 10.1016/0042-6822(85)90115-1; RICHARDS FM, 1974, J MOL BIOL, V82, P1, DOI 10.1016/0022-2836(74)90570-1; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; SUMMERS NL, 1987, J MOL BIOL, V196, P175, DOI 10.1016/0022-2836(87)90520-1; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TRONRUD DE, 1992, ACTA CRYSTALLOGR A, V48, P912, DOI 10.1107/S0108767392005415; TUFFERY P, 1991, J BIOMOL STRUCT DYN, V8, P1267, DOI 10.1080/07391102.1991.10507882; WILSON C, 1993, J MOL BIOL, V229, P996, DOI 10.1006/jmbi.1993.1100; ZHANG XJ, 1991, BIOCHEMISTRY-US, V30, P2012, DOI 10.1021/bi00222a001; 1970, J MOL BIOL, V52, P4	36	117	119	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1993	262	5140					1715	1718		10.1126/science.8259514	http://dx.doi.org/10.1126/science.8259514			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	8259514	Green Submitted			2022-12-28	WOS:A1993ML22000036
J	COHEN, JJ				COHEN, JJ			TRANSFORMING THE SIZE AND COMPOSITION OF THE PHYSICIAN WORK-FORCE TO MEET THE DEMANDS OF HEALTH-CARE REFORM	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											COHEN, JJ (corresponding author), SUNY STONY BROOK,STONY BROOK,NY 11794, USA.							MULLAN F, 1993, HLTH AFF MILLWO S138, V12, P51; ROCKEFELLER J, PRIMARY CARE WORKFOR; 1992, IMPROVING ACCESS HLT; 1993, PRIMARY CARE WORKFOR; 1993, ACAD MED, V68, P717; 1993, ANN REPORT C; 1993, ACAD MED, V68, P1	7	46	46	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 9	1993	329	24					1810	1812		10.1056/NEJM199312093292412	http://dx.doi.org/10.1056/NEJM199312093292412			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK096	8232493				2022-12-28	WOS:A1993MK09600012
J	MCDANIEL, R; EBERTKHOSLA, S; HOPWOOD, DA; KHOSLA, C				MCDANIEL, R; EBERTKHOSLA, S; HOPWOOD, DA; KHOSLA, C			ENGINEERED BIOSYNTHESIS OF NOVEL POLYKETIDES	SCIENCE			English	Article							STREPTOMYCES-COELICOLOR A3(2); FATTY-ACID BIOSYNTHESIS; SYNTHASE GENE-CLUSTER; NUCLEOTIDE-SEQUENCE; ANTIBIOTIC ACTINORHODIN; DEDUCED FUNCTION; GLAUCESCENS; CLONING; ORGANIZATION; ANTHRAQUINONES	Polyketide synthases (PKSs) are multifunctional enzymes that catalyze the biosynthesis of a huge variety of carbon chains differing in their length and patterns of functionality and cyclization. Many polyketides are valuable therapeutic agents. A Streptomyces host-vector system has been developed for efficient construction and expression of recombinant PKSs. Using this expression system, several novel compounds have been synthesized in vivo in significant quantities. Characterization of these metabolites has provided new insights into key features of actinomycete aromatic PKS specificity. Thus, carbon chain length is dictated, at least in part, by a protein that appears to be distinctive to this family of PKSs, whereas the acyl carrier proteins of different PKSs can be interchanged without affecting product structure. A given ketoreductase can recognize and reduce polyketide chains of different length; this ketoreduction always occurs at the C-9 position. The regiospecificity of the first cyclization of the nascent polyketide chain is either determined by the ketoreductase, or the chain-extending enzymes themselves. However, the regiospecificity of the second cyclization is determined by a distinct cyclase, which can discriminate between substrates of different chain lengths.	STANFORD UNIV, DEPT CHEM ENGN, STANFORD, CA 94305 USA; JOHN INNES INST, JOHN INNES CTR, DEPT GENET, NORWICH NR4 7UH, NORFOLK, ENGLAND	Stanford University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center				Khosla, Chaitan/0000-0001-6529-495X				BARTEL PL, 1990, J BACTERIOL, V172, P4816, DOI 10.1128/jb.172.9.4816-4826.1990; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; BIBB MJ, UNPUB; CABALLERO JL, 1991, MOL GEN GENET, V230, P401, DOI 10.1007/BF00280297; CAMERON DW, 1981, AUST J CHEM, V34, P2401, DOI 10.1071/CH9812401; CHATER KF, 1992, CIBA F SYMP, V171, P144; COLE SP, 1987, J ANTIBIOT, V40, P340, DOI 10.7164/antibiotics.40.340; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; FERNANDEZMORENO MA, 1991, CELL, V66, P769, DOI 10.1016/0092-8674(91)90120-N; FU H, UNPUB; GRAMAJO HC, 1993, MOL MICROBIOL, V7, P837, DOI 10.1111/j.1365-2958.1993.tb01174.x; HALLAM SE, 1988, GENE, V74, P305, DOI 10.1016/0378-1119(88)90165-5; Hopwood D.A., 1985, GENETIC MANIPULATION; HOPWOOD DA, 1992, CIBA F SYMP, V171, P88; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; HUTCHINSON CR, 1992, ACTINOMYCETOLOGY, V6, P49; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; KHOSLA C, 1992, MOL MICROBIOL, V6, P3237, DOI 10.1111/j.1365-2958.1992.tb01778.x; KIESER T, 1991, METHOD ENZYMOL, V204, P430; KRUPA J, 1989, LIEBIGS ANN CHEM, P699; LYDIATE DJ, 1985, GENE, V35, P223, DOI 10.1016/0378-1119(85)90001-0; MACNEIL DJ, 1992, GENE, V115, P119, DOI 10.1016/0378-1119(92)90549-5; MALPARTIDA F, 1986, MOL GEN GENET, V205, P66, DOI 10.1007/BF02428033; MALPARTIDA F, 1984, NATURE, V309, P462, DOI 10.1038/309462a0; MALPARTIDA F, 1987, NATURE, V325, P818, DOI 10.1038/325818a0; MALPARTIDA F, COMMUNICATION; MCDANIEL R, IN PRESS J AM CHEM S; MUTH G, 1989, MOL GEN GENET, V219, P341, DOI 10.1007/BF00259605; OHagan D., 1991, POLYKETIDE METABOLIT; ROBINSON JA, 1991, PHILOS T ROY SOC B, V332, P107, DOI 10.1098/rstb.1991.0038; SHERMAN DH, 1989, EMBO J, V8, P2717, DOI 10.1002/j.1460-2075.1989.tb08413.x; SHERMAN DH, 1992, J BACTERIOL, V174, P6184, DOI 10.1128/JB.174.19.6184-6190.1992; SHERMAN DH, 1991, TETRAHEDRON, V47, P6029, DOI 10.1016/S0040-4020(01)86494-2; SUMMERS RG, 1992, J BACTERIOL, V174, P1810, DOI 10.1128/jb.174.6.1810-1820.1992; VOELKER TA, 1992, SCIENCE, V257, P72, DOI 10.1126/science.1621095; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; YUE S, 1986, J BACTERIOL, V167, P581, DOI 10.1128/jb.167.2.581-586.1986; ZHANG HL, 1990, J ORG CHEM, V55, P1682, DOI 10.1021/jo00292a053	40	386	427	2	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1993	262	5139					1546	1550		10.1126/science.8248802	http://dx.doi.org/10.1126/science.8248802			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK329	8248802				2022-12-28	WOS:A1993MK32900033
J	SHEN, B; HUTCHINSON, CR				SHEN, B; HUTCHINSON, CR			ENZYMATIC-SYNTHESIS OF A BACTERIAL POLYKETIDE FROM ACETYL AND MALONYL COENZYME-A	SCIENCE			English	Article							ACYL CARRIER PROTEIN; 6-METHYLSALICYLIC ACID SYNTHASE; CELL-SUSPENSION CULTURES; STREPTOMYCES-GLAUCESCENS; TETRACENOMYCIN-C; PETROSELINUM-HORTENSE; FLAVANONE SYNTHASE; GENE-CLUSTER; PENICILLIUM-PATULUM; NUCLEOTIDE-SEQUENCE	Microorganisms and plants manufacture a large collection of medically and commercially useful natural products called polyketides by a process that resembles fatty acid biosynthesis. Genetically engineered microorganisms with modified polyketide synthase (PKS) genes can produce new metabolites that may have new or improved pharmacological activity. A potentially general method to prepare cell-free systems for studying bacterial type II PKS enzymes has been developed that facilitates the purification and reconstitution of their constituent proteins. Selective expression of different combinations of the Streptomyces glaucescens tetracenomycin (Tcm) tcmJKLMN genes in a tcmGHIJKLMNO null background has been used to show that the Tcm PKS consists of at least the TcmKLMN proteins. Addition of the TcmJ protein to the latter four enzymes resulted in a greater than fourfold increase of overall activity and thus represents the optimal Tcm PKS. Polyclonal antibodies raised against each of the TcmKLMN proteins strongly inhibit the Tcm PKS, as do known inhibitors targeted to the active site Cys and Ser residues of a fatty acid synthase. This system exhibits a strict starter unit specificity because neither propionyl, butyryl, or isobutyryl coenzyme A substitute for acetyl coenzyme A in assembly of the Tcm decaketide. Because the Tcm PKS activity is significantly diminished by removal of the TcmM acyl carrier protein and can be restored by addition of separately purified TcmM to two different types of TcmM-deficient PKS, it should be possible to use such preparations to assay for each of the constituents of the Tcm PKS.	UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706; UNIV WISCONSIN,SCH PHARM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL CANCER INSTITUTE [R01CA035381] Funding Source: NIH RePORTER; NCI NIH HHS [CA35381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AW, 1984, FATTY ACID METABOLIS, P29; Ali A., UNPUB; BECK J, 1990, EUR J BIOCHEM, V192, P487, DOI 10.1111/j.1432-1033.1990.tb19252.x; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; CAFFREY P, 1992, FEBS LETT, V304, P225, DOI 10.1016/0014-5793(92)80624-P; DECKER H, 1993, J BACTERIOL, V175, P3876, DOI 10.1128/JB.175.12.3876-3886.1993; DECKER H, 1992, J BACTERIOL, V174, P3887; DIMROTH P, 1970, EUR J BIOCHEM, V13, P98, DOI 10.1111/j.1432-1033.1970.tb00904.x; DONADIO S, 1993, P NATL ACAD SCI USA, V90, P7119, DOI 10.1073/pnas.90.15.7119; GRAMAJO HC, 1991, J BACTERIOL, V173, P6475, DOI 10.1128/jb.173.20.6475-6483.1991; GUILFOILE PG, 1992, J BACTERIOL, V174, P3651, DOI 10.1128/JB.174.11.3651-3658.1992; HARRIS TM, 1986, PURE APPL CHEM, V58, P283, DOI 10.1351/pac198658020283; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; HUNAITI AR, 1984, ARCH BIOCHEM BIOPHYS, V229, P426, DOI 10.1016/0003-9861(84)90172-3; HUTCHINSON CR, 1993, INDUSTRIAL MICROORGANISMS: BASIC AND APPLIED MOLECULAR GENETICS, P203; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; Katz L., 1992, ANNU REP MED CHEM, V27, P129; KAWAGUCHI A, 1981, J BIOCHEM-TOKYO, V89, P337, DOI 10.1093/oxfordjournals.jbchem.a133207; KHOSLA C, 1992, MOL MICROBIOL, V6, P3237, DOI 10.1111/j.1365-2958.1992.tb01778.x; KHOSLA C, 1993, J BACTERIOL, V175, P2197, DOI 10.1128/JB.175.8.2197-2204.1993; KIM YS, 1980, J BIOL CHEM, V255, P686; KREUZALER F, 1975, EUR J BIOCHEM, V56, P205, DOI 10.1111/j.1432-1033.1975.tb02223.x; KREUZALER F, 1978, FEBS LETT, V94, P175, DOI 10.1016/0014-5793(78)80931-4; KREUZALER F, 1979, EUR J BIOCHEM, V99, P89, DOI 10.1111/j.1432-1033.1979.tb13235.x; LANZ T, 1991, J BIOL CHEM, V266, P9971; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; MAYORGA ME, 1992, MOL GEN GENET, V235, P205, DOI 10.1007/BF00279362; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MONAGHAN RL, 1990, ANNU REV MICROBIOL, V44, P271; MOTAMEDI H, 1987, P NATL ACAD SCI USA, V84, P4445, DOI 10.1073/pnas.84.13.4445; OHAGEN D, 1991, POLYKETIDE METABOLIT; OKI T, 1981, J ANTIBIOT, V34, P783, DOI 10.7164/antibiotics.34.783; Omura S, 1981, Methods Enzymol, V72, P520; ROBERTS GA, 1993, EUR J BIOCHEM, V214, P305, DOI 10.1111/j.1432-1033.1993.tb17925.x; SCHOPPNER A, 1984, J BIOL CHEM, V259, P6806; SCHRODER G, 1988, EUR J BIOCHEM, V172, P161, DOI 10.1111/j.1432-1033.1988.tb13868.x; SCHUZ R, 1983, J BIOL CHEM, V258, P6730; SCOTTI C, 1993, GENE, V130, P65, DOI 10.1016/0378-1119(93)90347-6; SHEN B, 1992, J BACTERIOL, V174, P3818, DOI 10.1128/JB.174.11.3818-3821.1992; SHEN B, 1993, J NAT PROD, V56, P1288, DOI 10.1021/np50098a013; SHEN B, 1993, BIOCHEMISTRY-US, V32, P11149, DOI 10.1021/bi00092a026; SHEN B, 1993, BIOCHEMISTRY-US, V32, P6656, DOI 10.1021/bi00077a019; SIEBERS J, 1979, THESIS U GOTTINGEN G; SINGH N, 1987, ENZYME MECHANISMS, P534; SPENCER JB, 1992, BIOCHEM J, V288, P839, DOI 10.1042/bj2880839; SPENCER JB, 1992, BIOCHEMISTRY-US, V31, P9107, DOI 10.1021/bi00152a055; SUMMERS RG, 1992, J BACTERIOL, V174, P1810, DOI 10.1128/jb.174.6.1810-1820.1992; SUMMERS RG, UNPUB; SUMMERS RG, IN PRESS J BACTERIOL; TSAY JT, 1992, J BIOL CHEM, V267, P6807; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WANG IK, 1991, CAN J MICROBIOL, V37, P86, DOI 10.1139/m91-013; WEBER W, 1979, ARCH MICROBIOL, V121, P111, DOI 10.1007/BF00689973; YOSHIMOTO A, 1993, J ANTIBIOT, V46, P56, DOI 10.7164/antibiotics.46.56; [No title captured]	55	113	120	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 3	1993	262	5139					1535	1540		10.1126/science.8248801	http://dx.doi.org/10.1126/science.8248801			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK329	8248801				2022-12-28	WOS:A1993MK32900030
J	WIGHTMAN, B; HA, I; RUVKUN, G				WIGHTMAN, B; HA, I; RUVKUN, G			POSTTRANSCRIPTIONAL REGULATION OF THE HETEROCHRONIC GENE LIN-14 BY LIN-4 MEDIATES TEMPORAL PATTERN-FORMATION IN C-ELEGANS	CELL			English	Article							DOUBLE-STRANDED-RNA; CAENORHABDITIS-ELEGANS; MESSENGER-RNA; COVALENT MODIFICATION; DEVELOPMENTAL SWITCH; ELEMENTS; EXPRESSION; SEQUENCES; PROTEIN; REGION	During C. elegans development, the temporal pattern of many cell lineages is specified by graded activity of the heterochronic gene Lin-14. Here we demonstrate that a temporal gradient in Lin-14 protein is generated posttranscriptionally by multiple elements in the lin-14 3'UTR that are regulated by the heterochronic gene Lin-4. The lin-14 3'UTR is both necessary and sufficient to confer lin-4-mediated posttranscriptional temporal regulation. The function of the lin-14 3'UTR is conserved between C. elegans and C. briggsae. Among the conserved sequences are seven elements that are each complementary to the lin-4 RNAs. A reporter gene bearing three of these elements shows partial temporal gradient activity. These data suggest a molecular mechanism for Lin-14p temporal gradient formation: the lin-4 RNAs base pair to sites in the lin-14 3'UTR to form multiple RNA duplexes that down-regulate lin-14 translation.	MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital				Wightman, Bruce/0000-0001-7811-8760	NIGMS NIH HHS [GM44619] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044619] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROS V, 1989, CELL, V57, P49, DOI 10.1016/0092-8674(89)90171-2; AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; AMBROS V, 1987, GENE DEV, V1, P398, DOI 10.1101/gad.1.4.398; ARASU P, 1991, GENE DEV, V5, P1825, DOI 10.1101/gad.5.10.1825; CHALFIE M, 1981, CELL, V24, P59, DOI 10.1016/0092-8674(81)90501-8; DIBB NJ, 1985, J MOL BIOL, V183, P543, DOI 10.1016/0022-2836(85)90170-6; DIBB NJ, 1989, J MOL BIOL, V205, P603, DOI 10.1016/0022-2836(89)90229-5; EDERY I, 1989, CELL, V56, P303, DOI 10.1016/0092-8674(89)90904-5; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; MACDONALD PM, 1990, DEVELOPMENT, V110, P161; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MILLER DM, 1986, P NATL ACAD SCI USA, V83, P2305, DOI 10.1073/pnas.83.8.2305; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SIMON JA, 1987, NUCLEIC ACIDS RES, V15, P2971, DOI 10.1093/nar/15.7.2971; SKEIKY YAW, 1991, J MOL BIOL, V218, P517, DOI 10.1016/0022-2836(91)90698-6; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; WIGHTMAN B, 1991, GENE DEV, V5, P1813, DOI 10.1101/gad.5.10.1813; ZUCKERAPRISON E, 1989, J MOL EVOL, V28, P487, DOI 10.1007/BF02602929	27	2880	3150	6	207	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 3	1993	75	5					855	862		10.1016/0092-8674(93)90530-4	http://dx.doi.org/10.1016/0092-8674(93)90530-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252622	Bronze			2022-12-28	WOS:A1993MK96600006
J	STICCA, RP; PALMER, ML				STICCA, RP; PALMER, ML			IMAGES IN CLINICAL MEDICINE - POLYP OF THE APPENDIX	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											STICCA, RP (corresponding author), NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,BUFFALO,NY 14263, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 2	1993	329	23					1709	1709						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ707	8232460				2022-12-28	WOS:A1993MJ70700006
J	TAVLADORAKI, P; BENVENUTO, E; TRINCA, S; DEMARTINIS, D; CATTANEO, A; GALEFFI, P				TAVLADORAKI, P; BENVENUTO, E; TRINCA, S; DEMARTINIS, D; CATTANEO, A; GALEFFI, P			TRANSGENIC PLANTS EXPRESSING A FUNCTIONAL SINGLE-CHAIN FV-ANTIBODY ARE SPECIFICALLY PROTECTED FROM VIRUS ATTACK	NATURE			English	Article							BUSHY STUNT VIRUS; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; MOSAIC-VIRUS; PROTEIN; INFECTION; GENE; RESOLUTION; DOMAINS; TOBACCO	EXPRESSION Of Viral genes in transgenic plants is a very effective tool for attenuating plant viral infection1-3. Nevertheless, the lack of generality and risk issues related to the expression of viral genes in plants4 might limit the exploitation of this strategy. Expression in plants of antibodies against essential viral proteins could provide an alternative approach to engineer viral resistance. Recently, expression of complete5-7 or engineered7-9 antibodies has been successfully achieved in plants. The engineered single-chain Fv antibody scFv (refs 10, 11) is particularly suitable for expression in plants because of its small size and the lack of assembly requirements. Here we present evidence that constitutive expression in transgenic plants of a scFv antibody, directed against the plant icosahedral tombusvirus artichoke mottled crinkle virus, causes reduction of infection incidence and delay in symptom development.	ENEA, DIPARTIMENTO RIC & SVILUPPO AGROIND, DIV INGN GENET, CP 2400, I-00100 ROME, ITALY; SISSA, I-34013 TRIESTE, ITALY	Italian National Agency New Technical Energy & Sustainable Economics Development; International School for Advanced Studies (SISSA)			DE MARTINIS, DOMENICO/G-2311-2015; Cattaneo, Antonino/AAA-7252-2019; CATTANEO, ANTONINO/K-4471-2016	DE MARTINIS, DOMENICO/0000-0002-7194-0564; Galeffi, Patrizia/0000-0002-0101-1751; TAVLADORAKI, Paraskevi/0000-0002-2570-6662; CATTANEO, ANTONINO/0000-0002-6975-8923				BEACHY RN, 1990, ANNU REV PHYTOPATHOL, V28, P451, DOI 10.1146/annurev.py.28.090190.002315; BENVENUTO E, 1991, PLANT MOL BIOL, V17, P865, DOI 10.1007/BF00037067; BIOCCA S, 1990, EMBO J, V9, P101, DOI 10.1002/j.1460-2075.1990.tb08085.x; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; DENEVE M, 1993, TRANSGENIC RES, V2, P227, DOI 10.1007/BF01977353; DEZOETEN GA, 1991, PHYTOPATHOLOGY, V81, P585; DURING K, 1990, PLANT MOL BIOL, V15, P281, DOI 10.1007/BF00036914; HANLEYBOWDOIN L, 1992, GENETIC ENG PLANT VI, P251; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRISON SC, 1978, NATURE, V276, P368, DOI 10.1038/276368a0; HIATT A, 1989, NATURE, V342, P76, DOI 10.1038/342076a0; HOGLE J, 1983, J MOL BIOL, V171, P95, DOI 10.1016/S0022-2836(83)80315-5; JEFFERSON RA, 1987, EMBO J, V6, P3901; KIHLBERG BM, 1992, J BIOL CHEM, V267, P25583; LEI SP, 1987, J BACTERIOL, V169, P4379, DOI 10.1128/jb.169.9.4379-4383.1987; MAULE AJ, 1983, J GEN VIROL, V64, P2655, DOI 10.1099/0022-1317-64-12-2655; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; OTSUKI Y, 1969, VIROLOGY, V38, P497, DOI 10.1016/0042-6822(69)90167-6; OWEN M, 1992, BIO-TECHNOL, V10, P790, DOI 10.1038/nbt0792-790; PLUCKTHUN A, 1989, METHOD ENZYMOL, V178, P497; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; SELA I, 1986, METHOD ENZYMOL, V119, P734; TAVAZZA M, 1989, PLANT MOL BIOL, V13, P685, DOI 10.1007/BF00016023; TAVAZZA R, 1988, J PLANT PHYSIOL, V133, P640, DOI 10.1016/S0176-1617(88)80022-1; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WERGE TM, 1990, FEBS LETT, V274, P193, DOI 10.1016/0014-5793(90)81362-R; WILSON TMA, 1993, P NATL ACAD SCI USA, V90, P3134, DOI 10.1073/pnas.90.8.3134; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; ZHU XY, 1991, LABORATORY GUIDE CEL, P18	30	326	405	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 2	1993	366	6454					469	472		10.1038/366469a0	http://dx.doi.org/10.1038/366469a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK098	8247156				2022-12-28	WOS:A1993MK09800066
J	GHISLAIN, M; UDVARDY, A; MANN, C				GHISLAIN, M; UDVARDY, A; MANN, C			SACCHAROMYCES-CEREVISIAE 26S PROTEASE MUTANTS ARREST CELL-DIVISION IN G2/METAPHASE	NATURE			English	Article							N-END RULE; SACCHAROMYCES-CEREVISIAE; UBIQUITIN PATHWAY; INVIVO FUNCTION; YEAST; CYCLE; DEGRADATION; MITOSIS; MEMBER; FAMILY	WE isolated two mutants from the yeast Saccharomyces cerevisiae, cim3-1 and cim5-1, that arrest cell division in G2/metaphase at 37-degrees-C. CIM3 (identical to SUG1; ref. 1) and CIM5 are similar to each other and are members of a family of putative ATPases that have been proposed to be 26S protease subunits2. We show here that CIM5 is the functional yeast homologue of the human MSS1 protein3 and that homologues of CIM3 and CIM5 are present in a highly purified preparation of the Drosophila 26S protease4. The short-lived ubiquitin-proline-beta-galactosidase fusion protein is stabilized in cim mutants, but Leu-beta-galactosidase is not. The CLB2 and CLB3 cyclins also accumulate in the cim mutants. Thus the 26S protease is required in vivo for the degradation of ubiquitinated substrates and for anaphase chromosome separation.	CTR ETUD SACLAY, DEPT BIOL CELLULAIRE & MOLEC, SERV BIOCHIM & GENET MOLEC, F-91191 GIF SUR YVETTE, FRANCE; HUNGARIAN ACAD SCI, INST BIOCHEM, BIOL RES CTR, H-6701 SZEGED, HUNGARY	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center				Mann, Carl/0000-0001-7212-1512				BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; GRANDIN N, 1993, MOL CELL BIOL, V13, P2113, DOI 10.1128/MCB.13.4.2113; HARTWELL LH, 1985, GENETICS, V110, P381; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HUTTER KJ, 1979, J GEN MICROBIOL, V113, P369, DOI 10.1099/00221287-113-2-369; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; OHANA B, 1993, P NATL ACAD SCI USA, V90, P138, DOI 10.1073/pnas.90.1.138; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RICHTERRUOFF B, 1992, FEBS LETT, V302, P192, DOI 10.1016/0014-5793(92)80438-M; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K	30	383	386	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1993	366	6453					358	362		10.1038/366358a0	http://dx.doi.org/10.1038/366358a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ705	8247132				2022-12-28	WOS:A1993MJ70500053
J	SOLALCELIGNY, P; LEPAGE, E; BROUSSE, N; REYES, F; HAIOUN, C; LEPORRIER, M; PEUCHMAUR, M; BOSLY, A; PARLIER, Y; BRICE, P; COIFFIER, B; GISSELBRECHT, C				SOLALCELIGNY, P; LEPAGE, E; BROUSSE, N; REYES, F; HAIOUN, C; LEPORRIER, M; PEUCHMAUR, M; BOSLY, A; PARLIER, Y; BRICE, P; COIFFIER, B; GISSELBRECHT, C			RECOMBINANT INTERFERON-ALFA-2B COMBINED WITH A REGIMEN CONTAINING DOXORUBICIN IN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-HODGKINS-LYMPHOMA; LOW-GRADE; PROGNOSTIC FACTORS; SURVIVAL; CHEMOTHERAPY; COMBINATION; MANAGEMENT; STAGE; TRIAL	Background. Interferon alfa and cytotoxic drugs have synergistic effects in patients with non-Hodgkin's lymphoma. In 1986, we designed a clinical trial to evaluate the benefit of concomitant administration of recombinant interferon alfa with a regimen containing doxorubicin in patients with follicular non-Hodgkin's lymphoma. Methods. The trial involved 242 patients with advanced low-grade follicular non-Hodgkin's lymphoma selected on the basis of clinical, radiographic, and biologic criteria. All patients were treated with a regimen consisting of cyclophosphamide, doxorubicin, teniposide, and prednisone (CHVP), given monthly for six cycles and then every two months for one year. After randomization, 123 patients also received interferon alfa-2b at a dosage of 5 million units three times weekly for 18 months. The remaining 119 patients received chemotherapy alone. Results. As compared with the patients treated with CHVP only, the patients treated with CHVP plus interferon alfa had a higher overall rate of response (85 percent vs. 69 percent, P = 0.006), a longer median event-free survival (34 months vs. 19 months, P<0.001), and a higher rate of survival at 3 years (86 percent vs. 69 percent, P = 0.02). Granulocyte toxicity was greater in the patients treated with CHVP plus interferon alfa than in those treated with CHVP alone. There were no treatment-related deaths. Interferon alfa had to be stopped because of toxic effects (fatigue and hepatitis) in 13 patients (11 percent). Conclusions. The addition of interferon alfa to a regimen containing doxorubicin increased the rate of response, event-free survival, and overall survival in patients with advanced follicular non-Hodgkin's lymphoma, without serious toxicity, although some patients were unable to tolerate the side effects.	HOP ST LOUIS,DEPT BIOSTAT & MED INFORMAT SYST,F-75010 PARIS,FRANCE; HOP NECKER ENFANTS MALAD,DEPT PATHOL,F-75730 PARIS 15,FRANCE; HOP HENRI MONDOR,F-94010 CRETEIL,FRANCE; CHU CAEN,F-14033 CAEN,FRANCE; UNIV CATHOLIQUE LOUVAIN,B-1348 LOUVAIN,BELGIUM; CTR HOSP LYON SUD,F-69310 PIERRE BENITE,FRANCE; SCHERING PLOUGH CORP,LEVALLOIS PERRET,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; CHU de Caen NORMANDIE; Universite de Caen Normandie; Universite Catholique Louvain; CHU Lyon; Merck & Company; Schering Plough Corporation	SOLALCELIGNY, P (corresponding author), HOP ST LOUIS,DEPT HEMATOL,CTR HAYEM,1 AVE CL VELLEFAUX,F-75010 PARIS,FRANCE.			Haioun, Corinne/0000-0003-0095-5379				[Anonymous], 1982, CANCER, V49, P2112; BASTION Y, 1991, ANN ONCOL, V2, P123, DOI 10.1093/annonc/2.suppl_2.123; COX DR, 1972, J R STAT SOC B, V34, P187; FOON KA, 1984, NEW ENGL J MED, V311, P1148, DOI 10.1056/NEJM198411013111803; Gallagher C J, 1987, Baillieres Clin Haematol, V1, P141, DOI 10.1016/S0950-3536(87)80048-3; GALLAGHER CJ, 1986, J CLIN ONCOL, V4, P1470, DOI 10.1200/JCO.1986.4.10.1470; HAGENBEEK A, 1992, BLOOD S1, V80, pA288; HORNING SJ, 1984, NEW ENGL J MED, V311, P1471, DOI 10.1056/NEJM198412063112303; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEONARD RCF, 1991, ANN ONCOL, V2, P655, DOI 10.1093/oxfordjournals.annonc.a058044; LEPAGE E, 1990, HEMATOL ONCOL, V8, P31, DOI 10.1002/hon.2900080105; LICHT JD, 1990, CANCER, V66, P632, DOI 10.1002/1097-0142(19900815)66:4<632::AID-CNCR2820660405>3.0.CO;2-B; MCLAUGHLIN P, 1993, ANN ONCOL, V4, P205, DOI 10.1093/oxfordjournals.annonc.a058457; PORTLOCK CS, 1990, SEMIN ONCOL, V17, P51; PRICE CGA, 1991, ANN ONCOL, V2, P141, DOI 10.1093/annonc/2.suppl_2.141; ROHATINER AZS, 1991, BRIT J HAEMATOL, V79, P26, DOI 10.1111/j.1365-2141.1991.tb08114.x; ROMAGUERA JE, 1991, J CLIN ONCOL, V9, P762, DOI 10.1200/JCO.1991.9.5.762; SMALLEY RV, 1992, NEW ENGL J MED, V327, P1336, DOI 10.1056/NEJM199211053271902; STANLEY KE, 1980, J NATL CANCER I, V65, P25; STEWARD WP, 1988, CANCER-AM CANCER SOC, V61, P441, DOI 10.1002/1097-0142(19880201)61:3<441::AID-CNCR2820610306>3.0.CO;2-N; SULLIVAN KM, 1983, BLOOD, V62, P51; WADLER S, 1990, CANCER RES, V50, P3473; YOUNG RC, 1988, SEMIN HEMATOL, V25, P11; 1986, LANCET, V1, P1346	24	227	232	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1993	329	22					1608	1614		10.1056/NEJM199311253292203	http://dx.doi.org/10.1056/NEJM199311253292203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ546	8232429				2022-12-28	WOS:A1993MJ54600003
J	HOLTON, TA; BRUGLIERA, F; LESTER, DR; TANAKA, Y; HYLAND, CD; MENTING, JGT; LU, CY; FARCY, E; STEVENSON, TW; CORNISH, EC				HOLTON, TA; BRUGLIERA, F; LESTER, DR; TANAKA, Y; HYLAND, CD; MENTING, JGT; LU, CY; FARCY, E; STEVENSON, TW; CORNISH, EC			CLONING AND EXPRESSION OF CYTOCHROME-P450 GENES-CONTROLLING FLOWER COLOR	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; FLAVONOIDS; HYBRIDA	BLUE and violet flowers generally contain derivatives of delphinidin; red and pink flowers generally contain derivatives of cyanidin or pelargonidin1. Differences in hydroxylation patterns of these three major classes of anthocyanidins are controlled by the cytochrome P450 enzymes flavonoid 3'-hydroxylase and flavonoid 3',5'-hydroxylase. Here we report on the isolation of complementary DNA clones of two different flavonoid 3',5'-hydroxylase genes that are expressed in petunia flowers. Restriction-fragment length polymorphism mapping and complementation of mutant petunia lines showed that the flavonoid 3',5'-hydroxylase genes correspond to the genetic loci Hf1 and Hf2.	SUNTORY LTD,SHIMAMOTO,OSAKA 618,JAPAN; INRA,GENET & AMELIORAT PLANTES STN,F-21034 DIJON,FRANCE	Suntory Holdings Ltd; INRAE	HOLTON, TA (corresponding author), CALGENE PACIFIC PTY LTD,16 GIPPS ST,COLLINGWOOD,VIC 3066,AUSTRALIA.		Holton, Timothy A/A-7198-2011; Lester, Daniel/AAC-6429-2020	Lester, Daniel/0000-0003-2927-1384; Holton, Timothy/0000-0002-6651-8166; Menting, John/0000-0003-3638-3544				ASHIKARI T, 1989, APPL MICROBIOL BIOT, V30, P515; BOZAK KR, 1990, P NATL ACAD SCI USA, V87, P3904, DOI 10.1073/pnas.87.10.3904; BRUGLIERA F, IN PRESS PL J; CORNU A, 1990, GENETIC MAPS LOCUS M; DOONER HK, 1991, ANNU REV GENET, V25, P173, DOI 10.1146/annurev.ge.25.120191.001133; FORKMANN G, 1991, PLANT BREEDING, V106, P1, DOI 10.1111/j.1439-0523.1991.tb00474.x; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JERVIS L, 1989, J BIOTECHNOL, V11, P161, DOI 10.1016/0168-1656(89)90117-X; LAZO GR, 1991, BIO-TECHNOL, V9, P963, DOI 10.1038/nbt1091-963; MENTING JGT, 1992, THESIS LA TROBE U; MITZUTANI M, 1993, BIOCHEM BIOPH RES CO, V190, P875; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; OEDA K, 1985, DNA-J MOLEC CELL BIO, V4, P203, DOI 10.1089/dna.1985.4.203; RIVIERE JL, 1987, BIOCHIMIE, V69, P743, DOI 10.1016/0300-9084(87)90195-7; STEWART CB, 1989, PLANT PHYSIOL, V90, P534, DOI 10.1104/pp.90.2.534; STOTZ G, 1982, Z NATURFORSCH C, V37, P19; TURPEN T H, 1986, Biotechniques, V4, P14; WALLROTH M, 1986, MOL GEN GENET, V202, P6, DOI 10.1007/BF00330509; WIERING H, 1974, Genen en Phaenen, V17, P117	21	260	323	6	77	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 18	1993	366	6452					276	279		10.1038/366276a0	http://dx.doi.org/10.1038/366276a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH325	8232589				2022-12-28	WOS:A1993MH32500067
J	LUPSKI, JR; CHANCE, PF; GARCIA, CA				LUPSKI, JR; CHANCE, PF; GARCIA, CA			INHERITED PRIMARY PERIPHERAL NEUROPATHIES - MOLECULAR-GENETICS AND CLINICAL IMPLICATIONS OF CMT1A AND HNPP	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MARIE-TOOTH DISEASE; TREMBLER-J MOUSE; HEREDITARY MOTOR; TYPE-1A DUPLICATION; MYELIN PROTEIN; LINKAGE; MUTATION; FAMILIES; 17P11.2; PMP-22		BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; BAYLOR COLL MED,CTR HUMAN GENOME,HOUSTON,TX 77030; TEXAS CHILDRENS HOSP,HOUSTON,TX 77030; UNIV UTAH,MED CTR,DEPT PEDIAT,DIV MED GENET,SALT LAKE CITY,UT 84112; LOUISIANA STATE UNIV,MED CTR,SCH MED,DEPT NEUROL,NEW ORLEANS,LA 70112; LOUISIANA STATE UNIV,MED CTR,SCH MED,DEPT PATHOL,NEW ORLEANS,LA 70112	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Utah System of Higher Education; University of Utah; Louisiana State University System; Louisiana State University System	LUPSKI, JR (corresponding author), BAYLOR COLL MED,INST MOLEC GENET,1 BAYLOR PLAZA,ANDERSON 609E,HOUSTON,TX 77030, USA.		Chance, Phillip/AAX-5826-2020					BEHSE F, 1972, BRAIN, V95, P777, DOI 10.1093/brain/95.4.777; BELLONE E, 1992, J MED GENET, V29, P492; BENOTHMANE K, 1993, GENOMICS, V17, P370; BIRD TD, 1982, AM J HUM GENET, V34, P388; BRADLEY WG, 1975, BRAIN, V98, P381, DOI 10.1093/brain/98.3.381; BRICE A, 1992, J MED GENET, V29, P807, DOI 10.1136/jmg.29.11.807; CHANCE PF, 1992, NEUROLOGY, V42, P2295, DOI 10.1212/WNL.42.12.2295; CHANCE PF, 1990, AM J HUM GENET, V47, P915; CHANCE PF, 1993, CELL, V72, P143, DOI 10.1016/0092-8674(93)90058-X; CHANCE PF, 1992, NEUROLOGY, V42, P2037, DOI 10.1212/WNL.42.10.2037; Charcot JM, 1886, REV MED-PARIS, V6, P97; COLLINS FS, 1992, CLIN RES, V39, P615; DAVIES DM, 1954, LANCET, V2, P266; De Jong J, 1947, PSYCHIAT NEUROL BL A, V50, P60; DEBRUYNE J, 1980, J NEUROL SCI, V47, P385, DOI 10.1016/0022-510X(80)90091-X; Dejerine J J, 1893, COMPTES RENDUS SOC B, V45, P63; Dyck P, 1993, PERIPHERAL NEUROPATH; Dyck P.J, 1993, PNP, P1094; DYCK PJ, 1968, ARCH NEUROL-CHICAGO, V18, P619, DOI 10.1001/archneur.1968.00470360041003; DYCK PJ, 1968, ARCH NEUROL-CHICAGO, V18, P603, DOI 10.1001/archneur.1968.00470360025002; DYCK PJ, 1981, ANN NEUROL, V10, P222, DOI 10.1002/ana.410100304; EARL CJ, 1964, Q J MED, V33, P481; GARCIA C A, 1990, Neurology, V40, P301; HALLAM PJ, 1992, ANN NEUROL, V31, P570, DOI 10.1002/ana.410310518; HAYASAKA K, 1992, BIOCHEM BIOPH RES CO, V186, P827, DOI 10.1016/0006-291X(92)90820-B; HAYASAKA K, 1993, NAT GENET, V5, P31, DOI 10.1038/ng0993-31; HENTATI A, 1992, GENOMICS, V12, P155, DOI 10.1016/0888-7543(92)90419-S; HOOGENDIJK JE, 1992, LANCET, V339, P181; KAKU DA, 1993, NEUROLOGY, V43, P1806, DOI 10.1212/WNL.43.9.1806; KAKU DA, IN PRESS NEUROLOGY; KILLIAN JM, 1979, ANN NEUROL, V5, P515, DOI 10.1002/ana.410050604; LUPSKI JR, 1993, AM J MED GENET, V45, P92, DOI 10.1002/ajmg.1320450122; LUPSKI JR, 1992, NAT GENET, V1, P29, DOI 10.1038/ng0492-29; LUPSKI JR, 1992, CLIN RES, V40, P645; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; LUPSKI JR, 1992, BRAIN PATHOL, V2, P337, DOI 10.1111/j.1750-3639.1992.tb00710.x; LUPSKI JR, 1991, CURRENT NEUROLOGY, P1; MACMILLAN JC, 1992, J MED GENET, V29, P12, DOI 10.1136/jmg.29.1.12; MADRID R, 1975, J NEUROL SCI, V25, P415, DOI 10.1016/0022-510X(75)90263-4; MATSUNAMI N, 1992, NAT GENET, V1, P176, DOI 10.1038/ng0692-176; McKusick V.A., 1992, MENDELIAN INHERITANC; NICHOLSON GA, 1991, NEUROLOGY, V41, P547, DOI 10.1212/WNL.41.4.547; PATEL PI, 1992, NAT GENET, V1, P159, DOI 10.1038/ng0692-159; PENTAO L, 1992, NAT GENET, V2, P292, DOI 10.1038/ng1292-292; RAEYMAEKERS P, 1992, J MED GENET, V29, P5, DOI 10.1136/jmg.29.1.5; Raeymaekers P, 1991, Neuromuscul Disord, V1, P93, DOI 10.1016/0960-8966(91)90055-W; ROA BB, 1993, NAT GENET, V5, P189, DOI 10.1038/ng1093-189; ROA BB, 1993, NEW ENGL J MED, V329, P96, DOI 10.1056/NEJM199307083290205; ROA BB, 1993, NAT GENET, V5, P269, DOI 10.1038/ng1193-269; ROA BB, 1991, AM J MED SCI, V306, P177; Roa Benjamin B., 1993, V384, P187; SKRE H, 1974, CLIN GENET, V6, P98; STAAL A, 1965, NEUROLOGY, V15, P1008, DOI 10.1212/WNL.15.11.1008; SUTER U, 1993, TRENDS NEUROSCI, V16, P50, DOI 10.1016/0166-2236(93)90015-E; SUTER U, 1992, P NATL ACAD SCI USA, V89, P4382, DOI 10.1073/pnas.89.10.4382; SUTER U, 1992, NATURE, V356, P241, DOI 10.1038/356241a0; TIMMERMAN V, 1992, J NEUROL SCI, V109, P41, DOI 10.1016/0022-510X(92)90091-X; TIMMERMAN V, 1992, NAT GENET, V1, P171, DOI 10.1038/ng0692-171; TOOTH H, 1986, PERONEAL TYPE PROGRE; UPADHYAYA M, 1993, HUM GENET, V91, P392; VALENTIJN LJ, 1992, NAT GENET, V2, P288, DOI 10.1038/ng1292-288; VALENTIJN LJ, 1992, NAT GENET, V1, P166, DOI 10.1038/ng0692-166; VANCE JM, 1989, EXP NEUROL, V104, P186, DOI 10.1016/S0014-4886(89)80013-5; WISE CA, 1993, AM J HUM GENET, V53, P853	64	77	77	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1993	270	19					2326	2330		10.1001/jama.270.19.2326	http://dx.doi.org/10.1001/jama.270.19.2326			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF993	8230595				2022-12-28	WOS:A1993MF99300027
J	KUNDIG, TM; SCHORLE, H; BACHMANN, MF; HENGARTNER, H; ZINKERNAGEL, RM; HORAK, I				KUNDIG, TM; SCHORLE, H; BACHMANN, MF; HENGARTNER, H; ZINKERNAGEL, RM; HORAK, I			IMMUNE-RESPONSES IN INTERLEUKIN-2 DEFICIENT MICE	SCIENCE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; VESICULAR STOMATITIS-VIRUS; T-CELL PROLIFERATION; NATURAL-KILLER CELLS; DIFFERENTIATION FACTOR; INFECTION; ACTIVATION; INVIVO; EXPRESSION; MECHANISMS	The role of costimulatory signals in T cell induction was evaluated in mice lacking the interleukin-2 (IL-2) gene. In vitro secondary antiviral T cell responses were absent unless IL-2 was added, confirming the crucial role of IL-2 in vitro. In vivo, primary and secondary cytotoxic T cell responses against vaccinia and lymphocytic choriomeningitis virus were within normal ranges. B cell reactivity to vesicular stomatitis virus was not impaired. T helper cell responses were delayed but biologically functional. Natural killer cell activity was markedly reduced but inducible. These normal in vivo immune responses in IL-2-deficient mice question the importance of IL-2 as defined by in vitro studies.	UNIV WURZBURG,INST VIROL & IMMUNOBIOL,W-8700 WURZBURG,GERMANY	University of Wurzburg	KUNDIG, TM (corresponding author), UNIV ZURICH,INST EXPTL CHIRURG,SCHMELZBERGSTR 12,CH-8006 ZURICH,SWITZERLAND.		Schorle, Hubert/M-5001-2016; Schorle, Hubert/S-1713-2019	Schorle, Hubert/0000-0001-8272-0076; 				ASHMAN RB, 1979, J EXP MED, V150, P1277, DOI 10.1084/jem.150.5.1277; BENNINK JR, 1978, NATURE, V276, P829, DOI 10.1038/276829a0; BIRON CA, 1990, J EXP MED, V171, P173, DOI 10.1084/jem.171.1.173; BLANDEN RV, 1974, TRANSPLANT REV, V19, P56; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; BULLER RML, 1987, NATURE, V328, P77, DOI 10.1038/328077a0; CHARAN S, 1986, J VIROL, V57, P1139, DOI 10.1128/JVI.57.3.1139-1144.1986; CHARAN S, 1986, J IMMUNOL, V136, P3057; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; Claman H N, 1980, Adv Immunol, V30, P121, DOI 10.1016/S0065-2776(08)60195-9; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; FERNANDEZBOTRAN R, 1987, J EXP MED, V166, P1774; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; GROMO G, 1987, NATURE, V327, P424, DOI 10.1038/327424a0; ISHIDA Y, 1989, J EXP MED, V170, P1103, DOI 10.1084/jem.170.4.1103; KASAIAN MT, 1990, J EXP MED, V171, P745, DOI 10.1084/jem.171.3.745; KASAIAN MT, 1989, J IMMUNOL, V142, P1287; KAST WM, 1986, J EXP MED, V164, P723, DOI 10.1084/jem.164.3.723; KUNDIG TM, UNPUB; LEFRANCOIS L, 1984, J VIROL, V51, P208, DOI 10.1128/JVI.51.1.208-214.1984; LEIST TP, 1989, SCAND J IMMUNOL, V30, P679, DOI 10.1111/j.1365-3083.1989.tb02476.x; LEIST TP, 1987, J IMMUNOL, V138, P2278; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; MEUER SC, 1984, P NATL ACAD SCI-BIOL, V81, P1509, DOI 10.1073/pnas.81.5.1509; MIMS CA, 1987, PATHOGENESIS INFECTI; MIZOUCHI T, 1989, J IMMUNOL, V142, P270; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; MOSKOPHIDIS D, 1989, P NATL ACAD SCI USA, V86, P3291, DOI 10.1073/pnas.86.9.3291; MOSKOPHIDIS D, 1987, EUR J IMMUNOL, V17, P937, DOI 10.1002/eji.1830170707; NOGUCHI M, 1993, CELL, V73, P247; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; OEHREN S, 1992, J EXP MED, V176, P1273; OGARRA A, 1986, P NATL ACAD SCI USA, V83, P5228, DOI 10.1073/pnas.83.14.5228; SADLACK B, IN PRESS CELL; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; TAKATSU K, 1987, P NATL ACAD SCI USA, V84, P4234, DOI 10.1073/pnas.84.12.4234; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; WAGNER H, 1978, J EXP MED, V148, P1523, DOI 10.1084/jem.148.6.1523; WAGNER RR, 1987, RHABDOVIRUSES; WIDMER MB, 1987, J EXP MED, V166, P1447, DOI 10.1084/jem.166.5.1447; ZINKERNAGEL RM, 1990, NATURE, V345, P68, DOI 10.1038/345068a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P897, DOI 10.1084/jem.147.3.897	49	405	415	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1059	1061		10.1126/science.8235625	http://dx.doi.org/10.1126/science.8235625			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	8235625				2022-12-28	WOS:A1993MG18700037
J	LAWSON, CL				LAWSON, CL			TANDEM BINDING IN CRYSTALS OF A TRP REPRESSOR-OPERATOR HALF-SITE COMPLEX	NATURE			English	Article							ESCHERICHIA-COLI; DNA; CRYSTALLOGRAPHY; DETECTOR	THE crystal structure of trp repressor tandemly bound in a 2:1 complex to a 16-base-pair palindromic DNA containing a central trp operator half-site has been determined and refined to 2.4 angstrom resolution. Despite dramatically different DNA sequence contexts and crystallization conditions, the protein/DNA interface is essentially identical to that seen in the original trp repressor/operator complex structure1. Water-mediated sequence recognition by trp repressor is likely to be related to the unusual end-on approach of the recognition helix (E), which allows sharing of the major groove by tandem dimers. The tandem complex model accounts for the mutational sensitivity of all trp operator base pairs. The structure also provides the first detailed view of the tandem interaction, revealing a key role for the amino-terminal arms.	PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544	Princeton University	LAWSON, CL (corresponding author), BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973, USA.			Lawson, Catherine/0000-0002-3261-7035				BASS S, 1987, GENE DEV, V1, P565, DOI 10.1101/gad.1.6.565; BENNETT GN, 1978, J MOL BIOL, V121, P179, DOI 10.1016/S0022-2836(78)80004-7; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BRUNGER AT, 1991, ANNU REV PHYS CHEM, V42, P197, DOI 10.1146/annurev.pc.42.100191.001213; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAREY J, 1993, J MOL BIOL, V234, P496, DOI 10.1006/jmbi.1993.1602; CAREY J, 1989, J BIOL CHEM, V264, P1941; CAREY J, 1991, J BIOL CHEM, V266, P24509; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; HARAN TE, 1992, EMBO J, V11, P3021, DOI 10.1002/j.1460-2075.1992.tb05372.x; HODEL A, IN PRESS ACTA CRYS A; HURLBURT BK, 1990, J BIOL CHEM, V265, P7853; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAMOTO AA, 1987, GENE DEV, V1, P556, DOI 10.1101/gad.1.6.556; LAWSON CL, 1988, PROTEINS, V3, P18, DOI 10.1002/prot.340030103; LUISI BF, 1990, BIOCHIM BIOPHYS ACTA, V1048, P113, DOI 10.1016/0167-4781(90)90047-6; MARMORSTEIN RQ, 1989, NUCLEIC ACIDS MOL BI, V3, P56; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P226; SCHEVITZ RW, 1985, NATURE, V317, P782, DOI 10.1038/317782a0; SIGLER PB, 1992, TRANSCRIPTIONAL REGU, V1, P475; STAACKE D, 1990, EMBO J, V9, P1963, DOI 10.1002/j.1460-2075.1990.tb08324.x; STRAUSS MG, 1990, NUCL INSTRUM METH A, V297, P275, DOI 10.1016/0168-9002(90)91376-M; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0	29	151	153	1	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 11	1993	366	6451					178	182		10.1038/366178a0	http://dx.doi.org/10.1038/366178a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG216	8232559				2022-12-28	WOS:A1993MG21600064
J	LEIRS, H; DEBRUYN, L				LEIRS, H; DEBRUYN, L			NEW IDEAS FOR PERSONAL LIBRARY MAINTENANCE SOFTWARE	NATURE			English	Article											LEIRS, H (corresponding author), UNIV ANTWERP,DEPT BIOL,GROENENBORGERLAAN 171,B-2020 ANTWERP,BELGIUM.		Leirs, Herwig/B-8197-2008; De Bruyn, Luc/C-7030-2008	Leirs, Herwig/0000-0002-7612-5024; De Bruyn, Luc/0000-0002-8968-8862				LEIRS H, 1990, Belgian Journal of Zoology, V120, P42; NEAL PR, 1993, BIOSCIENCE, V43, P44, DOI 10.2307/1312105	2	1	1	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 11	1993	366	6451					183	184		10.1038/366183a0	http://dx.doi.org/10.1038/366183a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MG216	8232560				2022-12-28	WOS:A1993MG21600065
J	ROWAN, KM; KERR, JH; MAJOR, E; MCPHERSON, K; SHORT, A; VESSEY, MP				ROWAN, KM; KERR, JH; MAJOR, E; MCPHERSON, K; SHORT, A; VESSEY, MP			INTENSIVE-CARE SOCIETY APACHE-II STUDY IN BRITAIN AND IRELAND .1. VARIATIONS IN CASE-MIX OF ADULT ADMISSIONS TO GENERAL INTENSIVE-CARE UNITS AND IMPACT ON OUTCOME	BRITISH MEDICAL JOURNAL			English	Article							SCORING SYSTEM; MORTALITY; CLASSIFICATION; PREDICTION; SEVERITY; SURVIVAL; DISEASE; TERM; ICU	Objectives-To describe the extent of variation in the case mix of adult admissions to general intensive care units in Britain and Ireland and investigate the impact of such variation on outcome. Design-Prospective, cohort study of consecutive admissions to intensive care units. Setting-26 general intensive care units in Britain and Ireland. Subjects-9099 admissions to the intensive care units studied. Main outcome measure-Death or survival at discharge before and after adjustment of case mix (age, history of chronic conditions, surgical status, diagnosis, and severity of illness) according to the APACHE II method. Results-Important differences in case mix were found, with large variations between the units. Hospital mortality was significantly associated with most of the case mix factors investigated. Conclusions-Comparing crude death rates in hospital between intensive care units may be misleading indicators of performance. The collection of data on case mix needs to be standardised and differences in case mix adjusted for when comparing outcome between different intensive care units.	MORRISTON HOSP,INTENS THERAPY UNIT,SWANSEA SA9 6NL,WALES; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,HLTH PROMOT SCI UNIT,LONDON WC1E 7HT,ENGLAND; BROOMFIELD HOSP,INTENS CARE UNIT,CHELMSFORD CM1 5ET,ESSEX,ENGLAND; UNIV OXFORD,RADCLIFFE INFIRM,NUFFIELD DEPT ANAESTHET,OXFORD OX2 6HE,ENGLAND	Morriston Hospital; University of London; London School of Hygiene & Tropical Medicine; Mid Essex Hospital Services NHS Trust; Broomfield Hospital; Radcliffe Infirmary; University of Oxford	ROWAN, KM (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,GIBSON LABS BLDG,OXFORD OX2 6HE,ENGLAND.							BION JF, 1988, INTENS CARE MED, V14, P167; CHISAKUTA AM, 1990, ULSTER MED J, V59, P161; DRAGSTED L, 1989, CRIT CARE MED, V17, P418, DOI 10.1097/00003246-198905000-00008; Draper E A, 1981, Health Care Financ Rev, V3, P49; EAGLE KA, 1991, MED CARE, V29, P1237, DOI 10.1097/00005650-199112000-00006; GILBERTSON AA, 1991, INTENS CARE MED, V17, P204, DOI 10.1007/BF01709878; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1982, CRIT CARE MED, V10, P491, DOI 10.1097/00003246-198208000-00001; LEMESHOW S, 1988, CRIT CARE MED, V16, P470, DOI 10.1097/00003246-198805000-00002; LEMESHOW S, 1985, CRIT CARE MED, V13, P519, DOI 10.1097/00003246-198507000-00001; MAHUL P, 1991, INTENS CARE MED, V17, P7, DOI 10.1007/BF01708401; MARKS RJ, 1991, INTENS CARE MED, V17, P159, DOI 10.1007/BF01704720; MARSH HM, 1990, MAYO CLIN PROC, V65, P1549, DOI 10.1016/S0025-6196(12)62188-0; RIDLEY S, 1990, BRIT MED J, V301, P1127, DOI 10.1136/bmj.301.6761.1127; Shiell A M, 1990, Clin Intensive Care, V1, P256; TEASDALE G, 1974, LANCET, V2, P81; WATERS M, 1990, ARCH EMERG MED, V7, P16; 1989, ANAESTHESIA, V44, P428; 1989, INTENS CARE MED, V15, P260	20	119	120	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1993	307	6910					972	977		10.1136/bmj.307.6910.972	http://dx.doi.org/10.1136/bmj.307.6910.972			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC441	8241908	Green Published			2022-12-28	WOS:A1993MC44100018
J	WILLIAMS, EGN; DYMOCK, M				WILLIAMS, EGN; DYMOCK, M			LESSON OF THE WEEK - ACUTE AIRWAY-OBSTRUCTION AFTER ASPIRATION OF BOILING TEA FROM TEAPOT SPOUT	BRITISH MEDICAL JOURNAL			English	Article											WILLIAMS, EGN (corresponding author), GLAN GLWYD GEN HOSP,RHYL LL18 5UJ,WALES.							BRAHAMS D, 1989, LANCET, V1, P1089; MAZROOA AA, 1990, ANAESTHESIA, V45, P884, DOI 10.1111/j.1365-2044.1990.tb14583.x	2	4	4	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1993	307	6909					923	923		10.1136/bmj.307.6909.923	http://dx.doi.org/10.1136/bmj.307.6909.923			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB847	8241858	Bronze, Green Published			2022-12-28	WOS:A1993MB84700025
J	INFANTERIVARD, C; FERNANDEZ, A; GAUTHIER, R; DAVID, M; RIVARD, GE				INFANTERIVARD, C; FERNANDEZ, A; GAUTHIER, R; DAVID, M; RIVARD, GE			FETAL LOSS ASSOCIATED WITH CAFFEINE INTAKE BEFORE AND DURING PREGNANCY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPONTANEOUS-ABORTION; CONSUMPTION	Objective.-To determine if caffeine intake before and during pregnancy was associated with an increased risk for fetal loss. Design.-Incidence-density case-control study. Setting.-University-affiliated obstetric and pediatric hospital in Montreal, Quebec. Participants.-A total of 331 women with fetal loss and 993 controls with a normal pregnancy at the same period of pregnancy as the case. Outcome Measures.-Crude and adjusted odds ratios (ORs) for fetal loss were estimated using conditional logistic regression. A trend test for increasing caffeine intake was also used. Results.-Caffeine intake was divided into quartiles; the baseline for comparison was less than 48 mg per day. The adjusted ORs for fetal loss associated with caffeine intake before pregnancy were 1.29 (95% confidence interval [CI], 0.85 to 1.95) for 48 to 162 mg; 1.37 (95% CI, 0.92 to 2.04) for 163 to 321 mg; and 1.85 (95% CI, 1.18 to 2.89) for more than 321 mg. The same comparisons were made for caffeine intake during pregnancy, and the respective adjusted ORs were 1.15 (95% CI, 0.82 to 1.63), 1.95 (95% CI, 1.29 to 2.93), and 2.62 (95% CI, 1.38 to 5.01). After controlling for confounding factors, there was a strong association of caffeine intake during pregnancy and fetal loss, compatible with a linear trend on the logistic scale in which ORs increased by a factor of 1.22 (1.10 to 1.34) for each 100 mg of caffeine ingested daily during pregnancy. Conclusions.-Caffeine intake before and during pregnancy was associated with an increased risk of fetal loss, supporting the US Food and Drug Administration recommendation to pregnant women, largely based on animal studies, to reduce their caffeine intake.	UNIV MONTREAL,HOP ST JUSTINE,DEPT COMMUNITY HLTH,MONTREAL H3T 1C5,QUEBEC,CANADA; UNIV MONTREAL,HOP ST JUSTINE,DEPT OBSTET,MONTREAL H3T 1C5,QUEBEC,CANADA; UNIV MONTREAL,HOP ST JUSTINE,DEPT HEMATOL,MONTREAL H3T 1C5,QUEBEC,CANADA	Universite de Montreal; Universite de Montreal; Universite de Montreal	INFANTERIVARD, C (corresponding author), MCGILL UNIV,FAC MED,DEPT OCCUPAT HLTH,1130 AVE PINS OUEST,MONTREAL H3A 1A3,PQ,CANADA.							ARMSTRONG BG, 1992, AM J PUBLIC HEALTH, V82, P85, DOI 10.2105/AJPH.82.1.85; Breslow N. E., 1987, STATISTICAL METHODS, VII; DLUGOSZ L, 1992, EPIDEMIOL REV, V14, P83, DOI 10.1093/oxfordjournals.epirev.a036093; Fenster L, 1991, Epidemiology, V2, P168, DOI 10.1097/00001648-199105000-00002; INFANTERIVARD C, 1991, NEW ENGL J MED, V325, P1063, DOI 10.1056/NEJM199110103251503; INFANTERIVARD C, 1993, EPIDEMIOLOGY, V4, P73, DOI 10.1097/00001648-199301000-00013; Kihlman B.A., 1977, CAFFEINE CHROMOSOMES; KIHLMAN BA, 1983, DNA REPAIR ITS INHIB, P319; KLINE J, 1991, EPIDEMIOLOGY, V2, P409, DOI 10.1097/00001648-199111000-00004; MILLS JL, 1993, JAMA-J AM MED ASSOC, V269, P593, DOI 10.1001/jama.269.5.593; Mirkin BL, 1976, PERINATAL PHARM THER, P1; MORRIS MB, 1981, AM J OBSTET GYNECOL, V140, P607, DOI 10.1016/0002-9378(81)90191-5; RALL TW, 1985, PHARMACOL BASIS THER, P589; Rothman K, 1986, MODERN EPIDEMIOLOGY; SRISUPHAN W, 1986, AM J OBSTET GYNECOL, V154, P14, DOI 10.1016/0002-9378(86)90385-6; STEIN Z, 1991, EPIDEMIOLOGY, V2, P85; WEINBERG CR, 1993, AM J EPIDEMIOL, V137, P1; Yesair D W, 1984, Prog Clin Biol Res, V158, P215	19	82	87	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1993	270	24					2940	2943		10.1001/jama.270.24.2940	http://dx.doi.org/10.1001/jama.270.24.2940			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM119	8254854				2022-12-28	WOS:A1993MM11900028
J	GOMMERSAMPT, JH; VANLEEUWEN, F; DEBEER, ALJ; VLIEGENTHART, JFG; DIZDAROGLU, M; KOWALAK, JA; CRAIN, PF; BORST, P				GOMMERSAMPT, JH; VANLEEUWEN, F; DEBEER, ALJ; VLIEGENTHART, JFG; DIZDAROGLU, M; KOWALAK, JA; CRAIN, PF; BORST, P			BETA-D-GLUCOSYL-HYDROXYMETHYLURACIL - A NOVEL MODIFIED BASE PRESENT IN THE DNA OF THE PARASITIC PROTOZOAN TRYPANOSOMA-BRUCEI	CELL			English	Article							TRYPANOSOMA-BRUCEI; HOMOLOGOUS RECOMBINATION; ANTIGENIC VARIATION; MAGNETIC-RESONANCE; MASS-SPECTROMETRY; HIGH-RESOLUTION; H-1-NMR; DAMAGE	We have previously shown that the DNA of the unicellular eukaryote T. brucei contains about 0.1% of a novel modified base, called J. The presence of J correlates with a DNA modification associated with the silencing of telomeric expression sites for the variant surface antigens of trypanosomes. Here we show that J is 5-((beta-D-glucopyranosyloxy)-methyl)-uracil (shortened to beta-D-glucosyl-hydroxymethyluracil), a base not previously found in DNA. We discuss putative pathways for the introduction of this base modification at specific positions in the DNA and the possible contribution of this modification to repression of surface antigen gene expression.	UNIV UTRECHT, BIJVOET CTR, DEPT BIOORGAN CHEM, 3584 CH UTRECHT, NETHERLANDS; NATL INST STANDARDS & TECHNOL, CHEM SCI & TECHNOL LAB, GAITHERSBURG, MD 20899 USA; UNIV UTAH, DEPT BIOCHEM, DEPT MED CHEM, SALT LAKE CITY, UT 84112 USA	Utrecht University; National Institute of Standards & Technology (NIST) - USA; Utah System of Higher Education; University of Utah	GOMMERSAMPT, JH (corresponding author), NETHERLANDS CANC INST, DIV MOLEC BIOL, PLESMANIAAN 121, 1066 CX AMSTERDAM, NETHERLANDS.		van Leeuwen, Fred/A-7698-2010	van Leeuwen, Fred/0000-0002-7267-7251	NIGMS NIH HHS [GM 29812] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029812] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNARDS A, 1981, CELL, V27, P497, DOI 10.1016/0092-8674(81)90391-3; BERNARDS A, 1984, NUCLEIC ACIDS RES, V12, P4153, DOI 10.1093/nar/12.10.4153; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BORST P, 1991, IMMUNOPARASITOL TOD, pA29, DOI 10.1016/S0167-5699(05)80009-X; BRUN R, 1979, ACTA TROP, V36, P289; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; CROZATIER M, 1988, MOL BIOCHEM PARASIT, V31, P127, DOI 10.1016/0166-6851(88)90163-6; DIZDAROGLU M, 1991, FREE RADICAL BIO MED, V10, P225, DOI 10.1016/0891-5849(91)90080-M; DIZDAROGLU M, 1984, J CHROMATOGR, V295, P103, DOI 10.1016/S0021-9673(01)87602-0; EID J, 1991, P NATL ACAD SCI USA, V88, P2118, DOI 10.1073/pnas.88.6.2118; GAJEWSKI E, 1990, BIOCHEMISTRY-US, V29, P7876, DOI 10.1021/bi00486a014; GOMMERSAMPT J, 1991, NUCLEIC ACIDS RES, V19, P1745, DOI 10.1093/nar/19.8.1745; GOMMERSAMPT JH, 1993, NUCLEIC ACIDS RES, V21, P2039, DOI 10.1093/nar/21.9.2039; GUPTA RC, 1982, CARCINOGENESIS, V3, P1081, DOI 10.1093/carcin/3.9.1081; Kornberg A., 1992, DNA REPLICATION; KORNBERG S, 1961, J BIOL CHEM, V236, P1487; LEE MGS, 1990, SCIENCE, V250, P1583, DOI 10.1126/science.2177225; LEHMAN IR, 1960, J BIOL CHEM, V235, P3254; LICHTENSTEIN J, 1960, J BIOL CHEM, V235, P1134; LYON MF, 1993, TRENDS GENET, V9, P123, DOI 10.1016/0168-9525(93)90206-W; NISHIDA Y, 1984, TETRAHEDRON LETT, V25, P1575, DOI 10.1016/S0040-4039(01)90014-0; PAYS E, 1984, NUCLEIC ACIDS RES, V12, P5235, DOI 10.1093/nar/12.13.5235; PERKINS SJ, 1977, CARBOHYD RES, V59, P19, DOI 10.1016/S0008-6215(00)83289-9; RAE PMM, 1978, BIOSYSTEMS, V10, P37, DOI 10.1016/0303-2647(78)90027-8; SCHANBAC.FL, 1970, J BIOL CHEM, V245, P5057; SMITH RD, 1990, ANAL CHEM, V62, P882, DOI 10.1021/ac00208a002; TENASBROEK ALMA, 1990, NATURE, V348, P174, DOI 10.1038/348174a0; TENASBROEK ALMA, 1993, MOL BIOCHEM PARASIT, V59, P133, DOI 10.1016/0166-6851(93)90014-O; VANDERPLOEG LHT, 1987, CELL, V51, P159, DOI 10.1016/0092-8674(87)90140-1; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WOOD DJ, 1974, CAN J CHEM, V52, P3353, DOI 10.1139/v74-495; WYATT GR, 1953, BIOCHEM J, V55, P774, DOI 10.1042/bj0550774	32	158	163	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 17	1993	75	6					1129	1136		10.1016/0092-8674(93)90322-H	http://dx.doi.org/10.1016/0092-8674(93)90322-H			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	8261512	Green Submitted			2022-12-28	WOS:A1993MM89300011
J	GAZIANO, JM; BURING, JE; BRESLOW, JL; GOLDHABER, SZ; ROSNER, B; VANDENBURGH, M; WILLETT, W; HENNEKENS, CH				GAZIANO, JM; BURING, JE; BRESLOW, JL; GOLDHABER, SZ; ROSNER, B; VANDENBURGH, M; WILLETT, W; HENNEKENS, CH			MODERATE ALCOHOL INTAKE, INCREASED LEVELS OF HIGH-DENSITY-LIPOPROTEIN AND ITS SUBFRACTIONS, AND DECREASED RISK OF MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; APOLIPOPROTEIN-A-I; CARDIOVASCULAR MORTALITY; PRECIPITATION PROCEDURE; CIGARETTE-SMOKING; ARTERY DISEASE; CONSUMPTION; CHOLESTEROL; MEN; FRAMINGHAM	Background. Previous studies have suggested that moderate alcohol intake exerts a protective effect against coronary heart disease. Alterations in plasma lipoprotein levels represent one plausible mechanism of this apparent protective effect. Methods. We therefore examined the interrelation among alcohol consumption, plasma lipoprotein levels, and the risk of myocardial infarction in 340 patients who had had myocardial infarctions and an equal number of age- and sex-matched controls. The case patients were men or women less than 76 years of age with no history of coronary disease who were discharged from one of six hospitals in the Boston area with a diagnosis of a confirmed myocardial infarction. Alcohol consumption was estimated by means of a food-frequency questionnaire. Results. We observed a significant inverse association between alcohol consumption and the risk of myocardial infarction (P for trend, <0.001 after control for known coronary risk factors). In multivariate analyses, the relative risk for the highest intake category (subjects who consumed three or more drinks per day) as compared with the lowest (those who had less than one drink a month) was 0.45 (95 percent confidence interval, 0.26 to 0.80). The levels of total high-density lipoprotein cholesterol (HDL) and its HDL2 and HDL3 subtractions were strongly associated with alcohol consumption (P for trend, <0.001 for each). The addition of HDL or either of its subtractions to the multivariate model substantially reduced the inverse association between alcohol intake and myocardial infarction, whereas the addition of the other plasma lipid measurements did not materially alter the relation. Conclusions. These data confirm the inverse association ot moderate alcohol intake with the risk of myocardial infarction and support the view that the effect is mediated, in large part, by increases in both HDL2 and HDL3.	HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA 02115 USA; VET AFFAIRS MED CTR, DEPT MED, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT ENDOCRINOL, BOSTON, MA 02115 USA; ROCKEFELLER UNIV, BIOCHEM GENET & METAB LAB, NEW YORK, NY 10021 USA	Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Rockefeller University	GAZIANO, JM (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV PREVENT MED, 900 COMMONWEALTH AVE E, BOSTON, MA 02115 USA.		CLIHON, Residencia Medica/K-4896-2013; Breslow, Jan L/B-7544-2008	CLIHON, Residencia Medica/0000-0001-6734-2513; 	NHLBI NIH HHS [HL-21006, HL-07575, HL-24423] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVOGARO P, 1982, ARTERY, V10, P317; BALLANTYNE FC, 1982, METABOLISM, V31, P433, DOI 10.1016/0026-0495(82)90230-X; BARR DP, 1951, AM J MED, V11, P480, DOI 10.1016/0002-9343(51)90183-0; BLUM CB, 1980, J CLIN INVEST, V66, P1240, DOI 10.1172/JCI109975; BURING JE, 1992, CIRCULATION, V85, P22, DOI 10.1161/01.CIR.85.1.22; CAMARGO C A JR, 1985, Journal of the American Medical Association, V253, P2854, DOI 10.1001/jama.253.19.2854; CASTELLI WP, 1977, CIRCULATION, V55, P767, DOI 10.1161/01.CIR.55.5.767; CASTELLI WP, 1977, LANCET, V2, P153; COLDITZ GA, 1985, AM HEART J, V109, P886, DOI 10.1016/0002-8703(85)90654-4; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; CULLEN K, 1982, INT J EPIDEMIOL, V11, P67, DOI 10.1093/ije/11.1.67; DAI WS, 1985, AM J EPIDEMIOL, V122, P620, DOI 10.1093/oxfordjournals.aje.a114141; DANIELSSON B, 1978, SCAND J CLIN LAB INV, V38, P113, DOI 10.1080/00365517809156078; DEUTSCHER S, 1984, AM HEART J, V108, P988, DOI 10.1016/0002-8703(84)90465-4; DIEHL AK, 1988, ATHEROSCLEROSIS, V69, P145, DOI 10.1016/0021-9150(88)90008-1; DYER AR, 1980, PREV MED, V9, P78, DOI 10.1016/0091-7435(80)90060-2; ERNST N, 1980, CIRCULATION, V62, P41; FRASER GE, 1981, AM J EPIDEMIOL, V114, P462, DOI 10.1093/oxfordjournals.aje.a113212; FRASER GE, 1983, ATHEROSCLEROSIS, V46, P275, DOI 10.1016/0021-9150(83)90178-8; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; GIDEZ LI, 1982, J LIPID RES, V23, P1206; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GLUECK CJ, 1980, AM J CLIN NUTR, V33, P2287, DOI 10.1093/ajcn/33.11.2287; GOFMAN JW, 1966, CIRCULATION, V34, P679, DOI 10.1161/01.CIR.34.4.679; GORDON T, 1985, AM HEART J, V110, P331, DOI 10.1016/0002-8703(85)90152-8; GORDON T, 1983, AM HEART J, V105, P667, DOI 10.1016/0002-8703(83)90492-1; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HAFFNER SM, 1985, ARTERIOSCLEROSIS, V5, P169, DOI 10.1161/01.ATV.5.2.169; HARTUNG GH, 1983, JAMA-J AM MED ASSOC, V249, P747, DOI 10.1001/jama.249.6.747; HASKELL WL, 1984, NEW ENGL J MED, V310, P805, DOI 10.1056/NEJM198403293101301; HAYNES SG, 1978, AM J EPIDEMIOL, V107, P362, DOI 10.1093/oxfordjournals.aje.a112556; HENNEKENS CH, 1978, AM J EPIDEMIOL, V107, P196, DOI 10.1093/oxfordjournals.aje.a112525; HERBERT PN, 1985, J CLIN INVEST, V76, P403, DOI 10.1172/JCI111986; HULLEY SB, 1981, CIRCULATION, V64, P57; KLATSKY AL, 1974, ANN INTERN MED, V81, P294, DOI 10.7326/0003-4819-81-3-294; KLATSKY AL, 1981, ANN INTERN MED, V95, P139, DOI 10.7326/0003-4819-95-2-139; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LANGER RD, 1992, CIRCULATION, V85, P910, DOI 10.1161/01.CIR.85.3.910; MILLER GJ, 1975, LANCET, V1, P16; MILLER NE, 1981, BRIT MED J, V282, P1741, DOI 10.1136/bmj.282.6278.1741; MOORE RD, 1986, MEDICINE, V65, P242, DOI 10.1097/00005792-198607000-00004; MUSLINER TA, 1982, ARTERIOSCLEROSIS, V2, P160, DOI 10.1161/01.ATV.2.2.160; Pell S, 1973, J Occup Med, V15, P120; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; ROSENBERG L, 1981, AM J PUBLIC HEALTH, V71, P82, DOI 10.2105/AJPH.71.1.82; ROSENGREN A, 1988, ACTA MED SCAND, V223, P111; ROSS RK, 1981, LANCET, V1, P858; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SHAPER AG, 1988, LANCET, V2, P1267; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STASON WB, 1976, AM J EPIDEMIOL, V104, P603, DOI 10.1093/oxfordjournals.aje.a112338; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; TALL AR, 1982, J BIOL CHEM, V257, P198; TASKINEN MR, 1982, METABOLISM, V31, P1168, DOI 10.1016/0026-0495(82)90169-X; TAYLOR KG, 1981, ATHEROSCLEROSIS, V38, P11, DOI 10.1016/0021-9150(81)90098-8; THORARINSSON AA, 1979, J STUD ALCOHOL, V40, P704, DOI 10.15288/jsa.1979.40.704; VALIMAKI M, 1986, ATHEROSCLEROSIS, V59, P147, DOI 10.1016/0021-9150(86)90043-2; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; YANO K, 1984, AM J EPIDEMIOL, V119, P653, DOI 10.1093/oxfordjournals.aje.a113787; [No title captured]; 1980, DHHS NIH801527 DDEP, P28; 1974, DHEW NIH75628 NAT HE, P51	64	822	840	2	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 16	1993	329	25					1829	1834		10.1056/NEJM199312163292501	http://dx.doi.org/10.1056/NEJM199312163292501			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML588	8247033				2022-12-28	WOS:A1993ML58800001
J	KAMTEKAR, S; SCHIFFER, JM; XIONG, HY; BABIK, JM; HECHT, MH				KAMTEKAR, S; SCHIFFER, JM; XIONG, HY; BABIK, JM; HECHT, MH			PROTEIN DESIGN BY BINARY PATTERNING OF POLAR AND NONPOLAR AMINO-ACIDS	SCIENCE			English	Article							MOLTEN-GLOBULE STATE; HELIX-FORMING TENDENCIES; ESCHERICHIA-COLI; LAMBDA-REPRESSOR; GROWTH-HORMONE; DENOVO DESIGN; STABILITY; SEQUENCES; CONFORMATION; EXPRESSION	A general strategy is described for the de novo design of proteins. In this strategy the sequence locations of hydrophobic and hydrophilic residues were specified explicitly, but the precise identities of the side chains were not constrained and varied extensively. This strategy was tested by constructing a large collection of synthetic genes whose protein products were designed to fold into four-helix bundle proteins. Each gene encoded a different amino acid sequence, but all sequences shared the same pattern of polar and nonpolar residues. Characterization of the expressed proteins indicated that most of the designed sequences folded into compact alpha-helical structures. Thus, a simple binary code of polar and nonpolar residues arranged in the appropriate order can drive polypeptide chains to collapse into globular alpha-helical folds.	PRINCETON UNIV, DEPT CHEM, PRINCETON, NJ 08544 USA; PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	Princeton University; Princeton University				Hecht, Michael/0000-0002-5538-9813				AHMAD F, 1986, BIOPOLYMERS, V25, P1623, DOI 10.1002/bip.360250906; ALTER JE, 1973, MACROMOLECULES, V6, P564, DOI 10.1021/ma60034a019; BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BETZ SF, 1993, CURR OPIN STRUC BIOL, V3, P601, DOI 10.1016/0959-440X(93)90090-8; BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; BOWIE JU, 1990, PROTEINS, V7, P257, DOI 10.1002/prot.340070307; BOWIE JU, 1989, P NATL ACAD SCI USA, V86, P2152, DOI 10.1073/pnas.86.7.2152; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P33; BREMS DN, 1989, PROTEINS, V5, P93, DOI 10.1002/prot.340050110; BREYER RM, 1990, EMBO J, V9, P2679, DOI 10.1002/j.1460-2075.1990.tb07453.x; BRUNET AP, 1993, NATURE, V364, P355, DOI 10.1038/364355a0; BULLOCK PA, 1978, BIOCHEMISTRY-US, V17, P3084, DOI 10.1021/bi00608a022; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CARUTHERS MH, 1991, ACCOUNTS CHEM RES, V24, P278, DOI 10.1021/ar00009a005; CHAN HS, 1991, J CHEM PHYS, V95, P3775, DOI 10.1063/1.460828; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; de Boer HA., 1986, MAXIMIZING GENE EXPR, P225; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DOLGIKH DA, 1984, FEBS LETT, V165, P88, DOI 10.1016/0014-5793(84)80020-4; GHADIRI MR, 1992, J AM CHEM SOC, V114, P4000, DOI 10.1021/ja00036a072; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HAHN KW, 1990, SCIENCE, V248, P1544, DOI 10.1126/science.2360048; HANDEL TM, 1993, SCIENCE, V261, P879, DOI 10.1126/science.8346440; HECHT MH, 1984, P NATL ACAD SCI-BIOL, V81, P5685, DOI 10.1073/pnas.81.18.5685; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; HOLLADAY LA, 1974, BIOCHEMISTRY-US, V13, P1653, DOI 10.1021/bi00705a015; ITAGAKI E, 1966, J BIOL CHEM, V241, P3687; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KAMTEKAR S, UNPUB; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAU KF, 1990, P NATL ACAD SCI USA, V87, P638, DOI 10.1073/pnas.87.2.638; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MCCALDON P, 1988, PROTEINS, V4, P99, DOI 10.1002/prot.340040204; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; NICHOLSON LK, 1992, BIOCHEMISTRY-US, V31, P5253, DOI 10.1021/bi00138a003; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OSTERMAN DG, 1985, J CELL BIOCHEM, V29, P57, DOI 10.1002/jcb.240290202; PACE C N, 1975, Critical Reviews in Biochemistry, V3, P1, DOI 10.3109/10409237509102551; PACE CN, 1990, TRENDS BIOCHEM SCI, V15, P14, DOI 10.1016/0968-0004(90)90124-T; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; PAKULA AA, 1986, P NATL ACAD SCI USA, V83, P8829, DOI 10.1073/pnas.83.23.8829; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; RALEIGH DP, 1992, J AM CHEM SOC, V114, P10079, DOI 10.1021/ja00051a061; REGAN L, 1988, SCIENCE, V241, P976, DOI 10.1126/science.3043666; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; RICHARDSON JS, 1989, TRENDS BIOCHEM SCI, V14, P304, DOI 10.1016/0968-0004(89)90070-4; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; Richardson JS, 1987, PROTEIN ENG, P149; SASAKI T, 1989, J AM CHEM SOC, V111, P380, DOI 10.1021/ja00183a065; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; UNSON CG, 1984, FED PROC, V93, P1837; WAGNER G, 1993, CURR OPIN STRUC BIOL, V3, P748, DOI 10.1016/0959-440X(93)90059-T; WEBER PC, 1980, NATURE, V287, P82, DOI 10.1038/287082a0; YBE JA, UNPUB; YUE K, 1992, P NATL ACAD SCI USA, V89, P4163, DOI 10.1073/pnas.89.9.4163; [No title captured]	63	629	655	1	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1993	262	5140					1680	1685		10.1126/science.8259512	http://dx.doi.org/10.1126/science.8259512			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	8259512				2022-12-28	WOS:A1993ML22000030
J	GUADAGNO, TM; OHTSUBO, M; ROBERTS, JM; ASSOIAN, RK				GUADAGNO, TM; OHTSUBO, M; ROBERTS, JM; ASSOIAN, RK			A LINK BETWEEN CYCLIN-A EXPRESSION AND ADHESION-DEPENDENT CELL-CYCLE PROGRESSION	SCIENCE			English	Article							PROTEIN-KINASE; DNA-REPLICATION; GENE-EXPRESSION; DIVISION CYCLE; MESSENGER-RNA; S-PHASE; CDC2; PROLIFERATION; GROWTH; EVENTS	Cell adhesion has an essential role in regulating proliferation during the G1 phase of the cell cycle, and loss of this adhesion requirement is a classic feature of oncogenic transformation. The appearance of cyclin A messenger RNA and protein in late G1 was dependent on cell adhesion in both NRK and NIH 3T3 fibroblasts. In contrast, the expression of Cdc2, Cdk2, cyclin D1, and cyclin E was independent of adhesion in both cell lines. Transfection of NRK cells with a cyclin A complementary DNA resulted in adhesion-independent accumulation of cyclin A protein and cyclin A-associated kinase activity. These transfected cells also entered S phase and complete multiple rounds of cell division in the absence of cell adhesion. Thus, cyclin A is a target of the adhesion-dependent signals that control cell proliferation.	FRED HUTCHINSON CANC RES CTR, DEPT BASIC SCI, SEATTLE, WA 98104 USA; COLUMBIA UNIV, CTR REPROD SCI, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA	Fred Hutchinson Cancer Center; Columbia University; Columbia University				ohtsubo, motoaki/0000-0002-2479-3178	NIGMS NIH HHS [GM48224] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048224] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BENECKE BJ, 1978, CELL, V14, P931, DOI 10.1016/0092-8674(78)90347-1; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; CARLSON KE, UNPUB; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; DOU QP, 1993, CANCER RES, V53, P1493; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; HAN EKH, 1993, J CELL BIOL, V122, P461, DOI 10.1083/jcb.122.2.461; HARTWELL LH, 1973, GENETICS, V74, P267; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HOCK RA, 1989, BLOOD, V74, P876; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MATSUHISA T, 1981, EXP CELL RES, V135, P393, DOI 10.1016/0014-4827(81)90176-2; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OTSUKA H, 1976, J CELL PHYSIOL, V87, P213, DOI 10.1002/jcp.1040870209; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PLEDGER WJ, 1978, P NATL ACAD SCI USA, V75, P2839, DOI 10.1073/pnas.75.6.2839; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; STOKER M, 1968, INT J CANCER, V3, P683, DOI 10.1002/ijc.2910030517; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	53	381	390	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1993	262	5139					1572	1575		10.1126/science.8248807	http://dx.doi.org/10.1126/science.8248807			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK329	8248807				2022-12-28	WOS:A1993MK32900041
J	GURDON, JB; LEMAIRE, P; KATO, K				GURDON, JB; LEMAIRE, P; KATO, K			COMMUNITY EFFECTS AND RELATED PHENOMENA IN DEVELOPMENT	CELL			English	Review							ELEGANS SEX DETERMINATION; CAENORHABDITIS-ELEGANS; CELL-INTERACTIONS; DROSOPHILA; ENCODES; PROTEIN				GURDON, JB (corresponding author), UNIV CAMBRIDGE, DEPT ZOOL, WELLCOME CANC RES CAMPAIGN INST, TENNIS COURT RD, CAMBRIDGE CB2 1QR, ENGLAND.		Lemaire, Patrick/D-4237-2009; Lemaire, Patrick/P-8228-2019; Lemaire, Patrick/B-5560-2012	Lemaire, Patrick/0000-0003-4925-2009; Lemaire, Patrick/0000-0003-4925-2009; GURDON, JOHN/0000-0002-5621-3799; Kato, Kazuto/0000-0001-9006-9551	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BASLER K, 1991, BIOESSAYS, V13, P621, DOI 10.1002/bies.950131202; BOTAS J, 1988, ROUX ARCH DEV BIOL, V197, P424, DOI 10.1007/BF00398994; CABRERA CV, 1985, NATURE, V318, P569, DOI 10.1038/318569a0; DAVIDSON EH, 1986, GENE ACTIVITY EARLY, P430; Furshpan E J, 1968, Curr Top Dev Biol, V3, P95; GAO WQ, 1992, CELL, V68, P841, DOI 10.1016/0092-8674(92)90028-B; GEHRING W, 1967, DEV BIOL, V16, P438, DOI 10.1016/0012-1606(67)90058-9; GERISCH G, 1986, J CELL SCI, P201; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; GONZALEZGAITAN MA, 1990, GENETICS, V126, P139; GURDON JB, 1988, NATURE, V336, P772, DOI 10.1038/336772a0; GURDON JB, 1987, DEVELOPMENT, V99, P285; GURDON JB, 1993, CURR BIOL, V3, P1, DOI 10.1016/0960-9822(93)90139-F; HADORN E, 1965, BROOKHAVEN SYM BIOL, V7, P617; HEASMAN J, 1984, CELL, V37, P185, DOI 10.1016/0092-8674(84)90314-3; HO RK, 1992, DEVELOPMENT, P65; HUNTER CP, 1992, NATURE, V355, P551, DOI 10.1038/355551a0; JOUANNEAU J, 1994, IN PRESS P NATL ACAD; KATO K, 1993, P NATL ACAD SCI USA, V90, P1310, DOI 10.1073/pnas.90.4.1310; KUWABARA PE, 1992, MOL BIOL CELL, V3, P461, DOI 10.1091/mbc.3.4.461; LOPASCHOV G., 1935, BIOL ZENTRALBL, V55, P606; Mangold O, 1933, NATURWISSENSCHAFTEN, V21, P761, DOI 10.1007/BF01503740; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; REPRESA J, 1989, International Journal of Developmental Biology, V33, P397; SLACK JMW, 1991, EGG EMBRYO, P93; Spemann H., 1938, EMBRYONIC DEV INDUCT; STUTTEM I, 1991, DEVELOPMENT, P39; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TRINKAUS JP, 1956, AM NAT, V90, P273, DOI 10.1086/281936; WARNER AE, 1985, J EMBRYOL EXP MORPH, V89, P365	30	170	172	1	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 3	1993	75	5					831	834		10.1016/0092-8674(93)90526-V	http://dx.doi.org/10.1016/0092-8674(93)90526-V			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252618	Bronze			2022-12-28	WOS:A1993MK96600002
J	HUNTER, T				HUNTER, T			BRAKING THE CYCLE	CELL			English	Review							CELL-CYCLE; S-PHASE; REPLICATION; KINASES				HUNTER, T (corresponding author), SALK INST BIOL STUDIES, MOLEC BIOL & VIROL LAB, LA JOLLA, CA 92037 USA.							BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENOCH T, 1991, CELL, V65, P921, DOI 10.1016/0092-8674(91)90542-7; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARPER JW, 1993, CELL, V75, P805; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MILLAR JBA, 1992, EMBO J, V11, P4933, DOI 10.1002/j.1460-2075.1992.tb05600.x; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NODA A, 1994, IN PRESS EXP CELL RE; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; WAN J, 1992, J BIOL CHEM, V267, P11274; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	22	440	469	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 3	1993	75	5					839	841		10.1016/0092-8674(93)90528-X	http://dx.doi.org/10.1016/0092-8674(93)90528-X			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252620	Bronze			2022-12-28	WOS:A1993MK96600004
J	KABATA, H; KUROSAWA, O; ARAI, I; WASHIZU, M; MARGARSON, SA; GLASS, RE; SHIMAMOTO, N				KABATA, H; KUROSAWA, O; ARAI, I; WASHIZU, M; MARGARSON, SA; GLASS, RE; SHIMAMOTO, N			VISUALIZATION OF SINGLE MOLECULES OF RNA-POLYMERASE SLIDING ALONG DNA	SCIENCE			English	Article							DIFFUSION-DRIVEN MECHANISMS; REPRESSOR-OPERATOR INTERACTION; ONE-DIMENSIONAL DIFFUSION; PROTEIN TRANSLOCATION; NUCLEIC-ACIDS; LAC REPRESSOR; ECORI ENDONUCLEASE; PROMOTER SELECTION; GENE-TRANSCRIPTION; ACTIN-FILAMENTS	Transcription requires that RNA polymerase binds to promoters buried in nonspecific sites on DNA. The search for promoters may be facilitated if the polymerase slides along the molecule of DNA. Single molecules of Escherichia coli RNA polymerase were visualized, and their movements on immobilized bacteriophage lambda and T7 DNAs were examined. Deviating from drifts by bulk flow, about 40 percent of the enzyme molecules moved along the extended DNA. The results provide direct evidence for sliding as a mechanism for relocation of the enzyme on DNA.	NATL INST GENET,DNA RES CTR,MISHIMA,SHIZUOKA 411,JAPAN; GRAD UNIV ADV STUDIES,SCH LIFE SCI,MISHIMA 411,JAPAN; SEIKEI UNIV,DEPT ELECT ENGN & ELECTR,TOKYO 103,JAPAN; ADVANCE CO,TOKYO 103,JAPAN; UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT BIOCHEM,NOTTINGHAM NG7 2UH,ENGLAND	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan; Seikei University; University of Nottingham			Shimamoto, Nobuo/AAJ-4999-2020	Shimamoto, Nobuo/0000-0001-7579-0084				BEINLSTEV BN, 1980, NUCLEIC ACIDS RES, V8, P1391; BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; BURGESS RR, 1971, ANNU REV BIOCHEM, V40, P711, DOI 10.1146/annurev.bi.40.070171.003431; Coligan JE, 1991, CURRENT PROTOCOL IMM; EHBRECHT HJ, 1985, J BIOL CHEM, V260, P6160; FICKERT R, 1992, J MOL BIOL, V226, P59, DOI 10.1016/0022-2836(92)90124-3; FUJIOKA M, 1991, BIOCHEMISTRY-US, V30, P1801, DOI 10.1021/bi00221a011; HOCHSCHILD A, 1986, CELL, V44, P681, DOI 10.1016/0092-8674(86)90833-0; IGARASHI K, 1991, J MOL BIOL, V218, P1, DOI 10.1016/0022-2836(91)90865-4; JACK WE, 1982, P NATL ACAD SCI-BIOL, V79, P4010, DOI 10.1073/pnas.79.13.4010; KIM JG, 1987, J MOL BIOL, V196, P149, DOI 10.1016/0022-2836(87)90517-1; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; MARGARSON SA, UNPUB; NARDONE G, 1986, J BIOL CHEM, V261, P2128; NICKELL C, 1992, BIOCHEMISTRY-US, V31, P4189, DOI 10.1021/bi00132a006; PARK CS, 1982, J BIOL CHEM, V257, P6944; PARK CS, 1982, J BIOL CHEM, V257, P6950; RICCHETTI M, 1988, P NATL ACAD SCI USA, V85, P4610, DOI 10.1073/pnas.85.13.4610; RUUSALA T, 1992, P NATL ACAD SCI USA, V89, P4903, DOI 10.1073/pnas.89.11.4903; SHIMAMOTO N, 1992, STRUCTURAL TOOLS ANA, P241; SINGER P, 1987, J BIOL CHEM, V262, P14178; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TERRY BJ, 1985, J BIOL CHEM, V260, P3130; TERRY BJ, 1983, J BIOL CHEM, V258, P9820; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WASHIZU M, 1990, IEEE T IND APPL, V26, P1165, DOI 10.1109/28.62403; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6948, DOI 10.1021/bi00527a029; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0	31	231	239	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 3	1993	262	5139					1561	1563		10.1126/science.8248804	http://dx.doi.org/10.1126/science.8248804			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK329	8248804				2022-12-28	WOS:A1993MK32900037
J	MA, CY; ZHOU, Y; BEACHY, PA; MOSES, K				MA, CY; ZHOU, Y; BEACHY, PA; MOSES, K			THE SEGMENT POLARITY GENE HEDGEHOG IS REQUIRED FOR PROGRESSION OF THE MORPHOGENETIC FURROW IN THE DEVELOPING DROSOPHILA EYE	CELL			English	Article							PATTERN-FORMATION; CELL-INTERACTIONS; IMAGINAL DISKS; EGF RECEPTOR; PATCHED GENE; BETA FAMILY; PROTEIN; EXPRESSION; MUTATIONS; HOMOLOG	Cell-type specification in the Drosophila compound eye begins at the morphogenetic furrow. The furrow sweeps across the developing eye epithelium and is coincident with four classes of cellular events: coordinated changes in cell shape, changes in gene expression, synchronization of the cell cycle, and the specification of a regular array of ommatidial founder cells. The molecular mechanisms that induce these events in the developing eye have hitherto been unknown. We identify here a gene specifically required for furrow progression, hedgehog (hh). We show that hh expression posterior to the morphogenetic furrow is continuously required for its progression. We propose that forward diffusion of hh protein induces anterior cells to enter the furrow.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University	MA, CY (corresponding author), UNIV SO CALIF,DEPT BIOL SCI,LOS ANGELES,CA 90089, USA.				NEI NIH HHS [1RO1EYO922-02] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; BAKER NE, 1992, DEV BIOL, V150, P381, DOI 10.1016/0012-1606(92)90250-K; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BAKER NE, 1992, J NEUROGENET, V8, P85, DOI 10.3109/01677069209084154; BASLER K, 1991, BIOESSAYS, V13, P621, DOI 10.1002/bies.950131202; Bernard F, 1937, B BIOL FR BELG S, V23; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BROWER DL, 1986, EMBO J, V5, P2649, DOI 10.1002/j.1460-2075.1986.tb04547.x; BROWN NL, 1991, DEVELOPMENT, V113, P1245; BRYANT PJ, 1993, SCIENCE, V259, P229; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; DOE CQ, 1985, PHILOS T R SOC B, V312, P67, DOI 10.1098/rstb.1985.0178; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GARCIABELLIDO A, 1969, J EXP ZOOL, V170, P61, DOI 10.1002/jez.1401700106; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN SM, 1975, ROUX ARCH DEVEL BIOL, V177, P61; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; Hardie R.C., 1985, Progress in Sensory Physiology, V5, P1; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HYDE CAT, 1972, J EMBRYOL EXP MORPH, V27, P367; INGHAM PW, 1985, GENETICS, V111, P463; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; Jan YN, 1992, CURR OPIN GENET DEV, V2, P608, DOI 10.1016/S0959-437X(05)80180-7; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; LEBOVITZ RM, 1986, DEV BIOL, V117, P663, DOI 10.1016/0012-1606(86)90335-0; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MELAMED J, 1975, J ULTRA MOL STRUCT R, V51, P79, DOI 10.1016/S0022-5320(75)80010-4; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; MOSES K, 1989, NATURE, V340, P531, DOI 10.1038/340531a0; MOSES K, 1991, GENE DEV, V5, P583, DOI 10.1101/gad.5.4.583; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NOWEL MS, 1980, J EMBRYOL EXP MORPH, V60, P329; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PEIFER M, 1992, TRENDS GENET, V8, P243, DOI 10.1016/0168-9525(92)90394-J; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SCHALLER HC, 1981, P NATL ACAD SCI-BIOL, V78, P7000, DOI 10.1073/pnas.78.11.7000; SHELTON PMJ, 1974, J EMBRYOL EXP MORPH, V32, P337; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TASHIRO S, 1993, GENE, V124, P183; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; WHITE RH, 1961, J EXP ZOOL, V148, P223, DOI 10.1002/jez.1401480305; WHITE RH, 1963, J EXP ZOOL, V152, P139, DOI 10.1002/jez.1401520204; Wieschaus E., 1986, P199; WOLFF T, 1991, DEVELOPMENT, V113, P841; XU T, 1993, DEVELOPMENT, V117, P1223; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	62	353	369	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 3	1993	75	5					927	938		10.1016/0092-8674(93)90536-Y	http://dx.doi.org/10.1016/0092-8674(93)90536-Y			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252628	Bronze			2022-12-28	WOS:A1993MK96600012
J	DEHAY, C; GIROUD, P; BERLAND, M; SMART, I; KENNEDY, H				DEHAY, C; GIROUD, P; BERLAND, M; SMART, I; KENNEDY, H			MODULATION OF THE CELL-CYCLE CONTRIBUTES TO THE PARCELLATION OF THE PRIMATE VISUAL-CORTEX	NATURE			English	Article							CORTICAL AREAS; NEOCORTEX; NEURONS; MONKEY; SPECIFICATION; BRAIN; RAT	AN as-vet unresolved issue in developmental neurobiology is whether the discrete areas that form the mammalian cortex emerge from a uniform cortical plate or whether they are already specified in the germinal zone1,2. A feature of the primate striate cortex is that the number of neurons per unit area is twice that of anywhere else in the cerebral cortex3. Here we take advantage of this unique structural feature to investigate whether the extra striate cortical cells are due to increased neuron production during neurogenesis. We labelled precursors undergoing terminal cell division with H-3-thymidine and allowed them to migrate to the cortical plate. Cell counts revealed that their rate of production in the germinal zone of striate cortex is higher than in that giving rise to extrastriate cortex. Also, we used H-3-thymidine pulse injections to investigate cell cycle dynamics and found that this phase of increased production of striate cortical cells is associated with changes in the parameters of the cell cycle. These results show that cortical area identity is at least partially determined at the level of the ventricular zone.	INSERM,U371,18 AVE DOYEN LEPINE,F-69500 BRON,FRANCE; HOP CLAUDE BERNARD,FAC MED LYON NORD,SERV GYNECOL & OBSTET,F-69600 OULLINS,FRANCE; UNIV DUNDEE,DUNDEE DD1 4HN,SCOTLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Dundee			Dehay, Colette/H-4437-2014; Giroud, Pascale/B-9313-2013; Kennedy, Henry/B-9636-2013	Dehay, Colette/0000-0002-5196-1464; Kennedy, Henry/0000-0002-2796-7663				ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; ARIMATSU Y, 1992, P NATL ACAD SCI USA, V89, P8879, DOI 10.1073/pnas.89.19.8879; BARBE MF, 1991, J NEUROSCI, V11, P519; BISCONTE JC, 1975, EXP BRAIN RES, V22, P37; COHENTANNOUDJI M, 1992, THESIS PARIS U; DEHAY C, 1989, NATURE, V337, P265, DOI 10.1038/337265a0; FERRI RT, 1993, CEREB CORTEX, V3, P187, DOI 10.1093/cercor/3.3.187; FINLAY BL, 1983, SCIENCE, V219, P1349, DOI 10.1126/science.6828866; JOHNSTON JG, 1989, P NATL ACAD SCI USA, V86, P1066, DOI 10.1073/pnas.86.3.1066; KENNEDY H, 1993, CEREB CORTEX, V3, P171, DOI 10.1093/cercor/3.3.171; Korr H, 1980, Adv Anat Embryol Cell Biol, V61, P1; KOSTOVIC I, 1984, J NEUROSCI, V4, P25; LASKEY RA, 1989, SCIENCE, V246, P609, DOI 10.1126/science.2683076; MACAULEY A, 1993, DEVELOPMENT, V117, P873; OLEARY DDM, 1989, J NEUROSCI, V9, P2230; OLEARY DDM, 1989, TRENDS NEUROSCI, V12, P400, DOI 10.1016/0166-2236(89)90080-5; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; RAKIC P, 1976, EXPL BRAINR ES S, V1, P439; ROCKEL AJ, 1980, BRAIN, V103, P221, DOI 10.1093/brain/103.2.221; SCHLAGGAR BL, 1991, SCIENCE, V252, P1556, DOI 10.1126/science.2047863; SCHULTZE B, 1981, CELL TISSUE KINET, V14, P309, DOI 10.1111/j.1365-2184.1981.tb00535.x; TAKAHASHI T, 1993, J NEUROSCI, V13, P820; WAECHTER RV, 1972, BRAIN RES, V46, P235, DOI 10.1016/0006-8993(72)90018-2; WILLIAMS R W, 1987, Society for Neuroscience Abstracts, V13, P1044	26	122	122	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 2	1993	366	6454					464	466		10.1038/366464a0	http://dx.doi.org/10.1038/366464a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK098	8247154				2022-12-28	WOS:A1993MK09800064
J	GUYATT, GH; SACKETT, DL; COOK, DJ				GUYATT, GH; SACKETT, DL; COOK, DJ			USERS GUIDES TO THE MEDICAL LITERATURE .2. HOW TO USE AN ARTICLE ABOUT THERAPY OR PREVENTION .A. ARE THE RESULTS OF THE STUDY VALID	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEVERE LUPUS NEPHRITIS; CONTROLLED TRIAL; CLINICAL-TRIALS; PLASMAPHERESIS; RISK		MCMASTER UNIV, DEPT MED, HAMILTON L8S 4L8, ONTARIO, CANADA; MCMASTER UNIV, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON L8S 4L8, ONTARIO, CANADA	McMaster University; McMaster University								ASHER WL, 1973, AM J CLIN NUTR, V26, P211, DOI 10.1093/ajcn/26.2.211; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; CARETTE S, 1991, NEW ENGL J MED, V325, P1002, DOI 10.1056/NEJM199110033251405; CHALMERS TC, 1983, NEW ENGL J MED, V309, P1358, DOI 10.1056/NEJM198312013092204; COLDITZ GA, 1989, STAT MED, V8, P441, DOI 10.1002/sim.4780080408; EMERSON JD, 1990, CONTROL CLIN TRIALS, V11, P339, DOI 10.1016/0197-2456(90)90175-2; FULLER R, 1983, J CHRON DIS, V36, P161, DOI 10.1016/0021-9681(83)90090-5; GUYATT GH, 1984, THORAX, V39, P818, DOI 10.1136/thx.39.11.818; HAYNES RB, 1987, JAMA-J AM MED ASSOC, V257, P2043, DOI 10.1001/jama.257.15.2043; HOGARTY GE, 1973, ARCH GEN PSYCHIAT, V28, P54; HORWITZ RI, 1990, LANCET, V336, P542, DOI 10.1016/0140-6736(90)92095-Y; LEVEY AS, 1992, ANN INTERN MED, V116, P114, DOI 10.7326/0003-4819-116-2-114; LEWIS EJ, 1992, NEW ENGL J MED, V326, P1373, DOI 10.1056/NEJM199205213262101; MILLER FW, 1992, NEW ENGL J MED, V326, P1380, DOI 10.1056/NEJM199205213262102; OXMAN AD, 1993, JAMA-J AM MED ASSOC, V270, P2093; PIZZO PA, 1983, J PEDIATR-US, V102, P125, DOI 10.1016/S0022-3476(83)80310-2; POHL MA, 1991, ANN INTERN MED, V114, P924, DOI 10.7326/0003-4819-114-11-924; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SACKS HS, 1983, AM J MED, V309, P1353; 1980, NEW ENGL J MED, V303, P1038	20	782	812	1	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1993	270	21					2598	2601		10.1001/jama.270.21.2598	http://dx.doi.org/10.1001/jama.270.21.2598			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ266	8230645				2022-12-28	WOS:A1993MJ26600028
J	LI, E; BEARD, C; JAENISCH, R				LI, E; BEARD, C; JAENISCH, R			ROLE FOR DNA METHYLATION IN GENOMIC IMPRINTING	NATURE			English	Article							DETERMINES METHYLATION; TRANSGENIC MICE; GENE; GAMETOGENESIS; EMBRYOGENESIS; EXPRESSION; RNA	THE paternal and maternal genomes are not equivalent and both are required for mammalian development1,2. The difference between the parental genomes is believed to be due to gamete-specific differential modification, a process known as genomic imprinting. The study of transgene methylation has shown that methylation patterns can be inherited in a parent-of-origin-specific manner3-7, suggesting that DNA methylation may play a role in genomic imprinting. The functional significance of DNA methylation in genomic imprinting was strengthened by the recent finding that CpG islands (or sites) in three imprinted genes, H19, insulin-like growth factor 2 (Igf-2), and Igf-2 receptor (Igf-2r), are differentially methylated depending on their parental origin8-12. We have examined the expression of these three imprinted genes in mutant mice that are deficient in DNA methyltransferase activity13. We report here that expression of all three genes was affected in mutant embryos: the normally silent paternal allele of the H19 gene was activated, whereas the normally active paternal allele of die Igf-2 gene and the active maternal allele of the Igf-2r gene were repressed. Our results demonstrate that a normal level of DNA methylation is required for controlling differential expression of the paternal and maternal alleles of imprinted genes.	MIT,WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)			Hu, Ruogu/B-2203-2008	Edsall, Lee Elizabeth/0000-0002-0326-2829				BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHAILLET JR, 1991, CELL, V66, P77, DOI 10.1016/0092-8674(91)90140-T; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; HADCHOUEL M, 1987, NATURE, V329, P454, DOI 10.1038/329454a0; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MCGRATH J, 1984, CELL, V37, P179, DOI 10.1016/0092-8674(84)90313-1; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; SAPIENZA C, 1987, NATURE, V328, P251, DOI 10.1038/328251a0; SASAKI H, 1991, DEVELOPMENT, V111, P573; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; SURANI MAH, 1984, NATURE, V308, P548, DOI 10.1038/308548a0; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8	21	1718	1779	4	190	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 25	1993	366	6453					362	365		10.1038/366362a0	http://dx.doi.org/10.1038/366362a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ705	8247133				2022-12-28	WOS:A1993MJ70500054
J	LITTLE, DN				LITTLE, DN			THE HYMN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1993	270	20					2408	2408						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG671	8230605				2022-12-28	WOS:A1993MG67100001
J	KANE, DJ; SARAFIAN, TA; ANTON, R; HAHN, H; GRALLA, EB; VALENTINE, JS; ORD, T; BREDESEN, DE				KANE, DJ; SARAFIAN, TA; ANTON, R; HAHN, H; GRALLA, EB; VALENTINE, JS; ORD, T; BREDESEN, DE			BCL-2 INHIBITION OF NEURAL DEATH - DECREASED GENERATION OF REACTIVE OXYGEN SPECIES	SCIENCE			English	Article							MITOCHONDRIAL GLUTATHIONE; RAT HEPATOCYTES; TOXICITY; CELLS; PROLIFERATION; MECHANISM; ASSAY	The proto-oncogene bcl-2 inhibits apoptotic and necrotic neural cell death. Expression of Bcl-2 in the GT1-7 neural cell line prevented death as a result of glutathione depletion. Intracellular reactive oxygen species and lipid peroxides rose rapidly in control cells depleted of glutathione, whereas cells expressing Bcl-2 displayed a blunted increase and complete survival. Modulation of the increase in reactive oxygen species influenced the degree of cell death. Yeast mutants null for superoxide dismutase were partially rescued by expression of Bcl-2. Thus, Bcl-2 prevents cell death by decreasing the net cellular generation of reactive oxygen species.	UNIV CALIF LOS ANGELES,BRAIN RES INST,DEPT NEUROL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT PATHOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Örd, Tõnis/G-8113-2012; Valentine, Joan S/B-6665-2008	Örd, Tõnis/0000-0001-8778-2508; Valentine, Joan S/0000-0002-7174-925X	NIGMS NIH HHS [GM 28222] Funding Source: Medline; NINDS NIH HHS [NS27812] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS027812] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; GRIFFITH OW, 1985, P NATL ACAD SCI USA, V82, P4668, DOI 10.1073/pnas.82.14.4668; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KANE D, UNPUB; KILBOURN RG, 1990, BIOCHEM BIOPH RES CO, V172, P1132, DOI 10.1016/0006-291X(90)91565-A; KU RH, 1986, ARCH BIOCHEM BIOPHYS, V247, P183, DOI 10.1016/0003-9861(86)90547-3; MAH SP, 1993, J NEUROCHEM, V60, P1183, DOI 10.1111/j.1471-4159.1993.tb03275.x; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MEREDITH J, 1982, J BIOL CHEM, V257, P3747; MOREL I, 1992, FREE RADICAL BIO MED, V13, P499, DOI 10.1016/0891-5849(92)90144-6; RICHARDS WL, 1985, EXP CELL RES, V159, P235, DOI 10.1016/S0014-4827(85)80052-5; ROSENKRANZ AR, 1992, J IMMUNOL METHODS, V156, P39, DOI 10.1016/0022-1759(92)90008-H; SHRIEVE DC, 1988, J BIOL CHEM, V263, P14107; STARKE PE, 1985, J BIOL CHEM, V260, P86; YAGI K, 1976, BIOCHEM MED METAB B, V15, P212, DOI 10.1016/0006-2944(76)90049-1; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	20	1644	1685	2	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1274	1277		10.1126/science.8235659	http://dx.doi.org/10.1126/science.8235659			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	8235659				2022-12-28	WOS:A1993MH32400042
J	ANNAS, GJ				ANNAS, GJ			PRIVACY RULES FOR DNA DATA-BANKS - PROTECTING CODED FUTURE DIARIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GENETICS	In privacy terms, genetic information is like medical information. But the information contained in the DNA molecule itself is more sensitive because it contains an individual's probabilistic ''future diary,'' is written in a code that has only partially been broken, and contains information about an individual's parents, siblings, and children. Current rules for protecting the privacy of medical information cannot protect either genetic information or identifiable DNA samples stored in DNA databanks. A review of the legal and public policy rationales for protecting genetic privacy suggests that specific enforceable privacy rules for DNA databanks are needed. Four preliminary rules are proposed to govern the creation of DNA databanks, the collection of DNA samples for storage, limits on the use of information derived from the samples, and continuing obligations to those whose DNA samples are in the databanks.	BOSTON UNIV,SCH PUBL HLTH,BOSTON,MA 02118	Boston University	ANNAS, GJ (corresponding author), BOSTON UNIV,SCH MED,DEPT HLTH LAW,80 E CONCORD ST,BOSTON,MA 02118, USA.			Annas, George/0000-0001-5836-7831				ANDREWS L. B., 1990, GENETIC SCREENING NE, P217; ANNAS GJ, 1992, NEW ENGL J MED, V326, P1641, DOI 10.1056/NEJM199206113262418; ANNAS GJ, 1992, NEW ENGL J MED, V327, P651, DOI 10.1056/NEJM199208273270920; ANNAS GJ, 1992, GENE MAPPING USING L; [Anonymous], 1992, DNA TECHNOLOGY FOREN; BENNETT CJ, 1969, REGULATING PRIVACY D; CASKEY CT, 1993, JAMA-J AM MED ASSOC, V269, P1986, DOI 10.1001/jama.269.15.1986; DEGORGEY A, 1990, AM J LAW MED, V16, P381; Flaherty D, 1989, PROTECTING PRIVACY S; GLANTZ LH, 1989, AM J PUBLIC HEALTH, V79, P1427, DOI 10.2105/AJPH.79.10.1427; HARPER PS, 1993, LANCET, V341, P224, DOI 10.1016/0140-6736(93)90080-Z; JUENGST ET, 1991, JAMA-J AM MED ASSOC, V266, P1835, DOI 10.1001/jama.266.13.1835; Miller AR., 1968, MICH LAW REV, V67, P1091; NOBLES K, 1992, SOUTHERN CALIF LAW R, V65, P2081; PROCTOR R, 1987, RACIAL HYGIENE MED N; Shapiro E Donald, 1990, Clevel State Law Rev, V38, P455; SOLZHENITSYN A, 1969, CANCER WARD; Westin Alan F, 1967, PRIVACY FREEDOM, P7; Wilker Nachama L., 1992, P141; YATES JRW, 1989, J MED GENET, V26, P245, DOI 10.1136/jmg.26.4.245; 1991, JAMA-J AM MED ASSOC, V266, P1827; 1977, PERSONAL PRIVACY INF; 1992, ADV GENETIC INFORMAT; 1986, AM J HUM GENET, V42, P781; 1992, GENETIC TESTING PRIV	25	126	127	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1993	270	19					2346	2350		10.1001/jama.270.19.2346	http://dx.doi.org/10.1001/jama.270.19.2346			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MF993	8230598				2022-12-28	WOS:A1993MF99300030
J	BREO, DL				BREO, DL			RESEARCHERS LUPSKI AND CHANCE STUDY A BAFFLING GENETIC-DISEASE - THEIR OWN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; LUPSKI JR, 1993, NEW ENGL J MED, V329, P96	2	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1993	270	19					2374	2375		10.1001/jama.270.19.2374	http://dx.doi.org/10.1001/jama.270.19.2374			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF993	8230603				2022-12-28	WOS:A1993MF99300035
J	MACCOLLIN, M; MOHNEY, T; TROFATTER, J; WERTELECKI, W; RAMESH, V; GUSELLA, J				MACCOLLIN, M; MOHNEY, T; TROFATTER, J; WERTELECKI, W; RAMESH, V; GUSELLA, J			DNA DIAGNOSIS OF NEUROFIBROMATOSIS-2 - ALTERED CODING SEQUENCE OF THE MERLIN TUMOR-SUPPRESSOR IN AN EXTENDED PEDIGREE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BILATERAL ACOUSTIC NEUROFIBROMATOSIS; TYPE-2 NEUROFIBROMATOSIS; UNITED-KINGDOM; CHROMOSOME-22; DISEASE; SCHWANNOMAS; DELETIONS; MUTATIONS; MARKERS; LINKAGE	Objective.-To define the DNA mutation causing neurofibromatosis 2 (NF2), a severe genetic disorder involving the development of multiple nervous system tumors in adulthood, in a large, well-studied NF2 pedigree previously used to chromosomally map and to isolate the disease gene. Design.-Single-strand conformational polymorphism (SSCP) and DNA sequence analysis of the NF2 gene amplified from affected and unaffected family members. Participants.-Affected, unaffected, and at-risk members of a large pedigree segregating NF2, an autosomal dominant disorder caused by inactivation of the merlin tumor suppressor encoded in chromosome band 22q12. Results.-A DNA alteration in the merlin coding sequence caused a shift on SSCP gels that was characteristic of the disease chromosome in this NF2 pedigree, being transmitted with the disorder, present only in affected members of the pedigree, absent in unaffected members of the family, and absent from 158 unrelated individuals. The alteration caused substitution of a tyrosine for an asparagine at position 220 of the merlin protein, in a region highly conserved in closely related members of the family of cytoskeletal-associated proteins. The DNA change could also be detected by restriction enzyme digestion with Rsa I. Conclusion.-Current practice dictates screening of all those ''at risk'' for NF2 with magnetic resonance imaging, but the frequency and duration of screening are problematic because of the variable course of the disease. The identification of a DNA alteration in the NF2 gene will permit predictive molecular testing of individuals at risk in this specific family, sparing the expense and emotional burden of protracted screening programs. This information, by providing diagnostic certainty, should also reduce psychological and financial burdens and improve medical care for affected family members. A similar approach to defining the underlying lesion and developing a predictive test is applicable in any documented NF2 family.	MASSACHUSETTS GEN HOSP,MOLEC NEUROGENET UNIT,BOSTON,MA 02129; UNIV SO ALABAMA,DEPT MED GENET,MOBILE,AL 36688	Harvard University; Massachusetts General Hospital; University of South Alabama					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024279] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24279] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; BIJLSMA EK, 1992, GENE CHROMOSOME CANC, V5, P201, DOI 10.1002/gcc.2870050305; COUTURIER J, 1990, CANCER GENET CYTOGEN, V45, P55, DOI 10.1016/0165-4608(90)90066-J; EVANS DGR, 1992, J MED GENET, V29, P847, DOI 10.1136/jmg.29.12.847; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; FIEDLER W, 1991, GENOMICS, V10, P786, DOI 10.1016/0888-7543(91)90464-P; FONTAINE B, 1991, ANN NEUROL, V29, P183, DOI 10.1002/ana.410290211; FONTAINE B, 1991, GENOMICS, V10, P280, DOI 10.1016/0888-7543(91)90513-E; GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919; HARPER PS, 1990, LANCET, V335, P1205, DOI 10.1016/0140-6736(90)92713-R; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; MULVIHILL JJ, 1990, ANN INTERN MED, V113, P39, DOI 10.7326/0003-4819-113-1-39; NAROD SA, 1992, AM J HUM GENET, V51, P486; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Park James K., 1992, Human Mutation, V1, P293, DOI 10.1002/humu.1380010405; ROULEAU GA, 1990, AM J HUM GENET, V46, P323; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; ROULEAU GA, 1987, NATURE, V329, P246, DOI 10.1038/329246a0; SEIZINGER BR, 1986, NATURE, V322, P644, DOI 10.1038/322644a0; SEIZINGER BR, 1987, SCIENCE, V236, P317, DOI 10.1126/science.3105060; SEIZINGER BR, 1987, P NATL ACAD SCI USA, V84, P5419, DOI 10.1073/pnas.84.15.5419; TCHERNIA G, 1981, J CLIN INVEST, V68, P454, DOI 10.1172/JCI110275; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; WERTELECKI W, 1988, NEW ENGL J MED, V319, P278, DOI 10.1056/NEJM198808043190505; WIGGINS S, 1992, NEW ENGL J MED, V327, P1401, DOI 10.1056/NEJM199211123272001; WOLFF RK, 1992, AM J HUM GENET, V51, P478; 1988, ARCH NEUROL-CHICAGO, V45, P515	28	57	59	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1993	270	19					2316	2320		10.1001/jama.270.19.2316	http://dx.doi.org/10.1001/jama.270.19.2316			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF993	8230593				2022-12-28	WOS:A1993MF99300025
J	RASOOLY, A; NOVICK, RP				RASOOLY, A; NOVICK, RP			REPLICATION-SPECIFIC INACTIVATION OF THE PT181 PLASMID INITIATOR PROTEIN	SCIENCE			English	Article							ORIGIN; INVITRO	Replication of the Staphylococcus aureus plasmid pT181, which occurs by the rolling circle mechanism, is accompanied by the covalent attachment of a almost-equal-to 12-residue oligodeoxynucleotide to one subunit of the dimeric plasmid-coded initiator protein, RepC. This oligonucleotide represents the plasmid sequence immediately 3' to the initiating nick site. The resulting heterodimeric protein lacks the topoisomerase and replication activities of unmodified RepC, suggesting that the regulation of plasmid DNA replication requires post-replicational inactivation of the initiator protein as well as control of its synthesis.	PUBL HLTH RES INST CITY NEW YORK INC,DEPT PLASMID BIOL,NEW YORK,NY 10016				Rasooly, Avraham/AAH-4518-2021	Novick, richard/0000-0003-4418-7893	NIGMS NIH HHS [GM14372] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM014372] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARGONETTI J, 1990, MOL BIOL STAPHYLOCOC, P283; GENNARO ML, 1989, J MOL BIOL, V205, P355, DOI 10.1016/0022-2836(89)90346-X; KHAN SA, 1981, P NATL ACAD SCI-BIOL, V78, P4902, DOI 10.1073/pnas.78.8.4902; KOEPSEL RR, 1985, J BIOL CHEM, V260, P8571; KOEPSEL RR, 1985, P NATL ACAD SCI USA, V82, P6845, DOI 10.1073/pnas.82.20.6845; KUMAR CC, 1985, P NATL ACAD SCI USA, V82, P638, DOI 10.1073/pnas.82.3.638; MANCHCITRON J, 1986, PLASMID, V108, pB16; NOIROT P, 1990, P NATL ACAD SCI USA, V87, P8560, DOI 10.1073/pnas.87.21.8560; NOVICK RP, 1984, EMBO J, V3, P2399, DOI 10.1002/j.1460-2075.1984.tb02146.x; NOVICK RP, UNPUB; THOMAS CD, 1990, J BIOL CHEM, V265, P5519	11	57	57	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1048	1050		10.1126/science.8235621	http://dx.doi.org/10.1126/science.8235621			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	8235621				2022-12-28	WOS:A1993MG18700033
J	KOHNER, EM				KOHNER, EM			FORTNIGHTLY REVIEW - DIABETIC-RETINOPATHY	BRITISH MEDICAL JOURNAL			English	Article							RETINAL BLOOD-FLOW; GLYCEMIC CONTROL; PERICYTES; GROWTH; GLUCOSE; MUSCLE; CELLS				KOHNER, EM (corresponding author), HAMMERSMITH HOSP,LONDON W12 0HS,ENGLAND.							[Anonymous], 1987, Int Ophthalmol Clin, V27, P265; [Anonymous], 1976, AM J OPHTHALMOL, V81, P383; BAUDOIN C, 1989, DIABETES, V38, P491; BRINCHMANNHANSEN O, 1988, ARCH OPHTHALMOL-CHIC, V106, P1242; CAGLIERO E, 1988, J CLIN INVEST, V82, P735, DOI 10.1172/JCI113655; DAVIES E G, 1989, Eye (London), V3, P764; DELARUBIA G, 1992, DIABETES, V41, P1533, DOI 10.2337/diabetes.41.12.1533; ENGERMAN RL, 1984, DIABETES, V33, P97, DOI 10.2337/diabetes.33.1.97; ENGLER CB, 1993, EUR J OPHTHALMOL, V3, P107; GRUNWALD JE, 1990, DIABETES, V39, P602, DOI 10.2337/diabetes.39.5.602; HANSEN AP, 1970, J CLIN INVEST, V49, P1467, DOI 10.1172/JCI106364; HERMAN IM, 1985, J CELL BIOL, V101, P43, DOI 10.1083/jcb.101.1.43; HYER SL, 1988, DIABETIC MED, V5, P356, DOI 10.1111/j.1464-5491.1988.tb01005.x; JOB D, 1976, DIABETES, V25, P463, DOI 10.2337/diab.25.5.463; KADOR PF, 1990, ARCH OPHTHALMOL-CHIC, V108, P1301, DOI 10.1001/archopht.1990.01070110117035; KLEIN BEK, 1987, DIABETES CARE, V10, P273, DOI 10.2337/diacare.10.3.273; Kohner EM, 1992, SCREENING DIABETIC R; LORENZI M, 1991, DIABETES METAB REV, V8, P85; ORLIDGE A, 1987, J CELL BIOL, V105, P1455, DOI 10.1083/jcb.105.3.1455; PATEL V, 1992, BMJ-BRIT MED J, V305, P678, DOI 10.1136/bmj.305.6855.678; PRESS M, 1984, NEW ENGL J MED, V310, P810, DOI 10.1056/NEJM198403293101302; Prospective U. K., 1991, DIABETOLOGIA, V34, P877; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; ROY S, 1991, DIABETES S1, V40, P91; SHARP PS, 1987, DIABETOLOGIA, V33, P199; SHOTLIFF KP, 1993, DIABETOLOGIA SA, V36, P72; SULLIVAN P, 1990, DIABETIC MED, V7, P788, DOI 10.1111/j.1464-5491.1990.tb01493.x; SULLIVAN PM, 1990, INVEST OPHTH VIS SCI, V31, P2041; TOOKE JE, 1986, CLIN SCI, V70, P119, DOI 10.1042/cs0700119; WHO/IDF Europe, 1990, DIABETIC MED, V7, P360; 1983, DIABETES, V32, P1010; 1984, NEW ENGL J MED, V311, P365; 1985, ARCH OPHTHALMOL VIS, V103, P1798	33	81	82	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1993	307	6913					1195	1199		10.1136/bmj.307.6913.1195	http://dx.doi.org/10.1136/bmj.307.6913.1195			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF824	8251848	Bronze, Green Published			2022-12-28	WOS:A1993MF82400029
J	ENGLANDER, SW				ENGLANDER, SW			IN PURSUIT OF PROTEIN-FOLDING	SCIENCE			English	Editorial Material							INTERMEDIATE				ENGLANDER, SW (corresponding author), UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,JOHNSON RES FDN,PHILADELPHIA,PA 19104, USA.				NIGMS NIH HHS [R01 GM031847] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031847] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN RL, 1993, CURR OPIN STRUC BIOL, V3, P84, DOI 10.1016/0959-440X(93)90206-Z; ELOVE GA, 1991, ACS SYM SER, V470, P50; ENGLANDER SW, 1992, ANNU REV BIOPH BIOM, V21, P243, DOI 10.1146/annurev.biophys.21.1.243; ENGLANDER SW, 1984, Q REV BIOPHYS, V16, P521; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; JENNINGS PA, 1993, SCIENCE, V262, P892, DOI 10.1126/science.8235610; MAYO SL, 1993, SCIENCE, V262, P873, DOI 10.1126/science.8235609; MIRANKER A, 1993, SCIENCE, V262, P896, DOI 10.1126/science.8235611; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0	10	29	29	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 5	1993	262	5135					848	849		10.1126/science.8235606	http://dx.doi.org/10.1126/science.8235606			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	8235606	Green Accepted			2022-12-28	WOS:A1993MF43800023
J	MIRANKER, A; ROBINSON, CV; RADFORD, SE; APLIN, RT; DOBSON, CM				MIRANKER, A; ROBINSON, CV; RADFORD, SE; APLIN, RT; DOBSON, CM			DETECTION OF TRANSIENT PROTEIN-FOLDING POPULATIONS BY MASS-SPECTROMETRY	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; HYDROGEN-EXCHANGE BEHAVIOR; EGG-WHITE LYSOZYME; STRUCTURAL CHARACTERIZATION; RIBONUCLEASE-A; CYTOCHROME-C; NMR; INTERMEDIATE; PROTECTION; ELEMENTS	Hydrogen-deuterium exchange measurements are becoming increasingly important in studies of the dynamics of protein molecules and, particularly, of their folding behavior. Electrospray ionization mass spectrometry (ESI-MS) has been used to obtain the distribution of masses within a population of protein molecules that had undergone hydrogen exchange in solution. This information is complementary to that from nuclear magnetic resonance spectroscopy (NMR) experiments, which measure the average occupancy of individual sites over the distribution of protein molecules. In experiments with hen lysozyme, a combination of ESI-MS and NMR was used to distinguish between alternative mechanisms of hydrogen exchange, providing insight into the nature and populations of transient folding intermediates. These results have helped to detail the pathways available to a protein during refolding.	UNIV OXFORD, NEW CHEM LAB, OXFORD OX1 3QT, ENGLAND; UNIV OXFORD, DYSON PERRINS LAB, OXFORD OX1 3QY, ENGLAND; UNIV OXFORD, OXFORD CTR MOLEC SCI, OXFORD OX1 3QY, ENGLAND	University of Oxford; University of Oxford; University of Oxford	MIRANKER, A (corresponding author), UNIV OXFORD, OXFORD CTR MOLEC SCI, S PARKS RD, OXFORD OX1 3QT, ENGLAND.			robinson, carol/0000-0001-7829-5505; Radford, Sheena/0000-0002-3079-8039				BALDWIN RL, 1993, CURR OPIN STRUC BIOL, V3, P84, DOI 10.1016/0959-440X(93)90206-Z; BRIGGS MS, 1992, P NATL ACAD SCI USA, V89, P2017, DOI 10.1073/pnas.89.6.2017; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; DELEPIERRE M, 1987, J MOL BIOL, V197, P111, DOI 10.1016/0022-2836(87)90613-9; DOBSON CM, 1984, BIOCHEMISTRY-US, V23, P4267, DOI 10.1021/bi00314a001; ENGLANDER SW, 1992, ANNU REV BIOPH BIOM, V21, P243, DOI 10.1146/annurev.biophys.21.1.243; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; Imoto T., 1972, ENZYMES, V7, P665; ITZHAKI L, UNPUB; JENG MF, 1991, J MOL BIOL, V221, P1045, DOI 10.1016/0022-2836(91)80191-V; KATO S, 1982, BIOCHEMISTRY-US, V21, P38, DOI 10.1021/bi00530a007; KATTA V, 1991, RAPID COMMUN MASS SP, V5, P214, DOI 10.1002/rcm.1290050415; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KOSSIAKOFF AA, 1991, BIOCHEMISTRY-US, V30, P1211, DOI 10.1021/bi00219a008; LU JR, 1992, BIOCHEMISTRY-US, V31, P4749, DOI 10.1021/bi00135a002; MCCAMMON JA, 1976, NATURE, V262, P325, DOI 10.1038/262325a0; MCEWEN CN, 1992, RAPID COMMUN MASS SP, V6, P173, DOI 10.1002/rcm.1290060304; MIRANKER A, 1991, NATURE, V349, P633, DOI 10.1038/349633a0; PEDERSEN TG, 1991, J MOL BIOL, V218, P413, DOI 10.1016/0022-2836(91)90722-I; POST CB, 1989, PROTEINS, V5, P337, DOI 10.1002/prot.340050409; RADFORD SE, 1992, PROTEINS, V14, P237, DOI 10.1002/prot.340140210; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; RODER H, 1989, METHOD ENZYMOL, V176, P446; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SCHMID FX, 1979, J MOL BIOL, V135, P199, DOI 10.1016/0022-2836(79)90347-4; SEGAWA SI, 1981, BIOPOLYMERS, V20, P1691, DOI 10.1002/bip.1981.360200810; SMITH LJ, 1993, J MOL BIOL, V229, P930, DOI 10.1006/jmbi.1993.1097; SUCKAU D, 1993, P NATL ACAD SCI USA, V90, P790, DOI 10.1073/pnas.90.3.790; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; WOODWARD C, 1982, MOL CELL BIOCHEM, V48, P135, DOI 10.1007/BF00421225; ZHANG YP, 1992, BIOCHEMISTRY-US, V31, P11572, DOI 10.1021/bi00161a041; ZHANG ZQ, 1993, PROTEIN SCI, V2, P522	34	547	552	1	98	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	1993	262	5135					896	900		10.1126/science.8235611	http://dx.doi.org/10.1126/science.8235611			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	8235611				2022-12-28	WOS:A1993MF43800034
J	BLACK, ME				BLACK, ME			LETTER FROM SERBIA AND MONTENEGRO - COLLAPSING HEALTH-CARE IN SERBIA AND MONTENEGRO	BRITISH MEDICAL JOURNAL			English	Article											BLACK, ME (corresponding author), REDBRIDGE & WALTHAM FOREST DIST HLTH AUTHOR,DEPT PUBL HLTH MED,ILFORD IG2 7RL,ENGLAND.							BLACK ME, 1993, BRIT MED J, V306, P1481, DOI 10.1136/bmj.306.6890.1481; DILLNER L, 1993, BRIT MED J, V307, P887; REDMOND T, 1992, MISSION REPORT FEDER; TOSIC O, 1992, LANCET, V340, P295; WAREING R, 1993, REPORT PROVISION HLT; 1992, RESOLUTIONS 757 820	6	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1993	307	6912					1135	1137		10.1136/bmj.307.6912.1135	http://dx.doi.org/10.1136/bmj.307.6912.1135			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME918	8251816	Green Published, Bronze			2022-12-28	WOS:A1993ME91800026
J	LAMB, TM; KNECHT, AK; SMITH, WC; STACHEL, SE; ECONOMIDES, AN; STAHL, N; YANCOPOLOUS, GD; HARLAND, RM				LAMB, TM; KNECHT, AK; SMITH, WC; STACHEL, SE; ECONOMIDES, AN; STAHL, N; YANCOPOLOUS, GD; HARLAND, RM			NEURAL INDUCTION BY THE SECRETED POLYPEPTIDE NOGGIN	SCIENCE			English	Article							XENOPUS-LAEVIS; NERVOUS-SYSTEM; ANTEROPOSTERIOR AXIS; MESODERM INDUCTION; EARLY RESPONSE; MESSENGER-RNA; EXPRESSION; EMBRYOS; GENE; ORGANIZER	The Spemann organizer induces neural tissue from dorsal ectoderm and dorsalizes lateral and ventral mesoderm in Xenopus. The secreted factor noggin, which is expressed in the organizer, can mimic the dorsalizing signal of the organizer. Data are presented showing that noggin directly induces neural tissue, that it induces neural tissue in the absence of dorsal mesoderm, and that it acts at the appropriate stage to be an endogenous neural inducing signal. Noggin induces cement glands and anterior brain markers, but not hind-brain or spinal cord markers. Thus, noggin has the expression pattern and activity expected of an endogenous neural inducer.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,401 BARKER HALL,BERKELEY,CA 94720; REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591	University of California System; University of California Berkeley; Regeneron				Economides, Aris/0000-0002-6508-8942				ALTABA ARI, 1990, DEVELOPMENT, V108, P595; AMAYA E, 1993, DEVELOPMENT, V118, P477; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; Ausubel F.M., 1989, CURRENT PROTOCOLS MO, V2; BALAK K, 1987, DEV BIOL, V119, P540, DOI 10.1016/0012-1606(87)90057-1; BIEKER JJ, 1992, J HISTOCHEM CYTOCHEM, V40, P1117, DOI 10.1177/40.8.1619277; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; COOKE J, 1987, DEVELOPMENT, V101, P893; DALE L, 1987, DEVELOPMENT, V100, P279; DIXON JE, 1989, DEVELOPMENT, V106, P749; DONIACH T, 1993, J NEUROBIOL, V24, P1256, DOI 10.1002/neu.480241003; DONIACH T, 1992, SCIENCE, V257, P542, DOI 10.1126/science.1636091; GILBERT SF, 1993, MECH DEVELOP, V41, P73, DOI 10.1016/0925-4773(93)90039-Z; GODSAVE SF, 1991, DEVELOPMENT, V111, P523; GOOD PJ, 1989, NUCLEIC ACIDS RES, V17, P8000, DOI 10.1093/nar/17.19.8000; GOOD PJ, 1990, DEV BIOL, V137, P414; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1990, DEVELOPMENT, V108, P173; GRUNZ H, 1989, CELL DIFFER DEV, V28, P211, DOI 10.1016/0922-3371(89)90006-3; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; HAMBRUGER V, 1988, HERITAGE EXPT EMBRYO; HARLAND RM, 1991, METHOD CELL BIOL, V36, P675; HARRIS WA, 1991, NEURON, V6, P499, DOI 10.1016/0896-6273(91)90053-3; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLO.JR, 1991, DEVELOPMENT, V111, P715; HEMMATIBRIVANLOU A, 1990, SCIENCE, V250, P800, DOI 10.1126/science.1978411; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; JONES EA, 1989, DEVELOPMENT, V107, P785; KINTNER CR, 1991, DEVELOPMENT, V113, P1495; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KUSHNER PD, UNPUB; LATTICE LA, 1993, DEVELOPMENT, V117, P263; MCDONALD NQ, 1993, TRENDS BIOCHEM SCI, V18, P208, DOI 10.1016/0968-0004(93)90190-X; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; SARGENT TD, 1986, DEV BIOL, V114, P238, DOI 10.1016/0012-1606(86)90399-4; SERVETNICK M, 1991, DEV BIOL, V147, P73, DOI 10.1016/S0012-1606(05)80008-9; SHARPE CR, 1989, DEVELOPMENT, V107, P701; SHARPE CR, 1990, DEVELOPMENT, V109, P765; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; SIVE HL, 1989, CELL, V58, P171, DOI 10.1016/0092-8674(89)90413-3; SLACK JMW, 1992, DEVELOPMENT, V114, P285; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WW, UNPUB; SOKOL SY, 1993, DEVELOPMENT, V118, P1335; Spemann H., 1938, EMBRYONIC DEV INDUCT; STEWART RM, 1990, DEVELOPMENT, V109, P363; STJOHNSTON D, 1992, CELL, V68, P201; VALENZUELA DM, UNPUB; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WRIGHT CV, 1990, DEVELOPMENT, V1099, P225	57	688	721	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 29	1993	262	5134					713	718		10.1126/science.8235591	http://dx.doi.org/10.1126/science.8235591			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	8235591				2022-12-28	WOS:A1993MD95200033
J	BROX, JI; STAFF, PH; LJUNGGREN, AE; BREVIK, JI				BROX, JI; STAFF, PH; LJUNGGREN, AE; BREVIK, JI			ARTHROSCOPIC SURGERY COMPARED WITH SUPERVISED EXERCISES IN PATIENTS WITH ROTATOR CUFF DISEASE (STAGE-II IMPINGEMENT SYNDROME)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LIGAMENTS; TENDONS	Objective-To compare the effectiveness of arthroscopic surgery, a supervised exercise regimen, and placebo soft laser treatment in patients with rotator cuff disease (stage II impingement syndrome). Design-Randomised clinical trial. Setting-Hospital departments of orthopaedics and of physical medicine and rehabilitation. Patients-125 patients aged 18-66 who had had rotator cuff disease for at least three months and whose condition was resistant to treatment. Interventions-Arthroscopic subacromial decompression performed by two experienced surgeons; exercise regimen over three to six months supervised by one experienced physiotherapist; or 12 sessions of detuned soft laser treatment over six weeks. Main outcome measures-Change in the overall Neer shoulder score (pain during previous week and blinded evaluation of function and range of movement by one clinician) after six months. Results-No differences were found between the three groups in duration of sick leave and daily intake of analgesics. After six months the difference in improvement in overall Neer score between surgery and supervised exercises was 4.0 (95% confidence interval -2 to 11) and 2.0 (-1.4 to 5.4) after adjustment for sex. The condition improved significantly compared with placebo in both groups given the active treatments. Treatment costs were higher for those given surgery (720 Pounds v 390 Pounds). Conclusions-Surgery or a supervised exercise regimen significantly, and equally, improved rotator cuff disease compared with placebo.	ULLEVAL UNIV HOSP, DEPT SOCIAL NETWORKS & HLTH, N-0407 OSLO, NORWAY	University of Oslo	BROX, JI (corresponding author), ULLEVAL UNIV HOSP, DEPT PHYS MED & REHABIL, N-0407 OSLO, NORWAY.		Brox, Jens Ivar/N-1601-2018; Zmistowski, Ben/AAI-7901-2020					[Anonymous], 1990, GUIDELINES ATC CLASS; Bergunnud H., 1988, CLIN ORTHOP RELAT R, V231, P234; BJORKENHEIM JM, 1988, CLIN ORTHOP RELAT R, P148; Bohmer AS, 1984, FYSIOTERAPEUTEN, V51, P192; BYE A, 1991, Tidsskrift for den Norske Laegeforening, V111, P337; Cyriax JH, 1982, TXB ORTHOPAEDIC MED, V1; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; EDELSON JG, 1992, J BONE JOINT SURG BR, V74, P589, DOI 10.1302/0301-620X.74B4.1624522; Ellman H, 1987, Arthroscopy, V3, P173, DOI 10.1016/S0749-8063(87)80061-0; FU FH, 1991, CLIN ORTHOP RELAT R, P162; HARDY DC, 1986, AM J ROENTGENOL, V147, P557, DOI 10.2214/ajr.147.3.557; HERBERTS P, 1981, ACTA ORTHOP SCAND, V52, P299, DOI 10.3109/17453678109050107; JARVHOLM U, 1989, CLIN ORTHOP RELAT R, V245, P102; LEHMAN RC, 1988, CLIN SPORT MED, V7, P309; Lo Y P, 1990, Br J Sports Med, V24, P173; NEER CS, 1970, J BONE JOINT SURG AM, VA 52, P1090, DOI 10.2106/00004623-197052060-00002; NIRSCHL RP, 1987, INSTRUCTIONAL COURSE, V41, P439; OZAKI J, 1988, J BONE JOINT SURG AM, V70A, P1224, DOI 10.2106/00004623-198870080-00015; Ryan B. F., 1985, MINITAB HDB; TIPTON CM, 1975, MED SCI SPORT EXER, V7, P165; WOO SLY, 1982, BIORHEOLOGY, V19, P397	21	194	196	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 9	1993	307	6909					899	903		10.1136/bmj.307.6909.899	http://dx.doi.org/10.1136/bmj.307.6909.899			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB847	8241852	Bronze, Green Published			2022-12-28	WOS:A1993MB84700016
J	PILGER, E; DECRINIS, M; STARK, G; KOCH, G; OBERNOSTERER, A; TISCHLER, R; LAFER, M; DODER, A				PILGER, E; DECRINIS, M; STARK, G; KOCH, G; OBERNOSTERER, A; TISCHLER, R; LAFER, M; DODER, A			THROMBOLYTIC TREATMENT AND BALLOON ANGIOPLASTY IN CHRONIC OCCLUSION OF THE AORTIC BIFURCATION	ANNALS OF INTERNAL MEDICINE			English	Article								Objective: To evaluate nonsurgical alternatives in reopening chronically occluded aortic bifurcation. Design: Uncontrolled randomized study. Setting: University-affiliated referral center for vascular diseases. Patients: Twenty-five of 39 consecutive patients with chronic aortoiliac disease including a totally occluded aortic bifurcation were found to be acceptable candidates for an aortobifemoral prosthetic graft. Intervention: Patients were randomly assigned to receive either streptokinase or urokinase or recombinant tissue-type plasminogen activator (rt-PA). In cases of successful thrombolysis and residual obstructions, subsequent balloon angioplasty was attempted. Prosthetic bypass grafting was done if thrombolytic treatment and balloon angioplasty failed. Results: Complete lysis was achieved in 5 of 25 patients (20%). In 10 (40%) patients, lysis showed residual obstructions, which were reopened mechanically in 8 patients; 2 patients had extra-anatomical bypass grafts. Ten patients (40%) without thrombolysis had surgical aortobifemoral bypass grafts. Overall, recanalization and clinical improvement were achieved in 13 of 25 patients (52%) by thrombolytic therapy and subsequent balloon angioplasty. The recanalization rate did not differ among the different thrombolytic drugs. However, rt-PA therapy resulted in reopening after 4 days of treatment; streptokinase, after 6 days; and urokinase, after 9 days (P < 0.005). No major complications or deaths occurred. Conclusion: Thrombolytic treatment followed by balloon angioplasty may help avoid the need for aortobifemoral prosthetic bypass grafting in more than 50% of patients with chronic aortoiliac disease.			PILGER, E (corresponding author), KARL FRANZENS UNIV, DEPT INTERNAL MED, DIV ANGIOL, AUENBRUGGERPLATZ 15, A-8036 GRAZ, AUSTRIA.							BREWSTER DC, 1991, CIRCULATION, V83, P42; DANIEL WW, 1987, BIOSTATISTICS F ANAL, P531; DERSIMONIAN R, 1982, NEW ENGL J MED, V306, P1332, DOI 10.1056/NEJM198206033062204; DOWNS AR, 1985, COMPLICATIONS VASCUL, P25; HESS M, 1970, JAMA-J AM MED ASSOC, V211, P1169; RAMPLING MW, 1976, CLIN CHIM ACTA, V67, P43, DOI 10.1016/0009-8981(76)90215-1; RUTHERFORD RB, 1986, J VASC SURG, V4, P80; RYLATT DB, 1983, THROMB RES, V31, P767, DOI 10.1016/0049-3848(83)90108-1; SAILER S, 1968, WIEN MED WOCHENSCHR, V118, P1	9	20	22	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1994	120	1					40	44		10.7326/0003-4819-120-1-199401010-00007	http://dx.doi.org/10.7326/0003-4819-120-1-199401010-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP280	8250455				2022-12-28	WOS:A1994MP28000007
J	CLARK, LR				CLARK, LR			JOSHUA KNEW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1993	270	24					2902	2902		10.1001/jama.270.24.2902	http://dx.doi.org/10.1001/jama.270.24.2902			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM119	8254837				2022-12-28	WOS:A1993MM11900002
J	TELZAK, EE; CHIASSON, MA; BEVIER, PJ; STONEBURNER, RL; CASTRO, KG; JAFFE, HW				TELZAK, EE; CHIASSON, MA; BEVIER, PJ; STONEBURNER, RL; CASTRO, KG; JAFFE, HW			HIV-1 SEROCONVERSION IN PATIENTS WITH AND WITHOUT GENITAL ULCER DISEASE - A PROSPECTIVE-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS SEROPOSITIVITY; CHANCROID; SYPHILIS; HERPES GENITALIS	HUMAN-IMMUNODEFICIENCY-VIRUS; SEXUALLY-TRANSMITTED DISEASES; RISK-FACTORS; INFECTION; TRANSMISSION; TYPE-1; MEN; AFRICA; FEMALE; AIDS	Objective: To determine the relative risk for human immunodeficiency virus (HIV-1) seroconversion in patients with and without genital ulcers caused by chancroid, syphilis, and herpes. Design: A prospective cohort study Setting: An inner-city, sexually transmitted disease clinic. Patients: Patients seronegative for HIV-1 with and without genital ulcers who were followed for a minimum of 3 months. Interventions: Questionnaire to obtain data on demographics, sexual behavior, and illicit drug use; testing for HIV-1 at entry and at a minimum of 3 months after entry; medical examination for the presence or absence of genital ulcer disease. Results: Overall, 758 heterosexual men with no history of injection drug use completed the study; HIV-1 seroconversion occurred in 10 of 344 (2.9%; 95% CI, 1.4% to 5.3%) men with a genital ulcer and in 4 of 414 (1%; CI, 0.2% to 2.5%) without a genital ulcer (relative risk, 3.0; P = 0.05). In a multiple logistic regression analysis, those men with chancroid and a new sexually transmitted disease during follow-up each had about three times the risk for HIV-1 seroconversion (P less-than-or-equal-to 0.04). Conclusions: In this group of heterosexual men, chancroid and repeated acquisition of sexually transmitted diseases appeared to facilitate the sexual transmission of HIV-1.	NEW YORK CITY DEPT HLTH, NEW YORK, NY 10013 USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA USA	New York City Department of Health & Mental Hygiene; Centers for Disease Control & Prevention - USA	TELZAK, EE (corresponding author), ALBERT EINSTEIN COLL MED, BRONX LEBANON HOSP CTR, DIV INFECT DIS, 1650 GRAND CONCOURSE, BRONX, NY 10457 USA.		Castro, Kenneth G/P-1882-2018	Castro, Kenneth G/0000-0001-7964-6354	PHS HHS [U64/CCU203312] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CAMERON DW, 1989, LANCET, V2, P403; CHIASSON MA, 1991, AIDS, V5, P1121, DOI 10.1097/00002030-199109000-00011; CHIASSON MA, 1990, AM J EPIDEMIOL, V131, P208, DOI 10.1093/oxfordjournals.aje.a115491; GREENBLATT RM, 1988, AIDS, V2, P47, DOI 10.1097/00002030-198802000-00008; HOLMBERG SD, 1988, JAMA-J AM MED ASSOC, V259, P1048, DOI 10.1001/jama.259.7.1048; KREISS JK, 1989, J INFECT DIS, V160, P380, DOI 10.1093/infdis/160.3.380; MERTENS TE, 1990, AIDS, V4, P57, DOI 10.1097/00002030-199001000-00008; OBERHOFER TR, 1982, J CLIN MICROBIOL, V15, P625, DOI 10.1128/JCM.15.4.625-629.1982; PIOT P, 1988, SCIENCE, V239, P573, DOI 10.1126/science.3277271; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; QUINN TC, 1988, NEW ENGL J MED, V318, P197, DOI 10.1056/NEJM198801283180401; QUINN TC, 1986, SCIENCE, V234, P955, DOI 10.1126/science.3022379; SCHMID GP, 1987, JAMA-J AM MED ASSOC, V258, P3265, DOI 10.1001/jama.258.22.3265; SHELDON WH, 1946, AM J PATHOL, V22, P415; SIMONSEN JN, 1988, NEW ENGL J MED, V319, P274, DOI 10.1056/NEJM198808043190504; STAMM WE, 1988, JAMA-J AM MED ASSOC, V260, P1429, DOI 10.1001/jama.260.10.1429; 1990, 5TH CONC C TEST HUM; 1991, MMWR MORBID MORTAL W, V40, P357; 1991, MMWR MORBID MORTAL W, V40, P369; 1989, MMWR MORBID MORTAL W, V38, P165	20	136	138	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1993	119	12					1181	1186		10.7326/0003-4819-119-12-199312150-00005	http://dx.doi.org/10.7326/0003-4819-119-12-199312150-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM121	8239249				2022-12-28	WOS:A1993MM12100005
J	MILLER, HI; GUNARY, D				MILLER, HI; GUNARY, D			SERIOUS FLAWS IN THE HORIZONTAL APPROACH TO BIOTECHNOLOGY RISK	SCIENCE			English	Editorial Material											MILLER, HI (corresponding author), US FDA,OFF BIOTECHNOL,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.							[Anonymous], 1992, Nature, V356, P1; CRAWLEY MJ, 1993, NATURE, V363, P620, DOI 10.1038/363620a0; FIKSEL J, 1988, NATO ASI SERIES; ISRAEL MA, 1990, SCIENCE, V203, P883; KAREIVA P, 1993, NATURE, V363, P580, DOI 10.1038/363580a0; MELLON M, 1991, GENETIC REVOLUTION S, P60; MILLER HI, IN PRESS BIOTECHNOLO; MOONEY HA, 1990, INTRO GENETICALLY MO, pR19; National Academy of Science Committee on the Introduction of Genetically Engineered Organisms into the Environment, 1987, INTRO RECOMBINANT DN; 1987, 3RD M WORK GROUP PAR; 1989, FIELD TESTING GENETI; 1993, FED REGISTER, V58, P17044	12	13	13	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 3	1993	262	5139					1500	1501		10.1126/science.8248795	http://dx.doi.org/10.1126/science.8248795			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK329	8248795				2022-12-28	WOS:A1993MK32900012
J	SULLENGER, BA; CECH, TR				SULLENGER, BA; CECH, TR			TETHERING RIBOZYMES TO A RETROVIRAL PACKAGING SIGNAL FOR DESTRUCTION OF VIRAL-RNA	SCIENCE			English	Article							FLUORESCENCE INSITU HYBRIDIZATION; CONSTRUCTION; SEQUENCES; SAFE; LINE	Cellular compartmentalization of RNAs is thought to influence their susceptibility to ribozyme cleavage. As a test of this idea, two retroviral vectors-one encoding a hammer-head ribozyme designed to cleave lacZ transcripts and another encoding the lacZ messenger RNA-were coexpressed inside retroviral packaging cells. Because of the retroviral packaging signal, the ribozyme would be expected to colocalize with the lacZ-containing viral genomic RNA but not with the lacZ messenger RNA. The ribozyme was found to reduce the titer of infectious virus containing lacZ by 90 percent, but had no effect on translation of lacZ messenger RNA. These results indicate that sorting gene inhibitors to appropriate intracellular sites may increase their effectiveness.	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder								BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; CARTER KC, 1993, SCIENCE, V259, P1330, DOI 10.1126/science.8446902; CECH TR, 1988, JAMA-J AM MED ASSOC, V260, P3030; CECH TR, 1992, J BIOL CHEM, V267, P17479; COFFIN JM, 1984, RNA TUMOR VIRUSES 1, P261; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; FERAMISCO JJ, 1982, P NATL ACAD SCI USA, V257, P11024; GOFF SP, 1989, RETROVIRUSES DISEASE, P1; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; LAWRENCE JB, 1990, P NATL ACAD SCI USA, V87, P5420, DOI 10.1073/pnas.87.14.5420; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; RAAP AK, 1991, EXP CELL RES, V197, P319, DOI 10.1016/0014-4827(91)90439-2; ROSSI J J, 1992, Current Opinion in Biotechnology, V3, P3, DOI 10.1016/0958-1669(92)90117-2; SANES J, 1985, EMBO J, V5, P3133; SHIH CC, 1988, CELL, V53, P531, DOI 10.1016/0092-8674(88)90569-7; SMITH C, 1993, LEUKEMIA, V7, P310; SULLENGER BA, UNPUB; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901	25	182	231	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 3	1993	262	5139					1566	1569		10.1126/science.8248806	http://dx.doi.org/10.1126/science.8248806			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK329	8248806				2022-12-28	WOS:A1993MK32900039
J	GOLDSTEIN, R				GOLDSTEIN, R			LETTER FROM BOSNIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											GOLDSTEIN, R (corresponding author), CHILDRENS HOSP MED CTR,BOSTON,MA 02115, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 2	1993	329	23					1745	1747		10.1056/NEJM199312023292322	http://dx.doi.org/10.1056/NEJM199312023292322			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ707	8232483				2022-12-28	WOS:A1993MJ70700036
J	WILLICH, SN; LEWIS, M; LOWEL, H; ARNTZ, HR; SCHUBERT, F; SCHRODER, R				WILLICH, SN; LEWIS, M; LOWEL, H; ARNTZ, HR; SCHUBERT, F; SCHRODER, R			PHYSICAL EXERTION AS A TRIGGER OF ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUDDEN CARDIAC DEATH; CIRCADIAN VARIATION; PLATELET AGGREGABILITY; MORNING INCREASE; HEART-ATTACK; FOLLOW-UP; ONSET; EXERCISE; RISK; ACTIVATION	Background. It is controversial whether the onset of myocardial infarction occurs randomly or is precipitated by identifiable stimuli. Previous studies have suggested a higher risk of cardiac events in association with exertion. Methods. Consecutive patients with acute myocardial infarction were identified by recording all admissions to our hospital in Berlin and by monitoring a general population of 330,000 residents in Augsburg, Germany. Information on the circumstances of each infarction was obtained by means of standardized interviews. The data analysis included a comparison of patients with matched controls and a case-crossover comparison (one in which each patient serves as his or her own control) of the patient's usual frequency of exertion with the last episode of exertion before the onset of myocardial infarction. Results. From January 1989 through December 1991, 1194 patients (74 percent of whom were men; mean age [+/-SD], 61+/-9 years) completed the interview 13+/-6 days after infarction. We found that 7.1 percent of the case patients had engaged in physical exertion (greater-than-or-equal-to 6 metabolic equivalents) at the onset of infarction, as compared with 3.9 percent of the controls at the onset of the control event. For the patients as compared with the matched controls, the adjusted relative risk of having engaged in strenuous physical activity at the onset of infarction or the control event was 2.1 (95 percent confidence interval, 1.1 to 3.6). The case-crossover comparison yielded a similar relative risk of 2.1 (95 percent confidence interval, 1.6 to 3.1) for having engaged in strenuous physical activity within one hour before myocardial infarction. Patients whose frequency of regular exercise was less than four and four or more times per week had relative risks of 6.9 and 1.3, respectively (P<0.01). Conclusions. A period of strenuous physical activity is associated with a temporary increase in the risk of having a myocardial infarction, particularly among patients who exercise infrequently. These findings should aid in the identification of the triggering mechanisms for myocardial infarction and improve prevention of this common and serious disorder.	ZENT KLINIKUM, AUGSBURG, GERMANY		WILLICH, SN (corresponding author), FREE UNIV BERLIN, KLINIKUM STEGLITZ, DEPT MED, DIV CARDIOPULM, HINDENBURGDAMM 30, D-12200 BERLIN, GERMANY.							ANDREOTTI F, 1988, AM J CARDIOL, V62, P635, DOI 10.1016/0002-9149(88)90669-8; BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; BREZINSKI DA, 1988, CIRCULATION, V78, P35, DOI 10.1161/01.CIR.78.1.35; Conway J, 1984, J Hypertens, V2, P203, DOI 10.1097/00004872-198404000-00013; Fitzhugh G, 1933, J AMER MED ASSOC, V100, P475, DOI 10.1001/jama.1933.02740070013005; FRIEDEWALD VE, 1990, AM J CARDIOL, V66, P183, DOI 10.1016/0002-9149(90)90585-O; GOLDBERG RJ, 1990, AM J CARDIOL, V66, P140, DOI 10.1016/0002-9149(90)90577-N; GREEN LH, 1980, NEW ENGL J MED, V302, P193, DOI 10.1056/NEJM198001243020403; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; HJALMARSON A, 1989, CIRCULATION, V80, P267, DOI 10.1161/01.CIR.80.2.267; LOWEL H, 1991, J CLIN EPIDEMIOL, V44, P249, DOI 10.1016/0895-4356(91)90036-9; LUBBECKE F, 1991, EUR HEART J, V12, P88; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; MASTER AM, 1960, JAMA-J AM MED ASSOC, V174, P942, DOI 10.1001/jama.1960.03030080004002; MATSUDA M, 1985, AM J CARDIOL, V55, P1255, DOI 10.1016/0002-9149(85)90484-9; MEYERSABELLEK W, 1987, NEPHRON, V47, P42, DOI 10.1159/000184552; MITTLEMAN MA, 1993, NEW ENGL J MED, V329, P1677, DOI 10.1056/NEJM199312023292301; MULCAHY D, 1988, LANCET, V2, P755; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; MULLER JE, 1989, CIRCULATION, V79, P733, DOI 10.1161/01.CIR.79.4.733; NAESH O, 1985, THROMB HAEMOSTASIS, V54, P849; NAESH O, 1990, CLIN PHYSIOL, V10, P221, DOI 10.1111/j.1475-097X.1990.tb00090.x; OBRAZTSOV VP, 1910, Z KLIN MED, V71, P116; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PANZA JA, 1991, NEW ENGL J MED, V325, P986, DOI 10.1056/NEJM199110033251402; Phipps C, 1936, J AMER MED ASSOC, V106, P761; Prineas R., 1982, MINNESOTA CODE MANUA; RIDKER PM, 1990, CIRCULATION, V82, P897, DOI 10.1161/01.CIR.82.3.897; Rosner B., 1986, FUNDAMENTALS BIOSTAT, V2nd, P442; Rothman K, 1986, MODERN EPIDEMIOLOGY; SISCOVICK DS, 1984, NEW ENGL J MED, V311, P874, DOI 10.1056/NEJM198410043111402; SPEISER W, 1988, THROMB RES, V51, P543, DOI 10.1016/0049-3848(88)90119-3; SUMIYOSHI T, 1986, JPN CIRC J, V50, P164, DOI 10.1253/jcj.50.164; THOMPSON PD, 1982, JAMA-J AM MED ASSOC, V247, P2535, DOI 10.1001/jama.247.18.2535; TOFLER GH, 1990, AM J CARDIOL, V66, P22, DOI 10.1016/0002-9149(90)90729-K; TOFLER GH, 1987, NEW ENGL J MED, V316, P1514, DOI 10.1056/NEJM198706113162405; TRICHOPOULOS D, 1983, LANCET, V1, P441; *WHO MONICA PROJ P, 1988, J CLIN EPIDEMIOL, V41, P105, DOI [DOI 10.1016/0895-4356(88)90084-4, 10.1016/0895-4356(88)90084-4]; WILLICH SN, 1991, CIRCULATION, V84, P62; WILLICH SN, 1989, CIRCULATION, V80, P853, DOI 10.1161/01.CIR.80.4.853; WILLICH SN, 1993, CIRCULATION, V87, P1442, DOI 10.1161/01.CIR.87.5.1442; WILLICH SN, 1987, AM J CARDIOL, V60, P801, DOI 10.1016/0002-9149(87)91027-7; WILLICH SN, 1992, AM J CARDIOL, V70, P65, DOI 10.1016/0002-9149(92)91391-G	45	469	479	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 2	1993	329	23					1684	1690		10.1056/NEJM199312023292302	http://dx.doi.org/10.1056/NEJM199312023292302			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ707	8232457				2022-12-28	WOS:A1993MJ70700002
J	MAHY, BWJ; ALMOND, JW; BERNS, KI; CHANOCK, RM; LVOV, DK; PETTERSSON, RF; SCHATZMAYR, HG; FENNER, F				MAHY, BWJ; ALMOND, JW; BERNS, KI; CHANOCK, RM; LVOV, DK; PETTERSSON, RF; SCHATZMAYR, HG; FENNER, F			THE REMAINING STOCKS OF SMALLPOX VIRUS SHOULD BE DESTROYED	SCIENCE			English	Article							DNA		DI IVANOVSKII INST VIROL,MOSCOW,RUSSIA; LUDWIG INST CANC RES,STOCKHOLM,SWEDEN; OSWALDO CRUZ FDN,DEPT VIROL,RIO JANEIRO,BRAZIL; UNIV READING,SCH ANIM & MICROBIAL SCI,READING RG6 2AH,BERKS,ENGLAND; CORNELL UNIV,MED CTR,COLL MED,DEPT MICROBIOL,NEW YORK,NY 10021; NIAID,INFECT DIS LAB,BETHESDA,MD 20892; KAROLINSKA INST,S-10401 STOCKHOLM 60,SWEDEN; AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,CANBERRA,ACT 2601,AUSTRALIA	Russian Academy of Medical Sciences; Gamaleya National Research Center for Epidemiology & Microbiology, RAMS; Ludwig Institute for Cancer Research; Fundacao Oswaldo Cruz; University of Reading; Cornell University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Karolinska Institutet; Australian National University; John Curtin School of Medical Research	MAHY, BWJ (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333, USA.			Lvov, D.K./0000-0001-8176-6582				[Anonymous], 1980, REPORT INVESTIGATION; ARITA I, 1979, NATURE, V279, P293, DOI 10.1038/279293a0; DEQUADROS CA, 1992, ANNU REV PUBL HEALTH, V13, P239, DOI 10.1146/annurev.publhealth.13.1.239; DEQUADROS CA, 1988, GLOBAL ERADICATION P; ESPOSITO JJ, 1978, VIROLOGY, V89, P53, DOI 10.1016/0042-6822(78)90039-9; ESPOSITO JJ, 1985, VIROLOGY, V143, P230, DOI 10.1016/0042-6822(85)90111-4; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; Hopkins Donald R., 1993, P687, DOI 10.1017/CHOL9780521332866.100; HOPKINS DR, 1983, EPIDEMIOL REV, V5, P208, DOI 10.1093/oxfordjournals.epirev.a036259; HUGHES JM, IN PRESS SCIENCE; Jezek Z, 1988, HUMAN MONKEYPOX; MACKETT M, 1979, J GEN VIROL, V45, P683, DOI 10.1099/0022-1317-45-3-683; MAHY BWJ, 1991, ASM NEWS, V57, P577; MASSUNG RF, IN PRESS NATURE; SCHCHELKUNOV SN, 1993, CONCEPTS VIROLOGY IV, P93; 1986, WEEKLY EPIDEMIOLOGIC, V61, P289	16	31	31	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1223	1224		10.1126/science.8235651	http://dx.doi.org/10.1126/science.8235651			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	8235651				2022-12-28	WOS:A1993MH32400026
J	BLINKHORN, SF				BLINKHORN, SF			GRAPHOLOGY - THE WRITING IS ON THE WALL	NATURE			English	Editorial Material											BLINKHORN, SF (corresponding author), PSYCHOMETR RES & DEV LTD,BREWMASTER HOUSE,ST ALBANS AL1 3HT,HERTS,ENGLAND.							BENSHAKHAR G, 1986, J APPL PSYCHOL, V71, P645, DOI 10.1037/0021-9010.71.4.645; COX J, 1991, OCCUPATIONAL PSYCHOL; FLUCKIGER FA, 1961, PERCEPT MOTOR SKILL, V12, P67; KLIMOSKI RJ, 1983, J OCCUP PSYCHOL, V6, P191	4	4	4	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 18	1993	366	6452					208	208		10.1038/366208a0	http://dx.doi.org/10.1038/366208a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MH325	8232577	Bronze			2022-12-28	WOS:A1993MH32500032
J	YANG, J; ELLINOR, PT; SATHER, WA; ZHANG, JF; TSIEN, RW				YANG, J; ELLINOR, PT; SATHER, WA; ZHANG, JF; TSIEN, RW			MOLECULAR DETERMINANTS OF CA2+ SELECTIVITY AND ION PERMEATION IN L-TYPE CA2+ CHANNELS	NATURE			English	Article							SENSITIVE CALCIUM-CHANNEL; MONO-VALENT CATIONS; CONCENTRATION-DEPENDENCE; FUNCTIONAL EXPRESSION; K+ CHANNEL; PORE; MUTATIONS; BINDING; BLOCKADE; VOLTAGE	VOLTAGE-GATED Ca2+ channels link changes in membrane potential to the delivery of Ca2+, a key second messenger for many cellular responses1. Ca2+ channels show selectivity for Ca2+ over more plentiful ions such as Na+ or K+ by virtue of their high-affinity binding of Ca2+ within the pore2-6. It has been suggested that this binding involves four conserved glutamate residues7-10 in equivalent positions in the putative pore-lining regions of repeats I-IV in the Ca2+ channel alpha1 subunit. We have carried out a systematic series of single amino-acid substitutions in each of these positions and find that all four glutamates participate in high-affinity binding of Ca2+ or Cd2+. Each glutamate carboxylate makes a distinct contribution to ion binding, with the carboxylate in repeat III having the strongest effect. Some single glutamate-to-lysine mutations completely abolish micromolar Ca2+ block, indicating that the pore does not possess any high-affinity binding site that acts independently of the four glutamate residues. The prevailing model of Ca2+ permeation2,3 must thus be modified to allow binding of two Ca2+ ions in close proximity11,12, within the sphere of influence of the four glutamates. The functional inequality of the glutamates may be advantageous in allowing simultaneous interactions with multiple Ca2+ ions moving single-file within the pore. Competition among Ca2+ ions for individual glutamates11,12, together With repulsive ion-ion electrostatic interaction2,3, may help achieve rapid flux rates through the channel2-5.	STANFORD UNIV, MED CTR, BECKMAN CTR, DEPT MOLEC & CELLULAR PHYSIOL, STANFORD, CA 94305 USA	Stanford University				Ellinor, Patrick/0000-0002-2067-0533; Sather, William/0000-0003-1482-8055				ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; ARMSTRONG CM, 1991, ANN NY ACAD SCI, V635, P18, DOI 10.1111/j.1749-6632.1991.tb36477.x; CHOW RH, 1992, J GEN PHYSIOL, V98, P483; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FUKUSHIMA Y, 1985, J PHYSIOL-LONDON, V358, P255, DOI 10.1113/jphysiol.1985.sp015550; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HESS P, 1986, J GEN PHYSIOL, V88, P293, DOI 10.1085/jgp.88.3.293; Hille B., 1992, IONIC CHANNELS EXCIT; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; KIM MS, 1993, FEBS LETT, V318, P145, DOI 10.1016/0014-5793(93)80009-J; KOSTYUK PG, 1983, J MEMBRANE BIOL, V76, P83, DOI 10.1007/BF01871455; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KUO CC, 1993, J PHYSIOL-LONDON, V466, P629; LANSMAN JB, 1986, J GEN PHYSIOL, V88, P321, DOI 10.1085/jgp.88.3.321; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Miller Christopher, 1992, Current Biology, V2, P573, DOI 10.1016/0960-9822(92)90146-2; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; ROSENBERG RL, 1991, J GEN PHYSIOL, V97, P1207, DOI 10.1085/jgp.97.6.1207; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; TANG SQ, 1993, J BIOL CHEM, V268, P13026; TOMASELLI GF, 1993, CIRC RES, V72, P491, DOI 10.1161/01.RES.72.3.491; Williams R.J.P., 1991, BIOL CHEM ELEMENTS; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZHENG W, 1991, MOL PHARMACOL, V40, P734	30	513	524	0	18	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 11	1993	366	6451					158	161		10.1038/366158a0	http://dx.doi.org/10.1038/366158a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG216	8232554				2022-12-28	WOS:A1993MG21600058
J	FRASER, WD; MARCOUX, S; MOUTQUIN, JM; CHRISTEN, A				FRASER, WD; MARCOUX, S; MOUTQUIN, JM; CHRISTEN, A			EFFECT OF EARLY AMNIOTOMY ON THE RISK OF DYSTOCIA IN NULLIPAROUS WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTIVE MANAGEMENT; LABOR; TRIAL	Background. Early amniotomy has been advocated as a means of preventing dystocia, but its efficacy has not been studied prospectively. The purpose of this multicenter study was to determine whether routine early amniotomy reduces the risk of dystocia for nulliparous women in spontaneous labor. Methods. We studied 925 nulliparous women in labor, who were stratified according to the degree of cervical dilatation (<3 cm vs. greater-than-or-equal 3 cm) and randomly assigned to either early rupture of the membranes (amniotomy group) or conservative management of labor (conservative-management group). Dystocia was defined as a period of at least four hours after dilatation of the cervix to 3 cm had been reached during which the mean rate of cervical dilatation was less than 0.5 cm per hour. Results. Dystocia was significantly less frequent in the amniotomy group than in the conservative-management group (34 percent vs. 45 percent; relative risk, 0.8; 95 percent confidence interval, 0.6 to 0.9). The median length of time from randomization to full dilatation was 136 minutes shorter in the amniotomy group, and there was a trend toward less frequent use of oxytocin among the women assigned to amniotomy (36 percent vs. 41 percent; relative risk, 0.9; 95 percent confidence interval, 0.8 to 1.0). In a stratified analysis, the frequency of dystocia associated with amniotomy was reduced only among women with greater-than-or-equal 3 cm initial dilatation. The cesarean-section rate was similar in the two groups (amniotomy, 12 percent; conservative management, 11 percent). There were no statistically significant differences in outcome between the infants delivered by the women in the two groups; the measures of an adverse outcome included admission to a neonatal intensive care unit, five-minute Apgar score below 7. and arterial cord-blood pH below 7.2. Conclusions. Early amniotomy is an effective method of shortening the duration of labor and reducing the frequency of dystocia among nulliparous women in labor, but it does not lower the rate of cesarean section.	UNIV LAVAL, DEPT OBSTET & GYNECOL, QUEBEC CITY G1K 7P4, QUEBEC, CANADA; UNIV LAVAL, DEPT SOCIAL & PREVENT MED, QUEBEC CITY G1K 7P4, QUEBEC, CANADA	Laval University; Laval University								AKOURY HA, 1988, AM J OBSTET GYNECOL, V158, P255, DOI 10.1016/0002-9378(88)90133-0; BARRETT JFR, 1992, BRIT J OBSTET GYNAEC, V99, P5, DOI 10.1111/j.1471-0528.1992.tb14382.x; BAUMGARTEN K, 1976, Journal of Perinatal Medicine, V4, P3; BISHOP EH, 1964, OBSTET GYNECOL, V24, P266; COHEN GR, 1987, AM J OBSTET GYNECOL, V157, P1174, DOI 10.1016/S0002-9378(87)80288-0; FRANKS P, 1990, J FAM PRACTICE, V30, P49; FRASER WD, 1991, BRIT J OBSTET GYNAEC, V98, P84, DOI 10.1111/j.1471-0528.1991.tb10316.x; Friedman EA, 1978, LABOR CLIN EVALUATIO, V2nd; KAMINSKI M, 1992, EVALUATION PRE PERI, P43; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LOMAS J, 1986, CAN MED ASSOC J, V134, P1348; LOPEZZENO JA, 1992, NEW ENGL J MED, V326, P450, DOI 10.1056/NEJM199202133260705; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; ODRISCOLL K, 1984, OBSTET GYNECOL, V63, P485; PHILPOTT RH, 1972, J OBSTET GYN BR COMM, V79, P592; STEWART P, 1982, BRIT J OBSTET GYNAEC, V89, P39, DOI 10.1111/j.1471-0528.1982.tb04632.x; STUDD J, 1975, BMJ-BRIT MED J, V2, P545, DOI 10.1136/bmj.2.5970.545; WETRICH DW, 1970, OBSTET GYNECOL, V35, P800; 1988, PARTOGRAPH MANAGERIA	20	74	78	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 22	1993	328	16					1145	1149		10.1056/NEJM199304223281602	http://dx.doi.org/10.1056/NEJM199304223281602			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY447	8257472				2022-12-28	WOS:A1993KY44700002
J	OREN, R; MATZNER, Y				OREN, R; MATZNER, Y			ASSEMBLING A COHERENT STORY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							HEMOPHILUS-PARAINFLUENZAE ENDOCARDITIS; INFECTIVE ENDOCARDITIS; INFLUENZAE ENDOCARDITIS		HADASSAH UNIV HOSP,HEMATOL UNIT,IL-91240 JERUSALEM,ISRAEL	Hebrew University of Jerusalem	OREN, R (corresponding author), HADASSAH UNIV HOSP,DEPT MED,MT SCOPUS,IL-91240 JERUSALEM,ISRAEL.							CALIO AJ, 1987, HEART LUNG, V16, P222; CHUNN CJ, 1977, MEDICINE, V56, P99, DOI 10.1097/00005792-197703000-00002; ELLNER JJ, 1979, MEDICINE, V58, P145, DOI 10.1097/00005792-197903000-00003; GRAY IR, 1991, DRUGS, V41, P729, DOI 10.2165/00003495-199141050-00005; GRAY JJ, 1992, J INFECTION, V25, P39, DOI 10.1016/0163-4453(92)93465-3; JEMSEK JG, 1979, AM J MED, V66, P51, DOI 10.1016/0002-9343(79)90481-9; KASSIRER JP, 1991, LEARNING CLIN REASON, P28; Krantz SB, 1991, HEMATOLOGY BASIC PRI, P172; LYNN DJ, 1977, MEDICINE, V56, P115, DOI 10.1097/00005792-197703000-00003; SIMON MW, 1985, PEDIATR INFECT DIS J, V4, P183, DOI 10.1097/00006454-198503000-00015; SKEHAN JD, 1988, BRIT HEART J, V59, P62	11	3	3	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 6	1994	330	1					48	50		10.1056/NEJM199401063300109	http://dx.doi.org/10.1056/NEJM199401063300109			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP649	8259144				2022-12-28	WOS:A1994MP64900009
J	TYMSTRA, T; ANDELA, M				TYMSTRA, T; ANDELA, M			OPINIONS OF DUTCH PHYSICIANS, NURSES, AND CITIZENS ON HEALTH-CARE POLICY, RATIONING, AND TECHNOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							NETHERLANDS; INSURANCE		DUTCH CONSUMERS ORG, THE HAGUE, NETHERLANDS		TYMSTRA, T (corresponding author), UNIV GRONINGEN, DEPT HLTH SCI, A DEUSINGLAAN 1, 9713 AV GRONINGEN, NETHERLANDS.							BLENDON RJ, 1990, HEALTH AFFAIR, V9, P185, DOI 10.1377/hlthaff.9.2.185; BLENDON RJ, 1993, NEW ENGL J MED, V328, P1011, DOI 10.1056/NEJM199304083281407; BLENDON RJ, 1990, NEW ENGL J MED, V323, P208, DOI 10.1056/NEJM199007193230329; CALLAHAN D, 1990, WHAT KIND LIFE LIMIT; JAJICHTOTH C, 1990, HEALTH AFFAIR, V9, P149, DOI 10.1377/hlthaff.9.4.149; Kirkman-Liff B., 1991, JAMA-J AM MED ASSOC, V265, P2496; SCHRIJVERS AJP, 1991, JAMA-J AM MED ASSOC, V266, P2215, DOI 10.1001/jama.266.16.2215; STARFIELD B, 1991, JAMA-J AM MED ASSOC, V266, P2268, DOI 10.1001/jama.266.16.2268; TYMSTRA TJ, 1992, MED CONTACT, V47, P1119; 1991, CHOICES HLTH CARE RE	10	18	18	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1993	270	24					2995	2999		10.1001/jama.270.24.2995	http://dx.doi.org/10.1001/jama.270.24.2995			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM119	8254863				2022-12-28	WOS:A1993MM11900039
J	GU, Y; TURCK, CW; MORGAN, DO				GU, Y; TURCK, CW; MORGAN, DO			INHIBITION OF CDK2 ACTIVITY IN-VIVO BY AN ASSOCIATED 20K REGULATORY SUBUNIT	NATURE			English	Article							HUMAN CELL-CYCLE; DNA-REPLICATION; KINASES; ACTIVATION; PROTEINS	THE major events of the cell division cycle are triggered by periodic changes in the activity of cyclin-dependent protein kinases (CDKs). In mammals, the members of the CDK family include CDK2 and CDC2, which are thought to be involved in the control of DNA replication and mitosis, respectively1-3. The protein kinase activity of these enzymes is controlled by a complex array of mechanisms4-6. Activation of the CDK catalytic subunit requires association with a positive regulatory subunit (cyclin) and phosphorylation (at Thr 160 in CDK2). This activated complex can be inhibited by additional phosphorylation at Thr 14 and Tyr 15. Here we report the identification of a new mechanism for the regulation of CDK2 activity. We find that CDK2/cyclin complexes in mouse fibroblasts associate tightly with a 20K protein (CAP20). Complexes containing CAP20 were isolated from cell lysates and found to have negligible kinase activity, indicating that CAP20 association in vivo may inhibit CDK2 activity. We purified CAP20 from 3T3 cells and found that low concentrations of the protein completely inhibit the kinase activity of CDK2 in vitro. Thus CAP20 represents a new negative regulatory subunit that inhibits the activity of CDK2/cyclin complexes in mammalian cells.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco				Morgan, David/0000-0001-8753-4416				DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; Draetta Giulio, 1993, Trends in Cell Biology, V3, P287, DOI 10.1016/0962-8924(93)90001-H; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HARPER JW, 1993, CELL, V75, P805; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; NODA A, IN PRESS EXP CELL RE; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; TSAI LH, 1993, ONCOGENE, V8, P1593; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	22	779	804	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 16	1993	366	6456					707	710		10.1038/366707a0	http://dx.doi.org/10.1038/366707a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM265	8259216				2022-12-28	WOS:A1993MM26500076
J	THERIOT, JA; MITCHISON, TJ				THERIOT, JA; MITCHISON, TJ			THE 3 FACES OF PROFILIN	CELL			English	Review							ACTIN-FILAMENTS; SACCHAROMYCES-CEREVISIAE; LIVING CELLS; MECHANISM; POLYMERIZATION; PROFILACTIN; EXCHANGE; END		UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	THERIOT, JA (corresponding author), WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.		Theriot, Julie/HHN-2034-2022	Theriot, Julie/0000-0002-2334-2535	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI036929] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI036929] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUSS F, 1992, CELL MOTIL CYTOSKEL, V22, P51, DOI 10.1002/cm.970220106; CAO LG, 1992, J CELL BIOL, V117, P1023, DOI 10.1083/jcb.117.5.1023; CARLIER MF, 1993, P NATL ACAD SCI USA, V90, P5034, DOI 10.1073/pnas.90.11.5034; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; COOLEY L, 1992, CELL, V69, P173, DOI 10.1016/0092-8674(92)90128-Y; FINKEL T, 1993, IN PRESS P NATL ACAD; Goldschmidt-Clermont P. J., 1992, Current Biology, V2, P669, DOI 10.1016/0960-9822(92)90135-W; GOLDSCHMIDTCLERMONT PJ, 1992, MOL BIOL CELL, V3, P1015, DOI 10.1091/mbc.3.9.1015; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; SAFER D, 1990, P NATL ACAD SCI USA, V87, P2536, DOI 10.1073/pnas.87.7.2536; SANDERS MC, 1990, J CELL BIOL, V110, P359, DOI 10.1083/jcb.110.2.359; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; THERIOT JA, 1994, IN PRESS CELL; TILNEY LG, 1983, J CELL BIOL, V97, P112, DOI 10.1083/jcb.97.1.112; VINSON VK, 1993, J CELL BIOL, V122, P1277, DOI 10.1083/jcb.122.6.1277; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1	24	156	159	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 3	1993	75	5					835	838		10.1016/0092-8674(93)90527-W	http://dx.doi.org/10.1016/0092-8674(93)90527-W			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252619	Bronze			2022-12-28	WOS:A1993MK96600003
J	EISELE, JL; BERTRAND, S; GALZI, JL; DEVILLERSTHIERY, A; CHANGEUX, JP; BERTRAND, D				EISELE, JL; BERTRAND, S; GALZI, JL; DEVILLERSTHIERY, A; CHANGEUX, JP; BERTRAND, D			CHIMERIC NICOTINIC SEROTONERGIC RECEPTOR COMBINES DISTINCT LIGAND-BINDING AND CHANNEL SPECIFICITIES	NATURE			English	Article							GATED ION CHANNEL; MARMORATA ACETYLCHOLINE-RECEPTOR; ALPHA-SUBUNIT; DELTA-SUBUNIT; XENOPUS OOCYTES; 5-HYDROXYTRYPTAMINE; EXPRESSION; SEQUENCES; CALCIUM; NEURONS	THE neuronal nicotinic alpha7 (nAChR) and 5-hydroxytryptamine (5HT3) receptors1-3 are ligand-gated ion channels with a homologous topological organization and have activation and desensitization reactions in common. Yet these homo-oligomeric receptors differ in the pharmacology of their binding sites for agonists and competitive antagonists3,4, and in their sensitivity to Ca2+ ions. The alpha7 channel is highly permeable to Ca2+ ions5,6 and external Ca2+ ions potentiate, in an allosteric manner, the permeability response to acetylcholine, as shown for other neuronal nAChRs7,8. The 5HT3 channel, in contrast, is not permeable to Ca2+ ions, but blocked by them3,9. To assign these properties to delimited domains of the primary structure, we constructed several recombinant chimaeric alpha7-5HT3 receptors. We report here that one of the constructs expresses a functional receptor that contains the serotonergic channel still blocked by Ca2+ ions, but is activated by nicotinic ligands and potentiated by external Ca2+ ions.	UNIV GENEVA, MED CTR, FAC MED, DEPT PHYSIOL, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva	EISELE, JL (corresponding author), INST PASTEUR, CNRS, UNITE NEUROBIOL MOLEC D1284, 25 RUE DR ROUX, F-75724 PARIS 15, FRANCE.							BERTRAND D, 1992, NEUROSCI LETT, V146, P87, DOI 10.1016/0304-3940(92)90179-B; BERTRAND D, 1993, P NATL ACAD SCI USA, V90, P6971, DOI 10.1073/pnas.90.15.6971; BERTRAND D, 1991, ELECTROPHYSIOLOGY NE; BRADLEY PB, 1986, NEUROPHARMACOLOGY, V25, P563, DOI 10.1016/0028-3908(86)90207-8; CLAUDIO T, 1983, P NATL ACAD SCI-BIOL, V80, P1111, DOI 10.1073/pnas.80.4.1111; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DEVILLERSTHIERY A, 1983, P NATL ACAD SCI-BIOL, V80, P2067, DOI 10.1073/pnas.80.7.2067; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; HIGASHI H, 1982, J PHYSIOL-LONDON, V323, P543, DOI 10.1113/jphysiol.1982.sp014091; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; IMOTO K, 1986, NATURE, V324, P670, DOI 10.1038/324670a0; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; KUHSE J, 1990, NEURON, V5, P867, DOI 10.1016/0896-6273(90)90346-H; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; MAYNE KM, 1987, MOL BRAIN RES, V2, P191, DOI 10.1016/0169-328X(87)90026-X; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; MULLE C, 1992, NEURON, V8, P937, DOI 10.1016/0896-6273(92)90208-U; NODA M, 1983, NATURE, V301, P251, DOI 10.1038/301251a0; PETERS JA, 1988, EUR J PHARMACOL, V151, P491, DOI 10.1016/0014-2999(88)90550-X; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; SCHOEPFER R, 1990, NEURON, V5, P35, DOI 10.1016/0896-6273(90)90031-A; SEGUELA P, 1993, J NEUROSCI, V13, P596; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SUMIKAWA K, 1992, MOL BRAIN RES, V13, P349, DOI 10.1016/0169-328X(92)90218-Z; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; VANDENBERG RJ, 1992, P NATL ACAD SCI USA, V89, P1765, DOI 10.1073/pnas.89.5.1765; VERNINO S, 1992, NEURON, V8, P127, DOI 10.1016/0896-6273(92)90114-S; YAKEL JL, 1993, P NATL ACAD SCI USA, V90, P5030, DOI 10.1073/pnas.90.11.5030; YANG J, 1992, J PHYSIOL-LONDON, V448, P237, DOI 10.1113/jphysiol.1992.sp019039; YANG J, 1990, J GEN PHYSIOL, V96, P1177, DOI 10.1085/jgp.96.6.1177; YU XM, 1991, NATURE, V352, P64, DOI 10.1038/352064a0	35	346	368	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 2	1993	366	6454					479	483		10.1038/366479a0	http://dx.doi.org/10.1038/366479a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK098	8247158				2022-12-28	WOS:A1993MK09800069
J	VOWELS, MR; LAMPOTANG, R; BERDOUKAS, V; FORD, D; THIERRY, D; PURTILO, D; GLUCKMAN, E				VOWELS, MR; LAMPOTANG, R; BERDOUKAS, V; FORD, D; THIERRY, D; PURTILO, D; GLUCKMAN, E			CORRECTION OF X-LINKED LYMPHOPROLIFERATIVE DISEASE BY TRANSPLANTATION OF CORD-BLOOD STEM-CELLS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							BONE-MARROW TRANSPLANTATION; HEMATOPOIETIC STEM; FANCONIS ANEMIA; COMPLICATIONS; PATIENT		PRINCE WALES CHILDRENS HOSP,DEPT HAEMATOL,SYDNEY,AUSTRALIA; PRINCE WALES CHILDRENS HOSP,DEPT ONCOL,SYDNEY,AUSTRALIA; PRINCE WALES CHILDRENS HOSP,DEPT BONE MARROW TRANSPLATAT,SYDNEY,AUSTRALIA; UNIV NEW S WALES,SYDNEY,NSW,AUSTRALIA; INST PROTECT SURETE NUCL,PARIS,FRANCE; UNIV NEBRASKA,MED CTR,DEPT PATHOL,OMAHA,NE 68105; UNIV NEBRASKA,MED CTR,DEPT MICROBIOL,OMAHA,NE 68105; HOP ST LOUIS,F-75010 PARIS,FRANCE	University of New South Wales Sydney; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite			eliane, Gluckman/AAA-5024-2021					BORTIN MM, 1983, EXP HEMATOL, V11, P916; BROXMEYER HE, 1992, BONE MARROW TRANSPL, V9, P7; BROXMEYER HE, 1989, P NATL ACAD SCI USA, V86, P3828, DOI 10.1073/pnas.86.10.3828; BROXMEYER HE, 1991, BLOOD CELLS, V17, P313; CLINE MJ, 1974, NATURE, V248, P703, DOI 10.1038/248703a0; DEEG HJ, 1984, BRIT J HAEMATOL, V57, P185, DOI 10.1111/j.1365-2141.1984.tb08521.x; FILIPOVICH AH, 1986, TRANSPLANTATION, V42, P222; FISCHER A, 1991, NEW ENGL J MED, V324, P1451, DOI 10.1056/NEJM199105233242102; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; GLUCKMAN E, 1990, NOUV REV FR HEMATOL, V32, P423; HONIG GR, 1991, BLOOD S1, V78, pA313; METCALF D, 1977, RECENT RES CANCER, V61, P1; MULLEY JC, 1992, CLIN GENET, V42, P76; NEMUNAITIS J, 1991, BLOOD, V77, P2065; PURTILO DT, 1991, CANCER GENET CYTOGEN, V51, P143, DOI 10.1016/0165-4608(91)90127-G; TAPP H, 1992, TRANSPLANT P, V24, P2267; Thierry D, 1991, Bone Marrow Transplant, V7 Suppl 2, P123; TURNER AM, 1992, J PAEDIATR CHILD H, V28, P184, DOI 10.1111/j.1440-1754.1992.tb02639.x; URBAN C, 1990, BONE MARROW TRANSPL, V6, P443; VILMER E, 1992, TRANSPLANTATION, V53, P1155; VOWELS MR, 1990, MED J AUSTRALIA, V153, P580, DOI 10.5694/j.1326-5377.1990.tb126265.x; WAGNER JE, 1992, BLOOD, V79, P1874; ZUTTER MM, 1988, BLOOD, V72, P520	24	76	77	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1993	329	22					1623	1625		10.1056/NEJM199311253292205	http://dx.doi.org/10.1056/NEJM199311253292205			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ546	8232431				2022-12-28	WOS:A1993MJ54600005
J	GORLICH, D; RAPOPORT, TA				GORLICH, D; RAPOPORT, TA			PROTEIN TRANSLOCATION INTO PROTEOLIPOSOMES RECONSTITUTED FROM PURIFIED COMPONENTS OF THE ENDOPLASMIC-RETICULUM MEMBRANE	CELL			English	Article							SIGNAL RECOGNITION PARTICLE; RIBOSOME-BINDING-ACTIVITY; SEQUENCE RECEPTOR; POLYPEPTIDE TRANSLOCATION; NASCENT PREPROLACTIN; MICROSOMAL-MEMBRANES; SECRETORY PROTEINS; ESCHERICHIA-COLI; ROUGH MICROSOMES; YEAST	We have reproduced the process of protein transport across and of protein integration into the mammalian endoplasmic reticulum membrane by the use of proteoliposomes reconstituted from pure phospholipids and purified membrane proteins. The transport of some proteins requires only two membrane protein complexes: the signal recognition particle receptor, needed for targeting of a nascent chain to the membrane, and a novel complex, the Sec61p complex, that consists of Sec61p and two smaller polypeptides. The translocation of other proteins also needs the presence of the translocating chain-associating membrane (TRAM) protein. The integration of two membrane proteins of different topologies into the membrane does not require additional components. These results indicate a surprising simplicity of the basic translocation machinery. They suggest that the Sec61p complex binds the ribosome during translocation and forms the postulated protein-conducting channel.	MAX DELBRUCK CTR MOLEC MED,D-13122 BERLIN,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine			Görlich, Dirk/B-8296-2017	Görlich, Dirk/0000-0002-4343-5210				AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; COLLINS PG, 1991, J CELL BIOL, V114, P639, DOI 10.1083/jcb.114.4.639; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CRIMAUDO C, 1987, EMBO J, V6, P75, DOI 10.1002/j.1460-2075.1987.tb04721.x; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HARTMANN E, 1993, EUR J BIOCHEM, V214, P375, DOI 10.1111/j.1432-1033.1993.tb17933.x; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; ICHIMURA T, 1992, FEBS LETT, V296, P7, DOI 10.1016/0014-5793(92)80391-S; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KATZ FN, 1977, P NATL ACAD SCI USA, V74, P3278, DOI 10.1073/pnas.74.8.3278; KLAPPA P, 1991, EMBO J, V10, P2795, DOI 10.1002/j.1460-2075.1991.tb07828.x; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LAUFFER L, 1985, NATURE, V318, P334, DOI 10.1038/318334a0; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; MEYER DI, 1982, NATURE, V297, P503; MIGLIACCIO G, 1992, J CELL BIOL, V117, P15, DOI 10.1083/jcb.117.1.15; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; NUNNARI JM, 1991, NATURE, V352, P638, DOI 10.1038/352638a0; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SAVITZ AJ, 1993, J CELL BIOL, V120, P853, DOI 10.1083/jcb.120.4.853; SAVITZ AJ, 1990, NATURE, V346, P540, DOI 10.1038/346540a0; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; TAZAWA S, 1991, J BIOCHEM-TOKYO, V109, P89; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; Wiech H, 1990, Semin Cell Biol, V1, P55; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; ZIMMERMAN DL, 1991, CELL REGUL, V2, P851, DOI 10.1091/mbc.2.10.851	49	540	548	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					615	630		10.1016/0092-8674(93)90483-7	http://dx.doi.org/10.1016/0092-8674(93)90483-7			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242738	Green Accepted, Bronze			2022-12-28	WOS:A1993MH74900008
J	LI, XX; WU, YJ; ZHANG, DZ; GILLIKIN, JW; BOSTON, RS; FRANCESCHI, VR; OKITA, TW				LI, XX; WU, YJ; ZHANG, DZ; GILLIKIN, JW; BOSTON, RS; FRANCESCHI, VR; OKITA, TW			RICE PROLAMINE PROTEIN BODY BIOGENESIS - A BIP-MEDIATED PROCESS	SCIENCE			English	Article							MOLECULAR CHAPERONE; MAIZE ENDOSPERM; PEPTIDE-BINDING; POLYRIBOSOMES; TRANSLOCATION; EXPRESSION; HOMOLOG; BODIES	Rice prolamines are sequestered within the endoplasmic reticulum (ER) lumen even though they lack a lumenal retention signal. Immunochemical and biochemical data show that BiP, a protein that binds lumenal polypeptides, is localized on the surface of the aggregated prolamine protein bodies (PBs). BiP also forms complexes with nascent chains of prolamines in polyribosomes and with free prolamines with distinct adenosine triphosphate sensitivities. Thus, BiP retains prolamines in the lumen by facilitating their folding and assembly into PBs.	WASHINGTON STATE UNIV, INST BIOL CHEM, PULLMAN, WA 99164 USA; WASHINGTON STATE UNIV, DEPT GENET & CELL BIOL, PULLMAN, WA 99164 USA; WASHINGTON STATE UNIV, DEPT BOT, PULLMAN, WA 99164 USA; N CAROLINA STATE UNIV, DEPT BOT, RALEIGH, NC 27695 USA	Washington State University; Washington State University; Washington State University; University of North Carolina; North Carolina State University				Okita, Tom/0000-0002-2246-0599				ABE S, 1991, PROTOPLASMA, V165, P139, DOI 10.1007/BF01322284; ARGOS P, 1982, J BIOL CHEM, V257, P9984; BOSTON RS, 1991, PLANT CELL, V3, P497, DOI 10.1105/tpc.3.5.497; BURR B, 1976, P NATL ACAD SCI USA, V73, P515, DOI 10.1073/pnas.73.2.515; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FONTES EBP, 1991, PLANT CELL, V3, P483, DOI 10.1105/tpc.3.5.483; HAAS IG, 1991, CURR TOP MICROBIOL, V167, P71; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; KIM WT, 1988, PLANT PHYSIOL, V88, P649, DOI 10.1104/pp.88.3.649; KRISHNAN HB, 1986, PLANTA, V169, P471, DOI 10.1007/BF00392095; LARKINS BA, 1976, PLANT PHYSIOL, V57, P740, DOI 10.1104/pp.57.5.740; LENK R, 1977, CELL, V10, P67, DOI 10.1016/0092-8674(77)90141-6; Li X., UNPUB; LI XX, 1993, CELL, V72, P869, DOI 10.1016/0092-8674(93)90576-C; LI XX, 1993, PLANT CELL PHYSIOL, V34, P385; MAROCCO A, 1991, PLANT CELL, V3, P507, DOI 10.1105/tpc.3.5.507; MIERNYK JA, 1992, PLANT CELL, V4, P821, DOI 10.1105/tpc.4.7.821; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; OKITA TW, 1989, PLANT NITROGEN METAB, pCH9; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; YAMAGATA H, 1986, PLANT CELL PHYSIOL, V27, P135	24	150	168	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	1993	262	5136					1054	1056		10.1126/science.8235623	http://dx.doi.org/10.1126/science.8235623			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	8235623				2022-12-28	WOS:A1993MG18700035
J	NICHOL, ST; SPIROPOULOU, CF; MORZUNOV, S; ROLLIN, PE; KSIAZEK, TG; FELDMANN, H; SANCHEZ, A; CHILDS, J; ZAKI, S; PETERS, CJ				NICHOL, ST; SPIROPOULOU, CF; MORZUNOV, S; ROLLIN, PE; KSIAZEK, TG; FELDMANN, H; SANCHEZ, A; CHILDS, J; ZAKI, S; PETERS, CJ			GENETIC IDENTIFICATION OF A HANTAVIRUS ASSOCIATED WITH AN OUTBREAK OF ACUTE RESPIRATORY ILLNESS	SCIENCE			English	Article							NUCLEOTIDE-SEQUENCE; GENOME SEGMENT; VIRUS; RNA; EPIDEMIOLOGY; HANTAAN	A mysterious respiratory illness with high mortality was recently reported in the southwestern United States. Serologic studies implicated the hantaviruses, rodent-borne RNA viruses usually associated elsewhere in the world with hemorrhagic fever with renal syndrome. A genetic detection assay amplified hantavirus-specific DNA fragments from RNA extracted from the tissues of patients and deer mice (Peromyscus maniculatus) caught at or near patient residences. Nucleotide sequence analysis revealed the associated virus to be a new hantavirus and provided a direct genetic link between infection in patients and rodents.			NICHOL, ST (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333, USA.		MORZUNOV, SERGEY/AAP-3003-2021	MORZUNOV, SERGEY/0000-0002-5932-5163; Rollin, Pierre/0000-0002-4608-2641				ARIKAWA J, 1990, VIROLOGY, V176, P114, DOI 10.1016/0042-6822(90)90236-K; ARTHUR RR, 1992, AM J TROP MED HYG, V47, P210, DOI 10.4269/ajtmh.1992.47.210; GIEBEL LB, 1989, VIROLOGY, V172, P498, DOI 10.1016/0042-6822(89)90192-X; GLASS GE, IN PRESS NEPHRON; GONZALEZSCARANO F, 1990, VIROLOGY; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; KSIAZEK TG, UNPUB; LEDUC JW, 1987, LAB ANIM SCI, V37, P413; MCKEE KT, 1991, TXB HUMAN VIROLOGY, P615; PARRINGTON MA, 1991, J GEN VIROL, V72, P1845, DOI 10.1099/0022-1317-72-8-1845; RODRIGUEZ LL, 1993, J CLIN MICROBIOL, V31, P2016, DOI 10.1128/JCM.31.8.2016-2020.1993; SCHMALJOHN CS, 1987, VIROLOGY, V157, P31, DOI 10.1016/0042-6822(87)90310-2; YANAGIHARA R, 1990, REV INFECT DIS, V12, P449; ZAKI S, UNPUB; 1993, MORB MORTAL WKLY REP, V42, P441; 1993, MORB MORTAL WKLY REP, V42, P421; 1993, MORB MORTAL WKLY REP, V42, P477	17	899	944	1	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 5	1993	262	5135					914	917		10.1126/science.8235615	http://dx.doi.org/10.1126/science.8235615			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	8235615				2022-12-28	WOS:A1993MF43800041
J	GOVAERT, TME; DINANT, GJ; ARETZ, K; MASUREL, N; SPRENGER, MJW; KNOTTNERUS, JA				GOVAERT, TME; DINANT, GJ; ARETZ, K; MASUREL, N; SPRENGER, MJW; KNOTTNERUS, JA			ADVERSE REACTIONS TO INFLUENZA VACCINE IN ELDERLY PEOPLE - RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FREQUENCY; EPIDEMICS	Objective-To assess the frequency and type of side effects after influenza vaccination in elderly people. Design-Randomised double blind placebo controlled study. Setting-15 general practices in the southern Netherlands. Subjects-1806 patients aged 60 or older, of whom 904 received influenza vaccine and 902 placebo. Main outcome measures-Adverse reactions reported on postal questionnaire completed four weeks after vaccination. Results-210 (23%) patients given vaccine reported one or more adverse reactions compared with 127 (14%) given placebo. The frequency of local adverse reactions were 17.5% in the vaccine group and 7.3% in the placebo group (p < 0.001). There was no difference in systemic adverse reactions (11% v 9.4%; p=0.34). In general, men reported fewer side effects than women. Conclusion-Only local side effects were more common in vaccinated patients and all side effects were mild.	UNIV LIMBURG, DEPT GEN PRACTICE, 6200 MD MAASTRICHT, NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT, DEPT INFECT DIS EPIDEMIOL, BILTHOVEN, NETHERLANDS; ERASMUS UNIV ROTTERDAM, WHO INFLUENZA CTR, 3000 DR ROTTERDAM, NETHERLANDS; ERASMUS UNIV ROTTERDAM, DEPT VIROL, 3000 DR ROTTERDAM, NETHERLANDS	Hasselt University; Maastricht University; Netherlands National Institute for Public Health & the Environment; Erasmus University Rotterdam; Erasmus University Rotterdam			Knottnerus, Johannes A/A-3829-2009; Knottnerus, Andre/F-4866-2013					ALLING DW, 1981, AM J EPIDEMIOL, V113, P30, DOI 10.1093/oxfordjournals.aje.a113063; BARKER WH, 1982, ARCH INTERN MED, V142, P85, DOI 10.1001/archinte.142.1.85; BARKER WH, 1980, AM J EPIDEMIOL, V112, P798, DOI 10.1093/oxfordjournals.aje.a113052; CATE TR, 1977, J INFECT DIS, V136, pS518, DOI 10.1093/infdis/136.Supplement_3.S518; ERAKER SA, 1984, ANN INTERN MED, V100, P258, DOI 10.7326/0003-4819-100-2-258; GANGULY R, 1989, J AM GERIATR SOC, V37, P387, DOI 10.1111/j.1532-5415.1989.tb05511.x; GOVAERT TME, 1991, HUISARTS WETENSCHAP, V34, P478; HELLIWELL BE, 1988, CAN J PUBLIC HEALTH, V79, P175; HOFSTRA ML, 1990, HUISARTS WET, V33, P429; LAMONTAGNE JR, 1983, REV INFECT DIS, V5, P723; MARGOLIS KL, 1990, AM J MED, V88, P27, DOI 10.1016/0002-9343(90)90123-U; MARGOLIS KL, 1990, JAMA-J AM MED ASSOC, V264, P1139, DOI 10.1001/jama.264.9.1139; MASUREL N, 1984, J HYG-CAMBRIDGE, V92, P263, DOI 10.1017/S0022172400064500; MOSTOW SR, 1977, J INFECT DIS, V136, pS533, DOI 10.1093/infdis/136.Supplement_3.S533; MOSTOW SR, 1969, B WORLD HEALTH ORGAN, V41, P525; NICHOL KL, 1992, ARCH INTERN MED, V152, P106, DOI 10.1001/archinte.152.1.106; PALACHE AM, 1993, VACCINE, V11, P3, DOI 10.1016/0264-410X(93)90333-S; PALACHE AM, 1991, THESIS ERASMUS U ROT; RUBEN FL, 1972, J INFECT DIS, V125, P656, DOI 10.1093/infdis/125.6.656; SCHEIFELE DW, 1990, CAN MED ASSOC J, V142, P127; Sprenger M J, 1991, Ned Tijdschr Geneeskd, V135, P2208; SPRENGER MJW, 1993, INT J EPIDEMIOL, V22, P334, DOI 10.1093/ije/22.2.334; SPRENGER MJW, 1987, TIJDSCHR SOC GEZONDH, V65, P222; VANVEEN WA, 1990, HUISARTS WET, V33, P415; 1991, COMMISSIE VACCINATIE; 1990, MMWR, V39, P111	26	169	183	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 16	1993	307	6910					988	990		10.1136/bmj.307.6910.988	http://dx.doi.org/10.1136/bmj.307.6910.988			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC441	8241913	Bronze, Green Published			2022-12-28	WOS:A1993MC44100023
J	PINCUS, T; BROOKS, RH; CALLAHAN, LF				PINCUS, T; BROOKS, RH; CALLAHAN, LF			PREDICTION OF LONG-TERM MORTALITY IN PATIENTS WITH RHEUMATOID-ARTHRITIS ACCORDING TO SIMPLE QUESTIONNAIRE AND JOINT COUNT MEASURES	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH ASSESSMENT QUESTIONNAIRE; CORONARY-ARTERY DISEASE; FOLLOW-UP; RADIOGRAPHIC DAMAGE; FORMAL EDUCATION; WORK DISABILITY; NATURAL-HISTORY; WALKING TIME; BUTTON TEST; MORBIDITY	Objective: To describe mortality over 15 years in a cohort of patients with rheumatoid arthritis, according to a simple questionnaire and joint count. Design: A cohort study with 15 years of follow-up. Setting: University hospital outpatient clinic. Patients: A cohort of 75 patients with rheumatoid arthritis. Measurements: Quantitative baseline measures: demographic, articular (joint counts), clinical, questionnaire, and physical measures, including modified questionnaire and joint count measures with substantially fewer items. Results: Although few deaths were seen in the first 3 years after baseline, the standard mortality ratio over 15 years was 1.62, similar to findings in other series. Significant predictors of mortality included age, formal education level, joint count, activities-of-daily-living questionnaire scores, disease adjustment scores, morning stiffness, comorbid cardiovascular disease, grip strength, modified walking time, and button test. Five-year survival in patients with the poorest status according to these quantitative measures was 40% to 60%, comparable to expected survival at that time of patients with three-vessel coronary artery disease or with stage 4 Hodgkin disease. Simplified measures, including a count using only 28 joints and a questionnaire using only 8 activities of daily living, were similar to the more elaborate traditional measures for predicting mortality. Conclusion: Higher mortality rates in patients with rheumatoid arthritis are predicted by more severe clinical disease, as in other chronic diseases. Severe rheumatoid arthritis may be identified using quantitative functional status questionnaires and joint counts, which can be ascertained in about 10 to 15 minutes in any clinical setting.			PINCUS, T (corresponding author), VANDERBILT UNIV, MED CTR,SCH MED,DEPT MED,DIV RHEUMATOL & IMMUNOL, T-3219 MED CTR N, NASHVILLE, TN 37232 USA.		Callahan, Leigh/X-3799-2018	Callahan, Leigh/0000-0001-6362-7220	NCRR NIH HHS [5M01RR-0095] Funding Source: Medline; NIADDK NIH HHS [AM-21393] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R18AM021393] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000095] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALLEBECK P, 1981, SCAND J RHEUMATOL, V10, P301, DOI 10.3109/03009748109095320; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; ATWATER EC, 1967, ARTHRITIS RHEUM, V10, P259, DOI 10.1002/art.1780100313; BRENNER H, 1991, J CLIN EPIDEMIOL, V44, P807, DOI 10.1016/0895-4356(91)90133-T; BROOKS RH, 1988, ARTHRIT CARE RES, V1, P23; Callahan L F, 1989, Arthritis Care Res, V2, P122, DOI 10.1002/anr.1790020406; CALLAHAN LF, 1988, ARTHRITIS RHEUM-US, V31, P1346, DOI 10.1002/art.1780311102; Clawson D K, 1971, Clin Orthop Relat Res, V77, P203; COBB S, 1953, NEW ENGL J MED, V249, P553, DOI 10.1056/NEJM195310012491402; COX DR, 1972, J R STAT SOC B, V34, P187; DIXON WJ, 1981, BMDP STATISTICAL SOF; DUTHIE JJR, 1964, ANN RHEUM DIS, V23, P193, DOI 10.1136/ard.23.3.193; EBERHARDT KB, 1990, RHEUMATOL INT, V10, P135, DOI 10.1007/BF02274837; EGGER MJ, 1985, ARTHRITIS RHEUM, V28, P613, DOI 10.1002/art.1780280603; FEINSTEIN AR, 1983, ANN INTERN MED, V99, P843, DOI 10.7326/0003-4819-99-6-843; FELSON DT, 1993, ARTHRITIS RHEUM-US, V36, P729, DOI 10.1002/art.1780360601; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; FRIES JF, 1990, J RHEUMATOL, V17, P12; FUCHS HA, 1992, J RHEUMATOL, V19, P1655; FUCHS HA, 1989, J RHEUMATOL, V16, P585; FUCHS HA, 1989, ARTHRITIS RHEUM, V32, P531, DOI 10.1002/anr.1780320504; Fuchs V. R., 1982, EC ASPECTS HLTH; GORDON DA, 1973, AM J MED, V54, P445, DOI 10.1016/0002-9343(73)90040-5; Hawley D J, 1992, Arthritis Care Res, V5, P130, DOI 10.1002/art.1790050304; ISOMAKI H, 1984, SCAND J RHEUMATOL, V13, P33, DOI 10.3109/03009748409102665; KAPLAN HS, 1972, HODGKINS DISEASE, P360; KAZIS LE, 1990, J CLIN EPIDEMIOL, V43, P1243, DOI 10.1016/0895-4356(90)90025-K; KELSEY JL, 1988, ANNU REV PUBL HEALTH, V9, P379, DOI 10.1146/annurev.pu.09.050188.002115; KITAGAWA EM, 1973, DIFFERENTIAL MORTALI, P1; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LEIGH JP, 1991, J RHEUMATOL, V18, P1307; LICHTENSTEIN MJ, 1991, J RHEUMATOL, V18, P989; LUUKKAINEN R, 1983, CLIN EXP RHEUMATOL, V1, P295; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/jech.32.4.244; MASI AT, 1983, AM J MED, V75, P16, DOI 10.1016/0002-9343(83)90471-0; MCCARTY DJ, 1990, J RHEUMATOL, V17, P1115; MCCARTY DJ, 1985, ARTHRITIS ALLIED CON, P675; MEENAN RF, 1987, J RHEUMATOL, V14, P411; MIKKELSE.WM, 1969, ARTHRITIS RHEUM, V12, P87, DOI 10.1002/art.1780120205; MITCHELL DM, 1986, ARTHRITIS RHEUM-US, V29, P706, DOI 10.1002/art.1780290602; OSULLIVAN JB, 1972, ANN INTERN MED, V76, P573, DOI 10.7326/0003-4819-76-4-573; PINCUS T, 1987, J RHEUMATOL, V14, P240; PINCUS T, 1984, ARTHRITIS RHEUM-US, V27, P864, DOI 10.1002/art.1780270805; PINCUS T, 1990, J RHEUMATOL, V17, P1582; PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107; PINCUS T, 1988, J RHEUMATOL, V15, P1457; PINCUS T, 1988, J CLIN EPIDEMIOL, V41, P1037, DOI 10.1016/0895-4356(88)90072-8; PINCUS T, 1992, SEMIN ARTHRITIS RHEU, V21, P2, DOI 10.1016/0049-0172(92)90008-2; PINCUS T, 1985, J CHRON DIS, V38, P973, DOI 10.1016/0021-9681(85)90095-5; PINCUS T, 1986, J RHEUMATOL, V13, P841; PINCUS T, 1989, ANN INTERN MED, V110, P259, DOI 10.7326/0003-4819-110-4-259; PINCUS T, 1991, ANN INTERN MED, V115, P825, DOI 10.7326/0003-4819-115-10-825; PINCUS T, 1992, J RHEUMATOL, V19, P1051; Pincus T, 1989, Scand J Rheumatol Suppl, V79, P67; Pincus T, 1988, J MUSCULOSKEL MED, V5, P27; PROUDFIT WL, 1978, PROG CARDIOVASC DIS, V21, P53, DOI 10.1016/S0033-0620(78)80004-8; RASKER JJ, 1984, CLIN RHEUMATOL, V3, P11, DOI 10.1007/BF02715690; REILLY PA, 1990, ANN RHEUM DIS, V49, P363, DOI 10.1136/ard.49.6.363; ROPES M W, 1958, Bull Rheum Dis, V9, P175; SCOTT DL, 1987, LANCET, V1, P1108; SCOTT DL, 1984, ANN RHEUM DIS, V43, P8, DOI 10.1136/ard.43.1.8; SHARP JT, 1991, ARTHRITIS RHEUM, V34, P660, DOI 10.1002/art.1780340606; SHERRER YS, 1986, ARTHRITIS RHEUM, V29, P494, DOI 10.1002/art.1780290406; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; VANDERHEIJDE MFM, 1988, SEMIN ARTHRITIS RHEU, V17, P284, DOI 10.1016/0049-0172(88)90013-3; WEINBLATT E, 1978, NEW ENGL J MED, V299, P60, DOI 10.1056/NEJM197807132990202; WILSKE KR, 1989, J RHEUMATOL, V16, P565; WOLFE F, 1991, J RHEUMATOL, V18, P643; WOLFE F, 1988, J RHEUMATOL, V15, P1480; WOLFE F, 1991, J RHEUMATOL, V18, P1290; WOLFE F, 1986, J RHEUMATOL, V13, P277; WOLFE F, 1991, PROGNOSIS RHEUMATIC, P37; YELIN E, 1980, ANN INTERN MED, V93, P551, DOI 10.7326/0003-4819-93-4-551; YOUNG A, 1987, Clinical Rheumatology, V6, P12, DOI 10.1007/BF02203380; 1987, SAS STAT GUIDE PERSO; 1977, VITAL STATISTICS US, V2	76	334	346	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1994	120	1					26	34		10.7326/0003-4819-120-1-199401010-00005	http://dx.doi.org/10.7326/0003-4819-120-1-199401010-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP280	8250453				2022-12-28	WOS:A1994MP28000005
J	KAHN, RA; YUCEL, JK; MALHOTRA, V				KAHN, RA; YUCEL, JK; MALHOTRA, V			ARF SIGNALING - A POTENTIAL ROLE FOR PHOSPHOLIPASE-D IN MEMBRANE TRAFFIC	CELL			English	Review							ADP-RIBOSYLATION FACTOR; GOLGI-COMPLEX; BREFELDIN-A; PROTEINS; TRANSPORT; PATHWAY		UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	KAHN, RA (corresponding author), NCI,DIV CANC TREATMENT,SAKYO KU PROGRAM,BIOL CHEM LAB,BETHESDA,MD 20892, USA.		Malhotra, Vivek/O-9811-2014; Kahn, Richard/ABD-2666-2020	Malhotra, Vivek/0000-0001-6198-7943; Kahn, Richard/0000-0002-0259-0601				BALCH WE, 1992, J BIOL CHEM, V267, P13053; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BROWN HA, 1993, CELL, V75; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; Cleves A, 1991, Trends Cell Biol, V1, P30, DOI 10.1016/0962-8924(91)90067-J; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1994, IN PRESS HDB EXPT PH; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STUTCHFIELD J, 1993, BIOCHEM J, V293, P649, DOI 10.1042/bj2930649; SUDHOF TC, 1993, CELL, V75, P1; TAKIZAWA PA, 1993, CELL, V75, P593, DOI 10.1016/0092-8674(93)90477-8; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J	21	164	164	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 17	1993	75	6					1045	1048		10.1016/0092-8674(93)90314-G	http://dx.doi.org/10.1016/0092-8674(93)90314-G			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	8261507				2022-12-28	WOS:A1993MM89300003
J	LEACH, FS; NICOLAIDES, NC; PAPADOPOULOS, N; LIU, B; JEN, J; PARSONS, R; PELTOMAKI, P; SISTONEN, P; AALTONEN, LA; NYSTROMLAHTI, M; GUAN, XY; ZHANG, J; MELTZER, PS; YU, JW; KAO, FT; CHEN, DJ; CEROSALETTI, KM; FOURNIER, REK; TODD, S; LEWIS, T; LEACH, RJ; NAYLOR, SL; WEISSENBACH, J; MECKLIN, JP; JARVINEN, H; PETERSEN, GM; HAMILTON, SR; GREEN, J; JASS, J; WATSON, P; LYNCH, HT; TRENT, JM; DELACHAPELLE, A; KINZLER, KW; VOGELSTEIN, B				LEACH, FS; NICOLAIDES, NC; PAPADOPOULOS, N; LIU, B; JEN, J; PARSONS, R; PELTOMAKI, P; SISTONEN, P; AALTONEN, LA; NYSTROMLAHTI, M; GUAN, XY; ZHANG, J; MELTZER, PS; YU, JW; KAO, FT; CHEN, DJ; CEROSALETTI, KM; FOURNIER, REK; TODD, S; LEWIS, T; LEACH, RJ; NAYLOR, SL; WEISSENBACH, J; MECKLIN, JP; JARVINEN, H; PETERSEN, GM; HAMILTON, SR; GREEN, J; JASS, J; WATSON, P; LYNCH, HT; TRENT, JM; DELACHAPELLE, A; KINZLER, KW; VOGELSTEIN, B			MUTATIONS OF A MUTS HOMOLOG IN HEREDITARY NONPOLYPOSIS COLORECTAL-CANCER	CELL			English	Article							MISMATCH REPAIR; ESCHERICHIA-COLI; CHROMOSOME MICRODISSECTION; SACCHAROMYCES-CEREVISIAE; HUMAN GENOME; DNA; GENE; IDENTIFICATION; CLONING; LOCUS	Recent studies have shown that a locus responsible for hereditary nonpolyposis colorectal cancer (HNPCC) is on chromosome 2p and that tumors developing in these patients contain alterations in microsatellite sequences (RER+ phenotype). We have used chromosome microdissection to obtain highly polymorphic markers from chromosome 2p16. These and other markers were ordered in a panel of somatic cell hybrids and used to define a 0.8 Mb interval containing the HNPCC locus. Candidate genes were then mapped, and one was found to lie within the 0.8 Mb interval. We identified this candidate by virtue of its homology to mutS mismatch repair genes. cDNA clones were obtained and the sequence used to detect germline mutations, including those producing termination codons, in HNPCC kindreds. Somatic as well as germline mutations of the gene were identified in RER+ tumor cells. This mutS homolog is therefore likely to be responsible for HNPCC.	UNIV HELSINKI, DEPT MED GENET, SF-00290 HELSINKI 29, FINLAND; JOHNS HOPKINS ONCOL CTR, BALTIMORE, MD 21231 USA; NATL CTR HUMAN GENOME RES, BETHESDA, MD 20892 USA; ELEANOR ROOSEVELT INST CANC RES, DENVER, CO 80206 USA; LOS ALAMOS NATL LAB, DIV LIFE SCI, LOS ALAMOS, NM 87545 USA; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA; UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX 78284 USA; GENETHON, EVRY, FRANCE; INST PASTEUR, CNRS, URA 1445, UNITE GENET MOLEC HUMAINE, F-75724 PARIS 15, FRANCE; JOHNS HOPKINS UNIV, SCH PUBL HLTH & HYG, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, BALTIMORE, MD 21205 USA; MEM UNIV NEWFOUNDLAND, ST JOHNS A1B 3V6, NEWFOUNDLAND, CANADA; UNIV AUCKLAND, SCH MED, DEPT PATHOL, 92019 AUCKLAND, NEW ZEALAND	University of Helsinki; Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); United States Department of Energy (DOE); Los Alamos National Laboratory; Fred Hutchinson Cancer Center; University of Texas System; University of Texas Health San Antonio; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Johns Hopkins University; Johns Hopkins University; Memorial University Newfoundland; University of Auckland			Mecklin, Jukka-Pekka/AAC-9650-2019; Aaltonen, Lauri/A-5375-2010; Papadopoulos, Nickolas/K-7272-2012; Guan, Xin-Yuan/A-3639-2009; /A-3639-2009	Aaltonen, Lauri/0000-0001-6839-4286; Leach, Robin/0000-0002-3201-5579; Peltomaki, Paivi/0000-0001-8819-2980; Nystrom, Minna/0000-0003-0827-0243; Guan, Xin-Yuan/0000-0002-4485-6017; Parsons, Ramon/0000-0002-6656-3514; /0000-0003-1874-9805	NATIONAL CANCER INSTITUTE [R01CA047527, R01CA035494, R37CA035494] Funding Source: NIH RePORTER; NCI NIH HHS [CA47527, CA09320, CA35494] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; BAYLIN SB, 1991, CANCER CELL, V3, P390; Boveri T, 1914, FRAGE ENTSTEHUNG MAL, V1; BURKS RT, 1993, IN PRESS ONCOGENE; BUSSEY HJR, 1990, FAMILIAL ADENOMATOUS, P1; CHEN DJ, 1992, GENOMICS, V13, P1088, DOI 10.1016/0888-7543(92)90023-L; CHEN DJ, 1994, IN PRESS GENOMICS; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GUAN XY, 1993, HUM MOL GENET, V2, P1117, DOI 10.1093/hmg/2.8.1117; HAN HJ, 1993, CANCER RES, V53, P5087; HANASH SM, 1993, GENE CHROMOSOME CANC, V8, P34, DOI 10.1002/gcc.2870080107; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JASS JR, 1992, GUT, V33, P783, DOI 10.1136/gut.33.6.783; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KAO FT, 1991, P NATL ACAD SCI USA, V88, P1844, DOI 10.1073/pnas.88.5.1844; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNUDSON AG, 1993, NAT GENET, V5, P103, DOI 10.1038/ng1093-103; KOURI M, 1990, CANCER, V65, P1825, DOI 10.1002/1097-0142(19900415)65:8<1825::AID-CNCR2820650827>3.0.CO;2-H; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LOTHE RA, 1993, CANCER RES, V53, P5849; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; LYNCH HT, 1966, ARCH INTERN MED, V117, P206, DOI 10.1001/archinte.117.2.206; MELTZER PS, 1992, NAT GENET, V1, P24, DOI 10.1038/ng0492-24; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; PARSONS R, 1993, CELL, V75; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1993, CANCER RES, V53, P5853; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; PUKKILA PJ, 1983, GENETICS, V104, P571; REENAN RAG, 1992, GENETICS, V132, P963; RISINGER JI, 1993, CANCER RES, V53, P5100; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; Spurr Nigel K., 1993, Cytogenetics and Cell Genetics, V64, P69, DOI 10.1159/000133564; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TRASK B, 1989, GENOMICS, V5, P710, DOI 10.1016/0888-7543(89)90112-2; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; VOGELSTEIN B, 1987, CANCER RES, V47, P4806; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; Warthin AS, 1913, ARCH INTERN MED, V12, P546; WATSON P, 1993, CANCER, V71, P677, DOI 10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#; WEBB GC, 1993, GENOMICS, V18, P14, DOI 10.1006/geno.1993.1421; Weber J, 1989, AM J HUM GENET, V44, P338; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	61	2108	2178	1	123	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 17	1993	75	6					1215	1225		10.1016/0092-8674(93)90330-S	http://dx.doi.org/10.1016/0092-8674(93)90330-S			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	8261515	hybrid			2022-12-28	WOS:A1993MM89300019
J	HUANG, D; OBRIEN, RG; HARMAN, E; AULL, L; REENTS, S; VISSER, J; SHIEH, G; HENDELES, L				HUANG, D; OBRIEN, RG; HARMAN, E; AULL, L; REENTS, S; VISSER, J; SHIEH, G; HENDELES, L			DOES AMINOPHYLLINE BENEFIT ADULTS ADMITTED TO THE HOSPITAL FOR AN ACUTE EXACERBATION OF ASTHMA	ANNALS OF INTERNAL MEDICINE			English	Article						AMINOPHYLLINE; ASTHMA; THERPHYLLINE; ALBUTEROL; METHYLPREDNISOLONE	DOSE-RESPONSE; THEOPHYLLINE; TOXICITY; THERAPY; MODELS	Objective: To determine the effect of adding intravenous theophylline (administered as aminophylline) to nebulizations of albuterol and intravenous methylprednisolone in adults hospitalized for acute asthma. Design: Randomized, placebo-controlled, double-blind study. Setting: Inpatient service of a tertiary-care, university teaching hospital. Patients: 21 adults (22 to 48 years old)-10 in the aminophylline group and 11 in the placebo group. Interventions: Nebulized albuterol, 2.5 or 5.0 mg every 0.5 to 4 hours; intravenous methylprednisolone, 60 mg every 6 hours; and either individualized doses of aminophylline or placebo for 48 hours. Measurements: Forced expiratory volume in 1 second (FEV1), the number of ''as needed'' albuterol nebulizations and total dose, asthma symptom scores, and adverse effects. Results: At admission from the emergency department, the mean +/- SD baseline FEV1 was 49% +/- 19% of the predicted value in the aminophylline group and 43% +/- 13% of the predicted value in the placebo group. The improvement in FEV1 at 3 hours was greater in the aminophylline group (29% +/- 23% compared with 10% +/- 10% in the placebo group; mean difference, 19 percentage points; 95% CI, 3 to 35 percentage points; P = 0.023). At 48 hours, FEV1 was 75% +/- 19% of the predicted value in the aminophylline group and 58% +/- 15% of the predicted value in the placebo group (mean difference, 17 percentage points; CI, 0.2 to 34.8 percentage points; P = 0.048). Aminophylline-treated patients required fewer nebulizations of albuterol (10.3 +/- 3.8 compared with 16.4 +/- 5.3; mean difference, -6.1; CI, -10.3 to -1.8) and less total dosage (34 +/- 16 mg compared with 70 +/- 34 mg; mean difference, -36 mg; CI, -60.6 to -11.3 mg P = 0.02). No statistical differences were observed in asthma symptom scores or frequency of adverse effects. Conclusions: Individualized doses of intravenous theophylline added to frequent nebulizations of albuterol and intravenous methylprednisolone appear to benefit adults admitted to the hospital with acute asthma and are well tolerated when serum concentrations are maintained in the therapeutic range.	UNIV FLORIDA, HLTH SCI CTR, BOX 100486, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida			Shieh, Gwowen/E-2837-2013	Shieh, Gwowen/0000-0001-8611-4495				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BROWN MB, 1974, J AM STAT ASSOC, V69, P364, DOI 10.2307/2285659; CARTER E, 1993, J PEDIATR-US, V122, P470, DOI 10.1016/S0022-3476(05)83443-2; CONLON M, 1990, COMPUT STAT DATA AN, V9, P237, DOI 10.1016/0167-9473(90)90123-Y; COSTAIN D, 1990, BRIT MED J, V301, P797; FANTA CH, 1986, AM J MED, V80, P5, DOI 10.1016/0002-9343(86)90041-0; GUMPERTZ M, 1989, AM STAT, V43, P203, DOI 10.2307/2685362; HENDELES L, 1977, DRUG INTEL CLIN PHAR, V11, P12, DOI 10.1177/106002807701100101; HENDELES L, 1982, AM J HOSP PHARM, V39, P249, DOI 10.1093/ajhp/39.2.249; HERMANN G, 1987, J LAB CLIN MED, V23, P135; HESS D, 1989, Respiratory Care, V34, P717; JENNE JW, 1992, PULM PHARMACOL, V5, P239, DOI 10.1016/0952-0600(92)90066-P; JOLLEY ME, 1981, J ANAL TOXICOL, V5, P236, DOI 10.1093/jat/5.5.236; MITCHELL CA, 1983, EUR J RESPIR DIS, V64, P340; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; OBRIEN RG, 1979, J AM STAT ASSOC, V74, P877, DOI 10.2307/2286416; SCHIFF GD, 1991, ANN INTERN MED, V114, P748, DOI 10.7326/0003-4819-114-9-748; SELF TH, 1990, CHEST, V98, P1317, DOI 10.1378/chest.98.6.1317; SIEGEL D, 1985, AM REV RESPIR DIS, V132, P283; TINKELMAN DG, 1977, J ALLERGY CLIN IMMUN, V59, P109, DOI 10.1016/0091-6749(77)90211-1; VAUGHAN LM, 1986, LANCET, V1, P184; 1991, NIH913042 NAT HEART, P89	22	43	44	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1993	119	12					1155	1160		10.7326/0003-4819-119-12-199312150-00001	http://dx.doi.org/10.7326/0003-4819-119-12-199312150-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM121	8239245				2022-12-28	WOS:A1993MM12100001
J	BREWER, BJ; FANGMAN, WL				BREWER, BJ; FANGMAN, WL			INITIATION AT CLOSELY SPACED REPLICATION ORIGINS IN A YEAST CHROMOSOME	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE CHROMOSOME; S-PHASE; ACTIVATION; TIME; MAP	Replication of eukaryotic chromosomes involves initiation at origins spaced an average of 50 to 100 kilobase pairs. In yeast, potential origins can be recognized as autonomous replication sequences (ARSs) that allow maintenance of plasmids. However, there are more ARS elements than active chromosomal origins. The possibility was examined that close spacing of ARSs can lead to inactive origins. Two ARSs located 6.5 kilobase pairs apart can indeed interfere with each other. Replication is initiated from one or the other ARS with equal probability, but rarely (<5%) from both ARSs on the same DNA molecule.			BREWER, BJ (corresponding author), UNIV WASHINGTON,DEPT GENET SK50,SEATTLE,WA 98195, USA.				PHS HHS [18926] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BREWER B, UNPUB; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; CLARKE L, 1980, NATURE, V287, P504, DOI 10.1038/287504a0; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; FERGUSON BM, 1992, CELL, V68, P333, DOI 10.1016/0092-8674(92)90474-Q; GREENFEDER SA, 1992, MOL BIOL CELL, V3, P999, DOI 10.1091/mbc.3.9.999; HAMLIN JL, 1992, BIOESSAYS, V14, P651, DOI 10.1002/bies.950141002; HUBERMAN JA, 1968, J MOL BIOL, V32, P327, DOI 10.1016/0022-2836(68)90013-2; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; NEWLON CS, 1991, GENETICS, V129, P343; NEWLON CS, 1980, ICN UCLA S MOL CELL, V19, P211; RIVIN CJ, 1980, J CELL BIOL, V85, P108, DOI 10.1083/jcb.85.1.108	16	88	89	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 10	1993	262	5140					1728	1731		10.1126/science.8259517	http://dx.doi.org/10.1126/science.8259517			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	8259517				2022-12-28	WOS:A1993ML22000040
J	SELKER, EU; FRITZ, DY; SINGER, MJ				SELKER, EU; FRITZ, DY; SINGER, MJ			DENSE NONSYMMETRICAL DNA METHYLATION RESULTING FROM REPEAT-INDUCED POINT MUTATION IN NEUROSPORA	SCIENCE			English	Article							CRASSA; GENE; SEQUENCE; CPG; INACTIVATION; BINDING; DENOVO; RIP	Cytosine methylation has been implicated in epigenetic control of gene expression in animals, plants, and fungi. It has been assumed that all methylation in eukaryotes is at symmetrical sequences such as CpG/GpC, because this can explain perpetuation of methylation states. Here the bisulfite genomic sequencing method was used to examine methylation in DNA from a Neurospora gene exposed to repeat-induced point mutation. 5-Methylcytosine was not limited to symmetrical sites and individual molecules showed different patterns and amounts of modification. The methylation extended beyond the mutated region and even beyond the edge of the duplicated segment.	UNIV OREGON, DEPT BIOL, EUGENE, OR 97403 USA	University of Oregon	SELKER, EU (corresponding author), UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035690, R01GM035690] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35690] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antequera F., 1993, Experientia Supplementum (Basel), V64, P169; CAMBARERI EB, 1991, GENETICS, V127, P699; Finnegan E J, 1993, EXS, V64, P218; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GRAYBURN WS, 1989, MOL CELL BIOL, V9, P4416, DOI 10.1128/MCB.9.10.4416; GRUENBAUM Y, 1981, NATURE, V292, P860, DOI 10.1038/292860a0; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; KINNAIRD JH, 1983, GENE, V26, P253, DOI 10.1016/0378-1119(83)90195-6; MARGOLIN B, UNPUB; MIAO V, UNPUB; PALUH JL, 1988, P NATL ACAD SCI USA, V85, P3728, DOI 10.1073/pnas.85.11.3728; RHOUNIM L, 1992, EMBO J, V11, P4451, DOI 10.1002/j.1460-2075.1992.tb05546.x; RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315; Saluz H, 1993, EXS, V64, P11; Sasaki H., 1993, DNA methylation: molecular biology and biological significance., P469; SCHWEIZER M, 1981, P NATL ACAD SCI-BIOL, V78, P5086, DOI 10.1073/pnas.78.8.5086; SELKER E, UNPUB; SELKER EU, 1987, SCIENCE, V238, P48, DOI 10.1126/science.2958937; SELKER EU, 1985, P NATL ACAD SCI USA, V82, P8114, DOI 10.1073/pnas.82.23.8114; SELKER EU, 1990, TRENDS BIOCHEM SCI, V15, P103, DOI 10.1016/0968-0004(90)90193-F; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SELKER EU, 1988, P NATL ACAD SCI USA, V85, P6870, DOI 10.1073/pnas.85.18.6870; SELKER EU, 1993, DNA METHYLATION MOL, P212; TOTH M, 1990, J MOL BIOL, V214, P673, DOI 10.1016/0022-2836(90)90285-T; TURKER MS, 1989, J BIOL CHEM, V264, P11632; WOODCOCK DM, 1987, BIOCHEM BIOPH RES CO, V145, P888, DOI 10.1016/0006-291X(87)91048-5; YISRAELI J, 1984, DNA METHYLATION BIOC, P353	27	115	119	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1993	262	5140					1724	1728		10.1126/science.8259516	http://dx.doi.org/10.1126/science.8259516			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	8259516				2022-12-28	WOS:A1993ML22000039
J	SPIRIO, L; OLSCHWANG, S; GRODEN, J; ROBERTSON, M; SAMOWITZ, W; JOSLYN, G; GELBERT, L; THLIVERIS, A; CARLSON, M; OTTERUD, B; LYNCH, H; WATSON, P; LYNCH, P; LAURENTPUIG, P; BURT, R; HUGHES, JP; THOMAS, G; LEPPERT, M; WHITE, R				SPIRIO, L; OLSCHWANG, S; GRODEN, J; ROBERTSON, M; SAMOWITZ, W; JOSLYN, G; GELBERT, L; THLIVERIS, A; CARLSON, M; OTTERUD, B; LYNCH, H; WATSON, P; LYNCH, P; LAURENTPUIG, P; BURT, R; HUGHES, JP; THOMAS, G; LEPPERT, M; WHITE, R			ALLELES OF THE APC GENE - AN ATTENUATED FORM OF FAMILIAL POLYPOSIS	CELL			English	Article							MULTIPLE INTESTINAL NEOPLASIA; GERM-LINE MUTATIONS; ADENOMATOUS POLYPOSIS; COLON CANCER; GEL-ELECTROPHORESIS; COLORECTAL CANCERS; IDENTIFICATION; CHROMOSOME-5; LOCUS; DNA	An attenuated form of familial adenomatous polyposis coli, AAPC, causes relatively few colonic polyps, but still carries a significant risk of colon cancer. The mutant alleles responsible for this attenuated phenotype have been mapped in several families to the adenomatous polyposis coli (APC) locus on human chromosome 5q. Four distinct mutations in the APC gene have now been identified in seven AAPC families. These mutations that predict truncation products, either by single base pair changes or frameshifts, are similar to mutations identified in families with classical APC. However, they differ in that the four mutated sites are located very close to one another and nearer the 5' end of the APC gene than any base substitutions or small deletions yet discovered in patients with classical APC.	INST CURIE,GENET TUMEURS LAB,F-75231 PARIS,FRANCE; UNIV CINCINNATI,MED CTR,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267; UNIV UTAH,SCH MED,DEPT PATHOL,SALT LAKE CITY,UT 84112; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; BRISTOL MYERS SQUIBB CO,PHARMACEUT RES INST,PRINCETON,NJ 08543; CREIGHTON UNIV,SCH MED,DEPT PREVENT MED PUBL HLTH,OMAHA,NE 68178; CREIGHTON UNIV,SCH MED,DEPT MED GASTROENTEROL,OMAHA,NE 68178; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MED ONCOL,HOUSTON,TX 77030; HOP BICETRE,SERV GASTROENTEROL,F-94270 LE KREMLIN BICETR,FRANCE; UNIV UTAH,SCH MED,DIV GASTROENTEROL,SALT LAKE CITY,UT 84112; ST MARKS HOSP,SALT LAKE CITY,UT 84124	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University System of Ohio; University of Cincinnati; Utah System of Higher Education; University of Utah; Fred Hutchinson Cancer Center; Bristol-Myers Squibb; Creighton University; Creighton University; University of Texas System; UTMD Anderson Cancer Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Utah System of Higher Education; University of Utah	SPIRIO, L (corresponding author), UNIV UTAH,HOWARD HUGHES MED INST,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.		Olschwang, Sylviane/G-2716-2013	Olschwang, Sylviane/0000-0001-7078-3029				BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOURNE HR, 1991, NATURE, V353, P696, DOI 10.1038/353696b0; BOURNE HR, 1991, NATURE, V351, P188, DOI 10.1038/351188a0; BURT RW, 1988, GASTROENTEROL CLIN N, V17, P657; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FISCHER SG, 1983, P NATL ACAD SCI-BIOL, V80, P1579, DOI 10.1073/pnas.80.6.1579; FODDE R, 1992, GENOMICS, V13, P1162, DOI 10.1016/0888-7543(92)90032-N; GORDON A, 1992, NATURE, V358, P288, DOI 10.1038/358288a0; GRODEN J, 1993, AM J HUM GENET, V52, P263; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; JOSLYN G, 1993, IN PRESS P NATL ACAD; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; LINDGREN V, 1992, AM J HUM GENET, V50, P988; LYNCH HT, 1992, DIS COLON RECTUM, V35, P411, DOI 10.1007/BF02049396; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MOSER AR, 1992, J CELL BIOL, V116, P517; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAKAMURA Y, 1988, AM J HUM GENET, V43, P638; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OLSCHWANG S, 1993, AM J HUM GENET, V52, P273; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SPIRIO L, 1992, AM J HUM GENET, V51, P92; SPIRIO L, 1991, NUCLEIC ACIDS RES, V19, P6348, DOI 10.1093/nar/19.22.6348; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, CANCER RES, V53, P2728; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VARESCO L, 1993, AM J HUM GENET, V52, P280; 1979, 3 UT CANC REG REP	41	495	501	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 3	1993	75	5					951	957		10.1016/0092-8674(93)90538-2	http://dx.doi.org/10.1016/0092-8674(93)90538-2			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252630	Bronze			2022-12-28	WOS:A1993MK96600014
J	SCHALL, JD; HANES, DP				SCHALL, JD; HANES, DP			NEURAL BASIS OF SACCADE TARGET SELECTION IN FRONTAL EYE FIELD DURING VISUAL-SEARCH	NATURE			English	Article							RHESUS-MONKEYS; NEURONS; MOVEMENTS	CONSPICUOUS visual features commonly attract gaze1,2, but how the brain selects targets for eye movements is not known. We investigated target selection in rhesus monkeys performing a visual search task3 by recording neurons in the frontal eye field, an area known to be responsible for generating purposive eye movements4,5. Neurons with combined visual- and eye movement-related activity were analysed. We found that the initial visual responses to search stimulus arrays were the same whether the target or a distractor was in the response field. We also found that the neural activity evolved to specify target location before the execution of eye movements, ultimately peaking when the target was in the response field and being suppressed when the target was beside but not distant from the response field. These results demonstrate a possible mechanism by which a desired target is fixated and inappropriate eye movements are prevented.			SCHALL, JD (corresponding author), VANDERBILT UNIV,DEPT PSYCHOL,WILSON HALL,NASHVILLE,TN 37240, USA.							ALLMAN J, 1985, ANNU REV NEUROSCI, V8, P407, DOI 10.1146/annurev.ne.08.030185.002203; BRUCE CJ, 1985, J NEUROPHYSIOL, V54, P714, DOI 10.1152/jn.1985.54.3.714; BRUCE CJ, 1985, J NEUROPHYSIOL, V53, P603, DOI 10.1152/jn.1985.53.3.603; CAVE KR, 1990, COGNITIVE PSYCHOL, V22, P225, DOI 10.1016/0010-0285(90)90017-X; CHELAZZI L, 1993, NATURE, V363, P345, DOI 10.1038/363345a0; ENGEL FL, 1977, VISION RES, V17, P95, DOI 10.1016/0042-6989(77)90207-3; GLIMCHER PW, 1992, NATURE, V355, P542, DOI 10.1038/355542a0; KOCH C, 1985, HUM NEUROBIOL, V4, P219; Leichnetz G R, 1988, Rev Oculomot Res, V2, P365; OTTES FP, 1987, EXP BRAIN RES, V66, P465, DOI 10.1007/BF00270679; SCHALL JD, 1991, J NEUROPHYSIOL, V66, P530, DOI 10.1152/jn.1991.66.2.530; SCHALL JD, 1991, J NEUROPHYSIOL, V66, P559, DOI 10.1152/jn.1991.66.2.559; SEGRAVES MA, 1987, J NEUROPHYSIOL, V58, P1387, DOI 10.1152/jn.1987.58.6.1387; SEGRAVES MA, 1992, J NEUROPHYSIOL, V68, P1967, DOI 10.1152/jn.1992.68.6.1967; TREISMAN A, 1988, Q J EXP PSYCHOL-A, V40, P201, DOI 10.1080/02724988843000104; Yarbus A.L., 1967, EYE MOVEMENTS VISION, DOI 10.1007/978-1-4899-5379-7	16	330	332	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 2	1993	366	6454					467	469		10.1038/366467a0	http://dx.doi.org/10.1038/366467a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK098	8247155				2022-12-28	WOS:A1993MK09800065
J	HABRAKEN, Y; SUNG, P; PRAKASH, L; PRAKASH, S				HABRAKEN, Y; SUNG, P; PRAKASH, L; PRAKASH, S			YEAST EXCISION-REPAIR GENE RAD2 ENCODES A SINGLE-STRANDED-DNA ENDONUCLEASE	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; COMPLEX; PROTEIN; HOMOLOG; SSL2	IN eukaryotes nucleotide excision repair of DNA damaged by ultraviolet radiation requires several gene products; defects in this process result in the cancer-prone syndrome xeroderma pigmentosum (XP) in humans1,2. The RAD2 gene is one of at least seven genes indispensable for excision repair in the yeast Saccharomyces cerevisiae2, and its encoded protein shares remarkable homology with the XP group-G gene product3. Here we overproduce the RAD2-encoded protein in S. cerevisiae, purify it to near homogeneity, and show that RAD2 protein in the presence of magnesium degrades circular single-stranded DNA. The RAD2 endonuclease is specific for single-stranded DNA as it does not act on double-stranded DNA. Given the absolute requirement for RAD2 in the incision step of excision repair, our findings directly implicate RAD2 protein and its human homologue XPG protein as a catalytic component that incises the damaged DNA strand during excision repair. Furthermore, our results indicate that eukaryotes probably employ two distinct endonuclease activities to mediate the dual incision at the damage site.	UTMB,SEALY CTR MOLEC SCI,MED RES BLDG,ROUTE J61,11TH ST & MECH,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444				BAILLY V, 1992, P NATL ACAD SCI USA, V89, P8273, DOI 10.1073/pnas.89.17.8273; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; KINGSMAN SM, 1987, METHOD ENZYMOL, V152, P330; MADURA K, 1986, J BACTERIOL, V166, P914, DOI 10.1128/jb.166.3.914-923.1986; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; PARK E, 1992, P NATL ACAD SCI USA, V89, P11416, DOI 10.1073/pnas.89.23.11416; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SUNG P, 1993, J BIOL CHEM, V268, P26391; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1992, NATURE, V355, P743, DOI 10.1038/355743a0; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0	16	125	128	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 25	1993	366	6453					365	368		10.1038/366365a0	http://dx.doi.org/10.1038/366365a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ705	8247134				2022-12-28	WOS:A1993MJ70500055
J	GYURIS, J; GOLEMIS, E; CHERTKOV, H; BRENT, R				GYURIS, J; GOLEMIS, E; CHERTKOV, H; BRENT, R			CDI1, A HUMAN G1-PHASE AND S-PHASE PROTEIN PHOSPHATASE THAT ASSOCIATES WITH CDK2	CELL			English	Article							YEAST TRANSCRIPTIONAL ACTIVATORS; HOMEODOMAIN RECOGNITION HELIX; AMINO-ACID SEQUENCE; CELL-CYCLE; TYROSINE-PHOSPHATASE; FISSION-YEAST; SACCHAROMYCES-CEREVISIAE; DNA SPECIFICITY; HUMAN HOMOLOG; G1 CYCLIN	We used the interaction trap, a yeast genetic selection for interacting proteins, to isolate human cyclin-dependent kinase interactor 1 (Cdi1). In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Ckd4. In HeLa cells, Cdi1 is expressed at the G1 to S transition, and the protein forms stable complexes with Cdk2. Cdi1 bears weak sequence similarity to known tyrosine and dual specificity phosphatases. In vitro, Cdi1 removes phosphate from tyrosine residues in model substrates, but a mutant protein that bears a lesion in the putative active site cysteine does not. Overexpression of wild-type Cdi1 delays progression through the cell cycle in yeast and HeLa cells; delay is dependent on Cdi1 phosphatase activity. These experiments identify Cdi1 as a novel type of protein phosphatase that forms complexes with cyclin-dependent kinases.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Golemis, Erica/0000-0003-3618-3673				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BRENT R, 1984, NATURE, V312, P612, DOI 10.1038/312612a0; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EBINA Y, 1983, J BIOL CHEM, V258, P3258; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ENOCH T, 1991, CELL, V65, P921, DOI 10.1016/0092-8674(91)90542-7; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUAN K, 1991, J BIOL CHEM, V266, P12964; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HALL FL, 1993, ONCOGENE, V8, P1377; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HARLOW E, 1988, ANTIBODIES LABORATOR; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HUSE WD, 1988, STRATEGIES, V1, P1; ISHABASHI T, 1992, P NATL ACAD SCI USA, V89, P12170; JIMENEZ J, 1990, EMBO J, V9, P3565, DOI 10.1002/j.1460-2075.1990.tb07567.x; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1988, CELL, V55, P443, DOI 10.1016/0092-8674(88)90030-X; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OTTILIE S, 1991, P NATL ACAD SCI USA, V88, P3455, DOI 10.1073/pnas.88.8.3455; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SILVER PA, 1986, MOL CELL BIOL, V6, P4763, DOI 10.1128/MCB.6.12.4763; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAN J, 1992, J BIOL CHEM, V267, P11274; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	90	1339	1449	1	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					791	803		10.1016/0092-8674(93)90498-F	http://dx.doi.org/10.1016/0092-8674(93)90498-F			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242750	Bronze			2022-12-28	WOS:A1993MH74900023
J	KHAN, IH; CATTO, GRD; MACLEOD, AM				KHAN, IH; CATTO, GRD; MACLEOD, AM			LESSON OF THE WEEK - SEVERE LACTIC-ACIDOSIS IN PATIENT RECEIVING CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS	BRITISH MEDICAL JOURNAL			English	Article							LACTATE		ABERDEEN ROYAL INFIRM,RENAL UNIT,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen								DIXON SR, 1970, CLIN SCI, V39, P51, DOI 10.1042/cs0390051; FALLER B, 1984, PERITON DIALYSIS B, V4, P10; ING TS, 1981, INT J ARTIF ORGANS, V4, P308, DOI 10.1177/039139888100400611; LIM P-S, 1992, Taiwan yixuehui zazhi, V91, P374; NAPARSTEK Y, 1982, ISRAEL J MED SCI, V18, P513; OH MS, 1985, METABOLISM, V34, P621, DOI 10.1016/0026-0495(85)90088-5; VARIZI ND, 1979, AM J MED, V67, P392	7	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1993	307	6911					1056	1057		10.1136/bmj.307.6911.1056	http://dx.doi.org/10.1136/bmj.307.6911.1056			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD556	8251784	Bronze, Green Published			2022-12-28	WOS:A1993MD55600027
J	NAZARETH, I; KING, M; HAINES, A; TAI, SS; HALL, G				NAZARETH, I; KING, M; HAINES, A; TAI, SS; HALL, G			CARE OF SCHIZOPHRENIA IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article									ROYAL FREE HOSP, SCH MED, ACAD DEPT PSYCHIAT, LONDON NW3 2QG, ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	NAZARETH, I (corresponding author), UCL, WHITTINGTON HOSP, SCH MED, DEPT PRIMARY HLTH CARE, LONDON N19 5NF, ENGLAND.		King, Michael B/D-7477-2011	King, Michael B/0000-0003-4715-7171; Haines, Andy/0000-0002-8053-4605; Nazareth, Irwin/0000-0003-2146-9628				Breslow N, 1980, STATISTICAL METHODS, V32; BRUGHA TS, 1989, BRIT J PSYCHIAT, V155, P777, DOI 10.1192/bjp.155.6.777; NAZARETH I, 1993, BRIT MED J, V307, P32, DOI 10.1136/bmj.307.6895.32; NAZARETH ID, 1992, FAM PRACT, V9, P171, DOI 10.1093/fampra/9.2.171; PULLEN I, IN PRESS PSYCHIATRY	5	29	29	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 9	1993	307	6909					910	910		10.1136/bmj.307.6909.910	http://dx.doi.org/10.1136/bmj.307.6909.910			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB847	8241855	Green Published, Bronze			2022-12-28	WOS:A1993MB84700020
J	VERKASALO, PK; PUKKALA, E; HONGISTO, MY; VALJUS, JE; JARVINEN, P; HEIKKILA, KV; KOSKENVUO, M				VERKASALO, PK; PUKKALA, E; HONGISTO, MY; VALJUS, JE; JARVINEN, P; HEIKKILA, KV; KOSKENVUO, M			RISK OF CANCER IN FINNISH CHILDREN LIVING CLOSE TO POWER-LINES	BRITISH MEDICAL JOURNAL			English	Article							ELECTRICAL WIRING CONFIGURATIONS; CHILDHOOD-CANCER; MAGNETIC-FIELDS; LEUKEMIA; EXPOSURE; TUMORS	Objective-To investigate the risk of cancer in children living close to overhead power lines with magnetic fields of greater-than-or-equal-to 0.01 microteslas (muT). Design-Cohort study. Setting-The whole of Finland. Subjects-8300 boys and 66500 girls aged 0-19 years living during 1970-89 within 500 m of overhead power lines of 110-400 kV in magnetic fields calculated to be greater-than-or-equal-to 0.01 muT. Subjects were identified by record linkages of nationwide registers. Main outcome measures-Numbers of observed cases in follow up for cancer and standardised incidence ratios for all cancers and particularly for nervous system tumours, leukemia, and lymphoma. Results-In the whole cohort 140 cases of cancer were observed (145 expected; standardised incidence ratio 0.97, 95% confidence interval 0.81 to 1.1). No statistically significant increases in all cancers and in leukaemia and lymphoma were found in children at any exposure level. A statistically significant excess of nervous system tumours was found in boys (but not in girls) who were exposed to magnetic fields of greater-than-or-equal-to 0.20 muT or cumulative exposure of greater-than-or-equal-to 0.40 muT years. Conclusions-Residential magnetic fields of transmission power lines do not constitute a major public health problem regarding childhood cancer. The small numbers do not allow further conclusions about the risk of cancer in stronger magnetic fields.	UNIV TURKU,DEPT PUBL HLTH,LEMMINKAISENKATU 1,SF-20520 TURKU 52,FINLAND; UNIV HELSINKI,DEPT PUBL HLTH,SF-00014 HELSINKI,FINLAND; FINNISH CANC REGISTRY,INST STAT & EPIDEMIOL CANC RES,SF-00170 HELSINKI,FINLAND; IMATRAN VOIMA OY,SF-01019 VANTAA,FINLAND	University of Turku; University of Helsinki; Finnish Cancer Registry			Heikkilä, Kauko/E-5578-2019	Heikkilä, Kauko/0000-0002-9256-8028				DOLL R, 1992, DOCUMENTS NRPB, V3, P35; FEYCHTING M, 1992, IMM692 KAR I PUBL; Floderus B, 1992, OCCUPATIONAL EXPOSUR; FULTON JP, 1980, AM J EPIDEMIOL, V111, P292, DOI 10.1093/oxfordjournals.aje.a112899; HIGGINSON J, 1992, HUMAN CANCER EPIDEMI, P479; JUUTILAINEN J, 1990, INT ARCH OCC ENV HEA, V62, P289, DOI 10.1007/BF00640835; JUUTILAINEN J, 1989, 289 IM VOIM OY RES R; LI FP, 1982, CANCER EPIDEMIOL, P1012; LONDON SJ, 1991, AM J EPIDEMIOL, V134, P923, DOI 10.1093/oxfordjournals.aje.a116176; MYERS A, 1990, BRIT J CANCER, V62, P1008, DOI 10.1038/bjc.1990.428; OLSEN JH, 1993, BRIT MED J, V307, P891, DOI 10.1136/bmj.307.6909.891; SAVITZ DA, 1988, AM J EPIDEMIOL, V128, P21, DOI 10.1093/oxfordjournals.aje.a114943; TOMENIUS L, 1986, BIOELECTROMAGNETICS, V7, P191, DOI 10.1002/bem.2250070209; VALJUS J, 1993, ELECTRICITY AND MAGNETISM IN BIOLOGY AND MEDICINE, P426; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273, DOI 10.1093/oxfordjournals.aje.a112681; 1951, MANUAL TUMOR NOMENCL; 1992, PUBLICATION NATIONAL, V51	17	177	178	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1993	307	6909					895	899		10.1136/bmj.307.6909.895	http://dx.doi.org/10.1136/bmj.307.6909.895			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB847	8241851	Green Published, Bronze			2022-12-28	WOS:A1993MB84700015
J	MARK, DB; LAM, LC; LEE, KL; JONES, RH; PRYOR, DB; STACK, RS; WILLIAMS, RB; CLAPPCHANNING, NE; CALIFF, RM; HLATKY, MA				MARK, DB; LAM, LC; LEE, KL; JONES, RH; PRYOR, DB; STACK, RS; WILLIAMS, RB; CLAPPCHANNING, NE; CALIFF, RM; HLATKY, MA			EFFECTS OF CORONARY ANGIOPLASTY, CORONARY-BYPASS SURGERY, AND MEDICAL THERAPY ON EMPLOYMENT IN PATIENTS WITH CORONARY-ARTERY DISEASE - A PROSPECTIVE COMPARISON STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						CORONARY ARTERY BYPASS; ANGIOPLASTY; TRANSLUMINAL; PERCUTANEOUS CORONARY ABSENTEEISM; ANGINA PECTORIS; MYOCARDIAL ISCHEMIA	WORK; RETURN; REVASCULARIZATION; PATTERNS; MEN	Objective: To compare return-to-work rates after coronary angioplasty, coronary bypass surgery, and medical therapy in patients with coronary disease. Design: Prospective cohort study. Setting: Tertiary care referral center. Patients: Between March 1986 and June 1990, we enrolled 1252 patients who were younger than 65 years, who had not had previous coronary revascularization, and who were employed. All patients were followed for 1 year. Main Outcome Measure: One-year employment status. Results: After 1 year, 84% of patients who had coronary angioplasty were still working compared with 79% of patients who had bypass surgery and with 76% of patients who received medicine. After adjusting for the more favorable baseline characteristics of patients who had angioplasty (less severe coronary artery disease, better left ventricular function, and less functional impairment), however, no significant differences were noted in 1-year employment rates among the three groups. These adjusted 1-year return-to-work rates were 84% for angioplasty, 80% for surgery, and 79% for medicine (P > 0.05). In a random subset of 72 patients, 23 patients who had angioplasty returned to work after a median of 18 days (mean, 27 days) compared with 54 days (mean, 67 days) for 24 patients having bypass surgery and with 14 days (mean, 45 days) for 25 patients receiving medicine (P = 0.002). Conclusions: Patients who had coronary angioplasty were able to return to work earlier than those who had bypass surgery, but by 1 year no significant difference was noted in employment rates. Neither revascularization strategy improved employment rates when compared with initial treatment using medical therapy.	DUKE UNIV, MED CTR, DEPT MED, DIV CARDIOL, DURHAM, NC 27705 USA; STANFORD UNIV, MED CTR, SCH MED, STANFORD, CA 94305 USA	Duke University; Stanford University				Mark, Daniel/0000-0001-6340-8087; Hlatky, Mark/0000-0003-4686-9441	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL017670, R01HL045702, P01HL036587] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-17670, HL-45702, HL-36587, P01 HL036587] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN JK, 1990, AM J CARDIOL, V66, P921, DOI 10.1016/0002-9149(90)90926-R; ALMEIDA D, 1983, CIRCULATION, V68, P205; BARNES GK, 1977, JAMA-J AM MED ASSOC, V238, P1259, DOI 10.1001/jama.238.12.1259; BOOTH DC, 1991, CIRCULATION, V83, P87, DOI 10.1161/01.CIR.83.1.87; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; DANCHIN N, 1989, EUR HEART J, V10, P54, DOI 10.1093/eurheartj/10.suppl_G.54; DAVIDSON DM, 1983, J CARDIAC REHABIL, V3, P60; DENNIS C, 1988, JAMA-J AM MED ASSOC, V260, P214, DOI 10.1001/jama.260.2.214; FAZIO AF, 1977, CONCURRENT VALIDATIO, P78; FISHER L, 1983, CIRCULATION, V68, P951; FITZGERALD ST, 1989, AM J CARDIOL, V64, P1108, DOI 10.1016/0002-9149(89)90861-8; GUNDLE MJ, 1980, AM J PSYCHIAT, V137, P1591; GUTMANN MC, 1982, CIRCULATION, V66, P33; HAMMERMEISTER KE, 1979, AM J CARDIOL, V44, P105, DOI 10.1016/0002-9149(79)90258-3; Harlan WR, 1989, NATIONAL MED CARE C, V7, P1; HLATKY MA, 1986, AM J CARDIOL, V58, P911, DOI 10.1016/S0002-9149(86)80009-1; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; HLATKY MA, 1990, CIRCULATION, V82, P208; HLATKY MA, 1984, STAT MED, V3, P375, DOI 10.1002/sim.4780030415; HOLMES DR, 1983, AM J CARDIOL, V52, P710, DOI 10.1016/0002-9149(83)90403-4; HOLMES DR, 1984, AM J CARDIOL, V53, pC48, DOI 10.1016/0002-9149(84)90745-8; JOHNSON WD, 1982, CIRCULATION, V65, P1086, DOI 10.1161/01.CIR.65.6.1086; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KARASEK R, 1981, AM J PUBLIC HEALTH, V71, P694, DOI 10.2105/AJPH.71.7.694; KARASEK RA, 1988, AM J PUBLIC HEALTH, V78, P910, DOI 10.2105/AJPH.78.8.910; Mark Daniel B., 1993, Journal of the American College of Cardiology, V21, p216A; MARK DB, 1992, CIRCULATION, V86, P1485, DOI 10.1161/01.CIR.86.5.1485; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; PRYOR DB, 1987, CIRCULATION, V76, P13; PRYOR DB, 1988, TRENDS CORONARY HEAR, P76; RIMM AA, 1976, JAMA-J AM MED ASSOC, V236, P361, DOI 10.1001/jama.236.4.361; ROSATI RA, 1975, ARCH INTERN MED, V135, P1017, DOI 10.1001/archinte.135.8.1017; SMITH HC, 1982, CIRCULATION, V65, P120, DOI 10.1161/01.CIR.65.7.120; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.2307/2333860; 1981, SELECTED CHARACTERIS; 1982, CLASSIFIED INDEX IND	36	56	58	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1994	120	2					111	117		10.7326/0003-4819-120-2-199401150-00003	http://dx.doi.org/10.7326/0003-4819-120-2-199401150-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ671	8256969				2022-12-28	WOS:A1994MQ67100003
J	GREENSPAN, SL; MYERS, ER; MAITLAND, LA; RESNICK, NM; HAYES, WC				GREENSPAN, SL; MYERS, ER; MAITLAND, LA; RESNICK, NM; HAYES, WC			FALL SEVERITY AND BONE-MINERAL DENSITY AS RISK-FACTORS FOR HIP FRACTURE IN AMBULATORY ELDERLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OSTEOPOROSIS; WOMEN; AGE	Objective.-To determine the relative importance of fall characteristics, body habitus, and femoral bone mineral density (BMD) in predicting hip fracture in community-dwelling elderly. Design.-Prospective case-control study. Setting.-Community-based academic hospital. Participants.-A total of 149 ambulatory, community-dwelling fallers (126 women, 23 men) aged 65 years and older, including 72 case patients (fallers with hip fracture) and 77 control fallers (fallers with no hip fracture). Main Outcome Measures.-Fall characteristics, body habitus, femoral BMD. Results.-Significant and independent risk factors for hip fracture in both sexes were direction of the fall (adjusted odds ratio [OR], 5.7; 95% confidence interval [CI], 2.3 to 14.0; P<.001); femoral neck BMD (a decrease of 1 SD; adjusted OR, 2.795% CI, 1.6 to 4.6; P<.001); potential energy of the fall (an increase of 1 SD; adjusted OR, 2.8; 95% CI, 1.5 to 5.2; P<.001); and body mass index (a decrease of 1 SD; adjusted OR, 2.2; 95% CI, 1.2 to 3.8; P<.01). Importantly, the OR for the fall direction was unaffected by the addition or removal of BMD from the model. Conclusions.-We conclude that among elderly fallers-in most of whom hip BMD is already less than the fracture threshold-fall characteristics and body habitus are important risk factors for hip fracture and touch on a domain entirely missed by knowledge of BMD. These data suggest new targets for preventive therapy. In addition to the maintenance of bone density, reductions in fall severity (eg, by use of trochanteric padding or enhancement of muscle strength) may provide additional strategies for prevention of hip fracture in this age group.	BETH ISRAEL HOSP,DEPT MED,DIV GERONTOL,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT ORTHOPAED SURG,ORTHOPAED BIOMECH LAB,BOSTON,MA 02215; BETH ISRAEL HOSP,CHARLES A DANA RES INST,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV GERONTOL,BOSTON,MA 02115; VET ADM MED CTR W ROXBURY,CTR GERIATR RES EDUC & CLIN,BOSTON,MA 02132	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Geriatric Research Education & Clinical Center	GREENSPAN, SL (corresponding author), BETH ISRAEL HOSP,DEPT MED,DIV BONE & MINERAL METAB,330 BROOKLINE AVE,BOSTON,MA 02215, USA.				NCI NIH HHS [CA41295] Funding Source: Medline; NCRR NIH HHS [RR01032] Funding Source: Medline; ODCDC CDC HHS [CC102550] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041295] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001032] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); ODCDC CDC HHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BESDINE RW, 1983, J AM GERIATR SOC, V31, P651, DOI 10.1111/j.1532-5415.1983.tb04150.x; BOHR H, 1983, CLIN ORTHOP RELAT R, V179, P240; CHRISCHILLES EA, 1991, ARCH INTERN MED, V151, P2026, DOI 10.1001/archinte.151.10.2026; CHUMLEA WC, 1985, J AM GERIATR SOC, V33, P116, DOI 10.1111/j.1532-5415.1985.tb02276.x; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; CUMMINGS SR, 1985, AM J MED, V78, P487, DOI 10.1016/0002-9343(85)90343-2; FELSON DT, 1989, J AM GERIATR SOC, V37, P495, DOI 10.1111/j.1532-5415.1989.tb05678.x; GLUER CC, 1990, RADIOLOGY, V174, P223, DOI 10.1148/radiology.174.1.2294552; GRISSO JA, 1991, NEW ENGL J MED, V324, P1326, DOI 10.1056/NEJM199105093241905; GRYFE C I, 1977, Age and Ageing, V6, P201, DOI 10.1093/ageing/6.4.201; HAYES WC, 1993, CALCIFIED TISSUE INT, V52, P192, DOI 10.1007/BF00298717; Hayes WC, 1985, BONE MINERAL RES, P259; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; LAURITZEN JB, 1993, LANCET, V341, P11, DOI 10.1016/0140-6736(93)92480-H; MAITLAND LA, 1993, CALCIFIED TISSUE INT, V52, P85, DOI 10.1007/BF00308313; Melton L J 3rd, 1985, Clin Geriatr Med, V1, P525; MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902; MELTON LJ, 1990, ANN INTERN MED, V112, P516, DOI 10.7326/0003-4819-112-7-516; MELTON LJ, 1988, OSTEOPOROSIS ETIOLOG, P111; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; PRAEMER A, 1992, MUSCULOSKELETAL COND, P143; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; RESNICK NM, 1989, NEW ENGL J MED, V320, P1, DOI 10.1056/NEJM198901053200101; RESNICK NM, 1989, JAMA-J AM MED ASSOC, V261, P1025, DOI 10.1001/jama.261.7.1025; RIGGS BL, 1982, J CLIN INVEST, V70, P716, DOI 10.1172/JCI110667; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; ROSS PD, 1990, CALCIFIED TISSUE INT, V46, P149, DOI 10.1007/BF02555036; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; 1992, HOLOGIC QDR 1000 XRA	31	447	451	0	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	1994	271	2					128	133		10.1001/jama.271.2.128	http://dx.doi.org/10.1001/jama.271.2.128			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MQ083	8264067				2022-12-28	WOS:A1994MQ08300022
J	MADDOX, J				MADDOX, J			A MODEL INSTITUTION ON TRIAL	NATURE			English	Editorial Material																			0	0	0	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 16	1993	366	6456					619	620						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM265	8259203				2022-12-28	WOS:A1993MM26500030
J	MULLER, W; RINGSDORF, H; RUMP, E; WILDBURG, G; ZHANG, X; ANGERMAIER, L; KNOLL, W; LILEY, M; SPINKE, J				MULLER, W; RINGSDORF, H; RUMP, E; WILDBURG, G; ZHANG, X; ANGERMAIER, L; KNOLL, W; LILEY, M; SPINKE, J			ATTEMPTS TO MIMIC DOCKING PROCESSES OF THE IMMUNE-SYSTEM - RECOGNITION-INDUCED FORMATION OF PROTEIN MULTILAYERS	SCIENCE			English	Article							SURFACE RECOGNITION; STREPTAVIDIN; MONOLAYERS; LIPIDS	The assemblage of protein multilayers induced by molecular recognition, as seen, for example, in the immune cascade, has been mimicked by using streptavidin as a docking matrix. For these experiments, this protein matrix was organized on liposomes, monolayers at the air-water interface, and self-assembled layers on gold, all three containing biotin lipids. The docking of streptavidin to biotin at liposomal surfaces was confirmed by circular dichroism. Mixed double and triple layers of streptavidin, concanavalin A, antibody Fab fragments, and hormones were prepared at the air-water interface and on gold surfaces and were characterized by fluorescence microscopy and plasmon spectroscopy. With the use of biotin analogs that have lower binding constants it has been possible to achieve multiple formation and competitive replacement of the oriented protein assemblages.	INST ORGAN CHEM,JJ BECHERWEG 18-20,D-55099 MAINZ,GERMANY; MAX PLANCK INST POLYMER RES,D-55021 MAINZ,GERMANY	Max Planck Society			Zhang, Xi/AAF-9871-2021; Zhang, Xi/C-8136-2011					AHLERS M, 1990, ANGEW CHEM INT EDIT, V29, P1269, DOI 10.1002/anie.199012691; AHLERS M, 1991, MAKROMOL CHEM-M SYMP, V46, P307, DOI 10.1002/masy.19910460143; Ahlers M., 1990, ANGEW CHEM, V102, P1310, DOI [10.1002/ange.19901021114, DOI 10.1002/ANGE.19901021114]; BLANKENBURG R, 1989, BIOCHEMISTRY-US, V28, P8214, DOI 10.1021/bi00446a037; CHAIET L, 1964, ARCH BIOCHEM BIOPHYS, V106, P1, DOI 10.1016/0003-9861(64)90150-X; COOPER NR, 1985, ADV IMMUNOL, V37, P151, DOI 10.1016/S0065-2776(08)60340-5; DARST SA, 1991, BIOPHYS J, V59, P387, DOI 10.1016/S0006-3495(91)82232-9; EBATO H, 1992, ANGEW CHEM, V104, P1064; EBATO H, 1992, ANGEW CHEM INT EDIT, V31, P1078; EBERSOLE RC, 1990, J AM CHEM SOC, V112, P3239, DOI 10.1021/ja00164a070; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; GREEN NM, 1990, METHOD ENZYMOL, V184, P51; HAUSSLING L, 1991, MAKROMOL CHEM-M SYMP, V46, P145, DOI 10.1002/masy.19910460118; HAUSSLING L, 1991, ANGEW CHEM, V103, P568; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; HERRON JN, 1992, LANGMUIR, V8, P1413, DOI 10.1021/la00041a028; MORGAN H, 1992, BIOSENS BIOELECTRON, V7, P405, DOI 10.1016/0956-5663(92)85039-D; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; SPINKE J, 1992, THESIS U MAINZ MAINZ	19	189	207	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 10	1993	262	5140					1706	1708		10.1126/science.8259513	http://dx.doi.org/10.1126/science.8259513			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	8259513				2022-12-28	WOS:A1993ML22000032
J	ROSENZWEIG, AC; FREDERICK, CA; LIPPARD, SJ; NORDLUND, P				ROSENZWEIG, AC; FREDERICK, CA; LIPPARD, SJ; NORDLUND, P			CRYSTAL-STRUCTURE OF A BACTERIAL NONHEME IRON HYDROXYLASE THAT CATALYZES THE BIOLOGICAL OXIDATION OF METHANE	NATURE			English	Article								The 2.2 angstrom crystal structure of the 251K alpha2beta2gamma2 dimeric hydroxylase protein of methane mono-oxygenase from Methylococcus capsulatus (Bath) reveals the geometry of the catalytic di-iron core. The two iron atoms are bridged by exogenous hydroxide and acetate ligands and further coordinated by four glutamate residues, two histidine residues and a water molecule. The dinuclear iron centre lies in a hydrophobic active-site cavity for binding methane. An extended canyon runs between alphabeta pairs, which have many long alpha-helices, for possible docking of the reductase and coupling proteins required for catalysis.	MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; UNIV STOCKHOLM, DEPT MOLEC BIOL, S-10691 STOCKHOLM, SWEDEN	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Stockholm University			reddy, indra p/C-5363-2011					ANDERSSON KK, 1992, J AM CHEM SOC, V114, P8711, DOI 10.1021/ja00048a061; ATTA M, 1993, EUR J BIOCHEM, V217, P217, DOI 10.1111/j.1432-1033.1993.tb18236.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; COLBY J, 1978, BIOCHEM J, V171, P461, DOI 10.1042/bj1710461; COLBY J, 1977, BIOCHEM J, V165, P395, DOI 10.1042/bj1650395; DEROSE VJ, 1993, J AM CHEM SOC, V115, P6440, DOI 10.1021/ja00067a081; DEWITT JG, 1991, J AM CHEM SOC, V113, P9219, DOI 10.1021/ja00024a031; ERICSON A, 1988, J AM CHEM SOC, V110, P2330, DOI 10.1021/ja00215a070; FOX BG, 1988, J BIOL CHEM, V263, P10553; FOX BG, 1990, BIOCHEMISTRY-US, V29, P6419, DOI 10.1021/bi00479a013; FOX BG, 1989, J BIOL CHEM, V264, P10023; FOX BG, 1991, J BIOL CHEM, V266, P540; FOX BG, 1993, J AM CHEM SOC, V115, P3688, DOI 10.1021/ja00062a039; FOX BG, 1993, P NATL ACAD SCI USA, V90, P2486, DOI 10.1073/pnas.90.6.2486; FROLAND WA, 1992, J BIOL CHEM, V267, P17588; GREEN J, 1989, J BIOL CHEM, V264, P17698; GREEN J, 1985, J BIOL CHEM, V260, P5795; HAMMAN S, 1993, BIOCHEM BIOPH RES CO, V195, P594, DOI 10.1006/bbrc.1993.2087; HIGGINS IJ, 1980, NATURE, V286, P561, DOI 10.1038/286561a0; JIANG Y, 1993, BIOCHIM BIOPHYS ACTA, V1163, P105, DOI 10.1016/0167-4838(93)90285-Y; JONES TA, 1985, EMBO J, V5, P829; JONES TA, 1989, CRYSTALLOGRAPHIC COM; JONES TA, 1992, MOL REPLACEMENT, P91; KNIGHT S, 1989, THESIS SWEDISH U AGR; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURTZ DM, 1991, BIOCHEM BIOPH RES CO, V181, P337, DOI 10.1016/S0006-291X(05)81423-8; LINDSTROM JE, 1991, APPL ENVIRON MICROB, V57, P2514, DOI 10.1128/AEM.57.9.2514-2522.1991; LIU KE, 1991, J BIOL CHEM, V266, P12836; LIU KE, 1993, J AM CHEM SOC, V115, P939, DOI 10.1021/ja00056a018; LIU KE, 1993, ACTIVATION DIOXYGEN; LUND J, 1985, EUR J BIOCHEM, V147, P291, DOI 10.1111/j.1432-1033.1985.tb08749.x; NORDLUND I, 1990, J BACTERIOL, V172, P6826, DOI 10.1128/jb.172.12.6826-6833.1990; NORDLUND P, 1992, FEBS LETT, V307, P257, DOI 10.1016/0014-5793(92)80690-I; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; NORDLUND P, 1990, THESIS SWEDISH U AGR; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PEARMAN GI, 1988, NATURE, V332, P489, DOI 10.1038/332489a0; PERIANA RA, 1993, SCIENCE, V259, P340, DOI 10.1126/science.259.5093.340; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1985, J BIOL CHEM, V260, P6122; PRIESTLEY ND, 1992, J AM CHEM SOC, V114, P7561, DOI 10.1021/ja00045a037; PRIOR SD, 1985, FEMS MICROBIOL LETT, V29, P105; PRITCHARD PH, 1991, ENVIRON SCI TECHNOL, V25, P372, DOI 10.1021/es00015a002; QUE L, 1990, PROG INORG CHEM, V38, P97; RAAG R, 1991, BIOCHEMISTRY-US, V30, P11420, DOI 10.1021/bi00112a008; RARDIN RL, 1991, NEW J CHEM, V15, P417; ROSENZWEIG AC, 1992, J MOL BIOL, V227, P583, DOI 10.1016/0022-2836(92)90913-5; ROULD MA, 1992, ACTA CRYSTALLOGR A, V48, P751, DOI 10.1107/S0108767392003404; STAINTHORPE AC, 1989, ARCH MICROBIOL, V152, P154, DOI 10.1007/BF00456094; STAINTHORPE AC, 1990, GENE, V91, P27, DOI 10.1016/0378-1119(90)90158-N; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; THOMANN H, 1993, J AM CHEM SOC, V115, P8881, DOI 10.1021/ja00072a068; VINCENT JB, 1990, CHEM REV, V90, P1447, DOI 10.1021/cr00106a004; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WOODLAND MP, 1986, BIOCHIM BIOPHYS ACTA, V873, P237, DOI 10.1016/0167-4838(86)90050-6; YEN KM, 1991, J BACTERIOL, V173, P5315, DOI 10.1128/jb.173.17.5315-5327.1991	57	837	855	3	391	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	1993	366	6455					537	543		10.1038/366537a0	http://dx.doi.org/10.1038/366537a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	8255292				2022-12-28	WOS:A1993ML21800061
J	MILLER, JD; WILHELM, H; GIERASCH, L; GILMORE, R; WALTER, P				MILLER, JD; WILHELM, H; GIERASCH, L; GILMORE, R; WALTER, P			GTP-BINDING AND HYDROLYSIS BY THE SIGNAL RECOGNITION PARTICLE DURING INITIATION OF PROTEIN TRANSLOCATION	NATURE			English	Article							METHIONINE-RICH DOMAIN; ENDOPLASMIC-RETICULUM; MICROSOMAL MEMBRANE; DOCKING PROTEIN; 54-KD PROTEIN; RECEPTOR; SEQUENCE; SUBUNIT; CONTAINS; POLYPEPTIDE	THE signal recognition particle (SRP) consists of one RNA and six protein subunits1,2. The N-terminal domain of the 54K subunit contains a putative GTP-binding site, whereas the C-terminal domain binds signal sequences and SRP RNA3-7. Binding of SRP to the signal sequence as it emerges from the ribosome creates a cytosolic targeting complex containing the nascent polypeptide chain, the translating ribosome, and SRP8. This complex is directed to the endoplasmic reticulum membrane as a result of its interaction with the SRP receptor9-11, a membrane protein composed of two subunits, SRalpha and SRbeta, each of which also contains a GTP-binding domain12,13. In the presence of GTP, SRP receptor binding to SRP causes the latter to dissociate from both the signal sequence and the ribosome13,14. GTP is then hydrolysed so that SRP can be released from the SRP receptor and returned to the cytosol15. Here we show that the 54K subunit (M(r) 54,000) of SRP (SRP54) is a GTP-binding protein stabilized in a nucleotide-free state by signal sequences and that the SRP receptor both increases the affinity of SRP54 for GTP and activates its GTPase. We propose that nucleotide-mediated conformational changes in SRP54 regulate the release of signal sequences and the docking of ribosomes at the endoplasmic reticulum.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; UNIV MASSACHUSETTS, DEPT BIOCHEM, WORCESTER, MA 01655 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Massachusetts System; University of Massachusetts Worcester	MILLER, JD (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.		Gierasch, Lila M/D-1494-2009					BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHEN LL, 1987, J BIOL CHEM, V262, P1427; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CONNOLLY T, IN PRESS J CELL BIOL; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; HIGH S, 1991, J CELL BIOL, V113, P229, DOI 10.1083/jcb.113.2.229; LUTCKE H, 1992, EMBO J, V11, P1543, DOI 10.1002/j.1460-2075.1992.tb05199.x; MCKNIGHT CJ, 1989, J BIOL CHEM, V264, P17293; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MIGLIACCIO G, 1992, J CELL BIOL, V117, P15, DOI 10.1083/jcb.117.1.15; NATH JP, 1985, BIOCHEMISTRY-US, V24, P1555, DOI 10.1021/bi00327a040; NUNNARI J, 1992, Current Opinion in Cell Biology, V4, P573, DOI 10.1016/0955-0674(92)90074-M; PASHEV IG, 1991, TRENDS BIOCHEM SCI, V16, P323, DOI 10.1016/0968-0004(91)90133-G; RAPIEJKO PJ, 1992, J CELL BIOL, V117, P493, DOI 10.1083/jcb.117.3.493; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; SEGEL IH, 1975, ENZYME KINETICS, P105; SIEGEL V, 1985, J CELL BIOL, V100, P1913, DOI 10.1083/jcb.100.6.1913; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WALTER P, 1983, CELL, V34, P525, DOI 10.1016/0092-8674(83)90385-9; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WATANABE M, 1986, NATURE, V323, P71, DOI 10.1038/323071a0; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	32	156	157	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1993	366	6453					351	354		10.1038/366351a0	http://dx.doi.org/10.1038/366351a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ705	8247130				2022-12-28	WOS:A1993MJ70500051
J	GILMORE, R				GILMORE, R			PROTEIN TRANSLOCATION ACROSS THE ENDOPLASMIC-RETICULUM - A TUNNEL WITH TOLL BOOTHS AT ENTRY AND EXIT	CELL			English	Review							SIGNAL-RECOGNITION PARTICLE; POLYPEPTIDE TRANSLOCATION; SECRETORY PROTEINS; ESCHERICHIA-COLI; YEAST; MEMBRANE; COMPLEX; BINDING; ER; MICROSOMES				GILMORE, R (corresponding author), UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01655 USA.							BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KLAPPA P, 1991, EMBO J, V10, P2795, DOI 10.1002/j.1460-2075.1991.tb07828.x; MAYINGER P, 1993, EMBO J, V12, P659, DOI 10.1002/j.1460-2075.1993.tb05699.x; MILLER JD, 1993, IN PRESS NATURE; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; RAPIEJKO PJ, 1992, J CELL BIOL, V117, P493, DOI 10.1083/jcb.117.3.493; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SAVITZ AJ, 1993, J CELL BIOL, V120, P853, DOI 10.1083/jcb.120.4.853; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; YU Y, 1990, J CELL BIOL, V111, P1335, DOI 10.1083/jcb.111.4.1335	31	83	86	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 19	1993	75	4					589	592		10.1016/0092-8674(93)90476-7	http://dx.doi.org/10.1016/0092-8674(93)90476-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242733	Bronze			2022-12-28	WOS:A1993MH74900001
J	YUAN, JY; SHAHAM, S; LEDOUX, S; ELLIS, HM; HORVITZ, HR				YUAN, JY; SHAHAM, S; LEDOUX, S; ELLIS, HM; HORVITZ, HR			THE C-ELEGANS CELL-DEATH GENE CED-3 ENCODES A PROTEIN SIMILAR TO MAMMALIAN INTERLEUKIN-1-BETA-CONVERTING ENZYME	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; CONVERTING ENZYME; BCL-2; GENOME; IDENTIFICATION; INTERLEUKIN-1; ABNORMALITIES; CHROMOSOME; PREVENTION; EXPRESSION	We have cloned the C. elegans cell death gene ced-3. A ced-3 transcript is most abundant during embryogenesis, the stage during which most programmed cell deaths occur. The predicted CED-3 protein shows similarity to human and murine interleukin-1beta-converting enzyme and to the product of the mouse nedd-2 gene, which is expressed in the embryonic brain. The sequences of 12 ced-3 mutations as well as the sequences of ced-3 genes from two related nematode species identify sites of potential functional importance. We propose that the CED-3 protein acts as a cysteine protease in the initiation of programmed cell death in C. elegans and that cysteine proteases also function in programmed cell death in mammals.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139; MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,BOSTON,MA 02129	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital	YUAN, JY (corresponding author), HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024663, R01GM024663] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24663] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BEKTESH S, 1988, GENE DEV, V2, P1277, DOI 10.1101/gad.2.10.1277; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BRENNER S, 1974, GENETICS, V77, P71; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; COHEN JJ, 1984, J IMMUNOL, V132, P38; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; DIGIOVINE FS, 1990, IMMUNOL TODAY, V11, P13; DINARELLO CA, 1991, BLOOD, V77, P1627; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, DEVELOPMENT, V112, P591; ELLIS RE, 1991, GENETICS, V129, P79; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EMMONS SW, 1983, CELL, V32, P55, DOI 10.1016/0092-8674(83)90496-8; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FUKUHARA S, 1979, CANCER RES, V39, P3119; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; GREENWALD IS, 1980, GENETICS, V96, P147; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HODGKIN J, 1988, NEMATODE CAENORHABDI, P491; HOGOQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485; HORVITZ HR, 1979, MOL GEN GENET, V175, P129, DOI 10.1007/BF00425528; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P8640, DOI 10.1073/pnas.86.22.8640; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; KIM SK, 1990, GENE DEV, V4, P357, DOI 10.1101/gad.4.3.357; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; Krause M., 1984, P287; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; LEVINE EG, 1985, BLOOD, V66, P1414; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MCCONKEY DJ, 1990, J IMMUNOL, V145, P1227; MENEELY PM, 1979, GENETICS, V92, P99; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Oppenheim R. W., 1981, STUDIES DEV NEUROBIO, P74; PALUMBO GJ, 1989, VIROLOGY, V172, P262, DOI 10.1016/0042-6822(89)90128-1; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RUVKUN G, 1989, GENETICS, V121, P501; Sambrook J, 1989, MOL CLONING LABORATO; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SPENCE AM, 1990, CELL, V60, P981, DOI 10.1016/0092-8674(90)90346-G; STANISIC T, 1978, INVEST UROL, V16, P19; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRENT C, 1983, GENETICS, V104, P619; TRIEZENBERG SJ, 1991, CURRENT PROTOCOLS MO; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204	61	2189	2318	4	67	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					641	652		10.1016/0092-8674(93)90485-9	http://dx.doi.org/10.1016/0092-8674(93)90485-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242740	Bronze			2022-12-28	WOS:A1993MH74900010
J	HUGHES, JM; PETERS, CJ; COHEN, ML; MAHY, BWJ				HUGHES, JM; PETERS, CJ; COHEN, ML; MAHY, BWJ			HANTAVIRUS PULMONARY SYNDROME - AN EMERGING INFECTIOUS-DISEASE	SCIENCE			English	Editorial Material							KOREAN HEMORRHAGIC-FEVER; ETIOLOGIC AGENT				HUGHES, JM (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, ATLANTA, GA 30333 USA.							Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P258; Edwards D. D., 1993, ASM News (Washington), V59, P342; FELDMANN H, IN PRESS VIRUS RES, V30; FRENCH GR, 1981, SCIENCE, V211, P1046, DOI 10.1126/science.6110243; FRIEDEN TR, 1993, LANCET, V342, P76, DOI 10.1016/0140-6736(93)91285-T; GLASS GE, 1993, J INFECT DIS, V167, P614, DOI 10.1093/infdis/167.3.614; Kirkland G.L., 1989, ADV STUDY PEROMYSCUS; Lederberg J., 1992, EMERGING INFECTIONS; LEE HW, 1978, J INFECT DIS, V137, P298, DOI 10.1093/infdis/137.3.298; MCKEE KT, 1991, TXB HUMAN VIROLOGY, P615; NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; SCHMALJOHN CS, 1985, SCIENCE, V227, P1041, DOI 10.1126/science.2858126; SHEEDY JA, 1954, AM J MED, V16, P619, DOI 10.1016/0002-9343(54)90268-5; ZAKI S, UNPUB; 1993, MORB MORTAL WKLY REP, V42, P1; 1993, MORB MORTAL WKLY REP, V42, P385	17	87	88	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	1993	262	5135					850	851		10.1126/science.8235607	http://dx.doi.org/10.1126/science.8235607			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	8235607				2022-12-28	WOS:A1993MF43800024
J	GIBSON, NA; HOLLMAN, AS; PATON, JY				GIBSON, NA; HOLLMAN, AS; PATON, JY			VALUE OF RADIOLOGICAL FOLLOW-UP OF CHILDHOOD PNEUMONIA	BRITISH MEDICAL JOURNAL			English	Article									ROYAL HOSP SICK CHILDREN,DEPT CHILD HLTH,GLASGOW G3 8SJ,SCOTLAND; ROYAL HOSP SICK CHILDREN,DEPT RADIOL,GLASGOW G3 8SJ,SCOTLAND	University of Glasgow; University of Glasgow								KRAMER MS, 1992, PEDIATRICS, V90, P11; PHELAN PD, 1990, RESPIRATORY ILLNESS; SINGLETON EB, 1988, RADIOGRAPHIC ATLAS P; 1990, PATIENT DOSE REDUCTI	4	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1993	307	6912					1117	1117		10.1136/bmj.307.6912.1117	http://dx.doi.org/10.1136/bmj.307.6912.1117			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME918	8251812	Green Published, Bronze			2022-12-28	WOS:A1993ME91800020
J	FREW, AJ				FREW, AJ			INJECTION IMMUNOTHERAPY	BRITISH MEDICAL JOURNAL			English	Article							DOUBLE-BLIND; DERMATOPHAGOIDES-PTERONYSSINUS; VENOM IMMUNOTHERAPY; PERENNIAL RHINITIS; ALLERGIC RHINITIS; CONTROLLED TRIAL; INDUCED ASTHMA; HAY-FEVER; EXTRACT; HYPOSENSITIZATION	A working party of the British Society for Allergy and Clinical Immunology has reviewed the role of specific allergen immunotherapy in the treatment of allergic disease and produced a position statement summarising the available evidence for efficacy and safety. The working party recommends specific allergen immunotherapy for treating summer hay fever uncontrolled by conventional medication and for wasp and bee venom hypersensitivity. It is not recommended for asthma or for allergic rhinitis due to other allergens. For the recommended indications the risk:benefit ratio is acceptable provided patients are carefully selected; in particular, patients with asthma should be excluded as they are especially vulnerable to adverse reactions. Injections should be given only by doctors experienced in this form of treatment in a clinic where full resuscitative facilities are immediately available. Provided patients remain symptom free a 60 minute observation period after injection is sufficient to detect all serious adverse reactions.			FREW, AJ (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,DEPT MED,SOUTHAMPTON S09 4XY,ENGLAND.		Kelly, Frank J/C-6125-2009	Kelly, Frank J/0000-0003-2558-8392				BLAINEY AD, 1984, ALLERGY, V39, P521, DOI 10.1111/j.1398-9995.1984.tb00873.x; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V79, P947, DOI 10.1016/0091-6749(87)90245-4; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V86, P292, DOI 10.1016/S0091-6749(05)80091-0; CORRADO OJ, 1989, ALLERGY, V44, P108, DOI 10.1111/j.1398-9995.1989.tb02233.x; DREBORG S, 1986, ALLERGY, V41, P131, DOI 10.1111/j.1398-9995.1986.tb00289.x; DREBORG S, 1993, ALLERGY, V48, pS14; EWAN PW, 1985, J ROY SOC MED, V78, P234, DOI 10.1177/014107688507800312; EWAN PW, 1988, CLIN ALLERGY, V18, P501, DOI 10.1111/j.1365-2222.1988.tb02900.x; Freeman J, 1914, LANCET, V1, P1178; GILLMAN SA, 1980, ANN ALLERGY, V45, P351; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; HAJJAOUI A, 1990, J ALLERGY CLIN IMMUN, V85, P473; HEDLIN G, 1986, J ALLERGY CLIN IMMUN, V77, P488, DOI 10.1016/0091-6749(86)90184-3; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; MALLING HJ, 1993, ALLERGY, V48, pS14; MCHUGH SM, 1990, J ALLERGY CLIN IMMUN, V86, P521, DOI 10.1016/S0091-6749(05)80208-8; MULLER U, 1979, ALLERGY, V34, P369, DOI 10.1111/j.1398-9995.1979.tb02006.x; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1990, J ALLERGY CLIN IMMUN, V86, P522; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; ORTOLANI C, 1984, J ALLERGY CLIN IMMUN, V73, P283, DOI 10.1016/S0091-6749(84)80021-4; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SOBOTKA AK, 1976, J IMMUNOL, V117, P84; TAUDORF E, 1987, J ALLERGY CLIN IMMUN, V80, P153, DOI 10.1016/0091-6749(87)90124-2; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; VARNEY VA, IN PRESS J CLIN INVE; WARNER JO, 1978, LANCET, V2, P912; ZEISS CR, 1977, CLIN EXP IMMUNOL, V28, P250; 1992, ALLERGY CONVENTIONAL; 1993, CLIN EXP ALLERGY S3, V23; 1990, J ALLERGY CLIN IMMUN, V85, P526; 1986, BMJ, V293, P948	33	59	65	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1993	307	6909					919	923		10.1136/bmj.307.6909.919	http://dx.doi.org/10.1136/bmj.307.6909.919			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB847	8241857	Green Published, Bronze			2022-12-28	WOS:A1993MB84700024
J	KOUCHOUKOS, NT; DAVILAROMAN, VG; SPRAY, TL; MURPHY, SF; PERRILLO, JB				KOUCHOUKOS, NT; DAVILAROMAN, VG; SPRAY, TL; MURPHY, SF; PERRILLO, JB			REPLACEMENT OF THE AORTIC ROOT WITH A PULMONARY AUTOGRAFT IN CHILDREN AND YOUNG-ADULTS WITH AORTIC-VALVE DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOLLOW-UP; HOMOGRAFT	Background. The optimal substitute for severely diseased aortic valves in children and young adults is unknown. The use of a mechanical prosthesis requires permanent treatment of the patient with anticoagulants and is associated with thromboembolic and hemorrhagic complications. Aortic-valve allografts and porcine bioprostheses, which do not necessitate anticoagulant therapy, may deteriorate and have limited durability. Methods. We therefore evaluated the use of the autologous pulmonary valve (i.e., the patient's own pulmonary valve) and the adjacent pulmonary artery as a replacement for the aortic valve and aortic sinuses in 33 patients. Five of the patients were from 8 to 16 years of age, and 28 were from 20 to 47 years of age. The pulmonary valve and the main pulmonary artery were used to replace the diseased aortic valve and the adjacent aorta. The coronary arteries were detached from the aorta and implanted into the pulmonary artery. The pulmonary valve and artery were replaced with a cryopreserved pulmonary allograft. Results. There were no deaths during follow-up of up to 48 months (mean, 21 months). There were no episodes of infective endocarditis, and no reoperations on the aortic root were necessary. Also, there was no evidence on echocardiography of progressive dilatation of the autografts. With color-flow Doppler imaging, 22 patients were found to have only trivial regurgitation or none, 9 patients to have mild regurgitation, and no patients to have moderate or severe regurgitation across the autograft at the most recent follow-up visit. The mean peak velocity of flow across the autograft was 1.3 m per second (upper limit of normal, 1.8), indicating the absence of stenosis. One patient required reoperation for stenosis of the pulmonary allograft. Conclusions. Although the pulmonary-autograft procedure is more complex than simple aortic-valve replacement, it has been safely applied in selected patients, including young adults. Intermediate follow-up indicates satisfactory function of the autografts, with no dilatation or progressive valvular regurgitation. Pulmonary-root autografts may thus be the best available substitute for diseased aortic valves in children and young adults.	WASHINGTON UNIV,SCH MED,DIV CARDIOTHORAC SURG,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV CARDIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)								ALKHAJA N, 1991, EUR J CARDIO-THORAC, V5, P635, DOI 10.1016/1010-7940(91)90119-5; BARRATTBOYES BG, 1987, CIRCULATION, V75, P768, DOI 10.1161/01.CIR.75.4.768; EDMUNDS LH, 1987, ANN THORAC SURG, V44, P430, DOI 10.1016/S0003-4975(10)63816-7; ELKINS RC, 1992, ANN SURG, V216, P363, DOI 10.1097/00000658-199209000-00016; GEENS M, 1971, J THORAC CARDIOV SUR, V62, P262, DOI 10.1016/S0022-5223(19)42082-5; GEROSA G, 1991, J THORAC CARDIOV SUR, V102, P51; GEROSA G, 1991, ANN THORAC SURG, V51, P424, DOI 10.1016/0003-4975(91)90858-N; GORCZYNSKI A, 1982, THORAX, V37, P535, DOI 10.1136/thx.37.7.535; KOUCHOUKOS NT, 1991, ANN SURG, V214, P308, DOI 10.1097/00000658-199109000-00013; PERRY GJ, 1987, J AM COLL CARDIOL, V9, P952, DOI 10.1016/S0735-1097(87)80254-1; RADLEYSMITH R, 1982, AM J CARDIOL, V49, P1035, DOI 10.1016/0002-9149(82)92546-2; ROMAN MJ, 1989, AM J CARDIOL, V64, P507, DOI 10.1016/0002-9149(89)90430-X; ROSS D, 1992, EUR J CARDIO-THORAC, V6, P113, DOI 10.1016/1010-7940(92)90115-E; ROSS D, 1991, ANN THORAC SURG, V52, P1346, DOI 10.1016/0003-4975(91)90032-L; ROSS DN, 1967, LANCET, V2, P956; Schenck Margaret H., 1993, Journal of the American College of Cardiology, V21, p81A; SIEVERS HH, 1993, J THORAC CARDIOV SUR, V105, P775; STELZER P, 1989, CIRCULATION, V80, P209; WEERASENA N, 1992, EUR J CARDIO-THORAC, V6, P350, DOI 10.1016/1010-7940(92)90171-S	19	216	226	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 6	1994	330	1					1	6		10.1056/NEJM199401063300101	http://dx.doi.org/10.1056/NEJM199401063300101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP649	8259138				2022-12-28	WOS:A1994MP64900001
J	DETSKY, AS; SMALLEY, PS; CHANG, J				DETSKY, AS; SMALLEY, PS; CHANG, J			IS THIS PATIENT MALNOURISHED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUBJECTIVE GLOBAL ASSESSMENT; PARENTERAL-NUTRITION; GASTROINTESTINAL SURGERY; SURGICAL PATIENTS		TORONTO GEN HOSP,DIV GEN INTERNAL MED & CLIN EPIDEMIOL,TORONTO M5G 1L7,ONTARIO,CANADA; WELLESLEY COLL HOSP,DIV GEN INTERNAL MED,TORONTO M4Y 1J3,ONTARIO,CANADA; UNIV TORONTO,DEPT HLTH ADM,TORONTO M5S 1A1,ONTARIO,CANADA; OSHAWA ONTARIO GEN HOSP,DEPT MED,OTTAWA,ON,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	DETSKY, AS (corresponding author), UNIV TORONTO,DEPT MED,TORONTO M5S 1A1,ONTARIO,CANADA.							BAKER JP, 1982, NEW ENGL J MED, V306, P969, DOI 10.1056/NEJM198204223061606; BISTRIAN BR, 1974, JAMA-J AM MED ASSOC, V230, P858, DOI 10.1001/jama.230.6.858; BISTRIAN BR, 1976, JAMA-J AM MED ASSOC, V235, P1567, DOI 10.1001/jama.235.15.1567; BUZBY GP, 1988, AM J CLIN NUTR, V47, P357, DOI 10.1093/ajcn/47.2.357; DETSKY AS, 1987, ANN INTERN MED, V107, P195, DOI 10.7326/0003-4819-107-2-195; DETSKY AS, 1987, JPEN-PARENTER ENTER, V11, P440, DOI 10.1177/0148607187011005440; DETSKY AS, 1987, JPEN-PARENTER ENTER, V11, P8, DOI 10.1177/014860718701100108; DETSKY AS, 1984, JPEN-PARENTER ENTER, V8, P153, DOI 10.1177/0148607184008002153; DETSKY AS, 1984, JPEN-PARENTER ENTER, V8, P245, DOI 10.1177/0148607184008003245; DETSKY AS, 1991, NEW ENGL J MED, V325, P573, DOI 10.1056/NEJM199108223250808; HIRSCH S, 1991, NUTRITION, V7, P35; WINDSOR JA, 1988, ANN SURG, V207, P290, DOI 10.1097/00000658-198803000-00011; 1991, NEW ENGL J MED, V325, P525	13	183	194	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	1994	271	1					54	58		10.1001/jama.271.1.54	http://dx.doi.org/10.1001/jama.271.1.54			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN725	8258889				2022-12-28	WOS:A1994MN72500032
J	WALKERRENARD, PB; VAUGHAN, LM; SAHN, SA				WALKERRENARD, PB; VAUGHAN, LM; SAHN, SA			CHEMICAL PLEURODESIS FOR MALIGNANT PLEURAL EFFUSIONS	ANNALS OF INTERNAL MEDICINE			English	Review							INTRAPLEURAL CORYNEBACTERIUM-PARVUM; UREMIC PERICARDIAL-EFFUSION; INTRACAVITARY BLEOMYCIN; TETRACYCLINE PLEURODESIS; LUNG-CANCER; SPONTANEOUS PNEUMOTHORAX; BREAST-CANCER; TALC POUDRAGE; INSTILLATION; MANAGEMENT	Purpose: To provide information about available agents for chemical pleurodesis. Data Sources: A MEDLINE search (1966 to October 1992) was conducted using the terms malignant pleural effusion and pleurodesis. Study Selection: All articles containing references to patients with recurrent, symptomatic, malignant pleural effusions treated with chemical pleurodesis were selected and reviewed for pleurodesis regimen, number of patients treated, success rate (complete response), and adverse effects. The agents studied included doxycycline, minocycline, tetracycline, bleomycin, cisplatin, doxorubicin, etoposide, fluorouracil, interferon-beta, mitomycin-c, Corynebacterium parvum, methylprednisolone, and talc. Data Extraction: Independent extraction by three observers. Results: Studies including a total of 1168 patients with malignant pleural effusions were reviewed for efficacy of the pleurodesis agent and studies including 1140 patients were reviewed for toxicity. Chemical pleurodesis produced a complete response in 752 (64%) of 1168 patients. The success rate of the pleurodesis agents varied from 0% with etoposide to 93% with talc. Corynebacterium parvum, the tetracyclines, and bleomycin had success rates of 76%, 67%, and 54%, respectively. The most commonly reported adverse effects were pain.(265 of 1140, 23%) and fever (220 of 1140,19%). Conclusions: Doxycycline and minocycline, with success rates of 72% and 86%, respectively, appear to be effective tetracycline-replacement agents in the few patients studied. Talc appears to be the most effective and least expensive agent; however, insufflation has the disadvantages of the expense of thoracoscopy and the usual need for general anesthesia. Bleomycin appears to be less effective than talc and the tetracyclines and is substantially more expensive.	MED UNIV S CAROLINA, COLL MED, 171 ASHLEY AVE, CHARLESTON, SC 29425 USA	Medical University of South Carolina								ADLER RH, 1976, ANN THORAC SURG, V22, P8, DOI 10.1016/S0003-4975(10)63944-6; AELONY Y, 1991, ANN INTERN MED, V115, P778, DOI 10.7326/0003-4819-115-10-778; ALBERTS DS, 1979, CANCER CHEMOTH PHARM, V2, P127; ANDERSEN AP, 1968, ACTA RADIOL THER PHY, V7, P369, DOI 10.3109/02841866809133211; ANTONY VB, 1992, AM REV RESPIR DIS, V146, P1009, DOI 10.1164/ajrccm/146.4.1009; BARTAL AH, 1991, CANCER, V67, P3136, DOI 10.1002/1097-0142(19910615)67:12<3136::AID-CNCR2820671233>3.0.CO;2-N; BAUMANN MH, 1993, INFLAMMATION, V17, P1, DOI 10.1007/BF00916387; BAYLY TC, 1978, CANCER, V41, P1188, DOI 10.1002/1097-0142(197803)41:3<1188::AID-CNCR2820410357>3.0.CO;2-O; BERRY RB, 1992, AM REV RESPIR DIS, V145, P445, DOI 10.1164/ajrccm/145.2_Pt_1.445; BITRAN JD, 1981, J SURG ONCOL, V16, P273, DOI 10.1002/jso.2930160312; Boutin C, 1991, PRACTICAL THORACOSCO; BUBIK JS, 1992, AM J HOSP PHARM, V49, P562, DOI 10.1093/ajhp/49.3.562a; BUSELMEIER TJ, 1976, NEPHRON, V16, P371, DOI 10.1159/000180622; BUSELMEIER TJ, 1978, JAMA-J AM MED ASSOC, V240, P1358, DOI 10.1001/jama.240.13.1358; CASALI A, 1988, CANCER, V62, P806, DOI 10.1002/1097-0142(19880815)62:4<806::AID-CNCR2820620428>3.0.CO;2-4; CHERNOW B, 1977, AM J MED, V63, P695, DOI 10.1016/0002-9343(77)90154-1; DANIEL TM, 1990, ANN THORAC SURG, V50, P186, DOI 10.1016/0003-4975(90)90730-T; DESAI SD, 1979, LANCET, V1, P872; DRYZER SR, 1993, AM REV RESPIR DIS, V147, pA795; ESELIN J, 1991, DICP ANN PHARMAC, V25, P1187; FACTOR SM, 1975, ARCH PATHOL, V99, P499; FELLETTI R, 1983, THORAX, V38, P22, DOI 10.1136/thx.38.1.22; FENTIMAN IS, 1986, EUR J CANCER CLIN ON, V22, P1079, DOI 10.1016/0277-5379(86)90009-X; FINGAR BL, 1992, HOSP PHARM, V27, P622; FRACCHIA AA, 1970, CANCER, V26, P626, DOI 10.1002/1097-0142(197009)26:3<626::AID-CNCR2820260320>3.0.CO;2-3; GRAVELYN TR, 1987, CANCER, V59, P1973, DOI 10.1002/1097-0142(19870601)59:11<1973::AID-CNCR2820591124>3.0.CO;2-2; HAMED H, 1989, BRIT J SURG, V76, P1266, DOI 10.1002/bjs.1800761214; HARTMAN D L, 1992, American Review of Respiratory Disease, V145, pA868; Hatta T, 1990, Kyobu Geka, V43, P283; HAUSHEER FH, 1985, SEMIN ONCOL, V12, P54; HEFFNER JE, 1992, CHEST, V101, P5, DOI 10.1378/chest.101.1.5; HILLERDAL G, 1986, EUR J RESPIR DIS, V69, P204; HOLOYE PY, 1990, CANCER CHEMOTH PHARM, V26, P147, DOI 10.1007/BF02897262; JONES GR, 1969, THORAX, V24, P69, DOI 10.1136/thx.24.1.69; KEFFORD RF, 1980, MED J AUSTRALIA, V2, P447, DOI 10.5694/j.1326-5377.1980.tb131916.x; KESSINGER A, 1987, J SURG ONCOL, V36, P81, DOI 10.1002/jso.2930360202; KITAMURA S, 1981, CURR THER RES CLIN E, V30, P515; LANDVATER L, 1988, CHEST, V93, P1196, DOI 10.1378/chest.93.6.1196; LEAHY BC, 1985, EUR J RESPIR DIS, V66, P50; LEES AW, 1979, CHEST, V75, P51, DOI 10.1378/chest.75.1.51; LESAR TS, 1988, PHARMACOTHERAPY PATH, P922; LIGHT RW, 1990, JAMA-J AM MED ASSOC, V264, P2224, DOI 10.1001/jama.264.17.2224; LIGHT RW, 1992, CHEST, V120, pA524; LUH KT, 1992, CANCER-AM CANCER SOC, V69, P674; MANSSON T, 1988, SCAND J INFECT DIS, P29; MARKMAN M, 1985, MED PEDIATR ONCOL, V13, P191, DOI 10.1002/mpo.2950130406; MASUNO T, 1991, CANCER, V68, P1495, DOI 10.1002/1097-0142(19911001)68:7<1495::AID-CNCR2820680705>3.0.CO;2-6; MCEVOY GK, 1992, AHFS DRUG INFORMATIO, P318; MCLEOD DT, 1985, THORAX, V40, P515, DOI 10.1136/thx.40.7.515; MEJER J, 1977, SCAND J RESPIR DIS, V58, P319; MILLAR JW, 1979, THORAX, V35, P56; MUIR JF, 1987, REV MAL RESPIR, V4, P29; OSTROWSKI MJ, 1986, CANCER, V57, P721, DOI 10.1002/1097-0142(19860215)57:4<721::AID-CNCR2820570407>3.0.CO;2-5; OSTROWSKI MJ, 1989, J SURG ONCOL, P7; OSZKO MA, 1988, DRUG INTEL CLIN PHAR, V22, P15, DOI 10.1177/106002808802200102; PALADINE W, 1976, CANCER, V38, P1903, DOI 10.1002/1097-0142(197611)38:5<1903::AID-CNCR2820380506>3.0.CO;2-A; PEARSON FG, 1966, J THORAC CARDIOV SUR, V51, P732, DOI 10.1016/S0022-5223(19)43303-5; RICHMAN SP, 1981, CANCER TREAT REP, V65, P383; RINALDO JE, 1983, J THORAC CARDIOV SUR, V85, P523; ROSSI GA, 1987, AM REV RESPIR DIS, V135, P885, DOI 10.1164/arrd.1987.135.4.885; ROSSO R, 1988, ONCOLOGY, V45, P253, DOI 10.1159/000226571; RUCKDESCHEL JC, 1991, CHEST, V100, P1528, DOI 10.1378/chest.100.6.1528; RUSCH VW, 1991, J CLIN ONCOL, V9, P313, DOI 10.1200/JCO.1991.9.2.313; SAHN SA, 1988, AM REV RESPIR DIS, V138, P184, DOI 10.1164/ajrccm/138.1.184; SAHN SA, 1985, CLIN CHEST MED, V6, P113; SAHN SA, 1987, SEMIN RESPIR MED, V9, P43, DOI 10.1055/s-2007-1012687; SHEDBALKAR AR, 1971, J THORAC CARDIOV SUR, V61, P492, DOI 10.1016/S0022-5223(19)42241-1; SHERMAN S, 1987, SOUTH MED J, V80, P716, DOI 10.1097/00007611-198706000-00013; SITTON DW, 1992, DRUG TOPICS RED BOOK; SORENSEN PG, 1984, EUR J RESPIR DIS, V65, P131; STIKSA G, 1979, SCAND J RESPIR DIS, V60, P197; STRANGE C, 1993, AM REV RESPIR DIS, V147, pA795; SUHRLAND LG, 1965, ARCH INTERN MED, V116, P431, DOI 10.1001/archinte.1965.03870030111019; VARGAS FS, 1992, CHEST, V102, pA524; VAUGHAN LM, 1992, ANN PHARMACOTHER, V26, P562, DOI 10.1177/106002809202600421; WALLACH HW, 1975, CHEST, V68, P510, DOI 10.1378/chest.68.4.510; WEBB HE, 1978, BRIT MED J, V1, P338, DOI 10.1136/bmj.1.6109.338; WEBB WR, 1992, J THORAC CARDIOV SUR, V103, P881; WOOTEN SA, 1988, CHEST, V94, P960, DOI 10.1378/chest.94.5.960; YOUMANS CR, 1970, AM J SURG, V120, P644, DOI 10.1016/S0002-9610(70)80185-4; YUICHI Y, 1976, GANN, V67, P669; ZALOZNIK AJ, 1983, CANCER-AM CANCER SOC, V51, P752, DOI 10.1002/1097-0142(19830215)51:4<752::AID-CNCR2820510434>3.0.CO;2-7	82	287	300	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1994	120	1					56	64		10.7326/0003-4819-120-1-199401010-00010	http://dx.doi.org/10.7326/0003-4819-120-1-199401010-00010			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP280	8250457				2022-12-28	WOS:A1994MP28000010
J	CHIAVARELLI, M; GUNDRY, SR; RAZZOUK, AJ; BAILEY, LL				CHIAVARELLI, M; GUNDRY, SR; RAZZOUK, AJ; BAILEY, LL			CARDIAC TRANSPLANTATION FOR INFANTS WITH HYPOPLASTIC LEFT-HEART SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FONTAN OPERATION; ALLOTRANSPLANTATION; RECONSTRUCTION	Objective.-To determine whether cardiac transplantation improves the natural history of infants with hypoplastic left-heart syndrome and to examine differences in outcome as a function of the pretransplant period. Design.-Retrospective cohort study. Historical, clinical, and laboratory data were collected during the pretransplant period, the in-hospital period, and for up to 6 years following transplantation. Data were analyzed using the product-limit estimate and the log rank test. Setting.-A tertiary, acute care, university teaching hospital. Patients.-All 111 infants with hypoplastic left-heart syndrome who entered and completed a protocol leading to transplantation from November 19,1985, to December 31, 1991. Infants who died while waiting for transplantation were included. Intervention.-Orthotopic cardiac allotransplantation. Main Outcome Measures.-Pretransplant waiting mortality and its influence on posttransplant survival, operative (in-hospital or within 30 postoperative days in discharged patients) and intermediate-term mortality (5 years), and reoperation rates for cardiac surgery. Results.-Transplantation procedures were performed in 84 infants (76%; 95% confidence interval [CI], 66% to 83%) ranging in age from 3 hours to 151 days. Twenty-seven infants registered for transplantation died while awaiting a donor heart. Operative mortality was 13% (CI, 7% to 23%), and 69 patients were late survivors (62% [CI, 52% to 71%] of the study group and 82% [CI, 72% to 89%] of the transplant recipients). Overall 5-year actuarial survival was 61% (CI, 52% to 70%). Transplant recipients had a 5-year survival of 81% (CI, 71% to 88%). Freedom from reoperation was 89% (CI, 76% to 95%) at 5 years. Conclusions.-Cardiac transplantation for hypoplastic left-heart syndrome has a significant positive impact on the natural history of this uniformly lethal lesion.	LOMA LINDA UNIV,MED CTR,DEPT SURG,LOMA LINDA,CA 92354; LOMA LINDA UNIV,MED CTR,LOMA LINDA INT HEART INST,LOMA LINDA,CA 92354; SUNY HLTH SCI CTR,DIV CARDIOTHORAC SURG,BROOKLYN,NY	Loma Linda University; Loma Linda University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center								ALLAN LD, 1991, LANCET, V337, P959, DOI 10.1016/0140-6736(91)91582-F; BAILEY LL, 1993, J THORAC CARDIOV SUR, V105, P805; BAILEY LL, 1986, NEW ENGL J MED, V315, P949, DOI 10.1056/NEJM198610093151507; BAUM MF, 1991, J HEART LUNG TRANSPL, V10, P848; BOVE EL, 1991, ANN THORAC SURG, V52, P701, DOI 10.1016/0003-4975(91)90981-U; CHIAVARELLI M, 1992, ARCH SURG-CHICAGO, V127, P1072; DRISCOLL DJ, 1992, CIRCULATION, V85, P469, DOI 10.1161/01.CIR.85.2.469; FIXLER DE, 1993, J AM COLL CARDIOL, V21, P1722, DOI 10.1016/0735-1097(93)90393-F; FONTAN F, 1990, CIRCULATION, V81, P1520, DOI 10.1161/01.CIR.81.5.1520; FYLER DC, 1980, PEDIATRICS, V65, P436; JOHNSTON J, 1990, WESTERN J MED, V152, P70; JONAS RA, 1992, 72ND ANN M AM ASS TH; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MURDISON KA, 1990, CIRCULATION, V82, P199; Norwood W I, 1989, Cardiol Clin, V7, P377; NORWOOD WI, 1983, NEW ENGL J MED, V308, P23, DOI 10.1056/NEJM198301063080106; NORWOOD WI, 1991, ANN THORAC SURG, V52, P688, DOI 10.1016/0003-4975(91)90978-Y; NORWOOD WI, 1992, ANN THORAC SURG, V54, P1025, DOI 10.1016/0003-4975(92)90065-C; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; RUIZ CE, 1993, NEW ENGL J MED, V328, P1605, DOI 10.1056/NEJM199306033282205	20	44	44	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1993	270	24					2944	2947		10.1001/jama.270.24.2944	http://dx.doi.org/10.1001/jama.270.24.2944			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM119	8254855				2022-12-28	WOS:A1993MM11900029
J	WOOD, RC; MACDONALD, KL; WHITE, KE; HEDBERG, CW; HANSON, M; OSTERHOLM, MT				WOOD, RC; MACDONALD, KL; WHITE, KE; HEDBERG, CW; HANSON, M; OSTERHOLM, MT			RISK-FACTORS FOR LACK OF DETECTABLE ANTIBODY FOLLOWING HEPATITIS-B VACCINATION OF MINNESOTA HEALTH-CARE WORKERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOMOSEXUAL MEN; EFFICACY; IMMUNOGENICITY; PERSISTENCE; REVACCINATION; EPIDEMIOLOGY; IMMUNIZATION; INJECTION; VIRUS; STAFF	Objective.-To assess the presence of antibody to hepatitis B surface antigen (anti-HBs) at postvaccination testing in Minnesota health care workers receiving recombinant hepatitis B vaccines, and to identify risk factors for lacking anti-HBs following hepatitis B vaccination. Design.-Retrospective cohort study. Setting.-Ten acute care hospitals in Minnesota. Participants.-A total of 595 health care workers who had received hepatitis B vaccine (Recombivax HB or Engerix-B) between June 1987 and December 1991 and who underwent postvaccination testing for anti-HBs within 6 months after receiving the third dose of vaccine. Main Outcome Measure.-Presence or absence of anti-HBs following hepatitis B vaccination. Results.-Five variables were independently associated with lacking anti-HBs by multivariate analysis: vaccine brand, smoking status, gender, age, and body mass index. Stratifying by vaccine brand demonstrated that age (P=.01), body mass index (P<.01), and smoking status (P<.01) were associated with lacking anti-HBs only for Recombivax HB recipients; and gender (P=.03) was associated with lacking anti-HBs only for Engerix-B recipients. After controlling for smoking status, age, gender, and body mass index, recipients of Recombivax HB were more likely to lack anti-HBs than recipients of Engerix-B (relative risk, 2.3; 95% confidence interval, 1.1 to 4.7; P=.02). Conclusions.-Results indicate that certain populations of health care workers are at increased risk of not responding to hepatitis B vaccination. Further studies evaluating immunogenicity of currently available recombinant hepatitis B vaccines in persons at high risk for primary vaccine failure are needed.	MINNESOTA DEPT HLTH, DIV DIS PREVENT & CONTROL, ACUTE DIS EPIDEMIOL SECT, 717 DELAWARE ST SE, MINNEAPOLIS, MN 55440 USA; MEM BLOOD CTR MINNEAPOLIS, MINNEAPOLIS, MN USA; CTR DIS CONTROL & PREVENT, EPIDEMIOL PROGRAM OFF, DIV FIELD EPIDEMIOL, EPIDEM INTELLIGENCE SERV, ATLANTA, GA USA	Minnesota Department of Health (MHD); Centers for Disease Control & Prevention - USA								ANDRE F E, 1988, Southeast Asian Journal of Tropical Medicine and Public Health, V19, P501; ANDRE FE, 1989, AM J MED, V87, pS14, DOI 10.1016/0002-9343(89)90525-1; Breslow N.E., 1980, STAT METHODS CANC RE, P192; COURSAGET P, 1986, LANCET, V2, P1143; COURSAGET P, 1991, LANCET, V337, P1180, DOI 10.1016/0140-6736(91)92857-X; DENTICO P, 1991, VACCINE, V9, P438, DOI 10.1016/0264-410X(91)90132-P; GILKS WR, 1989, LANCET, V2, P1273; Hadler S C, 1990, Infect Dis Clin North Am, V4, P29; HADLER SC, 1986, NEW ENGL J MED, V315, P209, DOI 10.1056/NEJM198607243150401; HADLER SC, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P766; JILG W, 1988, J HEPATOL, V6, P201, DOI 10.1016/S0168-8278(88)80032-1; JILG W, 1990, LANCET, V335, P173, DOI 10.1016/0140-6736(90)90050-F; KRUGMAN S, 1988, VACCINES, P458; LEVY BS, 1977, AM J EPIDEMIOL, V105, P127, DOI 10.1093/oxfordjournals.aje.a112364; MACDONALD KL, 1991, 31ST INT C ANT AG CH; NOMMENSEN FE, 1990, LANCET, V335, P479, DOI 10.1016/0140-6736(90)90716-I; NOMMENSEN FE, 1989, LANCET, V2, P847; OSTERHOLM M, 1979, MINN MED, V62, P683; OSTERHOLM M T, 1985, Journal of the American Medical Association, V254, P3207, DOI 10.1001/jama.254.22.3207; Prevention and control of influenza, 1990, MMWR MORB MORTAL WKL, V39, P1; PRINSEN H, 1987, POSTGRAD MED J, V63, P147; ROGAN PD, 1991, J INFECTION, V22, P5, DOI 10.1016/0163-4453(91)90786-R; SHAPIRO CN, 1990, EPIDEMIOL REV, V12, P221, DOI 10.1093/oxfordjournals.epirev.a036055; SHAW FE, 1989, VACCINE, V7, P425, DOI 10.1016/0264-410X(89)90157-6; Snedicor G.W., 1967, STATISTICAL METHODS, P128; STEVENS CE, 1991, SEMIN PEDIATR INFECT, V2, P135; STREET AC, 1990, INFECT CONT HOSP EP, V11, P525; SZMUNESS W, 1980, NEW ENGL J MED, V303, P833, DOI 10.1056/NEJM198010093031501; UKENA T, 1985, NEW ENGL J MED, V313, P579; WAINWRIGHT RB, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P762; WEBER DJ, 1985, JAMA-J AM MED ASSOC, V254, P3187, DOI 10.1001/jama.254.22.3187; WEST DJ, 1989, AM J INFECT CONTROL, V17, P172, DOI 10.1016/0196-6553(89)90213-7; WESTMORELAND D, 1990, EPIDEMIOL INFECT, V104, P499, DOI 10.1017/S0950268800047506; WIEDERMANN G, 1987, POSTGRAD MED J, V63, P109; ZAJAC BA, 1986, J INFECTION, V13, P39, DOI 10.1016/S0163-4453(86)92668-X; ZOULEK G, 1984, INT S VIRAL HEPATITI, P142; 1991, FED REGISTER, V56, P64004; 1991, JAMA-J AM MED ASSOC, V266, P1338; 1989, MMWR MORB MORTAL WKL, V38, pS9	39	215	228	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1993	270	24					2935	2939		10.1001/jama.270.24.2935	http://dx.doi.org/10.1001/jama.270.24.2935			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM119	8254853				2022-12-28	WOS:A1993MM11900027
J	MYERBURG, RJ; KESSLER, KM; CASTELLANOS, A				MYERBURG, RJ; KESSLER, KM; CASTELLANOS, A			SUDDEN CARDIAC DEATH - EPIDEMIOLOGY, TRANSIENT RISK, AND INTERVENTION ASSESSMENT	ANNALS OF INTERNAL MEDICINE			English	Review							IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; ARRHYTHMIA SUPPRESSION TRIAL; ACUTE MYOCARDIAL-INFARCTION; MALIGNANT VENTRICULAR ARRHYTHMIAS; CORONARY-ARTERY DISEASE; HEART-RATE-VARIABILITY; LATE HOSPITAL PHASE; UNSTABLE ANGINA; EARLY AFTERDEPOLARIZATIONS; ANTIARRHYTHMIC DRUGS	Purpose: To integrate information from the various disciplines that contribute to the understanding of the cause and prevention of sudden cardiac death: identification of new approaches from applied clinical epidemiology; identification and control of transient risk factors; and evaluation of the results of interventions. Data Sources: A broad range of research reports and interpretations of data from English-language journal articles and reviews, published primarily between 1970 and 1993. The fields of study included epidemiology, experimental electrophysiology, clinical observations, and interventions. Study Selection: Continuous literature surveys, done in relation to ongoing clinical and experimental research on sudden cardiac death since 1972. Data Extraction: Included on the basis of relevance to the topics discussed and with confirmation of data and concepts by more than one investigator when available. Data Synthesis: Information from several disciplines was integrated by the authors to synthesize new ways to view the problem of sudden cardiac death. Quantitative information was used primarily to derive qualitative statements about new perspectives on sudden cardiac death. Conclusions: Progress in the prevention of sudden death will require development of new approaches, including epidemiologic techniques to address risk characteristics specific to the problem; characterization of triggering events and identification of specific persons at risk for responding adversely to these events; and methods of evaluating outcomes appropriate to the nature of sudden cardiac death.	VET AFFAIRS MED CTR, MIAMI, FL USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	MYERBURG, RJ (corresponding author), UNIV MIAMI, SCH MED, DIV CARDIOL D39, POB 016960, MIAMI, FL 33101 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021735, R01HL028130] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28130, HL21735] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKHTAR M, 1992, CIRCULATION, V85, P131; AKHTAR M, 1990, CIRCULATION, V81, P1123, DOI 10.1161/01.CIR.81.3.1123; ANDERSON KP, 1984, J CARDIOVASC PHARM, V6, pS498; BARBER MJ, 1983, CIRCULATION, V67, P787, DOI 10.1161/01.CIR.67.4.787; BAUM RS, 1974, CIRCULATION, V50, P1231, DOI 10.1161/01.CIR.50.6.1231; BIGGER JT, 1984, AM J CARDIOL, V53, pB8, DOI 10.1016/0002-9149(84)90494-6; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; BIGGER JT, 1987, AM J CARDIOL, V59, pE2, DOI 10.1016/0002-9149(87)90195-0; BIGGER JT, 1992, CIRCULATION, V85, P164, DOI 10.1161/01.CIR.85.1.164; BRETT AS, 1989, NEW ENGL J MED, V321, P676, DOI 10.1056/NEJM198909073211009; CALKINS H, 1989, CIRCULATION, V79, P687, DOI 10.1161/01.CIR.79.3.687; COX MM, 1991, J MOL CELL CARDIOL, V23, P127, DOI 10.1016/0022-2828(91)90100-Z; CUPPLES LA, 1992, CIRCULATION, V85, P11; DESOYZA N, 1979, CIRCULATION, V60, P814, DOI 10.1161/01.CIR.60.4.814; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; ECHT DS, 1985, CIRCULATION, V71, P289, DOI 10.1161/01.CIR.71.2.289; EDEL TB, 1992, PACE, V15, P60, DOI 10.1111/j.1540-8159.1992.tb02902.x; EPSTEIN FH, NIH791610 PUBL; FOGOROS RN, 1987, ANN INTERN MED, V107, P635, DOI 10.7326/0003-4819-107-5-635; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FURUKAWA T, 1990, CIRCULATION, V82, P522; FURUKAWA T, 1991, CIRC RES, V68, P1693, DOI 10.1161/01.RES.68.6.1693; FURUKAWA T, 1992, CIRC RES, V70, P91, DOI 10.1161/01.RES.70.1.91; FURUKAWA T, 1991, CIRCULATION, V84, P368, DOI 10.1161/01.CIR.84.1.368; FURUKAWA T, 1989, CIRCULATION, V80, P599, DOI 10.1161/01.CIR.80.3.599; FURUKAWA T, 1993, J CLIN INVEST, V91, P1521, DOI 10.1172/JCI116358; GAIDE MS, 1983, AM J PHYSIOL, V245, pH646, DOI 10.1152/ajpheart.1983.245.4.H646; GETTES LS, 1992, CIRCULATION, V85, P70; GILLUM RF, 1981, NIH832035 PUBL, V2, P114; GINZTON LE, 1989, CIRCULATION, V80, P816, DOI 10.1161/01.CIR.80.4.816; GOHN DC, 1992, NEW ENGL J MED, V326, P1435; GOLDSTEIN S, 1982, AM HEART J, V103, P156, DOI 10.1016/0002-8703(82)90552-X; GOTTLIEB SO, 1986, NEW ENGL J MED, V314, P1214, DOI 10.1056/NEJM198605083141903; GUARNIERI T, 1987, AM J CARDIOL, V60, P1061, DOI 10.1016/0002-9149(87)90352-3; Hill Ian G W, 1932, Edinb Med J, V39, P533; Hill IGW, 1932, LANCET, V1, P1139; HUIKURI HV, 1989, J AM COLL CARDIOL, V13, P646; HUIKURI HV, 1989, AM J CARDIOL, V64, P1305, DOI 10.1016/0002-9149(89)90572-9; HUIKURI HV, 1993, CIRCULATION, V87, P1220, DOI 10.1161/01.CIR.87.4.1220; HUIKURI HV, 1992, AM J CARDIOL, V70, P610, DOI 10.1016/0002-9149(92)90200-I; IDEKER RE, 1981, CIRCULATION, V63, P1371, DOI 10.1161/01.CIR.63.6.1371; INTERIAN A, 1990, CIRCULATION, V82, P435; JACKMAN WM, 1988, PROG CARDIOVASC DIS, V31, P115, DOI 10.1016/0033-0620(88)90014-X; JANUARY CT, 1989, CIRC RES, V64, P977, DOI 10.1161/01.RES.64.5.977; KAMMERLING JJ, 1987, CIRCULATION, V76, P383, DOI 10.1161/01.CIR.76.2.383; KANNEL WB, 1982, ANN NY ACAD SCI, V382, P3, DOI 10.1111/j.1749-6632.1982.tb55203.x; KANNEL WB, 1975, CIRCULATION, V51, P606, DOI 10.1161/01.CIR.51.4.606; KELLY PA, 1988, J AM COLL CARDIOL, V11, P1278, DOI 10.1016/0735-1097(88)90292-6; KIMURA S, 1992, CIRCULATION, V85, P2227, DOI 10.1161/01.CIR.85.6.2227; KJEKSHUS J, 1990, AM J CARDIOL, V65, pI42; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; KOHYA T, 1988, J MOL CELL CARDIOL, V20, P159, DOI 10.1016/S0022-2828(88)80029-4; KOZLOVSKIS PL, 1990, J MOL CELL CARDIOL, V22, P311, DOI 10.1016/0022-2828(90)91464-I; KULLER LH, 1980, PROG CARDIOVASC DIS, V23, P1, DOI 10.1016/0033-0620(80)90002-X; LAB MJ, 1982, CIRC RES, V50, P757, DOI 10.1161/01.RES.50.6.757; LAROVERE MT, 1988, CIRCULATION, V78, P816, DOI 10.1161/01.CIR.78.4.816; LEAK A, 1989, NEW ENGL J MED, V321, P680; LECLERCQ JF, 1986, ARCH MAL COEUR VAISS, V79, P1024; LEHMANN MH, 1991, PACE, V14, P969, DOI 10.1111/j.1540-8159.1991.tb04143.x; LEVINE JH, 1991, CIRCULATION, V84, P558, DOI 10.1161/01.CIR.84.2.558; LOWN B, 1967, J AMER MED ASSOC, V199, P188, DOI 10.1001/jama.199.3.188; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; MERCANDO AD, 1988, PACE, V11, P2059, DOI 10.1111/j.1540-8159.1988.tb06350.x; MESSERLI FH, 1984, AM J MED, V77, P18, DOI 10.1016/0002-9343(84)90430-3; MINARDO JD, 1988, NEW ENGL J MED, V319, P257, DOI 10.1056/NEJM198808043190501; MIROWSKI M, 1983, ANN INTERN MED, V98, P585, DOI 10.7326/0003-4819-98-5-585; MIROWSKI M, 1980, NEW ENGL J MED, V303, P322, DOI 10.1056/NEJM198008073030607; MORGANROTH J, 1987, AM J CARDIOL, V59, pE32, DOI 10.1016/0002-9149(87)90199-8; MOSS AJ, 1971, ANN INTERN MED, V75, P837, DOI 10.7326/0003-4819-75-6-837; MULCAHY R, 1985, AM HEART J, V109, P753, DOI 10.1016/0002-8703(85)90634-9; MULLER JE, 1989, CIRCULATION, V79, P733, DOI 10.1161/01.CIR.79.4.733; MYERBURG RJ, 1992, CIRCULATION, V85, P2; MYERBURG RJ, 1989, AM J CARDIOL, V63, P1512, DOI 10.1016/0002-9149(89)90017-9; MYERBURG RJ, 1984, AM J CARDIOL, V54, P1355, DOI 10.1016/S0002-9149(84)80096-X; MYERBURG RJ, 1992, NEW ENGL J MED, V326, P1451, DOI 10.1056/NEJM199205283262202; MYERBURG RJ, 1992, J CARDIOVASC ELECTR, V3, P626, DOI 10.1111/j.1540-8167.1992.tb01941.x; MYERBURG RJ, 1982, JAMA-J AM MED ASSOC, V247, P1485, DOI 10.1001/jama.247.10.1485; MYERBURG RJ, 1991, PACE, V14, P935, DOI 10.1111/j.1540-8159.1991.tb04138.x; MYERBURG RJ, 1992, CIRCULATION, V86, P691, DOI 10.1161/01.CIR.86.2.691; MYERBURG RJ, 1989, J AM COLL CARDIOL, V14, P508, DOI 10.1016/0735-1097(89)90209-X; MYERBURG RJ, 1993, IN PRESS ION CHANNEL; MYERBURG RJ, 1992, HEART DIS TXB CARDIO, P756; NADEMANEE K, 1987, J AM COLL CARDIOL, V10, P1, DOI 10.1016/S0735-1097(87)80152-3; NATTEL S, 1981, CARDIOVASC RES, V15, P80, DOI 10.1093/cvr/15.2.80; NEARING BD, 1991, SCIENCE, V252, P437, DOI 10.1126/science.2017682; NEWMAN D, 1992, AM J CARDIOL, V69, P899, DOI 10.1016/0002-9149(92)90789-2; NIKOLIC G, 1982, CIRCULATION, V66, P218, DOI 10.1161/01.CIR.66.1.218; PACKER M, 1985, CIRCULATION, V72, P681, DOI 10.1161/01.CIR.72.4.681; POSER RF, 1985, AM HEART J, V110, P9, DOI 10.1016/0002-8703(85)90507-1; PRIORI SG, 1990, CIRCULATION, V81, P1911, DOI 10.1161/01.CIR.81.6.1911; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; RINKENBERGER RL, 1982, AM HEART J, V103, P177, DOI 10.1016/0002-8703(82)90490-2; ROBINSON JS, 1965, AM HEART J, V69, P740, DOI 10.1016/0002-8703(65)90448-5; RODEN DM, 1988, CIRC RES, V62, P1055, DOI 10.1161/01.RES.62.5.1055; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; RUBERMAN W, 1981, CIRCULATION, V64, P297, DOI 10.1161/01.CIR.64.2.297; RUSKIN JN, 1989, NEW ENGL J MED, V321, P386, DOI 10.1056/NEJM198908103210608; SCHECHTMAN KB, 1989, CIRCULATION, V80, P1148, DOI 10.1161/01.CIR.80.5.1148; SCHULZE RA, 1977, AM J MED, V62, P192, DOI 10.1016/0002-9343(77)90314-X; SCHWARTZ PJ, 1988, CIRCULATION, V78, P969, DOI 10.1161/01.CIR.78.4.969; SCHWARTZ PJ, 1984, CIRCULATION, V69, P790, DOI 10.1161/01.CIR.69.4.790; SCHWARTZ PJ, 1992, CIRCULATION, V85, P77; SELZER A, 1964, CIRCULATION, V30, P17, DOI 10.1161/01.CIR.30.1.17; STARMER CF, 1991, CIRCULATION, V84, P1364, DOI 10.1161/01.CIR.84.3.1364; TULI M, 1987, Journal of Nuclear Medicine, V28, P669; VELEBIT V, 1982, CIRCULATION, V65, P886, DOI 10.1161/01.CIR.65.5.886; VISMARA LA, 1975, AM J MED, V59, P6, DOI 10.1016/0002-9343(75)90315-0; WEINTRAUB RM, 1979, AM J CARDIOL, V43, P877, DOI 10.1016/0002-9149(79)90348-5; WINKLE RA, 1981, AM HEART J, V102, P857, DOI 10.1016/0002-8703(81)90036-3; WINKLE RA, 1989, J AM COLL CARDIOL, V13, P1353, DOI 10.1016/0735-1097(89)90310-0; WOOSLEY RL, 1993, JAMA-J AM MED ASSOC, V269, P1532, DOI 10.1001/jama.269.12.1532; [No title captured]; 1989, NEW ENGL J MED, V331, P406	114	383	394	2	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1993	119	12					1187	1197		10.7326/0003-4819-119-12-199312150-00006	http://dx.doi.org/10.7326/0003-4819-119-12-199312150-00006			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM121	8239250				2022-12-28	WOS:A1993MM12100006
J	HESS, DT; PATTERSON, SI; SMITH, DS; SKENE, JHP				HESS, DT; PATTERSON, SI; SMITH, DS; SKENE, JHP			NEURONAL GROWTH CONE COLLAPSE AND INHIBITION OF PROTEIN FATTY ACYLATION BY NITRIC-OXIDE	NATURE			English	Article							LONG-TERM POTENTIATION; SYNAPTOSOMAL-ASSOCIATED PROTEIN; SOLUBLE GUANYLATE-CYCLASE; INTERCELLULAR MESSENGER; NERVOUS-SYSTEM; NMDA RECEPTORS; COMPLEX; STIMULATION; CEREBELLUM; GLUTAMATE	NITRIC oxide, a free-radical gas produced endogenously by several mammalian cell types1-6, has been implicated as a diffusible intercellular messenger subserving use-dependent modification of synaptic efficacy in the mature central nervous system7-10. It has been suggested on theoretical grounds that nitric oxide might play an analogous role during the establishment of ordered connections by developing neurons11. We report here that nitric oxide rapidly and reversibly inhibits growth of neurites of rat dorsal root ganglion neurons in vitro. In addition, we show that exposure to nitric oxide inhibits thioester-linked long-chain fatty acylation of neuronal proteins, possibly through a direct modification of substrate cysteine thiols. Our results demonstrate a potential role for nitric oxide in the regulation of process outgrowth and remodelling during neuronal development, which may be effected at least in part through modulation of dynamic protein fatty acylation in neuronal growth cones.	DUKE UNIV,MED CTR,DEPT NEUROBIOL,DURHAM,NC 27710	Duke University	HESS, DT (corresponding author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232, USA.		Smith, Deanna/AFU-2285-2022	Smith, Deanna/0000-0002-3014-641X				BOHME E, 1984, ADV CYCLIC NUCL PROT, V17, P259; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BOTTENSTEIN JE, 1983, ADV CELL NEUROBIOL, V4, P333; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3574; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; HESS DT, 1992, J NEUROSCI, V12, P4634; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; JUGUELIN H, 1984, ANAL BIOCHEM, V142, P329, DOI 10.1016/0003-2697(84)90472-X; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; LINDSAY RM, 1988, J NEUROSCI, V8, P2394; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MANZONI O, 1992, NEURON, V8, P653, DOI 10.1016/0896-6273(92)90087-T; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; OSENSAND A, 1993, NATURE, V364, P445, DOI 10.1038/364445a0; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PATTERSON PH, 1988, NEURON, V1, P263, DOI 10.1016/0896-6273(88)90074-8; PATTERSON SI, IN PRESS J CELL BIOL; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SKENE JHP, 1986, SCIENCE, V233, P783, DOI 10.1126/science.3738509; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; SMITH DS, 1990, NEUR ABSTR, V16, P1163; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; WALTER J, 1990, TRENDS NEUROSCI, V13, P447, DOI 10.1016/0166-2236(90)90097-T	31	290	294	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 9	1993	366	6455					562	565		10.1038/366562a0	http://dx.doi.org/10.1038/366562a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	8255294				2022-12-28	WOS:A1993ML21800069
J	SUTTON, BJ; GOULD, HJ				SUTTON, BJ; GOULD, HJ			THE HUMAN IGE NETWORK	NATURE			English	Review							FC-EPSILON-RI; EPSTEIN-BARR-VIRUS; EPIDERMAL LANGERHANS CELLS; COMPLEMENT RECEPTOR TYPE-2; HIGH-AFFINITY RECEPTOR; IMMUNOGLOBULIN-E; LYMPHOCYTES-B; SIGNAL TRANSDUCTION; BINDING PROTEIN; LIGAND-BINDING	IgE and its receptors are believed to have evolved as a mechanism to protect mammals against parasites. But other and intrinsically innocuous antigens can subvert this system to provoke an allergic response. For human populations in industrialized countries, allergy and asthma now represent a far greater threat than parasitic infection, and the main impetus for current studies of the IgE system is the hope of understanding and intervening in the aetiology of allergic diseases.			SUTTON, BJ (corresponding author), UNIV LONDON KINGS COLL, RANDALL INST, 26-29 DRURY LANE, LONDON WC2B 5RL, ENGLAND.			Gould, Hannah/0000-0003-0411-688X				ABDELILAH SG, IN PRESS NATURE; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; BACON K, 1993, EUR J IMMUNOL, V23, P2721, DOI 10.1002/eji.1830231054; BANIYASH M, 1986, J IMMUNOL, V136, P588; BARNES PJ, 1991, TRENDS BIOCHEM SCI, V16, P365, DOI 10.1016/0968-0004(91)90152-L; BASU M, 1993, J BIOL CHEM, V268, P13118; BEAVIL AJ, 1992, P NATL ACAD SCI USA, V89, P753, DOI 10.1073/pnas.89.2.753; BEAVIL AJ, 1993, BIOCHEM SOC T, V21, P968, DOI 10.1042/bst0210968; BETTLER B, 1992, J BIOL CHEM, V267, P185; BHATTI L, 1992, CELL IMMUNOL, V144, P117, DOI 10.1016/0008-8749(92)90230-M; Bibel DJ, 1988, MILESTONES IMMUNOLOG; BIEBER T, 1989, J EXP MED, V170, P309, DOI 10.1084/jem.170.1.309; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BLANK U, 1991, J BIOL CHEM, V266, P2639; BONNEFOY JY, 1993, EUR J IMMUNOL, V23, P969; BUTTERWORTH AE, 1992, IMMUNOL INVEST, V21, P391, DOI 10.3109/08820139209069381; CAMBIER JC, 1992, FASEB J, V6, P3207, DOI 10.1096/fasebj.6.13.1397843; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CAPRON A, 1986, IMMUNOL TODAY, V7, P15, DOI 10.1016/0167-5699(86)90184-2; CAPRON A, 1992, IMMUNOL INVEST, V21, P409, DOI 10.3109/08820139209069382; CAPRON A, 1982, PROG ALLERGY, V31, P234; CAREL JC, 1990, J BIOL CHEM, V265, P12293; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CARTER RH, 1991, J IMMUNOL, V147, P3663; CHAN SC, 1993, J LAB CLIN MED, V121, P44; CHEN SSA, 1991, J IMMUNOL, V147, P1581; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; DAVIS FM, 1993, SPRINGER SEMIN IMMUN, V15, P51; DAVIS FM, 1991, BIO-TECHNOL, V9, P53, DOI 10.1038/nbt0191-53; DELESPESSE G, 1991, ADV IMMUNOL, V49, P149; DELESPESSE G, 1992, IMMUNOL REV, V125, P77, DOI 10.1111/j.1600-065X.1992.tb00626.x; DIERKS SE, 1993, J IMMUNOL, V150, P2372; EISEMAN E, 1992, NATURE, V355, P78; ERDEI A, 1985, EUR J IMMUNOL, V15, P184, DOI 10.1002/eji.1830150214; ERLANGER BF, 1993, IMMUNOL TODAY, V14, P369, DOI 10.1016/0167-5699(93)90238-G; ERLANGER BF, 1992, IMMUNOL TODAY, V13, P487, DOI 10.1016/0167-5699(92)90023-Z; ESPARZA I, 1991, EUR J IMMUNOL, V21, P2829, DOI 10.1002/eji.1830211126; FANSLOW WC, 1992, J IMMUNOL, V149, P655; FEARON DT, 1993, CURR OPIN IMMUNOL, V5, P341, DOI 10.1016/0952-7915(93)90051-S; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FINKELMAN FD, 1991, INT IMMUNOL, V3, P599, DOI 10.1093/intimm/3.6.599; FLORESROMO L, 1993, SCIENCE, V261, P1038, DOI 10.1126/science.8351517; FRADE R, 1992, J IMMUNOL, V149, P3232; GALLI SJ, 1991, CURR OPIN IMMUNOL, V3, P865, DOI 10.1016/S0952-7915(05)80005-6; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; GILFILLAN AM, 1992, J IMMUNOL, V149, P2445; GORDON J, 1987, IMMUNOLOGY, V60, P517; GORDON J, IN PRESS ADV MOL CEL; Gould H, 1991, Monogr Allergy, V29, P28; GOULD HJ, 1992, GENETICS ASTHMA, P293; GRANGETTE C, 1989, J IMMUNOL, V143, P3580; HALL TJ, 1992, IMMUNOLOGY, V77, P462; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; HELM BA, 1991, EUR J IMMUNOL, V21, P1543, DOI 10.1002/eji.1830210631; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOGARTH PM, 1992, IMMUNOL REV, V125, P21, DOI 10.1111/j.1600-065X.1992.tb00623.x; HOPKINS CR, 1992, TRENDS BIOCHEM SCI, V17, P27, DOI 10.1016/0968-0004(92)90423-7; HULETT MD, 1993, EUR J IMMUNOL, V23, P640, DOI 10.1002/eji.1830230310; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; KAY B, 1993, NEW SCI, V137, P38; KIKUTANI H, 1990, RES IMMUNOL, V141, P249, DOI 10.1016/0923-2494(90)90116-G; KINET JP, 1991, INT ARCH ALLER A IMM, V94, P51, DOI 10.1159/000235323; KITANI S, 1988, J IMMUNOL, V140, P2585; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; KUROSAKI T, 1992, J EXP MED, V175, P447, DOI 10.1084/jem.175.2.447; LEE WT, 1987, J IMMUNOL, V139, P1191; LIU FT, 1993, IMMUNOL TODAY, V14, P486, DOI 10.1016/0167-5699(93)90263-K; LIU YJ, 1991, EUR J IMMUNOL, V21, P1107, DOI 10.1002/eji.1830210504; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; LOWELL CA, 1989, J EXP MED, V170, P1931, DOI 10.1084/jem.170.6.1931; LUO HY, 1991, J IMMUNOL, V146, P2122; MALLAMACI MA, 1993, J BIOL CHEM, V268, P22076; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; MOORE MD, 1989, J BIOL CHEM, V264, P20576; MOSSALAYI MD, 1992, EMBO J, V11, P4323, DOI 10.1002/j.1460-2075.1992.tb05531.x; NISSIM A, 1993, J IMMUNOL, V150, P1365; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; ORTEGA E, 1991, BIOCHEMISTRY-US, V30, P3473, DOI 10.1021/bi00228a018; PADLAN EA, 1986, MOL IMMUNOL, V23, P1063, DOI 10.1016/0161-5890(86)90005-2; PIRRON U, 1990, EUR J IMMUNOL, V20, P1547, DOI 10.1002/eji.1830200721; POCHON S, 1992, J EXP MED, V176, P389, DOI 10.1084/jem.176.2.389; Prausnitz C., 1921, ZENTRALBLATT F UR BA, V86, P160; PRESTA LG, 1993, J IMMUNOL, V151, P2623; RA C, 1993, INT IMMUNOL, V5, P47, DOI 10.1093/intimm/5.1.47; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RICHARDS ML, 1990, J IMMUNOL, V144, P2638; RISKE F, 1991, J BIOL CHEM, V266, P11245; ROBERTSON MW, 1993, J BIOL CHEM, V268, P12736; SARFATI M, 1992, IMMUNOLOGY, V76, P662; SHERR E, 1989, J IMMUNOL, V142, P481; SHIMIZU A, 1988, P NATL ACAD SCI USA, V85, P1907, DOI 10.1073/pnas.85.6.1907; SPEISS M, 1990, BIOCHEMISTRY-US, V29, P10009; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STANWORTH DR, 1990, LANCET, V336, P1279, DOI 10.1016/0140-6736(90)92963-I; SUGDEN B, 1989, CELL, V57, P5, DOI 10.1016/0092-8674(89)90165-7; SUGIE K, 1991, P NATL ACAD SCI USA, V88, P9132, DOI 10.1073/pnas.88.20.9132; TRUONG MJ, 1993, J EXP MED, V177, P243, DOI 10.1084/jem.177.1.243; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; VERCELLI D, 1991, J ALLERGY CLIN IMMUN, V88, P285, DOI 10.1016/0091-6749(91)90087-5; VERCELLI D, 1989, NATURE, V338, P649, DOI 10.1038/338649a0; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WANG F, 1991, J VIROL, V65, P4101, DOI 10.1128/JVI.65.8.4101-4106.1991; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILSON APM, 1993, EUR J IMMUNOL, V23, P240, DOI 10.1002/eji.1830230137; WUTHRICH B, 1989, INT ARCH ALLER A IMM, V90, P3, DOI 10.1159/000235067; YOKOTA A, 1992, P NATL ACAD SCI USA, V89, P5030, DOI 10.1073/pnas.89.11.5030; ZHENG Y, 1991, BIOCHEMISTRY-US, V30, P9125, DOI 10.1021/bi00102a002	112	450	475	0	31	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 2	1993	366	6454					421	428		10.1038/366421a0	http://dx.doi.org/10.1038/366421a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK098	8247150				2022-12-28	WOS:A1993MK09800052
J	GORDON, C; MCGURK, G; DILLON, P; ROSEN, C; HASTIE, ND				GORDON, C; MCGURK, G; DILLON, P; ROSEN, C; HASTIE, ND			DEFECTIVE MITOSIS DUE TO A MUTATION IN THE GENE FOR A FISSION YEAST 26S PROTEASE SUBUNIT	NATURE			English	Article							CYCLIN	WE have isolated a mutant, mts2, in the fission yeast Schizosaccharomyces pombe which is defective in chromosome segregation. The predicted amino-acid sequence of the cloned mts2+ gene product is 75% identical to the S4 subunit of the human 26S ATP/ubiquitin-dependent protease1. The human S4 subunit complementary DNA expressed from an S. pombe expression plasmid can rescue an S. pombe mts2 gene disruption. Both observations demonstrate that the mts2+ gene is the S. pombe homologue of the human S4 subunit. In addition, we provide genetic evidence for a physical interaction between the S4 and the related S7 subunit in the 26S multiprotein protease. We show that polyubiquitin-conjugated proteins accumulate in the mts2 mutant at the restrictive temperature, demonstrating that the mutant has an in vivo defect in the ubiquitin-dependent proteolysis pathway. Finally, the phenotype for the mts2 mutant indicates that protein degradation by the 26S protease is essential not for entry into but for the completion of mitosis.	ROCHE INST MOLEC BIOL, ROCHE RES CTR, DEPT GENE REGULAT, NUTLEY, NJ 07110 USA; HUMAN GENOME SCI, ROCKVILLE, MD 20850 USA	Roche Holding; GlaxoSmithKline; Human Genome Sciences Inc	GORDON, C (corresponding author), WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, CREWE RD, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.							BUENO A, 1991, CELL, V66, P149, DOI 10.1016/0092-8674(91)90147-Q; BUENO A, 1993, MOL CELL BIOL, V13, P2286, DOI 10.1128/MCB.13.4.2286; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HAGAN IM, 1988, J CELL SCI, V89, P343; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; SAZER S, 1990, J CELL SCI, V97, P509; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; YANAGIDA M, 1989, J CELL SCI, P213	17	220	223	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1993	366	6453					355	357		10.1038/366355a0	http://dx.doi.org/10.1038/366355a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ705	8247131				2022-12-28	WOS:A1993MJ70500052
J	PAPA, FR; HOCHSTRASSER, M				PAPA, FR; HOCHSTRASSER, M			THE YEAST DOA4 GENE ENCODES A DEUBIQUITINATING ENZYME RELATED TO A PRODUCT OF THE HUMAN TRE-2 ONCOGENE	NATURE			English	Article							N-END RULE; UBIQUITIN-CONJUGATING ENZYME; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL REGULATOR; FUNCTIONAL-ANALYSIS; PROTEIN; INVIVO; CELLS; TRANSFORMATION; DEGRADATION	Modification of specific intracellular proteins by ubiquitin targets them for degradation. We describe a yeast enzyme, Doa4, that is integral to the degradation of ubiquitinated proteins and is required in diverse physiological processes. Doa4 appears to function late in the proteolytic pathway by cleaving ubiquitin from substrate remnants still bound to protease. The human tre-2 oncogene encodes a deubiquitinating enzyme similar to Doa4, indicating a role for the ubiquitin system in mammalian growth control.			PAPA, FR (corresponding author), UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,920 E 58TH ST,CHICAGO,IL 60637, USA.			Papa, Feroz/0000-0002-3684-9108; Hochstrasser, Mark/0000-0002-1131-5484				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1988, MOL REPROD DEV; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1992, J BIOL CHEM, V267, P23364; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; COOK WJ, 1992, J BIOL CHEM, V267, P16467; DAYHOFF MO, 1988, METHOD ENZYMOL, V91, P534; DEVERAUX Q, 1990, J BIOL CHEM, V265, P6323; DEVIRGILIO C, 1993, EUR J BIOCHEM, V212, P315; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FINLEY D, 1991, REV CELL BIOL, V7, P25; FISCHERVIZE JA, 1992, DEVELOPMENT, V116, P985; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GUPTA K, 1993, ONCOGENE, V8, P2307; HADARI T, 1992, J BIOL CHEM, V267, P719; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; Hochstrasser Mark, 1992, Current Opinion in Cell Biology, V4, P1024, DOI 10.1016/0955-0674(92)90135-Y; JENTSCH S, 1992, ANNU REV GENET, V26, P177; JONNALAGADDA S, 1989, J BIOL CHEM, V264, P10637; KLEIN G, 1993, FASEB J, V7, P821, DOI 10.1096/fasebj.7.10.8344481; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MILLER AD, 1984, CELL, V36, P51; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; NAKAMURA T, 1992, ONCOGENE, V7, P733; OKAZAKI K, 1992, EMBO J, V11, P2447, DOI 10.1002/j.1460-2075.1992.tb05309.x; ONNO M, 1993, DNA CELL BIOL, V12, P107, DOI 10.1089/dna.1993.12.107; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; Rose I. A., 1988, UBIQUITIN, P135; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K	45	345	352	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 25	1993	366	6453					313	319		10.1038/366313a0	http://dx.doi.org/10.1038/366313a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ705	8247125				2022-12-28	WOS:A1993MJ70500039
J	PIJNAPPEL, WWM; HENDRIKS, HFJ; FOLKERS, GE; VANDENBRINK, CE; DEKKER, EJ; EDELENBOSCH, C; VANDERSAAG, PT; DURSTON, AJ				PIJNAPPEL, WWM; HENDRIKS, HFJ; FOLKERS, GE; VANDENBRINK, CE; DEKKER, EJ; EDELENBOSCH, C; VANDERSAAG, PT; DURSTON, AJ			THE RETINOID LIGAND 4-OXO-RETINOIC ACID IS A HIGHLY-ACTIVE MODULATOR OF POSITIONAL SPECIFICATION	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; XENOPUS-LAEVIS; 13-CIS-4-OXORETINOIC ACID; 13-CIS-RETINOIC ACID; CARCINOMA-CELLS; IDENTIFICATION; METABOLISM; RECEPTOR; EXPRESSION; ACTIVATION	RETINOIDS (vitamin A and its metabolites) are suspected of regulating diverse aspects of growth, differentiation, and patterning during embryogenesis1, but many questions remain about the identities and functions of the endogenous active retinoids involved. The pleiotropic effects of retinoids may be explained by the existence of complex signal transduction pathways involving diverse nuclear receptors of the retinoic acid receptor (RAR) and retinoid X receptor (RXR) families, and at least two types of cellular retinoic acid binding proteins (CRABP-I and -II)2. The different RARs, RXRs, and CRABPs have different expression patterns during vertebrate embryogenesis2,3, suggesting that they each have particular functions. Another level at which fine tuning of retinoid action could occur is the metabolism of vitamin A to active metabolites, which may include all-trans-retinoic acid4-7, all-trans-3,4-didehydroretinoic acid8, 9-cis-retinoic acid9,10, and 14-hydroxy-4,14-retroretinol11. Formation of the metabolite all-trans-4-oxo-retinoic acid from retinoic acid was considered to be an inactivation pathway during growth and differentiation12,14. We report here that, in contrast, 4-oxo-retinoic acid is a highly active metabolite which can modulate positional specification in early embryos. We also show that this retinoid binds avidly to and activates RARbeta, and that it is available in early embryos. The different activities of 4-oxo-retinoic acid and retinoic acid in modulating positional specification on the one hand, and growth and differentiation on the other, interest us in the possibility that specific retinoid ligands regulate different physiological processes in vivo.	TNO, INST AGEING & VASC RES, 2300 AK LEIDEN, NETHERLANDS	Netherlands Organization Applied Science Research	PIJNAPPEL, WWM (corresponding author), NETHERLANDS INST DEV BIOL, HUBRECHT LAB, UPPSALALAAN 8, 3584 CT UTRECHT, NETHERLANDS.		Folkers, Gert E/C-2863-2009; Hendriks, Henk/AAU-5987-2021	Folkers, Gert E/0000-0003-1070-0505; Pijnappel, Pim/0000-0002-7042-2482				ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; DEKKER EJ, 1993, MECH DEVELOP, V40, P3, DOI 10.1016/0925-4773(93)90083-A; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; ECKHOFF C, 1990, J LIPID RES, V31, P1445; ELLINGERZIEGELBAUER H, 1991, GENE DEV, V5, P94, DOI 10.1101/gad.5.1.94; FIORELLA PD, 1991, J BIOL CHEM, V266, P16572; FOLKERS GE, 1993, MOL ENDOCRINOL, V7, P616, DOI 10.1210/me.7.4.616; FROLIK CA, 1980, J BIOL CHEM, V255, P8057; FROLIK CA, 1979, BIOCHEMISTRY-US, V18, P2092, DOI 10.1021/bi00577a039; HANDYSIDE AH, 1989, ROUX ARCH DEV BIOL, V198, P48, DOI 10.1007/BF00376370; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOGAN BLM, 1992, NATURE, V359, P237, DOI 10.1038/359237a0; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MADEN M, 1992, BIOESSAYS, V14, P431, DOI 10.1002/bies.950140702; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NIEUWKOOP PD, 1952, J EXP ZOOL, V120, P1, DOI 10.1002/jez.1401200102; PALMER FBSC, 1971, BIOCHIM BIOPHYS ACTA, V231, P134, DOI 10.1016/0005-2760(71)90261-X; RAO MSS, 1972, INT J VITAM NUTR RES, V42, P368; ROBERTS AB, 1980, ARCH BIOCHEM BIOPHYS, V199, P374, DOI 10.1016/0003-9861(80)90293-3; SANI BP, 1993, RETINOIDS PROGR RES, P237; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIVE HL, 1990, GENE DEV, V4, P932, DOI 10.1101/gad.4.6.932; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILLIAMS JB, 1987, ANAL BIOCHEM, V160, P267, DOI 10.1016/0003-2697(87)90046-7	31	245	253	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1993	366	6453					340	344		10.1038/366340a0	http://dx.doi.org/10.1038/366340a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ705	8247127				2022-12-28	WOS:A1993MJ70500048
J	EVENSON, JW; KARPLUS, M				EVENSON, JW; KARPLUS, M			EFFECTIVE COUPLING IN BIOLOGICAL ELECTRON-TRANSFER - EXPONENTIAL OR COMPLEX DISTANCE DEPENDENCE	SCIENCE			English	Article							PHOTOSYNTHETIC REACTION CENTER; RHODOPSEUDOMONAS-VIRIDIS; TUNNELING PATHWAYS; CYTOCHROME-C; MOLECULES; PROTEINS	Calculations for a simple model electron transfer system and tuna cytochrome c demonstrate a dichotomy in the distance dependence of the effective coupling. In one regime, the effective coupling varies exponentially with distance and depends primarily on the average properties of the bridging material; in the other regime, the effective coupling has a complex distance dependence and is more sensitive to the details of the bridging material. Experiments and theory indicate that both regimes may occur in biological systems, providing a perspective on a recent controversy over the nature of the distance dependence.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT PHYS,CAMBRIDGE,MA 02138	Harvard University; Harvard University								[Anonymous], 1971, INTRO PROBABILITY TH; BAUM RM, 1993, CHEM ENG NEWS, P20; BERATAN DN, 1992, J PHYS CHEM-US, V96, P2852, DOI 10.1021/j100186a014; BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; BRUN AM, 1992, J PHYS CHEM-US, V96, P710, DOI 10.1021/j100181a036; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; DEVAULT D, 1984, QUANTUM MECHANICAL T; Economou E.N., 1990, GREENS FUNCTIONS QUA; EVENSON JW, 1992, J CHEM PHYS, V96, P5272, DOI 10.1063/1.462712; EVENSON JW, UNPUB; HUSH NS, 1961, T FARADAY SOC, V57, P557, DOI 10.1039/tf9615700557; HUSH NS, 1958, J CHEM PHYS, V28, P964; Marcus R. A., 1960, DISCUSS FARADAY SOC, V29, P21, DOI [10.1039/DF9602900021, DOI 10.1039/DF9602900021]; MARCUS RA, 1956, J CHEM PHYS, V24, P966, DOI 10.1063/1.1742723; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MARCUS RA, 1965, J CHEM PHYS, V43, P679, DOI 10.1063/1.1696792; MCCONNELL H, 1961, J CHEM PHYS, V35, P508, DOI 10.1063/1.1731961; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NEWTON MD, 1991, CHEM REV, V91, P767, DOI 10.1021/cr00005a007; ONUCHIC JN, 1991, J CHEM PHYS, V95, P1131, DOI 10.1063/1.461142; ONUCHIC JN, 1992, ANNU REV BIOPH BIOM, V21, P349, DOI 10.1146/annurev.biophys.21.1.349; SIDDARTH P, 1993, J PHYS CHEM-US, V97, P2400, DOI 10.1021/j100112a047; TAKANO T, 1981, J MOL BIOL, V153, P95, DOI 10.1016/0022-2836(81)90529-5; THOMPSON MA, 1991, J AM CHEM SOC, V113, P8210, DOI 10.1021/ja00022a003; TREUTLEIN H, 1992, P NATL ACAD SCI USA, V89, P75, DOI 10.1073/pnas.89.1.75; WUTTKE DS, 1992, SCIENCE, V256, P1007, DOI 10.1126/science.256.5059.1007	26	109	110	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1247	1249		10.1126/science.8235654	http://dx.doi.org/10.1126/science.8235654			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	8235654				2022-12-28	WOS:A1993MH32400033
J	JOKLIK, WK; MOSS, B; FIELDS, BN; BISHOP, DHL; SANDAKHCHIEV, LS				JOKLIK, WK; MOSS, B; FIELDS, BN; BISHOP, DHL; SANDAKHCHIEV, LS			WHY THE SMALLPOX VIRUS STOCKS SHOULD NOT BE DESTROYED	SCIENCE			English	Editorial Material							VACCINIA VIRUS; MYXOMA VIRUS; COWPOX VIRUS; PROTEIN; RECEPTOR; ENCODES; PATHOGENESIS; INHIBITION		NERC, INST VIROL & ENVIRONM MICROBIOL, OXFORD OX1 3SR, ENGLAND; NPO VECTOR, INST MOLEC BIOL, KOLTSOV 632159, RUSSIA; NIAID, VIRAL DIS LAB, BETHESDA, MD 20892 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA	UK Centre for Ecology & Hydrology (UKCEH); UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); State Research Center of Virology & Biotechnology VECTOR; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Harvard Medical School	JOKLIK, WK (corresponding author), DUKE UNIV, DURHAM, NC 27710 USA.		Sandakhchiev, Lev S/B-7035-2012	Moss, Bernard/0000-0002-2154-8564				ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; [Anonymous], 1980, REPORT INVESTIGATION; BROWN JP, 1985, NATURE, V313, P491, DOI 10.1038/313491a0; BULLER RML, 1991, MICROBIOL REV, V55, P80, DOI 10.1128/MMBR.55.1.80-122.1991; Colwell Report, 1974, REPORT COMMITTEE INQ; Fenner Frank, 1993, P176; KOTWAL GJ, 1988, NATURE, V335, P176, DOI 10.1038/335176a0; KOTWAL GJ, 1990, SCIENCE, V250, P827, DOI 10.1126/science.2237434; MAHY BWJ, 1991, ASM NEWS, V57, P577; PALUMBO GJ, 1989, VIROLOGY, V172, P262, DOI 10.1016/0042-6822(89)90128-1; PICKUP DJ, 1986, P NATL ACAD SCI USA, V83, P7698, DOI 10.1073/pnas.83.20.7698; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SANDAKHCHIEV LS, UNPUB; SENKEVICH TG, IN PRESS VIROLOGY; SPRIGGS MK, 1992, CELL, V71, P145, DOI 10.1016/0092-8674(92)90273-F; TURNER PC, 1990, CURR TOP MICROBIOL, V163, P125; TWARDZIK DR, 1985, P NATL ACAD SCI USA, V82, P5300, DOI 10.1073/pnas.82.16.5300; UPTON C, 1992, SCIENCE, V258, P1369, DOI 10.1126/science.1455233; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; ZEZEK Z, 1988, MONOGRAPHS VIROLOGY, V17; 1980, HIST INT PUBLIC HLTH, V4; 1986, 4TH M COMM ORTH INF	22	25	25	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	1993	262	5137					1225	1226		10.1126/science.8235652	http://dx.doi.org/10.1126/science.8235652			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	8235652				2022-12-28	WOS:A1993MH32400027
J	COLE, DG; CHINN, SW; WEDAMAN, KP; HALL, K; VUONG, T; SCHOLEY, JM				COLE, DG; CHINN, SW; WEDAMAN, KP; HALL, K; VUONG, T; SCHOLEY, JM			NOVEL HETEROTRIMERIC KINESIN-RELATED PROTEIN PURIFIED FROM SEA-URCHIN EGGS	NATURE			English	Article							DRIVEN MICROTUBULE MOTILITY; HEAVY-CHAIN; PEPTIDE ANTIBODIES; MITOTIC APPARATUS; LIGHT-CHAINS; IDENTIFICATION; LOCALIZATION; SEQUENCE; ATPASE	KINESIN heavy chain and kinesin-related polypeptides (KRPs) comprise a family of motor proteins with diverse intracellular transport functions1-7. Using pan-kinesin peptide antibodies that react with these proteins8,9, we have previously purified from sea urchin eggs a trimeric microtubule-binding and bundling protein, KRP(85/95) (ref. 8) comprising subunits of M(r) 115,000 (115K), 95K and 85K. We report here that kinesin-related genes encode the 85K and 95K subunits, and that the protein can be immunoprecipitated from cytosol as a trimeric complex using an 85K monoclonal antibody. We also find that purified KRP(85/95) directs movements towards the 'plus' ends of microtubules. To our knowledge, this protein is the first kinesin-related motor to be purified from its natural host cell in a native multimeric state.	UNIV CALIF DAVIS,DIV BIOL SCI,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616	University of California System; University of California Davis								AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; COHN SA, 1989, J BIOL CHEM, V264, P4290; COLE DG, 1992, J CELL SCI, V101, P291; CYR JL, 1991, P NATL ACAD SCI USA, V88, P10114, DOI 10.1073/pnas.88.22.10114; Goldstein L S, 1991, Trends Cell Biol, V1, P93, DOI 10.1016/0962-8924(91)90036-9; HYMAN AA, IN PRESS METH CELL B, V39; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; JOHNSON CS, 1990, CELL MOTIL CYTOSKEL, V16, P204, DOI 10.1002/cm.970160307; KUZNETSOV SA, 1989, J BIOL CHEM, V264, P589; PATTERSON SD, 1992, ANAL BIOCHEM, V202, P193, DOI 10.1016/0003-2697(92)90227-X; RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956; SAWIN KE, 1992, J CELL SCI, V101, P303; SCHOLEY JM, 1985, NATURE, V318, P483, DOI 10.1038/318483a0; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; Skoufias DA, 1993, CURR OPIN CELL BIOL, V5, P95, DOI 10.1016/S0955-0674(05)80014-6; STEWART RJ, 1991, P NATL ACAD SCI USA, V88, P8470, DOI 10.1073/pnas.88.19.8470; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1992, TRENDS BIOCHEM SCI, V17, P300, DOI 10.1016/0968-0004(92)90440-K; WEDAMAN KP, 1993, J MOL BIOL, V231, P155, DOI 10.1006/jmbi.1993.1267; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	22	221	229	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 18	1993	366	6452					268	270		10.1038/366268a0	http://dx.doi.org/10.1038/366268a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH325	8232586				2022-12-28	WOS:A1993MH32500064
J	OKSENBERG, JR; BEGOVICH, AB; ERLICH, HA; STEINMAN, L				OKSENBERG, JR; BEGOVICH, AB; ERLICH, HA; STEINMAN, L			GENETIC-FACTORS IN MULTIPLE-SCLEROSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							T-CELL RECEPTOR; MYELIN BASIC-PROTEIN; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MAJOR HISTOCOMPATIBILITY COMPLEX; TUMOR-NECROSIS-FACTOR; CLASS-II MOLECULES; BETA-CHAIN GENES; HLA-DP ANTIGENS; MHC CLASS-II	Objective.-To evaluate the role of candidate genes in the susceptibility to multiple sclerosis (MS) and describe the role of T-cell receptor (TCR) gene rearrangements in the MS brain lesion in identifying a major target of the immune response in this disease. Data Sources.-MEDLINE, bibliography review of published data, and unpublished studies. Study Selection.-Published studies using novel molecular approaches to analyze the role of the major histocompatibility complex (MHC) and TCR gene complexes, as well as other candidate genes, in susceptibility to MS. We analyze epigenetic events involving TCR genes in individuals with MS and describe recent clinical trials in which immunotherapy has been attempted. Data Synthesis.-Consistent with a polygenic model for disease predisposition, MHC and TCR gene associations with MS are relatively weak. Despite intensive research, no other putative ''MS genes'' have been firmly established. The analysis of TCR rearrangements in the brain lesion has helped to identify a major target of the immune response in MS. Conclusion.-Understanding the genetic basis for autoimmune demyelination will offer new possibilities for the treatment of this illness.	STANFORD UNIV, MED CTR, SCH MED, DEPT NEUROL & NEUROL SCI, STANFORD, CA 94305 USA; ROCHE MOLEC SYST, DEPT HUMAN GENET, ALAMEDA, CA USA	Stanford University; Roche Holding				Steinman, Lawrence/0000-0002-2437-2250				ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; ALTMANN DM, 1991, IMMUNOL TODAY, V12, P267, DOI 10.1016/0167-5699(91)90124-C; BEALL SS, 1993, J NEUROIMMUNOL, V45, P53, DOI 10.1016/0165-5728(93)90163-S; BEALL SS, 1989, J NEUROIMMUNOL, V21, P59, DOI 10.1016/0165-5728(89)90159-8; BEGOVICH AB, 1990, HUM IMMUNOL, V28, P365, DOI 10.1016/0198-8859(90)90031-J; BEGOVICH AB, 1992, J IMMUNOL, V148, P249; BERTRAMS J, 1972, TISSUE ANTIGENS, V2, P405; BIRNBAUM G, 1993, ANN NEUROL, V34, P18, DOI 10.1002/ana.410340106; BITAR DM, 1988, CELL IMMUNOL, V112, P364, DOI 10.1016/0008-8749(88)90305-X; Blankenhorn Elizabeth P., 1992, Regional Immunology, V4, P331; BORNSTEIN MB, 1988, NEUROLOGY, V38, P66; BORNSTEIN MB, 1990, HDB MULTIPLE SCLEROS, P469; BOYLAN KB, 1990, GENOMICS, V6, P16, DOI 10.1016/0888-7543(90)90443-X; BOYLAN KB, 1990, ANN NEUROL, V27, P291, DOI 10.1002/ana.410270311; BROSNAN CF, 1988, J NEUROIMMUNOL, V18, P87, DOI 10.1016/0165-5728(88)90137-3; BURGER D, IN PRESS J NEUROCHEM; CAILLATZUCMAN S, 1993, HUM IMMUNOL, V36, P49; CAMPBELL RD, 1993, IMMUNOL TODAY, V14, P349, DOI 10.1016/0167-5699(93)90234-C; CHARMLEY P, 1991, J NEUROIMMUNOL, V32, P231, DOI 10.1016/0165-5728(91)90193-B; COLONNA M, 1992, P NATL ACAD SCI USA, V89, P3932, DOI 10.1073/pnas.89.9.3932; CONCANNON P, 1987, J EXP MED, V165, P1130, DOI 10.1084/jem.165.4.1130; DEROSBO NK, IN PRESS J CLIN INVE; DJILALISAIAH I, 1993, HUM IMMUNOL, V36, P49, DOI 10.1016/0198-8859(93)90033-W; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; EBERS GC, 1986, NEW ENGL J MED, V315, P1638, DOI 10.1056/NEJM198612253152603; ERLICH H, 1991, EUR J IMMUNOGENET, V18, P33, DOI 10.1111/j.1744-313X.1991.tb00005.x; FRANCIS DA, 1987, BRAIN, V110, P181, DOI 10.1093/brain/110.1.181; FUGGER L, 1990, IMMUNOGENETICS, V31, P278; FUGGER L, 1990, IMMUNOGENETICS, V32, P150, DOI 10.1007/BF02114968; FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848; GAUTAM AM, 1992, J EXP MED, V176, P605, DOI 10.1084/jem.176.2.605; GOLD DP, 1992, J IMMUNOL, V148, P1712; GOVERMAN J, 1993, CELL, V72, P551, DOI 10.1016/0092-8674(93)90074-Z; GULWANIAKOLKAR B, 1991, J EXP MED, V174, P1139, DOI 10.1084/jem.174.5.1139; HAEGERT DG, 1993, NEUROLOGY, V43, P548, DOI 10.1212/WNL.43.3_Part_1.548; HAEGERT DG, 1989, HUM IMMUNOL, V23, P45; HAWES GE, 1993, J IMMUNOL, V150, P2033; HIGGINS PJ, 1988, J IMMUNOL, V140, P440; HILLERT J, 1992, IMMUNOL TODAY, V13, P47, DOI 10.1016/0167-5699(92)90132-Q; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; HOWELL WM, 1991, TISSUE ANTIGENS, V37, P156, DOI 10.1111/j.1399-0039.1991.tb01864.x; HVAS J, 1993, J NEUROIMMUNOL, V46, P225, DOI 10.1016/0165-5728(93)90253-U; JAHNKE U, 1985, SCIENCE, V229, P282, DOI 10.1126/science.2409602; JERSILD C, 1973, LANCET, V2, P1221; JOHNSON RT, 1984, NEW ENGL J MED, V310, P137, DOI 10.1056/NEJM198401193100301; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KARIN N, 1993, J IMMUNOL, V150, P4116; KAUFMAN JF, 1984, CELL, V36, P1, DOI 10.1016/0092-8674(84)90068-0; KOTZIN BL, 1991, P NATL ACAD SCI USA, V88, P9161, DOI 10.1073/pnas.88.20.9161; Kurtzke JF, 2000, MULTIPLE SCLEROSIS: DIAGNOSIS, MEDICAL MANAGEMENT, AND REHABILITATION, P49; LIBLAU R, 1993, NEUROLOGY, V43, P1192, DOI 10.1212/WNL.43.6.1192; LIDER O, 1989, J IMMUNOL, V142, P748; LUNDBERG AS, 1992, P NATL ACAD SCI USA, V89, P6545, DOI 10.1073/pnas.89.14.6545; MAIMONE D, 1991, J NEUROIMMUNOL, V32, P67, DOI 10.1016/0165-5728(91)90073-G; MARROSU MG, 1992, NEUROLOGY, V42, P883, DOI 10.1212/WNL.42.4.883; MARTELL M, 1987, CR HEBD ACAD SCI, V3, P105; MARTIN R, 1991, J EXP MED, V173, P19, DOI 10.1084/jem.173.1.19; MILLER A, 1991, CURR OPIN IMMUNOL, V3, P936, DOI 10.1016/S0952-7915(05)80017-2; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; MOEN T, 1984, TISSUE ANTIGENS, V24, P126, DOI 10.1111/j.1399-0039.1984.tb02116.x; MONACO JJ, 1992, CURR OPIN IMMUNOL, V4, P70, DOI 10.1016/0952-7915(92)90128-2; MUNTONI F, 1991, TISSUE ANTIGENS, V38, P34, DOI 10.1111/j.1399-0039.1991.tb02033.x; NAITO S, 1972, TISSUE ANTIGENS, V2, P1; NEPOM GT, 1991, ANNU REV IMMUNOL, V9, P493; ODUM N, 1989, J IMMUNOGENET, V16, P467; ODUM N, 1988, TISSUE ANTIGENS, V31, P235, DOI 10.1111/j.1399-0039.1988.tb02088.x; OHGURO H, 1993, P NATL ACAD SCI USA, V90, P3241, DOI 10.1073/pnas.90.8.3241; OKSENBERG JR, 1990, CURR OPIN IMMUNOL, V2, P619, DOI 10.1016/0952-7915(90)90021-8; OKSENBERG JR, 1990, NATURE, V345, P344, DOI 10.1038/345344a0; OKSENBERG JR, 1988, HUM IMMUNOL, V22, P111, DOI 10.1016/0198-8859(88)90041-9; OKSENBERG JR, 1989, P NATL ACAD SCI USA, V86, P988, DOI 10.1073/pnas.86.3.988; OKSENBERG JR, 1993, NATURE, V362, P68, DOI 10.1038/362068a0; OLERUP O, 1989, P NATL ACAD SCI USA, V86, P7113, DOI 10.1073/pnas.86.18.7113; OLERUP O, 1991, TISSUE ANTIGENS, V38, P1, DOI 10.1111/j.1399-0039.1991.tb02029.x; POWIS SH, 1993, IMMUNOGENETICS, V37, P373, DOI 10.1007/BF00216802; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; Pryse-Phillips W., 1990, HDB MULTIPLE SCLEROS, P1; PULLEN AM, 1989, IMMUNOL REV, V107, P125, DOI 10.1111/j.1600-065X.1989.tb00006.x; ROBINSON MA, 1991, J IMMUNOL, V146, P4392; ROBINSON MA, 1989, P NATL ACAD SCI USA, V86, P9422, DOI 10.1073/pnas.86.23.9422; Robinson Mary Ann, 1992, Regional Immunology, V4, P274; RONNIGEN KS, 1993, 12TH INT IMM DIAB WO, V6; ROSE J, 1993, LANCET, V341, P1179, DOI 10.1016/0140-6736(93)91003-5; ROSENBERG WMC, 1992, EUR J IMMUNOL, V22, P541, DOI 10.1002/eji.1830220237; SAKAI K, 1989, P NATL ACAD SCI USA, V86, P9470, DOI 10.1073/pnas.86.23.9470; SEBOUN E, 1989, CELL, V57, P1095, DOI 10.1016/0092-8674(89)90046-9; SELMAJ K, 1991, P NATL ACAD SCI USA, V88, P6452, DOI 10.1073/pnas.88.15.6452; SHARIEF MK, 1991, NEW ENGL J MED, V325, P467, DOI 10.1056/NEJM199108153250704; SHERRITT MA, 1992, INT IMMUNOL, V4, P177, DOI 10.1093/intimm/4.2.177; SINHA AA, 1991, J NEUROIMMUNOL, V32, P61, DOI 10.1016/0165-5728(91)90072-F; SPURKLAND A, 1991, HUM IMMUNOL, V30, P69, DOI 10.1016/0198-8859(91)90073-I; STEINMAN L, 1991, ADV IMMUNOL, V49, P357; STEINMAN L, 1981, P NATL ACAD SCI-BIOL, V78, P7111, DOI 10.1073/pnas.78.11.7111; STEINMAN L, 1992, IMMUNOL TODAY, V13, P49, DOI 10.1016/0167-5699(92)90133-R; STEINMAN L, 1993, MONOCLONAL ANTIBODY, P253; SUDWEEKS JD, 1993, P NATL ACAD SCI USA, V90, P3700, DOI 10.1073/pnas.90.8.3700; SUN JB, 1991, J IMMUNOL, V146, P1490; SWINGLER RJ, 1987, J NEUROL NEUROSUR PS, V50, P1153, DOI 10.1136/jnnp.50.9.1153; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; TEITELBAUM D, 1988, P NATL ACAD SCI USA, V85, P9724, DOI 10.1073/pnas.85.24.9724; TIENARI PJ, 1992, LANCET, V340, P987, DOI 10.1016/0140-6736(92)93007-A; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; TROWSDALE J, 1993, TRENDS GENET, V9, P117, DOI 10.1016/0168-9525(93)90205-V; UNANUE ER, 1992, CURR OPIN IMMUNOL, V4, P63, DOI 10.1016/0952-7915(92)90127-Z; VALLI A, 1993, J CLIN INVEST, V91, P616, DOI 10.1172/JCI116242; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; VARTDAL F, 1989, HUM IMMUNOL, V25, P103, DOI 10.1016/0198-8859(89)90074-8; WATANABE R, 1983, NATURE, V305, P150, DOI 10.1038/305150a0; WEINER HL, 1993, SCIENCE, V259, P1321, DOI 10.1126/science.7680493; WHITACRE CC, 1991, J IMMUNOL, V147, P2155; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0; WUCHERPFENNIG KW, 1992, J EXP MED, V175, P993, DOI 10.1084/jem.175.4.993; WUCHERPFENNIG KW, 1992, P NATL ACAD SCI USA, V89, P4588, DOI 10.1073/pnas.89.10.4588; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; ZALLER DM, 1990, J EXP MED, V171, P1943, DOI 10.1084/jem.171.6.1943; Zamvil Scott S., 1992, P129	117	57	59	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1993	270	19					2362	2369		10.1001/jama.270.19.2362	http://dx.doi.org/10.1001/jama.270.19.2362			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF993	8230601				2022-12-28	WOS:A1993MF99300033
J	MUELLER, MW; ALLMAIER, M; ESKES, R; SCHWEYEN, RJ				MUELLER, MW; ALLMAIER, M; ESKES, R; SCHWEYEN, RJ			TRANSPOSITION OF GROUP-II INTRON AL1 IN YEAST AND INVASION OF MITOCHONDRIAL GENES AT NEW LOCATIONS	NATURE			English	Article							NUCLEAR GENES; RNA; TETRAHYMENA; PODOSPORA; DELETION; MATURASE; MOBILITY; INVITRO; ORIGIN; DNA	INTRON mobility at the RNA level1-8 by splicing reversal at allelic (homing) and non-allelic locations (transposition) has been reported in vitro9-12. In the living cell, however, only intron homing by unidirectional gene conversion has been described5,6,13,14. Supposing that intron insertions at non-allelic sites might occur in vivo, we speculated that group II splice-site-associated macro-deletions15-18 in fungal mitochondrial DNA might result from group II intron transposition to new locations followed by recombination. We used polymerase chain reaction techniques to detect this critical, infrequent intermediate in mtDNA populations. Here we report on group II intron aI1 transposition to non-allelic, splicing-compatible locations within the cox1 gene of yeast mtDNA. The identified integration sites are preceded by motifs similar to the upstream exon A1. Sequences flanking intron aI1 are not co-converted to the insertion sites and cis- and trans-acting mutations within aI1 reduce intron mobility below detection levels. These findings suggest the involvement of an RNA intermediate in group II intron transposition.			MUELLER, MW (corresponding author), UNIV VIENNA,INST MICROBIOL & GENET,VIENNA BIOCTR,A-1030 VIENNA,AUSTRIA.							AHNE A, 1988, J MOL BIOL, V202, P725, DOI 10.1016/0022-2836(88)90553-0; AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; BELCOUR L, 1991, P NATL ACAD SCI USA, V88, P3579, DOI 10.1073/pnas.88.9.3579; CARIGNANI G, 1983, CELL, V35, P733, DOI 10.1016/0092-8674(83)90106-X; CAVALIERSMITH T, 1991, TRENDS GENET, V7, P145, DOI 10.1016/0168-9525(91)90102-V; COPERTINO DW, 1991, EMBO J, V10, P433, DOI 10.1002/j.1460-2075.1991.tb07965.x; DEFONTAINE A, 1991, NUCLEIC ACIDS RES, V19, P185, DOI 10.1093/nar/19.1.185; DOOLITTLE WF, 1985, TRENDS GENET, V1, P64; DUJON B, 1989, GENE, V82, P91, DOI 10.1016/0378-1119(89)90034-6; Gargouri A., 1983, MITOCHONDRIA 1983, P259; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; LEVRAJUILLET E, 1989, MOL GEN GENET, V217, P168, DOI 10.1007/BF00330957; Meunier B, 1990, STRUCTURE FUNCTION B, P169; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MORL M, 1990, CELL, V60, P629, DOI 10.1016/0092-8674(90)90666-3; MUELLER M W, 1991, Journal of Molecular Biology, V222, P145; OSIEWACZ HD, 1984, CURR GENET, V8, P299, DOI 10.1007/BF00419728; PERLMAN PS, 1989, SCIENCE, V246, P1106, DOI 10.1126/science.2479980; QUIRK SM, 1989, CELL, V56, P455, DOI 10.1016/0092-8674(89)90248-1; ROGERS JH, 1989, TRENDS GENET, V5, P213, DOI 10.1016/0168-9525(89)90084-X; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; WEILLER GF, 1986, THESIS U MUNCHEN; WENZLAU JM, 1989, CELL, V56, P421, DOI 10.1016/0092-8674(89)90245-6; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9	30	84	86	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 11	1993	366	6451					174	176		10.1038/366174a0	http://dx.doi.org/10.1038/366174a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG216	8232557				2022-12-28	WOS:A1993MG21600062
J	SCHAFMEISTER, CE; MIERCKE, LJW; STROUD, RM				SCHAFMEISTER, CE; MIERCKE, LJW; STROUD, RM			STRUCTURE AT 2.5 ANGSTROM OF A DESIGNED PEPTIDE THAT MAINTAINS SOLUBILITY OF MEMBRANE-PROTEINS	SCIENCE			English	Article							HELIX DIPOLE MODEL; ALPHA-HELICES; DENOVO DESIGN; RESOLUTION; STABILIZATION; PURIFICATION; REFINEMENT; PACKING	A 24-amino acid peptide designed to solubilize integral membrane proteins has been synthesized. The design was for an amphipathic alpha helix with a ''flat'' hydrophobic surface that would interact with a transmembrane protein as a detergent. When mixed with peptide, 85 percent of bacteriorhodopsin and 60 percent of rhodopsin remained in solution over a period of 2 days in their native forms. The crystal structure of peptide alone showed it to form an antiparallel four-helix bundle in which monomers interact, flat surface to flat surface, as predicted.			SCHAFMEISTER, CE (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.				NIGMS NIH HHS [GM24485] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024485, R37GM024485] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPLEBURY ML, 1986, VISION RES, V26, P1881, DOI 10.1016/0042-6989(86)90115-X; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CASARI G, 1992, J MOL BIOL, V224, P725, DOI 10.1016/0022-2836(92)90556-Y; CHAMBERS JL, 1977, ACTA CRYSTALLOGR B, V33, P1824, DOI 10.1107/S0567740877007146; CHOTHIA C, 1977, P NATL ACAD SCI USA, V74, P4130, DOI 10.1073/pnas.74.10.4130; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DEGRIP WJ, 1979, CHEM PHYS LIPIDS, V23, P321, DOI 10.1016/0009-3084(79)90010-0; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; FAIRMAN R, 1989, PROTEINS, V5, P1, DOI 10.1002/prot.340050102; FINZEL BC, 1985, J MOL BIOL, V186, P627, DOI 10.1016/0022-2836(85)90135-4; GARAVITO RM, 1988, DETERGENT PHENOMENA, P89; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; HERRMANN KW, 1962, J PHYS CHEM-US, V66, P295, DOI 10.1021/j100808a025; HILL CP, 1990, SCIENCE, V249, P543, DOI 10.1126/science.2382133; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; HOLMES MA, 1991, J MOL BIOL, V220, P723, DOI 10.1016/0022-2836(91)90113-K; JAP BK, 1990, Q REV BIOPHYS, V23, P367, DOI 10.1017/S003358350000559X; KUHLBRANDT W, 1988, Q REV BIOPHYS, V21, P429, DOI 10.1017/S0033583500004625; LITMAN BJ, 1982, METHOD ENZYMOL, V81, P150; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; MICHEL H, 1988, DETERGENT PHENOMENA, P73; MILDER SJ, 1991, BIOCHEMISTRY-US, V30, P1751, DOI 10.1021/bi00221a004; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PERUTZ MF, 1988, PROTEINS, V4, P294, DOI 10.1002/prot.340040408; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; REGAN L, 1988, SCIENCE, V241, P976, DOI 10.1126/science.3043666; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; SACK J, 1988, J MOL GRAPHICS, V6, P225; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; STOECKENIUS W, 1982, ANNU REV BIOCHEM, V51, P587, DOI 10.1146/annurev.bi.51.070182.003103; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; ZULAUF M, 1988, DETERGENT PHENOMENA, P53	35	163	175	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	1993	262	5134					734	738		10.1126/science.8235592	http://dx.doi.org/10.1126/science.8235592			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	8235592				2022-12-28	WOS:A1993MD95200040
J	RAMSEY, PG; WENRICH, MD; CARLINE, JD; INUI, TS; LARSON, EB; LOGERFO, JP				RAMSEY, PG; WENRICH, MD; CARLINE, JD; INUI, TS; LARSON, EB; LOGERFO, JP			USE OF PEER RATINGS TO EVALUATE PHYSICIAN PERFORMANCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OF-INTERNAL-MEDICINE; COMPETENCE; CERTIFICATION; TIME	Objective.-To assess the feasibility and measurement characteristics of ratings completed by professional associates to evaluate the performance of practicing physicians. Design.-The clinical performance of physicians was evaluated using written questionnaires mailed to professional associates (physicians and nurses). Physician-associates were randomly selected from lists provided by both the subjects and medical supervisors, and detailed information was collected concerning the professional and social relationships between the associate and the subject. Responses were analyzed to determine factors that affect ratings and measurement characteristics of peer ratings. Setting and Participants.-Physician-subjects were selected from among practicing internists in New York, New Jersey, and Pennsylvania who received American Board of Internal Medicine certification 5 to 15 years previously. Main Outcome Measure.-Physician performance as assessed by peers. Results.-Peer ratings are not biased substantially by the method of selection of the peers or the relationship between the rater and the subject. Factor analyses suggest a two-dimensional conceptualization of clinical skills: one factor represents cognitive and clinical management skills and the other factor represents humanistic qualities and management of psychosocial aspects of illness. Ratings from 11 peer physicians are needed to provide a reliable assessment in these two areas. Conclusions.-These findings suggest that it is feasible to obtain assessments from professional associates of practicing physicians in areas such as clinical skills, humanistic qualities, and communication skills. Using a shorter version of the questionnaire used in this study, peer ratings provide a practical method to assess clinical performance in areas such as humanistic qualities and communication skills that are difficult to assess with other measures.	UNIV WASHINGTON,SCH MED,DEPT MED EDUC,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	RAMSEY, PG (corresponding author), UNIV WASHINGTON,SCH MED,DEPT MED,RG-20,SEATTLE,WA 98195, USA.							BLURTON RR, 1985, J MED EDUC, V60, P648; CARLINE JD, 1989, EVAL HEALTH PROF, V12, P409, DOI 10.1177/016327878901200403; CARLINE JD, 1992, J GEN INTERN MED, V7, P506, DOI 10.1007/BF02599454; GLASSOCK RJ, 1991, ANN INTERN MED, V114, P59, DOI 10.7326/0003-4819-114-1-59; GOURMAN J, 1980, GOURMAN REPORT RATIN, P64; KEELER EB, 1992, JAMA-J AM MED ASSOC, V268, P1709, DOI 10.1001/jama.268.13.1709; KEYNAN A, 1987, MED EDUC, V21, P477, DOI 10.1111/j.1365-2923.1987.tb01406.x; LANGSLEY DG, 1991, JAMA-J AM MED ASSOC, V266, P977, DOI 10.1001/jama.266.7.977; LINN LS, 1987, MED CARE, V25, P504, DOI 10.1097/00005650-198706000-00005; Neufeld VR, 1985, ASSESSING CLIN COMPE; RAMSEY PG, 1989, ANN INTERN MED, V110, P719, DOI 10.7326/0003-4819-110-9-719; RAMSEY PG, 1991, JAMA-J AM MED ASSOC, V266, P1103, DOI 10.1001/jama.266.8.1103; RAMSEY PG, 1990, FINAL REPORT AM BOAR; Winer B.J., 1971, STATISTICAL PRINCIPL, P283	14	277	283	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	1993	269	13					1655	1660		10.1001/jama.269.13.1655	http://dx.doi.org/10.1001/jama.269.13.1655			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KV349	8240483				2022-12-28	WOS:A1993KV34900029
J	GESSNER, BD; BELLER, M; MIDDAUGH, JP; WHITFORD, GM				GESSNER, BD; BELLER, M; MIDDAUGH, JP; WHITFORD, GM			ACUTE FLUORIDE POISONING FROM A PUBLIC WATER-SYSTEM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FATAL HYPERKALEMIA; INTOXICATION; CHILDREN	Background. Acute fluoride poisoning produces a clinical syndrome characterized by nausea, vomiting, diarrhea, abdominal pain, and paresthesias. In May 1992, excess fluoride in one of two public water systems serving a village in Alaska caused an outbreak of acute fluoride poisoning. Methods. We surveyed residents, measured their urinary fluoride concentrations, and analyzed their serum-chemistry profiles. A case of fluoride poisoning was defined as an illness consisting of nausea, vomiting, diarrhea, abdominal pain, or numbness or tingling of the face or extremities that began between May 21 and 23. Results. Among 47 residents studied who drank water obtained on May 21, 22, or 23 from the implicated well, 43 (91 percent) had an illness that met the case definition, as compared with only 6 of 21 residents (29 percent) who drank water obtained from the implicated well at other times and 2 of 94 residents (2 percent) served by the other water system. We estimated that 296 people were poisoned; 1 person died. Four to five days after the outbreak, 10 of the 25 case patients who were tested, but none of the 15 control subjects, had elevated urinary fluoride concentrations. The case patients had elevated serum fluoride concentrations and other abnormalities consistent with fluoride poisoning, such as elevated serum lactate dehydrogenase and aspartate aminotransferase concentrations. The fluoride concentration of a water sample from the implicated well was 150 mg per liter, and that of a sample from the other system was 1.1 mg per liter. Failure to monitor and respond appropriately to elevated fluoride concentrations, an unreliable control system, and a mechanism that allowed fluoride concentrate to enter the well led to this outbreak. Conclusions. Inspection of public water systems and monitoring of fluoride concentrations are needed to prevent outbreaks of fluoride poisoning.	ALASKA DIV PUBL HLTH,EPIDEMIOL SECT,POB 240249,ANCHORAGE,AK 99524; CTR DIS CONTROL & PREVENT,EPIDEMIOL PROGRAM OFF,DIV FIELD EPIDEMIOL,ATLANTA,GA; MED COLL GEORGIA,DEPT ORAL BIOL,AUGUSTA,GA 30912	Centers for Disease Control & Prevention - USA; University System of Georgia; Augusta University					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE006113, R01DE006429] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-06113, DE-06429] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABUKURAH AR, 1972, J AMER MED ASSOC, V222, P816; AUGENSTEIN WL, 1991, PEDIATRICS, V88, P907; BALTAZAR RF, 1980, CHEST, V78, P660, DOI 10.1378/chest.78.4.660; Dean A. G., 1990, EPI INFO VERSION 5 W; DUSBURY AJ, 1982, BR DENT J, V153, P64; EKSTRAND J, 1980, EUR J CLIN PHARMACOL, V18, P189, DOI 10.1007/BF00561589; HEIFETZ SB, 1986, PEDIATRICS, V77, P876; HOFFMAN R, 1980, PEDIATRICS, V65, P897; LELAND DE, 1980, J AM WATER WORKS ASS, V72, P238; Levy P, 1980, SAMPLING HLTH PROFES; MCIVOR ME, 1987, ANN EMERG MED, V16, P1165; MCIVOR ME, 1987, ANN EMERG MED, V16, P777; PETERSEN LR, 1988, AM J PUBLIC HEALTH, V78, P711, DOI 10.2105/AJPH.78.6.711; SPOERKE DG, 1980, J FAM PRACTICE, V10, P139; VOGT RL, 1982, AM J PUBLIC HEALTH, V72, P1168, DOI 10.2105/AJPH.72.10.1168; WHITFORD GM, 1979, J DENT RES, V58, P2058, DOI 10.1177/00220345790580110401; Whitford GM, 1989, MONOGRAPHS ORAL SCI, V13; 1991, FLUORIDATION CENSUS; 1962, PHS PUBLICATION, V956; 1987, HP41C HEWL PACK PORT; 1992, MMWR MORB MORTAL WKL, V41, P372; 1980, MMWR MORB MORTAL WKL, V29, P134; 1992, MMWR MORB MORTAL WKL, V41, P381; 1974, MMWR MORB MORTAL WKL, V23, P199; 1991, REV FLUORIDE BENEFIT	25	89	93	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 13	1994	330	2					95	99		10.1056/NEJM199401133300203	http://dx.doi.org/10.1056/NEJM199401133300203			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ670	8259189				2022-12-28	WOS:A1994MQ67000003
J	IGLEHART, JK				IGLEHART, JK			HEALTH-CARE REFORM - THE STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INSURANCE; MARKET											Altman D E, 1983, Health Aff (Millwood), V2, P7; ANDERSON G, 1993, HEALTH AFFAIR, V12, P40, DOI 10.1377/hlthaff.12.2.40; ANTOS JR, 1993, HEALTH AFFAIR, V12, P178, DOI 10.1377/hlthaff.12.1.178; BROWN LD, 1991, HEALTH AFFAIR, V10, P28, DOI 10.1377/hlthaff.10.2.28; CRITTENDEN RA, 1993, HEALTH AFFAIR, V12, P82, DOI 10.1377/hlthaff.12.2.82; DEAN HM, 1993, HEALTH AFFAIR, V12, P183, DOI 10.1377/hlthaff.12.1.183; DOBSON A, 1993, HLTH AFF MILLWOOD, V11, P72; DUKAKIS MS, 1992, NEW ENGL J MED, V327, P1090, DOI 10.1056/NEJM199210083271510; ENTHOVEN AC, 1992, NEW ENGL J MED, V327, P807, DOI 10.1056/NEJM199209103271113; FELDMAN PH, 1992, HEALTH AFFAIR, V11, P207, DOI 10.1377/hlthaff.11.4.207; HELMS WD, 1992, HEALTH AFFAIR, V11, P7, DOI 10.1377/hlthaff.11.2.7; HERRMANN J, 1993, HLTH SYST REV, V26, P14; Ladenheim K, 1993, Health Syst Rev, V26, P10; LEVIT KR, 1993, HEALTH AFFAIR, V12, P7, DOI 10.1377/hlthaff.12.3.7; MARINER WK, 1992, NEW ENGL J MED, V327, P1682, DOI 10.1056/NEJM199212033272312; MCLAUGHLIN CG, 1992, HEALTH AFFAIR, V11, P28, DOI 10.1377/hlthaff.11.2.28; MILES SH, 1992, NEW ENGL J MED, V327, P1092, DOI 10.1056/NEJM199210083271511; MORGAN D, 1993, WASHINGTON POST 1119, pA1; NELSON H, 1993, STATES COULD WAIT LE; NEUBAUER D, 1993, HEALTH AFFAIR, V12, P31, DOI 10.1377/hlthaff.12.2.31; PAUL RR, 1993, LESSONS STATE EFFORT; PEAR R, 1993, NY TIMES        1007, pA27; PRINA LL, 1992, HEALTH AFFAIR, V11, P226, DOI 10.1377/hlthaff.11.4.226; REDBURN T, 1993, NY TIMES        1105, pA1; STARR P, 1993, NEW ENGL J MED, V329, P1666, DOI 10.1056/NEJM199311253292228; STEINBROOK R, 1992, NEW ENGL J MED, V326, P340, DOI 10.1056/NEJM199201303260511; STEINMETZ G, 1993, WALL ST J       0602; 1993, GAOHRD941; 1993, MASSACHUSETTS PUBLIC; 1993, GAOHRD9346	30	16	16	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 6	1994	330	1					75	79		10.1056/NEJM199401063300128	http://dx.doi.org/10.1056/NEJM199401063300128			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MP649	8259164				2022-12-28	WOS:A1994MP64900037
J	MATUCHANSKY, C; LENORMAND, Y				MATUCHANSKY, C; LENORMAND, Y			IMAGES IN CLINICAL MEDICINE - MULTIPLE JEJUNOILEAL DIVERTICULA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											MATUCHANSKY, C (corresponding author), ST LAZARE HOSP,PARIS,FRANCE.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 6	1994	330	1					31	31						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP649	8259142				2022-12-28	WOS:A1994MP64900006
J	SMITH, RM; NEUMAN, TS				SMITH, RM; NEUMAN, TS			ELEVATION OF SERUM CREATINE-KINASE IN DIVERS WITH ARTERIAL GAS EMBOLIZATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIR-EMBOLISM; ISOENZYME; BRAIN	Background. Arterial gas embolism due to pulmonary barotrauma and the resultant cerebral gas embolism are catastrophic complications of diving. Previous studies have only rarely noted evidence of gas embolism to noncranial sites. Methods. Among 142 persons with diving-related injuries evaluated between January 1982 and July 1991, we identified 29 who had arterial gas embolism and who underwent biochemical studies indicative of muscle injury. Of the 29 patients, 4 were excluded because cardiopulmonary resuscitation had been performed and 3 were excluded because the duration of their dives met or exceeded standard limits set for dives not requiring staged decompression. The outcome at the time of hospital discharge in the remaining 22 patients was correlated with clinical factors and the results of biochemical studies. We also studied 22 subjects after uncomplicated dives and 11 patients who had sustained blunt trauma. Results. All the patients with diving-associated gas embolism had elevated serum creatine kinase activity (normal, less-than-or-equal-to 175 U per liter); the values were markedly elevated (> 900 U per liter) in 14. The MB isoenzyme of creatine kinase was detected in the serum of 13 of 20 patients in whom it was measured and was greater-than-or-equal-to 4 percent of total creatine kinase activity in 6 patients. In three patients electrocardiography showed myocardial injury. Changes in serum creatine kinase activity of similar magnitude were not present in the subjects who had uncomplicated dives or in the patients with blunt trauma. Thirteen patients recovered fully, four had minor residual neurologic deficits, three were severely impaired, and two died. Logistic-regression analysis revealed a significant correlation between peak serum creatine kinase values and clinical outcome. Conclusions. Biochemical evidence of muscle injury is frequently found after diving-associated arterial gas embolism. The correlation between serum creatine kinase activity and outcome suggests that serum creatine kinase is a marker of the size and severity of arterial gas embolism.	UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,DIV PULM & CRIT CARE MED,SAN DIEGO,CA 92103; UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,DIV EMERGENCY MED,SAN DIEGO,CA 92103	University of California System; University of California San Diego; University of California System; University of California San Diego								BENDZ R, 1981, SCAND J THORAC CARD, V15, P199, DOI 10.3109/14017438109101046; BERRY CC, 1990, AM J ROENTGENOL, V154, P477, DOI 10.2214/ajr.154.3.2106207; BUTLER BD, 1988, ANN THORAC SURG, V45, P198, DOI 10.1016/S0003-4975(10)62437-X; DAWSON DM, 1967, ARCH NEUROL-CHICAGO, V16, P175, DOI 10.1001/archneur.1967.00470200063005; DICK APK, 1985, NEUROLOGY, V35, P667, DOI 10.1212/WNL.35.5.667; EVANS DE, 1981, STROKE, V12, P338; FEINSTEIN EI, 1981, ARCH INTERN MED, V141, P753, DOI 10.1001/archinte.141.6.753; GHOSH PK, 1985, J CARDIOVASC SURG, V26, P248; Glantz SA., 1987, PRIMER BIOSTATISTICS; HAMBURG RJ, 1990, J BIOL CHEM, V265, P6403; HORROW JC, 1982, ANESTHESIOLOGY, V56, P212, DOI 10.1097/00000542-198203000-00012; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; INGWALL JS, 1985, NEW ENGL J MED, V313, P1050, DOI 10.1056/NEJM198510243131704; KASTE M, 1977, ARCH NEUROL-CHICAGO, V34, P142, DOI 10.1001/archneur.1977.00500150028004; KING MW, 1984, J TRAUMA, V24, P753, DOI 10.1097/00005373-198408000-00012; LEITCH DR, 1986, AVIAT SPACE ENVIR MD, V57, P931; LONGSTRETH WT, 1981, NEUROLOGY, V31, P455; NEUMAN TS, 1964, CLIN SPORTS MED, V6, P647; ROBERTS R, 1975, AM J CARDIOL, V36, P433, DOI 10.1016/0002-9149(75)90890-5; TRAINER TD, 1968, CLIN CHIM ACTA, V21, P151, DOI 10.1016/0009-8981(68)90023-5; TRASK RV, 1990, BIOCHIM BIOPHYS ACTA, V1049, P182, DOI 10.1016/0167-4781(90)90039-5; Whitcraft D D 3rd, 1976, JACEP, V5, P355, DOI 10.1016/S0361-1124(76)80061-5; WILLIAMS J, 1988, CLIN CHEM, V34, P1514	23	42	45	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 6	1994	330	1					19	24		10.1056/NEJM199401063300104	http://dx.doi.org/10.1056/NEJM199401063300104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP649	8259140	Bronze			2022-12-28	WOS:A1994MP64900004
J	KOLACZYNSKI, JW; CARO, JF				KOLACZYNSKI, JW; CARO, JF			INSULIN-LIKE GROWTH FACTOR-I THERAPY IN DIABETES - PHYSIOLOGICAL-BASIS, CLINICAL BENEFITS, AND RISKS	ANNALS OF INTERNAL MEDICINE			English	Review							FACTOR-BINDING-PROTEIN; FACTOR-I RECEPTOR; STIMULATED GLUCOSE-TRANSPORT; AMINO-ACID-METABOLISM; IGF-I; RAT-LIVER; ENDOTHELIAL-CELLS; HUMAN-SERUM; MONOCLONAL-ANTIBODY; TISSUE DISTRIBUTION	Purpose: To review the effects of insulin-like growth factor-1 (IGF-1) and to discuss the clinical benefits and risks of using it in patients with diabetes. Data Sources: Recent publications identified through a MEDLINE search using relevant keywords. Study Selection: Selected studies on the metabolic effects and kinetic mechanisms of in vitro IGF-1 and existing literature on the effects of IGF-1 on glucose and lipid metabolism in vivo with special emphasis on data from humans. Data Synthesis: The substantial stimulatory effect of IGF-1 on glucose uptake suggests that, in selected clinical situations, the drug may be an alternative to standard treatment of diabetes. Metabolic control in patients with extreme insulin resistance is improved after using IGF-1. Moreover, patients with type II (non-insulin-dependent) diabetes who receive IGF-1 have improved glucose tolerance and decreased hyperinsulinemia and hypertriglyceridemia. The complications associated with long-term administration of IGF-1 are unknown but might include the progression of certain neoplasms and diabetic complications, such as nephropathy and retinopathy. Conclusions: Insulin-like growth factor-1 may be a useful adjunct for treatment of diabetes and may even be the drug of choice in some patients with extreme insulin resistance who have metabolic emergencies. However, further data are needed to evaluate the risks and benefits of IGF-1 use in diabetes and in other states associated with impaired insulin action.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL,DEPT MED,COLL BLDG,SUITE 821, 1025 WALNUT ST, PHILADELPHIA, PA 19107 USA	Jefferson University					NIDDK NIH HHS [R01 DK45592] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045592] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBOTT AM, 1992, J BIOL CHEM, V267, P10759; ALITALO T, 1989, HUM GENET, V83, P335, DOI 10.1007/BF00291377; BAR RS, 1990, ENDOCRINOLOGY, V127, P497, DOI 10.1210/endo-127-1-497; BASERGA R, 1993, IN PRESS MOL ONCOLOG; BAXTER RC, 1989, P NATL ACAD SCI USA, V86, P6898, DOI 10.1073/pnas.86.18.6898; BAXTER RC, 1986, J CLIN INVEST, V78, P1504, DOI 10.1172/JCI112742; BINOUX M, 1991, ACTA ENDOCRINOL-COP, V124, P41; BINOUX M, 1988, J CLIN ENDOCR METAB, V67, P509, DOI 10.1210/jcem-67-3-509; BOULWARE SD, 1992, AM J PHYSIOL, V262, pE130, DOI 10.1152/ajpendo.1992.262.1.E130; BREWER MT, 1988, BIOCHEM BIOPH RES CO, V152, P1289, DOI 10.1016/S0006-291X(88)80425-X; BURGUERA B, 1991, J CLIN ENDOCR METAB, V72, P1238, DOI 10.1210/jcem-72-6-1238; CARO JF, 1988, J CLIN INVEST, V81, P976, DOI 10.1172/JCI113451; CASCIERI MA, 1989, DIABETOLOGIA, V32, P342, DOI 10.1007/BF00277256; CASCIERI MA, 1986, BIOCHIM BIOPHYS ACTA, V886, P491, DOI 10.1016/0167-4889(86)90186-2; CHAN SJ, 1990, P NATL ACAD SCI USA, V87, P9319, DOI 10.1073/pnas.87.23.9319; CLEMMONS DR, 1989, ENDOCRINOLOGY, V125, P2967, DOI 10.1210/endo-125-6-2967; CLEMMONS DR, 1992, J CLIN ENDOCR METAB, V75, P1183, DOI 10.1210/jc.75.5.1183; COHEN P, 1991, ACTA ENDOCRINOL-COP, V124, P74; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; CONOVER CA, 1991, ENDOCRINOLOGY, V129, P710, DOI 10.1210/endo-129-2-710; CONTI FG, 1988, ENDOCRINOLOGY, V122, P2788, DOI 10.1210/endo-122-6-2788; COTTERILL AM, 1988, J CLIN ENDOCR METAB, V67, P882, DOI 10.1210/jcem-67-5-882; CUBBAGE ML, 1990, J BIOL CHEM, V265, P12642; DAVIS SN, 1992, AM J PHYSIOL, V263, pE28, DOI 10.1152/ajpendo.1992.263.1.E28; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; DEMEYTS P, 1975, BIOCHEM BIOPH RES CO, V66, P1118, DOI 10.1016/0006-291X(75)90473-8; DERCOLE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P935, DOI 10.1073/pnas.81.3.935; DEVROEDE MA, 1984, ENDOCRINOLOGY, V114, P1917, DOI 10.1210/endo-114-5-1917; DIMITRIADIS G, 1992, BIOCHEM J, V285, P269, DOI 10.1042/bj2850269; DOHM GL, 1990, DIABETES, V39, P1028, DOI 10.2337/diabetes.39.9.1028; DOI T, 1989, AM J PATHOL, V134, P395; DUCKWORTH WC, 1988, AM J MED, V85, P71, DOI 10.1016/0002-9343(88)90399-3; DULAK NC, 1973, J CELL PHYSIOL, V81, P161, DOI 10.1002/jcp.1040810205; EHRENBORG E, 1991, BIOCHEM BIOPH RES CO, V176, P1250, DOI 10.1016/0006-291X(91)90420-C; FROESCH ER, 1963, J CLIN INVEST, V42, P1816, DOI 10.1172/JCI104866; FROESCH ER, 1966, BIOCHIM BIOPHYS ACTA, V121, P360, DOI 10.1016/0304-4165(66)90125-5; FROESCH ER, 1985, DIABETOLOGIA, V28, P485, DOI 10.1007/BF00281982; FROESCH ER, 1990, TRENDS ENDOCRIN MET, V1, P254, DOI 10.1016/1043-2760(90)90006-O; GELATO MC, 1992, DIABETES, V41, P1511, DOI 10.2337/diabetes.41.12.1511; GIACCA A, 1990, DIABETES, V39, P340, DOI 10.2337/diabetes.39.3.340; GULER HP, 1987, NEW ENGL J MED, V317, P137, DOI 10.1056/NEJM198707163170303; GULER HP, 1989, ACTA ENDOCRINOL-COP, V121, P101, DOI 10.1530/acta.0.1210101; GULER HP, 1989, ACTA ENDOCRINOL-COP, V121, P753, DOI 10.1530/acta.0.1210753; HAN VKM, 1988, J CLIN ENDOCR METAB, V66, P422, DOI 10.1210/jcem-66-2-422; HARDOUIN S, 1989, J CLIN ENDOCR METAB, V69, P1291, DOI 10.1210/jcem-69-6-1291; HAYES GR, 1987, P NATL ACAD SCI USA, V84, P8115, DOI 10.1073/pnas.84.22.8115; HINTZ RL, 1981, J CLIN ENDOCR METAB, V53, P100, DOI 10.1210/jcem-53-1-100; HOLLY JMP, 1989, J ENDOCRINOL, V122, P611, DOI 10.1677/joe.0.1220611; HOLLY JMP, 1991, ACTA ENDOCRINOL-COP, V124, P55; HOSSENLOPP P, 1990, J CLIN ENDOCR METAB, V71, P797, DOI 10.1210/jcem-71-4-797; HYER SL, 1988, DIABETIC MED, V5, P356, DOI 10.1111/j.1464-5491.1988.tb01005.x; ISAKSSON OGP, 1987, GROWTH HORMONE BASIC, P307; JACOB R, 1989, J CLIN INVEST, V83, P1717, DOI 10.1172/JCI114072; JACOB RJ, 1991, AM J PHYSIOL, V260, pE262, DOI 10.1152/ajpendo.1991.260.2.E262; JACOB RJ, 1992, DIABETES, V41, P691, DOI 10.2337/diabetes.41.6.691; KADOWAKI T, 1990, J CLIN INVEST, V86, P254, DOI 10.1172/JCI114693; KAJIMOTO Y, 1990, MOL ENDOCRINOL, V4, P217, DOI 10.1210/mend-4-2-217; KASUGA M, 1981, J BIOL CHEM, V256, P5305; KERN PA, 1989, DIABETES, V38, P710, DOI 10.2337/diabetes.38.6.710; KERR D, 1993, J CLIN INVEST, V91, P141, DOI 10.1172/JCI116163; KING GL, 1985, SCIENCE, V227, P1583, DOI 10.1126/science.3883490; KING GL, 1985, J CLIN INVEST, V75, P1028, DOI 10.1172/JCI111764; KLAPPER DG, 1983, ENDOCRINOLOGY, V112, P2215, DOI 10.1210/endo-112-6-2215; KRUPP M, 1981, J BIOL CHEM, V257, P10852; LAMAS E, 1991, HEPATOLOGY, V13, P936, DOI 10.1002/hep.1840130522; LARON Z, 1988, LANCET, V2, P1170; LINDSTROM T, 1990, ATHEROSCLEROSIS, V81, P137, DOI 10.1016/0021-9150(90)90020-J; LONNING PE, 1992, CANCER RES, V52, P4719; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MARTIN JL, 1986, J BIOL CHEM, V261, P8754; MASSAGUE J, 1982, J BIOL CHEM, V257, P5038; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; MAYER PW, 1983, ENDOCRINOLOGY, V113, P588, DOI 10.1210/endo-113-2-588; MCCLAIN DA, 1990, J BIOL CHEM, V265, P1678; McCusker RH, 1992, INSULIN LIKE GROWTH, P110; MERIMEE TJ, 1983, NEW ENGL J MED, V309, P527, DOI 10.1056/NEJM198309013090904; MOGENSEN CE, 1990, DIABETES, V39, P761, DOI 10.2337/diabetes.39.7.761; MOSES AC, 1980, EUR J BIOCHEM, V103, P387, DOI 10.1111/j.1432-1033.1980.tb04325.x; NAKAOHAYASHI J, 1992, ATHEROSCLEROSIS, V92, P141, DOI 10.1016/0021-9150(92)90273-J; OELZ O, 1970, EUR J CLIN INVEST, V1, P48, DOI 10.1111/j.1365-2362.1970.tb00596.x; OOI GT, 1990, MOL ENDOCRINOL, V4, P321, DOI 10.1210/mend-4-2-321; PEKONEN F, 1989, FERTIL STERIL, V51, P972; PIETRZKOWSKI Z, 1992, CANCER RES, V52, P6447; POGGI C, 1979, ENDOCRINOLOGY, V105, P723, DOI 10.1210/endo-105-3-723; RASMUSSEN H, 1990, DIABETES CARE, V13, P655, DOI 10.2337/diacare.13.6.655; RINDERKNECHT E, 1978, J BIOL CHEM, V253, P2769; RINDERKNECHT E, 1976, P NATL ACAD SCI USA, V73, P2365, DOI 10.1073/pnas.73.7.2365; ROBERTS CT, 1987, MOL ENDOCRINOL, V1, P243, DOI 10.1210/mend-1-3-243; ROGHANI M, 1989, FEBS LETT, V255, P253, DOI 10.1016/0014-5793(89)81101-9; ROSENBLOOM AL, 1990, NEW ENGL J MED, V323, P1367, DOI 10.1056/NEJM199011153232002; Rosenfeld R G, 1990, Recent Prog Horm Res, V46, P99; ROSSETTI L, 1991, DIABETES, V40, P444, DOI 10.2337/diabetes.40.4.444; SALMON WD, 1957, J LAB CLIN MED, V49, P825; SCHMITZ F, 1991, DIABETOLOGIA, V34, P144, DOI 10.1007/BF00418267; SCHOENLE EJ, 1991, DIABETOLOGIA, V34, P675, DOI 10.1007/BF00400998; SCHWANDER JC, 1983, ENDOCRINOLOGY, V113, P297, DOI 10.1210/endo-113-1-297; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SINHA MK, 1989, DIABETES, V38, P1217, DOI 10.2337/diabetes.38.10.1217; STRAUS DS, 1989, MOL CELLULAR BIOL DI, V2, P143; SUIKKARI AM, 1988, J CLIN ENDOCR METAB, V66, P266, DOI 10.1210/jcem-66-2-266; TAMURA K, 1989, J BIOL CHEM, V264, P5616; TASKINEN MR, 1988, ARTERIOSCLEROSIS, V8, P168, DOI 10.1161/01.ATV.8.2.168; TOLLEFSEN SE, 1988, J BIOL CHEM, V263, P16267; TURKALJ I, 1992, J CLIN ENDOCR METAB, V75, P1186, DOI 10.1210/jc.75.5.1186; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; USALA AL, 1992, NEW ENGL J MED, V327, P853, DOI 10.1056/NEJM199209173271205; Van Wyk J J, 1974, Recent Prog Horm Res, V30, P259; VANDENBRANDEJL, 1992, INSULIN LIKE GROWTH, P24; VANWYK JJ, 1985, J CLIN ENDOCR METAB, V61, P639; VENKATESAN N, 1990, AM J PHYSIOL, V258, pE329, DOI 10.1152/ajpendo.1990.258.2.E329; VERSPOHL EJ, 1984, J CLIN INVEST, V74, P1436, DOI 10.1172/JCI111555; WALKER JL, 1991, NEW ENGL J MED, V324, P1483, DOI 10.1056/NEJM199105233242107; YKIJARVINEN H, 1992, NEW ENGL J MED, V327, P1426, DOI 10.1056/NEJM199211123272005; ZAPF J, 1990, J CLIN INVEST, V86, P952, DOI 10.1172/JCI114797; ZAPF J, 1981, EUR J BIOCHEM, V113, P605, DOI 10.1111/j.1432-1033.1981.tb05105.x; ZENOBI PD, 1992, J CLIN INVEST, V89, P1908, DOI 10.1172/JCI115796; ZENOBI PD, 1992, J CLIN INVEST, V90, P2234, DOI 10.1172/JCI116109	118	59	63	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1994	120	1					47	55		10.7326/0003-4819-120-1-199401010-00009	http://dx.doi.org/10.7326/0003-4819-120-1-199401010-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP280	8250456				2022-12-28	WOS:A1994MP28000009
J	BRAUNWALD, E				BRAUNWALD, E			CARDIOLOGY - DIVISION OR DEPARTMENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							FUTURE		HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School								BRAUNWALD E, 1982, CIRCULATION, V66, P487, DOI 10.1161/01.CIR.66.3.487; BRAUNWALD E, 1988, CIRCULATION, V77, P13, DOI 10.1161/01.CIR.77.1.13; BRAUNWALD E, 1991, ANN INTERN MED, V114, P76, DOI 10.7326/0003-4819-114-1-76; GLICKMAN RM, 1993, ANN INTERN MED, V118, P903, DOI 10.7326/0003-4819-118-11-199306010-00014; ZARET BL, 1993, AM J CARDIOL, V72, P968, DOI 10.1016/0002-9149(93)91116-Y; ZARET BL, 1992, 1992 AM BOARD INT ME, P53; 1993, ARCH INTERN MED, V153, P2305	7	9	9	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 16	1993	329	25					1887	1890		10.1056/NEJM199312163292513	http://dx.doi.org/10.1056/NEJM199312163292513			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML588	8247044				2022-12-28	WOS:A1993ML58800013
J	BLUMENTHAL, D; MEYER, GS				BLUMENTHAL, D; MEYER, GS			THE FUTURE OF THE ACADEMIC-MEDICAL-CENTER UNDER HEALTH-CARE REFORM	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814	Uniformed Services University of the Health Sciences - USA	BLUMENTHAL, D (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA.							EBERT RH, 1983, NEW ENGL J MED, V308, P1200, DOI 10.1056/NEJM198305193082006; EPSTEIN AM, 1993, NEW ENGL J MED, V329, P1672, DOI 10.1056/NEJM199311253292229; FOX PD, 1993, HEALTH AFFAIR, V12, P85, DOI 10.1377/hlthaff.12.1.85; GROSSMAN JH, 1988, HEALTH AFFAIR, V7, P70, DOI 10.1377/hlthaff.7.2.70; IGLEHART JK, 1993, NEW ENGL J MED, V329, P1052, DOI 10.1056/NEJM199309303291428; KRONICK R, 1993, NEW ENGL J MED, V328, P148, DOI 10.1056/NEJM199301143280225; NELSON RR, 1977, RES POLICY, V6, P36, DOI 10.1016/0048-7333(77)90029-4; SCHROEDER SA, 1989, JAMA-J AM MED ASSOC, V262, P803, DOI 10.1001/jama.262.6.803; SHOWSTACK J, 1992, JAMA-J AM MED ASSOC, V267, P2497, DOI 10.1001/jama.267.18.2497; STARR P, 1993, NEW ENGL J MED, V329, P1666, DOI 10.1056/NEJM199311253292228; 1985, CONTRIBUTION ACADEMI	11	69	69	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 9	1993	329	24					1812	1814		10.1056/NEJM199312093292413	http://dx.doi.org/10.1056/NEJM199312093292413			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MK096	8232494				2022-12-28	WOS:A1993MK09600013
J	MORSE, RH				MORSE, RH			NUCLEOSOME DISRUPTION BY TRANSCRIPTION FACTOR-BINDING IN YEAST	SCIENCE			English	Article							RNA POLYMERASE-II; TUMOR VIRUS PROMOTER; DNA-BINDING; POSITIONED NUCLEOSOMES; SACCHAROMYCES-CEREVISIAE; REGULATORY PROTEINS; CHROMATIN STRUCTURE; PHO5 PROMOTER; MAJOR LATE; GENE	Studies in vivo and in vitro have shown that the packaging of DNA into chromatin can affect gene expression. Here, binding of the yeast transcriptional activator GAL4 to DNA in chromatin has been investigated in vivo with a yeast episome. A positioned nucleosome that is present in cells grown in glucose and contains a single GAL4 binding site is disrupted by GAL4 binding in galactose. GAL4 can also bind to DNA in chromatin when the carboxyl-terminal activation domain of GAL4 is either masked by GAL80 or is absent. These results show that a transcription factor can bind to its site in vivo in what would appear to be a repressive chromatin structure.	NIDDKD, CELLULAR & DEV BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Morse, Randall/0000-0003-0000-8718				ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; BAJWA W, 1988, MOL CELL BIOL, V8, P3439, DOI 10.1128/MCB.8.8.3439; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; DOLLARD C, UNPUB; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FEDOR MJ, 1989, MOL CELL BIOL, V9, P1721, DOI 10.1128/MCB.9.4.1721; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GRIGGS DW, 1991, P NATL ACAD SCI USA, V88, P8597, DOI 10.1073/pnas.88.19.8597; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1987, NATURE, V328, P353, DOI 10.1038/328353a0; JOHNSTON SA, 1987, CELL, V50, P143, DOI 10.1016/0092-8674(87)90671-4; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAUGHON A, 1984, MOL CELL BIOL, V4, P260, DOI 10.1128/MCB.4.2.260; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LOHR D, 1984, NUCLEIC ACIDS RES, V12, P8457, DOI 10.1093/nar/12.22.8457; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MADDEN SL, 1988, NUCLEIC ACIDS RES, V16, P2625, DOI 10.1093/nar/16.6.2625; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; MORSE RH, 1989, EMBO J, V8, P2343, DOI 10.1002/j.1460-2075.1989.tb08362.x; MORSE RH, 1992, MOL CELL BIOL, V12, P4015, DOI 10.1128/MCB.12.9.4015; MORSE RH, UNPUB; NEDOSPASOV SA, 1980, BIOCHEM BIOPH RES CO, V92, P532, DOI 10.1016/0006-291X(80)90366-6; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; Rose MD., 1990, METHODS YEAST GENETI; ROTH SY, 1991, METHOD CELL BIOL, V35, P289; SAMBROOK I, 1989, MOL CLONING LABORATO; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; THOMA F, 1984, J MOL BIOL, V177, P715, DOI 10.1016/0022-2836(84)90046-9; THOMA F, 1992, BIOCHIM BIOPHYS ACTA, V1130, P1, DOI 10.1016/0167-4781(92)90455-9; WOLFFE AP, 1989, P NATL ACAD SCI USA, V86, P9817, DOI 10.1073/pnas.86.24.9817; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0	56	65	65	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1993	262	5139					1563	1566		10.1126/science.8248805	http://dx.doi.org/10.1126/science.8248805			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK329	8248805				2022-12-28	WOS:A1993MK32900038
J	GADDE, J; SPENCE, M; WHEELER, B; ADKINSON, NF				GADDE, J; SPENCE, M; WHEELER, B; ADKINSON, NF			CLINICAL-EXPERIENCE WITH PENICILLIN SKIN TESTING IN A LARGE INNER-CITY STD CLINIC	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALLERGY; HYPERSENSITIVITY; DESENSITIZATION; ANTIBIOTICS	Objective.-To establish (1) the prevalence of positive penicillin skin tests among outpatients with well-defined but variable history of penicillin allergy and (2) the reproducibility, safety, and negative predictive value of skin testing with benzylpenicilloyl polylysine (PPL) and a minor-determinant mixture (MDM). Design.-Serial consenting outpatients with current indications for penicillin therapy were skin-tested in duplicate with PPL and MDM. Subjects with negative skin tests (93% of those positive by history and 95% of those negative by history) received therapeutic courses of benzylpenicillin (81%) or ampicillin (19%). Negative predictive value of skin testing was established by 72-hour follow-up for adverse reactions to drug. Setting/Patients.-A total of 5063 consecutive, qualifying outpatients in a Baltimore, Md, sexually transmitted disease (STD) clinic. The study group was young (73% between 20 and 40 years old), 66% male, and 90% black; 25% had history of atopy. Follow-up was 94% complete. Results.-Positive skin tests were observed in 7.1% of 776 individuals with previous history of penicillin allergy and in 1.7% of 4287 subjects negative by history (P<<.001). Previous history of anaphylaxis or urticaria was associated with significantly higher rates of positive skin tests of 17.3% and 12.4%, respectively (P<<.001). Only 4% with history of exanthem had positive skin tests (P=.03). The coefficient of variation for duplicate skin tests was 11%. Time intervals since last penicillin treatment did not influence the rate of positive skin tests. Adverse reactions to skin tests occurred in 13 (1.2% of patients positive by history; 9.4% of those with positive skin tests). A mild anaphylactic reaction occurred in one individual whose preliminary scratch testing was inadvertently omitted; systemic pruritus or urticaria occurred in 11 subjects; one had a large local reaction. After penicillin administration to individuals with negative skin tests, acute allergic reactions occurred in 0.5% of subjects negative by history compared with 2.9% of subjects positive by history (chi2=33.3; P=.0001). Reactions were generally mild and self-limited; only two cases of mild anaphylactic reaction occurred, both in patients with history of severe IgE-mediated reaction. Conclusions.-Skin testing with both major and minor penicillin determinants is safe using current recommendations, and both reagents are necessary for maximizing the identification of sensitized subjects. Routine penicillin skin testing can facilitate the safe use of penicillin in 90% of individuals with a previous history of penicillin allergy.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV ALLERGY & CLIN IMMUNOL, BALTIMORE, MD 21205 USA; BALTIMORE CITY EASTERN HLTH DIST CLIN SEXUALLY TRA, BALTIMORE, MD USA	Johns Hopkins University					NIAID NIH HHS [AI 11936] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADKINSON NF, 1971, NEW ENGL J MED, V285, P22, DOI 10.1056/NEJM197107012850104; BOGER WP, 1953, J ALLERGY, V24, P383, DOI 10.1016/0021-8707(53)90038-0; BROWN BC, 1964, JAMA-J AM MED ASSOC, V189, P599; BROWN LA, 1982, J ALLERGY CLIN IMMUN, V69, P51, DOI 10.1016/0091-6749(82)90087-2; BUDD MA, 1964, JAMA-J AM MED ASSOC, V190, P115; CHANDRA RK, 1980, ARCH DIS CHILD, V55, P857, DOI 10.1136/adc.55.11.857; DOGLIOTTI M, 1968, DERMATOLOGICA, V136, P489, DOI 10.1159/000254145; FINKE SR, 1965, AM J MED, V38, P71, DOI 10.1016/0002-9343(65)90161-0; GOREVIC PD, 1981, J ALLERGY CLIN IMMUN, V68, P267, DOI 10.1016/0091-6749(81)90150-0; GRAYBILL JR, 1974, SOUTH MED J, V67, P62, DOI 10.1097/00007611-197401000-00017; GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P339, DOI 10.1016/0091-6749(77)90064-1; LENTZ J W, 1970, British Journal of Venereal Diseases, V46, P457; LEVINE BB, 1966, J CLIN INVEST, V45, P1895, DOI 10.1172/JCI105494; LEVINE BB, 1969, J ALLERGY, V43, P231, DOI 10.1016/0021-8707(69)90066-5; MENDELSON LM, 1984, J ALLERGY CLIN IMMUN, V73, P76, DOI 10.1016/0091-6749(84)90487-1; NACLERIO R, 1982, Journal of Allergy and Clinical Immunology, V69, P139; PARKER CW, 1962, J EXP MED, V115, P821, DOI 10.1084/jem.115.4.821; REDELMEIER DA, 1990, ARCH INTERN MED, V150, P1939, DOI 10.1001/archinte.150.9.1939; RYTEL MW, 1963, JAMA-J AM MED ASSOC, V186, P894; SHEPHERD G, 1992, ARCH INTERN MED, V152, P2505; SIEGEL BB, 1964, J ALLERGY, V35, P488, DOI 10.1016/0021-8707(64)90080-2; SOGN DD, 1983, J ALLERGY CLIN IMMUN, V71, P147, DOI 10.1016/0091-6749(83)90358-5; SOGN DD, 1984, J ALLERGY CLIN IMMUN, V74, P589, DOI 10.1016/0091-6749(84)90111-8; SOGN DD, 1992, ARCH INTERN MED, V152, P1025, DOI 10.1001/archinte.152.5.1025; SOGN DD, 1986, J ALLERGY CLIN IMMUN, V78, P1051, DOI 10.1016/0091-6749(86)90303-9; SOLLEY GO, 1982, J ALLERGY CLIN IMMUN, V69, P238, DOI 10.1016/0091-6749(82)90105-1; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; SULLIVAN TJ, 1982, PEDIATR INFECT DIS J, V1, P344, DOI 10.1097/00006454-198209000-00015; TUCHINDA M, 1980, J MED ASSOC THAILAND, V63, P143; VOSS HE, 1966, J AMER MED ASSOC, V196, P679, DOI 10.1001/jama.1966.03100210049014; WARRINGTON RJ, 1978, CAN MED ASSOC J, V118, P787; WEISS ME, 1988, CLIN ALLERGY, V18, P515, DOI 10.1111/j.1365-2222.1988.tb02904.x	32	245	251	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1993	270	20					2456	2463		10.1001/jama.270.20.2456	http://dx.doi.org/10.1001/jama.270.20.2456			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG671	8230623				2022-12-28	WOS:A1993MG67100027
J	NICHOLSON, DA; DRISCOLL, PA				NICHOLSON, DA; DRISCOLL, PA			ABC OF EMERGENCY RADIOLOGY - THE ABDOMEN .1.	BRITISH MEDICAL JOURNAL			English	Article											NICHOLSON, DA (corresponding author), HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1993	307	6915					1342	1346		10.1136/bmj.307.6915.1342	http://dx.doi.org/10.1136/bmj.307.6915.1342			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH556	8257892	Green Published, Bronze			2022-12-28	WOS:A1993MH55600029
J	RONALD, PJM; ROBERTSON, JR; WYLD, R; WEIGHTMAN, R				RONALD, PJM; ROBERTSON, JR; WYLD, R; WEIGHTMAN, R			HETEROSEXUAL TRANSMISSION OF HIV IN INJECTING DRUG-USERS	BRITISH MEDICAL JOURNAL			English	Article							INFECTION		EDINBURGH DRUG ADDICT STUDY,EDINBURGH EH4 4PL,SCOTLAND; MRC,HETEROSEXUAL TRANSMISS STUDY,EDINBURGH EH4 4PL,SCOTLAND									DONOGHOE MC, 1992, SYRINGE EXCHANGE ENG; JOHNSON AM, 1992, BRIT MED J, V304, P1125, DOI 10.1136/bmj.304.6835.1125; ROBERTSON JR, 1986, BRIT MED J, V292, P527, DOI 10.1136/bmj.292.6519.527; ROBERTSON JR, 1990, AIDS DRUG MISUSE; RONALD PJM, 1992, BRIT J ADDICT, V87, P115	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1993	307	6913					1184	1185		10.1136/bmj.307.6913.1184	http://dx.doi.org/10.1136/bmj.307.6913.1184			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF824	8251845	Green Published, Bronze			2022-12-28	WOS:A1993MF82400024
J	ROSENGREN, A; ORTHGOMER, K; WEDEL, H; WILHELMSEN, L				ROSENGREN, A; ORTHGOMER, K; WEDEL, H; WILHELMSEN, L			STRESSFUL LIFE EVENTS, SOCIAL SUPPORT, AND MORTALITY IN MEN BORN IN 1933	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; MIDDLE-AGED MEN; MYOCARDIAL-INFARCTION; HOST-RESISTANCE; RISK-FACTORS; A BEHAVIOR; HEALTH; POPULATION; SWEDEN; INEQUALITIES	Objective-To examine relations between stressful life events and mortality in middle aged men. Design-Prospective population study. Data on stressful life events, social network, occupation, and other psychosocial factors derived from self administered questionnaires. Mortality data obtained from official registers. Setting-City of Gothenburg, Sweden. Subjects-752 men from a random population sample of 1016 men aged 50. Main outcome measure-Mortality from all causes during seven years' follow up. Results-Life events which had occurred in the year before the baseline examination were significantly associated with mortality from all causes during seven years' follow up. Of the men who had experienced three or more events during the past year 10.9% had died compared with 3.3% among those with no life events (odds ratio 3.6; 95% confidence interval 1.5 to 8.5). The association between recent life events and mortality remained true after smoking, self perceived health, occupational class, and indices of social support were controlled for. Many of the deaths were alcohol related, but the number of deaths was too small to allow for analyses of specific causes of death. The association between life events and mortality was evident only in men with low emotional support. Conclusion-Stressful life events are associated with high mortality in middle aged men. Men with adequate emotional support seem to be protected.	KAROLINSKA INST,NATL INST PSYCHOSOCIAL FACTORS & HLTH,S-10401 STOCKHOLM 60,SWEDEN; NORD SCH PUBL HLTH,GOTHENBURG,SWEDEN	Karolinska Institutet	ROSENGREN, A (corresponding author), GOTHENBURG UNIV,OSTRA HOSP,DEPT MED,PREVENT CARDIOL SECT,S-41685 GOTHENBURG,SWEDEN.		Tanne, David/F-2560-2010	Tanne, David/0000-0002-6699-2220				BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; Billings AC, 1982, HEALTH PSYCHOL, V1, P99, DOI DOI 10.1037/0278-6133.1.2.99; BRADLEY JV, 1968, DISTRIBUTION FREE ST, P68; CASSEL J, 1976, AM J EPIDEMIOL, V104, P107, DOI 10.1093/oxfordjournals.aje.a112281; COBB S, 1976, PSYCHOSOM MED, V38, P300, DOI 10.1097/00006842-197609000-00003; DOHRENWEND BS, 1978, J HEALTH SOC BEHAV, V19, P205, DOI 10.2307/2136536; FORSEN A, 1991, PSYCHOTHER PSYCHOSOM, V55, P176, DOI 10.1159/000288427; GOLDBERG EL, 1976, AM J EPIDEMIOL, V104, P146, DOI 10.1093/oxfordjournals.aje.a112285; HANEY CA, 1980, SOC SCI MED-MED SOC, V14, P119, DOI 10.1016/S0271-7123(80)80030-7; HELSING KJ, 1981, AM J EPIDEMIOL, V114, P41, DOI 10.1093/oxfordjournals.aje.a113172; HENDERSON S, 1980, PSYCHOL MED, V10, P723, DOI 10.1017/S003329170005501X; HOLLIS JF, 1990, J BEHAV MED, V13, P263, DOI 10.1007/BF00846834; HOLME I, 1980, J EPIDEMIOL COMMUN H, V34, P48, DOI 10.1136/jech.34.1.48; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; HOUSE JS, 1982, AM J EPIDEMIOL, V116, P123, DOI 10.1093/oxfordjournals.aje.a113387; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1037/0003-066X.59.8.676; JONES DR, 1987, J PSYCHOSOM RES, V31, P325, DOI 10.1016/0022-3999(87)90052-3; KASL SV, 1984, ANNU REV PUBL HEALTH, V5, P319; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P422; KOBASA SC, 1981, J HEALTH SOC BEHAV, V22, P368, DOI 10.2307/2136678; LUNDBERG U, 1975, J PSYCHOSOM RES, V19, P27, DOI 10.1016/0022-3999(75)90047-1; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MARMOT MG, 1984, LANCET, V1, P1003; MCFARLANE AH, 1983, J HEALTH SOC BEHAV, V24, P160, DOI 10.2307/2136642; MELLSTROM D, 1982, SCAND J SOC MED, V10, P33, DOI 10.1177/140349488201000201; ORTHGOMER K, 1990, PSYCHOSOM MED, V52, P59, DOI 10.1097/00006842-199001000-00005; ORTHGOMER K, 1987, J CHRON DIS, V40, P949, DOI 10.1016/0021-9681(87)90145-7; RAHE RH, 1971, J PSYCHOSOM RES, V15, P33, DOI 10.1016/0022-3999(71)90071-7; RAHE RH, 1973, AM J PSYCHIAT, V130, P1222, DOI 10.1176/ajp.130.11.1222; RAHE RH, 1974, ARCH INTERN MED, V133, P221, DOI 10.1001/archinte.133.2.221; ROSENGREN A, 1991, AM J CARDIOL, V68, P1171, DOI 10.1016/0002-9149(91)90189-R; ROSENGREN A, 1987, ACTA MED SCAND, V222, P201; ROSENGREN A, 1990, BRIT MED J, V300, P634, DOI 10.1136/bmj.300.6725.634; ROSENGREN A, 1988, BRIT MED J, V297, P1497, DOI 10.1136/bmj.297.6662.1497; RUBERMAN W, 1984, NEW ENGL J MED, V311, P552, DOI 10.1056/NEJM198408303110902; SLAP GB, 1991, J ADOLESCENT HEALTH, V12, P263, DOI 10.1016/0197-0070(91)90021-D; THEORELL T, 1975, INT J EPIDEMIOL, V4, P281, DOI 10.1093/ije/4.4.281; Theorell T G, 1982, Adv Cardiol, V29, P140; THIEL HG, 1973, J PSYCHOSOM RES, V17, P43, DOI 10.1016/0022-3999(73)90086-X; UNDEN AL, 1989, SOC SCI MED, V29, P1387, DOI 10.1016/0277-9536(89)90240-2; WELIN L, 1985, LANCET, V1, P915; WINSA B, 1991, LANCET, V338, P1475, DOI 10.1016/0140-6736(91)92298-G; 1985, SAS USERS GUIDE STAT; 1982, SWEDISH SOCIOECONOMI	44	193	195	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1993	307	6912					1102	1105		10.1136/bmj.307.6912.1102	http://dx.doi.org/10.1136/bmj.307.6912.1102			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ME918	8251807	Bronze, Green Published			2022-12-28	WOS:A1993ME91800015
J	YE, BH; LISTA, F; LOCOCO, F; KNOWLES, DM; OFFIT, K; CHAGANTI, RSK; DALLAFAVERA, R				YE, BH; LISTA, F; LOCOCO, F; KNOWLES, DM; OFFIT, K; CHAGANTI, RSK; DALLAFAVERA, R			ALTERATIONS OF A ZINC-FINGER ENCODING GENE, BCL-6, IN DIFFUSE LARGE-CELL LYMPHOMA	SCIENCE			English	Article							NON-HODGKINS-LYMPHOMA; ACUTE LEUKEMIAS; CHROMOSOME-TRANSLOCATION; DROSOPHILA-TRITHORAX; FOLLICULAR LYMPHOMA; REGION; PROTEINS; REARRANGEMENT; BREAKPOINT; LOCUS	The molecular pathogenesis of diffuse large-cell lymphoma (DLCL), the most frequent and clinically relevant type of lymphoma, is unknown. A gene was cloned from chromosomal translocations affecting band 3q27, which are common in DLCL. This gene, BCL-6, codes for a 79-kilodalton protein that is homologous with zinc finger-transcription factors. In 33 percent (13 of 39) of DLCL samples, but not in other types of lymphoid malignancies, the BCL-6 gene is truncated within its 5' noncoding sequences, suggesting that its expression is deregulated. Thus, BCL-6 may be a proto-oncogene specifically involved in the pathogenesis of DLCL.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT PATHOL,NEW YORK,NY 10021; CTR STUDI & RIC SANITA ESERCITO,ROME,ITALY; UNIV ROMA LA SAPIENZA,DIPARTIMENTO BIOPATOL UMANA,SEZ EMATOL,I-00185 ROME,ITALY	Columbia University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Sapienza University Rome				lista, florigio/0000-0001-5700-4772	NATIONAL CANCER INSTITUTE [R01CA044029, R01CA048236] Funding Source: NIH RePORTER; NCI NIH HHS [CA 48236, CA 44029] Funding Source: Medline; NEI NIH HHS [EY 06337] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAKSHI A, 1985, CELL, V41, P899; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BASTARD C, 1992, BLOOD, V79, P2527; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BELLEFROID EJ, 1989, DNA-J MOLEC CELL BIO, V8, P377, DOI 10.1089/dna.1.1989.8.377; CHAGANTI RSK, 1989, MOL DIAGNOSTICS HUMA, P33; CHAGANTI RSK, UNPUB; CHARDIN P, 1991, NUCLEIC ACIDS RES, V19, P1431, DOI 10.1093/nar/19.7.1431; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1991, CELL, V66, P663; DIBELLO PR, 1991, GENETICS, V129, P385; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; ELBARADI T, 1991, MECH DEVELOP, V35, P155, DOI 10.1016/0925-4773(91)90015-X; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FICHELSON S, 1992, LEUKEMIA, V6, P93; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KNOCHEL W, 1989, P NATL ACAD SCI USA, V86, P6097, DOI 10.1073/pnas.86.16.6097; KOONIN EV, 1992, TRENDS BIOCHEM SCI, V17, P213, DOI 10.1016/0968-0004(92)90379-N; KORSMEYER SJ, 1992, BLOOD, V80, P879; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LADANYI M, 1991, BLOOD, V77, P1057; MAGRATH IT, 1990, NONHODGKINS LYMPHOMA, P1; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MEDEIROS LJ, 1992, NEOPLASTIC HEMATOPAT, P263; MEEKER TC, 1989, BLOOD, V74, P1801; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NATHWANI BN, 1992, NEOPLASTIC HEMATOPAT, P555; OFFIT K, 1989, BRIT J HAEMATOL, V72, P178, DOI 10.1111/j.1365-2141.1989.tb07680.x; OFFIT K, 1989, BLOOD, V74, P1876; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; SUGAWARA MM, 1993, UNPUB; TAUB R, 1993, CAUSES CONSEQUENCES, P313; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WILLIAMS ME, 1991, BLOOD, V78, P493; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; YE BH, UNPUB; YE BHH, 1993, CANCER RES, V53, P2732	48	601	628	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 29	1993	262	5134					747	750		10.1126/science.8235596	http://dx.doi.org/10.1126/science.8235596			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	8235596				2022-12-28	WOS:A1993MD95200044
J	HOLLINGWORTH, W; TODD, C; PARKER, M; ROBERTS, JA; WILLIAMS, R				HOLLINGWORTH, W; TODD, C; PARKER, M; ROBERTS, JA; WILLIAMS, R			COST-ANALYSIS OF EARLY DISCHARGE AFTER HIP FRACTURE	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT; FEMUR	Objective-To ascertain the economic impact of an early discharge scheme for hip fracture patients. Design-Population based study comparing costs of care for patients who had ''hospital at home'' as an option for rehabilitation and those who had no early discharge service available in their area of residence. Setting-District hospital orthopaedic and rehabilitation wards and community hospital at home scheme. Patients-1104 consecutively admitted patients with fractured neck of femur. 24 patients from outside the district were excluded. Main outcome measures-Cost per patient episode and number of bed days spent in hospital. Results-Patients with the hospital at home option spent significantly less time as inpatients (mean of 32.5 v 41.7 days; p<0.001). Those patients who were discharged early spent a mean of 11.5 days under hospital at home care. The total direct cost to the health service was significantly less for those patients with access to early discharge than those with no early discharge option (4884 Pounds v 5606 Pounds; p=0.048). Conclusions-About 40% of patients with fractured neck of femur are suitable for early discharge to a scheme such as hospital at home. The availability of such a scheme leads to lower direct costs of rehabilitative care despite higher readmission costs. These savings accrue largely from shorter stays in orthopaedic and geriatric wards.	PETERBOROUGH DIST GEN HOSP,PETERBOROUGH PE3 6DA,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	HOLLINGWORTH, W (corresponding author), UNIV CAMBRIDGE,INST PUBL HLTH,HLTH SERV RES GRP,UNIV FORVIE SITE,ROBINSON WAY,CAMBRIDGE CB2 2SR,ENGLAND.		Todd, Chris/A-7904-2010; Todd, Chris/AAD-8661-2022	Todd, Chris/0000-0001-6645-4505; Todd, Chris/0000-0001-6645-4505; Hollingworth, William/0000-0002-0840-6254				BORGQUIST L, 1990, Scandinavian Journal of Primary Health Care, V8, P139, DOI 10.3109/02813439008994947; BOYCE WJ, 1985, LANCET, V1, P150; CAMPION EW, 1987, J GEN INTERN MED, V2, P78, DOI 10.1007/BF02596300; Drummond M.F., 1980, PRINCIPLES EC APPRAI; GREATOREX IF, 1988, J EPIDEMIOL COMMUN H, V42, P365, DOI 10.1136/jech.42.4.365; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; MOWAT IG, 1982, BRIT MED J, V284, P641, DOI 10.1136/bmj.284.6316.641; PARKER MJ, 1991, ACTA ORTHOP SCAND, V62, P563, DOI 10.3109/17453679108994497; PARKER MJ, 1992, J BONE JOINT SURG BR, V74, P261, DOI 10.1302/0301-620X.74B2.1544965; PRYOR GA, 1989, J BONE JOINT SURG BR, V71, P471, DOI 10.1302/0301-620X.71B3.2722942; PRYOR GA, 1988, LANCET, V1, P401; REID N, 1991, INT J NURS STUD, V28, P47, DOI 10.1016/0020-7489(91)90049-9; ROBBINS JA, 1984, LANCET, V2, P1028; RUSSELL EM, 1974, SCOTTISH HLTH SERVIC, V31; SOMMERS LS, 1990, CLIN ORTHOP RELAT R, V258, P168; TODD CJ, 1991, HLTH SERVICES RES PR, P185; Townsend P., 1962, LAST REFUGE; 1991, BRIT NATIONAL FORMUL, V22; 1982, LANCET, V2, P419; 1987, HOSPITAL IN PATIENT; 1992, SOCIAL TRENDS, V22, P27	21	90	90	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1993	307	6909					903	906		10.1136/bmj.307.6909.903	http://dx.doi.org/10.1136/bmj.307.6909.903			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB847	8241853	Bronze, Green Published			2022-12-28	WOS:A1993MB84700017
J	GILES, WH; ANDA, RF; JONES, DH; SERDULA, MK; MERRITT, RK; DESTEFANO, F				GILES, WH; ANDA, RF; JONES, DH; SERDULA, MK; MERRITT, RK; DESTEFANO, F			RECENT TRENDS IN THE IDENTIFICATION AND TREATMENT OF HIGH BLOOD CHOLESTEROL BY PHYSICIANS - PROGRESS AND MISSED OPPORTUNITIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; SERUM-CHOLESTEROL; UNITED-STATES; PRESSURE; TRIAL; RISK; ATHEROSCLEROSIS; MORTALITY; REMINDERS; PROJECT	Objective.-To investigate recent trends in the percentage and characteristics of patients being treated by a physician for high blood cholesterol (HBC) and to assess missed clinical opportunities to screen for HBC. Design, Setting, Participants.-Telephone interviews of 154 735 adults in 37 states that participated in the Behavioral Risk Factor Surveillance System during 1988-1990 to assess trends in the percentage of patients treated for HBC by a physician. An opportunity was considered missed if a person did not report being screened for HBC despite seeing a physician for preventive care in the last 2 years. Results.-Between the first quarter of 1988 and the last quarter of 1990, the percentage of persons treated by a physician for HBC increased from 7.6% to 11.7% (P<.001). However, since an estimated 36% of US adults need treatment for HBC, fewer than one third of persons who need treatment are receiving it. Persons with two or more cardiac risk factors were more likely to be treated, while men, blacks, persons in lower socioeconomic groups, and persons between 20 and 34 years of age were less likely to be treated. Among the 126 571 persons who had seen a physician for preventive care within the last 2 years, missed opportunities to screen for HBC were most common among persons aged 20 through 34 years (59%) and among women who had seen obstetricians/gynecologists for preventive care (43%). Conclusions.-Fewer than one third of persons who need treatment for HBC as estimated by data from the second National Health and Nutrition and Nutrition Examination Survey are receiving treatment. Better use of clinical opportunities to screen for HBC could substantially accelerate the progress in identifying persons, young adults in particular, who are likely to benefit from cholesterol reduction.	CTR DIS CONTROL & PREVENT,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,DIV NUTR,EPIDEMIOL BRANCH,ATLANTA,GA; CTR DIS CONTROL & PREVENT,DIV CHRON DIS CONTROL & COMMUNITY INTERVENT,ATLANTA,GA; UNIV MARYLAND,DEPT EPIDEMIOL & PREVENT MED,BALTIMORE,MD 21201	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University System of Maryland; University of Maryland Baltimore								BERENSON GS, 1987, AM J MED SCI, V294, P429, DOI 10.1097/00000441-198712000-00008; BLOCK L, 1988, AM J PREV MED, V4, P255, DOI 10.1016/S0749-3797(18)31158-9; BOSTICK RM, 1991, ARCH INTERN MED, V151, P478; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; COLLINS JG, 1983, PHS831572 US DEP 10; DAVIDSON RA, 1984, ARCH INTERN MED, V144, P2167, DOI 10.1001/archinte.144.11.2167; FLETCHER GF, 1992, CIRCULATION, V86, P340, DOI 10.1161/01.CIR.86.1.340; FORTMANN SP, 1990, AM J EPIDEMIOL, V132, P629, DOI 10.1093/oxfordjournals.aje.a115705; Foster J D, 1988, J Cancer Educ, V3, P121; Gregorio D I, 1990, Conn Med, V54, P370; GRUNDY SM, 1986, JAMA-J AM MED ASSOC, V256, P2849, DOI 10.1001/jama.256.20.2849; HEADRICK LA, 1992, ARCH INTERN MED, V152, P2490, DOI 10.1001/archinte.152.12.2490; HULLEY SB, 1982, METABOLISM, V31, P773, DOI 10.1016/0026-0495(82)90074-9; MARTIN MJ, 1986, LANCET, V2, P933; MCDOWELL I, 1989, MED CARE, V27, P297, DOI 10.1097/00005650-198903000-00008; NEWMAN WP, 1986, NEW ENGL J MED, V314, P138, DOI 10.1056/NEJM198601163140302; PYE G, 1988, J EPIDEMIOL COMMUN H, V42, P66, DOI 10.1136/jech.42.1.66; REMINGTON PL, 1988, PUBLIC HEALTH REP, V103, P366; SCHUCKER B, 1991, ARCH INTERN MED, V151, P666, DOI 10.1001/archinte.151.4.666; SCHUCKER B, 1987, JAMA-J AM MED ASSOC, V258, P3521, DOI 10.1001/jama.258.24.3521; SEMPOS C, 1989, JAMA-J AM MED ASSOC, V262, P45, DOI 10.1001/jama.262.1.45; SHAH BV, 1981, SESUDAAN STANDARD ER; SHAH BV, 1984, RTI LOGIT PROCEDURE; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; STEWART AL, 1982, J CHRON DIS, V35, P295, DOI 10.1016/0021-9681(82)90085-6; TURNER BJ, 1989, J GEN INTERN MED, V4, P403, DOI 10.1007/BF02599691; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WETZER HP, 1985, AM J PUBLIC HEALTH, V75, P129; WYSOWSKI DK, 1990, JAMA-J AM MED ASSOC, V263, P2185, DOI 10.1001/jama.263.16.2185; 1985, JAMA-J AM MED ASSOC, V253, P2080; 1988, ARCH INTERN MED, V148, P36; 1990, MMWR, V39, P633; 1993, JAMA-J AM MED ASSOC, V269, P505; 1987, JAMA-J AM MED ASSOC, V257, P937; 1984, JAMA-J AM MED ASSOC, V251, P351; 1990, MMWR, V39, P304; 1990, MMWR, V39, P311; 1984, CIRCULATION, V70, pA157	38	102	103	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1993	269	9					1133	1138		10.1001/jama.269.9.1133	http://dx.doi.org/10.1001/jama.269.9.1133			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN611	8240474				2022-12-28	WOS:A1993KN61100030
J	GRIDLEY, G; KLIPPEL, JH; HOOVER, RN; FRAUMENI, JF				GRIDLEY, G; KLIPPEL, JH; HOOVER, RN; FRAUMENI, JF			INCIDENCE OF CANCER AMONG MEN WITH THE FELTY SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article							RENAL-TRANSPLANT RECIPIENTS; RHEUMATOID-ARTHRITIS; MALIGNANT NEOPLASMS; HODGKINS-DISEASE; NEUTROPENIA; MORTALITY; RISK; MANIFESTATIONS; LYMPHOMA; SPLENECTOMY	Objective: To estimate the incidence of cancer (especially lymphoproliferative malignancies) in patients with the Felty syndrome. Design: A retrospective cohort study. Setting: A computerized database of all discharge records for 1969 to 1990 from a Veterans Affairs hospital. Patients: 906 men with a discharge diagnosis of the Felty syndrome. Measurements: Standardized incidence ratios (SIR) (ratios of observed-to-expected events) estimated the risk for specific cancers. Hospital records confirmed the diagnoses of the Felty syndrome and cancer. Results: We observed a twofold increase in total cancer incidence (137 patients; SIR = 2.09; 95% CI, 1.8 to 2.5). The risk for non-Hodgkin lymphoma (19 patients; SIR = 12.8, CI, 7.7 to 20.0) was much greater than the twofold increase in risk for lymphoma generally reported for rheumatoid arthritis. The risk for leukemia was increased but only within 5 years of the first hospitalization for the Felty syndrome, (13 patients; SIR = 7.67; CI, 4.1 to 13.1). Conclusion: The increased risk for non-Hodgkin lymphoma after the Felty syndrome in our study is similar to the risk associated with the Sjogren syndrome and may reflect similar immunostimulatory mechanisms.	NATL INST ARTHRITIS & MUSCULOSKELETAL & SKIN DISOR, BETHESDA, MD 20892 USA		GRIDLEY, G (corresponding author), NCI, EPN 443, BETHESDA, MD 20892 USA.							ABDOU NI, 1983, ARTHRITIS RHEUM, V26, P947, DOI 10.1002/art.1780260802; ALLEBECK P, 1982, SCAND J RHEUMATOL, V11, P81, DOI 10.3109/03009748209098167; BUTLER RC, 1987, J ROY SOC MED, V80, P168, DOI 10.1177/014107688708000314; CAMPION G, 1990, MEDICINE, V69, P69, DOI 10.1097/00005792-199069020-00001; FRAUMENI JF, 1975, AM J MED, V59, P145, DOI 10.1016/0002-9343(75)90333-2; GEOGHEGAN GE, 1984, BIOMETRICS MONOGRAPH, V18; GONZALESCHAMBERS R, 1992, ARTHRITIS RHEUM, V35, P516, DOI 10.1002/art.1780350505; GREENE MH, 1981, LANCET, V1, P1196, DOI 10.1016/S0140-6736(81)92359-X; GRIDLEY G, 1993, JNCI-J NATL CANCER I, V85, P307, DOI 10.1093/jnci/85.4.307; HELMERS R, 1991, CHEST, V100, P235, DOI 10.1378/chest.100.1.235; HIRAYAMA K, 1987, NATURE, V327, P426, DOI 10.1038/327426a0; HOOVER R, 1973, LANCET, V2, P55; ISOMAKI HA, 1978, J CHRON DIS, V31, P691, DOI 10.1016/0021-9681(78)90071-1; KAMEL OW, 1993, NEW ENGL J MED, V328, P1317, DOI 10.1056/NEJM199305063281806; KASSAN SS, 1978, ANN INTERN MED, V89, P888, DOI 10.7326/0003-4819-89-6-888; KATUSIC S, 1985, AM J MED, V78, P50, DOI 10.1016/0002-9343(85)90246-3; LIDDELL FDK, 1984, J EPIDEMIOL COMMUN H, V38, P85, DOI 10.1136/jech.38.1.85; LINCH DC, 1984, SCAND J HAEMATOL, V33, P342; LOUGHRAN TP, 1987, MEDICINE, V66, P397, DOI 10.1097/00005792-198709000-00005; MEADOWS AT, 1989, MED PEDIATR ONCOL, V17, P477; MONSON RR, 1976, J CHRON DIS, V29, P459, DOI 10.1016/0021-9681(76)90086-2; NASSIF PS, 1992, BRIT J OPHTHALMOL, V76, P173, DOI 10.1136/bjo.76.3.173; PALADINI G, 1991, Recenti Progressi in Medicina, V82, P133; Pedersen-Bjergaard J, 1988, Eur J Haematol Suppl, V48, P39; PORTER D, 1991, ANN RHEUM DIS, V50, P275, DOI 10.1136/ard.50.5.275; RIES LAG, 1991, NIH912789 NCI PUBL; ROBINETTE CD, 1977, LANCET, V2, P127; ROSENSTEIN ED, 1991, SEMIN ARTHRITIS RHEU, V21, P129, DOI 10.1016/0049-0172(91)90002-H; SNOWDEN N, 1991, Q J MED, V78, P65; SYMMONS DPM, 1988, J RHEUMATOL, V15, P1319; TUCKER MA, 1985, ANN INTERN MED, V102, P37, DOI 10.7326/0003-4819-102-1-37; TURA S, 1993, J CLIN ONCOL, V11, P925, DOI 10.1200/JCO.1993.11.5.925	32	80	80	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1994	120	1					35	39		10.7326/0003-4819-120-1-199401010-00006	http://dx.doi.org/10.7326/0003-4819-120-1-199401010-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP280	8250454				2022-12-28	WOS:A1994MP28000006
J	SU, LK; VOGELSTEIN, B; KINZLER, KW				SU, LK; VOGELSTEIN, B; KINZLER, KW			ASSOCIATION OF THE APC TUMOR-SUPPRESSOR PROTEIN WITH CATENINS	SCIENCE			English	Article							CELL CELL-ADHESION; E-CADHERIN; TYROSINE PHOSPHORYLATION; POSSIBLE INVOLVEMENT; CYTOPLASMIC DOMAIN; COLORECTAL-CANCER; EPITHELIAL-CELLS; ALPHA-CATENIN; IDENTIFICATION; UVOMORULIN	Mutations of APC appear to initiate sporadic and inherited forms of human colorectal cancer. Although these mutations have been well characterized, little is known about the function of the APC gene product. Two cellular proteins that associate with APC were identified by nucleotide sequence analysis and peptide mapping as the E-cadherin-associated proteins alpha- and beta-catenin. A 27-residue fragment of APC containing a 15-amino acid repeat was sufficient for the interaction with the catenins. These results suggest an important link between tumor initiation and cell adhesion.	JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21231	Johns Hopkins University					NATIONAL CANCER INSTITUTE [R01CA057345, R37CA057345] Funding Source: NIH RePORTER; NCI NIH HHS [CA-57345] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BUTZ S, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142-a; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HARLOW E, 1988, ANTIBODIES LABORATOR; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; MORTON RA, 1993, CANCER RES, V53, P3585; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEYRIERAS N, 1985, P NATL ACAD SCI USA, V82, P8067, DOI 10.1073/pnas.82.23.8067; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; POWELL SM, IN PRESS N ENGL J ME; RANSOHOFF DF, 1991, NEW ENGL J MED, V325, P37; RON D, 1992, BIOTECHNIQUES, V13, P866; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Sambrook J, 1989, MOL CLONING LABORATO; SHIMOYAMA Y, 1989, CANCER RES, V49, P2128; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; Su L., UNPUB; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, CANCER RES, V53, P2728; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x	42	1138	1169	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 10	1993	262	5140					1734	1737		10.1126/science.8259519	http://dx.doi.org/10.1126/science.8259519			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	8259519				2022-12-28	WOS:A1993ML22000042
J	JONES, A; REGAN, M; LEDINGHAM, J; PATTRICK, M; MANHIRE, A; DOHERTY, M				JONES, A; REGAN, M; LEDINGHAM, J; PATTRICK, M; MANHIRE, A; DOHERTY, M			IMPORTANCE OF PLACEMENT OF INTRAARTICULAR STEROID INJECTIONS	BRITISH MEDICAL JOURNAL			English	Article							OSTEOARTHRITIS; KNEE		MALMO GEN HOSP,S-21401 MALMO,SWEDEN		JONES, A (corresponding author), CITY HOSP NOTTINGHAM,RHEUMATOL UNIT,NOTTINGHAM NG5 1PD,ENGLAND.			Doherty, Michael/0000-0002-5763-8326				DOHERTY M, 1988, ANN RHEUM DIS, V47, P190, DOI 10.1136/ard.47.3.190; JONES A, 1992, ANN RHEUM DIS, V51, P243, DOI 10.1136/ard.51.2.243; MCALINDON T, 1990, BRIT J RHEUMATOL, V29, P471; RITCHIE DM, 1968, Q J MED, V37, P393; STOKER DJ, 1991, BRIT MED J, V303, P123	5	294	303	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1993	307	6915					1329	1330		10.1136/bmj.307.6915.1329	http://dx.doi.org/10.1136/bmj.307.6915.1329			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH556	8257889	Bronze, Green Published			2022-12-28	WOS:A1993MH55600023
J	MUNRO, AJ				MUNRO, AJ			PUBLISHING THE FINDINGS OF CLINICAL RESEARCH	BRITISH MEDICAL JOURNAL			English	Article								Current regulations and practice may not prevent a sponsor of clinical research from delaying or preventing the dissemination of findings that do not support his or her commercial, professional, or managerial interests. Pharmaceutical trials are particularly subject to this concern, but the issue of non-publication has a wider significance. Patients participate in research on the understanding that it will be of public benefit. To be fair to these patients we must confirm that data will be analysed without bias and that findings will be regarded as being in the public domain and hence available to interested reviewers even if the results do not justify publication. Clinical investigators and ethics committees have the power and the duty to enforce this outcome.			MUNRO, AJ (corresponding author), MARGARET AXHORN MED CTR,CRANFORD TW5 9TN,MIDDX,ENGLAND.							ADAM K, 1993, BRIT MED J, V306, P1475, DOI 10.1136/bmj.306.6890.1475-b; 1989, DECLARATION HELSINKI; 1990, RES INVOLVING PATIEN; 1990, GUIDELINES PRACTICE; 1988, GUIDELINES GOOD CLIN	5	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1993	307	6915					1340	1341		10.1136/bmj.307.6915.1340	http://dx.doi.org/10.1136/bmj.307.6915.1340			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH556	8257891	Green Published, Bronze			2022-12-28	WOS:A1993MH55600028
J	MCCAFFREY, PG; LUO, C; KERPPOLA, TK; JAIN, J; BADALIAN, TM; HO, AM; BURGEON, E; LANE, WS; LAMBERT, JN; CURRAN, T; VERDINE, GL; RAO, A; HOGAN, PG				MCCAFFREY, PG; LUO, C; KERPPOLA, TK; JAIN, J; BADALIAN, TM; HO, AM; BURGEON, E; LANE, WS; LAMBERT, JN; CURRAN, T; VERDINE, GL; RAO, A; HOGAN, PG			ISOLATION OF THE CYCLOSPORINE-SENSITIVE T-CELL TRANSCRIPTION FACTOR NFATP	SCIENCE			English	Article							LYMPHOCYTES-T; INTERLEUKIN-2 ENHANCER; NUCLEAR FACTOR; ACTIVATION; BINDING; FOS; CALCINEURIN; SEQUENCE; PROTEIN; FK-506	Nuclear factor of activated T cells (NFAT) is a transcription factor that regulates expression of the cytokine interleukin-2 (IL-2) in activated T cells. The DNA-binding specificity of NFAT is conferred by NFATp, a phosphoprotein that is a target for the immunosuppressive compounds cyclosporin A and FK506. Here, the purification of NFATp from murine T cells and the isolation of a complementary DNA clone encoding NFATp are reported. A truncated form of NFATp, expressed as a recombinant protein in bacteria, binds specifically to the NFAT site of the murine IL-2 promoter and forms a transcriptionally active complex with recombinant c-Fos and c-Jun. Antisera to tryptic peptides of the purified protein or to the recombinant protein fragment react with T cell NFATp. The molecular cloning of NFATp should allow detailed analysis of a T cell transcription factor that is central to initiation of the immune response.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR VIROL,BOSTON,MA 02115; ROCHE INST MOLEC BIOL,ROCHE RES CTR,DEPT MOLEC ONCOL & VIROL,NUTLEY,NJ 07110; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; HARVARD UNIV,MICROCHEM FACIL,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Roche Holding; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard University			Curran, Tom/F-5234-2018; Curran, Thomas/AAE-7631-2019; Kerppola, Tom/AFK-6155-2022; Kerppola, Tom/AAG-4457-2022; Curran, Tom/D-7515-2011; Curran, Tom/C-1164-2008	Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Kerppola, Tom/0000-0002-0611-9446; Kerppola, Tom/0000-0002-0611-9446; Curran, Tom/0000-0003-1444-7551	NCI NIH HHS [CA42471] Funding Source: Medline; NIGMS NIH HHS [GM46227] Funding Source: Medline; NINDS NIH HHS [NS25078] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA042471, R01CA042471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS025078] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1993, J IMMUNOL, V151, P837; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LARSON CJ, 1992, NUCLEIC ACIDS RES, V20, P3525, DOI 10.1093/nar/20.13.3525; LIU J, 1993, IMMUNOL TODAY, V14, P290, DOI 10.1016/0167-5699(93)90048-P; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; RAO A, 1984, J EXP MED, V159, P479, DOI 10.1084/jem.159.2.479; ROONEY JM, UNPUB; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; VALGEARCHER VE, 1990, J IMMUNOL, V145, P4355; WALTER G, 1980, P NATL ACAD SCI-BIOL, V77, P5197, DOI 10.1073/pnas.77.9.5197	32	417	430	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 29	1993	262	5134					750	754		10.1126/science.8235597	http://dx.doi.org/10.1126/science.8235597			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	8235597				2022-12-28	WOS:A1993MD95200045
J	LELLIOTT, P; SIMS, A; WING, J				LELLIOTT, P; SIMS, A; WING, J			WHO PAYS FOR COMMUNITY CARE - THE SAME OLD QUESTION	BRITISH MEDICAL JOURNAL			English	Article								Trends in mental health service funding over the past 40 years show that the programme of hospital closures has not resulted in a significant release of resources to fund community based services. Far from being excessive, the current provision of residential services (both NHS and non-NHS) for mentally ill people is now below levels recommended as sufficient by the government, the Royal College of Psychiatrists, and the National Schizophrenia Fellowship. What clinical research evidence there is suggests that more rather than fewer residential places are required. This situation is likely to be compounded by the recent transfer of responsibility for funding private and voluntary residential care from the Department of Social Security to local authority social services departments.			LELLIOTT, P (corresponding author), ROYAL COLL PSYCHIATRISTS,LONDON SW1X 8PG,ENGLAND.							FAULKNER A, 1992, WHO IS PROVIDING WHA; Griffiths R, 1988, COMMUNITY CARE AGEND; HAMMOND T, 1991, HOUSING PEOPLE WHO A; HOLLANDER D, 1990, BRIT MED J, V301, P664, DOI 10.1136/bmj.301.6753.664; RAFTERY J, 1992, BRIT J PSYCHIAT, V161, P589, DOI 10.1192/bjp.161.5.589; THORNICROFT G, 1993, BRIT MED J, V306, P768, DOI 10.1136/bmj.306.6880.768; WOOFF K, 1986, PSYCHOL MED, V16, P407, DOI 10.1017/S0033291700009235; 1993, COMMUNITY CARE FUNDI; 1993, ADSS FEARS COMMUNITY; 1992, FACILITIES SERVICES; 1968, CMND3707; 1992, MENTAL HLTH NATION C; 1993, HC489 HOUS COMM HLTH; 1989, MENTAL HLTH 1990S CU; 1992, CM2212; 1985, 2ND DEP HLTH SOC SEC	16	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1993	307	6910					991	994		10.1136/bmj.307.6910.991	http://dx.doi.org/10.1136/bmj.307.6910.991			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MC441	8241914	Bronze, Green Published			2022-12-28	WOS:A1993MC44100025
J	PARKER, L; CRAFT, AW; SMITH, J; DICKINSON, H; WAKEFORD, R; BINKS, K; MCELVENNY, D; SCOTT, L; SLOVAK, A				PARKER, L; CRAFT, AW; SMITH, J; DICKINSON, H; WAKEFORD, R; BINKS, K; MCELVENNY, D; SCOTT, L; SLOVAK, A			GEOGRAPHICAL-DISTRIBUTION OF PRECONCEPTIONAL RADIATION-DOSES TO FATHERS EMPLOYED AT THE SELLAFIELD NUCLEAR INSTALLATION, WEST CUMBRIA	BRITISH MEDICAL JOURNAL			English	Article							CONFIDENCE-LIMITS; CHILDREN BORN; YOUNG-PEOPLE; LEUKEMIA; LYMPHOMA; SEASCALE; FOLLOW; COHORT; PLANT	Objective-To examine whether the geographical distribution of births associated with preconceptional exposure of fathers to radiation at the Sellafield nuclear installation is consistent with the suggestion that this exposure explains the excess of childhood lymphoid malignancy in the adjacent village of Seascale. Design-Retrospective birth cohort study. Setting-Cumbria, West Cumbria health district, and Seascale civil parish. Subjects-The 10 363 children born in Cumbria during 1950-89 to fathers employed at Sellafield. Main outcome measures-The doses of external whole body ionising radiation received by fathers at Sellafield in the total time and in the six months before conception of their children; the proportions of the collective doses associated with Seascale and the rest of West Cumbria. Results-9256 children were born to fathers who had been exposed to radiation before the child's conception. Of these, 7318 had fathers who were exposed in the six months before conception. Overall 7% (38 person-Sv) of the collective total preconceptional dose and 7% (3 person-Sv) of the collective dose for the six months before conception were associated with children born in Seascale. Of all the children whose fathers worked at Sellafield, 842 (8%) were born in Seascale. The mean individual doses before conception were consistently lower in Seascale than in the rest of West Cumbria. Conclusions-The distribution of the paternal preconceptional radiation dose is statistically incompatible with this exposure providing a causal explanation for the cluster of childhood leukaemias in Seascale.	BRITISH NUCL FUELS PLC,HLTH & SAFETY DIRECTORATE,WARRINGTON WA3 6AS,CHESHIRE,ENGLAND; WESTLAKES RES INST,DEPT OCCUPAT HLTH & MED STAT,WHITEHAVEN CA24 3JZ,CUMBRIA,ENGLAND	University of Central Lancashire	PARKER, L (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT CHILD HLTH,CHILDRENS CANC UNIT,NEWCASTLE TYNE NE2 4HH,ENGLAND.		Wakeford, Richard/I-1978-2019	Wakeford, Richard/0000-0002-2934-0987; PARKER, LOUISE/0000-0002-5188-8113				BRENNER DJ, 1990, INT J RADIAT BIOL, V57, P1031, DOI 10.1080/09553009014551141; BRENNER DJ, 1990, STATISTICIAN, V39, P391, DOI DOI 10.2307/2349083; DRAPER GJ, 1993, BRIT MED J, V306, P89, DOI 10.1136/bmj.306.6870.89; FINDLAY W, 1987, PASCAL INTRO METHODI; GARDNER MJ, 1992, BRIT MED J, V305, P715, DOI 10.1136/bmj.305.6855.715; GARDNER MJ, 1987, BRIT MED J, V295, P819, DOI 10.1136/bmj.295.6602.819; GARDNER MJ, 1990, BRIT MED J, V300, P429, DOI 10.1136/bmj.300.6722.429; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GARDNER MJ, 1987, BRIT MED J, V295, P822, DOI 10.1136/bmj.295.6602.822; KENDALL GM, 1986, NRPBM136 NAT RAD PRO; KINLEN LJ, 1993, BRIT MED J, V306, P1153, DOI 10.1136/bmj.306.6886.1153; KINLEN LJ, 1993, BRIT MED J, V306, P1718, DOI 10.1136/bmj.306.6894.1718; LITTLE M P, 1990, Journal of Radiological Protection, V10, P185, DOI 10.1088/0952-4746/10/3/002; Little M. P., 1992, Journal of Radiological Protection, V12, P203, DOI 10.1088/0952-4746/12/4/001; LITTLE M P, 1991, Journal of Radiological Protection, V11, P231, DOI 10.1088/0952-4746/11/4/002; LITTLE M P, 1991, Journal of Radiological Protection, V11, P77, DOI 10.1088/0952-4746/11/2/001; MCLAUGHLIN JR, 1993, BRIT MED J, V307, P959, DOI 10.1136/bmj.307.6910.959; ROMAN E, 1993, BMJ-BRIT MED J, V306, P615, DOI 10.1136/bmj.306.6878.615; ROSE K S B, 1990, Journal of Radiological Protection, V10, P177, DOI 10.1088/0952-4746/10/3/001; URQUHART JD, 1991, BRIT MED J, V302, P687, DOI 10.1136/bmj.302.6778.687; YOSHIMOTO Y, 1990, AM J HUM GENET, V46, P1041; 1991, ARC VERSION 601; 1992, BOUNDARY LINE DIGITA; 1989, 4TH DIMENSION DESIGN; 1991, INFO 9 42; 1984, INVESTIGATION POSSIB; 1992, POSTZON	27	76	76	1	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1993	307	6910					966	971		10.1136/bmj.307.6910.966	http://dx.doi.org/10.1136/bmj.307.6910.966			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC441	8241907	Green Published, Bronze			2022-12-28	WOS:A1993MC44100017
J	DRISCOLL, PA; ROSS, R; NICHOLSON, DA				DRISCOLL, PA; ROSS, R; NICHOLSON, DA			ABC OF EMERGENCY RADIOLOGY - THE PELVIS	BRITISH MEDICAL JOURNAL			English	Article											DRISCOLL, PA (corresponding author), HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1993	307	6909					927	931		10.1136/bmj.307.6909.927	http://dx.doi.org/10.1136/bmj.307.6909.927			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB847	8241860	Bronze, Green Published			2022-12-28	WOS:A1993MB84700028
J	BAUMGARTEN, M; HANLEY, JA; INFANTERIVARD, C; BATTISTA, RN; BECKER, R; GAUTHIER, S				BAUMGARTEN, M; HANLEY, JA; INFANTERIVARD, C; BATTISTA, RN; BECKER, R; GAUTHIER, S			HEALTH OF FAMILY MEMBERS CARING FOR ELDERLY PERSONS WITH DEMENTIA - A LONGITUDINAL-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						DEMENTIA; SENILE; DEPRESSION; CAREGIVERS; ALZHEIMERS DISEASE; FAMILY HEALTH	DEPRESSIVE SYMPTOMS; PHYSICAL HEALTH; SOCIAL SUPPORT; SPOUSE CAREGIVERS; OLDER ADULTS; BURDEN; CARE; PEOPLE; STRESS; MODEL	Objective: To estimate the change in depression and physical symptoms during a 1-year period in a group of caregivers for elderly persons with dementia and in a group of comparison participants. Design: Cohort study with a comparison group. Setting: Outpatient geriatric assessment unit and ophthalmology service in an acute care hospital. Participants: 218 close family members of a consecutive sample of patients with dementia and patients having cataract surgery were interviewed to obtain a baseline assessment. Of these, 86 caregivers (family members of patients with dementia) and 95 comparison participants (family members of patients with cataracts) were interviewed again approximately 1 year later. Main Outcome Measures: Center for Epidemiologic Studies depression scale and Aday and Andersen's 24-item physical symptom checklist. Results: For the Center for Epidemiologic Studies depression score, the difference between caregivers and comparison participants with respect to change during the 1-year study period was 2.1 (95% CI, 1.0 to 5.2); for physical symptoms, the difference was 0.4 (CI, -0.3 to 1.1). A higher level of behavioral disturbance in the patients with dementia at time 1 and institutionalization of the patient between time 1 and time 2 were predictive of worsening caregiver depression and physical symptoms during the study period. The magnitude and direction of changes in caregiver health varied considerably. Conclusions: Overall mean changes in depression and physical symptoms during 1 year were small. The observed variability in the individual response to the caregiving situation suggests that future research should focus on the identification of salient prognostic factors.	MCGILL UNIV, DEPT EPIDEMIOL & BIOSTAT, MONTREAL H3A 1A2, PQ, CANADA; MCGILL UNIV, SCH OCCUPAT HLTH, MONTREAL H3A 1A3, PQ, CANADA; ST JUSTINE HOSP, MONTREAL, PQ, CANADA	McGill University; McGill University; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine								Aday LA, 1980, HLTH CARE US EQUITAB; BAUMGARTEN M, 1990, J AM GERIATR SOC, V38, P221, DOI 10.1111/j.1532-5415.1990.tb03495.x; BAUMGARTEN M, 1989, J CLIN EPIDEMIOL, V42, P1137, DOI 10.1016/0895-4356(89)90111-X; BAUMGARTEN M, 1992, J CLIN EPIDEMIOL, V45, P61, DOI 10.1016/0895-4356(92)90189-T; BECKER J, 1988, PSYCHOL AGING, V3, P300, DOI 10.1037/0882-7974.3.3.300; BERKMAN LF, 1986, AM J EPIDEMIOL, V124, P372, DOI 10.1093/oxfordjournals.aje.a114408; CORNONIHUNTLEY J, 1986, NIH862443 NAT I AG P; CUTRONA CE, 1986, J PERS SOC PSYCHOL, V50, P349, DOI 10.1037/0022-3514.50.2.349; DEFORGE BR, 1988, INT J PSYCHIAT MED, V18, P325, DOI 10.2190/8XGR-YUFH-0GVM-K4XB; EAGLES JM, 1987, BRIT J PSYCHIAT, V150, P293, DOI 10.1192/bjp.150.3.293; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GATZ M, 1990, PSYCHOL AGING, V5, P284, DOI 10.1037/0882-7974.5.2.284; GEORGE LK, 1985, J AM GERIATR SOC, V33, P607, DOI 10.1111/j.1532-5415.1985.tb06317.x; GEORGE LK, 1986, GERONTOLOGIST, V26, P253, DOI 10.1093/geront/26.3.253; Gilleard C J, 1982, Arch Gerontol Geriatr, V1, P151, DOI 10.1016/0167-4943(82)90015-2; GILLEARD CJ, 1984, J EPIDEMIOL COMMUN H, V38, P319, DOI 10.1136/jech.38.4.319; HALEY WE, 1988, GERONTOLOGICAL SOC A; JORM AF, 1987, ACTA PSYCHIAT SCAND, V76, P465, DOI 10.1111/j.1600-0447.1987.tb02906.x; KENNEDY GJ, 1989, AM J PSYCHIAT, V146, P220; KIECOLTGLASER JK, 1991, PSYCHOSOM MED, V53, P345, DOI 10.1097/00006842-199107000-00001; KINNEY JM, 1989, PSYCHOL AGING, V4, P402, DOI 10.1037/0882-7974.4.4.402; KOSBERG JI, 1990, GERONTOLOGIST, V30, P236, DOI 10.1093/geront/30.2.236; LIPTZIN B, 1988, GERONTOLOGIST, V28, P397, DOI 10.1093/geront/28.3.397; MORRIS RG, 1988, BRIT J PSYCHIAT, V153, P147, DOI 10.1192/bjp.153.2.147; MORTIMER JA, 1988, EPIDEMIOLOGY AGING I; MURRELL SA, 1984, J COMMUNITY PSYCHOL, V12, P301, DOI 10.1002/1520-6629(198410)12:4<301::AID-JCOP2290120403>3.0.CO;2-I; NORUSIS MJ, 1990, SPSS PC PLUS STATIST; OCONNOR DW, 1990, BRIT J PSYCHIAT, V156, P835, DOI 10.1192/bjp.156.6.835; OLSON DH, 1982, FAMILY INVENTORIES; PAGEL MD, 1985, J ABNORM PSYCHOL, V94, P169, DOI 10.1037/0021-843X.94.2.169; PHIFER JF, 1986, J ABNORM PSYCHOL, V95, P282; PRUCHNO RA, 1990, J GERONTOL, V45, pP192, DOI 10.1093/geronj/45.5.P192; RABINS PV, 1990, AGE AGEING, V19, P185; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RADLOFF LS, 1986, CLIN GERONTOLOGY GUI; RUSSELL DW, 1991, PSYCHOL AGING, V6, P190, DOI 10.1037/0882-7974.6.2.190; SCHULZ R, 1990, J GERONTOL, V45, pP181, DOI 10.1093/geronj/45.5.P181; SCHULZ R, 1991, PSYCHOL AGING, V6, P569, DOI 10.1037/0882-7974.6.4.569; SHAPIRO MF, 1986, ANN INTERN MED, V104, P246, DOI 10.7326/0003-4819-104-2-246; STOKES JP, 1983, AM J COMMUN PSYCHOL, V11, P141, DOI 10.1007/BF00894363; STONE R, 1987, GERONTOLOGIST, V27, P616, DOI 10.1093/geront/27.5.616; TOWNSEND A, 1989, PSYCHOL AGING, V4, P393, DOI 10.1037/0882-7974.4.4.393; VITALIANO PP, 1991, GERONTOLOGIST, V31, P76, DOI 10.1093/geront/31.1.76; WILDER DE, 1983, DEMENTIAS; WILLIAMSON GM, 1990, PSYCHOL AGING, V5, P502, DOI 10.1037/0882-7974.5.4.502; ZARIT SH, 1986, GERONTOLOGIST, V26, P260, DOI 10.1093/geront/26.3.260; 1981, HLTH CANADIANS REPOR; 1980, DIAGNOSTIC STATISTIC; 1978, MULTIDIMENSIONAL FUN	49	86	87	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1994	120	2					126	132		10.7326/0003-4819-120-2-199401150-00005	http://dx.doi.org/10.7326/0003-4819-120-2-199401150-00005			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ671	8256971				2022-12-28	WOS:A1994MQ67100005
J	HOYER, LW				HOYER, LW			HEMOPHILIA-A	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HUMAN FACTOR-VIII; PORCINE FACTOR-VIII; GRADIENT GEL-ELECTROPHORESIS; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; VONWILLEBRAND FACTOR COMPLEX; VON WILLEBRAND FACTOR; TISSUE FACTOR PATHWAY; FACTOR-IX INHIBITORS; ACTIVATED PROTEIN-C; CLASSIC HEMOPHILIA				HOYER, LW (corresponding author), AMER RED CROSS BIOMED SERV, HOLLAND LAB, 15601 CRABBS BRANCH WAY, ROCKVILLE, MD 20855 USA.				NHLBI NIH HHS [HL 36099, HL 44336] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL044336, R01HL036099] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADDIEGO JE, 1992, THROMB HAEMOSTASIS, V67, P19; ALEDORT LM, 1985, BLOOD, V66, P367; ALLAIN JP, 1976, BLOOD, V47, P973; ALY AM, 1992, J CLIN INVEST, V89, P1382, DOI 10.1172/JCI115726; ALY AM, 1990, BRIT J HAEMATOL, V76, P238, DOI 10.1111/j.1365-2141.1990.tb07878.x; ANTONARAKIS SE, 1988, ADV HUM GENET, V17, P27; ARAI M, 1989, P NATL ACAD SCI USA, V86, P4277, DOI 10.1073/pnas.86.11.4277; BARTLES JR, 1982, BIOCHIM BIOPHYS ACTA, V687, P129, DOI 10.1016/0005-2736(82)90538-7; BLOOM AL, 1991, THROMB HAEMOSTASIS, V66, P166; BLOOM AL, 1987, THROMB DIATH HAEMO, P447; BLOOM AL, 1987, HAEMOSTASIS THROMBOS, P393; Boedeker Berthold G. D., 1992, Transfusion Medicine Reviews, V6, P256, DOI 10.1016/S0887-7963(92)70177-1; BONA RD, 1989, AM J HEMATOL, V32, P8, DOI 10.1002/ajh.2830320103; BONTEMPO FA, 1987, BLOOD, V69, P1721; Bray Gordon L., 1992, Transfusion Medicine Reviews, V6, P252, DOI 10.1016/S0887-7963(92)70176-X; BRETTLER DB, 1989, ARCH INTERN MED, V149, P1381, DOI 10.1001/archinte.149.6.1381; BRETTLER DB, 1989, BLOOD, V73, P2067; BROZE GJ, 1992, SEMIN HEMATOL, V29, P159; BURKE RL, 1986, J BIOL CHEM, V261, P2574; DELAFUENTE B, 1985, ANN INTERN MED, V103, P6, DOI 10.7326/0003-4819-103-1-6; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; EHRENFORTH S, 1992, LANCET, V339, P594, DOI 10.1016/0140-6736(92)90874-3; EYSTER ME, 1985, JAMA-J AM MED ASSOC, V253, P2219, DOI 10.1001/jama.253.15.2219; FAY PJ, 1989, J BIOL CHEM, V264, P14005; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1990, J BIOL CHEM, V265, P6197; FAY PJ, 1988, BIOCHIM BIOPHYS ACTA, V952, P181, DOI 10.1016/0167-4838(88)90114-8; FIRSHEIN SI, 1979, NEW ENGL J MED, V300, P937, DOI 10.1056/NEJM197904263001701; FOSTER PA, 1989, BLOOD REV, V3, P180, DOI 10.1016/0268-960X(89)90015-5; FOWLER WE, 1990, P NATL ACAD SCI USA, V87, P7648, DOI 10.1073/pnas.87.19.7648; FULCHER CA, 1984, BLOOD, V63, P486; FULCHER CA, 1982, P NATL ACAD SCI-BIOL, V79, P1648, DOI 10.1073/pnas.79.5.1648; GAUCHER C, 1991, BLOOD, V77, P1937; GIANNELLI F, 1991, NUCLEIC ACIDS RES, V19, P2193, DOI 10.1093/nar/19.suppl.2193; GITSCHIER J, 1985, LANCET, V1, P1093; GITSCHIER J, 1985, NATURE, V314, P738, DOI 10.1038/314738a0; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; GITSCHIER J, 1989, COAGULATION BLEEDING, P23; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GOEDERT JJ, 1985, BLOOD, V65, P492; Gomperts Edward, 1992, Transfusion Medicine Reviews, V6, P247, DOI 10.1016/S0887-7963(92)70175-8; GRAHAM JB, 1977, NEW ENGL J MED, V296, P996, DOI 10.1056/NEJM197704282961712; GREEN D, 1991, AM J MED, V91, pS14, DOI 10.1016/S0002-9343(91)80142-9; GROWE G H, 1992, Transfusion Medicine Reviews, V6, P137, DOI 10.1016/S0887-7963(92)70163-1; HANDIN RI, 1989, PROG HEMOST THROMB, V9, P233; Hay C R, 1991, Transfus Med Rev, V5, P293, DOI 10.1016/S0887-7963(91)70224-1; HAY CRM, 1990, BLOOD, V76, P882; HAY CRM, 1991, BLOOD COAGUL FIBRIN, V2, P31; HEATH AB, 1992, THROMB HAEMOSTASIS, V68, P155; HEDNER U, 1988, LANCET, V2, P1193; HIGUCHI M, 1991, P NATL ACAD SCI USA, V88, P8307, DOI 10.1073/pnas.88.19.8307; HIGUCHI M, 1991, P NATL ACAD SCI USA, V88, P7405, DOI 10.1073/pnas.88.16.7405; HILLEUBANKS DC, 1990, J BIOL CHEM, V265, P17854; HILLEUBANKS DC, 1989, P NATL ACAD SCI USA, V86, P6508, DOI 10.1073/pnas.86.17.6508; HOLMAN RC, 1992, AM J HEMATOL, V39, P275, DOI 10.1002/ajh.2830390408; HOYER LW, 1981, BLOOD, V58, P1; HOYER LW, 1985, BLOOD, V65, P1312, DOI 10.1182/blood.V65.6.1312.bloodjournal6561312; HOYER LW, 1991, BLOOD COAGUL FIBRIN, V2, P11; HULTIN MB, 1981, BLOOD, V57, P476; INGRAM GIC, 1976, J CLIN PATHOL, V29, P469, DOI 10.1136/jcp.29.6.469; ISRAEL DI, 1990, BLOOD, V75, P1074; JACKSON JB, 1988, JAMA-J AM MED ASSOC, V260, P2236; JONES PK, 1991, ANN INTERN MED, V114, P641, DOI 10.7326/0003-4819-114-8-641; KANE WH, 1988, BLOOD, V71, P539; KASPER CK, 1989, PROG HEMOST THROMB, V9, P57; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P612; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233, DOI 10.1128/MCB.9.3.1233; KITCHENS CS, 1980, JOHNS HOPKINS MED J, V146, P255; KLEIN HG, 1977, NEW ENGL J MED, V296, P959, DOI 10.1056/NEJM197704282961702; KOGAN S, 1990, P NATL ACAD SCI USA, V87, P2092, DOI 10.1073/pnas.87.6.2092; LAKICH D, 1993, NAT GENET, V5, P236, DOI 10.1038/ng1193-236; LALLOZ MRA, 1991, LANCET, V338, P207, DOI 10.1016/0140-6736(91)90348-S; LARSSON SA, 1985, BRIT J HAEMATOL, V59, P593, DOI 10.1111/j.1365-2141.1985.tb07353.x; LETHAGEN S, 1990, BLUT, V60, P187, DOI 10.1007/BF01720274; LEVINE PH, 1987, HEMOSTASIS THROMBOSI, P97; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1991, MAYO CLIN PROC, V66, P524, DOI 10.1016/S0025-6196(12)62395-7; LUSHER JM, 1980, NEW ENGL J MED, V303, P421, DOI 10.1056/NEJM198008213030803; LUSHER JM, 1993, NEW ENGL J MED, V328, P453, DOI 10.1056/NEJM199302183280701; LUSHER JM, 1983, BLOOD, V62, P1135; LUSHER JM, 1990, SEMIN HEMATOL, V27, P1; MANN KG, 1990, BLOOD, V76, P1; MANNUCCI PM, 1990, ANNU REV MED, V41, P55; MAZURIER C, 1990, BLOOD, V75, P20; MCGRADY GA, 1987, AM J EPIDEMIOL, V126, P25, DOI 10.1093/oxfordjournals.aje.a114657; MCMILLAN CW, 1970, BRIT J HAEMATOL, V18, P659, DOI 10.1111/j.1365-2141.1970.tb01591.x; MILLER CH, 1987, AM J MED GENET, V26, P591, DOI 10.1002/ajmg.1320260313; MOSESSON MW, 1990, J CLIN INVEST, V85, P1983, DOI 10.1172/JCI114662; NAYLOR JA, 1992, LANCET, V340, P1066, DOI 10.1016/0140-6736(92)93080-7; NAYLOR JA, 1991, LANCET, V337, P635, DOI 10.1016/0140-6736(91)92450-G; NESHEIM M, 1991, J BIOL CHEM, V266, P17815; NILSSON IM, 1992, J INTERN MED, V232, P25, DOI 10.1111/j.1365-2796.1992.tb00546.x; NILSSON IM, 1988, NEW ENGL J MED, V318, P947, DOI 10.1056/NEJM198804143181503; NILSSON IM, 1981, BLOOD, V58, P38; NISHINO M, 1989, BLOOD, V74, P1591; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; Otto JC., 1803, MED REPOS, VVI, P1; PEAKE I, 1992, THROMB HAEMOSTASIS, V67, P277; PIERCE GF, 1989, JAMA-J AM MED ASSOC, V261, P3434; PITTMAN DD, 1992, BLOOD, V79, P389; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; POOL JG, 1964, NATURE, V203, P312, DOI 10.1038/203312a0; POOLE S, 1981, J MOL BIOL, V153, P273, DOI 10.1016/0022-2836(81)90278-3; RAGNI MV, 1986, BLOOD, V67, P592; RASI V, 1990, BRIT J HAEMATOL, V76, P369, DOI 10.1111/j.1365-2141.1990.tb06370.x; REPKE D, 1990, P NATL ACAD SCI USA, V87, P7623, DOI 10.1073/pnas.87.19.7623; RICK ME, 1977, BRIT J HAEMATOL, V36, P585, DOI 10.1111/j.1365-2141.1977.tb00999.x; ROBERTS HR, 1993, THROMB HAEMOSTASIS, V70, P1; ROSENDAAL FR, 1991, ANN HEMATOL, V62, P5, DOI 10.1007/BF01714977; ROTBLAT F, 1985, BIOCHEMISTRY-US, V24, P4294, DOI 10.1021/bi00337a007; RUGGERI ZM, 1991, MAYO CLIN PROC, V66, P847, DOI 10.1016/S0025-6196(12)61204-X; SADLER JE, 1990, SEMIN THROMB HEMOST, V16, P341, DOI 10.1055/s-2007-1002687; SJAMSOEDIN LJM, 1981, NEW ENGL J MED, V305, P717, DOI 10.1056/NEJM198109243051301; SLOCOMBE GW, 1981, BRIT J HAEMATOL, V47, P577, DOI 10.1111/j.1365-2141.1981.tb02687.x; SMIT C, 1989, BRIT MED J, V298, P235, DOI 10.1136/bmj.298.6668.235; STEHRGREEN JK, 1988, AM J PUBLIC HEALTH, V78, P439, DOI 10.2105/AJPH.78.4.439; SULTAN Y, 1992, THROMB HAEMOSTASIS, V67, P600; SULTAN Y, 1991, AM J MED, V91, pS35, DOI 10.1016/S0002-9343(91)80147-E; TEDGARD U, 1989, ACTA PAEDIATR SCAND, V78, P692, DOI 10.1111/j.1651-2227.1989.tb11128.x; THOMPSON AR, 1991, THROMB HAEMOSTASIS, V66, P119; TOOLE JJ, 1986, P NATL ACAD SCI USA, V83, P5939, DOI 10.1073/pnas.83.16.5939; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TRAYSTMAN MD, 1990, GENOMICS, V6, P293, DOI 10.1016/0888-7543(90)90569-G; TUDDENHAM EGD, 1991, NUCLEIC ACIDS RES, V19, P4821, DOI 10.1093/nar/19.18.4821; TUDDENHAM EGD, 1989, BLOOD REV, V3, P251, DOI 10.1016/0268-960X(89)90032-5; UEHLINGER J, 1991, TRANSFUSION, V31, P265, DOI 10.1046/j.1537-2995.1991.31391165179.x; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VAREKAMP I, 1990, AM J MED GENET, V37, P147, DOI 10.1002/ajmg.1320370134; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WEISS HJ, 1977, J CLIN INVEST, V60, P390, DOI 10.1172/JCI108788; WEISS HJ, 1973, J CLIN INVEST, V52, P2708, DOI 10.1172/JCI107465; WHITE GC, 1989, NEW ENGL J MED, V320, P166, DOI 10.1056/NEJM198901193200307; WHITE GC, 1989, BLOOD, V73, P1; ZIMMERMAN TS, 1971, J CLIN INVEST, V50, P255, DOI 10.1172/JCI106481; 1991, B WORLD HEALTH ORGAN, V69, P17	140	327	337	1	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 6	1994	330	1					38	47		10.1056/NEJM199401063300108	http://dx.doi.org/10.1056/NEJM199401063300108			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP649	8259143				2022-12-28	WOS:A1994MP64900008
J	LOE, H				LOE, H			BROAD PAYOFFS FROM ORAL-TISSUE RESEARCH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											LOE, H (corresponding author), NIDR,BETHESDA,MD 20892, USA.							1992, BIOCHEM BIOPH RES CO, V188, P740; 1993, J PERIDONTOL S, V64, P819	2	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	1994	271	1					14	14		10.1001/jama.271.1.14	http://dx.doi.org/10.1001/jama.271.1.14			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN725	8258872				2022-12-28	WOS:A1994MN72500005
J	SAGIE, A; LARSON, MG; LEVY, D				SAGIE, A; LARSON, MG; LEVY, D			THE NATURAL-HISTORY OF BORDERLINE ISOLATED SYSTOLIC HYPERTENSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLOOD-PRESSURE; MEN; RISK; DISEASE; TRIAL; DEATH	Background. Patients with isolated systolic hypertension are at increased risk for cardiovascular disorders. We attempted to determine whether those with borderline isolated systolic hypertension (defined as a systolic blood pressure of 140 to 159 mm Hg and a diastolic blood pressure below 90 mm Hg) have a greater risk of progression to definite (more severe) hypertension and of major morbid or fatal events than people with normal blood pressure (<140/90 mm Hg). Methods. A total of 2767 of the original participants in the Framingham Heart Study were monitored with biennial examinations for up to 34 years for the development of definite hypertension (defined as a systolic blood pressure of greater-than-or-equal-to 160 mm Hg, a diastolic blood pressure of greater-than-or-equal-to 90 mm Hg, or the initiation of antihypertensive therapy) and for major cardiovascular events. Results. Borderline isolated systolic hypertension was the most common type of untreated hypertension among adults over the age of 60. After 20 years of follow-up, 80 percent of those with borderline isolated systolic hypertension had progression to definite hypertension, as compared with 45 percent of the normotensive participants (P<0.001). After adjustment for age, sex, and risk factors for cardiovascular disease, participants with borderline isolated systolic hypertension had an excess long-term risk of cardiovascular disease (hazard ratio, 147; 95 percent confidence interval, 1.24 to 1.74) and death from cardiovascular disease (hazard ratio, 1.57; 95 percent confidence interval, 1.24 to 2.00), as compared with normotensive participants. In an analysis of pooled data from biennial examinations to study short-term sequelae, subjects with borderline isolated systolic hypertension had an increased risk of progression to definite hypertension (odds ratio, 3.84; 95 percent confidence interval, 3.35 to 4.41) and of cardiovascular disease (odds ratio, 1.39; 95 percent confidence interval, 1.06 to 1.82). Conclusions. In both the short term and the long term, subjects with borderline isolated systolic hypertension are at increased risk of progression to definite hypertension and the development of cardiovascular disease.	FRAMINGHAM HEART DIS EPIDEMIOL STUDY, 5 THURBER ST, FRAMINGHAM, MA 01701 USA; NHLBI, BETHESDA, MD 20892 USA; BOSTON UNIV, SCH MED, DIV EPIDEMIOL, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DIV PREVENT MED, BOSTON, MA 02118 USA; BETH ISRAEL HOSP, DIV CARDIOL, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DIV CLIN EPIDEMIOL, BOSTON, MA 02215 USA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center			Levy, Daniel/ABB-2752-2021; Levy, Daniel/ABF-6873-2021	Levy, Daniel/0000-0003-1843-8724; Larson, Martin/0000-0002-9631-1254				[Anonymous], 1985, Hypertension, V7, P641; BRONTESTEWART B, 1954, J PATHOL BACTERIOL, V68, P407, DOI 10.1002/path.1700680214; COLANDREA MA, 1970, CIRCULATION, V41, P239, DOI 10.1161/01.CIR.41.2.239; Cox DR, 1984, ANAL SURVIVAL DATA, P1; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; FROOM P, 1983, CIRCULATION, V68, P467, DOI 10.1161/01.CIR.68.3.467; Hosmer D.W., 1989, APPL LOGISTIC REGRES, P1; Hypertension Prevention Trial Research Group, 1990, ARCH INTERN MED, V150, P153, DOI [10.1001/archinte.1990.00390130131021, DOI 10.1001/ARCHINTE.1990.00390130131021]; KANNEL WB, 1980, CIRCULATION, V61, P1179, DOI 10.1161/01.CIR.61.6.1179; KANNEL WB, 1974, PROG CARDIOVASC DIS, V27, P5; KANNEL WB, 1987, DHHS NIH872703 PUBL; LEITSCHUH M, 1991, HYPERTENSION, V17, P22, DOI 10.1161/01.HYP.17.1.22; MOSES C, 1954, CIRC RES, V2, P243, DOI 10.1161/01.RES.2.3.243; NEATON JD, 1992, ARCH INTERN MED, V152, P56, DOI 10.1001/archinte.152.1.56; PSATY BM, 1992, JAMA-J AM MED ASSOC, V268, P1287, DOI 10.1001/jama.268.10.1287; RUTAN GH, 1988, CIRCULATION, V77, P504, DOI 10.1161/01.CIR.77.3.504; SCHATZKIN A, 1984, AM HEART J, V107, P1300, DOI 10.1016/0002-8703(84)90302-8; SHEKELLE RB, 1974, STROKE, V5, P71, DOI 10.1161/01.STR.5.1.71; STAESSEN J, 1990, J HYPERTENS, V8, P393, DOI 10.1097/00004872-199005000-00001; STAMLER R, 1989, JAMA-J AM MED ASSOC, V262, P1801, DOI 10.1001/jama.262.13.1801; The 1988 report of the Joint National Committee on Detection, 1988, ARCH INTERN MED, V148, P1203; WILKING S V B, 1988, Journal of the American Medical Association, V260, P3451, DOI 10.1001/jama.260.23.3451; 1980, BLOOD PRESSURE STUDY, P64; 1991, SAS P217 TECHN REP, P1; 1993, ARCH INTERN MED, V153, P154; 1959, BUILD BLOOD PRESSURE, V1, P121; 1991, JAMA-J AM MED ASSOC, V265, P3255; 1993, HYPERTENSION, V22, P392; 1990, SAS STAT USERS GUIDE, V2, P1027; 1985, HYPERTENSION, V7, P457; 1978, AHA MONOGRAPH, V60	33	214	220	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1993	329	26					1912	1917		10.1056/NEJM199312233292602	http://dx.doi.org/10.1056/NEJM199312233292602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM885	8247055				2022-12-28	WOS:A1993MM88500002
J	LEVIS, RW; GANESAN, R; HOUTCHENS, K; TOLAR, LA; SHEEN, FM				LEVIS, RW; GANESAN, R; HOUTCHENS, K; TOLAR, LA; SHEEN, FM			TRANSPOSONS IN-PLACE OF TELOMERIC REPEATS AT A DROSOPHILA TELOMERE	CELL			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; BROKEN CHROMOSOME ENDS; DNA-SEQUENCES; SACCHAROMYCES-CEREVISIAE; GENOME EVOLUTION; CODING SEQUENCES; Y-CHROMOSOME; WHITE LOCUS; HET DNA; MELANOGASTER	We present the first isolation of the terminal DNA of an intact Drosophila telomere. lt differs from those isolated from other eukaryotes by the lack of short tandem repeats at the terminus. The terminal 14.5 kb is composed of four tandem elements derived from two families of non-long terminal repeat retrotransposons and is subject to slow terminal loss. One of these transposon families, TART (telomere-associated retrotransposon), is described for the first time here. The other element, HeT-A, has previously been shown to transpose to broken chromosome ends. Our results provide key evidence that these elements also transpose to natural chromosome ends. We propose that the telomere-associated repetitive DNA is maintained by saltatory expansions, including terminal transpositions of specialized retrotransposons, which serve to balance terminal loss.			LEVIS, RW (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.			Levis, Robert/0000-0003-3453-2390; Sheen, Fangmiin/0000-0002-5112-253X	NATIONAL CANCER INSTITUTE [P30CA015704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038259] Funding Source: NIH RePORTER; NCI NIH HHS [CA15704] Funding Source: Medline; NIGMS NIH HHS [GM38259] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSHIRE RC, 1988, NATURE, V332, P656, DOI 10.1038/332656a0; Ashburner M, 1989, DROSOPHILA LABORATOR, P44; BALAKIREVA MD, 1992, NUCLEIC ACIDS RES, V20, P3731, DOI 10.1093/nar/20.14.3731; BIESSMANN H, 1993, CHROMOSOMA, V102, P297, DOI 10.1007/BF00661272; BIESSMANN H, 1992, ADV GENET, V30, P185, DOI 10.1016/S0065-2660(08)60321-1; BIESSMANN H, 1988, EMBO J, V7, P1081, DOI 10.1002/j.1460-2075.1988.tb02916.x; BIESSMANN H, 1992, EMBO J, V11, P4459, DOI 10.1002/j.1460-2075.1992.tb05547.x; BIESSMANN H, 1990, P NATL ACAD SCI USA, V87, P1758, DOI 10.1073/pnas.87.5.1758; BIESSMANN H, 1990, CELL, V61, P663, DOI 10.1016/0092-8674(90)90478-W; BIESSMANN H, 1992, MOL CELL BIOL, V12, P3910, DOI 10.1128/MCB.12.9.3910; BLACKBURN EH, 1984, CELL, V37, P7, DOI 10.1016/0092-8674(84)90295-2; BLACKBURN EH, 1993, REVERSE TRANSCRIPTAS, P411; BROSIUS J, 1991, SCIENCE, V251, P753, DOI 10.1126/science.1990437; BROWN W R A, 1992, Current Biology, V2, P127, DOI 10.1016/0960-9822(92)90248-9; CABOT EL, 1989, COMPUT APPL BIOSCI, V5, P233; CHARLESWORTH B, 1991, SCIENCE, V251, P1030, DOI 10.1126/science.1998119; CHARLESWORTH B, 1989, ANNU REV GENET, V23, P251, DOI 10.1146/annurev.ge.23.120189.001343; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARK D, 1994, IN PRESS METH MOL BI, V31; DANILEVSKAYA O, 1993, GENETICS, V134, P531; DANILEVSKAYA ON, 1992, CHROMOSOMA, V102, P32, DOI 10.1007/BF00352288; DANILEVSKAYA ON, 1991, CHROMOSOMA, V100, P118, DOI 10.1007/BF00418245; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; DOOLITTLE WF, 1980, NATURE, V284, P601, DOI 10.1038/284601a0; EICHER EM, 1989, GENETICS, V122, P181; EICKBUSH TH, 1992, NEW BIOL, V4, P430; ENGELS WR, 1979, GENETICS, V92, P161; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINNEGAN DJ, 1989, TRENDS GENET, V5, P103, DOI 10.1016/0168-9525(89)90039-5; GARZINO V, 1992, EMBO J, V11, P4471, DOI 10.1002/j.1460-2075.1992.tb05548.x; Gilson Eric, 1993, Trends in Cell Biology, V3, P128, DOI 10.1016/0962-8924(93)90175-Z; GOLDSTEIN LSB, 1986, J CELL BIOL, V102, P2076, DOI 10.1083/jcb.102.6.2076; GREIDER CW, 1991, CELL, V67, P645, DOI 10.1016/0092-8674(91)90058-7; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HAZELRIGG T, 1984, CELL, V36, P469, DOI 10.1016/0092-8674(84)90240-X; HENIKOFF S, 1986, CELL, V44, P33, DOI 10.1016/0092-8674(86)90482-4; HENIKOFF S, 1987, GENETICS, V117, P711; HENNIG W, 1990, CHROMOSOMES EUKARYOT, P214; IRMINGERFINGER I, 1990, J CELL BIOL, V111, P2563, DOI 10.1083/jcb.111.6.2563; JOHNSONSCHLITZ D, 1987, GENETICS, V115, P701; KARPEN GH, 1992, GENETICS, V132, P737; LEVIS R, 1982, P NATL ACAD SCI-BIOL, V79, P564, DOI 10.1073/pnas.79.2.564; LEVIS RW, 1989, CELL, V58, P791, DOI 10.1016/0092-8674(89)90112-8; LEVIS RW, 1993, MOL GEN GENET, V236, P440, DOI 10.1007/BF00277145; LOUIS EJ, 1990, GENETICS, V124, P547; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; MASON JM, 1984, P NATL ACAD SCI-BIOL, V81, P6090, DOI 10.1073/pnas.81.19.6090; McClintock B, 1941, GENETICS, V26, P234; MCCLINTOCK B, 1938, MO AGR EXP STN RES B, V163, P1; MCKEE BD, 1992, GENETICS, V132, P529; Muller H. J., 1941, Cold Spring Harbor Symposia on Quantitative Biology, V9, P151; MULLER HJ, 1938, COLLECTING NET, V13, P182; OHARE K, 1987, TRENDS GENET, V3, P87, DOI 10.1016/0168-9525(87)90186-7; OKAZAKI S, 1993, MOL CELL BIOL, V13, P1424, DOI 10.1128/MCB.13.3.1424; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; ORGEL LE, 1980, NATURE, V284, P604, DOI 10.1038/284604a0; PARDUE ML, 1992, DYNAMIC GENOME, P145; PEREIRA A, 1992, J CELL BIOL, V116, P377, DOI 10.1083/jcb.116.2.377; PETRACEK ME, 1990, P NATL ACAD SCI USA, V87, P8222, DOI 10.1073/pnas.87.21.8222; PLUTA AF, 1989, NATURE, V337, P429, DOI 10.1038/337429a0; PRIIMAGI AF, 1988, GENE, V70, P253, DOI 10.1016/0378-1119(88)90197-7; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RICHARDS EJ, 1988, CELL, V53, P127, DOI 10.1016/0092-8674(88)90494-1; RICHARDS G, 1985, COMPREHENSIVE INSECT, V2, P255; RUBIN GM, 1978, COLD SPRING HARB SYM, V42, P1041; SANDELL LL, 1993, IN PRESS CELL, V75; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAMPAY J, 1988, P NATL ACAD SCI USA, V85, P534, DOI 10.1073/pnas.85.2.534; SIMON JA, 1985, CHROMOSOMA, V93, P26, DOI 10.1007/BF01259442; TOWER J, 1993, GENETICS, V133, P347; TRAVERSE KL, 1988, P NATL ACAD SCI USA, V85, P8116, DOI 10.1073/pnas.85.21.8116; VALGEIRSDOTTIR K, 1990, P NATL ACAD SCI USA, V87, P7998, DOI 10.1073/pnas.87.20.7998; VAURY C, 1989, CHROMOSOMA, V98, P215, DOI 10.1007/BF00329686; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WANG SS, 1990, MOL CELL BIOL, V10, P4415, DOI 10.1128/MCB.10.8.4415; WANG SS, 1990, NATURE, V345, P456, DOI 10.1038/345456a0; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WERTMAN KF, 1986, GENE, V49, P253, DOI 10.1016/0378-1119(86)90286-6; WILLIAMSON JR, 1993, P NATL ACAD SCI USA, V90, P3214; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; Yao MC, 1989, MOBILE DNA, P715; YOUNG BS, 1983, CELL, V34, P85, DOI 10.1016/0092-8674(83)90138-1; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579; ZHANG P, 1993, GENETICS, V133, P361	86	361	373	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 17	1993	75	6					1083	1093		10.1016/0092-8674(93)90318-K	http://dx.doi.org/10.1016/0092-8674(93)90318-K			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	8261510				2022-12-28	WOS:A1993MM89300007
J	NOEL, JP; HAMM, HE; SIGLER, PB				NOEL, JP; HAMM, HE; SIGLER, PB			THE 2.2-ANGSTROM CRYSTAL-STRUCTURE OF TRANSDUCIN-ALPHA COMPLEXED WITH GTP-GAMMA-S	NATURE			English	Article							AMINO-ACID-SEQUENCE; ROD OUTER SEGMENTS; G-PROTEIN; BIOCHEMICAL-PROPERTIES; ADENYLATE-CYCLASE; BINDING PROTEINS; CDNA SEQUENCE; RAS P21; SUBUNIT; IDENTIFICATION	The 2.2 angstrom crystal structure of activated rod transducin, G(talpha) . GTPgammaS, shows the bound GTPgammaS molecule occluded deep in a cleft between a domain structurally homologous to small GTPases and a helical domain unique to heterotrimeric G proteins. The structure, when combined with biochemical and genetic studies, suggests: how an activated receptor might open this cleft to allow nucleotide exchange; a mechanism for GTP-induced changes in effector and receptor binding surfaces; and a mechanism for GTPase activity not evident from previous data.	YALE UNIV, BOYER CTR MOLEC MED, DEPT MOLEC BIOPHYS & BIOCHEM, 295 CONGRESS AVE, NEW HAVEN, CT 06510 USA; YALE UNIV, BOYER CTR MOLEC MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA; UNIV ILLINOIS, DEPT PHYSIOL & BIOPHYS, CHICAGO, IL 60680 USA; UNIV SASSARI, IST FISIOL GEN & CHIM BIOL, I-07100 SASSARI, ITALY	Yale University; Howard Hughes Medical Institute; Yale University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Sassari			Noel, Joseph P/A-9459-2009; Hamm, Heidi E/G-2374-2014					ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARTEMYEV NO, 1993, J BIOL CHEM, V268, P23611; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BLUMER KJ, 1991, ANNU REV PHYSIOL, V53, P37; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GIBBS JB, 1985, TRENDS BIOCHEM SCI, V10, P350, DOI 10.1016/0968-0004(85)90110-0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LAURSEN RA, 1981, J BIOL CHEM, V256, P8102; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; MAZZONI MR, 1993, J PROTEIN CHEM, V12, P215, DOI 10.1007/BF01026043; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; NUKADA T, 1986, FEBS LETT, V197, P305, DOI 10.1016/0014-5793(86)80347-7; OTWINOWSKI Z, 1976, ML PHARE CCP4 P WARR, P80; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PFISTER C, 1993, CELL SIGNAL, V5, P235, DOI 10.1016/0898-6568(93)90015-E; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; ROBISHAW JD, 1986, P NATL ACAD SCI USA, V83, P1251, DOI 10.1073/pnas.83.5.1251; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STEITZ TA, 1992, 36 F C CHEM RES REG, P173; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TANG WJ, 1991, J BIOL CHEM, V266, P8595; VANDOP C, 1984, J BIOL CHEM, V259, P23; VANDOP C, 1984, J BIOL CHEM, V259, P696; VANMEURS KP, 1987, P NATL ACAD SCI USA, V84, P3107, DOI 10.1073/pnas.84.10.3107; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P4316, DOI 10.1073/pnas.82.13.4316; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	52	723	737	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1993	366	6456					654	663		10.1038/366654a0	http://dx.doi.org/10.1038/366654a0			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM265	8259210				2022-12-28	WOS:A1993MM26500060
J	XIONG, Y; HANNON, GJ; ZHANG, H; CASSO, D; KOBAYASHI, R; BEACH, D				XIONG, Y; HANNON, GJ; ZHANG, H; CASSO, D; KOBAYASHI, R; BEACH, D			P21 IS A UNIVERSAL INHIBITOR OF CYCLIN KINASES	NATURE			English	Article							ACTIVATION	DEREGULATION of cell proliferation is a hallmark of neoplastic. transformation. Alteration in growth control pathways must translate into changes in the cell-cycle regulatory machinery, but the mechanism by which this occurs is largely unknown. Compared with normal human fibroblasts, cells transformed with a variety of viral oncoproteins show striking changes in the subunit composition of the cyclin-dependent kinases (CDKs)1. In normal cells, CDKs exist predominantly in multiple quaternary complexes, each containing a CDK, cyclin, proliferating cell nuclear antigen and the p21 protein. However, in many transformed cells, proliferating cell nuclear antigen and p21 are lost from these multiprotein enzymes. Here we have investigated the significance of this phenomenon by molecular cloning of p21 and in vitro reconstitution of the quaternary cell-cycle kinase complexes. We find that p21 inhibits the activity of each member of the cyclin/CDK family. Furthermore, overexpression of p21 inhibits the proliferation of mammalian cells. Our results indicate that p21 may be a universal inhibitor of cyclin kinases.	COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute			Hannon, Gregory/AAB-3568-2019					DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAWASAKI H, 1990, ANAL BIOCHEM, V191, P332, DOI 10.1016/0003-2697(90)90227-Z; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	13	3271	3386	4	123	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1993	366	6456					701	704		10.1038/366701a0	http://dx.doi.org/10.1038/366701a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM265	8259214				2022-12-28	WOS:A1993MM26500074
J	RUBINFELD, B; SOUZA, B; ALBERT, I; MULLER, O; CHAMBERLAIN, SH; MASIARZ, FR; MUNEMITSU, S; POLAKIS, P				RUBINFELD, B; SOUZA, B; ALBERT, I; MULLER, O; CHAMBERLAIN, SH; MASIARZ, FR; MUNEMITSU, S; POLAKIS, P			ASSOCIATION OF THE APC GENE-PRODUCT WITH BETA-CATENIN	SCIENCE			English	Article							COLORECTAL TUMORIGENESIS; CYTOPLASMIC DOMAIN; CELL-ADHESION; E-CADHERIN; MUTATIONS; PLAKOGLOBIN; PROTEIN; CANCER; CHROMOSOME-5Q21; IDENTIFICATION	Mutations in the human APC gene are linked to familial adenomatous polyposis and to the progression of sporadic colorectal and gastric tumors. To gain insight into APC function, APC-associated proteins were identified by immunoprecipitation experiments. Antibodies to APC precipitated a 95-kilodalton protein that was purified and identified by sequencing as beta-catenin, a protein that binds to the cell adhesion molecule E-cadherin. An antibody specific to beta-catenin also recognized the 95-kilodalton protein in the immunoprecipitates. These results suggest that APC is involved in cell adhesion.	ONYX PHARMACEUT,3031 RES DR,RICHMOND,CA 94806; CHIRON CORP,PROT CHEM SECT,EMERYVILLE,CA 94608; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143	Novartis; University of California System; University of California San Francisco				Rubinfeld, Bonnee/0000-0001-9861-6775				BUTZ S, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142-a; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FUJIMORI T, 1993, MOL BIOL CELL, V4, P37, DOI 10.1091/mbc.4.1.37; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HUELSKEN J, 1992, UNPUB; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; MARRS JA, 1993, J CELL BIOL, V123, P149, DOI 10.1083/jcb.123.1.149; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAKATSURU S, 1992, HUM MOL GENET, V1, P559, DOI 10.1093/hmg/1.8.559; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; RUBINFELD B, 1992, MOL CELL BIOL, V12, P4634, DOI 10.1128/MCB.12.10.4634; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; SU LK, 1993, CANCER RES, V53, P2728	23	1190	1220	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 10	1993	262	5140					1731	1734		10.1126/science.8259518	http://dx.doi.org/10.1126/science.8259518			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	8259518				2022-12-28	WOS:A1993ML22000041
J	FISHEL, R; LESCOE, MK; RAO, MRS; COPELAND, NG; JENKINS, NA; GARBER, J; KANE, M; KOLODNER, R				FISHEL, R; LESCOE, MK; RAO, MRS; COPELAND, NG; JENKINS, NA; GARBER, J; KANE, M; KOLODNER, R			THE HUMAN MUTATOR GENE HOMOLOG MSH2 AND ITS ASSOCIATION WITH HEREDITARY NONPOLYPOSIS COLON-CANCER	CELL			English	Article							DNA MISMATCH CORRECTION; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; HUMAN-CELLS; COLORECTAL-CANCER; NUCLEAR EXTRACTS; G.T MISPAIRS; REPAIR; CONVERSION; PROTEIN	We have identified a human homolog of the bacterial MutS and S. cerevisiae MSH proteins, called hMSH2. Expression of hMSH2 in E. coli causes a dominant mutator phenotype, suggesting that hMSH2, like other divergent MutS homologs, interferes with the normal bacterial mismatch repair pathway. hMSH2 maps to human chromosome 2p22-21 near a locus implicated in hereditary nonpolyposis colon cancer (HNPCC). A T to C transition mutation has been detected in the -6 position of a splice acceptor site in sporadic colon tumors and in affected individuals of two small HNPCC kindreds. These data and reports indicating that S. cerevisiae msh2 mutations cause an instability of dinucleotide repeats like those associated with HNPCC suggest that hMSH2 is the HNPCC gene.	NCI, FREDERICK CANC RES & DEV CTR,ADV BIOSCI LABS, BASIC RES PROGRAM,MAMMALIAN GENET LAB, FREDERICK, MD 21702 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CANC EPIDEMIOL & CONTROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CELLULAR & MOLEC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	FISHEL, R (corresponding author), UNIV VERMONT, SCH MED, MARKEY CTR MOLEC GENET, DEPT MICROBIOL & MOLEC GENET, BURLINGTON, VT 05405 USA.				NATIONAL CANCER INSTITUTE [R01CA056542] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050006] Funding Source: NIH RePORTER; NCI NIH HHS [CA56542] Funding Source: Medline; NHGRI NIH HHS [HG00305] Funding Source: Medline; NIGMS NIH HHS [GM50006] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALANI E, 1994, IN PRESS GENETICS; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; [Anonymous], 1985, DNA REPAIR; AU KG, 1988, P NATL ACAD SCI USA, V85, P9163, DOI 10.1073/pnas.85.23.9163; AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; BAILIS AM, 1990, GENETICS, V126, P535; BISHOP DK, 1987, NATURE, V328, P362, DOI 10.1038/328362a0; BISHOP DT, 1990, CANCER SURV, V9, P585; COOPER DL, 1993, J BIOL CHEM, V268, P11823; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; DZIDIC S, 1989, MOL GEN GENET, V217, P254, DOI 10.1007/BF02464889; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHEL R, 1989, J BACTERIOL, V171, P3046, DOI 10.1128/jb.171.6.3046-3052.1989; FISHEL RA, 1986, J MOL BIOL, V188, P147, DOI 10.1016/0022-2836(86)90300-1; FRIEDBERG EC, 1990, MUTAT RES, V236, P145, DOI 10.1016/0921-8777(90)90001-L; Green E., 1981, GENETICS PROBABILITY, DOI 10.1007/978-1-349-04904-2; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; GROMPE M, 1993, NAT GENET, V5, P111, DOI 10.1038/ng1093-111; HAN HJ, 1993, CANCER RES, V53, P5087; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; ICELY PL, 1991, J BIOL CHEM, V266, P16073; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; KUHL DPA, 1993, CURR OPIN GENET DEV, V3, P404, DOI 10.1016/0959-437X(93)90112-3; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LIEB M, 1987, J BACTERIOL, V169, P5241, DOI 10.1128/jb.169.11.5241-5246.1987; LYNCH HT, 1991, SEMIN ONCOL, V18, P337; MATSON SW, 1987, J BIOL CHEM, V262, P2066; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MODRICH P, 1989, J BIOL CHEM, V264, P6597; MOORE SP, 1990, J BIOL CHEM, V265, P11108; NENE V, 1982, MOL GEN GENET, V188, P399, DOI 10.1007/BF00330040; NEW L, 1993, MOL GEN GENET, V239, P97, DOI 10.1007/BF00281607; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PROFFITT JH, 1984, MOL CELL BIOL, V4, P985, DOI 10.1128/MCB.4.5.985; PRUDHOMME M, 1991, J BACTERIOL, V173, P7196, DOI 10.1128/jb.173.22.7196-7203.1991; RADICELLA JP, 1988, P NATL ACAD SCI USA, V85, P9674, DOI 10.1073/pnas.85.24.9674; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; REENAN RAG, 1992, GENETICS, V132, P963; REENAN RAG, 1992, GENETICS, V132, P975; REICHMANN A, 1981, INT J CANCER, V28, P431, DOI 10.1002/ijc.2910280407; RENAN MJ, 1993, MOL CARCINOGEN, V7, P139; RISINGER JI, 1993, CANCER RES, V53, P5100; ROSCIGNO RF, 1993, J BIOL CHEM, V268, P11222; RYDBERG B, 1978, MUTAT RES, V52, P11, DOI 10.1016/0027-5107(78)90091-X; RZHETSKY A, 1992, J MOL EVOL, V35, P367, DOI 10.1007/BF00161174; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; VARLET I, 1990, P NATL ACAD SCI USA, V87, P7883, DOI 10.1073/pnas.87.20.7883; VISSCHER DW, 1990, PATHOL ANNU, V25, P171; WAGNER R, 1976, P NATL ACAD SCI USA, V73, P4135, DOI 10.1073/pnas.73.11.4135; WEBB GC, 1993, GENOMICS, V18, P14, DOI 10.1006/geno.1993.1421; WELSH KM, 1987, J BIOL CHEM, V262, P15624; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0; WILLIAMSON MS, 1985, GENETICS, V110, P609	70	2468	2566	2	194	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 3	1993	75	5					1027	1038		10.1016/0092-8674(93)90546-3	http://dx.doi.org/10.1016/0092-8674(93)90546-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252616				2022-12-28	WOS:A1993MK96600022
J	LEE, RC; FEINBAUM, RL; AMBROS, V				LEE, RC; FEINBAUM, RL; AMBROS, V			THE C-ELEGANS HETEROCHRONIC GENE LIN-4 ENCODES SMALL RNAS WITH ANTISENSE COMPLEMENTARITY TO LIN-14	CELL			English	Article							3' UNTRANSLATED REGION; MESSENGER-RNA; CAENORHABDITIS-ELEGANS; TRANSLATION INITIATION; DEVELOPMENTAL SWITCH; POLY(A) TAIL; TRANSCRIPT; SEQUENCES; PROTEIN; YEAST	lin-4 is essential for the normal temporal control of diverse postembryonic developmental events in C. elegans. lin-4 acts by negatively regulating the level of LIN-14 protein, creating a temporal decrease in LIN-14 protein starting in the first larval stage (L1). We have cloned the C. elegans lin-4 locus by chromosomal walking and transformation rescue. We used the C. elegans clone to isolate the gene from three other Caenorhabditis species; all four Caenorhabditis clones functionally rescue the lin-4 null allele of C. elegans. Comparison of the lin-4 genomic sequence from these four species and site-directed mutagenesis of potential open reading frames indicated that lin-4 does not encode a protein. Two small lin-4 transcripts of approximately 22 and 61 nt were identified in C. elegans and found to contain sequences complementary to a repeated sequence element in the 3' untranslated region (UTR) of lin-14 mRNA, suggesting that lin-4 regulates lin-14 translation via an antisense RNA-RNA interaction.	HARVARD UNIV, DEPT CELLULAR & DEV BIOL, CAMBRIDGE, MA 02138 USA	Harvard University			Duarte, Graziela Biude Silva/Q-7728-2016; Jackson, Benjamin L/C-4297-2012		NIGMS NIH HHS [GM34028, GM15396, R01 GM034028] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034028] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHRINGER J, 1992, EMBO J, V11, P2303, DOI 10.1002/j.1460-2075.1992.tb05289.x; AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0; AMBROS V, 1989, CELL, V57, P49, DOI 10.1016/0092-8674(89)90171-2; AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; AMBROS V, 1987, GENE DEV, V1, P398, DOI 10.1101/gad.1.4.398; ARASU P, 1991, GENE DEV, V5, P1825, DOI 10.1101/gad.5.10.1825; Ausubel FM, 1988, MOL REPROD DEV; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BRENNER S, 1974, GENETICS, V77, P71; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; CARLE GF, 1985, P NATL ACAD SCI USA, V82, P3756, DOI 10.1073/pnas.82.11.3756; CHALFIE M, 1981, CELL, V24, P59, DOI 10.1016/0092-8674(81)90501-8; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; GOODWIN EB, 1993, CELL, V75, P329, DOI 10.1016/0092-8674(93)80074-O; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HILDEBRANDT M, 1992, CELL, V69, P197, DOI 10.1016/0092-8674(92)90130-5; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JAEGER JA, 1990, METHOD ENZYMOL, V183, P281; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KITTLE JD, 1989, J MOL BIOL, V210, P561, DOI 10.1016/0022-2836(89)90132-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KWON YK, 1991, P NATL ACAD SCI USA, V88, P3584, DOI 10.1073/pnas.88.9.3584; LEVERETTE RD, 1992, CELL, V71, P1215, DOI 10.1016/S0092-8674(05)80069-8; LIAO SM, 1987, GENE DEV, V1, P197, DOI 10.1101/gad.1.2.197; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; RUVKUN G, 1989, GENETICS, V121, P501; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMONS RW, 1988, GENE, V72, P35, DOI 10.1016/0378-1119(88)90125-4; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TYCOWSKI KT, 1993, GENE DEV, V7, P1176, DOI 10.1101/gad.7.7a.1176; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; WIGHTMAN B, 1991, GENE DEV, V5, P1813, DOI 10.1101/gad.5.10.1813; WOD WB, 1988, NEMATODE CAENORHABDI; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	52	8720	10037	43	963	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 3	1993	75	5					843	854		10.1016/0092-8674(93)90529-Y	http://dx.doi.org/10.1016/0092-8674(93)90529-Y			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252621	Bronze			2022-12-28	WOS:A1993MK96600005
J	SADOSHIMA, J; XU, YH; SLAYTER, HS; IZUMO, S				SADOSHIMA, J; XU, YH; SLAYTER, HS; IZUMO, S			AUTOCRINE RELEASE OF ANGIOTENSIN-II MEDIATES STRETCH-INDUCED HYPERTROPHY OF CARDIAC MYOCYTES IN-VITRO	CELL			English	Article							GENE-EXPRESSION; CONVERTING ENZYME; PRESSURE-OVERLOAD; GROWTH; RENIN; RAT; SYSTEM; CELLS; IMMUNOREACTIVITY; REGRESSION	Hypertrophy is a fundamental adaptive process employed by postmitotic cardiac and skeletal muscle in response to mechanical load. How muscle cells convert mechanical stimuli into growth signals has been a long-standing question. Using an in vitro model of load (stretch)-induced cardiac hypertrophy, we demonstrate that mechanical stretch causes release of angiotensin II (Ang II) from cardiac myocytes and that Ang II acts as an initial mediator of the stretch-induced hypertrophic response. The results not only provide direct evidence for the autocrine mechanism in load-induced growth of cardiac muscle cells, but also define the pathophysiological role of the local (cardiac) renin-angiotensin system.	BETH ISRAEL HOSP, DIV CARDIOVASC, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, PROGRAM CELL & DEV BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	SADOSHIMA, J (corresponding author), BETH ISRAEL HOSP, DIV MOLEC MED, BOSTON, MA 02215 USA.			Sadoshima, Junichi/0000-0003-3724-4132				BAKER KM, 1990, AM J PHYSIOL, V259, pH324, DOI 10.1152/ajpheart.1990.259.2.H324; BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.physiol.54.1.227; BEINLICH CJ, 1991, J MOL CELL CARDIOL, V23, P1031, DOI 10.1016/0022-2828(91)91638-8; BLOCH KD, 1986, CELL, V47, P695, DOI 10.1016/0092-8674(86)90512-X; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CAMPBELL DJ, 1987, J CLIN INVEST, V79, P1, DOI 10.1172/JCI112768; CELIO MR, 1981, P NATL ACAD SCI-BIOL, V78, P3897, DOI 10.1073/pnas.78.6.3897; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; DESILVA PE, 1988, ANAL BIOCHEM, V174, P80, DOI 10.1016/0003-2697(88)90521-0; DOSTAL DE, 1992, AM J PHYSIOL, V263, pC838, DOI 10.1152/ajpcell.1992.263.4.C838; DZAU VJ, 1993, RENIN ANGIOTENSIN SY; HAMMOND GL, 1982, SCIENCE, V216, P529, DOI 10.1126/science.6461921; HOLMQUIST B, 1979, ANAL BIOCHEM, V95, P540, DOI 10.1016/0003-2697(79)90769-3; INAGAMI T, 1993, RENIN ANGIOTENSIN SY; Ingber D, 1991, CURR OPIN CELL BIOL, V3, P841, DOI 10.1016/0955-0674(91)90058-7; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; KIFOR I, 1991, ENDOCRINOLOGY, V128, P1277, DOI 10.1210/endo-128-3-1277; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1991, J BIOL CHEM, V266, P1265; LINDPAINTNER K, 1991, CIRC RES, V68, P905, DOI 10.1161/01.RES.68.4.905; LINZ W, 1989, CLIN EXP HYPERTENS A, V11, P1325, DOI 10.3109/10641968909038172; MANN DL, 1989, CIRC RES, V64, P1079, DOI 10.1161/01.RES.64.6.1079; OKAMURA T, 1981, P NATL ACAD SCI-BIOL, V78, P6940, DOI 10.1073/pnas.78.11.6940; PFEFFER JM, 1982, P NATL ACAD SCI-BIOL, V79, P3310, DOI 10.1073/pnas.79.10.3310; PFEFFER MA, 1988, NEW ENGL J MED, V319, P80, DOI 10.1056/NEJM198807143190204; RAVAZZOLA M, 1980, NATURE, V284, P66, DOI 10.1038/284066a0; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SADOSHIMA J, 1992, P NATL ACAD SCI USA, V89, P9905, DOI 10.1073/pnas.89.20.9905; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SCHNEIDER M D, 1991, Progress in Growth Factor Research, V3, P1, DOI 10.1016/0955-2235(91)90010-2; VANDENBURGH H, 1979, SCIENCE, V203, P265, DOI 10.1126/science.569901; VANDENBURGH HH, 1992, AM J PHYSIOL, V262, pR350, DOI 10.1152/ajpregu.1992.262.3.R350; WATKINS SC, 1990, HISTOCHEM J, V22, P507, DOI 10.1007/BF01007236; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069	37	1123	1147	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 3	1993	75	5					977	984		10.1016/0092-8674(93)90541-W	http://dx.doi.org/10.1016/0092-8674(93)90541-W			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252633	Bronze			2022-12-28	WOS:A1993MK96600017
J	EPSTEIN, AM				EPSTEIN, AM			CHANGES IN THE DELIVERY OF CARE UNDER COMPREHENSIVE HEALTH-CARE REFORM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	EPSTEIN, AM (corresponding author), WHITE HOUSE,WASHINGTON,DC 20500, USA.							Fuchs V., 1974, WHO SHALL LIVE; GONZALEZ ML, 1993, SOCIOECONOMIC CHARAC; HIMMELSTEIN DU, 1986, NEW ENGL J MED, V314, P441, DOI 10.1056/NEJM198602133140710; HOY EW, 1991, HEALTH AFFAIR, V10, P18, DOI 10.1377/hlthaff.10.4.18; KOHUT A, 1993, PUBLIC THEIR DOCTORS; Letsch S W, 1992, Health Care Financ Rev, V14, P1; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; MULLAN F, 1993, HEALTH AFFAIR, V12, P138, DOI 10.1377/hlthaff.12.suppl_1.138; POPE GC, 1992, HEALTH AFFAIR, V11, P181, DOI 10.1377/hlthaff.11.1.181; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805; 1983, CURRENT POPULATION R; 1989, ANN REPORT C 1989; AGING 2000	13	26	26	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1993	329	22					1672	1676		10.1056/NEJM199311253292229	http://dx.doi.org/10.1056/NEJM199311253292229			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MJ546	8232455				2022-12-28	WOS:A1993MJ54600039
J	FISHBEIN, DB; ROBINSON, LE				FISHBEIN, DB; ROBINSON, LE			RABIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RACCOONS PROCYON-LOTOR; MID-ATLANTIC STATES; RECOMBINANT VIRUS-VACCINE; UNITED-STATES; ACETYLCHOLINE-RECEPTOR; POSTEXPOSURE TREATMENT; ORAL IMMUNIZATION; PROPHYLAXIS; EPIDEMIOLOGY; INFECTION		CTR DIS CONTROL, NATL CTR INFECT DIS, DIV VIRAL & RICKETTSIAL DIS, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA	FISHBEIN, DB (corresponding author), CTR DIS CONTROL, DIV FIELD EPIDEMIOL, EPIDEMIOL PROGRAM OFF, INT BRANCH, ATLANTA, GA 30333 USA.							AFSHAR A, 1979, BRIT VET J, V135, P142, DOI 10.1016/S0007-1935(17)32935-4; ANDERSON LJ, 1984, ANN INTERN MED, V100, P728, DOI 10.7326/0003-4819-100-5-728; ANDERSON LJ, 1980, J INFECT DIS, V142, P133, DOI 10.1093/infdis/142.2.133; Babes V, 1912, TRAITE RAGE, P81; BAER GM, 1990, LANCET, V335, P664, DOI 10.1016/0140-6736(90)90454-D; BAHMANYAR M, 1976, JAMA-J AM MED ASSOC, V236, P2751, DOI 10.1001/jama.236.24.2751; BECK AM, 1987, AM J PUBLIC HEALTH, V77, P42, DOI 10.2105/AJPH.77.1.42; BERNARD KW, 1991, VACCINE, V9, P833, DOI 10.1016/0264-410X(91)90221-Q; Blancou J., 1991, P257; BOGEL K, 1986, B WORLD HEALTH ORGAN, V64, P883; BOGEL K, 1992, WILDLIFE RABIES CONT; BRUGGEMANN EP, 1992, BIOSCIENCE, V42, P694, DOI 10.2307/1312176; COYNE MJ, 1989, AM J VET RES, V50, P2148; DATO VM, IN PRESS N J MED; DEAN DJ, 1963, B WORLD HEALTH ORGAN, V28, P477; DEVRIENDT J, 1982, JAMA-J AM MED ASSOC, V248, P2304, DOI 10.1001/jama.248.18.2304; Fishbein D B, 1991, Infect Dis Clin North Am, V5, P53; FISHBEIN DB, 1986, J WILDLIFE DIS, V22, P151, DOI 10.7589/0090-3558-22.2.151; FISHBEIN DB, 1987, POSTGRAD MED, V82, P83, DOI 10.1080/00325481.1987.11699951; Fishbein DB, 1991, NATURAL HIST RABIES, V2nd, P519; HANLON CL, 1989, J WILDLIFE DIS, V25, P555, DOI 10.7589/0090-3558-25.4.555; HATTWICK MA, 1974, PUBLIC HEALTH REV, V3, P229; HELD JR, 1967, PUBLIC HEALTH REP, V82, P1009, DOI 10.2307/4593183; HELMICK CG, 1983, JAMA-J AM MED ASSOC, V250, P1990, DOI 10.1001/jama.250.15.1990; HELMICK CG, 1987, REV INFECT DIS, V9, P511; HUMPHREY GL, 1960, PUBLIC HEALTH REP, V75, P317, DOI 10.2307/4590791; JENKINS SR, 1987, AM J EPIDEMIOL, V126, P429, DOI 10.1093/oxfordjournals.aje.a114674; KREBS JW, 1992, J AM VET MED ASSOC, V201, P1836; LENTZ TL, 1982, SCIENCE, V215, P182, DOI 10.1126/science.7053569; LODMELL DL, 1983, J EXP MED, V157, P451, DOI 10.1084/jem.157.2.451; MANN JM, 1984, AM J PUBLIC HEALTH, V74, P720, DOI 10.2105/AJPH.74.7.720; MANN JM, 1980, AM J PUBLIC HEALTH, V70, P128, DOI 10.2105/AJPH.70.2.128; MCLEAN RG, 1971, J INFECT DIS, V123, P680, DOI 10.1093/infdis/123.6.680; MURPHY FA, 1974, INTERVIROLOGY, V3, P256, DOI 10.1159/000149762; MURPHY FA, 1977, ARCH VIROL, V54, P279, DOI 10.1007/BF01314774; NETTLES VF, 1979, AM J PUBLIC HEALTH, V69, P601, DOI 10.2105/AJPH.69.6.601; NICHOLSON KG, 1990, LANCET, V335, P1540; ROSATTE RC, 1992, J WILDLIFE DIS, V28, P562, DOI 10.7589/0090-3558-28.4.562; RUPPRECHT CE, 1988, REV INFECT DIS, V10, pS803; RUPPRECHT CE, 1986, P NATL ACAD SCI USA, V83, P7947, DOI 10.1073/pnas.83.20.7947; SHILL M, 1987, NEW ENGL J MED, V316, P1257, DOI 10.1056/NEJM198705143162006; SIKES RK, 1962, AM J VET RES, V23, P1041; SIWASONTIWAT D, 1992, T ROY SOC TROP MED H, V86, P443, DOI 10.1016/0035-9203(92)90262-B; SMITH JS, 1992, J INFECT DIS, V166, P296, DOI 10.1093/infdis/166.2.296; SMITH JS, 1991, NEW ENGL J MED, V324, P205, DOI 10.1056/NEJM199101243240401; SMITH JS, 1989, ADV VIRUS RES, V36, P215; SMITH JS, 1988, REV INFECT DIS, V10, pS637; SOSIN DM, 1992, ACCIDENT ANAL PREV, V24, P685, DOI 10.1016/0001-4575(92)90022-B; STECK F, 1982, COMP IMMUNOL MICROB, V5, P165, DOI 10.1016/0147-9571(82)90031-5; Steele J.H., 1991, P1; STEHRGREEN JK, 1987, VET CLIN N AM-SMALL, V17, P1, DOI 10.1016/S0195-5616(87)50601-5; SWADDIWUDHIPONG W, 1988, Southeast Asian Journal of Tropical Medicine and Public Health, V19, P563; TIERKEL ES, 1975, NATURAL HIST RABIES, V2, P189; TSIANG H, 1993, ADV VIRUS RES, V42, P375, DOI 10.1016/S0065-3527(08)60090-1; TUFFEREAU C, 1985, J GEN VIROL, V66, P2285, DOI 10.1099/0022-1317-66-10-2285; UHAA IJ, 1992, J AM VET MED ASSOC, V201, P1873; WANDELER AI, 1988, REV INFECT DIS, V10, pS649; WARRELL DA, 1976, T ROY SOC TROP MED H, V70, P188, DOI 10.1016/0035-9203(76)90037-7; WARRELL DA, 1988, REV INFECT DIS, V10, pS726; WHITLEY RJ, 1990, NEW ENGL J MED, V323, P242, DOI 10.1056/NEJM199007263230406; WILDE H, 1989, VACCINE, V7, P49, DOI 10.1016/0264-410X(89)90010-8; WILSON JM, 1975, LANCET, V2, P1139; WINKLER WG, 1992, SCI AM, V266, P86, DOI 10.1038/scientificamerican0692-86; WINKLER WG, 1972, J INFECT DIS, V126, P565, DOI 10.1093/infdis/126.5.565; WINKLER WG, 1973, JAMA-J AM MED ASSOC, V226, P1219, DOI 10.1001/jama.226.10.1219; WUNNER WH, 1988, REV INFECT DIS, V10, pS771; ZECKHAUSER RJ, 1990, SCIENCE, V248, P559, DOI 10.1126/science.2333509; 1981, MMWR MORB MORTAL WKL, V30, P349; 1985, MMWR MORB MORTAL WKL, V34, P705; 1991, MMWR MORB MORTAL WKL, V40, P1; 1989, MMWR MORB MORTAL WKL, V38, P335; 1987, MMWR MORB MORTAL WKL, V36, P759; 1990, LANCET, V335, P896; 1991, ARCH VIROL S, V2; 1983, MMWR MORB MORTAL WKL, V32, P159; 1983, MMWR MORB MORTAL WKL, V32, P85; 1985, MMWR MORB MORTAL WKL, V34, P235; 1992, MMWR MORB MORTAL WKL, V41, P461; 1992, WORLD HLTH ORGAN TEC, V824, P1; 1987, MMWR MORB MORTAL WKL, V36, P765; 1991, MMWR MORB MORTAL WKL, V40, P765; 1984, MMWR MORB MORTAL WKL, V33, P469; 1988, MMWR MORB MORTAL WKL, V37, P559; 1985, MMWR MORB MORTAL WKL, V34, P700; 1983, MMWR MORB MORTAL WKL, V32, P494; 1981, MMWR MORB MORTAL WKL, V30, P537; 1988, MMWR MORB MORTAL WKL, V37, P305; 1983, MMWR MORB MORTAL WKL, V32, P78; 1990, MMWR MORB MORTAL WKL, V39, P759; 1992, MMWR MORB MORTAL WKL, V41, P518; 1984, MMWR MORB MORTAL WKL, V33, P633; 1981, MMWR MORB MORTAL WKL, V30, P343; 1988, LANCET, V1, P917; 1963, MMWR MORB MORTAL WKL, V12, P300; 1991, MMWR MORB MORTAL WKL, V40, P132	95	92	96	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1993	329	22					1632	1638		10.1056/NEJM199311253292208	http://dx.doi.org/10.1056/NEJM199311253292208			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ546	8232433				2022-12-28	WOS:A1993MJ54600008
J	KERLIKOWSKE, K; GRADY, D; BARCLAY, J; SICKLES, EA; EATON, A; ERNSTER, V				KERLIKOWSKE, K; GRADY, D; BARCLAY, J; SICKLES, EA; EATON, A; ERNSTER, V			POSITIVE PREDICTIVE VALUE OF SCREENING MAMMOGRAPHY BY AGE AND FAMILY HISTORY OF BREAST-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOLLOW-UP; MEDICAL AUDIT; DEATH RATES; OLDER WOMEN; LOW-COST; COMMUNITY; MORTALITY; PROGRAM; TRIAL; CARCINOMA	Objective.-To determine the positive predictive value (PPV) of low-cost screening mammography according to age and family history of breast cancer. Design.-Cross-sectional. Setting.-Six counties in northern California. Participants.-A total of 31 814 women aged 30 years and older referred for mammography to the University of California, San Francisco, Mobile Mammography Screening Program from April 18, 1985, through November 20, 1992. Measurements.-Breast cancer risk profile, two standard mammographic views per breast, and follow-up of abnormal screening examinations. Results.-Although women aged 50 years or older constituted only 38.3% of all women who received first-screening mammography, 74% of breast cancers were detected in this group. Ten cancers were diagnosed per 1000 first-screening examinations in women aged 50 years or older, with 14.8 diagnostic procedures per cancer diagnosed compared with two cancers per 1000 screening examinations and 48.3 diagnostic tests per cancer diagnosed in women younger than 50 years. The PPV of first-screening mammography (number of breast cancers detected per abnormal examination) increased with age: .03 for those aged 30 to 39 years; .04 for those aged 40 to 49; .09 for those aged 50 to 59; .17 for those aged 60 to 69; and .1 9 for those aged 70 years or older (chi2 for trend, P<.001). Women aged 50 to 59 years had a higher PPV for first-screening mammography than women aged 40 to 49 years (.09 vs.04; P=.004), and women with a family history of breast cancer had higher PPVs compared with women without history (40 to 49 years of age, 13 vs .04, P=.01; and 50 to 59 years of age, .22 vs .09, P=.01). Conclusion.-Five times as many cancers per 1000 first-screening mammographic examinations were diagnosed in women aged 50 years or older compared with women aged less than 50 years. The highest PPVs for mammography were in women aged 50 years or older and in women aged 40 years or older with a family history of breast cancer. Efforts to promote screening mammography should focus on women in these groups, in whom the majority of breast cancers occur and for whom mammography has the highest PPVs.	UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT RADIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT VET AFFAIRS,GEN INTERNAL MED SECT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								ALGHISI A, 1990, TUMORI, V76, P22, DOI 10.1177/030089169007600105; ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; ARNESSON LG, 1989, BRIT J SURG, V76, P672, DOI 10.1002/bjs.1800760707; BIRD RE, 1989, RADIOLOGY, V171, P87, DOI 10.1148/radiology.171.1.2494683; CIATTO S, 1990, J CLIN EPIDEMIOL, V43, P419, DOI 10.1016/0895-4356(90)90129-D; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P338, DOI 10.1001/jama.270.3.338; COLLETTE HJA, 1988, SCREENING BREAST CAN, P17; COSTANZA ME, 1992, CANCER, V69, P1925, DOI 10.1002/1097-0142(19920401)69:7+<1925::AID-CNCR2820691709>3.0.CO;2-U; DERSHAW DD, 1992, RADIOLOGY, V184, P415, DOI 10.1148/radiology.184.2.1620839; DEWAARD F, 1984, J CHRON DIS, V37, P1, DOI 10.1016/0021-9681(84)90123-1; Elwood JM, 1993, ONLINE J CURR CLIN T; Farrow J H, 1970, Cancer, V25, P468, DOI 10.1002/1097-0142(197002)25:2<468::AID-CNCR2820250226>3.0.CO;2-0; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; FOX SA, 1991, ARCH INTERN MED, V151, P50, DOI 10.1001/archinte.151.1.50; FRISELL J, 1991, BREAST CANCER RES TR, V18, P49, DOI 10.1007/BF01975443; GOODNO JA, 1990, AM J OBSTET GYNECOL, V162, P1393, DOI 10.1016/0002-9378(90)90897-G; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HARRIS RP, 1991, CANCER, V67, P2010, DOI 10.1002/1097-0142(19910401)67:7<2010::AID-CNCR2820670730>3.0.CO;2-8; HAYWARD RSA, 1991, ANN INTERN MED, V114, P758, DOI 10.7326/0003-4819-114-9-758; HUMPHREY LL, 1988, WESTERN J MED, V149, P95; HURLEY SF, 1992, EPIDEMIOL REV, V14, P101, DOI 10.1093/oxfordjournals.epirev.a036082; KETCHAM AS, 1990, CANCER, V65, P387, DOI 10.1002/1097-0142(19900201)65:3<387::AID-CNCR2820650302>3.0.CO;2-Y; KOPANS DB, 1992, AM J ROENTGENOL, V158, P521, DOI 10.2214/ajr.158.3.1310825; KOPANS DB, 1992, J GERONTOL, V47, P59; KUNI CC, 1993, AM J PREV MED, V9, P185, DOI 10.1016/S0749-3797(18)30736-0; LAGIOS MD, 1989, CANCER, V63, P618, DOI 10.1002/1097-0142(19890215)63:4<618::AID-CNCR2820630403>3.0.CO;2-J; LERMAN C, 1991, ANN INTERN MED, V114, P657, DOI 10.7326/0003-4819-114-8-657; LINVER MN, 1992, RADIOLOGY, V184, P39, DOI 10.1148/radiology.184.1.1609100; MILLER AB, 1992, CAN MED ASSOC J, V147, P1477; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; MONTICCIOLO DL, 1990, AM J ROENTGENOL, V155, P751, DOI 10.2214/ajr.155.4.2119104; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; OMALLEY MS, 1990, DOES SCREENING BREAS; PAGE DL, 1982, CANCER, V49, P751, DOI 10.1002/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y; PEETERS PHM, 1989, INT J CANCER, V43, P226, DOI 10.1002/ijc.2910430209; PILLSBURY SG, 1991, AM J OBSTET GYNECOL, V164, P1643, DOI 10.1016/0002-9378(91)91449-7; REINIG JW, 1991, RADIOLOGY, V180, P393, DOI 10.1148/radiology.180.2.2068301; ROBERTS MM, 1990, LANCET, V335, P241; RUBIN E, 1990, SOUTHERN MED J, V83, P178, DOI 10.1097/00007611-199002000-00011; Shapiro S, 1988, PERIODIC SCREENING B; SICKLES EA, 1986, RADIOLOGY, V160, P95, DOI 10.1148/radiology.160.1.3715053; SICKLES EA, 1992, RADIOL CLIN N AM, V30, P265; SICKLES EA, 1990, RADIOLOGY, V175, P323, DOI 10.1148/radiology.175.2.2326455; SICKLES EA, 1987, RADIOL CLIN N AM, V25, P1015; STACEYCLEAR A, 1992, LANCET, V340, P991; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; VERBEEK ALM, 1991, BRIT J CANCER, V63, P261, DOI 10.1038/bjc.1991.61; Warren D L, 1989, J Ky Med Assoc, V87, P169; WOOLF SH, 1992, CANCER, V69, P1913, DOI 10.1002/1097-0142(19920401)69:7+<1913::AID-CNCR2820691707>3.0.CO;2-6; 1990, JAMA-J AM MED ASSOC, V264, P54; 1988, NCI902789 PUBL; 1988, MANUAL STAGING CANCE; 1993, CANCER INCIDENCE MOR; 1988, LANCET, V2, P411; 1988, MMWR MORB MORTAL WKL, V37, P357; 1992, MMWR MORB MORTAL WKL, V41, P454	56	291	297	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1993	270	20					2444	2450		10.1001/jama.270.20.2444	http://dx.doi.org/10.1001/jama.270.20.2444			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG671	8230621				2022-12-28	WOS:A1993MG67100025
J	SANDELL, LL; ZAKIAN, VA				SANDELL, LL; ZAKIAN, VA			LOSS OF A YEAST TELOMERE - ARREST, RECOVERY, AND CHROMOSOME LOSS	CELL			English	Article							CELL-CYCLE ARREST; MATING-TYPE LOCUS; SACCHAROMYCES-CEREVISIAE; DNA-SEQUENCES; DROSOPHILA; TRANSMISSION; ELONGATION; DAMAGE; GENES; RAD9	Yeast strains were constructed in which a single telomere could be eliminated from the end of a dispensable chromosome. In wild-type cells, elimination of a telomere caused a RAD9-mediated cell cycle arrest, indicating that telomeres help cells to distinguish intact chromosomes from damaged DNA. However, many cells recovered from the arrest without repairing the damaged chromosome, replicating and segregating it for as many as ten cell divisions prior to its eventual loss. Telomere elimination caused a dramatic increase in loss of the chromosome in all strains examined, demonstrating that yeast telomeres are also essential for maintaining chromosome stability. Thus, in spite of checkpoint and DNA damage repair systems, many chromosomes that lose a telomere are themselves destined for loss.	UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	SANDELL, LL (corresponding author), FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104, USA.		Sandell, Lisa L/M-4238-2013	Sandell, Lisa L/0000-0002-1735-8223	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026938, R37GM026938] Funding Source: NIH RePORTER; NIA NIH HHS [AG00057] Funding Source: Medline; NIGMS NIH HHS [GM26938] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIESSMANN H, 1988, EMBO J, V7, P1081, DOI 10.1002/j.1460-2075.1988.tb02916.x; BIESSMANN H, 1990, P NATL ACAD SCI USA, V87, P1758, DOI 10.1073/pnas.87.5.1758; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; DUTCHER SK, 1981, MOL CELL BIOL, V1, P245, DOI 10.1128/MCB.1.3.245; HABER JE, 1984, GENETICS, V106, P207; HARLEY CB, 1989, TRENDS GENET, V5, P326; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HENIKOFF S, 1987, GENETICS, V117, P711; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KENDAL WS, 1988, CANCER RES, V48, P1060; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LEVIS RW, 1989, CELL, V58, P791, DOI 10.1016/0092-8674(89)90112-8; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; Luria SE, 1943, GENETICS, V28, P491; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; MASON JM, 1984, P NATL ACAD SCI-BIOL, V81, P6090, DOI 10.1073/pnas.81.19.6090; McClintock B, 1939, P NATL ACAD SCI USA, V25, P405, DOI 10.1073/pnas.25.8.405; McClintock B, 1941, GENETICS, V26, P234; MCCUSKER JH, 1981, GENETICS, V99, P383; MEEKSWAGNER D, 1986, CELL, V44, P43, DOI 10.1016/0092-8674(86)90483-6; MORTIMER RK, 1981, P NATL ACAD SCI-BIOL, V78, P5778, DOI 10.1073/pnas.78.9.5778; Muller H, 1938, COLLECTING NET, V13, P181; Muller H. J., 1941, Cold Spring Harbor Symposia on Quantitative Biology, V9, P151; Muller H.J., 1938, COLLECTING NET, V13, P181; PAQUIN CE, 1986, MOL CELL BIOL, V6, P70, DOI 10.1128/MCB.6.1.70; RUNGE KW, 1991, MOL CELL BIOL, V11, P2919, DOI 10.1128/MCB.11.6.2919; RUNGE KW, 1989, MOL CELL BIOL, V9, P1488, DOI 10.1128/MCB.9.4.1488; SCHIESTL RH, 1989, MOL CELL BIOL, V9, P1882, DOI 10.1128/MCB.9.5.1882; SMITH KA, 1992, P NATL ACAD SCI USA, V89, P5427, DOI 10.1073/pnas.89.12.5427; TATCHELL K, 1981, CELL, V27, P25, DOI 10.1016/0092-8674(81)90357-3; Therman E., 1986, HUMAN CHROMOSOMES ST; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; ZAKIAN VA, 1982, MOL CELL BIOL, V2, P221, DOI 10.1128/MCB.2.3.221; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579; ZHANG P, 1993, GENETICS, V133, P361	36	701	711	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					729	739		10.1016/0092-8674(93)90493-A	http://dx.doi.org/10.1016/0092-8674(93)90493-A			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242745	Bronze			2022-12-28	WOS:A1993MH74900018
J	GOULD, SJ; ELDREDGE, N				GOULD, SJ; ELDREDGE, N			PUNCTUATED EQUILIBRIUM COMES OF AGE	NATURE			English	Review							CHESAPEAKE GROUP MOLLUSKS; PHYLETIC GRADUALISM; PALEONTOLOGICAL DOCUMENTATION; EVOLUTIONARY PATTERNS; MORPHOLOGICAL STASIS; NEOGENE BRYOZOAN; SPECIES LEVEL; TURKANA BASIN; SPECIATION; TEMPO	The intense controversies that surrounded the youth of punctuated equilibrium have helped it mature to a useful extension of evolutionary theory. As a complement to phyletic gradualism, its most important implications remain the recognition of stasis as a meaningful and predominant pattern within the history of species, and in the recasting of macroevolution as the differential success of certain species (and their descendants) within clades.	AMER MUSEUM NAT HIST, DEPT INVERTEBRATES, NEW YORK, NY 10024 USA	American Museum of Natural History (AMNH)	GOULD, SJ (corresponding author), HARVARD UNIV, MUSEUM COMPARAT ZOOL, CAMBRIDGE, MA 02138 USA.							AGER D V, 1976, Proceedings of the Geologists' Association, V87, P131; AGER DV, 1983, PALAEONTOLOGY, V26, P555; AVISE JC, 1977, P NATL ACAD SCI USA, V74, P5083, DOI 10.1073/pnas.74.11.5083; Barnosky A.D., 1987, Current Mammalogy, V1, P109; Bergstrom J., 1978, Geologica et Palaeontologica, V12, P1; Brandon R.N., 1990, ADAPTATION ENV; BRETT CE, 1992, GEOL SOC AM ANN M BO, P139; BUDD AF, 1992, PALEOBIOLOGY, V18, P425, DOI 10.1017/S0094837300010988; CHALINE J, 1986, PALEOBIOLOGY, V12, P203, DOI 10.1017/S009483730001366X; CHEETHAM AH, 1987, PALEOBIOLOGY, V13, P286; CHEETHAM AH, 1986, PALEOBIOLOGY, V12, P190, DOI 10.1017/S0094837300013658; COOPE GR, 1979, ANNU REV ECOL SYST, V10, P247, DOI 10.1146/annurev.es.10.110179.001335; CRONIN TM, 1985, SCIENCE, V227, P60, DOI 10.1126/science.227.4682.60; Dawkins R., 1986, BLIND WATCHMAKER; Eldredge N., 1972, P82; Eldredge N., 1984, LIVING FOSSILS; ELDREDGE N, 1979, B CARNEGIE MUS NAT H, V13, P7; ELDREDGE N, 1982, MONKEY BUSINESS SCI; ELDREDGE N, 1989, MACROEVOLUTIONARY DY; ERWIN D, 1992, SPECIATION FOSSIL RE, P138; FINNEY SC, 1986, GEOLOGICAL SOC SPECI, V20, P103; Flynn L. J., 1986, CONTRIBUTIONS GEOLOG, V3, P273; FORTEY RA, 1985, SPEC PAP PALAEONTOL, P17; FRYER G, 1983, BIOL J LINN SOC, V20, P195, DOI 10.1111/j.1095-8312.1983.tb00363.x; FUTUYMA DJ, 1987, AM NAT, V130, P465, DOI 10.1086/284724; GINGERICH PD, 1976, AM J SCI, V276, P1, DOI 10.2475/ajs.276.1.1; Gould S.J., 1982, P83; GOULD S J, 1977, Paleobiology, V3, P115; GOULD SJ, 1986, AM SCI, V74, P60; GOULD SJ, 1988, J PALEONTOL, V62, P319, DOI 10.1017/S0022336000059126; Gould SJ, 1983, HENS TEETH HORSES TO; HALDANE JBS, 1949, EVOLUTION, V3, P51, DOI 10.2307/2405451; HALLAM A, 1978, PALEOBIOLOGY, V4, P16, DOI 10.1017/S0094837300005650; Hanson NorwoodRussell., 1969, PERCEPTION DISCOVERY, P91; Hoffman A., 1998, ARGUMENTS EVOLUTION; JACKSON JBC, 1990, SCIENCE, V248, P579, DOI 10.1126/science.248.4955.579; JOHNSON JG, 1975, J PALEONTOL, V49, P646; JOHNSON JG, 1982, J PALEONTOL, V56, P1329; KELLEY PH, 1984, J PALEONTOL, V58, P1235; KELLEY PH, 1983, J PALEONTOL, V57, P581; Kellogg V. L., 1907, DARWINISM TODAY; Kuhn T. S., 1996, STRUCTURE SCI REVOLU; LEMEN CA, 1989, EVOLUTION, V43, P1538, DOI 10.1111/j.1558-5646.1989.tb02602.x; Levinton J. S., 1988, GENETICS PALEONTOLOG; LICH DK, 1990, PALEOBIOLOGY, V16, P384, DOI 10.1017/S0094837300010083; Lloyd EA, 1988, STRUCTURE CONFIRMATI; MacGillavry H. J., 1968, Bijdragen tot de Dierkunde, V38, P69; MACLEOD N, 1991, PALEOBIOLOGY, V17, P167, DOI 10.1017/S0094837300010472; Martin R.A., 1992, Historical Biology, V6, P73; MAYDEN RL, 1986, SYST ZOOL, V35, P591, DOI 10.2307/2413118; Mayr E., 1992, DYNAMICS EVOLUTION, P21; Mayr E., 1963, ANIMAL SPECIES EVOLU; MAYR E, 1992, DYNAMICS EVOLUTION P; MICHAUX B, 1989, BIOL J LINN SOC, V38, P239, DOI 10.1111/j.1095-8312.1989.tb01577.x; MINDELL DP, 1990, J EVOLUTION BIOL, V3, P125, DOI 10.1046/j.1420-9101.1990.3010125.x; MINDELL DP, 1989, CLADISTICS, V5, P49, DOI 10.1111/j.1096-0031.1989.tb00482.x; Moore R.C, 1952, INVERTEBRATE FOSSILS; MORRIS PJ, 1992, GEOL SOC AM ANN M BO, P313; NEHM RH, 1992, PALEONTOL SOC SP PUB, V6, P222; Prothero D. R., 1992, SKEPTIC, V1, P38; PROTHERO DR, 1989, EVOLUTION PERISSODAC, P142; RAUP DM, 1982, SCIENCE, V215, P1501, DOI 10.1126/science.215.4539.1501; Ridley M., 1993, EVOLUTION; RUSE M, 1992, DYNAMICS EVOLUTION, P139; SCHANKLER DM, 1981, NATURE, V293, P135, DOI 10.1038/293135a0; SHAPIRO EA, 1978, GEOL SOC AM ANN M BO, P490; SHELDON PR, 1990, NATURE, V345, P772, DOI 10.1038/345772a0; Simpson G. G., 1953, MAJOR FEATURES EVOLU, DOI DOI 10.7312/SIMP93764; Simpson G.G., 1951, HORSES; SMITH AB, 1985, SPEC PAP PALAEONTOL, P29; SMITH JM, 1983, ANNU REV GENET, V17, P11, DOI 10.1146/annurev.ge.17.120183.000303; SORHANNUS U, 1990, HIST BIOL, V31, P241; STANLEY SM, 1987, PALEOBIOLOGY, V13, P113; STANLEY SM, 1975, P NATL ACAD SCI USA, V72, P646, DOI 10.1073/pnas.72.2.646; STANLEY SM, 1973, EVOLUTION, V27, P1, DOI 10.1111/j.1558-5646.1973.tb05912.x; STANLEY SM, 1978, PALEOBIOLOGY, V4, P26, DOI 10.1017/S0094837300005662; STANLEY SM, 1979, MARCROEVOLUTION; Thomas E, 1980, UTRECHT MICROPALEONT, V23, P1; Valentine J.W., 1992, P17; Vrba E.S., 1984, P62; VRBA ES, 1985, S AFR J SCI, V81, P229; VRBA ES, 1986, PALEOBIOLOGY, V12, P217, DOI 10.1017/S0094837300013671; VRBA ES, 1980, S AFR J SCI, V76, P61; WAGNER PJ, 1992, GEOL SOC AM ANN M BO, P139; WEI KY, 1988, PALEOBIOLOGY, V14, P345, DOI 10.1017/S0094837300012094; WEST RM, 1979, PALEOBIOLOGY, V5, P252, DOI 10.1017/S0094837300006540; Williams G. C., 1966, P307; Williams G. C, 1992, NATURAL SELECTION DO; WILLIAMSON PG, 1985, BIOL J LINN SOC, V26, P307, DOI 10.1111/j.1095-8312.1985.tb02042.x; WILLIAMSON PG, 1981, NATURE, V293, P437, DOI 10.1038/293437a0	90	611	628	5	279	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	1993	366	6452					223	227		10.1038/366223a0	http://dx.doi.org/10.1038/366223a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH325	8232582				2022-12-28	WOS:A1993MH32500051
J	LORD, GM; SCOTT, J; PUSEY, CD; REES, AJ; WALPORT, MJ; DAVIES, KAA; BULPITT, C; BLOOM, SR; MUNTONI, FM				LORD, GM; SCOTT, J; PUSEY, CD; REES, AJ; WALPORT, MJ; DAVIES, KAA; BULPITT, C; BLOOM, SR; MUNTONI, FM			GRAND ROUNDS - HAMMERSMITH-HOSPITAL - DIABETES AND RHABDOMYOLYSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Discussion							ACUTE-RENAL-FAILURE; HYPEROSMOLAR NONKETOTIC COMA; STATE; HYPOPHOSPHATEMIA				LORD, GM (corresponding author), HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT MED, LONDON W12 0NN, ENGLAND.		Abraham, Sabu/E-1144-2019; Lord, Graham M/B-3797-2011	Abraham, Sabu/0000-0002-0916-5827; Lord, Graham/0000-0003-2069-4743; Walport, Mark/0000-0001-7220-5273				ARIEFF AI, 1972, MEDICINE, V51, P73, DOI 10.1097/00005792-197203000-00001; Bywaters EGL, 1941, BRIT MED J, V1941, P427, DOI 10.1136/bmj.1.4185.427; CHANG PT, 1988, CHIN MED J, V41, P309; GABOW PA, 1982, MEDICINE, V61, P141, DOI 10.1097/00005792-198205000-00002; GROSSMAN RA, 1974, NEW ENGL J MED, V291, P807, DOI 10.1056/NEJM197410172911601; KNOCHEL JP, 1992, AM J MED, V92, P455, DOI 10.1016/0002-9343(92)90739-X; KNOCHEL JP, 1975, ANN NY ACAD SCI, V252, P274, DOI 10.1111/j.1749-6632.1975.tb19168.x; KNOCHEL JP, 1985, KIDNEY INT, V27, P489, DOI 10.1038/ki.1985.37; LEUNG CB, 1992, RENAL FAILURE, V14, P81, DOI 10.3109/08860229209039121; SCHLEPPHORST E, 1985, DIABETES CARE, V8, P198, DOI 10.2337/diacare.8.2.198; SINGHAL PC, 1987, NEPHRON, V47, P202, DOI 10.1159/000184492; SINGHAL PC, 1992, AM J MED, V92, P458, DOI 10.1016/0002-9343(92)90740-3; SINGHAL PC, 1991, AM J NEPHROL, V11, P447, DOI 10.1159/000168357; SINGHAL PC, 1990, AM J MED, V88, P9, DOI 10.1016/0002-9343(90)90120-3; WARD MM, 1988, ARCH INTERN MED, V148, P1553, DOI 10.1001/archinte.148.7.1553; WOOD MLB, 1988, DIABETES RES CLIN EX, V8, P97; ZOBEL G, 1986, INT J PED NEPHROL, V7, P239	17	12	13	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 30	1993	307	6912					1126	1128		10.1136/bmj.307.6912.1126	http://dx.doi.org/10.1136/bmj.307.6912.1126			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME918	8251814	Green Submitted, Bronze, Green Published			2022-12-28	WOS:A1993ME91800024
J	DUCKWORTH, GJ				DUCKWORTH, GJ			FORTNIGHTLY REVIEW - DIAGNOSIS AND MANAGEMENT OF METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS INFECTION	BRITISH MEDICAL JOURNAL			English	Article							STREPTOCOCCUS-FAECALIS; BACTEREMIA; VANCOMYCIN; OUTBREAK				DUCKWORTH, GJ (corresponding author), UNIV LONDON LONDON HOSP,COLL MED,DEPT MED MICROBIOL,LONDON E1 2AD,ENGLAND.							Annear D I, 1968, Med J Aust, V1, P444; BAIRD D, 1987, LANCET, V2, P387; BENNER EJ, 1967, NEW ENGL J MED, V277, P678, DOI 10.1056/NEJM196709282771303; BOROWSKI J, 1964, BMJ-BRIT MED J, V1, P983, DOI 10.1136/bmj.1.5388.983; BRADLEY JM, 1985, LANCET, V1, P1493; CAFFERKEY MT, 1982, J ANTIMICROB CHEMOTH, V9, P69, DOI 10.1093/jac/9.1.69; CETIN ET, 1962, BRIT MED J, V2, P51, DOI 10.1136/bmj.2.5296.51-b; CHENG AF, 1988, J HOSP INFECT, V12, P91, DOI 10.1016/0195-6701(88)90131-4; COLLATZ E, 1983, J BACTERIOL, V156, P1373, DOI 10.1128/JB.156.3.1373-1377.1983; COOKE EM, 1987, BRIT MED J, V294, P371, DOI 10.1136/bmj.294.6568.371; DUCKWORTH G, 1990, J HOSP INFECT, V16, P351; DUCKWORTH GJ, 1986, LANCET, V1, P565; DUCKWORTH GJ, 1988, J HOSP INFECT, V11, P1, DOI 10.1016/0195-6701(88)90034-5; FOSTER JK, 1986, ANTIMICROB AGENTS CH, V30, P823, DOI 10.1128/AAC.30.6.823; GRUNEBERG RN, 1980, J ANTIMICROB CHEMOTH, V6, P562, DOI 10.1093/jac/6.4.562; HILL RLR, 1988, J ANTIMICROB CHEMOTH, V22, P377, DOI 10.1093/jac/22.3.377; Hone R, 1981, J Hosp Infect, V2, P119, DOI 10.1016/0195-6701(81)90020-7; JENSEN K, 1968, LANCET, V2, P1078; JEVONS MP, 1961, BRIT MED J, V1, P124, DOI 10.1136/bmj.1.5219.124-a; KNOX R, 1961, BRIT MED J, V1, P126, DOI 10.1136/bmj.1.5219.126; MANDELL GL, 1972, J INFECT DIS, V125, P486, DOI 10.1093/infdis/125.5.486; MYERS JP, 1982, J INFECT DIS, V145, P532, DOI 10.1093/infdis/145.4.532; RIGHTER J, 1987, J ANTIMICROB CHEMOTH, V20, P595, DOI 10.1093/jac/20.4.595; SABATH LD, 1977, J ANTIMICROB CHEMOTH, V3, P47, DOI 10.1093/jac/3.suppl_C.47; SCHABERG DR, 1982, ANTIMICROB AGENTS CH, V22, P204, DOI 10.1128/AAC.22.2.204; SOEDIRMAN EN, 1980, J BACTERIOL, V142, P407; TOWNSEND DE, 1984, MED J AUSTRALIA, V2, P339; WOODLEY DW, 1961, ANN INTERN MED, V55, P235, DOI 10.7326/0003-4819-55-2-235; 1993, COMMUNICABLE DISEASE, V3, P25; 1986, J HOSPINFECT, V7, P193	30	54	55	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1993	307	6911					1049	1052		10.1136/bmj.307.6911.1049	http://dx.doi.org/10.1136/bmj.307.6911.1049			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD556	8251781	Green Published, Bronze			2022-12-28	WOS:A1993MD55600023
J	ROWAN, KM; KERR, JH; MAJOR, E; MCPHERSON, K; SHORT, A; VESSEY, MP				ROWAN, KM; KERR, JH; MAJOR, E; MCPHERSON, K; SHORT, A; VESSEY, MP			INTENSIVE-CARE SOCIETY APACHE-II STUDY IN BRITAIN AND IRELAND .2. OUTCOME COMPARISONS OF INTENSIVE-CARE UNITS AFTER ADJUSTMENT FOR CASE-MIX BY THE AMERICAN APACHE-II METHOD	BRITISH MEDICAL JOURNAL			English	Article							DISEASE CLASSIFICATION-SYSTEM; SEVERITY; MORTALITY; STATES	Objectives-To compare outcome between intensive care units in Britain and Ireland both before and after adjustment for case mix with the American APACHE II method and to validate the American APACHE II method in Britain and Ireland. Design-Prospective, cohort study of consecutive admissions to intensive care units. Setting-26 general intensive care units in Britain and Ireland. Subjects-8796 admissions to the study intensive care units. Main outcome measure-Death or survival at discharge from intensive care unit and hospital. Results-At discharge from both intensive care unit and hospital there was a greater than twofold variation in crude mortality between the 26 units. After adjustment for case mix, variations in mortality were still apparent. For four intensive care units the observed numbers of deaths were significantly different from the number predicted by the American APACHE II equation. The overall goodness of fit, or predictive ability, of the APACHE II equation for the British and Irish data was good, being only slightly inferior to that obtained when the equation was tested on the data from which it had been derived. When patients were grouped by various factors such as age and diagnosis, the equation did not adjust across the subgroups in a uniform manner. Conclusions-The American APACHE II equation did not fit the British and Irish data. Use of the American equation could be of advantage or disadvantage to individual intensive care units, depending on the mix of patients treated.	UNIV OXFORD,RADCLIFFE INFIRM,NUFFIELD DEPT ANAESTHET,OXFORD OX2 6HE,ENGLAND; MORRISTON HOSP,INTENS THERAPY UNIT,SWANSEA SA9 6NL,WALES; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,HLTH PROMOT SCI UNIT,LONDON WC1E 7HT,ENGLAND; BROOMFIELD HOSP,INTENS CARE UNIT,CHELMSFORD CM1 5ET,ESSEX,ENGLAND	Radcliffe Infirmary; University of Oxford; Morriston Hospital; University of London; London School of Hygiene & Tropical Medicine; Mid Essex Hospital Services NHS Trust; Broomfield Hospital	ROWAN, KM (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,GIBSON LABS BLDG,OXFORD OX2 6HE,ENGLAND.							AGARWAL N, 1989, CRIT CARE MED, V17, pS85; CHISAKUTA AM, 1990, ULSTER MED J, V59, P161; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; GARDNER MJ, 1989, BRIT MED J; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; MARSH HM, 1990, MAYO CLIN PROC, V65, P1549, DOI 10.1016/S0025-6196(12)62188-0; PAYER L, 1989, MED CULTURE, P15; ROWAN KM, 1993, BRIT MED J, V307, P972, DOI 10.1136/bmj.307.6910.972; SIRIO CA, 1992, CRIT CARE MED, V20, P1207, DOI 10.1097/00003246-199209000-00006; TURNER JS, 1991, CRIT CARE MED, V19, P1266; TURNER JS, 1991, CRIT CARE MED, V19, P301, DOI 10.1097/00003246-199102000-00037; WAGNER DP, 1986, HLTH AFF MILLWOOD, V5, P149; ZIMMERMAN JE, 1988, CRIT CARE MED, V16, P318, DOI 10.1097/00003246-198804000-00003	16	201	208	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1993	307	6910					977	981		10.1136/bmj.307.6910.977	http://dx.doi.org/10.1136/bmj.307.6910.977			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC441	8241909	Green Published, Bronze			2022-12-28	WOS:A1993MC44100019
J	SKINNER, M; LEWIS, WD; JONES, LA; KASIRSKY, J; KANE, K; JU, ST; JENKINS, R; FALK, RH; SIMMS, RW; COHEN, AS				SKINNER, M; LEWIS, WD; JONES, LA; KASIRSKY, J; KANE, K; JU, ST; JENKINS, R; FALK, RH; SIMMS, RW; COHEN, AS			LIVER-TRANSPLANTATION AS A TREATMENT FOR FAMILIAL AMYLOIDOTIC POLYNEUROPATHY	ANNALS OF INTERNAL MEDICINE			English	Note							VARIANT		BOSTON CITY HOSP, DEPT MED, BOSTON, MA 02118 USA; NEW ENGLAND DEACONESS HOSP, DIV HEPATOBILIARY SURG & LIVER TRANSPLANTAT, BOSTON, MA 02215 USA	Boston Medical Center				Simms, Robert/0000-0002-0101-1807	NCRR NIH HHS [RR 533] Funding Source: Medline; NIAMS NIH HHS [AR 20613, AR 40414] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020613, R01AR040414] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTLAND K, 1986, ELECTROPHORESIS, V7, P529, DOI 10.1002/elps.1150071110; Benson MD, 1989, METABOLIC BASIS INHE, P2439; COHEN AS, 1990, ARQ MEDICIN, P25; EWING DJ, 1982, BRIT MED J, V285, P916, DOI 10.1136/bmj.285.6346.916; HOLMGREN G, 1993, LANCET, V341, P1113, DOI 10.1016/0140-6736(93)93127-M; SKARE JC, 1991, CLIN GENET, V39, P6	6	83	85	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1994	120	2					133	134		10.7326/0003-4819-120-2-199401150-00006	http://dx.doi.org/10.7326/0003-4819-120-2-199401150-00006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ671	8256972				2022-12-28	WOS:A1994MQ67100006
J	LILLIOJA, S; MOTT, DM; SPRAUL, M; FERRARO, R; FOLEY, JE; RAVUSSIN, E; KNOWLER, WC; BENNETT, PH; BOGARDUS, C				LILLIOJA, S; MOTT, DM; SPRAUL, M; FERRARO, R; FOLEY, JE; RAVUSSIN, E; KNOWLER, WC; BENNETT, PH; BOGARDUS, C			INSULIN-RESISTANCE AND INSULIN SECRETORY DYSFUNCTION AS PRECURSORS OF NON-INSULIN-DEPENDENT DIABETES-MELLITUS - PROSPECTIVE STUDIES OF PIMA-INDIANS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMPAIRED GLUCOSE-TOLERANCE; BODY-FAT DISTRIBUTION; RISK-FACTORS; FOLLOW-UP; BETA-CELL; NIDDM; PATHOGENESIS; POPULATION; AMERICANS; OBESITY	Background. The relative roles of obesity, insulin resistance, insulin secretory dysfunction, and excess hepatic glucose production in the development of non-insulin-dependent diabetes mellitus (NIDDM) are controversial. We conducted a prospective study to determine which of these factors predicted the development of the disease in a group of Pima Indians. Methods. A body-composition assessment, oral and intravenous glucose-tolerance tests, and a hyperinsulinemic-euglycemic clamp study were performed in 200 nondiabetic Pima Indians (87 women and 113 men; mean [+/-SD] age, 26+/-6 years). The subjects were followed yearly thereafter for an average of 5.3 years. Results. Diabetes developed in 38 subjects during follow-up. Obesity, insulin resistance (independent of obesity), and low acute plasma insulin response to intravenous glucose (with the degree of obesity and insulin resistance taken into account) were predictors of NIDDM. The six-year cumulative incidence of NIDDM was 39 percent in persons with values below the median for both insulin action and acute insulin response, 27 percent in those with values below the median for insulin action but above that for acute insulin response, 13 percent in those with values above the median for insulin action and below that for acute insulin response, and 0 in those with values originally above the median for both characteristics. Conclusions. Insulin resistance is a major risk factor for the development of NIDDM. A low acute insulin response to glucose is an additional but weaker risk factor.	NIDDKD, PHOENIX EPIDEMIOL & CLIN RES BRANCH, CLIN DIABET & NUTR SECT,4212 N 16TH ST,RM 541, PHOENIX, AZ 85016 USA; SANDOZ INC, SANDOZ RES INST, E HANOVER, NJ 07936 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Novartis; Sandoz			Steib, Lori/B-6628-2014; Bennett, Peter/AAH-9605-2021; Ravussin, Eric/N-1985-2017; Lillioja, Stephen/A-8185-2012	Steib, Lori/0000-0001-8274-318X; Ravussin, Eric/0000-0003-2129-547X; Lillioja, Stephen/0000-0001-5333-5240				BANERJI MA, 1992, DIABETES CARE, V15, P1295, DOI 10.2337/diacare.15.10.1295; BERGSTROM RW, 1990, DIABETES, V39, P104, DOI 10.2337/diabetes.39.1.104; BEST JD, 1981, DIABETES, V30, P847, DOI 10.2337/diabetes.30.10.847; BOGARDUS C, 1984, J CLIN INVEST, V74, P1238, DOI 10.1172/JCI111533; CHARLES MA, 1991, DIABETES, V40, P796, DOI 10.2337/diabetes.40.7.796; CHEN M, 1976, J CLIN ENDOCR METAB, V42, P1168, DOI 10.1210/jcem-42-6-1168; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; EFENDIC S, 1984, ENDOCR REV, V5, P395, DOI 10.1210/edrv-5-3-395; FAJANS SS, 1989, DIABETES METAB REV, V5, P579, DOI 10.1002/dmr.5610050705; Goldman R., 1961, TECHNIQUES MEASURING, P78; GOTTESMAN I, 1983, AM J PHYSIOL, V244, pE632, DOI 10.1152/ajpendo.1983.244.6.E632; GROOP L, 1988, DIABETES, V37, P99, DOI 10.2337/diabetes.37.1.99; HAFFNER SM, 1990, DIABETES, V39, P283, DOI 10.2337/diabetes.39.3.283; KADOWAKI T, 1984, DIABETOLOGIA, V26, P44, DOI 10.1007/BF00252262; KEEN H, 1982, DIABETOLOGIA, V22, P73, DOI 10.1007/BF00254832; KNOWLER WC, 1990, DIABETES METAB REV, V6, P1, DOI 10.1002/dmr.5610060101; KOSAKA K, 1977, DIABETES, V26, P944, DOI 10.2337/diab.26.10.944; LEAHY JL, 1986, J CLIN INVEST, V77, P908, DOI 10.1172/JCI112389; LILLIOJA S, 1991, J CLIN ENDOCR METAB, V73, P866, DOI 10.1210/jcem-73-4-866; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; LILLIOJA S, 1988, DIABETES METAB REV, V4, P517, DOI 10.1002/dmr.5610040508; LUNDGREN H, 1990, DIABETIC MED, V7, P407, DOI 10.1111/j.1464-5491.1990.tb01415.x; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; SICREE RA, 1987, DIABETES, V36, P179, DOI 10.2337/diabetes.36.2.179; Siri W., 1961, TECHNIQUES MEASURING, P223; STEELE R, 1959, ANN NY ACAD SCI, V82, P420, DOI 10.1111/j.1749-6632.1959.tb44923.x; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; 1985, WHO TECH REP SER, V727, P9; 1986, SUGI SUPPLEMENTAL LI, P437	32	1268	1292	1	47	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1993	329	27					1988	1992		10.1056/NEJM199312303292703	http://dx.doi.org/10.1056/NEJM199312303292703			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN573	8247074	Green Published			2022-12-28	WOS:A1993MN57300003
J	DEMARCHI, S; CECCHIN, E; BASILE, A; BERTOTTI, A; NARDINI, R; BARTOLI, E				DEMARCHI, S; CECCHIN, E; BASILE, A; BERTOTTI, A; NARDINI, R; BARTOLI, E			RENAL TUBULAR DYSFUNCTION IN CHRONIC ALCOHOL-ABUSE - EFFECTS OF ABSTINENCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSTNATAL-DEVELOPMENT; ETHANOL; PLASMA; KIDNEY; INTOXICATION; DOPAMINE; ACIDOSIS; LIVER	Background. Alcohol abuse may be accompanied by a variety of disorders of electrolyte and acid-base metabolism. The role of the kidney in the pathogenesis of these disturbances is obscure. We sought to evaluate the alcohol-induced abnormalities of renal function and improvement during abstinence and to assess the relation between renal dysfunction and electrolyte and acid-base disorders. Methods. We measured biochemical constituents of blood and renal function before and after four weeks of abstinence in 61 patients with chronic alcoholism who had little or no liver disease. Results. On admission, 18 patients (30 percent) had hypophosphatemia and hypomagnesemia, 13 patients (21 percent) had hypocalcemia, and 8 patients (13 percent) had hypokalemia. Twenty-two patients (36 percent) had a variety of simple and mixed acid-base disorders. Twenty of these patients had metabolic acidosis, and among them, 80 percent had alcoholic acidosis. A wide range of defects in renal tubular function, with normal glomerular filtration rate, was detected in these patients. The defects included decreases in the threshold and maximal reabsorptive ability for glucose (38 percent of patients) and in the renal threshold for phosphate excretion (36 percent); increases in the fractional excretion of beta2-microglobulin (38 percent), uric acid (12 percent), calcium (23 percent), and magnesium (21 percent); and aminoaciduria (38 percent). Seventeen patients (28 percent) had a defect in tubular acidification, and five an impairment in urinary concentrating ability. Urinary excretion of N-acetyl-beta-D-glucosaminidase and alanine aminopeptidase was increased in 41 and 34 percent of patients, respectively. The abnormalities of blood chemistry and renal tubular function disappeared after four weeks of abstinence. Conclusions. Transient defects in renal tubular function are common in patients with chronic alcoholism and may contribute to their abnormalities of serum electrolyte and blood acid-base profiles.	GEN HOSP,DEPT INTERNAL MED,SAN VITO TAGLIAMENTO,ITALY; UNIV UDINE,SCH MED,DEPT INTERNAL MED,I-33100 UDINE,ITALY; INST HYG,CHEM LAB,UDINE,ITALY	University of Udine								ALBERT MS, 1967, ANN INTERN MED, V66, P312, DOI 10.7326/0003-4819-66-2-312; ASSADI FK, 1990, PEDIATR NEPHROL, V4, P48, DOI 10.1007/BF00858439; ASSADI FK, 1991, ALCOHOL, V8, P259, DOI 10.1016/0741-8329(91)90321-M; BANNAN LT, 1984, CLIN SCI, V66, P659, DOI 10.1042/cs0660659; BLACHLEY J, 1990, FLUIDS ELECTROLYTES, P649; CARUANA RJ, 1988, MEDICINE, V67, P84, DOI 10.1097/00005792-198803000-00002; CRABB DW, 1991, ADV EXP MED BIOL, V284, P277; DAPRADA M, 1976, LIFE SCI, V19, P1161, DOI 10.1016/0024-3205(76)90251-4; DEMARCHI S, 1984, BRIT MED J, V288, P1457, DOI 10.1136/bmj.288.6428.1457-c; DEMARCHI S, 1984, AM J NEPHROL, V4, P280, DOI 10.1159/000166826; DEMARCHI S, 1986, BRIT MED J, V293, P138, DOI 10.1136/bmj.293.6539.138-a; GONZALEZCALVIN JL, 1983, BIOCHEM PHARMACOL, V32, P1723, DOI 10.1016/0006-2952(83)90116-8; HALPERIN ML, 1983, METABOLISM, V32, P308, DOI 10.1016/0026-0495(83)90197-X; HOWES LG, 1986, CLIN SCI, V71, P9, DOI 10.1042/cs0710009; JUNG K, 1987, CLIN CHIM ACTA, V168, P287, DOI 10.1016/0009-8981(87)90004-0; KNOCHEL JP, 1988, KIDNEY LIVER DISEASE, P132; LAITINEN K, 1991, NEW ENGL J MED, V324, P721, DOI 10.1056/NEJM199103143241103; LEMIEUX G, 1980, AM J PHYSIOL, V239, pF420, DOI 10.1152/ajprenal.1980.239.5.F420; LIEBER CS, 1988, NEW ENGL J MED, V319, P1639; LINKOLA J, 1978, ACTA PHYSIOL SCAND, V104, P180, DOI 10.1111/j.1748-1716.1978.tb06265.x; MONSON JP, 1978, BRIT MED J, V1, P24, DOI 10.1136/bmj.1.6104.24; OSTER JR, 1975, NEPHRON, V14, P281, DOI 10.1159/000180458; PARE P, 1984, ARCH INTERN MED, V144, P941, DOI 10.1001/archinte.144.5.941; PARENTI P, 1991, BIOCHIM BIOPHYS ACTA, V1070, P2; QULALI M, 1991, ARCH BIOCHEM BIOPHYS, V288, P406, DOI 10.1016/0003-9861(91)90213-3; RODRIGO R, 1991, CELL BIOCHEM FUNCT, V9, P215, DOI 10.1002/cbf.290090310; ROTHMAN A, 1992, BIOCHEM PHARMACOL, V43, P2034, DOI 10.1016/0006-2952(92)90648-3; ROUT UK, 1991, BIOL NEONATE, V59, P93; SCHAEFER RM, 1987, MINER ELECTROL METAB, V13, P1; SCHARDIJN GHC, 1987, KIDNEY INT, V32, P635, DOI 10.1038/ki.1987.255; SHAFIK IM, 1992, OXFORD TXB CLIN NEPH, V3, P1802; WILLIAMSON DH, 1962, BIOCHEM J, V82, P90, DOI 10.1042/bj0820090; WRENN KD, 1991, AM J MED, V91, P119, DOI 10.1016/0002-9343(91)90003-G; 1982, MED DISORDERS ALCOHO	34	135	139	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1993	329	26					1927	1934		10.1056/NEJM199312233292605	http://dx.doi.org/10.1056/NEJM199312233292605			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MM885	8247056	Bronze			2022-12-28	WOS:A1993MM88500005
J	BURTON, MD; WAIN, JC				BURTON, MD; WAIN, JC			CLUBBING AND HYPERTROPHIC OSTEOARTHROPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											BURTON, MD (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 16	1993	329	25					1861	1861						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML588	8247039				2022-12-28	WOS:A1993ML58800007
J	TICHELLI, A; GRATWOHL, A; EGGER, T; ROTH, J; PRUNTE, A; NISSEN, C; SPECK, B				TICHELLI, A; GRATWOHL, A; EGGER, T; ROTH, J; PRUNTE, A; NISSEN, C; SPECK, B			CATARACT FORMATION AFTER BONE-MARROW TRANSPLANTATION	ANNALS OF INTERNAL MEDICINE			English	Article						BONE MARROW TRANSPLANTATION; CATARACT; CATARACT EXTRACTION; WHOLE-BODY IRRADIATION	TOTAL-BODY IRRADIATION; DELAYED COMPLICATIONS; OCULAR COMPLICATIONS; CHILDREN; HEALTH; SURVIVORS; LIFE	Objective: To evaluate the incidence, time course and factors associated with cataract formation in bone marrow transplant recipients. Design: Prospective cohort study Setting: University Hospitals, Basel Switzerland Patients: 197 patients treated with allogeneic or autologous bone marrow grafts at least 180 days before the start of the study. Intervention: Three regimens for bone marrow transplant were used: 74 patients received single-dose, total-body irradiation (TBI), 90 patients received fractionated TBI, and 33 received chemotherapy alone. Results: Three and one half years after single-dose TBI, 51 of the 74 patients (69%) were alive and cataracts had developed in all of these 51 patients. Cataracts developed in 18 of the 90 (20%) patients treated with fractionated TBI, with an 83% (95% CI, 63% to 100%) risk for lens opacification at 6 years. Cataracts developed in only 1 of the 33 (3%) patients treated with chemotherapy alone. Incidence of cataracts is higher and lens opacification occurs earlier after single-dose TBI than after fractionated TBI (P < 0.01). With Cox regression analysis, the use of irradiation (relative risk, 21.0), the mode of irradiation (relative risk, 7.4), and the use of steroid treatment (relative risk, 2.9) for more than 3 months after bone marrow transplantation increased the risk for cataract formation. In contrast, age, sex, and chronic graft-versus-host disease did not influence the rate of cataract development. The probability of requiring cataract surgery after 6 years was 85% (CI, 75% to 95%) for the patients treated with single-dose TBI and 20% (CI, 0% to 49%) for those prepared with fractionated irradiation. Conclusions: Patients treated with TBI, regardless of fractionation, are likely to have cataracts within 10 years, and some will need surgical repair. Long-term steroid treatment accelerates cataract formation. Preventive measures, such as lens shielding during TBI, should be considered.	UNIV HOSP BASEL, CH-4031 BASEL, SWITZERLAND	University of Basel								BERNAUER W, 1991, ANN INTERN MED, V115, P925, DOI 10.7326/0003-4819-115-12-925; BLACK RL, 1960, JAMA-J AM MED ASSOC, V174, P166, DOI 10.1001/jama.1960.63030020005014; BRAY LC, 1991, BRIT J OPHTHALMOL, V75, P611, DOI 10.1136/bjo.75.10.611; CALISSENDORFF B, 1991, BONE MARROW TRANSPL, V7, P427; CHOSHI K, 1983, RADIAT RES, V96, P560, DOI 10.2307/3576122; COX DR, 1972, J R STAT SOC B, V34, P187; DEEG HJ, 1984, INT J RADIAT ONCOL, V10, P957, DOI 10.1016/0360-3016(84)90163-9; DEEG HJ, 1984, BRIT J HAEMATOL, V57, P185, DOI 10.1111/j.1365-2141.1984.tb08521.x; DEEG HJ, 1990, HEMATOL ONCOL CLIN N, V4, P641; DIETERLE A, 1990, TRANSPLANTATION, V49, P1093, DOI 10.1097/00007890-199006000-00013; GRATWHOL AA, 1977, ANN INTERN MED, V87, P703, DOI 10.7326/0003-4819-87-6-703; GRATWOHL A, 1988, BONE MARROW TRANSPL, V3, P577; HAVRE DC, 1965, ARCH OPHTHALMOL-CHIC, V73, P818; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOBAYASHI Y, 1974, AM J DIS CHILD, V128, P671, DOI 10.1001/archpedi.1974.02110300081010; KOLB HJ, 1990, BONE MARROW TRANSPL, V6, P61; LAPPI M, 1990, GRAEF ARCH CLIN EXP, V228, P218, DOI 10.1007/BF00920023; LIVESEY SJ, 1989, EYE, V3, P271, DOI 10.1038/eye.1989.37; Meier P, 1985, ASAIO J, V8, P3; MERRIAM G R Jr, 1962, Trans Am Ophthalmol Soc, V60, P35; MERRIAM GR, 1983, B NEW YORK ACAD MED, V59, P372; NIEMI M, 1990, Bone Marrow Transplantation, V5, P83; OZSAHIN M, 1992, CANCER, V69, P2853, DOI 10.1002/1097-0142(19920601)69:11<2853::AID-CNCR2820691135>3.0.CO;2-2; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; SANDERS J, 1989, BONE MARROW TRANSPL, V4, P27; Sanders J E, 1990, Radiother Oncol, V18 Suppl 1, P82, DOI 10.1016/0167-8140(90)90181-U; SONNEVELD P, 1979, RADIOLOGY, V133, P227, DOI 10.1148/133.1.227; SPECK B, 1988, TRANSPLANT P, V20, P505; SPECK B, 1986, EXP HEMATOL, V14, P126; THOMAS ED, 1984, ANNU REV MED, V35, P1; TICHELLI A, 1991, SCHWEIZ MED WSCHR, V121, P1473; TICHELLI A, 1987, Bone Marrow Transplantation, V2, P250; VANWEELSIPMAN MH, 1990, RADIOTHER ONCOL S1, V18, P2155; VOGLER WR, 1990, BONE MARROW TRANSPL, V6, P405; WINGARD JR, 1991, ANN INTERN MED, V114, P113, DOI 10.7326/0003-4819-114-2-113; WOLCOTT DL, 1986, TRANSPLANTATION, V41, P478, DOI 10.1097/00007890-198604000-00013	36	82	83	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1993	119	12					1175	1180		10.7326/0003-4819-119-12-199312150-00004	http://dx.doi.org/10.7326/0003-4819-119-12-199312150-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM121	8239248				2022-12-28	WOS:A1993MM12100004
J	GRUNBERG, SM; HESKETH, PJ				GRUNBERG, SM; HESKETH, PJ			DRUG-THERAPY - CONTROL OF CHEMOTHERAPY-INDUCED EMESIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CISPLATIN-INDUCED EMESIS; HIGH-DOSE METOCLOPRAMIDE; PATIENTS RECEIVING CHEMOTHERAPY; DOUBLE-BLIND CROSSOVER; ANTI-CANCER THERAPY; INDUCED NAUSEA; PLUS DEXAMETHASONE; ANTIEMETIC EFFICACY; RANDOMIZED TRIAL; AREA POSTREMA		BOSTON UNIV, MED CTR, EVANS MEM DEPT CLIN RES, MED ONCOL SECT, BOSTON, MA 02215 USA	Boston University	GRUNBERG, SM (corresponding author), UNIV VERMONT, VERMONT CANC CTR, HEMATOL ONCOL SECT, 1 S PROSPECT ST, BURLINGTON, VT 05402 USA.							AAPRO MS, 1991, RECENT RES CANCER, V121, P91; ADDELMAN M, 1990, J CLIN ONCOL, V8, P337, DOI 10.1200/JCO.1990.8.2.337; ALLAN SG, 1984, BRIT MED J, V289, P878, DOI 10.1136/bmj.289.6449.878-a; ANDREWS PLR, 1988, TRENDS PHARMACOL SCI, V9, P334, DOI 10.1016/0165-6147(88)90106-X; ANDREWS PLR, 1990, CAN J PHYSIOL PHARM, V68, P325, DOI 10.1139/y90-047; BECK TM, 1993, ANN INTERN MED, V118, P407, DOI 10.7326/0003-4819-118-6-199303150-00002; BLANCQUAERT JP, 1986, EUR J PHARMACOL, V128, P143, DOI 10.1016/0014-2999(86)90760-0; BONNETERRE J, 1990, J CLIN ONCOL, V8, P1063, DOI 10.1200/JCO.1990.8.6.1063; BORISON HL, 1953, PHARMACOL REV, V5, P193; BOWCOCK SJ, 1984, BRIT MED J, V288, P1879, DOI 10.1136/bmj.288.6434.1879; BRADLEY PB, 1986, NEUROPHARMACOLOGY, V25, P563, DOI 10.1016/0028-3908(86)90207-8; BREGNI M, 1991, EUR J CANCER, V27, P561, DOI 10.1016/0277-5379(91)90217-2; CARPENTER DO, 1984, BEHAV BRAIN RES, V11, P277, DOI 10.1016/0166-4328(84)90220-1; CARPENTER DO, 1990, CAN J PHYSIOL PHARM, V68, P230, DOI 10.1139/y90-036; CARPENTER DO, 1983, CELL MOL NEUROBIOL, V3, P113, DOI 10.1007/BF00735276; CARR BI, 1987, CANCER, V60, P2165, DOI 10.1002/1097-0142(19871101)60:9<2165::AID-CNCR2820600908>3.0.CO;2-C; CASSILETH PA, 1984, ANN INTERN MED, V100, P701, DOI 10.7326/0003-4819-100-5-701; CHIARA S, 1987, AM J CLIN ONCOL-CANC, V10, P264, DOI 10.1097/00000421-198706000-00021; CLARK RA, 1990, P AN M AM SOC CLIN, V9, P322; COATES A, 1983, EUR J CANCER CLIN ON, V19, P203, DOI 10.1016/0277-5379(83)90418-2; CODY R, 1991, P AN M AM SOC CLIN, V10, P340; COSTELLO DJ, 1977, J PHARMACOL EXP THER, V203, P222; CUBEDDU LX, 1990, NEW ENGL J MED, V322, P810, DOI 10.1056/NEJM199003223221204; CUNNINGHAM D, 1985, BRIT MED J, V291, P864, DOI 10.1136/bmj.291.6499.864; D'ACQUISTO R, 1986, Proceedings American Society of Clinical Oncology Annual Meeting, V5, P257; ENDO T, 1990, Journal of Toxicological Sciences, V15, P235; FOZARD JR, 1984, NEUROPHARMACOLOGY, V23, P1473, DOI 10.1016/0028-3908(84)90091-1; FOZARD JR, 1978, EUR J PHARMACOL, V49, P109, DOI 10.1016/0014-2999(78)90228-5; GEZ E, 1989, ONCOLOGY, V46, P150; GOLDSTEIN D, 1989, ONCOLOGY, V46, P105; GRALLA RJ, 1981, NEW ENGL J MED, V305, P905, DOI 10.1056/NEJM198110153051601; GRALLA RJ, 1983, DRUGS, V25, P63, DOI 10.2165/00003495-198300251-00007; GREENBERG DB, 1987, CANCER TREAT REP, V71, P549; GRUNBERG SM, 1989, J CLIN ONCOL, V7, P1137, DOI 10.1200/JCO.1989.7.8.1137; GRUNBERG SM, 1988, J NATL CANCER I, V80, P864, DOI 10.1093/jnci/80.11.864; GRUNBERG SM, 1984, J CLIN ONCOL, V2, P782, DOI 10.1200/JCO.1984.2.7.782; GRUNBERG SM, 1986, CANCER INVEST, V4, P379, DOI 10.3109/07357908609017518; GUNNING S J, 1987, British Journal of Pharmacology, V90, p135P; Harris A. L., 1986, NAUSEA VOMITING MECH, P78; HARRIS AL, 1982, LANCET, V1, P714; HERRSTEDT J, 1993, NEW ENGL J MED, V328, P1076, DOI 10.1056/NEJM199304153281502; HESKETH PJ, 1991, J NATL CANCER I, V83, P613, DOI 10.1093/jnci/83.9.613; HESKETH PJ, 1989, J CLIN ONCOL, V7, P700, DOI 10.1200/JCO.1989.7.6.700; HESKETH PJ, 1992, MECH CONTROL EMESIS, P25; JACKSON M, 1985, DRUG INTEL CLIN PHAR, V19, P841, DOI 10.1177/106002808501901114; JORDAN NS, 1985, J CLIN ONCOL, V3, P559, DOI 10.1200/JCO.1985.3.4.559; KILPATRICK GJ, 1989, EUR J PHARMACOL, V159, P157, DOI 10.1016/0014-2999(89)90700-0; KOBRINSKY NL, 1988, AM J PEDIAT HEMATOL, V10, P209; KRIS MG, 1985, J CLIN ONCOL, V3, P1379, DOI 10.1200/JCO.1985.3.10.1379; KRIS MG, 1988, J CLIN ONCOL, V6, P659, DOI 10.1200/JCO.1988.6.4.659; KRIS MG, 1989, J CLIN ONCOL, V7, P108, DOI 10.1200/JCO.1989.7.1.108; KRIS MG, 1985, CANCER, V55, P527, DOI 10.1002/1097-0142(19850201)55:3<527::AID-CNCR2820550310>3.0.CO;2-2; KRIS MG, 1983, NEW ENGL J MED, V309, P433; KRIS MG, 1987, CANCER, V60, P2816, DOI 10.1002/1097-0142(19871201)60:11<2816::AID-CNCR2820601137>3.0.CO;2-7; LESLIE RA, 1985, NEUROCHEM INT, V7, P191, DOI 10.1016/0197-0186(85)90106-8; LESLIE RA, 1990, CAN J PHYSIOL PHARM, V68, P279, DOI 10.1139/y90-042; LIVREA P, 1985, J NEUROL, V231, P336, DOI 10.1007/BF00313712; LONGO DL, 1982, CANCER TREAT REP, V66, P1975; MARTINJIMENEZ M, 1987, TUMORI, V73, P499, DOI 10.1177/030089168707300512; MARTY M, 1990, NEW ENGL J MED, V322, P816, DOI 10.1056/NEJM199003223221205; MCCABE M, 1988, INVEST NEW DRUG, V6, P243; MECHOULAM R, 1991, FARMACO, V46, P267; MEYER BR, 1987, J CLIN ONCOL, V5, P1994, DOI 10.1200/JCO.1987.5.12.1994; MILLER AD, 1983, BRAIN RES, V270, P154, DOI 10.1016/0006-8993(83)90805-3; MOERTEL CG, 1963, JAMA-J AM MED ASSOC, V186, P116, DOI 10.1001/jama.1963.03710020036011; MORRAN C, 1979, BMJ-BRIT MED J, V1, P1323, DOI 10.1136/bmj.1.6174.1323-a; MORROW GR, 1982, J NATL CANCER I, V68, P585; NIIRANEN A, 1987, AM J CLIN ONCOL-CANC, V10, P325, DOI 10.1097/00000421-198708000-00014; NIIRANEN A, 1985, AM J CLIN ONCOL-CANC, V8, P336, DOI 10.1097/00000421-198508000-00013; OLVER IN, 1989, EUR J CANCER CLIN ON, V25, P1457, DOI 10.1016/0277-5379(89)90104-1; OLVER IN, 1986, CANCER TREAT REP, V70, P555; OLVER IN, 1991, P AN M AM SOC CLIN, V10, P321; PALACIOS JM, 1981, NEUROSCIENCE, V6, P15, DOI 10.1016/0306-4522(81)90240-2; PLASSE TF, 1991, PHARMACOL BIOCHEM BE, V40, P695, DOI 10.1016/0091-3057(91)90385-F; POMEROY M, 1986, CANCER CHEMOTH PHARM, V17, P285; PRATT G D, 1989, British Journal of Pharmacology, V97, p414P; RICH WM, 1980, GYNECOL ONCOL, V9, P193, DOI 10.1016/0090-8258(80)90027-X; ROILA F, 1987, EUR J CANCER CLIN ON, V23, P615, DOI 10.1016/0277-5379(87)90255-0; ROILA F, 1991, J CLIN ONCOL, V9, P675, DOI 10.1200/JCO.1991.9.4.675; Sakata Y, 1986, Gan To Kagaku Ryoho, V13, P2415; SALLAN SE, 1980, NEW ENGL J MED, V302, P135, DOI 10.1056/NEJM198001173020302; SALLAN SE, 1975, NEW ENGL J MED, V293, P795, DOI 10.1056/NEJM197510162931603; SALLER R, 1986, EUR J CANCER CLIN ON, V22, P1199, DOI 10.1016/0277-5379(86)90321-4; SANGER GJ, 1990, CAN J PHYSIOL PHARM, V68, P314, DOI 10.1139/y90-046; SAWICKA J, 1977, P AM ASSOC CANC RES, V18, P302; SCHWARTZ JC, 1986, NAUSEA VOMITING MECH, P18; SEYNAEVE C, 1991, PHARM WEEKBLAD, V13, P1, DOI 10.1007/BF01963876; SILVEY L, 1988, J CLIN ONCOL, V6, P1397, DOI 10.1200/JCO.1988.6.9.1397; SMYTH JF, 1991, BRIT MED J, V303, P1423, DOI 10.1136/bmj.303.6815.1423; STAMATAKIS L, 1989, P ASCO, V8, P327; STEFANINI E, 1981, EUR J PHARMACOL, V74, P257, DOI 10.1016/0014-2999(81)90540-9; STRUM SB, 1984, CANCER, V53, P1432, DOI 10.1002/1097-0142(19840315)53:6<1432::AID-CNCR2820530636>3.0.CO;2-E; SULLIVAN JR, 1983, NEW ENGL J MED, V309, P796; TONATO M, 1991, ANN ONCOL, V2, P107, DOI 10.1093/oxfordjournals.annonc.a057871; TORTORICE PV, 1990, PHARMACOTHERAPY, V10, P129; TYERS MB, 1990, ANN NY ACAD SCI, V600, P194, DOI 10.1111/j.1749-6632.1990.tb16882.x; TYSON LB, 1985, AM J CLIN ONCOL-CANC, V8, P528, DOI 10.1097/00000421-198512000-00014; VANHAZEL GA, 1983, P ASCO, V2, P85; WAMSLEY JK, 1981, J NEUROSCI, V1, P176; Wang S. C., 1965, PHYSIOL PHARMACOL, VII, P255; WYANT G M, 1962, Can Anaesth Soc J, V9, P399; ZAGLAMA NE, 1986, ONCOLOGY, V43, P27, DOI 10.1159/000226099	102	169	175	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 9	1993	329	24					1790	1796						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK096	8232489				2022-12-28	WOS:A1993MK09600008
J	PANTALONI, D; CARLIER, MF				PANTALONI, D; CARLIER, MF			HOW PROFILIN PROMOTES ACTIN FILAMENT ASSEMBLY IN THE PRESENCE OF THYMOSIN-BETA-4	CELL			English	Article							BOUND ADENOSINE 5'-TRIPHOSPHATE; ACANTHAMOEBA PROFILIN; ATP HYDROLYSIS; F-ACTIN; POLYMERIZATION; BINDING; PROFILACTIN; PROTEIN; CELLS; GELSOLIN	The role of profilin in the regulation of actin assembly has been reexamined. The affinity of profilin for ATP-actin appears 10-fold higher than previously thought. in the presence of ATP, the participation of the profilin-actin complex to filament elongation at the barbed end is linked to a decrease in the steady-state concentration of globular actin. This surprising effect is made possible by the involvement of the irreversible ATP hydrolysis accompanying actin polymerization. As a consequence, in the presence of thymosin beta4 (Tbeta4), low amounts of profilin promote extensive actin assembly off of the pool of actin-Tbeta4 complex. When barbed ends are capped, profilin simply sequesters globular actin. A model is proposed for the function of profilin in actin-based motility.			PANTALONI, D (corresponding author), CNRS,ENZYMOL LAB,F-91198 GIF SUR YVETTE,FRANCE.							CAO LG, 1992, J CELL BIOL, V117, P1023, DOI 10.1083/jcb.117.5.1023; CARLIER MF, 1993, P NATL ACAD SCI USA, V90, P5034, DOI 10.1073/pnas.90.11.5034; CARLIER MF, 1988, J BIOL CHEM, V263, P817; CARLIER MF, 1991, J BIOL CHEM, V266, P1; CARLIER MF, 1986, J BIOL CHEM, V261, P2041; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; COOPER JA, 1991, ANNU REV PHYSIOL, V53, P585, DOI 10.1146/annurev.ph.53.030191.003101; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DINUBILE MJ, 1985, J BIOL CHEM, V260, P7402; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; KAISER DA, 1986, J CELL BIOL, V102, P221, DOI 10.1083/jcb.102.1.221; KORN ED, 1987, SCIENCE, V238, P638, DOI 10.1126/science.3672117; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAL AA, 1985, J BIOL CHEM, V260, P132; LARSSON H, 1988, BIOCHIM BIOPHYS ACTA, V953, P95, DOI 10.1016/0167-4838(88)90013-1; LIND SE, 1987, J CELL BIOL, V105, P833, DOI 10.1083/jcb.105.2.833; LINDBERG U, 1988, BIOCHIM BIOPHYS ACTA, V967, P391, DOI 10.1016/0304-4165(88)90102-X; MALM B, 1984, FEBS LETT, V173, P399, DOI 10.1016/0014-5793(84)80813-3; MCLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18; MCLEOD JF, 1989, J BIOL CHEM, V264, P1260; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; PANTALONI D, 1985, P NATL ACAD SCI USA, V82, P7207, DOI 10.1073/pnas.82.21.7207; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; SAFER D, 1991, J BIOL CHEM, V266, P4029; SCHAFER DA, 1992, J CELL BIOL, V118, P335, DOI 10.1083/jcb.118.2.335; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; TILNEY LG, 1973, J CELL BIOL, V59, P109, DOI 10.1083/jcb.59.1.109; TILNEY LG, 1983, J CELL BIOL, V97, P112, DOI 10.1083/jcb.97.1.112; TOBACMAN LS, 1983, J BIOL CHEM, V258, P8806; WEBER A, 1992, BIOCHEMISTRY-US, V31, P6179, DOI 10.1021/bi00142a002; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3	38	476	490	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 3	1993	75	5					1007	1014		10.1016/0092-8674(93)90544-Z	http://dx.doi.org/10.1016/0092-8674(93)90544-Z			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252614				2022-12-28	WOS:A1993MK96600020
J	PAUKER, SG; KOPELMAN, RI				PAUKER, SG; KOPELMAN, RI			WHEN GOING FOR THE GOLD IS NOT AN OPTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV GEN INTERNAL MED,BOSTON,MA 02111	Tufts Medical Center; Tufts University	PAUKER, SG (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV CLIN DECIS MAKING,MAILSTOP 35K9,BOX 302,BOSTON,MA 02111, USA.				NATIONAL LIBRARY OF MEDICINE [R01LM004493] Funding Source: NIH RePORTER; NLM NIH HHS [LM 4493] Funding Source: Medline	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		ARNOLD WJ, 1993, TXB RHEUMATOLOGY, V2, P1429; BALLOU SP, 1993, TXB RHEUMATOLOGY, V1, P671; CARR PL, 1990, J GEN INTERN MED, V5, P138, DOI 10.1007/BF02600516; CRYSTAL RG, 1991, HARRISONS PRINCIPLES, V2, P1463; CUSH JJ, 1991, HARRISONS PRINCIPLES, V2, P1472; DOYLE AC, 1930, COMPLETE S HOLMES, P1000; FANBURG BL, 1992, CECIL TXB MED, P430; FANBURG BL, 1983, SARCOIDOSIS OTHER GR, P263; FRIES JF, 1992, CECIL TXB MED, P1488; Glick JH, 1992, CECIL TXB MED, P955; GOTTLIEB JE, 1983, SARCOIDOSIS OTHER GR, P349; ISRAEL HL, 1983, SARCOIDOSIS OTHER GR, P273; Katz S, 1983, SARCOIDOSIS OTHER GR, P3; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; SCHUMACHER HR, 1988, PRIMER RHEUMATIC DIS, P190; SERGENT JS, 1993, TXB RHEUMATOLOGY, V1, P381; SHARMA OP, 1990, DIS MON, V36, P474; STEVENS MB, 1988, PRINCIPLES PRACTICE, P535; STEVENS MB, 1988, PRINCIPLES PRACTICE, P491; WHITE R, 1992, ORIGEN HOMBRE MODERN, P327; ZVAIFLER NJ, 1990, INTERNAL MED, P1721; 1988, PRIMER RHEUMATIC DIS, P51	22	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 2	1993	329	23					1716	1719		10.1056/NEJM199312023292308	http://dx.doi.org/10.1056/NEJM199312023292308			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ707	8232461				2022-12-28	WOS:A1993MJ70700008
J	YAO, TP; FORMAN, BM; JIANG, ZY; CHERBAS, L; CHEN, JD; MCKEOWN, M; CHERBAS, P; EVANS, RM				YAO, TP; FORMAN, BM; JIANG, ZY; CHERBAS, L; CHEN, JD; MCKEOWN, M; CHERBAS, P; EVANS, RM			FUNCTIONAL ECDYSONE RECEPTOR IS THE PRODUCT OF ECR AND ULTRASPIRACLE GENES	NATURE			English	Article							RETINOIC ACID; RESPONSE ELEMENTS; INDUCIBLE GENE; DNA-BINDING; EARLY PUFF; ENCODES 2; DROSOPHILA; TRANSCRIPTION; SUPERFAMILY; ACTIVATION	ALTHOUGH the biological activity of the insect moulting hormone ecdysone, is manifested through a hormonally regulated transcriptional cascade associated with chromosomal puffing1-3, a direct association of the receptor with the puff has yet to be established. The cloned ecdysone receptor4 (EcR) is by itself incapable of high-affinity DNA binding or transcriptional activation. Rather, these activities are dependent on heterodimer formation with Ultraspiracle5 (USP) the insect homologue of vertebrate retinoid X receptor6. Here we report that native EcR and USP are co-localized on ecdysone-responsive loci of polytene chromosomes. Moreover, we show that natural ecdysones selectively promote physical association between EcR and USP, and conversely, that high-affinity hormone binding requires both EcR and USP. Replacement of USP with retinoid X receptor produces heterodimers with distinct pharmacological and functional properties. These results redefine the ecdysone receptor as a dynamic complex whose activity may be altered by combinatorial interactions among subunits and ligand.	UNIV CALIF SAN DIEGO,GRAD PROGRAM BIOMED SCI,LA JOLLA,CA 92037; INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405	University of California System; University of California San Diego; Indiana University System; Indiana University Bloomington	YAO, TP (corresponding author), SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037, USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				ALLAN GF, 1992, J BIOL CHEM, V267, P19513; Ashburner M, 1972, Results Probl Cell Differ, V4, P101; Ashburner M, 1974, Cold Spring Harb Symp Quant Biol, V38, P655; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHERBAS L, 1991, GENE DEV, V5, P120, DOI 10.1101/gad.5.1.120; CHERBAS P, 1988, P NATL ACAD SCI USA, V85, P2096, DOI 10.1073/pnas.85.7.2096; CHRISTIANSON AMK, 1992, P NATL ACAD SCI USA, V89, P11503, DOI 10.1073/pnas.89.23.11503; CHRISTOPHERSON KS, 1992, P NATL ACAD SCI USA, V89, P6314, DOI 10.1073/pnas.89.14.6314; CLEVER U, 1960, EXP CELL RES, V20, P623, DOI 10.1016/0014-4827(60)90141-5; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KOELLE MR, IN PRESS P NATN ACAD; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; RIDDIHOUGH G, 1987, EMBO J, V6, P3729, DOI 10.1002/j.1460-2075.1987.tb02707.x; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; TALBOT WS, 1993, CELL, V73, P1323, DOI 10.1016/0092-8674(93)90359-X; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; ZINK B, 1991, EMBO J, V10, P153, DOI 10.1002/j.1460-2075.1991.tb07931.x	22	747	802	7	57	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 2	1993	366	6454					476	479		10.1038/366476a0	http://dx.doi.org/10.1038/366476a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK098	8247157				2022-12-28	WOS:A1993MK09800068
J	BRIEGER, GH				BRIEGER, GH			GETTING INTO MEDICAL-SCHOOL IN THE GOOD OLD DAYS - GOOD FOR WHOM - THE 1ST DAVIES,NICHOLAS,E. MEMORIAL LECTURE	ANNALS OF INTERNAL MEDICINE			English	Article								Admission to medical school became selective in the 1920s and by the 1960s became increasingly expensive for applicants. The stories of three applicants, a white man who easily walked into medical school in 1908, a black woman who overcame a double hurdle in the 1930s, and a white man who entered medical school by court order, provide insight into the admissions process and its changes.			BRIEGER, GH (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT HIST SCI MED & TECHNOL, 1900 E MONUMENT ST, BALTIMORE, MD 21205 USA.							BRIEGER GH, 1991, B HIST MED, V65, P88; BRIEGER GH, 1983, B HIST MED, V57, P1; CASTLE WB, 1952, NEW ENGL J MED, V247, P585, DOI 10.1056/NEJM195210162471601; Dreyfuss Joel, 1979, BAKKE CASE POLITICS; LIGHTFOOT SL, 1988, BALM GILEAD J HEALER; LINDSEY R, 1977, Y TIMES MAGAZIN 0403; O'Neill T. J., 1985, BAKKE POLITICS EQUAL; OSLER W, 1911, COMMUNICATION   0901; RACKEMANN FM, 1956, INQUISITIVE PHYSICIA, P17; SEVERINGHAUS AE, 1953, PREPARATION MED ED L, P19; SINDLER AP, 1978, DEFUNIS MINORITY ADM; STORANDT PC, 1977, NY TIMES        0703; Zapffe FC, 1937, J ASSOC AM MED COLL, V12, P193	13	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1993	119	11					1138	1143		10.7326/0003-4819-119-11-199312010-00012	http://dx.doi.org/10.7326/0003-4819-119-11-199312010-00012			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ335	8239234				2022-12-28	WOS:A1993MJ33500012
J	FLANAGAN, CA; SCHNIEDERS, EA; EMERICK, AW; KUNISAWA, R; ADMON, A; THORNER, J				FLANAGAN, CA; SCHNIEDERS, EA; EMERICK, AW; KUNISAWA, R; ADMON, A; THORNER, J			PHOSPHATIDYLINOSITOL 4-KINASE - GENE STRUCTURE AND REQUIREMENT FOR YEAST-CELL VIABILITY	SCIENCE			English	Article							PROTEIN KINASE-C; SACCHAROMYCES-CEREVISIAE; SIGNAL TRANSDUCTION; INOSITOL TRISPHOSPHATE; CONSERVED FEATURES; CATALYTIC SUBUNIT; KINETIC-ANALYSIS; POINT MUTATION; ALPHA-FACTOR; PURIFICATION	Phosphatidylinositol (PtdIns) 4-kinase catalyzes the first step in the biosynthesis of PtdIns-4,5-bisphosphate (PtdIns[4,5]P2). Hydrolysis of PtdIns[4,5]P2 in response to extracellular stimuli is thought to initiate intracellular signaling cascades that modulate cell proliferation and differentiation. The PIK1 gene encoding a PtdIns 4-kinase from the yeast Saccharomyces cerevisiae was isolated by polymerase chain reaction (PCR) with oligonucleotides based on the sequence of peptides derived from the purified enzyme. The sequence of the PIK1 gene product bears similarities to that of PtdIns 3-kinases from mammals (p110) and yeast (Vps34p). Expression of PIK1 from a multicopy plasmid elevated PtdIns 4-kinase activity and enhanced the response to mating pheromone. A pik1 null mutant was inviable, indicating that PtdIns4P and presumably PtdIns[4,5]P2 are indispensable phospholipids.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley			THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X; Admon, Arie/0000-0003-0504-3950	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007232, R37GM021841, R01GM021841] Funding Source: NIH RePORTER; NCI NIH HHS [CA09041] Funding Source: Medline; NIGMS NIH HHS [GM07232, GM21841] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438, DOI 10.1016/0968-0004(92)90016-3; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AUGER KR, 1989, J BIOL CHEM, V264, P20181; BELUNIS CJ, 1988, J BIOL CHEM, V263, P18897; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CULBERTSON MR, 1975, GENETICS, V80, P23; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; CYERT MS, UNPUB; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLANAGAN CA, 1992, J BIOL CHEM, V267, P24117; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; GOLDSCHMIDTCLERMONT PJ, 1991, CELL, V66, P419, DOI 10.1016/0092-8674(81)90002-7; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HENRY SA, 1984, ANNU REV GENET, V18, P207; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HOU WM, 1988, BIOCHIM BIOPHYS ACTA, V959, P67; JULIUS D, 1983, CELL, V32, P839, DOI 10.1016/0092-8674(83)90070-3; KAIBUCHI K, 1986, P NATL ACAD SCI USA, V83, P8172, DOI 10.1073/pnas.83.21.8172; KATAKAMI Y, 1992, BIOCHIM BIOPHYS ACTA, V1122, P123, DOI 10.1016/0167-4838(92)90314-4; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LI YS, 1989, BIOCHEM BIOPH RES CO, V160, P202, DOI 10.1016/0006-291X(89)91641-0; MAGDOLEN V, 1988, MOL CELL BIOL, V8, P5108, DOI 10.1128/MCB.8.12.5108; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; NICKELS JT, 1992, J BIOL CHEM, V267, P16297; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; NIKOLOFF DM, 1991, ANNU REV GENET, V25, P559; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAUSCH MH, 1991, EMBO J, V10, P1511, DOI 10.1002/j.1460-2075.1991.tb07671.x; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PORTER FD, 1988, J BIOL CHEM, V263, P8989; RAGHUNATHAN V, 1992, FEBS LETT, V297, P46, DOI 10.1016/0014-5793(92)80324-A; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; RINE J, 1991, METHOD ENZYMOL, V194, P239; RINE J, 1983, P NATL ACAD SCI-BIOL, V80, P6750, DOI 10.1073/pnas.80.22.6750; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J, 1989, MOL CLONING LABORATO; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SIKORSKI RS, 1989, GENETICS, V122, P19; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; STACK JH, COMMUNICATION; TALWALKAR RT, 1974, BIOCHIM BIOPHYS ACTA, V360, P306, DOI 10.1016/0005-2760(74)90060-5; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WALKER DH, 1988, BIOCHEMISTRY-US, V27, P6504, DOI 10.1021/bi00417a046; WELLS GB, 1983, J BIOL CHEM, V258, P200; WHEELER GE, 1972, BIOCHEM J, V127, pP64; WHITE MJ, 1991, ADV MICROB PHYSIOL, V32, P1, DOI 10.1016/S0065-2911(08)60004-1; YAMAKAWA A, 1991, J BIOL CHEM, V266, P17580; YAMAKAWA A, 1992, J BIOL CHEM, V267, P25620	66	180	184	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	1993	262	5138					1444	1448		10.1126/science.8248783	http://dx.doi.org/10.1126/science.8248783			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ046	8248783				2022-12-28	WOS:A1993MJ04600040
J	DIAZBENJUMEA, FJ; COHEN, SM				DIAZBENJUMEA, FJ; COHEN, SM			INTERACTION BETWEEN DORSAL AND VENTRAL CELLS IN THE IMAGINAL DISC DIRECTS WING DEVELOPMENT IN DROSOPHILA	CELL			English	Article							CHICK-EMBRYO HINDBRAIN; ENGRAILED EXPRESSION; LINEAGE RESTRICTIONS; CLONAL ANALYSIS; GENITAL DISK; MELANOGASTER; COMPARTMENTS; GENE; FIELDS; REGENERATION	The adult appendages of Drosophila develop from imaginal discs. An early step in disc patterning involves the formation of developmental boundaries that subdivide the discs into compartments. Anterior and posterior compartments are established in the embryo. Later in development a new boundary originates to subdivide the wing disc into dorsal and ventral compartments, which correspond to the dorsal and ventral surfaces of the adult wing. We report here that spatially localized expression of the homeobox gene apterous (ap) specifies the identity of dorsal cells in the wing. The boundary of cell lineage restriction between dorsal and ventral compartments coincides with the limit of the domain of ap expression. Using genetic mosaics, we show that juxtaposition of dorsal and ventral cells induces formation of the wing margin. We present evidence that the dorsal-ventral boundary promotes growth and serves as a pattern-organizing center in the wing disc.			DIAZBENJUMEA, FJ (corresponding author), EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAM, MEYERHOFSTR 1, D-69017 HEIDELBERG, GERMANY.		Cohen, Stephen M/G-9930-2011; Diaz-Benjumea, Fernando/K-7667-2014	Cohen, Stephen M/0000-0003-2858-9163; Diaz-Benjumea, Fernando/0000-0003-3007-2489				BAKER NE, 1988, DEVELOPMENT, V102, P489; BLAIR SS, 1992, DEVELOPMENT, V115, P21; BROWER DL, 1985, CELL, V41, P361, DOI 10.1016/S0092-8674(85)80008-8; BROWER DL, 1984, NATURE, V310, P496, DOI 10.1038/310496a0; Bryant P.J., 1978, P230; BRYANT PJ, 1975, J EXP ZOOL, V193, P49, DOI 10.1002/jez.1401930106; BRYANT PJ, 1993, SCIENCE, V259, P471, DOI 10.1126/science.8424169; BRYANT PJ, 1988, DEV BIOL, V127, P197, DOI 10.1016/0012-1606(88)90201-1; BUTTERWORTH FM, 1965, GENETICS, V52, P1153; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; DEROBERTIS EM, 1991, DEVELOPMENT, V112, P669; DUBENDORFER K, 1982, ROUX ARCH DEV BIOL, V191, P42, DOI 10.1007/BF00848545; FERRUS A, 1975, GENETICS, V79, P589; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; GARCIABELLIDO A, 1976, DEV BIOL, V48, P132, DOI 10.1016/0012-1606(76)90052-X; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GARCIABELLIDO A, 1972, GENETICS, V72, P87; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; GUTHRIE S, 1993, DEVELOPMENT, V118, P527; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; JAMES AA, 1981, DEV BIOL, V85, P39, DOI 10.1016/0012-1606(81)90234-7; KORNBERG T, 1981, DEV BIOL, V86, P363, DOI 10.1016/0012-1606(81)90194-9; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KORNBERG T, 1981, P NATL ACAD SCI-BIOL, V78, P1095, DOI 10.1073/pnas.78.2.1095; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LAWRENCE PA, 1982, EMBO J, V1, P827, DOI 10.1002/j.1460-2075.1982.tb01255.x; LAWRENCE PA, 1977, DEV BIOL, V56, P40, DOI 10.1016/0012-1606(77)90153-1; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LUMSDEN A, 1991, PHILOS T R SOC B, V331, P281, DOI 10.1098/rstb.1991.0017; MARTINEZARIAS A, 1985, NATURE, V313, P639, DOI 10.1038/313639a0; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; MEINHARDT H, 1991, SEMIN DEV BIOL, V12, P129; MORATA G, 1979, DEV BIOL, V70, P355, DOI 10.1016/0012-1606(79)90033-2; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OBROCHTA DA, 1985, NATURE, V313, P138, DOI 10.1038/313138a0; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; SCHUPBACH T, 1978, ROUX ARCH DEV BIOL, V185, P249, DOI 10.1007/BF00848355; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SIMCOX AA, 1989, DEVELOPMENT, V107, P715; SKAER H, 1992, DEVELOPMENT, V116, P745; STEINER E, 1976, ROUX ARCH DEV BIOL, V180, P9, DOI 10.1007/BF00848882; STRUHL G, 1977, NATURE, V270, P723, DOI 10.1038/270723a0; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B; WIESCHAUS E, 1976, DEV BIOL, V50, P249, DOI 10.1016/0012-1606(76)90150-0; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; XU T, 1993, DEVELOPMENT, V117, P1223	56	305	308	0	15	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 19	1993	75	4					741	752		10.1016/0092-8674(93)90494-B	http://dx.doi.org/10.1016/0092-8674(93)90494-B			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242746	Bronze			2022-12-28	WOS:A1993MH74900019
J	DIETRICH, WF; LANDER, ES; SMITH, JS; MOSER, AR; GOULD, KA; LUONGO, C; BORENSTEIN, N; DOVE, W				DIETRICH, WF; LANDER, ES; SMITH, JS; MOSER, AR; GOULD, KA; LUONGO, C; BORENSTEIN, N; DOVE, W			GENETIC IDENTIFICATION OF MOM-1, A MAJOR MODIFIER LOCUS AFFECTING MIN-INDUCED INTESTINAL NEOPLASIA IN THE MOUSE	CELL			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; UNDERLYING QUANTITATIVE TRAITS; MENDELIAN FACTORS; COLORECTAL-CANCER; GENERAL-METHOD; COLON CANCER; LINKAGE MAP; LOCALIZATION; MUTATION; CHROMOSOME-5Q21	Mutations in the human APC gene cause various familial colon cancer syndromes. The Multiple intestinal neoplasia (Min) mouse provides an excellent model for familial colon cancer: it carries a mutant mouse Apc gene and develops many intestinal adenomas. Here, we analyze how this tumor phenotype is dramatically modified by genetic background. We report the genetic mapping of a locus that strongly modifies tumor number in Min/+ animals. This gene, Mom-1 (Modifier of Min-1), maps to distal chromosome 4 and controls about 50% of genetic variation in tumor number in two intraspecific backcrosses. The mapping is supported by a LOD score exceeding 14. Interestingly, Mom-1 lies in a region of synteny conservation with human chromosome 1p35-36, a region of frequent somatic loss of heterozygosity in a variety of human tumors, including colon tumors. These results provide evidence of a major modifier affecting expression of an inherited cancer syndrome.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142; UNIV WISCONSIN,GENET LAB,MADISON,WI 53706; UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706	Massachusetts Institute of Technology (MIT); University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	DIETRICH, WF (corresponding author), MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.				NCI NIH HHS [CA07075] Funding Source: Medline; NHGRI NIH HHS [HG00126, HG00098] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; BISHOP DT, 1984, J CELL PHYSIOL, V3, P63; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BLOOM JL, 1964, J NATL CANCER I, V33, P607; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BULOW S, 1987, DAN MED BULL, V34, P1; BURT RW, 1992, GENETIC BASIS COMMON, P650; CONNEALLY PM, 1985, CYTOGENET CELL GENET, V40, P356, DOI 10.1159/000132186; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH W, 1992, GENETIC MAPS LOCUS M; EIPERS PG, 1991, GENOMICS, V11, P621, DOI 10.1016/0888-7543(91)90069-Q; ELLMEIER W, 1992, EMBO J, V11, P2563, DOI 10.1002/j.1460-2075.1992.tb05321.x; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAMILTON SR, 1989, FAMILIAL ADENOMATOUS, P35; HANSEN MF, 1987, CANCER RES, V47, P5518; HESTON WE, 1951, J NATL CANCER I, V11, P1057; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; KEMP CJ, 1989, P NATL ACAD SCI USA, V86, P7505, DOI 10.1073/pnas.86.19.7505; KENDALL MG, 1983, ADV THEORY STATISTIC, V3; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LANDER ES, 1989, GENETICS, V121, P185; LEISTER I, 1990, CANCER RES, V50, P7232; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; LUONGO C, 1993, GENOMICS, V15, P3, DOI 10.1006/geno.1993.1002; LYNCH HT, 1992, CANCER, V70, P1300, DOI 10.1002/1097-0142(19920901)70:3+<1300::AID-CNCR2820701517>3.0.CO;2-O; LYNCH HT, 1992, DIS COLON RECTUM, V35, P411, DOI 10.1007/BF02049396; MARTH JD, 1986, P NATL ACAD SCI USA, V83, P7400, DOI 10.1073/pnas.83.19.7400; MATTHEW CGP, 1987, NATURE, V328, P524; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MOSER AR, 1993, IN PRESS P NATL ACAD; Nadeau J H, 1991, Mamm Genome, V1 Spec No, pS461, DOI 10.1007/BF00656504; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Ott J., 1991, ANAL HUMAN GENETIC L; PATERSON AH, 1991, GENETICS, V127, P181; PATERSON AH, 1988, NATURE, V335, P721, DOI 10.1038/335721a0; PHILLIPS S, 1984, MOUSE NEWSLETTER, V70, P83; SHAPIRO JR, 1951, CANCER RES, V11, P644; SHEDLOVSKY A, 1993, GENETICS, V134, P1205; SMITHIES O, 1993, TRENDS GENET, V9, P112, DOI 10.1016/0168-9525(93)90204-U; SOMMER SS, 1992, BIOTECHNIQUES, V12, P82; SPIRIO L, 1992, AM J HUM GENET, V51, P92; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Wright S., 1968, EVOLUTION GENETICS P, P373; YANGFENG TL, 1985, AM J HUM GENET, V37, P1117	48	629	637	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					631	639		10.1016/0092-8674(93)90484-8	http://dx.doi.org/10.1016/0092-8674(93)90484-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242739				2022-12-28	WOS:A1993MH74900009
J	HACCARD, O; SARCEVIC, B; LEWELLYN, A; HARTLEY, R; ROY, L; IZUMI, T; ERIKSON, E; MALLER, JL				HACCARD, O; SARCEVIC, B; LEWELLYN, A; HARTLEY, R; ROY, L; IZUMI, T; ERIKSON, E; MALLER, JL			INDUCTION OF METAPHASE ARREST IN CLEAVING XENOPUS-EMBRYOS BY MAP KINASE	SCIENCE			English	Article							ACTIVATED PROTEIN-KINASE; MATURATION-PROMOTING FACTOR; MEIOTIC MATURATION; OOCYTE MATURATION; M-PHASE; TYROSINE PHOSPHORYLATION; ONCOGENE PRODUCT; EGGS; INVITRO; CELLS	The natural arrest of vertebrate unfertilized eggs in second meiotic metaphase results from the activity of cytostatic factor (CSF). The product of the c-mos(xe) proto-oncogene is thought to be a component of CSF and can induce metaphase arrest when injected into blastomeres of two-cell embryos. The c-Mos(xe) protein can directly activate the mitogen-activated protein kinase kinase (MAP kinase kinase) in vitro, leading to activation of MAP kinase. MAP kinase and c-Mos(xe) are active in unfertilized eggs and are rapidly inactivated after fertilization. Microinjection of thiophosphorylated MAP kinase into one blastomere of a two-cell embryo induced metaphase arrest similar to that induced by c-Mos(xe). However, only arrest with c-Mos(xe) was associated with activation of endogenous MAP kinase. These results indicate that active MAP kinase is a component of CSF in Xenopus and suggest that the CSF activity of C-Mos(xe) is mediated by MAP kinase.	UNIV COLORADO,SCH MED,HOWARD HUGHES MED INST,DENVER,CO 80262; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Sarcevic, Boris/0000-0002-8063-1050; Haccard, Olivier/0000-0002-4305-2746	NCI NIH HHS [F32CA0981] Funding Source: Medline; NIGMS NIH HHS [GM26743] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026743] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1991, J BIOL CHEM, V266, P4220; BARRETT CB, 1992, J BIOL CHEM, V267, P4408; BARRETT CB, 1990, MOL CELL BIOL, V10, P4408; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; GABRIELLI BG, 1993, SCIENCE, V259, P1766, DOI 10.1126/science.8456304; GABRIELLI BG, 1992, J BIOL CHEM, V267, P1969; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GERHART JC, 1984, J CELL BIOL, V98, P185; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P266; HACCARD O, 1990, EUR J BIOCHEM, V192, P633, DOI 10.1111/j.1432-1033.1990.tb19270.x; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Masui Y, 1979, Int Rev Cytol, V57, P185, DOI 10.1016/S0074-7696(08)61464-3; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MURRAY AW, 1993, CURR BIOL, V3, P291, DOI 10.1016/0960-9822(93)90182-N; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; ROY L, UNPUB; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SARCEVIC B, IN PRESS J BIOL CHEM; SEGER R, 1992, J BIOL CHEM, V267, P25628; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SHINA N, 1992, EMBO J, V11, P3977; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TONKS NK, 1988, J BIOL CHEM, V263, P6722; VANRENTERGHEM B, 1993, J BIOL CHEM, V268, P19935; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	49	249	254	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1262	1265		10.1126/science.8235656	http://dx.doi.org/10.1126/science.8235656			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	8235656				2022-12-28	WOS:A1993MH32400038
J	BRENNER, S; ELGAR, G; SANDFORD, R; MACRAE, A; VENKATESH, B; APARICIO, S				BRENNER, S; ELGAR, G; SANDFORD, R; MACRAE, A; VENKATESH, B; APARICIO, S			CHARACTERIZATION OF THE PUFFERFISH (FUGU) GENOME AS A COMPACT MODEL VERTEBRATE GENOME	NATURE			English	Article							MAMMALIAN GENOMES; DNA-SEQUENCE; MICROSATELLITES; EVOLUTION	CLONING and sequencing techniques now allow us to characterize genes directly instead of having to deduce their properties from their effects. This new genetics reaches its apotheosis in the plan to obtain the complete DNA sequence of the human genome, but this is far beyond the capacity of present sequencing methods. Small 'model' genomes, such as those of Escherichia coli (4.7 megabases (Mb)1 and yeast (14 Mb)2, or even those of Caenorhabditis elegans (100 Mb) and Drosophila (165 Mb), are better scaled to existing technology. The yeast genome will contain genes with functions common to all eukaryotic cells, and those of simple multicellular organisms may throw light on the genetic specification of more complex functions. However, vertebrates differ in their morphology and development, so the ideal model would be a vertebrate genome of minimum size and complexity but with maximum homology to the human genome. Here we report the characterization of the small genome (400 Mb) of the tetraodontoid fish, Fugu rubripes5. A random sequencing approach supported by gene probing shows that the haploid genome contains 400 Mb of DNA, of which more that 90% is unique. This genome is 7.5 times smaller than the human genome and because it has a similar gene repertoire it is the best model genome for the discovery of human genes.	UNIV CAMBRIDGE, ADDENBROOKES HOSP, SCH CLIN, MRC, MOLEC GENET UNIT, CAMBRIDGE CB2 2QQ, ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	BRENNER, S (corresponding author), UNIV CAMBRIDGE, ADDENBROOKES HOSP, SCH CLIN, DEPT MED, CAMBRIDGE CB2 2QQ, ENGLAND.			Elgar, Greg/0000-0001-7323-1596; Aparicio, Samuel/0000-0002-0487-9599; Venkatesh, Byrappa/0000-0003-3620-0277				AJIOKA JW, 1991, CHROMOSOMA, V100, P459; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BECKMANN JS, 1992, GENOMICS, V12, P627, DOI 10.1016/0888-7543(92)90285-Z; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; HINEGARD.R, 1968, AM NAT, V102, P517, DOI 10.1086/282564; HINEGARDNER R, 1972, AM NAT, V106, P621, DOI 10.1086/282801; KARN J, 1984, GENE, V32, P217, DOI 10.1016/0378-1119(84)90049-0; LANZA F, 1990, J BIOL CHEM, V265, P18098; MOORE SS, 1991, GENOMICS, V10, P654, DOI 10.1016/0888-7543(91)90448-N; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; PARSONS JD, 1992, COMPUT APPL BIOSCI, V8, P461; PIZON V, 1984, EUR J BIOCHEM, V140, P25, DOI 10.1111/j.1432-1033.1984.tb08062.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH CL, 1987, SCIENCE, V236, P1448, DOI 10.1126/science.3296194; STALLINGS RL, 1991, GENOMICS, V10, P807, DOI 10.1016/0888-7543(91)90467-S; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; 1984, PUFFERFISHES AVAILAB	19	488	535	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	1993	366	6452					265	268		10.1038/366265a0	http://dx.doi.org/10.1038/366265a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH325	8232585				2022-12-28	WOS:A1993MH32500063
J	SELLEM, CH; LECELLIER, G; BELCOUR, L				SELLEM, CH; LECELLIER, G; BELCOUR, L			TRANSPOSITION OF A GROUP-II INTRON	NATURE			English	Article							PODOSPORA-ANSERINA; MITOCHONDRIAL PLASMID; RNA; DNA; SENESCENCE; GENE; PROTEIN; INVITRO	AMONG mobile genetic elements, self-splicing introns are of particular interest. They belong to either group I or group II depending on their three-dimensional structure1-3. Homing, the systematic intron invasion of an intronless gene when it encounters its homologous intron-bearing allele, is the only means for intron mobility so far demonstrated4. It depends on the activity of the intron-encoded protein and is very specific for the acceptor site4-7. Intron transposition, the transfer of an intron to a novel site, predicted on the basis of phylogenetic studies8,9 and in vitro reverse-splicing experiments, has been proposed to be responsible for evolutionary intron spreading2,10-14. Here we present results from polymerase chain reaction experiments consistent with transposition of a group II intron. This event is proposed to account for the site-specific deletion in the mitochondrial chromosome of the fungus Podospora anserina that is associated with the premature death syndrome15 and might also be involved in the senescence process16 affecting this species.			BELCOUR, L (corresponding author), CNRS,CTR GENET MOLEC,F-91198 GIF SUR YVETTE,FRANCE.		Lecellier, Gael/D-3782-2009	Lecellier, Gael/0000-0003-3331-6311				AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; BELCOUR L, 1977, MOL GEN GENET, V153, P11, DOI 10.1007/BF01035991; BELCOUR L, 1991, P NATL ACAD SCI USA, V88, P3579, DOI 10.1073/pnas.88.9.3579; BELCOUR L, 1981, CURR GENET, V3, P13, DOI 10.1007/BF00419575; CECH TR, 1985, INT REV CYTOL, V93, P3, DOI 10.1016/S0074-7696(08)61370-4; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CUMMINGS DJ, 1990, CURR GENET, V17, P375, DOI 10.1007/BF00334517; DUJON B, 1989, GENE, V82, P91, DOI 10.1016/0378-1119(89)90034-6; DUJON B, 1986, EXTRACHROMOSOMAL ELE, P5; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JACQUIER A, 1985, CELL, V41, P383, DOI 10.1016/S0092-8674(85)80011-8; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; KUCH U, 1981, CURR GENET, V3, P151; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; MACREADIE IG, 1985, CELL, V41, P395, DOI 10.1016/S0092-8674(85)80012-X; Meunier B, 1990, STRUCTURE FUNCTION B, P169; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1985, CURR GENET, V10, P69, DOI 10.1007/BF00418495; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; MORL M, 1990, CELL, V60, P629, DOI 10.1016/0092-8674(90)90666-3; OSIEWACZ HD, 1984, CURR GENET, V8, P299, DOI 10.1007/BF00419728; RIZET G, 1953, CR HEBD ACAD SCI, V237, P8328; SAINSARDCHANET A, 1990, NUCLEIC ACIDS RES, V18, P779, DOI 10.1093/nar/18.4.779; SAISARTCHANET A, IN PRESS J MOL BIOL; SCHMIDT U, 1900, EMBO J, V9, P2289; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9; WRIGHT RM, 1983, CURR GENET, V7, P457, DOI 10.1007/BF00377611; WRIGHT RM, 1982, CELL, V29, P505, DOI 10.1016/0092-8674(82)90167-2	30	103	106	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 11	1993	366	6451					176	178		10.1038/366176a0	http://dx.doi.org/10.1038/366176a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG216	8232558				2022-12-28	WOS:A1993MG21600063
J	MILLS, CM; HILL, SA; MARKS, R				MILLS, CM; HILL, SA; MARKS, R			ALTERED INFLAMMATORY RESPONSES IN SMOKERS	BRITISH MEDICAL JOURNAL			English	Article							SMOKING				MILLS, CM (corresponding author), UNIV HOSP WALES,DEPT DERMATOL,CARDIFF CF4 4XN,WALES.							MILLS CM, 1993, CLIN EXP DERMATOL, V18, P100, DOI 10.1111/j.1365-2230.1993.tb00986.x; MOTLEY RJ, 1987, DIGESTION, V37, P125, DOI 10.1159/000199478; NADLER JL, 1983, LANCET, V1, P1248; PEARSE AD, 1990, INT J COSMETIC SCI, V12, P63, DOI 10.1111/j.1467-2494.1990.tb00521.x; Roth GM, 1944, J AMER MED ASSOC, V125, P761, DOI 10.1001/jama.1944.02850290001001	5	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1993	307	6909					911	911		10.1136/bmj.307.6909.911	http://dx.doi.org/10.1136/bmj.307.6909.911			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB847	8241856	Green Published, Bronze			2022-12-28	WOS:A1993MB84700021
J	LISTOKIN, T				LISTOKIN, T			HES STILL ALIVE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											LISTOKIN, T (corresponding author), NYU MED CTR, 333 E 30TH ST, NEW YORK, NY 10016 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1994	120	2					159	160		10.7326/0003-4819-120-2-199401150-00009	http://dx.doi.org/10.7326/0003-4819-120-2-199401150-00009			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ671	8256975				2022-12-28	WOS:A1994MQ67100009
J	BREWSTER, A				BREWSTER, A			A STUDENTS VIEW OF A MEDICAL TEACHING EXERCISE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note																			0	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1993	329	26					1971	1972		10.1056/NEJM199312233292622	http://dx.doi.org/10.1056/NEJM199312233292622			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM885	8247071				2022-12-28	WOS:A1993MM88500029
J	WILFOND, BS; NOLAN, K				WILFOND, BS; NOLAN, K			NATIONAL POLICY DEVELOPMENT FOR THE CLINICAL-APPLICATION OF GENETIC DIAGNOSTIC TECHNOLOGIES - LESSONS FROM CYSTIC-FIBROSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POPULATION; DISEASE; DISCRIMINATION; ETHICS; DNA	In recognition of the earlier experiences with genetic diagnostic services and in anticipation of a greater potential for genetic testing for presymptomatic disease and disease susceptibility, this article provides an analysis of policy development for cystic fibrosis carrier screening. The deficiencies of relying on an extemporaneous model for health policy development are described. Preferably, an evidentiary model, based on the evaluation of clinical research and incorporating professional and public attention to underlying normative issues, should define the standard of care. Appropriate procedural mechanisms should be established at both state and federal levels to prevent the unnecessary confusion, expense, and personal or social harms likely to result from a completely unrestrained application of developing genetic technologies or continuing ad hoc responses to rapid increases in genetic diagnostic capabilities. A broadly constituted national advisory commission on the ethical, legal, and social implications of the Human Genome Project would provide an important locus for national decision making and may offer an efficient mechanism for implementing the evidentiary model, promoting public involvement at a time when social policy decisions must be made to restructure the health care system to be more sensitive to issues of access, allocation, and costs.	UNIV ARIZONA,ARIZONA HLTH SCI CTR,ARIZONA BIOETH PROGRAM,TUCSON,AZ 85724; UNIV ARIZONA,ARIZONA HLTH SCI CTR,CTR & RESP SCI,TUCSON,AZ 85724; UNIV ARIZONA,ARIZONA HLTH SCI CTR,STEELE MEM CHILDRENS RES CTR,TUCSON,AZ 85724; HASTINGS CTR,BRIARCLIFF MANOR,NY	University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences	WILFOND, BS (corresponding author), UNIV ARIZONA,ARIZONA HLTH SCI CTR,DEPT PEDIAT,1501 N CAMPBELL AVE,TUCSON,AZ 85724, USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000418] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01 HG00418-0] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ABRAM MB, 1984, NEW ENGL J MED, V310, P627, DOI 10.1056/NEJM198403083101005; ANDREWS LB, 1993, ASSESSING GENETIC RI; Annas GJ, 1992, GENE MAPPING USING L, P3; [Anonymous], 1986, HIST THEORY INFORM C; [Anonymous], 1990, CLIN PRACTICE GUIDEL; BEKKER H, 1993, BRIT MED J, V306, P1584, DOI 10.1136/bmj.306.6892.1584; Bessman Samuel P., 1971, HUMAN ASPECTS BIOMED, p[49, 51]; BICK D, 1990, LANCET, V336, P1324, DOI 10.1016/0140-6736(90)93012-E; BIESECKER BB, 1993, JAMA-J AM MED ASSOC, V269, P1970, DOI 10.1001/jama.269.15.1970; BIESECKER L, 1992, AM J HUM GENET, V50, P438; BILLINGS PR, 1992, AM J HUM GENET, V50, P476; BROCK D, 1990, AM J HUM GENET, V47, P164; CARMEN IH, 1992, AM J HUM GENET, V50, P245; CASKEY CT, 1993, JAMA-J AM MED ASSOC, V269, P1986, DOI 10.1001/jama.269.15.1986; CASKEY CT, 1990, AM J HUM GENET, V46, P393; CHILDS B, 1976, AM J HUM GENET, V28, P550; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; ELIAS S, 1992, GENE MAPPING USING L, P186; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; FOST N, 1992, FASEB J, V6, P2813, DOI 10.1096/fasebj.6.10.1634044; GORE A, 1987, J LAW REFORM, V20, P965; HANNA KE, 1993, POLIT LIFE SCI, V12, P205, DOI 10.1017/S0730938400024163; HOLTZMAN NA, 1992, AM J HUM GENET, V50, P457; HOLTZMAN NA, 1992, FASEB J, V6, P2806, DOI 10.1096/fasebj.6.10.1634043; HOLTZMAN NA, 1989, PROCEED CAUTION PRED; Holtzman Neil A., 1980, GENETICS LAW, p[247, 253]; KOLATA G, 1990, NY TIMES, pB7; LAPPE M, 1972, NEW ENGL J MED, V286, P1129; LEVINE C, 1990, MILBANK Q, V68, P321, DOI 10.2307/3350109; LOBECK C, 1974, PSYCHOSOCIAL ASPECTS; MACCLUER JW, 1991, AM J HUM GENET, V49, P1139; MOERTEL CG, 1993, JAMA-J AM MED ASSOC, V270, P943, DOI 10.1001/jama.270.8.943; NISHIMI RY, 1993, JAMA-J AM MED ASSOC, V269, P1921, DOI 10.1001/jama.269.15.1921; NOLAN K, 1988, HASTINGS CENT REP, V18, P40, DOI 10.2307/3562223; NOLAN K, 1992, HASTINGS CENT REP, V22, pS2, DOI 10.2307/3563030; OSTRER H, 1993, AM J HUM GENET, V52, P565; Reilly P., 1977, GENETICS LAW SOCIAL; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROBERTS L, 1990, SCIENCE, V250, P1076, DOI 10.1126/science.2251497; ROBERTS L, 1990, SCIENCE, V247, P1296, DOI 10.1126/science.2315698; ROBERTS L, 1990, SCIENCE, V247, P17, DOI 10.1126/science.2294585; SCHULMAN JD, 1990, AM J HUM GENET, V47, P470; WALTERS L, 1991, HUM GENE THER, V2, P115, DOI 10.1089/hum.1991.2.2-115; WALTERS L, 1992, GENE MAPPING USING L, P255; WHITTEN CF, 1973, NEW ENGL J MED, V288, P316; WIGGINS S, 1992, NEW ENGL J MED, V327, P1401, DOI 10.1056/NEJM199211123272001; WILFOND BS, 1992, MILBANK Q, V70, P629, DOI 10.2307/3350214; WILFOND BS, 1990, JAMA-J AM MED ASSOC, V263, P2777, DOI 10.1001/jama.263.20.2777; WILFOND BS, 1990, UNPUB CYSTIC FIBROSI; 1993, JAMA-J AM MED ASSOC, V270, P369; 1990, NEW ENGL J MED, V323, P70; 1975, GENETIC SCREENING PR; 1990, SCIENCE, V250, P1514; 1992, GUIDELINES CLIN PRAC; 1992, DESIGNING GENETIC IN; 1992, CYSTIC FIBROSIS DNA; 1991, AM COLLEGE OBSTETRIC; 1982, SPLICING LIFE SOCIAL; 1991, ETHICAL ISSUES CARRI; 1967, PEDIATRICS, V39, P623; 1983, SCREENING COUNSELING; 1992, AM J HUM GENET, V51, P1443	62	85	85	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1993	270	24					2948	2954		10.1001/jama.270.24.2948	http://dx.doi.org/10.1001/jama.270.24.2948			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MM119	8254856				2022-12-28	WOS:A1993MM11900030
J	HAASS, C; SELKOE, DJ				HAASS, C; SELKOE, DJ			CELLULAR PROCESSING OF BETA-AMYLOID PRECURSOR PROTEIN AND THE GENESIS OF AMYLOID BETA-PEPTIDE	CELL			English	Review							ALZHEIMERS-DISEASE; DERIVATIVES; CLEAVAGE; MUTATION; CELLS				HAASS, C (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,SCH MED,BOSTON,MA 02115, USA.							BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DOVEY R, 1993, NEUROREPORT, V4, P1039; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HARDY J, 1992, NAT GENET, V1, P233, DOI 10.1038/ng0792-233; HUNG A, 1994, IN PRESS EMBO J; HUNG AY, 1993, J BIOL CHEM, V268, P22959; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; NORDSTEDT C, 1993, J BIOL CHEM, V268, P608; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	28	739	780	0	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 17	1993	75	6					1039	1042		10.1016/0092-8674(93)90312-E	http://dx.doi.org/10.1016/0092-8674(93)90312-E			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	8261505				2022-12-28	WOS:A1993MM89300001
J	HUANG, XY; MORIELLI, AD; PERALTA, EG				HUANG, XY; MORIELLI, AD; PERALTA, EG			TYROSINE KINASE-DEPENDENT SUPPRESSION OF A POTASSIUM CHANNEL BY THE G-PROTEIN-COUPLED M1-MUSCARINIC ACETYLCHOLINE-RECEPTOR	CELL			English	Article							GLIOMA HYBRID-CELLS; TISSUE-SPECIFIC EXPRESSION; SWISS 3T3 CELLS; MUSCARINIC RECEPTOR; MOLECULAR-BASIS; PHOSPHORYLATION; SUBTYPES; HYDROLYSIS; ACTIVATION; CLONING	Neurotransmitter receptors alter membrane excitability and synaptic efficacy by generating intracellular signals that ultimately change the properties of ion channels. Through expression studies in Xenopus oocytes and mammalian cells, we found that the G protein-coupled m1 muscarinic acetylcholine receptor potently suppresses a cloned delayed rectifier K+ channel through a pathway involving phospholipase C activation and direct tyrosine phosphorylation of the K+ channel. Furthermore, analysis of neuroblastoma cells revealed that a similar tyrosine kinase-dependent pathway links endogenous G protein-coupled receptors to suppression of the native RAK channel. These results suggest a novel mechanism by which neurotransmitters and hormones may regulate a specific type of K+ channel that is widely expressed in the mammalian brain and heart.			HUANG, XY (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA.							AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ASHKENAZI A, 1989, NATURE, V340, P146, DOI 10.1038/340146a0; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; ASHKENAZI A, 1994, IN PRESS CRC HDB REC, V1; BEECH DJ, 1991, P NATL ACAD SCI USA, V88, P652, DOI 10.1073/pnas.88.2.652; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; BROWN DA, 1988, J PHYSIOL-LONDON, V397, P185, DOI 10.1113/jphysiol.1988.sp016995; BROWN DA, 1980, NATURE, V283, P673, DOI 10.1038/283673a0; CATARSI S, 1993, NATURE, V363, P353, DOI 10.1038/363353a0; CATTERALL WA, 1984, SCIENCE, V223, P653, DOI 10.1126/science.6320365; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COLE AE, 1984, J PHYSIOL-LONDON, V352, P173, DOI 10.1113/jphysiol.1984.sp015285; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; DISALVO J, 1993, BIOCHEM BIOPH RES CO, V190, P968, DOI 10.1006/bbrc.1993.1144; ENRIGHT WJ, 1991, FOCUS, V13, P79; FELDER CC, 1989, J BIOL CHEM, V264, P20356; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P1706, DOI 10.1073/pnas.90.5.1706; FORCE T, 1991, J BIOL CHEM, V266, P6650; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HAN HQ, 1991, NATURE, V349, P697, DOI 10.1038/349697a0; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; Hille B., 1992, IONIC CHANNELS EXCIT; HOGER JH, 1991, NEURON, V6, P227, DOI 10.1016/0896-6273(91)90358-7; HUGANIR RL, 1984, P NATL ACAD SCI USA, V81, P6963; Kaczmarek LK, 1987, NEUROMODULATION BIOC; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MALENKA RC, 1986, J NEUROSCI, V6, P475; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MCKINNON D, 1989, J BIOL CHEM, V264, P8230; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NATHANSON NM, 1987, ANNU REV NEUROSCI, V10, P195, DOI 10.1146/annurev.ne.10.030187.001211; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; PAULMICHL M, 1991, P NATL ACAD SCI USA, V88, P7892, DOI 10.1073/pnas.88.17.7892; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; PERNEY TM, 1989, J BIOL CHEM, V264, P7317; PFAFFINGER PJ, 1988, NEURON, V1, P477, DOI 10.1016/0896-6273(88)90178-X; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; REPP H, 1993, P NATL ACAD SCI USA, V90, P3403, DOI 10.1073/pnas.90.8.3403; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; SANDMANN J, 1991, J BIOL CHEM, V266, P6031; SCHAFER S, 1991, PFLUG ARCH EUR J PHY, V418, P581, DOI 10.1007/BF00370575; STANSFELD CE, 1993, NEURON, V10, P639, DOI 10.1016/0896-6273(93)90166-O; STRATTON KR, 1989, P NATL ACAD SCI USA, V86, P2498, DOI 10.1073/pnas.86.7.2498; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TAYLOR P, 1990, PHARMACOL BASIS THER, P122; TREJO J, 1991, J BIOL CHEM, V266, P7876; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	62	258	263	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 17	1993	75	6					1145	1156		10.1016/0092-8674(93)90324-J	http://dx.doi.org/10.1016/0092-8674(93)90324-J			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	8261514				2022-12-28	WOS:A1993MM89300013
J	BOGUSKI, MS; MCCORMICK, F				BOGUSKI, MS; MCCORMICK, F			PROTEINS REGULATING RAS AND ITS RELATIVES	NATURE			English	Review							GTP-BINDING PROTEIN; ADP-RIBOSYLATION FACTOR; GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; CELL-CYCLE GENE; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; ACTIVATING PROTEIN; CDC25 GENE; GERANYLGERANYL TRANSFERASE	GTPases of the Ras superfamily regulate many aspects of cell growth, differentiation and action. Their functions depend on their ability to alternate between inactive and active forms, and on their cellular localization. Numerous proteins affecting the GTPase activity, nucleotide exchange rates and membrane localization of Ras superfamily members have now been identified. Many of these proteins are much larger and more complex than their targets, containing multiple domains capable of interacting with an intricate network of cellular enzymes and structures.	ONOX PHARMACEUT, RICHMOND, CA 94806 USA		BOGUSKI, MS (corresponding author), NIH, NATL LIB MED, NATL CTR BIOTECHNOL INFORMAT, BETHESDA, MD 20894 USA.							AGNEL M, 1992, MOL CELL BIOL, V12, P5111, DOI 10.1128/MCB.12.11.5111; ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; ANDO S, 1992, J BIOL CHEM, V267, P25709; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ANDRES DA, 1993, J BIOL CHEM, V268, P1383; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2019, DOI 10.1093/nar/20.suppl.2019; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BANU TN, 1992, NATURE, V356, P713; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BOGUSKI MS, 1992, NEW BIOL, V4, P408; BOGUSKI MS, 1992, J LIPID RES, V33, P957; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; BOGUSKI MS, 1992, NATURE, V358, P113, DOI 10.1038/358113a0; BOGUSKI MS, 1992, NEW BIOL, V4, P247; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; CHUANG TH, 1993, J BIOL CHEM, V268, P775; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARKE SA, 1992, REV BIOCH, V61, P355; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GEORGE JM, 1992, MOL BRAIN RES, V12, P323, DOI 10.1016/0169-328X(92)90134-W; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GOMEZ R, 1993, BIOCHEM J, V289, P25, DOI 10.1042/bj2890025; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GUTMANN DH, 1993, ONCOGENE, V8, P761; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HANCOCK JF, 1993, EMBO J, V12, P1915, DOI 10.1002/j.1460-2075.1993.tb05840.x; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HART MJ, IN PRESS J BIOL CHEM; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JIANG Y, 1993, NATURE, V366, P84, DOI 10.1038/366084a0; KAHN RA, 1992, FASEB J, V6, P2512, DOI 10.1096/fasebj.6.8.1592203; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KIM JH, 1991, MOL CELL BIOL, V11, P3894, DOI 10.1128/MCB.11.8.3894; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOHL NE, 1991, J BIOL CHEM, V266, P18884; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LECLERC S, 1991, J BIOL CHEM, V266, P17333; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI R, 1993, NATURE, V366, P82, DOI 10.1038/366082a0; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MAYER ML, 1992, J BIOL CHEM, V267, P20589; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MIZOGUCHI A, 1989, BIOCHEM BIOPH RES CO, V162, P1438, DOI 10.1016/0006-291X(89)90835-8; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; MUNDER T, 1992, MOL CELL BIOL, V12, P2091, DOI 10.1128/MCB.12.5.2091; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OHGA N, 1989, BIOCHEM BIOPH RES CO, V163, P1523, DOI 10.1016/0006-291X(89)91153-4; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; OHYA Y, 1991, J BIOL CHEM, V266, P12356; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; ORZAKISADCOCK M, 1993, NATURE, V363, P83; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; PAWSON T, 1988, ONCOGENE, V3, P491; PETITJEAN A, 1990, GENETICS, V124, P797; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, J BIOL CHEM, V266, P10672; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBERGE M, 1992, Trends in Cell Biology, V2, P277, DOI 10.1016/0962-8924(92)90201-W; RON D, 1991, NEW BIOL, V3, P372; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; RUBINFELD B, 1992, MOL CELL BIOL, V12, P4634, DOI 10.1128/MCB.12.10.4634; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHANNON KM, IN PRESS NEW ENGL J; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; TAN TJ, 1991, FEBS LETT, V291, P322, DOI 10.1016/0014-5793(91)81312-V; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; TYERS M, 1989, J CELL BIOCHEM, V40, P133, DOI 10.1002/jcb.240400202; UCHIDA S, 1990, MOL CELL BIOL, V10, P577, DOI 10.1128/MCB.10.2.577; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALDHERR M, 1993, NAT GENET, V3, P193, DOI 10.1038/ng0393-193; WALSORTH NC, 1992, MOL CELL BIOL, V12, P2017; WANG Y, 1991, CELL REGUL, V2, P453, DOI 10.1091/mbc.2.6.453; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WIGLER MH, 1990, NATURE, V346, P696, DOI 10.1038/346696a0; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026; ZAHNER JE, 1993, MOL CELL BIOL, V13, P217, DOI 10.1128/MCB.13.1.217; ZEUZEM S, 1992, P NATL ACAD SCI USA, V89, P6619, DOI 10.1073/pnas.89.14.6619; ZHANG F, IN PRESS J BIOL CHEM; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	127	1789	1835	4	90	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1993	366	6456					643	654		10.1038/366643a0	http://dx.doi.org/10.1038/366643a0			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM265	8259209				2022-12-28	WOS:A1993MM26500059
J	ABBADIE, C; KABRUN, N; BOUALI, F; SMARDOVA, J; STEHELIN, D; VANDENBUNDER, B; ENRIETTO, PJ				ABBADIE, C; KABRUN, N; BOUALI, F; SMARDOVA, J; STEHELIN, D; VANDENBUNDER, B; ENRIETTO, PJ			HIGH-LEVELS OF C-REL EXPRESSION ARE ASSOCIATED WITH PROGRAMMED CELL-DEATH IN THE DEVELOPING AVIAN EMBRYO AND IN BONE-MARROW CELLS IN-VITRO	CELL			English	Article							NF-KAPPA-B; DNA-BINDING SUBUNIT; V-REL; RETICULOENDOTHELIOSIS VIRUS; GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVATION; HEMATOPOIETIC-CELLS; PROTEIN COMPLEXES; LYMPHOID-CELLS; MESSENGER-RNAS	To determine the physiological processes in which the transcription factor c-Rel may act, we have examined its pattern of expression in the avian embryo by in situ hybridization. These studies showed that c-rel is expressed ubiquitously at low levels and at high levels in isolated cells undergoing programmed cell death by apoptosis or autophagocytosis. To further establish a functional link between expression of c-rel and cell death, we examined the biological consequences of c-rel overexpression in vitro. In primary avian fibroblasts, overexpression of c-rel leads to transformation and dramatic life span extension. In contrast, bone marrow cells expressing high levels of c-rel undergo a process of programmed cell death displaying features of both apoptosis and autophagocylic cell death. Thus, these experiments suggest a critical role for c-rel not only in the control of cell proliferation, but also in the induction of cell death.	UNIV LILLE 1, BIOL DEV LAB, F-59655 VILLENEUVE DASCQ, FRANCE; SUNY STONY BROOK, DEPT MICROBIOL, STONY BROOK, NY 11794 USA	Universite de Lille - ISITE; Universite de Lille; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	ABBADIE, C (corresponding author), INST PASTEUR, ONCOL MOLEC LAB, CNRS, UNITE RECH ASSOCIEE 1160, 1 RUE CALMETTE, F-59019 LILLE, FRANCE.		ABBADIE, Corinne/F-4949-2018	ABBADIE, Corinne/0000-0002-8174-2393	NCI NIH HHS [5T32CA09176, CA51792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051792, T32CA009176] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BARTH CF, 1988, J EXP MED, V167, P89, DOI 10.1084/jem.167.1.89; BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BREWTON RG, 1988, DEV BIOL, V126, P327, DOI 10.1016/0012-1606(88)90142-X; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DAVIS JN, 1990, ONCOGENE, V5, P1109; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FRANKLIN RB, 1977, VIROLOGY, V83, P313, DOI 10.1016/0042-6822(77)90176-3; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GRUMONT RJ, 1990, CELL GROWTH DIFFER, V1, P345; GRUMONT RJ, 1990, ONCOGENE RES, V5, P245; HANNINK M, 1990, ONCOGENE, V5, P1843; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HAYAT MA, 1973, ELECTRON MICROSCOPY, V1; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; HINCHLIFFE JR, 1973, J EMBRYOL EXP MORPH, V30, P753; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HURLE JM, 1986, J EMBRYOL EXP MORPH, V94, P231; HYAT MA, 1974, ELECTRON MICROSCOPY; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOCHEL T, 1991, ONCOGENE, V6, P615; KOCHEL T, 1992, ONCOGENE, V7, P567; LARSEN J, 1992, ONCOGENE, V7, P1903; LASTER SM, 1988, J IMMUNOL, V141, P2629; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; Lucas AM, 1961, AGR MONOGRAPH, V25; MACCABE JA, 1991, J EXP ZOOL, V257, P208, DOI 10.1002/jez.1402570209; MOORE BE, 1989, ONCOGENE, V4, P845; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1989, ONCOGENE, V4, P677; MORRISON LE, 1992, ONCOGENE, V7, P1137; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OPPENHEIM RW, 1988, SCIENCE, V240, P919, DOI 10.1126/science.3363373; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; QUEVA C, 1992, DEVELOPMENT, V114, P125; REDDY EPA, 1988, ONCOGENE HDB; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; ROSL F, 1992, NUCLEIC ACIDS RES, V20, P5243, DOI 10.1093/nar/20.19.5243; ROWE DA, 1982, DEV BIOL, V93, P83, DOI 10.1016/0012-1606(82)90241-X; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SIMEK S, 1988, ONCOGENE RES, V2, P103; STEWARD R, 1985, COLD SPRING HARB SYM, V50, P223, DOI 10.1101/SQB.1985.050.01.028; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; TOMEI LD, 1991, APOPTOSIS MOL BASIS; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCKER DS, 1987, NATURE, V327, P62, DOI 10.1038/327062a0; WILLIAMS DE, 1992, DEV BIOL, V151, P368, DOI 10.1016/0012-1606(92)90176-H; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112	76	222	224	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 3	1993	75	5					899	912		10.1016/0092-8674(93)90534-W	http://dx.doi.org/10.1016/0092-8674(93)90534-W			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252626				2022-12-28	WOS:A1993MK96600010
J	KREK, W; LIVINGSTON, DM; SHIRODKAR, S				KREK, W; LIVINGSTON, DM; SHIRODKAR, S			BINDING TO DNA AND THE RETINOBLASTOMA GENE-PRODUCT PROMOTED BY COMPLEX-FORMATION OF DIFFERENT E2F FAMILY MEMBERS	SCIENCE			English	Article							TRANSCRIPTION FACTOR E2F; CELL-CYCLE; SUSCEPTIBILITY GENE; PROTEIN; PHOSPHORYLATION; IDENTIFICATION; CLONING	The E2F family of transcription factors functions in the control of the mammalian cell cycle. Here it is shown that two family members, E2F-1 and DP-1, form specific heterodimers in vivo, a process that enhances DNA binding, transactivation, and the binding of the retinoblastoma gene product. These results suggest that heterodimerization regulates E2F function and contributes to cell cycle control.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School								Ausubel F, 1990, CURRENT PROTOCOLS MO, V1; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GINSBERG DM, UNPUB; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P35; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KREK W, UNPUB; LEES J, IN PRESS MOL CELL BI; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; NEVINS JR, 1992, SCIENCE, V258, P424; Qin X., UNPUB; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SHIRODKAR S, UNPUB	27	244	253	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 3	1993	262	5139					1557	1560		10.1126/science.8248803	http://dx.doi.org/10.1126/science.8248803			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK329	8248803				2022-12-28	WOS:A1993MK32900036
J	WILSON, GF; KACZMAREK, LK				WILSON, GF; KACZMAREK, LK			MODE-SWITCHING OF A VOLTAGE-GATED CATION CHANNEL IS MEDIATED BY A PROTEIN KINASE-A REGULATED TYROSINE PHOSPHATASE	NATURE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; BAG CELL NEURONS; ION CHANNELS; ABDOMINAL-GANGLION; APLYSIA; PHOSPHORYLATION; EXPRESSION; AFTERDISCHARGE; MODULATION; CD45	Tyrosine kinases and tyrosine phosphatases are abundant in central nervous system tissue, yet the role of these enzymes in the modulation of neuronal excitability is unknown. Patch-clamp studies of an Aplysia voltage-gated cation channel now demonstrate that a tyrosine phosphatase endogenous to excised patches determines both the gating mode of the channel and the response of the channel to protein kinase A. Moreover, a switch in gating modes similar to that triggered by the phosphatase occurs at the onset of a prolonged change in the excitability of Aplysia bag cell neurons.	YALE UNIV,DEPT PHARMACOL,NEW HAVEN,CT 06510	Yale University								ALEXANDER D R, 1990, New Biologist, V2, P1049; ALONSO A, 1989, NATURE, V342, P175, DOI 10.1038/342175a0; BYRNE JH, 1993, ADV SEC MESS PHOSPH, V27, P47; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; GREEN DJ, 1983, NATURE, V306, P784, DOI 10.1038/306784a0; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HELLER E, 1980, P NATL ACAD SCI-BIOL, V77, P2328, DOI 10.1073/pnas.77.4.2328; Hille B., 1992, IONIC CHANNELS EXCIT; HOEHN K, 1993, NEURON, V10, P543, DOI 10.1016/0896-6273(93)90341-N; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; KACZMAREK LK, 1981, J NEUROSCI, V1, P626; KACZMAREK LK, 1978, P NATL ACAD SCI USA, V75, P5200, DOI 10.1073/pnas.75.10.5200; KACZMAREK LK, 1979, J NEUROBIOL, V10, P535, DOI 10.1002/neu.480100604; Kaczmarek LK, 1987, NEUROMODULATION BIOC; KAUER JA, 1985, J NEUROSCI, V5, P1339; KRAMER RH, 1990, NEURON, V2, P335; KUPFERMANN I, 1970, J NEUROPHYSIOL, V33, P865, DOI 10.1152/jn.1970.33.6.865; LEVITAN IB, 1985, J MEMBRANE BIOL, V87, P177, DOI 10.1007/BF01871217; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P171, DOI 10.1113/jphysiol.1980.sp013357; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P21551; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; OSTERGAARD HL, 1991, SCIENCE, V253, P1423, DOI 10.1126/science.1654595; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PARTRIDGE LD, 1987, PFLUG ARCH EUR J PHY, V410, P627, DOI 10.1007/BF00581323; REINHART PH, 1991, J NEUROSCI, V11, P1627; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; SIGWORTH FJ, 1983, SINGLE CHANNEL RECOR, P301; STRAFSTROM CE, 1985, NEUROPHYSIOL, V53, P153; STRONG JA, 1987, NATURE, V325, P714, DOI 10.1038/325714a0; SUGANUMA M, 1992, TOXICON, V30, P873, DOI 10.1016/0041-0101(92)90385-I; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WEST JW, 1991, SCIENCE, V254, P866, DOI 10.1126/science.1658937; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; ZANDER NF, 1991, BIOCHEMISTRY-US, V30, P6964, DOI 10.1021/bi00242a022	40	112	113	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 2	1993	366	6454					433	438		10.1038/366433a0	http://dx.doi.org/10.1038/366433a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK098	8247151				2022-12-28	WOS:A1993MK09800054
J	WELCH, PJ; WANG, JYJ				WELCH, PJ; WANG, JYJ			A C-TERMINAL PROTEIN-BINDING DOMAIN IN THE RETINOBLASTOMA PROTEIN REGULATES NUCLEAR C-ABL TYROSINE KINASE IN THE CELL-CYCLE	CELL			English	Article							E2F TRANSCRIPTION FACTOR; LARGE T-ANTIGEN; GENE-PRODUCT; SUSCEPTIBILITY GENE; CDC2 KINASE; ESCHERICHIA-COLI; FUSION PROTEINS; HUMAN LEUKEMIAS; RB GENE; PHOSPHORYLATION	The ubiquitously expressed c-Abl tyrosine kinase is localized to the nucleus and binds to DNA. The DNA binding activity is regulated by cdc2-mediated phosphorylation, suggesting a cell cycle function for c-Abl. Here we show that the tyrosine kinase activity of nuclear c-Abl is regulated in the cell cycle through a specific interaction with the retinoblastoma protein (RB). A domain in the C-terminus of RB, outside of the A/B pocket, binds to the ATP-binding lobe of the c-Abl tyrosine kinase, resulting in kinase inhibition. The RB-cAbl interaction is not affected by the viral oncoproteins that bind to RB. Hyperphosphorylation of RB correlates with release of c-Abl and activation of the tyrosine kinase in S phase cells. The nuclear c-Abl tyrosine kinase can enhance transcription, and this activity is inhibited by RB. Nuclear c-Abl is an S phase-activated tyrosine kinase that may participate directly in the regulation of transcription.	UNIV CALIF SAN FRANCISCO,CTR MOLEC GENET,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	WELCH, PJ (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOL,SAN FRANCISCO,CA 94143, USA.				NCI NIH HHS [CA58320, CA43054, R01 CA043054, R01 CA058320] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058320, R37CA043054, R01CA043054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BASKARAN R, 1993, IN PRESS P NATL ACAD; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DAHMUS ME, 1992, TRANSCRIPTIONAL REGU, P109; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN J, 1981, J MOL BIOL, V152, P663, DOI 10.1016/0022-2836(81)90122-4; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAMEL PA, 1993, FASEB J, V7, P846, DOI 10.1096/fasebj.7.10.8344484; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSEN MF, 1990, CANCER GENET CYTOGEN, V49, P15, DOI 10.1016/0165-4608(90)90159-8; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1992, DNA CELL BIOL, V11, P539, DOI 10.1089/dna.1992.11.539; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEE EYHP, 1988, P NATL ACAD SCI USA, V85, P6017, DOI 10.1073/pnas.85.16.6017; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LIN BTY, 1992, CIBA F SYMP, V170, P227; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RICHARDSON JM, 1987, CANCER RES, V47, P4066; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG JYJ, 1982, J BIOL CHEM, V257, P13181; WANG JYJ, 1992, BIOCHIM BIOPHYS ACTA, V1114, P179, DOI 10.1016/0304-419X(92)90014-P; WANG JYJ, 1988, ONCOGENE RES, V3, P293; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WEINBERG RA, 1992, CANCER SURV, V12, P43; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	75	378	390	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					779	790		10.1016/0092-8674(93)90497-E	http://dx.doi.org/10.1016/0092-8674(93)90497-E			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242749	Bronze			2022-12-28	WOS:A1993MH74900022
J	LORCA, T; CRUZALEGUI, FH; FESQUET, D; CAVADORE, JC; MERY, J; MEANS, A; DOREE, M				LORCA, T; CRUZALEGUI, FH; FESQUET, D; CAVADORE, JC; MERY, J; MEANS, A; DOREE, M			CALMODULIN-DEPENDENT PROTEIN KINASE-II MEDIATES INACTIVATION OF MPF AND CSF UPON FERTILIZATION OF XENOPUS EGGS	NATURE			English	Article							LIGHT CHAIN KINASE; PROTOONCOGENE PRODUCT; LIMITED PROTEOLYSIS; SKELETAL-MUSCLE; MEIOTIC ARREST; ACTIVATION; CALCIUM; CYCLIN; DEGRADATION; OOCYTES	IN vertebrates, unfertilized eggs are arrested at second meiotic metaphase by a cytostatic factor (CSF)1, an essential component of which is the product of the c-mos proto-oncogene2. CSF prevents ubiquitin-dependent degradation of mitotic cyclins and thus inactivation of the M phase-promoting factor (MPF)3,4. Fertilization or parthenogenetic activation triggers a transient increase in the cytoplasmic free Ca2+ (reviewed in refs 5 and 6), inactivates both CSF and MPF, and releases eggs from meiotic metaphase arrest7-10. A calmodulin-dependent process is required for cyclin degradation to occur in cell-free extracts prepared from metaphase II-arrested eggs (CSF extracts) when the free Ca2+ concentration is transiently raised in the physiological micromolar range10. Here we show that when a constitutively active mutant of calmodulin-dependent protein kinase II (CaM K(II)) is added to a CSF extract, cyclin degradation and Cdc2 kinase inactivation occur even in the absence of Ca2+, and the extract loses its ability to cause metaphase arrest when transferred into embryos. Furthermore, specific inhibitors of CaM K(II) prevent cyclin degradation after calcium addition. Finally, the direct microinjection of constitutively active CaM K(II) into unfertilized eggs inactivates Cdc2 kinase and CSF, even in the absence of a Ca2+ transient. The target for Ca2+-calmodulin is thus CaM K(II).	INSERM, F-34100 MONTPELLIER, FRANCE; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA; DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Baylor College of Medicine; Duke University	LORCA, T (corresponding author), CNRS, BP 5051, F-34033 MONTPELLIER, FRANCE.		Fesquet, didier/M-9750-2019; Fesquet, Didier/A-1490-2009	Fesquet, didier/0000-0001-5657-9689; Lorca, Thierry/0000-0003-2007-8924				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; CHEUNG WY, 1971, J BIOL CHEM, V246, P2859; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; DEPAOLIROACH AA, 1979, FEBS LETT, V105, P321, DOI 10.1016/0014-5793(79)80639-0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; JAFFE LF, 1983, DEV BIOL, V99, P265, DOI 10.1016/0012-1606(83)90276-2; LABBE JC, 1991, METHOD ENZYMOL, V200, P291; LORCA T, 1991, EMBO J, V10, P2087, DOI 10.1002/j.1460-2075.1991.tb07741.x; LORCA T, 1992, J CELL SCI, V102, P55; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MEYERHOF PG, 1977, DEV BIOL, V61, P214, DOI 10.1016/0012-1606(77)90293-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NIGGLI V, 1981, J BIOL CHEM, V256, P8588; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; PAUSCH MH, 1991, EMBO J, V10, P1511, DOI 10.1002/j.1460-2075.1991.tb07671.x; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SCHULMAN H, 1989, TRENDS BIOCHEM SCI, V14, P62, DOI 10.1016/0968-0004(89)90045-5; SMITH MK, 1990, J BIOL CHEM, V265, P1837; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; WANGH LJ, 1989, J CELL SCI, V93, P1; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0; WEBER M, 1991, DEV BIOL, V148, P393, DOI 10.1016/0012-1606(91)90347-6; WOODGETT JR, 1983, EUR J BIOCHEM, V136, P481, DOI 10.1111/j.1432-1033.1983.tb07766.x	29	405	412	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	1993	366	6452					270	273		10.1038/366270a0	http://dx.doi.org/10.1038/366270a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH325	8232587				2022-12-28	WOS:A1993MH32500065
J	BRESSLER, SL; COPPOLA, R; NAKAMURA, R				BRESSLER, SL; COPPOLA, R; NAKAMURA, R			EPISODIC MULTIREGIONAL CORTICAL COHERENCE AT MULTIPLE FREQUENCIES DURING VISUAL TASK-PERFORMANCE	NATURE			English	Article							OSCILLATORY NEURONAL RESPONSES; CORTEX; CAT; SYNCHRONIZATION; MONKEY; PATTERNS; STRIATE	THE way in which the brain integrates fragmentary neural events at multiple locations to produce unified perceptual experience and behaviour is called the binding problem1,2. Binding has been proposed to involve correlated activity at different cortical sites during perceptuomotor behaviour3-5, particularly by synchronization of narrow-band oscillations in the gamma-frequency range (30-80 Hz)6,7. In the rabbit olfactory system, inhalation induces increased gamma-correlation between sites in olfactory bulb and cortex8. In the cat visual system, coherent visual stimuli increase gamma-correlation between sites in both the same and different visual cortical areas9-12. In monkeys, some groups have found that gamma-ocillations transiently synchronize within striate cortex13, superior temporal sulcus14 and somatosensorimotor cortex15,16. Others have report that visual stimuli produce increased broad-band power, but not gamma-oscillations, in several visual cortical areas17,18. But the absence of narrow-band oscillations in itself does not disprove inter-regional synchronization, which may be a broad-band phenomenon. We now describe episodes of increased broad-band coherence among local field potentials from sensory, motor and higher-order cortical sites of macaque monkeys performing a visual discrimination task. Widely distributed sites become coherent without involving other interverting sites. Spatially selective multiregional cortical binding, in the form of broad-band synchronization, may thus play a role in primate perceptuomotor behaviour.	ST ELIZABETH HOSP,NIMH,CTR NEUROSCI,WASHINGTON,DC 20032; NIMH,NEUROPSYCHOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	BRESSLER, SL (corresponding author), FLORIDA ATLANTIC UNIV,CTR COMPLEX SYST,BOCA RATON,FL 33431, USA.			Nakamura, Richard/0000-0002-7846-6017; Coppola, Richard/0000-0003-0273-0675				Abeles M., 1982, LOCAL CORTICAL CIRCU; BRESSLER SL, 1993, COMPUTATION AND NEURAL SYSTEMS, P515; BRESSLER SL, 1990, TRENDS NEUROSCI, V13, P161, DOI 10.1016/0166-2236(90)90039-D; BRESSLER SL, 1987, BRAIN RES, V409, P285, DOI 10.1016/0006-8993(87)90713-X; Crick F., 1990, Seminars in the Neurosciences, V2, P263; Damasio AR, 1989, NEURAL COMPUT, V1, P123, DOI 10.1162/neco.1989.1.1.123; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; ENGEL AK, 1992, TRENDS NEUROSCI, V15, P218, DOI 10.1016/0166-2236(92)90039-B; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P6048, DOI 10.1073/pnas.88.14.6048; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; FREEMAN WJ, 1987, BRAIN RES, V422, P267, DOI 10.1016/0006-8993(87)90933-4; GEVINS AS, 1987, SCIENCE, V235, P580, DOI 10.1126/science.3810158; GLASER EM, 1976, PRINCIPLES NEUROBIOL, P168; GRAY CM, 1992, VISUAL NEUROSCI, V8, P337, DOI 10.1017/S0952523800005071; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; GREVINS AS, 1988, FUNCTIONAL BRAIN IMA, P99; KREITER AK, 1992, EUR J NEUROSCI, V4, P369, DOI 10.1111/j.1460-9568.1992.tb00884.x; Livanov M.N., 1977, SPATIAL ORG CEREBRAL; MURTHY VN, 1992, P NATL ACAD SCI USA, V89, P5670, DOI 10.1073/pnas.89.12.5670; PFURTSCHELLER G, 1992, NEUROREPORT, V3, P1057, DOI 10.1097/00001756-199212000-00006; SANES JN, 1993, P NATL ACAD SCI USA, V90, P4470, DOI 10.1073/pnas.90.10.4470; SHEER DE, 1970, MOLECULAR MECHANISMS, P177; SINGER WA, 1993, REV PHYSL, V55, P349; TOVEE MJ, 1992, NEUROREPORT, V3, P369, DOI 10.1097/00001756-199204000-00020; VONDERMALSBURG C, 1986, BIOL CYBERN, V54, P29, DOI 10.1007/BF00337113; YOUNG MP, 1992, J NEUROPHYSIOL, V67, P1464, DOI 10.1152/jn.1992.67.6.1464	26	378	382	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 11	1993	366	6451					153	156		10.1038/366153a0	http://dx.doi.org/10.1038/366153a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG216	8232553				2022-12-28	WOS:A1993MG21600056
J	GILLARD, JH; DENT, THS; AARONS, EJ; CRIMLISK, HL; SMYTHPIGOTT, PJ; NICHOLLS, MWN				GILLARD, JH; DENT, THS; AARONS, EJ; CRIMLISK, HL; SMYTHPIGOTT, PJ; NICHOLLS, MWN			PREREGISTRATION HOUSE OFFICERS IN THE THAMES REGIONS - CHANGES IN QUALITY OF TRAINING AFTER 4 YEARS	BRITISH MEDICAL JOURNAL			English	Article							EXPERIENCE	Objective-To measure changes in the training and workload of preregistration house officers over four years. Design-Postal questionnaire. Setting-The Thames health regions. Participants-1049 preregistration house officers. Results-Response rate was 69% (725 replies). The proportion of house officers officially on duty > 83 hours a week fell from at least 42% to 21%, and the proportion officially on duty less-than-or-equal-to 72 hours rose from no more than 9% to 40%. Adequate guidance in breaking bad news increased from 25% to 46% (p<0.0001; 95% confidence interval for difference, 16.2% to 25.8%) and guidance in pain control increased from 36% to 46% (p < 0.01; 5.0% to 15.0%). The number of house officers attending an induction course increased from 61% to 94% (p < 0.001; 28.9% to 37.1%). There was no change in the proportion unable to attend formal educational sessions because of clinical commitments or in levels of satisfaction with consultants' educational supervision. The median number of inpatients under house officers' care fell from 20 to 17, but the numbers of patients clerked in an average week showed little change. House officers were less satisfied with the clinical experience their post provided (proportion dissatisfied rose from 30% to 39%; p<0.01; 4.2% to 13.8%) and less enthusiastic about recommending their post to a friend (proportion neutral or not recommending rose from 30% to 42%, p < 0.0001; 7.9% to 16.9%). Conclusion-Despite progress in reducing hours of duty and providing induction courses, the training that hospitals and consultants provide for house officers is still unsatisfactory and inconsistent with the General Medical Council's recommendations.	FULBOURNE HOSP,DEPT PUBL HLTH MED,CAMBRIDGE CB1 5EF,ENGLAND; JOHNS HOPKINS UNIV HOSP,DIV NEURORADIOL,BALTIMORE,MD 21287; MONSALL HOSP,MANCHESTER M10 8WR,ENGLAND; MAUDSLEY HOSP & INST PSYCHIAT,LONDON SE5 8AZ,ENGLAND; BETHLEM ROYAL & MAUDSLEY HOSP,LONDON SE5 8AZ,ENGLAND; BRITISH POSTGRAD MED FEDERAT,LONDON WC1N 3EJ,ENGLAND; JOHNS HOPKINS UNIV HOSP,DEPT NEUROL,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins Medicine; South London & Maudsley NHS Trust; University of London; King's College London; South London & Maudsley NHS Trust; University of London; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University				Crimlisk, Helen/0000-0003-0448-4850				CALMAN KC, 1991, MED EDUC, V25, P51, DOI 10.1111/j.1365-2923.1991.tb00026.x; DENT THS, 1990, BRIT MED J, V300, P713, DOI 10.1136/bmj.300.6726.713; GALE R, 1992, BRIT MED J, V304, P1619, DOI 10.1136/bmj.304.6842.1619; GARRUD P, 1990, BRIT MED J, V300, P445, DOI 10.1136/bmj.300.6722.445; MARTEAU TM, 1990, BRIT MED J, V300, P849, DOI 10.1136/bmj.300.6728.849; 1987, RECOMMENDATIONS GENE; 1991, JUNIOR DOCTORS NEW D; 1992, RECOMMENDATIONS GENE; 1990, PREREGISTRATION YEAR	9	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1993	307	6913					1176	1179		10.1136/bmj.307.6913.1176	http://dx.doi.org/10.1136/bmj.307.6913.1176			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF824	8251843	Green Published, Bronze			2022-12-28	WOS:A1993MF82400021
J	NGUYEN, T; SAMBROOK, P; KELLY, P; JONES, G; LORD, S; FREUND, J; EISMAN, J				NGUYEN, T; SAMBROOK, P; KELLY, P; JONES, G; LORD, S; FREUND, J; EISMAN, J			PREDICTION OF OSTEOPOROTIC FRACTURES BY POSTURAL INSTABILITY AND BONE-DENSITY	BRITISH MEDICAL JOURNAL			English	Article							MINERAL DENSITY; HIP FRACTURE; NORMAL WOMEN; FALLS; RISK; POPULATION; AGE; COMMUNITY; PEOPLE; SWAY	Objective-To investigate the utility of risk factors such as bone mineral density, lifestyle, and postural stability in the prediction of osteoporotic fractures. Design-Longitudinal, epidemiological, and population based survey. Setting-City of Dubbo, New South Wales. Subjects-All residents of Dubbo aged greater-than-or-equal-to 60 on 1 January 1989. Main outcome measure-Incidence of fracture for individual subjects. Results-The overall incidence of atraumatic fractures in men and women was 1.9% and 3.1% per annum respectively. The predominant sites of fracture were hip (18.9%), distal radius (18.5%), ribs and humerus (11.9% in each case), and ankle and foot (9.1% and 6.6% respectively). Major predictors of fractures in men and women were femoral neck bone mineral density, body sway, and quadriceps strength. Age, years since menopause, height, weight, and lifestyle factors were also correlated with bone mineral density and body sway and hence were indirect risk factors for fracture. Discriminant function analysis correctly identified 96% and 93% (sensitivities 88% and 81%) of men and women, respectively, who subsequently developed atraumatic fractures. Predictions based on this model indicated that a woman with a bone mineral density in the lowest quartile in the hip together with high body sway had a 8.4% probability of fracture per annum. This represented an almost 14-fold increase in risk of fracture compared with a woman in the highest bone mineral density quartile with low postural sway. An individual with all three predictors in the ''highest risk'' quartile had a 13.1% risk of fracture per annum. Conclusions-Bone mineral density, body sway, and muscle strength are independent and powerful synergistic predictors of fracture incidence.	UNIV NEW S WALES,SCH COMMUNITY MED,KENSINGTON,NSW 2033,AUSTRALIA; ST VINCENTS HOSP,DEPT NUCL MED,SYDNEY,NSW 2010,AUSTRALIA	University of New South Wales Sydney; St Vincents Hospital Sydney	NGUYEN, T (corresponding author), ST VINCENTS HOSP,GARVAN INST MED RES,DIV BONE & MINERAL RES,DARLINGHURST,NSW 2010,AUSTRALIA.		Nguyen, Tuan V/B-6147-2008; Eisman, John A/C-2886-2014; Lord, Stephen R/C-9612-2011; Nguyen, Tuan V./AAD-9503-2020	Nguyen, Tuan V/0000-0002-3246-6281; Nguyen, Tuan V./0000-0002-3246-6281; Lord, Stephen R/0000-0002-7111-8802				ANGUS R, 1989, BONE MINER, V4, P265; ANGUS RM, 1989, J AM DIET ASSOC, V89, P209; BLAKE AJ, 1988, AGE AGEING, V17, P365, DOI 10.1093/ageing/17.6.365; BROCKLEHURST JC, 1982, AGE AGEING, V11, P1, DOI 10.1093/ageing/11.1.1; COOPER AP, 1824, TREATISE DISLOCATION; COOPER C, 1991, OSTEOPOROSIS INT, V2, P48, DOI 10.1007/BF01627079; COOPER C, 1992, J BONE MINER RES, V7, P221, DOI 10.1002/jbmr.5650070214; Cox DR., 1989, ANAL BINARY DATA; CUMMINGS SR, 1989, J GERONTOL, V44, pM107; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DESCHEPPER J, 1991, J NUCL MED, V32, P216; DICHGANS J, 1972, SCIENCE, V178, P1217, DOI 10.1126/science.178.4066.1217; FERNIE GR, 1982, AGE AGEING, V11, P11, DOI 10.1093/ageing/11.1.11; GALLAGHER JC, 1987, J BONE MINER RES, V2, P491; GRISSO JA, 1991, J BONE MINER RES, V6, P865; HAND DJ, 1982, DISCRIMINATION CLASS; HANLEY JA, 1982, RADIOLOGY, V50, P23; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; HERMANDEZAVILA M, 1991, AM J CLIN NUTR, V54, P157; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; KRALL EA, 1991, J BONE MINER RES, V6, P331; LIBANATI CR, 1992, J CLIN ENDOCR METAB, V74, P351, DOI 10.1210/jc.74.2.351; LINDSAY R, 1992, J BONE MINER RES, V7, P55; LORD SR, 1992, GERONTOLOGY, V38, P338, DOI 10.1159/000213351; LORD SR, 1991, J AM GERIATR SOC, V39, P1194, DOI 10.1111/j.1532-5415.1991.tb03574.x; LORD SR, 1991, J GERONTOL, V46, pM57; MAZESS RB, 1990, J BONE MINER RES, V5, P645; MAZESS RB, 1991, AM J CLIN NUTR, V53, P132, DOI 10.1093/ajcn/53.1.132; MELTON LJ, 1986, AM J EPIDEMIOL, V124, P254, DOI 10.1093/oxfordjournals.aje.a114383; MeltonIII L. J., 1988, OSTEOPOROSIS ETIOLOG, P133; POCOCK N, 1989, J BONE MINER RES, V4, P441; POCOCK NA, 1986, J CLIN INVEST, V78, P618, DOI 10.1172/JCI112618; POCOCK NA, 1989, BONE, V10, P329, DOI 10.1016/8756-3282(89)90128-2; Semmes J., 1960, YALE J BIOL MED, V33, P249; SIMONS LA, 1990, AUST NZ J MED, V20, P783, DOI 10.1111/j.1445-5994.1990.tb00423.x; SLEMENDA CW, 1989, J BONE MINER RES, V4, P737, DOI 10.1002/jbmr.5650040513; SNOWHARTER C, 1990, J BONE MINER RES, V5, P589; VANHEMERT AM, 1990, AM J EPIDEMIOL, V132, P123, DOI 10.1093/oxfordjournals.aje.a115624; WASNICH RD, 1985, AM J OBSTET GYNECOL, V153, P745, DOI 10.1016/0002-9378(85)90338-2; 1990, SAS STAT USERS GUIDE	40	486	494	0	21	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1993	307	6912					1111	1115		10.1136/bmj.307.6912.1111	http://dx.doi.org/10.1136/bmj.307.6912.1111			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME918	8251809	Bronze, Green Published			2022-12-28	WOS:A1993ME91800017
J	RAFF, MC; BARRES, BA; BURNE, JF; COLES, HS; ISHIZAKI, Y; JACOBSON, MD				RAFF, MC; BARRES, BA; BURNE, JF; COLES, HS; ISHIZAKI, Y; JACOBSON, MD			PROGRAMMED CELL-DEATH AND THE CONTROL OF CELL-SURVIVAL - LESSONS FROM THE NERVOUS-SYSTEM	SCIENCE			English	Article							GROWTH-FACTOR DEPRIVATION; NEURONAL DEATH; OLIGODENDROCYTE DEVELOPMENT; NEUROTROPHIN RECEPTORS; CAENORHABDITIS-ELEGANS; LIVER HYPERPLASIA; BCL-2 PROTEIN; B-CELLS; APOPTOSIS; RAT	During the development of the vertebrate nervous system, up to 50 percent or more of many types of neurons normally die soon after they form synaptic connections with their target cells. This massive cell death is thought to reflect the failure of these neurons to obtain adequate amounts of specific neurotrophic factors that are produced by the target cells and that are required for the neurons to survive. This neurotrophic strategy for the regulation of neuronal numbers may be only one example of a general mechanism that helps to regulate the numbers of many other vertebrate cell types, which also require signals from other cells to survive. These survival signals seem to act by suppressing an intrinsic cell suicide program, the protein components of which are apparently expressed constitutively in most cell types.	UNIV LONDON UNIV COLL, DEPT BIOL, LONDON WC1E 6BT, ENGLAND	University of London; University College London	RAFF, MC (corresponding author), UNIV LONDON UNIV COLL, MRC, MOLEC CELL BIOL LAB, DEV NEUROBIOL PROGRAMME, LONDON WC1E 6BT, ENGLAND.		Ishizaki, Yasuki/AAB-1209-2020					ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; ALTIN JG, 1992, NEUROTROPHIC FACTORS, P129; ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; ARAKI S, 1990, BIOCHEM BIOPH RES CO, V168, P1194, DOI 10.1016/0006-291X(90)91155-L; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BARRES BA, 1993, CURR BIOL, V3, P489, DOI 10.1016/0960-9822(93)90039-Q; BARRES BA, 1993, DEVELOPMENT, V118, P283; BARRES BA, UNPUB; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BOWEN ID, 1981, DEATH BIOL PATHOLOGY; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; BURSCH W, 1985, VIRCHOWS ARCH B, V50, P153; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHENG B, 1991, NEURON, V7, P1031, DOI 10.1016/0896-6273(91)90347-3; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Clarke P.G.H., 1991, Concepts in Neuroscience, V2, P201; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COHEN S, 1960, P NATL ACAD SCI USA, V46, P302, DOI 10.1073/pnas.46.3.302; COHEN S, 1954, P NATL ACAD SCI USA, V40, P1014, DOI 10.1073/pnas.40.10.1014; COLES HSR, 1993, DEVELOPMENT, V118, P777; COLES HSR, UNPUB; COLUMBANO A, 1985, LAB INVEST, V52, P670; Cowan W.M., 1973, DEV AGING NERVOUS SY, P19; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; Detwiler SR, 1924, J COMP NEUROL, V37, P1, DOI 10.1002/cne.900370102; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; Durken B, 1911, Z WISS ZOOL ABT A, V99, P189; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ERNST MAX, 1926, ZEITSCHR GES ANAT 1 ABT, V79, P228, DOI 10.1007/BF02118264; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GARD AL, 1990, NEURON, V5, P615, DOI 10.1016/0896-6273(90)90216-3; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GLUCKMAN P, 1992, BIOCHEM BIOPH RES CO, V182, P593, DOI 10.1016/0006-291X(92)91774-K; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; GOLDSTEIN P, 1991, IMMUNOL REV, V121, P29; GORIN PD, 1979, P NATL ACAD SCI USA, V76, P5382, DOI 10.1073/pnas.76.10.5382; HAMBURGER V, 1981, J NEUROSCI, V1, P60, DOI 10.1523/JNEUROSCI.01-01-00060.1981; HAMBURGER V, 1992, J NEUROBIOL, V23, P1116, DOI 10.1002/neu.480230904; HAMBURGER V, 1949, J EXP ZOOL, V111, P457, DOI 10.1002/jez.1401110308; HARDY R, 1991, DEVELOPMENT, V111, P1061; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HENGARTNER MO, COMMUNICATION; HOFER MM, 1988, NATURE, V331, P261, DOI 10.1038/331261a0; HUGHES A, 1958, J ANAT, V92, P498; ISHIZAKI Y, 1993, J CELL BIOL, V121, P899, DOI 10.1083/jcb.121.4.899; ISHIZAKI Y, UNPUB; JACOBSON M, 1991, DEV NEUROBIOL, P311; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; JACOBSON MP, UNPUB; JD Biggers, 1971, METHODS MAMMALIAN EM; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KERR JFR, 1973, VIRCHOWS ARCH B, V13, P87; KLINGMAN GERDA I., 1967, INT J NEUROPHARMACOL, V6, P501; KORSCHING S, 1983, P NATL ACAD SCI-BIOL, V80, P3513, DOI 10.1073/pnas.80.11.3513; KORSCHING S, 1993, J NEUROSCI, V13, P2739; KOSEKI C, 1992, J CELL BIOL, V119, P1327, DOI 10.1083/jcb.119.5.1327; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KRYPIANOU N, 1988, ENDOCRINOLOGY, V122, P552; LEDDACOLUMBANO GM, 1989, AM J PATHOL, V135, P657; LEVIMONTALCINI R, 1960, P NATL ACAD SCI USA, V46, P373, DOI 10.1073/pnas.46.3.373; LEVIMONTALCINI R, 1960, P NATL ACAD SCI USA, V46, P384, DOI 10.1073/pnas.46.3.384; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; Martin Seamus J., 1993, Trends in Cell Biology, V3, P141, DOI 10.1016/0962-8924(93)90128-N; MATTSON MP, 1989, J NEUROSCI, V9, P3728; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MCEWEN BS, 1990, BIOCHEM PHARMACOL, V40, P2393, DOI 10.1016/0006-2952(90)90079-Z; MCKINNON RD, 1990, NEURON, V5, P603, DOI 10.1016/0896-6273(90)90215-2; MILLER RH, 1985, DEV BIOL, V111, P35, DOI 10.1016/0012-1606(85)90432-4; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OATES PS, 1986, AM J PHYSIOL, V250, pG9, DOI 10.1152/ajpgi.1986.250.1.G9; OITVAI ZN, 1993, CELL, V74, P609; Oppenheim R. W., 1981, STUDIES DEV NEUROBIO, P74; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; OPPENHEIMER RW, 1992, NATURE, V360, P24; PURVES D, 1988, BODY BRAIN TROPHIC T, P44; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFFIONI S, 1993, ANNU REV BIOCHEM, V62, P823; RICHARDSON WD, 1988, CELL, V53, P309, DOI 10.1016/0092-8674(88)90392-3; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; Saxen L., 1987, ORGANOGENESIS KIDNEY; SELLINS KS, 1991, RADIAT RES, V126, P88, DOI 10.2307/3578175; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHIGENO T, 1991, J NEUROSCI, V11, P2914; SLOVITER RS, 1989, SCIENCE, V243, P535, DOI 10.1126/science.2911756; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TATA JR, 1966, DEV BIOL, V13, P77, DOI 10.1016/0012-1606(66)90050-9; TEMPLE S, 1986, CELL, V44, P773, DOI 10.1016/0092-8674(86)90843-3; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; TSCHAN T, 1990, J CELL BIOL, V111, P257, DOI 10.1083/jcb.111.1.257; TSUJIMOTO Y, 1987, ONCOGENE, V2, P3; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WELLER A, 1991, DEV BIOL, V144, P248, DOI 10.1016/0012-1606(91)90419-4; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112	108	1339	1369	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	1993	262	5134					695	700		10.1126/science.8235590	http://dx.doi.org/10.1126/science.8235590			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	8235590				2022-12-28	WOS:A1993MD95200032
J	ZOLTIE, N; DEDOMBAL, FT				ZOLTIE, N; DEDOMBAL, FT			THE HIT AND MISS OF ISS AND TRISS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRAUMA; AUDIT; CARE	Objective-To measure interobserver variation in recording injury from case notes and its effect on calculating injury severity scores (ISS) from identical data and predicting probabilities of survival by using the combined trauma and injury severity score (TRISS). Design-Observer variation study using injury severity scoring and subsequent calculation of probability of survival based on combined trauma and injury severity scores. Subjects-16 patients with a range of injury severity scores, and 15 observers. Results-There was a wide variation in recorded injury severity scores, the probability of two observers agreeing on the score being 0.28 (28%). The probability of any two observers agreeing over which severity band the patient should be in was 0.5 (50%). Observer variation was independent of the training and type of observer. Survival probability (calculated by combined trauma and injury severity scoring methodology from individual observers' scores) varied by over 0.2 in six of the 16 patients and by over 0.5 in three. Conclusions-There is wide observer variation in injury severity scoring, which highlights a potential fallibility in its use for trauma audit. The use of combined trauma and injury severity scoring for individual prediction of survival is potentially inaccurate except at the extremes of probabilities. The use of the 0.5 survival fine on a combined trauma and injury severity score ''pre-chart'' is statistically and clinically inappropriate.			ZOLTIE, N (corresponding author), UNIV LEEDS, CLIN INFORMAT SCI UNIT, 22 HYDE TERRACE, LEEDS LS2 9LN, W YORKSHIRE, ENGLAND.							BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; BRENNAN P, 1992, BMJ-BRIT MED J, V304, P1491, DOI 10.1136/bmj.304.6840.1491; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; CRAWFORD R, 1991, BRIT J SURG, V78, P1362, DOI 10.1002/bjs.1800781130; DEDOMBAL FT, 1987, GUT, V28, P474, DOI 10.1136/gut.28.4.474; PHAIR IC, 1991, ANN ROY COLL SURG, V73, P53; SAIGER GL, 1982, AM J INTERNAL MED, V56, P860; SCHEFF TJ, 1963, BEHAV SCI, V8, P97; WEINER N, 1956, 3RD P BERK S MATH ST, V3, P247; YATES DW, 1992, BRIT MED J, V305, P737, DOI 10.1136/bmj.305.6856.737; 1988, REPORT WORKING PARTY	11	45	46	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 9	1993	307	6909					906	909		10.1136/bmj.307.6909.906	http://dx.doi.org/10.1136/bmj.307.6909.906			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB847	8241854	Green Published			2022-12-28	WOS:A1993MB84700018
J	VALMAN, HB				VALMAN, HB			ABC OF ONE TO 7 - FEBRILE CONVULSIONS	BRITISH MEDICAL JOURNAL			English	Article									CLIN RES CTR,HARROW HA1 3UJ,MIDDX,ENGLAND		VALMAN, HB (corresponding author), NORTHWICK PK HOSP & CLIN RES CTR,HARROW HA1 3UJ,MIDDX,ENGLAND.								0	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1993	306	6894					1743	1745		10.1136/bmj.306.6894.1743	http://dx.doi.org/10.1136/bmj.306.6894.1743			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK367	8257494	Bronze, Green Published			2022-12-28	WOS:A1993LK36700031
J	JOHNSTON, ME; LANGTON, KB; HAYNES, RB; MATHIEU, A				JOHNSTON, ME; LANGTON, KB; HAYNES, RB; MATHIEU, A			EFFECTS OF COMPUTER-BASED CLINICAL DECISION-SUPPORT SYSTEMS ON CLINICIAN PERFORMANCE AND PATIENT OUTCOME - A CRITICAL-APPRAISAL OF RESEARCH	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-CARE-UNIT; PREDICTIVE INSTRUMENT; WARFARIN THERAPY; AIDED DIAGNOSIS; MEDICAL RECORD; BLOOD-PRESSURE; REMINDERS; MANAGEMENT; TRIAL; HYPERTENSION	Objective: To review the evidence from controlled trials of the effects of computer-based clinical decision support systems (CDSSs) on clinician performance and patient outcomes. Data Sources: The literature in the MEDLARS, EMBASE, SCISEARCH, and INSPEC databases was searched from 1974 to the present. Conference proceedings and reference lists of relevant articles were reviewed. Evaluators of CDSSs were asked to identify additional studies. Study Selection: 793 citations were examined, and 28 controlled trials that met predefined criteria were reviewed in detail. Data Extraction: Study quality was assessed, and data on setting, clinicians and patients, method of allocation, computer system, and outcomes were abstracted and verified using a structured form. Separate summaries were prepared for physician and patient outcomes. Within each of these categories, studies were classified further according to the primary purpose of the CDSS: drug dose determination, diagnosis, or quality assurance. Results: Three of 4 studies of computer-assisted dosing, 1 of 5 studies of computer-aided diagnosis, 4 of 6 studies of preventive care reminder systems, and 7 of 9 studies of computer-aided quality assurance for active medical care that assessed clinician performance showed improvements in clinician performance using a CDSS. Three of 10 studies that assessed patient outcomes reported significant improvements. Conclusions: Strong evidence suggests that some CDSSs can improve physician performance. Additional well-designed studies are needed to assess their effects and cost-effectiveness, especially on patient outcomes.	MCMASTER UNIV, HLTH SCI CTR, ROOM 3H7, 1200 MAIN ST W, HAMILTON L8N 3Z5, ONTARIO, CANADA; MCMASTER UNIV, HLTH SCI CTR, DEPT CLIN EPIDEMIOL & BIOSTAT, HLTH INFORMAT RES UNIT, HAMILTON L8N 3Z5, ONTARIO, CANADA; UNIV CINCINNATI, MED CTR, DEPT ANESTHESIA, CINCINNATI, OH 45267 USA	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; University System of Ohio; University of Cincinnati				Haynes, Robert Brian/0000-0002-1453-3196				BARNETT GO, 1983, MED CARE, V21, P400, DOI 10.1097/00005650-198304000-00003; Breslow N, 1980, STATISTICAL METHODS, V32; BROWNBRIDGE G, 1986, J ROY COLL GEN PRACT, V36, P198; CHASE CR, 1983, MED CARE, V21, P410, DOI 10.1097/00005650-198304000-00004; COE FL, 1977, J CHRON DIS, V30, P81, DOI 10.1016/0021-9681(77)90077-7; DOMBAL FTD, 1974, BRIT MED J, V1, P376, DOI 10.1136/bmj.1.5904.376; GONZALEZ ER, 1989, AM J EMERG MED, V7, P395, DOI 10.1016/0735-6757(89)90046-6; HAYNES RB, 1987, ARCH INTERN MED, V147, P1297, DOI 10.1001/archinte.147.7.1297; Hedges L, 1985, STATISTICAL METHODS; KELLER LS, 1991, 15TH P ANN S COMP AP, P38; MAZOUE JG, 1990, J MED PHILOS, V15, P559, DOI 10.1093/jmp/15.6.559; MCALISTER NH, 1986, BRIT MED J, V293, P670, DOI 10.1136/bmj.293.6548.670; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MCDONALD CJ, 1976, ANN INTERN MED, V84, P162, DOI 10.7326/0003-4819-84-2-162; MCDONALD CJ, 1980, JAMA-J AM MED ASSOC, V244, P1579, DOI 10.1001/jama.244.14.1579; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MCDOWELL I, 1989, J FAM PRACTICE, V28, P420; MCDOWELL I, 1989, MED CARE, V27, P297, DOI 10.1097/00005650-198903000-00008; MCDOWELL I, 1986, CAN MED ASSOC J, V135, P991; MILLER PL, 1986, COMPUT METH PROG BIO, V22, P5; PATERSONBROWN S, 1990, BRIT J SURG, V77, P13, DOI 10.1002/bjs.1800770105; PETRUCCI K, 1991, 15TH P ANN S COMP AP, P43; POZEN MW, 1980, ANN INTERN MED, V92, P238, DOI 10.7326/0003-4819-92-2-238; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; RODMAN JH, 1984, ARCH INTERN MED, V144, P703, DOI 10.1001/archinte.144.4.703; Rogers J L, 1984, QRB Qual Rev Bull, V10, P65; ROGERS JL, 1979, MED CARE, V17, P618, DOI 10.1097/00005650-197906000-00006; ROGERS JL, 1982, MED CARE, V20, P63, DOI 10.1097/00005650-198201000-00005; ROSSER WW, 1992, CAN MED ASSOC J, V146, P911; SHORTLIFFE EH, 1987, JAMA-J AM MED ASSOC, V258, P61, DOI 10.1001/jama.258.1.61; SHORTLIFFE EH, 1984, READINGS MED ARTIFIC, P35; SUTTON GC, 1989, BRIT J SURG, V76, P82, DOI 10.1002/bjs.1800760126; TIERNEY WM, 1988, JAMA-J AM MED ASSOC, V259, P1194, DOI 10.1001/jama.259.8.1194; TIERNEY WM, 1986, MED CARE, V24, P659, DOI 10.1097/00005650-198608000-00001; WELLWOOD J, 1992, ANN ROY COLL SURG, V74, P40; WEXLER JR, 1975, AM J DIS CHILD, V129, P203, DOI 10.1001/archpedi.1975.02120390037008; WHITE KS, 1984, J AM COLL CARDIOL, V4, P571, DOI 10.1016/S0735-1097(84)80104-7; WHITE RH, 1987, J GEN INTERN MED, V2, P141, DOI 10.1007/BF02596140; WHITE RH, 1991, THER DRUG MONIT, V13, P46, DOI 10.1097/00007691-199101000-00006; WYATT J, 1990, MED INFORM, V15, P205, DOI 10.3109/14639239009025268; WYATT J, 1991, 15TH P ANN S COMP AP, P3; WYATT J, 1989, 6TH P WORLD C MED IN, P111; YOUNG DW, 1981, MED INFORM, V6, P13, DOI 10.3109/14639238109017764; 1991, ANN REPORT RES DEV R	44	524	527	0	33	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1994	120	2					135	142		10.7326/0003-4819-120-2-199401150-00007	http://dx.doi.org/10.7326/0003-4819-120-2-199401150-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ671	8256973				2022-12-28	WOS:A1994MQ67100007
J	GUYATT, GH; SACKETT, DL; COOK, DJ				GUYATT, GH; SACKETT, DL; COOK, DJ			USERS GUIDES TO THE MEDICAL LITERATURE .2. HOW TO USE AN ARTICLE ABOUT THERAPY OR PREVENTION .B. WHAT WERE THE RESULTS AND WILL THEY HELP ME IN CARING FOR MY PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRIAL; MORTALITY		MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON L8N 3Z5,ONTARIO,CANADA	McMaster University	GUYATT, GH (corresponding author), MCMASTER UNIV,HLTH SCI CTR,DEPT MED,1200 MAIN ST W,ROOM 2C12,HAMILTON L8N 3Z5,ONTARIO,CANADA.			Bass, Eric/0000-0001-9106-527X; Tugwell, Peter/0000-0001-5062-0556; Gerstein, Hertzel/0000-0001-8072-2836				ALTMAN DG, 1989, STATISTICS CONFIDENC, P83; DETSKY AS, 1985, ARCH INTERN MED, V145, P709, DOI 10.1001/archinte.145.4.709; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; EDDY DM, 1982, NEW ENGL J MED, V307, P343, DOI 10.1056/NEJM198208053070604; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; GUYATT G, 1992, THORAX, V47, P598, DOI 10.1136/thx.47.8.598; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LEVINE MN, 1992, CHEST, V102, pS352, DOI 10.1378/chest.102.4.352S; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P218; 1992, NEW ENGL J MED, V327, P227	13	587	602	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	1994	271	1					59	63		10.1001/jama.271.1.59	http://dx.doi.org/10.1001/jama.271.1.59			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN725	8258890				2022-12-28	WOS:A1994MN72500033
J	CALLAHAN, CM				CALLAHAN, CM			THE GHOST OF SAID	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											CALLAHAN, CM (corresponding author), INDIANA UNIV, SCH MED, INDIANAPOLIS, IN 46202 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1994	120	1					80	81		10.7326/0003-4819-120-1-199401010-00013	http://dx.doi.org/10.7326/0003-4819-120-1-199401010-00013			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP280	8250461				2022-12-28	WOS:A1994MP28000013
J	NISHIMI, RY				NISHIMI, RY			BIOMEDICAL ETHICS IN UNITED-STATES PUBLIC-POLICY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											NISHIMI, RY (corresponding author), OTA,BIOL & BEHAV SCI PROGRAM,WASHINGTON,DC 20510, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1993	270	24					2911	2911		10.1001/jama.270.24.2911	http://dx.doi.org/10.1001/jama.270.24.2911			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MM119	8254841				2022-12-28	WOS:A1993MM11900006
J	BRENNICK, J; DUNCAN, L				BRENNICK, J; DUNCAN, L			IMAGES IN CLINICAL MEDICINE - VULVAR HERPES-SIMPLEX INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											BRENNICK, J (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 9	1993	329	24					1783	1783						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK096	8232487				2022-12-28	WOS:A1993MK09600006
J	KONFORTI, BB; KOZIOLKIEWICZ, MJ; KONARSKA, MM				KONFORTI, BB; KOZIOLKIEWICZ, MJ; KONARSKA, MM			DISRUPTION OF BASE-PAIRING BETWEEN THE 5' SPLICE-SITE AND THE 5' END OF U1 SNRNA IS REQUIRED FOR SPLICEOSOME ASSEMBLY	CELL			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR RIBONUCLEOPROTEIN; JUNCTION SEQUENCES; CLEAVAGE SITE; U6 SNRNA; YEAST; INVITRO; SELECTION; PARTICLES; MUTATIONS	A short RNA oligonucleotide comprising the 51 splice site consensus sequence (5'SS RNA) is sufficient to bind U1 small nuclear ribonucleoprotein particle (snRNP) or to induce the association of U2 snRNP and U4-U5-U6 triple snRNP. Analysis of the requirements of these interactions demonstrates that the 5'SS RNA is recognized independently by at least two different elements during spliceosome assembly: the 51 end of U1 snRNA and a component(s) of the U2-U4-U5-U6 snRNP complex. Since stable 5'SS RNA-U1 snRNA base pairing prevents interaction of the 5SS RNA with U2-U4-U5-U6 snRNP complex, we conclude that disruption of the initial base pairing between the 5'SS RNA and the 5' end of U1 snRNA is required for subsequent spliceosome assembly.			KONFORTI, BB (corresponding author), ROCKEFELLER UNIV, 1230 YORK AVE, NEW YORK, NY 10021 USA.		Konarska, Maria M./AAT-2572-2021; Konarska, Maria/ABG-6405-2020	Konarska, Maria M./0000-0001-9235-1702; Koziolkiewicz, Maria/0000-0003-4628-4566	NIGMS NIH HHS [GM49044] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049044] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; BARABINO SML, 1990, CELL, V63, P293, DOI 10.1016/0092-8674(90)90162-8; BLACK DL, 1986, CELL, V46, P697, DOI 10.1016/0092-8674(86)90345-4; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BRUZIK JP, 1990, CELL, V62, P889, DOI 10.1016/0092-8674(90)90264-F; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENGLAND TE, 1980, NUCLEIC ACIDS, P65; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; FRADIN A, 1984, CELL, V37, P927, DOI 10.1016/0092-8674(84)90427-6; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HALL KB, 1992, P NATL ACAD SCI USA, V89, P10969, DOI 10.1073/pnas.89.22.10969; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KRAMER A, 1984, CELL, V38, P299, DOI 10.1016/0092-8674(84)90551-8; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; Moore M., 1993, RNA WORLD, P303; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NELSON KK, 1990, P NATL ACAD SCI USA, V87, P6253, DOI 10.1073/pnas.87.16.6253; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; OHSHIMA Y, 1987, J MOL BIOL, V195, P247, DOI 10.1016/0022-2836(87)90647-4; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; ROSE JK, 1976, NATURE, V262, P32, DOI 10.1038/262032a0; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SEIWERT SD, 1993, MOL CELL BIOL, V13, P3135, DOI 10.1128/MCB.13.6.3135; SERAPHIN B, 1993, CELL, V73, P803, DOI 10.1016/0092-8674(93)90258-R; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SPROAT BS, 1989, NUCLEIC ACIDS RES, V17, P3373, DOI 10.1093/nar/17.9.3373; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; VANSANTEN VL, 1986, NUCLEIC ACIDS RES, V14, P9911, DOI 10.1093/nar/14.24.9911; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; YUAN ZA, 1987, MOL CELL BIOL, V7, P3018, DOI 10.1128/MCB.7.8.3018; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	46	82	82	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 3	1993	75	5					863	873		10.1016/0092-8674(93)90531-T	http://dx.doi.org/10.1016/0092-8674(93)90531-T			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252623				2022-12-28	WOS:A1993MK96600007
J	VOLOVITZ, B; AMIR, J; MALIK, H; KAUSCHANSKY, A; VARSANO, I				VOLOVITZ, B; AMIR, J; MALIK, H; KAUSCHANSKY, A; VARSANO, I			GROWTH AND PITUITARY-ADRENAL-FUNCTION IN CHILDREN WITH SEVERE ASTHMA TREATED WITH INHALED BUDESONIDE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LONG-TERM TREATMENT; BECLOMETHASONE DIPROPIONATE AEROSOL; CHILDHOOD ASTHMA; THERAPY; CORTICOSTEROIDS; SUPPRESSION; RETARDATION; CANDIDIASIS; PREDNISONE; CATARACTS	Background. The increased use of inhaled corticosteroids in the management of asthma raises concern about the safety of these drugs in children. We sought to determine the safety of long-term administration of inhaled budesonide in young children with asthma. Methods. We studied 15 children 2 to 7 years old who had severe perennial asthma. They inhaled 100 mug of budesonide twice daily for three to five years. Efficacy was assessed by serial evaluation of respiratory symptoms and the need for other medications, and safety by serial evaluation of height, height velocity, weight, bone age, and pituitary-adrenal function. Results. The severity of asthma decreased within the first month after the initiation of therapy, as demonstrated by a 58 percent reduction in the number of days with symptoms of asthma and a 75 percent decrease in the use of bronchodilators. This improvement was maintained thereafter. The growth pattern of all patients, including their height, weight, and bone age, was normal (as compared with standard normal values) throughout the treatment period. Pituitary-adrenal function was not adversely affected by the treatment, as demonstrated by normal serum cortisol concentrations in the morning and 60 minutes after stimulation with corticotropin, normal 24-hour serum cortisol concentrations (mean [+/-SD] of samples collected at 30-minute intervals for 24 hours, 8.4+/-4.2 mug per deciliter [232+/-116 nmol per liter]), and normal urinary cortisol excretion (34+/-9 mug [95+/-25 nmol] per day). Conclusions. Prolonged administration of 200 mug of inhaled budesonide daily to young children with severe asthma does not impair growth or pituitary-adrenal function.			VOLOVITZ, B (corresponding author), HASHARON HOSP, GOLDA MED CTR, DEPT PEDIAT, POB 121, IL-49372 PETAH TIQWA, ISRAEL.		Malik, Hrudananda/AAU-1515-2020	Malik, Hrudananda/0000-0003-1213-4455				BALFOURLYNN L, 1988, LANCET, V1, P476; BALFOURLYNN L, 1986, ARCH DIS CHILD, V61, P1049, DOI 10.1136/adc.61.11.1049; BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BISGAARD H, 1988, J ALLERGY CLIN IMMUN, V81, P1088, DOI 10.1016/0091-6749(88)90874-3; BISGAARD H, 1991, ACTA PAEDIATR SCAND, V80, P213, DOI 10.1111/j.1651-2227.1991.tb11836.x; BRATTSAND R, 1982, EUR J RESPIR DIS, V63, P62; FIELD HV, 1982, ARCH DIS CHILD, V57, P864, DOI 10.1136/adc.57.11.864; FRANCIS RS, 1976, THORAX, V31, P309, DOI 10.1136/thx.31.3.309; GODFREY S, 1978, J ALLERGY CLIN IMMUN, V62, P335, DOI 10.1016/0091-6749(78)90133-1; GOLDSTEIN DE, 1983, PEDIATRICS, V72, P60; GRAFFLONNEVIG V, 1979, ALLERGY, V34, P57, DOI 10.1111/j.1398-9995.1979.tb02001.x; Greulich WW., 1959, CALIF MED, V91, P53; HAUSPIE R, 1977, J ALLERGY CLIN IMMUN, V59, P200, DOI 10.1016/0091-6749(77)90150-6; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; KERREBIJN KF, 1976, J PEDIATR-US, V89, P821, DOI 10.1016/S0022-3476(76)80816-5; KEWLEY GD, 1980, AUST PAEDIATR J, V16, P117; KONIG P, 1993, J PEDIATR-US, V122, P219, DOI 10.1016/S0022-3476(06)80116-2; LAW CM, 1987, LANCET, V1, P1321; LITTLEWOOD JM, 1988, LANCET, V1, P115; PEDERSEN S, 1988, EUR RESPIR J, V1, P433; PHILLIP M, 1992, PEDIATR PULM, V12, P84, DOI 10.1002/ppul.1950120205; PRAHL P, 1991, CLIN EXP ALLERGY, V21, P145, DOI 10.1111/j.1365-2222.1991.tb00817.x; RIBEIRO LB, 1987, GLUCOCORTICOSTEROIDS, P95; ROOKLIN AR, 1979, J ALLERGY CLIN IMMUN, V63, P383, DOI 10.1016/0091-6749(79)90210-0; SCHULLER CF, 1986, EUR J RESPIR DIS, V69, pA152; SHAW NJ, 1986, ARCH DIS CHILD, V61, P788, DOI 10.1136/adc.61.8.788; SMITH MJ, 1983, LANCET, V1, P265, DOI 10.1016/S0140-6736(83)91686-0; TABACHNIK E, 1991, J PEDIATR-US, V118, P294, DOI 10.1016/S0022-3476(05)80506-2; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; TOOGOOD JH, 1989, J ALLERGY CLIN IMMUN, V84, P688, DOI 10.1016/0091-6749(89)90297-2; TOOGOOD JH, 1980, J ALLERGY CLIN IMMUN, V65, P145, DOI 10.1016/0091-6749(80)90200-6; TOOGOOD JH, 1984, AM REV RESPIR DIS, V129, P723, DOI 10.1164/arrd.1984.129.5.723; TOOGOOD JH, 1984, EUR J RESPIR DIS, V65, P35; VARSANO I, 1990, J ALLERGY CLIN IMMUN, V85, P914, DOI 10.1016/0091-6749(90)90077-H; WOLTHERS OD, 1992, PEDIATRICS, V89, P839; WOLTHERS OD, 1991, BMJ-BRIT MED J, V303, P163, DOI 10.1136/bmj.303.6795.163; WYATT R, 1978, NEW ENGL J MED, V299, P1387, DOI 10.1056/NEJM197812212992504	37	128	130	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 2	1993	329	23					1703	1708		10.1056/NEJM199312023292305	http://dx.doi.org/10.1056/NEJM199312023292305			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ707	8232459				2022-12-28	WOS:A1993MJ70700005
J	FINE, HA; MAYER, RJ				FINE, HA; MAYER, RJ			PRIMARY CENTRAL-NERVOUS-SYSTEM LYMPHOMA	ANNALS OF INTERNAL MEDICINE			English	Review							IMMUNE-DEFICIENCY-SYNDROME; NON-HODGKINS-LYMPHOMA; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PRIMARY MALIGNANT-LYMPHOMA; EPSTEIN-BARR-VIRUS; PRIMARY CEREBRAL LYMPHOMA; PRIMARY BRAIN LYMPHOMA; PRIMARY CNS LYMPHOMA; RETICULUM-CELL SARCOMA; HIGH-DOSE METHOTREXATE	Objective: To compare the pathogenesis, clinical presentation, therapy, and prognosis of primary central nervous system lymphoma in immunocompetent persons with these characteristics of the disease in patients with AIDS. Data Sources and Extraction: All English-language papers published between 1980 and 1992 dealing with either lymphoma and the central nervous system or AIDS were reviewed. Patient characteristics, clinical presentation, histologic findings, and treatment and survival data were extracted from each case report and review. Data Synthesis: Data were available on 792 patients (from 40 reported series) with non-AIDS-associated primary central nervous system lymphoma and 315 patients (from 32 series) with AIDS-associated primary central nervous system lymphoma. Patients with AIDS initially consulted a physician more often when they had global neurologic symptoms compared with patients without AIDS, with more than 50% of the lesions on computed tomographic (CT) scans in patients with AIDS being ring-enhancing and multifocal, a pattern rarely described in immunocompetent patients. The overall survival of the patients without AIDS was 18.9 months compared with 2.6 months for patients with AIDS, with substantial differences remaining even for subgroups of patients similarly treated with radiation and chemotherapy. Conclusion: Primary central nervous system lymphoma is probably a substantially different disease in persons with and without AIDS with regard to patient characteristics, clinical and radiographic presentation, and prognosis. Recent advances in the treatment of this disease in patients without AIDS have not largely affected patients with AIDS. Substantial improvements in survival in these patients await advances in controlling their human immunodeficiency virus-associated disease.	BRAIN TUMOR CTR, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	FINE, HA (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV MED ONCOL, 44 BINNEY ST, BOSTON, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R13CA124293] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELSON HT, 1981, CANCER TREAT REP, V65, P137; AHMED T, 1987, CANCER, V60, P719, DOI 10.1002/1097-0142(19870815)60:4<719::AID-CNCR2820600402>3.0.CO;2-U; ALLEGRANZA A, 1984, HISTOPATHOLOGY, V8, P781, DOI 10.1111/j.1365-2559.1984.tb02394.x; ANDERS KH, 1986, AM J PATHOL, V124, P537; ANDERS KH, 1989, HUM PATHOL, V20, P326, DOI 10.1016/0046-8177(89)90041-5; BARNETT LB, 1974, J NEUROL NEUROSUR PS, V37, P966, DOI 10.1136/jnnp.37.8.966; BASHIR RM, 1989, NEUROLOGY, V39, P813, DOI 10.1212/WNL.39.6.813; BAUMGARTNER JE, 1990, J NEUROSURG, V73, P206, DOI 10.3171/jns.1990.73.2.0206; BENEDEK L, 1941, DEUTSCH Z NERVENHEIL, V152, P159; BERRY MP, 1981, INT J RADIAT ONCOL, V7, P55, DOI 10.1016/0360-3016(81)90060-2; BERTONCELLI C, 1987, HAEMATOLOGICA, V72, P137; BIGNON YJ, 1991, NEUROLOGY, V41, P1152, DOI 10.1212/WNL.41.7.1152; BLEYER WA, 1988, CURR PROB CANCER, V12, P185; BOGDAHN U, 1986, ACTA NEUROL SCAND, V73, P602, DOI 10.1111/j.1600-0404.1986.tb04607.x; BUSH RS, 1977, CANCER TREAT REP, V61, P1129; CAPANNA AH, 1987, NEUROSURGERY, V21, P920, DOI 10.1227/00006123-198712000-00024; CASADEI GP, 1985, TUMORI, V71, P501, DOI 10.1177/030089168507100515; CHAPPELL ET, 1992, NEUROSURGERY, V30, P825, DOI 10.1227/00006123-199206000-00001; COHEN IJ, 1986, CANCER, V57, P6, DOI 10.1002/1097-0142(19860101)57:1<6::AID-CNCR2820570104>3.0.CO;2-B; DEANGELIS LM, 1992, J CLIN ONCOL, V10, P635, DOI 10.1200/JCO.1992.10.4.635; DEWEESE TL, 1991, INT J RADIAT ONCOL, V20, P803, DOI 10.1016/0360-3016(91)90027-2; DICARLO EF, 1986, ARCH PATHOL LAB MED, V110, P1012; DIMARCO A, 1986, TUMORI, V72, P565, DOI 10.1177/030089168607200605; DINA TS, 1991, RADIOLOGY, V179, P823, DOI 10.1148/radiology.179.3.2027999; DUGGAN DB, 1988, BLOOD, V71, P1027; EBY NL, 1988, CANCER, V62, P2461, DOI 10.1002/1097-0142(19881201)62:11<2461::AID-CNCR2820621135>3.0.CO;2-M; ERVIN T, 1980, CANCER, V45, P1556, DOI 10.1002/1097-0142(19800401)45:7<1556::AID-CNCR2820450707>3.0.CO;2-B; EZRINWATERS C, 1984, ANN NEUROL, V16, P668, DOI 10.1002/ana.410160608; FORMENTI SC, 1989, CANCER, V63, P1101, DOI 10.1002/1097-0142(19890315)63:6<1101::AID-CNCR2820630611>3.0.CO;2-R; FRANK G, 1985, SURG NEUROL, V23, P3, DOI 10.1016/0090-3019(85)90150-8; FREEMAN C, 1972, CANCER, V29, P252, DOI 10.1002/1097-0142(197201)29:1<252::AID-CNCR2820290138>3.0.CO;2-#; FREEMAN CR, 1986, CANCER, V58, P1106, DOI 10.1002/1097-0142(19860901)58:5<1106::AID-CNCR2820580521>3.0.CO;2-3; FUKS Z, 1973, RADIOLOGY, V108, P675, DOI 10.1148/108.3.675; GABBAI AA, 1989, J NEUROSURG, V70, P190, DOI 10.3171/jns.1989.70.2.0190; GILL PS, 1985, AM J MED, V78, P742, DOI 10.1016/0002-9343(85)90277-3; GOLDSTEIN JD, 1991, CANCER, V67, P2756, DOI 10.1002/1097-0142(19910601)67:11<2756::AID-CNCR2820671108>3.0.CO;2-3; GOLDSTEIN JD, 1991, J COMPUT ASSIST TOMO, V15, P39, DOI 10.1097/00004728-199101000-00004; GONZALEZ DG, 1983, CANCER, V51, P2048, DOI 10.1002/1097-0142(19830601)51:11<2048::AID-CNCR2820511115>3.0.CO;2-T; GRANT JW, 1986, ARCH PATHOL LAB MED, V110, P897; HANBERY JW, 1964, ARCH NEUROL PSYCHIAT, V74, P732; HELLE TL, 1984, J NEUROSURG, V60, P94, DOI 10.3171/jns.1984.60.1.0094; HENRY JM, 1974, CANCER, V34, P1293, DOI 10.1002/1097-0142(197410)34:4<1293::AID-CNCR2820340441>3.0.CO;2-P; HERBST KD, 1976, CANCER, V38, P1476, DOI 10.1002/1097-0142(197610)38:4<1476::AID-CNCR2820380405>3.0.CO;2-J; HO M, 1985, J INFECT DIS, V152, P876, DOI 10.1093/infdis/152.5.876; HO M, 1988, TRANSPLANTATION, V45, P719, DOI 10.1097/00007890-198804000-00011; HOBSON DE, 1986, CAN J NEUROL SCI, V13, P55, DOI 10.1017/S0317167100035800; HOCHBERG FH, 1983, NEW ENGL J MED, V309, P745, DOI 10.1056/NEJM198309293091301; HOCHBERG FH, 1988, J NEUROSURG, V68, P835, DOI 10.3171/jns.1988.68.6.0835; HOCHBERG FH, 1991, J NEURO-ONCOL, V10, P191; Jellinger K, 1975, Acta Neuropathol Suppl, VSuppl 6, P95; JONES GR, 1985, CANCER, V56, P2804, DOI 10.1002/1097-0142(19851215)56:12<2804::AID-CNCR2820561216>3.0.CO;2-D; KALTER SP, 1985, BLOOD, V66, P655; KAPLAN LD, 1989, JAMA-J AM MED ASSOC, V261, P719; Kaplan M H, 1987, Am J Med, V82, P389, DOI 10.1016/0002-9343(87)90435-9; KAWAKAMI Y, 1985, J NEUROSURG, V62, P522, DOI 10.3171/jns.1985.62.4.0522; KLEIN G, 1979, P NATL ACAD SCI USA, V76, P2442, DOI 10.1073/pnas.76.5.2442; KNOWLES DM, 1988, ANN INTERN MED, V108, P744, DOI 10.7326/0003-4819-108-5-744; KOPPEL BS, 1985, ACTA NEUROL SCAND, V71, P337; LEVINE AM, 1991, CANCER, V68, P2466, DOI 10.1002/1097-0142(19911201)68:11<2466::AID-CNCR2820681124>3.0.CO;2-G; LEVINE AM, 1992, BLOOD, V80, P8; LITTMAN P, 1975, CANCER, V35, P1412, DOI 10.1002/1097-0142(197505)35:5<1412::AID-CNCR2820350526>3.0.CO;2-T; LOEFFLER JS, 1985, J CLIN ONCOL, V3, P490, DOI 10.1200/JCO.1985.3.4.490; LOUREIRO C, 1988, CANCER, V62, P735, DOI 10.1002/1097-0142(19880815)62:4&lt;735::AID-CNCR2820620416&gt;3.0.CO;2-E; LOWENTHAL DA, 1988, CANCER, V61, P2325, DOI 10.1002/1097-0142(19880601)61:11<2325::AID-CNCR2820611130>3.0.CO;2-0; MACMAHON EME, 1991, LANCET, V338, P969, DOI 10.1016/0140-6736(91)91837-K; MAGRATH I, 1985, ESPTEIN BARR VIRUS A, P631; MCARTHUR JC, 1987, MEDICINE, V66, P407, DOI 10.1097/00005792-198711000-00001; MCLAUGHLIN P, 1988, J NATL CANCER I, V80, P1408, DOI 10.1093/jnci/80.17.1408; MENDENHALL NP, 1983, CANCER-AM CANCER SOC, V52, P1993, DOI 10.1002/1097-0142(19831201)52:11<1993::AID-CNCR2820521104>3.0.CO;2-C; MERKEL KHH, 1986, PATHOL RES PRACT, V181, P430, DOI 10.1016/S0344-0338(86)80078-4; MERNICK MH, 1986, MT SINAI J MED, V53, P664; MICHALSKI JM, 1990, RADIOLOGY, V176, P855, DOI 10.1148/radiology.176.3.2389047; MODEL LM, 1977, ARCH NEUROL-CHICAGO, V34, P633, DOI 10.1001/archneur.1977.00500220067012; MONFARDINI S, 1988, JNCI-J NATL CANCER I, V80, P855, DOI 10.1093/jnci/80.11.855; MURRAY K, 1986, J NEUROSURG, V65, P600, DOI 10.3171/jns.1986.65.5.0600; NAKHLEH RE, 1989, ARCH PATHOL LAB MED, V113, P1050; NEUWELT EA, 1991, J CLIN ONCOL, V9, P1580, DOI 10.1200/JCO.1991.9.9.1580; NEUWELT EA, 1986, CANCER, V58, P1609, DOI 10.1002/1097-0142(19861015)58:8<1609::AID-CNCR2820580805>3.0.CO;2-7; ONEILL BP, 1989, MAYO CLIN PROC, V64, P1005, DOI 10.1016/S0025-6196(12)61228-2; OTT RJ, 1991, EUR J CANCER, V27, P1356, DOI 10.1016/0277-5379(91)90009-3; PENN I, 1977, TRANSPLANT P, V9, P1121; PITLIK SD, 1983, J INFECT DIS, V148, P771, DOI 10.1093/infdis/148.4.771; PITTMAN KB, 1991, ONCOLOGY, V48, P184; PLUDA JM, 1990, ANN INTERN MED, V113, P276, DOI 10.7326/0003-4819-113-4-276; POLLACK IF, 1989, CANCER-AM CANCER SOC, V63, P939, DOI 10.1002/1097-0142(19890301)63:5<939::AID-CNCR2820630526>3.0.CO;2-V; POON T, 1989, J COMPUT ASSIST TOMO, V13, P6, DOI 10.1097/00004728-198901000-00002; RAMPEN FHJ, 1980, EUR J CANCER, V16, P177, DOI 10.1016/0014-2964(80)90149-8; REMICK SC, 1990, MEDICINE, V69, P345, DOI 10.1097/00005792-199011000-00003; SAGERMAN RH, 1983, RADIOLOGY, V149, P567, DOI 10.1148/radiology.149.2.6353480; SAGERMAN RH, 1967, RADIOLOGY, V88, P552, DOI 10.1148/88.3.542; SCHAUMBURG HH, 1972, BRAIN, V95, P199, DOI 10.1093/brain/95.2.199; SCHIFFER D, 1987, TUMORI, V73, P585, DOI 10.1177/030089168707300607; SCHNECK SA, 1971, LANCET, V1, P983; SHIBATA S, 1989, NEUROSURGERY, V25, P14, DOI 10.1227/00006123-198907000-00003; SINGH A, 1982, NEUROLOGY, V32, P1267, DOI 10.1212/WNL.32.11.1267; SKARIN AT, 1977, BLOOD, V50, P1039; SNIDER WD, 1983, ANN NEUROL, V14, P403, DOI 10.1002/ana.410140404; SNIDER WD, 1983, NEW ENGL J MED, V308, P45; SNOW RB, 1985, NEUROSURGERY, V16, P148, DOI 10.1227/00006123-198502000-00004; SO YT, 1986, ANN NEUROL, V20, P566, DOI 10.1002/ana.410200503; SONG SK, 1986, MT SINAI J MED, V53, P686; SPAUN E, 1985, SURG NEUROL, V24, P646, DOI 10.1016/0090-3019(85)90123-5; SPILLANE JA, 1982, J NEUROL NEUROSUR PS, V45, P199, DOI 10.1136/jnnp.45.3.199; STEWART DJ, 1983, CANCER TREAT REP, V67, P287; VAKILI ST, 1986, J SURG ONCOL, V33, P95, DOI 10.1002/jso.2930330208; VAQUERO J, 1984, J NEUROSURG, V60, P174, DOI 10.3171/jns.1984.60.1.0174; WATANABE M, 1992, NEURORADIOLOGY, V34, P36, DOI 10.1007/BF00588431; WEINTRAUB J, 1982, TRANSPLANTATION, V33, P347, DOI 10.1097/00007890-198204000-00002; WOODMAN R, 1985, MEDICINE, V64, P425, DOI 10.1097/00005792-198511000-00006; YASUNAGA T, 1986, ACTA ONCOL, V25, P23, DOI 10.3109/02841868609136372; ZIEGLER JL, 1984, NEW ENGL J MED, V311, P565, DOI 10.1056/NEJM198408303110904; Zimmerman H M, 1975, Acta Neuropathol Suppl, VSuppl 6, P69	112	333	348	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1993	119	11					1093	1104		10.7326/0003-4819-119-11-199312010-00007	http://dx.doi.org/10.7326/0003-4819-119-11-199312010-00007			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ335	8239229				2022-12-28	WOS:A1993MJ33500007
J	GHADIRI, MR; GRANJA, JR; MILLIGAN, RA; MCREE, DE; KHAZANOVICH, N				GHADIRI, MR; GRANJA, JR; MILLIGAN, RA; MCREE, DE; KHAZANOVICH, N			SELF-ASSEMBLING ORGANIC NANOTUBES BASED ON A CYCLIC PEPTIDE ARCHITECTURE	NATURE			English	Article							MOLECULAR-SIEVE; GRAMICIDIN-A; NANOCHEMISTRY; MICROTUBULES; PROTEINS; CARBON; PORE	HOLLOW tubular structures of molecular dimensions may offer a variety of applications in chemistry, biochemistry and materials science. Concentric carbon nanotubes1,2 have attracted a great deal of attention, while the three-dimensional tubular pore structures of molecular sieves have long been exploited industrially3-8. Nanoscale tubes based on organic materials have also been reported previously9-13. Here we report the design, synthesis and characterization of a new class of organic nanotubes based on rationally designed cyclic polypeptides. When protonated, these compounds crystallize into tubular structures hundreds of nanometres long, with internal diameters of 7-8 angstrom. Support for the proposed tubular structures is provided by electron microscopy, electron diffraction, Fourier-transform infrared spectroscopy and molecular modelling. These tubes are open-ended, with uniform shape and internal diameter. We anticipate that they may have possible applications in inclusion chemistry, catalysis, molecular electronics and molecular separation technology.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92307 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92307 USA	Scripps Research Institute; Scripps Research Institute	GHADIRI, MR (corresponding author), SCRIPPS RES INST, DEPT CHEM, LA JOLLA, CA 92307 USA.		Granja, Juan R/P-7646-2014	Granja, Juan R/0000-0002-5842-7504				ADRIAN M, 1984, NATURE, V308, P32, DOI 10.1038/308032a0; BRUMLIK CJ, 1991, J AM CHEM SOC, V113, P3174, DOI 10.1021/ja00008a057; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; DAVIS ME, 1988, NATURE, V331, P698, DOI 10.1038/331698a0; DESSAU RM, 1990, ZEOLITES, V10, P522, DOI 10.1016/S0144-2449(05)80306-9; EBBESEN TW, 1992, NATURE, V358, P220, DOI 10.1038/358220a0; ESTERMANN M, 1991, NATURE, V352, P320, DOI 10.1038/352320a0; FUHRHOP JH, 1993, J AM CHEM SOC, V115, P1600, DOI 10.1021/ja00057a069; GEORGER JH, 1987, J AM CHEM SOC, V109, P6169, DOI 10.1021/ja00254a042; HARADA A, 1993, NATURE, V364, P516, DOI 10.1038/364516a0; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LANGS DA, 1988, SCIENCE, V241, P188, DOI 10.1126/science.2455345; LOTZ B, 1976, J MOL BIOL, V106, P915, DOI 10.1016/0022-2836(76)90343-0; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MEIER WM, 1988, ATLAS ZEOLITE STRUCT; MILLIGAN RA, 1984, ULTRAMICROSCOPY, V13, P1, DOI 10.1016/0304-3991(84)90051-2; MONNIER A, 1993, SCIENCE, V261, P1299, DOI 10.1126/science.261.5126.1299; NAIK VM, 1986, BIOPHYS J, V49, P1147, DOI 10.1016/S0006-3495(86)83743-2; OZIN GA, 1992, ADV MATER, V4, P612, DOI 10.1002/adma.19920041003; ROVERO P, 1991, TETRAHEDRON LETT, V32, P2639, DOI 10.1016/S0040-4039(00)78806-X; SALEMME FR, 1983, PROG BIOPHYS MOL BIO, V42, P95, DOI 10.1016/0079-6107(83)90005-6; SCHROETER JP, 1992, J STRUCT BIOL, V109, P235, DOI 10.1016/1047-8477(92)90036-A; STICKLE DF, 1992, J MOL BIOL, V226, P1143, DOI 10.1016/0022-2836(92)91058-W; WALLACE BA, 1988, SCIENCE, V241, P182, DOI 10.1126/science.2455344; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191	27	1432	1479	9	496	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 25	1993	366	6453					324	327		10.1038/366324a0	http://dx.doi.org/10.1038/366324a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	MJ705	8247126				2022-12-28	WOS:A1993MJ70500042
J	AABY, P; ANDERSEN, M; SODEMANN, M; JAKOBSEN, M; GOMES, J; FERNANDES, M				AABY, P; ANDERSEN, M; SODEMANN, M; JAKOBSEN, M; GOMES, J; FERNANDES, M			REDUCED CHILDHOOD MORTALITY AFTER STANDARD MEASLES VACCINATION AT 4-8 MONTHS COMPARED WITH 9-11 MONTHS OF AGE	BRITISH MEDICAL JOURNAL			English	Article							EDMONSTON-ZAGREB; GUINEA-BISSAU; COMMUNITY; EXPOSURE; IMMUNIZATION; EFFICACY; SCHWARZ	Objective-To evaluate the impact on mortality of standard Schwarz measles immunisation before 9 months of age. Design-Children vaccinated in 1980-3 at 4-5, 6-8, and 9-11 months of age were followed to migration, death, or the age of 5 years. Setting-One urban district and nine villages in two rural areas of Guinea-Bissau. Subjects-307 children vaccinated at 4-8 months and 256 at 9-11 months. Main outcome measures-Mortality from 9 months to 5 years of age for children immunised at 4-5, 6-8, and 9-11 months. Results-Mortality was significantly lower in children vaccinated at 6-8 months than at 9-11 months (mortality ratio=0.63, (95% confidence interval 0.41 to 0.97), p=0.047). As vaccination was provided in semiannual or annual campaigns it is unlikely that age at vaccination reflected a selection bias. The trend was the same in all three study areas. Improved survival after early immunisation was not related to better protection against measles infection. With a Cox multivariate regression model to adjust for age, sex, season at risk, season at birth, measles infection, and region, children vaccinated at 4-8 months had a mortality ratio of 0.61 (0.40 to 0.92, p=0.020) compared with children vaccinated at 9-11 months. Reimmunised children tended to have lower mortality than children who received only one vaccine (0.59 (0.28 to 1.27, p=0.176)). Conclusion-Standard measles vaccination before 9 months is not associated with higher childhood mortality than is the currently recommended strategy of immunising from 9 months, and it may reduce mortality. This has implications for measles immunisation strategy in developing countries.	UNIV COPENHAGEN,STAT PROGRAM,DK-1168 COPENHAGEN,DENMARK; MINIST PUBL HLTH,BISSAU,GUINEA BISSAU	University of Copenhagen	AABY, P (corresponding author), STATENS SERUM INST,ENDOCRINOL PROGRAM,ARTILLERIVEJ 5,DK-2300 COPENHAGEN,DENMARK.			Sodemann, Morten/0000-0001-8992-2500; Aaby, Peter/0000-0001-8331-1389				AABY P, 1989, PEDIATR INFECT DIS J, V8, P197; AABY P, 1986, J PEDIATR-US, V109, P40, DOI 10.1016/S0022-3476(86)80569-8; AABY P, 1990, AM J EPIDEMIOL, V132, P211, DOI 10.1093/oxfordjournals.aje.a115650; AABY P, 1988, LANCET, V2, P809; AABY P, 1990, J INFECT DIS, V162, P1043, DOI 10.1093/infdis/162.5.1043; AABY P, 1991, MED VIROL, V10, P83; AABY P, 1984, J TROP PEDIATRICS, V30, P164, DOI 10.1093/tropej/30.3.164; AABY P, 1993, J PEDIATR-US, V122, P904, DOI 10.1016/S0022-3476(09)90015-4; AABY P, 1983, J INFECT DIS, V147, P693, DOI 10.1093/infdis/147.4.693; AABY P, 1989, B WORLD HEALTH ORGAN, V67, P443; AABY P, 1984, J INFECTION, V8, P13, DOI 10.1016/S0163-4453(84)93192-X; BLACK FL, 1984, B WORLD HEALTH ORGAN, V62, P315; CLEMENS JD, 1988, AM J EPIDEMIOL, V128, P1330, DOI 10.1093/oxfordjournals.aje.a115086; Cox D. R., 1984, ANAL SURVIVAL DATA; GARENNE M, 1990, J INFECT DIS, V161, P1088, DOI 10.1093/infdis/161.6.1088; HALL AJ, 1990, INT J EPIDEMIOL, V19, P777, DOI 10.1093/ije/19.4.777; HOLT EA, 1990, PEDIATRICS, V85, P188; HULL HF, 1983, LANCET, V1, P972; MARKOWITZ LE, 1990, NEW ENGL J MED, V322, P580, DOI 10.1056/NEJM199003013220903; PETRALLI JK, 1965, LANCET, V2, P401; PRESTON NW, 1993, LANCET, V341, P688, DOI 10.1016/0140-6736(93)90454-O; ROOTH I, 1991, J TROP MED HYG, V94, P195; ROSENTHAL SR, 1988, AM J SURG, V156, P1, DOI 10.1016/S0002-9610(88)80158-2; TIDJANI O, 1989, LANCET, V2, P1357; VELEMA JP, 1991, INT J EPIDEMIOL, V20, P474, DOI 10.1093/ije/20.2.474; WHITTLE H, 1988, LANCET, V2, P811; 1991, WEEKLY EPIDEMIOLOGIC, V66, P249; 1990, WEEKLY EPIDEMIOLOGIC, V2, P5; 1981, LANCET, V1, P764; 1992, WEEKLY EPIDEMIOLOGIC, V67, P357	30	64	64	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1993	307	6915					1308	1311		10.1136/bmj.307.6915.1308	http://dx.doi.org/10.1136/bmj.307.6915.1308			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH556	8257884	Green Published, Bronze			2022-12-28	WOS:A1993MH55600018
J	MONSON, JRT				MONSON, JRT			MINIMALLY INVASIVE SURGERY - ADVANCED TECHNIQUES IN ABDOMINAL-SURGERY	BRITISH MEDICAL JOURNAL			English	Article								Almost every abdominal organ is now amenable to laparoscopic surgery. Laparoscopic appendicectomy is a routine procedure which also permits identification of other conditions initially confused with an inflamed appendix. However, assessment of appendiceal inflammation is more difficult. Almost all colonic procedures can be performed laparoscopically, at least partly, though resection for colonic cancer is still controversial. For simple patch repair of perforated duodenal ulcers laparoscopy is ideal, and inguinal groin hernia can be repaired satisfactorily with a patch of synthetic mesh. Many upper abdominal procedures, however, still take more time than the open operations. These techniques reduce postoperative pain and the incidence of wound infections and allow a much earlier return to normal activity compared with open surgery. They have also brought new disciplines: surgeons must learn different hand-eye coordination, meticulous haemostasis is needed to maintain picture quality, and delivery of specimens may be problematic. The widespread introduction of laparoscopic techniques has emphasised the need for adequate training (operations that were straight-forward open procedures may require considerable laparoscopic expertise) and has raised questions about trainee surgeons acquiring adequate experience of open procedures.	IMPERIAL COLL SCI TECHNOL & MED,LONDON W2 1NY,ENGLAND	Imperial College London	MONSON, JRT (corresponding author), ST MARYS HOSP,ACAD SURG UNIT,LONDON W2 1NY,ENGLAND.							ARREGUI ME, 1993, SURG CLIN N AM, V73, P513; Corbitt J D Jr, 1991, Surg Laparosc Endosc, V1, P23; DUBOIS F, 1991, PROBL GEN SURG, V8, P348; KURATA JH, 1984, CLIN GASTROENTEROL, V13, P289; MONSON JRT, 1992, LANCET, V340, P831, DOI 10.1016/0140-6736(92)92694-B; POLISTER P, 1989, SOCIOECONOMIC FACTBO, P348; 1991, AM J SURG, V161, P324	7	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1993	307	6915					1346	1350		10.1136/bmj.307.6915.1346	http://dx.doi.org/10.1136/bmj.307.6915.1346			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH556	8257893	Green Published, Bronze			2022-12-28	WOS:A1993MH55600030
J	STENSVOLD, I; TVERDAL, A; URDAL, P; GRAFFIVERSEN, S				STENSVOLD, I; TVERDAL, A; URDAL, P; GRAFFIVERSEN, S			NONFASTING SERUM TRIGLYCERIDE CONCENTRATION AND MORTALITY FROM CORONARY HEART-DISEASE AND ANY CAUSE IN MIDDLE-AGED NORWEGIAN WOMEN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RISK FACTOR; CARDIOVASCULAR RISK; MEN; INSULIN	Objective-To study the association between non-fasting serum triglyceride concentrations and mortality in women from coronary and cardiovascular disease and all causes. Design-Follow up by ambulatory teams of men and women who underwent cardiovascular screening for a mean of 14.6 years. Setting-National health screening service in Norway. Subjects-25 058 men and 24 535 women aged 35-49 years. Main outcome measure-Predictive value of non-fasting serum triglyceride concentrations. Results-At initial screening total serum cholesterol concentration, serum triglyceride concentration, blood pressure, height, and weight were measured, and self reported information about smoking habits, physical activity, and time since last meal were recorded. During subsequent follow up 108 women died from coronary heart disease, 238 from cardiovascular diseases, and 931 from all causes. In women mortality increased steadily with increasing triglyceride concentration for all three causes of death. With the proportional hazards model and adjustment for age, systolic blood pressure, total cholesterol concentration, time since last meal, and number of cigarettes a day the relative risk between triglyceride concentration greater-than-or-equal-to 3.5 mmol/l and <1.5 mmol/l was 4.7 (95% confidence interval 2.5 to 8.9) for deaths from coronary heart disease, 3.0 (1.9 to 4.8) for deaths from cardiovascular disease, 2.3 (1.8 to 2.9) for total deaths in all women. Conclusions-A raised non-fasting concentration of triglycerides is an independent risk factor for mortality from coronary heart disease, cardiovascular disease, and any cause mortality among middle aged Norwegian women in contrast to what is seen in men.	UNIV OSLO, ULLEVAL HOSP, DEPT CLIN CHEM, OSLO 1, NORWAY; NATL HLTH SCREENING SERV, DEPT HLTH INFORMAT, N-0033 OSLO, NORWAY	University of Oslo	STENSVOLD, I (corresponding author), NATL HLTH SCREENING SERV, COMP SERV, POB 8155 DEP, N-0033 OSLO, NORWAY.			Tverdal, Aage/0000-0002-2909-5678				AUSTIN MA, 1989, AM J EPIDEMIOL, V129, P249, DOI 10.1093/oxfordjournals.aje.a115130; AUSTIN MA, 1986, LANCET, V2, P592; Bjartveit K, 1979, Acta Med Scand Suppl, V634, P1; CARLSON LA, 1985, ACTA MED SCAND, V218, P207; COSTONGS GMPJ, 1985, J CLIN CHEM CLIN BIO, V23, P7; Dixon W. J., 1990, BMDP STATISTICAL SOF; FOLSOM AR, 1991, ATHEROSCLEROSIS, V91, P191, DOI 10.1016/0021-9150(91)90167-2; FONTBONNE A, 1991, CIRCULATION, V84, P1442, DOI 10.1161/01.CIR.84.3.1442; FREEDMAN DS, 1988, AM J EPIDEMIOL, V127, P1118, DOI 10.1093/oxfordjournals.aje.a114906; GIANTURCO SH, 1991, CURR OPIN LIPIDOL, V2, P324; HALL WH, 1993, JAMA-J AM MED ASSOC, V269, P505; HAMSTEN A, 1991, CURRENT OPINION LIPI, V2, P26; HULLEY SB, 1980, NEW ENGL J MED, V302, P1383, DOI 10.1056/NEJM198006193022503; KASHYAP ML, 1991, CURRENT OPINION LIPI, V2, P379; LAPIDUS L, 1985, ACTA MED SCAND, V217, P481; NATVIG H, 1968, SCAND J CLIN LAB INV, VS 22, P1; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; STENSVOLD I, 1992, EUR HEART J, V13, P1155, DOI 10.1093/oxfordjournals.eurheartj.a060331; TVERDAL A, 1989, AM J EPIDEMIOL, V129, P458, DOI 10.1093/oxfordjournals.aje.a115157; WESTLUND K, 1972, SCAND J CLIN LAB INV, V30, P1; 1973, INT CLASSIFICATION D; 1988, CARDIOVASCULAR DISEA; 1986, INT CLASSIFICATION D	23	113	115	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 20	1993	307	6915					1318	1322		10.1136/bmj.307.6915.1318	http://dx.doi.org/10.1136/bmj.307.6915.1318			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH556	8257886	Bronze, Green Published			2022-12-28	WOS:A1993MH55600020
J	EBNER, R; CHEN, RH; LAWLER, S; ZIONCHECK, T; DERYNCK, R				EBNER, R; CHEN, RH; LAWLER, S; ZIONCHECK, T; DERYNCK, R			DETERMINATION OF TYPE-I RECEPTOR SPECIFICITY BY THE TYPE-II RECEPTORS FOR TGF-BETA OR ACTIVIN	SCIENCE			English	Article							SERINE THREONINE KINASE; XENOPUS EMBRYOS; EXPRESSION; CLONING	Transforming growth factor-beta (TGF-beta) and activin signal primarily through interaction with type I and type II receptors, which are transmembrane serine-threonine kinases. Tsk 7L is a type I receptor for TGF-beta and requires coexpression of the type II TGF-beta receptor for ligand binding. Tsk 7L also specifically bound activin, when coexpressed with the type IIA activin receptor. Tsk 7L could associate with either type II receptor and the ligand binding specificity of Tsk 7L was conferred by the type II receptor. Tsk 7L can therefore act as type I receptor for both activin and TGF-beta, and possibly other ligands.	UNIV CALIF SAN FRANCISCO,DEPT GROWTH & DEV,SAN FRANCISCO,CA 94143; GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080; UNIV CALIF SAN FRANCISCO,DEPT ANAT,PROGRAM CELL BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; Roche Holding; Genentech; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Chen, Ruey-Hwa/G-6121-2019	Chen, Ruey-Hwa/0000-0001-8124-5832				ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; EBNER R, UNPUB; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GAZIT D, 1993, MOL ENDOCRINOL, V7, P189, DOI 10.1210/me.7.2.189; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAWLER S, UNPUB; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN HY, 1992, CELL, V70, P1069; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATTHEWS LS, 1991, CELL, V65, P973; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P379; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; SHUM LI, UNPUB; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TSUCHIDA K, IN PRESS P NATL ACAD; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	28	220	229	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 5	1993	262	5135					900	902		10.1126/science.8235612	http://dx.doi.org/10.1126/science.8235612			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	8235612				2022-12-28	WOS:A1993MF43800035
J	EAMES, M; BENSHLOMO, Y; MARMOT, MG				EAMES, M; BENSHLOMO, Y; MARMOT, MG			SOCIAL DEPRIVATION AND PREMATURE MORTALITY - REGIONAL COMPARISON ACROSS ENGLAND	BRITISH MEDICAL JOURNAL			English	Article							HEALTH; INEQUALITIES; LIFE; AREAS; WALES; RISK	Objective-To investigate the pattern and size of the relationship between social deprivation in electoral wards and premature mortality for each health region in England. Design-Ecological study using 1981 census variables and data on mortality for 1981-5. Setting-14 regional health authorities in England. Main outcome measure-Mortality under the age of 65 years from all causes, coronary heart disease, and smoking related diseases in men and women. Results-Increasing deprivation was significantly associated with mortality from all causes, coronary heart disease, and smoking related diseases. The relationship was linear with no apparent threshold. Correlation coefficients were generally greater for deaths from all causes and smoking related diseases and for men compared with women. The slope of the relationship between deprivation and mortality varied among regions. Variations in mortality still existed between regions for equal levels of deprivation. Conclusion-Deprivation of an area and premature mortality are strongly linked. The effects of deprivation can be seen throughout the range of affluence and are not limited to the poorest areas. Current targets for reducing coronary heart disease mortality may be achievable if the mortality in poor areas can be reduced to the rates in affluent areas.	UNIV LONDON UNIV COLL,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,LONDON WC1E 6BT,ENGLAND	University of London; University College London; UCL Medical School			Marmot, M G/Y-3920-2019; Ben-Shlomo, Yoav/ABD-2004-2021	Marmot, M G/0000-0002-2431-6419; Ben-Shlomo, Yoav/0000-0001-6648-3007; Eames, Margaret Anne/0000-0002-2430-5226	Medical Research Council [G8802774] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Ashton J, 1992, HLTH CITIES; BARKER DJP, 1986, LANCET, V1, P1077; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; Black D., 1980, INEQUALITIES HLTH; BLANE D, 1990, BRIT MED J, V301, P429, DOI 10.1136/bmj.301.6749.429; BRITTON M, 1990, MORTALITY GEOGRAPHY, P58; CARSTAIRS V, 1989, BRIT MED J, V299, P886, DOI 10.1136/bmj.299.6704.886; Carstairs V., 1991, DEPRIVATION HLTH SCO; EGOLF B, 1992, AM J PUBLIC HEALTH, V82, P1089, DOI 10.2105/AJPH.82.8.1089; ELLIOTT P, 1992, LANCET, V339, P854, DOI 10.1016/0140-6736(92)90290-J; Goldblatt P, 1990, SERIES LS, V6; GRAHAM H, 1987, SOC SCI MED, V25, P47, DOI 10.1016/0277-9536(87)90206-1; HAAN M, 1987, AM J EPIDEMIOL, V125, P989, DOI 10.1093/oxfordjournals.aje.a114637; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; JOHNSON K, 1991, SMOKING EPIDEMIC; JOHNSON Z, 1991, INT J EPIDEMIOL, V20, P989, DOI 10.1093/ije/20.4.989; MACKENBACH JP, 1990, J EPIDEMIOL COMMUN H, V44, P106, DOI 10.1136/jech.44.2.106; MAJOR, 1990, LANCET, V336, P1547; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MARMOT MG, 1984, LANCET, V1, P1003; MARMOT MG, 1986, LANCET, V2, P274; MOHAN J, 1990, HLTH ED J, V49, P176; PAYNE JN, 1993, J PUBLIC HEALTH MED, V15, P161; PHILLIMORE PR, 1991, SOC SCI MED, V33, P139, DOI 10.1016/0277-9536(91)90174-B; POCOCK SJ, 1980, BRIT MED J, V280, P1243, DOI 10.1136/bmj.280.6226.1243; POCOCK SJ, 1982, J ROY STAT SOC A STA, V145, P313, DOI 10.2307/2981866; ROBINE JM, 1991, BMJ-BRIT MED J, V302, P457, DOI 10.1136/bmj.302.6774.457; ROSS A, 1990, J EPIDEMIOL COMMUN H, V44, P142, DOI 10.1136/jech.44.2.142; SMITH GD, 1990, BMJ-BRIT MED J, V301, P373, DOI 10.1136/bmj.301.6748.373; SMITH SJ, 1990, SOC SCI MED, V31, P753, DOI 10.1016/0277-9536(90)90170-W; Townsend PP., 1988, HLTH DEPRIVATION INE; 1984, GENERAL HOUSEHOLD SU, P189; 1992, HLTH NATION STRATEGY; [No title captured]; 1989, SASPAC USER MANUAL, V3; 1989, SASPAC USER MANUAL, V1	36	183	183	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1993	307	6912					1097	1102		10.1136/bmj.307.6912.1097	http://dx.doi.org/10.1136/bmj.307.6912.1097			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ME918	8251806	Green Published, Bronze			2022-12-28	WOS:A1993ME91800014
J	ROBINSON, R				ROBINSON, R			ECONOMIC-EVALUATION AND HEALTH-CARE - THE POLICY CONTEXT	BMJ-BRITISH MEDICAL JOURNAL			English	Article								The final article in the series considers the ways in which the methods described previously are used in the formation of policy. When health authorities are making decisions about how to spend their money they have to draw on several sources of information about priorities: diktats from policy makers, opinions of consumers and of the professional bodies involved, and evidence gained from research. They must also consider the various methods of costing and select the right one for their circumstances. Some of these methods are still in the early stages of development, but more are being developed all the time and they have a valuable role in helping decision making throughout the NHS.			ROBINSON, R (corresponding author), UNIV SOUTHAMPTON, FAC SOCIAL SCI, INST HLTH POLICY STUDIES, SOUTHAMPTON SO9 5NH, HANTS, ENGLAND.							COCHRANE M, 1991, BRIT MED J, V303, P1039, DOI 10.1136/bmj.303.6809.1039; Drummond M, 1992, Health Econ, V1, P85, DOI 10.1002/hec.4730010202; FRANKEL S, 1993, RATIONING RATIONALIT; Gerard K, 1993, Health Econ, V2, P59, DOI 10.1002/hec.4730020108; HAM C, 1993, BMJ-BRIT MED J, V307, P435, DOI 10.1136/bmj.307.6901.435; IBBOTSON SL, 1993, J MANAGEMENT MED, V7, P50; KLEIN R, 1992, PATTERNS PRIORITIES; MASON J, 1993, BRIT MED J, V306, P570, DOI 10.1136/bmj.306.6877.570; Mooney G, 1992, PRIORITY SETTING PUR; ROBINSON R, 1992, BRIT MED J, V305, P1361, DOI 10.1136/bmj.305.6865.1361; 1993, RES HLTH; 1993, THEIR HLTH YOUR BUSI; 1990, HLTH CARE SYSTES TRA; 1992, LOCAL VOICES VIEWS L	14	17	17	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 16	1993	307	6910					994	996		10.1136/bmj.307.6910.994	http://dx.doi.org/10.1136/bmj.307.6910.994			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC441	8241915	Bronze, Green Published			2022-12-28	WOS:A1993MC44100026
J	DIAMOND, T; VINE, J; SMART, R; BUTLER, P				DIAMOND, T; VINE, J; SMART, R; BUTLER, P			THYROTOXIC BONE-DISEASE IN WOMEN - A POTENTIALLY REVERSIBLE DISORDER	ANNALS OF INTERNAL MEDICINE			English	Article							L-THYROXINE THERAPY; MINERAL CONTENT; SERUM OSTEOCALCIN; THYROID-HORMONES; HYPERTHYROIDISM; DENSITY; METABOLISM; FRACTURES; TURNOVER	Objective: To measure changes in spinal and femoral neck bone mineral densities in patients treated for Graves thyrotoxicosis. Design: Cohort study. Setting: Tertiary care center. Patients: Fifteen women with active Graves thyrotoxicosis. Six patients were premenopausal and nine were postmenopausal. All patients had evidence of thyrotoxicosis as indicated by a raised total serum thyroxine, suppressed serum thyroid-stimulating hormone, and an elevated technetium-99m pertechnetate thyroid scan. A control group of 15 healthy volunteers matched for age, sex, and menopausal status were followed during the same period. Measurements: Bone mineral density was measured by dual-energy x-ray absorptiometry at baseline and after 12 months of antithyroid therapy when euthyroidism had been achieved. Results: After 12 months of therapy, total serum thyroxine, total serum triiodothyronine, serum alkaline phosphatase, and serum bone Gla-protein activities had returned to normal in all patients (P < 0.001 for all comparison between initial and final biochemical measurements). During this interval, the mean lumbar spine bone mineral increased from an initial value of 1.01 g/cm2 to 1.07 g/cm2, an increase of 6.6% per year (95% CI, 3.6% to 9.6%) (P < 0.001 compared with controls). Increases in femoral neck (1.2%/y; CI, -2.1 % to 4.5%; P = 0.2 compared with controls) and femoral trochanter bone mineral (3.2%/y; CI, 2.4% to 8.7%; P = 0.2 compared with controls) were not statistically significant. Using forced-entry multiple regression analysis, the severity of the thyrotoxicosis was independently associated with the percentage increment in lumbar spine bone mineral density after 12 months of antithyroid therapy. Conclusion: Effective treatment of Graves thyrotoxicosis was associated with increases in lumbar spine and femoral neck bone mineral. Although the changes in bone mineral were modest, our data suggest that thyrotoxic bone loss may be a reversible disorder.			DIAMOND, T (corresponding author), ST GEORGE HOSP, DEPT ENDOCRINOL, KOGARAH, NSW 2217, AUSTRALIA.							ADAMS P, 1967, ENDOCRINOLOGY, V81, P735, DOI 10.1210/endo-81-4-735; ADLIN EV, 1991, AM J MED, V90, P360, DOI 10.1016/0002-9343(91)90577-K; AUWERX J, 1986, Q J MED, V60, P737; BAUER DC, 1992, J BONE MINER RES, V7, pS121; BAYLEY TA, 1980, J CLIN ENDOCR METAB, V50, P916, DOI 10.1210/jcem-50-5-916; BRITTO JM, 1992, ANN SCI M AUSTR NZ B, P27; DIAMOND T, 1991, J CLIN ENDOCR METAB, V72, P1184, DOI 10.1210/jcem-72-6-1184; FRASER SA, 1971, LANCET, V1, P981; GARREL DR, 1986, J CLIN ENDOCR METAB, V62, P1052, DOI 10.1210/jcem-62-5-1052; HARVEY RD, 1991, J CLIN ENDOCR METAB, V72, P1189, DOI 10.1210/jcem-72-6-1189; KROLNER B, 1983, CLIN ENDOCRINOL, V18, P439, DOI 10.1111/j.1365-2265.1983.tb02873.x; LARNACH TA, 1992, CALCIFIED TISSUE INT, V51, P255, DOI 10.1007/BF00334484; LEE MS, 1990, J CLIN ENDOCR METAB, V70, P766, DOI 10.1210/jcem-70-3-766; MOSEKILDE L, 1990, ENDOCRIN METAB CLIN, V19, P35, DOI 10.1016/S0889-8529(18)30338-4; MUNDY GR, 1976, J CLIN INVEST, V58, P529, DOI 10.1172/JCI108497; ONGPHIPHADHANAKUL B, 1992, J BONE MINER RES, V7, P1227; PAUL TL, 1988, JAMA-J AM MED ASSOC, V259, P3137, DOI 10.1001/jama.259.21.3137; RIBOT C, 1990, CLIN ENDOCRINOL, V33, P143, DOI 10.1111/j.1365-2265.1990.tb00477.x; ROSEN CJ, 1992, 74TH ANN M END SOC S, P436; SEEMAN E, 1982, J CLIN INVEST, V69, P1302, DOI 10.1172/JCI110570; SOLOMON B, 1992, 74TH ANN M END SOC S, P157; STALL GM, 1990, ANN INTERN MED, V113, P265, DOI 10.7326/0003-4819-113-4-265; TAELMAN P, 1990, CLIN ENDOCRINOL, V33, P107, DOI 10.1111/j.1365-2265.1990.tb00471.x; TOH SH, 1985, ARCH INTERN MED, V145, P883, DOI 10.1001/archinte.145.5.883; von Recklinghausen FC, 1891, FESTSCHRIFT R VIRCHO, P1; WILKINSON MR, 1986, ARCH INTERN MED, V146, P268, DOI 10.1001/archinte.146.2.268; YAKAMOTO M, 1992, 6TH INT C BON MORPH, P39	27	89	92	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1994	120	1					8	11		10.7326/0003-4819-120-1-199401010-00002	http://dx.doi.org/10.7326/0003-4819-120-1-199401010-00002			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP280	8250460				2022-12-28	WOS:A1994MP28000002
J	DERMAN, AI; PRINZ, WA; BELIN, D; BECKWITH, J				DERMAN, AI; PRINZ, WA; BELIN, D; BECKWITH, J			MUTATIONS THAT ALLOW DISULFIDE BOND FORMATION IN THE CYTOPLASM OF ESCHERICHIA-COLI	SCIENCE			English	Article							THIOREDOXIN REDUCTASE; ALKALINE-PHOSPHATASE; GLUTATHIONE; CLONING; GENE; IDENTIFICATION; GLUTAREDOXIN; STABILITY; SECRETION; UROKINASE	Disulfide bonds are rarely found in cytoplasmic proteins. Mutations were selected for in Escherichia coli that allow disulfide bond formation in the cytoplasm. In the presence of these mutations, export-defective versions of alkaline phosphatase and mouse urokinase were able to fold into their enzymatically active conformations in the cytoplasm because their disulfide bonds were formed. The mutations were mapped to the gene for thioredoxin reductase and diminish or eliminate the activity of this enzyme. Thioredoxin itself was found to be unnecessary for this disulfide bond formation. Thioredoxin reductase, but not thioredoxin, is thus implicated in keeping cysteines reduced in cytoplasmic proteins.	HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; UNIV GENEVA, MED CTR, DEPT PATHOL, CH-1211 GENEVA 4, SWITZERLAND	Harvard University; Harvard Medical School; University of Geneva								BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BEEBE JS, 1990, J BIOL CHEM, V265, P312; BELIN D, 1984, EMBO J, V3, P1901, DOI 10.1002/j.1460-2075.1984.tb02065.x; BELIN D, 1985, EUR J BIOCHEM, V148, P225, DOI 10.1111/j.1432-1033.1985.tb08829.x; BERGMAN LW, 1979, J BIOL CHEM, V254, P5690; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; Branden C, 1991, INTRO PROTEIN STRUCT, P5; CHAU MH, 1992, J MOL BIOL, V31, P4445; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; DELANEY JM, 1992, J BACTERIOL, V174, P3824, DOI 10.1128/JB.174.11.3824-3825.1992; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; DOIG AJ, 1991, J MOL BIOL, V217, P389, DOI 10.1016/0022-2836(91)90551-G; DUBOSE RF, 1991, EVOLUTION AT THE MOLECULAR LEVEL, P58; FRAENKEL DG, 1965, J BACTERIOL, V90, P837, DOI 10.1128/JB.90.4.837-842.1965; FUCHS J, 1977, J BACTERIOL, V129, P967, DOI 10.1128/JB.129.2.967-972.1977; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; HALLER BL, 1984, J BACTERIOL, V159, P1060, DOI 10.1128/JB.159.3.1060-1062.1984; HEPPEL LA, 1962, J BIOL CHEM, V237, P841; HOLMGREN A, 1984, METHOD ENZYMOL, V107, P295; HOLMGREN A, 1979, J BIOL CHEM, V254, P3664; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOLMGREN A, 1986, THIOREDOXIN GLUTARED, P1; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KIM EE, 1990, CLIN CHIM ACTA, V186, P175, DOI 10.1016/0009-8981(90)90035-Q; LUCKEY M, 1991, J BIOL CHEM, V266, P1866; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; MOORE EC, 1964, J BIOL CHEM, V239, P3453; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; ODONNELL ME, 1986, THIOREDOXIN GLUTARED, P131; PIZER LI, 1963, J BIOL CHEM, V238, P3934; POLLITT S, 1983, J BACTERIOL, V153, P27, DOI 10.1128/JB.153.1.27-32.1983; ROEDER W, 1979, MOL GEN GENET, V176, P361, DOI 10.1007/BF00333098; RUSSEL M, 1988, J BIOL CHEM, V263, P9015; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; RUSSEL M, 1986, THIOREDOXIN GLUTARED, P331; Schulz G. E., 1979, PRINCIPLES PROTEIN S, P53; SEDIVY JM, 1984, J BACTERIOL, V158, P1048, DOI 10.1128/JB.158.3.1048-1053.1984; TORRIANI A, 1960, BIOCHIM BIOPHYS ACTA, V38, P460, DOI 10.1016/0006-3002(60)91281-6; TUGGLE CK, 1985, J BACTERIOL, V162, P448, DOI 10.1128/JB.162.1.448-450.1985; WANNER BL, 1987, CELLULAR MOL BIOL, V2, P1326	44	381	415	2	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1993	262	5140					1744	1747		10.1126/science.8259521	http://dx.doi.org/10.1126/science.8259521			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	8259521				2022-12-28	WOS:A1993ML22000045
J	PEIFER, M				PEIFER, M			CANCER, CATENINS, AND CUTICLE PATTERN - A COMPLEX CONNECTION	SCIENCE			English	Editorial Material							SEGMENT POLARITY GENE; BETA-CATENIN; E-CADHERIN; PROTEIN; DROSOPHILA; PLAKOGLOBIN; HOMOLOG; PHOSPHORYLATION; IDENTIFICATION; VINCULIN				PEIFER, M (corresponding author), UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599, USA.		Peifer, Mark/A-1152-2010	Peifer, Mark/0000-0003-1412-3987				Behrens J, 1992, Semin Cell Biol, V3, P169; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BRADLEY RS, IN PRESS J CELL BIOL; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MCCREA PD, 1993, J CELL BIOL, V123, P477, DOI 10.1083/jcb.123.2.477; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; ODA H, 1993, J CELL BIOL, V121, P1133, DOI 10.1083/jcb.121.5.1133; PEIFER M, 1993, J CELL SCI, V105, P993; PEIFER M, 1993, DEVELOPMENT, V118, P1191; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, IN PRESS DEVELOPMENT; PEIFER M, UNPUB; PIEPENHAGEN PA, 1993, J CELL SCI, V104, P751; Reynolds Alice, COMMUNICATION; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKEICHI M, COMMUNICATION; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x	27	68	72	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 10	1993	262	5140					1667	1668		10.1126/science.8259511	http://dx.doi.org/10.1126/science.8259511			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	8259511				2022-12-28	WOS:A1993ML22000027
J	HAY, JC; MARTIN, TFJ				HAY, JC; MARTIN, TFJ			PHOSPHATIDYLINOSITOL TRANSFER PROTEIN REQUIRED FOR ATP-DEPENDENT PRIMING OF CA2+-ACTIVATED SECRETION	NATURE			English	Article								ELUCIDATION of the reactions responsible for the calcium-regulated fusion of secretory granules with the plasma membrane in secretory cells would be facilitated by the identification of participant proteins having known biochemical activities. The successful characterization of cytosolic1-3 and vesicle 4,5 proteins that may function in calcium-regulated secretion has not yet revealed the molecular events underlying this process. Regulated secretion consists of sequential priming and triggering steps which depend on ATP and Ca2+, respectively, and require distinct cytosolic proteins6. Characterization of priming-specific factors (PEP proteins) should enable the ATP-requiring reactions to be identified. Here we show that one of the mammalian priming factors (PEP3) is identical to phosphatidylinositol transfer protein (PITP)7. The physiological role of PITP was previously unknown. We also find that SEC14p, the yeast phosphatidylinositol transfer protein which is essential for constitutive secretion8-10, can substitute for PEP3/PITP in priming. Our results indicate that a role for phospholipid transfer proteins is conserved in the constitutive and regulated secretory pathways.	UNIV WISCONSIN, PROGRAM CELL & MOLEC BIOL, 1117 W JOHNSON ST, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT ZOOL, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								AITKEN JF, 1990, J BIOL CHEM, V265, P4711; ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; DAUM G, 1984, BIOCHIM BIOPHYS ACTA, V794, P385, DOI 10.1016/0005-2760(84)90004-3; DICKESON SK, 1989, J BIOL CHEM, V264, P16557; DICORLETO PE, 1979, J BIOL CHEM, V254, P7795; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HELMKAMP GM, 1974, J BIOL CHEM, V249, P6382; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HUSEBYE ES, 1988, BIOCHIM BIOPHYS ACTA, V968, P261, DOI 10.1016/0167-4889(88)90015-8; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MARTIN TFJ, 1989, METHOD ENZYMOL, V168, P225; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; PHILLIPS JH, 1973, BIOCHEM J, V136, P579, DOI 10.1042/bj1360579; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; SZOLDERITS G, 1989, BIOCHIM BIOPHYS ACTA, V986, P301, DOI 10.1016/0005-2736(89)90481-1; VANPARIDON PA, 1987, BIOCHIM BIOPHYS ACTA, V898, P172, DOI 10.1016/0005-2736(87)90035-6; WALENT JH, 1992, J CELL, V70, P765; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79; WU YN, 1992, BIOCHEM J, V285, P697, DOI 10.1042/bj2850697	30	309	314	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	1993	366	6455					572	575		10.1038/366572a0	http://dx.doi.org/10.1038/366572a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	8255295				2022-12-28	WOS:A1993ML21800072
J	ALBRIGHT, AL; BARRON, WB; FASICK, MP; POLINKO, P; JANOSKY, J				ALBRIGHT, AL; BARRON, WB; FASICK, MP; POLINKO, P; JANOSKY, J			CONTINUOUS INTRATHECAL BACLOFEN INFUSION FOR SPASTICITY OF CEREBRAL ORIGIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							SPINAL-CORD; PALSY	Objective.-To determine if continuous intrathecal baclofen infusion (CIBI) would provide continuous relief of spasticity in patients with spasticity of cerebral origin, especially children with cerebral palsy. Design.-Prospective, unblinded trial, before and after CIBI. Setting.-Children's Hospital of Pittsburgh (Pa). Patients.-Thirty-seven patients, 5 to 27 years of age, with spasticity of cerebral origin. Intervention.-Continuous intrathecal baclofen infusion for 3 to 48 months. Main Outcome Measures.-Muscle tone, range of motion, upper extremity timed tasks, activities of daily living (ADLs). Results.-Six and 12 months after CIBI, muscle tone was significantly decreased in the upper (P=.04) and lower (P=.001) extremities. There was a significant relationship between baclofen dosage and muscle tone in the upper (P=.02) and lower (P=.001) extremities. Hamstring motion, upper extremity function, and ADLs were significantly improved in 25 patients who were capable of self-care. Conclusion.-Spasticity of cerebral origin can be effectively treated with CIBI. Because baclofen dosages can be titrated for the desired clinical response, CIBI is particularly useful for patients who need some spasticity to stand and ambulate.	CHILDRENS HOSP PITTSBURGH,DEPT OCCUPAT THERAPY,PITTSBURGH,PA; CHILDRENS HOSP PITTSBURGH,DEPT SOCIAL SERV,PITTSBURGH,PA; UNIV PITTSBURGH,SCH MED,DEPT NEUROSURG,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT CLIN EPIDEMIOL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	ALBRIGHT, AL (corresponding author), CHILDRENS HOSP PITTSBURGH,DEPT NEUROSURG,3705 5TH AVE,PITTSBURGH,PA 15213, USA.				PHS HHS [5M01R-R00084] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALBRIGHT AL, 1991, JAMA-J AM MED ASSOC, V265, P1418, DOI 10.1001/jama.265.11.1418; ASHWORTH B, 1964, PRACTITIONER, V192, P540; BROSETA J, 1990, STEREOT FUNCT NEUROS, V54-5, P147, DOI 10.1159/000100205; COFFEY RJ, 1993, J NEUROSURG, V78, P226, DOI 10.3171/jns.1993.78.2.0226; DAVIDOFF RA, 1985, ANN NEUROL, V17, P107, DOI 10.1002/ana.410170202; DRALLE D, 1985, LANCET, V2, P1003; Feldman RG, 1980, SPASTICITY DISORDERE, P41; LAZORTHES Y, 1990, J NEUROSURG, V72, P393, DOI 10.3171/jns.1990.72.3.0393; LOUBSER PG, 1991, PARAPLEGIA, V29, P48, DOI 10.1038/sc.1991.7; MULLER H, 1992, DEV MED CHILD NEUROL, V34, P739; OCHS G, 1989, J NEUROL NEUROSUR PS, V52, P933, DOI 10.1136/jnnp.52.8.933; OTSUKA M, 1980, J EXP BIOL, V89, P201; PANETH N, 1984, EPIDEMIOLOGY CEREBRA, P35; PARK TS, 1992, NEW ENGL J MED, V326, P745; PEACOCK WJ, 1987, PEDIATR NEUROSCI, V13, P61, DOI 10.1159/000120302; PENN RD, 1992, J NEUROSURG, V77, P236, DOI 10.3171/jns.1992.77.2.0236; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; Zieglgansberger W, 1988, LOCAL SPINAL THERAPY, DOI [10.1007/978-3-642-72954-6_4, DOI 10.1007/978-3-642-72954-6_4]; Zierski J, 1988, Acta Neurochir Suppl (Wien), V43, P94	19	237	242	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1993	270	20					2475	2477		10.1001/jama.270.20.2475	http://dx.doi.org/10.1001/jama.270.20.2475			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG671	8230625				2022-12-28	WOS:A1993MG67100030
J	FLAHERTY, KM; ZOZULYA, S; STRYER, L; MCKAY, DB				FLAHERTY, KM; ZOZULYA, S; STRYER, L; MCKAY, DB			3-DIMENSIONAL STRUCTURE OF RECOVERIN, A CALCIUM SENSOR IN VISION	CELL			English	Article							CANCER-ASSOCIATED RETINOPATHY; ROD GUANYLATE-CYCLASE; RAY-DIFFRACTION DATA; BINDING PROTEIN; MODULATED PROTEINS; SKELETAL-MUSCLE; PEPTIDE COMPLEX; TROPONIN-C; RESOLUTION; CALMODULIN	Recoverin, a recently discovered member of the EF hand superfamily, serves as a calcium sensor in vision. We report here the crystal structure of recombinant unmyristoylated recoverin at 1.9 angstrom resolution. The four EF hands of the protein are arranged in a compact array that contrasts with the dumbbell shape of calmodulin and troponin C. A calcium ion is bound to EF hand 3, while EF hand 2 can bind samarium but not calcium in this crystal form. The other two EF hands have novel structural features that prevent or impair calcium binding. A concave hydrophobic surface formed by EF hands 1 and 2 may participate in the readout of calcium signals by recoverin and its homologs.			FLAHERTY, KM (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,BECKMAN LABS STRUCT BIOL,STANFORD,CA 94305, USA.		Zozulya, Sergey A/F-2986-2015	Zozulya, Sergey A/0000-0002-1179-2993	NEI NIH HHS [EY02005] Funding Source: Medline; NIGMS NIH HHS [GM24032, GM39928] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY002005, R01EY002005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039928, R37GM024032, R01GM024032] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; COOK WJ, 1991, J BIOL CHEM, V266, P652; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GRAYKELLER MP, 1993, NEURON, V10, P523, DOI 10.1016/0896-6273(93)90339-S; HANSON JC, 1979, ACTA CRYSTALLOGR A, V35, P616, DOI 10.1107/S0567739479001443; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HISATOMI O, 1992, 18TH P TAN INT S, P235; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; HURLEY JB, 1993, SCIENCE, V260, P740, DOI 10.1126/science.8097896; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAUPP UB, 1992, ANNU REV PHYSIOL, V54, P153; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KAWAMURA S, 1992, BIOCHEM BIOPH RES CO, V186, P411, DOI 10.1016/S0006-291X(05)80823-X; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNO T, 1992, BIOCHEM BIOPH RES CO, V184, P1219, DOI 10.1016/S0006-291X(05)80012-9; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; LENZ SE, 1992, MOL BRAIN RES, V15, P133, DOI 10.1016/0169-328X(92)90160-D; MCGINNIS JF, 1992, FEBS LETT, V302, P172, DOI 10.1016/0014-5793(92)80433-H; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; MURAKAMI A, 1992, BIOCHEM BIOPH RES CO, V187, P234, DOI 10.1016/S0006-291X(05)81483-4; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462, DOI 10.1016/0166-2236(89)90097-0; POLANS AS, 1991, J CELL BIOL, V112, P981, DOI 10.1083/jcb.112.5.981; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; SEMPLEROWLAND SL, 1992, BIOCHEM BIOPH RES CO, V183, P456, DOI 10.1016/0006-291X(92)90503-D; SENGUPTA B, 1987, J BIOL CHEM, V262, P16663; STEIGEMANN W, 1974, THESIS TU MUNCHEN; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TAKAMATSU K, 1992, BIOCHEM BIOPH RES CO, V183, P245, DOI 10.1016/0006-291X(92)91635-4; TAYLOR DA, 1991, J BIOL CHEM, V266, P21375; TERASAWA M, 1992, J BIOL CHEM, V267, P19596; THIRKILL CE, 1992, INVEST OPHTH VIS SCI, V33, P2768; WANG BC, 1985, METHOD ENZYMOL, V115, P90; YAMAGATA K, 1990, NEURON, V2, P469; Yau K W, 1991, Curr Opin Neurobiol, V1, P252, DOI 10.1016/0959-4388(91)90086-M; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	51	227	230	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					709	716		10.1016/0092-8674(93)90491-8	http://dx.doi.org/10.1016/0092-8674(93)90491-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242744	Bronze			2022-12-28	WOS:A1993MH74900016
J	OSTFELD, RS; CANHAM, CD; PUGH, SR				OSTFELD, RS; CANHAM, CD; PUGH, SR			INTRINSIC DENSITY-DEPENDENT REGULATION OF VOLE POPULATIONS	NATURE			English	Article							ANIMAL POPULATIONS; SMALL MAMMALS; CYCLES	CONSIDERABLE controversy exists over the role of density-dependent processes in controlling animal population size. In populations that fluctuate cyclically or erratically, for example many voles and insects1,2, theory predicts that either density-dependence is weak1,3, or that density-dependent responses lag behind density4-6. One key mechanism for lagged density-dependence is a delay in regeneration of food resources following heavy exploitation. Here we show that meadow vole (Microtus pennsylvanicus) populations respond immediately to high density by reducing breeding effort and hence population growth, disproving the hypothesis that density-dependence is weak. In addition, vole populations do not show a delay in growth following marked reduction in plant biomass (their source of food and cover). We conclude that intrinsic density-dependence processes tend to stabilize vole populations, and that cyclic dynamics are not caused by lagged effects of resource exploitation.	BOSTON UNIV, COLL GEN STUDIES, BOSTON, MA 02215 USA	Boston University	OSTFELD, RS (corresponding author), INST ECOSYST STUDIES, BOX AB, MILLBROOK, NY 12545 USA.		Canham, Charles D/F-6161-2011	Canham, Charles D/0000-0001-8361-9148; Ostfeld, Richard/0000-0002-3707-9301				AKCAKAYA HR, 1992, ECOL MONOGR, V62, P119, DOI 10.2307/2937172; ANDREWARTHA HG, 1954, DISTRIBUTION ABUNDAN; BROWN MW, 1989, ECOLOGY, V70, P776, DOI 10.2307/1940227; CHITTY D, 1987, CAN J ZOOL, V65, P2555, DOI 10.1139/z87-385; COCKBURN A, 1988, SOCIAL BEHAVIOUR FLU; DEMPSTER JP, 1986, OIKOS, V46, P413, DOI 10.2307/3565842; Elton C., 1942, VOLES MICE LEMMINGS; GAINES MS, 1980, ANNU REV ECOL SYST, V11, P163, DOI 10.1146/annurev.es.11.110180.001115; GASTON KJ, 1987, OECOLOGIA, V74, P404, DOI 10.1007/BF00378937; HANSKI I, 1991, J ANIM ECOL, V60, P353, DOI 10.2307/5465; HANSKI I, 1990, PHILOS T R SOC B, V330, P141, DOI 10.1098/rstb.1990.0188; HANSKI I, 1993, NATURE, V364, P232, DOI 10.1038/364232a0; HANSSON L, 1988, TRENDS ECOL EVOL, V3, P195, DOI 10.1016/0169-5347(88)90006-7; HASLER J F, 1975, Biologist (Charleston), V57, P52; HASSELL MP, 1987, J ANIM ECOL, V56, P705, DOI 10.2307/5078; HASSELL MP, 1986, TRENDS ECOL EVOL, V1, P90, DOI 10.1016/0169-5347(86)90031-5; Keller B.L., 1985, Special Publication American Society of Mammalogists, P725; Krebs C.J., 1974, ADV ECOL RES, V8, P267, DOI DOI 10.1016/S0065-2504(08)60280-9; LIDICKER WZ, 1985, SPEC PUBL AM SOC MAM, V8, P420; May R.M., 1976, P4; MCCRAVY KW, 1992, J MAMMAL, V73, P151, DOI 10.2307/1381877; MIHOK S, 1992, CAN J ZOOL, V70, P1561, DOI 10.1139/z92-215; OSTFELD RS, 1992, WILDLIFE 2001 : POPULATIONS, P851; SCHAFFER WM, 1973, EVOLUTION, V27, P111, DOI 10.1111/j.1558-5646.1973.tb05923.x; STENSETH NC, 1986, THEOR POPUL BIOL, V29, P365, DOI 10.1016/0040-5809(86)90015-8; STILING P, 1989, ECOLOGY, V70, P779, DOI 10.2307/1940228; STRONG DR, 1986, TRENDS ECOL EVOL, V1, P39, DOI 10.1016/0169-5347(86)90071-6; TURCHIN P, 1990, NATURE, V344, P660, DOI 10.1038/344660a0; WOIWOD IP, 1992, J ANIM ECOL, V61, P619, DOI 10.2307/5617	29	84	90	0	23	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 18	1993	366	6452					259	261		10.1038/366259a0	http://dx.doi.org/10.1038/366259a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH325	8232583				2022-12-28	WOS:A1993MH32500061
J	GIBBONS, A				GIBBONS, A			WHAT WORKS - BUILDING A GLOBAL LAB	SCIENCE			English	Editorial Material																			0	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1111	1111		10.1126/science.8235630	http://dx.doi.org/10.1126/science.8235630			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	8235630				2022-12-28	WOS:A1993MG18700057
J	OLDEN, K				OLDEN, K			CLASHING CULTURES - BRINGING SCIENCE BACK TO THE NEIGHBORHOOD	SCIENCE			English	Editorial Material											OLDEN, K (corresponding author), NIEHS,RES TRIANGLE PK,NC 27709, USA.								0	5	5	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1116	1116		10.1126/science.8235631	http://dx.doi.org/10.1126/science.8235631			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	8235631				2022-12-28	WOS:A1993MG18700058
J	DALAKAS, MC; ILLA, I; DAMBROSIA, JM; SOUEIDAN, SA; STEIN, DP; OTERO, C; DINSMORE, ST; MCCROSKY, S				DALAKAS, MC; ILLA, I; DAMBROSIA, JM; SOUEIDAN, SA; STEIN, DP; OTERO, C; DINSMORE, ST; MCCROSKY, S			A CONTROLLED TRIAL OF HIGH-DOSE INTRAVENOUS IMMUNE GLOBULIN INFUSIONS AS TREATMENT FOR DERMATOMYOSITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INCLUSION-BODY MYOSITIS; MEMBRANE ATTACK COMPLEX; MEDIATED CYTO-TOXICITY; INFLAMMATORY MYOPATHIES; MONONUCLEAR-CELLS; PLASMA-EXCHANGE; GAMMA-GLOBULIN; POLYMYOSITIS; THERAPY; IMMUNOGLOBULIN	Background. Dermatomyositis is a clinically distinct myopathy characterized by rash and a complement-mediated microangiopathy that results in the destruction of muscle fibers. In some patients the condition becomes resistant to therapy and causes severe physical disabilities. Methods. We conducted a double-blind, placebo-controlled study of 15 patients (age, 18 to 55 years) with biopsy-proved, treatment-resistant dermatomyositis. The patients continued to receive prednisone (mean daily dose, 25 mg) and were randomly assigned to receive one infusion of immune globulin (2 g per kilogram of body weight) or placebo per month for three months, with the option of crossing over to the alternative therapy for three more months. Clinical response was gauged by assessing muscle strength, neuromuscular symptoms, and changes in the rash. Changes in immune-mediated muscle abnormalities were determined by repeated muscle biopsies. Results. The eight patients assigned to immune globulin had a significant improvement in scores of muscle strength (P<0.018) and neuromuscular symptoms (P<0.035), whereas the seven patients assigned to placebo did not With crossovers, a total of 12 patients received immune globulin. Of these, nine with severe disabilities had a major improvement to nearly normal function. Their mean muscle-strength scores increased from 74.5 to 84.7, and their neuromuscular symptoms improved. Two of the other three patients had mild improvement, and one had no change in his condition. Of 11 placebo-treated patients, none had major improvement, 3 had mild improvement, 3 had no change in their condition, and 5 had worsening of their condition. Repeated biopsies in five patients of muscles whose strength improved to almost normal showed an increase in muscle-fiber diameter (P<0.04), an increase in the number and a decrease in the diameter of capillaries (P<0.01), resolution of complement deposits on capillaries, and a reduction in the expression of intercellular adhesion molecule 1 and major-histocompatibility-complex class I antigens. Conclusions. High-dose intravenous immune globulin is a safe and effective treatment for refractory dermatomyositis.	NINCDS,BIOMETRY & FIELD STUDIES BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	DALAKAS, MC (corresponding author), NINCDS,MED NEUROL BRANCH,NEUROMUSCULAR DIS SECT,BLDG 10,RM 4N248,BETHESDA,MD 20892, USA.		ILLA, Isabel/AAD-1816-2019					BACCHI VF, 1992, LANCET, V340, P63, DOI 10.1016/0140-6736(92)92486-Y; BALLOW M, 1991, CANCER, V68, P1430, DOI 10.1002/1097-0142(19910915)68:6+<1430::AID-CNCR2820681405>3.0.CO;2-4; BANKER BQ, 1986, MYOLOGY, P1385; BASTA M, 1989, J CLIN INVEST, V84, P1974, DOI 10.1172/JCI114387; BLASCZYK R, 1993, LANCET, V341, P789, DOI 10.1016/0140-6736(93)90563-V; CHERIN P, 1991, AM J MED, V91, P162, DOI 10.1016/0002-9343(91)90009-M; DALAKAS M, 1990, CURR OPIN NEUROL NEU, V3, P689; DALAKAS MC, 1991, NEW ENGL J MED, V325, P1487, DOI 10.1056/NEJM199111213252107; DALAKAS MC, 1992, CLIN NEUROPHARMACOL, V15, P327, DOI 10.1097/00002826-199210000-00001; DALAKAS MC, 1992, CURR OPIN NEUROL NEU, V5, P645; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DALAKAS MC, 1988, POLYMYOSITIS DERMATO; DALAKAS MC, 1992, HDB CLIN NEUROLOGY, V18, P369; Daniels L, 1972, MUSCLE TESTING TECHN, P2; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; DWYER JM, 1992, NEW ENGL J MED, V326, P107; EMSLIESMITH AM, 1989, HUM PATHOL, V20, P224, DOI 10.1016/0046-8177(89)90128-7; EMSLIESMITH AM, 1990, ANN NEUROL, V27, P343, DOI 10.1002/ana.410270402; ENGEL AG, 1982, ANN NEUROL, V12, P289, DOI 10.1002/ana.410120314; ENGEL AG, 1986, HUM PATHOL, V17, P704, DOI 10.1016/S0046-8177(86)80180-0; ENGEL AG, 1984, ANN NEUROL, V16, P209, DOI 10.1002/ana.410160207; GELFAND EW, 1990, CLIN IMMUNOL IMMUNOP, V55, P492; GELFAND EW, 1989, CLIN IMMUNOL IMMUNOP, V53, pS1, DOI 10.1016/0090-1229(89)90064-0; ILLA I, 1992, ANN NEUROL, V31, P46, DOI 10.1002/ana.410310109; KISSEL JT, 1986, NEW ENGL J MED, V314, P329, DOI 10.1056/NEJM198602063140601; LANG BA, 1991, AM J MED, V91, P169, DOI 10.1016/0002-9343(91)90010-U; LEHMANN EL, 1975, NONPARAMETRICS; MAHONEY F I, 1965, Md State Med J, V14, P61; MILLER FW, 1992, NEW ENGL J MED, V326, P1380, DOI 10.1056/NEJM199205213262102; ROIFMAN CM, 1987, JAMA-J AM MED ASSOC, V258, P513, DOI 10.1001/jama.1987.03400040111034; Rowland L P, 1977, Adv Neurol, V17, P63; ROWLAND LP, 1989, MERRITTS TXB NEUROLO, P733; SOUEIDAN SA, 1993, PEDIATR RES, V33, pS95, DOI 10.1203/00006450-199304001-00017; SOUEIDAN SA, 1993, NEUROLOGY, V43, P876, DOI 10.1212/WNL.43.5.876; STEIN DP, 1993, ANN NEUROL, V34, P268; STEIN DP, 1993, NEUROLOGY S, V43, P356; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705; WHITAKER JN, 1972, NEW ENGL J MED, V286, P333, DOI 10.1056/NEJM197202172860701	38	788	819	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1993	329	27					1993	2000		10.1056/NEJM199312303292704	http://dx.doi.org/10.1056/NEJM199312303292704			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN573	8247075				2022-12-28	WOS:A1993MN57300004
J	LIU, HP; STYLES, CA; FINK, GR				LIU, HP; STYLES, CA; FINK, GR			ELEMENTS OF THE YEAST PHEROMONE RESPONSE PATHWAY REQUIRED FOR FILAMENTOUS GROWTH OF DIPLOIDS	SCIENCE			English	Article							PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; USTILAGO-MAYDIS; SIGNALING COMPONENTS; CONSTITUTIVE MUTANTS; GAMMA-SUBUNITS; FISSION YEAST; GENES; STE12; TRANSCRIPTION	Transmission of an external signal from receptors to downstream targets is often mediated by a conserved set of protein kinases that act in sequence (a kinase cascade). In haploid strains of Saccharomyces cerevisiae, a signal initiated by peptide pheromones is transmitted through this kinase cascade to a transcription factor STE12, which is required for the expression of many mating-specific genes. Here it was shown that in diploids some of the same kinases and STE12 are required for filamentous growth, but the pheromone receptors and guanosine triphosphate-binding protein are not required for filament formation. Thus, a similar kinase cascade is activated by different signals in haploids and diploids and mediates different developmental outcomes in the two cell types.	MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Whitehead Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035010, R37GM035010] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35010] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANUETT F, 1992, TRENDS GENET, V8, P174, DOI 10.1016/0168-9525(92)90091-H; BANUETT F, 1989, P NATL ACAD SCI USA, V86, P5878, DOI 10.1073/pnas.86.15.5878; BENDER A, 1991, CELL, V65, P1203; BLINDER D, 1989, CELL, V56, P479, DOI 10.1016/0092-8674(89)90250-X; BOLKER M, 1992, CELL, V68, P441, DOI 10.1016/0092-8674(92)90182-C; CHALEFF DT, 1985, MOL CELL BIOL, V5, P1878, DOI 10.1128/MCB.5.8.1878; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; DOLAN JW, 1990, GENE DEV, V4, P492, DOI 10.1101/gad.4.4.492; ELION EA, 1991, COLD SPRING HARB SYM, V56, P41; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; FIELDS S, 1985, CELL, V42, P923, DOI 10.1016/0092-8674(85)90288-0; GILLISSEN B, 1992, CELL, V68, P647, DOI 10.1016/0092-8674(92)90141-X; GIMENO CJ, 1992, SCIENCE, V257, P626, DOI 10.1126/science.1496375; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; NADINDAVIS SA, 1988, EMBO J, V7, P985, DOI 10.1002/j.1460-2075.1988.tb02905.x; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WRIGHT RM, 1993, CURR GENET, V23, P388, DOI 10.1007/BF00312623	31	420	432	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 10	1993	262	5140					1741	1744		10.1126/science.8259520	http://dx.doi.org/10.1126/science.8259520			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	8259520				2022-12-28	WOS:A1993ML22000044
J	FAIRALL, L; SCHWABE, JWR; CHAPMAN, L; FINCH, JT; RHODES, D				FAIRALL, L; SCHWABE, JWR; CHAPMAN, L; FINCH, JT; RHODES, D			THE CRYSTAL-STRUCTURE OF A 2 ZINC-FINGER PEPTIDE REVEALS AN EXTENSION TO THE RULES FOR ZINC-FINGER DNA RECOGNITION	NATURE			English	Article							PROTEIN; BINDING; GENE; SPECIFICITY; DOMAINS; PROGRAM	THE Cys2-His2 zinc-finger is the most widely occurring DNA-binding motif1-3. The first structure of a zinc-finger/DNA complex revealed a fairly simple mechanism for DNA recognition4 suggesting that the zinc-finger might represent a candidate template for designing proteins to recognize DNA-5. Residues at three key positions in an alpha-helical 'reading head' play a dominant role in base-recognition and have been targets for mutagenesis experiments aimed at deriving a recognition code6-8. Here we report the structure of a two zinc-finger DNA-binding domain from the protein Tramtrack complexed with DNA. The amino-terminal zinc-finger and its interaction with DNA illustrate several novel features. These include the use of a serine residue, which is semi-conserved and located outside the three key positions, to make a base contact. Its role in base-recognition correlates with a large, local, protein-induced deformation of the DNA helix at a flexible A-T-A sequence and may give insight into previous mutagenesis experiments9,10. It is apparent from this structure that zinc-finger/DNA recognition is more complex than was originally perceived.			FAIRALL, L (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Fairall, Louise/G-6763-2013; Schwabe, John WR/A-9132-2008	Schwabe, John WR/0000-0003-2865-4383; Fairall, Louise/0000-0001-9456-3047				BERG JM, 1993, CURR OPIN STRUC BIOL, V3, P11, DOI 10.1016/0959-440X(93)90195-Q; BROWN JL, 1991, EMBO J, V10, P665, DOI 10.1002/j.1460-2075.1991.tb07995.x; BRUNGER AT, 1992, XPLOR V 3 ZERO MANUA; DESJARALAIS JR, 1992, PROTEINS, V13, P282; DESJARLAIS JR, 1992, PROTEINS, V12, P101, DOI 10.1002/prot.340120202; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; FAIRALL L, 1992, J MOL BIOL, V226, P349, DOI 10.1016/0022-2836(92)90952-G; GREER J, 1985, METHOD ENZYMOL, V115, P206; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; HOOVERS JMN, 1992, GENOMICS, V12, P254, DOI 10.1016/0888-7543(92)90372-Y; JACOBS GH, 1992, EMBO J, V11, P4507, DOI 10.1002/j.1460-2075.1992.tb05552.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; LESLIE AGW, 1992, 26 JOINT CCP4 ESF EA; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NARDELLI J, 1992, NUCLEIC ACIDS RES, V20, P4137, DOI 10.1093/nar/20.16.4137; NEUHAUS D, 1992, J MOL BIOL, V228, P637, DOI 10.1016/0022-2836(92)90846-C; OMICHINSKI JG, 1990, BIOCHEMISTRY-US, V29, P9324, DOI 10.1021/bi00492a004; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; READ D, 1992, EMBO J, V11, P1035, DOI 10.1002/j.1460-2075.1992.tb05142.x; Travers A. A., 1990, DNA TOPOLOGY ITS BIO, P57; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; YOON C, 1988, P NATL ACAD SCI USA, V85, P6332, DOI 10.1073/pnas.85.17.6332	30	313	359	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 2	1993	366	6454					483	487		10.1038/366483a0	http://dx.doi.org/10.1038/366483a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK098	8247159				2022-12-28	WOS:A1993MK09800070
J	BARZA, M				BARZA, M			SKIN AND NAIL LESIONS IN ENDOCARDITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											BARZA, M (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR,BOSTON,MA 02111, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1993	329	22					1626	1626						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ546	8232432				2022-12-28	WOS:A1993MJ54600006
J	ATTISANO, L; CARCAMO, J; VENTURA, F; WEIS, FMB; MASSAGUE, J; WRANA, JL				ATTISANO, L; CARCAMO, J; VENTURA, F; WEIS, FMB; MASSAGUE, J; WRANA, JL			IDENTIFICATION OF HUMAN ACTIVIN AND TGF-BETA TYPE-I RECEPTORS THAT FORM HETEROMERIC KINASE COMPLEXES WITH TYPE-II RECEPTORS	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; SERINE THREONINE KINASE; PROTEIN-KINASE; SIGNAL TRANSDUCTION; EXPRESSION CLONING; CELL-PROLIFERATION; BINDING; SYSTEM; COMPONENT; SURFACE	Transforming growth factor beta (TGFbeta) and activin each bind to pairs of membrane proteins, known as receptor types I and II, that associate to form a signaling complex. We report that TSR-I and ActR-I, two human transmembrane serine/threonine kinases distantly related to TGFbeta and activin type II receptors, act as type I receptors for these factors. TSR-I is a type I receptor shared by TGFbeta and activin, whereas ActR-I is an activin type I receptor. ActR-I, but not TSR-I, signals a particular transcriptional response in concert with activin type II receptors. The results indicate that type I receptors are transmembrane protein kinases that associate with type II receptors to generate diverse heteromeric serine/threonine kinase complexes of different signaling capacities.			ATTISANO, L (corresponding author), MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021, USA.		Ventura, Francesc/K-9700-2014; Ventura, Francesc/ABG-2285-2020; Wrana, Jeffrey/F-8857-2013	Ventura, Francesc/0000-0001-9673-9405; Ventura, Francesc/0000-0001-9673-9405; Massague, Joan/0000-0001-9324-8408				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; CHEIFETZ S, 1988, J BIOL CHEM, V263, P17225; CHILDS SR, 1993, P NATL ACAD SCI USA, V90, P9475, DOI 10.1073/pnas.90.20.9475; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GONZALEZMANCHON C, 1989, ENDOCRINOLOGY, V125, P1666, DOI 10.1210/endo-125-3-1666; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KISHIMOTO T, 1992, SCIENCE, V258, P583; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATSUZAKI K, 1993, J BIOL CHEM, V268, P12719; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; NISHIMATSU SI, 1992, FEBS LETT, V303, P81, DOI 10.1016/0014-5793(92)80482-V; PARALKAR VM, 1991, P NATL ACAD SCI USA, V88, P3397, DOI 10.1073/pnas.88.8.3397; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Sambrook J, 1989, MOL CLONING LABORATO; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEGARINI PR, 1988, J BIOL CHEM, V263, P8366; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALE W, 1990, PEPTIDE GROWTH FACTO, P211; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1991, BIOCHEM J, V273, P523, DOI 10.1042/bj2730523; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YING SY, 1986, BIOCHEM BIOPH RES CO, V135, P950, DOI 10.1016/0006-291X(86)91020-X	56	623	659	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					671	680		10.1016/0092-8674(93)90488-C	http://dx.doi.org/10.1016/0092-8674(93)90488-C			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242742				2022-12-28	WOS:A1993MH74900013
J	LU, X; LANE, DP				LU, X; LANE, DP			DIFFERENTIAL INDUCTION OF TRANSCRIPTIONALLY ACTIVE P53 FOLLOWING UV OR IONIZING-RADIATION - DEFECTS IN CHROMOSOME INSTABILITY SYNDROMES	CELL			English	Article							WILD-TYPE P53; CELLULAR TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; ATAXIA-TELANGIECTASIA; MONOCLONAL-ANTIBODIES; ACTIVATING MUTATIONS; TRANSFORMED-CELLS; CHO CELLS; T-ANTIGEN; EXPRESSION	Accumulation of p53 protein was seen in the nuclei of mammalian cells following DNA damage caused by ultraviolet radiation (UV), X-ray, or a restriction enzyme. Promoters containing p53-binding sites show a dramatic transcriptional response to DNA damage. The p53 response to X-ray is rapid, reaching a peak at 2 hr after radiation, but is very transitory and reduced in magnitude compared with that seen in response to UV. We find no substantive defect in the p53 response of cells from ataxia telangiectasia or xeroderma pigmentosum complementation group A patients. In contrast, 2 out of 11 primary cultures from Bloom's patients showed a complete absence of p53 accumulation following UV irradiation or SV40 infection and a grossly delayed and aberrant response following X-ray.			LU, X (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,CANC RES CAMPAIGN LABS,CELL TRANSFORMAT RES GRP,DUNDEE DD1 4HN,SCOTLAND.		Lane, David P/C-4920-2008	Lu, Xin/0000-0002-6587-1152; Lane, David/0000-0003-0551-3545				ARLETT CF, 1988, INT J RADIAT BIOL, V54, P911, DOI 10.1080/09553008814552321; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BRYANT PE, 1992, MUTAT RES, V268, P27, DOI 10.1016/0027-5107(92)90079-H; BURKI HJ, 1980, MUTAT RES, V69, P347; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DING RC, 1992, J BIOL CHEM, V267, P12804; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FORNACE AJ, 1982, MUTAT RES, V94, P263, DOI 10.1016/0027-5107(82)90290-1; FRANHENBERG F, 1969, PHYS MED BIOL, V14, P487; FRIEDBERG EC, 1985, DNA REPAIR, P505; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HALL PA, 1993, ONCOGENE, V8, P203; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW EE, 1988, ANTIBODDIES LABORATO; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; LU X, 1990, CELL, V62, P681, DOI 10.1016/0092-8674(90)90114-T; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, ONCOGENE, V5, P973; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MURNANE JP, 1993, SEMIN CANCER BIOL, V4, P93; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; Sambrook J, 1989, MOL CLONING LABORATO; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SHERLEY JL, 1991, J BIOL CHEM, V266, P24815; SIRVASTAVA S, 1990, NATURE, V348, P747; STURZBECHER HW, 1988, ONCOGENE, V3, P405; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	55	835	852	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					765	778		10.1016/0092-8674(93)90496-D	http://dx.doi.org/10.1016/0092-8674(93)90496-D			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242748	Bronze			2022-12-28	WOS:A1993MH74900021
J	LOWE, G; GOLD, GH				LOWE, G; GOLD, GH			NONLINEAR AMPLIFICATION BY CALCIUM-DEPENDENT CHLORIDE CHANNELS IN OLFACTORY RECEPTOR-CELLS	NATURE			English	Article							SENSITIVE ADENYLATE-CYCLASE; 2ND MESSENGER PATHWAYS; CYCLIC-NUCLEOTIDES; ODORANT; CILIA; ACTIVATION; CONDUCTANCE; NEWT; RAT; TRANSDUCTION	THE sense of smell is highly evolved in mammals, allowing discrimination between a vast number of odorants, with detection thresholds as low as 10(-17) M (ref. 1). Although several features of mammalian olfactory transduction have been revealed by biochemical and molecular biological studies2-11, the odorant-induced membrane current has remained elusive. In amphibians this current is mediated by cyclic-nucleotide-gated channels12-15, which depolarize the cell by Na+ and Ca+ influx16,17 and consequent Cl- efflux through Ca2+-dependent Cl- channels18,19. The Cl- current may be absent in mammals, however, because its proposed role is linked to the aquatic habitat of amphibians18. Here we show that the transduction current in rat olfactory receptor cells is initiated by cyclic-nucleotide-gated channels. The Cl- current is also present and endows the transduction current with a steep sigmoidal dependence on cyclic AMP concentration in both rat and in an amphibian, indicating a new function for the Cl- channel: nonlinear amplification of the transduction signal, whereby suprathreshold responses are boosted relative to basal transduction noise.			LOWE, G (corresponding author), MONELL CHEM SENSES CTR,3500 MARKET ST,PHILADELPHIA,PA 19104, USA.							BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BENARIE N, 1993, BIOCHEM J, V292, P379, DOI 10.1042/bj2920379; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BREER H, 1991, CHEM SENSES, V16, P19, DOI 10.1093/chemse/16.1.19; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; FIRESTEIN S, 1989, SCIENCE, V244, P79, DOI 10.1126/science.2704991; FIRESTEIN S, 1993, J PHYSIOL-LONDON, V468, P1; FIRESTEIN S, 1991, J NEUROSCI, V11, P3565; FRINGS S, 1991, J GEN PHYSIOL, V97, P1, DOI 10.1085/jgp.97.1.1; FRINGS S, 1992, J GEN PHYSIOL, V100, P45, DOI 10.1085/jgp.100.1.45; HUQUE T, 1986, BIOCHEM BIOPH RES CO, V137, P36, DOI 10.1016/0006-291X(86)91172-1; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KLEENE SJ, 1993, NEURON, V11, P123, DOI 10.1016/0896-6273(93)90276-W; KLEENE SJ, 1991, J NEUROSCI, V11, P3624; KURAHASHI T, 1990, J PHYSIOL-LONDON, V430, P355, DOI 10.1113/jphysiol.1990.sp018295; KURAHASHI T, 1990, BRAIN RES, V515, P261, DOI 10.1016/0006-8993(90)90605-B; KURAHASHI T, 1989, J PHYSIOL-LONDON, V419, P177, DOI 10.1113/jphysiol.1989.sp017868; KURAHASHI T, 1993, NATURE, V363, P71, DOI 10.1038/363071a0; LOWE G, 1991, J PHYSIOL-LONDON, V442, P147, DOI 10.1113/jphysiol.1991.sp018787; LOWE G, 1993, J PHYSIOL-LONDON, V462, P175, DOI 10.1113/jphysiol.1993.sp019550; LYNCH JW, 1989, BIOPHYS J, V55, P755, DOI 10.1016/S0006-3495(89)82874-7; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NERBONNE JM, 1984, NATURE, V310, P74, DOI 10.1038/310074a0; PASSE DH, 1985, NEUROSCI BIOBEHAV R, V9, P431, DOI 10.1016/0149-7634(85)90021-1; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; RESTREPO D, 1992, AM J PHYSIOL, V263, pC667, DOI 10.1152/ajpcell.1992.263.3.C667; RONNETT GV, 1991, P NATL ACAD SCI USA, V88, P2366, DOI 10.1073/pnas.88.6.2366; SHIRLEY SG, 1986, BIOCHEM J, V240, P605, DOI 10.1042/bj2400605; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; ZUFALL F, 1993, P NATL ACAD SCI USA, V90, P935	30	276	279	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 18	1993	366	6452					283	286		10.1038/366283a0	http://dx.doi.org/10.1038/366283a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH325	8232590				2022-12-28	WOS:A1993MH32500069
J	WHITE, TD; SUWA, G; HART, WK; WALTER, RC; WOLDEGABRIEL, G; DEHEINZELIN, J; CLARK, JD; ASFAW, B; VRBA, E				WHITE, TD; SUWA, G; HART, WK; WALTER, RC; WOLDEGABRIEL, G; DEHEINZELIN, J; CLARK, JD; ASFAW, B; VRBA, E			NEW DISCOVERIES OF AUSTRALOPITHECUS AT MAKA IN ETHIOPIA	NATURE			English	Article							MIDDLE AWASH VALLEY; AFARENSIS; MORPHOLOGY; EVOLUTION; STRATIGRAPHY; HOMINIDS; AGE	THE taxonomy of Australopithecus afarensis, the oldest known hominid species, has been a matter of debate since its description in 1978 (ref. 1). Some authorities regard all specimens assigned to A. afarensis as belonging to a single taxon2-4 whereas others regard the Tanzanian and Ethiopian specimens as each representing a different species5,6. Further controversy surrounds the issues of sexual dimorphism and locomotion among these hominids. Resolution of these problems would shed light on hominid phylogeny in general and on the ancestry of later Australopithecus and Homo. Fossils discovered in the Afar of Ethiopia in 1990 constitute the first major addition to the 3-4 million year (Myr) hominid record since the 1970s. We report here the discovery of new fossils from Maka, dated to 3.4 Myr ago, which provide powerful support for the interpretation of A. afarensis as a single, ecologically diverse, sexually dimorphic, bipedal Pliocene primate species whose known range encompassed Ethiopia and Tanzania.	UNIV TOKYO,DEPT ANTHROPOL,BUNKYO KU,TOKYO 113,JAPAN; MIAMI UNIV,DEPT GEOL,OXFORD,OH 45056; INST HUMAN ORIGINS,CTR GEOCHRONOL,BERKELEY,CA 94709; LOS ALAMOS NATL LAB,LOS ALAMOS,NM 87545; INST ROYAL SCI NAT BELGIQUE,B-1040 BRUSSELS,BELGIUM; UNIV CALIF BERKELEY,DEPT ANTHROPOL,BERKELEY,CA 94720; PALEOANTHROPOL LAB,ADDIS ABABA,ETHIOPIA; YALE UNIV,DEPT GEOL & GEOPHYS,NEW HAVEN,CT 06511	University of Tokyo; University System of Ohio; Miami University; United States Department of Energy (DOE); Los Alamos National Laboratory; University of California System; University of California Berkeley; Yale University	WHITE, TD (corresponding author), UNIV CALIF BERKELEY,DEPT ANTHROPOL,HUMAN EVOLUT STUDIES LAB,BERKELEY,CA 94720, USA.		Klein, Richard G/B-5910-2009; Walter, Robert/AAD-7642-2020	Walter, Robert/0000-0001-8761-5355				ADAMSON DA, 1987, J HUM EVOL, V16, P597, DOI 10.1016/0047-2484(87)90015-7; ASFAW B, 1987, J HUM EVOL, V16, P611, DOI 10.1016/0047-2484(87)90016-9; BOAZ NT, 1988, YEARB PHYS ANTHROPOL, V31, P85; Brown F.H., 1992, QUATERN INT, V13-14, P55, DOI DOI 10.1016/1040-6182(92)90010-Y; CLARK JD, 1984, NATURE, V307, P423, DOI 10.1038/307423a0; CONROY GC, 1978, NATURE, V275, P67; COPPENS Y, 1983, SINGLE; CRONIN JE, 1981, NATURE, V292, P113, DOI 10.1038/292113a0; DAY MH, 1982, NATURE, V300, P574, DOI 10.1038/300574a0; DEINO A, 1990, J GEOL, V98, P567, DOI 10.1086/629425; GORTANI M, 1973, MISSIONE GEOLOGICA A; HAILEAB B, 1992, J HUM EVOL, V22, P453, DOI 10.1016/0047-2484(92)90080-S; HALL CM, 1984, NATURE, V308, P26, DOI 10.1038/308026a0; HART WK, 1992, QUATERN INT, V13, P77; JOHANSON DC, 1982, AM J PHYS ANTHROPOL, V57, P373, DOI 10.1002/ajpa.1330570402; JOHANSON DC, 1978, KIRTLANDIA, V28, P1; JOHANSON DC, 1979, SCIENCE, V202, P321; Kalb J.E., 1982, Newsletters on Stratigraphy, V11, P95; KALB JE, 1982, NATURE, V298, P25, DOI 10.1038/298025a0; KALB JE, 1982, NATURE, V298, P17, DOI 10.1038/298017a0; LATIMER B, 1989, AM J PHYS ANTHROPOL, V78, P369, DOI 10.1002/ajpa.1330780306; Latimer B., 1991, P169; LEAKEY MD, 1981, PHIL T R SOC B, V292, P9; LEAKEY RE, 1976, AM SCI, V64, P174; LEONARD WR, 1987, AM J PHYS ANTHROPOL, V73, P41, DOI 10.1002/ajpa.1330730105; LOVEJOY CO, 1988, SCI AM, V256, P118; Mayr E, 1982, HIST AM PHYSICAL ANT, P231; Olson T. R., 1981, ASPECTS HUMAN EVOLUT, P99; Rose M.D., 1991, P37; SENUT B, 1983, B MEM SOC ANTHRO PAR, V10, P325, DOI 10.3406/bmsap.1983.3906; STERN JT, 1983, AM J PHYS ANTHROPOL, V60, P279, DOI 10.1002/ajpa.1330600302; Susman R.L., 1991, P121; TAIEB M, 1974, THESIS U PARIS; Tobias P.V., 1980, Palaeontologia Africana, V23, P1; TUTTLE RH, 1988, ANNU REV ANTHROPOL, V17, P391; WALTER RC, 1993, J HUM EVOL, V25, P229, DOI 10.1006/jhev.1993.1046; WALTER RC, 1991, NATURE, V354, P145, DOI 10.1038/354145a0; WALTER RC, 1985, GEOL SOC AM ABSTR, V17, P743; WHITE TD, 1985, ANCESTORS HARD EVIDE, P139; WOLDEGABRIEL G, 1987, GEOLOGY, V15, P432; WOLDEGABRIEL G, 1992, QUATERN INT, V13, P69, DOI DOI 10.1016/1040-6182(92)90011-P; ZIHLMAN A, 1981, HOMINID EVOLUTION PA, P213; [No title captured]	43	133	134	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 18	1993	366	6452					261	265		10.1038/366261a0	http://dx.doi.org/10.1038/366261a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MH325	8232584				2022-12-28	WOS:A1993MH32500062
J	ROWLEY, JD; ASTER, JC; SKLAR, J				ROWLEY, JD; ASTER, JC; SKLAR, J			THE CLINICAL-APPLICATIONS OF NEW DNA DIAGNOSTIC TECHNOLOGY ON THE MANAGEMENT OF CANCER-PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEUKEMIA; ABERRATIONS; NEOPLASMS; BREAST; GENES		UNIV CHICAGO, MED CTR, DEPT MED, 5841 S MARYLAND AVE, MC 2115, CHICAGO, IL 60637 USA; UNIV CHICAGO, MED CTR, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; INST MED, WASHINGTON, DC USA	University of Chicago; University of Chicago Medical Center; University of Chicago; University of Chicago Medical Center; Harvard University; Brigham & Women's Hospital			Aster, Jon C/B-6857-2009					BLOOMFIELD CD, 1989, CANCER GENET CYTOGEN, V40, P171, DOI 10.1016/0165-4608(89)90023-X; BRODEUR GM, 1993, PRINCIPLES PRACTICE, P749; FLETCHER JA, 1991, NEW ENGL J MED, V324, P436, DOI 10.1056/NEJM199102143240702; KEATING MJ, 1988, LEUKEMIA, V2, P403; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Mertens F., 1991, CATALOG CHROMOSOME A; NUCIFORA G, 1993, BLOOD, V81, P883; PU L, 1993, SCIENCE, V261, P1041; ROWLEY JD, 1990, SEMIN HEMATOL, V27, P122; ROWLEY JD, 1993, ARCH PATHOL LAB MED, V117, P1104; ROWLEY JD, 1993, CANCER PRINCIPLES PR, P67; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA; SKLAR J, 1988, ANNU REV MED, V39, P315, DOI 10.1146/annurev.me.39.020188.001531; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	18	21	21	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1993	270	19					2331	2337		10.1001/jama.270.19.2331	http://dx.doi.org/10.1001/jama.270.19.2331			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF993	8230596				2022-12-28	WOS:A1993MF99300028
J	SIMPSON, JL; ELIAS, S				SIMPSON, JL; ELIAS, S			ISOLATING FETAL CELLS FROM MATERNAL BLOOD - ADVANCES IN PRENATAL-DIAGNOSIS THROUGH MOLECULAR TECHNOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MULTIPARAMETER FLOW-CYTOMETRY; PERIPHERAL-BLOOD; PREGNANT-WOMEN; NUCLEATED ERYTHROCYTES; DNA AMPLIFICATION; TROPHOBLAST CELLS; SEX DETERMINATION; DISEASE; AGE	Objectives.-To review the rationale for and progress toward the goal of isolating and analyzing fetal cells circulating in maternal blood, and to explore the feasibility of this method in providing noninvasive prenatal cytogenetic diagnosis. Data Sources.-Critical review of data published since the first report (1969) of fetal metaphases in maternal blood. Emphasis is placed on data since the demonstration by polymerase chain reaction (PCR) in 1989 and 1990 that fetal cells indeed exist in maternal blood. Data Synthesis.-Clinical evaluations have not yet been conducted, but it is already clear that molecular technologies have allowed the unequivocal demonstration of fetal cells in maternal blood. Using PCR, our own group and others have demonstrated Y sequences and single gene sequences (eg, hemoglobin Lepore(Boston)) in maternal blood. Thus, fetal DNA sequences indeed exist in maternal blood. Among the various candidate cells, the most promising appear to be fetal nucleated red blood cells. We isolated nucleated red blood cells on the basis of flow-sorting for the transferrin receptor and glycophorin-A. Enriched samples were then subjected to fluorescence in situ hybridization with chromosome-specific probes. This approach allowed us to detect trisomy 21 and trisomy 18, work later confirmed by others. Conclusions.-Isolating and analyzing fetal cells from maternal blood is clearly possible. Several key biologic questions remain-the optimal cells for isolation, frequency of cells in maternal blood, timing during gestation for maternal blood sampling, and the likelihood of persistence of fetal cells after delivery. Clinical evaluations planned by the National Institute of Child Health and Human Development will determine the sensitivity and specificity of this method and its precise role in prenatal cytogenetic diagnosis.			SIMPSON, JL (corresponding author), UNIV TENNESSEE,DEPT OBSTET & GYNECOL,853 JEFFERSON AVE,MEMPHIS,TN 38103, USA.				NICHD NIH HHS [HD8-2903, HD8-2904] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD082904, N01HD082903] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BIANCHI DW, 1993, PRENATAL DIAG, V13, P293, DOI 10.1002/pd.1970130408; BIANCHI DW, 1992, HUM GENET, V90, P368; BIANCHI DW, 1990, P NATL ACAD SCI USA, V87, P3279, DOI 10.1073/pnas.87.9.3279; BIANCHI DW, 1991, PRENATAL DIAG, V11, P523, DOI 10.1002/pd.1970110807; BRUCH JF, 1991, PRENATAL DIAG, V11, P787, DOI 10.1002/pd.1970111007; CACHEUX V, 1992, FETAL DIAGN THER, V7, P190, DOI 10.1159/000263699; CAMASCHELLA C, 1990, BLOOD, V75, P2102; COVONE AE, 1984, LANCET, V2, P841; COVONE AE, 1988, PRENATAL DIAG, V8, P591, DOI 10.1002/pd.1970080807; de Grouchy J, 1971, Ann Genet, V14, P133; ELIAS S, 1992, LANCET, V340, P1033, DOI 10.1016/0140-6736(92)93041-K; Elias S., 1992, American Journal of Human Genetics, V51, pA4; ELIAS S, IN PRESS SCREENING D; ERSLEV AJ, 1990, HEMATOLOGY, P389; GANSHIRTAHLERT D, 1992, AM J OBSTET GYNECOL, V166, P1350; GANSHIRTAHLERT D, 1992, AM J HUM GENET, V51, pA48; GIANCHI DW, 1992, GENETIC DISORDERS FE, P759; GROSSET L, 1974, AM J OBSTET GYNECOL, V120, P60, DOI 10.1016/0002-9378(74)90179-3; Hall Jeff M., 1992, American Journal of Human Genetics, V51, pA257; HERZENBERG LA, 1979, P NATL ACAD SCI USA, V76, P1453, DOI 10.1073/pnas.76.3.1453; HOLZGREVE W, 1992, PRENAT DIAGN S, V12, pS17; IVERSON GM, 1981, PRENATAL DIAG, V1, P61, DOI 10.1002/pd.1970010111; KLINGER K, 1992, AM J HUM GENET, V51, P55; LO YMD, 1993, LANCET, V341, P1147, DOI 10.1016/0140-6736(93)93161-S; LO YMD, 1990, LANCET, V335, P1463, DOI 10.1016/0140-6736(90)91491-R; LO YMD, 1989, LANCET, V2, P1363; MUELLER UW, 1990, LANCET, V336, P197, DOI 10.1016/0140-6736(90)91731-O; PHILLIPS OP, 1992, OBSTET GYNECOL, V80, P353; PRICE JO, 1991, AM J OBSTET GYNECOL, V165, P1731, DOI 10.1016/0002-9378(91)90024-L; SCHRODER J, 1974, TRANSPLANTATION, V17, P346, DOI 10.1097/00007890-197404000-00003; SCHRODER J, 1972, BLOOD-J HEMATOL, V39, P153, DOI 10.1182/blood.V39.2.153.153; SIEBERS JW, 1975, HUMANGENETIK, V28, P273; SIMPSON JL, 1992, PRENAT DIAGN, V12, pS34; SIMPSON JL, IN PRESS INFER REPRO; SIMPSON JL, 1993, IN PRESS 8 P WORLD C; THARAPEL AT, 1993, FETAL DIAGN THER, V8, P95, DOI 10.1159/000263755; THARAPEL AT, 1989, AM J HUM GENET, V45, P271; TIPTON RE, 1990, AM J OBSTET GYNECOL, V163, P1546; TOVEY G H, 1952, Med Press, V228, P300; VOAK D, 1971, BRIT J HAEMATOL, V20, P9, DOI 10.1111/j.1365-2141.1971.tb00782.x; WACHTEL S, 1991, HUM REPROD, V6, P1466, DOI 10.1093/oxfordjournals.humrep.a137290; WALKNOWSKA J, 1969, LANCET, V1, P1119; WESSMAN M, 1992, PRENATAL DIAG, V12, P993, DOI 10.1002/pd.1970121204; WILSON RD, 1992, PREVANT DIAGN, V12, pS177; YEOH SC, 1991, PRENATAL DIAG, V11, P117, DOI 10.1002/pd.1970110207; ZILLIACUS R, 1975, SCAND J HAEMATOL, V15, P333	46	159	194	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1993	270	19					2357	2361		10.1001/jama.270.19.2357	http://dx.doi.org/10.1001/jama.270.19.2357			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF993	8230600				2022-12-28	WOS:A1993MF99300032
J	AHMAD, M; CASHMORE, AR				AHMAD, M; CASHMORE, AR			HY4 GENE OF A-THALIANA ENCODES A PROTEIN WITH CHARACTERISTICS OF A BLUE-LIGHT PHOTORECEPTOR	NATURE			English	Article							COLI DNA PHOTOLYASE; ARABIDOPSIS-THALIANA; INSERTION MUTAGENESIS; HYPOCOTYL ELONGATION; DOMAINS	SPECIFIC responses to blue light are found throughout the biological kingdom. These responses-which in higher plants include phototropism, inhibition of hypocotyl elongation, and stomatal opening1-are in many cases thought to be mediated by flavin-type photoreceptors2. But no such blue-light photoreceptor has yet been identified or isolated, although blue-light responses in plants were reported by Darwin over a century ago3, long before the discovery of the now relatively well characterized red/far-red light photoreceptor, phytochrome. Here we describe the isolation of a gene corresponding to the HY4 locus of Arabidopsis thaliana. The hy4 mutant5 is one of several mutants6 that are selectively insensitive to blue light during the blue-light-dependent inhibition of hypocotyl elongation response, which suggests that they lack an essential component of the cryptochrome-associated light-sensing pathway. The HY4 gene, isolated by gene tagging, was shown to encode a protein with significant homology to microbial DNA photolyases. As photolyases are a rare class of flavoprotein that catalyse blue-light-dependent reactions7, the protein encoded by HY4 has a structure consistent with that of a flavin-type blue-light photoreceptor.			AHMAD, M (corresponding author), UNIV PENN,INST PLANT SCI,DEPT BIOL,PHILADELPHIA,PA 19104, USA.			Ahmad, Margaret/0000-0003-4524-5813				Ausubel FM, 1988, MOL REPROD DEV; DARWIN C, 1981, POWER MOVEMENT PLANT; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; Galland Paul, 1991, P65; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; KAUFMAN LS, 1993, PLANT PHYSIOL, V102, P333, DOI 10.1104/pp.102.2.333; KOBAYASHI T, 1989, NUCLEIC ACIDS RES, V17, P4731, DOI 10.1093/nar/17.12.4731; KOORNNEEF M, 1980, Z PFLANZENPHYSIOL, V100, P147, DOI 10.1016/S0044-328X(80)80208-X; LI YF, 1990, BIOCHEMISTRY-US, V29, P5698, DOI 10.1021/bi00476a009; LISCUM E, 1991, PLANT CELL, V3, P685, DOI 10.1105/tpc.3.7.685; MALHOTRA K, 1992, J BIOL CHEM, V267, P2909; Maniatis T., 1982, MOL CLONING; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; PANG QS, 1991, PLANT PHYSIOL, V95, P536, DOI 10.1104/pp.95.2.536; QUAIL PH, 1991, ANNU REV GENET, V25, P389, DOI 10.1146/annurev.ge.25.120191.002133; REYMOND P, 1992, P NATL ACAD SCI USA, V89, P4718, DOI 10.1073/pnas.89.10.4718; RUIZOPAZO N, 1987, J BIOL CHEM, V262, P4755; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINDLER U, 1992, EMBO J, V11, P1261, DOI 10.1002/j.1460-2075.1992.tb05170.x; YAJIMA H, 1991, NUCLEIC ACIDS RES, V19, P5359, DOI 10.1093/nar/19.19.5359; YAMAMOTO K, 1992, MOL GEN GENET, V232, P1, DOI 10.1007/BF00299129; YASUHIRA S, 1992, J BIOL CHEM, V267, P25644	23	971	1032	9	188	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 11	1993	366	6451					162	166		10.1038/366162a0	http://dx.doi.org/10.1038/366162a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG216	8232555				2022-12-28	WOS:A1993MG21600059
J	RIZZUTO, R; BRINI, M; MURGIA, M; POZZAN, T				RIZZUTO, R; BRINI, M; MURGIA, M; POZZAN, T			MICRODOMAINS WITH HIGH CA2+ CLOSE TO IP(3)-SENSITIVE CHANNELS THAT ARE SENSED BY NEIGHBORING MITOCHONDRIA	SCIENCE			English	Article							RAT-HEART MITOCHONDRIA; CALCIUM OSCILLATIONS; FLUORESCENT-PROBES; ACINAR-CELLS; CA-2+; RECEPTOR; HEPATOCYTES; STORES; HETEROGENEITY; ACTIVATION	Microdomains of high intracellular calcium ion concentration, [Ca2+]i, have been hypothesized to occur in living cells exposed to stimuli that generate inositol 1,4,5-trisphosphate (IP3). Mitochondrially targeted recombinant aequorin was used to show that IP3-induced Ca2+ mobilization from intracellular stores caused increases of mitochondrial Ca2+ concentration, [Ca2+]m, the speed and amplitude of which are not accounted for by the relatively small increases in mean [Ca2+]i. A similar response was obtained by the addition of IP3 to permeabilized cells but not by perfusion of cells with Ca2+ at concentrations similar to those measured in intact cells. It is concluded that in vivo, domains of high [Ca2+]i are transiently generated close to IP3-gated channels and sensed by nearby mitochondria; this may provide an efficient mechanism for optimizing mitochondrial activity upon cell stimulation.			RIZZUTO, R (corresponding author), UNIV PADUA,DEPT BIOMED SCI,CNR,CTR STUDY MITOCHONDRIAL PHYSIOL,VIA TRIESTE 75,I-35121 PADUA,ITALY.		Rizzuto, Rosario/B-6312-2008; Brini, Marisa/K-5189-2016	Brini, Marisa/0000-0001-5141-0243; Rizzuto, Rosario/0000-0001-7044-5097	Telethon [126] Funding Source: Medline	Telethon(Fondazione Telethon)		Augustine G J, 1992, Curr Opin Neurobiol, V2, P302, DOI 10.1016/0959-4388(92)90119-6; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; CHAD JE, 1984, BIOPHYS J, V45, P993, DOI 10.1016/S0006-3495(84)84244-7; Cobbold PH, 1991, CELLULAR CALCIUM PRA, P55; DENTON RM, 1990, ANNU REV PHYSIOL, V52, P451, DOI 10.1146/annurev.ph.52.030190.002315; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; FABIATO A, 1991, CELLULAR CALCIUM PRA, P159; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MCCORMACK JG, 1989, BIOCHIM BIOPHYS ACTA, V973, P420, DOI 10.1016/S0005-2728(89)80384-6; MELDOLESI J, 1990, BIOCHIM BIOPHYS ACTA, V1055, P130, DOI 10.1016/0167-4889(90)90113-R; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; PIETROBON D, 1990, EUR J BIOCHEM, V193, P599, DOI 10.1111/j.1432-1033.1990.tb19378.x; POENIE M, 1987, EMBO J, V6, P2223, DOI 10.1002/j.1460-2075.1987.tb02494.x; RIZZUTO R, 1987, BIOCHEM J, V246, P271, DOI 10.1042/bj2460271; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; RIZZUTO R, UNPUB; RIZZUTO R, IN PRESS METHODS CEL; ROBERTS WM, 1990, J NEUROSCI, V10, P3554; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; RUTTER GA, 1990, BIOCHEM J, V271, P627, DOI 10.1042/bj2710627; SATIN LS, 1989, J MEMBRANE BIOL, V112, P213, DOI 10.1007/BF01870952; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SIMON SM, 1985, BIOPHYS J, V48, P485, DOI 10.1016/S0006-3495(85)83804-2; TAKEI K, 1992, J NEUROSCI, V12, P489; TAYLOR CW, 1992, TRENDS BIOCHEM SCI, V17, P403, DOI 10.1016/0968-0004(92)90009-X; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.neuro.12.1.227; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	37	984	1000	2	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 29	1993	262	5134					744	747		10.1126/science.8235595	http://dx.doi.org/10.1126/science.8235595			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	8235595				2022-12-28	WOS:A1993MD95200043
J	CASLEYSMITH, JR; WANG, CT; CASLEYSMITH, JR; CUI, ZH				CASLEYSMITH, JR; WANG, CT; CASLEYSMITH, JR; CUI, ZH			TREATMENT OF FILARIAL LYMPHEDEMA AND ELEPHANTIASIS WITH 5,6-BENZO-ALPHA-PYRONE (COUMARIN)	BRITISH MEDICAL JOURNAL			English	Article							LYMPHEDEMA	Objective-To study efficacy of treatment of filarial lymphoedema and elephantiasis with 5,6-benzo-alpha-pyrone. Design-Randomised, double blind, placebo controlled study with matching for grade and duration of disease, age, and sex. Treatment was given for 367 days, and subjects were followed up for another year. Setting-A town in Shandong Province, China. Subjects-104 men and women with chronic unilateral filarial lymphoedema or elephantiasis of the leg: 64 were randomised to benzopyrone and 40 to placebo. By the end of the study 19 patients had dropped out of the treatment group and two out of the placebo group. Interventions-Two 200 mg tablets of 5,6-benzo-alpha-pyrone or two placebo tablets given daily. Main outcome measures-Volumes of the affected and normal legs estimated every three months, and daily listing of any side effects. Results-Benzopyrone reduced oedema for all grades of lymphoedema during the year of treatment (pW0.001) and the follow up year (p=0.026). During treatment the mean monthly reductions in leg volume were 0.62% (95% confidence intervals 0.4% to 0.85%), 1.1% (0.71% to 1.6%), and 1.6% (0.89% to 2.3%) of the volume of the normal leg for grades 1, 2, and 3.5 (elephantiasis) of lymphoedema respectively. During follow up the mean monthly reductions were 0.18% (0.01% to 0.35%), 0.54% (0.27% to 0.82%), and 0.87% (0.51% to 1.2%). At the end of the trial the total reduction in oedema was 1000/o, 95%, and 45% for grades 1, 2, and 3-5. Symptoms and complications were considerably reduced, including attacks of secondary acute inflammation, while side effects were minor and disappeared after one month. In the placebo group there were no changes in the severity of lymphoedema. Conclusions-5,6 - benzo - alpha - pyrone reduces the oedema and many symptoms of filarial lymphoedema and elephantiasis. It has few side effects, and its relatively slow action makes it ideal for use without compression garments.	SHANDONG INST PARASIT DIS,JINING 272133,PEOPLES R CHINA		CASLEYSMITH, JR (corresponding author), UNIV ADELAIDE,HENRY THOMAS LAB,BOX 498 GPO,ADELAIDE,SA 5001,AUSTRALIA.							ANDERSON J, 1924, LONDON SCH TROPICAL, V5, P13; Braun H D, 1971, Munch Med Wochenschr, V113, P1630; Casley-Smith J.R., 1986, HIGH PROTEIN OEDEMAS; CASLEYSMITH JR, 1981, J PATHOL, V133, P243, DOI 10.1002/path.1711330307; CASLEYSMITH JR, 1985, LYMPHOLOGY, V18, P175; CASLEYSMITH JR, 1993, ANN TROP MED PARASIT, V87, P247, DOI 10.1080/00034983.1993.11812763; CASLEYSMITH JR, 1986, THERAPIEWOCHE, V12, P1068; CASLEYSMITH JR, IN PRESS N ENGL J ME; CASLEYSMITH JR, 1990, EXCERPTA MED INT C S, V887, P389; CASLEYSMITH JR, 1992, EXCERPTA MED INT C S, V994, P537; Clodius L., 1982, ADV LYMPHOLOGY, P471; CLUZAN R, 1990, PROGR LYMPHOLOGY, V887, P453; DESPREZCURELY JP, 1985, PROGR LYMPHOLOGY, V10, P203; FOLDI E, 1989, ANN PLAS SURG, V22, P505; FOLDI M, 1989, LEHRBUCH LYMPHOLOGIE; HOU LQ, 1983, NATIONAL MED J CHINA, V36, P349; LENNIHAN R, 1973, AM J SURG, V126, P649, DOI 10.1016/S0002-9610(73)80014-5; MORGAN RG, 1992, J HAND SURGERY BRIT, V4, P437; PILLER NB, 1988, BRIT J PLAST SURG, V41, P20, DOI 10.1016/0007-1226(88)90139-7; PILLER NB, 1982, ADV LYMPHOLOGY, P475; SASA M, 1976, HUMAN FILARIASIS GLO; Song J. M., 1988, Chinese Journal of Parasitology and Parasitic Diseases, V6, P71; Stranden E, 1981, J Oslo City Hosp, V31, P153; TAN TJ, 1985, PROGR LYMPHOLOGY, V10, P156; WORMS MJ, 1982, J HELMINTHOL, V56, P235, DOI 10.1017/S0022149X00034593; YAMAUCHI S, 1983, LYMPHANGIOLOGY, P747; 1984, WHO TECHNICAL REPORT, V702	28	35	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1993	307	6911					1037	1041		10.1136/bmj.307.6911.1037	http://dx.doi.org/10.1136/bmj.307.6911.1037			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD556	8251778	Green Published, Bronze			2022-12-28	WOS:A1993MD55600017
J	CLIFFORD, CP; DAVIES, GJ; SCOTT, J; SHAUNAK, S; SAVILL, J; SCHOFIELD, JB				CLIFFORD, CP; DAVIES, GJ; SCOTT, J; SHAUNAK, S; SAVILL, J; SCHOFIELD, JB			GRAND ROUNDS - HAMMERSMITH-HOSPITAL - TUBERCULOUS PERICARDITIS WITH RAPID PROGRESSION TO CONSTRICTION	BMJ-BRITISH MEDICAL JOURNAL			English	Discussion							DIAGNOSIS				CLIFFORD, CP (corresponding author), ROYAL POSTGRAD MED SCH, LONDON W12 0NN, ENGLAND.							BHAN GL, 1980, J INFECTION, V2, P360, DOI 10.1016/S0163-4453(80)92840-6; BRISSONNOEL A, 1989, LANCET, V2, P1069; COMBS DL, 1990, ANN INTERN MED, V112, P397, DOI 10.7326/0003-4819-76-3-112-6-397; DESAI HN, 1979, S AFR MED J, V55, P877; FOWLER N O, 1973, Progress in Cardiovascular Diseases, V16, P323, DOI 10.1016/S0033-0620(73)80004-0; FOWLER NO, 1991, JAMA-J AM MED ASSOC, V266, P99, DOI 10.1001/jama.266.1.99; GOOI HC, 1978, THORAX, V33, P94, DOI 10.1136/thx.33.1.94; LONG R, 1989, AM HEART J, V117, P1133, DOI 10.1016/0002-8703(89)90873-9; MCCAUGHAN BC, 1985, J THORAC CARDIOV SUR, V89, P340; ROONEY JJ, 1970, ANN INTERN MED, V72, P73, DOI 10.7326/0003-4819-72-1-73; SAGRISTASAULEDA J, 1988, J AM COLL CARDIOL, V11, P724, DOI 10.1016/0735-1097(88)90203-3; STRANG JIG, 1987, LANCET, V2, P1418	12	8	8	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 23	1993	307	6911					1052	1054		10.1136/bmj.307.6911.1052	http://dx.doi.org/10.1136/bmj.307.6911.1052			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD556	8251782	Green Published, Bronze			2022-12-28	WOS:A1993MD55600024
J	NICHOLSON, DA; DRISCOLL, PA				NICHOLSON, DA; DRISCOLL, PA			ABC OF EMERGENCY RADIOLOGY - THE ELBOW	BRITISH MEDICAL JOURNAL			English	Article											NICHOLSON, DA (corresponding author), HOPE COLL,HOLLAND,MI 49423, USA.								0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1993	307	6911					1058	1062		10.1136/bmj.307.6911.1058	http://dx.doi.org/10.1136/bmj.307.6911.1058			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD556	8251786	Green Published, Bronze			2022-12-28	WOS:A1993MD55600030
J	SWARTZ, K				SWARTZ, K			DYNAMICS OF PEOPLE WITHOUT HEALTH-INSURANCE - DONT LET THE NUMBERS FOOL YOU	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL PATIENTS; RESOURCE				SWARTZ, K (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HEALTH POLICY & MANAGEMENT,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.							BILLINGS J, 1990, HLTH AFF, V4, P158; BLENDON RJ, 1988, JAMA-J AM MED ASSOC, V260, P3176; FRANKS P, 1993, JAMA-J AM MED ASSOC, V270, P737, DOI 10.1001/jama.270.6.737; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; MISHEL L, 1993, JOYLESS RECOVERY DET; SHORT K, 1992, CURRENT POPULATION P, V70; SWARTZ K, 1993, INQUIRY-J HEALTH CAR, V30, P64; SWARTZ K, 1990, INQUIRY-J HEALTH CAR, V27, P281; WEISSMAN J, 1989, JAMA-J AM MED ASSOC, V261, P3572, DOI 10.1001/jama.261.24.3572; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; 1993, SOURCES HLTH INSURAN; 1993, WALL STREET J   1018, pA16; 1993, HALF US FAMILIES PRI; 1992, PHS921232 US DEP HLT; 1993, MED SAVINGS ACCOUNTS, P6	15	32	32	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	1994	271	1					64	66						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN725	8258891				2022-12-28	WOS:A1994MN72500034
J	POWELL, SM; PETERSEN, GM; KRUSH, AJ; BOOKER, S; JEN, J; GIARDIELLO, FM; HAMILTON, SR; VOGELSTEIN, B; KINZLER, KW				POWELL, SM; PETERSEN, GM; KRUSH, AJ; BOOKER, S; JEN, J; GIARDIELLO, FM; HAMILTON, SR; VOGELSTEIN, B; KINZLER, KW			MOLECULAR DIAGNOSIS OF FAMILIAL ADENOMATOUS POLYPOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GERM-LINE MUTATIONS; APC GENE; SULINDAC; COLI; IDENTIFICATION; DNA; CHROMOSOME-5Q21; DELETION; LINKAGE; TISSUE	Background. Familial adenomatous polyposis is an inherited disease characterized by multiple colorectal tumors. The diagnosis has classically been based on the detection of multiple colorectal adenomas. The recent identification of germline mutations of the APC gene in patients with familial adenomatous polyposis makes presymptomatic molecular diagnosis possible, but the widespread distribution of the many mutations within this very large gene have heretofore made the search for such mutations impractical. We describe a novel approach that allows molecular genetic diagnosis in the majority of patients with the disease. Methods. We screened 62 unrelated patients from the Johns Hopkins Familial Adenomatous Polyposis Registry for germline APC mutations. Primary screening was accomplished by analysis of protein synthesized in vitro from surrogate APC genes. In addition, the relative amount of transcript from each APC allele was determined with an allele-specific-expression assay. Results. The protein assay revealed truncated protein in 51 of the 62 patients (82 percent). In 3 of the 11 remaining patients, the allele-specific-expression assay revealed significantly reduced expression of one allele of the APC gene. The use of these two assays in combination successfully identified germline APC mutations in 87 percent of the 62 patients. Conclusions. The protein and allele-specific-expression assays provide a practical and sensitive method for molecular diagnosis of familial adenomatous polyposis. This approach will facilitate care, allowing routine testing of subjects at risk and genetic confirmation of spontaneous mutations.	JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NCI NIH HHS [CA-57345, CA-44688, CA-35494] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA057345, R37CA035494, R01CA057345, R01CA044688, R01CA035494] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALM T, 1973, CLIN GASTROENTEROL, V2, P577; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BULOW S, 1986, DIS COLON RECTUM, V29, P102, DOI 10.1007/BF02555389; BUSSEY HJR, 1990, FAMILIAL ADENOMATOUS, P1; CACHONGONZALEZ MB, 1991, J MED GENET, V28, P681, DOI 10.1136/jmg.28.10.681; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COTTRELL S, 1992, LANCET, V340, P626, DOI 10.1016/0140-6736(92)92169-G; FODDE R, 1992, GENOMICS, V13, P1162, DOI 10.1016/0888-7543(92)90032-N; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GRODEN J, 1993, AM J HUM GENET, V52, P263; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; LANDEGREN U, 1988, SCIENCE, V241, P1077, DOI 10.1126/science.3413476; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Nagase Hiroki, 1992, Human Mutation, V1, P467, DOI 10.1002/humu.1380010603; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OLSCHWANG S, 1993, AM J HUM GENET, V52, P273; PETERSEN GM, 1991, GASTROENTEROLOGY, V100, P1658, DOI 10.1016/0016-5085(91)90666-9; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RIGAU J, 1991, ANN INTERN MED, V115, P952, DOI 10.7326/0003-4819-115-12-952; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SPIRIO L, 1993, AM J HUM GENET, V52, P286; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; VARESCO L, 1993, AM J HUM GENET, V52, P280; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119; WALSH PS, 1991, BIOTECHNIQUES, V10, P507	38	590	619	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1993	329	27					1982	1987		10.1056/NEJM199312303292702	http://dx.doi.org/10.1056/NEJM199312303292702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN573	8247073				2022-12-28	WOS:A1993MN57300002
J	WIMMER, EA; JACKLE, H; PFEIFLE, C; COHEN, SM				WIMMER, EA; JACKLE, H; PFEIFLE, C; COHEN, SM			A DROSOPHILA HOMOLOG OF HUMAN SP1 IS A HEAD-SPECIFIC SEGMENTATION GENE	NATURE			English	Article							BOX-BINDING-PROTEINS; TRANSCRIPTIONAL ACTIVATION; EMPTY SPIRACLES; HOMEOBOX GENES; EXPRESSION; PROMOTER; DOMAINS; REPRESSION; SEQUENCE; PATTERN	SEGMENTATION in Drosophila is based on a cascade of hierarchical gene interactions initiated by maternally deposited morphogens that define the spatially restricted domains of gap gene expression at blastoderm (reviewed in ref. 1). Although segmentation of the embryonic head is morphologically obscured, the repeated patterns of expression of the segment polarity genes reflect the formation of seven head segments2,3; two of these depend on the segmentation and homeotic genes used in the trunk, whereas the others form as a result of the activity of the head-specific genes orthodenticle (otd), empty spiracles (ems) and buttonhead (btd). The genes ems and otd encode homeodomain proteins. suggesting that they may function as transcription factors4-6. They are expressed in overlapping stripes in the early embryonic head of Drosophila, and their vertebrate homologues, otx and emx, are expressed in overlapping domains in the anterior central nervous system of the mouse embryo7,8. We show here that btd is expressed in a stripe covering the head anlagen of the segments affected in btd lack-of-function mutants and that btd encodes a zinc-finger-type transcription factor with sequence and functional similarity to the prototype mammalian transcription factor Sp1 (ref. 9). When expressed in the spatial pattern of btd, a transgene providing Sp1 activity can support development of the mandibular segment in the head of btd mutant embryos. A ubiquitous transcription factor from humans can therefore replace an essential component of the genetic circuitry required to specify the development of a particular head segment in the fly.	MAX PLANCK INST BIOPHYS CHEM,MOLEK ENTWICKLUNGSBIOL ABT,D-37018 GOTTINGEN,GERMANY	Max Planck Society	WIMMER, EA (corresponding author), BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT CELL BIOL,HOUSTON,TX 77030, USA.		Cohen, Stephen M/G-9930-2011; Wimmer, Ernst A./I-3333-2019	Cohen, Stephen M/0000-0003-2858-9163; Wimmer, Ernst A./0000-0002-2480-2804				CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COHEN S, 1991, TRENDS GENET, V7, P267; COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; GARZA D, 1989, SCIENCE, V246, P641, DOI 10.1126/science.2510296; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOHEISEL JD, 1991, J MOL BIOL, V220, P903, DOI 10.1016/0022-2836(91)90362-A; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2091, DOI 10.1073/pnas.89.6.2091; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SCHMIDTOTT U, 1992, DEVELOPMENT, V116, P111; SIMEONE A, 1992, EMBO J, V11, P2541, DOI 10.1002/j.1460-2075.1992.tb05319.x; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; STJOHNSTON D, 1992, CELL, V68, P201; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Thummel CS, 1992, DROS INF SERV, V71, P150; WALLDORF U, 1992, EMBO J, V11, P2247, DOI 10.1002/j.1460-2075.1992.tb05284.x	29	142	146	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 16	1993	366	6456					690	694		10.1038/366690a0	http://dx.doi.org/10.1038/366690a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM265	8259212				2022-12-28	WOS:A1993MM26500071
J	ANTO, JM; SUNYER, J; REED, CE; SABRIA, J; MARTINEZ, F; MORELL, F; CODINA, R; RODRIGUEZROISIN, R; RODRIGO, MJ; ROCA, J; SAEZ, M				ANTO, JM; SUNYER, J; REED, CE; SABRIA, J; MARTINEZ, F; MORELL, F; CODINA, R; RODRIGUEZROISIN, R; RODRIGO, MJ; ROCA, J; SAEZ, M			PREVENTING ASTHMA EPIDEMICS DUE TO SOYBEANS BY DUST-CONTROL MEASURES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRIMELLITIC ANHYDRIDE; IDENTIFICATION; AEROALLERGEN; ANTIBODIES; ALLERGENS; AVOIDANCE; EXPOSURE; TIME	Background. The inhalation of soybean dust released during the unloading of soybeans into a silo caused outbreaks of asthma in Barcelona, Spain. This study was designed to determine morbidity due to asthma and serum IgE reactivity before and after the installation of filters in the silo. Methods. We measured soybean-allergen concentrations in 136 samples of air collected for 9 months before and 24 months after the installation of filters. We compared the number of days on which there was an unexpected increase in emergency room visits for asthma, the number of days on which the number of emergency room visits for asthma in one four-hour period was so high that it was unlikely to be due to chance, and the mean daily number of emergency room and intensive care unit admissions for asthma for a total of 60 months before and after filter installation. Serum IgE antibodies against soybean allergens were measured in 38 patients before and after filter installation. Results. The concentration of airborne soybean allergens on days when soybeans were unloaded decreased from 324 to 25 U per cubic meter after the installation of filters (P<0.001). The number of days on which there was an unusually large number of visits to the hospital for asthma and the number of days on which asthma was epidemic both decreased significantly (both P<0.001), from 29 to 6 and from 18 to 0, respectively. The mean daily number of emergency room and intensive care unit admissions for asthma on days when soybeans were unloaded decreased from 8.3 to 5.4 and from 0.26 to 0.01, respectively (both P<0.001). The mean serum IgE antibody concentrations in the 38 patients studied decreased from 2 Pharmacia reference units per milliliter to 1 (P<0.001). Conclusions. Installing filters on silos to prevent airborne dissemination of allergenic soybean dust eliminates outbreaks of asthma caused by inhalation of the dust, thus supporting the idea that the avoidance of allergens helps prevent asthma.	MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55905; HOSP VALLE DE HEBRON,SERV BIOQUIM,BARCELONA,SPAIN; HOSP VALLE DE HEBRON,SERV PNEUMOL,BARCELONA,SPAIN; HOSP CLIN BARCELONA,SERV PNEUMOL & ALLERGIA RESP,BARCELONA 36,SPAIN	Mayo Clinic; Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron; University of Barcelona; Hospital Clinic de Barcelona	ANTO, JM (corresponding author), INST MUNICIPAL INVEST MED,DEPT EPIDEMIOL & SALUT PUBL,DOCTOR AIGUADER 80,E-08003 BARCELONA,SPAIN.		Anto, J M/H-2676-2014; Sunyer, Jordi/G-6909-2014	Anto, J M/0000-0002-4736-8529; Sunyer, Jordi/0000-0002-2602-4110; Morell Brotad, Ferran/0000-0002-7206-4543				AGARWAL MK, 1981, J ALLERGY CLIN IMMUN, V68, P194, DOI 10.1016/0091-6749(81)90183-4; ANTO JM, 1986, LANCET, V1, P900, DOI 10.1016/S0140-6736(86)90999-2; ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; ANTO JM, 1990, CHEST, V98, pS185, DOI 10.1378/chest.98.5_Supplement.185S; FERRER A, 1990, EUR RESPIR J, V3, P846; FERRER A, 1990, EUR RESPIR J, V3, P429; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; GOLDSTEIN IF, 1978, ENVIRON RES, V17, P266, DOI 10.1016/0013-9351(78)90029-4; GONZALEZ R, 1991, INT ARCH ALLER A IMM, V95, P53, DOI 10.1159/000235454; HENDRICK DJ, 1989, THORAX, V44, P609, DOI 10.1136/thx.44.8.609; HERNANDO L, 1989, LANCET, V1, P502; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; Knox E G, 1982, Stat Med, V1, P183, DOI 10.1002/sim.4780010210; MARTINEZ F, 1993, EUR RESPIR J, V6, P337; MCFADDEN ER, 1992, NEW ENGL J MED, V327, P1928, DOI 10.1056/NEJM199212313272708; MCGRATH KG, 1984, J OCCUP ENVIRON MED, V26, P671; NAVARRO C, 1993, EPIDEMIOLOGY, V4, P76, DOI 10.1097/00001648-199301000-00014; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PLATTSMILLS TAE, 1982, LANCET, V2, P675; RODRIGO MJ, 1990, J ALLERGY CLIN IMMUN, V85, P778, DOI 10.1016/0091-6749(90)90198-D; SUNYER J, 1992, AM REV RESPIR DIS, V145, P1098, DOI 10.1164/ajrccm/145.5.1098; SUNYER J, 1989, LANCET, V1, P179; SWANSON MC, 1991, J ALLERGY CLIN IMMUN, V87, P783, DOI 10.1016/0091-6749(91)90123-6; VENABLES KM, 1987, J ALLERGY CLIN IMMUN, V80, P212, DOI 10.1016/0091-6749(87)90131-X; WALLENSTEIN S, 1980, AM J EPIDEMIOL, V111, P367, DOI 10.1093/oxfordjournals.aje.a112908; WASSERFALLEN JB, 1990, AM REV RESPIR DIS, V142, P108, DOI 10.1164/ajrccm/142.1.108; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; 1989, LANCET, V2, P538	28	90	90	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 9	1993	329	24					1760	1763		10.1056/NEJM199312093292402	http://dx.doi.org/10.1056/NEJM199312093292402			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK096	8232484				2022-12-28	WOS:A1993MK09600002
J	ANDERSON, DR; OBRIEN, BJ; LEVINE, MN; ROBERTS, R; WELLS, PS; HIRSH, J				ANDERSON, DR; OBRIEN, BJ; LEVINE, MN; ROBERTS, R; WELLS, PS; HIRSH, J			EFFICACY AND COST OF LOW-MOLECULAR-WEIGHT HEPARIN COMPARED WITH STANDARD HEPARIN FOR THE PREVENTION OF DEEP-VEIN THROMBOSIS AFTER TOTAL HIP-ARTHROPLASTY	ANNALS OF INTERNAL MEDICINE			English	Review							FATAL PULMONARY-EMBOLISM; UNFRACTIONATED HEPARIN; ORTHOPEDIC-SURGERY; VENOUS THROMBOSIS; REPLACEMENT; PROPHYLAXIS	Purpose: To compare the efficacy, safety, and cost-effectiveness of low-molecular-weight heparin with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Data identification: Studies were identified by MEDLINE search and review of bibliographies of retrieved articles. Hospital resources used in treating deep vein thrombosis and bleeding complications after total hip arthroplasty were estimated using retrospectively collected data from 447 patients who participated in a recently completed randomized controlled deep vein thrombosis prophylaxis trial at our center. Study Selection: Randomized controlled trials directly comparing a low-molecular-weight heparin preparation with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty were potentially eligible for the meta-analysis. Data Extraction: Data from eligible studies were extracted independently by two of the authors. Multiple regression analysis of data from the patient cohort was used to estimate the effect of deep vein thrombosis and bleeding on length of hospital stay. A hypothetical North American price for low-molecular-weight heparin was determined based on the ratio between low-molecular-weight heparin and standard heparin in France. Costs were based on weighted per-diem hospital expenditures and physician fees for procedures and reported in 1992 U.S. dollars. Results of Data Synthesis: Meta-analysis of six eligible trials determined that low-molecular-weight heparin was significantly more effective than standard heparin at preventing deep vein thrombosis after total hip arthroplasty (common odds ratio, 0.72; 95% CI, 0.53 to 0.95). However, this benefit was restricted to the prevention of proximal deep vein thrombosis (common odds ratio, 0.40; Cl, 0.28 to 0.59). No significant differences were found in the rates of distal deep vein thrombosis or total, major, or minor bleeding between the two groups. Based on a 2.6 to 1 price ratio between low-molecular-weight heparin and standard heparin, use of low-molecular-weight heparin would save the health care system about $50 000 per 1 000 patients treated. Sensitivity analysis shows that if the low-molecular-weight heparin/standard heparin price ratio exceeds 3.7 (the threshold value lies between 0.8 and 5.5 based on the extremes of the 95% CI of the common odds ratios for deep vein thrombosis and bleeding complications), use of low-molecular-weight heparin is more expensive. At a price ratio of 10, it would cost more than $250 000 to treat 1000 patients with low-molecular-weight heparin compared with standard heparin or about $5000 for each additional deep vein thrombosis prevented with low-molecular-weight heparin. Conclusions: Low-molecular-weight heparin is more effective and is at least as safe as standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Based on the current French price ratio of low-molecular-weight heparin to standard heparin, the use of low-molecular-weight heparin in North America would result in overall savings in cost; however, the relative cost-effectiveness is critically dependent on the price ratio between the two drugs. Further research is needed to compare the cost-effectiveness of low-molecular-weight heparin with other prophylactic regimens and postoperative deep vein thrombosis management strategies.	HAMILTON CIV HOSP, RES CTR, HAMILTON L8V 1C3, ON, CANADA; MCMASTER UNIV, MED CTR, HAMILTON L8S 4L8, ONTARIO, CANADA	McMaster University; McMaster University				Anderson, David/0000-0003-0845-1722				ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; Barre J, 1987, J Mal Vasc, V12 Suppl B, P90; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; BRESLOW NE, 1980, WHO32 INT AG RES CAN; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; CORNFIELD J, 1956, 3RD P BERK S MATH ST, V4; DECHAVANNE M, 1989, HAEMOSTASIS, V19, P5; DOUBILET P, 1986, NEW ENGL J MED, V314, P253, DOI 10.1056/NEJM198601233140421; ERIKSSON BI, 1991, J BONE JOINT SURG AM, V73A, P484, DOI 10.2106/00004623-199173040-00002; HIRSH J, 1992, BLOOD, V79, P1; HIRSH J, 1990, CLIN HAEMATOL, V3, P685; HULL RD, 1982, CAN MED ASSOC J, V127, P990; HYERS TM, 1989, CHEST, V95, pS37, DOI 10.1378/chest.95.2.37S; KAKKAR VV, 1975, LANCET, V2, P674; LEVINE MN, 1991, ANN INTERN MED, V114, P545, DOI 10.7326/0003-4819-114-7-545; LEYVRAZ PF, 1991, BRIT MED J, V303, P543, DOI 10.1136/bmj.303.6802.543; MANTEL N, 1959, J NATL CANCER I, V22, P719; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; OSTER G, 1987, JAMA-J AM MED ASSOC, V257, P203, DOI 10.1001/jama.257.2.203; PAIEMENT GD, 1991, AM J SURG, V161, P519, DOI 10.1016/0002-9610(91)91124-2; PLANES A, 1988, THROMB HAEMOSTASIS, V60, P407; 1992, 62001 PUBL DIV CAT	22	138	139	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1993	119	11					1105	1112		10.7326/0003-4819-119-11-199312010-00008	http://dx.doi.org/10.7326/0003-4819-119-11-199312010-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ335	8239230				2022-12-28	WOS:A1993MJ33500008
J	KRUMHOLZ, HM; FORMAN, DE; KUNTZ, RE; BAIM, DS; WEI, JY				KRUMHOLZ, HM; FORMAN, DE; KUNTZ, RE; BAIM, DS; WEI, JY			CORONARY REVASCULARIZATION AFTER MYOCARDIAL-INFARCTION IN THE VERY ELDERLY - OUTCOMES AND LONG-TERM FOLLOW-UP	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; AGED, 80 AND OLDER; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); QUALITY OF LIFE	ARTERY BYPASS; OCTOGENARIAN PATIENTS; ANGIOPLASTY; SURGERY; MORBIDITY; SURVIVAL	Objective: To determine the outcome of very elderly patients who had coronary revascularization during hospitalization for an acute myocardial infarction. Design: Retrospective cohort study. Setting: Community-based tertiary-care teaching hospital. Patients: A total of 1215 consecutive patients 80 years and older were hospitalized with a myocardial infarction between 1985 and 1990. The study sample included all 93 patients (8%) who had cardiac catheterization before discharge and had not been excluded from study because of the following: severe valvular disease, absence of significant coronary disease, or death before a decision about revascularization could be made. Measurements: Survival, quality of life, and functional status at least 1 year after discharge. Results: After catheterization, 41 patients had angioplasty, 18 had coronary artery bypass surgery, and 34 did not have revascularization. Among the patients alive at discharge, those who had revascularization had a high likelihood of achieving a good or excellent quality of life (angioplasty, 86% [31 of 36]; surgery, 89% [16 of 18]; medical therapy, 44% [11 of 25]) and of being able to care for themselves (angioplasty, 89% [32 of 36], surgery, 89% [16 of 18], medical therapy, 52% [13 of 25]). Mortality rates at 1 year were 24% (95% CI, 15% to 47%) for the angioplasty group, 6% (CI, 0% to 27%) for the surgery group, and 44% (CI, 27% to 62%) for the medical therapy group. In a Cox proportional hazards model that adjusted for clinical, demographic, hemodynamic, and anatomic differences between the groups, the performance of coronary revascularization was associated with increased survival (hazard ratio, 0.42; CI, 0.18 to 0.98). Conclusions: A small percentage of very elderly patients with complicated acute myocardial infarctions, selected by their physicians for invasive cardiovascular procedures, can tolerate these procedures, avoid serious complications, return to independent living, and have excellent probability of survival. Although our results suggest that coronary revascularization may have benefited these patients, the study design did not permit definite conclusions, and future studies are needed to resolve this important question.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; CHARLES A DANA RES INST, BOSTON, MA USA; BROCKTON W ROXBURY VET AFFAIRS MED CTR, GRECC, BOSTON, MA USA	Harvard University; Harvard Medical School; Harvard University; Geriatric Research Education & Clinical Center; Harvard University			, Harlan/AAI-2875-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007374] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-07374] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; COX DR, 1972, J R STAT SOC B, V34, P187; EDMUNDS LH, 1988, NEW ENGL J MED, V319, P131, DOI 10.1056/NEJM198807213190302; FORMAN DE, 1992, J AM GERIATR SOC, V40, P19, DOI 10.1111/j.1532-5415.1992.tb01823.x; GLOWER DD, 1992, AM J CARDIOL, V70, P567, DOI 10.1016/0002-9149(92)90192-2; HORVATH KA, 1990, J THORAC CARDIOV SUR, V99, P92; JEROUDI MO, 1990, ANN INTERN MED, V113, P423, DOI 10.7326/0003-4819-113-6-423; KERN MJ, 1988, AM J CARDIOL, V61, P457, DOI 10.1016/0002-9149(88)90304-9; KO W, 1991, J THORAC CARDIOV SUR, V102, P532; KO W, 1992, CIRCULATION, V86, P191; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; RICH JJ, 1990, AM J CARDIOL, V65, P675, DOI 10.1016/0002-9149(90)91051-7; RIZOPATRON C, 1990, AM J CARDIOL, V66, P857, DOI 10.1016/0002-9149(90)90365-8; SAFRAN C, 1989, ANN INTERN MED, V111, P751, DOI 10.7326/0003-4819-111-9-751; SMITH SC, 1990, J AM COLL CARDIOL, V16, P784, DOI 10.1016/S0735-1097(10)80322-5; TSAI TP, 1991, ANN THORAC SURG, V51, P983, DOI 10.1016/0003-4975(91)91024-P; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; UTLEY JR, 1991, J THORAC CARDIOV SUR, V101, P866; WEINTRAUB WS, 1991, AM J CARDIOL, V68, P1530, DOI 10.1016/0002-9149(91)90291-R; WYMAN RM, 1988, J AM COLL CARDIOL, V12, P1400, DOI 10.1016/S0735-1097(88)80002-0; 1988, AGING AM, P109; 1992, HLTH US 1991, P121	24	33	34	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1993	119	11					1084	1090		10.7326/0003-4819-119-11-199312010-00005	http://dx.doi.org/10.7326/0003-4819-119-11-199312010-00005			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ335	8239227				2022-12-28	WOS:A1993MJ33500005
J	HARBURY, PB; ZHANG, T; KIM, PS; ALBER, T				HARBURY, PB; ZHANG, T; KIM, PS; ALBER, T			A SWITCH BETWEEN 2-STRANDED, 3-STRANDED AND 4-STRANDED COILED COILS IN GCN4 LEUCINE-ZIPPER MUTANTS	SCIENCE			English	Article							HELIX-FORMING TENDENCIES; ALPHA-FIBROUS PROTEINS; FOS-JUN INTERACTION; HYDROPHOBIC CORE; AMINO-ACIDS; STAPHYLOCOCCAL NUCLEASE; INFLUENZA-VIRUS; SIDE-CHAIN; REFINEMENT; STABILITY	Coiled-coil sequences in proteins consist of heptad repeats containing two characteristic hydrophobic positions. The role of these buried hydrophobic residues in determining the structures of coiled coils was investigated by studying mutants of the GCN4 leucine zipper. When sets of buried residues were altered, two-, three-, and four-helix structures were formed. The x-ray crystal structure of the tetramer revealed a parallel, four-stranded coiled coil. In the tetramer conformation, the local packing geometry of the two hydrophobic positions in the heptad repeat is reversed relative to that in the dimer. These studies demonstrate that conserved, buried residues in the GCN4 leucine zipper direct dimer formation. In contrast to proposals that the pattern of hydrophobic and polar amino acids in a protein sequence is sufficient to determine three-dimensional structure, the shapes of buried side chains in coiled coils are essential determinants of the global fold.	MIT,DEPT BIOL,WHITEHEAD INST,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02142; UNIV UTAH,SCH MED,DEPT BIOCHEM,SALT LAKE CITY,UT 84132	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Utah System of Higher Education; University of Utah	HARBURY, PB (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044162, R01GM048958] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44162, GM48958] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINS EDT, 1967, J MOL BIOL, V24, P139, DOI 10.1016/0022-2836(67)90099-X; BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Carr M. J., UNPUB; CHAN HS, 1990, P NATL ACAD SCI USA, V87, P6388, DOI 10.1073/pnas.87.16.6388; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CONWAY JF, 1990, INT J BIOL MACROMOL, V12, P328, DOI 10.1016/0141-8130(90)90023-4; CONWAY JF, 1991, INT J BIOL MACROMOL, V13, P14, DOI 10.1016/0141-8130(91)90004-E; Creighton T.E., 1993, PROTEINS; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P683; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; DEGRADO WF, 1990, BIOPOLYMERS, V29, P205, DOI 10.1002/bip.360290125; DeGrado WF, 1991, CURR OPIN STRUC BIOL, V1, P984, DOI 10.1016/0959-440X(91)90095-B; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HANDEL TM, 1993, SCIENCE, V261, P879, DOI 10.1126/science.8346440; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; HU JC, 1992, PROGR NUCLEIC ACIDS, V6, P82; HURLEY JH, 1992, J MOL BIOL, V224, P1143, DOI 10.1016/0022-2836(92)90475-Y; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU KF, 1989, MACROMOLECULES, V22, P3986, DOI 10.1021/ma00200a030; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LIM WA, 1991, J MOL BIOL, V219, P359, DOI 10.1016/0022-2836(91)90570-V; LOCKHART DJ, 1992, SCIENCE, V257, P947, DOI 10.1126/science.1502559; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; LUMB KJ, UNPUB; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MERUTKA G, 1991, BIOCHEMISTRY-US, V30, P1591, DOI 10.1021/bi00220a021; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; OAS TG, 1990, BIOCHEMISTRY-US, V29, P289; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; RALEIGH DP, 1992, J AM CHEM SOC, V114, P10079, DOI 10.1021/ja00051a061; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; SIKORSKI A, 1989, BIOPOLYMERS, V28, P1097, DOI 10.1002/bip.360280605; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; STITES WE, 1991, J MOL BIOL, V221, P7, DOI 10.1016/0022-2836(91)80195-Z; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WEIS WI, 1990, J MOL BIOL, V212, P737, DOI 10.1016/0022-2836(90)90234-D; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; ZHU BY, 1993, PROTEIN SCI, V2, P383; [No title captured]	58	1338	1474	4	153	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 26	1993	262	5138					1401	1407		10.1126/science.8248779	http://dx.doi.org/10.1126/science.8248779			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ046	8248779				2022-12-28	WOS:A1993MJ04600028
J	REYNET, C; KAHN, CR				REYNET, C; KAHN, CR			RAD - A MEMBER OF THE RAS FAMILY OVEREXPRESSED IN MUSCLE OF TYPE-II DIABETIC HUMANS	SCIENCE			English	Article							INVIVO INSULIN ACTION; PIMA-INDIANS; SIGNAL TRANSDUCTION; XENOPUS-OOCYTES; GENE-EXPRESSION; BETA-CELL; MELLITUS; NIDDM; PROTEINS; P21	To identify the gene or genes associated with insulin resistance in Type II (non-insulin-dependent) diabetes mellitus, subtraction libraries were prepared from skeletal muscle of normal and diabetic humans and screened with subtracted probes. Only one clone out of 4000 was selectively overexpressed in Type II diabetic muscle as compared to muscle of non-diabetic or Type I diabetic individuals. This clone encoded a new 29-kilodalton member of the Ras-guanosine triphosphatase superfamily and was termed Rad (Ras associated with diabetes). Messenger ribonucleic acid of Rad was expressed primarily in skeletal and cardiac muscle and was increased an average of 8.6-fold in the muscle of Type II diabetics as compared to normal individuals.	HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 36836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; BECKNIELSEN H, 1992, DIABETES CARE, V15, P418, DOI 10.2337/diacare.15.3.418; BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; BELL GI, 1991, DIABETES, V40, P413, DOI 10.2337/diabetes.40.4.413; BOGARDUS C, 1989, DIABETES, V38, P1423, DOI 10.2337/diabetes.38.11.1423; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1989, MOL CELL BIOL, V9, P4312, DOI 10.1128/MCB.9.10.4312; CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; CHUNG DL, 1991, BIOCHEM BIOPH RES CO, V181, P1378, DOI 10.1016/0006-291X(91)92091-W; CORMONT M, 1993, J BIOL CHEM, V268, P19491; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; COX NJ, 1989, DIABETES, V38, P653, DOI 10.2337/diabetes.38.5.653; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DRUGUID JR, 1988, P NATL ACAD SCI USA, V85, P5738; ELBEIN SC, 1988, DIABETES, V37, P377, DOI 10.2337/diabetes.37.4.377; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FLIER JS, 1992, DIABETES, V41, P416; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HATTERSLEY AT, 1992, LANCET, V339, P1307, DOI 10.1016/0140-6736(92)91958-B; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KLARLUND JK, 1993, J BIOL CHEM, V268, P7646; KNOWLER WC, 1990, DIABETES METAB REV, V6, P1, DOI 10.1002/dmr.5610060101; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; Krolewski A.S., 1985, JOSLINS DIABETES MEL, P12; LILLIOJA S, 1987, DIABETES, V36, P1329, DOI 10.2337/diabetes.36.11.1329; LU KH, 1992, P NATL ACAD SCI USA, V89, P3889, DOI 10.1073/pnas.89.9.3889; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; MARTIN BC, 1992, DIABETES, V41, P850, DOI 10.2337/diabetes.41.7.850; MCCLAIN DA, 1988, DIABETES, V37, P1071, DOI 10.2337/diabetes.37.8.1071; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MOLLER DE, 1991, J BIOL CHEM, V266, P10995; NEWMAN B, 1987, DIABETOLOGIA, V30, P763; OKAMOTO T, 1991, J BIOL CHEM, V266, P1085; OSTEROP APRM, 1992, J BIOL CHEM, V267, P14647; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; PORRAS A, 1992, J BIOL CHEM, V267, P21124; RICH SS, 1990, DIABETES, V39, P1315, DOI 10.2337/diabetes.39.11.1315; SANDERS DA, 1990, CELL GROWTH DIFFER, V1, P251; SCHULMAN GI, 1990, NEW ENGL J MED, V322, P223; SCHUMACHER MC, 1992, DIABETES, V41, P416, DOI 10.2337/diabetes.41.4.416; SCHWEINFEST CW, 1990, GENET ANAL-BIOMOL E, V7, P64, DOI 10.1016/0735-0651(90)90042-E; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STEINER DF, 1990, DIABETES CARE, V13, P600, DOI 10.2337/diacare.13.6.600; TAYLOR SI, 1991, J CLIN ENDOCR METAB, V73, P1158, DOI 10.1210/jcem-73-6-1158; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANDEROUWELAND MW, 1992, NAT GENET, V1, P368; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909	59	285	291	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 26	1993	262	5138					1441	1444		10.1126/science.8248782	http://dx.doi.org/10.1126/science.8248782			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ046	8248782				2022-12-28	WOS:A1993MJ04600039
J	DELWART, EL; SHPAER, EG; LOUWAGIE, J; MCCUTCHAN, FE; GREZ, M; RUBSAMENWAIGMANN, H; MULLINS, JI				DELWART, EL; SHPAER, EG; LOUWAGIE, J; MCCUTCHAN, FE; GREZ, M; RUBSAMENWAIGMANN, H; MULLINS, JI			GENETIC-RELATIONSHIPS DETERMINED BY A DNA HETERODUPLEX MOBILITY ASSAY - ANALYSIS OF HIV-1 ENV GENES	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEOTIDE-SEQUENCE; HTLV-III; INFECTION; TYPE-1; NEUTRALIZATION; DIVERSITY; GENERATION; EVOLUTION; EMERGENCE	The genetic diversity of human immunodeficiency virus (HIV) is a major concern thought to impact on immunologic escape and eventual vaccine efficacy. Here, simple and rapid methods are described for the detection and estimation of genetic divergence between HIV strains on the basis of the observation that DNA heteroduplexes formed between related sequences have a reduced mobility in polyacrylamide gels proportional to their degree of divergence. Reliable phylogenetic subtypes were assigned for HIV-1 strains from around the world. Relationships between viruses were closest when derived from the same or epidemiologically linked individuals. When derived from epidemiologically unlinked individuals, the relationships between viruses in a given geographic region correlated with the length of time HIV-1 had been detected in the population and the number of strains initiating widespread infection. Heteroduplex mobility analysis thus provides a tool to expedite epidemiological investigations by assisting in the classification of HIV and is readily applicable to the screening and characterization of other infectious agents and cellular genes.	STANFORD UNIV,MED CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305; FDN ADVANCEMENT MIL MED,ROCKVILLE,MD 20850; GEORG SPEYER HAUS CHEMOTHERAPEUT FORSCHUNGSINST,D-700251 FRANKFURT,GERMANY	Stanford University				Delwart, Eric/0000-0002-6296-4484	NIAID NIH HHS [AI32885, AI85007, AI07328] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI085007, R01AI032885] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ALBERT J, 1990, AIDS, V4, P107, DOI 10.1097/00002030-199002000-00002; ARENDRUP M, 1992, J ACQ IMMUN DEF SYND, V5, P303; BALFE P, 1990, J VIROL, V64, P6221, DOI 10.1128/JVI.64.12.6221-6233.1990; BROWN AL, 1988, AIDS RES HUM RETROV, V4, P399, DOI 10.1089/aid.1988.4.399; CHEINGSONGPOPOV R, 1992, J INFECT DIS, V165, P256, DOI 10.1093/infdis/165.2.256; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; COFFIN JM, 1992, CURR TOP MICROBIOL, V176, P143; CRANAGE MP, 1993, AIDS RES HUM RETROV, V9, P13, DOI 10.1089/aid.1993.9.13; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DELWART E, UNPUB; DIETRICH U, 1993, AIDS, V7, P23, DOI 10.1097/00002030-199301000-00003; Domingo E, 1992, CURR OPIN GENET DEV, V2, P61, DOI 10.1016/S0959-437X(05)80323-5; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; GREZ M, UNPUB; HO DD, 1985, ANN INTERN MED, V103, P880, DOI 10.7326/0003-4819-103-6-880; HO DD, 1985, NEW ENGL J MED, V313, P1493, DOI 10.1056/NEJM198512123132401; HOLLAND JJ, 1992, CURR TOP MICROBIOL, V176, P1; HSIEH CH, 1989, P NATL ACAD SCI USA, V86, P4833, DOI 10.1073/pnas.86.13.4833; ISSEL CJ, 1992, J VIROL, V66, P3398, DOI 10.1128/JVI.66.6.3398-3408.1992; KUSUMI K, 1992, J VIROL, V66, P875, DOI 10.1128/JVI.66.2.875-885.1992; LOUWAGIE J, 1993, AIDS, V7, P769, DOI 10.1097/00002030-199306000-00003; LOUWAGIE J, 1992, AIDS RES HUM RETROV, V8, P1467, DOI 10.1089/aid.1992.8.1467; MCCUTCHAN FE, 1992, AIDS RES HUM RETROV, V8, P1887, DOI 10.1089/aid.1992.8.1887; MCCUTCHAN FE, 1992, J ACQ IMMUN DEF SYND, V5, P441; MCCUTCHAN FE, UNPUB; MCKEATING JA, 1989, AIDS, V3, P777, DOI 10.1097/00002030-198912000-00001; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MYERS G, 1992, AIDS RES HUM RETROV, V8, P373, DOI 10.1089/aid.1992.8.373; MYERS G, 1992, HUMAN RETROVIRUSES A; PANG S, 1992, AIDS, V6, P453, DOI 10.1097/00002030-199205000-00003; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RUBSAMENWAIGMANN H, 1991, LANCET, V337, P550, DOI 10.1016/0140-6736(91)91333-P; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; SIMMONDS P, 1990, J VIROL, V64, P5840, DOI 10.1128/JVI.64.12.5840-5850.1990; SINGAL R, UNPUB; SRINIVASAN A, 1989, AIDS RES HUM RETROV, V5, P121, DOI 10.1089/aid.1989.5.121; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; WOLFS TFW, 1992, VIROLOGY, V189, P103, DOI 10.1016/0042-6822(92)90685-I; ZHANG LQ, 1993, J VIROL, V67, P3345, DOI 10.1128/JVI.67.6.3345-3356.1993; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	46	730	774	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1257	1261		10.1126/science.8235655	http://dx.doi.org/10.1126/science.8235655			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	8235655				2022-12-28	WOS:A1993MH32400037
J	ZOU, YR; GU, H; RAJEWSKY, K				ZOU, YR; GU, H; RAJEWSKY, K			GENERATION OF A MOUSE STRAIN THAT PRODUCES IMMUNOGLOBULIN-KAPPA CHAINS WITH HUMAN CONSTANT REGIONS	SCIENCE			English	Article							GERMINAL-CENTERS; HUMAN-ANTIBODY; TRANSGENIC MICE; LYMPHOID-TISSUE; IMMUNE-RESPONSE; B-CELLS; EXPRESSION; GENES; REPERTOIRE; MATURATION	Humanized antibodies are highly efficient as immunotherapeutic reagents and have many advantages over rodent antibodies. A mouse strain was generated by gene targeting to replace the mouse kappa light chain constant (C) region gene with the human C(kappa) gene. Mice homozygous for the replacement mutation (C(kappa)R) produced normal concentrations of serum antibodies, most of which carry chimeric kappa light chains, and mounted normal immune responses to hapten-protein conjugates. This technology provides a feasible option for the generation of high-affinity humanized antibodies by means of the powerful somatic hypermutation-selection mechanism.			ZOU, YR (corresponding author), UNIV COLOGNE,INST GENET,D-50931 COLOGNE,GERMANY.							APEL M, 1990, INT IMMUNOL, V2, P813, DOI 10.1093/intimm/2.9.813; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BORREBAECK CAK, 1988, IMMUNOL TODAY, V9, P335; BRUGGEMANN M, 1991, EUR J IMMUNOL, V21, P1323, DOI 10.1002/eji.1830210535; BRUGGEMANN M, 1989, J EXP MED, V170, P2153, DOI 10.1084/jem.170.6.2153; BRUGGEMANN M, 1989, P NATL ACAD SCI USA, V86, P6709, DOI 10.1073/pnas.86.17.6709; BUTCHER EC, 1982, J IMMUNOL, V129, P2698; CHOI TK, 1993, NAT GENET, V4, P17; COICO RF, 1983, J IMMUNOL, V131, P2254; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; GRIFFITHS AD, 1993, CURR OPIN IMMUNOL, V5, P263, DOI 10.1016/0952-7915(93)90015-K; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; HIETER PA, 1980, CELL, V22, P197, DOI 10.1016/0092-8674(80)90168-3; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; JERNE N K, 1971, European Journal of Immunology, V1, P1, DOI 10.1002/eji.1830010102; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; KAARTINEN M, 1988, EUR J IMMUNOL, V18, P1095, DOI 10.1002/eji.1830180719; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KLOBECK HG, 1984, NUCLEIC ACIDS RES, V12, P6995, DOI 10.1093/nar/12.18.6995; KOCKS C, 1989, ANNU REV IMMUNOL, V7, P537, DOI 10.1146/annurev.iy.07.040189.002541; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LUBIN I, 1991, SCIENCE, V252, P427, DOI 10.1126/science.1826797; MORRISON SL, 1984, P NATL ACAD SCI-BIOL, V81, P6851, DOI 10.1073/pnas.81.21.6851; NEUBERGER MS, 1985, NATURE, V314, P268, DOI 10.1038/314268a0; QUEEN C, 1989, P NATL ACAD SCI USA, V86, P10029, DOI 10.1073/pnas.86.24.10029; RAJEWSKY K, 1983, ANNU REV IMMUNOL, V1, P569, DOI 10.1146/annurev.iy.01.040183.003033; REICHMANN L, 1988, NATURE, V332, P323; RODER JC, 1986, METHOD ENZYMOL, V121, P140; ROSE ML, 1980, NATURE, V284, P364, DOI 10.1038/284364a0; SODERLIND E, 1992, IMMUNOL REV, V130, P109, DOI 10.1111/j.1600-065X.1992.tb01523.x; TAYLOR LD, 1992, NUCLEIC ACIDS RES, V20, P6287, DOI 10.1093/nar/20.23.6287; VERHOEYEN M, 1988, SCIENCE, V239, P1534, DOI 10.1126/science.2451287; Zou Y., UNPUB; ZOU YR, 1993, EMBO J, V12, P811, DOI 10.1002/j.1460-2075.1993.tb05721.x	35	37	50	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1271	1274		10.1126/science.8235658	http://dx.doi.org/10.1126/science.8235658			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	8235658				2022-12-28	WOS:A1993MH32400041
J	KIM, KH; KWON, BM; MYERS, AG; REES, DC				KIM, KH; KWON, BM; MYERS, AG; REES, DC			CRYSTAL-STRUCTURE OF NEOCARZINOSTATIN, AN ANTITUMOR PROTEIN-CHROMOPHORE COMPLEX	SCIENCE			English	Article							3-DIMENSIONAL SOLUTION STRUCTURE; MACROMOLECULAR CRYSTALLOGRAPHY; ACETYLCHOLINE-BINDING; APO-NEOCARZINOSTATIN; 2.8-A RESOLUTION; REFINEMENT; SYSTEM; DOMAIN; STABILIZATION; APOPROTEIN	Structures of the protein-chromophore complex and the apoprotein form of neocarzinostatin were determined at 1.8 angstrom resolution. Neocarzinostatin is composed of a labile chromophore with DNA-cleaving activity and a stabilizing protein. The chromophore displays marked nonlinearity of the triple bonds and is bound noncovalently in a pocket formed by the two protein domains. The chromophore pi-face interacts with the phenyl ring edges of Phe52 and Phe78. The amino sugar and carbonate groups of the chromophore are solvent exposed, whereas the epoxide, acetylene groups, and carbon C-12, the site of nucleophilic thiol addition during chromophore activation, are unexposed. The position of the amino group of the chromophore carbohydrate relative to C-12 supports the idea that the amino group plays a role in thiol activation.	CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125	California Institute of Technology					NCI NIH HHS [CA47148] Funding Source: Medline; NIGMS NIH HHS [GM45162] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047148, R29CA047148, R37CA047148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM045162, R01GM045162] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADJADJ E, 1992, EUR J BIOCHEM, V203, P505, DOI 10.1111/j.1432-1033.1992.tb16576.x; BETHGE PH, 1984, J APPL CRYSTALLOGR, V17, P215, DOI 10.1107/S0021889884011365; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; CHIMURA H, 1968, J ANTIBIOT, V21, P44, DOI 10.7164/antibiotics.21.44; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; COX JM, 1967, J MOL BIOL, V28, P151, DOI 10.1016/S0022-2836(67)80083-4; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; EDO K, 1986, J ANTIBIOT, V39, P1615, DOI 10.7164/antibiotics.39.1615; EDO K, 1985, TETRAHEDRON LETT, V26, P331, DOI 10.1016/S0040-4039(01)80810-8; EVANS SV, IN PRESS J MOL GRAPH; FALKSON G, 1984, J CLIN ONCOL, V2, P581, DOI 10.1200/JCO.1984.2.6.581; GAO XL, 1992, J MOL BIOL, V225, P125, DOI 10.1016/0022-2836(92)91030-S; GIBSON BW, 1984, J BIOL CHEM, V259, P801; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; HOPE H, 1988, ACTA CRYSTALLOGR B, V44, P22, DOI 10.1107/S0108768187008632; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; ISHIDA N, 1965, J ANTIBIOT, V18, P68; ISHIGURO M, 1991, J MED CHEM, V34, P2366, DOI 10.1021/jm00112a008; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KAPPEN LS, 1980, P NATL ACAD SCI-BIOL, V77, P1970, DOI 10.1073/pnas.77.4.1970; KHOKHLOV AS, 1969, J ANTIBIOT, V22, P541, DOI 10.7164/antibiotics.22.541; KIMOTO A, 1992, CANCER RES, V52, P1013; KOIDE Y, 1980, J ANTIBIOT, V33, P342, DOI 10.7164/antibiotics.33.342; KONNO T, 1992, EUR J CANCER, V28A, P403, DOI 10.1016/S0959-8049(05)80063-2; KUROMIZU K, 1986, ARCH BIOCHEM BIOPHYS, V246, P199, DOI 10.1016/0003-9861(86)90464-9; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; LYNDSAY M, 1990, BIOCHEMISTRY-US, V29, P8401; MAEDA H, 1974, ARCH BIOCHEM BIOPHYS, V164, P379, DOI 10.1016/0003-9861(74)90046-0; MAEDA H, 1981, ANTICANCER RES, V1, P175; MYERS AG, 1987, TETRAHEDRON LETT, V28, P4493, DOI 10.1016/S0040-4039(00)96545-6; MYERS AG, 1989, J AM CHEM SOC, V111, P1146, DOI 10.1021/ja00185a064; MYERS AG, 1988, J AM CHEM SOC, V110, P7212, DOI 10.1021/ja00229a045; MYERS AG, 1992, J AM CHEM SOC, V114, P1086, DOI 10.1021/ja00029a046; NAPIER MA, 1979, BIOCHEM BIOPH RES CO, V89, P635, DOI 10.1016/0006-291X(79)90677-6; PLETNEV VZ, 1982, BIOPOLYMERS, V21, P287, DOI 10.1002/bip.360210205; REEKE GN, 1984, J APPL CRYSTALLOGR, V17, P125, DOI 10.1107/S0021889884011171; RODMAN DA, 1993, NATURE, V362, P735; Rossmann M. G., 1972, MOL REPLACEMENT METH; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAKATA N, 1993, BIOL PHARM BULL, V16, P26; SHOJI JI, 1961, J ANTIBIOT, V14, P27; SIEKER LC, 1976, BIOCHEM BIOPH RES CO, V68, P358, DOI 10.1016/0006-291X(76)91152-9; STILL WC, 1988, MACROMODEL V2 5; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TANAKA T, 1991, TETRAHEDRON LETT, V32, P3175, DOI 10.1016/S0040-4039(00)79715-2; TANAKA T, 1993, J CHEM SOC CHEM COMM, V15, P1205; TEPLYAKOV A, 1993, EUR J BIOCHEM, V213, P737, DOI 10.1111/j.1432-1033.1993.tb17814.x; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VANROEY P, 1989, P NATL ACAD SCI USA, V86, P6587, DOI 10.1073/pnas.86.17.6587; VONHOFF DD, 1984, AM J CLIN ONCOL-CANC, V7, P135, DOI 10.1097/00000421-198404000-00006	57	82	83	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1042	1046		10.1126/science.8235619	http://dx.doi.org/10.1126/science.8235619			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	8235619				2022-12-28	WOS:A1993MG18700031
J	STERIADE, M; MCCORMICK, DA; SEJNOWSKI, TJ				STERIADE, M; MCCORMICK, DA; SEJNOWSKI, TJ			THALAMOCORTICAL OSCILLATIONS IN THE SLEEPING AND AROUSED BRAIN	SCIENCE			English	Article							NUCLEUS RETICULARIS THALAMI; LATERAL GENICULATE-NUCLEUS; MESOPONTINE CHOLINERGIC NUCLEI; ACTIVATED CATION CURRENT; CENTRAL-NERVOUS-SYSTEM; RELAY NEURONS; GUINEA-PIG; VISUAL-CORTEX; ELECTROPHYSIOLOGICAL PROPERTIES; LOW-FREQUENCY	Sleep is characterized by synchronized events in billions of synaptically coupled neurons in thalamocortical systems. The activation of a series of neuromodulatory transmitter systems during awakening blocks low-frequency oscillations, induces fast rhythms, and allows the brain to recover full responsiveness. Analysis of cortical and thalamic networks at many levels, from molecules to single neurons to large neuronal assemblies, with a variety of techniques, ranging from intracellular recordings in vivo and in vitro to computer simulations, is beginning to yield insights into the mechanisms of the generation, modulation, and function of brain oscillations.	YALE UNIV, SCH MED, NEUROBIOL SECT, NEW HAVEN, CT 06510 USA; SALK INST BIOL STUDIES, HOWARD HUGHES MED INST, LA JOLLA, CA 92037 USA	Yale University; Howard Hughes Medical Institute; Salk Institute	STERIADE, M (corresponding author), UNIV LAVAL, FAC MED, DEPT PHYSIOL, NEUROPHYSIOL LAB, QUEBEC CITY G1K 7P4, QUEBEC, CANADA.		Sejnowski, Terrence/AAV-5558-2021; McCormick, David A/J-2649-2015; Kobelt, Liza/F-5926-2011	McCormick, David A/0000-0002-9803-8335; 				AHISSAR E, 1990, P NATL ACAD SCI USA, V87, P8935, DOI 10.1073/pnas.87.22.8935; ASTONJONES G, 1991, PROG BRAIN RES, V88, P501; AVANZINI G, 1989, J PHYSIOL-LONDON, V416, P111, DOI 10.1113/jphysiol.1989.sp017752; AVOLI M, 1983, J NEUROPHYSIOL, V50, P819, DOI 10.1152/jn.1983.50.4.819; BAL T, 1993, J PHYSIOL-LONDON, V468, P669, DOI 10.1113/jphysiol.1993.sp019794; BALL GJ, 1977, ELECTROEN CLIN NEURO, V43, P346, DOI 10.1016/0013-4694(77)90258-9; BELL AJ, 1992, ADV NEUR IN, V4, P59; BOUYER JJ, 1981, ELECTROEN CLIN NEURO, V51, P244, DOI 10.1016/0013-4694(81)90138-3; Bremer F, 1935, CR SOC BIOL, V118, P1235; Bush Paul, 1993, Society for Neuroscience Abstracts, V19, P868; BUZSAKI G, 1989, NEUROSCIENCE, V31, P551, DOI 10.1016/0306-4522(89)90423-5; Churchland P. S., 1992, COMPUTATIONAL BRAIN, DOI 10.7551/mitpress/2010.001.0001; COENEN AML, 1972, EXP BRAIN RES, V14, P227, DOI 10.1007/BF00816160; COULTER DA, 1990, GENERALIZED EPILEPSY, P425; COULTER DA, 1989, NEUROSCI LETT, V98, P74, DOI 10.1016/0304-3940(89)90376-5; CRICK F, 1983, NATURE, V304, P111, DOI 10.1038/304111a0; DESCHENES M, 1985, BRAIN RES, V334, P165, DOI 10.1016/0006-8993(85)90580-3; DESTEXHE A, 1993, NEUROREPORT, V4, P223, DOI 10.1097/00001756-199302000-00028; Destexhe A., 1993, Society for Neuroscience Abstracts, V19, P516; DESTEXHE A, IN PRESS BIOPHYS J; DiFrancesco D., 1989, NEURONAL CELLULAR OS, P31; DOSSI RC, 1992, J PHYSIOL-LONDON, V447, P215, DOI 10.1113/jphysiol.1992.sp018999; DOSSI RC, 1991, J NEUROPHYSIOL, V65, P393, DOI 10.1152/jn.1991.65.3.393; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; FRIEDLANDER MJ, 1981, J NEUROPHYSIOL, V46, P80, DOI 10.1152/jn.1981.46.1.80; GHOSE GM, 1992, J NEUROPHYSIOL, V68, P1558, DOI 10.1152/jn.1992.68.5.1558; GHOSE GM, 1993, SOC NEUR ABSTR, V19, P869; GLENN LL, 1982, J NEUROSCI, V2, P1387; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; HALLANGER AE, 1987, J COMP NEUROL, V262, P105, DOI 10.1002/cne.902620109; HIRSCH JC, 1983, BRAIN RES, V259, P308, DOI 10.1016/0006-8993(83)91264-7; Hobson J. Allan, 1988, DREAMING BRAIN; HOPFIELD JJ, 1983, NATURE, V304, P158, DOI 10.1038/304158a0; HU B, 1989, NEUROSCIENCE, V31, P1, DOI 10.1016/0306-4522(89)90026-2; HUGUENARD JR, 1992, J NEUROPHYSIOL, V68, P1373, DOI 10.1152/jn.1992.68.4.1373; HUMPHREY AL, 1988, J COMP NEUROL, V268, P429, DOI 10.1002/cne.902680311; JACOBS BL, 1990, NEUROPSYCHOPHARMACOL, V3, P473; JAHNSEN H, 1984, J PHYSIOL-LONDON, V349, P227, DOI 10.1113/jphysiol.1984.sp015154; JAHNSEN H, 1984, J PHYSIOL-LONDON, V349, P205, DOI 10.1113/jphysiol.1984.sp015153; JOUVET M, 1973, ARCH ITAL BIOL, V111, P564; KELLAWAY P, 1985, EPILEPSIA, V26, pS15, DOI 10.1111/j.1528-1157.1985.tb05720.x; KOCH C, 1993, CURR OPIN NEUROBIOL, V3, P203, DOI 10.1016/0959-4388(93)90211-G; KONIG P, 1992, NEURAL COMPUT, V4, P666, DOI 10.1162/neco.1992.4.5.666; KOSTOPOULOS G, 1981, EXP NEUROL, V73, P55, DOI 10.1016/0014-4886(81)90045-5; LANCEL M, 1992, BRAIN RES, V596, P285, DOI 10.1016/0006-8993(92)91559-W; LEMASSON G, 1993, SCIENCE, V259, P1915, DOI 10.1126/science.8456317; LERESCHE N, 1991, J PHYSIOL-LONDON, V441, P155, DOI 10.1113/jphysiol.1991.sp018744; LIU Z, 1992, NEUROSCIENCE, V48, P87, DOI 10.1016/0306-4522(92)90340-8; LLINAS R, 1993, P NATL ACAD SCI USA, V90, P2078, DOI 10.1073/pnas.90.5.2078; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; LOWEL S, 1992, SCIENCE, V255, P209, DOI 10.1126/science.1372754; Lytton W. W., 1992, Society for Neuroscience Abstracts, V18, P305; LYTTON WW, 1992, ANN NEUROL, V32, P131, DOI 10.1002/ana.410320204; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059, DOI 10.1152/jn.1991.66.3.1059; MCCARLEY RW, 1983, SLEEP DISORDERS BASI, P363; MCCORMICK DA, 1992, J NEUROSCI, V12, P278; MCCORMICK DA, 1989, P NATL ACAD SCI USA, V86, P8098, DOI 10.1073/pnas.86.20.8098; MCCORMICK DA, 1992, PROG NEUROBIOL, V39, P337, DOI 10.1016/0301-0082(92)90012-4; MCCORMICK DA, 1991, J PHYSIOL-LONDON, V442, P235, DOI 10.1113/jphysiol.1991.sp018791; MCCORMICK DA, 1992, J NEUROPHYSIOL, V68, P1384, DOI 10.1152/jn.1992.68.4.1384; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P319, DOI 10.1113/jphysiol.1990.sp018332; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P291, DOI 10.1113/jphysiol.1990.sp018331; MCCORMICK DA, 1990, NEUROSCIENCE, V39, P103, DOI 10.1016/0306-4522(90)90225-S; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90066-8; MURTHY VN, 1992, P NATL ACAD SCI USA, V89, P5670, DOI 10.1073/pnas.89.12.5670; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; NUNEZ A, 1992, NEUROSCIENCE, V48, P75, DOI 10.1016/0306-4522(92)90339-4; NUNEZ A, 1992, NEUROSCIENCE, V51, P269, DOI 10.1016/0306-4522(92)90314-R; OHARA PT, 1985, J NEUROCYTOL, V14, P365, DOI 10.1007/BF01217752; OHARA PT, 1988, J ELECTRON MICR TECH, V10, P283, DOI 10.1002/jemt.1060100306; PAPE HC, 1992, J PHYSIOL-LONDON, V447, P729, DOI 10.1113/jphysiol.1992.sp019026; PAPE HC, 1992, NEURON, V9, P441, DOI 10.1016/0896-6273(92)90182-D; PARE D, 1987, J NEUROPHYSIOL, V57, P1669, DOI 10.1152/jn.1987.57.6.1669; PARENT A, 1988, J COMP NEUROL, V277, P281, DOI 10.1002/cne.902770209; PETSCHE H, 1984, NEUROSCIENCE, V11, P1, DOI 10.1016/0306-4522(84)90212-4; Quartz S. R., 1992, Society for Neuroscience Abstracts, V18, P1210; SCHWARTZ JC, 1991, PHYSIOL REV, V71, P1, DOI 10.1152/physrev.1991.71.1.1; SEJNOWSKI TJ, 1988, SCIENCE, V241, P1299, DOI 10.1126/science.3045969; SOLTESZ I, 1991, J PHYSIOL-LONDON, V441, P175, DOI 10.1113/jphysiol.1991.sp018745; SOLTESZ I, 1992, J PHYSIOL-LONDON, V457, P257, DOI 10.1113/jphysiol.1992.sp019377; STERIADE M, 1987, BRAIN RES, V408, P372, DOI 10.1016/0006-8993(87)90408-2; STERIADE M, 1988, PHYSIOL REV, V68, P649, DOI 10.1152/physrev.1988.68.3.649; STERIADE M, 1990, GENERALIZED EPILEPSY, P161; STERIADE M, 1990, J NEUROSCI, V10, P2541; STERIADE M, 1993, NEUROSCIENCE, V56, P1, DOI 10.1016/0306-4522(93)90556-U; STERIADE M, 1984, BRAIN RES REV, V8, P1, DOI 10.1016/0165-0173(84)90017-1; STERIADE M, 1986, J NEUROSCI, V6, P68; STERIADE M, 1993, J NEUROSCI, V13, P3284; STERIADE M, 1987, J NEUROPHYSIOL, V57, P260, DOI 10.1152/jn.1987.57.1.260; STERIADE M, 1976, ELECTROEN CLIN NEURO, V41, P641, DOI 10.1016/0013-4694(76)90009-2; STERIADE M, 1974, ELECTROEN CLIN NEURO, V37, P247, DOI 10.1016/0013-4694(74)90028-5; STERIADE M, 1993, J NEUROSCI, V13, P3266; STERIADE M, 1993, J NEUROPHYSIOL, V70, P1385, DOI 10.1152/jn.1993.70.4.1385; STERIADE M, 1991, J NEUROSCI, V11, P3200; STERIADE M, 1985, J NEUROPHYSIOL, V54, P1473, DOI 10.1152/jn.1985.54.6.1473; STERIADE M, 1982, EXP BRAIN RES, V46, P37; STERIADE M, 1974, ELECTROEN CLIN NEURO, V37, P633, DOI 10.1016/0013-4694(74)90076-5; STERIADE M, 1991, P NATL ACAD SCI USA, V88, P4396, DOI 10.1073/pnas.88.10.4396; STERIADE M, 1993, J NEUROSCI, V13, P3252, DOI 10.1523/jneurosci.13-08-03252.1993; STERIADE M, 1978, BEHAV BRAIN SCI, V1, P465, DOI 10.1017/S0140525X00076111; STERIADE M, 1990, BRAIN CHOLINERGIC SY; Steriade M, 1988, CELLULAR THALAMIC ME, P37; STERIADE M, 1989, PRINCIPLES PRACTICE, P86; Steriade M., 1990, THALAMIC OSCILLATION; Steriade M., 1993, ELECTROENCEPHALOGRAP, P27; Steriade M., 1991, NORMAL ALTERED STATE, V9, P279, DOI [10.1007/978-1-4615-6622-9_8, DOI 10.1007/978-1-4615-6622-9_8]; SWANSON LW, 1975, J COMP NEUROL, V163, P467, DOI 10.1002/cne.901630406; TORK I, 1990, ANN NY ACAD SCI, V600, P9; UCHIDA S, 1991, BRAIN RES BULL, V27, P93, DOI 10.1016/0361-9230(91)90286-S; USHER M, 1993, NEURAL COMPUT, V5, P570, DOI 10.1162/neco.1993.5.4.570; VONKROSIGK M, 1993, SCIENCE, V261, P361, DOI 10.1126/science.8392750; VONUEXKULL J, 1904, Z BIOL, V50, P168; WANG XJ, 1993, NEUROSCIENCE, V53, P899, DOI 10.1016/0306-4522(93)90474-T; WANG Z, 1993, J NEUROSCI, V13, P2199; YEN CT, 1985, J NEUROSCI, V5, P2254; [No title captured]	117	2581	2634	6	165	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	1993	262	5134					679	685		10.1126/science.8235588	http://dx.doi.org/10.1126/science.8235588			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	8235588				2022-12-28	WOS:A1993MD95200029
J	JARLAIS, DCD; FRIEDMAN, SR; SOTHERAN, JL; WENSTON, J; MARMOR, M; YANCOVITZ, SR; FRANK, B; BEATRICE, S; MILDVAN, D				JARLAIS, DCD; FRIEDMAN, SR; SOTHERAN, JL; WENSTON, J; MARMOR, M; YANCOVITZ, SR; FRANK, B; BEATRICE, S; MILDVAN, D			CONTINUITY AND CHANGE WITHIN AN HIV EPIDEMIC - INJECTING DRUG-USERS IN NEW-YORK-CITY, 1984 THROUGH 1992	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS; INFECTION; HEROIN; DISEASE; TRIAL	Objectives.-To examine trends in acquired immunodeficiency syndrome (AIDS) risk behavior and human immunodeficiency virus (HIV) seroprevalence among injecting drug users (IDUs) in New York City from 1984 through 1992. Design and Setting.-Comparisons were made between two surveys of IDUs at the same hospital-based New York City drug abuse detoxification program: 141 IDUs in 1984 and 974 IDUs in 1990 through 1992. National Death Registry, New York City Health Department, and drug treatment program records were also used. Participants.-Persons attending detoxification program randomly selected for participation. Eligibility was based on injection within previous 2 months; 99% acceptance rates were obtained. Participants in the 1984 and 1990 through 1992 surveys were 66% and 79% men, 21% and 19% white, 33% and 34% African American, and 45% and 46% Latin American, respectively. Interventions.-Community-based AIDS prevention programs, including underground syringe exchanges. Main Outcome Measures.-Acquired immunodeficiency syndrome risk behaviors; HIV serostatus; CD4+ cell counts; death rates among 1984 subjects; and injection and intranasal routes of drug administration. Results.-The HIV seroprevalence remained stable at slightly more than 50%. Mean CD4+ cell counts declined from 0.716x10(9)/L (716/muL) to 0.575x10(9)/L (P<.009). Annual death rate among 1984 subjects was 3%, with a significantly higher rate among HIV-seropositive subjects (relative risk, 2.57; 95% exact binomial confidence interval, 1.12 to 6.61). Large-scale declines were observed in AIDS risk behaviors, eg, use of potentially contaminated syringes declined from 51% to 7% of injections (P<.001). Recent additional risk reduction was associated with use of the underground syringe exchanges. Intranasal heroin use was the primary route of drug administration for 46% of heroin admissions to New York City drug treatment programs. Conclusions.-The HIV seroprevalence has remained stable among this population of New York City IDUs for almost a decade. Continuation of current trends should lead to further reduction in HIV transmission, although reversal of the trend to intranasal use could lead to substantially increased transmission.	NYU, NEW YORK STATE OFF ALCOHOLISM & SUBST ABUSE SERV, DEPT ENVIRONM MED, NEW YORK, NY 10003 USA; NEW YORK CITY DEPT HLTH, NEW YORK, NY 10013 USA	New York University; New York City Department of Health & Mental Hygiene	JARLAIS, DCD (corresponding author), BETH ISRAEL MED CTR, NATL DEV & RES INST INC, INST AIDS RES, 11 BEACH ST, NEW YORK, NY 10013 USA.			Marmor, Michael/0000-0001-6605-2661	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003574] Funding Source: NIH RePORTER; NIDA NIH HHS [DA03574, DA06001] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ABDULQUADER AS, 1987, CONTEMP DRUG PROBL, V14, P425; ANDERSON W, 1991, AM J PUBLIC HEALTH, V81, P1506, DOI 10.2105/AJPH.81.11.1506; [Anonymous], 1993, NEW YORK CITY AIDS S; BLIX O, 1988, 4TH INT C AIDS STOCK; BLOWER SM, 1991, PHILOS T R SOC B, V331, P171, DOI 10.1098/rstb.1991.0006; BROWN LS, 1988, 5TH INT C AIDS MONTR; CASRIEL C, 1990, J SUBST ABUSE TREAT, V7, P1, DOI 10.1016/0740-5472(90)90031-K; DESJARLAIS DC, 1992, BRIT J ADDICT, V87, P493; DESJARLAIS DC, 1989, JAMA-J AM MED ASSOC, V261, P1008, DOI 10.1001/jama.261.7.1008; DESJARLAIS DC, 1992, ANN AM ACAD POLIT SS, V521, P42; DESJARLAIS DC, 1992, SCI CHALLENGING AIDS, P207; FRANK B, 1992, EPIDEMIOLOGIC TRENDS, P220; FRENCH JF, 1989, LANCET, V1, P1082, DOI 10.1016/S0140-6736(89)92483-5; FRIEDMAN SR, 1987, INT J ADDICT, V22, P201, DOI 10.3109/10826088709027425; FRIEDMAN SR, 1992, 120TH ANN M AM PUBL; FRIEDMAN SR, 1993, 9TH INT C AIDS BERL; GALLI M, 1992, 8TH INT C AIDS AMST; GRIFFITHS P, 1992, BRIT J ADDICT, V87, P485; HAGAN H, 1992, 8TH INT C AIDS AMST; HARTEL D, 1988, 4TH INT C AIDS STOCK; JARLAIS DCD, 1992, AM J PUBLIC HEALTH, V82, P1531, DOI 10.2105/AJPH.82.11.1531; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MARMOR M, 1987, AIDS, V1, P39; Nicolosi A, 1990, Epidemiology, V1, P453, DOI 10.1097/00001648-199011000-00007; SCHOTTENFELD RS, 1993, J SUBST ABUSE TREAT, V10, P5, DOI 10.1016/0740-5472(93)90092-G; SELWYN PA, 1992, NEW ENGL J MED, V327, P1697, DOI 10.1056/NEJM199212103272401; SOTHERAN JL, 1992, 8TH INT C AIDS AMST; STONEBURNER RL, 1988, SCIENCE, V242, P916, DOI 10.1126/science.3187532; VLAHOV D, 1991, AM J DRUG ALCOHOL AB, V17, P39, DOI 10.3109/00952999108992808; 1985, SAS USERS GUIDE STAT; 1993, HIV AIDS SURVEILLANC	31	178	181	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	1994	271	2					121	127		10.1001/jama.1994.03510260053028	http://dx.doi.org/10.1001/jama.1994.03510260053028			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ083	8264066				2022-12-28	WOS:A1994MQ08300021
J	WATTERS, JK; ESTILO, MJ; CLARK, GL; LORVICK, J				WATTERS, JK; ESTILO, MJ; CLARK, GL; LORVICK, J			SYRINGE AND NEEDLE EXCHANGE AS HIV AIDS-PREVENTION FOR INJECTION-DRUG USERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ETHNIC-DIFFERENCES; RISK BEHAVIOR; SAN-FRANCISCO; INFECTION; PROGRAM; INITIATION; AMSTERDAM; RACE	Objective.-To evaluate an all-volunteer syringe exchange program in San Francisco, Calif. Data Sources.-Syringe exchange program records and 11 semiannual surveys administered during a 5.5-year period, using standard questionnaires. Interviews (N=5644) were conducted with injection drug users recruited in two 21-day drug detoxification clinics and three street settings. Main Outcome Measures.-Use of the syringe exchange program and self-reported data regarding sources of syringes, frequency of injection, initiation into drug injection, and frequency of syringe sharing. Results.-In spring 1992, 45% reported ''usually'' obtaining injection equipment from the syringe exchange, and 61% reported using the program within the past year. During the period from December 1986 through June 1992, the median reported frequency of injection declined from 1.9 injections per day to 0.7 injection per day, the mean age increased from 36 to 42 years, and the percentage of new initiates into injection drug use decreased from 3% to 1%. In logistic regression analysis (of fall 1991 through spring 1992 interviews; n=752), we found six independent factors associated with syringe sharing. Protective from syringe sharing were use of the syringe exchange program, having received human immunodeficiency virus (HIV) testing and counseling, condom use, older age, and African-American race. Injection of cocaine was a predictor for syringe sharing. The strength of association between use of the syringe exchange program and not sharing syringes was greatest in injection drug users younger than the median age of 40 years. Conclusions.-The syringe exchange program was rapidly adopted by injection drug users. Health interventions associated with not sharing needles included use of the syringe exchange program and voluntary, confidential HIV testing and counseling. Our data did not support the hypothesis that a syringe exchange program would stimulate increased drug abuse in terms of frequency of injection or recruitment of new and/or younger users.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA 94143; PREVENT POINT RES GRP,SAN FRANCISCO,CA	University of California System; University of California San Francisco	WATTERS, JK (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,URBAN HLTH STUDY,BOX 1304,SAN FRANCISCO,CA 94143, USA.			Lorvick, Jennifer/0000-0002-2836-3028	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004212] Funding Source: NIH RePORTER; NIDA NIH HHS [R01-DA04212] Funding Source: Medline; PHS HHS [U62-CCU902017, 83-0706] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1990, SPSS REFERENCE GUIDE; BUZOLIC A, 1988, NEEDLE SYRINGE AVAIL; CARVELL AM, 1990, BRIT J ADDICT, V85, P235; CATALANO RF, 1992, J STUD ALCOHOL, V53, P208, DOI 10.15288/jsa.1992.53.208; CHAISSON RE, 1989, JAMA-J AM MED ASSOC, V261, P561, DOI 10.1001/jama.261.4.561; CHOOPANYA K, 1991, AIDS, V5, P1509, DOI 10.1097/00002030-199112000-00014; DAQUILA RT, 1989, J ACQ IMMUN DEF SYND, V2, P503; DESJARLAIS DC, 1989, 5 INT C AIDS MONTR; Dinwiddie S H, 1992, J Subst Abuse, V4, P1, DOI 10.1016/0899-3289(92)90022-P; DINWIDDIE SH, 1992, COMPR PSYCHIAT, V33, P172; DONOGHOE MC, 1991, 7 INT C AIDS FLOR; ELLICKSON PL, 1992, J ABNORM PSYCHOL, V101, P441, DOI 10.1037/0021-843X.101.3.441; GRUND JPC, 1990, AIDS, V4, P819, DOI 10.1097/00002030-199008000-00020; GUYDISH J, 1993, AIDS, V7, P871, DOI 10.1097/00002030-199306000-00017; GUYDISH J, 1992, AIDS, V6, P739, DOI 10.1097/00002030-199207000-00021; HART GJ, 1989, AIDS, V3, P261, DOI 10.1097/00002030-198905000-00002; HARTGERS C, 1989, AIDS, V3, P571, DOI 10.1097/00002030-198909000-00003; HARTGERS C, 1992, PUBLIC HEALTH REP, V107, P675; KAPLAN EH, 1992, J ACQ IMMUN DEF SYND, V5, P163; KOBLIN BA, 1990, AM J EPIDEMIOL, V132, P837, DOI 10.1093/oxfordjournals.aje.a115726; KOZEL NJ, 1986, SCIENCE, V234, P970, DOI 10.1126/science.3490691; LAMPINEN T, 1989, JAMA-J AM MED ASSOC, V262, P1331, DOI 10.1001/jama.1989.03430100065027; LJUNGBERG B, 1991, J ACQ IMMUN DEF SYND, V4, P890; LURIE P, 1993, PUBLIC HLTH IMPACT N, V1; MANN J, 1993, AIDS WORLD; MORRISON V, 1991, DRUG ALCOHOL DEPEN, V27, P213, DOI 10.1016/0376-8716(91)90003-H; NELSON KE, 1991, JAMA-J AM MED ASSOC, V266, P2259, DOI 10.1001/jama.266.16.2259; PURCHASE D, 1989, 5 INT C AIDS MONTR; PYE M, 1989, 5TH INT C AIDS MONTR; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SCHOENBAUM EE, 1989, NEW ENGL J MED, V321, P874, DOI 10.1056/NEJM198909283211306; STIMSON GV, 1989, AIDS, V3, P253, DOI 10.1097/00002030-198905000-00001; STIMSON GV, 1992, 8TH INT C AIDS AMST; VANDENHOEK JA, 1989, AM J PUBLIC HEALTH, V10, P1355; WATTERS JK, 1990, AM J COMMUN PSYCHOL, V18, P587, DOI 10.1007/BF00938061; WATTERS JK, 1991, INT J ADDICT, V26, P1247, DOI 10.3109/10826089109062158; WATTERS JK, 1992, JAMA-J AM MED ASSOC, V268, P2374, DOI 10.1001/jama.268.17.2374; WILEY JA, 1989, AIDS S1, V3, P71; WODAK A, 1990, AIDS (London), V4, pS105; [No title captured]; 1989, PILOT NEEDLE EXCHANG; 1993, HIV AIDS SURVEILLANC, V5; 1991, TWIN EPIDEMICS SUBST	43	252	253	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	1994	271	2					115	120		10.1001/jama.271.2.115	http://dx.doi.org/10.1001/jama.271.2.115			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MQ083	8264065				2022-12-28	WOS:A1994MQ08300020
J	IFUDU, O; MAYERS, J; MATTHEW, J; TAN, CC; CAMBRIDGE, A; FRIEDMAN, EA				IFUDU, O; MAYERS, J; MATTHEW, J; TAN, CC; CAMBRIDGE, A; FRIEDMAN, EA			DISMAL REHABILITATION IN GERIATRIC INNER-CITY HEMODIALYSIS-PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STAGE RENAL-DISEASE; RECOMBINANT HUMAN ERYTHROPOIETIN; FUNCTIONAL STATUS; CLINICAL-TRIAL; DIALYSIS; LIFE; MORTALITY; SURVIVAL; THERAPY; QUALITY	Objective.-To assess the extent of functional and vocational rehabilitation achieved by elderly inner-city patients sustained on maintenance hemodialysis. Design.-Inception cohort study of elderly patients who have end-stage renal disease using a modified Karnofsky rating system. The need for a wheelchair, participation in household activities, and effect of comorbid conditions were noted. Current status was compared with patient's recollection of functional activity level 2 years before commencing maintenance hemodialysis. Setting.-Seven outpatient, hospital-affiliated and private hemodialysis units in Brooklyn, NY. Patients.-One hundred four patients aged 65 years or older who were receiving maintenance hemodialysis for at least 6 months. Main Outcome Measures.-A score of 76 or greater on a modified Karnofsky scale indicated independent function at a level that permitted participation in activities beyond those mandated by the hemodialysis regimen. A comorbidity score 6 or greater on a newly constructed index correlated with severe debility. Employment status was also recorded. Results.-Present functional activity had deteriorated to a modified Karnofsky score of 66+/-12.3 (+/-SD) compared with patients' recollection of a mean score of 84+/-14.3 (P<.001) 2 years before initiation of hemodialysis. Diabetic patients had a lower score than nondiabetic patients. The mean comorbidity index of the entire study group was 7.8+/-2.9 (mean+/-SD). Within the diabetic subset, severe debility constrained 71 patients (68%) to limit all activity to their residence with the exception of travel to and from their dialysis facility. By contrast, 2 years prior to commencing dialytic therapy, 81 diabetic patients (78%) had interests and activities that took them outside their homes (P<.001). Generalized weakness was the most common explanation given for the lack of outside activity by nine patients (9%) who were wheelchair bound. Erythropoietin, though regularly administered to 87 patients (84%) in the study group, was unsuccessful in raising mean hematocrit reading above 0.28+/-0.05 (mean+/-SD). Conclusions.-Maintenance hemodialysis does not return inner-city elderly patients to their predialysis level of functioning. Few elderly, diabetic hemodialysis patients conduct any substantive portion of their lives outside their homes. For nondiabetic patients, the modified Karnofsky score of whites (70.4+/-11.9) and blacks (66.5+/-15.3), though low, was equivalent (P<.4).			IFUDU, O (corresponding author), SUNY HLTH SCI CTR,DEPT MED,DIV RENAL DIS,BOX 52,450 CLARKSON AVE,BROOKLYN,NY 11203, USA.							AVRAM MR, 1991, AM J KIDNEY DIS, V26, P342; BONNEY S, 1978, ARCH INTERN MED, V138, P1510, DOI 10.1001/archinte.138.10.1510; BRANCHE GC, 1991, AM J MED, V91, P37; CANTOR M, 1976, GERONTOLOGIST, V16, P17, DOI 10.1093/geront/16.1_Part_1.17; CARDENAS DD, 1982, NEPHRON, V62, P626; CARLSON DM, 1987, MAYO CLIN PROC, V62, P338, DOI 10.1016/S0025-6196(12)65436-6; CHESTER AC, 1979, ARCH INTERN MED, V139, P1001, DOI 10.1001/archinte.139.9.1001; EASTERLING RE, 1977, T AM SOC ART INT ORG, V23, P28; Eggers P W, 1984, Health Care Financ Rev, V5, P69; EGGERS PW, 1990, AM J KIDNEY DIS, V15, P414, DOI 10.1016/S0272-6386(12)70359-1; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; FRANCIS CK, 1990, AM J MED, V91, P29; GILLUM RF, 1974, JAMA-J AM MED ASSOC, V228, P1563; GUTMAN RA, 1988, ANN INTERN MED, V108, P898, DOI 10.7326/0003-4819-108-6-898; GUTMAN RA, 1981, NEW ENGL J MED, V304, P309, DOI 10.1056/NEJM198102053040601; GUTMAN RA, 1978, POSTGRAD MED, V64, P183, DOI 10.1080/00325481.1978.11714980; HELD PJ, 1987, JAMA-J AM MED ASSOC, V257, P645, DOI 10.1001/jama.257.5.645; HUTCHINSON TA, 1979, J CHRON DIS, V32, P661, DOI 10.1016/0021-9681(79)90096-1; IGLEHART JK, 1993, NEW ENGL J MED, V328, P366, DOI 10.1056/NEJM199302043280528; JULIUS M, 1989, AM J KIDNEY DIS, V13, P61, DOI 10.1016/S0272-6386(89)80118-0; Karnofsky D., 1949, CLIN EVALUATION CHEM, P191; KRAUS JF, 1980, AM J EPIDEMIOL, V111, P407, DOI 10.1093/oxfordjournals.aje.a112915; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; MCCLELLAN WM, 1991, J CLIN EPIDEMIOL, V44, P83, DOI 10.1016/0895-4356(91)90204-M; MCKEVITT PM, 1990, AJKD, V26, P346; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; PORT FK, 1989, AM J NEPHROL, V9, P145, DOI 10.1159/000167954; PRETCHERS MK, 1988, GERONTOLOGIST, V28, P213; REUBEN DB, 1992, AM J MED, V93, P663, DOI 10.1016/0002-9343(92)90200-U; RICHARDSON YW, 1987, TRANSPLANT P, V19, P111; ROSTAND SG, 1982, NEW ENGL J MED, V306, P1276, DOI 10.1056/NEJM198205273062106; SHAPIRO FL, 1983, AM SOC ARTIF INT ORG, V6, P176; SHIDEMAN JR, 1976, ARCH INTERN MED, V136, P1126, DOI 10.1001/archinte.136.10.1126; Uva J L, 1990, JAMA, V263, P139, DOI 10.1001/jama.263.1.135; WESTLIE L, 1984, T AM SOC ART INT ORG, V30, P21; WRIGHT LF, 1991, AM J KIDNEY DIS, V17, P25, DOI 10.1016/S0272-6386(12)80245-9; 1990, USRDS NIH1990 NAT I	39	89	91	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	1994	271	1					29	33		10.1001/jama.271.1.29	http://dx.doi.org/10.1001/jama.271.1.29			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN725	8258883				2022-12-28	WOS:A1994MN72500026
J	PARSONS, R; LI, GM; LONGLEY, MJ; FANG, WH; PAPADOPOULOS, N; JEN, J; DELACHAPELLE, A; KINZLER, KW; VOGELSTEIN, B; MODRICH, P				PARSONS, R; LI, GM; LONGLEY, MJ; FANG, WH; PAPADOPOULOS, N; JEN, J; DELACHAPELLE, A; KINZLER, KW; VOGELSTEIN, B; MODRICH, P			HYPERMUTABILITY AND MISMATCH REPAIR DEFICIENCY IN RER+ TUMOR-CELLS	CELL			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; DNA; MUTATION; MUTANTS; CARCINOGENESIS; EXTRACTS; SYSTEM; LINES	A subset of sporadic colorectal tumors and most tumors developing in hereditary nonpolyposis colorectal cancer patients display frequent alterations in microsatellite sequences. Such tumors have been thought to manifest replication errors (RER+), but the basis for the alterations has remained conjectural. We demonstrate that the mutation rate of (CA)n repeats in RER+ tumor cells is at least 100-fold that in RER- tumor cells and show by in vitro assay that increased mutability of RER+ cells is associated with a profound defect in strand-specific mismatch repair. This deficiency was observed with microsatellite heteroduplexes as well as with heteroduplexes containing single base-base mismatches and affected an early step in the repair pathway. Thus, a true mutator phenotype exists in a subset of tumor cells, the responsible defect is likely to cause transitions and transversions in addition to microsatellite alterations, and a biochemical basis for this phenotype has been identified.	JOHNS HOPKINS ONCOL CTR, BALTIMORE, MD 21231 USA; UNIV HELSINKI, DEPT MED GENET, SF-00014 HELSINKI, FINLAND; NATL TAIWAN UNIV, INST MED TECHNOL, TAIPEI 10016, TAIWAN	Johns Hopkins University; Johns Hopkins Medicine; University of Helsinki; National Taiwan University	PARSONS, R (corresponding author), DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA.		Li, Guo-Min/I-5016-2014; Papadopoulos, Nickolas/K-7272-2012	FANG, WOEI-HORNG/0000-0003-4728-5931; Li, Guo-Min/0000-0002-9842-4578; Parsons, Ramon/0000-0002-6656-3514; Modrich, Paul/0000-0001-8708-9885	NCI NIH HHS [CA09320, CA35494] Funding Source: Medline; NIGMS NIH HHS [GM45190] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035494, R37CA035494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BRATTAIN MG, 1981, CANCER RES, V41, P1751; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; FANG WH, 1993, J BIOL CHEM, V268, P11838; FANG WH, 1993, IN PRESS COLD SPRING, V58; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; HARWOOD J, 1991, MOL CELL BIOL, V11, P3163, DOI 10.1128/MCB.11.6.3163; HENDERSON ST, 1992, MOL CELL BIOL, V12, P2749, DOI 10.1128/MCB.12.6.2749; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; IVANOV EL, 1989, MUTAT RES, V213, P105, DOI 10.1016/0027-5107(89)90141-3; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KUHL DPA, 1993, CURR OPIN GENET DEV, V3, P404, DOI 10.1016/0959-437X(93)90112-3; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LOEB LA, 1991, CANCER RES, V51, P3075; MESELSON M, 1988, RECOMBINATION GENETI, P91; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PETIT MA, 1991, GENETICS, V129, P327; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; ULLMANN A, 1967, J MOL BIOL, V24, P339, DOI 10.1016/0022-2836(67)90341-5; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	41	983	1024	26	163	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 17	1993	75	6					1227	1236		10.1016/0092-8674(93)90331-J	http://dx.doi.org/10.1016/0092-8674(93)90331-J			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	8261516	hybrid			2022-12-28	WOS:A1993MM89300020
J	HIRST, SJ; HAYES, NA; BURRIDGE, J; PEARCE, FL; FOREMAN, JC				HIRST, SJ; HAYES, NA; BURRIDGE, J; PEARCE, FL; FOREMAN, JC			HUMAN BASOPHIL DEGRANULATION IS NOT TRIGGERED BY VERY DILUTE ANTISERUM AGAINST HUMAN IGE	NATURE			English	Article								We have attempted to reproduce the findings of Benveniste and co-workers, who reported in 1988 that degranulation of human basophil leukocytes is triggered by very dilute (10(2)-10(120)) antiserum against IgE. The results were contrary to conventional scientific theory and were not satisfactorily explained. Following as closely as possible the methods of the original study, we can find no evidence for any periodic or polynomial change of degranulation as a function of anti-IgE dilution. Our results contain a source of variation for which we cannot account, but no aspect of the data is consistent with the previously published claims.	UNIV LONDON UNIV COLL,DEPT PHARMACOL,GOWER ST,LONDON WC1E 6BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT CHEM,LONDON WC1E 6BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT STAT SCI,LONDON WC1E 6BT,ENGLAND	University of London; University College London; University of London; University College London; University of London; University College London								DAVENAS E, 1988, NATURE, V333, P816, DOI 10.1038/333816a0	1	71	74	2	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 9	1993	366	6455					525	527		10.1038/366525a0	http://dx.doi.org/10.1038/366525a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	8255290				2022-12-28	WOS:A1993ML21800058
J	LANGA, KM; SUSSMAN, EJ				LANGA, KM; SUSSMAN, EJ			THE EFFECT OF COST-CONTAINMENT POLICIES ON RATES OF CORONARY REVASCULARIZATION IN CALIFORNIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITAL PATIENTS; HEART-DISEASE; CASE-MIX; MASSACHUSETTS; CARE; TRIAL	Background. Lower rates of use of resources have been reported for the treatment of hospitalized patients covered by Medicaid than for privately insured patients. Cost-containment policies may exacerbate such differences in the use of hospital resources. We studied patients with ischemic heart disease who received care at nonfederal hospitals in California in 1983 (the year a Medicaid cost-containment program was implemented), in 1985, or in 1988. Within this sample of patients, we compared the rates of coronary revascularization (coronary-artery bypass surgery or coronary angioplasty) among patients covered by Medicaid, patients with private insurance covering fee-for-service care, and patients enrolled in a health maintenance organization (HMO). Methods. Logistic-regression models were used to determine adjusted odds ratios for the use of coronary revascularization procedures in patients with different types of insurance, with control for demographic, clinical, and hospital characteristics. The study samples were made up of 49,167 patients in 1983, 47,809 in 1985, and 44,631 in 1988. Results. The frequency of revascularization increased in all three insurance groups from 1983 to 1988, but it did so much faster in the fee-for-service and HMO groups than in the Medicaid group. Patients with private fee-for-service insurance were 1.66 times as likely as Medicaid patients to undergo revascularization in 1983 (P<0.01), 2.01 times as likely in 1985 (P<0.01), and 2.33 times as likely in 1988 (P<0.01). Patients enrolled in HMOs were 0.96 times as likely as Medicaid patients to undergo revascularization in 1983 (P<0.05), 1.23 times as likely in 1985 (P<0.01), and 1.53 times as likely in 1988 (P<0.01). Conclusions. The frequency of coronary revascularization in California in 1983 was nearly twice as high for patients with private fee-for-service insurance as for patients enrolled in HMOs or for Medicaid recipients. The implementation that year of stringent cost-control measures by Medicaid may explain the slower increase in the frequency of revascularization over five years among Medicaid recipients as compared with patients in the fee-for-service and HMO groups. Different incentives in fee-for-service and HMO practice may explain the lower frequency of revascularization among patients enrolled in HMOs, although the rates of increase for these two groups were about the same from 1983 to 1988.	UNIV CHICAGO,HARRIS GRAD SCH PUBL POLICY STUDIES,CHICAGO,IL 60637; UNIV CHICAGO,PRITZKER SCH MED,CHICAGO,IL 60637	University of Chicago; University of Chicago				Langa, Kenneth/0000-0002-2798-1836	AHRQ HHS [HS 06948-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BRAVEMAN PA, 1991, JAMA-J AM MED ASSOC, V266, P3300, DOI 10.1001/jama.266.23.3300; DAVIS K, 1990, HLTH CARE COST CONTA; Ginsburg P B, 1986, Health Care Financ Rev, V7, P51; Gujarati D, 2006, N BASIC ECONOMETRICS; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; IGLEHART JK, 1985, NEW ENGL J MED, V313, P59, DOI 10.1056/NEJM198507043130134; JOHNS L, 1985, INQUIRY-J HEALTH CAR, V22, P24; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; MELNICK GA, 1989, HEALTH AFFAIR, V8, P129, DOI 10.1377/hlthaff.8.2.129; MITCHELL JB, 1983, MED CARE, V21, P929, DOI 10.1097/00005650-198309000-00008; SIU AL, 1988, JAMA-J AM MED ASSOC, V259, P1343, DOI 10.1001/jama.259.9.1343; STEINWALD B, 1989, HEALTH AFFAIR, V8, P35, DOI 10.1377/hlthaff.8.2.35; WEISSFELD JL, 1989, CLIN RES, V37, pA328; WEISSMAN J, 1989, JAMA-J AM MED ASSOC, V261, P3572, DOI 10.1001/jama.261.24.3572; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505; YOUNG GJ, 1991, INQUIRY-J HEALTH CAR, V28, P255; 1989, LICENSED SERVICES UT; 1987, DHHS HCFA03249 HLTH; 1989, HOSPITAL STATISTICS; 1989, GUIDE HLTH CARE FIEL; 1983, HOSPITAL STATISTICS; 1990, ANN REPORT LEGISLATU	25	70	70	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 9	1993	329	24					1784	1789		10.1056/NEJM199312093292407	http://dx.doi.org/10.1056/NEJM199312093292407			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MK096	8232488				2022-12-28	WOS:A1993MK09600007
J	FRANZEN, P; TENDIJKE, P; ICHIJO, H; YAMASHITA, H; SCHULZ, P; HELDIN, CH; MIYAZONO, K				FRANZEN, P; TENDIJKE, P; ICHIJO, H; YAMASHITA, H; SCHULZ, P; HELDIN, CH; MIYAZONO, K			CLONING OF A TGF-BETA TYPE-I RECEPTOR THAT FORMS A HETEROMERIC COMPLEX WITH THE TGF-BETA TYPE-II RECEPTOR	CELL			English	Article							GROWTH-FACTOR-BETA; SERINE THREONINE KINASE; PROTEIN-TYROSINE KINASE; HUMAN ENDOTHELIAL-CELLS; EXPRESSION CLONING; MEMBRANE PROTEOGLYCAN; SIGNAL TRANSDUCTION; BINDING-PROTEINS; ACTIVIN RECEPTOR; HUMAN-PLATELETS	A cDNA clone encoding a 53 kd serine/threonine kinase receptor with an overall structure similar to that of the type II receptor for transforming growth factor beta (TGFbeta) was obtained. I-125-TGFbeta1 bound to porcine endothelial cells transfected with the cDNA and formed a cross-linked complex of 70 kd, characteristic of a TGFbeta type I receptor. Immunoprecipitation of the cross-linked complexes by antibodies against the cloned receptor revealed the 70 kd complex as well as a 94 kd TGFbeta type II receptor complex. The immunoprecipitated novel serine/threonine kinase receptor had biochemical properties of the TGFbeta type I receptor and was observed in different cell types. Transfection of the cloned cDNA into TGFbeta type I receptor-deficient cells restored TGFbeta-induced plasminogen activator inhibitor 1 production. These results suggest that signal transduction by TGFbeta involves the formation of a heteromeric complex of two different serine/threonine kinase receptors.			FRANZEN, P (corresponding author), LUDWIG INST CANC RES,CTR BIOMED,S-75124 UPPSALA,SWEDEN.		Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Ichijo, Hidenori/0000-0002-5005-6438				AKHURST R J, 1990, Progress in Growth Factor Research, V2, P153, DOI 10.1016/0955-2235(90)90002-2; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CHEIFETZ S, 1991, J BIOL CHEM, V266, P20767; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; CHEIFETZ S, 1988, J BIOL CHEM, V263, P17225; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOUGOS A, 1988, J IMMUNOL, V141, P1925; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; ICHIJO H, 1993, J BIOL CHEM, V268, P14505; ICHIJO H, 1990, EXP CELL RES, V187, P263, DOI 10.1016/0014-4827(90)90090-W; ICHIJO H, 1991, J BIOL CHEM, V266, P22459; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATSUZAKI K, 1993, J BIOL CHEM, V268, P12719; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MIYAZONO K, 1994, IN PRESS ADV IMMUNOL; MOREN A, 1992, BIOCHEM BIOPH RES CO, V189, P356, DOI 10.1016/0006-291X(92)91566-9; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOSES HL, 1985, CANCER CELL, V3, P65; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; TENDIJKE P, 1993, ONCOGENE, V8, P2879; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; VALE W, 1990, PEPTIDE GROWTH FACTO, P211; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WEINSTEIN JN, 1982, J MEMBRANE BIOL, V66, P203, DOI 10.1007/BF01868495; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	65	741	778	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					681	692		10.1016/0092-8674(93)90489-D	http://dx.doi.org/10.1016/0092-8674(93)90489-D			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242743	Bronze			2022-12-28	WOS:A1993MH74900014
J	FERNANDEZSARABIA, MJ; BISCHOFF, JR				FERNANDEZSARABIA, MJ; BISCHOFF, JR			BCL-2 ASSOCIATES WITH THE RAS-RELATED PROTEIN R-RAS P23	NATURE			English	Article							PROGRAMMED CELL-DEATH; MEMBRANE PROTEIN; C-MYC; GENE; SURVIVAL; PRODUCT; EXPRESSION; PREVENTION; LINES	APOPTOSIS is an important but poorly understood mechanism of cell regulation. Growth factor deprivation can trigger apoptosis in a variety of cells1-3, suggesting the existence of a signal transduction pathway responding to external signals and leading to apoptosis. Overexpression of the proto-oncogene bcl-2 can override these signals and block apoptosis4-14, indicating that the bcl-2 protein (Bcl-2) is an important component of the apoptotic response. The identification of Bcl-2-binding proteins might help explain how Bcl-2 acts to regulate apoptosis. Here we use the yeast two-hybrid system15 to show that the human ras-related protein R-ras p23 (refs 16-18) binds to Bcl-2. This association is also detected in immunoprecipitates from human cell extracts. The association requires full-length Bcl-2 but the C-terminal 60 amino acids of R-ras p23 are sufficient for the interaction. These results provide evidence of a putative component of a signal transduction pathway involved in the regulation of apoptosis.			FERNANDEZSARABIA, MJ (corresponding author), ONYX PHARMACEUT,3031 RES DR,BLDG A,RICHMOND,CA 94806, USA.							ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; HALDAR S, 1989, NATURE, V342, P195, DOI 10.1038/342195a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Lee S, 1993, CURR OPIN CELL BIOL, V5, P286, DOI 10.1016/0955-0674(93)90118-A; LEROSEY I, 1991, J BIOL CHEM, V266, P4315; LOWE DG, 1988, P NATL ACAD SCI USA, V85, P1015, DOI 10.1073/pnas.85.4.1015; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MONICA K, 1990, NATURE, V346, P189, DOI 10.1038/346189a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; SEIGEL RM, 1992, P NATL ACAD SCI USA, V89, P7003; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TANAKA S, 1993, J BIOL CHEM, V268, P10920; UX DL, 1993, P NATL ACAD SCI USA, V90, P786; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432	24	216	227	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 18	1993	366	6452					274	275		10.1038/366274a0	http://dx.doi.org/10.1038/366274a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH325	8232588				2022-12-28	WOS:A1993MH32500066
J	RAVICHANDRAN, KS; LEE, KK; ZHOU, SY; CANTLEY, LC; BURN, P; BURAKOFF, SJ				RAVICHANDRAN, KS; LEE, KK; ZHOU, SY; CANTLEY, LC; BURN, P; BURAKOFF, SJ			INTERACTION OF SHC WITH THE ZETA-CHAIN OF THE T-CELL RECEPTOR UPON T-CELL ACTIVATION	SCIENCE			English	Article							MITOGENIC SIGNAL TRANSDUCTION; PROTEIN TYROSINE KINASE; ANTIGEN RECEPTOR; CYTOPLASMIC TAIL; RAS; DOMAIN; PHOSPHORYLATION; IDENTIFICATION; INDUCTION; PATHWAYS	The shc oncogene product is tyrosine-phosphorylated by Src family kinases and after its phosphorylation interacts with the adapter protein Grb2 (growth factor receptor-bound protein 2). In turn, Grb2 interacts with the guanine nucleotide exchange factor for Ras, mSOS. Because several Src family kinases participate in T cell activation and Shc functions upstream of Ras, the role of Shc in T cell signaling was examined. Shc was phosphorylated on tyrosine after activation through the T cell receptor (TCR), and subsequently interacted with Grb2 and mSOS. The Src homology region 2 (SH2) domain of Shc directly interacted with the tyrosine-phosphorylated zeta chain of the TCR. Thus, Shc may couple TCR activation to the Ras signaling pathway.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV PEDIAT ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02215 USA; F HOFFMANN LA ROCHE & CO LTD, PHARMACEUT RES NEW TECHNOL, DEPT BIOL, CH-4002 BASEL, SWITZERLAND	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Roche Holding			Ravichandran, Kattur Soundarapandian/AAG-7319-2019; Cantley, Lewis C/D-1800-2014	Ravichandran, Kattur Soundarapandian/0000-0003-2397-461X; Cantley, Lewis C/0000-0002-1298-7653	NIAID NIH HHS [AI-17258] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017258] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMREIN KE, IN PRESS P NATL ACAD; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HSI ED, 1989, J BIOL CHEM, V264, P10836; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KITAS EA, 1991, HELV CHIM ACTA, V74, P1314, DOI 10.1002/hlca.19910740621; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAVICHANDRAN KS, UNPUB; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; SONGYANG Z, UNPUB; SZEBERENYI J, 1992, MOL CELL BIOL, V7, P2105; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	46	348	354	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	1993	262	5135					902	905		10.1126/science.8235613	http://dx.doi.org/10.1126/science.8235613			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	8235613				2022-12-28	WOS:A1993MF43800036
J	KELLY, WF; MAHMOOD, R; KELLY, MJ; TURNER, S; ELLIOTT, K				KELLY, WF; MAHMOOD, R; KELLY, MJ; TURNER, S; ELLIOTT, K			INFLUENCE OF SOCIAL DEPRIVATION ON ILLNESS IN DIABETIC-PATIENTS	BRITISH MEDICAL JOURNAL			English	Article									UNIV TEESSIDE,SCH COMP & MATH,MIDDLESBROUGH TS1 3BA,ENGLAND; CLEVELAND CTY COUNCIL,RES & INTELLIGENCE UNIT,MIDDLESBROUGH TS1 2YW,ENGLAND	University of Teesside	KELLY, WF (corresponding author), MIDDLESBROUGH GEN HOSP,CTR DIABET CARE,MIDDLESBROUGH TS5 5AZ,ENGLAND.							Black D., 1980, MANNERS CUSTOMS POLI; MARSH GN, 1986, BRIT MED J, V292, P1173, DOI 10.1136/bmj.292.6529.1173; PHILLIMORE PR, 1991, SOC SCI MED, V33, P139, DOI 10.1016/0277-9536(91)90174-B; Townsend P, 1992, INEQUALITIES HLTH BL; Townsend PP., 1988, HLTH DEPRIVATION INE	5	48	49	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1993	307	6912					1115	1116		10.1136/bmj.307.6912.1115	http://dx.doi.org/10.1136/bmj.307.6912.1115			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ME918	8251810	Green Published, Bronze			2022-12-28	WOS:A1993ME91800018
J	POSNER, MI				POSNER, MI			SEEING THE MIND	SCIENCE			English	Editorial Material							POSITRON-EMISSION TOMOGRAPHY; HUMAN VISUAL-CORTEX; HUMAN-BRAIN; ATTENTION; IMAGERY		UNIV OREGON,INST COGNIT & DECIS SCI,EUGENE,OR 97403	University of Oregon	POSNER, MI (corresponding author), UNIV OREGON,DEPT PSYCHOL,EUGENE,OR 97403, USA.							CORBETTA M, 1991, J NEUROSCI, V11, P2383; FOX PT, 1987, J NEUROSCI, V7, P913; GOLDENBERG G, 1989, NEUROPSYCHOLOGIA, V27, P641, DOI 10.1016/0028-3932(89)90110-3; Kandel ER, 1991, PRINCIPLES NEURAL SC, P5; Kosslyn S. M., 1980, IMAGE MIND; KOSSLYN SM, 1993, J COGNITIVE NEUROSCI, V5, P263, DOI 10.1162/jocn.1993.5.3.263; MANGUN GR, 1993, ATTENTION PERFORM, V14, P219; MCCARTHY G, 1993, P NATL ACAD SCI USA, V90, P4952, DOI 10.1073/pnas.90.11.4952; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; Petersen S E, 1989, J Cogn Neurosci, V1, P153, DOI 10.1162/jocn.1989.1.2.153; PETERSEN SE, 1990, SCIENCE, V249, P1041, DOI 10.1126/science.2396097; POSNER MI, 1988, SCIENCE, V240, P1627, DOI 10.1126/science.3289116; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Posner MI, 1992, NEUROPSYCHOLOGY CONS, P91, DOI DOI 10.1016/B978-0-12-498045-7.50010-4; PYLYSHYN ZW, 1981, PSYCHOL REV, V88, P16, DOI 10.1037/0033-295X.88.1.16; RAICHLE ME, IN PRESS CEREBRAL CO; RIACHLE ME, 1987, HDB PHYSL 2 1, V5, P643; WIKSWO JP, 1993, IN PRESS EEG CLIN NE; ZEKI S, 1991, J NEUROSCI, V11, P641	19	48	48	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 29	1993	262	5134					673	674		10.1126/science.8235585	http://dx.doi.org/10.1126/science.8235585			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MD952	8235585				2022-12-28	WOS:A1993MD95200026
J	RAWAL, J; BARNETT, P; LLOYD, BW				RAWAL, J; BARNETT, P; LLOYD, BW			USE OF STRUCTURED LETTERS TO IMPROVE COMMUNICATION BETWEEN HOSPITAL DOCTORS AND GENERAL-PRACTITIONERS	BRITISH MEDICAL JOURNAL			English	Article											RAWAL, J (corresponding author), N MIDDLESEX HOSP,NHS TRUST,DEPT PAEDIAT,LONDON N18 1QX,ENGLAND.							BADO W, 1984, BRIT MED J, V288, P1813, DOI 10.1136/bmj.288.6433.1813; DEALARCON R, 1960, BRIT MED J, V2, P1663, DOI 10.1136/bmj.2.5213.1663; LLOYD BW, 1993, BRIT MED J, V306, P247, DOI 10.1136/bmj.306.6872.247; NEWTON J, 1992, BRIT MED J, V304, P821, DOI 10.1136/bmj.304.6830.821	4	65	65	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1993	307	6911					1044	1044		10.1136/bmj.307.6911.1044	http://dx.doi.org/10.1136/bmj.307.6911.1044			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD556	8251779	Green Published, Bronze			2022-12-28	WOS:A1993MD55600019
J	TINT, GS; IRONS, M; ELIAS, ER; BATTA, AK; FRIEDEN, R; CHEN, TS; SALEN, G				TINT, GS; IRONS, M; ELIAS, ER; BATTA, AK; FRIEDEN, R; CHEN, TS; SALEN, G			DEFECTIVE CHOLESTEROL-BIOSYNTHESIS ASSOCIATED WITH THE SMITH-LEMLI-OPITZ SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BILE-ACIDS; CEREBROTENDINOUS XANTHOMATOSIS; CHENODEOXYCHOLIC ACID; SITOSTEROLEMIA; METABOLISM; PLASMA; RATS	Background. The Smith-Lemli-Opitz syndrome (frequency, 1:20,000 to 1:40,000) is defined by a constellation of severe birth defects affecting most organ systems. Abnormalities frequently include profound mental retardation, severe failure to thrive, and a high infant-mortality rate. The syndrome has heretofore been diagnosed only from its clinical presentation. Methods. Using capillary-column gas chromatography-mass spectrometry, we measured the sterol composition of plasma, erythrocytes, lens, cultured fibroblasts, and feces from five children with the syndrome (three girls and two boys). Results. Plasma cholesterol levels were abnormally low (8 to 101 mg per deciliter [0.20 to 2.60 mmol per liter]) in every patient, being well below the 5th percentile for age- and sex-matched controls. Concentrations of the cholesterol precursor 7-dehydrocholesterol (cholest-5,7-dien-3beta-ol), which was not detectable in most of our controls, were elevated (11 to 31 mg per deciliter) more than 2000-fold above normal and were similar to the levels of cholesterol in all tissues from all patients. An isomeric dehydrocholesterol with a structure similar to that of 7-dehydrocholesterol was also detected. Conclusions. The combination of abnormally low plasma cholesterol levels and a high concentration of the cholesterol precursor 7-dehydrocholesterol points to a major block in cholesterol biosynthesis at the step in which the C-7(8) double bond of 7-dehydrocholesterol is reduced, forming cholesterol. The block may be sufficient to deprive an embryo or fetus of cholesterol and prevent normal development, whereas the incorporation of 7-dehydrocholesterol into all membranes may interfere with proper membrane function.	VET AFFAIRS MED CTR,DEPT PATHOL,E ORANGE,NJ; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,NEWARK,NJ 07103; TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DEPT PEDIAT,CLIN GENET SECT,BOSTON,MA 02111	US Department of Veterans Affairs; Veterans Health Administration (VHA); Rutgers State University New Brunswick; Rutgers State University Medical Center; Tufts Medical Center; Tufts University	TINT, GS (corresponding author), VET AFFAIRS MED CTR,DEPT MED,385 TREMONT AVE,E ORANGE,NJ 07018, USA.				NHLBI NIH HHS [HL-17818] Funding Source: Medline; NIDDK NIH HHS [DK-18707] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL017818, R37HL017818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018707] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVIGAN J, 1960, J BIOL CHEM, V235, P3123; AXELSON M, 1991, J LIPID RES, V32, P1441; BARBU V, 1988, J NUTR, V118, P774, DOI 10.1093/jn/118.6.774; BATTA AK, 1985, J LIPID RES, V26, P690; CHASALOW FI, 1985, STEROIDS, V46, P827, DOI 10.1016/0039-128X(85)90032-7; CLAYTON RB, 1965, Q REV CHEM SOC, V19, P168, DOI 10.1039/qr9651900168; CURRY C J R, 1987, American Journal of Medical Genetics, V26, P45, DOI 10.1002/ajmg.1320260110; DVORNIK D, 1968, J LIPID RES, V9, P587; FRANTZ ID, 1967, ANNU REV BIOCHEM, V36, P691, DOI 10.1146/annurev.bi.36.070167.003355; FUMAGALLI R, 1969, J NEUROCHEM, V16, P1329, DOI 10.1111/j.1471-4159.1969.tb05983.x; FUMAGALLI R, 1965, J AM OIL CHEM SOC, V42, P1018, DOI 10.1007/BF02636895; Gorlin RJ, 1990, SYNDROMES HEAD NECK, P890; GRUNDY SM, 1971, J LAB CLIN MED, V78, P94; IGARASHI M, 1975, BRAIN RES, V90, P97, DOI 10.1016/0006-8993(75)90685-X; KANDUTSCH AA, 1960, J BIOL CHEM, V235, P2256; KOROLY MJ, 1981, LIPIDS, V16, P755, DOI 10.1007/BF02535344; NORTON WT, 1984, ISOLATION CHARACTERI, P147; OPITZ JM, 1987, AM J MED GENET, V28, P745, DOI 10.1002/ajmg.1320280324; PILL J, 1990, METHOD FIND EXP CLIN, V12, P167; PILL J, 1985, HORM METAB RES, V17, P543, DOI 10.1055/s-2007-1013600; POBER B, 1990, BIRTH DEFECTS ENCY, P1570; RAWLINS FA, 1979, ACTA CIENT VENEZ, V30, P551; REPETTO M, 1990, TERATOLOGY, V42, P611, DOI 10.1002/tera.1420420605; ROUX C, 1980, J NUTR, V110, P2310, DOI 10.1093/jn/110.11.2310; ROUX C, 1966, CR SOC BIOL, V160, P1353; SALEN G, 1989, J LIPID RES, V30, P1319; SALEN G, 1973, J CLIN INVEST, V52, P2822, DOI 10.1172/JCI107478; SALEN G, 1985, J LIPID RES, V26, P1126; SCHROEPFER G, 1961, J BIOL CHEM, V236, P3137; SHEFER S, 1992, J LIPID RES, V33, P1193; SMITH DW, 1964, J PEDIATR-US, V64, P210, DOI 10.1016/S0022-3476(64)80264-X; SMITH ME, 1970, LIPIDS, V5, P665, DOI 10.1007/BF02531432; STEINBERG D, 1960, J BIOL CHEM, V235, P3127; SUZUKI K, 1971, LAB INVEST, V25, P546; TINT GS, 1977, METABOLISM, V26, P721, DOI 10.1016/0026-0495(77)90059-2; TINT GS, 1990, J LIPID RES, V31, P1301; TINT GS, 1974, J LIPID RES, V15, P256; 1980, DHHS NIH801527 DEP H, P29	38	637	647	0	30	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 13	1994	330	2					107	113		10.1056/NEJM199401133300205	http://dx.doi.org/10.1056/NEJM199401133300205			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ670	8259166				2022-12-28	WOS:A1994MQ67000005
J	FITZGIBBON, JE; GAUR, S; FRENKEL, LD; LARAQUE, F; EDLIN, BR; DUBIN, DT				FITZGIBBON, JE; GAUR, S; FRENKEL, LD; LARAQUE, F; EDLIN, BR; DUBIN, DT			TRANSMISSION FROM ONE CHILD TO ANOTHER OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH A ZIDOVUDINE-RESISTANCE MUTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; HIGH-LEVEL RESISTANCE; HOUSEHOLD CONTACTS; SEQUENCE DIVERSITY; HIV-1; INFECTION; INFANTS; RISK; AIDS; DNA	Background and Methods. We describe a child who apparently acquired human immunodeficiency virus type 1 (HIV-1) infection in the home setting. The suspected source of infection was a child with the acquired immunodeficiency syndrome who had received zidovudine and whose virus contained a mutation associated with in vitro zidovudine resistance. The children were born to different HIV-1-infected mothers, but they lived in the same home between the ages of two and five years. Child 1 was infected perinatally; Child 2 was not and was repeatedly found to be seronegative. Child 2 was examined because of acute lymphadenopathy and had seroconverted to HIV-1 positivity. HIV-1 proviral DNA was amplified from peripheral-blood mononuclear cells and subjected to sequence analysis. Sequences from Child 2 were compared with those from Child 2's mother, Child 1, and local HIV-1-infected control children. Results. HIV-1 nucleotide sequences from the third hypervariable region (V3) of the env gene from Child 2 were much more similar to those of Child 1 (with a difference of 1.3 percent) than to those of Child 2's mother (a difference of 9.9 percent) or those of four local, epidemiologically unrelated children (differences of 10.1 to 16.3 percent). A zidovudine-resistance mutation at codon 215 of the reverse transcriptase gene (Thr-->Tyr) was found in Children 1 and 2, but not in Child 2's mother. Although the children had no documented exposure to each other's blood, there had been numerous opportunities, including nosebleeds, bleeding gums, and a laceration in Child 1. Conclusions. In the case we describe, HIV-1 with a mutation associated with zidovudine resistance was transmitted from one young child to another, apparently in the home and probably through unrecognized exposure to blood.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333; NEW JERSEY DEPT HLTH,TRENTON,NJ; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PEDIAT,PISCATAWAY,NJ 08854; CTR DIS CONTROL,NATL CTR INFECT DIS,EPIDEMIOL PROGRAM OFF,DIV FIELD EPIDEMIOL,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; New Jersey Department of Health & Senior Services; Rutgers State University New Brunswick; Rutgers State University Medical Center; Centers for Disease Control & Prevention - USA	DUBIN, DT (corresponding author), UMDNJ,ROBERT WOOD JOHNSON MED SCH,DEPT MOLEC GENET & MICROBIOL,675 HOES LN,PISCATAWAY,NJ 08854, USA.		Edlin, Brian R/F-2966-2018	Edlin, Brian R/0000-0001-8172-8797				ALBERT J, 1993, NATURE, V361, P595, DOI 10.1038/361595b0; BERTHIER A, 1986, LANCET, V2, P598; BURGER H, 1991, P NATL ACAD SCI USA, V88, P11236, DOI 10.1073/pnas.88.24.11236; CICHUTEK K, 1991, AIDS, V5, P1185, DOI 10.1097/00002030-199110000-00005; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDWARDS JR, 1989, J PEDIATR-US, V115, P200, DOI 10.1016/S0022-3476(89)80065-4; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; FISCHL MA, 1987, JAMA-J AM MED ASSOC, V257, P640, DOI 10.1001/jama.257.5.640; FITZGIBBON JE, 1991, AIDS RES HUM RETROV, V7, P265, DOI 10.1089/aid.1991.7.265; FRIEDLAND GH, 1986, NEW ENGL J MED, V314, P344, DOI 10.1056/NEJM198602063140604; GABIANO C, 1992, PEDIATRICS, V90, P369; GERSHON RRM, 1990, AIDS, V4, P645, DOI 10.1097/00002030-199007000-00006; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; KORBER B, 1992, AIDS RES HUM RETROV, V8, P1549, DOI 10.1089/aid.1992.8.1549; KRONE WJA, 1990, J ACQ IMMUN DEF SYND, V3, P517; LAND S, 1992, J INFECT DIS, V166, P1139, DOI 10.1093/infdis/166.5.1139; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LAURE F, 1988, LANCET, V2, P538; MAYERS DL, 1992, J ACQ IMMUN DEF SYND, V5, P749; MCNEARNEY T, 1992, P NATL ACAD SCI USA, V89, P10247, DOI 10.1073/pnas.89.21.10247; MODROW S, 1987, J VIROL, V61, P570, DOI 10.1128/JVI.61.2.570-578.1987; MYERS G, 1992, HUMAN RETROVIRUSES A; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; OU CY, 1988, SCIENCE, V240, P130; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PATERLINI P, 1990, J MED VIROL, V30, P53, DOI 10.1002/jmv.1890300112; RICHMAN DD, 1992, AIDS RES HUM RETROV, V8, P1065, DOI 10.1089/aid.1992.8.1065; ROGERS MF, 1990, PEDIATRICS, V85, P210; SALMINEN M, 1992, AIDS RES HUM RETROV, V8, P1733, DOI 10.1089/aid.1992.8.1733; SIMMONDS P, 1990, J VIROL, V64, P5840, DOI 10.1128/JVI.64.12.5840-5850.1990; SIMONDS RJ, 1993, PEDIATR INFECT DIS J, V12, P845, DOI 10.1097/00006454-199310000-00010; TUDORWILLIAMS G, 1992, LANCET, V339, P15, DOI 10.1016/0140-6736(92)90140-X; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WAHN V, 1986, LANCET, V2, P694; WOLFS TFW, 1992, VIROLOGY, V189, P103, DOI 10.1016/0042-6822(92)90685-I; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; 1987, MMWR MORB MORTAL WKL, V36, pS1; 1992, MMWR MORB MORTAL WKL, V41, P228	41	77	77	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 16	1993	329	25					1835	1841		10.1056/NEJM199312163292502	http://dx.doi.org/10.1056/NEJM199312163292502			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML588	8247034				2022-12-28	WOS:A1993ML58800002
J	MADDOX, J				MADDOX, J			30-DISH ARRAY AIMING TO SEE FURTHER THAN VLA	NATURE			English	Editorial Material																			0	1	1	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 16	1993	366	6456					626	626						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM265	8259205				2022-12-28	WOS:A1993MM26500040
J	SHANNON, M				SHANNON, M			PREDICTORS OF MAJOR TOXICITY AFTER THEOPHYLLINE OVERDOSE	ANNALS OF INTERNAL MEDICINE			English	Article						THEOPHYLLINE; DRUG TOXICITY; SEIZURES; ARRHYTHMIA; HEMOPERFUSION	ORAL ACTIVATED-CHARCOAL; SERUM CONCENTRATIONS; CLINICAL-FEATURES; HEMOPERFUSION; INTOXICATION; MANAGEMENT; INFANTS	Objective: To identify patients at high risk for major toxicity after theophylline intoxication who might benefit from early charcoal hemoperfusion. Design: A 67-month prospective study Setting: Massachusetts Poison Control System. Patients: 249 consecutive patients referred after theophylline intoxication (defined by a peak serum theophylline concentration greater-than-or-equal 167 mumol/L [30 mg/L]). Interventions: Uniform, protocol-directed management recommendations. Main Outcome Measures: Identification of risk factors for major toxicity. Results: 119 patients (48%) not receiving theophylline therapy had acute intoxication; among those receiving such therapy, 92 (37%) had theophylline intoxication because of chronic overmedication and 38 (15%) had acute intoxication. Major toxicity developed in 62 patients (25%); 13 patients (5%) died. Major toxicity was more common in patients with intoxication due to chronic overmedication than in those with acute intoxication who were not receiving theophylline therapy (49% compared with 10%, risk ratio, 4.85; 95% CI, 2.96 to 7.94), even though the former group had lower peak serum theophylline concentrations (283 mumol/L compared with 777 mumol/L, P = 0.001). Logistic regression analysis identified two major factors associated with the development of major toxicity: 1) peak serum theophylline concentrations in cases of acute intoxication and 2) patient age in cases of chronic overmedication. Receiver-operating characteristic curve analysis indicated that major toxicity occurred in patients with a peak serum theophylline concentration of greater than 555 mumol/L (100 mg/L) after acute intoxication and in patients older than 60 years (regardless of peak serum theophylline concentration) after chronic overmedication. Conclusions: Predictors for major toxicity after theophylline intoxication differ by type of overdose.	MASSACHUSETTS POISON CONTROL CTR, BOSTON, MA USA		SHANNON, M (corresponding author), HARVARD UNIV, CHILDRENS HOSP, SCH MED, 300 LONGWOOD AVE, BOSTON, MA 02115 USA.							AITKEN ML, 1987, CHEST, V91, P10, DOI 10.1378/chest.91.1.10; AMITAI Y, 1987, J TOXICOL-CLIN TOXIC, V25, P539, DOI 10.3109/15563658708992656; AMITAI Y, 1986, ANN INTERN MED, V105, P386, DOI 10.7326/0003-4819-105-3-386; BERTINO JS, 1987, ARCH INTERN MED, V147, P757, DOI 10.1001/archinte.147.4.757; BIBERSTEIN MP, 1984, WESTERN J MED, V141, P485; CAMPOS N, 1989, AM J EPIDEMIOL, V129, P439, DOI 10.1093/oxfordjournals.aje.a115148; DAVI MJ, 1978, J PEDIATR-US, V92, P91, DOI 10.1016/S0022-3476(78)80084-5; DAWSON AH, 1989, MED J AUSTRALIA, V151, P689, DOI 10.5694/j.1326-5377.1989.tb139649.x; DERBY LE, 1990, PHARMACOTHERAPY, V10, P112; EASON J, 1989, RESP MED, V83, P219, DOI 10.1016/S0954-6111(89)80035-6; EMERMAN CL, 1990, ANN EMERG MED, V19, P643, DOI 10.1016/S0196-0644(05)82468-0; GAUDREAULT P, 1986, MED TOXICOL ADV DRUG, V1, P169, DOI 10.1007/BF03259836; GAUDREAULT P, 1983, J PEDIATR-US, V102, P474, DOI 10.1016/S0022-3476(83)80682-9; GOLDBERG MJ, 1986, J ALLERGY CLIN IMMUN, V78, P811, DOI 10.1016/0091-6749(86)90066-7; GREENBERG A, 1984, AM J MED, V76, P854, DOI 10.1016/0002-9343(84)90997-5; HEATH A, 1987, MED TOXICOL ADV DRUG, V2, P294, DOI 10.1007/BF03259871; KNODEL AR, 1984, WESTERN J MED, V140, P741; KULIG KW, 1987, ANN EMERG MED, V16, P842, DOI 10.1016/S0196-0644(87)80519-X; LITOVITZ TL, 1992, AM J EMERG MED, V10, P452, DOI 10.1016/0735-6757(92)90075-9; LYNN KL, 1988, NEW ZEAL MED J, V101, P4; MCNEIL BJ, 1975, NEW ENGL J MED, V293, P211, DOI 10.1056/NEJM197507312930501; MURCIANO D, 1989, NEW ENGL J MED, V320, P1521, DOI 10.1056/NEJM198906083202304; MYERS TF, 1980, J PEDIATR-US, V96, P99, DOI 10.1016/S0022-3476(80)80339-8; OLSON KR, 1985, AM J EMERG MED, V3, P386, DOI 10.1016/0735-6757(85)90195-0; PARK GD, 1983, AM J MED, V74, P961, DOI 10.1016/0002-9343(83)90790-8; ROSSING TH, 1989, ANN INTERN MED, V110, P502, DOI 10.7326/0003-4819-110-7-502; ROTHMAN KJ, 1979, NIH791649 PUBL; RUSSO ME, 1979, NEW ENGL J MED, V300, P24, DOI 10.1056/NEJM197901043000107; SAHNEY S, 1983, PEDIATRICS, V71, P615; SESSLER CN, 1990, AM J MED, V88, P567, DOI 10.1016/0002-9343(90)90519-J; SHANNON M, 1987, PEDIATRICS, V80, P368; SHANNON M, 1992, J PEDIATR-US, V121, P125, DOI 10.1016/S0022-3476(05)82558-2; SHANNON M, 1990, ARCH INTERN MED, V150, P2045, DOI 10.1001/archinte.150.10.2045; SKINNER MH, 1990, DRUG SAFETY, V5, P275, DOI 10.2165/00002018-199005040-00004; TSIU SJ, 1990, ANN ALLERGY, V64, P241; ZWILLICH CW, 1975, ANN INTERN MED, V82, P784, DOI 10.7326/0003-4819-82-6-784	36	61	65	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1993	119	12					1161	1167		10.7326/0003-4819-119-12-199312150-00002	http://dx.doi.org/10.7326/0003-4819-119-12-199312150-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM121	8239246				2022-12-28	WOS:A1993MM12100002
J	COHEN, CB; JONSEN, AR				COHEN, CB; JONSEN, AR			THE FUTURE OF THE FETAL TISSUE-BANK	SCIENCE			English	Article							PARKINSONS-DISEASE; TRANSPLANTATION; PREVALENCE; CELLS				COHEN, CB (corresponding author), NATL ADVISORY BOARD ETH REPROD,409 12TH ST SW,WASHINGTON,DC 20024, USA.							ANNAS GJ, 1989, NEW ENGL J MED, V320, P1079, DOI 10.1056/NEJM198904203201610; [Anonymous], 1989, REV GUIDANCE RES USE; CAMPBELL CS, 1992, HASTINGS CENT REP, V22, P34, DOI 10.2307/3562143; FANTEL A, COMMUNICATION; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; GLADWELL M, 1992, WASH POST       0714, pA3; GOLDBERG DJ, 1992, BMJ-BRIT MED J, V304, P1082, DOI 10.1136/bmj.304.6834.1082; HAMILTON DP, 1992, SCIENCE, V257, P869, DOI 10.1126/science.1502549; LEVALLOIS P, 1987, CAN MED ASSOC J, V137, P33; LEWIS SH, 1990, LANCET, V335, P565, DOI 10.1016/0140-6736(90)90349-A; Oskarsson T, 1990, ACTA OBSTET GYN SCAN, V69, P635, DOI 10.3109/00016349009028709; Polkinghorne J., 1992, FETAL TISSUE TRANSPL, P323; SPENCER DD, 1992, NEW ENGL J MED, V327, P1541, DOI 10.1056/NEJM199211263272201; VAWTER DE, 1990, USE HUMAN FETAL TISS, P66; WONG L, 1992, FETAL TISSUE TRANSPL, P129; ZOLER ML, 1993, OB GYN NEWS, V1, P24; 1988, REPORT HUMAN FETAL T; 1993, NIH GUIDE, V22; 1991, LANCET, V337, P253	19	19	19	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 10	1993	262	5140					1663	1665		10.1126/science.8259510	http://dx.doi.org/10.1126/science.8259510			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ML220	8259510				2022-12-28	WOS:A1993ML22000025
J	KNOWLTON, BJ; SQUIRE, LR				KNOWLTON, BJ; SQUIRE, LR			THE LEARNING OF CATEGORIES - PARALLEL BRAIN SYSTEMS FOR ITEM MEMORY AND CATEGORY KNOWLEDGE	SCIENCE			English	Article							MEDIAL TEMPORAL-LOBE; HUNTINGTONS-DISEASE; CONTEXT THEORY; CLASSIFICATION; AMNESIA; RECOGNITION	A fundamental question about cognition concerns how knowledge about a category is acquired through encounters with examples of the category. Amnesic patients and control subjects performed similarly at classifying novel patterns according to whether they belonged to the same category as a set of training patterns. In contrast, the amnesic patients were impaired at recognizing which dot patterns had been presented for training. Category learning appears to be independent of declarative (explicit) memory for training instances and independent of the brain structures essential for declarative memory that are damaged in amnesia. Knowledge about categories can be acquired implicitly by cumulating information from multiple examples.	UNIV CALIF SAN DIEGO,DEPT PSYCHIAT,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego	KNOWLTON, BJ (corresponding author), VET AFFAIRS MED CTR,SAN DIEGO,CA 92161, USA.				NIMH NIH HHS [MH24600] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH024600, R37MH024600] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AGGLETON JP, 1992, AMYGDALA; Brooks L., 1978, COGNITION CATEGORIZA; Cohen N. J., 1984, NEUROPSYCHOLOGY MEMO, P83; COHEN NJ, 1981, THESIS U CALIFORNIA; ESTES WK, 1991, ANNU REV PSYCHOL, V42, P1; ESTES WK, 1993, PSYCHOL SCI, V4, P143, DOI 10.1111/j.1467-9280.1993.tb00478.x; FRIED LS, 1984, J EXP PSYCHOL LEARN, V10, P234, DOI 10.1037/0278-7393.10.2.234; HAYESROTH B, 1977, J VERB LEARN VERB BE, V16, P321, DOI 10.1016/S0022-5371(77)80054-6; HEINDEL WC, 1991, J CLIN EXP NEUROPSYC, V13, P189, DOI 10.1080/01688639108401037; HINTZMAN DL, 1986, PSYCHOL REV, V93, P411, DOI 10.1037/0033-295X.93.4.411; KNOPMAN D, 1991, NEUROPSYCHOLOGIA, V29, P245, DOI 10.1016/0028-3932(91)90085-M; KNOWLTON BJ, 1992, PSYCHOL SCI, V3, P172, DOI 10.1111/j.1467-9280.1992.tb00021.x; KNOWLTON BJ, IN PRESS J EXP PSYCH; MCCLELLAND JL, 1985, J EXP PSYCHOL GEN, V114, P159, DOI 10.1037/0096-3445.114.2.159; MEDIN DL, 1978, PSYCHOL REV, V85, P207, DOI 10.1037/0033-295X.85.3.207; MISHKIN M, 1989, VISION MEMORY TEMPOR, P427; Mishkin M., 1984, NEUROBIOL LEARN MEM, P65, DOI DOI 10.1523/JNEUROSCI.0840-16.2016; NOSOFSKY RM, 1984, J EXP PSYCHOL LEARN, V10, P104, DOI 10.1037/0278-7393.10.1.104; PACKARD MG, 1989, J NEUROSCI, V9, P1465; Petri HL, 1984, NEUROPSYCHOLOGY MEMO, P287; POSNER MI, 1967, J EXP PSYCHOL, V73, P28, DOI 10.1037/h0024135; POSNER MI, 1968, J EXP PSYCHOL, V77, P353, DOI 10.1037/h0025953; REBER AS, 1967, J VERB LEARN VERB BE, V6, P855, DOI 10.1016/S0022-5371(67)80149-X; REBER AS, 1989, J EXP PSYCHOL GEN, V118, P219, DOI 10.1037/0096-3445.118.3.219; REED SK, 1972, COGNITIVE PSYCHOL, V3, P382, DOI 10.1016/0010-0285(72)90014-X; Rosch Eleanor H., 1973, COGNITIVE DEV ACQUIS, P111; SAINTCYR JA, 1988, BRAIN, V111, P941, DOI 10.1093/brain/111.4.941; SCHACTER DL, 1993, ANNU REV NEUROSCI, V16, P159, DOI 10.1146/annurev.ne.16.030193.001111; SCHACTER DL, 1987, J EXP PSYCHOL LEARN, V13, P501, DOI 10.1037/0278-7393.13.3.501; SHERRY DF, 1987, PSYCHOL REV, V94, P439, DOI 10.1037/0033-295X.94.4.439; SHIMAMURA AP, 1988, J NEUROSCI, V8, P4400; Smith EE, 1981, CATEGORIES CONCEPTS; SQUIRE LR, 1982, ANNU REV NEUROSCI, V5, P241, DOI 10.1146/annurev.ne.05.030182.001325; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; SQUIRE LR, 1993, ANNU REV PSYCHOL, V44, P453, DOI 10.1146/annurev.ps.44.020193.002321; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SQUIRE LR, 1990, J NEUROSCI, V10, P3106; THOMPSON RF, 1990, BEHAVIOURAL NEURAL A, P63; TULVING E, 1985, AM PSYCHOL, V40, P385, DOI 10.1037/0003-066x.40.4.385; TULVING E, 1990, SCIENCE, V247, P301, DOI 10.1126/science.2296719; WANG J, 1990, Society for Neuroscience Abstracts, V16, P617; WEISKRANTZ L, 1987, HUM NEUROBIOL, V6, P93; ZOLAMORGAN S, 1993, ANNU REV NEUROSCI, V16, P547, DOI 10.1146/annurev.ne.16.030193.002555	43	338	339	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 10	1993	262	5140					1747	1749		10.1126/science.8259522	http://dx.doi.org/10.1126/science.8259522			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ML220	8259522				2022-12-28	WOS:A1993ML22000046
J	INGHAM, PW				INGHAM, PW			LOCALIZED HEDGEHOG ACTIVITY CONTROLS SPATIAL LIMITS OF WINGLESS TRANSCRIPTION IN THE DROSOPHILA EMBRYO	NATURE			English	Article								CELL patterning in the body segments of the Drosophila embryo requires activity of the segment polarity genes, a molecularly heterogeneous group defined by a generic mutant phenotype1. Two of these genes, wingless (wg) and hedgehog (hh), encode proteins that enter the secretory pathway2-4, implicating them as signals that instruct the fates of neighbouring cells5. Genetic analysis has identified wg transcription as one of the targets of hh activity6,7 and it has been suggested that the spatial control of wg expression depends on the limited range of the hh signal and the differential competence of responding cells8. I have tested this model by driving ubiquitous expression of the hh gene using the Hsp70 promoter. Here I report that, as predicted, this causes the ectopic activation of wg in only a subset of the cells of each parasegment. Using another target of hh activity as a probe, I demonstrate that the competence of cells to express wg is independent of their ability to receive the hh signal. Finally, I show that wg activation requires the function of the segment polarity gene fused, suggesting that the putative hh signal is transduced by the serine/threonine kinase that fused encodes.			INGHAM, PW (corresponding author), ICRF, DEV BIOL UNIT, DEPT ZOOL, MOLEC EMBRYOL LAB, S PARKS RD, OXFORD OX1 3PS, ENGLAND.		Ingham, Philip W/E-6710-2010; Ingham, Philip William/AAH-5884-2020; Ingham, Philip W/G-9903-2011	Ingham, Philip William/0000-0001-8224-9958; Ingham, Philip W/0000-0001-8224-9958				ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1993, DEVELOPMENT, V117, P283; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LIMBOURGBOUCHON B, 1991, DEVELOPMENT, V112, P417; MARTINEZARIAS A, 1985, J EMBRYOL EXP MORPH, V87, P99; MARTINEZARIAS A, 1985, NATURE, V313, P639, DOI 10.1038/313639a0; MOHLER J, 1992, DEVELOPMENT, V115, P957; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Roberts D.B., 1986, P1; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TASHIRO S, 1993, GENE, V124, P183; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2	28	167	177	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	1993	366	6455					560	562		10.1038/366560a0	http://dx.doi.org/10.1038/366560a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	8255293				2022-12-28	WOS:A1993ML21800068
J	KITSBERG, D; SELIG, S; KESHET, I; CEDAR, H				KITSBERG, D; SELIG, S; KESHET, I; CEDAR, H			REPLICATION STRUCTURE OF THE HUMAN BETA-GLOBIN GENE DOMAIN	NATURE			English	Article							DIHYDROFOLATE-REDUCTASE DOMAIN; DNA-REPLICATION; CHROMOSOME-REPLICATION; NUCLEOSOME SEGREGATION; MAMMALIAN-CELLS; ORIGIN; LOCUS; IDENTIFICATION; ACTIVATION; ELEMENT	THE animal cell genome is organized into a series of replicons with an average size of 50-300 kilobases1; each of these units is characterized by its own origin of replication which serves as the point of initiation for DNA synthesis. In animal viruses, origin usage can be regulated by cis-acting elements2, and in some cases, replication may be cell-type specific3. Little is known, however, about the organization and control of endogenous tissue-specific gene replication. To understand this process, we have used a replication direction assay to examine DNA fragments covering more than 200 kilobases of the human beta-like globin domain, and have identified a single bidirectional origin located upstream of the beta-globin itself. This locus is used to initiate DNA synthesis in expressing cells, where the globin domain replicates early, and in non-expressing cells, which are characterized by late replication of the same region4,5. Deletion of this origin sequence, as occurs in the haemoglobin Lepore syndrome6, cancels bidirectional DNA synthesis at this site and leads to a striking reversal of replication direction upstream to the locus. This represents the first genetic proof of the existence of specific, discrete origins of replication in animal cells.			KITSBERG, D (corresponding author), HEBREW UNIV JERUSALEM,SCH MED,DEPT CELLULAR BIOCHEM,IL-91010 JERUSALEM,ISRAEL.							ANACHKOVA B, 1989, MOL CELL BIOL, V9, P532, DOI 10.1128/MCB.9.2.532; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BURHANS WC, 1991, EMBO J, V10, P4351, DOI 10.1002/j.1460-2075.1991.tb05013.x; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DEVILLIERS J, 1984, NATURE, V312, P242, DOI 10.1038/312242a0; DHAR V, 1988, MOL CELL BIOL, V8, P4958, DOI 10.1128/MCB.8.11.4958; EDENBERG HJ, 1975, ANNU REV GENET, V9, P245, DOI 10.1146/annurev.ge.09.120175.001333; EPNER E, 1988, P NATL ACAD SCI USA, V85, P8081, DOI 10.1073/pnas.85.21.8081; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; FERGUSON BM, 1992, CELL, V68, P333, DOI 10.1016/0092-8674(92)90474-Q; FLAVELL RA, 1978, CELL, V15, P25, DOI 10.1016/0092-8674(78)90080-6; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; HANDELI S, 1989, CELL, V57, P909, DOI 10.1016/0092-8674(89)90329-2; HATTON KS, 1988, MOL CELL BIOL, V8, P2149, DOI 10.1128/MCB.8.5.2149; KIOUSSIS D, 1983, NATURE, V306, P662, DOI 10.1038/306662a0; MEARS JG, 1978, P NATL ACAD SCI USA, V75, P1222, DOI 10.1073/pnas.75.3.1222; ROUFA DJ, 1982, P NATL ACAD SCI-BIOL, V79, P1810, DOI 10.1073/pnas.79.6.1810; SEIDMAN MM, 1979, CELL, V18, P439, DOI 10.1016/0092-8674(79)90063-1; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; TARMELLI R, 1986, NUCLEIC ACIDS RES, V15, P7017; TREMPE JP, 1988, MOL CELL BIOL, V8, P1657, DOI 10.1128/MCB.8.4.1657; VANIN EF, 1983, CELL, V35, P701, DOI 10.1016/0092-8674(83)90103-4; VASSILEV LT, 1990, MOL CELL BIOL, V10, P4685, DOI 10.1128/MCB.10.9.4685; VAUGHN JP, 1990, CELL, V61, P1075, DOI 10.1016/0092-8674(90)90071-L	25	256	260	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 9	1993	366	6455					588	590		10.1038/366588a0	http://dx.doi.org/10.1038/366588a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	8255298				2022-12-28	WOS:A1993ML21800077
J	ROE, JL; RIVIN, CJ; SESSIONS, RA; FELDMANN, KA; ZAMBRYSKI, PC				ROE, JL; RIVIN, CJ; SESSIONS, RA; FELDMANN, KA; ZAMBRYSKI, PC			THE TOUSLED GENE IN A-THALIANA ENCODES A PROTEIN-KINASE HOMOLOG THAT IS REQUIRED FOR LEAF AND FLOWER DEVELOPMENT	CELL			English	Article							FLORAL HOMEOTIC GENES; ARABIDOPSIS-THALIANA; TRANSCRIPTION FACTORS; SEQUENCE DATABASE; ANTIRRHINUM-MAJUS; COILED COILS; CELL LINEAGE; LINKAGE MAP; DNA-BINDING; MADS-BOX	Mutation at the TOUSLED locus of A. thaliana results in a complex phenotype, the most dramatic aspect of which being the abnormal flowers produced in mutant plants. tsl flowers show a random loss of floral organs, and organ development is impaired. The TSL gene appears to be required in the floral meristem for correct initiation of floral organ primordia and for proper development of organ primordia. Loss of TSL function also affects flowering time and leaf morphology. Using a mutation derived by T-DNA insertion mutagenesis, we have cloned the TSL gene and found that it encodes a protein kinase homolog with a novel N-terminal domain. This protein kinase gene identifies a novel signaling/regulatory pathway used during development in Arabidopsis.	OREGON STATE UNIV, DEPT BOT & PLANT PATHOL, CORVALLIS, OR 97331 USA; UNIV ARIZONA, DEPT PLANT SCI, TUCSON, AZ 85721 USA	Oregon State University; University of Arizona	ROE, JL (corresponding author), UNIV CALIF BERKELEY, DEPT PLANT BIOL, BERKELEY, CA 94720 USA.				NIGMS NIH HHS [1-F32-GM13292-01-BI-3] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013292] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; Becraft PW, 1992, CURR OPIN GENET DEV, V2, P571, DOI 10.1016/S0959-437X(05)80174-1; BERNIER G, 1988, ANNU REV PLANT PHYS, V39, P175, DOI 10.1146/annurev.arplant.39.1.175; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1992, DEVELOPMENT, V114, P599; BOWMAN JL, 1991, PLANT CELL, V3, P749, DOI 10.1105/tpc.3.8.749; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; BRADLEY D, 1993, CELL, V72, P85, DOI 10.1016/0092-8674(93)90052-R; BRUTLAG DL, 1990, COMPUT APPL BIOSCI, V6, P237; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Clarke MC, 1992, PLANT MOL BIOL REP, V10, P178, DOI 10.1007/BF02668345; Coen Enrico S., 1992, Current Opinion in Cell Biology, V4, P929, DOI 10.1016/0955-0674(92)90120-2; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1991, ANNU REV PLANT PHYS, V42, P241, DOI 10.1146/annurev.pp.42.060191.001325; COEN ES, 1993, IN PRESS PLANT CELL; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; CONDIT C, 1983, GENE, V25, P101, DOI 10.1016/0378-1119(83)90172-5; DAWE RK, 1991, PLANT J, V1, P3, DOI 10.1111/j.1365-313X.1991.00003.x; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELDMANN KA, 1987, MOL GEN GENET, V208, P1, DOI 10.1007/BF00330414; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GHEYSEN G, 1991, GENE DEV, V5, P287, DOI 10.1101/gad.5.2.287; GORING DR, 1993, PLANT CELL, V5, P531, DOI 10.1105/tpc.5.5.531; HALL TC, 1978, P NATL ACAD SCI USA, V75, P3196, DOI 10.1073/pnas.75.7.3196; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HAUGE BM, 1993, PLANT J, V3, P745, DOI 10.1111/j.1365-313X.1993.00745.x; HAUGHN GW, 1988, DEV GENET, V9, P73, DOI 10.1002/dvg.1020090202; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; HONMA MA, 1993, P NATL ACAD SCI USA, V90, P6242, DOI 10.1073/pnas.90.13.6242; Irish VF, 1991, CURR OPIN GENET DEV, V1, P169, DOI 10.1016/S0959-437X(05)80065-6; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; JACK T, 1993, SEMIN DEV BIOL, V4, P51; JORGENSEN RA, 1987, PLANT MOL BIOL, V8, P3, DOI 10.1007/BF00016429; KARLSSON BH, 1993, AM J BOT, V80, P646, DOI 10.2307/2445435; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KOMAKI MK, 1988, DEVELOPMENT, V104, P195; KOORNNEEF M, 1983, J HERED, V74, P265, DOI 10.1093/oxfordjournals.jhered.a109781; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; KUNST L, 1989, PLANT CELL, V1, P1195, DOI 10.1105/tpc.1.12.1195; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEYSER HMO, 1992, DEVELOPMENT, V116, P397; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MA H, 1993, TRENDS GENET, V9, P228, DOI 10.1016/0168-9525(93)90075-S; MALDONADO F, 1988, NUCLEIC ACIDS RES, V16, P8189, DOI 10.1093/nar/16.16.8189; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MARTINEZ MC, 1992, P NATL ACAD SCI USA, V89, P7360, DOI 10.1073/pnas.89.16.7360; MARTINEZZAPATER JM, 1990, PLANT PHYSIOL, V92, P770, DOI 10.1104/pp.92.3.770; MARTON L, 1991, PLANT CELL REP, V10, P235, DOI 10.1007/BF00232565; MCLEOD M, 1986, EMBO J, V5, P3665, DOI 10.1002/j.1460-2075.1986.tb04697.x; MEDFORD JI, 1992, PLANT CELL, V4, P631, DOI 10.1105/tpc.4.6.631; NAM HG, 1989, PLANT CELL, V1, P699, DOI 10.1105/tpc.1.7.699; OKADA K, 1989, CELL DIFFER DEV, V28, P27, DOI 10.1016/0922-3371(89)90020-8; POETHIG S, 1989, TRENDS GENET, V5, P273, DOI 10.1016/0168-9525(89)90101-7; PRUITT RE, 1986, J MOL BIOL, V187, P169, DOI 10.1016/0022-2836(86)90226-3; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROGERS SG, 1987, METHOD ENZYMOL, V153, P253; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTZ EA, 1991, PLANT CELL, V3, P1221, DOI 10.1105/tpc.3.11.1221; SCHWARZSOMMER Z, 1992, EMBO J, V11, P251, DOI 10.1002/j.1460-2075.1992.tb05048.x; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SHANNON S, 1993, PLANT CELL, V5, P639, DOI 10.1105/tpc.5.6.639; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; SUSSEX IM, 1989, CELL, V56, P225, DOI 10.1016/0092-8674(89)90895-7; SZYMKOWIAK EJ, 1992, PLANT CELL, V4, P1089, DOI 10.1105/tpc.4.9.1089; TROBNER W, 1992, EMBO J, V11, P4693, DOI 10.1002/j.1460-2075.1992.tb05574.x; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	74	137	143	3	8	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 3	1993	75	5					939	950		10.1016/0092-8674(93)90537-Z	http://dx.doi.org/10.1016/0092-8674(93)90537-Z			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252629				2022-12-28	WOS:A1993MK96600013
J	THEA, DM; STLOUIS, ME; ATIDO, U; KANJINGA, K; KEMBO, B; MATONDO, M; TSHIAMALA, T; KAMENGA, C; DAVACHI, F; BROWN, C; RAND, WM; KEUSCH, GT				THEA, DM; STLOUIS, ME; ATIDO, U; KANJINGA, K; KEMBO, B; MATONDO, M; TSHIAMALA, T; KAMENGA, C; DAVACHI, F; BROWN, C; RAND, WM; KEUSCH, GT			A PROSPECTIVE-STUDY OF DIARRHEA AND HIV-1 INFECTION AMONG 429 ZAIRIAN INFANTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERSISTENT DIARRHEA; AFRICAN CHILDREN; RURAL BANGLADESH; MALNUTRITION; ASSOCIATION; DURATION; MOTHERS; AIDS; BORN	Background. Persistent diarrhea is a prominent feature of the acquired immunodeficiency syndrome in adults, but its cause and its effect on children with human immunodeficiency virus (HIV) infection are largely unknown, particularly in Africa. Methods. We studied a birth cohort of 429 infants born to HIV-positive or HIV-negative mothers in Zaire to determine the incidence of acute, recurrent (greater-than-or-equal-to 2 episodes), and persistent (greater-than-or-equal-to 14 days) diarrhea; outcome; and risk factors. Results. Of the 238 infants whose mothers were HIV-positive, 53 were infected, 139 were uninfected, and the HIV status of 46 could not be determined. As compared with uninfected infants, infected infants had higher incidence rates for acute diarrhea (170 vs. 100 episodes per 100 child-years, P = 0.003), recurrent diarrhea (21 vs. 11, P = 0.12), and persistent diarrhea (19 vs. 4, P<0.003). Persistent diarrhea developed in 11 HIV-infected infants; all but 1 died. It also developed in 19 uninfected infants; all but 1 survived. The prevalence of stool pathogens was similar in the two groups. In a multivariate model, persistent diarrhea in an infant was independently associated with symptomatic HIV type 1 infection in the mother (relative hazard, 1.5; P = 0.08). The incidence of persistent diarrhea in the uninfected infants of seropositive mothers was nearly double that in the uninfected infants of seronegative mothers (4.9 vs. 2.7 episodes per 100 child-years), and the risk increased if the mother died (relative hazard, 10.4). Significant growth impairment and severe immunosuppression occurred in the six to eight weeks before the onset of persistent diarrhea. Conclusions. In Zaire, infants with HIV infection have an 11-fold increased risk of death from diarrhea, largely persistent diarrhea, which is often preceded by recurrent episodes of acute diarrhea, malnutrition, or immunosuppression. illness and death of the mother increase that risk, even among her uninfected infants.	TUFTS UNIV NEW ENGLAND MED CTR, DIV GEOG MED & INFECT DIS, BOX 041, 750 WASHINGTON ST, BOSTON, MA 02111 USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA USA; INT COOPERAT AIDS RES UNIT, PROJET SIDA, KINSHASA, DEM REP CONGO; MAMA YEMO HOSP, DEPT PEDIAT, KINSHASA, DEM REP CONGO; NIAID, BETHESDA, MD 20892 USA	Tufts Medical Center; Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Thea, Donald/0000-0002-6933-1030; /0000-0001-5724-2965	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI026698] Funding Source: NIH RePORTER; NIAID NIH HHS [P01-AI-26698] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAIRAGI R, 1987, INT J EPIDEMIOL, V16, P477, DOI 10.1093/ije/16.3.477; BENEDETTI J, 1990, BMDP STATISTICAL SOF, P739; BHANDARI N, 1989, BMJ-BRIT MED J, V298, P1284, DOI 10.1136/bmj.298.6683.1284; BLACK RE, 1984, AM J CLIN NUTR, V39, P87, DOI 10.1093/ajcn/39.1.87; BROWN KH, 1989, PEDIATRICS, V83, P31; CHIN J, 1990, LANCET, V336, P221, DOI 10.1016/0140-6736(90)91743-T; COHEN MB, 1993, J CLIN MICROBIOL, V31, P351, DOI 10.1128/JCM.31.2.351-353.1993; FAUVEAU V, 1992, ACTA PAEDIATR, V81, P12, DOI 10.1111/j.1651-2227.1992.tb12365.x; HIRA SK, 1989, BRIT MED J, V299, P1250, DOI 10.1136/bmj.299.6710.1250; HOPKINS A, 1990, BMDP STATISTICAL SOF, P769; HUTTLY SRA, 1989, INT J EPIDEMIOL, V18, P964, DOI 10.1093/ije/18.4.964; KEUSCH GT, 1990, NESTLE NUTR WORKS SE, V19, P37; KIRKWOOD B, 1988, ESSENTIALS MED STAT, P129; MALEK ANA, 1989, 5TH P INT C AIDS MON, P392; NSANGA B, 1989, 5TH P INT C AIDS MON, P324; PAVIA AT, 1992, PEDIATR INFECT DIS J, V11, P996, DOI 10.1097/00006454-199211120-00002; PREBLE EA, 1990, SOC SCI MED, V31, P671, DOI 10.1016/0277-9536(90)90249-R; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; ROTHMAN K, 1979, DHHS NIH791649 PUBL; SAMBROOK J, 1989, MOL CLONING, V1, P90; SCHORLING JB, 1990, INT J EPIDEMIOL, V19, P728, DOI 10.1093/ije/19.3.728; SEPULVEDA J, 1988, AM J EPIDEMIOL, V127, P365, DOI 10.1093/oxfordjournals.aje.a114810; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2853, DOI 10.1001/jama.269.22.2853; 1989, MMWR MORB MORTAL S7, V38, P1; [No title captured]; 1984, PROGRAMME CONTROL DI	26	124	124	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 2	1993	329	23					1696	1702		10.1056/NEJM199312023292304	http://dx.doi.org/10.1056/NEJM199312023292304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ707	8232458				2022-12-28	WOS:A1993MJ70700004
J	FLAHERTY, JP; GARCIAHOUCHINS, S; CHUDY, R; ARNOW, PM				FLAHERTY, JP; GARCIAHOUCHINS, S; CHUDY, R; ARNOW, PM			AN OUTBREAK OF GRAM-NEGATIVE BACTEREMIA TRACED TO CONTAMINATED O-RINGS IN REPROCESSED DIALYZERS	ANNALS OF INTERNAL MEDICINE			English	Article						BACTEREMIA; GRAM-NEGATIVE BACTERIA; HEMODIALYSIS; DISINFECTION; EQUIPMENT CONTAMINATION	HIGH-FLUX DIALYSIS; PYROGENIC REACTIONS; HEMODIALYSIS	Objective: To investigate an outbreak of gram-negative bacteremia in an outpatient hemodialysis unit and to identify the source of contaminating bacteria and the route by which bacteria gained access to the bloodstream. Design: A matched-pair, case-control study and a bacteriologic investigation of the hemodialysis unit and the implicated dialyzers. Setting: A university outpatient hemodialysis unit. Patients: Eleven patients receiving long-term hemodialysis who had a total of 12 episodes of primary gram-negative bacteremia and 12 matched controls. Measurements: Clinical and demographic data were obtained for patients and controls. Dialysis unit procedures were observed for compliance with aseptic technique. Cultures of potential environmental sources of bacteria were obtained. Hemodialyzers from bacteremic and nonbacteremic patients were dismantled, and the component parts were cultured. Inoculation of O-rings (from Hemoflow F-80 dialyzer) with bacteria and simulated dialysis were done. Results: During January to October 1988, 12 episodes of primary gram-negative bacteremia caused by Pseudomonas cepacia, Xanthomonas maltophilia, Citrobacter freundii, Acinetobacter calcoaceticus var. anitratus, or Enterobacter cloacae occurred in 11 patients. In 11 episodes, symptoms developed within 3 hours of starting hemodialysis. Intravenous antibiotics were administered for 11 episodes, 3 episodes resulted in hospitalization, and all patients recovered. Case patients were more likely to have received high-flux dialysis with Hemoflow F-80 dialyzers (odds ratio congruent-to 11) than were controls. O-rings from dialyzers used by bacteremic patients were culture positive for the organism responsible for bacteremia. Three of the four dialyzers were disinfected using the standard automated method and were recultured 72 hours later; the O-rings of all three dialyzers remained culture positive. Simulated dialysis using dialyzers with contaminated O-rings caused blood pathway contamination despite intervening reprocessing. When the disinfection method for F-80 dialyzers included removal and complete disinfection of the O-rings, O-ring and blood pathway cultures were consistently negative. After this procedure was made routine, no episodes of primary gram-negative bacteremia occurred during the next 6 months. Conclusions: Because dialyzers with removable headers and O-rings are widely used in patients receiving long-term hemodialysis, disinfection procedures should include measures to ensure adequate disinfection of O-rings.	UNIV CHICAGO, CHICAGO, IL 60637 USA	University of Chicago								ALTER MJ, 1988, JAMA-J AM MED ASSOC, V260, P2073, DOI 10.1001/jama.260.14.2073; ALTER MJ, 1991, T AM SOC ART INT ORG, V37, P97; BECKSAGUE CM, 1990, AM J NEPHROL, V10, P397, DOI 10.1159/000168155; Bland L A, 1989, ASAIO Trans, V35, P314, DOI 10.1097/00002480-198907000-00044; BOLAN G, 1985, J INFECT DIS, V152, P1013, DOI 10.1093/infdis/152.5.1013; FAVERO MS, 1975, HEALTH LAB SCI, V12, P321; FLEMING SJ, 1991, AM J NEPHROL, V11, P27, DOI 10.1159/000168268; GOETZ A, 1983, ARCH INTERN MED, V143, P1909, DOI 10.1001/archinte.143.10.1909; GORDON SM, 1992, J AM SOC NEPHROL, V2, P1436; JONES DM, 1970, BRIT MED J, V3, P135, DOI 10.1136/bmj.3.5715.135; KUEHNEL E, 1976, DIALYSIS TRANSPLANT, V5, P44; LOWRY PW, 1990, J INFECT DIS, V161, P85, DOI 10.1093/infdis/161.1.85; MURPHY J, 1987, AM SOC ARTIF INTERN, V16, P51; POLLAK VE, 1986, NEPHRON, V42, P217, DOI 10.1159/000183670; ROBSON MD, 1986, AM J NEPHROL, V6, P101, DOI 10.1159/000167063; SHUSTERMAN NH, 1989, AM J KIDNEY DIS, V14, P81, DOI 10.1016/S0272-6386(89)80181-7; SMOLLICH BP, 1991, NEPHROL DIAL TRANSPL, V6, P83; TOBIN BM, 1970, BRIT MED J, V3, P226, DOI 10.1136/bmj.3.5716.226-b; UMAN SJ, 1977, AM J MED, V62, P667, DOI 10.1016/0002-9343(77)90868-3; VONALBERTINI B, 1991, AM J NEPHROL, V11, P169, DOI 10.1159/000168298; WAGNILD JP, 1977, AM J MED, V62, P672, DOI 10.1016/0002-9343(77)90869-5; 1981, AM NATIONAL STANDARD; 1986, MMWR, V35, P417	23	53	57	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1993	119	11					1072	1078		10.7326/0003-4819-119-11-199312010-00003	http://dx.doi.org/10.7326/0003-4819-119-11-199312010-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ335	8239225				2022-12-28	WOS:A1993MJ33500003
J	KESSLER, DA; MERKATZ, RB; SCHAPIRO, R				KESSLER, DA; MERKATZ, RB; SCHAPIRO, R			A CALL FOR HIGHER STANDARDS FOR BREAST IMPLANTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											KESSLER, DA (corresponding author), US FDA,OFF COMMISS,HF-1,ROCKVILLE,MD 20857, USA.							BRIDGES AJ, 1993, ANN INTERN MED, V118, P929, DOI 10.7326/0003-4819-118-12-199306150-00003; KESSLER DA, 1992, NEW ENGL J MED, V326, P1713, DOI 10.1056/NEJM199206183262525; MERKATZ RB, 1993, J WOMENS HEALTH, V2, P105; NAIM JO, 1993, IMMUNOL INVEST, V2, P151; TEUBER SS, 1993, J AUTOIMMUN, V6, P367, DOI 10.1006/jaut.1993.1031; 1993, JAMA-J AM MED ASSOC, V270, P2602	6	34	35	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1993	270	21					2607	2608		10.1001/jama.270.21.2607	http://dx.doi.org/10.1001/jama.270.21.2607			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ266	8230647				2022-12-28	WOS:A1993MJ26600030
J	PELHAM, HRB; MUNRO, S				PELHAM, HRB; MUNRO, S			SORTING OF MEMBRANE-PROTEINS IN THE SECRETORY PATHWAY	CELL			English	Review							TRANSPORT				PELHAM, HRB (corresponding author), MRC,MRC,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.			Munro, Sean/0000-0001-6160-5773				BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MATTER K, 1993, CELL, V75, P1053; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NILSSON T, 1993, J CELL BIOL, V120, P3; NILSSON T, 1993, IN PRESS EMBO J; NOTHWEHR SF, 1993, J CELL BIOL, V121, P1197, DOI 10.1083/jcb.121.6.1197; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; VAZ WLC, 1993, CURR OPIN STRUC BIOL, V3, P482, DOI 10.1016/0959-440X(93)90071-R; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185	19	164	164	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					603	605		10.1016/0092-8674(93)90479-A	http://dx.doi.org/10.1016/0092-8674(93)90479-A			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242736	Green Published, Bronze			2022-12-28	WOS:A1993MH74900004
J	MCKUSICK, VA				MCKUSICK, VA			MEDICAL GENETICS - A 40-YEAR PERSPECTIVE ON THE EVOLUTION OF A MEDICAL SPECIALTY FROM A BASIC SCIENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN GENOME; CLINICAL MEDICINE; MORBID ANATOMY				MCKUSICK, VA (corresponding author), JOHNS HOPKINS UNIV HOSP, CTR MED GENET, BALTIMORE, MD 21205 USA.							ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; Burnet F., 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; DONAHUE RP, 1968, P NATL ACAD SCI USA, V61, P949, DOI 10.1073/pnas.61.3.949; GIANNELLI F, 1993, NUCLEIC ACIDS RES, V21, P3075, DOI 10.1093/nar/21.13.3075; Gorlin RJ, 1990, PLAST RECONSTR SURG; HALDANE JBS, 1948, PROC R SOC SER B-BIO, V135, P147, DOI 10.1098/rspb.1948.0002; HOBBS HH, 1992, MOL GENET, V1, P445; Jones KL, 1988, SMITHS RECOGNIZABLE; MACKAY IR, 1963, AUTOIMMUNE DISEASES; MCCURDY PR, 1971, NEW ENGL J MED, V285, P218, DOI 10.1056/NEJM197107222850409; McKusick V.A., 1992, MENDELIAN INHERITANC; MCKUSICK VA, 1975, AM J HUM GENET, V27, P261; MCKUSICK VA, 1989, JAMA-J AM MED ASSOC, V261, P3155, DOI 10.1001/jama.261.21.3155; MCKUSICK VA, 1992, AM J HUM GENET, V50, P663; MCKUSICK VA, 1989, NEW ENGL J MED, V320, P910, DOI 10.1056/NEJM198904063201406; MCKUSICK VA, 1969, PERSPECT BIOL MED, V12, P298; MCKUSICK VA, 1993, J MED GENET, V30, P1, DOI 10.1136/jmg.30.1.1; MCKUSICK VA, 1985, J MED GENET, V22, P431, DOI 10.1136/jmg.22.6.431; MCKUSICK VA, 1987, MEDICINE, V66, P1; MCKUSICK VA, 1988, MEDICINE, V67, P1; MCKUSICK VA, 1991, FASEB J, V5, P12, DOI 10.1096/fasebj.5.1.1991580; MCKUSICK VA, 1987, MEDICINE, V66, P237, DOI 10.1097/00005792-198707000-00001; MCKUSICK VA, 1986, MEDICINE, V65, P1; MCKUSICK VA, 1970, CONGENITAL MALFORMAT, V3, P407; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NOWEOLL PC, 1907, SCIENCE, V132, P149; SCHROTT HG, 1973, CLIN GENET, V4, P38; SCHROTT HG, 1975, NEUROLOGY, V25, P789, DOI 10.1212/WNL.25.8.789; SEEGMILLER JE, 1967, SCIENCE, V155, P1682, DOI 10.1126/science.155.3770.1682; SOLOMON E, 1979, LANCET, V1, P923; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WAIKAN Y, 1978, P NATL ACAD SCI USA, V75, P5631, DOI 10.1073/pnas.75.11.5631; Weatherall David J., 1991, NEW GENETICS CLIN PR	34	20	23	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1993	270	19					2351	2356		10.1001/jama.270.19.2351	http://dx.doi.org/10.1001/jama.270.19.2351			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF993	8230599				2022-12-28	WOS:A1993MF99300031
J	FAUCI, AS				FAUCI, AS			MULTIFACTORIAL NATURE OF HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE - IMPLICATIONS FOR THERAPY	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; BONE-MARROW TRANSPLANTATION; B-CELL ACTIVATION; IMMUNE-DEFICIENCY SYNDROME; GROWTH-FACTOR-BETA; FOLLICULAR DENDRITIC CELLS; INTERLEUKIN-1 RECEPTOR ANTAGONIST; PLASMODIUM-FALCIPARUM MALARIA; AIDS-RELATED LYMPHADENOPATHY; FACTOR-ALPHA PRODUCTION	The immunopathogenic mechanisms underlying human immunodeficiency virus (HIV) disease are extremely complex; the disease process is multifactorial with multiple overlapping phases. Viral burden is substantial and viral replication occurs throughout the entire course of HIV infection. Inappropriate immune activation and elevated secretion of certain cytokines compound the pathogenic process. Profound immunosuppression ultimately occurs together with a disruption of the microenvironment of the immune system, which is probably unable to regenerate spontaneously. Thus, therapeutic strategies in HIV disease must not be unidimensional, but rather must be linked to the complex pathogenic components of the disease and must address where feasible each of the recognized pathogenic processes for the possibility of therapeutic intervention.			FAUCI, AS (corresponding author), NIAID, IMMUNOREGULAT LAB, BETHESDA, MD 20892 USA.							ABBAS AK, 1991, CELLULAR MOL IMMUNOL, P3; ABOULAFIA DM, 1991, AIDS, V5, P344; ADERKA D, 1991, CANCER RES, V51, P5602; AGOSTI J, UNPUB; ALDROVANDI GM, 1993, NATURE, V363, P732, DOI 10.1038/363732a0; ALLEN JB, 1990, J CLIN INVEST, V85, P192, DOI 10.1172/JCI114412; AMADORI A, 1989, J IMMUNOL, V143, P2146; AMADORI A, 1990, IMMUNOL TODAY, V11, P374, DOI 10.1016/0167-5699(90)90144-X; AMADORI A, 1992, J IMMUNOL, V148, P2709; AMEISEN JC, 1992, IMMUNOL TODAY, V13, P388, DOI 10.1016/0167-5699(92)90086-M; AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; ANDRIEU JM, 1988, CLIN IMMUNOL IMMUNOP, V47, P181, DOI 10.1016/0090-1229(88)90071-2; ANTONEN J, 1986, CLIN EXP IMMUNOL, V65, P489; AREND WP, 1991, J CLIN INVEST, V88, P1445, DOI 10.1172/JCI115453; ARMSTRONG JA, 1985, IMMUNOL TODAY, V6, P121, DOI 10.1016/0167-5699(85)90076-3; ARMSTRONG JA, 1991, ACCESSORY CELLS IN HIV AND OTHER RETROVIRAL INFECTIONS, P69; ARMSTRONG JA, 1984, LANCET, V2, P370; ASCHER MS, 1990, J ACQ IMMUN DEF SYND, V3, P177; ASCHER MS, 1988, CLIN EXP IMMUNOL, V73, P165; BAGASRA O, 1992, NEW ENGL J MED, V326, P1385, DOI 10.1056/NEJM199205213262103; BAGNARELLI P, 1992, J VIROL, V66, P7328, DOI 10.1128/JVI.66.12.7328-7335.1992; BALKWILL FR, 1989, IMMUNOL TODAY, V10, P299, DOI 10.1016/0167-5699(89)90085-6; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BARNES PF, 1990, J IMMUNOL, V145, P149; BARONI CD, 1988, AM J PATHOL, V133, P498; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BENSON EM, 1993, J ACQ IMMUN DEF SYND, V6, pS61; BERTAGNOLLI MM, 1992, J IMMUNOL, V149, P3778; BERTINI R, 1993, EUR CYTOKINE NETW, V4, P39; BEUTLER B, 1987, NEW ENGL J MED, V316, P379; BIANCO JA, 1991, BLOOD, V78, P1205; BIBERFELD P, 1988, AM J PATHOL, V2, P299; BISSET LR, 1993, AIDS RES HUM RETROV, V9, P241, DOI 10.1089/aid.1993.9.241; BONYHADI ML, 1993, NATURE, V363, P728, DOI 10.1038/363728a0; BOUE F, 1992, J IMMUNOL, V148, P3761; BOWDEN RA, 1989, ANN INTERN MED, V111, P973; BUSCHLE M, 1993, J EXP MED, V177, P213, DOI 10.1084/jem.177.1.213; CARNEY WP, 1983, J IMMUNOL, V130, P390; CERAMI A, 1988, IMMUNOL TODAY, V9, P28, DOI 10.1016/0167-5699(88)91353-9; CERAMI A, 1992, CLIN IMMUNOL IMMUNOP, V62, pS3, DOI 10.1016/0090-1229(92)90035-M; CHEHIMI J, 1992, J EXP MED, V175, P789, DOI 10.1084/jem.175.3.789; CIMA MA, 1993, 5TH INT WORLD C INFL; CLARK AG, 1993, J ACQ IMMUN DEF SYND, V167, P519; CLARK SJ, 1993, P NATL ACAD SCI USA, V90, P6405; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CREEMERS PC, 1986, IMMUNOLOGY, V59, P627; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DALGLEISH AG, 1992, LANCET, V339, P824, DOI 10.1016/0140-6736(92)90277-A; DANNER SA, 1986, ARCH INTERN MED, V146, P1133, DOI 10.1001/archinte.146.6.1133; DEFRANCO AL, 1991, NATURE, V352, P754, DOI 10.1038/352754a0; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; DEZUBE BJ, 1993, J ACQ IMMUN DEF SYND, V6, P787; DEZUBE BJ, 1990, LANCET, V335, P662, DOI 10.1016/0140-6736(90)90450-J; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; DWYER JM, 1987, ARCH INTERN MED, V147, P513, DOI 10.1001/archinte.147.3.513; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; EPSTEIN LG, 1993, ANN NEUROL, V33, P429, DOI 10.1002/ana.410330502; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FAHEY JL, 1992, CLIN EXP IMMUNOL, V88, P1; FAUCI AS, 1987, ANN INTERN MED, V106, P421, DOI 10.7326/0003-4819-106-3-421; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FAUCI AS, 1989, TXB RHEUMATOLOGY, P862; FAZELY F, 1991, BLOOD, V77, P1653; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; FOX CH, 1989, J INFECT DIS, V159, P467, DOI 10.1093/infdis/159.3.467; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; FOXWELL B M J, 1990, Cardiology Clinics, V8, P107; FUCHS D, 1990, CLIN EXP IMMUNOL, V80, P44, DOI 10.1111/j.1365-2249.1990.tb06439.x; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GATELY MK, 1991, J IMMUNOL, V147, P874; GAZZINELLI RT, 1993, P NATL ACAD SCI USA, V90, P6115, DOI 10.1073/pnas.90.13.6115; GELEZIUNAS R, 1992, AIDS, V6, P1411, DOI 10.1097/00002030-199212000-00001; GENDELMAN HE, 1990, J IMMUNOL, V145, P2669; GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428; GIORGI JV, 1987, J IMMUNOL, V138, P3725; GIRI N, 1992, J PAEDIATR CHILD H, V28, P331, DOI 10.1111/j.1440-1754.1992.tb02681.x; GOROCHOV G, 1992, 8TH INT C AIDS AMST; Gougeon M L, 1993, Semin Immunol, V5, P187, DOI 10.1006/smim.1993.1022; GOUGEON ML, 1993, AIDS RES HUM RETROV, V9, P287, DOI 10.1089/aid.1993.9.287; GOUGEON ML, 1991, CR ACAD SCI III-VIE, V312, P529; GOUGEON ML, 1993, AIDS RES HUM RETROV, V9, P553, DOI 10.1089/aid.1993.9.553; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404; GRODY WW, 1985, AM J CLIN PATHOL, V84, P85, DOI 10.1093/ajcp/84.1.85; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HADDEN JW, 1993, IMMUNOL TODAY, V14, P275, DOI 10.1016/0167-5699(93)90045-M; HARSHORN KL, 1987, AIDS RES HUM RETROV, V3, P125; HAYNES BF, 1991, HARRISONS PRINCIPLES, P76; HERBERMAN RB, 1992, SEMIN HEMATOL, V29, P35; HERSH EM, 1985, CANCER RES, V45, P406; HERSH EM, 1991, INT J IMMUNOPHARMACO, V13, P9, DOI 10.1016/0192-0561(91)90119-R; Higuchi Shigenori, 1993, Acta Paediatrica Japonica, V35, P39; HIRSCH MS, 1993, NEW ENGL J MED, V328, P1686, DOI 10.1056/NEJM199306103282307; HO DD, 1985, LANCET, V1, P602; HO M, 1993, BLOOD, V81, P2093; HODARA VL, 1993, AIDS, V7, P633, DOI 10.1097/00002030-199305000-00004; HOLLER E, 1990, BLOOD, V75, P1011; HONG R, 1986, CLIN IMMUNOL IMMUNOP, V40, P136, DOI 10.1016/0090-1229(86)90077-2; HOWARD OMZ, 1993, P NATL ACAD SCI USA, V90, P2335, DOI 10.1073/pnas.90.6.2335; IMBERTI L, 1991, SCIENCE, V254, P860, DOI 10.1126/science.1948066; JANEWAY C, 1991, NATURE, V349, P459, DOI 10.1038/349459a0; JENKINSON EJ, 1989, EUR J IMMUNOL, V19, P2175, DOI 10.1002/eji.1830191132; JOSKE FA, 1958, MED J AUSTRALIA, V45, P859; KAGNOFF MF, 1981, GASTROINTESTINAL DIS, P114; KAPASI ZF, 1993, J IMMUNOL, V150, P2648; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; KARPAS A, 1992, P NATL ACAD SCI USA, V89, P8351, DOI 10.1073/pnas.89.17.8351; KATZ DH, 1993, AIDS RES HUM RETROV, V9, P489, DOI 10.1089/aid.1993.9.489; KATZ IR, 1986, CLIN IMMUNOL IMMUNOP, V39, P359, DOI 10.1016/0090-1229(86)90164-9; KAZAZI F, 1992, J GEN VIROL, V73, P941, DOI 10.1099/0022-1317-73-4-941; KERN P, 1989, AM J MED, V87, P139, DOI 10.1016/S0002-9343(89)80688-6; Kincade P W, 1990, Adv Cancer Res, V54, P235, DOI 10.1016/S0065-230X(08)60813-1; KLATZMANN D, 1986, CR HEBD ACAD SCI, V9, P343; Kovacs J.J., UNPUB; KOYANAGI Y, 1988, SCIENCE, V241, P1673, DOI 10.1126/science.3047875; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; LANE HC, 1984, J BIOL RESP MODIF, V3, P512; LANE HC, 1989, AIDS, V3, pS181, DOI 10.1097/00002030-198901001-00026; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LANE HC, 1990, ANN INTERN MED, V113, P512, DOI 10.7326/0003-4819-113-7-512; LANE HC, 1985, ANN INTERN MED, V103, P714, DOI 10.7326/0003-4819-103-5-714; LANG JM, 1988, IMMUNOL LETT, V19, P99, DOI 10.1016/0165-2478(88)90126-5; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LAZDINS JK, 1991, J IMMUNOL, V147, P1201; LESSLAUER W, 1991, EUR J IMMUNOL, V21, P2883, DOI 10.1002/eji.1830211134; LEVINE AM, 1993, 9TH INT C AIDS BERL; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; LINKERISRAELI M, 1988, CLIN EXP IMMUNOL, V73, P236; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; LUM LG, 1987, BLOOD, V69, P369; MAKONKAWKEYOON S, 1993, P NATL ACAD SCI USA, V90, P5974, DOI 10.1073/pnas.90.13.5974; MALORNI W, 1993, FEBS LETT, V327, P75, DOI 10.1016/0014-5793(93)81043-Y; MANGAN DF, 1991, J IMMUNOL, V147, P3408; MARTINEZMAZA O, 1987, J IMMUNOL, V138, P3720; MATHISEN GE, 1990, ARCH DERMATOL, V126, P833, DOI 10.1001/archderm.126.6.833; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MIEDEMA F, 1988, J CLIN INVEST, V82, P1908, DOI 10.1172/JCI113809; MILLER JFA, 1964, ANN NY ACAD SCI, V120, P205, DOI 10.1111/j.1749-6632.1964.tb34718.x; MILLER JFA, 1967, PHYSIOL REV, V47, P437, DOI 10.1152/physrev.1967.47.3.437; MITSUYASU RT, 1991, REV INFECT DIS, V13, P979; MOHLER KM, 1993, J IMMUNOL, V151, P1548; MONTANER LJ, 1993, J EXP MED, V178, P743, DOI 10.1084/jem.178.2.743; MULLER JG, 1993, AM J PATHOL, V143, P699; NAMIKAWA R, 1988, SCIENCE, V242, P1684, DOI 10.1126/science.3201256; NEUHAUS T J, 1986, Pediatric Pathology, V5, P251; NIETO MA, 1989, J IMMUNOL, V143, P4166; NIETO MA, 1990, J IMMUNOL, V145, P1364; NOVAK RM, 1990, AIDS RES HUM RETROV, V6, P973, DOI 10.1089/aid.1990.6.973; OLIFF A, 1988, CELL, V54, P141, DOI 10.1016/0092-8674(88)90543-0; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PACIUCCI PA, 1984, AIDS RES, V1, P149; PAHWA S, 1985, P NATL ACAD SCI USA, V82, P8198, DOI 10.1073/pnas.82.23.8198; PANTALEO G, 1990, P NATL ACAD SCI USA, V87, P4818, DOI 10.1073/pnas.87.12.4818; PANTALEO G, 1990, J IMMUNOL, V144, P1696; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PATTERSON BK, 1993, SCIENCE, V260, P976, DOI 10.1126/science.8493534; PAUL WE, 1989, CELL, V57, P521, DOI 10.1016/0092-8674(89)90121-9; PERUSSIA B, 1992, J IMMUNOL, V149, P3495; PETERSEN J, 1989, J PEDIATR-US, V115, P944, DOI 10.1016/S0022-3476(89)80747-4; PETERSON PK, 1991, J IMMUNOL, V146, P81; PHAIR J, 1986, ARCH INTERN MED, V146, P1074, DOI 10.1001/archinte.146.6.1074; PHILLIPS A, 1989, CAN MED ASSOC J, V140, P1456; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PISA P, 1990, J INFECT DIS, V161, P988, DOI 10.1093/infdis/161.5.988; PITTS FN, 1987, CLIN IMMUNOL IMMUNOP, V43, P277, DOI 10.1016/0090-1229(87)90136-X; PITZALIS C, 1987, J RHEUMATOL, V14, P662; POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151; Poli G, 1993, Semin Immunol, V5, P165, DOI 10.1006/smim.1993.1020; POLI G, 1992, AIDS RES HUM RETROV, V8, P191, DOI 10.1089/aid.1992.8.191; POLI G, 1989, SCIENCE, V244, P575, DOI 10.1126/science.2470148; POLI G, 1992, P NATL ACAD SCI USA, V89, P2689, DOI 10.1073/pnas.89.7.2689; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; POLI G, 1991, J EXP MED, V173, P589, DOI 10.1084/jem.173.3.589; POLI G, IN PRESS P NATL ACAD; POSNETT DN, 1993, AIDS, V7, P625, DOI 10.1097/00002030-199305000-00003; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; RACZ P, 1993, LAB INVEST, V68, pA106; RAMILO O, 1993, J IMMUNOL, V150, P5202; REDFIELD RR, 1991, NEW ENGL J MED, V324, P1677, DOI 10.1056/NEJM199106133242401; RIDDELL SR, 1992, HUM GENE THER, V3, P319, DOI 10.1089/hum.1992.3.3-319; RIECKMANN P, 1991, J IMMUNOL, V147, P2922; RIECKMANN P, 1991, J EXP MED, V173, P1, DOI 10.1084/jem.173.1.1; ROCHA B, 1992, IMMUNOL TODAY, V13, P449, DOI 10.1016/0167-5699(92)90074-H; ROSENBERG ZF, 1989, ADV IMMUNOL, V47, P377, DOI 10.1016/S0065-2776(08)60665-3; ROSENBERG ZF, 1989, AIDS RES HUM RETROV, V5, P1, DOI 10.1089/aid.1989.5.1; ROSENBERG ZF, IN PRESS FUNDAMENTAL; ROSSOL S, 1989, J INFECT DIS, V159, P815, DOI 10.1093/infdis/159.5.815; SAMPAIO EP, 1992, J EXP MED, V175, P1729, DOI 10.1084/jem.175.6.1729; SAMPAIO EP, 1991, J EXP MED, V173, P699, DOI 10.1084/jem.173.3.699; SCHUITEMAKER H, 1992, J CLIN INVEST, V89, P1154, DOI 10.1172/JCI115697; SCHUURMAN HJ, 1989, AM J PATHOL, V134, P1329; SCHWARTZ DH, 1991, J ACQ IMMUN DEF SYND, V4, P11; SCHWARZ A, 1993, TRANSPLANTATION, V55, P95, DOI 10.1097/00007890-199301000-00019; SCOTT P, 1993, SCIENCE, V260, P496, DOI 10.1126/science.8097337; SEEMAYER TA, 1984, HUM PATHOL, V15, P469, DOI 10.1016/S0046-8177(84)80082-9; SHAFFER N, 1991, J INFECT DIS, V163, P96, DOI 10.1093/infdis/163.1.96; SHEPPARD HW, 1992, CLIN IMMUNOL IMMUNOP, V64, P63; SHIRAZI Y, 1992, J VIROL, V66, P1321, DOI 10.1128/JVI.66.3.1321-1328.1992; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; Soudeyns H, 1993, Semin Immunol, V5, P175, DOI 10.1006/smim.1993.1021; SPIEGEL H, 1992, AM J PATHOL, V140, P15; STANLEY SK, 1993, J EXP MED, V178, P1151, DOI 10.1084/jem.178.4.1151; STANLEY SK, 1992, J IMMUNOL, V149, P689; STRICKER RB, 1991, IMMUNOL LETT, V29, P191, DOI 10.1016/0165-2478(91)90169-B; STRICKER RB, 1993, 9TH INT AIDS C BERL; STRIETER RM, 1988, BIOCHEM BIOPH RES CO, V155, P1230, DOI 10.1016/S0006-291X(88)81271-3; STUTTE HJ, 1990, RES VIROLOGY, V141, P195, DOI 10.1016/0923-2516(90)90021-A; SUN NCJ, 1989, AM J CLIN PATHOL, V92, P589, DOI 10.1093/ajcp/92.5.589; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; TADMORI W, 1991, J VIROL, V65, P6425, DOI 10.1128/JVI.65.12.6425-6429.1991; TAUB D, 1993, ANN INTERN MED, V119, P89, DOI 10.7326/0003-4819-119-1-199307010-00016; TENNERRACZ K, 1986, AM J PATHOL, V123, P9; TENNERRACZ K, 1985, LANCET, V1, P105; TEPPLER H, 1993, J INFECT DIS, V167, P291, DOI 10.1093/infdis/167.2.291; TEPPLER H, 1993, J EXP MED, V177, P483, DOI 10.1084/jem.177.2.483; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; THOMPSON AW, 1992, ANNU REV IMMUNOL, V10, P519; THOMSON AW, 1989, IMMUNOL TODAY, V10, P6, DOI 10.1016/0167-5699(89)90057-1; TINDALL B, 1991, AIDS, V5, P1, DOI 10.1097/00002030-199101000-00001; TINDALL B, 1991, 9TH INT C AIDS BERL, P31; TOMKINSON BE, 1987, J IMMUNOL, V139, P3802; TRINCHIERI G, 1993, IMMUNOL TODAY, V14, P335, DOI 10.1016/0167-5699(93)90230-I; VANDEWIJNGAERT FP, 1984, CELL TISSUE RES, V237, P227, DOI 10.1007/BF00217140; VIA CS, 1990, IMMUNOL TODAY, V11, P250, DOI 10.1016/0167-5699(90)90099-U; WARD A, 1987, DRUGS, V34, P50, DOI 10.2165/00003495-198734010-00003; WEISSMAN D, UNPUB; WHITESIDE TL, 1993, BLOOD, V81, P2085; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Wood G S, 1990, Prog AIDS Pathol, V2, P25; YANG YL, 1993, P NATL ACAD SCI USA, V90, P6170, DOI 10.1073/pnas.90.13.6170; YARCHOAN R, 1986, J CLIN INVEST, V78, P439, DOI 10.1172/JCI112595; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZIEGLER JL, 1986, CLIN IMMUNOL IMMUNOP, V41, P305, DOI 10.1016/0090-1229(86)90001-2; ZON LI, 1987, BRIT J HAEMATOL, V66, P251, DOI 10.1111/j.1365-2141.1987.tb01307.x; ZUMLA A, 1992, CLIN INFECT DIS, V15, P313, DOI 10.1093/clinids/15.2.313; 1993, 9TH INT AIDS C BERL	250	791	822	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	1993	262	5136					1011	1018		10.1126/science.8235617	http://dx.doi.org/10.1126/science.8235617			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	8235617				2022-12-28	WOS:A1993MG18700024
J	TOVEY, SJ; BONELL, CP				TOVEY, SJ; BONELL, CP			CONDOMS - A WIDER RANGE NEEDED	BRITISH MEDICAL JOURNAL			English	Article									GUYS HOSP,CLIN AUDIT TEAM,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust	TOVEY, SJ (corresponding author), GUYS HOSP,LLOYD CLIN,DEPT GENITOURINARY MED,LONDON SE1 9RT,ENGLAND.							BS3704 BRIT STAND I; 1992, SPECIFICATIONS GUIDE	2	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1993	307	6910					987	987		10.1136/bmj.307.6910.987	http://dx.doi.org/10.1136/bmj.307.6910.987			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC441	8241912	Bronze, Green Published			2022-12-28	WOS:A1993MC44100022
J	ALOIA, JF; VASWANI, A; YEH, JK; ROSS, PL; FLASTER, E; DILMANIAN, FA				ALOIA, JF; VASWANI, A; YEH, JK; ROSS, PL; FLASTER, E; DILMANIAN, FA			CALCIUM SUPPLEMENTATION WITH AND WITHOUT HORMONE REPLACEMENT THERAPY TO PREVENT POSTMENOPAUSAL BONE LOSS	ANNALS OF INTERNAL MEDICINE			English	Article						OSTEOPOROSIS; POSTMENOPAUSAL; CALCIUM; ESTROGEN REPLACEMENT THERAPY; BONE DENSITY	CONTROLLED TRIAL; WOMEN; OSTEOPOROSIS; FRACTURES; ESTROGEN; HIP; FOREARM; SERUM; RISK	Objective: To determine whether augmentation of dietary calcium is effective in the prevention of early postmenopausal bone loss. Design: Three-arm, placebo-controlled, randomized parallel trial. The study duration was 2.9 +/- 1.1 (SD) years. Setting: General community. Participants: 118 healthy, white women 3 to 6 years after spontaneous menopause, recruited by community announcement. Interventions: Random allocation to daily intake of 1700 mg of calcium (calcium carbonate given in divided doses with meals); placebo; or conjugated equine estrogens (0.625 mg; days 1 to 25), progesterone (10 mg; days 16 to 25), and 1700 mg of elemental calcium daily. Each participant received 400 IU of vitamin D daily. Main Outcome Measures: Total body calcium measured by delayed gamma neutron activation analysis and whole-body counting; bone mineral density of the spine, femur, and radius measured by photon absorptiometry. Results: Bone mineral density declined in the placebo group for the lumbar spine (-2.1%/y; 95% CI, -3.3 to -0.9), femoral neck (-2.0%/y; CI,-2.6 to -1.2), trochanter (-1.6%/y; CI, -2.4 to -0.8), Ward triangle (-2.7%/y; CI, -3.7 to -1.7), and total body calcium (-2.0%/y; CI, -2.2 to -1.8). Rates of change were intermediate for calcium augmentation compared with placebo and estrogen-progesterone-calcium but statistically significant compared with placebo for total body calcium (-0.5%/y; CI, -0.9 to -0.1; P = 0.006) and the femoral neck (-0.8%/y; CI, -1.4 to -0.2; P = 0.03). Conclusions: Although less effective than estrogen-progesterone-calcium, calcium augmentation alone significantly retards bone loss from the femoral neck and improves calcium balance in recently postmenopausal women. Dietary calcium augmentation should be recommended as a strategic option in helping to prevent early postmenopausal bone loss.	BROOKHAVEN NATL LAB, UPTON, NY 11973 USA	United States Department of Energy (DOE); Brookhaven National Laboratory	ALOIA, JF (corresponding author), WINTHROP UNIV HOSP, DEPT MED, 259 1ST ST, MINEOLA, NY 11501 USA.		Dilmanian, Farrokh Avraham/AAD-5567-2019		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037520] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR37520-05] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBANESE AA, 1975, NEW YORK STATE J MED, V75, P326; BARRETTCONNOR E, 1989, NEW ENGL J MED, V321, P319, DOI 10.1056/NEJM198908033210510; BEHR W, 1986, CLIN CHEM, V32, P1960; COHN SH, 1986, CALCIFIED TISSUE INT, V38, P9, DOI 10.1007/BF02556588; COHN SH, 1969, PHYS MED BIOL, V14, P645, DOI 10.1088/0031-9155/14/4/006; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; DILMANIAN FA, 1990, IN VIVO BODY COMPOSI, V55, P309; ELDERS PJM, 1991, J CLIN ENDOCR METAB, V73, P533, DOI 10.1210/jcem-73-3-533; ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003-4819-106-1-40; Fiske CH, 1925, J BIOL CHEM, V66, P375; HEANEY RP, 1977, AM J CLIN NUTR, V30, P1603, DOI 10.1093/ajcn/30.10.1603; HEINEGAR.D, 1973, CLIN CHIM ACTA, V43, P305, DOI 10.1016/0009-8981(73)90466-X; HUTCHINSON TA, 1979, LANCET, V2, P705; LAPORTE RE, 1982, J CHRON DIS, V35, P787, DOI 10.1016/0021-9681(82)90090-X; LINDSAY R, 1980, LANCET, V2, P1151; MATKOVIC V, 1979, AM J CLIN NUTR, V32, P540, DOI 10.1093/ajcn/32.3.540; NILAS L, 1984, BRIT MED J, V289, P1103, DOI 10.1136/bmj.289.6452.1103; NORDIN BEC, 1988, ANN CHIR GYNAECOL FE, V77, P212; OTT SM, 1987, J BONE MINER RES, V2, P201; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; POLLEY KJ, 1987, J NUTR, V117, P1929, DOI 10.1093/jn/117.11.1929; PRINCE RL, 1991, NEW ENGL J MED, V325, P1189, DOI 10.1056/NEJM199110243251701; PROCKOP DJ, 1960, ANAL BIOCHEM, V1, P228, DOI 10.1016/0003-2697(60)90050-6; RECKER RR, 1977, ANN INTERN MED, V87, P649, DOI 10.7326/0003-4819-87-6-649; REID IR, 1993, NEW ENGL J MED, V328, P460, DOI 10.1056/NEJM199302183280702; RIGGS BL, 1987, J CLIN INVEST, V80, P979, DOI 10.1172/JCI113191; RIIS B, 1987, NEW ENGL J MED, V316, P173, DOI 10.1056/NEJM198701223160401; SNEDECOR GW, 1972, STATISTICAL METHODS, P438; SNYDER WS, 1984, ICRP PUBLICATION, V23; SOMMER A J, 1954, Am J Med Technol, V20, P244; STEVENSON JC, 1988, BRIT MED J, V297, P15, DOI 10.1136/bmj.297.6640.15; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102	32	180	187	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1994	120	2					97	103		10.7326/0003-4819-120-2-199401150-00001	http://dx.doi.org/10.7326/0003-4819-120-2-199401150-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ671	8256988				2022-12-28	WOS:A1994MQ67100001
J	MARCANTONIO, ER; GOLDMAN, L; MANGIONE, CM; LUDWIG, LE; MURACA, B; HASLAUER, CM; DONALDSON, MC; WHITTEMORE, AD; SUGARBAKER, DJ; POSS, R; HAAS, S; COOK, EF; ORAV, J; LEE, TH				MARCANTONIO, ER; GOLDMAN, L; MANGIONE, CM; LUDWIG, LE; MURACA, B; HASLAUER, CM; DONALDSON, MC; WHITTEMORE, AD; SUGARBAKER, DJ; POSS, R; HAAS, S; COOK, EF; ORAV, J; LEE, TH			A CLINICAL-PREDICTION RULE FOR DELIRIUM AFTER ELECTIVE NONCARDIAC SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ELDERLY HOSPITALIZED-PATIENTS; SURGICAL PATIENTS; ACTIVITY SCALE; RISK-FACTORS; MORBIDITY; CONFUSION	Objective.-To develop and validate a clinical prediction rule for postoperative delirium using data available to clinicians preoperatively. Design.-Prospective cohort study. Setting.-General surgery, orthopedic surgery, and gynecology services at Brigham and Women's Hospital, Boston, Mass. Patients.-Consenting patients older than 50 years admitted for major elective noncardiac surgery between November 1, 1990, and March 15, 1992 (N=1341). Measurements.-All patients underwent preoperative evaluations, including a medical history, physical examination, laboratory tests, and assessments of physical and cognitive function using the Specific Activity Scale and the Telephone Interview for Cognitive Status. Postoperative delirium was diagnosed using the Confusion Assessment Method or using data f rom the medical record and the hospital's nursing intensity index. Patients were followed up for the duration of hospitalization to determine major complication rates, length of stay, and discharge disposition. Results.-Postoperative delirium occurred in 117 (9%) of the 1341 patients studied. Independent correlates included age 70 years or older; self-reported alcohol abuse; poor cognitive status; poor functional status; markedly abnormal preoperative serum sodium, potassium or glucose level; noncardiac thoracic surgery; and aortic aneurysm surgery. Using these seven preoperative factors, a simple predictive rule was developed. In an independent population, the rule stratified patients into groups with low (2%), medium (8%, 13%), and high (50%) rates of postoperative delirium. Patients who developed delirium had higher rates of major complications, longer lengths of stay, and higher rates of discharge to long-term care or rehabilitative facilities. Conclusions.- Using data available preoperatively, clinicians can stratify patients into risk groups for the development of delirium. Since delirium is associated with a variety of adverse outcomes, patients with substantial risk for this complication could be candidates for interventions to reduce the incidence of postoperative delirium and potentially improve overall surgical outcomes.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV CLIN EPIDEMIOL,75 FRANCIS ST, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV GEN MED, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT SURG, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT ORTHOPED SURG, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT OBSTET & GYNECOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School			Marcantonio, Edward R/U-3929-2017	Marcantonio, Edward R/0000-0002-2911-4250; Haas, Susan/0000-0003-1077-9823	AHRQ HHS [1RO1-HS06573] Funding Source: Medline; BHP HRSA HHS [5T32PE110011-04] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); BHP HRSA HHS		CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; DRIPPS RD, 1961, JAMA-J AM MED ASSOC, V178, P261, DOI 10.1001/jama.1961.03040420001001; EISENDRATH SJ, 1987, AM J PSYCHIAT, V144, P1062; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; FRANCIS J, 1990, J GEN INTERN MED, V5, P65, DOI 10.1007/BF02602312; Francis Joseph, 1992, Journal of the American Geriatrics Society, V40, pSA10; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; GOLINGER RC, 1987, AM J PSYCHIAT, V144, P1218; GUSTAFSON Y, 1991, J AM GERIATR SOC, V39, P655, DOI 10.1111/j.1532-5415.1991.tb03618.x; GUSTAFSON Y, 1988, J AM GERIATR SOC, V36, P325; Hegyvary ST, 1979, USERS MANUAL RUSH ME; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; LEE TH, 1988, AM HEART J, V115, P203, DOI 10.1016/0002-8703(88)90545-5; LEVKOFF SE, 1992, ARCH INTERN MED, V152, P334, DOI 10.1001/archinte.152.2.334; LEVKOFF SE, 1988, J AM GERIATR SOC, V36, P1099, DOI 10.1111/j.1532-5415.1988.tb04396.x; LIPOWSKI ZJ, 1989, NEW ENGL J MED, V320, P578; Lopez Oscar L, 2010, Neuroepidemiology, V34, P63, DOI 10.1159/000264678; MILLAR HR, 1981, BRIT J PSYCHIAT, V138, P17, DOI 10.1192/bjp.138.1.17; MORSE RM, 1969, AM J PSYCHIAT, V126, P388, DOI 10.1176/ajp.126.3.388; ROCKWOOD K, 1989, J AM GERIATR SOC, V37, P150, DOI 10.1111/j.1532-5415.1989.tb05874.x; ROGERS MP, 1989, INT J PSYCHIAT MED, V19, P109; SCHOR JD, 1992, JAMA-J AM MED ASSOC, V267, P827, DOI 10.1001/jama.267.6.827; SEYMOUR DG, 1983, GERONTOLOGY, V29, P262, DOI 10.1159/000213125; SIER H, 1987, JAMA-J AM MED ASSOC, V257, P1776; Sox HC, 1988, MED DECISION MAKING; THOMAS RI, 1988, ARCH GEN PSYCHIAT, V45, P937; WILLIAMSRUSSO P, 1992, J AM GERIATR SOC, V40, P759, DOI 10.1111/j.1532-5415.1992.tb01846.x; 1987, DIAGNOSTIC STATISTIC	30	627	654	0	26	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	1994	271	2					134	139		10.1001/jama.271.2.134	http://dx.doi.org/10.1001/jama.271.2.134			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ083	8264068				2022-12-28	WOS:A1994MQ08300023
J	KOST, RG; HILL, EL; TIGGES, M; STRAUS, SE				KOST, RG; HILL, EL; TIGGES, M; STRAUS, SE			BRIEF REPORT - RECURRENT ACYCLOVIR-RESISTANT GENITAL HERPES IN AN IMMUNOCOMPETENT PATIENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; SIMPLEX VIRUS TYPE-2; ALTERED SUBSTRATE-SPECIFICITY; VARICELLA-ZOSTER VIRUS; THYMIDINE KINASE GENE; ORAL ACYCLOVIR; DOUBLE-BLIND; PLAQUE AUTORADIOGRAPHY; NUCLEOTIDE-SEQUENCE; THERAPY		NIAID, CLIN INVEST LAB,MED VIROL SECT,BLDG 10, ROOM 11N228, BETHESDA, MD 20892 USA; BURROUGHS WELLCOME CO, DIV VIROL, RES TRIANGLE PK, NC 27709 USA; CHIRON CORP, EMERYVILLE, CA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Burroughs Wellcome Fund; Novartis								CHATIS PA, 1989, NEW ENGL J MED, V320, P297, DOI 10.1056/NEJM198902023200507; CHENG YC, 1981, ANTIMICROB AGENTS CH, V20, P420, DOI 10.1128/AAC.20.3.420; COEN DM, 1980, P NATL ACAD SCI-BIOL, V77, P2265, DOI 10.1073/pnas.77.4.2265; COLLINS P, 1989, J GEN VIROL, V70, P375, DOI 10.1099/0022-1317-70-2-375; DARBY G, 1986, J GEN VIROL, V67, P753, DOI 10.1099/0022-1317-67-4-753; DARBY G, 1981, NATURE, V289, P81, DOI 10.1038/289081a0; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DEKKER C, 1983, J ANTIMICROB CHEMOTH, V12, P137, DOI 10.1093/jac/12.suppl_B.137; DOUGLAS JM, 1984, NEW ENGL J MED, V310, P1551, DOI 10.1056/NEJM198406143102402; ELLIS MN, 1987, ANTIMICROB AGENTS CH, V31, P1117, DOI 10.1128/AAC.31.7.1117; ENGLUND JA, 1990, ANN INTERN MED, V112, P416, DOI 10.7326/0003-4819-76-3-112-6-416; ERLICH KS, 1989, NEW ENGL J MED, V320, P293, DOI 10.1056/NEJM198902023200506; ERLICH KS, 1989, ANN INTERN MED, V110, P710, DOI 10.7326/0003-4819-110-9-710; FIELD H, 1981, J INFECT DIS, V143, P281, DOI 10.1093/infdis/143.2.281; FIELD HJ, 1982, ANTIMICROB AGENTS CH, V21, P744, DOI 10.1128/AAC.21.5.744; FIELD HJ, 1980, J GEN VIROL, V49, P115, DOI 10.1099/0022-1317-49-1-115; FURMAN PA, 1979, J VIROL, V32, P72, DOI 10.1128/JVI.32.1.72-77.1979; FYFE JA, 1983, MOL PHARMACOL, V24, P316; FYFE JA, 1978, J BIOL CHEM, V253, P8721; HALSOS AM, 1985, ACTA DERM-VENEREOL, V65, P59; HILL EL, 1991, ANTIMICROB AGENTS CH, V35, P2322, DOI 10.1128/AAC.35.11.2322; INNIS MA, 1990, PCR PROTOCOLS, P54; JAMES SP, 1991, CURRENT PROTOCOLS IM; KIT S, 1987, ANTIMICROB AGENTS CH, V31, P1483, DOI 10.1128/AAC.31.10.1483; KIT S, 1985, MICROBIOL SCI, V2, P369; KROON S, 1989, DAN MED BULL, V36, P298; LEHRMAN SN, 1986, J ANTIMICROB CHEMOTH, V18, P85, DOI 10.1093/jac/18.Supplement_B.85; LEHRMAN SN, 1986, ANN INTERN MED, V104, P786, DOI 10.7326/0003-4819-104-6-786; MARTIN JL, 1985, ANTIMICROB AGENTS CH, V28, P181, DOI 10.1128/AAC.28.2.181; MCLAREN C, 1983, J INFECT DIS, V148, P868, DOI 10.1093/infdis/148.5.868; MILLER WH, 1982, BIOCHEM PHARMACOL, V31, P3879, DOI 10.1016/0006-2952(82)90305-7; MILLER WH, 1980, J BIOL CHEM, V255, P7204; ROIZMAN B, 1982, LANCET, V1, P677; SACKS SL, 1989, ANN INTERN MED, V111, P893, DOI 10.7326/0003-4819-111-11-893; SAFRIN S, 1991, NEW ENGL J MED, V325, P551, DOI 10.1056/NEJM199108223250805; SAMBROOK J, 1989, MOL CLONING LABORATO, V2; SIBRACK CD, 1982, J INFECT DIS, V146, P673, DOI 10.1093/infdis/146.5.673; STRAUS SE, 1984, NEW ENGL J MED, V310, P1545, DOI 10.1056/NEJM198406143102401; STRAUS SE, 1981, J VIROL, V40, P516, DOI 10.1128/JVI.40.2.516-525.1981; SUMMERS WC, 1977, J VIROL, V24, P314, DOI 10.1128/JVI.24.1.314-318.1977; SWAIN MA, 1983, J VIROL, V46, P1045, DOI 10.1128/JVI.46.3.1045-1050.1983; TENSER RB, 1983, J CLIN MICROBIOL, V17, P122, DOI 10.1128/JCM.17.1.122-127.1983; WHITLEY RJ, 1992, NEW ENGL J MED, V327, P782; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266	44	133	137	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 9	1993	329	24					1777	1782		10.1056/NEJM199312093292405	http://dx.doi.org/10.1056/NEJM199312093292405			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK096	8232486	Bronze			2022-12-28	WOS:A1993MK09600005
J	HEBERLEIN, U; WOLFF, T; RUBIN, GM				HEBERLEIN, U; WOLFF, T; RUBIN, GM			THE TGF-BETA-HOMOLOG DPP AND THE SEGMENT POLARITY GENE HEDGEHOG ARE REQUIRED FOR PROPAGATION OF A MORPHOGENETIC WAVE IN THE DROSOPHILA RETINA	CELL			English	Article							SITE-SPECIFIC RECOMBINATION; DECAPENTAPLEGIC GENE; PATTERN-FORMATION; CELL-DEATH; IMAGINAL DISKS; MOLECULAR-ORGANIZATION; EGF RECEPTOR; GERM LAYERS; EYE; EXPRESSION	Development of the Drosophila retina occurs asynchronously; differentiation, its front marked by the morphogenetic furrow, progresses across the eye disc epithelium over a 2 day period. We have investigated the mechanisms by which this front advances, and our results suggest that developing retinal cells drive the progression of morphogenesis utilizing the products of the hedgehog (hh) and decapentaplegic (dpp) genes. Analysis of hh and dpp genetic mosaics indicates that the products of these genes act as diffusible signals in this process. Expression of dpp in the morphogenetic furrow is closely correlated with the progression of the furrow under a variety of conditions. We show that hh, synthesized by differentiating cells, induces the expression of dpp, which appears to be a primary mediator of furrow movement.	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley	HEBERLEIN, U (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,GALLO CTR,SAN FRANCISCO,CA 94110, USA.			Rubin, Gerald/0000-0001-8762-8703				ALPHEY L, 1992, CELL, V69, P977, DOI 10.1016/0092-8674(92)90616-K; BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; BAKER NE, 1992, DEV BIOL, V150, P381, DOI 10.1016/0012-1606(92)90250-K; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BROWN NL, 1991, DEVELOPMENT, V113, P1245; BRYANT PJ, 1988, DEV BIOL, V128, P386, DOI 10.1016/0012-1606(88)90300-4; Bryant PJ., 1978, GENET BIOL DROSOPHIL, P229; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; FRISTROM D, 1968, J CELL BIOL, V39, P488, DOI 10.1083/jcb.39.2.488; GELBART WM, 1989, DEVELOPMENT, V107, P65; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; HEBERLEIN U, 1991, DEV BIOL, V144, P353, DOI 10.1016/0012-1606(91)90427-5; HEBERLEIN U, 1993, IN PRESS DEV BIOL; HOFFMANN FM, 1992, MOL REPROD DEV, V32, P173, DOI 10.1002/mrd.1080320214; HORTSCH M, 1990, NEURON, V4, P697, DOI 10.1016/0896-6273(90)90196-M; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; LEBOVITZ RM, 1986, DEV BIOL, V117, P663, DOI 10.1016/0012-1606(86)90335-0; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; Poulson D. F., 1950, BIOL DROSOPHILA, P168; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; RENFRANZ PJ, 1989, DEV BIOL, V136, P411, DOI 10.1016/0012-1606(89)90267-4; REUTER R, 1990, DEVELOPMENT, V110, P1031; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TASHIRO S, 1993, GENE, V124, P183; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; Whittle J R, 1990, Semin Cell Biol, V1, P241; WILKINS AS, 1991, DEV BIOL, V145, P1, DOI 10.1016/0012-1606(91)90208-K; WOLFF T, 1991, DEVELOPMENT, V113, P841; WOLFF T, 1991, DEVELOPMENT, V113, P825; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XU T, 1993, DEVELOPMENT, V117, P1223	55	361	375	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 3	1993	75	5					913	926		10.1016/0092-8674(93)90535-X	http://dx.doi.org/10.1016/0092-8674(93)90535-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252627				2022-12-28	WOS:A1993MK96600011
J	OSTERMANN, J; ORCI, L; TANI, K; AMHERDT, M; RAVAZZOLA, M; ELAZAR, Z; ROTHMAN, JE				OSTERMANN, J; ORCI, L; TANI, K; AMHERDT, M; RAVAZZOLA, M; ELAZAR, Z; ROTHMAN, JE			STEPWISE ASSEMBLY OF FUNCTIONALLY ACTIVE-TRANSPORT VESICLES	CELL			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING-PROTEIN; CLATHRIN-COATED VESICLES; CELL-FREE SYSTEM; GOLGI STACK; BREFELDIN-A; VESICULAR TRANSPORT; BETA-COP; INTERCOMPARTMENTAL TRANSPORT; SUCCESSIVE COMPARTMENTS	Budding of COP-coated vesicles (the likely carriers of newly synthesized proteins from the endoplasmic reticulum through the Golgi stack) from Golgi cisternae requires ADP-ribosylation factor (ARF), coatomer proteins from the cytosol, GTP, and fatty acyl-coenzyme A (CoA). The assembly of coated buds on the membranes requires coatomer, ARF, and GTP. When palmitoyl-CoA is added, membrane fission occurs at the coated bud, releasing coated vesicles. We show that COP-coated vesicles can be generated stepwise in vitro and isolated in a functionally active form, demonstrating that the minimal set of cytosolic components required for their formation as well as principal steps in their assembly have been identified.	UNIV GENEVA, SCH MED, INST HISTOL & EMBRYOL, DEPT MORPHOL, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva	OSTERMANN, J (corresponding author), MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, 1275 YORK AVE, NEW YORK, NY 10021 USA.							BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; BARLOWE C, 1993, J BIOL CHEM, V268, P873; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BRAELL WA, 1984, CELL, V39, P511, DOI 10.1016/0092-8674(84)90458-6; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DENFERT C, 1991, J CELL BIOL, V114, P663, DOI 10.1083/jcb.114.4.663; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P7344, DOI 10.1073/pnas.87.18.7344; FRIES E, 1980, P NATL ACAD SCI-BIOL, V77, P3870, DOI 10.1073/pnas.77.7.3870; FRIES E, 1981, J CELL BIOL, V90, P697, DOI 10.1083/jcb.90.3.697; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; HEUSER J, 1980, J CELL BIOL, V84, P560, DOI 10.1083/jcb.84.3.560; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KUGE O, 1993, IN PRESS J CELL BIOL; LIN HC, 1991, J CELL BIOL, V114, P881, DOI 10.1083/jcb.114.5.881; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1991, CELL, V64, P1183; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PEARSE BMF, 1981, ANNU REV BIOCHEM, V50, P85, DOI 10.1146/annurev.bi.50.070181.000505; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PFANNER N, 1990, J CELL BIOL, V110, P955, DOI 10.1083/jcb.110.4.955; POLOKOFF MA, 1978, J BIOL CHEM, V253, P7173; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHMAN JE, 1984, J CELL BIOL, V99, P260, DOI 10.1083/jcb.99.1.260; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SMYTHE E, 1989, J CELL BIOL, V108, P843, DOI 10.1083/jcb.108.3.843; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; TANIGAWA G, 1993, IN PRESS J CELL BIOL; TSAI SC, 1993, J BIOL CHEM, V268, P10820; WALKER MW, 1992, J BIOL CHEM, V267, P3230; WATERS MG, 1992, METHOD ENZYMOL, V219, P331; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WATTENBERG BW, 1992, J CELL BIOL, V118, P1321, DOI 10.1083/jcb.118.6.1321; WEISS O, 1989, J BIOL CHEM, V264, P21066; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	66	261	266	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 3	1993	75	5					1015	1025		10.1016/0092-8674(93)90545-2	http://dx.doi.org/10.1016/0092-8674(93)90545-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252615				2022-12-28	WOS:A1993MK96600021
J	GRAETZ, MJ; MASHAW, JL				GRAETZ, MJ; MASHAW, JL			PRAISE REFORM AND START THE LITIGATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											GRAETZ, MJ (corresponding author), YALE UNIV,SCH MED,NEW HAVEN,CT 06510, USA.								0	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 2	1993	329	23					1735	1736		10.1056/NEJM199312023292313	http://dx.doi.org/10.1056/NEJM199312023292313			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ707	8232466				2022-12-28	WOS:A1993MJ70700013
J	SILVER, RT				SILVER, RT			INTERFERON-ALPHA-2B - A NEW TREATMENT FOR POLYCYTHEMIA-VERA	ANNALS OF INTERNAL MEDICINE			English	Note							ALPHA				SILVER, RT (corresponding author), CORNELL UNIV, MED CTR,NEW YORK HOSP, CLIN ONCOL CHEMOTHERAPY RES SECT,525 E 68 ST, BOX 581, NEW YORK, NY 10021 USA.		Silver MD, Richard T/GRE-5925-2022					ARIAD S, 1991, BLOOD, V77, P670; BERK PD, 1986, SEMIN HEMATOL, V23, P132; DONOVAN PB, 1984, AM J HEMATOL, V17, P329, DOI 10.1002/ajh.2830170402; KEUTZER JC, 1991, BLOOD S, V78, P1204; LIN SL, 1986, SCIENCE, V233, P356, DOI 10.1126/science.3726533; MEANS RT, 1991, BLOOD, V78, P2564; NAND S, 1990, AM J HEMATOL, V34, P32, DOI 10.1002/ajh.2830340108; SACCHI S, 1991, ANN HEMATOL, V63, P206, DOI 10.1007/BF01703444; SILVER RT, 1990, BLOOD, V76, P664; TALPAZ M, 1983, ANN INTERN MED, V99, P789, DOI 10.7326/0003-4819-99-6-789	10	57	61	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1993	119	11					1091	1092		10.7326/0003-4819-119-11-199312010-00006	http://dx.doi.org/10.7326/0003-4819-119-11-199312010-00006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ335	8239228				2022-12-28	WOS:A1993MJ33500006
J	KABACK, M; LIMSTEELE, J; DABHOLKAR, D; BROWN, D; LEVY, N; ZEIGER, K				KABACK, M; LIMSTEELE, J; DABHOLKAR, D; BROWN, D; LEVY, N; ZEIGER, K			TAY-SACHS-DISEASE - CARRIER SCREENING, PRENATAL-DIAGNOSIS, AND THE MOLECULAR ERA - AN INTERNATIONAL PERSPECTIVE, 1970 TO 1993	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEXOSAMINIDASE-A DEFICIENCY; ALPHA-CHAIN; GM2 GANGLIOSIDOSIS; HUMAN-GENETICS; BETA-CHAIN; MUTATIONS; THALASSEMIA; PSEUDODEFICIENCY; CHROMOSOME-5; POPULATIONS	Objectives.-To provide an update of the international experience with carrier screening and prenatal diagnosis for Tay-Sachs disease (TSD), to assess the impact of these efforts, and to review the recent developments in DNA technology with application to TSD carrier detection and screening. Design.-Through the International TSD Testing, Quality Control, and Data Collection Center, all testing centers in the world were surveyed annually to assess overall experience with carrier testing and prenatal diagnosis. Quality control and laboratory surveillance of testing centers were performed through an annual assessment, using samples provided by the center. Setting.-Tay-Sachs disease testing centers around the world. Participants.-Nearly 1 million young adults from both Jewish and non-Jewish populations. Intervention.-Gene product screening (enzyme testing) and DNA-based mutation analysis (in some populations). Main Outcome Measure.-Impact of screening program on disease incidence. Results.-Data from all centers in the international TSD network on experience with TSD carrier testing and prenatal diagnosis since 1974 indicated that more than 36 000 heterozygotes were identified and 1056 couples found to be at risk for TSD in their offspring. A total of 2416 pregnancies at increased risk for TSD were monitored by amniocentesis or chorionic villus sampling. A dramatic decrease in the incidence of TSD in the Jewish populations was demonstrated. With both serum and leukocyte proficiency testing, there have been only 16 instances (of 845 cumulative laboratory evaluations) of one or more errors reported by a laboratory since 1983 resulting in nonaccreditation. Conclusions.-This analysis represents a prototypic effort in coordinating adult education, carrier testing, and genetic counseling directed toward prospective prevention of a uniformly fatal childhood disease and demonstrates that such an effort can dramatically affect disease incidence.			KABACK, M (corresponding author), UNIV CALIF SAN DIEGO, CHILDRENS HOSP & HLTH CTR, DEPT PEDIAT & REPROD MED, 8110 BIRMINGHAM WAY, SAN DIEGO, CA 92123 USA.							Akerman B. R., 1992, Human Mutation, V1, P303, DOI 10.1002/humu.1380010407; AKLI S, 1991, GENOMICS, V11, P124, DOI 10.1016/0888-7543(91)90109-R; AKLI S, IN PRESS EUR J HUM G; ARONSON SM, 1964, TAY SACHS DISEASE; BACH G, 1992, GENETIC DIVERSITY JE; Becker M H, 1975, J Community Health, V1, P3, DOI 10.1007/BF01318939; BERNHEIMER H, 1968, Wiener Klinische Wochenschrift, V80, P163; BEUTLER E, 1993, AM J HUM GENET, V52, P85; BEUTLER E, 1976, BIOCHEM J, V159, P541, DOI 10.1042/bj1590541; BOEDECKER HJ, 1975, EXP CELL RES, V93, P468, DOI 10.1016/0014-4827(75)90473-5; BROIDE E, IN PRESS AM J MED GE; BURG J, 1985, ANN HUM GENET, V49, P41, DOI 10.1111/j.1469-1809.1985.tb01674.x; CAO A, 1989, CLIN GENET, V36, P277; CAO A, 1989, BRIT J HAEMATOL, V71, P309; CAO Z, IN PRESS AM J HUM GE; CASKEY CT, 1990, AM J HUM GENET, V46, P393; CHASE A, 1977, PROGR CLIN BIOL RES, V18, P107; CHASE GA, 1972, AM J HUM GENET, V24, P339; CHERN CJ, 1977, SOMAT CELL GENET, V3, P553, DOI 10.1007/BF01539065; CHILDS B, 1976, AM J HUM GENET, V28, P550; CLOW CL, 1977, PEDIATRICS, V59, P86; CONZELMANN E, 1978, P NATL ACAD SCI USA, V75, P3979, DOI 10.1073/pnas.75.8.3979; FIGUEROA ML, 1992, NEW ENGL J MED, V327, P1632, DOI 10.1056/NEJM199212033272304; GEIGER B, 1976, BIOCHEMISTRY-US, V15, P3484, DOI 10.1021/bi00661a014; Kaback M., 1972, SPHINGOLIPIDS SPHING, V19, P613; Kaback M M, 1977, Prog Clin Biol Res, V18, P267; KABACK MM, 1977, PROG CLIN BIOL RES, V18; KABACK MM, 1974, BIRTH DEFECTS, V10, P124; KABACK MM, IN PRESS INT J TECHN; KABACK MM, 1972, METHOD ENZYMOL, V28, P862; KABACK MM, 1981, LYSOSOMES LYSOSOMAL; Klenk E, 1939, H-S Z PHYSIOL CHEM, V262, P128, DOI 10.1515/bchm2.1939.262.3-5.128; KOLODNY EH, 1969, BIOCHEM BIOPH RES CO, V37, P526, DOI 10.1016/0006-291X(69)90947-4; KYTZIA HJ, 1983, EMBO J, V2, P1201, DOI 10.1002/j.1460-2075.1983.tb01567.x; LANDELS EC, 1993, J MED GENET, V30, P479, DOI 10.1136/jmg.30.6.479; LEINEKUGEL P, 1992, HUM GENET, V88, P513, DOI 10.1007/BF00219337; LOUKOPOULOS D, 1991, AM J HUM GENET, V49, P79; MCDOWELL GA, 1992, AM J HUM GENET, V51, P1071; MERZ B, 1987, JAMA-J AM MED ASSOC, V258, P2636, DOI 10.1001/jama.1987.03400190018005; MODELL B, 1980, BMJ-BRIT MED J, V280, P1347, DOI 10.1136/bmj.280.6228.1347; MOTULSKY AG, 1971, BIRTH DEFECTS, V5, P22; Mules Emilie H., 1992, Human Mutation, V1, P298, DOI 10.1002/humu.1380010406; MYEROWITZ R, 1985, P NATL ACAD SCI USA, V82, P7830, DOI 10.1073/pnas.82.23.7830; MYRIANTHOPOULOS N, 1967, TAY SACHS DISEASE IN; Myrianthopoulos N C, 1977, Prog Clin Biol Res, V18, P95; MYRIANTHOPOULOS NC, 1966, AM J HUM GENET, V18, P313; MYRIANTHOPOULOS NC, 1962, CEREBRAL SPHINGOLIPI; NAVON R, 1986, AM J MED GENET, V24, P179, DOI 10.1002/ajmg.1320240123; NAVON R, 1971, BRIT MED J, V4, P17, DOI 10.1136/bmj.4.5778.17; OBRIEN JS, 1970, NEW ENGL J MED, V283, P15, DOI 10.1056/NEJM197007022830104; OBRIEN JS, 1971, SCIENCE, V172, P61, DOI 10.1126/science.172.3978.61; OBRIEN JS, 1978, AM J HUM GENET, V30, P602; OBRIEN JS, 1973, FED PROC, V32, P191; OKADA S, 1969, SCIENCE, V165, P698, DOI 10.1126/science.165.3894.698; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PAW BH, 1990, AM J HUM GENET, V47, P698; PETERSEN GM, 1983, AM J HUM GENET, V35, P1258; PROIA RL, 1988, P NATL ACAD SCI USA, V85, P1883, DOI 10.1073/pnas.85.6.1883; PROIA RL, 1987, J BIOL CHEM, V262, P5677; RAPIN I, 1976, ARCH NEUROL-CHICAGO, V33, P120, DOI 10.1001/archneur.1976.00500020048008; ROBINSON D, 1968, BIOCHEM J, V107, P321, DOI 10.1042/bj1070321; ROTTER JI, 1987, NATURE, V329, P289, DOI 10.1038/329289a0; Sachs B, 1887, J NERV MENT DIS, V14, P541, DOI [10.1097/00005053-188714090-00001, DOI 10.1097/00005053-188709000-00001]; SAIFER A, 1973, CLIN CHIM ACTA, V43, P417, DOI 10.1016/0009-8981(73)90481-6; SANDHOFF K, 1969, FEBS LETT, V4, P351, DOI 10.1016/0014-5793(69)80274-7; Sandhoff K., 1989, METABOLIC BASIS INHE; SCHNECK L, 1970, LANCET, V1, P582; SLOME D, 1933, GENET, V27, P363; SVENNERHOLM L, 1962, BIOCHEM BIOPH RES CO, V9, P436, DOI 10.1016/0006-291X(62)90030-X; Tatar S E, 1977, Prog Clin Biol Res, V18, P367; TERRY RD, 1960, NATURE, V188, P1000, DOI 10.1038/1881000a0; TRIGGSRAINE BL, 1991, AM J HUM GENET, V49, P1041; TRIGGSRAINE BL, 1992, AM J HUM GENET, V51, P793; TRIGGSRAINE BL, 1990, NEW ENGL J MED, V323, P6, DOI 10.1056/NEJM199007053230102; 1990, NEW ENGL J MED, V323, P70; 1991, SCREENING TAY SACHS; 1992, CYSTIC FIBROSIS DNA; 1983, SCREENING COUNSELING	78	193	196	2	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1993	270	19					2307	2315		10.1001/jama.270.19.2307	http://dx.doi.org/10.1001/jama.270.19.2307			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF993	8230592				2022-12-28	WOS:A1993MF99300024
J	BRADLOW, J; COULTER, A				BRADLOW, J; COULTER, A			EFFECT OF FUNDHOLDING AND INDICATIVE PRESCRIBING SCHEMES ON GENERAL-PRACTITIONERS PRESCRIBING COSTS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To compare general practitioners' prescribing costs in fundholding and non-fundholding practices before and after implementation of the NHS reforms in April 1991. Design-Analysis of prescribing and cost information (PACT data; levels 2 and 3) over two six month periods in 1991 and 1992. Setting-Oxford region. Participants-Three dispensing fundholding practices; five non-dispensing fundholding practices; and seven non-dispensing, non-fundholding practices. Main outcome measures-Percentage change in net cost of ingredients, number of items prescribed, average cost per item, and proportion of generic drugs prescribed after NHS reforms. Results-Prescribing costs increased in all practices in the six months after the reforms. The net costs of ingredients increased among dispensing fundholders by 10.2%, among non-dispensing fundholders by 13.2%, and among non-fundholders by 18.7%. The number of items prescribed also increased in all three groups (by 5.2%, 7.5%, and 6.1% respectively). The increase in average cost per item was 4.8% for dispensing fundholders, 5.3% for non-dispensing fundholders, and 11.9% for non-fundholders. Dispensing fundholders increased the proportion of generic drugs prescribed from 26.9% to 34.5% and non-dispensing fundholders from 44.5% to 48.7%; non-fundholders showed no change (47%). Five of the eight fundholding practices made savings in their drugs budgets at the end of the first year of fundholding (range 2.9-10.7%; the three other practices overspent by up to 3.6%). All non-fundholding practices exceeded their indicative prescribing amounts (range 3.2-20.0%). Conclusions-Fundholding has helped to curb increases in prescribing costs, even among dispensing general practitioners, for whom the incentives are different. Indicative prescribing amounts for non-fundholding practices do not seem to have had the same effect.			BRADLOW, J (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,HLTH SERV RES UNIT,OXFORD OX2 6HE,ENGLAND.		Coulter, Angela/N-6998-2019	Coulter, Angela/0000-0002-6308-8375				CHEW R, 1992, ABPI BRIEFING    JUL, P1; CHEW R, 1992, COMPENDIUM HLTH STAT; COULTER A, 1993, BRIT MED J, V306, P433, DOI 10.1136/bmj.306.6875.433; COULTER A, 1992, BRIT MED J, V304, P397, DOI 10.1136/bmj.304.6824.397; HARRIS C, 1991, FACTORS INFLUENCING; JONES T, 1993, PRIMARY CARE MANAGEM, V3, P5; MORTONJONES TJ, 1993, BRIT MED J, V306, P1244, DOI 10.1136/bmj.306.6887.1244; WEINER J, 1990, GP BUDGET HOLDING UK; 1993, STATISTICAL B; 1991, INDICATIVE PRESCRIBI; 1989, INDICATIVE PRESCRIBI; 1990, IMPROVING PRESCRIBIN	12	88	88	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1993	307	6913					1186	1189		10.1136/bmj.307.6913.1186	http://dx.doi.org/10.1136/bmj.307.6913.1186			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF824	8251847	Green Published, Bronze			2022-12-28	WOS:A1993MF82400026
J	JENNINGS, PA; WRIGHT, PE				JENNINGS, PA; WRIGHT, PE			FORMATION OF A MOLTEN GLOBULE INTERMEDIATE EARLY IN THE KINETIC FOLDING PATHWAY OF APOMYOGLOBIN	SCIENCE			English	Article							ALPHA-LACTALBUMIN; CYTOCHROME-C; STRUCTURAL CHARACTERIZATION; NATIVE APOMYOGLOBIN; HYDROGEN-EXCHANGE; NMR-SPECTROSCOPY; RIBONUCLEASE-A; PROTON NMR; PROTEIN; MYOGLOBIN	Hydrogen exchange pulse labeling and stopped-flow circular dichroism were used to establish that the structure of the earliest detectable intermediate formed during refolding of apomyoglobin corresponds closely to that of a previously characterized equilibrium molten globule. This compact, cooperatively folded intermediate was formed in less than 5 milliseconds and contained stable, hydrogen-bonded secondary structure localized in the A, G, and H helices and part of the B helix. The remainder of the B helix folded on a much slower time scale, followed by the C and E helices and the CD loop. The data indicate that a molten globule intermediate was formed on the kinetic folding pathway.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute				Wright, Peter/0000-0002-1368-0223	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034909, R37DK034909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014541] Funding Source: NIH RePORTER; NCRR NIH HHS [RR04953] Funding Source: Medline; NIDDK NIH HHS [DK-34909] Funding Source: Medline; NIGMS NIH HHS [GM14541] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1970, BIOCHEMISTRY-US, V9, P4723, DOI 10.1021/bi00826a015; BALDWIN R L, 1991, Current Biology, V1, P218, DOI 10.1016/0960-9822(91)90061-Z; BALDWIN RL, 1991, CIBA F SYMP, V161, P190; BARRICK D, 1993, BIOCHEMISTRY-US, V32, P3790, DOI 10.1021/bi00065a035; BASHFORD D, 1988, PROTEINS, V4, P211, DOI 10.1002/prot.340040308; BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BRIGGS MS, 1992, P NATL ACAD SCI USA, V89, P2017, DOI 10.1073/pnas.89.6.2017; BROOKS CL, 1992, J MOL BIOL, V227, P375, DOI 10.1016/0022-2836(92)90893-O; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; CHELVANAYAGAM G, 1992, J MOL BIOL, V227, P901, DOI 10.1016/0022-2836(92)90230-H; CHENG XD, 1991, J MOL BIOL, V220, P381, DOI 10.1016/0022-2836(91)90020-7; CHRISTENSEN H, 1991, EUR BIOPHYS J, V19, P221, DOI 10.1007/BF00183530; COCCO MJ, 1992, BIOCHEMISTRY-US, V31, P6481, DOI 10.1021/bi00143a018; COCCO MJ, 1990, BIOCHEMISTRY-US, V29, P11067, DOI 10.1021/bi00502a008; COHEN FE, 1980, NATURE, V286, P632, DOI 10.1038/286632a0; COHEN FE, 1979, J MOL BIOL, V132, P275, DOI 10.1016/0022-2836(79)90260-2; CREIGHTON T E, 1991, Current Biology, V1, P8, DOI 10.1016/0960-9822(91)90110-I; ELOVE GA, 1992, BIOCHEMISTRY-US, V31, P6876, DOI 10.1021/bi00145a003; ELOVE GA, 1991, PROTEIN REFOLDING, P51; ENGLANDER SW, 1992, ANNU REV BIOPH BIOM, V21, P243, DOI 10.1146/annurev.biophys.21.1.243; GERRITSEN M, 1985, BIOPOLYMERS, V24, P1271, DOI 10.1002/bip.360240714; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRIKO YV, 1988, J MOL BIOL, V202, P127, DOI 10.1016/0022-2836(88)90525-6; HUGHSON FM, 1989, BIOCHEMISTRY-US, V28, P4415, DOI 10.1021/bi00436a044; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; IKEGUCHI M, 1986, BIOCHEMISTRY-US, V25, P6965, DOI 10.1021/bi00370a034; JENG MF, 1991, J MOL BIOL, V221, P1045, DOI 10.1016/0022-2836(91)80191-V; JENG MF, 1990, BIOCHEMISTRY-US, V29, P10433, DOI 10.1021/bi00498a001; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KUWAJIMA K, 1985, BIOCHEMISTRY-US, V24, P874, DOI 10.1021/bi00325a010; LU JR, 1992, BIOCHEMISTRY-US, V31, P4749, DOI 10.1021/bi00135a002; MABBUTT BC, 1985, BIOCHIM BIOPHYS ACTA, V832, P175, DOI 10.1016/0167-4838(85)90329-2; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; PTITSYN OB, 1975, BIOPHYS CHEM, V3, P1, DOI 10.1016/0301-4622(75)80033-0; PTITSYN OB, 1991, FEBS LETT, V285, P176, DOI 10.1016/0014-5793(91)80799-9; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; PTITSYN OB, 1973, VESTN AN SSSR+, P57; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; RICHMOND TJ, 1978, J MOL BIOL, V119, P537, DOI 10.1016/0022-2836(78)90201-2; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SCHREIER AA, 1976, J MOL BIOL, V105, P409, DOI 10.1016/0022-2836(76)90101-7; SHIN HC, 1993, BIOCHEMISTRY-US, V32, P6356, DOI 10.1021/bi00076a008; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; THERIAULT Y, UNPUB; UDGAONKAR JB, 1990, P NATL ACAD SCI USA, V87, P8197, DOI 10.1073/pnas.87.21.8197; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; VARLEY P, 1993, SCIENCE, V260, P1110, DOI 10.1126/science.8493553; WALTHO JP, 1993, BIOCHEMISTRY-US, V32, P6337, DOI 10.1021/bi00076a006	48	782	790	2	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 5	1993	262	5135					892	896		10.1126/science.8235610	http://dx.doi.org/10.1126/science.8235610			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	8235610				2022-12-28	WOS:A1993MF43800033
J	LI, R; HAVEL, C; WATSON, JA; MURRAY, AW				LI, R; HAVEL, C; WATSON, JA; MURRAY, AW			THE MITOTIC FEEDBACK-CONTROL GENE MAD2 ENCODES THE ALPHA-SUBUNIT OF A PRENYLTRANSFERASE	NATURE			English	Article							PROTEIN TRANSFERASES; RAS PROTEIN; YEAST; YPT1; ATTACHMENT; TRANSPORT; MECHANISM; HOMOLOGY; INVITRO; MUTANTS	THE mad2-1 mutation inactivates the cell-cycle feedback control that prevents budding yeast cells from leaving mitosis until spindle assembly is complete1. The gene product of MAD2 shows significant sequence similarity to the alpha-subunit of prenyltransferases2. Here we isolate a new temperature-sensitive mad2 mutant, mad2-2ts, and find that Mad2p is required for the membrane association of Ypt1p and Sec4p, two prenylated small GTP-binding proteins involved in protein trafficking. Extracts from mad2-2ts mutant cells fail to geranylgeranylate a number of substrates at the non-permissive temperature. mad2-2ts is synthetically lethal with bet2-1, a mutation in the gene that encodes for the beta-subunit of the Ypt1p and Sec4p geranylgeranyl transferase3,4. Therefore MAD2 and BET2 gene products may physically interact to form a geranylgeranyl transferase complex. In addition, the difference between the phenotypes of mad2-1 and mad2-2ts suggests that MAD2 has distinct roles in protein transport and the mitotic feedback control.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; ARMSTRONG SA, IN PRESS J BIOL CHEM; BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BARNES G, 1992, MOL BIOL CELL, V3, P29, DOI 10.1091/mbc.3.1.29; BOGUSKI MS, 1992, NEW BIOL, V4, P408; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; FINEGOLD AA, 1990, SCIENCE, V249, P165, DOI 10.1126/science.1695391; GLOMSET J, 1992, CURR OPIN LIPIDOL, V2, P118; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P315; HAVEL CM, 1992, ARCH BIOCHEM BIOPHYS, V295, P410, DOI 10.1016/0003-9861(92)90535-5; JIANG Y, 1993, NATURE, V366, P84, DOI 10.1038/366084a0; KELLER RK, 1986, J BIOL CHEM, V261, P2053; KOHL NE, 1991, J BIOL CHEM, V266, P18884; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; NEWMAN AP, 1987, J CELL BIOL, V105, P1587, DOI 10.1083/jcb.105.4.1587; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x	21	42	46	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 4	1993	366	6450					82	84		10.1038/366082a0	http://dx.doi.org/10.1038/366082a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF007	8232541				2022-12-28	WOS:A1993MF00700060
J	NICHOLSON, DA; LANG, I; HUGHES, P; DRISCOLL, PA				NICHOLSON, DA; LANG, I; HUGHES, P; DRISCOLL, PA			ABC OF EMERGENCY RADIOLOGY - THE SHOULDER	BRITISH MEDICAL JOURNAL			English	Article											NICHOLSON, DA (corresponding author), HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND.								0	4	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1993	307	6912					1129	1134		10.1136/bmj.307.6912.1129	http://dx.doi.org/10.1136/bmj.307.6912.1129			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME918	8251815	Bronze, Green Published			2022-12-28	WOS:A1993ME91800025
J	OLSEN, JH; NIELSEN, A; SCHULGEN, G				OLSEN, JH; NIELSEN, A; SCHULGEN, G			RESIDENCE NEAR HIGH-VOLTAGE FACILITIES AND RISK OF CANCER IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							ELECTRICAL WIRING CONFIGURATIONS; CHILDHOOD-CANCER; MAGNETIC-FIELDS; LEUKEMIA; EXPOSURE	Objective-To investigate whether residence before and after birth near 50 Hz high voltage installations increases a child's risk of cancer and whether risk correlates with the strength of the magnetic field. Design-A population based case-control study. Setting-Denmark. Subjects-1707 children under the age of 15 with leukaemia, tumour of the central nervous system, or malignant lymphoma diagnosed in 1968-86 and 4788 children taken from the central population register. Main outcome measures-Proximity before and after birth to existing or former 50-400 kV electrical transmission connections and substations and associated historical electromagnetic fields calculated on the basis of current load on line, phase ordering of line, and distance from the dwelling. Results-A significant association was seen between all major types of childhood cancer combined and exposure to magnetic fields from high voltage installations of greater-than-or-equal-to 0.4 muT (odds ratio 5.6). At greater-than-or-equal-to 0.25 muT no significant association was seen (odds ratio 1.5). A possible association was also seen with cases of Hodgkin's disease separately at greater-than-or-equal-to 0.1 muT. Conclusion-On the basis these results and additional descriptive data on electricity consumption and incidence of childhood cancer in Denmark since the 1940s it was concluded that the proportion of childhood cancer possibly caused by 50 Hz electromagnetic fields must be small.	UNIV FREIBURG,INST MED BIOMETRY & INFORMAT,W-7800 FREIBURG,GERMANY	University of Freiburg	OLSEN, JH (corresponding author), DANISH CANC SOC,DIV CANC EPIDEMIOL,STRANDBLVD 49,DK-2100 COPENHAGEN 0,DENMARK.			Olsen, Jorgen Helge/0000-0001-9633-5662				BIRCH JM, 1987, INT J CANCER, V40, P620, DOI 10.1002/ijc.2910400508; BLETTNER M, 1984, METHOD INFORM MED, V24, P37; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; BROWN PD, 1989, INT J EPIDEMIOL, V18, P546, DOI 10.1093/ije/18.3.546; COLEMAN MP, 1989, BRIT J CANCER, V60, P793, DOI 10.1038/bjc.1989.362; FEYCHTING M, 1992, IMM692 KAR I REP; FULTON JP, 1980, AM J EPIDEMIOL, V111, P292, DOI 10.1093/oxfordjournals.aje.a112899; Jensen O M, 1985, Natl Cancer Inst Monogr, V68, P245; LAUSEN B, 1992, BIOMETRICS, V48, P73, DOI 10.2307/2532740; LONDON SJ, 1991, AM J EPIDEMIOL, V134, P923, DOI 10.1093/oxfordjournals.aje.a116176; MYERS A, 1990, BRIT J CANCER, V62, P1008, DOI 10.1038/bjc.1990.428; OLSEN JH, 1991, EUR J CANCER, V27, P958, DOI 10.1016/0277-5379(91)90258-F; SAVITZ DA, 1988, AM J EPIDEMIOL, V128, P21, DOI 10.1093/oxfordjournals.aje.a114943; SKOTTE J, 1993, IN PRESS EXPOSURE EL; TOMENIUS L, 1986, BIOELECTROMAGNETICS, V7, P191, DOI 10.1002/bem.2250070209; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273, DOI 10.1093/oxfordjournals.aje.a112681; 1992, DOCUMENTS NRPB, V3; 1990, ELSAM N90NR254A REP	18	201	204	1	18	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1993	307	6909					891	895		10.1136/bmj.307.6909.891	http://dx.doi.org/10.1136/bmj.307.6909.891			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB847	8241850	Green Published, Bronze			2022-12-28	WOS:A1993MB84700014
J	DUFFY, TP				DUFFY, TP			GETTING THE STORY RIGHT	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							SYNCOPE; SPASM				DUFFY, TP (corresponding author), YALE UNIV,SCH MED,333 CEDAR ST,NEW HAVEN,CT 06510, USA.							BANKS JT, 1992, LIT MED, V11, P185; DVORAK AM, 1986, NEW ENGL J MED, V315, P969; EAGLE KA, 1985, AM J MED, V79, P455, DOI 10.1016/0002-9343(85)90032-4; FORMAN MB, 1985, NEW ENGL J MED, V313, P1138, DOI 10.1056/NEJM198510313131807; GINSBURG R, 1981, AM HEART J, V102, P819, DOI 10.1016/0002-8703(81)90030-2; KAPOOR WN, 1990, MEDICINE, V69, P160, DOI 10.1097/00005792-199005000-00004; MARKEL ML, 1987, MEDICINE, V66, P114, DOI 10.1097/00005792-198703000-00003; MICHELASSI F, 1982, SCIENCE, V217, P841, DOI 10.1126/science.6808665; PRYOR DB, 1993, ANN INTERN MED, V118, P81, DOI 10.7326/0003-4819-118-2-199301150-00001; RATZAN RM, 1992, LIT MED, V11, P94, DOI 10.1353/lm.2011.0263; Roberts L J 2nd, 1982, Trans Assoc Am Physicians, V95, P36; TRAVIS WD, 1988, MEDICINE, V67, P345, DOI 10.1097/00005792-198811000-00001; TRAVIS WD, 1990, MEDICINE, V69, P34	13	10	10	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 6	1993	328	18					1333	1336		10.1056/NEJM199305063281809	http://dx.doi.org/10.1056/NEJM199305063281809			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ640	8240484				2022-12-28	WOS:A1993KZ64000009
J	PORTER, DL; ROTH, MS; MCGARIGLE, C; FERRARA, JLM; ANTIN, JH				PORTER, DL; ROTH, MS; MCGARIGLE, C; FERRARA, JLM; ANTIN, JH			INDUCTION OF GRAFT-VERSUS-HOST DISEASE AS IMMUNOTHERAPY FOR RELAPSED CHRONIC MYELOID-LEUKEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; CHRONIC MYELOGENOUS LEUKEMIA; DONOR LEUKOCYTE INFUSIONS; POLYMERASE CHAIN-REACTION; CHRONIC PHASE; SELECTIVE DEPLETION; LYMPHOCYTES-T; INTERFERON; CELLS; TRANSFUSIONS	Background. The ability of allogeneic bone marrow transplantation to cure chronic myeloid leukemia (CML) is due to both the conditioning regimen and the antileukemic effects of the lymphocytes in the grafted marrow. We studied the ability of interferon alfa-2b and infusions of mononuclear cells from the marrow donor to induce a graft-versus-leukemia reaction in patients with CML in relapse after bone marrow transplantation. Methods. Eleven patients with relapsed CML after allogeneic bone marrow transplantation were treated with interferon alfa-2b and infusions of mononuclear cells. The patients were monitored for toxic effects, for hematologic and cytogenetic responses, and, with use of the polymerase chain reaction, for elimination of cells containing the bcr/abl messenger RNA transcript characteristic of the leukemic cells. Results. Six of the eight patients with stable CML after relapse had complete remissions according to molecular genetic criteria, since no cells with bcr/abl messenger RNA transcripts were detected (the method can identify 1 leukemic cell among 1 million normal cells). The three patients with accelerated CML after relapse did not enter remission. Myelosuppression was prominent in eight patients. Grade I acute graft-versus-host disease (GVHD) occurred in six patients, and grade III acute GVHD occurred in three. Limited chronic GVHD developed in five patients. Conclusions. The induction of a graft-versus-leukemia reaction with interferon alfa-2b and infusions of donor mononuclear cells in patients with CML in relapse after bone marrow transplantation is an effective antileukemic therapy that may off er an alternative to a second marrow transplantation.	BRIGHAM & WOMENS HOSP,DIV HEMATOL ONCOL,75 FRANCIS ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; UNIV MICHIGAN,MED CTR,DIV HEMATOL ONCOL,ANN ARBOR,MI 48109	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Michigan System; University of Michigan					NCI NIH HHS [CA58661, CA39542] Funding Source: Medline; NHLBI NIH HHS [T32-HL07623] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058661, P01CA039542] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007623] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS PT, 1992, BLOOD, V80, P551; ANTIN JH, 1992, BLOOD, V80, P2964; ANTIN JH, 1991, BLOOD, V78, P2139; APPERLEY JF, 1988, BRIT J HAEMATOL, V69, P239, DOI 10.1111/j.1365-2141.1988.tb07628.x; BALKWILL FR, 1989, CYTOKINES CANCER THE, P8; BARNES DWH, 1957, BRIT J HAEMATOL, V3, P241, DOI 10.1111/j.1365-2141.1957.tb05793.x; COLLINS RH, 1992, BONE MARROW TRANSPL, V10, P391; CULLIS JO, 1992, BLOOD, V79, P1379; DROBYSKI WR, 1992, BONE MARROW TRANSPL, V10, P301; FERRARA JLM, 1992, BLOOD SA, V80, pA270; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; GOLDMAN JM, 1988, ANN INTERN MED, V108, P806, DOI 10.7326/0003-4819-108-6-806; HAUCH M, 1990, BLOOD, V75, P2250; HENDY GN, 1981, P NATL ACAD SCI-BIOL, V78, P7365, DOI 10.1073/pnas.78.12.7365; HERBERMAN RB, 1981, J CLIN IMMUNOL, V1, P149, DOI 10.1007/BF00922756; HIGANO CS, 1992, BLOOD, V80, P1437; HOROWITZ MM, 1990, BLOOD, V75, P555; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; MCGLAVE P, 1987, J CLIN ONCOL, V5, P1033, DOI 10.1200/JCO.1987.5.7.1033; MRSIC M, 1992, BONE MARROW TRANSPL, V9, P269; MYERS JD, 1987, ANN INTERN MED, V107, P809; OPALKA B, 1991, BLOOD, V78, P2188, DOI 10.1182/blood.V78.9.2188.bloodjournal7892188; ROTH MS, 1990, TRANSPLANTATION, V49, P714, DOI 10.1097/00007890-199004000-00012; ROTH MS, 1992, BLOOD, V79, P276; SHULMAN HM, 1980, AM J MED, V69, P204, DOI 10.1016/0002-9343(80)90380-0; SHULMAN HM, 1988, HEPATOLOGY, V8, P463, DOI 10.1002/hep.1840080305; SOIFFER RJ, 1992, J CLIN ONCOL, V10, P1191, DOI 10.1200/JCO.1992.10.7.1191; SPECK B, 1984, LANCET, V1, P665; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; SULLIVAN KM, 1989, NEW ENGL J MED, V320, P828, DOI 10.1056/NEJM198903303201303; SULLIVAN KM, 1989, BLOOD, V73, P1720; SULLIVAN KM, 1989, BLOOD, V74, P1180; TALPAZ M, 1991, ANN INTERN MED, V114, P532, DOI 10.7326/0003-4819-114-7-532; TRUITT RL, 1990, GRAFT VS HOST DISEAS, P177; UPADHYAYA G, 1991, J CLIN INVEST, V88, P2131, DOI 10.1172/JCI115543; WAGNER JE, 1990, BLOOD, V75, P1370; WEIDEN PL, 1976, J IMMUNOL, V116, P1212	38	431	445	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 13	1994	330	2					100	106		10.1056/NEJM199401133300204	http://dx.doi.org/10.1056/NEJM199401133300204			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ670	8259165	Bronze			2022-12-28	WOS:A1994MQ67000004
J	GROSSMAN, ME; STEVENS, AW; COHEN, PR				GROSSMAN, ME; STEVENS, AW; COHEN, PR			BRIEF REPORT - HERPETIC GEOMETRIC GLOSSITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							IMMUNOCOMPROMISED PATIENTS; SIMPLEX VIRUS; INFECTION		COLUMBIA PRESBYTERIAN MED CTR,DERMATOL CONSULTAT SERV,NEW YORK,NY 10032; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MED SPECIALTIES,DERMATOL SECT,HOUSTON,TX 77025; UNIV TEXAS,HOUSTON MED SCH,DEPT DERMATOL,HOUSTON,TX 77025; UNIV TEXAS,HOUSTON MED SCH,DEPT PATHOL,HOUSTON,TX 77025	Columbia University; NewYork-Presbyterian Hospital; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston								BERGMANN OJ, 1990, EUR J CLIN MICROBIOL, V9, P184, DOI 10.1007/BF01963835; COHEN PR, 1987, CUTIS, V40, P406; COHEN PR, IN PRESS DERMATOL; COHEN SG, 1985, ORAL SURG ORAL MED O, V59, P465, DOI 10.1016/0030-4220(85)90085-4; LEMING PD, 1984, CANCER, V54, P3043, DOI 10.1002/1097-0142(19841215)54:12<3043::AID-CNCR2820541237>3.0.CO;2-6; Miller C S, 1992, Dent Clin North Am, V36, P879; Schubert M M, 1991, Curr Opin Dent, V1, P384	7	23	23	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 16	1993	329	25					1859	1860		10.1056/NEJM199312163292506	http://dx.doi.org/10.1056/NEJM199312163292506			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML588	8247038				2022-12-28	WOS:A1993ML58800006
J	MADDOX, J				MADDOX, J			A VALVE THAT COULD DO GOOD	NATURE			English	Editorial Material																			0	0	0	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 16	1993	366	6456					620	620						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM265	8259204				2022-12-28	WOS:A1993MM26500031
J	BECK, RW; CLEARY, PA; TROBE, JD; KAUFMAN, DI; KUPERSMITH, MJ; PATY, DW; BROWN, CH				BECK, RW; CLEARY, PA; TROBE, JD; KAUFMAN, DI; KUPERSMITH, MJ; PATY, DW; BROWN, CH			THE EFFECT OF CORTICOSTEROIDS FOR ACUTE OPTIC NEURITIS ON THE SUBSEQUENT DEVELOPMENT OF MULTIPLE-SCLEROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOLLOW-UP; RISK; PROGNOSIS; LESIONS; BRAIN	Background. Optic neuritis is often the first clinical manifestation of multiple sclerosis, but little is known about the effect of corticosteroid treatment for optic neuritis on the subsequent risk of multiple sclerosis. Methods. We conducted a multicenter study in which 389 patients with acute optic neuritis (and without known multiple sclerosis) were randomly assigned to receive intravenous methylprednisolone (250 mg every six hours) for 3 days followed by oral prednisone (1 mg per kilogram of body weight) for 11 days, oral prednisone (1 mg per kilogram) alone for 14 days, or placebo for 14 days. Neurologic status was assessed over a period of two to four years. The patients in the first group were hospitalized for three days; the others were treated as outpatients. Results. Definite multiple sclerosis developed within the first two years in 7.5 percent of the intravenous-methylprednisolone group (134 patients), 14.7 percent of the oral-prednisone group (129 patients), and 1 6.7 percent of the placebo group (126 patients). The adjusted rate ratio for the development of definite multiple sclerosis within two years in the intravenous-methylprednisolone group was 0.34 (95 percent confidence interval, 0.16 to 0.74) as compared with the placebo group and 0.38 (95 percent confidence interval, 0.17 to 0.83) as compared with the oral-prednisone group. The beneficial effect of the intravenous-steroid regimen appeared to lessen after the first two years of follow-up. Signal abnormalities on magnetic resonance imaging (MRI) of the brain were a strong indication of risk for the development of definite multiple sclerosis (adjusted rate ratio in patients with three or more lesions, 5.53; 95 percent confidence interval, 2.41 to 12.66). The beneficial effect of treatment was most apparent in patients with abnormal MRI scans at entry. Conclusions. In patients with acute optic neuritis, treatment with a three-day course of high-dose intravenous methylprednisolone (followed by a short course of prednisone) reduces the rate of development of multiple sclerosis over a two-year period.	UNIV S FLORIDA,DEPT OPHTHALMOL,TAMPA,FL 33620; UNIV S FLORIDA,DEPT NEUROL,TAMPA,FL 33620; UNIV S FLORIDA,DEPT EPIDEMIOL & BIOSTAT,TAMPA,FL 33620; GEORGE WASHINGTON UNIV,CTR BIOSTAT,ROCKVILLE,MD; UNIV MICHIGAN,KELLOGG EYE CTR,ANN ARBOR,MI 48109; MICHIGAN STATE UNIV,DIV VISUAL SCI,E LANSING,MI 48824; NYU,DEPT OPHTHALMOL,NEW YORK,NY 10003; UNIV BRITISH COLUMBIA,DEPT NEUROL,VANCOUVER V6T 1W5,BC,CANADA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; George Washington University; University of Michigan System; University of Michigan; Michigan State University; New York University; University of British Columbia	BECK, RW (corresponding author), JAEB CTR HLTH RES,3010 E 138 AVE,SUITE 13,TAMPA,FL 33613, USA.			Brown, C Hendricks/0000-0002-0294-2419; Wall, Michael/0000-0002-9802-4806; Trobe, Jonathan/0000-0003-0728-6729	NATIONAL EYE INSTITUTE [U10EY007212, U10EY007460, U01EY007212, U01EY007461, U01EY007460, U10EY007461] Funding Source: NIH RePORTER; NEI NIH HHS [EY07212, EY07460, EY07461] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BECK RW, 1993, ARCH NEUROL-CHICAGO, V50, P841, DOI 10.1001/archneur.1993.00540080050013; BECK RW, 1992, NEW ENGL J MED, V326, P581, DOI 10.1056/NEJM199202273260901; BECK RW, 1993, ARCH OPHTHALMOL-CHIC, V111, P773, DOI 10.1001/archopht.1993.01090060061023; CHROUSOS GA, 1993, JAMA-J AM MED ASSOC, V269, P2110, DOI 10.1001/jama.269.16.2110; CLEARY PA, 1993, CONTROL CLIN TRIALS, V14, P123, DOI 10.1016/0197-2456(93)90015-6; COX DR, 1972, J R STAT SOC B, V34, P187; EBERS GC, 1985, ARCH NEUROL-CHICAGO, V42, P702, DOI 10.1001/archneur.1985.04060070096025; FRANCIS DA, 1987, J NEUROL NEUROSUR PS, V50, P758, DOI 10.1136/jnnp.50.6.758; FREDERIKSEN JL, 1989, ACTA NEUROL SCAND, V80, P512, DOI 10.1111/j.1600-0404.1989.tb03919.x; GEHAN EA, 1965, BIOMETRIKA, V52, P203, DOI 10.2307/2333825; HELY MA, 1986, J NEUROL NEUROSUR PS, V49, P1125, DOI 10.1136/jnnp.49.10.1125; HUTCHINSON WM, 1976, J NEUROL NEUROSUR PS, V39, P283, DOI 10.1136/jnnp.39.3.283; JACOBS L, 1986, ARCH NEUROL-CHICAGO, V43, P452, DOI 10.1001/archneur.1986.00520050032017; JACOBS L, 1991, NEUROLOGY, V41, P15, DOI 10.1212/WNL.41.1.15; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MANTEL N, 1959, J NATL CANCER I, V22, P719; MARTINELLI V, 1991, ACTA NEUROL SCAND, V84, P231, DOI 10.1111/j.1600-0404.1991.tb04944.x; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MILLER DH, 1992, J NEUROL NEUROSUR PS, V55, P450, DOI 10.1136/jnnp.55.6.450; MYERS LW, 1992, TREATMENT MULTIPLE S, P135; NIKOSKELAINEN E, 1975, ACTA OPHTHALMOL, V53, P254; NIKOSKELAINEN E, 1981, ANN NEUROL, V9, P545, DOI 10.1002/ana.410090606; ORMEROD IEC, 1986, J NEUROL NEUROSUR PS, V49, P124, DOI 10.1136/jnnp.49.2.124; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; PERKIN GD, 1979, OPTIC NEURITIS ITS D, P43; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; RIZZO JF, 1988, NEUROLOGY, V38, P185, DOI 10.1212/WNL.38.2.185; SANDBERG-WOLLHEIM M, 1990, Annals of Neurology, V27, P386, DOI 10.1002/ana.410270406; STENDAHLBRODIN L, 1983, ACTA NEUROL SCAND, V67, P301, DOI 10.1111/j.1600-0404.1983.tb04579.x; The IFNB Multiple Sclerosis Study Group, 1993, NEUROLOGY, V43, P655; 1991, ARCH OPHTHALMOL-CHIC, V109, P1673	31	449	468	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 9	1993	329	24					1764	1769		10.1056/NEJM199312093292403	http://dx.doi.org/10.1056/NEJM199312093292403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK096	8232485	Bronze			2022-12-28	WOS:A1993MK09600003
J	REID, RT; LIVE, DH; FAULKNER, DJ; BUTLER, A				REID, RT; LIVE, DH; FAULKNER, DJ; BUTLER, A			A SIDEROPHORE FROM A MARINE BACTERIUM WITH AN EXCEPTIONAL FERRIC ION AFFINITY CONSTANT	NATURE			English	Article							IRON TRANSPORT COMPOUNDS; COORDINATION CHEMISTRY; GROWTH; PHYTOPLANKTON; ALTEROMONAS; INHIBITION; ANALOGS; WATERS	VIRTUALLY all microorganisms require iron for growth. The paucity of iron in surface ocean water (approximately 0.02-1.0 nM (refs 1, 2)) has spurred a lively debate concerning iron limitation of primary productivity3-6, yet little is known about the molecular mechanisms used by marine microorganisms to sequester iron. Terrestrial bacteria use a siderophore-mediated ferric uptake systems7. A siderophore is a low-molecular-mass compound with a high affinity for ferric ion which is secreted by microorganisms in response to low-iron environments; siderophore biosynthesis is regulated by iron levels, with repression by high iron. Although open-ocean marine microorganisms (such as phytoplankton8 and bacteria9) produce siderophores, the nature of these siderophores has not been investigated. We report here the first structure determination, to our knowledge, of the siderophores from an open-ocean bacterium, alterobactin A and B from Alteromonas luteoviolacea. A. luteoviolacea is found in oligotrophic10 and coastal11 waters. Alterobactin A has an exceptionally high affinity constant for ferric ion. We suggest that at least some marine microorganisms may have developed higher-affinity iron chelators as part of an efficient iron-uptake mechanism which is more effective than that of their terrestrial counterparts.	UNIV CALIF SANTA BARBARA,DEPT CHEM,SANTA BARBARA,CA 93106; MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021; UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,LA JOLLA,CA 92093	University of California System; University of California Santa Barbara; Memorial Sloan Kettering Cancer Center; University of California System; University of California San Diego; Scripps Institution of Oceanography			Butler, Alison/D-5094-2015	Butler, Alison/0000-0002-3525-7864				ABDALLAH MA, 1989, 27 INT C COORD CHEM; ANDEREGG G, 1963, HELV CHIM ACTA, V46, P1409, DOI 10.1002/hlca.19630460436; ANDERSEN RJ, 1974, MAR BIOL, V27, P281, DOI 10.1007/BF00394363; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BRONZLI P, 1990, J AM CHEM SOC, V112, P3719; BRULAND KW, 1991, LIMNOL OCEANOGR, V36, P1555, DOI 10.4319/lo.1991.36.8.1555; CHABEREK S, 1959, ORGANIC SEQUESTERING; GAUTHIER MJ, 1976, CAN J MICROBIOL, V22, P1612, DOI 10.1139/m76-237; HARRIS DC, 1982, QUANTITATIVE CHEM; HARRIS WR, 1979, J AM CHEM SOC, V101, P2213, DOI 10.1021/ja00502a053; HARRIS WR, 1979, J AM CHEM SOC, V101, P2722, DOI 10.1021/ja00504a038; JALAL MAF, 1989, J AM CHEM SOC, V111, P292, DOI 10.1021/ja00183a044; LOOMIS LD, 1991, INORG CHEM, V30, P9036; MARFEY P, 1984, CARLSBERG RES COMMUN, V49, P591, DOI 10.1007/BF02908688; MARTIN JH, 1991, LIMNOL OCEANOGR, V36, P1793, DOI 10.4319/lo.1991.36.8.1793; MARTIN JH, 1988, NATURE, V331, P341, DOI 10.1038/331341a0; MARTIN JH, 1990, NATURE, V345, P156, DOI 10.1038/345156a0; MAYOR S, 1985, MAGN RESON CHEM, V23, P470, DOI 10.1002/mrc.1260230613; Neilands J B, 1990, Adv Inorg Biochem, V8, P63; Perrin D. D., 2012, BUFFERS PH METAL ION; PRICE NM, 1991, DEEP-SEA RES, V38, P1361, DOI 10.1016/0198-0149(91)90011-4; REID RT, 1991, LIMNOL OCEANOGR, V36, P1783, DOI 10.4319/lo.1991.36.8.1783; RICH DH, 1980, J MED CHEM, V23, P27, DOI 10.1021/jm00175a006; SALITURO FG, 1987, J MED CHEM, V30, P286, DOI 10.1021/jm00385a010; SCHWARZENBACH G, 1963, HELV CHIM ACTA, V46, P1390, DOI 10.1002/hlca.19630460434; Smith RM, 1974, CRITICAL STABILITY C, V1-6; SUNDA WG, 1991, NATURE, V351, P55, DOI 10.1038/351055a0; TAKAHASHI A, 1987, J ANTIBIOT, V40, P1671, DOI 10.7164/antibiotics.40.1671; TEINTZE M, 1981, BIOCHEMISTRY-US, V20, P6457, DOI 10.1021/bi00525a026; TRICK CG, 1989, CURR MICROBIOL, V18, P375, DOI 10.1007/BF01571131; TRICK CG, 1983, SCIENCE, V219, P306, DOI 10.1126/science.219.4582.306; WONG GB, 1983, J AM CHEM SOC, V105, P810, DOI 10.1021/ja00342a027	32	187	191	2	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 2	1993	366	6454					455	458		10.1038/366455a0	http://dx.doi.org/10.1038/366455a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK098	8247152				2022-12-28	WOS:A1993MK09800061
J	TODD, JS				TODD, JS			REFORM OF THE HEALTH-CARE SYSTEM AND PROFESSIONAL LIABILITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											TODD, JS (corresponding author), AMER MED ASSOC,CHICAGO,IL 60610, USA.								0	8	8	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 2	1993	329	23					1733	1735		10.1056/NEJM199312023292312	http://dx.doi.org/10.1056/NEJM199312023292312			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MJ707	8232465				2022-12-28	WOS:A1993MJ70700012
J	BACHMANN, MF; ROHRER, UH; KUNDIG, TM; BURKI, K; HENGARTNER, H; ZINKERNAGEL, RM				BACHMANN, MF; ROHRER, UH; KUNDIG, TM; BURKI, K; HENGARTNER, H; ZINKERNAGEL, RM			THE INFLUENCE OF ANTIGEN ORGANIZATION ON B-CELL RESPONSIVENESS	SCIENCE			English	Article							VESICULAR STOMATITIS-VIRUS; MAJOR SURFACE GLYCOPROTEIN; REACTIVE LYMPHOCYTES-B; TRANSGENIC MICE; SELF-TOLERANCE; MONOCLONAL-ANTIBODIES; MYASTHENIA-GRAVIS; CLONAL DELETION; IMMUNE-RESPONSE; VIRAL-ANTIGENS	The influence of antigen epitope density and order on B cell induction and antibody production was assessed with the glycoprotein of vesicular stomatitis virus serotype Indiana [VSV-G(IND)]. VSV-G(IND) can be found in a highly repetitive form in the envelope of VSV-IND and in a poorly organized form on the surface of infected cells. In VSV-G (IND) transgenic mice, B cells were unresponsive to the poorly organized VSV-G (IND) present as self antigen but responded promptly to the same antigen presented in the highly organized form. Thus, antigen organization influences B cell tolerance.	UNIV ZURICH,DEPT PATHOL,INST EXPTL IMMUNOL,STERNWARTSTR 2,CH-8091 ZURICH,SWITZERLAND	University of Zurich								ADAMS E, 1990, P NATL ACAD SCI USA, V87, P5687, DOI 10.1073/pnas.87.15.5687; ADELSTEIN S, 1991, SCIENCE, V251, P1223, DOI 10.1126/science.1900950; ARNOLD B, 1988, P NATL ACAD SCI USA, V85, P2269, DOI 10.1073/pnas.85.7.2269; BACHMANN MF, 1993, J VIROL, V67, P3917, DOI 10.1128/JVI.67.7.3917-3922.1993; BASTEN A, 1991, IMMUNOL REV, V122, P5, DOI 10.1111/j.1600-065X.1991.tb00593.x; BROMBACHER F, 1991, J EXP MED, V174, P1335, DOI 10.1084/jem.174.6.1335; BURNS WH, 1975, NATURE, V256, P654, DOI 10.1038/256654a0; CHARAN S, 1987, J VIROL, V61, P2509, DOI 10.1128/JVI.61.8.2509-2514.1987; CHARAN S, 1986, J IMMUNOL, V136, P3057; COUTINHO A, 1975, ADV IMMUNOL, P113; DINTZIS HM, 1976, P NATL ACAD SCI USA, V73, P3671, DOI 10.1073/pnas.73.10.3671; DINTZIS RZ, 1989, J IMMUNOL, V143, P1239; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; FAMBROUGH DM, 1973, SCIENCE, V182, P293, DOI 10.1126/science.182.4109.293; GOODMANSNITKOFF G, 1981, J EXP MED, V153, P489; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; Kelley J M, 1972, J Virol, V10, P1231; KUNDIG TM, 1993, J VIROL, V67, P3680; LEFRANCOIS L, 1982, VIROLOGY, V121, P157, DOI 10.1016/0042-6822(82)90125-8; LEFRANCOIS L, 1982, VIROLOGY, V121, P168, DOI 10.1016/0042-6822(82)90126-X; LEIST TP, 1987, J IMMUNOL, V138, P2278; LINDSTROM J, 1985, ANNU REV IMMUNOL, V3, P109; MOLLER G, 1975, TRANSPLANT REV, V23, P126; MOSKOPHIDIS D, 1984, J IMMUNOL, V133, P3366; NEMAZEE D, 1991, IMMUNOL REV, V122, P117, DOI 10.1111/j.1600-065X.1991.tb00600.x; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NOSSAL GJV, 1975, TRANSPLANT REV, V23, P138; ODERMATT B, 1991, P NATL ACAD SCI USA, V88, P8252, DOI 10.1073/pnas.88.18.8252; PIKE BL, 1982, P NATL ACAD SCI-BIOL, V79, P2013, DOI 10.1073/pnas.79.6.2013; RATH S, 1988, J IMMUNOL METHODS, V106, P245, DOI 10.1016/0022-1759(88)90204-9; ROOST HP, 1990, EUR J IMMUNOL, V20, P2547, DOI 10.1002/eji.1830201204; ROOST HP, 1991, THESIS U ZURICH; WAGNER RR, 1987, RHABDOVIRUSES; YEWDELL JW, 1986, J EXP MED, V163, P1529, DOI 10.1084/jem.163.6.1529; ZINKERNAGEL RM, 1990, NATURE, V345, P68, DOI 10.1038/345068a0; ZINKERNAGEL RM, 1991, IMMUNOL REV, V122, P133, DOI 10.1111/j.1600-065X.1991.tb00601.x	38	559	594	2	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 26	1993	262	5138					1448	1451		10.1126/science.8248784	http://dx.doi.org/10.1126/science.8248784			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ046	8248784				2022-12-28	WOS:A1993MJ04600041
J	KIM, K; SOLDATI, D; BOOTHROYD, JC				KIM, K; SOLDATI, D; BOOTHROYD, JC			GENE REPLACEMENT IN TOXOPLASMA-GONDII WITH CHLORAMPHENICOL ACETYLTRANSFERASE AS SELECTABLE MARKER	SCIENCE			English	Article							PLASMODIUM-FALCIPARUM; EXPRESSION; CLINDAMYCIN	A system for stable transformation of Toxoplasma gondii tachyzoites was developed that exploited the susceptibility of Toxoplasma to chloramphenicol. Introduction of the chloramphenicol acetyltransferase (CAT) gene fused to Toxoplasma flanking sequences followed by chloramphenicol selection resulted in parasites stably expressing CAT. A construct incorporating the tandemly repeated gene, B1, targeted efficiently to its homologous chromosomal locus. Knockout of the single-copy gene, ROP1, was also successful. Stable transformation should permit the identification and analysis of Toxoplasma genes important in the interaction of this opportunistic parasite with its host.	STANFORD UNIV,MED CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	Stanford University			Soldati-Favre, Dominique/A-2999-2009	Kim, Kami/0000-0003-3384-152X; Boothroyd, John C./0000-0001-9719-745X				BURG JL, 1989, J CLIN MICROBIOL, V27, P1787, DOI 10.1128/JCM.27.8.1787-1792.1989; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; DANNEMANN B, 1992, ANN INTERN MED, V116, P33, DOI 10.7326/0003-4819-116-1-33; DIVO AA, 1985, ANTIMICROB AGENTS CH, V27, P21, DOI 10.1128/AAC.27.1.21; GARDNER MJ, 1991, MOL BIOCHEM PARASIT, V48, P77, DOI 10.1016/0166-6851(91)90166-4; KIM KK, UNPUB; LABAN A, 1990, NATURE, V343, P572, DOI 10.1038/343572a0; MINEO JR, 1993, J IMMUNOL, V150, P3951; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PFEFFERKORN ER, 1992, ANTIMICROB AGENTS CH, V36, P1091, DOI 10.1128/AAC.36.5.1091; SIBLEY LD, 1992, MOL BIOCHEM PARASIT, V51, P291, DOI 10.1016/0166-6851(92)90079-Y; SOLDATI D, 1993, SCIENCE, V260, P349, DOI 10.1126/science.8469986; SOLDATI D, UNPUB; TENASBROEK ALMA, 1990, NATURE, V348, P174, DOI 10.1038/348174a0; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902	15	229	242	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 5	1993	262	5135					911	914		10.1126/science.8235614	http://dx.doi.org/10.1126/science.8235614			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	8235614				2022-12-28	WOS:A1993MF43800040
J	JOHNSON, G				JOHNSON, G			CHILDLESS WOMEN REVISITED	BRITISH MEDICAL JOURNAL			English	Article											JOHNSON, G (corresponding author), WIGMORE LANE HLTH CTR,LUTON LU2 8BG,ENGLAND.							GREENHALL E, 1990, FERTIL STERIL, V54, P978; JOHNSON G, 1987, BRIT MED J, V294, P804, DOI 10.1136/bmj.294.6575.804; JONES C, 1992, POPULATION TRENDS, V67, P10; TEMPLETON A, 1990, BRIT MED J, V301, P148, DOI 10.1136/bmj.301.6744.148	4	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1993	307	6912					1116	1117		10.1136/bmj.307.6912.1116	http://dx.doi.org/10.1136/bmj.307.6912.1116			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME918	8251811	Green Published, Bronze			2022-12-28	WOS:A1993ME91800019
J	REDMAYNE, S; KLEIN, R				REDMAYNE, S; KLEIN, R			RATIONING IN PRACTICE - THE CASE OF INVITRO FERTILIZATION	BRITISH MEDICAL JOURNAL			English	Article								One of the few examples of explicit rationing in the National Health Service is provided by in vitro fertilisation. Of six purchasing authorities examined three have decided against buying in vitro fertilisation while three have decided in favour. The. decisions reflect local factors such as the absence or presence of local providers and the views of the public and health professionals. But in vitro fertilisation also illustrates some of the wider issues involved in all decisions about purchasing: questions about what should be provided by the National Health Service, about what procedures should be compared when weighing up value for money, and whether equity demands national decisions about what to provide.			REDMAYNE, S (corresponding author), UNIV BATH,CTR ANAL SOCIAL POLICY,BATH BA2 7AY,AVON,ENGLAND.							[Anonymous], 1992, ANN REPORT; GUNNING J, 1990, HUMAN IVF EMBRYO RES; HULL MGR, 1992, BRIT MED J, V304, P1465, DOI 10.1136/bmj.304.6840.1465; HUNT L, 1992, INDEPENDENT     1102, P4; KLEIN R, 1992, BRIT MED J, V304, P1457, DOI 10.1136/bmj.304.6840.1457; KLEIN R, 1992, PATTERNS PRIORITIES; MAZOR MD, 1984, INFERTILITY MED EMOT, P29; 1991, BMJ, V302, P1345; 1992, MANAGEMENT SUBFERTIL, V3; 1992, INFERTILITY GUIDELIN	10	38	38	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 5	1993	306	6891					1521	1524		10.1136/bmj.306.6891.1521	http://dx.doi.org/10.1136/bmj.306.6891.1521			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF940	8257491	Bronze, Green Published			2022-12-28	WOS:A1993LF94000030
J	FARCI, P; MANDAS, A; COIANA, A; LAI, ME; DESMET, V; VANEYKEN, P; GIBO, Y; CARUSO, L; SCACCABAROZZI, S; CRISCUOLO, D; RYFF, JC; BALESTRIERI, A				FARCI, P; MANDAS, A; COIANA, A; LAI, ME; DESMET, V; VANEYKEN, P; GIBO, Y; CARUSO, L; SCACCABAROZZI, S; CRISCUOLO, D; RYFF, JC; BALESTRIERI, A			TREATMENT OF CHRONIC HEPATITIS-D WITH INTERFERON-ALFA-2A	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							B SURFACE-ANTIGEN; DELTA-VIRUS; CONTROLLED TRIAL; INFECTION; MECHANISMS; DISEASE; ALPHA; SERUM	Background and Methods. Chronic hepatitis D is a severe and rapidly progressive liver disease for which no therapy has been proved effective. To evaluate the efficacy of treatment with interferon, we studied 42 patients with chronic hepatitis D who were randomly assigned to receive either 9 million or 3 million units of recombinant interferon alfa-2a (three times a week for 48 weeks) or no treatment. Results. By the end of the treatment period, serum alanine aminotransferase values had become normal in 10 of 14 patients receiving 9 million units (71 percent), as compared with 4 of 14 treated with 3 million units (29 percent, P = 0.029) and 1 of 13 untreated controls (8 percent, P = 0.001). Seven patients treated with the higher dose of interferon (50 percent) had a complete response (normal levels of alanine aminotransferase and no detectable serum hepatitis delta virus [HDV] RNA), as compared with three of those who received the lower dose (21 percent, P = 0.118), and none of the controls (P = 0.004). Treatment with 9 million units of interferon was associated with a marked improvement in the histologic findings (reduced periportal necrosis and portal and lobular inflammation), whereas in the untreated controls there was considerable histologic deterioration. In 5 of the 10 patients treated with 9 million units of interferon whose alanine aminotransferase values became normal, the biochemical responses persisted for up to 4 years (mean, 39 months), but the effects of treatment on viral replication were not sustained. In contrast, none of those who received 3 million units and none of the untreated controls had a sustained biochemical or virologic response. Conclusions. In about half the patients with chronic hepatitis D treated with high doses of interferon alfa-2a (9 million units three times a week for 48 weeks), the serum alanine aminotransferase level becomes normal, HDV RNA becomes undetectable in serum, and there is histologic improvement. However, a relapse is common after treatment has been stopped.	ROCHE SPA,CLIN RES,MILAN,ITALY; UNIV CAGLIARI,IST MED INTERNA,I-09100 CAGLIARI,ITALY; CATHOLIC UNIV LEUVEN,DEPT PATHOL,B-3000 LOUVAIN,BELGIUM; UNIV CATANIA,IST MED INTERNA,I-95124 CATANIA,ITALY; F HOFFMANN LA ROCHE & CO LTD,CLIN RES,CH-4002 BASEL,SWITZERLAND	Roche Holding; University of Cagliari; KU Leuven; University of Catania; Roche Holding			scaccabarozzi, Sergio/ABH-3719-2020	scaccabarozzi, Sergio/0000-0003-0682-4871; Van Eyken, Peter/0000-0002-2086-8582; Coiana, Alessandra/0000-0002-1039-5486				BARON S, 1991, JAMA-J AM MED ASSOC, V266, P1375, DOI 10.1001/jama.266.10.1375; Bonino F, 1987, Prog Clin Biol Res, V234, P145; CHELEY S, 1984, ANAL BIOCHEM, V137, P15, DOI 10.1016/0003-2697(84)90339-7; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1990, J HEPATOL, V11, pS151, DOI 10.1016/0168-8278(90)90185-T; DORR RT, 1993, DRUGS, V45, P177, DOI 10.2165/00003495-199345020-00003; FARCI P, 1989, Q J MED, V73, P1045; FARCI P, 1986, JAMA-J AM MED ASSOC, V255, P1443, DOI 10.1001/jama.255.11.1443; FARCI P, 1991, PROG CLIN BIOL RES, V364, P41; HADZIYANNIS SJ, 1991, J HEPATOL, V13, pS21, DOI 10.1016/0168-8278(91)91716-T; HENNES U, 1987, J BIOL STAND, V15, P231, DOI 10.1016/0092-1157(87)90026-6; Hoofnagle J, 1987, Prog Clin Biol Res, V234, P291; HOOFNAGLE JH, 1989, JAMA-J AM MED ASSOC, V261, P3552; HOOFNAGLE JH, 1989, JAMA-J AM MED ASSOC, V261, P1321, DOI 10.1001/jama.261.9.1321; HOOFNAGLE JH, 1988, VIRAL HEPATITIS LIVE, P823; KATKOV WN, 1991, SEMIN LIVER DIS, V11, P165, DOI 10.1055/s-2008-1040433; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; LAI ME, 1989, BLOOD, V73, P17; MARINUCCI G, 1991, PROG CLIN BIOL RES, V364, P405; PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503; PETERS M, 1989, SEMIN LIVER DIS, V9, P235, DOI 10.1055/s-2008-1040516; PORRES JC, 1989, J HEPATOL, V9, P338, DOI 10.1016/0168-8278(89)90143-8; PURCELL RH, 1990, FIELDS VIROLOGY, V2, P2275; RIZZETTO M, 1986, PROG LIVER DIS, V8, P417; RIZZETTO M, 1983, ANN INTERN MED, V98, P437, DOI 10.7326/0003-4819-98-4-437; RIZZETTO M, 1985, J HEPATOL, V1, P187, DOI 10.1016/S0168-8278(85)80766-2; Rosina F, 1987, Prog Clin Biol Res, V234, P299; ROSINA F, 1991, HEPATOLOGY, V13, P1052; SARACCO G, 1987, J HEPATOL, V5, P274, DOI 10.1016/S0168-8278(87)80032-6; SMEDILE A, 1982, LANCET, V2, P945, DOI 10.1016/S0140-6736(82)90156-8; TAYLOR J, 1990, SEMIN VIROL, V1, P135; Thomas H C, 1987, Prog Clin Biol Res, V234, P277; THOMAS HC, 1982, HEPATOLOGY, V2, pS116; VANDENOORD JJ, 1986, HEPATOLOGY, V6, P981, DOI 10.1002/hep.1840060529	34	243	255	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 13	1994	330	2					88	94		10.1056/NEJM199401133300202	http://dx.doi.org/10.1056/NEJM199401133300202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ670	8259188				2022-12-28	WOS:A1994MQ67000002
J	MCCORMACK, WM				MCCORMACK, WM			PELVIC INFLAMMATORY DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SEXUALLY-TRANSMITTED DISEASES; CHLAMYDIA-TRACHOMATIS; NEISSERIA-GONORRHOEAE; OUTPATIENT TREATMENT; ACUTE SALPINGITIS; UNITED-STATES; WOMEN; RISK; INFERTILITY; ASSOCIATION		SUNY HLTH SCI CTR,DEPT OBSTET & GYNECOL,BROOKLYN,NY	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	MCCORMACK, WM (corresponding author), SUNY HLTH SCI CTR,DEPT MED,BOX 56,450 CLARKSON AVE,BROOKLYN,NY 11203, USA.							ARAL SO, 1991, JAMA-J AM MED ASSOC, V266, P2570, DOI 10.1001/jama.266.18.2570; BELL TA, 1984, SEX TRANSM DIS, V11, P291, DOI 10.1097/00007435-198410000-00005; BOWIE WR, 1981, ANN INTERN MED, V95, P685, DOI 10.7326/0003-4819-95-6-685; CATES W, 1990, EPIDEMIOL REV, V12, P199, DOI 10.1093/oxfordjournals.epirev.a036054; CHOW JM, 1990, JAMA-J AM MED ASSOC, V263, P3164, DOI 10.1001/jama.263.23.3164; ESCHENBACH DA, 1988, AM J OBSTET GYNECOL, V158, P819, DOI 10.1016/0002-9378(88)90078-6; ESCHENBACH DA, 1975, NEW ENGL J MED, V293, P166, DOI 10.1056/NEJM197507242930403; FORREST KA, 1989, J NATL MED ASSOC, V81, P159; GILSTRAP LC, 1977, JAMA-J AM MED ASSOC, V238, P965, DOI 10.1001/jama.238.9.965; GRIMES DA, 1987, CONTRACEPTION, V36, P97, DOI 10.1016/0010-7824(87)90063-1; GRIMES DA, 1990, SEXUALLY TRANSMITTED, P1087; HASSELQUIST MB, 1991, SEX TRANSM DIS, V18, P146, DOI 10.1097/00007435-199107000-00004; HOEGSBERG B, 1990, AM J OBSTET GYNECOL, V163, P1135, DOI 10.1016/0002-9378(90)90671-S; JACOBSON L, 1969, AM J OBSTET GYNECOL, V105, P1088, DOI 10.1016/0002-9378(69)90132-X; JONES RB, 1982, FERTIL STERIL, V38, P553; KAHN JG, 1991, JAMA-J AM MED ASSOC, V266, P2594, DOI 10.1001/jama.266.18.2594; LANDERS DV, 1991, AM J OBSTET GYNECOL, V164, P849, DOI 10.1016/0002-9378(91)90528-Y; MCCORMACK WM, 1977, SEX TRANSM DIS, V4, P125, DOI 10.1097/00007435-197710000-00001; MOORE DE, 1982, LANCET, V2, P574; PAAVONEN J, 1985, AM J OBSTET GYNECOL, V151, P645, DOI 10.1016/0002-9378(85)90156-5; PATTEN RM, 1990, J ULTRAS MED, V9, P681; PLATT R, 1983, JAMA-J AM MED ASSOC, V250, P3205, DOI 10.1001/jama.250.23.3205; ROLFS RT, 1992, AM J OBSTET GYNECOL, V166, P983, DOI 10.1016/0002-9378(92)91377-M; SCHOLES D, 1990, AM J EPIDEMIOL, V132, P759; SELLORS J, 1991, AM J OBSTET GYNECOL, V164, P113, DOI 10.1016/0002-9378(91)90639-9; STAMM WE, 1984, NEW ENGL J MED, V310, P545, DOI 10.1056/NEJM198403013100901; SWEET RL, 1983, JAMA-J AM MED ASSOC, V250, P2641, DOI 10.1001/jama.250.19.2641; SWEET RL, 1986, JAMA-J AM MED ASSOC, V255, P2062, DOI 10.1001/jama.255.15.2062; SWEET RL, 1979, AM J OBSTET GYNECOL, V134, P68, DOI 10.1016/0002-9378(79)90798-1; THOMPSON SE, 1985, AM J OBSTET GYNECOL, V152, P635, DOI 10.1016/S0002-9378(85)80036-3; WASHINGTON AE, 1991, JAMA-J AM MED ASSOC, V266, P2565, DOI 10.1001/jama.266.18.2565; WASSERHEIT J N, 1987, MMJ (Maryland Medical Journal), V36, P58; WASSERHEIT JN, 1986, ANN INTERN MED, V104, P187, DOI 10.7326/0003-4819-104-2-187; WESTROM L, 1980, AM J OBSTET GYNECOL, V138, P880, DOI 10.1016/0002-9378(80)91077-7; WESTROM L, 1992, SEX TRANSM DIS, V19, P185, DOI 10.1097/00007435-199207000-00001; WESTROM L, 1975, AM J OBSTET GYNECOL, V121, P707, DOI 10.1016/0002-9378(75)90477-9; WOLNERHANSSEN P, 1990, JAMA-J AM MED ASSOC, V263, P1936, DOI 10.1001/jama.263.14.1936; WOLNERHANSSEN P, 1990, JAMA-J AM MED ASSOC, V263, P54, DOI 10.1001/jama.263.1.54; WOLNERHANSSEN P, 1988, OBSTET GYNECOL, V71, P595; WOLNERHANSSEN P, 1990, SEXUALLY TRANSMITTED, P615; 1991, MMWR MORB MORTAL WKL, V40, P1; 1991, SEX TRANSM DIS, V18, P46; 1993, MMWR MORB MORTAL WKL, V42, P75	43	92	97	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 13	1994	330	2					115	119		10.1056/NEJM199401133300207	http://dx.doi.org/10.1056/NEJM199401133300207			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ670	8259168				2022-12-28	WOS:A1994MQ67000007
J	DOMBROWICZ, D; FLAMAND, V; BRIGMAN, KK; KOLLER, BH; KINET, JP				DOMBROWICZ, D; FLAMAND, V; BRIGMAN, KK; KOLLER, BH; KINET, JP			ABOLITION OF ANAPHYLAXIS BY TARGETED DISRUPTION OF THE HIGH-AFFINITY IMMUNOGLOBULIN-E RECEPTOR ALPHA-CHAIN GENE	CELL			English	Article							FC-EPSILON-RI; MOUSE MAST-CELLS; IMMEDIATE HYPERSENSITIVITY REACTIONS; EPIDERMAL LANGERHANS CELLS; IGE RECEPTOR; SURFACE EXPRESSION; TRANSFECTED CELLS; BONE-MARROW; RESISTANCE; MICE	Mast cells and basophils, which are activated by immunoglobulin E (IgE) and allergen, play a prominent role in anaphylaxis. However, they express at least three types of IgE receptor, including the high affinity IgE receptor (FcepsilonRI). The relative contribution of these IgE receptors, and possibly other receptors such as FcepsilonRII/CD23 and Mac-2, to the genesis of in vivo anaphylaxis is still unclear. To address this question, we have generated FcepsilonRI-deficient mice. These mice appear normal and express a normal number of mast cells, but they are resistant to cutaneous and systemic anaphylaxis. These data demonstrate that FcepsilonRI is necessary for the initiation of IgE-dependent anaphylactic reactions. Therefore, interfering with its function should be an effective means of treating allergy, regardless of the allergen specificity.	UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill	DOMBROWICZ, D (corresponding author), NIAID,MOLEC ALLERGY & IMMUNOL SECT,ROCKVILLE,MD 20852, USA.		Dombrowicz, David/F-7044-2013	Dombrowicz, David/0000-0002-0485-8923; Flamand, Veronique/0000-0002-8906-3758	NIDDK NIH HHS [R01 DK 46003-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046003] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDE A, 1993, J CLIN INVEST, V92, P1639; ASHMAN RI, 1991, J IMMUNOL, V146, P211; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BLANK U, 1991, J BIOL CHEM, V266, P2639; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CHEN SSA, 1991, J IMMUNOL, V147, P1581; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; CONRAD DH, 1990, ANNU REV IMMUNOL, V8, P623, DOI 10.1146/annurev.immunol.8.1.623; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DUNNE DW, 1992, EUR J IMMUNOL, V22, P1483, DOI 10.1002/eji.1830220622; FRIGERI LG, 1992, J IMMUNOL, V148, P861; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; HABA S, 1985, J IMMUNOL, V134, P3291; HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243a0; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; ISHIZAKA K, 1989, CURR OPIN IMMUNOL, V4, P625; KATZ HR, 1992, J IMMUNOL, V148, P868; KINET JP, 1992, CURR OPIN IMMUNOL, V4, P43, DOI 10.1016/0952-7915(92)90122-U; KINET JP, 1992, INFLAMMATION BASIC P, P701; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; MARTIN TR, 1993, J IMMUNOL, V151, P367; MAURER D, UNPUB HUMAN PERIPHER; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; RA C, 1989, J BIOL CHEM, V264, P15323; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RIHET P, 1991, EUR J IMMUNOL, V21, P2679, DOI 10.1002/eji.1830211106; ROBERTSON MW, 1993, J BIOL CHEM, V268, P12736; ROTTEM M, 1992, BLOOD, V79, P972; SERAFIN WE, 1987, NEW ENGL J MED, V317, P30, DOI 10.1056/NEJM198707023170106; TAKIZAWA F, 1992, J EXP MED, V176, P469, DOI 10.1084/jem.176.2.469; TEPLER I, 1989, J BIOL CHEM, V264, P5912; THOMPSON HL, 1990, J CLIN INVEST, V85, P1227, DOI 10.1172/JCI114557; TRUONG MJ, 1993, J EXP MED, V177, P243, DOI 10.1084/jem.177.1.243; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WERSHIL BK, 1987, J IMMUNOL, V139, P2605; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; YE ZS, 1992, J IMMUNOL, V149, P897	43	319	327	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 3	1993	75	5					969	976		10.1016/0092-8674(93)90540-7	http://dx.doi.org/10.1016/0092-8674(93)90540-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252632	Bronze			2022-12-28	WOS:A1993MK96600016
J	ROSS, W; GOSINK, KK; SALOMON, J; IGARASHI, K; ZOU, C; ISHIHAMA, A; SEVERINOV, K; GOURSE, RL				ROSS, W; GOSINK, KK; SALOMON, J; IGARASHI, K; ZOU, C; ISHIHAMA, A; SEVERINOV, K; GOURSE, RL			A 3RD RECOGNITION ELEMENT IN BACTERIAL PROMOTERS - DNA-BINDING BY THE ALPHA-SUBUNIT OF RNA-POLYMERASE	SCIENCE			English	Article							FACTOR-INDEPENDENT ACTIVATION; COLI GALACTOSE OPERON; RRNB P1 PROMOTER; ESCHERICHIA-COLI; RIBOSOMAL-RNA; TRANSCRIPTION ACTIVATION; UPSTREAM ACTIVATION; BACILLUS-SUBTILIS; INVITRO TRANSCRIPTION; FEEDBACK-REGULATION	A DNA sequence rich in (A + T), located upstream of the -10, -35 region of the Escherichia coli ribosomal RNA promoter rrnB P1 and called the UP element, stimulates transcription by a factor of 30 in vivo, as well as in vitro in the absence of protein factors other than RNA polymerase (RNAP). When fused to other promoters, such as lacUV5, the UP element also stimulates transcription, indicating that it is a separable promoter module. Mutations in the carboxyl-terminal region of the alpha subunit of RNAP prevent stimulation of these promoters by the UP element although the mutant enzymes are effective in transcribing the ''core'' promoters (those lacking the UP element). Protection of UP element DNA by the mutant RNAPs is severely reduced in footprinting experiments, suggesting that the selective decrease in transcription might result from defective interactions between alpha and the UP element. Purified alpha binds specifically to the UP element, confirming that alpha acts directly in promoter recognition. Transcription of three other promoters was also reduced by the COOH-terminal alpha mutations. These results suggest that UP elements comprise a third promoter recognition region (in addition to the -10, -35 recognition hexamers, which interact with the sigma subunit) and may account for the presence of (A + T)-rich DNA upstream of many prokaryotic promoters. Since the same alpha mutations also block activation by some transcription factors, mechanisms of promoter stimulation by upstream DNA elements and positive control by certain transcription factors may be related.	UNIV WISCONSIN,DEPT BACTERIOL,1550 LINDEN DR,MADISON,WI 53706; NATL INST GENET,DEPT MOLEC GENET,MISHIMA,SHIZUOKA 411,JAPAN; PUBL HLTH RES INST CITY NEW YORK INC,NEW YORK,NY 10016	University of Wisconsin System; University of Wisconsin Madison; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan			Severinov, Konstantin/C-8545-2016	Igarashi, Kazuhiko/0000-0002-2470-2475	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037048, R01GM049242] Funding Source: NIH RePORTER; NIAID NIH HHS [AI90035] Funding Source: Medline; NIGMS NIH HHS [GM49242, R01 GM37048] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANNER CDB, 1983, J MOL BIOL, V168, P351, DOI 10.1016/S0022-2836(83)80023-0; BARTLETT MS, UNPUB; BAUER BF, 1988, GENE, V63, P123, DOI 10.1016/0378-1119(88)90551-3; BERTRANDBURGGRAF E, 1990, EMBO J, V9, P2265, DOI 10.1002/j.1460-2075.1990.tb07397.x; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; Bremer H., 1987, ESCHERICHIA COLI SAL, V2, P1527, DOI [10.1046/j.1365-2486.2000.06017.x, DOI 10.1046/J.1365-2486.2000.06017.X]; BUSBY S, 1987, GENE, V53, P145, DOI 10.1016/0378-1119(87)90002-3; DEUSCHLE U, 1986, EMBO J, V5, P2987, DOI 10.1002/j.1460-2075.1986.tb04596.x; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; FRISBY D, 1991, J BACTERIOL, V173, P7557, DOI 10.1128/jb.173.23.7557-7564.1991; GAAL T, UNPUB; GALAS DJ, 1985, J MOL BIOL, V186, P17; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GARTENBERG MR, 1991, J MOL BIOL, V219, P217, DOI 10.1016/0022-2836(91)90563-L; GEIDUSCHEK EP, 1988, BACTERIOPHAGES, V1, P93; GILADI H, 1992, J MOL BIOL, V227, P985, DOI 10.1016/0022-2836(92)90514-K; GOSINK KK, 1993, J BACTERIOL, V175, P1580, DOI 10.1128/JB.175.6.1580-1589.1993; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; GOURSE RL, 1985, P NATL ACAD SCI USA, V82, P1069, DOI 10.1073/pnas.82.4.1069; GRAVES MC, 1986, J BIOL CHEM, V261, P1409; GUSSIN GN, 1992, J BACTERIOL, V174, P5156, DOI 10.1128/JB.174.15.5156-5160.1992; HAYWARD RS, 1991, J MOL BIOL, V221, P23, DOI 10.1016/0022-2836(91)80197-3; HSU LM, 1991, BIOCHEMISTRY-US, V30, P813, DOI 10.1021/bi00217a035; IGARASHI K, 1991, P NATL ACAD SCI USA, V88, P8958, DOI 10.1073/pnas.88.20.8958; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; IGARASHI K, 1992, J MOL BIOL, V218, P1; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; ISHIHAMA A, 1992, MOL MICROBIOL, V6, P3283, DOI 10.1111/j.1365-2958.1992.tb02196.x; JINKSROBERTSON S, 1983, CELL, V33, P865, DOI 10.1016/0092-8674(83)90029-6; JINKSROBERTSON S, 1987, ESCHERICHIA COLI SAL, P1358; JOSAITIS CA, 1990, BIOCHIM BIOPHYS ACTA, V1050, P307, DOI 10.1016/0167-4781(90)90186-6; JOSAITIS CA, UNPUB; KOLB A, 1993, NUCLEIC ACIDS RES, V21, P319, DOI 10.1093/nar/21.2.319; LAVIGNE M, 1992, J MOL BIOL, V224, P293, DOI 10.1016/0022-2836(92)90995-V; LEE HS, 1993, J BACTERIOL, V175, P2479, DOI 10.1128/JB.175.8.2479-2482.1993; LEIRMO S, 1991, J MOL BIOL, V220, P555, DOI 10.1016/0022-2836(91)90100-K; LUKACSOVICH T, 1989, GENE, V78, P189, DOI 10.1016/0378-1119(89)90328-4; MCALLISTER CF, 1988, J BIOL CHEM, V263, P11743; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; Miller J. H, 1972, EXPT MOL GENETICS; MORITA M, 1979, EUR J BIOCHEM, V97, P435, DOI 10.1111/j.1432-1033.1979.tb13131.x; NACHALIEL N, 1989, NUCLEIC ACIDS RES, V17, P9811, DOI 10.1093/nar/17.23.9811; NEWLANDS JT, 1992, NUCLEIC ACIDS RES, V20, P719, DOI 10.1093/nar/20.4.719; NEWLANDS JT, 1991, J MOL BIOL, V220, P569, DOI 10.1016/0022-2836(91)90101-B; NEWLANDS JT, 1993, J BACTERIOL, V175, P661, DOI 10.1128/JB.175.3.661-668.1993; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; PEREZMARTIN J, 1991, EMBO J, V10, P1375, DOI 10.1002/j.1460-2075.1991.tb07657.x; PETHO A, 1986, BIOCHIM BIOPHYS ACTA, V866, P37, DOI 10.1016/0167-4781(86)90098-9; PLASKON RR, 1987, NUCLEIC ACIDS RES, V15, P785, DOI 10.1093/nar/15.2.785; POLISKY B, 1988, CELL, V55, P929, DOI 10.1016/0092-8674(88)90235-8; RAO L, IN PRESS J MOL BIOL; ROSS W, 1990, EMBO J, V9, P3733, DOI 10.1002/j.1460-2075.1990.tb07586.x; ROSS W, UNPUB; RUSSO FD, 1992, J BIOL CHEM, V267, P14515; SAKUMI K, 1993, J BACTERIOL, V175, P2455, DOI 10.1128/JB.175.8.2455-2457.1993; SHARROCK RA, 1985, P NATL ACAD SCI USA, V82, P5275, DOI 10.1073/pnas.82.16.5275; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; TAO K, 1993, MOL MICROBIOL, V7, P859, DOI 10.1111/j.1365-2958.1993.tb01176.x; ZACHARIAS M, 1992, BIOCHEMISTRY-US, V31, P2621, DOI 10.1021/bi00124a024; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2; ZOU C, 1992, MOL MICROBIOL, V6, P2599, DOI 10.1111/j.1365-2958.1992.tb01437.x; ZUBER P, 1989, J MOL BIOL, V206, P605, DOI 10.1016/0022-2836(89)90569-X	66	639	664	2	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 26	1993	262	5138					1407	1413		10.1126/science.8248780	http://dx.doi.org/10.1126/science.8248780			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ046	8248780				2022-12-28	WOS:A1993MJ04600029
J	CAMERON, DL; WILLIAMS, JT				CAMERON, DL; WILLIAMS, JT			DOPAMINE D1 RECEPTORS FACILITATE TRANSMITTER RELEASE	NATURE			English	Article							RAT SUBSTANTIA NIGRA; POTASSIUM CONDUCTANCE; SYNAPTIC INPUTS; D2 RECEPTORS; NEURONS; AGONIST; ACTIVATION; DEPRESSION; MECHANISM; RESPONSES	A PHYSIOLOGICAL role for the dopamine D1 receptor has been difficult to define, particularly because of its complex pre- and postsynaptic localization in brain areas such as the striatum1. In the midbrain, however, D1 receptors are selectively localized to the terminals of GABA (gamma-aminobutyric acid)-containing afferents2-4. We have studied the actions of these D1 receptors on evoked GABA synaptic potentials recorded intracellularly from dopamine neurons in the ventral tegmental area (VTA). We report here that dopamine augmented GABA(B) inhibitory postsynaptic potentials (i.p.s.ps) in the presence of D2 receptor antagonists. This effect was mimicked by the D1 agonists SKF38393 and SKF82958 and blocked by the D1 antagonists SCH23390 and cis-flupenthixol. No modulation of the GABA(A) synaptic potential was observed. The postsynaptic actions of the GABA(B) agonist, baclofen, were unaffected by SKF38393, SCH23390 or cis-flupenthixol, confirming a presynaptic locus of D1 action. Additionally, D1 antagonists reduced the amplitude of the GABA(B) i.p.s.p. in the absence of D1 agonists. We conclude that dopamine acts tonically at presynaptic D1 receptors on the terminals of afferent GABA neurons to facilitate selectively GABA(B)-mediated neurotransmission in the midbrain.	OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201	Oregon Health & Science University								ARTALEJO CR, 1990, NATURE, V348, P239, DOI 10.1038/348239a0; BALMFORTH AJ, 1990, J NEUROCHEM, V55, P2111, DOI 10.1111/j.1471-4159.1990.tb05803.x; BRAUN AR, 1986, EUR J PHARMACOL, V131, P301, DOI 10.1016/0014-2999(86)90588-1; CARLSON JH, 1987, SYNAPSE, V1, P411, DOI 10.1002/syn.890010505; CHESSELET MF, 1984, NEUROSCIENCE, V12, P347, DOI 10.1016/0306-4522(84)90058-7; CIVELLI O, 1993, ANNU REV PHARMACOL, V33, P281, DOI 10.1146/annurev.pa.33.040193.001433; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; ELIOT LS, 1993, NATURE, V361, P634, DOI 10.1038/361634a0; FILOUX F, 1988, BRAIN RES B, V20, P447; FLORAN B, 1990, NEUROSCI LETT, V116, P136, DOI 10.1016/0304-3940(90)90399-T; GEFFEN LB, 1976, NATURE, V260, P258, DOI 10.1038/260258a0; GOLDSMITH BA, 1991, P NATL ACAD SCI USA, V88, P9021, DOI 10.1073/pnas.88.20.9021; HARRISON MB, 1990, BRAIN RES, V528, P317, DOI 10.1016/0006-8993(90)91674-6; JOHNSON SW, 1992, J NEUROSCI, V12, P2000; JOHNSON SW, 1992, J PHYSIOL-LONDON, V450, P455, DOI 10.1113/jphysiol.1992.sp019136; LACEY MG, 1988, J PHYSIOL-LONDON, V401, P437, DOI 10.1113/jphysiol.1988.sp017171; LACEY MG, 1987, J PHYSIOL-LONDON, V392, P397, DOI 10.1113/jphysiol.1987.sp016787; LLINAS R, 1984, BRAIN RES, V294, P127, DOI 10.1016/0006-8993(84)91316-7; MANSOUR A, 1991, NEUROSCIENCE, V42, P359; MEMO M, 1982, P NATL ACAD SCI-BIOL, V79, P4456, DOI 10.1073/pnas.79.14.4456; MINTZ I, 1991, J NEUROSCI, V11, P3359; MOTTOLA DM, 1992, J PHARMACOL EXP THER, V262, P383; REUBI JC, 1977, NATURE, V268, P652, DOI 10.1038/268652a0; ROBERTSON GS, 1987, TRENDS PHARMACOL SCI, V8, P295, DOI 10.1016/0165-6147(87)90121-0; SUGITA S, 1992, NEUROSCI LETT, V134, P207, DOI 10.1016/0304-3940(92)90518-C; SURMEIER DJ, 1993, TRENDS NEUROSCI, V16, P299, DOI 10.1016/0166-2236(93)90103-S; WEICK BG, 1987, BRAIN RES, V405, P234, DOI 10.1016/0006-8993(87)90293-9; WILLIAMS JT, 1984, NEUROSCIENCE, V13, P137, DOI 10.1016/0306-4522(84)90265-3; ZIOGAS J, 1991, BRIT J PHARMACOL, V103, P1196, DOI 10.1111/j.1476-5381.1991.tb12323.x	29	247	251	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 25	1993	366	6453					344	347		10.1038/366344a0	http://dx.doi.org/10.1038/366344a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ705	8247128				2022-12-28	WOS:A1993MJ70500049
J	ROSS, AM; SIMOONS, ML; LUNDERGAN, C; THOMPSON, M; REINER, J; DEYCHAK, Y; ROHRBECK, S; COYNE, K; WALKER, P; CHO, S; GREENHOUSE, S; LEE, K; GRANGER, C; WILDERMANN, N; FINK, C; HARRY, S; ALLISON, D; DRAOUI, Y; COSTIGAN, G; FOX, D; LEMPEL, M; WILLIAMS, M; ROSS, J; FLOURA, R; HICKS, J; VANDEBRAND, M; BALK, A; RODENBURG, L; BAARDMAN, T; HOEKMAN, I; AMO, D; VANOOSTEROM, I; VANHESSEM, G; DEZWART, I; JANSSEN, M; DEPUI, A; TERWOGT, C; HOUWELING, J; CORBEAU, N; IWEMA, J; PAMEIJER, J; DEJONG, R; TOPOL, E; CALIFF, R; ARMSTRONG, PW; AYLWARD, P; BARBASH, G; BATES, E; BETRIU, A; BOISSEL, J; CHESEBRO, J; COL, J; DEBONO, D; GORE, J; GUERCI, A; HAMPTON, A; HIRSH, J; HOLMES, D; HORGAN, J; KLEIMAN, N; MARDER, V; MORRIS, D; OHMAN, M; PFISTERER, M; RUTSCH, W; SADOWSKI, Z; SIMES, J; SIMOONS, ML; VAHANIAN, A; VANDEWERF, F; WEAVER, D; WHITE, H; WILCOX, R; KOPECKY, S; MCLAUGHLIN, A; BOWMAN, R; WASSERMAN, A; SEGAL, J; COYNE, K; WALKER, P; PICKERING, E; COTHAM, P; GABER, J; RIGBY, D; WHITEHEAD, S; PILCHER, G; GREENE, B; HIPPS, A; LANCASTER, L; LANSMAN, D; MITCHELL, J; STEGALL, G; SCHMIDT, P; MILLER, D; NESS, C; KRISHNASWAMI, V; HEYL, A; SIMONELLI, R; KAZMIERSKI, J; THOMPSON, L; HODGSON, J; HLADIK, L; DORCHAK, J; ROBINETTE, T; SMITH, J; HARRAH, L; BROWN, D; MCCARTER, T; GOSSMAN, D; WOODHEAD, G; BATES, E; KLINEROGERS, E; ISRAEL, N; LEBOEUF, R; PERRY, J; SCHVANEVELDT, W; MORRIS, D; BERNARD, W; PARRIS, T; STOAKES, K; SOLBERG, L; BROWN, A; GAINEY, P; GREENBUSH, R; WHITE, C; LEASURE, B; RAZAVI, A; ERTEL, P; HAMILTON, D; BLAKER, A; SHANE, J; SILVERMAN, I; WESZT, S; MCCORMICK, D; LUHMANN, S; JESSE, R; ROBERTS, C; SILVERMAN, I; WESZT, S; OTOOLE, J; HEILMAN, S; ANDRES, P; BAUER, D; LEW, B; MATVYA, C; SCHECHTER, C; KILLEBREW, K; HARNER, R; FISHER, M; SCHECHTER, C; KILLEBREW, K; KAVANAUGH, K; VOSS, M; MEENGS, W; STONE, B; ZIMMERMAN, J; HART, J; HSIEH, A; MCDERMOTT, B; PY, A; VAHANIAN, A; NALLET, O; GROLLIER, G; VALETTE, B; BESSE, P; DURRIEU, C; MOSSARD, M; ARBOGAST, R; BERNADET, P; CARRIE, D; CHARBONNIER, B; ALMANGE, C; LEBRETON, H; DAUBERT, J; CASSAGNES, J; BEAUFILS, P; RAPOPORT, P; JULIARD, J; STEG, G; GUERMONPREZ, J; GUIZE, L; ILIOU, M; GUEROT, C; GRENIER, O; BARRAINE, R; COISNE, D; BASSAND, J; SCHIELE, F; VANDEWERF, F; TENAERTS, P; BOLAND, J; CASTADOT, M; COLSOUL, D; SCHROEDER, E; VANDENHEUVEL, P; MOLHOEK, G; LALISANG, R; MULLER, E; SIMOONS, ML; VANDEBRAND, M; KINT, P; BURTON, J; KEE, C; KELLS, C; FAWCETT, T; FUNG, A; DAVIES, C; THOMPSON, C; HEINRICH, D; ROBSON, L; AYLWARD, P; THOMAS, C; NELSON, GIC; DWYER, B; PFISTERER, M; HAMMERLI, R; DISSMANN, W; TOPP, H; DJONLAGIC, H; KUROWSKI, V; DELCAN, J; GARCIA, E; WALSH, M; WALSH, N; SUGRUE, D				ROSS, AM; SIMOONS, ML; LUNDERGAN, C; THOMPSON, M; REINER, J; DEYCHAK, Y; ROHRBECK, S; COYNE, K; WALKER, P; CHO, S; GREENHOUSE, S; LEE, K; GRANGER, C; WILDERMANN, N; FINK, C; HARRY, S; ALLISON, D; DRAOUI, Y; COSTIGAN, G; FOX, D; LEMPEL, M; WILLIAMS, M; ROSS, J; FLOURA, R; HICKS, J; VANDEBRAND, M; BALK, A; RODENBURG, L; BAARDMAN, T; HOEKMAN, I; AMO, D; VANOOSTEROM, I; VANHESSEM, G; DEZWART, I; JANSSEN, M; DEPUI, A; TERWOGT, C; HOUWELING, J; CORBEAU, N; IWEMA, J; PAMEIJER, J; DEJONG, R; TOPOL, E; CALIFF, R; ARMSTRONG, PW; AYLWARD, P; BARBASH, G; BATES, E; BETRIU, A; BOISSEL, J; CHESEBRO, J; COL, J; DEBONO, D; GORE, J; GUERCI, A; HAMPTON, A; HIRSH, J; HOLMES, D; HORGAN, J; KLEIMAN, N; MARDER, V; MORRIS, D; OHMAN, M; PFISTERER, M; RUTSCH, W; SADOWSKI, Z; SIMES, J; SIMOONS, ML; VAHANIAN, A; VANDEWERF, F; WEAVER, D; WHITE, H; WILCOX, R; KOPECKY, S; MCLAUGHLIN, A; BOWMAN, R; WASSERMAN, A; SEGAL, J; COYNE, K; WALKER, P; PICKERING, E; COTHAM, P; GABER, J; RIGBY, D; WHITEHEAD, S; PILCHER, G; GREENE, B; HIPPS, A; LANCASTER, L; LANSMAN, D; MITCHELL, J; STEGALL, G; SCHMIDT, P; MILLER, D; NESS, C; KRISHNASWAMI, V; HEYL, A; SIMONELLI, R; KAZMIERSKI, J; THOMPSON, L; HODGSON, J; HLADIK, L; DORCHAK, J; ROBINETTE, T; SMITH, J; HARRAH, L; BROWN, D; MCCARTER, T; GOSSMAN, D; WOODHEAD, G; BATES, E; KLINEROGERS, E; ISRAEL, N; LEBOEUF, R; PERRY, J; SCHVANEVELDT, W; MORRIS, D; BERNARD, W; PARRIS, T; STOAKES, K; SOLBERG, L; BROWN, A; GAINEY, P; GREENBUSH, R; WHITE, C; LEASURE, B; RAZAVI, A; ERTEL, P; HAMILTON, D; BLAKER, A; SHANE, J; SILVERMAN, I; WESZT, S; MCCORMICK, D; LUHMANN, S; JESSE, R; ROBERTS, C; SILVERMAN, I; WESZT, S; OTOOLE, J; HEILMAN, S; ANDRES, P; BAUER, D; LEW, B; MATVYA, C; SCHECHTER, C; KILLEBREW, K; HARNER, R; FISHER, M; SCHECHTER, C; KILLEBREW, K; KAVANAUGH, K; VOSS, M; MEENGS, W; STONE, B; ZIMMERMAN, J; HART, J; HSIEH, A; MCDERMOTT, B; PY, A; VAHANIAN, A; NALLET, O; GROLLIER, G; VALETTE, B; BESSE, P; DURRIEU, C; MOSSARD, M; ARBOGAST, R; BERNADET, P; CARRIE, D; CHARBONNIER, B; ALMANGE, C; LEBRETON, H; DAUBERT, J; CASSAGNES, J; BEAUFILS, P; RAPOPORT, P; JULIARD, J; STEG, G; GUERMONPREZ, J; GUIZE, L; ILIOU, M; GUEROT, C; GRENIER, O; BARRAINE, R; COISNE, D; BASSAND, J; SCHIELE, F; VANDEWERF, F; TENAERTS, P; BOLAND, J; CASTADOT, M; COLSOUL, D; SCHROEDER, E; VANDENHEUVEL, P; MOLHOEK, G; LALISANG, R; MULLER, E; SIMOONS, ML; VANDEBRAND, M; KINT, P; BURTON, J; KEE, C; KELLS, C; FAWCETT, T; FUNG, A; DAVIES, C; THOMPSON, C; HEINRICH, D; ROBSON, L; AYLWARD, P; THOMAS, C; NELSON, GIC; DWYER, B; PFISTERER, M; HAMMERLI, R; DISSMANN, W; TOPP, H; DJONLAGIC, H; KUROWSKI, V; DELCAN, J; GARCIA, E; WALSH, M; WALSH, N; SUGRUE, D			THE EFFECTS OF TISSUE-PLASMINOGEN ACTIVATOR, STREPTOKINASE, OR BOTH ON CORONARY-ARTERY PATENCY, VENTRICULAR-FUNCTION, AND SURVIVAL AFTER ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAVENOUS STREPTOKINASE; THROMBOLYTIC THERAPY; INTRACORONARY STREPTOKINASE; PHASE-I; TRIAL; REPERFUSION; TIME; SIZE; ANGIOPLASTY; PREVENTION	Background. Although it is known that thrombolytic therapy improves survival after acute myocardial infarction, it has been debated whether the speed with which coronary-artery patency is restored after the initiation of therapy further affects outcome. Methods. To study this question, we randomly assigned 2431 patients to one of four treatment strategies for reperfusion: streptokinase with subcutaneous heparin; streptokinase with intravenous heparin; accelerated-dose tissue plasminogen activator (t-PA) with intravenous heparin; or a combination of both activators plus intravenous heparin. Patients were also randomly assigned to cardiac angiography at one of four times after the initiation of thrombolytic therapy: 90 minutes, 180 minutes, 24 hours, or 5 to 7 days. The group that underwent angiography at 90 minutes underwent it again after 5 to 7 days. Results. The rate of patency of the infarct-related artery at 90 minutes was highest in the group given accelerated-dose t-PA and heparin (81 percent), as compared with the group given streptokinase and subcutaneous heparin (54 percent, P<0.001), the group given streptokinase and intravenous heparin (60 percent, P<0.001), and the group given combination therapy (73 percent, P = 0.032). Flow through the infarct-related artery at 90 minutes was normal in 54 percent of the group given t-PA and heparin but in less than 40 percent of the three other groups (P<0.001). By 180 minutes, the patency rates were the same in the four treatment groups. Re-occlusion was infrequent and was similar in all four groups (range, 4.9 to 6.4 percent). Measures of left ventricular function paralleled the rate of patency at 90 minutes; ventricular function was best in the group given t-PA with heparin and in patients with normal flow through the infarct-related artery irrespective of treatment group. Mortality at 30 days was lowest (4.4 percent) among patients with normal coronary flow at 90 minutes and highest (8.9 percent) among patients with no flow (P = 0.009). Conclusions. This study supports the hypothesis that more rapid and complete restoration of coronary flow through the infarct-related artery results in improved ventricular performance and lower mortality among patients with myocardial infarction. This would appear to be the mechanism by which accelerated t-PA therapy produced the most favorable outcome in the GUSTO trial.	GEORGE WASHINGTON UNIV, ANGIOG SUBSTUDY COORDINATING CTR, WASHINGTON, DC 20052 USA; GEORGE WASHINGTON UNIV, CORE LAB, WASHINGTON, DC 20052 USA; NON-N AMER ANGIOG COORDINATING CTR CARDIALYSIS, ROTTERDAM, NETHERLANDS; ST MARYS HOSP, ROCHESTER, NY 14611 USA; GEORGE WASHINGTON UNIV HOSP, WASHINGTON, DC 20037 USA; TULSA REG MED CTR, TULSA, OK USA; MCKAY DEE HOSP, OGDEN, UT USA; ST VINCENTS MED CTR, JACKSONVILLE, FL USA; E ALABAMA MED CTR, OPELIKA, AL USA; ST MARYS HOSP, TUCSON, AL USA; PROCTOR COMMUNITY HOSP, PEORIA, IL USA; MERCY HOSP, PITTSBURGH, PA 15219 USA; MT CLEMENS GEN HOSP, MT CLEMENS, MI USA; UNIV HOSP CLEVELAND, CLEVELAND, OH 44106 USA; SPARTENBURG REG MED CTR, SPARTANBURG, SC USA; UNIV COMMUN HOSP, TAMPA, FL USA; HUMANA MED CITY, DALLAS, TX USA; LAHEY CLIN MED CTR, BURLINGTON, MA USA; UNIV MICHIGAN HOSP, ANN ARBOR, MI 48109 USA; MOTHER FRANCES HOSP, TYLER, TX USA; ST MARKS HOSP, SALT LAKE CITY, UT USA; CRAWFORD W LONG MEM HOSP, ATLANTA, GA USA; HAHNEMANN UNIV, PHILADELPHIA, PA 19102 USA; SIOUX VALLEY HOSP, SIOUX FALLS, SD USA; ST JOSEPHS HOSP, SAVANNAH, GA USA; OCHSNER FDN HOSP, NEW ORLEANS, GA USA; GOOD SAMARITAN HOSP, CINCINNATI, OH 45220 USA; MCLEOD REG MED CTR, FLORENCE, SC USA; EVANSTON HOSP CORP, EVANSTON, IL 60201 USA; ST AGNES MED CTR, PHILADELPHIA, PA USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, RICHMOND, VA 23298 USA; GLENBROOK HOSP, GLENVIEW, IL USA; SHADEYSIDE HOSP, PITTSBURGH, PA USA; TERRE HAUTE REG HOSP, TERRE HAUT, IN USA; LUTHERAN HOSP, FT WAYNE, IN USA; MEM MED CTR, CORPUS CHRISTI, TX USA; SWEDISH AMER HOSP, ROCKFORD, IL USA; SPOHN HOSP, CORPUS CHRISTI, TX USA; MCKENNAN HOSP, SIOUX FALLS, SD USA; NO MICHIGAN HOSP, PETOSKEY, MI USA; HACKENSACK MED CTR, HACKENSACK, NJ USA; LAKESIDE VET AFFAIRS MED CTR, CHICAGO, IL USA; HOP COCHIN, F-75674 PARIS 14, FRANCE; HOP TENON, F-75970 PARIS 20, FRANCE; CHU CAEN, F-14033 CAEN, FRANCE; HOP HAUT LEVEQUE, PESSAC, FRANCE; HOP HAUTE PIERRE, STRASBOURG, FRANCE; HOP PURPAN, TOULOUSE, FRANCE; HOP TROUSSEAU, TOURS, FRANCE; HOP HOTEL DIEU, RENNES, FRANCE; CTR HOSP RENNES, RENNES, FRANCE; HOP ST JACQUES, CLERMONT FERRAND, FRANCE; HOP LARIBOISIERE, F-75475 PARIS 10, FRANCE; HOP BICHAT, F-75877 PARIS 18, FRANCE; HOP BROUSSAIS, PARIS, FRANCE; HOP BOUCIAUT VAUGIRARD, PARIS, FRANCE; CHU LA MILETRIE, POITIERS, FRANCE; CTR HOSP REG BESANCON, BESANCON, FRANCE; UNIV ZIEKENHUIS RAPHAEL GASTHUISBERG, LOUVAIN, BELGIUM; HOP CITADELLE, LIEGE, BELGIUM; CLIN GEN ST JEAN, BRUSSELS, BELGIUM; CLIN UNIV MT GODINNE, YVOIR, BELGIUM; AKAD ZIEKENHUIS, ANTWERP, BELGIUM; MED SPECTRUM, ENSCHEDE, NETHERLANDS; SPAARNE ZIEKENHUIS, HEEMSTEDE, NETHERLANDS; DIJKZIGT, ROTTERDAM, NETHERLANDS; UNIV ALBERTA HOSP, EDMONTON T6G 2B7, ALBERTA, CANADA; VICTORIA GEN HOSP, HALIFAX B3H 2Y9, NS, CANADA; ST PAULS HOSP, VANCOUVER, BC, CANADA; FLINDERS UNIV S AUSTRALIA, MED CTR, BEDFORD PK, SA 5042, AUSTRALIA; ROYAL N SHORE HOSP, ST LEONARDS, NSW 2065, AUSTRALIA; UNIV CLIN BASEL, BASEL, SWITZERLAND; KRANKENHAUS URBAN, BERLIN, GERMANY; MED UNIV LUBEK, LUBECK, GERMANY; HOSP GEN GREGORIO MARANON, MADRID, SPAIN; ST JAMES HOSP, DUBLIN 8, IRELAND; MATER HOSP, DUBLIN, IRELAND	George Washington University; George Washington University; George Washington University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University Hospitals of Cleveland; Medical City Dallas Hospital; Lahey Hospital & Medical Center; University of Michigan System; University of Michigan; Drexel University; Good Samaritan Hospital - Cincinnati; NorthShore University Health System; Virginia Commonwealth University; NorthShore University Health System; Hackensack University Medical Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU de Caen NORMANDIE; Universite de Caen Normandie; CHU Bordeaux; CHU Strasbourg; CHU de Toulouse; CHU Tours; CHU Rennes; CHU Rennes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Poitiers; Universite de Poitiers; Universite de Franche-Comte; CHU Besancon; Universite Catholique Louvain; Universite Catholique Louvain Hospital; Medical Spectrum Twente; Spaarne Hospital; University of Alberta; Dalhousie University; University of Victoria; St. Paul's Hospital; University of Saskatchewan; Flinders University South Australia; Royal North Shore Hospital; University of Basel; General University Gregorio Maranon Hospital; Trinity College Dublin; Mater Misericordiae University Hospital; University College Dublin	ROSS, AM (corresponding author), GEORGE WASHINGTON UNIV, DIV CARDIOL, 2150 PENN AVE NW, WASHINGTON, DC 20037 USA.		Simes, Robert John/P-1497-2014; gaber, jaafar/B-1642-2010; Smith, Jane/B-6254-2009	gaber, jaafar/0000-0003-4356-6760; 				[Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1986, LANCET, V1, P397; BATES ER, 1989, J AM COLL CARDIOL, V13, P12, DOI 10.1016/0735-1097(89)90542-1; BELENKIE I, 1989, AM J CARDIOL, V63, P912, DOI 10.1016/0002-9149(89)90138-0; BOLSON EL, 1981, COMPUT CARDIOL, P245; CARNEY R, 1990, CIRCULATION, V82, P538; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; Conover WJ, 1980, PRACTICAL NONPARAMET, P229; DAVIES GJ, 1984, NEW ENGL J MED, V311, P1488, DOI 10.1056/NEJM198412063112306; DEBONO DP, 1992, BRIT HEART J, V67, P122; DODGE HT, 1960, AM HEART J, V60, P762, DOI 10.1016/0002-8703(60)90359-8; ELLIS SG, 1983, J AM COLL CARDIOL, V1, P1047, DOI 10.1016/S0735-1097(83)80107-7; HSIA J, 1992, J AM COLL CARDIOL, V20, P31, DOI 10.1016/0735-1097(92)90133-8; KARAGOUNIS L, 1992, J AM COLL CARDIOL, V19, P1, DOI 10.1016/0735-1097(92)90043-M; KOREN G, 1985, NEW ENGL J MED, V313, P1384, DOI 10.1056/NEJM198511283132204; MATHEY DG, 1985, J AM COLL CARDIOL, V6, P518, DOI 10.1016/S0735-1097(85)80107-8; MORGAN CD, 1991, J AM COLL CARDIOL, V17, P1451, DOI 10.1016/0735-1097(91)90630-R; NETER J, 1985, APPLIED LINEAR STATI, P950; NEUHAUS KL, 1989, J AM COLL CARDIOL, V14, P1566, DOI 10.1016/0735-1097(89)90399-9; OHMAN EM, 1990, CIRCULATION, V82, P781, DOI 10.1161/01.CIR.82.3.781; SCHMIDT SB, 1986, CIRCULATION, V73, P1354, DOI 10.1161/01.CIR.73.6.1354; SERRUYS PW, 1988, CIRCULATION, V77, P361, DOI 10.1161/01.CIR.77.2.361; SHEEHAN FH, 1987, CIRCULATION, V75, P817, DOI 10.1161/01.CIR.75.4.817; STACK RS, 1983, J CLIN INVEST, V72, P84, DOI 10.1172/JCI110987; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VANDEWERF F, 1989, LANCET, V1, P1367; VERSTRAETE M, 1985, LANCET, V1, P842, DOI 10.1016/S0140-6736(85)92208-1; VOGT A, 1993, J AM COLL CARDIOL, V21, P1391, DOI 10.1016/0735-1097(93)90314-Q; 1993, LANCET, V339, P753	29	1623	1672	0	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1993	329	22					1615	1622						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ546	8232430				2022-12-28	WOS:A1993MJ54600004
J	LOSICK, R; SHAPIRO, L				LOSICK, R; SHAPIRO, L			CHECKPOINTS THAT COUPLE GENE-EXPRESSION TO MORPHOGENESIS	SCIENCE			English	Article							SALMONELLA-TYPHIMURIUM; SIGMA-FACTOR; FLAGELLIN SYNTHESIS; SUBTILIS; REGULON		STANFORD UNIV,MED CTR,SCH MED,BECKMAN CTR,DEPT DEV BIOL,STANFORD,CA 94305	Stanford University	LOSICK, R (corresponding author), HARVARD UNIV,BIOL LABS,16 DIVIN AVE,CAMBRIDGE,MA 02138, USA.							ARNOSTI DN, 1989, P NATL ACAD SCI USA, V86, P830, DOI 10.1073/pnas.86.3.830; CHATER KF, 1989, CELL, V59, P133, DOI 10.1016/0092-8674(89)90876-3; CUTTING S, 1990, CELL, V62, P239, DOI 10.1016/0092-8674(90)90362-I; DREYFUS G, 1993, J BACTERIOL, V175, P3131, DOI 10.1128/JB.175.10.3131-3138.1993; GILLEN KL, 1991, J BACTERIOL, V173, P2301, DOI 10.1128/JB.173.7.2301-2310.1991; GILLEN KL, 1991, J BACTERIOL, V173, P6453, DOI 10.1128/jb.173.20.6453-6459.1991; HUGHES KT, 1993, SCIENCE, V262, P1277, DOI 10.1126/science.8235660; KAISER D, 1993, CELL, V73, P873, DOI 10.1016/0092-8674(93)90268-U; KUTSUKAKE K, 1990, J BACTERIOL, V172, P741, DOI 10.1128/jb.172.2.741-747.1990; KUTSUKAKE K, 1992, 15TH ANN M JAP SOC M; MACNAB RM, 1992, ANNU REV GENET, V26, P131, DOI 10.1146/annurev.ge.26.120192.001023; OHNISHI K, 1990, MOL GEN GENET, V221, P139, DOI 10.1007/BF00261713; OHNISHI K, 1992, MOL MICROBIOL, V6, P3149, DOI 10.1111/j.1365-2958.1992.tb01771.x; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; SAGER B, 1993, P NATL ACAD SCI USA, V90, P3690, DOI 10.1073/pnas.90.8.3690; YOUNG VB, 1990, MOL MICROBIOL, V4, P1119, DOI 10.1111/j.1365-2958.1990.tb00686.x	16	26	26	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1227	1228		10.1126/science.8235653	http://dx.doi.org/10.1126/science.8235653			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	8235653				2022-12-28	WOS:A1993MH32400028
J	TAKIZAWA, PA; MALHOTRA, V				TAKIZAWA, PA; MALHOTRA, V			COATOMERS AND SNARES IN PROMOTING MEMBRANE TRAFFIC	CELL			English	Review							COATED VESICLES; BETA-ADAPTIN; BREFELDIN-A				TAKIZAWA, PA (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.		Malhotra, Vivek/O-9811-2014	Malhotra, Vivek/0000-0001-6198-7943				Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, IN PRESS EMBO J; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; DDONALDSON JG, 1992, NATURE, V360, P350; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; FLEMING AM, 1993, CELL, V74, P863; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; POPOV SV, 1993, CELL, V73, P1247, DOI 10.1016/0092-8674(93)90352-Q; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SALAMA NR, 1993, IN PRESS EMBO J; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644; ZIMMERBERG J, 1993, ANNU REV BIOPH BIOM, V22, P433, DOI 10.1146/annurev.bb.22.060193.002245	29	36	36	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					593	596		10.1016/0092-8674(93)90477-8	http://dx.doi.org/10.1016/0092-8674(93)90477-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242734	Bronze			2022-12-28	WOS:A1993MH74900002
J	VONRUDEN, L; NEHER, E				VONRUDEN, L; NEHER, E			A CA-DEPENDENT EARLY STEP IN THE RELEASE OF CATECHOLAMINES FROM ADRENAL CHROMAFFIN CELLS	SCIENCE			English	Article							PATCH-CLAMP TECHNIQUES; CALCIUM; EXOCYTOSIS; SECRETION; PHOSPHORYLATION; RESOLUTION; ACTIVATION; CHANNELS; PROTEINS; CA-2+	Intense stimuli, such as trains of depolarizing pulses or the caffeine-induced release of calcium from intracellular stores, readily depress the secretory response in neuroendocrine cells. Secretory responses are restored by rest periods of minutes in duration. This recovery was accelerated when the concentration of cytosolic calcium was moderately increased and probably resulted from calcium-dependent replenishment of a pool of release-ready granules. Continuously increased concentrations of calcium led to the over-filling of such a pool. Subsequently, secretory responses to stronger calcium stimuli were augmented. Hormone-induced calcium transients with a plateau phase of increased concentration of calcium may enhance the secretory response in this way.	MAX PLANCK INST BIOPHYS CHEM,DEPT MEMBRANE BIOPHYS,AM FASSBERG,D-37077 GOTTINGEN,GERMANY	Max Planck Society			Neher, Erwin/A-2109-2013					ARTALEJO CR, 1991, J PHYSIOL-LONDON, V444, P213, DOI 10.1113/jphysiol.1991.sp018874; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; BOOKMAN RJ, 1992, ANN NY ACAD SCI, V635, P352; BYERLY L, 1988, CALCIUM CHANNEL MODU; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; ECKERT R, 1984, PROG BIOPHYS MOL BIO, V44, P215, DOI 10.1016/0079-6107(84)90009-9; FIDLER N, 1990, NATURE, V344, P499; FIRESTONE JA, 1992, J NEUROCHEM, V58, P441, DOI 10.1111/j.1471-4159.1992.tb09741.x; GILLIS KD, 1992, PFLUG ARCH EUR J PHY, V420, P121, DOI 10.1007/BF00378654; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAYCOCK JW, 1988, J NEUROSCI, V8, P3233; HEINEMANN C, 1993, PFLUG ARCH EUR J PHY, V424, P105, DOI 10.1007/BF00374600; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; KELLY RB, 1993, NEURON S, V10, P43; LINDAU M, 1992, BIOPHYS J, V61, P19, DOI 10.1016/S0006-3495(92)81812-X; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; LIU PS, 1991, J NEUROCHEM, V56, P172, DOI 10.1111/j.1471-4159.1991.tb02577.x; MELDOLESI J, 1991, TRENDS PHARMACOL SCI, V12, P289, DOI 10.1016/0165-6147(91)90577-F; MORO MA, 1990, ANAL BIOCHEM, V185, P243, DOI 10.1016/0003-2697(90)90287-J; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; PENNER R, 1987, BIOSCIENCE REP, V7, P313, DOI 10.1007/BF01121453; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; SAGE S O, 1992, Current Biology, V2, P312, DOI 10.1016/0960-9822(92)90885-E; SARAFIAN T, 1987, J BIOL CHEM, V262, P16671; THOMAS P, 1993, EMBO J, V12, P303, DOI 10.1002/j.1460-2075.1993.tb05657.x; THOMAS P, 1990, NEURON, V5, P723, DOI 10.1016/0896-6273(90)90226-6; TSE A, 1993, SCIENCE, V260, P82, DOI 10.1126/science.8385366; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754	35	275	277	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1061	1065		10.1126/science.8235626	http://dx.doi.org/10.1126/science.8235626			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	8235626				2022-12-28	WOS:A1993MG18700038
J	JIANG, Y; ROSSI, G; FERRONOVICK, S				JIANG, Y; ROSSI, G; FERRONOVICK, S			BET2P AND MAD2P ARE COMPONENTS OF A PRENYLTRANSFERASE THAT ADDS GERANYLGERANYL ONTO YPT1P AND SEC4P	NATURE			English	Article							GTP-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; VESICULAR TRANSPORT; GENE-PRODUCT; YEAST; FARNESYLTRANSFERASE; TRANSFERASE; CYS; DEPENDENCE; SECRETION	THREE different prenyltransferases have been identified in yeast and higher cells1-6, the farnesyltransferase and the type I and type II geranylgeranyltransferases (GGTase). The farnesyltransferase and GGTase-I modify peptides in vitro with the CAAX (C, Cys; A, aliphatic residue; X, terminal amino acid) consensus motif2,7. These enzymes are heterodimers that have different beta-subunits and a shared alpha-subunit8. In yeast, the RAM2 gene encodes this alpha-subunit9. RAM2 is also homologous to MAD2, a yeast gene whose product has been implicated in the feedback control of mitosis10,11. We have shown that Bet2p is a component of the yeast GGTase-II (refs 6, 12) that geranylgeranylates Ypt1p, a small GTP-binding protein that mediates transport from the endoplasmic reticulum to the Golgi complex13-15. Here we report that Mad2p is a component of this enzyme. Bet2p forms a complex with Mad2p that appears to bind geranylgeranyl pyrophosphate, but not farnesyl pyrophosphate. The efficient transfer of geranylgeranyl onto small GTP-binding proteins requires the presence of an additional activity.	YALE UNIV,SCH MED,DEPT CELL BIOL,333 CEDAR ST,NEW HAVEN,CT 06510	Yale University								ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARAKI S, 1990, J BIOL CHEM, V265, P13007; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BOGUSKI MS, 1992, NEW BIOL, V4, P1; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; KOHL NE, 1991, J BIOL CHEM, V266, P18884; LI R, 1993, NATURE, V366, P82, DOI 10.1038/366082a0; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; MAYER ML, 1992, J BIOL CHEM, V267, P20589; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; NEWMAN AP, 1987, J CELL BIOL, V105, P1587, DOI 10.1083/jcb.105.4.1587; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; WAGNER P, 1987, EMBO J, V6, P2373, DOI 10.1002/j.1460-2075.1987.tb02514.x; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017	27	55	61	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 4	1993	366	6450					84	86		10.1038/366084a0	http://dx.doi.org/10.1038/366084a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF007	8232542				2022-12-28	WOS:A1993MF00700061
J	LIU, B; WONG, ML; TINKER, RL; GEIDUSCHEK, EP; ALBERTS, BM				LIU, B; WONG, ML; TINKER, RL; GEIDUSCHEK, EP; ALBERTS, BM			THE DNA-REPLICATION FORK CAN PASS RNA-POLYMERASE WITHOUT DISPLACING THE NASCENT TRANSCRIPT	NATURE			English	Article							ESCHERICHIA-COLI; MAGNETIC-RESONANCE; TERNARY COMPLEXES; LATE PROMOTERS; BACTERIOPHAGE-T4; PROTEIN; INITIATION; ELONGATION; SITE; TERMINATION	Replication proteins encoded by bacteriophage T4 generate DNA replication forks that can pass a molecule of Escherichia coli RNA polymerase moving in the same direction as the fork in vitro. The RNA polymerase ternary transcription complex remains bound to the DNA and retains a transcription bubble after the fork passes. The by-passed ternary complex can resume faithful RNA synthesis, suggesting that the multisubunit RNA polymerase of E. coli has evolved to retain its transcript after DNA replication, allowing partially completed transcripts to be elongated into full-length RNA molecules.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Diego; University of California System; University of California San Francisco								ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; BEAN BL, 1977, BIOCHEMISTRY-US, V16, P3322, DOI 10.1021/bi00634a007; BEDINGER P, 1983, CELL, V34, P115, DOI 10.1016/0092-8674(83)90141-1; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BREMER H, 1987, CELLULAR MOL BIOL, P1527; CHA TA, 1986, J BIOL CHEM, V261, P7001; Chamberlin M., 1976, RNA POLYMERASE BOOK, P17; CHRISTENSEN AC, 1983, BACTERIOPHAGE T, V4, P184; DUBOCHET J, 1971, J ULTRA MOL STRUCT R, V35, P147, DOI 10.1016/S0022-5320(71)80148-X; FISHER R, 1982, J BIOL CHEM, V257, P1702; FRENCH S, 1992, SCIENCE, V258, P1362, DOI 10.1126/science.1455232; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GRALLA JD, 1985, P NATL ACAD SCI USA, V82, P3078, DOI 10.1073/pnas.82.10.3078; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HINKLE DC, 1972, J MOL BIOL, V70, P197, DOI 10.1016/0022-2836(72)90533-5; HIROSE S, 1983, MOL GEN GENET, V189, P422, DOI 10.1007/BF00325904; IDE H, 1985, NUCLEIC ACIDS RES, V13, P8035, DOI 10.1093/nar/13.22.8035; JOE JH, 1985, J MOL BIOL, V184, P441; Johnston D. E., 1976, RNA POLYMERASE, P413; KASSAVETIS GA, 1982, EMBO J, V1, P107, DOI 10.1002/j.1460-2075.1982.tb01132.x; KASSAVETIS GA, 1992, J MOL BIOL, V226, P47, DOI 10.1016/0022-2836(92)90123-2; KASSAVETIS GA, 1984, P NATL ACAD SCI-BIOL, V81, P5101, DOI 10.1073/pnas.81.16.5101; KASSAVETIS GA, 1986, J BIOL CHEM, V261, P14256; Kleinschmidt A.K.=, 1968, METHODS ENZYMOL, V12, P361; KUMAR SA, 1981, PROG BIOPHYS MOL BIO, V38, P165, DOI 10.1016/0079-6107(81)90013-4; KUMAR SA, 1975, J BIOL CHEM, V250, P2879; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MEYER TF, 1979, NATURE, V278, P365, DOI 10.1038/278365a0; MI H, 1983, EUR J BIOCHEM, V131, P113; MORRIS CF, 1979, J BIOL CHEM, V254, P6787; MORRIS CF, 1987, J BIOL CHEM, V254, P6796; NOSSAL NG, 1980, J BIOL CHEM, V255, P2176; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; RICHARDSON JP, 1993, CRIT REV BIOCHEM MOL, V28, P1, DOI 10.3109/10409239309082571; SASSEDWIGHT S, 1988, J MOL BIOL, V202, P107, DOI 10.1016/0022-2836(88)90523-2; SENTENAC A, 1992, TRANSCRIPTIONAL REGU, P27; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; STEIN PJ, 1978, BIOCHEMISTRY-US, V17, P2675, DOI 10.1021/bi00606a034; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WILLIAMS KP, 1987, J BIOL CHEM, V262, P12365; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	47	86	87	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 4	1993	366	6450					33	39		10.1038/366033a0	http://dx.doi.org/10.1038/366033a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF007	8232535				2022-12-28	WOS:A1993MF00700045
J	HOWITT, AJ; CHEALES, NA				HOWITT, AJ; CHEALES, NA			DIABETES REGISTERS - A GRASS-ROOTS APPROACH	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; COMMUNITY; POPULATION; DISTRICT; CARE	Objectives-To compile a register of diabetic patients within the catchment area of a district general hospital and evaluate the characteristics of the population using aggregated data from a general practice audit. Design-Cross sectional study. Practices identified all known diabetics and completed a questionnaire from information in each patient's medical record. Setting-Practices affiliated to a district audit group in south east England. Main outcome measures-Number of participating practices; prevalence of diabetes and its complications; and sex distribution of patients, age at diagnosis and review, treatment, and metabolic control. Comparisons with similar data from other studies. Results-41 out of 43 practices participated, and 2574 diabetic patients were identified (prevalence 1.18%). 52.4% of patients were male. The mean age was 61.6 years. 32% of patients were treated with insulin, 51.5% with oral hypoglycaemic agents, 16.5% with diet alone. The mean random blood glucose concentration was 10.4 mmol/l and glycosylated haemoglobin 10.1%. 8% had proteinuria, 7% a history of myocardial infarction, 5% a history of stroke, and 2% a diabetes related amputation. These proportions were not significantly different from those found in studies performed by different methods in Poole, Islington, Powys, Trowbridge, and Southall. Conclusion-It is feasible to compile a register of diabetic patients in a district and evaluate their characteristics by using only general practice sources.	KENT & SUSSEX HOSP,KENT MED AUDIT ADVISORY GRP,TURNBRIDGE WELLS AUDIT GRP,TUNBRIDGE WELLS TN4 8AT,KENT,ENGLAND									BURNETT SD, 1992, BRIT MED J, V305, P627, DOI 10.1136/bmj.305.6854.627; DONALDSON L, 1992, BRIT MED J, V305, P597, DOI 10.1136/bmj.305.6854.597; GATLING W, 1985, J ROY COLL PHYS LOND, V19, P248; GATLING W, 1988, PRACTICAL DIABETES, V5, P104; GIBBINS RL, 1989, J ROY COLL GEN PRACT, V39, P206; HIGGS ER, 1992, DIABETIC MED, V9, P550, DOI 10.1111/j.1464-5491.1992.tb01837.x; HILL RD, 1976, BRIT MED J, V1, P1137, DOI 10.1136/bmj.1.6018.1137; HURWITZ B, 1993, BRIT MED J, V306, P624, DOI 10.1136/bmj.306.6878.624; JONES JN, 1992, DIABETIC MED, V9, P176, DOI 10.1111/j.1464-5491.1992.tb01755.x; MANT D, 1987, BRIT MED J, V294, P223, DOI 10.1136/bmj.294.6566.223; MATHER HM, 1985, BRIT MED J, V291, P1081, DOI 10.1136/bmj.291.6502.1081; NEIL HAW, 1987, DIABETIC MED, V4, P539, DOI 10.1111/j.1464-5491.1987.tb00926.x; PARNELL SJ, 1993, BRIT J GEN PRACT, V43, P65; PRINGLE M, 1993, BRIT MED J, V306, P630, DOI 10.1136/bmj.306.6878.630; Ward J D, 1992, Qual Health Care, V1, P260, DOI 10.1136/qshc.1.4.260; WILSON AE, 1993, DIABETIC MED, V10, P378, DOI 10.1111/j.1464-5491.1993.tb00084.x; 1993, NEW HLTH PROMOTION P; 1990, EPI INFO VERSION 5 0	18	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1993	307	6911					1046	1048		10.1136/bmj.307.6911.1046	http://dx.doi.org/10.1136/bmj.307.6911.1046			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD556	8251780	Bronze, Green Published			2022-12-28	WOS:A1993MD55600021
J	LOZIER, JN; BRINKHOUS, KM				LOZIER, JN; BRINKHOUS, KM			GENE-THERAPY AND THE HEMOPHILIAS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN FACTOR-IX; HUMAN FACTOR-VIII; IMMUNODEFICIENCY VIRUS TYPE-1; RECOMBINANT DNA CLONES; COAGULATION FACTOR-IX; HAMSTER OVARY CELLS; SKIN FIBROBLASTS; ANTIHEMOPHILIC-FACTOR; ENDOTHELIAL-CELLS; MAMMALIAN-CELLS	Gene therapy for hemophilia A and B, now in the developmental stage, holds promise of a therapeutic revolution, resulting in amelioration or cure of the hemorrhagic diatheses. The genes for factor VIII and IX have been cloned, and vectors for the transfer of their cDNA into cells have been developed. Although viral and nonviral constructs containing the hemophilia gene have been used, most often modified retroviruses or adenoviruses have been employed. Cells that have been targeted for genetic modification to produce the antihemophilic proteins include hepatocytes, muscle cells, endothelial cells, keratinocytes, and fibroblasts. The delivery system may be (1) ex vivo, with implantation of modified cultured hemophilic cells in the donor, either in tissues or in semipermeable capsules, or (2) in vivo, the vector being delivered directly to target cells, genetically modifying them in situ. Successful in vivo therapy has been demonstrated in a hemophilic animal model, with conversion to a less severe hemophilic state.	UNIV N CAROLINA, CTR THROMBOSIS & HEMOSTASIS, CHAPEL HILL, NC 27514 USA; UNIV N CAROLINA, DEPT PATHOL, CHAPEL HILL, NC 27514 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	LOZIER, JN (corresponding author), UNIV N CAROLINA, DEPT MED, CB 7035, CHAPEL HILL, NC 27599 USA.				NCRR NIH HHS [RR00046] Funding Source: Medline; NHLBI NIH HHS [HL01648-46] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL001648] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANSON DS, 1985, NATURE, V315, P683, DOI 10.1038/315683a0; ARMENTANO D, 1990, P NATL ACAD SCI USA, V87, P6141, DOI 10.1073/pnas.87.16.6141; AXELROD JH, 1990, P NATL ACAD SCI USA, V87, P5173, DOI 10.1073/pnas.87.13.5173; BRINKHOUS KM, 1989, P NATL ACAD SCI USA, V86, P1382, DOI 10.1073/pnas.86.4.1382; BRINKHOUS KM, 1993, THROMB HAEMOSTASIS, V69, P852; BRINKHOUS KM, 1992, THROMB RES, V67, P329, DOI 10.1016/0049-3848(92)90008-X; BUSBY S, 1985, NATURE, V316, P271, DOI 10.1038/316271a0; CAMERINO G, 1984, P NATL ACAD SCI-BIOL, V81, P498, DOI 10.1073/pnas.81.2.498; CARDOSO JE, 1993, HUM GENE THER, V4, P411, DOI 10.1089/hum.1993.4.4-411; CARRBRENDEL V, 1993, J CELL BIOCHEM, P224; CHEUNG WF, 1992, J BIOL CHEM, V267, P20529; CORNETTA K, 1991, HUM GENE THER, V2, P5, DOI 10.1089/hum.1991.2.1-5; DAI Y, 1992, P NATL ACAD SCI USA, V89, P10892, DOI 10.1073/pnas.89.22.10892; DELASALLE H, 1985, NATURE, V316, P268, DOI 10.1038/316268a0; EVANS JP, 1989, P NATL ACAD SCI USA, V86, P10095, DOI 10.1073/pnas.86.24.10095; GAO L, 1993, HUM GENE THER, V4, P17, DOI 10.1089/hum.1993.4.1-17; GERRARD AJ, 1993, NAT GENET, V3, P180, DOI 10.1038/ng0293-180; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HOEBEN RC, 1993, HUM GENE THER, V4, P179, DOI 10.1089/hum.1993.4.2-179; HOEBEN RC, 1990, J BIOL CHEM, V265, P7318; ISRAEL DI, 1990, BLOOD, V75, P1074; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233, DOI 10.1128/MCB.9.3.1233; KAUFMAN RJ, 1986, J BIOL CHEM, V261, P9622; KAY MA, 1993, SCIENCE, V262, P117, DOI 10.1126/science.8211118; KAY MA, IN PRESS P NATL ACAD; KIM HC, 1992, BLOOD, V79, P568; LEVINE PH, 1991, HEMATOLOGY BASIC PRI, P1290; LEWIS JH, 1985, NEW ENGL J MED, V312, P1189; LOZIER J N, 1990, Hematologic Pathology, V4, P1; LOZIER JN, 1991, THROMB HAEMOSTASIS, V65, P1158; LOZIER JN, IN PRESS HUM GENE TH; LUSHER JM, 1993, NEW ENGL J MED, V328, P453, DOI 10.1056/NEJM199302183280701; MACIK BG, 1989, AM J HEMATOL, V32, P232, DOI 10.1002/ajh.2830320315; MANDEL J-L, 1988, Cytogenetics and Cell Genetics, V49, P107, DOI 10.1159/000132662; MILLER AD, 1990, HUM GENE THER, V1, P5, DOI 10.1089/hum.1990.1.1-5; MILLER AD, 1990, BLOOD, V76, P271; MIYANOHARA A, 1992, NEW BIOL, V4, P238; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; NEEL JV, 1993, HUM GENE THER, V4, P127, DOI 10.1089/hum.1993.4.2-127; NICHOLS EK, 1988, HUM GENE THER, P120; NOE DA, 1986, BLOOD, V67, P969; PALMER TD, 1989, BLOOD, V73, P438; QUANTIN B, 1992, P NATL ACAD SCI USA, V89, P2581, DOI 10.1073/pnas.89.7.2581; RAMESH N, 1993, HUM GENE THER, V4, P3, DOI 10.1089/hum.1993.4.1-3; REES DJG, 1985, NATURE, V316, P643, DOI 10.1038/316643a0; ROBERTS HR, 1992, HOSP PRACT, V27, P97; SALMONS B, 1993, HUM GENE THER, V4, P129, DOI 10.1089/hum.1993.4.2-129; SANDBERG H, 1991, THROMB HAEMOSTASIS, V65, P942; SCHIMPF K, 1987, NEW ENGL J MED, V316, P918, DOI 10.1056/NEJM198704093161505; SCHIMPF K, 1989, NEW ENGL J MED, V321, P1148, DOI 10.1056/NEJM198910263211702; SCHWARTZ RS, 1990, NEW ENGL J MED, V323, P1800, DOI 10.1056/NEJM199012273232604; SMITH TAG, 1993, NAT GENET, V5, P397, DOI 10.1038/ng1293-397; STERN DM, 1987, BRIT J HAEMATOL, V66, P227, DOI 10.1111/j.1365-2141.1987.tb01303.x; STLOUIS D, 1988, P NATL ACAD SCI USA, V85, P3150; THOMPSON AR, 1991, THROMB HAEMOSTASIS, V66, P119; TOOLE JJ, 1986, P NATL ACAD SCI USA, V83, P5939, DOI 10.1073/pnas.83.16.5939; TROISI CL, 1993, BLOOD, V81, P412; VERMA IM, 1990, SCI AM, V263, P68, DOI 10.1038/scientificamerican1190-68; WEBSTER WP, 1971, AM J PHYSIOL, V220, P1147, DOI 10.1152/ajplegacy.1971.220.5.1147; WHITE GC, 1989, NEW ENGL J MED, V320, P166, DOI 10.1056/NEJM198901193200307; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0; WU GY, 1991, J BIOL CHEM, V266, P14338; YAO SN, 1992, P NATL ACAD SCI USA, V89, P3357, DOI 10.1073/pnas.89.8.3357; YAO SN, 1991, P NATL ACAD SCI USA, V88, P8101, DOI 10.1073/pnas.88.18.8101; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	67	58	62	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	1994	271	1					47	51		10.1001/jama.271.1.47	http://dx.doi.org/10.1001/jama.271.1.47			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN725	8258886				2022-12-28	WOS:A1994MN72500030
J	CANTOR, JC				CANTOR, JC			HEALTH-CARE UNREFORM - THE NEW-JERSEY APPROACH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INSURANCE; MARKET; REFORM				CANTOR, JC (corresponding author), ROBERT WOOD JOHNSON FDN,COLLEGE RD,POB 2316,PRINCETON,NJ 08543, USA.							BROWN LD, 1992, INQUIRY, V9, P188; Coye M J, 1989, N J Med, V86, P189; DUNN DL, IN PRESS HLTH SERVIC; FRANKEL DH, 1993, LANCET, V341, P41; Helms W D, 1988, Bus Health, V6, P12; HELMS WD, 1992, HEALTH AFFAIR, V11, P7, DOI 10.1377/hlthaff.11.2.7; Hsiao W C, 1986, Health Aff (Millwood), V5, P32, DOI 10.1377/hlthaff.5.2.32; HSIAO WC, 1987, INQUIRY-J HEALTH CAR, V24, P212; MARINER WK, 1992, NEW ENGL J MED, V327, P1682, DOI 10.1056/NEJM199212033272312; MCLAUGHLIN CG, 1992, HEALTH AFFAIR, V11, P28, DOI 10.1377/hlthaff.11.2.28; MELNICK GA, 1992, J HEALTH ECON, V11, P217, DOI 10.1016/0167-6296(92)90001-H; MOON M, 1992, JAMA-J AM MED ASSOC, V268, P1588, DOI 10.1001/jama.268.12.1588; ROBINSON JC, 1988, JAMA-J AM MED ASSOC, V260, P2676, DOI 10.1001/jama.260.18.2676; SIEGAL B, 1991, U PUGET SOUND LAW RE, V14, P601; STARR P, 1993, HEALTH AFFAIR, V12, P7, DOI 10.1377/hlthaff.12.suppl_1.7; THORPE KE, 1992, JAMA-J AM MED ASSOC, V267, P945, DOI 10.1001/jama.267.7.945; WASSERMAN J, 1986, B NEW YORK ACAD MED, V62, P638; 1993, STANDARD POORS CREDI, P71; 1992, STATE INITIATIVES HL, V1, P3	19	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1993	270	24					2968	2970		10.1001/jama.270.24.2968	http://dx.doi.org/10.1001/jama.270.24.2968			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MM119	8254859				2022-12-28	WOS:A1993MM11900034
J	LEGALL, JR; LEMESHOW, S; SAULNIER, F				LEGALL, JR; LEMESHOW, S; SAULNIER, F			A NEW SIMPLIFIED ACUTE PHYSIOLOGY SCORE (SAPS-II) BASED ON A EUROPEAN NORTH-AMERICAN MULTICENTER STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE; CLASSIFICATION-SYSTEM; ICU PATIENTS; APACHE-II; MORTALITY; PREDICTION; SEVERITY	Objective.-To develop and validate a new Simplified Acute Physiology Score, the SAPS II, from a large sample of surgical and medical patients, and to provide a method to convert the score to a probability of hospital mortality. Design and Setting.-The SAPS II and the probability of hospital mortality were developed and validated using data from consecutive admissions to 137 adult medical and/or surgical intensive care units in 12 countries. Patients.-The 13152 patients were randomly divided into developmental (65%) and validation (35%) samples. Patients younger than 18 years, burn patients, coronary care patients, and cardiac surgery patients were excluded. Outcome Measure.-Vital status at hospital discharge. Results.-The SAPS II includes only 17 variables: 12 physiology variables, age, type of admission (scheduled surgical, unscheduled surgical, or medical), and three underlying disease variables (acquired immunodeficiency syndrome, metastatic cancer, and hematologic malignancy). Goodness-of-fit tests indicated that the model performed well in the developmental sample and validated well in an independent sample of patients (P=.883 and P=.104 in the developmental and validation samples, respectively). The area under the receiver operating characteristic curve was 0.88 in the developmental sample and 0.86 in the validation sample. Conclusion.-The SAPS II, based on a large international sample of patients, provides an estimate of the risk of death without having to specify a primary diagnosis. This is a starting point for future evaluation of the efficiency of intensive care units.	FAC MED LARIBOISIERE,PARIS,FRANCE; EVALUAT CTR,LILLE,FRANCE; UNIV MASSACHUSETTS,SCH PUBL HLTH,AMHERST,MA 01003	UDICE-French Research Universities; Universite Paris Cite; University of Massachusetts System; University of Massachusetts Amherst	LEGALL, JR (corresponding author), HOP ST LOUIS,SERV REANIMAT MED,1 AVE CLAUDE VELLEFAUX,F-75010 PARIS,FRANCE.							BAHLOUL F, 1988, PRESSE MED, V17, P1741; CHANG RWS, 1989, LANCET, V2, P143; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Fleiss J.L., 1986, DESIGN ANAL CLIN EXP; Fleiss JL, 1981, STAT METHODS RATES P; GASTINNE H, 1992, NEW ENGL J MED, V326, P594, DOI 10.1056/NEJM199202273260903; GUERRERO VM, 1982, BIOMETRIKA, V69, P309, DOI 10.2307/2335404; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LEGALL JR, 1984, CRIT CARE MED, V12, P975; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; LEMESHOW S, 1988, CRIT CARE MED, V16, P470, DOI 10.1097/00003246-198805000-00002; LEMESHOW S, 1985, CRIT CARE MED, V13, P519, DOI 10.1097/00003246-198507000-00001; Lemmonier E, 1992, INTENS CARE MED, V20, P581; MOREAU R, 1989, CRIT CARE MED, V17, P409, DOI 10.1097/00003246-198905000-00006; SIRIO CA, 1992, CRIT CARE MED, V20, P1207, DOI 10.1097/00003246-199209000-00006; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P329	21	5097	5239	1	131	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1993	270	24					2957	2963		10.1001/jama.270.24.2957	http://dx.doi.org/10.1001/jama.270.24.2957			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM119	8254858				2022-12-28	WOS:A1993MM11900032
J	ATKINSON, MA; BOWMAN, MA; KAO, KJ; CAMPBELL, L; DUSH, PJ; SHAH, SC; SIMELL, O; MACLAREN, NK				ATKINSON, MA; BOWMAN, MA; KAO, KJ; CAMPBELL, L; DUSH, PJ; SHAH, SC; SIMELL, O; MACLAREN, NK			LACK OF IMMUNE RESPONSIVENESS TO BOVINE SERUM-ALBUMIN IN INSULIN-DEPENDENT DIABETES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RHEUMATOID-ARTHRITIS; DIETARY ANTIGENS; MILK-PROTEINS; MELLITUS; IDDM; ANTIBODIES; CHILDREN; RISK; PERMEABILITY; TRIGGER	Background. Epidemiologic studies have implicated the ingestion of cow's milk in the pathogenesis of insulin-dependent diabetes mellitus (IDDM). Moreover, in a recent study, 100 percent of patients with new-onset IDDM had antibodies against bovine serum albumin (BSA), with a majority directed against a 17-amino-acid BSA peptide (ABBOS). Cellular immune mechanisms are thought to be the principal mediators of pancreatic beta-cell destruction in IDDM. Methods. We measured the responses of peripheral-blood mononuclear cells to BSA and ABBOS or serum IgG anti-BSA antibodies (by particle-concentration fluorescence immunoassay) in 71 patients with IDDM, 55 subjects at various degrees of risk for IDDM, 36 patients with other autoimmune disorders (chronic autoimmune thyroiditis, rheumatoid arthritis, and systemic lupus erythematosus), and 48 normal subjects. Results. The responses of peripheral-blood mononuclear cells to BSA or ABBOS were positive in 2 of 24 patients with new-onset IDDM, 1 of 25 first-degree relatives of patients with IDDM who were negative for islet-cell antibodies, 2 of 30 first-degree relatives of patients with IDDM who were positive for islet-cell antibodies, 1 of 28 patients with established IDDM, and 1 of 29 normal subjects. Similarly, anti-BSA antibodies were not detected significantly more often in patients with new-onset IDDM (3 of 31, 10 percent) than in normal subjects (1 of 37, 3 percent; P = 0.32). However, many patients with autoimmune disease and subjects at increased risk for IDDM had anti-BSA antibodies (frequency, 10 to 31 percent). Conclusions. Anti-BSA antibodies may reflect a general defect in the process of immunologic tolerance associated with a predisposition to autoimmunity rather than immunity specific to beta cells. The absence of cellular immunity to BSA and ABBOS in IDDM does not support a role for this antigen in the pathogenesis of the disorder.	UNIV S FLORIDA,DEPT PEDIAT,TAMPA,FL 33620; UNIV FLORIDA,COLL MED,DEPT PATHOL & LAB MED,GAINESVILLE,FL 32610; UNIV TURKU,DEPT PEDIAT,SF-20500 TURKU 50,FINLAND	State University System of Florida; University of South Florida; State University System of Florida; University of Florida; University of Turku			Campbell, Lesley V/B-2271-2008		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019469] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045342] Funding Source: NIH RePORTER; NICHD NIH HHS [R01HD19469] Funding Source: Medline; NIDDK NIH HHS [R29DK45342] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARVOLA T, 1992, PEDIATR RES, V32, P301, DOI 10.1203/00006450-199209000-00011; ATKINSON MA, 1990, SCI AM, V263, P62, DOI 10.1038/scientificamerican0790-62; ATKINSON MA, 1990, LANCET, V335, P1357, DOI 10.1016/0140-6736(90)91241-2; ATKINSON MA, 1992, LANCET, V339, P458, DOI 10.1016/0140-6736(92)91061-C; ATKINSON MA, 1990, SCI AM, V263, P66; BELLON T, 1989, SCAND J IMMUNOL, V30, P563, DOI 10.1111/j.1365-3083.1989.tb02463.x; BONIFACIO E, 1988, J IMMUNOL METHODS, V106, P83, DOI 10.1016/0022-1759(88)90274-8; BORCHJOHNSEN K, 1984, LANCET, V2, P1083; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; CHAPMAN J, 1993, INT ARCH ALLERGY IMM, V100, P42, DOI 10.1159/000236385; DAHLJORGENSEN K, 1991, DIABETES CARE, V14, P1081, DOI 10.2337/diacare.14.11.1081; DOSCH HM, 1988, PANDEX S PCFIA, P5; ELLIOTT RB, 1984, DIABETOLOGIA, V26, P297, DOI 10.1007/BF00283653; ELLIOTT RB, 1988, DIABETOLOGIA, V31, P62; GLERUM M, 1989, DIABETES RES CLIN EX, V10, P103; GONZALEZCABRERO J, 1987, CLIN EXP IMMUNOL, V68, P694; HARRISON LC, 1992, J CLIN INVEST, V89, P1161, DOI 10.1172/JCI115698; ISOLAURI E, 1989, J PEDIATR GASTR NUTR, V8, P466, DOI 10.1097/00005176-198905000-00008; JALONEN T, 1991, PEDIATR RES, V30, P290, DOI 10.1203/00006450-199109000-00019; JAMES SP, 1990, CURRENT PROTOCOLS IM; KARJALAINEN J, 1992, NEW ENGL J MED, V327, P302, DOI 10.1056/NEJM199207303270502; KARJALAINEN J, 1993, J AUTOIMMUN S1, V15, P62; KELLER RJ, 1990, J AUTOIMMUN, V3, P321, DOI 10.1016/0896-8411(90)90150-Q; KOSTRABA JN, 1993, DIABETES, V42, P288, DOI 10.2337/diabetes.42.2.288; KOSTRABA JN, 1992, DIABETES CARE, V15, P626, DOI 10.2337/diacare.15.5.626; MACLAREN N, 1992, NEW ENGL J MED, V327, P348, DOI 10.1056/NEJM199207303270509; MARTIN JM, 1991, ANN MED, V23, P447, DOI 10.3109/07853899109148088; MAYER EJ, 1988, DIABETES, V37, P1625, DOI 10.2337/diabetes.37.12.1625; MICHAELIS D, 1985, EXP CLIN ENDOCRINOL, V85, P61, DOI 10.1055/s-0029-1210420; MULLER W, 1983, PEDIATR RES, V17, P724, DOI 10.1203/00006450-198309000-00008; PATERAKI E, 1986, CLIN RHEUMATOL, V5, P338, DOI 10.1007/BF02054252; PEARSON JR, 1983, PEDIATR RES, V17, P406, DOI 10.1203/00006450-198305000-00017; PEREZMACEDA B, 1991, CLIN CHIM ACTA, V203, P153, DOI 10.1016/0009-8981(91)90287-M; PIETROPAOLO M, 1993, J CLIN INVEST, V92, P359, DOI 10.1172/JCI116574; RILEY WJ, 1990, NEW ENGL J MED, V323, P1167, DOI 10.1056/NEJM199010253231704; ROEP BO, 1991, LANCET, V337, P1439, DOI 10.1016/0140-6736(91)93127-U; Tamura N, 1982, Gastroenterol Jpn, V17, P469; Tamura N, 1982, Gastroenterol Jpn, V17, P310; VIRTANEN SM, 1991, DIABETES CARE, V14, P415, DOI 10.2337/diacare.14.5.415	39	163	163	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 16	1993	329	25					1853	1858		10.1056/NEJM199312163292505	http://dx.doi.org/10.1056/NEJM199312163292505			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML588	8247037	Bronze			2022-12-28	WOS:A1993ML58800005
J	GIAEVER, I; KEESE, CR				GIAEVER, I; KEESE, CR			A MORPHOLOGICAL BIOSENSOR FOR MAMMALIAN-CELLS	NATURE			English	Article							TISSUE-CULTURE; ELECTRIC-FIELDS; BEHAVIOR; MONITOR	An electrical biosensor is described that can continuously track morphological changes of adherent cells providing quantitative data from both sparse and confluent cultures. The method is capable of detecting vertical motion of cells of the order of 1 nm, much below the resolution of an optical microscope.	RENSSELAER POLYTECH INST,DEPT BIOL,TROY,NY 12180	Rensselaer Polytechnic Institute	GIAEVER, I (corresponding author), RENSSELAER POLYTECH INST,SCH SCI,TROY,NY 12180, USA.							GHOSH PM, 1993, BIOPHYS J, V64, P1602, DOI 10.1016/S0006-3495(93)81531-5; GIAEVER I, 1989, PHYSICA D, V38, P128, DOI 10.1016/0167-2789(89)90182-6; GIAEVER I, 1984, P NATL ACAD SCI-BIOL, V81, P3761, DOI 10.1073/pnas.81.12.3761; GIAEVER I, 1986, IEEE T BIO-MED ENG, V33, P242, DOI 10.1109/TBME.1986.325896; GIAEVER I, 1991, P NATL ACAD SCI USA, V88, P7896, DOI 10.1073/pnas.88.17.7896; GIAEVER I, 1992, CHEMTECH, P116; KEESE CR, 1990, IEEE P BIOMED ENG, V12, P500; KOWOLENKO M, 1990, J IMMUNOL METHODS, V127, P71, DOI 10.1016/0022-1759(90)90342-S; LO CM, 1993, EXP CELL RES, V204, P102, DOI 10.1006/excr.1993.1014; MITRA P, 1991, BIOTECHNIQUES, V11, P504; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919	11	601	624	3	90	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 9	1993	366	6455					591	592		10.1038/366591a0	http://dx.doi.org/10.1038/366591a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	8255299				2022-12-28	WOS:A1993ML21800078
J	ALDOUS, MB; EDMONSON, MB				ALDOUS, MB; EDMONSON, MB			MATERNAL AGE AT 1ST CHILDBIRTH AND RISK OF LOW-BIRTH-WEIGHT AND PRETERM DELIVERY IN WASHINGTON-STATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DELAYED CHILDBEARING; UNITED-STATES; PREGNANCY; POPULATION; PREVALENCE; OLDER; WOMEN	Objective.-To study the consequences of delayed first childbearing in a large, population-based US sample, with separate analysis of women aged 40 years or more and adjustment for socioeconomic factors, smoking, medical and reproductive conditions, and route of delivery. Design and Setting.-Retrospective survey of Washington State birth certificates from 1984 through 1988. Subjects.-First liveborn singleton infants of women aged at least 20 years. Of eligible white infants, all those born to women aged 35 to 39 years (n=4019) and 40 years or more (n=410) and a maternal age-stratified random sample of white infants of younger women were studied. All eligible black infants were studied. Outcome Measures.-Low (<2500 g) and very low (<1500 g) birth weight and preterm delivery (<37 weeks of gestation). Results.-Adjusted odds ratios for delivering a low-birth-weight white infant increased progressively with each 5-year maternal age group, reaching 2.3 (95% confidence interval, 1.6 to 3.4) for women aged 40 years or more compared with those aged 20 to 24 years. The maternal age effects for very low birth weight and preterm delivery were similar; for each, the odds ratio was 1.8 for the oldest group. No significant maternal age effect was found among births of black infants, but only 127 births to women aged 35 years or more were studied. Conclusion.-Increasing maternal age at first childbirth is an independent risk factor for low birth weight and preterm delivery of white infants in the United States.	UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, MATERNAL & CHILD HLTH PROGRAM, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle								ALES KL, 1990, SURG GYNECOL OBSTET, V171, P209; BARKAN SE, 1987, AM J EPIDEMIOL, V125, P101, DOI 10.1093/oxfordjournals.aje.a114491; BERKOWITZ GS, 1993, JAMA-J AM MED ASSOC, V269, P745, DOI 10.1001/jama.1993.03500060045020; BERKOWITZ GS, 1990, NEW ENGL J MED, V322, P659, DOI 10.1056/NEJM199003083221004; CNATTINGIUS S, 1993, AM J OBSTET GYNECOL, V168, P16, DOI 10.1016/S0002-9378(12)90878-9; CNATTINGIUS S, 1992, Journal of the American Medical Association, V268, P886, DOI 10.1001/jama.268.7.886; EISNER V, 1979, AM J PUBLIC HEALTH, V69, P887, DOI 10.2105/AJPH.69.9.887; FORMAN MR, 1984, JAMA-J AM MED ASSOC, V252, P3135, DOI 10.1001/jama.252.22.3135; FRIEDE A, 1988, OBSTET GYNECOL, V72, P152; FROST F, 1984, AM J PUBLIC HEALTH, V74, P505, DOI 10.2105/AJPH.74.5.505; GERONIMUS AT, 1991, PUBLIC HEALTH REP, V106, P393; GRIMES DA, 1981, OBSTET GYNECOL, V58, P614; Harrell F. E., 1986, SUGI SUPPLEMENTAL LI, P269; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; ISRAEL SL, 1964, OBSTET GYNECOL, V24, P411, DOI 10.1097/00006250-196409000-00014; KANE SH, 1967, OBSTET GYNECOL, V29, P409; KIRZ DS, 1985, AM J OBSTET GYNECOL, V152, P7, DOI 10.1016/S0002-9378(85)80166-6; LEE KS, 1988, AM J OBSTET GYNECOL, V158, P84, DOI 10.1016/0002-9378(88)90783-1; MONTGOMERY TA, 1962, CALIF MED, V96, P190; MORRISON I, 1975, AM J OBSTET GYNECOL, V121, P465, DOI 10.1016/0002-9378(75)90076-9; NAEYE RL, 1983, OBSTET GYNECOL, V61, P210; SPELLACY WN, 1986, OBSTET GYNECOL, V68, P452; STEIN ZA, 1985, AM J EPIDEMIOL, V121, P327, DOI 10.1093/oxfordjournals.aje.a114004; VEENTURA SJ, 1989, VITAL HLTH STAT, V21; VENTURA SJ, 1992, MONTHLY VITAL STAT S, V40, P1; YOUNG TK, 1991, CAN MED ASSOC J, V144, P318; 1990, VITAL STATISTICS US, V1; 1992, STATISTICAL ABSTRACT; 1990, MONTHLY VITAL STAT S, V39, P1	29	95	96	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1993	270	21					2574	2577		10.1001/jama.270.21.2574	http://dx.doi.org/10.1001/jama.270.21.2574			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ266	8230642				2022-12-28	WOS:A1993MJ26600024
J	CLARK, P; CASAS, E; TUGWELL, P; MEDINA, C; GHENO, C; TENORIO, G; OROZCO, JA				CLARK, P; CASAS, E; TUGWELL, P; MEDINA, C; GHENO, C; TENORIO, G; OROZCO, JA			HYDROXYCHLOROQUINE COMPARED WITH PLACEBO IN RHEUMATOID-ARTHRITIS - A RANDOMIZED CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						ARTHRITIS, RHEUMATOID; HYDROXYCHLOROQUINE; RANDOMIZED CONTROLLED TRIALS; ANTIMALARIALS; PLACEBOS	CLINICAL-TRIALS; 2ND-LINE DRUGS; CHLOROQUINE; EFFICACY; TOXICITY	Objective: To assess the efficacy of hydroxychloroquine, 400 mg daily, for rheumatoid arthritis. Design: Six-month, double-blind, randomized trial. Setting: Ambulatory referral clinic in a Mexico City, Mexico, teaching hospital. Patients: A total of 126 patients with early rheumatoid arthritis were randomly assigned to receive hydroxychloroquine, 400 mg/d, or placebo; 121 patients completed the study. Results: Hydroxychloroquine showed a clinically and statistically significant improvement over placebo in joint score (20% greater mean improvement; 10% more patients improved by >50%); pain (40% greater mean improvement; 19% more patients improved by >50%); grip strength (22% greater mean improvement; 21% more patients improved by >50%); patient global assessment (16% more patients stated they had improved); and physician global assessment (12% more patients were judged to have improved). Side effects were mild, and no patients in the hydroxychloroquine group required discontinuation of therapy. Patient compliance with the study medication was high. Conclusion: Hydroxychloroquine is moderately effective in early rheumatoid arthritis.	UNIV OTTAWA, DEPT MED, OTTAWA K1H 8L6, ON, CANADA; HOSP GEN MEXICO CITY, UNIDAD EPIDEMIOL CLIN, MEXICO CITY, MEXICO; OTTAWA GEN HOSP, OTTAWA K1H 8L6, ONTARIO, CANADA	University of Ottawa; Hospital General de Mexico; University of Ottawa; Ottawa Hospital Research Institute	CLARK, P (corresponding author), NATL AUTONOMOUS UNIV MEXICO, FAC MED, 148 COL DOCTORES, CP 06726, MEXICO CITY 04510, DF, MEXICO.		Tugwell, Peter/AFD-8076-2022	Tugwell, Peter/0000-0001-5062-0556; Clark, Patricia/0000-0001-7981-5357				ADAMS EM, 1983, AM J MED, V75, P321, DOI 10.1016/0002-9343(83)91211-1; ANDERSON JJ, 1989, ARTHRITIS RHEUM, V32, P1093, DOI 10.1002/anr.1780320907; ARDEN GB, 1978, BRIT J OPHTHALMOL, V62, P198, DOI 10.1136/bjo.62.4.198; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BOERS M, 1992, ARTHRITIS RHEUM, V35, pS202; BROOKS PM, 1992, 2ND LINE AGENTS TREA, P163; BUNCH TW, 1984, ARTHRITIS RHEUM, V27, P267, DOI 10.1002/art.1780270304; COHEN AS, 1958, ARTHRITIS RHEUM-US, V1, P297, DOI 10.1002/art.1780010403; DAVIS MJ, 1991, BRIT J RHEUMATOL, V30, P451; DWOSH IL, 1977, ARTHRITIS RHEUM, V20, P685, DOI 10.1002/art.1780200208; EASTERBROOK M, 1985, T OPHTHAL SOC UK, V104, P204; FELSON DT, 1992, ARTHRITIS RHEUM, V35, P1117, DOI 10.1002/art.1780351003; FELSON DT, 1990, ARTHRITIS RHEUM, V33, P1449, DOI 10.1002/art.1780331001; FREEDMAN A, 1956, ANN RHEUM DIS, V15, P251, DOI 10.1136/ard.15.3.251; FREEDMAN A, 1961, ANN RHEUM DIS, V20, P18; HAMILTON EB, 1962, ARTHRITIS RHEUM, V5, P502, DOI 10.1002/art.1780050507; HAYDU GG, 1953, AM J MED SCI, V225, P71; HEPBURN B, 1992, 2ND LINE AGENTS TREA, P145; KERSLLEY GD, 1959, LANCET, V13, P287; Mainland D., 1962, B RHEUM DIS, V13, P287; PAGE F, 1951, LANCET, V261, P755; Payne JF, 1894, CLIN J, V4, P223; POPERT AJ, 1961, ANN RHEUM DIS, V20, P18, DOI 10.1136/ard.20.1.18; PULLAR T, 1992, 2ND LINE AGENTS TREA, P153; RINEHART R, 1957, NW MED, V6, P703; RYNES RI, 1988, AM J MED, V85, P18, DOI 10.1016/0002-9343(88)90357-9; Rynes RI, 1985, TXB RHEUMATOLOGY, P774; RYNES RI, 1989, TXB RHEUMATOLOGY, V1, P796; SCHERBEL AL, 1957, CLEV CLIN Q, V28, P94; SCULL E, 1962, ARTHRITIS RHEUM-US, V5, P30, DOI 10.1002/art.1780050105; Stephens M.A., 1986, GOODNESS OF FIT TECH, DOI DOI 10.1201/9780203753064-4; TUGWELL P, 1990, LANCET, V335, P1051, DOI 10.1016/0140-6736(90)92630-Z; 1965, ARTHRITIS RHEUM, V8, P302	33	100	103	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1993	119	11					1067	1071		10.7326/0003-4819-119-11-199312010-00002	http://dx.doi.org/10.7326/0003-4819-119-11-199312010-00002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ335	8239224				2022-12-28	WOS:A1993MJ33500002
J	ISRAEL, E; RUBIN, P; KEMP, JP; GROSSMAN, J; PIERSON, W; SIEGEL, SC; TINKELMAN, D; MURRAY, JJ; BUSSE, W; SEGAL, AT; FISH, J; KAISER, HB; LEDFORD, D; WENZEL, S; ROSENTHAL, R; COHN, J; LANNI, C; PEARLMAN, H; KARAHALIOS, P; DRAZEN, JM				ISRAEL, E; RUBIN, P; KEMP, JP; GROSSMAN, J; PIERSON, W; SIEGEL, SC; TINKELMAN, D; MURRAY, JJ; BUSSE, W; SEGAL, AT; FISH, J; KAISER, HB; LEDFORD, D; WENZEL, S; ROSENTHAL, R; COHN, J; LANNI, C; PEARLMAN, H; KARAHALIOS, P; DRAZEN, JM			THE EFFECT OF INHIBITION OF 5-LIPOXYGENASE BY ZILEUTON IN MILD-TO-MODERATE ASTHMA	ANNALS OF INTERNAL MEDICINE			English	Article						ARACHIDONATE 5-LIPOXYGENASE; ASTHMA; ZILEUTON; FORCED EXPIRATORY VOLUME; LIPOXYGENASE INHIBITORS	LEUKOTRIENE-D4 RECEPTOR ANTAGONIST; INDUCED BRONCHOCONSTRICTION; URINARY LEUKOTRIENE-E4; INHALED BUDESONIDE; AIRWAY RESPONSES; CHALLENGE; HYPERRESPONSIVENESS; HYPERREACTIVITY; CORTICOSTEROIDS; RESPONSIVENESS	Objective: To evaluate the effectiveness of inhibiting the formation of the 5-lipoxygenase products of arachidonic acid by the 5-lipoxygenase inhibitor zileuton in the treatment of mild-to-moderate asthma. Design: Randomized, double-blind, placebo-controlled study. Setting: University hospitals and private allergy and pulmonary practices. Patients: A total of 139 persons with asthma who had a forced expiratory volume in 1 second (FEV1) of 40% to 75% of the predicted value and who were not being treated with inhaled or oral steroids. Intervention: Zileuton, 2.4 g/d or 1.6 g/d, or placebo for 4 weeks. Measurements: Airway function, beta-agonist use, and symptoms; inhibition of 5-lipoxygenase assessed by measurement of urinary leukotriene E4 (LTE4). Results: Zileuton produced a 0.35-L (95% CI, 0.25 to 0.45 L) increase in the FEV1 within 1 hour of administration (P < 0.001 compared with placebo), equivalent to a 14.6% increase from baseline. After 4 weeks of zileuton therapy, airway function and symptoms improved, with the greatest improvements occurring in the 2.4 g/d group: This group's FEV1 increased by 0.32 L (CI, 0.16 to 0.48 L), a 13.4% increase, compared with a 0.05-L (CI, -0.10 to 0.20 L) increase in patients taking placebo (P = 0.02). Symptoms and frequency of beta-agonist use also decreased with zileuton, 2.4 g/d. The mean urinary LTE4 level decreased by 39.2 pg/mg creatinine (CI, 18.1 to 60.4 pg/mg creatinine) and 26.5 pg/mg creatinine (CI, 6.6 to 46.5 pg/mg creatinine) in the 2.4 g/d and 1.6 g/d groups, respectively, compared with a slight increase in the placebo group (P = 0.007 and P = 0.05). No difference was noted in the number of adverse events among treatment groups. Conclusions: Inhibition of 5-lipoxygenase can improve airway function and decrease symptoms and medication use in patients with asthma, suggesting that this inhibition can be useful therapy for asthma. Also, 5-lipoxygenase products may mediate part of the baseline airway obstruction in patients with mild-to-moderate asthma.			ISRAEL, E (corresponding author), BETH ISRAEL HOSP, DIV PULM & CRIT CARE, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.		Drazen, Jeffrey M/E-5841-2012					ADELROTH E, 1986, NEW ENGL J MED, V315, P480, DOI 10.1056/NEJM198608213150803; ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; AXELROD L, 1976, MEDICINE, V55, P39, DOI 10.1097/00005792-197601000-00003; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRAND PLP, 1991, AM REV RESPIR DIS, V143, P916, DOI 10.1164/ajrccm/143.5_Pt_1.916; CARTER GW, 1991, J PHARMACOL EXP THER, V256, P929; CLOUD ML, 1989, AM REV RESPIR DIS, V140, P1336, DOI 10.1164/ajrccm/140.5.1336; DRAZEN JM, 1986, CHEST, V89, P414, DOI 10.1378/chest.89.3.414; DRAZEN JM, 1992, AM REV RESPIR DIS, V146, P104, DOI 10.1164/ajrccm/146.1.104; DRAZEN JM, 1987, AM REV RESPIR DIS, V136, P985, DOI 10.1164/ajrccm/136.4.985; DUTOIT JI, 1987, AM REV RESPIR DIS, V136, P1174, DOI 10.1164/ajrccm/136.5.1174; FINDLAY SR, 1992, J ALLERGY CLIN IMMUN, V89, P1040, DOI 10.1016/0091-6749(92)90227-S; FINNERTY JP, 1992, AM REV RESPIR DIS, V145, P746, DOI 10.1164/ajrccm/145.4_Pt_1.746; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HODSMAN AB, 1991, J CLIN ENDOCR METAB, V72, P530, DOI 10.1210/jcem-72-3-530; HUI KP, 1991, THORAX, V46, P184, DOI 10.1136/thx.46.3.184; HUI KP, 1991, LANCET, V337, P1062, DOI 10.1016/0140-6736(91)91709-4; ISRAEL E, 1989, AM REV RESPIR DIS, V140, P1348, DOI 10.1164/ajrccm/140.5.1348; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; KIPS JC, 1991, LANCET, V337, P1618, DOI 10.1016/0140-6736(91)93324-3; LAM A, 1990, CHEST, V98, P44, DOI 10.1378/chest.98.1.44; LEWIS RA, 1980, P NATL ACAD SCI-BIOL, V77, P3710, DOI 10.1073/pnas.77.6.3710; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; NEUKIRCH F, 1992, AM REV RESPIR DIS, V146, P71, DOI 10.1164/ajrccm/146.1.71; OWEN WF, 1987, J IMMUNOL, V138, P532; PIERSON WE, 1990, J ALLERGY CLIN IMMUN, V85, P618, DOI 10.1016/0091-6749(90)90102-A; RUBIN P, 1991, AGENT ACTION SUPPL, V35, P103; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SMITH LJ, 1985, AM REV RESPIR DIS, V131, P368; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; TAYLOR GW, 1989, LANCET, V1, P584; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; TOOGOOD JH, 1990, AM REV RESPIR DIS, V141, pS89; TOOGOOD JH, 1991, J ALLERGY CLIN IMMUN, V88, P572, DOI 10.1016/0091-6749(91)90150-M; VANSCHAYCK CP, 1991, BRIT MED J, V303, P1426, DOI 10.1136/bmj.303.6815.1426; VATHENEN AS, 1991, AM REV RESPIR DIS, V143, P1317, DOI 10.1164/ajrccm/143.6.1317; WEMPE JB, 1992, J ALLERGY CLIN IMMUN, V89, P679, DOI 10.1016/0091-6749(92)90374-B; WESTCOTT JY, 1990, J APPL PHYSIOL, V68, P2640, DOI 10.1152/jappl.1990.68.6.2640; WESTCOTT JY, 1991, AM REV RESPIR DIS, V143, P1322, DOI 10.1164/ajrccm/143.6.1322	42	298	303	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1993	119	11					1059	1066		10.7326/0003-4819-119-11-199312010-00001	http://dx.doi.org/10.7326/0003-4819-119-11-199312010-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ335	8239223				2022-12-28	WOS:A1993MJ33500001
J	FARAHBAKHSH, ZT; HIDEG, K; HUBBELL, WL				FARAHBAKHSH, ZT; HIDEG, K; HUBBELL, WL			PHOTOACTIVATED CONFORMATIONAL-CHANGES IN RHODOPSIN - A TIME-RESOLVED SPIN-LABEL STUDY	SCIENCE			English	Article							SCHIFF-BASE COUNTERION; BOVINE RHODOPSIN; METARHODOPSIN-II; DIFFERENCE SPECTROSCOPY; DISK MEMBRANE; PROTEIN; MUTANTS; TRANSDUCIN; SPECTRA; LOOPS	Rhodopsin has been selectively spin-labeled near the cytoplasmic termini of helices C and G. Photoactivation with a light flash induces an electron paramagnetic resonance spectral change in the millisecond time domain, coincident with the appearance of the active metarhodopsin II intermediate. The spectral change is consistent with a small movement near the cytoplasmic termination of the C helix and reverses upon formation of the MIII state. These results provide an important link between the optical changes associated with the retinal chromophore and protein conformational states.	UNIV CALIF LOS ANGELES,JULES STEIN EYE INST,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV PECS,CENT RES LAB,H-7643 PECS,HUNGARY	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Pecs					NATIONAL EYE INSTITUTE [R37EY005216, T32EY007026, R01EY005216] Funding Source: NIH RePORTER; NEI NIH HHS [EY07026, EY05216] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; CHABRE M, 1978, P NATL ACAD SCI USA, V75, P5471, DOI 10.1073/pnas.75.11.5471; CHABRE M, 1985, ANNU REV BIOPHYS BIO, V14, P331, DOI 10.1146/annurev.biophys.14.1.331; CHEN YS, 1978, MEMBRANE BIOCHEM, V1, P107, DOI 10.3109/09687687809064162; CHOTHIA C, 1985, TRENDS BIOCHEM SCI, V10, P116, DOI 10.1016/0968-0004(85)90270-1; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; DEGRIP WJ, 1988, PHOTOCHEM PHOTOBIOL, V48, P497, DOI 10.1111/j.1751-1097.1988.tb02852.x; DELMELLE M, 1977, BIOCHIM BIOPHYS ACTA, V464, P370, DOI 10.1016/0005-2736(77)90011-6; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; FARAHBAKHSH, 1992, PHOTOCHEM PHOTOBIOL, V56, P1019; FARAHBAKHSH ZT, 1992, PHOTOCHEM PHOTOBIOL, V56, P1019, DOI 10.1111/j.1751-1097.1992.tb09725.x; FINDLAY JBC, 1984, VISION RES, V24, P1501, DOI 10.1016/0042-6989(84)90312-2; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; GANTER UM, 1992, PHOTOCHEM PHOTOBIOL, V56, P57, DOI 10.1111/j.1751-1097.1992.tb09602.x; HIDEG K, UNPUB; HOFMANN KP, 1986, PHOTOBIOCH PHOTOBIOP, V13, P309; HOFMANN KP, 1985, J BIOL CHEM, V260, P7990; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KIBELBEK J, 1991, BIOCHEMISTRY-US, V30, P6761, DOI 10.1021/bi00241a019; KLINGER AL, 1992, BIOPHYS J, V63, P1244, DOI 10.1016/S0006-3495(92)81700-9; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUHN H, 1982, BIOCHIM BIOPHYS ACTA, V679, P95, DOI 10.1016/0005-2728(82)90259-6; MCPHALEN CA, 1992, J MOL BIOL, V227, P197, DOI 10.1016/0022-2836(92)90691-C; MOFFAT JK, 1971, J MOL BIOL, V55, P135, DOI 10.1016/0022-2836(71)90187-2; OGAWA S, 1967, P NATL ACAD SCI USA, V58, P19, DOI 10.1073/pnas.58.1.19; PELLICONE C, 1985, FEBS LETT, V184, P179; Rafferty C N, 1977, Biophys Struct Mech, V2, P227; RESEK J, IN PRESS BIOCHEMISTR; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; ROTHSCHILD KJ, 1987, BIOPHYS J, V51, P345, DOI 10.1016/S0006-3495(87)83341-6; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SUBRAMANIAM S, 1993, EMBO J, V12, P1; THORGEIRSSON TE, 1992, PHOTOCHEM PHOTOBIOL, V56, P1135, DOI 10.1111/j.1751-1097.1992.tb09738.x; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154; ZHUKOVSKY EA, 1992, BIOCHEMISTRY-US, V31, P10400, DOI 10.1021/bi00157a030	37	144	145	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 26	1993	262	5138					1416	1419		10.1126/science.8248781	http://dx.doi.org/10.1126/science.8248781			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ046	8248781				2022-12-28	WOS:A1993MJ04600031
J	NORTON, ME; MERRILL, J; COOPER, BAB; KULLER, JA; CLYMAN, RI				NORTON, ME; MERRILL, J; COOPER, BAB; KULLER, JA; CLYMAN, RI			NEONATAL COMPLICATIONS AFTER THE ADMINISTRATION OF INDOMETHACIN FOR PRETERM LABOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PATENT DUCTUS-ARTERIOSUS; PREMATURE LABOR; INTRAVENTRICULAR HEMORRHAGE; BLOOD-FLOW; INFANTS; TRIAL; BIRTH; OLIGOHYDRAMNIOS; CIRCULATION; PREVENTION	Background. The use of indomethacin as a tocolytic agent in pregnant women appears to be accompanied by a low incidence of neonatal complications. However, the neonatal effects of indomethacin have been studied primarily in infants born after 32 weeks' gestation. This study was designed to examine the incidence of neonatal complications in very premature infants. Methods. We identified 57 infants delivered at or before 30 weeks' gestation whose mothers had been treated with indomethacin for preterm labor and matched them with 57 infants whose mothers had not received indomethacin. The infants in the two groups were matched for sex, gestational age at delivery (mean [+/-SD], 27.6+/-2.0 weeks), exposure to betamethasone for 24 hours or more before delivery, and rupture of membranes 24 hours or more before delivery. Results. There were no significant differences between the two groups in birth weight, Apgar scores, cord-blood gas values, frequency of multiple gestation, or incidence of respiratory distress syndrome. The proportion of infants who required exogenous surfactant was similar, as were ventilator settings at 24 hours, the incidence of chronic lung disease, and the incidence of sepsis. The infants exposed to indomethacin had a lower urine output and higher serum creatinine concentrations during the first three days after delivery. More indomethacin-exposed infants had necrotizing enterocolitis (29 percent vs. 8 percent, P = 0.005), intracranial hemorrhage grade II to IV (28 percent vs. 9 percent, P = 0.02), and patent ductus arteriosus (62 percent vs. 44 percent, P = 0.65). More indomethacin-exposed infants with a patent ductus arteriosus required surgical ligation because of either a lack of initial response or a reopening of the duct after postnatal indomethacin therapy (50 percent vs. 20 percent of the unexposed infants, P = 0.05). Conclusions. Antenatal indomethacin therapy for preterm labor appears to increase the risk of serious neonatal complications in infants born at or before 30 weeks' gestation.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,BOX 0544,RM 1403 HSE,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; CALIF SCH PROFESS PSYCHOL,ALAMEDA,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL 46691] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046691] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAERTS W, 1990, DEV MED CHILD NEUROL, V32, P910; BAERTS W, 1990, DEV MED CHILD NEUROL, V32, P1032; BANDSTRA ES, 1988, PEDIATRICS, V82, P533; BESINGER RE, 1991, AM J OBSTET GYNECOL, V164, P981, DOI 10.1016/0002-9378(91)90569-D; CASSADY G, 1989, NEW ENGL J MED, V320, P1511, DOI 10.1056/NEJM198906083202302; CLYMAN RI, 1985, CIRCULATION, V71, P141, DOI 10.1161/01.CIR.71.1.141; CRONEN PW, 1982, J PEDIATR SURG, V17, P474, DOI 10.1016/S0022-3468(82)80092-4; EDWARDS AD, 1990, LANCET, V335, P1491, DOI 10.1016/0140-6736(90)93030-S; ERONEN M, 1991, AM J OBSTET GYNECOL, V164, P141, DOI 10.1016/0002-9378(91)90644-7; FEIGEN LP, 1981, J PHARMACOL EXP THER, V219, P679; FRIEDMAN Z, 1978, J CLIN PHARMACOL, V18, P272, DOI 10.1002/j.1552-4604.1978.tb02446.x; GLEASON CA, 1987, SEMIN PERINATOL, V11, P12; GOLDENBERG RL, 1989, AM J OBSTET GYNECOL, V160, P1196, DOI 10.1016/0002-9378(89)90188-9; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KRASNA IH, 1992, J PEDIATR SURG, V27, P805, DOI 10.1016/0022-3468(92)90369-I; KURKI T, 1991, OBSTET GYNECOL, V78, P1093; MCDONALD MM, 1984, PEDIATRICS, V74, P26; MENT LR, 1988, J PEDIATR-US, V112, P948, DOI 10.1016/S0022-3476(88)80225-7; MEYERS RL, 1991, PEDIATR RES, V29, P569; MOISE KJ, 1990, AM J OBSTET GYNECOL, V162, P549, DOI 10.1016/0002-9378(90)90427-9; MOISE KJ, 1988, NEW ENGL J MED, V319, P327, DOI 10.1056/NEJM198808113190602; MOMMA K, 1989, PEDIATR RES, V25, P69, DOI 10.1203/00006450-198901000-00016; MORALES WJ, 1989, OBSTET GYNECOL, V74, P567; NIEBYL JR, 1986, AM J OBSTET GYNECOL, V155, P747, DOI 10.1016/S0002-9378(86)80012-6; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; ROBERT A, 1977, PROSTAGLANDINS, V14, P333, DOI 10.1016/0090-6980(77)90178-2; Rudolph A M, 1978, Adv Prostaglandin Thromboxane Res, V4, P231; RUMACK CM, 1981, OBSTET GYNECOL, V58, pS52; VANBEL F, 1990, RADIOLOGY, V174, P165, DOI 10.1148/radiology.174.1.2403678; VANHAESEBROUCK P, 1988, J PEDIATR-US, V113, P738, DOI 10.1016/S0022-3476(88)80392-5; ZUCKERMAN H, 1974, OBSTET GYNECOL, V44, P787	31	309	314	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1993	329	22					1602	1607		10.1056/NEJM199311253292202	http://dx.doi.org/10.1056/NEJM199311253292202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ546	8232428				2022-12-28	WOS:A1993MJ54600002
J	MIURA, M; ZHU, H; ROTELLO, R; HARTWIEG, EA; YUAN, JY				MIURA, M; ZHU, H; ROTELLO, R; HARTWIEG, EA; YUAN, JY			INDUCTION OF APOPTOSIS IN FIBROBLASTS BY IL-1-BETA-CONVERTING ENZYME, A MAMMALIAN HOMOLOG OF THE C-ELEGANS CELL-DEATH GENE CED-3	CELL			English	Article							INTERLEUKIN-1-BETA CONVERTING ENZYME; CAENORHABDITIS-ELEGANS; MOLECULAR-CLONING; BCL-2; PREVENTION; MONOCYTES; SELECTION; RECEPTOR; SURVIVAL; PROTEIN	The mammalian interleukin-1beta-converting enzyme (ICE) has sequence similarity to the C. elegans cell death gene ced-3. We show here that overexpression of the murine ICE (mICE) gene or of the C. elegans ced-3 gene causes Rat-1 cells to undergo programmed cell death. Point mutations in a region homologous between mICE and CED-3 eliminate the ability of mICE and ced-3 to cause cell death. The cell death caused by mICE can be suppressed by overexpression of the crmA gene, a specific inhibitor of ICE, as well as by bcl-2, a mammalian oncogene that can act to prevent programmed cell death. Our results suggest that ICE may function during mammalian development to cause programmed cell death.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	MIURA, M (corresponding author), MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,BOSTON,MA 02129, USA.			Zhu, Hong/0000-0002-2575-4031				AMANO T, 1974, EXP CELL RES, V85, P399, DOI 10.1016/0014-4827(74)90142-6; [Anonymous], EPSTEIN BARR VIRUS; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DIGIOVINE FS, 1990, IMMUNOL TODAY, V11, P13; DINARELLO CA, 1991, BLOOD, V77, P1627; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FONTANA A, 1982, RHEUMATOL INT, V2, P49, DOI 10.1007/BF00541245; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HAZUDA DJ, 1988, J BIOL CHEM, V263, P8473; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOGOQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485; HORVITZ HR, 1982, NEUROSCI COMMENT, V1, P56; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; MAEKAWA T, 1991, ONCOGENE, V6, P627; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NETT MA, 1992, J IMMUNOL, V149, P3254; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Sambrook J, 1989, MOL CLONING LABORATO; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333; WOOD DD, 1983, ARTHRITIS RHEUM, V26, P975, DOI 10.1002/art.1780260806; Wyllie A.H., 1981, CELL DEATH BIOL PATH, P9; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; YUAN JY, 1993, CELL, V75, P653	43	1390	1490	0	34	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					653	660		10.1016/0092-8674(93)90486-A	http://dx.doi.org/10.1016/0092-8674(93)90486-A			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242741	Bronze			2022-12-28	WOS:A1993MH74900011
J	BRZOBOHATY, B; MOORE, I; KRISTOFFERSEN, P; BAKO, L; CAMPOS, N; SCHELL, J; PALME, K				BRZOBOHATY, B; MOORE, I; KRISTOFFERSEN, P; BAKO, L; CAMPOS, N; SCHELL, J; PALME, K			RELEASE OF ACTIVE CYTOKININ BY A BETA-GLUCOSIDASE LOCALIZED TO THE MAIZE ROOT-MERISTEM	SCIENCE			English	Article							ZEA-MAYS-L; MITOSIS	A beta-glucoside encoded by a cloned Zea mays complementary DNA (Zm-p60.1) cleaved the biologically inactive hormone conjugates cytokinin-O-glucosides and kinetin-N3-glucoside, releasing active cytokinin. Tobacco protoplasts that transiently expressed Zm-p60.1 could use the inactive cytokinin glucosides to initiate cell division. The ability of protoplasts to sustain growth in response to cytokinin glucosides persisted indefinitely after the likely disappearance of the expression vector. In the roots of maize seedlings, Zm-p60.1 was localized to the meristematic cells and may function in vivo to supply the developing maize embryo with active cytokinin.	MAX PLANCK INST ZUCHTUNGSFORSCH, CARL VON LINNE WEG 10, D-50829 COLOGNE 30, GERMANY; INST BIOPHYS, CS-61265 BRNO, CZECHOSLOVAKIA; DANISCO BIOTECHNOL, DK-1001 COPENHAGEN, DENMARK	Max Planck Society; Czech Academy of Sciences; Institute of Biophysics of the Czech Academy of Sciences			Palme, Klaus/A-9524-2013; Brzobohaty, Bretislav/D-7212-2012; Ding, Cheng-Qiang/B-6287-2011; Campos, Narciso/L-3608-2017	Palme, Klaus/0000-0002-2728-3835; Brzobohaty, Bretislav/0000-0002-1552-1314; Campos, Narciso/0000-0002-9685-0549				BRZOBOHATY B, UNPUB; CAMPOS N, 1992, PLANT J, V2, P675, DOI 10.1111/j.1365-313X.1992.tb00136.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOWES FAL, 1975, NEW PHYTOL, V74, P263, DOI 10.1111/j.1469-8137.1975.tb02614.x; COHEN JD, 1982, ANNU REV PLANT PHYS, V33, P403, DOI 10.1146/annurev.pp.33.060182.002155; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ESAU K, 1977, ANATOMY SEED PLANTS, P227; ESEN A, 1992, PLANT PHYSIOL, V98, P174, DOI 10.1104/pp.98.1.174; ESTRUCH JJ, 1991, EMBO J, V10, P2889, DOI 10.1002/j.1460-2075.1991.tb07838.x; LETHAM DS, 1983, ANNU REV PLANT PHYS, V34, P163, DOI 10.1146/annurev.pp.34.060183.001115; MEYER Y, 1979, PLANTA, V147, P181, DOI 10.1007/BF00388735; MOORE I, 1989, THESIS U EDINBURGH; NAGY JI, 1976, Z PFLANZENPHYSIOL, V78, P453, DOI 10.1016/S0044-328X(76)80093-1; NOWACKI J, 1980, PLANT PHYSIOL, V65, P422, DOI 10.1104/pp.65.3.422; Sambrook J, 1989, MOL CLONING LABORATO; SCHLIEMANN W, 1991, NATURWISSENSCHAFTEN, V78, P392, DOI 10.1007/BF01133410; SMITH AR, 1978, J EXP BOT, V29, P1067, DOI 10.1093/jxb/29.5.1067; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WIRTZ U, 1987, DNA-J MOLEC CELL BIO, V6, P245, DOI 10.1089/dna.1987.6.245	19	299	309	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	1993	262	5136					1051	1054		10.1126/science.8235622	http://dx.doi.org/10.1126/science.8235622			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	8235622				2022-12-28	WOS:A1993MG18700034
J	MILLER, SK				MILLER, SK			CAREER CHOICES - MINORITIES MOVE FROM LAB RATS TO POLICY WONKS	SCIENCE			English	Editorial Material																			0	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1101	1102		10.1126/science.8235629	http://dx.doi.org/10.1126/science.8235629			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MG187	8235629				2022-12-28	WOS:A1993MG18700054
J	GILLARD, JH; DENT, THS; AARONS, EJ; SMYTHPIGOTT, PJ; NICHOLLS, MWN				GILLARD, JH; DENT, THS; AARONS, EJ; SMYTHPIGOTT, PJ; NICHOLLS, MWN			PREREGISTRATION HOUSE OFFICERS IN 8 ENGLISH REGIONS - SURVEY OF QUALITY OF TRAINING	BRITISH MEDICAL JOURNAL			English	Article							PERIOD	Objective-To assess the quality of preregistration house officer training in eight English regions. Design-Postal questionnaire. Setting-Thames, East Anglian, Mersey, Northern, and Wessex regions. Participants-1670 preregistration house officers. Main outcome measures-Education, hours of work, workload, conditions of work, and attitudes to job and medicine as a career. Results-Response rate was 69% (1146 replies). Most house officers had attended induction courses (1036/1129 (92%)); 74% (757/1024) found them satisfactory. The proportions who had never received adequate guidance on how to break bad news and how to control pain were 59% (670/1135) and 56% (634/1136) respectively. There was much variation between regions. Overall, 65% (736/1138) reported confidence in performing cardiopulmonary resuscitation. Most respondents (95% (1089/1142)) worked an on call rota, 3% (36) a partial shift, and 0.6% (seven) a full shift; 19% (202) were on duty for average weekly hours that exceeded the targets for 1 April 1993. House officers had a median of 20 patients under their care and clerked a median of 10 emergency cases, six routine cases, and two day cases a week. Over half (690/1128 (61%)) could not obtain hot food after 8 pm, 20% (223/1095) did not always have clean sheets available in their on call room, and 45% (462/1036) did not consider the protection of staff against violence to be adequate at their hospital. The most important problems with the preregistration year were inappropriate or non-medical tasks (ranked first by 360 respondents), hours of work (359), and pay for out of hours work (167). Overall 57% (646/1125) would encourage a friend to apply for their post, but only 24% (266/1112) would encourage a friend to take up medicine and 44% (494/1112) would discourage the idea. Conclusions-House officers' training is deficient in important respects, with inappropriate tasks and heavy clinical workloads impeding the provision of proper education.	FULBOURNE HOSP,DEPT PUBL HLTH MED,CAMBRIDGE CB1 5EF,ENGLAND; JOHNS HOPKINS UNIV HOSP,DIV NEURORADIOL,BALTIMORE,MD 21287; MONSALL HOSP,MANCHESTER M10 8WR,ENGLAND; BRITISH POSTGRAD MED FEDERAT,LONDON WC1N 3EJ,ENGLAND; JOHNS HOPKINS UNIV HOSP,DEPT NEUROL,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins Medicine; University of London; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University								CALMAN KC, 1992, MAKING DOCTOR MED ED; CHRISTIE RAS, 1980, MED EDUC, V14, P210, DOI 10.1111/j.1365-2923.1980.tb02256.x; DENT THS, 1990, BRIT MED J, V300, P713, DOI 10.1136/bmj.300.6726.713; DENTON M, 1991, BRIT MED J, V302, P327, DOI 10.1136/bmj.302.6772.327-a; DOWIE R, 1991, PATTERNS HOSPITAL ME; DOWLING S, 1992, DOCTORS MAKING EXPER; GILLARD JH, 1993, BRIT MED J, V307, P1176, DOI 10.1136/bmj.307.6913.1176; GRANT J, 1989, BRIT MED J, V299, P1263, DOI 10.1136/bmj.299.6710.1263; LOWRY S, 1993, BRIT MED J, V306, P196, DOI 10.1136/bmj.306.6871.196; MCMANUS IC, 1977, LANCET, V1, P413; MORRIS F, 1991, BRIT MED J, V302, P626, DOI 10.1136/bmj.302.6777.626; NASMYTH DG, 1991, BRIT MED J, V302, P93, DOI 10.1136/bmj.302.6768.93; PAICE E, 1992, BRIT J HOSP MED, V48, P215; RICHARDS P, 1992, BRIT MED J, V304, P625, DOI 10.1136/bmj.304.6827.625; VASSALLO DJ, 1992, BRIT MED J, V305, P1005, DOI 10.1136/bmj.305.6860.1005; WILSON DH, 1993, BRIT MED J, V306, P194, DOI 10.1136/bmj.306.6871.194; 1987, RECOMMENDATIONS GENE; 1993, DOCTORS DENTISTS TRA; 1992, RECOMMENDATIONS GENE; 1993, HOUSE WORK PREREGIST; 1990, PREREGISTRATION YEAR	21	26	27	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1993	307	6913					1180	1184		10.1136/bmj.307.6913.1180	http://dx.doi.org/10.1136/bmj.307.6913.1180			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF824	8251844	Bronze, Green Published			2022-12-28	WOS:A1993MF82400023
J	MUMBY, K				MUMBY, K			SCIENCE OR FLAT EARTHERS - THE CLINICAL ECOLOGIST REPLIES	BRITISH MEDICAL JOURNAL			English	Article							PARKINSONS-DISEASE; FOOD; DEBRISOQUINE; COMMITTEE; THERAPY											BARBEAU A, 1985, LANCET, V2, P1213; BRENEMAN JC, 1973, ANN ALLERGY, V31, P382; BRENEMAN JC, 1974, ANN ALLERGY, V33, P164; BRONSKY EA, 1971, J ALLERGY, V47, P104; CALMAN KC, 1992, COMMUNICATION   1026; CAPLIN I, 1973, ANN ALLERGY, V31, P375; CRAWFORD LV, 1976, J ALLERGY CLIN IMMUN, V57, P236; HARDIN JA, 1992, TOXICOL APPL PHARM, V117, P155, DOI 10.1016/0041-008X(92)90232-H; JEWETT DL, 1990, NEW ENGL J MED, V323, P429, DOI 10.1056/NEJM199008163230701; KAILIN EW, 1971, J AMER MED ASSOC, V217, P78; KAY AB, 1993, BRIT MED J, V306, P122, DOI 10.1136/bmj.306.6870.122; KING WP, 1988, OTOLARYNG HEAD NECK, V99, P272, DOI 10.1177/019459988809900302; KING WP, 1988, OTOLARYNG HEAD NECK, V99, P263, DOI 10.1177/019459988809900301; LITTLEWOOD J, 1982, LANCET, V1, P983; REA WJ, 1984, ARCH OTOLARYNGOL, V110, P248; ROWAN RJ, 1990, HLTH CARE RIGHTS ADV, V5, P4; RUSZNAK C, IN PRESS CLIN EXP AL; SCADDING GK, 1986, CLIN ALLERGY, V16, P483, DOI 10.1111/j.1365-2222.1986.tb01983.x; SMITH CAD, 1992, LANCET, V339, P1375, DOI 10.1016/0140-6736(92)91196-F; WARING RH, 1989, LANCET, V2, P356; 1992, ALLERGY CONVENTIONAL; 1986, J ALLERGY CLIN IMMUN, V78, P269	22	3	3	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1993	307	6911					1055	1056		10.1136/bmj.307.6911.1055	http://dx.doi.org/10.1136/bmj.307.6911.1055			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD556	8251783	Bronze, Green Published			2022-12-28	WOS:A1993MD55600026
J	SATARIANO, WA; RAGLAND, DR				SATARIANO, WA; RAGLAND, DR			THE EFFECT OF COMORBIDITY ON 3-YEAR SURVIVAL OF WOMEN WITH PRIMARY BREAST-CANCER	ANNALS OF INTERNAL MEDICINE			English	Article						BREAST NEOPLASMS; COMORBIDITY; MASS SCREENING; NEOPLASM STAGING; AGE FACTORS	OLDER WOMEN; CLINICAL-TRIALS; QUALITY	Objective: To determine the effect of comorbidity and stage of disease on 3-year survival in women with primary breast cancer. Design: Longitudinal, observational study. Setting: Metropolitan Detroit. Patients: 936 women ages 40 to 84 years. Measurements: Data on stage of breast cancer, treatment type, and comorbidity were obtained from Metropolitan Detroit Cancer Surveillance System (MDCSS) files and medical records. Personal interviews were the source of information on social and behavioral factors. Vital status and cause of death were obtained from MDCSS files. Results: Patients who had 3 or more of 7 selected comorbid conditions had a 20-fold higher rate of mortality from causes other than breast cancer and a 4-fold higher rate of all-cause mortality when compared with patients who had no comorbid conditions. The effects of comorbidity were independent of age, disease stage, tumor size, histologic type, type of treatment, race, and social and behavioral factors. Moreover, women with severe comorbid conditions had uniformly higher mortality rates, and early diagnosis in these women conferred no survival advantage. Conclusion: Comorbidity in patients with breast cancer appears to be a strong predictor of 3-year survival, independent of the effects of breast cancer stage. This finding suggests that trials assessing the efficacy of screening should routinely include measures of comorbidity.			SATARIANO, WA (corresponding author), UNIV CALIF BERKELEY, GRAD SCH PUBL HLTH, EPIDEMIOL PROGRAM, BERKELEY, CA 94720 USA.		Ragland, David R/G-6302-2017	Ragland, David R/0000-0002-8996-1320	NCI NIH HHS [N01 CN-55423] Funding Source: Medline; NIA NIH HHS [R01-AG04969] Funding Source: Medline; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN055423] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG004969] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BASSETT MT, 1986, AM J PUBLIC HEALTH, V76, P1400, DOI 10.2105/AJPH.76.12.1400; BERKMAN LF, 1983, HLTH WAYS LIVING ALA, P83; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; COHEN HJ, 1992, J GERONTOL, V47, P134; COSTANZA ME, 1992, CANCER, V69, P1925, DOI 10.1002/1097-0142(19920401)69:7+<1925::AID-CNCR2820691709>3.0.CO;2-U; COX DR, 1972, J R STAT SOC B, V34, P187; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; GURALNIK JM, 1989, ADV DATA VITAL HLTH; MANDELBLATT JS, 1992, ANN INTERN MED, V116, P722, DOI 10.7326/0003-4819-116-9-722; MOINPOUR CM, 1989, J NATL CANCER I, V81, P485, DOI 10.1093/jnci/81.7.485; MOR V, 1992, J GERONTOL, V47, P43; RIES LAG, 1991, NIH912789 PUB; SATARIANO WA, 1992, J GERONTOL, V47, P24; Satariano WA, 1989, CANC ELDERLY APPROAC, P71; Shambaugh EM, 1977, SUMMARY STAGING GUID; SKEEL RT, 1989, J NATL CANCER I, V81, P472, DOI 10.1093/jnci/81.7.472; YOUNG JL, 1981, NCI MONOGRAPH, V57; 1989, J AM GERIATR SOC, V37, P883	18	550	553	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1994	120	2					104	110		10.7326/0003-4819-120-2-199401150-00002	http://dx.doi.org/10.7326/0003-4819-120-2-199401150-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ671	8256968				2022-12-28	WOS:A1994MQ67100002
J	CHEMELLO, L; ALBERTI, A; ROSE, K; SIMMONDS, P				CHEMELLO, L; ALBERTI, A; ROSE, K; SIMMONDS, P			HEPATITIS-C SEROTYPE AND RESPONSE TO INTERFERON THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							VIRUS		UNIV EDINBURGH,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	University of Edinburgh	CHEMELLO, L (corresponding author), UNIV PADUA,I-35100 PADUA,ITALY.		chemello, liliana/AAU-9414-2020	Simmonds, Peter/0000-0002-7964-4700; ALBERTI, ALFREDO/0000-0001-9926-2382				CHAN SW, 1992, J GEN VIROL, V73, P1131, DOI 10.1099/0022-1317-73-5-1131; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; SIMMONDS P, 1993, J CLIN MICROBIOL, V31, P1493, DOI 10.1128/JCM.31.6.1493-1503.1993; TAKADA N, 1992, J HEPATOL, V14, P35, DOI 10.1016/0168-8278(92)90128-C; TAKADA N, 1992, J HEPATOL, V14, P435; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203	6	135	136	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 13	1994	330	2					143	143		10.1056/NEJM199401133300215	http://dx.doi.org/10.1056/NEJM199401133300215			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ670	8259181	Bronze			2022-12-28	WOS:A1994MQ67000025
J	DELAMAZA, LM				DELAMAZA, LM			COCCIDIOIDES-IMMITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											DELAMAZA, LM (corresponding author), UNIV CALIF IRVINE,IRVINE,CA 92717, USA.								0	0	0	1	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1993	329	26					1935	1935						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM885	8247057				2022-12-28	WOS:A1993MM88500006
J	ZHOU, Z; ELLEDGE, SJ				ZHOU, Z; ELLEDGE, SJ			DUN1 ENCODES A PROTEIN-KINASE THAT CONTROLS THE DNA-DAMAGE RESPONSE IN YEAST	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; RIBONUCLEOTIDE REDUCTASE; CELL-CYCLE; SMALL SUBUNIT; GENE; IDENTIFICATION; EXPRESSION; TRANSCRIPTION; MUTAGENESIS; AGENTS	DNA damage induces the expression of many genes proposed to enhance DNA repair capacities. We investigated the mechanism by which DNA damage induces transcription of RNR3, a subunit of ribonucleotide reductase. Five complementation groups of DNA-damage uninducible (dun) mutants were identified. Each is sensitive to DNA damage. dun1 mutants are also defective for RNR1 and RNR2 induction but are proficient for induction of other genes, defining the existence of at least two distinct DNA damage induction pathways. DUN1 encodes a nuclear protein kinase that is also a phosphoprotein. Phosphorylation of Dun1 increases in response to DNA damage in a Dun1-dependent manner, suggesting an increase in autophosphorylation activity. These results establish the existence of a eukaryotic SOS response regulated by protein phosphorylation.	BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA; BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	ZHOU, Z (corresponding author), BAYLOR COLL MED, HOWARD HUGHES INST, HOUSTON, TX 77030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044664, R37GM044664] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44664] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOULET A, 1989, EMBO J, V8, P1849, DOI 10.1002/j.1460-2075.1989.tb03580.x; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ELLEDGE SJ, 1989, MOL CELL BIOL, V9, P4932, DOI 10.1128/MCB.9.11.4932; ELLEDGE SJ, 1993, BIOESSAYS, V15, P333, DOI 10.1002/bies.950150507; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; ELLEDGE SJ, 1987, MOL CELL BIOL, V7, P2783, DOI 10.1128/MCB.7.8.2783; ELLEDGE SJ, 1989, MOL CELL BIOL, V9, P5373, DOI 10.1128/MCB.9.12.5373; Friedberg E.C., 1991, MOL CELLULAR BIOL TE, P147; Gale E. F., 1981, MOL BASIS ANTIBIOTIC, V2nd; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HITTELMAN WN, 1974, CANCER RES, V34, P3433; HURD HK, 1987, MOL CELL BIOL, V7, P3673, DOI 10.1128/MCB.7.10.3673; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; LEVIN NA, 1993, GENETICS, V133, P799; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; OZKAYNAK E, 1984, NATURE, V312, P663, DOI 10.1038/312663a0; Radman M, 1974, MOL ENV ASPECTS MUTA, P128; Rose MD., 1990, METHODS YEAST GENETI; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SASSANFAR M, 1990, J MOL BIOL, V212, P79, DOI 10.1016/0022-2836(90)90306-7; SCHILD D, 1990, P NATL ACAD SCI USA, V87, P2916, DOI 10.1073/pnas.87.8.2916; SEIFERT HS, 1986, P NATL ACAD SCI USA, V83, P735, DOI 10.1073/pnas.83.3.735; SIKORSKI RS, 1989, GENETICS, V122, P19; TAN JL, 1991, J BIOL CHEM, V266, P16044; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREGER JM, 1990, MOL CELL BIOL, V10, P3174, DOI 10.1128/MCB.10.6.3174; TREGER JM, 1988, MOL CELL BIOL, V8, P1132, DOI 10.1128/MCB.8.3.1132; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WEINERT TA, 1993, GENETICS, V134, P63; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHOU Z, 1992, GENETICS, V131, P851	36	291	302	1	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 17	1993	75	6					1119	1127		10.1016/0092-8674(93)90321-G	http://dx.doi.org/10.1016/0092-8674(93)90321-G			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	8261511				2022-12-28	WOS:A1993MM89300010
J	MEADOR, WE; MEANS, AR; QUIOCHO, FA				MEADOR, WE; MEANS, AR; QUIOCHO, FA			MODULATION OF CALMODULIN PLASTICITY IN MOLECULAR RECOGNITION ON THE BASIS OF X-RAY STRUCTURES	SCIENCE			English	Article							SEQUENCE-INDEPENDENT RECOGNITION; LIGHT CHAIN KINASE; MULTIDIMENSIONAL NMR; SECONDARY STRUCTURE; PEPTIDE COMPLEX; BINDING DOMAIN	Calmodulin is the primary calcium-dependent signal transducer and regulator of a wide variety of essential cellular functions. The structure of calcium-calmodulin bound to the peptide corresponding to the calmodulin-binding domain of brain calmodulin-dependent protein kinase IIalpha was determined to 2 angstrom resolution. A comparison to two other calcium-calmodulin structures reveals how the central helix unwinds in order to position the two domains optimally in the recognition of different target enzymes and clarifies the role of calcium in maintaining recognition-competent domain structures.	BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine; Duke University								BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BRUNGER AT, X PLOR VERSION 3 1 Y; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; GELLMAN SH, 1991, BIOCHEMISTRY-US, V30, P6633, DOI 10.1021/bi00241a001; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HEIDORN DB, 1989, BIOCHEMISTRY-US, V28, P6757, DOI 10.1021/bi00442a032; IKURA M, 1991, BIOCHEMISTRY-US, V30, P9216, DOI 10.1021/bi00102a013; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KATOKA M, 1989, P NATL ACAD SCI USA, V86, P6944; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEADOR WE, UNPUB; MEANS AR, 1991, CELLULAR CALCIUM PRA, P205; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; ROTH SM, 1992, BIOCHEMISTRY-US, V31, P1443, DOI 10.1021/bi00120a022; Sack J. S., 1988, J MOL GRAPHICS, V6, P244; SEEHOLZER SH, 1989, BIOCHEMISTRY-US, V28, P4011, DOI 10.1021/bi00435a057; VORHERR T, 1992, BIOCHEMISTRY-US, V31, P8245, DOI 10.1021/bi00150a018	21	607	612	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 10	1993	262	5140					1718	1721		10.1126/science.8259515	http://dx.doi.org/10.1126/science.8259515			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	8259515				2022-12-28	WOS:A1993ML22000037
J	KENYON, C; CHANG, J; GENSCH, E; RUDNER, A; TABTIANG, R				KENYON, C; CHANG, J; GENSCH, E; RUDNER, A; TABTIANG, R			A C-ELEGANS MUTANT THAT LIVES TWICE AS LONG AS WILD-TYPE	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; LIFE-SPAN; GENETIC-ANALYSIS; DAUER LARVA; SENESCENCE	WE have found that mutations in the gene daf-2 can cause fertile, active, adult Caenorhabditis elegans hermaphrodites to live more than twice as long as wild type. This lifespan extension, the largest yet reported in any organism1, requires the activity of a second gene, daf-16. Both genes also regulate formation of the dauer larva, a developmentally arrested larval form that is induced by crowding and starvation and is very long-lived2-4. Our findings raise the possibility that the longevity of the dauer is not simply a consequence of its arrested growth, but instead results from a regulated lifespan extension mechanism that can be uncoupled from other aspects of dauer formation. daf-2 and daf-16 provide entry points into understanding how lifespan can be extended.			KENYON, C (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOPHYS, SAN FRANCISCO, CA 94143 USA.							Finch CE, 1990, LONGEVITY SENESCENCE; HODGKIN J, 1986, GENETICS, V114, P15; JOHNSON TE, 1982, P NATL ACAD SCI-BIOL, V79, P6603, DOI 10.1073/pnas.79.21.6603; JOHNSON TE, 1987, P NATL ACAD SCI USA, V84, P3777, DOI 10.1073/pnas.84.11.3777; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KLASS M, 1976, NATURE, V260, P523, DOI 10.1038/260523a0; KLASS MR, 1977, MECH AGEING DEV, V6, P413, DOI 10.1016/0047-6374(77)90043-4; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; Riddle DL., 1988, NEMATODE CAENORHABDI, P393; ROSE MR, 1984, CAN J ZOOL, V62, P1661, DOI 10.1139/z84-243; SERVICE PM, 1985, PHYSIOL ZOOL, V58, P380, DOI 10.1086/physzool.58.4.30156013; SULSTON J, 1975, J COMP NEUROL, V163, P215, DOI 10.1002/cne.901630207; Sulston J., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; SWANSON MM, 1981, DEV BIOL, V84, P27, DOI 10.1016/0012-1606(81)90367-5; THOMAS JH, 1993, GENETICS, V134, P1105; VANVOORHIES WA, 1992, NATURE, V360, P456, DOI 10.1038/360456a0; VOWELS JJ, 1992, GENETICS, V130, P105; WARING DA, 1990, CELL, V60, P123, DOI 10.1016/0092-8674(90)90722-Q; White J., 1988, NEMATODE CAENORHABDI, V17, P81; Woolson R. F, 1987, STATISTICAL METHODS; ZUCKERMAN BM, 1980, NEMATODES BIOL MODEL	22	2365	2445	9	354	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 2	1993	366	6454					461	464		10.1038/366461a0	http://dx.doi.org/10.1038/366461a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK098	8247153				2022-12-28	WOS:A1993MK09800063
J	HATA, Y; SLAUGHTER, CA; SUDHOF, TC				HATA, Y; SLAUGHTER, CA; SUDHOF, TC			SYNAPTIC VESICLE FUSION COMPLEX CONTAINS UNC-18 HOMOLOG BOUND TO SYNTAXIN	NATURE			English	Article							GLUTATHIONE-S-TRANSFERASE; CAENORHABDITIS-ELEGANS; ESCHERICHIA-COLI; PURIFICATION; CLEAVAGE; PROTEINS; CLONING; FAMILY	THREE synaptic proteins, syntaxin, SNAP-25 and synaptobrevin, were recently identified as targets of clostridial neurotoxins that irreversibly inhibit synaptic vesicle fusion1-4. Experiments searching for membrane receptors for N-ethylmaleimide-sensitive fusion protein (NSF), which has an important role in membrane fusion, revealed an ATP-dependent interaction of the same three synaptic proteins with NSF and its soluble attachment proteins5. Thus, two independent approaches identify syntaxin, synaptobrevin and SNAP-25 as components of the synaptic vesicle fusion machinery, but their mode of action is unclear6. We have now discovered a brain protein of relative molecular mass 67,000 (67K) which binds stably to syntaxin. Amino-acid sequencing and complementary DNA cloning revealed that the 67K protein is encoded by the mammalian homologue of the Caenorhabditis elegans gene unc-18. In C. elegans, unc-18 belongs to a group of genes defined by mutations with a paralytic phenotype and accumulations of acetylcholine, suggesting a defect in neurotransmitter release7,8. The binding of the mammalian homologue of unc-18 (Munc-18) to syntaxin requires the N terminus of syntaxin whereas that of SNAP-25 involves a more C-terminal sequence. Our data suggest that Munc-18 is a previously unidentified essential component of the synaptic vesicle fusion protein complex.	UNIV TEXAS,HLTH SCI CTR,SW MED SCH,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,HLTH SCI CTR,SW MED SCH,DEPT MOLEC GENET,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; AALTO MK, 1991, YEAST, V7, P643, DOI 10.1002/yea.320070613; AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, IN PRESS EMBO J; BRENNER S, 1974, GENETICS, V77, P71; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; INOUE A, 1992, J BIOL CHEM, V267, P10613; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; NONE TML, 1993, CELL, V73, P1291; NOVICK P, 1979, P NATL ACAD SCI USA, V76, P1858, DOI 10.1073/pnas.76.4.1858; PELHAM HRB, 1993, CELL, V73, P425, DOI 10.1016/0092-8674(93)90128-D; PELHAM HRB, 1993, NATURE, V364, P582, DOI 10.1038/364582a0; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; SALZBERG A, 1993, DEVELOPMENT, V117, P1309; Sambrook J, 1989, MOL CLONING LABORATO; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SOLLNER T, IN PRESS CELL; SUDHOF TC, 1993, CELL, V75, P1; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; WALCHSOLIMENA C, IN PRESS NEURON	30	585	607	1	77	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 25	1993	366	6453					347	351		10.1038/366347a0	http://dx.doi.org/10.1038/366347a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ705	8247129				2022-12-28	WOS:A1993MJ70500050
J	UBEL, PA; ARNOLD, RM; CAPLAN, AL				UBEL, PA; ARNOLD, RM; CAPLAN, AL			RATIONING FAILURE - THE ETHICAL LESSONS OF THE RETRANSPLANTATION OF SCARCE VITAL ORGANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIAC TRANSPLANTATION; CYCLOSPORINE; ALLOCATION; SURVIVAL; DONORS	Because of a shortage of transplantable livers and hearts, the transplant community has had to decide-by who gets an organ-who lives or dies. Despite this shortage, whether one has previously received a transplant is not used as a criterion to distribute organs. The existing allocation system distributes 10% to 20% of available hearts and livers to retransplant patients. This article examines three differences between primary transplantation and retransplantation that may affect the priority that retransplant candidates should receive in vying for organs: (1) the special obligations that transplant teams have not to abandon patients on whom they have already performed a transplant, (2) the fairness of allowing individuals to get multiple transplants while some die awaiting their first, and (3) the difference in efficacy between primary transplantation and retransplantation. Only this last difference holds up to critical analysis. Our moral duty to direct scarce, lifesaving resources to those likely to benefit from them, suggests that, all other things equal, primary transplant candidates should receive priority because their mortality after transplantation is lower. Consistency also demands that previous transplant history be taken into account, as we already allocate organs according to ABO blood group matching, a factor that affects transplant outcome approximately the same amount as a previous transplantation. We therefore conclude that the system should be revised so that primary transplant candidates have a better chance of receiving organs than retransplant candidates.	UNIV PITTSBURGH, CTR MED ETH, DIV GEN MED, PITTSBURGH, PA 15261 USA; UNIV MINNESOTA, CTR BIOMED ETH, MINNEAPOLIS, MN 55455 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Minnesota System; University of Minnesota Twin Cities	UBEL, PA (corresponding author), UNIV PITTSBURGH, DEPT MED, 167 LOTHROP HALL, 190 LOTHROP ST, PITTSBURGH, PA 15261 USA.							ABRAMS FR, 1986, JAMA-J AM MED ASSOC, V256, P1784; ANGELL M, 1985, JAMA-J AM MED ASSOC, V254, P1203, DOI 10.1001/jama.254.9.1203; BELLE SH, 1991, CLIN TRANSPLANTS; Bobbitt P., 1978, TRAGIC CHOICES; CARUANA RJ, 1988, TRANSPLANTATION, V46, P472, DOI 10.1097/00007890-198809000-00034; CASSEL CK, 1985, J HEALTH POLIT POLIC, V10, P549, DOI 10.1215/03616878-10-3-549; CASSELL EJ, 1981, JUSTICE HLTH CARE; COHEN B, 1985, SCAND J UROL NEPHROL, P77; COOPER DKC, 1990, TRANSPLANT P, V22, P1457; CWIEK MA, 1984, PUBLIC LAW FORUM, V4, P81; Daniels N, 1987, Theor Med, V8, P69, DOI 10.1007/BF00539767; DANIELS N, 1985, JUST HLTH CARE; DEIN JR, 1989, ANN THORAC SURG, V48, P350, DOI 10.1016/S0003-4975(10)62855-X; EVANS RW, 1992, JAMA-J AM MED ASSOC, V267, P239, DOI 10.1001/jama.267.2.239; HIATT HH, 1975, NEW ENGL J MED, V293, P235, DOI 10.1056/NEJM197507312930506; JECKER NS, 1990, THEOR MED, V11, P125, DOI 10.1007/BF00489456; JENKINS RL, 1987, TRANSPL P, V19, P184; Kilner J., 1990, WHO LIVES WHO DIES E; LAPUMA J, 1988, ARCH INTERN MED, V148, P1809, DOI 10.1001/archinte.148.8.1809; MARKUS BH, 1987, TRANSPLANT P, V19, P63; MILLER M, 1987, CIRCULATION, V75, P20, DOI 10.1161/01.CIR.75.1.20; NAKATANI T, 1989, J HEART TRANSPLANT, V8, P27; OLBRISCH ME, 1991, J HEART LUNG TRANSPL, V10, P948; Rawls J., 1971, THEORY JUSTICE; SHAO ZG, 1988, AM J CARDIOL, V62, P876, DOI 10.1016/0002-9149(88)90885-5; SHAW BW, 1985, TRANSPLANT P, V17, P264; SPITAL A, 1991, NEW ENGL J MED, V325, P1243, DOI 10.1056/NEJM199110243251710; STEVENSON LW, 1991, J AM COLL CARDIOL, V18, P919, DOI 10.1016/0735-1097(91)90747-W; STEVENSON LW, 1991, CIRCULATION S2, V84, P352; WALL WJ, 1988, CLIN TRANSPLANTS	31	127	127	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1993	270	20					2469	2474		10.1001/jama.270.20.2469	http://dx.doi.org/10.1001/jama.270.20.2469			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG671	8230624				2022-12-28	WOS:A1993MG67100029
J	HARPER, JW; ADAMI, GR; WEI, N; KEYOMARSI, K; ELLEDGE, SJ				HARPER, JW; ADAMI, GR; WEI, N; KEYOMARSI, K; ELLEDGE, SJ			THE P21 CDK-INTERACTING PROTEIN CIP1 IS A POTENT INHIBITOR OF G1 CYCLIN-DEPENDENT KINASES	CELL			English	Article							CELL-CYCLE; TYROSINE PHOSPHORYLATION; YEAST; PHASE; CDC2; IDENTIFICATION; EXPRESSION; ACTIVATION; P34CDC2; SYSTEM	The cyclin-dependent kinase Cdk2 associates with cyclins A, D, and E and has been implicated in the control of the G1 to S phase transition in mammals. To identify potential Cdk2 regulators, we have employed an improved two-hybrid system to isolate human genes encoding Cdk-interacting proteins (Cips). CIP1 encodes a novel 21 kd protein that is found in cyclin A, cyclin D1, cyclin E, and Cdk2 immunoprecipitates. p21CIP1 is a potent, tight-binding inhibitor of Cdks and can inhibit the phosphorylation of Rb by cyclin A-Cdk2, cyclin E-Cdk2, cyclin D1-Cdk4, and cyclin D2-Cdk4 complexes. Cotransfection experiments indicate that CIP1 and SV40 T antigen function in a mutually antagonistic manner to control cell cycle progression.	BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DIV MOLEC VIROL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CELL GROWTH & REGULAT, BOSTON, MA 02115 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	HARPER, JW (corresponding author), BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA.		Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849; Harper, Jeffrey/0000-0002-6944-7236	NATIONAL INSTITUTE ON AGING [R01AG011085, R01AG011066] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG 11066, AG-11085] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DOU QP, 1993, CANCER RES, V53, P1493; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARLOW E, ANTIBODDIES LAEBORAT; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUNT T, 1989, CURR OPIN CELL BIOL, V1, P274; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; KATO J, 1993, GENE DEV, V7, P331; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEACH FS, 1993, CANCER RES, V53, P1986; MALLER JL, 1991, CELL, V71, P323; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NEVINS JR, 1992, SCIENCE, V258, P424; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; TSAI LH, 1991, NATURE, V353, P555; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	49	5428	5662	11	272	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 19	1993	75	4					805	816						12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242751				2022-12-28	WOS:A1993MH74900024
J	MICKLEM, G; ROWLEY, A; HARWOOD, J; NASMYTH, K; DIFFLEY, JFX				MICKLEM, G; ROWLEY, A; HARWOOD, J; NASMYTH, K; DIFFLEY, JFX			YEAST ORIGIN RECOGNITION COMPLEX IS INVOLVED IN DNA-REPLICATION AND TRANSCRIPTIONAL SILENCING	NATURE			English	Article							S-CEREVISIAE; HO GENE; PLASMID; PHASE	THE HMR E silencer represses transcription of silent mating-type genes in the budding yeast Saccharomyces cerevisiae and contains three redundant regulatory elements A, E and B (ref. 1). The A element contains the 11 base pair consensus sequence that is essential for the firing of DNA replication origins2. A multisubunit protein called the origin recognition complex (ORC) binds specifically to this consensus sequence within yeast origins in vitro3 and in vivo4. We isolated mutants in A element-mediated silencing and report here that one of the genes we identified, RRR1, encodes ORC2, the 72K subunit of ORC. RRR1/ORC2 is an essential gene, but the rrr1-316 allele, which is viable, is defective in the replication of nuclear DNA and the maintenance of the 2-mum episomal DNA. This is, to our knowledge, the first genetic evidence that ORC is involved in DNA replication and silencing.	CRF, CLARE HALL LABS, S MIMMS EN6 3LD, HERTS, ENGLAND; RES INST MOLEC PATHOL, A-1030 VIENNA, AUSTRIA; MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); MRC Laboratory Molecular Biology				Nasmyth, Kim/0000-0001-7030-4403; Diffley, John/0000-0001-5184-7680; Micklem, Gos/0000-0002-6883-6168				BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BRAND AH, 1987, CELL, V51, P701; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BROACH JR, 1991, MOL BIOL YEAST SACCH, P297; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1989, SCIENCE, V246, P1034, DOI 10.1126/science.2511628; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LIVINGSTON DM, 1977, J MOL BIOL, V116, P249, DOI 10.1016/0022-2836(77)90215-7; MICKLEM TG, 1989, THESIS CAMBRIDGE U; MILLER AM, 1984, EMBO J, V3, P1061, DOI 10.1002/j.1460-2075.1984.tb01927.x; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SHORE D, 1984, EMBO J, V3, P2817, DOI 10.1002/j.1460-2075.1984.tb02214.x; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; ZAKIAN VA, 1979, CELL, V17, P923, DOI 10.1016/0092-8674(79)90332-5	25	207	212	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	1993	366	6450					87	89		10.1038/366087a0	http://dx.doi.org/10.1038/366087a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF007	8232543				2022-12-28	WOS:A1993MF00700062
J	TANAKA, K				TANAKA, K			NEURONAL MECHANISMS OF OBJECT RECOGNITION	SCIENCE			English	Article							INFERIOR TEMPORAL NEURONS; LONG-TERM-MEMORY; INFEROTEMPORAL CORTEX; VISUOTOPIC ORGANIZATION; VISUAL-CORTEX; MACAQUE; MONKEY; PRIMATE; RESPONSES; ATTENTION	Recognition of objects from their visual images is a key function of the primate brain. This recognition is not a template matching between the input image and stored images like the vision in lower animals but is a flexible process in which considerable change in images, resulting from different illumination, viewing angle, and articulation of the object, can be tolerated. Recent experimental findings about the representation of object images in the inferotemporal cortex, a brain structure that is thought to be essential for object vision, are summarized and discussed in relation to the computational frames proposed for object recognition.			TANAKA, K (corresponding author), INST PHYS & CHEM RES, INFORMAT SCI LAB, 2-1 HIROSAWA, WAKO, SAITAMA 35101, JAPAN.		Tanaka, Keiji/N-5917-2015	Tanaka, Keiji/0000-0002-1910-3427				BALLARD DH, 1986, BEHAV BRAIN SCI, V9, P67, DOI 10.1017/S0140525X00021555; BAYLIS GC, 1987, EXP BRAIN RES, V65, P614; BOUSSAOUD D, 1991, J COMP NEUROL, V306, P554, DOI 10.1002/cne.903060403; CHELAZZI L, 1993, NATURE, V363, P345, DOI 10.1038/363345a0; CRICK F, 1984, P NATL ACAD SCI-BIOL, V81, P4586, DOI 10.1073/pnas.81.14.4586; DEAN P, 1976, PSYCHOL BULL, V83, P41, DOI 10.1037/0033-2909.83.1.41; DESIMONE R, 1984, J NEUROSCI, V4, P2051; Edelman S, 1991, Curr Opin Neurobiol, V1, P270; EDELMAN S, 1990, MIT ARTIFICIAL INTEL, V1239; EDELMAN S, 1993, CS9310 WEIZM I SCI T; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P6048, DOI 10.1073/pnas.88.14.6048; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P9136, DOI 10.1073/pnas.88.20.9136; ERICKSON RP, 1968, PSYCHOL REV, V75, P447, DOI 10.1037/h0026752; Foldiak P, 1991, NEURAL COMPUT, V3, P194, DOI 10.1162/neco.1991.3.2.194; FUJITA I, 1992, NATURE, V360, P343, DOI 10.1038/360343a0; FUSTER JM, 1982, J NEUROSCI, V2, P361; FUSTER JM, 1981, SCIENCE, V212, P952, DOI 10.1126/science.7233192; GALLANT JL, 1993, SCIENCE, V259, P100, DOI 10.1126/science.8418487; GATTASS R, 1988, J NEUROSCI, V8, P1831; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; GROSS CG, 1972, HDB SENSORY PHYSL 3B, V8, P451; HINTON GE, 1988, PARALLEL DISTRIBUTED, V1, pCH3; Ito M., 1993, Society for Neuroscience Abstracts, V19, P771; KOBATAKE E, 1992, NEUROSCI RES, V13, P257, DOI 10.1016/0168-0102(92)90038-E; KOBATAKE K, 1991, SOC NEUR ABSTR, V17, P443; KOBATAKE K, 1992, SOC NEUR ABSTR, V18, P146; KOCH C, 1985, HUM NEUROBIOL, V4, P219; MAGUIRE WM, 1984, J NEUROSCI, V4, P1690; Marr D., 1982, VISION; MILLER EK, 1993, J NEUROSCI, V13, P1460; MILLER EK, 1991, SCIENCE, V254, P1377, DOI 10.1126/science.1962197; MISHKIN M, 1983, TRENDS NEUROSCI, V6, P414, DOI 10.1016/0166-2236(83)90190-X; MISHKIN M, 1982, PHILOS T R SOC B, V298, P85, DOI 10.1098/rstb.1982.0074; MIYASHITA Y, 1988, NATURE, V331, P68, DOI 10.1038/331068a0; MIYASHITA Y, 1988, NATURE, V335, P817, DOI 10.1038/335817a0; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; Palmer S., 1981, ATTENTION PERFORM, P135; POGGIO T, 1990, NATURE, V343, P263, DOI 10.1038/343263a0; RICHES IP, 1991, J NEUROSCI, V11, P1763; RICHMOND BJ, 1987, J NEUROPHYSIOL, V58, P1292, DOI 10.1152/jn.1987.58.6.1292; ROCK I, 1987, COGNITIVE PSYCHOL, V19, P280, DOI 10.1016/0010-0285(87)90013-2; ROLLS ET, 1987, NEURAL MOL BASES LEA; SAKAI K, 1991, NATURE, V354, P152, DOI 10.1038/354152a0; SALEEM KS, 1993, CEREB CORTEX, V3, P454, DOI 10.1093/cercor/3.5.454; SCHWARTZ EL, 1983, P NATL ACAD SCI-BIOL, V80, P5776, DOI 10.1073/pnas.80.18.5776; SNIPPE HP, 1992, BIOL CYBERN, V66, P543, DOI 10.1007/BF00204120; SPITZER H, 1988, SCIENCE, V240, P338, DOI 10.1126/science.3353728; TANAKA K, 1991, J NEUROPHYSIOL, V66, P170, DOI 10.1152/jn.1991.66.1.170; TOVEE MJ, 1992, NEUROREPORT, V3, P369, DOI 10.1097/00001756-199204000-00020; ULLMAN S, 1991, IEEE T PATTERN ANAL, V13, P992, DOI 10.1109/34.99234; ULLMAN S, 1989, COGNITION, V32, P193, DOI 10.1016/0010-0277(89)90036-X; VONDERMALSBURG C, 1986, BIOL CYBERN, V54, P29, DOI 10.1007/BF00337113; YOUNG MP, 1992, J NEUROPHYSIOL, V67, P1464, DOI 10.1152/jn.1992.67.6.1464	55	302	304	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	1993	262	5134					685	688		10.1126/science.8235589	http://dx.doi.org/10.1126/science.8235589			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	8235589				2022-12-28	WOS:A1993MD95200030
J	PAYNE, JN; MILNER, PC; SAUL, C; BOWNS, IR; HANNAY, DR; RAMSAY, LE				PAYNE, JN; MILNER, PC; SAUL, C; BOWNS, IR; HANNAY, DR; RAMSAY, LE			LOCAL CONFIDENTIAL INQUIRY INTO AVOIDABLE FACTORS IN DEATHS FROM STROKE AND HYPERTENSIVE DISEASE	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; GENERAL-PRACTICE; NORTHWEST LONDON; CARE; MANAGEMENT; SCOTLAND; QUALITY; HEART; AUDIT	Objective-To audit avoidable deaths from stroke and hypertensive disease. Design-Details of care before death were obtained from general practitioners and other doctors, anonymised, and assessed by two experts against agreed Minimum standards of good practice for detecting and managing hypertension. Setting-Health authority with population of 250000. Subjects-All patients under 75 years who died of stroke, hypertensive disease, or hypertension related causes during November 1990 to October 1991. Main outcome measures-Presence of important avoidable factors and departures from minimum standards of good practice. Results-Adequate information was obtained for 88% (123/139) of eligible cases. Agreement between the assessors was mostly satisfactory. 29% (36/123, 95% confidence interval 21% to 37%) of all cases and 44% (36/81, 34% to 55%) of those with definite hypertension had avoidable factors that may have contributed to death. These were most commonly failures of follow up and continuing smoking. Assessment against standards of minimum good practice showed that care was inadequate but not necessarily deemed to have contributed to death, in a large proportion of patients with definite hypertension. Common shortcomings were inadequate follow up, clinical investigation, and recording of smoking and other relevant risk behaviours. Conclusions-This method of audit can identify shortcomings in care of patients dying of hypertension related disease.	ROTHERHAM HLTH AUTHOR,DEPT PUBL HLTH,ROTHERHAM,ENGLAND; BARNSLEY HLTH AUTHOR,DEPT PUBL HLTH,BARNSLEY,ENGLAND; UNIV SHEFFIELD,SCH MED,DEPT GEN PRACTICE,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND; UNIV SHEFFIELD,SCH MED,DEPT PHARMACOL & THERAPEUT,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND	University of Sheffield; University of Sheffield			Payne, Nick/A-3073-2010					Buck N, 1987, REPORT CONFIDENTIAL; CHAPMAN A, 1989, PRACTITIONER, V233, P1018; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DOLL R, 1964, BMJ-BRIT MED J, V1, P1460, DOI 10.1136/bmj.1.5396.1460; DOLL R, 1964, BRIT MED J, V1, P1399, DOI 10.1136/bmj.1.5395.1399; Fleiss JL, 1981, STAT METHODS RATES P; GILL JS, 1986, NEW ENGL J MED, V315, P1041, DOI 10.1056/NEJM198610233151701; GORDON T, 1972, J AMER MED ASSOC, V221, P661, DOI 10.1001/jama.221.7.661; HALL JA, 1985, J ROY COLL GEN PRACT, V35, P243; KURJI KH, 1984, BMJ-BRIT MED J, V288, P903, DOI 10.1136/bmj.288.6421.903; MANT D, 1989, BRIT MED J, V298, P1360, DOI 10.1136/bmj.298.6684.1360; MICHAEL G, 1984, BMJ-BRIT MED J, V288, P906, DOI 10.1136/bmj.288.6421.906; RITCHIE LD, 1983, BMJ-BRIT MED J, V286, P107, DOI 10.1136/bmj.286.6359.107; RUTSTEIN DD, 1976, NEW ENGL J MED, V294, P582, DOI 10.1056/NEJM197603112941104; SHAPER AG, 1991, BRIT MED J, V302, P1111, DOI 10.1136/bmj.302.6785.1111; SMITH WCS, 1990, BRIT MED J, V300, P981, DOI 10.1136/bmj.300.6730.981; STERN D, 1986, J ROY COLL GEN PRACT, V36, P549; STRASSER T, 1986, J HYPERTENS, V4, P383; TAFFINDER AP, 1984, PRACTITIONER, V228, P595; WILSON JB, 1978, PRACTITIONER, V220, P689; 1992, BMJ, V304, P405; 1985, BMJ, V291, P97; 1992, HLTH NATION; [No title captured]; 1991, 1985 1987 DEP HLTH W	25	47	46	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1993	307	6911					1027	1030		10.1136/bmj.307.6911.1027	http://dx.doi.org/10.1136/bmj.307.6911.1027			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD556	8251776	Green Published, Bronze			2022-12-28	WOS:A1993MD55600015
J	NICHOLSON, KG; KENT, J; IRELAND, DC				NICHOLSON, KG; KENT, J; IRELAND, DC			RESPIRATORY VIRUSES AND EXACERBATIONS OF ASTHMA IN ADULTS	BRITISH MEDICAL JOURNAL			English	Article							RHINOVIRUS INFECTION; PULMONARY-FUNCTION; WHEEZY BRONCHITIS; CHILDREN; TRACT; PRECIPITANTS; VOLUNTEERS; AIRWAYS	Objective-To study the role of respiratory viruses in exacerbations of asthma in adults. Design-Longitudinal study of 138 adults with asthma. Setting-Leicestershire Health Authority. Subjects-48 men and 90 women 19-46 years of age with a mean duration of wheeze of 19.6 years. 75% received regular treatment with bronchodilators; 89% gave a history of eczema, hay fever, allergic rhinitis, nasal polyps, or allergies; 38% had been admitted to hospital with asthma. Main outcome measures-Symptomatic colds and asthma exacerbations; objective exacerbations of asthma with greater-than-or-equal-to 50 l/min reduction in mean peak expiratory flow rate when morning and night time readings on days 1-7 after onset of symptoms were compared with rates during an asymptomatic control period; laboratory confirmed respiratory tract infections. Results-Colds were reported in 80% (223/280) of episodes with symptoms of wheeze, chest tightness, or breathlessness, and 89% (223/250) of colds were associated with asthma symptoms. 24% of 115 laboratory confirmed non-bacterial infections were associated with reductions in mean peak expiratory flow rate greater-than-or-equal-to 50 l/min through days 1-7 and 48% had mean decreases greater-than-or-equal-to 25 l/min. 44% of episodes with mean decreases in flow rate greater-than-or-equal-to 50 l/min were associated with laboratory confirmed infections. Infections with rhinoviruses, coronaviruses OC43 and 229E, influenza B, respiratory syncytial virus, parainfluenza virus, and chlamydia were all associated with objective evidence of an exacerbation of asthma. Conclusions-These findings show that asthma symptoms and reductions in peak flow are often associated with colds and respiratory viruses; respiratory virus infections commonly cause or are associated with exacerbations of asthma in adults.			NICHOLSON, KG (corresponding author), UNIV LEICESTER,SCH MED,DEPT MICROBIOL,LEICESTER LE1 9HN,ENGLAND.							BEARE AS, 1977, CHEMOPROPHYLAXIS VIR, V2, P27; BEASLEY R, 1988, THORAX, V43, P679, DOI 10.1136/thx.43.9.679; BLAIR HT, 1976, AM REV RESPIR DIS, V114, P95; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; FRIDY WW, 1974, ANN INTERN MED, V80, P150, DOI 10.7326/0003-4819-80-2-150; HALL WJ, 1978, ANN INTERN MED, V88, P203, DOI 10.7326/0003-4819-88-2-203; HORN MEC, 1979, ARCH DIS CHILD, V54, P587, DOI 10.1136/adc.54.8.587; HORNER GJ, 1973, AM REV RESPIR DIS, V108, P150; HUDGEL DW, 1979, AM REV RESPIR DIS, V120, P393; HUHTI E, 1974, ANN ALLERGY, V33, P145; IRELAND DC, 1993, J MED VIROL, V40, P96, DOI 10.1002/jmv.1890400204; JOHANSON WG, 1969, AM REV RESPIR DIS, V100, P141; KRAAIJEVELD CA, 1980, J CLIN MICROBIOL, V12, P493, DOI 10.1128/JCM.12.4.493-497.1980; LAMBERT HP, 1972, BMJ-BRIT MED J, V3, P323, DOI 10.1136/bmj.3.5822.323; LO YMD, 1988, LANCET, V2, P679; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MERTSOLA J, 1991, ARCH DIS CHILD, V66, P124, DOI 10.1136/adc.66.1.124; MINOR TE, 1974, J PEDIATR-US, V85, P472, DOI 10.1016/S0022-3476(74)80447-6; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; MINOR TE, 1976, AM REV RESPIR DIS, V113, P149; NICHOLSON KG, 1990, EPIDEMIOL INFECT, V105, P609, DOI 10.1017/S0950268800048251; PICKEN JJ, 1972, AM J MED, V52, P738, DOI 10.1016/0002-9343(72)90079-4; WISELKA MJ, 1992, LANCET, V339, P367; WISELKA MJ, 1991, THORAX, V46, P706, DOI 10.1136/thx.46.10.706; 1962, AM REV RESPIR DIS, V85, P762	25	860	889	0	27	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1993	307	6910					982	986		10.1136/bmj.307.6910.982	http://dx.doi.org/10.1136/bmj.307.6910.982			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC441	8241910	Bronze, Green Published			2022-12-28	WOS:A1993MC44100020
J	SPEELMAN, A; SAVAGE, J; VERBURGH, M				SPEELMAN, A; SAVAGE, J; VERBURGH, M			USE OF CHAPERONES BY GENERAL-PRACTITIONERS	BRITISH MEDICAL JOURNAL			English	Article											SPEELMAN, A (corresponding author), SURGERY,STAITHE RD,LUDHAM NR29 5AB,NORFOLK,ENGLAND.							JONES RH, 1983, J ROY COLL GEN PRACT, V33, P25	1	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1993	307	6910					986	987		10.1136/bmj.307.6910.986	http://dx.doi.org/10.1136/bmj.307.6910.986			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC441	8241911	Bronze, Green Published			2022-12-28	WOS:A1993MC44100021
J	ROWE, JM; CIOBANU, N; ASCENSAO, J; STADTMAUER, EA; WEINER, RS; SCHENKEIN, DP; MCGLAVE, P; LAZARUS, HM				ROWE, JM; CIOBANU, N; ASCENSAO, J; STADTMAUER, EA; WEINER, RS; SCHENKEIN, DP; MCGLAVE, P; LAZARUS, HM			RECOMMENDED GUIDELINES FOR THE MANAGEMENT OF AUTOLOGOUS AND ALLOGENEIC BONE-MARROW TRANSPLANTATION - A REPORT FROM THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP (ECOG)	ANNALS OF INTERNAL MEDICINE			English	Review							VERSUS-HOST DISEASE; COLONY-STIMULATING FACTOR; STEM-CELL TRANSPLANTATION; HEPATIC VENOOCCLUSIVE DISEASE; CYTOMEGALO-VIRUS INFECTION; HIGH-DOSE CHEMOTHERAPY; ORTHOTOPIC LIVER-TRANSPLANTATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; HEMOLYTIC UREMIC SYNDROME; BLOOD PROGENITOR CELLS	Objective: To define the basic state-of-the-art medical care of the patients after bone marrow transplantation as practiced by the Eastern Cooperative Oncology Group. Data Identification: Studies examining the role of bone marrow transplantation in the care of neoplastic disorders identified using computer and bibliographic searches. Study Selection: More than 500 articles, book chapters, and abstracts from meetings, covering all therapeutic and diagnostic aspects of the patient having bone marrow transplantation were critically reviewed; information from over 200 publications is included. Results of Data Analysis: Enormous progress has been made in understanding the biology, therapy, and prophylaxis strategies of bone marrow transplantation and in extending the range of potential marrow donors to include unrelated persons. Dramatic advances have occurred in the prevention of serious infection, including cytomegalovirus infection, formerly a cause of a high rate of mortality. The advent of newer-combination, high-dose chemotherapy regimens and advances in cryopreservation and in vitro marrow purging techniques have led to increased use and greater efficacy of autologous transplantation. Recent advances using recombinant hematopoietic growth factors and autologous peripheral stem cells are likely to reduce morbidity and mortality and significantly shorten the length of hospitalization and the cost of bone marrow transplantation. Conclusions: Bone marrow transplantation now is a common procedure done throughout the world. Cooperative groups have assumed a major role in conducting clinical trials. A standardized approach defining basic standards of care will assure uniformity of management, better interpretation of data, and continued progress in the care of the patient who has had a bone marrow transplantation. Basic research and clinical trials are ongoing to define better methods for the treatment and prevention of graft-versus-host disease and hepatic veno-occlusive disease.	EASTERN ONCOL COOPERAT GRP, DENVER, CO USA		ROWE, JM (corresponding author), UNIV HOSP CLEVELAND, DEPT MED, 2074 ABINGTON RD, CLEVELAND, OH 44106 USA.				NATIONAL CANCER INSTITUTE [U10CA014548, U10CA021115, P30CA043703] Funding Source: NIH RePORTER; NCI NIH HHS [CA21115, CA14548, P30CA43703] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANASETTI C, 1990, HUM IMMUNOL, V29, P79, DOI 10.1016/0198-8859(90)90071-V; ANASETTI C, 1989, NEW ENGL J MED, V320, P197, DOI 10.1056/NEJM198901263200401; ANDERSON KC, 1987, PROG HEMATOL, V15, P137; ANDERSON KC, 1990, NEW ENGL J MED, V323, P315; ANDERSON KC, 1992, TRANSFUSION, V32, P272, DOI 10.1046/j.1537-2995.1992.32392213814.x; ANDERSON KC, HIGH DOSE CANCER THE, P437; ANTIN JH, 1987, J CLIN INVEST, V80, P325, DOI 10.1172/JCI113076; ANTMAN K, 1992, J CLIN ONCOL, V10, P102, DOI 10.1200/JCO.1992.10.1.102; APPELBAUM FR, 1988, BLOOD, V72, P179; APPELBAUM FR, 1990, ANN INTERN MED, V112, P590, DOI 10.7326/0003-4819-112-8-590; ATKINSON K, 1982, BLOOD, V60, P714; ATKINSON K, 1989, BONE MARROW TRANSPL, V4, P247; ATKINSON K, 1990, BLOOD, V75, P2459; ATKINSON K, 1982, BLOOD, V59, P1292; ATKINSON K, 1979, BLOOD, V53, P720; ATKINSON K, 1990, BONE MARROW TRANSPL, V5, P209; ATKINSON K, 1988, BONE MARROW TRANSPL, V3, P5; ATTAL M, 1992, BLOOD, V79, P2834; AUCOUTURIER P, 1987, BLOOD, V70, P779; AULT KA, 1985, J EXP MED, V161, P1483, DOI 10.1084/jem.161.6.1483; AYASH LJ, 1990, J CLIN ONCOL, V8, P1699, DOI 10.1200/JCO.1990.8.10.1699; BAGLIN TP, 1990, BONE MARROW TRANSPL, V5, P439; BARGE AJ, 1989, BLOOD, V74, P1477; BARLOGIE B, 1991, BONE MARROW TRANSPL, V7, P71; BARTHOLOMEW JR, 1989, ARCH INTERN MED, V149, P1959, DOI 10.1001/archinte.149.9.1959; BAUM C, 1902, P NATL ACAD SCI USA, V89, P2804; BEARMAN SI, 1988, J CLIN ONCOL, V6, P1562, DOI 10.1200/JCO.1988.6.10.1562; BEARMAN SI, 1990, BONE MARROW TRANSPL, V5, P407; BEARMAN SI, 1991, EXP HEMATOL, V19, P576; BEARMAN SI, 1992, P AN M AM SOC CLIN, V11, pA263; BEATTY PG, 1985, NEW ENGL J MED, V313, P765, DOI 10.1056/NEJM198509263131301; BEATTY PG, 1991, TRANSPLANTATION, V51, P443, DOI 10.1097/00007890-199102000-00034; BENGTSSON M, 1992, TRANSPLANTATION, V53, P882, DOI 10.1097/00007890-199204000-00032; BENSINGER WI, 1982, TRANSPLANTATION, V33, P427, DOI 10.1097/00007890-198204000-00017; BERENSON RJ, 1991, BLOOD, V77, P1717; BIERMAN SI, 1990, EXP HEMATOL, V18, P699; BLAISE D, 1990, BLOOD, V76, P1092; BLAZAR BR, 1989, BLOOD, V73, P849; BLUME KG, 1987, TRANSPLANTATION, V43, P389, DOI 10.1097/00007890-198703000-00014; BOWDEN RA, 1986, NEW ENGL J MED, V314, P1006, DOI 10.1056/NEJM198604173141602; BOWDEN RA, 1991, BLOOD, V78, P246; BRAINE HG, 1982, BLOOD, V60, P420; BRANDT SJ, 1988, NEW ENGL J MED, V318, P869, DOI 10.1056/NEJM198804073181401; BRANDWEIN JM, 1991, EXP HEMATOL, V19, P191; BUCKNER CD, 1978, TRANSPLANTATION, V26, P233, DOI 10.1097/00007890-197810000-00006; BURCH PA, 1987, J CLIN ONCOL, V5, P1985, DOI 10.1200/JCO.1987.5.12.1985; BUTTURINI A, 1987, BONE MARROW TRANSPL, V2, P233; BYERS VS, 1990, BLOOD, V75, P1426; CAHN JY, 1985, NOUV REV FR HEMATOL, V27, P27; CASSILETH PA, 1993, J CLIN ONCOL, V11, P314, DOI 10.1200/JCO.1993.11.2.314; CHAMPLIN RE, 1989, BLOOD, V73, P606; CHAPPELL ME, 1988, BONE MARROW TRANSPL, V3, P339; CHESON BD, 1989, ANN INTERN MED, V110, P51, DOI 10.7326/0003-4819-110-1-51; CHOPRA R, 1991, J ANTIMICROB CHEMOTH, V28, P93, DOI 10.1093/jac/28.suppl_B.93; CLIFT RA, 1990, BLOOD, V76, P1867; COSSET JM, 1989, RADIOTHER ONCOL, V15, P151, DOI 10.1016/0167-8140(89)90129-1; DEEG HJ, 1985, TRANSPLANTATION, V40, P162, DOI 10.1097/00007890-198508000-00011; DEEG HJ, 1986, BONE MARROW TRANSPL, V1, P151; DEEG HJ, 1989, BLOOD, V74, P2592; DEGRAANHENTZEN YCE, 1989, TRANSFUSION, V29, P757; DEWITTE T, 1990, TRANSPLANTATION, V50, P964, DOI 10.1097/00007890-199012000-00013; Donatsch P, 1981, J Immunoassay, V2, P19, DOI 10.1080/01971528108062989; DONEY KC, 1981, AM J HEMATOL, V11, P1, DOI 10.1002/ajh.2830110102; DULLEY FL, 1987, TRANSPLANTATION, V43, P870, DOI 10.1097/00007890-198743060-00020; DZIK WH, 1989, CONTROVERSIES LEUKOC, P49; ELFENBEIN G, 1991, P219; ELIAS AD, 1992, BLOOD, V79, P3036; EMANUEL D, 1988, ANN INTERN MED, V109, P777, DOI 10.7326/0003-4819-109-10-777; ENGELHARD D, 1991, BONE MARROW TRANSPL, V8, P295; ESSELL JH, 1992, BLOOD, V79, P2784; FAY JW, 1992, BLOOD, V80, pA531; FORMAN SJ, 1987, BLOOD, V70, P587; FREI E, 1989, J CLIN ONCOL, V7, P515, DOI 10.1200/JCO.1989.7.4.515; GAHRTON G, 1991, NEW ENGL J MED, V325, P1267, DOI 10.1056/NEJM199110313251802; GALE RP, 1991, BONE MARROW TRANSPL, V7, P153; GANTENBERG JB, 1990, J CLIN ONCOL, V8, P563; GARDNER FH, 1980, JAMA-J AM MED ASSOC, V243, P35, DOI 10.1001/jama.243.1.35; GIANNI AM, 1990, BONE MARROW TRANSPL, V6, P143; GIEDLUND MA, 1987, NATURE, V273, P759; GLUCKMAN E, 1990, BRIT J HAEMATOL, V74, P277, DOI 10.1111/j.1365-2141.1990.tb02583.x; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; GMUR J, 1983, BLOOD, V62, P473; GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301; GOODRICH JM, 1991, NEW ENGL J MED, V325, P1601, DOI 10.1056/NEJM199112053252303; GRATAMA JW, 1984, BLOOD, V63, P1416; GRATAMA JW, 1986, BONE MARROW TRANSPL, V1, P141; GRATWOHL A, 1983, TRANSPLANTATION, V36, P40, DOI 10.1097/00007890-198307000-00009; GRAW RG, 1971, TRANSPLANTATION, V11, P197, DOI 10.1097/00007890-197102000-00017; GUINAN EC, 1988, BLOOD, V72, P451; GULATI CG, 1982, ANN INTERN MED, V116, P177; HAAS R, 1990, EXP HEMATOL, V18, P94; HERSHKO C, 1980, BIOL BONE MARROW TRA, P159; HESLOP HE, 1989, BLOOD, V74, P1374; HOLLER E, 1989, BLOOD, V73, P2018; HOROWITZ MM, 1990, BLOOD, V75, P555; Ibrahim A, 1991, Bone Marrow Transplant, V7 Suppl 2, P53; JAMPEL RM, 1991, ARCH DERMATOL, V127, P1673, DOI 10.1001/archderm.127.11.1673; JONES RJ, 1987, TRANSPLANTATION, V44, P778, DOI 10.1097/00007890-198712000-00011; JONES RJ, 1991, BLOOD, V77, P649; JONES RJ, 1989, LANCET, V1, P754; JUCKETT M, 1991, BONE MARROW TRANSPL, V7, P405; JUTTNER CA, 1988, TRANSPLANT P, V20, P40; KALLAND T, 1985, J IMMUNOL, V134, P3956; KALLAND T, 1990, J IMMUNOL, V144, P4472; KENNEDY MJ, 1991, J NATL CANCER I, V83, P920, DOI 10.1093/jnci/83.13.920; KENNEDY MS, 1985, AM J MED, V78, P978, DOI 10.1016/0002-9343(85)90221-9; KERNAN NA, 1993, NEW ENGL J MED, V328, P593, DOI 10.1056/NEJM199303043280901; KESSINGER A, 1986, EXP HEMATOL, V14, P192; KESSINGER A, 1988, BLOOD, V71, P723; KESSINGER A, 1991, EXP HEMATOL, V19, P1013; KESSINGER A, 1991, BLOOD, V77, P211; KESSINGER A, 1989, BLOOD, V74, P1260; KORBLING M, 1986, BLOOD, V67, P529; KORBLING M, 1990, J CLIN ONCOL, V8, P978; KOSCIELNIAK E, 1987, BONE MARROW TRANSPL, V1, P379; LARSSON EL, 1987, INT J IMMUNOPHARMACO, V9, P425, DOI 10.1016/0192-0561(87)90016-6; LAZARUS HM, 1992, J CLIN ONCOL, V10, P1682, DOI 10.1200/JCO.1992.10.11.1682; LAZARUS HM, 1992, BONE MARROW TRANSPL, V10, P71; LAZARUS HM, 1991, BLOOD, V78, P830; LEITMAN SF, 1985, TRANSFUSION, V25, P293, DOI 10.1046/j.1537-2995.1985.25485273804.x; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; LERNER KG, 1974, TRANSPLANT P, V6, P367; LINDHOLM A, 1987, TRANSPLANTATION, V43, P680, DOI 10.1097/00007890-198705000-00016; LIVNAT S, 1980, J IMMUNOL, V124, P481; LJUNGMAN P, 1989, J INFECT DIS, V159, P610, DOI 10.1093/infdis/159.4.610; LOBO F, 1991, BONE MARROW TRANSPL, V8, P389; LOOMIS LJ, 1989, AM J KIDNEY DIS, V14, P324, DOI 10.1016/S0272-6386(89)80214-8; LOPEZ C, 1980, LANCET, V2, P1025; LOPEZBERESTEIN G, 1989, ARCH INTERN MED, V149, P2533, DOI 10.1001/archinte.149.11.2533; LOWRY PA, 1992, EXP HEMATOL, V20, P937; LUM LG, 1985, BLOOD, V65, P1422, DOI 10.1182/blood.V65.6.1422.bloodjournal6561422; LUM LG, 1987, BLOOD, V69, P369; MARKUS PM, 1991, SURGERY, V110, P357; MARTIN PJ, 1987, ADV IMMUNOL, V40, P379, DOI 10.1016/S0065-2776(08)60243-6; MARTIN PJ, 1990, BLOOD, V76, P1464, DOI 10.1182/blood.V76.8.1464.1464; MARTIN PJ, 1991, BLOOD, V77, P1821; MASAOKA T, 1989, EXP HEMATOL, V17, P1047; MCCARTHY PL, 1991, BLOOD, V78, P1915; McCullough J, 1989, Oncology (Williston Park), V3, P63; MCDONALD GB, 1991, HEPATOLOGY, V14, pA162; MCDONALD GB, 1984, HEPATOLOGY, V4, P116, DOI 10.1002/hep.1840040121; MCDONALD GB, 1985, TRANSPLANTATION, V39, P603, DOI 10.1097/00007890-198506000-00005; MCDONALD GB, 1987, SEMIN LIVER DIS, V7, P210, DOI 10.1055/s-2008-1040578; MERTELSMANN R, 1990, BONE MARROW TRANSPL, V6, P73; MEYERS JD, 1988, NEW ENGL J MED, V318, P70, DOI 10.1056/NEJM198801143180202; MEYERS JD, 1983, ANN INTERN MED, V98, P442, DOI 10.7326/0003-4819-98-4-442; MEYERS JD, 1986, AM J MED, V81, P27, DOI 10.1016/0002-9343(86)90511-5; MEYERS JD, 1985, CURRENT CLIN TOPICS, P261; MILLER WJ, 1991, BONE MARROW TRANSPL, V7, P227; MILLS J, 1988, ANTIMICROB AGENTS CH, V32, P1057, DOI 10.1128/AAC.32.7.1057; MORGAN M, 1991, BRIT J HAEMATOL, V77, P529; MOROFF G, 1992, TRANSFUSION, V32, P102, DOI 10.1046/j.1537-2995.1992.32292180135.x; MURPHY MF, 1992, TRANSFUSION MED, V2, P311, DOI 10.1111/j.1365-3148.1992.tb00175.x; MURRAY JA, 1987, GASTROENTEROLOGY, V92, P1073, DOI 10.1016/0016-5085(87)90985-1; NEMO GJ, 1991, TRANSFUSION, V31, P584, DOI 10.1046/j.1537-2995.1991.31791368332.x; NEMUNAITIS J, 1991, NEW ENGL J MED, V324, P1773, DOI 10.1056/NEJM199106203242504; NEMUNAITIS J, 1991, BLOOD, V78, P907; NEMUNAITIS J, 1990, BLOOD, V76, P245; NEVILL TJ, 1991, J CLIN ONCOL, V9, P1224, DOI 10.1200/JCO.1991.9.7.1224; NICHOLS CR, 1992, J CLIN ONCOL, V10, P1; NIMER SD, 1990, TRANSPLANTATION, V49, P819; OREILLY RJ, 1983, BLOOD, V62, P941; PACIUCCI PA, 1990, AM J MED, V89, P308, DOI 10.1016/0002-9343(90)90343-C; PECEGO R, 1986, TRANSPLANTATION, V42, P515, DOI 10.1097/00007890-198611000-00015; PERFECT JR, 1992, J INFECT DIS, V165, P891, DOI 10.1093/infdis/165.5.891; PERSSON U, 1987, TRANSPLANTATION, V43, P663, DOI 10.1097/00007890-198705000-00012; Petz L D, 1987, Transfus Med Rev, V1, P85, DOI 10.1016/S0887-7963(87)70009-1; PHILIP T, 1987, NEW ENGL J MED, V316, P1493, DOI 10.1056/NEJM198706113162401; POWDERLY WG, 1988, AM J MED, V84, P826, DOI 10.1016/0002-9343(88)90059-9; POWLES R, 1990, LANCET, V336, P1417, DOI 10.1016/0140-6736(90)93111-2; RADICH J, 1991, BLOOD, V78, pA241; RAPOPORT AP, 1991, BONE MARROW TRANSPL, V8, P421; RAPOPORT AP, 1992, AM J HEMATOL, V40, P86, DOI 10.1002/ajh.2830400203; RAVAGNANI F, 1990, EUR J CANCER, V26, P562, DOI 10.1016/0277-5379(90)90076-6; REED E, 1989, AUTOLOGOUS BONE MARR, P743; REED EC, 1988, ANN INTERN MED, V109, P783, DOI 10.7326/0003-4819-109-10-783; REIFFERS J, 1986, EXP HEMATOL, V14, P312; RHODES DF, 1990, GASTROENTEROLOGY, V99, P536, DOI 10.1016/0016-5085(90)91039-9; RICHMAN CM, 1976, BLOOD, V47, P1031; RINGDEN O, 1991, J ANTIMICROB CHEMOTH, V28, P73, DOI 10.1093/jac/28.suppl_B.73; RIO B, 1986, BLOOD, V67, P1773; ROSEN NR, 1993, TRANSFUSION, V33, P125, DOI 10.1046/j.1537-2995.1993.33293158043.x; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; ROSENBERG SA, 1988, IMMUNOL TODAY, V9, P58, DOI 10.1016/0167-5699(88)91261-3; ROUSEY SR, 1991, AM J MED, V91, P484, DOI 10.1016/0002-9343(91)90184-Y; SALE GE, 1977, AM J PATHOL, V89, P621; Santos G., 1987, CLIN TRANSPLANT, V1, P21; SCHIFFER CA, 1991, BLOOD, V77, P1; SCHIFFER CA, 1983, BLOOD, V62, P815; SCHMIDT GM, 1991, NEW ENGL J MED, V324, P1005, DOI 10.1056/NEJM199104113241501; SEMENZATO G, 1986, BLOOD, V68, P293; SHERIDAN JF, 1990, BLOOD, V75, P1583; SHERIDAN WP, 1992, LANCET, V339, P640, DOI 10.1016/0140-6736(92)90795-5; SHULMAN HM, 1992, BONE MARROW TRANSPL, V10, P197; SHULMAN HM, 1980, GASTROENTEROLOGY, V79, P1178; SHUMAN HM, 1980, AM J MED, V69, P204; SLOANE JP, 1980, J CLIN PATHOL, V33, P344, DOI 10.1136/jcp.33.4.344; SNOVER DC, 1989, HEPATOLOGY, V9, P443, DOI 10.1002/hep.1840090317; SOIFFER RJ, 1991, TRANSPLANTATION, V52, P1014, DOI 10.1097/00007890-199112000-00015; SROUR EF, 1991, BLOOD CELLS, V17, P287; STIFF PJ, 1987, BLOOD, V70, P974; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; STORB R, 1977, NEW ENGL J MED, V296, P61, DOI 10.1056/NEJM197701132960201; STROMEYER FW, 1981, HUM PATHOL, V12, P60, DOI 10.1016/S0046-8177(81)80242-0; SULLIVAN KM, 1991, SEMIN HEMATOL, V28, P250; SULLIVAN KM, 1981, BLOOD, V57, P267, DOI 10.1182/blood.V57.2.267.267; SULLIVAN KM, 1990, NEW ENGL J MED, V323, P705, DOI 10.1056/NEJM199009133231103; SULLIVAN KM, 1988, BLOOD, V72, P546; SULLIVAN KM, 1983, CLIN BONE MARROW TRA, P91; SULLIVAN KM, 1989, CURRENT CONTROVERSIE, P511; TALBOT DC, 1990, BONE MARROW TRANSPL, V6, P17; TAM JY, 1992, NEW ENGL J MED, V326, P891, DOI 10.1056/NEJM199203263261312; TARELLA C, 1991, EUR J CANCER, V27, P22, DOI 10.1016/0277-5379(91)90052-F; TAYLOR KM, 1989, J CLIN ONCOL, V7, P1791, DOI 10.1200/JCO.1989.7.12.1791; TERSTAPPEN LWMM, 1991, BLOOD, V77, P1218; THOMAS ED, 1983, J CLIN ONCOL, V1, P517, DOI 10.1200/JCO.1983.1.9.517; THOMAS ED, 1975, NEW ENGL J MED, V292, P895, DOI 10.1056/NEJM197504242921706; TIBERGHIEN P, 1991, TRANSPLANTATION, V52, P475, DOI 10.1097/00007890-199109000-00016; Tilly H, 1987, Haematol Blood Transfus, V30, P560; TO LB, 1990, EXP HEMATOL, V18, P442; VASSAL G, 1990, ANN INTERN MED, V112, P881, DOI 10.7326/0003-4819-112-11-881_1; VERDONCK LF, 1987, BONE MARROW TRANSPL, V2, P73; VOGELSANG GB, 1992, NEW ENGL J MED, V326, P1055, DOI 10.1056/NEJM199204163261604; VOGELSANG GB, 1988, MEDICINE, V67, P163, DOI 10.1097/00005792-198805000-00003; VOGELSANG GB, 1990, BONE MARROW TRANSPL, P55; WEISDORF D, 1990, BLOOD, V75, P1024, DOI 10.1182/blood.V75.4.1024.1024; WENTZ B, 1989, CONTROVERSIES LEUKOC, P27; WHITSETT CF, 1986, TRANSPLANTATION, V41, P663; WINGARD JR, 1988, BLOOD, V71, P1432; WINGARD JR, 1991, NEW ENGL J MED, V325, P1274, DOI 10.1056/NEJM199110313251803; WINSTON DJ, 1983, ARCH INTERN MED, V143, P1735, DOI 10.1001/archinte.143.9.1735; WITHERSPOON RP, 1986, TRANSPLANTATION, V41, P328, DOI 10.1097/00007890-198603000-00009; WITHERSPOON RP, 1981, BLOOD, V58, P360; WOLFORD JL, 1988, J CLIN GASTROENTEROL, V10, P419, DOI 10.1097/00004836-198808000-00015; WOODRUFF JM, 1976, TRANSPLANT P, V8, P675; YEAGER AM, 1992, BLOOD, V79, P3031; YEE GC, 1988, NEW ENGL J MED, V319, P65, DOI 10.1056/NEJM198807143190201; YEE GC, 1984, TRANSPL P, V17, P196; YORK A, 1992, BONE MARROW TRANSPL, V10, P415; 1989, JAMA-J AM MED ASSOC, V262, P335; 1991, REPORT NATIONAL MARR; 1991, MMWR MORBID MORTAL W, V40, P5	242	85	86	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1994	120	2					143	158		10.7326/0003-4819-120-2-199401150-00008	http://dx.doi.org/10.7326/0003-4819-120-2-199401150-00008			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ671	8256974				2022-12-28	WOS:A1994MQ67100008
J	SULTAN, AH; KAMM, MA; HUDSON, CN; THOMAS, JM; BARTRAM, CI				SULTAN, AH; KAMM, MA; HUDSON, CN; THOMAS, JM; BARTRAM, CI			ANAL-SPHINCTER DISRUPTION DURING VAGINAL DELIVERY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IDIOPATHIC FECAL INCONTINENCE; PELVIC FLOOR MUSCULATURE; ANORECTAL INCONTINENCE; FOLLOW-UP; CHILDBIRTH; DAMAGE; ENDOSONOGRAPHY; INNERVATION; INJURY	Background. Lacerations of the anal sphincter or injury to sphincter innervation during childbirth are major causes of fecal incontinence, but the incidence and importance of occult sphincter damage during routine vaginal delivery are unknown. We sought to determine the incidence of damage to the anal sphincter and the relation of injury to symptoms, anorectal physiologic function, and the mode of delivery. Methods. We studied 202 consecutive women six weeks before delivery, 150 of them six weeks after delivery, and 32 with abnormal findings six months after delivery. Symptoms of anal incontinence and fecal urgency were assessed, and anal endosonography, manometry, perineometry, and measurement of the terminal motor latency of the pudendal nerves were performed. Results. Ten of the 79 primiparous women (13 percent) and 11 of the 48 multiparous women (23 percent) who delivered vaginally had anal incontinence or fecal urgency when studied six weeks after delivery. Twenty-eight of the 79 primiparous women (35 percent) had a sphincter defect on endosonography at six weeks; the defect persisted in all 22 women studied at six months. Of the 48 multiparous women, 19 (40 percent) had a sphincter defect before delivery and 21 (44 percent) afterward. None of the 23 women who underwent cesarean section had a new sphincter defect after delivery. Eight of the 10 women who underwent forceps delivery had sphincter defects, but none of the 5 women who underwent vacuum extractions had such defects. Internal-sphincter defects were associated with a significantly lower mean (+/-SD) resting anal pressure (61+/-11 vs. 48+/-10 mm Hg, P<0.001) six weeks post partum, and external-sphincter defects were associated with a significantly lower squeeze pressure (increase above resting pressure, 70+/-38 vs. 44+/-13 mm Hg; P<0.001). There was a strong association (P<0.001) between sphincter defects and the development of bowel symptoms. Conclusions. Occult sphincter defects are common after vaginal delivery, especially forceps delivery, and are often associated with disturbance of bowel function.	ST MARKS HOSP,CITY RD,LONDON EC1V 2PS,ENGLAND; ST BARTHOLOMEWS HOMERTON HOSP,LONDON,ENGLAND	Imperial College London; University of London; Queen Mary University London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEN RE, 1990, BRIT J OBSTET GYNAEC, V97, P770, DOI 10.1111/j.1471-0528.1990.tb02570.x; BEERSIEK F, 1979, J NEUROL SCI, V42, P111, DOI 10.1016/0022-510X(79)90156-4; BROWNING GGP, 1983, BRIT MED J, V286, P1873, DOI 10.1136/bmj.286.6381.1873; BURNETT SJD, 1991, BRIT J RADIOL, V64, P225, DOI 10.1259/0007-1285-64-759-225; CAPUTO RM, 1992, CURR OPIN OBSTET GYN, V4, P565; CHERRY DA, 1988, SURG CLIN N AM, V68, P1217; COATS PM, 1980, BRIT J OBSTET GYNAEC, V87, P408, DOI 10.1111/j.1471-0528.1980.tb04569.x; HAADEM K, 1988, EUR J OBSTET GYN R B, V27, P27, DOI 10.1016/S0028-2243(88)80007-8; HAADEM K, 1991, OBSTET GYNECOL, V78, P823; HENRY MM, 1982, BRIT J SURG, V69, P470, DOI 10.1002/bjs.1800690813; JOHANSON RB, 1993, BRIT J OBSTET GYNAEC, V100, P524, DOI 10.1111/j.1471-0528.1993.tb15301.x; JONES PN, 1987, INT J COLORECTAL DIS, V2, P93, DOI 10.1007/BF01647699; LAURBERG S, 1989, DIS COLON RECTUM, V32, P737, DOI 10.1007/BF02562120; LAW PJ, 1989, GASTROINTEST RADIOL, V14, P349, DOI 10.1007/BF01889235; LAW PJ, 1991, BRIT J SURG, V78, P312, DOI 10.1002/bjs.1800780315; NEILL ME, 1980, J NEUROL NEUROSUR PS, V43, P343, DOI 10.1136/jnnp.43.4.343; NIELSEN MB, 1992, BRIT J SURG, V79, P104, DOI 10.1002/bjs.1800790204; ORROM WJ, 1990, BRIT J SURG, V77, P876, DOI 10.1002/bjs.1800770810; ROGERS J, 1988, GUT, V29, P1131, DOI 10.1136/gut.29.8.1131; SNOOKS SJ, 1985, BRIT J OBSTET GYNAEC, V92, P824, DOI 10.1111/j.1471-0528.1985.tb03053.x; SNOOKS SJ, 1990, BRIT J SURG, V77, P1358, DOI 10.1002/bjs.1800771213; SNOOKS SJ, 1984, LANCET, V2, P546; SULTAN AH, 1993, BRIT J SURG, V80, P508, DOI 10.1002/bjs.1800800435; SULTAN AH, 1992, GUT, V33, pS29; SULTAN AH, 1993, ATLAS GASTROINTESTIN, P115; SULTAN AH, IN PRESS DIS COLON R; SULTAN AH, IN PRESS BR J SURG; SUN WM, 1989, GASTROENTEROLOGY, V97, P130, DOI 10.1016/0016-5085(89)91425-X; SWASH M, 1992, COLOPROCTOLOGY PELVI, P184; Swash M, 1992, COLOPROCTOLOGY PELVI, P196; Thacker S B, 1983, Obstet Gynecol Surv, V38, P322, DOI 10.1097/00006254-198306000-00003; VACCA A, 1989, EFFECTIVE CARE PREGN, V2, P1216	32	1097	1125	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1993	329	26					1905	1911		10.1056/NEJM199312233292601	http://dx.doi.org/10.1056/NEJM199312233292601			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM885	8247054				2022-12-28	WOS:A1993MM88500001
J	YODAIKEN, RE				YODAIKEN, RE			THE MIRACLE OF THE EYE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1993	119	12					1214	1215		10.7326/0003-4819-119-12-199312150-00009	http://dx.doi.org/10.7326/0003-4819-119-12-199312150-00009			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM121	8239253				2022-12-28	WOS:A1993MM12100009
J	CHOY, B; GREEN, MR				CHOY, B; GREEN, MR			EUKARYOTIC ACTIVATORS FUNCTION DURING MULTIPLE STEPS OF PREINITIATION COMPLEX ASSEMBLY	NATURE			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR ATF; TATA-BINDING-PROTEIN; GAL4 DERIVATIVES; TFIID COMPLEX; INVITRO; MECHANISM; DNA; DOMAIN; PROMOTERS	Eukaryotic activator proteins (activators) stimulate transcription by increasing assembly of the preinitiation complex. We have developed methods to quantify the stable assembly of general transcription factors into transcriptional complexes in response to activators. We show that activators function during at least two stages of preinitiation complex assembly: first, to recruit the general transcription factor TFIIB, and then at a second step, after TFIIB entry. It is at this second step that the TATA-box binding protein associated factors act. This step also seems to be critical for activators to stimulate transcription synergistically.			CHOY, B (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,373 PLANTAT ST,WORCESTER,MA 01605, USA.							ARIAS JA, 1989, J BIOL CHEM, V264, P3223; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; CARCAMO J, 1989, J BIOL CHEM, V264, P7704; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CAREY MF, 1986, J BIOL CHEM, V261, P4309; COLGAN J, 1993, NATURE, V362, P549, DOI 10.1038/362549a0; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; HA H, 1993, GENE DEV, V7, P1021; HAGEMEIER C, 1992, J VIROL, V66, P4452, DOI 10.1128/JVI.66.7.4452-4456.1992; HAHN S, 1993, NATURE, V363, P672, DOI 10.1038/363672a0; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HAWLEY D, 1991, TRENDS BIOCHEM SCI, V16, P317, DOI 10.1016/0968-0004(91)90130-N; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; ING NH, 1992, J BIOL CHEM, V267, P17617; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JOHNSON FB, 1992, GENE DEV, V6, P2177, DOI 10.1101/gad.6.11.2177; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KATAGIRI F, 1990, GENE DEV, V4, P1899, DOI 10.1101/gad.4.11.1899; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1992, J BIOL CHEM, V267, P679; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUNDSETH R, 1992, J BIOL CHEM, V267, P7845; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WAMPLER SL, 1992, GENE DEV, V6, P1542, DOI 10.1101/gad.6.8.1542; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5291, DOI 10.1073/pnas.89.12.5291	50	264	267	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 9	1993	366	6455					531	536		10.1038/366531a0	http://dx.doi.org/10.1038/366531a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	8255291				2022-12-28	WOS:A1993ML21800060
J	OLSCHWANG, S; TIRET, A; LAURENTPUIG, P; MULERIS, M; PARC, R; THOMAS, G				OLSCHWANG, S; TIRET, A; LAURENTPUIG, P; MULERIS, M; PARC, R; THOMAS, G			RESTRICTION OF OCULAR FUNDUS LESIONS TO A SPECIFIC SUBGROUP OF APC MUTATIONS IN ADENOMATOUS POLYPOSIS-COLI PATIENTS	CELL			English	Article							RETINAL-PIGMENT EPITHELIUM; GARDNER SYNDROME; CONGENITAL HYPERTROPHY; DNA MARKERS; EXTRACOLONIC MANIFESTATIONS; COLORECTAL-CANCER; LONG ARM; GENE; CHROMOSOME-5; DELETION	In humans, alteration of the tumor suppressor gene, APC, causes adenomatous polyposis coll, a condition causing predisposition to colorectal cancer. The syndrome inconsistantly associates characteristic patches of congenital hypertrophy of the retinal pigment epithelium (CHRPE). Ocular examination revealed that patients expressing CHRPE tend to cluster within specific families. The exact APC mutation was identified in 42 unrelated patients. In all cases these mutations were predicted to lead to the synthesis of a truncated protein. The extent of CHRPE was found to be dependent on the position of the mutation along the coding sequence. CHRPE lesions are almost always absent if the mutation occurs before exon 9, but are systematically present if it occurs after this exon. Thus, the range of phenotypic expression observed among affected patients may result in part from different allelic manifestations of APC mutations.	HOP NECKER ENFANTS MALAD,SERV OPHTHALMOL,F-75015 PARIS,FRANCE; INST CURIE,STRUCT & MUTAGENESE CHROMOSOM LAB,F-75005 PARIS,FRANCE; HOP ST ANTOINE,SERV CHIRURG DIGEST,F-75571 PARIS 12,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	OLSCHWANG, S (corresponding author), INST CURIE,GENET TUMEURS LAB,26 RUE ULM,F-75005 PARIS,FRANCE.		Olschwang, Sylviane/G-2716-2013; Laurent-Puig, Pierre/K-3641-2019; laurent-puig, pierre/B-2226-2013	Olschwang, Sylviane/0000-0001-7078-3029; Laurent-Puig, Pierre/0000-0001-8475-5459; laurent-puig, pierre/0000-0001-8475-5459				AIELLO LP, 1993, ARCH OPHTHALMOL-CHIC, V111, P302, DOI 10.1001/archopht.1993.01090030020012; BABA S, 1990, DIS COLON RECTUM, V33, P660, DOI 10.1007/BF02150741; BELL B, 1993, DIGEST DIS SCI, V38, P185, DOI 10.1007/BF01296795; BLAIR NP, 1980, AM J OPHTHALMOL, V90, P661, DOI 10.1016/S0002-9394(14)75133-5; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BULOW S, 1986, SCAND J SOC MED, V14, P67; BURN J, 1991, J MED GENET, V28, P289, DOI 10.1136/jmg.28.5.289; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; CHAMOT L, 1993, AM J OPHTHALMOL, V115, P154, DOI 10.1016/S0002-9394(14)73918-2; COSTES B, 1993, HUM MOL GENET, V2, P393, DOI 10.1093/hmg/2.4.393; CROSS I, 1992, J MED GENET, V29, P175, DOI 10.1136/jmg.29.3.175; DUNLOP MG, 1990, AM J HUM GENET, V47, P982; DUNLOP MG, 1991, LANCET, V337, P313, DOI 10.1016/0140-6736(91)90940-Q; GARDNER EJ, 1953, AM J HUM GENET, V5, P139; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GRODEN J, 1993, AM J HUM GENET, V52, P263; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAMELIN R, 1993, ONCOGENE, V8, P2213; HEINEMANN MH, 1991, GRAEF ARCH CLIN EXP, V229, P213, DOI 10.1007/BF00167870; Herrera L, 1990, FAMILIAL ADENOMATOUS; HODGSON SV, 1993, J MED GENET, V30, P369, DOI 10.1136/jmg.30.5.369; HOULSTON R, 1990, LANCET, V335, P484, DOI 10.1016/0140-6736(90)90724-J; IWAMA T, 1990, BRIT J SURG, V77, P273, DOI 10.1002/bjs.1800770312; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KOBAYASHI T, 1991, AM J MED GENET, V41, P460, DOI 10.1002/ajmg.1320410416; KROPILAK M, 1989, DIS COLON RECTUM, V32, P778, DOI 10.1007/BF02562128; KRUSH AJ, 1988, AM J MED GENET, V29, P323, DOI 10.1002/ajmg.1320290211; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; LEWIS RA, 1984, OPHTHALMOLOGY, V91, P916; LYNCH HT, 1985, CA-CANCER J CLIN, V35, P95, DOI 10.3322/canjclin.35.2.95; MOORE AT, 1992, OPHTHALMIC PAED GEN, V13, P67, DOI 10.3109/13816819209087606; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MYIOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OLSCHWANG S, 1993, AM J HUM GENET, V52, P273; OLSCHWANG S, 1991, GASTROENTEROLOGY, V101, P154, DOI 10.1016/0016-5085(91)90472-W; OLSCHWANG S, 1991, LANCET, V337, P1171, DOI 10.1016/0140-6736(91)92849-W; PARKER JA, 1990, CAN J OPHTHALMOL, V25, P159; PAUL P, 1993, HUM MOL GENET, V2, P925, DOI 10.1093/hmg/2.7.925; PETERSEN GM, 1991, GASTROENTEROLOGY, V100, P1658, DOI 10.1016/0016-5085(91)90666-9; RAMOS R, 1990, FAMILIAL ADENOMATOUS, P133; Sambrook J, 1989, MOL CLONING LABORATO; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; SPIRIO L, 1991, NUCLEIC ACIDS RES, V19, P6348, DOI 10.1093/nar/19.22.6348; THOMPSON LH, 1973, P NATL ACAD SCI USA, V70, P3094, DOI 10.1073/pnas.70.11.3094; TRABOULSI EI, 1988, OPHTHALMOLOGY, V95, P964; TRABOULSI EI, 1987, NEW ENGL J MED, V316, P661, DOI 10.1056/NEJM198703123161104; TRABOULSI EI, 1990, AM J OPHTHALMOL, V110, P550, DOI 10.1016/S0002-9394(14)77880-8; VARESCO L, 1993, AM J HUM GENET, V52, P280; VARESCO L, 1989, P NATL ACAD SCI USA, V86, P10118, DOI 10.1073/pnas.86.24.10118; WILLIAMSON R, 1991, CYTOGENET CELL GENET, V58, P1190, DOI 10.1159/000133727	56	263	268	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 3	1993	75	5					959	968		10.1016/0092-8674(93)90539-3	http://dx.doi.org/10.1016/0092-8674(93)90539-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252631	Bronze			2022-12-28	WOS:A1993MK96600015
J	FOX, E; STOCKING, C				FOX, E; STOCKING, C			ETHICS CONSULTANTS RECOMMENDATIONS FOR LIFE-PROLONGING TREATMENT OF PATIENTS IN A PERSISTENT VEGETATIVE STATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-CARE; ILL PATIENTS; DECISIONS; PHYSICIANS; PRINCIPLES; CONSENSUS; SERVICE; SUPPORT; IMPACT	Objective.-Surprisingly little is known about the content of ethics consultants' recommendations. We chose to study this issue using hypothetical persistent vegetative state (PVS) cases. We addressed four questions: What recommendations do ethics consultants give regarding life-prolonging treatment (LPT) in PVS cases? To what degree is there consensus? What factors influence recommendations? Do recommendations conform to established guidelines? Design.-Questionnaire survey. Our questionnaire asked subjects what they would recommend for seven hypothetical vignettes involving a PVS patient that varied with respect to advance directives and family wishes. We also questioned subjects about demographic characteristics, ethics consultation experience, and personal preference for LPT in PVS. Subjects.-Attendees at an annual meeting of the Society for Bioethics Consultation (n=154). Results.-The response rate was 77%. Eighty-one percent of respondents were ethics committee members and 62% were ethics consultants. There was general agreement among respondents for only one of seven vignettes: in the case of a PVS patient whose advance directive and family agree that LPT be stopped, 93% recommended stopping all LPT. Responses to other vignettes varied considerably. Although patient wishes were an important factor influencing recommendations, none of the respondents adhered invariably to the patient's advance directive. Recommendations were also influenced by family wishes, resource allocation considerations, legal constraints, and personal preference for LPT in PVS. Guidelines we examined were generally too equivocal to be useful for evaluating ethics consultants' recommendations. Conclusions.-The finding of wide variability in ethics consultants' recommendations suggests a need to clarify standards for ethics consultation.	UNIV CHICAGO, CTR CLIN MED ETH, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago				Fox, Ellen/0000-0001-9029-7052				[Anonymous], 1990, CRIT CARE MED, V18, P1435; [Anonymous], 1989, NEUROLOGY, V39, P125; [Anonymous], 1993, ANN NEUROL, V33, P386; BONE RC, 1990, CHEST, V97, P949, DOI 10.1378/chest.97.4.949; BOYD K, 1991, LANCET, V337, P96; BRENNAN TA, 1988, JAMA-J AM MED ASSOC, V260, P803, DOI 10.1001/jama.260.6.803; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FLEISS JL, 1971, PSYCHOL BULL, V76, P378, DOI 10.1037/h0031619; FLETCHER JC, 1989, ETHICS CONSULTATION, P185; FRADER J, 1993, NEWSLETTER SOC BIOET, P2; La Puma J, 1992, QRB Qual Rev Bull, V18, P17; LANKEN PN, 1991, ANN INTERN MED, V115, P478; LAPUMA J, 1988, JAMA-J AM MED ASSOC, V260, P808, DOI 10.1001/jama.260.6.808; LAPUMA J, 1992, AM J MED, V92, P346, DOI 10.1016/0002-9343(92)90262-A; LAPUMA J, 1987, WESTERN J MED, V146, P633; LYNN J, 1986, BY NO EXTRAORDINARY; MEADOW W, 1992, PEDIATRICS, V89, P1083; MICETICH K, 1986, BY NO EXTRAORDINARY, P39; MILLER DK, 1992, J GEN INTERN MED, V7, P475, DOI 10.1007/BF02599446; PERKINS HS, 1988, AM J MED, V85, P761; PERKINS HS, 1990, AM J MED, V89, P185, DOI 10.1016/0002-9343(90)90298-R; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; SABINE M, 1992, J GEN INTERN MED, V7, P46; SELF DJ, 1991, THEOR MED, V12, P117, DOI 10.1007/BF00489792; SIEGLER M, 1988, MED ETHICS ANNOTATED; SMITH DG, 1987, ARCH INTERN MED, V147, P1242, DOI 10.1001/archinte.147.7.1242; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; STANLEY JM, 1989, J MED ETHICS, V15, P129, DOI 10.1136/jme.15.3.129; TULSKY JA, 1992, AM J MED, V92, P343, DOI 10.1016/0002-9343(92)90261-9; UHLMANN RF, 1987, ANN INTERN MED, V106, P879, DOI 10.7326/0003-4819-106-6-879; 1987, GUIDELINES TERMINATI; 1989, CURRENT OPINIONS; 1990, JAMA-J AM MED ASSOC, V263, P426	34	49	49	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1993	270	21					2578	2582		10.1001/jama.270.21.2578	http://dx.doi.org/10.1001/jama.270.21.2578			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ266	8230643				2022-12-28	WOS:A1993MJ26600025
J	KAELL, AT; REDECHA, PR; ELKON, KB; GOLIGHTLY, MG; SCHULMAN, PE; DATTWYLER, RJ; KAELL, DL; INMAN, RD; CHRISTIAN, CL; VOLKMAN, DJ				KAELL, AT; REDECHA, PR; ELKON, KB; GOLIGHTLY, MG; SCHULMAN, PE; DATTWYLER, RJ; KAELL, DL; INMAN, RD; CHRISTIAN, CL; VOLKMAN, DJ			OCCURRENCE OF ANTIBODIES TO BORRELIA-BURGDORFERI IN PATIENTS WITH NONSPIROCHETAL SUBACUTE BACTERIAL-ENDOCARDITIS	ANNALS OF INTERNAL MEDICINE			English	Article						BORRELIA BURGDORFERI; ENDOCARDITIS, SUBACUTE BACTERIAL; LYME DISEASE; RHEUMATOID FACTOR; ENZYME-LINKED IMMUNOSORBENT ASSAY	LINKED IMMUNOSORBENT-ASSAY; LYME-DISEASE SPIROCHETE; SEROLOGIC TESTS; INFECTIVE ENDOCARDITIS; T-CELL; ARTHRITIS; REACTIVITY; DIAGNOSIS; ANTIGENS	Objective: To determine the prevalence and specificity of antibodies to Borrelia burgdorferi in patients with nonspirochetal subacute bacterial endocarditis and assess whether increased levels of antibodies to B. burgdorferi were attributable to rheumatoid factor. Design: Retrospective case-control study. Setting: Urban referral center in an area devoid of infected ticks as a source of endocarditis sera. Patients: Sera from 30 consecutive patients with culture-proven subacute endocarditis between 1979 and 1981 were compared with 30 control sera collected between 1989 and 1990. In addition, sera from 20 consecutive patients with rheumatoid arthritis who were positive for rheumatoid factor were collected between 1991 and 1992. Sera were compared with a convenience sample from 15 patients who met the criteria for Lyme disease. Measurements: Antibodies to B. burgdorferi were assessed by enzyme-linked immunosorbent assay (ELISA) and immunoblot analysis, IgM rheumatoid factor was quantified using solid-phase radioimmunoassay or latex agglutination techniques. Results. Thirteen of 30 patients with endocarditis (43%) compared with 3 of 30 normal controls (10%) had increased levels of antibodies to B. burgdorferi (P < 0.01). Of these 13 patients, only 1 had an immunoblot consistent with previous infection. The other's had nonspecific immunoblots: 5 showed isolated 60-kd reactivity; 1 patient had isolated 41-kd reactivity; and 6 had no bands of reactivity. Immunoblots of the 3 controls with increased antibodies showed only isolated 41-kd reactivity. Thus, the specificity of the B. burgdorferi antibody test in patients with endocarditis was only 60% (95% Cl, 42% to 78%), compared with 90% (CI, 79% to 100%) in controls. No correlation was noted between IgM rheumatoid factor and antibodies to B. burgdorferi in patients with endocarditis (r = 0.2; P > 0.2). Only 1 of 20 patients with rheumatoid arthritis without known bacterial infections had antibodies to B. burgdorferi. Conclusions: Although a positive ELISA test for B. burgdorferi may be a ''true positive,'' a positive serologic test alone does not ensure that the clinical problem is due to Lyme borreliosis. Cross-reactive antibodies to shared epitopes between B. burgdorferi and the endocarditis organism may account for the high false-positive results.	CORNELL UNIV, MED CTR, NEW YORK, NY 10021 USA; TORONTO WESTERN HOSP, TORONTO M5T 2S8, ONTARIO, CANADA	Cornell University; University of Toronto; University Toronto Affiliates; University Health Network Toronto	KAELL, AT (corresponding author), SUNY STONY BROOK, STONY BROOK, NY 11794 USA.		Dattwyler, Raymond/ABH-2292-2021; Kaell, Alan T/AAI-2462-2019	Dattwyler, Raymond/0000-0002-1983-1301; Inman, Robert/0000-0002-4750-1422; Kaell, Alan/0000-0001-8473-4551	NIAID NIH HHS [P01 AI2972301] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; AZEVEDO J, 1987, EUR HEART J SUPPL, V5, P71; BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; BARBOUR AG, 1989, ANN INTERN MED, V110, P501, DOI 10.7326/0003-4819-110-7-501; BARBOUR AG, 1986, INFECT IMMUN, V52, P549, DOI 10.1128/IAI.52.2.549-554.1986; BECK G, 1990, BIOCHEM BIOPH RES CO, V167, P89, DOI 10.1016/0006-291X(90)91734-A; CHURCHILL MA, 1977, ANN INTERN MED, V87, P754, DOI 10.7326/0003-4819-87-6-754; COOKE W D, 1990, Arthritis and Rheumatism, V33, pS84; CORPUZ M, 1991, ARCH INTERN MED, V151, P1837, DOI 10.1001/archinte.151.9.1837; CRAFT JE, 1984, J INFECT DIS, V149, P789, DOI 10.1093/infdis/149.5.789; CRAFT JE, 1986, J CLIN INVEST, V78, P934, DOI 10.1172/JCI112683; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; DEJOY SQ, 1989, J EXP MED, V170, P369, DOI 10.1084/jem.170.2.369; DUFFY J, 1988, MAYO CLIN PROC, V63, P1116, DOI 10.1016/S0025-6196(12)65506-2; ELKON KB, 1983, AM J MED, V75, P785, DOI 10.1016/0002-9343(83)90408-4; Goebel K M, 1988, Scand J Rheumatol Suppl, V75, P314; GRODZICKI RL, 1988, J INFECT DIS, V157, P790, DOI 10.1093/infdis/157.4.790; HANSEN K, 1988, J CLIN MICROBIOL, V26, P338, DOI 10.1128/JCM.26.2.338-346.1988; HANSEN K, 1988, INFECT IMMUN, V56, P2047, DOI 10.1128/IAI.56.8.2047-2053.1988; HARDIN JA, 1990, CLIN ASPECTS AUTOIMM, V4, P23; KAELL AT, 1990, JAMA-J AM MED ASSOC, V264, P2916, DOI 10.1001/jama.264.22.2916; KUJALA GA, 1987, J RHEUMATOL, V14, P772; LAVOIE PE, 1988, ANN NY ACAD SCI, V539, P460, DOI 10.1111/j.1749-6632.1988.tb31907.x; LUFT BJ, 1991, J IMMUNOL, V146, P2776; LUGER SW, 1990, ARCH INTERN MED, V150, P761, DOI 10.1001/archinte.150.4.761; MAGNARELLI LA, 1989, J INFECT DIS, V159, P43, DOI 10.1093/infdis/159.1.43; MAGNARELLI LA, 1990, J CLIN MICROBIOL, V28, P1276, DOI 10.1128/JCM.28.6.1276-1279.1990; MAYO DR, 1991, NEW ENGL J MED, V324, P419; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; ROSA PA, 1989, J INFECT DIS, V160, P1018, DOI 10.1093/infdis/160.6.1018; RUSSELL H, 1984, J INFECT DIS, V149, P465, DOI 10.1093/infdis/149.3.465; SALATA RA, 1989, MEDICINE, V68, P225, DOI 10.1097/00005792-198907000-00005; SCHWARTZ BS, 1989, JAMA-J AM MED ASSOC, V262, P3431, DOI 10.1001/jama.262.24.3431; SHANAFELT MC, 1991, J IMMUNOL, V146, P3985; STEERE AC, 1991, NEW ENGL J MED, V324, P129; STEERE AC, 1993, JAMA-J AM MED ASSOC, V269, P1812, DOI 10.1001/jama.269.14.1812; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; TAKAYAMA K, 1987, INFECT IMMUN, V55, P2311, DOI 10.1128/IAI.55.9.2311-2313.1987; TERPENNING MS, 1987, AM J MED, V83, P626, DOI 10.1016/0002-9343(87)90890-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILLIAMS RC, 1962, J CLIN INVEST, V41, P666, DOI 10.1172/JCI104523; 1989, MMWR MORBID MORTAL W, V38, P668; 1991, MMWR MORBID MORTAL W, V39, P19	43	21	21	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1993	119	11					1079	1083		10.7326/0003-4819-119-11-199312010-00004	http://dx.doi.org/10.7326/0003-4819-119-11-199312010-00004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ335	8239226				2022-12-28	WOS:A1993MJ33500004
J	STARR, P				STARR, P			THE FRAMEWORK OF HEALTH-CARE REFORM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									PRINCETON UNIV,PRINCETON,NJ 08544	Princeton University									0	27	28	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1993	329	22					1666	1672		10.1056/NEJM199311253292228	http://dx.doi.org/10.1056/NEJM199311253292228			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MJ546	8232454				2022-12-28	WOS:A1993MJ54600038
J	LEMESHOW, S; TERES, D; KLAR, J; AVRUNIN, JS; GEHLBACH, SH; RAPOPORT, J				LEMESHOW, S; TERES, D; KLAR, J; AVRUNIN, JS; GEHLBACH, SH; RAPOPORT, J			MORTALITY PROBABILITY-MODELS (MPM-II) BASED ON AN INTERNATIONAL COHORT OF INTENSIVE-CARE UNIT PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLASSIFICATION-SYSTEM; ACUTE PHYSIOLOGY; ICU PATIENTS; APACHE; PREDICTION; HEMORRHAGE; SCORE; RISK	Objective.-To revise and update models in the Mortality Probability Model (MPM II) system to estimate the probability of hospital mortality among 19 124 intensive care unit (ICU) patients that can be used for quality assessment within and among ICUs. Design and Setting.-Models developed and validated on consecutive admissions to adult medical and surgical ICUs in 12 countries. Patients.-A total of 12 610 patients for model development, 6514 patients for model validation. Patients younger than 18 years and burn, coronary care, and cardiac surgery patients were excluded. Outcome Measure.-Vital status at hospital discharge. Results.-The admission model, MPM0, contains 15 readily obtainable variables. In developmental and validation samples it calibrated well (goodness-of-fit tests: P=.623 and P=.327, respectively, where a high P value represents good fit between observed and expected values) and discriminated well (area under the receiver operating characteristic curve=0.837 and 0.824, respectively). The 24-hour model, MPM24 (developed on 10 357 patients still in the ICU at 24 hours), contains five of the admission variables and eight additional variables easily ascertained at 24 hours. It also calibrated well (P=.764 and P=.231 in the developmental and validation samples, respectively) and discriminated well (area under the receiver operating characteristic curve=0.844 and 0.836 in the developmental and validation samples, respectively). Conclusions.-Among severity systems for intensive care patients, the MPM0 is the only model available for use at ICU admission. Both MPM0 and MPM2, are useful research tools and provide important clinical information when used alone or together.	BAYSTATE MED CTR,DIV CRIT CARE,SPRINGFIELD,MA 01199; UNIV MASSACHUSETTS,SCH PUBL HLTH,AMHERST,MA 01003; TUFTS UNIV,SCH MED,BOSTON,MA 02111; MT HOLYOKE COLL,DEPT ECON,S HADLEY,MA 01075	Baystate Medical Center; University of Massachusetts System; University of Massachusetts Amherst; Tufts University; Mount Holyoke College					AHRQ HHS [HS06026] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BROWN D, 1992, AUG CORTL FOR, P19; CAPLAN LR, 1992, LANCET, V339, P656, DOI 10.1016/0140-6736(92)90804-C; CIVETTA JM, 1992, CRIT CARE MED, V20, P1714, DOI 10.1097/00003246-199212000-00019; CIVETTA JM, 1989, PROBLEMS CRITICAL CA, P681; Hadorn DC., 1993, ASSESSING PERFORMANC; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LEGALL JR, 1984, CRIT CARE MED, V12, P975; LEGALL JR, IN PRESS JAMA; LEMESHOW S, 1988, CRIT CARE MED, V16, P470, DOI 10.1097/00003246-198805000-00002; LEMESHOW S, 1985, CRIT CARE MED, V13, P519, DOI 10.1097/00003246-198507000-00001; OPPENHEIMER S, 1992, LANCET, V339, P721, DOI 10.1016/0140-6736(92)90607-5; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; RAMFORD J, 1992, LANCET, V339, P400; VANGIJN J, 1992, LANCET, V339, P653, DOI 10.1016/0140-6736(92)90803-B	19	708	737	0	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1993	270	20					2478	2486		10.1001/jama.270.20.2478	http://dx.doi.org/10.1001/jama.270.20.2478			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG671	8230626				2022-12-28	WOS:A1993MG67100031
J	KEE, F; GAFFNEY, B; CURRIE, S; OREILLY, D				KEE, F; GAFFNEY, B; CURRIE, S; OREILLY, D			ACCESS TO CORONARY CATHETERIZATION - FAIR SHARES FOR ALL	BRITISH MEDICAL JOURNAL			English	Article							ARTERY DISEASE; HEART-DISEASE; ANGIOGRAPHY; PROBABILITY; DEPRIVATION; MORBIDITY; MORTALITY; PATTERNS; RATIOS; BIAS	Objective-To determine the effects of patient's sex and area's material deprivation on utilisation rates of coronary catheterisation and angiography in the investigation of ischaemic heart disease. Design-Retrospective analysis of routinely collected hospital statistics. Setting-Acute hospitals throughout Northern Ireland. Subjects-24179 episodes of patients discharged from hospital with a primary diagnosis of ischaemic heart disease and 1270 episodes relating to patients with an underlying diagnosis of ischaemic heart disease who had either coronary catheterisation or angiography. Main outcome measures-Age standardised admission rates for heart disease and age standardised utilisation rates for catheterisation or angiography, or both, for 566 electoral wards ranked by Townsend ''deprivation'' scores. Results-Catheterisation-angiography rates in men were over fivefold those of women, ranging from 85.5/100000 v 16/100000 in patients from ''well off'' areas to 123/100000 v 22/100000 for patients from deprived areas. After admission rates for heart disease were controlled for, the overall rate ratio for women was 0.48 (95% confidence interval 0.38 to 0.60). After differential admission rates for heart disease and other potential clinical confounders were controlled for, the investigation rates of patients from the least and most ''deprived'' areas were not significantly different (rate ratio 1.04 (0.87 to 1.25)). Conclusion-Although investigation rates were significantly lower in women than in men, further clinical data would be required before labelling this underutilisation as evidence of bias. There was no significant difference in invasive investigation rates for heart disease in areas of varying deprivation or affluence.	QUEENS UNIV,DEPT EPIDEMIOL & PUBL HLTH,KINGSTON K7L 3N6,ONTARIO,CANADA; NORTHERN HLTH & SOC SERV BOARD,BALLYMENA BT42 19B,NORTH IRELAND; EASTERN HLTH & SOCIAL SERV BOARD,DEPT PUBL HLTH MED,BELFAST,NORTH IRELAND	Queens University - Canada								Bernstein S J, 1993, Int J Technol Assess Health Care, V9, P3; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P766, DOI 10.1001/jama.269.6.766; BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; BOBBIO M, 1992, MED DECIS MAKING, V12, P197, DOI 10.1177/0272989X9201200305; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2543, DOI 10.1001/jama.258.18.2543; CROMBIE IK, 1990, BRIT HEART J, V64, P199; CROMBIE IK, 1989, BRIT HEART J, V61, P172; CURTIS SE, 1990, J EPIDEMIOL COMMUN H, V44, P62, DOI 10.1136/jech.44.1.62; ELDER AT, 1991, BRIT MED J, V303, P950, DOI 10.1136/bmj.303.6808.950; FEIBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092; FINDLAY IN, 1991, BRIT HEART J, V66, P70; GARBER CE, 1992, J CLIN EPIDEMIOL, V45, P715, DOI 10.1016/0895-4356(92)90048-R; GRAY D, 1990, LANCET, V335, P1317, DOI 10.1016/0140-6736(90)91196-H; KREIGER N, 1992, AM J PUBLIC HEALTH, V92, P703; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; MAYS N, 1989, J EPIDEMIOL COMMUN H, V43, P191, DOI 10.1136/jech.43.2.191; ORENCIA A, 1993, JAMA-J AM MED ASSOC, V269, P2392, DOI 10.1001/jama.269.18.2392; PARK RE, 1989, AM J PUBLIC HEALTH, V79, P445, DOI 10.2105/AJPH.79.4.445; PETTICREW M, 1993, BMJ-BRIT MED J, V306, P1164, DOI 10.1136/bmj.306.6886.1164; PRICE CE, 1992, J EPIDEMIOL COMMUN H, V46, P58, DOI 10.1136/jech.46.1.58; SOX HC, 1990, AM J MED, V89, P7, DOI 10.1016/0002-9343(90)90090-Z; TOFLER GH, 1993, AM J CARDIOL, V71, P1031, DOI 10.1016/0002-9149(93)90568-W; Townsend PP., 1988, HLTH DEPRIVATION INE; TUNIS SR, 1993, ARCH INTERN MED, V153, P991, DOI 10.1001/archinte.153.8.991; WILLIAMS RB, 1992, JAMA-J AM MED ASSOC, V267, P520, DOI 10.1001/jama.267.4.520; 1992, REGIONAL STRATEGIC F; 1990, SPATIAL SOCIAL VARIA	27	62	62	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1993	307	6915					1305	1307		10.1136/bmj.307.6915.1305	http://dx.doi.org/10.1136/bmj.307.6915.1305			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH556	8257883	Green Published, Bronze			2022-12-28	WOS:A1993MH55600017
J	NOVICK, P; BRENNWALD, P				NOVICK, P; BRENNWALD, P			FRIENDS AND FAMILY - THE ROLE OF THE RAB GTPASES IN VESICULAR TRAFFIC	CELL			English	Review							ENDOCYTIC PATHWAY; PROTEIN; EVENT				NOVICK, P (corresponding author), YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510, USA.							AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; CRAIGHEAD MW, 1993, IN PRESS MOL BIOL CE; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DUNN B, 1993, NATURE, V362, P563, DOI 10.1038/362563a0; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; GARRETT MD, 1993, FEBS LETT, V331, P233, DOI 10.1016/0014-5793(93)80343-S; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; JIANG Y, 1993, IN PRESS NATURE; JONES SM, 1993, J CELL BIOL, V122, P775, DOI 10.1083/jcb.122.4.775; KIBBE WA, 1993, RAS SUPERFAMILY GTPA, P367; LI R, 1993, IN PRESS NATURE; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; LLEDO PM, 1993, NATURE, V364, P540, DOI 10.1038/364540a0; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; MOYA M, 1993, NATURE, V460; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; SUDHOF TC, 1993, CELL, V75, P1; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAKIZAWA PA, 1993, CELL, V75, P593, DOI 10.1016/0092-8674(93)90477-8; TISDALE EJ, 1992, J CELL BIOL, V103, P755; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; WICHMANN H, 1992, CELL, V71, P1131, DOI 10.1016/S0092-8674(05)80062-5; ZAHNER JE, 1993, MOL CELL BIOL, V13, P217, DOI 10.1128/MCB.13.1.217	38	363	369	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					597	601		10.1016/0092-8674(93)90478-9	http://dx.doi.org/10.1016/0092-8674(93)90478-9			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242735	hybrid			2022-12-28	WOS:A1993MH74900003
J	KHAVARI, PA; PETERSON, CL; TAMKUN, JW; MENDEL, DB; CRABTREE, GR				KHAVARI, PA; PETERSON, CL; TAMKUN, JW; MENDEL, DB; CRABTREE, GR			BRG1 CONTAINS A CONSERVED DOMAIN OF THE SWI2/SNF2 FAMILY NECESSARY FOR NORMAL MITOTIC GROWTH AND TRANSCRIPTION	NATURE			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; PUTATIVE HELICASES; GLOBAL ACTIVATOR; GENE-EXPRESSION; PROTEINS; DROSOPHILA; SNF2/SWI2; ENCODES; REPAIR; SWI1	SEQUENCE-SPECIFIC DNA binding activators of gene transcription may be assisted by SWI2(SNF2)1,2, which contains a DNA-dependent ATPase domain3. We have isolated a human complementary, DNA encoding a 205K nuclear protein, BRG1, that contains extensive homology to SWI2 and Drosophila brahma4,5. We report here that a SWI2/BRG1 chimaera with the DNA-dependent ATPase domain replaced by corresponding human sequence restored normal mitotic growth and capacity for transcriptional activation to swi2- yeast cells. Point mutation of the conserved ATP binding site lysine abolished this complementation. This mutation in SW12 exerted a dominant negative effect on transcription in yeast. A lysine to arginine substitution at the corresponding residue of BRG1 also generated a transcriptional dominant negative in human cells. BRG1 is exclusively nuclear and present in a high M(r) complex of about 2 x 10(6). These results show that the SWI2 family DNA-dependent ATPase domain has functional conservation between yeast and humans and suggest that a SWI/SNF protein complex is required for the activation of selective mammalian genes.	STANFORD UNIV, BECKMAN CTR MOLEC & GENET MED, HOWARD HUGHES MED INST, B211 HHMI, STANFORD, CA 94305 USA; UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01650 USA; UNIV CALIF SANTA CRUZ, DEPT BIOL, SANTA CRUZ, CA 95064 USA	Howard Hughes Medical Institute; Stanford University; University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California Santa Cruz								DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; HAYNES SR, 1989, DEV BIOL, V134, P246, DOI 10.1016/0012-1606(89)90094-8; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; HENIKOFF S, 1993, TRENDS BIOCHEM SCI, V18, P291, DOI 10.1016/0968-0004(93)90037-N; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; KENNISON JA, 1988, P NATL ACAD SCI USA, V85, P8136, DOI 10.1073/pnas.85.21.8136; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NEIGEBORN L, 1984, GENETICS, V108, P845; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OKABE I, 1992, NUCLEIC ACIDS RES, V20, P4649, DOI 10.1093/nar/20.17.4649; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TRAVERS AA, 1992, CELL, V69, P573, DOI 10.1016/0092-8674(92)90218-2; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	31	543	557	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	1993	366	6451					170	174		10.1038/366170a0	http://dx.doi.org/10.1038/366170a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG216	8232556				2022-12-28	WOS:A1993MG21600061
J	ERIE, DA; HAJISEYEDJAVADI, O; YOUNG, MC; VONHIPPEL, PH				ERIE, DA; HAJISEYEDJAVADI, O; YOUNG, MC; VONHIPPEL, PH			MULTIPLE RNA-POLYMERASE CONFORMATIONS AND GREA - CONTROL OF THE FIDELITY OF TRANSCRIPTION	SCIENCE			English	Article							DNA-REPLICATION FIDELITY; ESCHERICHIA-COLI; KINETIC MECHANISM; TERNARY COMPLEXES; STRUCTURAL-ANALYSIS; ELONGATION-FACTOR; KLENOW FRAGMENT; I KLENOW; BACTERIOPHAGE-T4; EXONUCLEASE	Pre-steady state kinetics of misincorporation were used to investigate the addition of single nucleotides to nascent RNA by Escherichia coli RNA polymerase during transcription elongation. The results were fit with a branched kinetic mechanism that permits conformational switching, at each template position, between an activated and an unactivated enzyme complex, both of which can bind nucleotide triphosphates (NTPs) from solution. The complex exists most often in the long-lived activated state, and only becomes unactivated when transcription is slowed. This model permits multiple levels of nucleotide discrimination in transcription, since the complex can be ''kinetically trapped'' in the unactivated state in the absence of the correct NTP or if the 3' terminal residue is incorrectly matched. The transcription cleavage factor GreA (or an activity enhanced by GreA) increased the fidelity of transcription by preferential cleavage of transcripts containing misincorporated residues in the unactivated state of the elongation complex. This cleavage mechanism by GreA may prevent the formation of ''dead-end'' transcription complexes in vivo.	UNIV OREGON, DEPT CHEM, EUGENE, OR 97403 USA	University of Oregon	ERIE, DA (corresponding author), UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA.			von Hippel, Peter H./0000-0003-2512-8097	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM012915, R37GM015792, R01GM015792, R01GM029158] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29158, GM-15792, GM-12915] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Benkovic S. J, 1973, ENZYMES, P201; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; CHAMBERLIN MJ, IN PRESS HARVEY L 88; CHAN CL, IN PRESS TRANSCRIPTI; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; EGER BT, 1991, BIOCHEMISTRY-US, V30, P1441, DOI 10.1021/bi00219a039; EICHHORN G L, 1991, Biophysical Journal, V59, p565A; EICHHORN GL, COMMUNICATION; ERIE DA, 1992, ANNU REV BIOPH BIOM, V21, P379, DOI 10.1146/annurev.bb.21.060192.002115; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; Koshland D., 1959, ENZYMES, V1, P305; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDICK R, COMMUNICATION; LANDICK R, 1987, ESCHERICHIA COLI SAL, V2, P1276; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; MATSUZAKI H, IN PRESS J MOL BIOL; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; REDDY MK, 1992, J BIOL CHEM, V267, P14157; REINES D, 1992, J BIOL CHEM, V267, P3795; RHODES G, 1974, J BIOL CHEM, V249, P6675; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	37	257	262	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	1993	262	5135					867	873		10.1126/science.8235608	http://dx.doi.org/10.1126/science.8235608			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	8235608				2022-12-28	WOS:A1993MF43800026
J	ENA, J; DICK, RW; JONES, RN; WENZEL, RP				ENA, J; DICK, RW; JONES, RN; WENZEL, RP			THE EPIDEMIOLOGY OF INTRAVENOUS VANCOMYCIN USAGE IN A UNIVERSITY HOSPITAL - A 10-YEAR STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; ADVERSE DRUG-REACTIONS; ANTIMICROBIAL AGENTS; OPERATIONAL ASSESSMENT; ANTIBIOTIC USE; INFECTIONS; SURVEILLANCE; BACTEREMIA; GUIDELINES; MORTALITY	Objectives.-To examine the trends of intravenous vancomycin usage during a 10-year period, to classify the indications for which physicians prescribed the antibiotic, and to identify the independent predictors for empirical use of vancomycin. Design.-A descriptive epidemiological study, a cross-sectional study, and a case-control study were performed. Setting.-A 900-bed university-teaching hospital. Main Outcome Measures.-The annual crude usage (grams) and incidence density (grams/1 000 patient-days) of vancomycin were measured for 10 years (July 1981 to July 1991). In 109 randomly selected patient medical records, we evaluated the proportion of usage of vancomycin classified as prophylaxis, empirical therapy, or specifically directed therapy. Univariate and multivariate analyses were performed to identify determinants of empirical administration of vancomycin vs a penicillase-resistant penicillin to 64 case patients and 64 control patients. Results.-The rate of vancomycin usage increased 20-fold from 5.72 g/1000 patient-days in 1981 to 121.25 g/1000 patient-days in 1991. The use of vancomycin was significantly higher (P<.0001) in hematology-oncology areas compared with that in other hospital areas. The rates for each indication for vancomycin were 35.0% for prophylaxis, 31.8% for empirical therapy, and 33.2% for therapy specifically directed by culture results. In a multivariate analysis, the presence of ''plastic'' medical devices was the best independent predictor for patients receiving vancomycin: intravenous lines (odds ratio [OR], 6.23; 95% confidence interval [CI], 2.28 to 17.06; P<.001), Hickman catheters (OR, 76.12; 95% CI, 15.06 to 384.73; P<.001), and other medical devices (OR, 10.50; 95% CI, 2.54 to 43.38; P=.001). Conclusions.-Vancomycin use has increased linearly in the last decade primarily related to the presence of indwelling vascular devices in hematology-oncology patients. Use of vancomycin is equally divided among empirical therapy, prophylaxis, and specific therapy for a documented infection.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,DIV GEN MED CLIN EPIDEMIOL & HLTH SERV RES,C41-GH,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,ANTI INFECT RES CTR,DEPT PATHOL,IOWA CITY,IA 52242; UNIV IOWA HOSP & CLIN,DEPT PHARM,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa								ARCHER GL, 1990, PRINCIPLES PRACTICE, P1511; BRODERICK A, 1990, AM J EPIDEMIOL, V131, P734, DOI 10.1093/oxfordjournals.aje.a115558; CASTLE M, 1977, JAMA-J AM MED ASSOC, V237, P2819, DOI 10.1001/jama.237.26.2819; FARBER BF, 1983, J THORAC CARDIOV SUR, V85, P933; FARBER BF, 1983, ANTIMICROB AGENTS CH, V23, P138, DOI 10.1128/AAC.23.1.138; Fleiss JL., 1981, STAT METHODS RATES P, P14; FRENCH GL, 1988, J ANTIMICROB CHEMOTH, V21, P581, DOI 10.1093/jac/21.5.581; GRUBB WB, 1986, EUR J CLIN MICROBIOL, V5, P728, DOI 10.1007/BF02013314; HUGHES WT, 1990, J INFECT DIS, V161, P381, DOI 10.1093/infdis/161.3.381; HUTCHINSON TA, 1979, JAMA-J AM MED ASSOC, V242, P633, DOI 10.1001/jama.242.7.633; JONES SR, 1977, AM J MED SCI, V273, P79, DOI 10.1097/00000441-197701000-00008; KARP JE, 1986, AM J MED, V81, P237, DOI 10.1016/0002-9343(86)90257-3; KRAMER MS, 1979, JAMA-J AM MED ASSOC, V242, P623, DOI 10.1001/jama.242.7.623; KUNIN CM, 1973, ANN INTERN MED, V79, P555, DOI 10.7326/0003-4819-79-4-555; LANDRY SL, 1989, AM J INFECT CONTROL, V17, P323, DOI 10.1016/0196-6553(89)90001-1; MAKI DG, 1978, AM J MED SCI, V275, P271, DOI 10.1097/00000441-197805000-00005; MARR JJ, 1988, J INFECT DIS, V157, P869, DOI 10.1093/infdis/157.5.869; MARTIN MA, 1989, ANN INTERN MED, V110, P9, DOI 10.7326/0003-4819-110-1-9; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; MORRISON AJ, 1986, INFECT CONT HOSP EP, V7, P550, DOI 10.1017/S0195941700065309; ROBERTS AW, 1972, AM J HOSP PHARM, V29, P828, DOI 10.1093/ajhp/29.10.828; SANDFORD JP, 1991, GUIDE ANTIMICROBIAL; SCHECKLER WE, 1970, J AMER MED ASSOC, V213, P264, DOI 10.1001/jama.213.2.264; SORRELL TC, 1985, J ANTIMICROB CHEMOTH, V16, P235, DOI 10.1093/jac/16.2.235; UTTLEY AHC, 1988, LANCET, V1, P57; VEACH LA, 1990, J CLIN MICROBIOL, V28, P2064, DOI 10.1128/JCM.28.9.2064-2068.1990; WIDMER AF, 1991, EUR J CLIN MICROBIOL, V10, P46, DOI 10.1007/BF01967101; WILKINSON L, 1990, SYSTAT SYSTEM STATIS; WINSTON DJ, 1980, AM J MED, V69, P255, DOI 10.1016/0002-9343(80)90386-1; 1990, EGRET EPIDEMIOLOGY G; 1991, J INNFECT DIS, V163, P951; 1984, CDC SURVEILLANCE S2, V33, pSS922	32	150	153	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1993	269	5					598	602		10.1001/jama.269.5.598	http://dx.doi.org/10.1001/jama.269.5.598			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ444	8240468				2022-12-28	WOS:A1993KJ44400025
J	DANTAL, J; BIGOT, E; BOGERS, W; TESTA, A; KRIAA, F; JACQUES, Y; DELIGNY, BH; NIAUDET, P; CHARPENTIER, B; SOULILLOU, JP				DANTAL, J; BIGOT, E; BOGERS, W; TESTA, A; KRIAA, F; JACQUES, Y; DELIGNY, BH; NIAUDET, P; CHARPENTIER, B; SOULILLOU, JP			EFFECT OF PLASMA-PROTEIN ADSORPTION ON PROTEIN EXCRETION IN KIDNEY-TRANSPLANT RECIPIENTS WITH RECURRENT NEPHROTIC SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOCAL SEGMENTAL GLOMERULOSCLEROSIS; GLOMERULAR-PERMEABILITY FACTOR; RENAL-TRANSPLANTATION; SINGLE-CENTER; RISK-FACTORS; ALLOGRAFTS; EXCHANGE; IMMUNOADSORPTION; CYCLOSPORINE; IMMUNOGLOBULIN	Background. Among patients with the idiopathic nephrotic syndrome who have focal and segmental glomerulosclerosis and undergo renal transplantation, 15 to 55 percent have recurrent nephrotic syndrome. The recurrence may be caused by a plasma factor or factors that increase glomerular permeability, because plasma exchange transiently decreases or abolishes proteinuria in some patients. We studied the effect on proteinuria of the removal of protein (mostly immunoglobulins) by adsorption onto protein A from the plasma of patients with recurrent nephrotic syndrome. Methods. Eight patients were treated with one to three cycles of two to seven 1-day sessions of protein adsorption, and the patients' urinary protein excretion was measured repeatedly. Their immunosuppressive regimens were not changed during the treatment. The adsorbed proteins were eluted from the protein A and injected into rats, and the urinary albumin excretion of the rats was measured. Results. The protein-adsorption treatment consistently decreased urinary protein excretion by an average of 82 percent at the end of a cycle (P<0.001). In one patient proteinuria disappeared, and in another urinary protein excretion remained below 2.5 g per day with repeated cycles of protein adsorption. In all but one patient the effect of adsorption was limited in time, with a return to the preadsorption level of protein excretion within a maximum of two months. The administration to rats of material eluted from the protein A increased urinary albumin excretion 2.9- to 4.6-fold (P<0.001 and P = 0.005, respectively). Although protein A primarily binds immunoglobulins, the active fraction of the eluted proteins had a molecular weight below 100,000, indicating that immunoglobulin was not directly involved. Conclusions. Adsorption of plasma protein decreases urinary protein excretion in patients with recurrence of the nephrotic syndrome after renal transplantation. Studies of the adsorbed proteins should provide information about the mechanism of this disease.	CHRU,INSERM,U211,UNITE RECH EFFECTEURS LYMPHOCYTAIRES T,NANTES,FRANCE; HOP NECKER ENFANTS MALAD,SERV NEPHROL PEDIAT,PARIS,FRANCE; HOP BICETRE,SERV NEPHROL,F-94270 LE KREMLIN BICETR,FRANCE; CTR HOSP REG & UNIV CLEMENCEAU,SERV NEPHROL,CAEN,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; CHU de Caen NORMANDIE	DANTAL, J (corresponding author), CHRU,SERV NEPHROL IMMUNOL & CLIN,PL ALEXIS RICORDEAU,F-44035 NANTES,FRANCE.							ARTERO M, 1992, AM J MED, V92, P375, DOI 10.1016/0002-9343(92)90267-F; BANFI G, 1990, TRANSPLANTATION, V50, P594, DOI 10.1097/00007890-199010000-00013; BOGERS WMJM, 1990, SCAND J IMMUNOL, V31, P679, DOI 10.1111/j.1365-3083.1990.tb02819.x; CAMERON JS, 1989, TRANSPLANT P, V21, P2117; CAMERON JS, 1991, PEDIATR NEPHROL, V5, P412, DOI 10.1007/BF01453669; COCHAT P, 1993, PEDIATR NEPHROL, V7, P50, DOI 10.1007/BF00861567; DANTAL J, 1991, TRANSPLANTATION, V52, P827, DOI 10.1097/00007890-199111000-00014; DANTAL J, 1990, LANCET, V336, P190, DOI 10.1016/0140-6736(90)91724-O; DWYER JM, 1992, NEW ENGL J MED, V326, P107; ESNAULT V, 1990, TRANSPLANTATION, V50, P449, DOI 10.1097/00007890-199009000-00018; FRANCO A, 1987, CLIN NEPHROL, V28, P158; GJORSTRUP P, 1990, TRANSFUS SCI, V11, P281, DOI 10.1016/0955-3886(90)90028-H; HABIB R, 1987, AM J KIDNEY DIS, V10, P198, DOI 10.1016/S0272-6386(87)80175-0; Habib R, 1987, Contrib Nephrol, V55, P123; HOYER JR, 1972, LANCET, V2, P343; INGULLI E, 1991, TRANSPLANTATION, V51, P401, DOI 10.1097/00007890-199102000-00025; INGULLI E, 1990, TRANSPLANTATION, V49, P219, DOI 10.1097/00007890-199001000-00050; KOOIJMANSCOUTINHO MF, 1993, NEPHROL DIAL TRANSPL, V8, P469; KOYAMA A, 1991, KIDNEY INT, V40, P453, DOI 10.1038/ki.1991.232; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGRUE G, 1975, BIOMED EXPRESS, V23, P37; LAGRUE G, 1991, PRESSE MED, V20, P255; LANGONE JJ, 1982, ADV IMMUNOL, V32, P157; LAUFER J, 1988, TRANSPLANTATION, V46, P540, DOI 10.1097/00007890-198810000-00014; MUNOZ J, 1985, CLIN NEPHROL, V24, P213; PINTO J, 1981, TRANSPLANTATION, V32, P83, DOI 10.1097/00007890-198108000-00001; RODICIO JL, 1990, KIDNEY INT, V38, P590, DOI 10.1038/ki.1990.247; ROWE PC, 1990, PEDIATR NEPHROL, V4, P32, DOI 10.1007/BF00858434; ROZALSKA B, 1993, FEMS MICROBIOL IMMUN, V4, P305; SAVIN VJ, 1993, AM J KIDNEY DIS, V21, P347, DOI 10.1016/S0272-6386(12)80260-5; SENGGUTUVAN P, 1990, PEDIATR NEPHROL, V4, P21, DOI 10.1007/BF00858431; SEWELL RF, 1993, NEPHROL DIAL TRANSPL, V8, P108; SOLOMON BO, 1981, PROCESS BIOCHEM, V16, P44; SOULILLOU JP, 1990, NEW ENGL J MED, V322, P1175, DOI 10.1056/NEJM199004263221702; STRIEGEL JE, 1986, KIDNEY INT, V30, pS44; TOMIZAWA S, 1990, NEPHRON, V56, P341, DOI 10.1159/000186169; VERANI RR, 1986, AM J NEPHROL, V6, P263, DOI 10.1159/000167173; VINCENTI F, 1989, TRANSPLANTATION, V47, P595, DOI 10.1097/00007890-198904000-00006; YOSHIZAWA N, 1989, NEPHRON, V51, P370, DOI 10.1159/000185325; ZIMMERMAN SW, 1985, NEPHRON, V40, P241, DOI 10.1159/000183469; ZIMMERMAN SW, 1984, CLIN NEPHROL, V22, P32	41	332	343	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 6	1994	330	1					7	14		10.1056/NEJM199401063300102	http://dx.doi.org/10.1056/NEJM199401063300102			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP649	8259160				2022-12-28	WOS:A1994MP64900002
J	STEGEMAN, CA; TERVAERT, JWC; SLUITER, WJ; MANSON, WL; DEJONG, PE; KALLENBERG, CGM				STEGEMAN, CA; TERVAERT, JWC; SLUITER, WJ; MANSON, WL; DEJONG, PE; KALLENBERG, CGM			ASSOCIATION OF CHRONIC NASAL CARRIAGE OF STAPHYLOCOCCUS-AUREUS AND HIGHER RELAPSE RATES IN WEGENER GRANULOMATOSIS	ANNALS OF INTERNAL MEDICINE			English	Article							DISEASE-ACTIVITY; SULFAMETHOXAZOLE-TRIMETHOPRIM; PREFERENTIAL INDUCTION; AUTOANTIBODY SECRETION; POLYCLONAL ACTIVATION; PERITONEAL-DIALYSIS; LYSOSOMAL-ENZYMES; ENTEROTOXIN-A; HLA-DR; INFECTION	Objective: To examine possible risk factors for relapse, including chronic nasal carriage of Staphylococcus aureus and serial antineutrophil cytoplasmic antibody (ANCA) determinations in patients with Wegener granulomatosis. Design: Observational cohort study. Setting: Outpatient clinic at a university-affiliated hospital. Patients: Consecutive patients (n = 71) with biopsy-proven Wegener granulomatosis who were seen during follow-up at the outpatient clinic from January 1988 to July 1991. Fourteen patients were ineligible or dropped out; 57 patients were analyzed. Measurements: Serial ANCA determinations and swab cultures of both anterior nares for S. aureus taken at each visit every 4 to 6 weeks. Occurrence of infections and relapses of Wegener granulomatosis were identified according to strict, predefined criteria. Results: Thirty-six of the 57 patients (63%; 95% CI, 49% to 76%) were found to be chronic nasal carriers of S. aureus (greater-than-or-equal-to 75% of nasal cultures positive for S. aureua). Proportional-hazards regression analysis identified chronic nasal carriage of S. aureus (adjusted relative risk, 7.16; CI, 1.63 to 31.50), creatinine clearance above 60 mL . min-1 (adjusted relative risk, 2.94; CI, 1.27 to 6.67), and a history of previous relapses of Wegener granulomatosis (adjusted relative risk, 1.33; CI, 0.98 to 1.78) as independent risk factors for relapse. Twenty-two of 33 patients persistently or intermittently positive for ANCA had a relapse as opposed to only 1 of 21 persistently negative patients. Relapses of Wegener granulomatosis were not related to diagnosed infections. Conclusion: Chronic nasal carriage of S. aureus identifies a subgroup of patients with Wegener granulomatosis who are more prone to relapses of the disease, suggesting a role for S. aureus in its pathophysiology and a possible clue for treatment.			STEGEMAN, CA (corresponding author), UNIV GRONINGEN HOSP, DEPT INTERNAL MED, DIV NEPHROL, OOSTERSINGE 59, 9713 EZ GRONINGEN, NETHERLANDS.		tervaert, jan willem cohen/AAB-1111-2019	Stegeman, Coen/0000-0002-0224-0927				ARMSTRONGESTHER CA, 1976, ANN HUM BIOL, V3, P221, DOI 10.1080/03014467600001381; BATES EJ, 1991, IMMUNOLOGY, V72, P448; CAMPANELLI D, 1990, J EXP MED, V172, P1709, DOI 10.1084/jem.172.6.1709; CARLSSON R, 1988, J IMMUNOL, V140, P2484; CHINTAGUMPALA MM, 1991, J IMMUNOL, V147, P3876; COX DR, 1972, J R STAT SOC B, V34, P187; CUEVAS J, 1982, CLIN NEPHROL, V18, P109; DEREMEE RA, 1985, MAYO CLIN PROC, V60, P27, DOI 10.1016/S0025-6196(12)65279-3; DEREMEE RA, 1988, ARTHRITIS RHEUM, V31, P1068, DOI 10.1002/art.1780310821; DZIARSKI R, 1982, J IMMUNOL, V128, P1026; DZIARSKI R, 1982, J IMMUNOL, V128, P1018; EGNER W, 1990, CLIN EXP IMMUNOL, V82, P244; FALK RJ, 1990, P NATL ACAD SCI USA, V87, P4115, DOI 10.1073/pnas.87.11.4115; FAUCI AS, 1978, ANN INTERN MED, V89, P660, DOI 10.7326/0003-4819-89-5-660; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; GASKIN G, 1991, NEPHROL DIAL TRANSPL, V6, P689, DOI 10.1093/ndt/6.10.689; HAUSER C, 1984, CLIN EXP IMMUNOL, V57, P227; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; HOFFMAN GS, 1991, AM REV RESPIR DIS, V143, P401, DOI 10.1164/ajrccm/143.2.401; ISRAEL HL, 1988, ARCH INTERN MED, V148, P2293, DOI 10.1001/archinte.148.10.2293; JACOBS SI, 1961, J CLIN PATHOL, V14, P519, DOI 10.1136/jcp.14.5.519; KALLENBERG CGM, 1991, IMMUNOL TODAY, V12, P61, DOI 10.1016/0167-5699(91)90159-Q; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KUROSS S, 1981, CLIN NEPHROL, V16, P172; LUZAR MA, 1990, NEW ENGL J MED, V322, P505, DOI 10.1056/NEJM199002223220804; MAXWELL JG, 1969, AM J SURG, V118, P849, DOI 10.1016/0002-9610(69)90245-1; MILLIAN SJ, 1960, AM J PUBLIC HEALTH N, V50, P791, DOI 10.2105/AJPH.50.6_Pt_1.791; MORRIS JA, 1988, BRIT MED J, V296, P1313, DOI 10.1136/bmj.296.6632.1313; NOBLE WC, 1967, J HYG-CAMB, V65, P567, DOI 10.1017/S002217240004609X; PEDERSEN RS, 1990, SCAND J UROL NEPHROL, V24, P223, DOI 10.3109/00365599009180863; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PINCHING AJ, 1980, BRIT MED J, V281, P836, DOI 10.1136/bmj.281.6244.836; PINCHING AJ, 1983, Q J MED, V52, P435; POTEMPA J, 1986, J BIOL CHEM, V261, P14330; RAO NV, 1991, J BIOL CHEM, V266, P9540; SEWELL CM, 1982, JAMA-J AM MED ASSOC, V248, P1493, DOI 10.1001/jama.248.12.1493; TERVAERT JWC, 1989, ARCH INTERN MED, V149, P2461, DOI 10.1001/archinte.149.11.2461; TERVAERT JWC, 1990, KIDNEY INT, V37, P799, DOI 10.1038/ki.1990.48; TERVAERT JWC, 1990, LANCET, V336, P709; TUAZON CU, 1984, AM J MED, V76, P166, DOI 10.1016/0002-9343(84)90260-2; VALERIANOMARCET J, 1991, ARCH INTERN MED, V151, P1649, DOI 10.1001/archinte.151.8.1649; VANDERWOUDE FJ, 1985, LANCET, V1, P425; Wegener F, 1936, VERHANDLUNGEN DTSCH, V29, P202; WILLIAMS RE, 1963, BACTERIOL REV, V27, P56, DOI 10.1128/MMBR.27.1.56-71.1963; YU VL, 1986, NEW ENGL J MED, V315, P91, DOI 10.1056/NEJM198607103150204	47	556	582	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1994	120	1					12	17		10.7326/0003-4819-120-1-199401010-00003	http://dx.doi.org/10.7326/0003-4819-120-1-199401010-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP280	8250451				2022-12-28	WOS:A1994MP28000003
J	WINAWER, SJ; ZAUBER, AG; HO, MN; OBRIEN, MJ; GOTTLIEB, LS; STERNBERG, SS; WAYE, JD; SCHAPIRO, M; BOND, JH; PANISH, JF; ACKROYD, F; SHIKE, M; KURTZ, RC; HORNSBYLEWIS, L; GERDES, H; STEWART, ET				WINAWER, SJ; ZAUBER, AG; HO, MN; OBRIEN, MJ; GOTTLIEB, LS; STERNBERG, SS; WAYE, JD; SCHAPIRO, M; BOND, JH; PANISH, JF; ACKROYD, F; SHIKE, M; KURTZ, RC; HORNSBYLEWIS, L; GERDES, H; STEWART, ET			PREVENTION OF COLORECTAL-CANCER BY COLONOSCOPIC POLYPECTOMY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SCREENING SIGMOIDOSCOPY; SUBSEQUENT CARCINOMA; NATURAL-HISTORY; POLYPS; RISK; MORTALITY; INDIVIDUALS; POPULATION; ADENOMAS; RECTUM	Background. The current practice of removing adenomatous polyps of the colon and rectum is based on the belief that this will prevent colorectal cancer. To address the hypothesis that colonoscopic polypectomy reduces the incidence of colorectal cancer, we analyzed the results of the National Polyp Study with reference to other published results. Methods. The study cohort consisted of 1418 patients who had a complete colonoscopy during which one or more adenomas of the colon or rectum were removed. The patients subsequently underwent periodic colonoscopy during an average follow-up of 5.9 years, and the incidence of colorectal cancer was ascertained. The incidence rate of colorectal cancer was compared with that in three reference groups, including two cohorts in which colonic polyps were not removed and one general-population registry, after adjustment for sex, age, and polyp size. Results. Ninety-seven percent of the patients were followed clinically for a total of 8401 person-years, and 80 percent returned for one or more of their scheduled colonoscopies. Five asymptomatic early-stage colorectal cancers (malignant polyps) were detected by colonoscopy (three at three years, one at six years, and one at seven years). No symptomatic cancers were detected. The numbers of colorectal cancers expected on the basis of the rates in the three reference groups were 48.3, 43.4, and 20.7, for reductions in the incidence of colorectal cancer of 90, 88, and 76 percent, respectively (P<0.001). Conclusions. Colonoscopic polypectomy resulted in a lower-than-expected incidence of colorectal cancer. These results support the view that colorectal adenomas progress to adenocarcinomas, as well as the current practice of searching for and removing adenomatous polyps to prevent colorectal cancer.	BOSTON CITY HOSP,MALLORY INST PATHOL,BOSTON,MA 02118; MT SINAI MED CTR,NEW YORK,NY 10029; VALLEY PRESBYTERIAN HOSP,VAN NUYS,CA; VET AFFAIRS MED CTR,MINNEAPOLIS,MN; CEDARS SINAI MED CTR,LOS ANGELES,CA 90048; MASSACHUSETTS GEN HOSP,BOSTON,MA 02114; MILWAUKEE CTY MED CTR,MILWAUKEE,WI	Boston Medical Center; Icahn School of Medicine at Mount Sinai; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Cedars Sinai Medical Center; Harvard University; Massachusetts General Hospital	WINAWER, SJ (corresponding author), MEM SLOAN KETTERING CANC CTR,GASTROENTEROL & NUTR SERV,NATL POLYP STUDY HEADQUARTERS,NEW YORK,NY 10021, USA.		O'Brien, Michael J/R-7179-2019	O'Brien, Michael J/0000-0003-1124-3537	NATIONAL CANCER INSTITUTE [R01CA026852] Funding Source: NIH RePORTER; NCI NIH HHS [CA 26852] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; BRESLOW NE, 1987, IARC SCI PUBL, V32, P65; EIDE TJ, 1986, INT J CANCER, V38, P173, DOI 10.1002/ijc.2910380205; GILBERTSEN VA, 1978, CANCER, V41, P1137, DOI 10.1002/1097-0142(197803)41:3<1137::AID-CNCR2820410350>3.0.CO;2-G; GLOECKLERRIES LA, 1990, DHHS NIH902789 PUBL; LOTFI AM, 1986, MAYO CLIN PROC, V61, P337, DOI 10.1016/S0025-6196(12)61950-8; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MONSON RR, 1974, COMPUT BIOMED RES, V7, P325, DOI 10.1016/0010-4809(74)90010-X; MURAKAMI R, 1990, INT J CANCER, V46, P159, DOI 10.1002/ijc.2910460203; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; NEWCOMB PA, 1992, JNCI-J NATL CANCER I, V84, P1572, DOI 10.1093/jnci/84.20.1572; OBRIEN MJ, 1990, GASTROENTEROLOGY, V98, P371, DOI 10.1016/0016-5085(90)90827-N; SCHOTTENFELD D, 1982, CANCER EPIDEMIOL, P703; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SIMONS BD, 1992, J NATL CANCER I, V84, P962, DOI 10.1093/jnci/84.12.962; SPENCER RJ, 1984, MAYO CLIN PROC, V59, P305, DOI 10.1016/S0025-6196(12)61425-6; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; VASEN HF, 1993, DIS COLON RECTUM, V36, P1, DOI 10.1007/BF02050292; WINAWER S J, 1992, Gastroenterology, V102, pA409; WINAWER SJ, 1990, B WORLD HEALTH ORGAN, V68, P789; WINAWER SJ, 1992, CANCER, V70, P1236, DOI 10.1002/1097-0142(19920901)70:3+<1236::AID-CNCR2820701508>3.0.CO;2-4; WINAWER SJ, 1993, NEW ENGL J MED, V328, P901, DOI 10.1056/NEJM199304013281301; WINAWER SJ, 1993, J NATL CANCER I, V85, P1311, DOI 10.1093/jnci/85.16.1311; WINAWER SJ, 1993, NEW ENGL J MED, V328, P1416, DOI 10.1056/NEJM199305133281909	24	3473	3570	7	119	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1993	329	27					1977	1981		10.1056/NEJM199312303292701	http://dx.doi.org/10.1056/NEJM199312303292701			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN573	8247072				2022-12-28	WOS:A1993MN57300001
J	MODELL, JG; TAYLOR, JP; LEE, JY				MODELL, JG; TAYLOR, JP; LEE, JY			BREATH ALCOHOL VALUES FOLLOWING MOUTHWASH USE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To determine whether breath alcohol values (BrAV) attained following mouthwash use pose a realistic threat to the accuracy of blood alcohol determinations by breath analysis. Design.-Nonrandomized, open-label trial. Setting.-Outpatient research off ice. Participants.-Ten normal subjects; convenience sample. Interventions.-Breath alcohol measurements were made 2, 4, 6, 1 0, and 15 minutes following rinsing of the mouth with Listerine (29.6% alcohol), Scope (18.9% alcohol), and Lavoris (6.0% alcohol) using the Alco-Sensor III intoximeter. Main Outcome Measures.-Breath alcohol values over time. Results.-Breath alcohol values following mouthwash use decayed exponentially (r2 greater-than-or-equal-to .98, P<.001) from mean values 2 minutes following mouthwash use of 52.8 mmol/L (240 mg/dL) for Listerine, 37.4 mmoVL (1 70 mg/dL) for Scope, and 7.9 mmoVL (36 mg/dL) for Lavoris to mean and maximum values after 10 minutes that were well below the usual driving-while-intoxicated range (greater-than-or-equal-to 17.6 mmol/L [80 mg/dL]) for all three brands. The nonalcoholic mouthwash ingredients did not significantly affect the BrAVs attained. Conclusion.-The decay of BrAVs following mouthwash use is sufficiently rapid that mouthwash use would not pose a realistic threat to the accuracy of blood alcohol determinations by breath analysis under normal circumstances. Use of mouthwash immediately prior to breath testing, as might occur in the car or workplace in a mistaken attempt to hide the smell of alcohol or other substances, may, however, significantly increase the measured BrAV.	UNIV ALABAMA,SCH MED,CTR COMPREHENS CANC,BIOSTAT UNIT,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham	MODELL, JG (corresponding author), UNIV ALABAMA,SCH MED,DEPT PSYCHIAT,1700 7TH AVE S,209,BIRMINGHAM,AL 35294, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000032] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00032] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Gruner O, 1990, Blutalkohol, V27, P119; SNYDER MB, 1991, ALCOHOL DRUGS DRIVIN, V7, P251; VANBERKOM LC, 1991, ALCOHOL DRUGS DRIVIN, V7, P229; VOAS RB, 1991, ALCOHOL DRUGS DRIVIN, V7, P173	4	28	29	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1993	270	24					2955	2956		10.1001/jama.270.24.2955	http://dx.doi.org/10.1001/jama.270.24.2955			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM119	8254857				2022-12-28	WOS:A1993MM11900031
J	MADDOX, J				MADDOX, J			BRANCHING OUT IN CHEMICAL-SYSTEMS	NATURE			English	Editorial Material																			0	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1993	366	6456					626	626						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM265	8259205				2022-12-28	WOS:A1993MM26500039
J	SAMUEL, D; MULLER, R; ALEXANDER, G; FASSATI, L; DUCOT, B; BENHAMOU, JP; BISMUTH, H				SAMUEL, D; MULLER, R; ALEXANDER, G; FASSATI, L; DUCOT, B; BENHAMOU, JP; BISMUTH, H			LIVER-TRANSPLANTATION IN EUROPEAN PATIENTS WITH THE HEPATITIS-B SURFACE-ANTIGEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HBSAG-POSITIVE PATIENTS; VIRUS REINFECTION; VIRAL-HEPATITIS; DELTA-INFECTION; ALLOGRAFT RECIPIENTS; FOLLOW-UP; CARRIERS; DISEASE; IMMUNOPROPHYLAXIS; DNA	Background. The role of liver transplantation in patients positive for the hepatitis B surface antigen (HBsAg) is controversial because of the high rate of recurrent hepatitis B virus (HBV) infection. It has not been determined whether this risk is greater for certain patients and whether the administration of anti-hepatitis B surface antigen (anti-HBs) immune globulin is beneficial. Methods. We conducted a retrospective study at 17 European centers of 372 consecutive HBsAg-positive patients who underwent liver transplantation between 1977 and 1990. Recurrence of HBV infection was defined as the reappearance of HBsAg in serum. Results. For all 334 patients with follow-up data, the mean (+/-SE) three-year actuarial risk of recurrence of HBV was 50+/-3 percent. The risk was 67+/-4 percent among 163 patients with HBV-related cirrhosis, 32+/-5 percent among 110 patients with cirrhosis related to hepatitis delta virus, 40+/-16 percent among 14 patients with fulminant hepatitis delta infection, and 17+/-7 percent among 39 patients with fulminant HBV infection (P<0.001). Among the patients with HBV-related cirrhosis, the risk of HBV recurrence was greatest (83+/-6 percent) in those who were seropositive for HBV DNA at the time of transplantation and lowest (58+/-7 percent) in those with neither HBV DNA nor hepatitis B e antigen detectable in serum. With respect to the use of passive prophylaxis with anti-HBs immune globulin, the risk of HBV recurrence was 75+/-6 percent among the 67 patients given no immunoprophylaxis, 74+/-5 percent among the 83 treated for two months, and 36+/-4 percent among the 209 treated for six months or longer (P<0.001). In a multivariate analysis the predictors of a lower risk of HBV recurrence were the long-term administration of the immune globulin, hepatitis delta virus superinfection, and acute liver disease. For the entire study cohort, survival was 75 percent at one year and 63 percent at three years, but for those in whom HBV infection recurred, survival was 68 percent at one year and 44 percent at three years. Conclusions. In this retrospective study of HBsAg-positive patients, liver transplantation had better results in those who had fulminant hepatitis or delta virus superinfection. An absence of viral replication at the time of transplantation and long-term immunoprophylaxis were associated with a reduced risk of recurrent HBV infection and reduced mortality.	HANNOVER MED SCH,GASTROENTEROL & HEPATOL ABT,W-3000 HANNOVER 61,GERMANY; IST RICOVERO & CURA CARATTERE SCI,OSPED POLICLIN MILAN,CTR TRAPIANTI,MILAN,ITALY; INSERM,U292,LE KREMLIN BICETR,FRANCE; ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND; HOP BEAUJON,SERV HEPATOL,CLICHY,FRANCE	Hannover Medical School; IRCCS Ca Granda Ospedale Maggiore Policlinico; Institut National de la Sante et de la Recherche Medicale (Inserm); Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite	SAMUEL, D (corresponding author), HOP PAUL BROUSSE,HEPATOBILIARY SURG & LIVER TRANSPLANTAT RES UNIT,F-94800 VILLEJUIF,FRANCE.							BISMUTH H, 1987, LANCET, V2, P674; BISMUTH H, 1987, LANCET, V72, P1414; BONINO F, 1986, GASTROENTEROLOGY, V90, P1268, DOI 10.1016/0016-5085(86)90395-1; BRECHOT C, 1984, BRIT MED J, V288, P270, DOI 10.1136/bmj.288.6413.270; COLLEDAN M, 1987, TRANSPLANT P, V19, P4073; DAVIES SE, 1991, HEPATOLOGY, V13, P150, DOI 10.1002/hep.1840130122; DEMETRIS AJ, 1986, AM J PATHOL, V125, P161; DEMETRIS AJ, 1990, AM J PATHOL, V137, P667; Dixon W. J., 1990, BMDP STATISTICAL SOF; FERAY C, 1990, TRANSPLANTATION, V49, P1155, DOI 10.1097/00007890-199006000-00025; FREEMAN RB, 1991, TRANSPLANTATION, V51, P793, DOI 10.1097/00007890-199104000-00011; FUNG J, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P651; HADZIYANNIS SJ, 1983, HEPATOLOGY, V3, P656; HOPF U, 1991, J HEPATOL, V13, P339, DOI 10.1016/0168-8278(91)90078-P; JOHNSON PJ, 1978, BRIT MED J, V1, P216, DOI 10.1136/bmj.1.6107.216; KROGSGAARD K, 1987, HEPATOLOGY, V7, P42, DOI 10.1002/hep.1840070110; LAKE JR, 1991, HEPATOLOGY, V13, P796, DOI 10.1002/hep.1840130429; LAUCHART W, 1987, TRANSPLANT P, V19, P2387; LAUCHART W, 1987, TRANSPL P, V19, P4051; LAVINE JE, 1991, GASTROENTEROLOGY, V100, P263, DOI 10.1016/0016-5085(91)90611-N; MARCELLIN P, 1991, HEPATOLOGY, V14, pA71; MORA NP, 1990, TRANSPLANT P, V22, P1549; MULLER R, 1991, J HEPATOL, V13, P90, DOI 10.1016/0168-8278(91)90869-D; OGRADY JG, 1992, J HEPATOL, V14, P104, DOI 10.1016/0168-8278(92)90138-F; RIZZETTO M, 1991, J HEPATOL, V13, P5, DOI 10.1016/0168-8278(91)90855-6; SAMUEL D, 1991, LANCET, V337, P813, DOI 10.1016/0140-6736(91)92515-4; SCHALM SW, 1992, J HEPATOL, V15, P1, DOI 10.1016/0168-8278(92)90002-7; STARZL TE, 1989, NEW ENGL J MED, V321, P1092, DOI 10.1056/NEJM198910193211606; TODO S, 1991, HEPATOLOGY, V13, P619, DOI 10.1002/hep.1840130402; VANTHIEL DH, 1984, HEPATOLOGY, V4, pS79, DOI 10.1002/hep.1840040721; YOFFE B, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P813; ZIGNEGO AL, 1988, VIRAL HEPATITIS LIVE, P808	32	826	866	0	131	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 16	1993	329	25					1842	1847		10.1056/NEJM199312163292503	http://dx.doi.org/10.1056/NEJM199312163292503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML588	8247035	Green Published			2022-12-28	WOS:A1993ML58800003
J	SONTAG, E; FEDOROV, S; KAMIBAYASHI, C; ROBBINS, D; COBB, M; MUMBY, M				SONTAG, E; FEDOROV, S; KAMIBAYASHI, C; ROBBINS, D; COBB, M; MUMBY, M			THE INTERACTION OF SV40 SMALL TUMOR-ANTIGEN WITH PROTEIN PHOSPHATASE-2A STIMULATES THE MAP KINASE PATHWAY AND INDUCES CELL-PROLIFERATION	CELL			English	Article							SMALL-T-ANTIGEN; SIGNAL-REGULATED KINASES; NERVE GROWTH-FACTOR; SIMIAN VIRUS-40; INFECTED-CELLS; PHOSPHORYLATION; ACTIVATION; INSULIN; TRANSFORMATION; IDENTIFICATION	Interaction with SV40 small tumor antigen (small t) compromised the ability of multimeric protein phosphatase 2A to inactivate the mitogen-activated protein kinase ERK1 and the mitogen-activated protein kinase kinase MEK1. Transient expression of small t in CV-1 cells activated MEK and ERK but did not affect Raf activity. Small t stimulated the growth of quiescent CV-1 cells almost as effectively as did serum. Coexpression of kinase-deficient ERK2 blocked most, but not all, of the proliferation caused by small t. Activation of the mitogen-activated protein kinase pathway and stimulation of cell growth were dependent on the interaction of small t with protein phosphatase 2A. These findings indicate that SV40 small t is capable of inducing cell growth through blockade of protein phosphatase and deregulation of the mitogen-activated protein kinase cascade.			SONTAG, E (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235, USA.		SONTAG, ESTELLE/AAE-9805-2020	Cobb, Melanie/0000-0003-0833-5473	NATIONAL CANCER INSTITUTE [R01CA054726] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER; NCI NIH HHS [CA54726] Funding Source: Medline; NHLBI NIH HHS [HL31107] Funding Source: Medline; NIDDK NIH HHS [DK34128] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1993, P NATL ACAD SCI USA, V90, P5143, DOI 10.1073/pnas.90.11.5143; AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSI DR, 1993, ONCOGENE, V8, P2015; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BIKEL I, 1986, MOL CELL BIOL, V6, P1172, DOI 10.1128/MCB.6.4.1172; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; BOSSERT A, 1985, J VIROL, V56, P325, DOI 10.1128/JVI.56.1.325-327.1985; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHANG LS, 1984, VIROLOGY, V133, P341, DOI 10.1016/0042-6822(84)90400-8; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; ELLMAN M, 1984, J VIROL, V50, P623, DOI 10.1128/JVI.50.2.623-628.1984; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GORIS J, 1988, BIOCHEM J, V256, P1029, DOI 10.1042/bj2561029; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LOEKEN M, 1988, CELL, V55, P1171, DOI 10.1016/0092-8674(88)90261-9; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARTIN RG, 1979, CELL, V17, P635, DOI 10.1016/0092-8674(79)90271-X; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MONTANO X, 1990, P NATL ACAD SCI USA, V87, P7448, DOI 10.1073/pnas.87.19.7448; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; MUMBY MC, 1985, J BIOL CHEM, V260, P3763; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; RUNDELL K, 1987, J VIROL, V61, P1240, DOI 10.1128/JVI.61.4.1240-1243.1987; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIRAKABE K, 1992, J BIOL CHEM, V267, P16685; SLEIGH MJ, 1978, CELL, V14, P79, DOI 10.1016/0092-8674(78)90303-3; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN H, 1993, IN PRESS CELL, V75; TURK B, 1993, J VIROL, V67, P3671, DOI 10.1128/JVI.67.6.3671-3673.1993; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; YANG YC, 1979, J VIROL, V32, P147, DOI 10.1128/JVI.32.1.147-154.1979; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	61	472	480	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 3	1993	75	5					887	897		10.1016/0092-8674(93)90533-V	http://dx.doi.org/10.1016/0092-8674(93)90533-V			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252625	Bronze			2022-12-28	WOS:A1993MK96600009
J	CHROUSOS, GP; DETERAWADLEIGH, SD; KARL, M				CHROUSOS, GP; DETERAWADLEIGH, SD; KARL, M			SYNDROMES OF GLUCOCORTICOID RESISTANCE	ANNALS OF INTERNAL MEDICINE			English	Article							PRIMARY CORTISOL RESISTANCE; HORMONE-BINDING DOMAIN; RHEUMATOID-ARTHRITIS; DNA-BINDING; MINERALOCORTICOID RECEPTOR; FUNCTIONAL DOMAINS; GENE-TRANSCRIPTION; CUSHINGS-SYNDROME; TRANS-ACTIVATION; THYROID-HORMONE	Glucocorticoid resistance results from the partial, albeit apparently generalized, inability of glucocorticoids to exert their effects on target tissues. The condition is associated with compensatory increases in circulating pituitary corticotropin and cortisol, with the former causing excess secretion of both adrenal androgens and adrenal steroid biosynthesis intermediates with salt-retaining activity. The manifestations of glucocorticoid resistance vary from chronic fatigue (perhaps a result of glucocorticoid deficiency in the central nervous system) to various degrees of hypertension with or without hypokalemic alkalosis or hyperandrogenism, or both, caused by increased cortisol and other salt-retaining steroids and adrenal androgens, respectively. In women, hyperandrogenism can result in acne, hirsutism, menstrual irregularities, oligoanovulation, and infertility; in men, it may lead to infertility and in children, to precocious puberty. Different molecular defects, such as point mutations or a microdeletion of the highly conserved glucocorticoid receptor gene, alter the functional characteristics or concentrations of the intracellular receptor and appear to cause glucocorticoid resistance. The extreme variability in the clinical manifestations of glucocorticoid resistance and its mimicry of many common diseases can be explained by the overall degree of glucocorticoid resistance, differing sensitivity of target tissues to mineralocorticoids or androgens or both, and perhaps different biochemical defects of the glucocorticoid receptor, with selective resistance of certain glucocorticoid responses in specific tissues. The various different symptoms of classic glucocorticoid resistance and the theoretical potential of this condition to appear surreptitiously emphasize the importance of the glucocorticoid receptor in the pathogenesis of human disease.			CHROUSOS, GP (corresponding author), NIH, BLDG 10, ROOM 10N262, BETHESDA, MD 20892 USA.							AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Baxter J.D., 1979, GLUCOCORTICOID HORMO; BERKOVITZ GD, 1990, J CLIN ENDOCR METAB, V70, P1608, DOI 10.1210/jcem-70-6-1608; BOGGARAM V, 1991, MOL ENDOCRINOL, V5, P414, DOI 10.1210/mend-5-3-414; BRONNEGARD M, 1986, J CLIN INVEST, V78, P1270, DOI 10.1172/JCI112711; BROWN PH, 1991, LANCET, V337, P576, DOI 10.1016/0140-6736(91)91639-C; CASSORLA F, 1990, PRINCIPLES PRACTICE, P604; CHAKRABORTI PK, 1991, J BIOL CHEM, V266, P22075; CHIKANZA IC, 1992, ARTHRITIS RHEUM, V35, P1281, DOI 10.1002/art.1780351107; CHROUSOS GP, 1982, J CLIN INVEST, V69, P1261, DOI 10.1172/JCI110565; CHROUSOS GP, 1983, J CLIN ENDOCR METAB, V56, P1243, DOI 10.1210/jcem-56-6-1243; CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V267, P1244, DOI 10.1001/jama.267.9.1244; Clark J., 1992, WILLIAMS TXB ENDOCRI, P35; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1016, DOI 10.1164/ajrccm/144.5.1016; DALLMAN MF, 1987, RECENT PROG HORM RES, V43, P113; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DEKLOET ER, 1991, FRONT NEUROENDOCRIN, V12, P95; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DROUIN J, 1992, MOL ENDOCRINOL, V6, P1299, DOI 10.1210/me.6.8.1299; EDWARDS CRW, 1988, LANCET, V2, P986, DOI 10.1016/S0140-6736(88)90742-8; ENCIO IJ, 1991, J BIOL CHEM, V266, P7182; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRANCKE U, 1989, GENOMICS, V4, P610, DOI 10.1016/0888-7543(89)90287-5; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GILAD GM, 1987, LIFE SCI, V40, P2401, DOI 10.1016/0024-3205(87)90754-5; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HURLEY DM, 1991, J CLIN INVEST, V87, P680, DOI 10.1172/JCI115046; IIDA S, 1985, J CLIN ENDOCR METAB, V60, P967, DOI 10.1210/jcem-60-5-967; IIDA S, 1990, J CLIN ENDOCR METAB, V70, P729, DOI 10.1210/jcem-70-3-729; JACOBSON L, 1991, ENDOCR REV, V12, P118, DOI 10.1210/edrv-12-2-118; JAURSCH-HANCKE C, 1989, Acta Endocrinologica Supplementum, V120, P113; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAMILARIS T, 1989, DIAGNOSTIC ENDOCRINO, P79; KARL M, 1993, J CLIN ENDOCR METAB, V76, P683, DOI 10.1210/jc.76.3.683; KAWAI S, 1989, AM J MED SCI, V298, P167, DOI 10.1097/00000441-198909000-00004; KELLERWOOD ME, 1984, ENDOCR REV, V5, P1, DOI 10.1210/edrv-5-1-1; KERN JA, 1988, J CLIN INVEST, V81, P237, DOI 10.1172/JCI113301; KERR DS, 1992, P NATL ACAD SCI USA, V89, P8527, DOI 10.1073/pnas.89.18.8527; KIRKHAM BW, 1991, J RHEUMATOL, V18, P821; KRAINER AR, 1988, FRONTIERS MOL BIOL T; LAMBERTS SWJ, 1992, J CLIN ENDOCR METAB, V74, P313, DOI 10.1210/jc.74.2.313; LAMBERTS SWJ, 1986, J CLIN ENDOCR METAB, V63, P1328, DOI 10.1210/jcem-63-6-1328; LANE SJ, 1991, AM REV RESPIR DIS, V143, P1020, DOI 10.1164/ajrccm/143.5_Pt_1.1020; LAUE L, 1988, J STEROID BIOCHEM, V29, P591, DOI 10.1016/0022-4731(88)90156-2; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; LOOKINGBILL DP, 1991, J CLIN ENDOCR METAB, V72, P1242, DOI 10.1210/jcem-72-6-1242; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MALCHOFF CD, 1990, J CLIN ENDOCR METAB, V70, P503, DOI 10.1210/jcem-70-2-503; MCDERMOTT P, 1991, 73RD ANN M END SOC W; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MUNCK A, 1968, J BIOL CHEM, V243, P5556; Munck A, 1986, Adv Exp Med Biol, V196, P81; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; MYERS RM, 1985, NUCLEIC ACIDS RES, V13, P3131, DOI 10.1093/nar/13.9.3131; NAWATA H, 1987, J CLIN ENDOCR METAB, V65, P219, DOI 10.1210/jcem-65-2-219; NEECK G, 1990, J RHEUMATOL, V17, P24; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; NORBIATO G, 1992, J CLIN ENDOCR METAB, V74, P608, DOI 10.1210/jc.74.3.608; Orth DN, 1992, WILLIAMS TXB ENDOCRI, P489; ORTI E, 1989, J STEROID BIOCHEM, V34, P85, DOI 10.1016/0022-4731(89)90069-1; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRATT WB, 1990, PROG CLIN BIOL RES, V322, P119; RASTOGI RB, 1978, BRIT J PHARMACOL, V62, P131, DOI 10.1111/j.1476-5381.1978.tb07015.x; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SCHLAGHECKE R, 1992, ARTHRITIS RHEUM-US, V35, P740, DOI 10.1002/art.1780350704; Schleimer RP, 1989, ANTIINFLAMMATORY STE; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHARP PA, 1991, NATURE, V351, P16, DOI 10.1038/351016d0; SIMONS SS, 1987, J BIOL CHEM, V262, P9676; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; THEOPHILUS BDM, 1989, NUCLEIC ACIDS RES, V17, P7707, DOI 10.1093/nar/17.19.7707; TOMITA M, 1986, J CLIN ENDOCRINOL ME, V62; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; VECSEI P, 1989, CANCER RES, V49, pS2220; VESELY DL, 1980, J PHARMACOL EXP THER, V214, P561; VINGERHOEDS ACM, 1976, J CLIN ENDOCR METAB, V43, P1128, DOI 10.1210/jcem-43-5-1128; WERNER S, 1992, J CLIN ENDOCR METAB, V75, P1005, DOI 10.1210/jc.75.4.1005; WOLKOWITZ O, 1986, EUR J PHARMACOL, V122, P329, DOI 10.1016/0014-2999(86)90413-9; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZONG J, 1990, MOL CELL BIOL, V10, P5580, DOI 10.1128/MCB.10.10.5580	89	189	195	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1993	119	11					1113	1124		10.7326/0003-4819-119-11-199312010-00009	http://dx.doi.org/10.7326/0003-4819-119-11-199312010-00009			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ335	8239231				2022-12-28	WOS:A1993MJ33500009
J	MARKOVITZ, JH; MATTHEWS, KA; KANNEL, WB; COBB, JL; DAGOSTINO, RB				MARKOVITZ, JH; MATTHEWS, KA; KANNEL, WB; COBB, JL; DAGOSTINO, RB			PSYCHOLOGICAL PREDICTORS OF HYPERTENSION IN THE FRAMINGHAM-STUDY - IS THERE TENSION IN HYPERTENSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; HIGH BLOOD-PRESSURE; MIDDLE-AGED WOMEN; SUBSTANCE USE; RISK-FACTORS; RELAXATION; ANXIETY; ANGER; BIOFEEDBACK; KNOWLEDGE	Objective.-To test the hypothesis that heightened anxiety, heightened anger intensity, and suppressed expression of anger increase the risk of hypertension, using the Framingham Heart Study. Design.-A cohort of men and women without evidence of hypertension at baseline were followed up for 18 to 20 years. Baseline measures of anxiety (tension), anger symptoms, and expression of anger (anger-in and anger-out) were taken, along with biological and behavioral predictors of hypertension (initial systolic blood pressure, heart rate, relative weight, age, hematocrit, alcohol intake, smoking, education, and glucose intolerance). Participants.-A total of 1123 initially normotensive persons (497 men, 626 women) were included. Analyses were stratified by age (45 to 59 or greater-than-or-equal-to 60 years) and gender. Main Outcome Measures.-Hypertension was defined as either taking medication for hypertension or blood pressures higher than 160/95 mm Hg at a biennial examination. Results.-In univariate analyses, middle-aged men who went on to develop hypertension had greater baseline anxiety levels than men who remained normotensive (P=.04). Older hypertensive men had fewer anger symptoms at baseline (P=.04) and were less likely to hold their anger in (P=.01) than normotensives. In multivariate Cox regression analysis including biological predictors, anxiety remained an independent predictor of hypertension in middle-aged men (P=.02). Among older men, anger symptoms and anger-in did not remain significant predictors in the multivariate analysis. Further analysis showed that only middle-aged men with very high levels of anxiety were at increased risk (relative risk, 2.19; 95% confidence interval, 1.22 to 3.94). No psychological variable predicted hypertension in middle-aged or older women in either univariate or multivariate analyses. Conclusions.-The results indicate that among middle-aged men, but not women, anxiety levels are predictive of later incidence of hypertension.	UNIV PITTSBURGH,DEPT PSYCHIAT,PITTSBURGH,PA 15260; BOSTON UNIV,DEPT MATH,BOSTON,MA 02215; BOSTON UNIV,SCH MED,PREVENT MED & EPIDEMIOL SECT,BOSTON,MA 02118	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Boston University; Boston University	MARKOVITZ, JH (corresponding author), UNIV ALABAMA,SCH MED,DEPT MED,DIV PREVENT MED,1717 11TH AVE S,7TH FLOOR,BIRMINGHAM,AL 35205, USA.				NHLBI NIH HHS [HL38712, R01-HL40423-04, N01-HC38038] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038712, R01HL038712, R01HL040423] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexander F, 1939, PSYCHOSOM MED, V1, P175; ANDERSON NB, 1989, J HYPERTENS, V7, P161; [Anonymous], 1988, BMJ, V297, P319; BLANCHARD EB, 1989, BEHAV THER, V20, P405, DOI 10.1016/S0005-7894(89)80059-0; COTTIER C, 1984, ARCH INTERN MED, V144, P1954, DOI 10.1001/archinte.144.10.1954; DIAMOND EL, 1982, PSYCHOL BULL, V92, P410, DOI 10.1037/0033-2909.92.2.410; EAKER ED, 1992, AM J EPIDEMIOL, V135, P854, DOI 10.1093/oxfordjournals.aje.a116381; EGAN KJ, 1983, J HUM STRESS, V9, P4, DOI 10.1080/0097840X.1983.9935024; GOLDSTEIN HS, 1988, PSYCHOSOM MED, V50, P321, DOI 10.1097/00006842-198807000-00001; HAVLIK RJ, 1980, CIRCULATION, V61, P710, DOI 10.1161/01.CIR.61.4.710; HAYNES SG, 1978, AM J EPIDEMIOL, V107, P362, DOI 10.1093/oxfordjournals.aje.a112556; HENRY JP, 1988, SOC SCI MED, V26, P293, DOI 10.1016/0277-9536(88)90393-0; IRVINE MJ, 1989, PSYCHOSOM MED, V51, P537, DOI 10.1097/00006842-198909000-00005; JACOB R G, 1991, Annals of Behavioral Medicine, V13, P5; JENKINS CD, 1983, J HUM STRESS, V9, P4, DOI 10.1080/0097840X.1983.9936124; JOHNSON EH, 1987, J PSYCHOSOM RES, V31, P731, DOI 10.1016/0022-3999(87)90022-5; KAHN HA, 1972, AM HEART J, V84, P171, DOI 10.1016/0002-8703(72)90331-6; KATON W, 1986, J CLIN PSYCHIAT, V47, P21; LANGFORD HG, 1987, BIBLIOTHECA CARDIOLO, V41, P57; MARKOVITZ JH, 1991, J HYPERTENS, V9, P399, DOI 10.1097/00004872-199105000-00003; MATTHEWS KA, 1989, AM J EPIDEMIOL, V129, P1132, DOI 10.1093/oxfordjournals.aje.a115235; MCCELLAND DC, 1979, J ABNORM PSYCHOL, V88, P182; MCGRADY A, 1989, PSYCHOSOM MED, V51, P277, DOI 10.1097/00006842-198905000-00002; MILLER SB, 1992, J PSYCHOSOM RES, V36, P149, DOI 10.1016/0022-3999(92)90023-U; NOYES R, 1978, COMPR PSYCHIAT, V19, P407, DOI 10.1016/0010-440X(78)90069-X; PERNINI C, 1991, J HYPERTENS, V9, P499; PERNINI C, 1990, HYPERTENSION, V16, P627; PERNINI C, 1988, J CARDIOVASC PHAR S3, V12, pS130; REAVEN GM, 1987, LANCET, V2, P435; ROBBINS MA, 1990, EXP AGING RES, V16, P199; ROBERTS J, 1981, VITAL HLTH STAT, V11; ROSE RM, 1978, DCTFA73WA3211 FED AV; ROSTRUP M, 1992, J PSYCHOSOM RES, V36, P117, DOI 10.1016/0022-3999(92)90020-3; SCHNEIDER RH, 1986, PSYCHOSOM MED, V48, P242, DOI 10.1097/00006842-198603000-00009; SOMMERSFLANAGAN J, 1989, J NERV MENT DIS, V177, P15, DOI 10.1097/00005053-198901000-00003; SPARROW D, 1982, CIRCULATION, V65, P789, DOI 10.1161/01.CIR.65.4.789; Spielberger C., 1983, STAI MANUAL; Spielberger C.D., 1985, ANGER HOSTILITY CARD, P5; STAESSEN J, 1990, J HYPERTENS, V8, P393, DOI 10.1097/00004872-199005000-00001; WADDEN TA, 1983, J NERV MENT DIS, V171, P683, DOI 10.1097/00005053-198311000-00007; WELLS KB, 1989, AM J PSYCHIAT, V146, P1440; WELLS KB, 1989, GEN HOSP PSYCHIAT, V11, P320, DOI 10.1016/0163-8343(89)90119-9; YALOW RS, 1988, AM J MED, V85, P22, DOI 10.1016/0002-9343(88)90394-4; 1991, JAMA-J AM MED ASSOC, V265, P255	44	162	172	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1993	270	20					2439	2443						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MG671	8230620				2022-12-28	WOS:A1993MG67100024
J	WALDRON, HA; COOKSON, RF				WALDRON, HA; COOKSON, RF			AVOIDING THE PITFALLS OF SPONSORED MULTICENTER RESEARCH IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CLINICAL-TRIALS	Research in general practice is becoming increasingly popular, and most general practitioners will sooner or later have to decide whether to become involved with clinical trials sponsored by drug companies. This paper outlines the advantages and disadvantages of multicentre research-based on experience of running a research group since the early 1980s-to enable doctors to reach the appropriate decision and to avoid involvement in trials which are either unethical or ineffective.	JANSSEN PHARMACEUT LTD,DEPT RES & DEV,WANTAGE OX12 0DQ,ENGLAND	Johnson & Johnson; Janssen Pharmaceuticals								ABERGEL A, 1989, ANN GEOPHYS, V7, P129; BAILEY BJ, 1989, AM J OTOL, V10, P248; BINGHAM K, 1991, DOCTOR          0214, P29; Bope E T, 1988, Fam Pract Res J, V7, P197; FEINMANN J, 1990, GENERAL PRACTIT 0928, P40; GRAY DP, 1991, BRIT MED J, V302, P1380, DOI 10.1136/bmj.302.6789.1380; GREENBERG G, 1991, BMJ-BRIT MED J, V303, P940, DOI 10.1136/bmj.303.6808.940; JONKER PL, 1992, BRIT MED J, V304, P508, DOI 10.1136/bmj.304.6825.508; Maj M, 1989, Prog Neuropsychopharmacol Biol Psychiatry, V13, pix, DOI 10.1016/0278-5846(89)90030-4; MARLEY JE, 1989, BRIT J CLIN PRACT, V43, P158; PETO V, 1991, BRIT MED J, V303, P1549, DOI 10.1136/bmj.303.6816.1549-c; PHILIP IG, 1987, BRIT J CLIN PRACT, V41, P947; SILAGY C, 1993, BMJ-BRIT MED J, V306, P897, DOI 10.1136/bmj.306.6882.897; TOGNONI G, 1991, BRIT MED J, V303, P969, DOI 10.1136/bmj.303.6808.969; WARLOW C, 1990, BRIT MED J, V300, P180, DOI 10.1136/bmj.300.6718.180; 1993, GENERAL PRACTIT 0326, P72; 1990, GUIDELINES PRACTICE; 1988, GUIDELINES GOOD CLIN; 1992, CODE PRACTICE CLIN A	19	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1993	307	6915					1331	1334		10.1136/bmj.307.6915.1331	http://dx.doi.org/10.1136/bmj.307.6915.1331			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH556	8257890	Green Published, Bronze			2022-12-28	WOS:A1993MH55600025
J	TAKI, S; MEIERING, M; RAJEWSKY, K				TAKI, S; MEIERING, M; RAJEWSKY, K			TARGETED INSERTION OF A VARIABLE REGION GENE INTO THE IMMUNOGLOBULIN HEAVY-CHAIN LOCUS	SCIENCE			English	Article							TRANSGENIC MICE; ALLELIC EXCLUSION; LYMPHOCYTES-B; GERM-LINE; ANTIBODIES; MU; CELLS; DNA; IGM; EXPRESSION	A mutant mouse strain has been generated in which a rearranged immunoglobulin heavy (H) chain variable (V) region gene is placed into the heavy chain locus in its natural position, replacing the J(H) elements. In homozygous mutant mice, essentially all B cells in the spleen express the transgenic V(H) region in their antibodies. The proper location of the transgene relative to the constant region genes allows it to participate in isotype switching and undergo somatic hypermutation. Immunoglobulin transgenic mice generated in this fashion by gene targeting should prove useful for the exploration of immunoregulatory mechanisms.	UNIV COLOGNE,INST GENET,D-50931 COLOGNE,GERMANY	University of Cologne				Taki, Shinsuke/0000-0001-5143-3496				ALT F, 1987, EMBO J, V3, P1209; ANDERSON PN, 1969, NATURE, V222, P994, DOI 10.1038/222994a0; BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; BRINK R, 1992, J EXP MED, V176, P991, DOI 10.1084/jem.176.4.991; BURTON DR, 1992, ADV IMMUNOL, V51, P1, DOI 10.1016/S0065-2776(08)60486-1; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHIEN NC, 1988, J EXP MED, V167, P954, DOI 10.1084/jem.167.3.954; Coffman R L, 1982, Immunol Rev, V69, P5; COHN M, 1969, IMMUNOCHEMISTRY, V6, P111, DOI 10.1016/0019-2791(69)90183-9; DESAYMARD C, 1984, MOL IMMUNOL, V21, P961, DOI 10.1016/0161-5890(84)90154-8; DIAMOND B, 1992, ANNU REV IMMUNOL, V10, P731, DOI 10.1146/annurev.iy.10.040192.003503; DURDIK J, 1989, P NATL ACAD SCI USA, V86, P2346, DOI 10.1073/pnas.86.7.2346; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; FEENEY AJ, 1990, J EXP MED, V172, P1377, DOI 10.1084/jem.172.5.1377; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; GERSTEIN RM, 1990, CELL, V63, P537, DOI 10.1016/0092-8674(90)90450-S; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; GROSSCHEDL R, 1984, CELL, V38, P647, DOI 10.1016/0092-8674(84)90259-9; GRUTZMANN R, 1981, THESIS U COLOGNE; GUISE JW, 1988, J IMMUNOL, V140, P3988; HAYAKAWA K, 1992, ANN NY ACAD SCI, V651, P346; HERZENBERG LA, 1992, ANN NY ACAD SCI, V651, P1; HOOIJKAAS H, 1984, EUR J IMMUNOL, V14, P1127, DOI 10.1002/eji.1830141212; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; Kabat EA, 1991, SEQUENCES PROTEINS I; KEARNEY JF, 1981, EUR J IMMUNOL, V11, P877, DOI 10.1002/eji.1830111106; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KOCKS C, 1989, ANNU REV IMMUNOL, V7, P537, DOI 10.1146/annurev.iy.07.040189.002541; KOHNO A, 1983, IMMUNOGENETICS, V18, P513, DOI 10.1007/BF00364392; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MANZ J, 1988, J EXP MED, V168, P1368; MASMOUDI H, 1990, INT IMMUNOL, V2, P515, DOI 10.1093/intimm/2.6.515; MEIERING M, UNPUB; NEMAZEE D, 1991, IMMUNOL REV, V122, P117, DOI 10.1111/j.1600-065X.1991.tb00600.x; NISHIKAWA SI, 1986, IMMUNOGENETICS, V23, P137, DOI 10.1007/BF00377976; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; PAPOIAN R, 1977, IMMUNOLOGY, V32, P75; PERLMUTTER RM, 1984, ADV IMMUNOL, V35, P1, DOI 10.1016/S0065-2776(08)60572-6; RUSCONI S, 1985, NATURE, V314, P330, DOI 10.1038/314330a0; SCHITTEK B, 1992, J EXP MED, V176, P427, DOI 10.1084/jem.176.2.427; SCHLOMCHIK MJ, 1987, NATURE, V328, P805; SCHUPPEL R, 1987, EUR J IMMUNOL, V17, P739, DOI 10.1002/eji.1830170527; SHIMIZU A, 1984, CELL, V36, P801, DOI 10.1016/0092-8674(84)90029-1; TAKI S, 1992, ANN NY ACAD SCI, V651, P328; TAKI S, 1992, EUR J IMMUNOL, V22, P987, DOI 10.1002/eji.1830220417; TAKI S, UNPUB; TONEGAWA S, 1983, NATURE, V302, P79; WEAVER D, 1985, CELL, V42, P117, DOI 10.1016/S0092-8674(85)80107-0; WOOD C, 1983, P NATL ACAD SCI-BIOL, V80, P3030, DOI 10.1073/pnas.80.10.3030	52	100	145	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1268	1271		10.1126/science.8235657	http://dx.doi.org/10.1126/science.8235657			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	8235657				2022-12-28	WOS:A1993MH32400040
J	OTTERVANGER, JP; VANWITSEN, TB; VALKENBURG, HA; STRICKER, BHC				OTTERVANGER, JP; VANWITSEN, TB; VALKENBURG, HA; STRICKER, BHC			POSTMARKETING STUDY OF CARDIOVASCULAR ADVERSE REACTIONS ASSOCIATED WITH SUMATRIPTAN	BRITISH MEDICAL JOURNAL			English	Article									NETHERLANDS CTR MONITORING ADVERSE DRUG REACT,POB 5406,2280 HK RIJSWIJK,NETHERLANDS; UNIV GRONINGEN,CTR PHARM,SOCIAL PHARM SECT,GRONINGEN,NETHERLANDS; ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS	University of Groningen; Erasmus University Rotterdam								BROWN EG, 1991, EUR NEUROL, V31, P339, DOI 10.1159/000116762; MACINTYRE PD, 1993, CIRCULATION, V87, P401, DOI 10.1161/01.CIR.87.2.401; OTTERVANGER JP, 1993, LANCET, V341, P861, DOI 10.1016/0140-6736(93)93064-8; STRICKER BHC, 1992, BRIT MED J, V305, P118, DOI 10.1136/bmj.305.6845.118-a; WILLETT F, 1992, BRIT MED J, V304, P1415, DOI 10.1136/bmj.304.6839.1415	5	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1993	307	6913					1185	1185		10.1136/bmj.307.6913.1185	http://dx.doi.org/10.1136/bmj.307.6913.1185			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF824	8251846	Green Published, Bronze			2022-12-28	WOS:A1993MF82400025
J	OLSEN, JH; GARWICZ, S; HERTZ, H; JONMUNDSSON, G; LANGMARK, F; LANNING, M; LIE, SO; MOE, PJ; MOLLER, T; SANKILA, R; TULINIUS, H				OLSEN, JH; GARWICZ, S; HERTZ, H; JONMUNDSSON, G; LANGMARK, F; LANNING, M; LIE, SO; MOE, PJ; MOLLER, T; SANKILA, R; TULINIUS, H			2ND MALIGNANT NEOPLASMS AFTER CANCER IN CHILDHOOD OR ADOLESCENCE	BRITISH MEDICAL JOURNAL			English	Article							LEUKEMIA; SURVIVORS; CHILDREN; RISK	Objective-To assess the relative risk of developing a second malignant neoplasm in people with a diagnosis of cancer in childhood and adolescence. Design-Register based follow up study. Setting-Populations of Nordic countries. Subjects-30 880 people under the age of 20 with a first malignant neoplasm diagnosed during the period 1943-87. Main outcome measures-Relative and attributable risks of second malignant neoplasms by type of first cancer, age at first diagnosis, calendar period, sex, and country. Expected figures were based on the appropriate national incidence rates for cancer. Results-247 cases of second malignant neoplasms were observed in 238 patients, yielding a relative risk for cancer of 3-6 (95% confidence interval 3.1 to 4.1). The risk changed significantly from 2.6 in people first diagnosed during the 1940s and 1950s to 6.9 among cohort members included in the late 1970s and 1980s. Increases were observed for most types of cancer. Highest levels of the relative risk were seen during the 10 years immediately after first malignant diagnosis. The incidence of second malignant neoplasms attributable to the first cancer and associated treatments, however, showed a consistent rise throughout the 45 years of follow up. Conclusion-The estimated risks for a second malignant neoplasm were significantly lower than those found in most large hospital based studies but compatible with the results from a similar population based study in the United Kingdom. Extent of risk and cancer pattern were similar among the Nordic countries and are believed to be representative for a large part of the European population.			OLSEN, JH (corresponding author), DANISH CANC SOC,DIV CANC EPIDEMIOL,STRANDBOULEVARDEN 49,DK-2100 COPENHAGEN,DENMARK.			Olsen, Jorgen Helge/0000-0001-9633-5662				[Anonymous], 1976, INT CLASSIFICATION D; BIRCH JM, 1987, INT J CANCER, V40, P620, DOI 10.1002/ijc.2910400508; Boice J D Jr, 1985, Natl Cancer Inst Monogr, V68, P3; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; BROWN PD, 1989, INT J EPIDEMIOL, V18, P546, DOI 10.1093/ije/18.3.546; HAKULINEN T, 1986, ACTA PATHOL MIC S288, V94, P12; HAWKINS MM, 1987, BRIT J CANCER, V56, P399; Jensen O M, 1985, Natl Cancer Inst Monogr, V68, P245; LI FP, 1975, CANCER, V35, P1230, DOI 10.1002/1097-0142(197504)35:4<1230::AID-CNCR2820350430>3.0.CO;2-Q; MIKE V, 1982, LANCET, V2, P1326; NEGLIA JP, 1991, NEW ENGL J MED, V325, P1330, DOI 10.1056/NEJM199111073251902; NYGAARD R, 1991, ACTA PAEDIATR SCAND, V80, P1220, DOI 10.1111/j.1651-2227.1991.tb11812.x; OLSEN JH, 1986, CANCER, V57, P2250; Parkin D. M, 1988, IARC SCI PUBLICATION, V87; ROTHMAN KJ, 1979, DHSS NIH791649 PUB; TARBELL NJ, 1993, LANCET, V341, P1428, DOI 10.1016/0140-6736(93)90880-P; TERRACINI B, 1987, EUR J CANCER CLIN ON, V23, P499, DOI 10.1016/0277-5379(87)90309-9; TSUNEMATSU Y, 1985, JPN J CLIN ONCOL, V15, P223; TUCKER MA, 1987, J NATL CANCER I, V78, P459, DOI 10.1093/jnci/78.3.459; TUCKER MA, 1987, NEW ENGL J MED, V317, P588, DOI 10.1056/NEJM198709033171002; TUCKER MA, 1991, CANCER RES, V51, P2885; TUCKER MA, 1984, RAD CARCINOGENESIS E, P211; WITHERSPOON RP, 1989, NEW ENGL J MED, V321, P784, DOI 10.1056/NEJM198909213211203; 1976, SYSTEMATIZED NOMENCL; 1956, WHOHSCANC241; 1968, MANUAL TUMOR NOMENCL; 1989, INCIDENCE CANCER NOR, P7	27	148	150	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1993	307	6911					1030	1036		10.1136/bmj.307.6911.1030	http://dx.doi.org/10.1136/bmj.307.6911.1030			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD556	8251777	Green Published, Bronze			2022-12-28	WOS:A1993MD55600016
J	BASTARRACHEA, J; HORTOBAGYI, GN; SMITH, TL; KAU, SWC; BUZDAR, AU				BASTARRACHEA, J; HORTOBAGYI, GN; SMITH, TL; KAU, SWC; BUZDAR, AU			OBESITY AS AN ADVERSE PROGNOSTIC FACTOR FOR PATIENTS RECEIVING ADJUVANT CHEMOTHERAPY FOR BREAST-CANCER	ANNALS OF INTERNAL MEDICINE			English	Article							BODY-WEIGHT; STAGE-II; DOXORUBICIN; CARCINOMA; SURVIVAL; CYCLOPHOSPHAMIDE; MASTECTOMY; RELAPSE; THERAPY; TABLES	Objective: To determine whether obesity is an independent prognostic factor among women receiving adjuvant chemotherapy for lymph node-positive breast cancer and to determine how obesity relates to other commonly used prognostic indicators. Design: Retrospective review of the clinical characteristics and clinical course of 735 patients with stages II and III primary breast cancer who were treated using three consecutive postoperative adjuvant chemotherapy protocols. Univariate and multivariate analyses were used to determine the prognostic implications of obesity defined by weight and height tables and body mass index. In addition, we analyzed the relation between obesity and other known prognostic indicators for patients with primary breast cancer. Setting: A comprehensive cancer center. Patients: 735 patients with lymph node-positive primary breast cancer who were treated using three consecutive fluorouracil-doxorubicin-cyclophosphamide-containing adjuvant chemotherapy protocols and for whom complete data on weight, height, standard prognostic factors, and outcome were available. Main Outcome Measurements: Disease-free and overall survival for the entire group and obese and nonobese subgroups. Results: 24 percent of patients were more than 20% overweight. With a median follow-up of 10.7 years, the estimated 10-year, disease-free rate for patients not more than 20% overweight was 54% (95% CI, 50% to 58%) compared with 40% (CI, 33% to 47%) for remaining patients classified as obese. Although obese patients tended to have somewhat less favorable prognoses based on standard prognostic criteria, a proportional-hazards regression model adjusting for other factors indicated that risk for disease recurrence among obese patients was 1.33 times that of the nonobese population (CI, 1.05 to 1.68). Conclusions: Obesity is an indicator of poor prognosis for patients with primary breast cancer even after the administration of adjuvant chemotherapy. The effect of dietary interventions to reduce body weight on the outcome of breast cancer therapy must be investigated.	UNIV TEXAS, MD ANDERSON CANC CTR, 1515 HOLCOMBE BLVD, BOX 56, HOUSTON, TX 77025 USA	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA-16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE R, 1976, TOHOKU J EXP MED, V120, P351, DOI 10.1620/tjem.120.351; ANG PT, 1989, J CLIN ONCOL, V7, P1677, DOI 10.1200/JCO.1989.7.11.1677; [Anonymous], 1983, Stat Bull Metrop Life Found, V64, P3; BEAHRS OH, 1988, AM JOINT COMMITTEE C; BOYD NF, 1981, JNCI-J NATL CANCER I, V67, P785; BURT JR, 1983, P AN M AM SOC CLIN, pC6; BUZDAR A, 1981, ADJUVANT THERAPY CAN, V3, P419; BUZDAR AU, 1978, CANCER, V41, P1064, DOI 10.1002/1097-0142(197803)41:3<1064::AID-CNCR2820410340>3.0.CO;2-Q; BUZDAR AU, 1984, CANCER, V53, P384, DOI 10.1002/1097-0142(19840201)53:3<384::AID-CNCR2820530303>3.0.CO;2-G; BUZDAR AU, 1987, ADJUVANT THERAPY CAN, V5, P411; CAMORIANO JK, 1990, J CLIN ONCOL, V8, P1327, DOI 10.1200/JCO.1990.8.8.1327; CHLEBOWSKI RT, 1986, BREAST CANCER RES TR, V7, P23, DOI 10.1007/BF01886732; COX DR, 1972, J R STAT SOC B, V34, P187; de Waard F, 1982, Nutr Cancer, V4, P85, DOI 10.1080/01635588209513743; DEWAARD F, 1964, CANCER, V17, P141, DOI 10.1002/1097-0142(196402)17:2<141::AID-CNCR2820170202>3.0.CO;2-Z; DONEGAN WL, 1978, CANCER, V41, P1590, DOI 10.1002/1097-0142(197804)41:4<1590::AID-CNCR2820410449>3.0.CO;2-N; EBERLEIN T, 1985, BREAST CANCER RES TR, V5, P81, DOI 10.1007/BF01807654; GARFINKEL L, 1988, CANCER, V62, P1844, DOI 10.1002/1097-0142(19881015)62:1+<1844::AID-CNCR2820621328>3.0.CO;2-O; GARN SM, 1984, AM J CLIN NUTR, V39, P490, DOI 10.1093/ajcn/39.3.490; GOODWIN PJ, 1988, BREAST CANCER RES TR, V11, P59, DOI 10.1007/BF01807559; GOODWIN PJ, 1990, BREAST CANCER RES TR, V16, P205, DOI 10.1007/BF01806329; HEASMAN KZ, 1985, BREAST CANCER RES TR, V5, P195, DOI 10.1007/BF01805994; HEBERT JR, 1988, INT J CANCER, V42, P315, DOI 10.1002/ijc.2910420302; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KODAMA M, 1987, ANTICANCER RES, V559, P71; LIPPMAN ME, 1978, NEW ENGL J MED, V298, P1223, DOI 10.1056/NEJM197806012982203; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MCGUIRE WL, 1987, BREAST CANCER RES TR, V10, P5, DOI 10.1007/BF01806129; MOORE DH, 1983, ADV CANCER RES, V40, P189, DOI 10.1016/S0065-230X(08)60681-8; NEWMAN SC, 1986, AM J EPIDEMIOL, V123, P767, DOI 10.1093/oxfordjournals.aje.a114305; POWIS G, 1987, CANCER CHEMOTH PHARM, V20, P219, DOI 10.1007/BF00570489; RODVOLD KA, 1988, J CLIN ONCOL, V6, P1321, DOI 10.1200/JCO.1988.6.8.1321; SENIE RT, 1992, ANN INTERN MED, V116, P26, DOI 10.7326/0003-4819-116-1-26; SUISSA S, 1989, CANCER RES, V49, P3113; TARTTER PI, 1981, CANCER, V47, P2222, DOI 10.1002/1097-0142(19810501)47:9<2222::AID-CNCR2820470919>3.0.CO;2-5; THIJSSEN JHH, 1975, J STEROID BIOCHEM, V6, P729, DOI 10.1016/0022-4731(75)90060-6; ZUMOFF B, 1983, J SURG ONCOL, V22, P217, DOI 10.1002/jso.2930220402; 1973, VITAL HLTH STATIST 1; 1942, STAT B METROP LIFE F, V23, P6; 1959, STAT B METROP LIFE F, V40, P1	40	124	128	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1994	120	1					18	25		10.7326/0003-4819-120-1-199401010-00004	http://dx.doi.org/10.7326/0003-4819-120-1-199401010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP280	8250452				2022-12-28	WOS:A1994MP28000004
J	DAWSON, DM				DAWSON, DM			CURRENT CONCEPTS - ENTRAPMENT NEUROPATHIES OF THE UPPER EXTREMITIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CARPAL-TUNNEL SYNDROME; MEDIAN NERVE; DIAGNOSIS; LOCALIZATION; SURVEILLANCE; CONDUCTION; DEFINITION; DISORDERS; SURGERY; HEALTH				DAWSON, DM (corresponding author), VET AFFAIRS MED CTR,1400 VFW PKY,BOSTON,MA 02132, USA.							Charness M, 1992, OCCUPATIONAL DISORDE, P227; CHERINGTON M, 1986, MUSCLE NERVE, V9, P632, DOI 10.1002/mus.880090709; CSEUZ KA, 1966, MAYO CLIN PROC, V41, P232; Dawson DM, 1983, ENTRAPMENT NEUROPATH, P141; DEKEL S, 1979, LANCET, V2, P1024; DEKROM MCTFM, 1992, J CLIN EPIDEMIOL, V45, P373, DOI 10.1016/0895-4356(92)90038-O; EISEN A, 1974, NEUROLOGY, V24, P256, DOI 10.1212/WNL.24.3.256; FEINDEL W, 1957, CAN J SURG, V1, P287; FRANKLIN GM, 1991, AM J PUBLIC HEALTH, V81, P741, DOI 10.2105/AJPH.81.6.741; GELBERMAN RH, 1980, J BONE JOINT SURG AM, V62, P1181, DOI 10.2106/00004623-198062070-00020; GELBERMAN RH, 1981, J BONE JOINT SURG AM, V63, P380, DOI 10.2106/00004623-198163030-00009; GELLMAN H, 1986, J BONE JOINT SURG AM, V68A, P735, DOI 10.2106/00004623-198668050-00015; GREEN DP, 1984, J HAND SURG-AM, V9A, P850, DOI 10.1016/S0363-5023(84)80065-9; GRUNDBERG AB, 1983, J HAND SURG-AM, V8, P348, DOI 10.1016/S0363-5023(83)80179-8; HALLETT M, 1985, NEUROL CLIN, V3, P531, DOI 10.1016/S0733-8619(18)31020-X; HEITHOFF SJ, 1990, J HAND SURG-AM, V15A, P22, DOI 10.1016/S0363-5023(09)91100-5; KAPLAN SJ, 1990, J HAND SURG-BRIT EUR, V15B, P106, DOI 10.1016/0266-7681(90)90061-8; KATZ JN, 1990, ANN INTERN MED, V112, P321, DOI 10.7326/0003-4819-112-5-321; KATZ JN, 1991, AM J PUBLIC HEALTH, V81, P189, DOI 10.2105/AJPH.81.2.189; KIMURA J, 1979, BRAIN, V102, P619, DOI 10.1093/brain/102.3.619; KINKAID JC, 1988, MUSCLE NERVE, V11, P1005; LEFFERT RD, 1982, J HAND SURG-AM, V7, P147, DOI 10.1016/S0363-5023(82)80079-8; LISS GM, 1992, AM J IND MED, V22, P395, DOI 10.1002/ajim.4700220312; MASEAR VR, 1986, J HAND SURG-AM, V11A, P222, DOI 10.1016/S0363-5023(86)80055-7; MATTE TD, 1989, AM J PUBLIC HEALTH, V79, P21, DOI 10.2105/AJPH.79.Suppl.21; MILLENDER LH, 1992, OCCUPATIONAL DISORDE; MILLER RG, 1979, ANN NEUROL, V6, P56, DOI 10.1002/ana.410060113; MILLER RG, 1979, JAMA-J AM MED ASSOC, V242, P1636, DOI 10.1001/jama.242.15.1636; NATHAN PA, 1988, MUSCLE NERVE, V11, P1149, DOI 10.1002/mus.880111107; OMALLEY MJ, 1992, J HAND SURG-AM, V17A, P638, DOI 10.1016/0363-5023(92)90307-B; PAYAN J, 1969, J NEUROL NEUROSUR PS, V32, P208, DOI 10.1136/jnnp.32.3.208; PAYAN J, 1979, BRIT MED J, V2, P868, DOI 10.1136/bmj.2.6194.868; REDMOND MD, 1988, MUSCLE NERVE, V11, P511, DOI 10.1002/mus.880110515; REMPEL DM, 1992, JAMA-J AM MED ASSOC, V267, P838, DOI 10.1001/jama.267.6.838; Rosenbaum RB, 1993, CARPAL TUNNEL SYNDRO; SHEFNER JM, 1990, ARCH NEUROL-CHICAGO, V47, P341, DOI 10.1001/archneur.1990.00530030121028; SILVERSTEIN BA, 1987, AM J IND MED, V11, P343, DOI 10.1002/ajim.4700110310; SO YT, 1989, NEUROLOGY, V39, P1; STEVENS JC, 1988, NEUROLOGY, V38, P134, DOI 10.1212/WNL.38.1.134; STEVENS JC, 1987, MUSCLE NERVE, V10, P99, DOI 10.1002/mus.880100202; STEWART JD, 1978, BRIT MED J, V2, P1125, DOI 10.1136/bmj.2.6145.1125-a; STEWART JD, 1987, FOCAL PERIPHERAL NEU; STOCK SR, 1991, AM J IND MED, V19, P87, DOI 10.1002/ajim.4700190111; SZABO RM, 1989, J HAND SURG-AM, V14A, P624, DOI 10.1016/0363-5023(89)90178-0; WILBOURN AJ, 1988, MUSCLE NERVE, V11, P66, DOI 10.1002/mus.880110111; WINN FJ, 1990, MUSCLE NERVE, V13, P254, DOI 10.1002/mus.880130313; 1989, MMWR MORB MORTAL WKL, V38, P485; [No title captured]	48	155	162	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1993	329	27					2013	2018		10.1056/NEJM199312303292707	http://dx.doi.org/10.1056/NEJM199312303292707			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN573	8247077				2022-12-28	WOS:A1993MN57300007
J	WONG, TY; MIHM, MC				WONG, TY; MIHM, MC			MYCOSIS-FUNGOIDES	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											WONG, TY (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA.		Wong, Tien Yin/AAC-9724-2020	Wong, Tien Yin/0000-0002-8448-1264					0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1993	329	27					2001	2001						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN573	8247076				2022-12-28	WOS:A1993MN57300005
J	WU, JY; MANIATIS, T				WU, JY; MANIATIS, T			SPECIFIC INTERACTIONS BETWEEN PROTEINS IMPLICATED IN SPLICE-SITE SELECTION AND REGULATED ALTERNATIVE SPLICING	CELL			English	Article							PRE-MESSENGER-RNA; RIBONUCLEOPROTEIN AUXILIARY FACTOR; BIOCHEMICAL-CHARACTERIZATION; DROSOPHILA ENCODES; BINDING PROTEINS; ASSEMBLY PATHWAY; FACTOR SC35; INVITRO; GENE; U1	Specific recognition and pairing of the 5' and 3' splice sites are critical steps in pre-mRNA splicing. We report that the splicing factors SC35 and SF2/ASF specifically interact with both the integral U1 small nuclear ribonucleoprotein snRNP U1-70K) and with the 35 kd subunit of the splicing factor U2AF (U2AF35). Previous studies indicated that the U1 snRNP binds specifically to the 5' splice site, while U2AF35-U2AF65 heterodimer binds to the 3' splice site. Together, these observations suggest that SC35 and other members of the SR family of splicing factors may function in splice site selection by acting as a bridge between components bound to the 5' and 3' splice sites. Interestingly, SC35, SF2/ASF, and U2AF35 also interact with the Drosophila splicing regulators Transformer (Tra) and Transformer-2 (Tra2), suggesting that protein-protein interactions mediated by SR proteins may also play an important role in regulating alternative splicing.			WU, JY (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA.				NCI NIH HHS [R01 CA114197-01A2] Funding Source: Medline; NEI NIH HHS [R01 EY014576-03] Funding Source: Medline; NIGMS NIH HHS [R01 GM070967-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA114197] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY014576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070967] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BILLINGS PB, 1982, J IMMUNOL, V128, P1176; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XD, 1992, P NATL ACAD SCI USA, V89, P1725, DOI 10.1073/pnas.89.5.1725; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HOFFMAN BE, 1992, GENE DEV, V6, P2554, DOI 10.1101/gad.6.12b.2554; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; INOUE K, 1992, P NATL ACAD SCI USA, V89, P8092, DOI 10.1073/pnas.89.17.8092; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KIM YJ, 1993, MOL CELL BIOL, V13, P174, DOI 10.1128/MCB.13.1.174; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; LAMM GM, 1993, BIOCHIM BIOPHYS ACTA, V1173, P247, DOI 10.1016/0167-4781(93)90122-T; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; MCKEOWN M, 1987, CELL, V48, P489, DOI 10.1016/0092-8674(87)90199-1; MICHAUD S, 1993, GENE DEV, V7, P1008, DOI 10.1101/gad.7.6.1008; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; Moore M., 1993, RNA WORLD, P303; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; PINTO AL, 1989, P NATL ACAD SCI USA, V86, P8742, DOI 10.1073/pnas.86.22.8742; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; RUBY SW, 1991, TRENDS GENET, V7, P79; RYNER LC, 1991, GENE DEV, V5, P2071, DOI 10.1101/gad.5.11.2071; SPRITZ RA, 1987, NUCLEIC ACIDS RES, V15, P10373, DOI 10.1093/nar/15.24.10373; TAZI J, 1993, NATURE, V363, P283, DOI 10.1038/363283a0; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; WOPPMANN A, 1990, NUCLEIC ACIDS RES, V18, P4427, DOI 10.1093/nar/18.15.4427; WOPPMANN A, 1993, NUCLEIC ACIDS RES, V21, P2815, DOI 10.1093/nar/21.12.2815; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769	57	643	660	1	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 17	1993	75	6					1061	1070		10.1016/0092-8674(93)90316-I	http://dx.doi.org/10.1016/0092-8674(93)90316-I			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	8261509				2022-12-28	WOS:A1993MM89300005
J	GROEGER, JS; LUCAS, AB; THALER, HT; FRIEDLANDERKLAR, H; BROWN, AE; KIEHN, TE; ARMSTRONG, D				GROEGER, JS; LUCAS, AB; THALER, HT; FRIEDLANDERKLAR, H; BROWN, AE; KIEHN, TE; ARMSTRONG, D			INFECTIOUS MORBIDITY ASSOCIATED WITH LONG-TERM USE OF VENOUS ACCESS DEVICES IN PATIENTS WITH CANCER	ANNALS OF INTERNAL MEDICINE			English	Article						CATHETERIZATION, CENTRAL VENOUS; PORTS, IMPLANTED, SUBCUTANEOUS; FUNGEMIA; BACTEREMIA; NEOPLASMS	PROLONGED PARENTERAL NUTRITION; MARROW TRANSPLANT RECIPIENTS; QUANTITATIVE BLOOD CULTURES; PEDIATRIC ONCOLOGY PATIENTS; HICKMAN-BROVIAC CATHETERS; RIGHT ATRIAL CATHETERS; PORT-A-CATH; EXTERNAL CATHETERS; COMPLICATIONS; EXPERIENCE	Objective: To evaluate infectious morbidity associated with long-term use of venous access devices. Design: Prospective, observational study. Setting: Comprehensive cancer center at a university hospital. Participants: 1431 consecutive patients with cancer requiring 1630 venous access devices for long-term use inserted between 1 June 1987 and 31 May 1989. Measurements: Quantitative microbiologic tests to identify device-related bacteremia and fungemia, catheter tunnel infection, pocket infection in implantable port devices, and site infections; number of days the device remained in situ and time until infectious morbidity; vessel or device thrombosis and device breakage. Results: At least one device-related infection occurred with 341 of 788 (43% [95% CI, 39% to 47%]) catheters compared with 57 of 680 (8% [CI, 6% to 10%]) completely implanted ports (P less-than-or-equal-to 0.001). Device-related bacteremia or fungemia is the predominant infection occurring with catheters, whereas ports have a more equal distribution of pocket, site, and device-related bacteremia. The predominant organisms isolated in catheter-related bacteremia were gram-negative bacilli (55%) compared with gram-positive cocci (65.5%) in port-related bacteremia. The number of infections per 1000 device days was 2.77 (95% CI, 2.48 to 3.06) for catheters compared with 0.21 (CI, 0.16 to 0.27) for ports (P less-than-or-equal-to 0.001). Based on a parametric model of time to first infection, devices lasted longer in patients with solid tumors than in those with hematopoietic tumors. Ports lasted longer than catheters across all patient groups. Conclusions: The incidence of infections per device-day was 12 times greater with catheters than with ports. Patients with solid tumors were the least likely to have device-related infectious morbidity compared with those with hematologic cancers. The reasons for the difference in infectious complications is uncertain but may be attributable to type of disease, intensity of therapy, frequency with which devices are accessed, or duration of neutropenia.	CORNELL UNIV, MED CTR, COLL MED, NEW YORK, NY 10021 USA	Cornell University	GROEGER, JS (corresponding author), MEM SLOAN KETTERING CANC CTR, DEPT ANESTHESIOL & CRIT CARE MED, SPECIAL CARE UNIT, 1275 YORK AVE, NEW YORK, NY 10021 USA.							ANDREMONT A, 1988, J CLIN MICROBIOL, V26, P2297, DOI 10.1128/JCM.26.11.2297-2299.1988; BENEZRA D, 1988, AM J MED, V85, P495; BRINCKER H, 1986, CANCER, V57, P1124, DOI 10.1002/1097-0142(19860315)57:6<1124::AID-CNCR2820570611>3.0.CO;2-D; BROTHERS TE, 1988, SURG GYNECOL OBSTET, V166, P295; BROVIAC JW, 1974, SURG GYNECOL OBSTET, V139, P24; BRUNBUISSON C, 1987, ARCH INTERN MED, V147, P873, DOI 10.1001/archinte.147.5.873; CARDE P, 1989, EUR J CANCER CLIN ON, V25, P939, DOI 10.1016/0277-5379(89)90151-X; COOPER GL, 1988, J CLIN MICROBIOL, V26, P8, DOI 10.1128/JCM.26.1.8-12.1988; COOPER GL, 1985, NEW ENGL J MED, V312, P1142, DOI 10.1056/NEJM198505023121802; DAWSON S, 1991, AM J PEDIAT HEMATOL, V13, P126; FLYNN PM, 1987, PEDIATR INFECT DIS J, V6, P729, DOI 10.1097/00006454-198708000-00007; GRANNAN KJ, 1990, J SURG ONCOL, V44, P52, DOI 10.1002/jso.2930440112; GROEGER JS, 1993, ANN SURG, V218, P206, DOI 10.1097/00000658-199308000-00014; HICKMAN RO, 1979, SURG GYNECOL OBSTET, V148, P871; HOCKENBERRY MJ, 1989, AM J PEDIAT HEMATOL, V11, P295; INGRAM J, 1991, AM J PEDIAT HEMATOL, V13, P130; JACOBS MB, 1984, ARCH INTERN MED, V144, P1597, DOI 10.1001/archinte.144.8.1597; JOHNSON PR, 1986, J INFECT DIS, V154, P570, DOI 10.1093/infdis/154.4.570; KIEHN TE, 1990, EUR J CLIN MICROBIOL, V9, P869, DOI 10.1007/BF01967501; KLUNNE MCK, 1989, CANCER, V64, P1747; LOKICH JJ, 1985, J CLIN ONCOL, V3, P710, DOI 10.1200/JCO.1985.3.5.710; MAKI DG, 1988, AM J MED, V85, P307, DOI 10.1016/0002-9343(88)90579-7; Maki DG, 1982, CURRENT TOPICS CLIN, P309; MIRRO J, 1989, J CLIN ONCOL, V7, P214, DOI 10.1200/JCO.1989.7.2.214; MIRRO J, 1990, J PEDIATR SURG, V25, P120, DOI 10.1016/S0022-3468(05)80176-9; MOOSA HH, 1991, SURG GYNECOL OBSTET, V172, P275; NIEDERHUBER JE, 1982, SURGERY, V92, P706; PRESS OW, 1984, MEDICINE, V63, P189, DOI 10.1097/00005792-198407000-00001; RIELLA MC, 1976, SURG GYNECOL OBSTET, V143, P205; ROSS MN, 1988, SURG GYNECOL OBSTET, V167, P141; SCHWARTZ C, 1990, J CLIN ONCOL, V8, P1591, DOI 10.1200/JCO.1990.8.9.1591; SHULMAN RJ, 1987, J CLIN ONCOL, V5, P137, DOI 10.1200/JCO.1987.5.1.137; STRUM S, 1986, J CLIN ONCOL, V4, P596, DOI 10.1200/JCO.1986.4.4.596; TANCREDE CH, 1985, J INFECT DIS, V152, P99, DOI 10.1093/infdis/152.1.99; TENNEY JH, 1986, ARCH INTERN MED, V146, P1949, DOI 10.1001/archinte.146.10.1949; VANHOFF J, 1990, J CLIN ONCOL, V8, P1255, DOI 10.1200/JCO.1990.8.7.1255; WESENBERG F, 1987, PEDIATR HEMAT ONCOL, V4, P137, DOI 10.3109/08880018709141260; WHIMBEY E, 1984, J CLIN MICROBIOL, V19, P766, DOI 10.1128/JCM.19.6.766-771.1984; WURZEL CL, 1988, AM J DIS CHILD, V142, P536, DOI 10.1001/archpedi.1988.02150050074036	39	317	329	1	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1993	119	12					1168	1174		10.7326/0003-4819-119-12-199312150-00003	http://dx.doi.org/10.7326/0003-4819-119-12-199312150-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM121	8239247				2022-12-28	WOS:A1993MM12100003
J	JAN, YN; JAN, LY				JAN, YN; JAN, LY			HLH PROTEINS, FLY NEUROGENESIS, AND VERTEBRATE MYOGENESIS	CELL			English	Review							ACHAETE-SCUTE; NERVOUS-SYSTEM; SENSORY ORGANS; GENE-COMPLEX; DROSOPHILA; MUSCLE; EXPRESSION; INACTIVATION; MYF-5; MYOD		UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	JAN, YN (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.			Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299				BRAND M, 1993, DEVELOPMENT, V119, P1; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; CABRERA CV, 1991, EMBO J, V10, P2965, DOI 10.1002/j.1460-2075.1991.tb07847.x; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CUBAS P, 1992, EMBO J, V11, P3385, DOI 10.1002/j.1460-2075.1992.tb05417.x; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DAMBLYCHAUDIERE C, 1987, GENE DEV, V1, P297, DOI 10.1101/gad.1.3.297; DOMINGUEZ M, 1993, EMBO J, V12, P2049, DOI 10.1002/j.1460-2075.1993.tb05854.x; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HOPWOOD ND, 1992, DEVELOPMENT, V114, P31; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; MARTINBERMUDO MD, 1991, DEVELOPMENT, V113, P445; MARTINEZ C, 1991, SCIENCE, V251, P1485, DOI 10.1126/science.1900954; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; PARKHURST SM, 1993, DEVELOPMENT, V117, P737; RODRIGUEZ I, 1990, EMBO J, V9, P3583, DOI 10.1002/j.1460-2075.1990.tb07569.x; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; VANDOREN M, 1992, GENE DEV, V6, P2592, DOI 10.1101/gad.6.12b.2592; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YOUNGERSHEPHERD S, 1992, CELL, V70, P911, DOI 10.1016/0092-8674(92)90242-5	26	420	432	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 3	1993	75	5					827	830		10.1016/0092-8674(93)90525-U	http://dx.doi.org/10.1016/0092-8674(93)90525-U			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252617	Bronze			2022-12-28	WOS:A1993MK96600001
J	MYERS, JK; WIDLANSKI, TS				MYERS, JK; WIDLANSKI, TS			MECHANISM-BASED INACTIVATION OF PROSTATIC ACID-PHOSPHATASE	SCIENCE			English	Article							VIRULENCE DETERMINANT; TYROSINE KINASES; PROTEINS; YERSINIA	Protein phosphatases play important roles in the regulation of cell growth and metabolism, yet little is known about their enzymatic mechanism. By extrapolation from data on inhibitors of other types of hydrolases, an inhibitor of prostatic acid phosphatase was designed that is likely to function as a mechanism-based phosphotyrosine phosphatase inactivator. This molecule, 4-(fluoromethyl)phenyl phosphate, represents a useful paradigm for the design of potent and specific phosphatase inhibitors.	INDIANA UNIV,DEPT CHEM,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington					NIGMS NIH HHS [R01 GM47918-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047918] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER D R, 1990, New Biologist, V2, P1049; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; CHU TM, 1982, CLIN BIOCH ANAL, V11, P117; CLEMENS JC, 1991, MOL MICROBIOL, V5, P2617, DOI 10.1111/j.1365-2958.1991.tb01970.x; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GLENNEY JR, 1992, BIOCHIM BIOPHYS ACTA, V1134, P113, DOI 10.1016/0167-4889(92)90034-9; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; HALAZY S, 1990, BIOORG CHEM, V18, P330, DOI 10.1016/0045-2068(90)90007-R; HELLER JE, 1987, J UROLOGY, V137, P1091, DOI 10.1016/S0022-5347(17)44414-4; LEGOFF JM, 1988, ENDOCRINOLOGY, V123, P1693, DOI 10.1210/endo-123-3-1693; LIN MF, 1987, ADV PROT PHOSPHATASE, V4, P199; NGUYEN L, 1990, CLIN CHEM, V36, P1450; SILVERMAN RB, 1988, MECHANISM BASED ENZY; VANETTEN RL, 1978, CLIN CHEM, V24, P1525; VANETTEN RL, 1982, ANN NY ACAD SCI, V390, P27; WAKSELMAN M, 1983, NOUV J CHIM, V7, P439; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	17	75	82	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 26	1993	262	5138					1451	1453		10.1126/science.8248785	http://dx.doi.org/10.1126/science.8248785			3	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ046	8248785				2022-12-28	WOS:A1993MJ04600042
J	SCRAGG, R; MITCHELL, EA; TAYLOR, BJ; STEWART, AW; FORD, RPK; THOMPSON, JMD; ALLEN, EM; BECROFT, DMO				SCRAGG, R; MITCHELL, EA; TAYLOR, BJ; STEWART, AW; FORD, RPK; THOMPSON, JMD; ALLEN, EM; BECROFT, DMO			BED SHARING, SMOKING, AND ALCOHOL IN THE SUDDEN-INFANT-DEATH-SYNDROME	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PASSIVE SMOKING; HONG-KONG; NICOTINE; COTININE; CHILDREN; URINE	Objectives-To investigate why sharing the bed with an infant is a not consistent risk factor for the sudden infant death syndrome in ethnic subgroups in New Zealand and to see if the risk of sudden infant death associated with this practice is related to other factors, particularly maternal smoking and alcohol consumption. Design-Nationwide case-control study. Setting-Region of New Zealand with 78% of all births during 1987-90. Subjects-Home interviews were completed with parents of 393 (81.0% of total) infants who died from the sudden infant death syndrome in the postneonatal age group, and 1592 (88.4% of total) controls who were a representative sample of all hospital births in the study region. Results-Maternal smoking interacted with infant bed sharing on the risk of sudden infant death. Compared with infants not exposed to either risk factor, the relative risk for infants of mothers who smoked was 3.94 (95% confidence interval 2.47 to 6.27) for bed sharing in the last two weeks and 4.55 (2.63 to 7.88) for bed sharing in the last sleep, after other confounders were controlled for. The results for infants of non-smoking mothers were inconsistent with the relative risk being significantly increased for usual bed sharing in the last two weeks (1.73; 1.11 to 2.70) but not for bed sharing in the last sleep (0.98; 0.44 to 2.18). Neither maternal alcohol consumption nor the thermal resistance of the infant's clothing and bedding interacted with bed sharing to increase the risk of sudden infant death, and alcohol was not a risk factor by itself. Conclusion-Infant bed sharing is associated with a significantly raised risk of the sudden infant death syndrome, particularly among infants of mothers who smoke. The interaction between maternal smoking and bed sharing suggests that a mechanism involving passive smoking, rather than the previously proposed mechanisms of overlaying and hyperthermia, increases the risk of sudden infant death from bed sharing.	UNIV OTAGO, DUNEDIN, NEW ZEALAND	University of Otago	SCRAGG, R (corresponding author), UNIV AUCKLAND, DEPT COMMUNITY HLTH, AUCKLAND, NEW ZEALAND.		Taylor, Barry j/G-1410-2010	Taylor, Barry/0000-0002-6450-8677; Scragg, Robert/0000-0003-0013-2620				BALARAJAN R, 1989, BRIT MED J, V298, P716, DOI 10.1136/bmj.298.6675.716; BASS M, 1986, NEW ENGL J MED, V315, P100, DOI 10.1056/NEJM198607103150206; BRESLOW NE, 1985, AM J EPIDEMIOL, V122, P149, DOI 10.1093/oxfordjournals.aje.a114074; CARPENTER RG, 1972, SUDDEN UNEXPECTED DE, P7; DAVIES DP, 1985, LANCET, V2, P1346; ELLEY WB, 1976, NEW ZEAL J EDUC STUD, V11, P25; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; FORD RPK, 1993, IN PRESS INT J EPIDE; GANTLEY M, 1993, BRIT MED J, V306, P16, DOI 10.1136/bmj.306.6869.16; GREENBERG RA, 1984, NEW ENGL J MED, V310, P1075, DOI 10.1056/NEJM198404263101703; HOFFMAN HJ, 1988, ANN NY ACAD SCI, V533, P13, DOI 10.1111/j.1749-6632.1988.tb37230.x; KEMP JS, 1991, NEW ENGL J MED, V324, P1858, DOI 10.1056/NEJM199106273242605; LEE NNY, 1989, BRIT MED J, V298, P721, DOI 10.1136/bmj.298.6675.721; LOZOFF B, 1984, PEDIATRICS, V74, P171; LUCK W, 1985, J PEDIATR-US, V107, P816, DOI 10.1016/S0022-3476(85)80427-3; LUKE JL, 1978, J FORENSIC SCI, V23, P379; MACLURE M, 1992, AM J EPIDEMIOL, V135, P96; McKenna J J, 1986, Med Anthropol, V10, P9; MCKENNA JJ, 1993, SLEEP, V16, P263, DOI 10.1093/sleep/16.3.263; MITCHELL EA, 1991, NEW ZEAL MED J, V104, P71; MITCHELL EA, 1993, PEDIATRICS, V91, P893; MITCHELL EA, 1992, J PAEDIATR CHILD H, V28, pS3, DOI 10.1111/j.1440-1754.1992.tb02729.x; MITCHELL EA, 1993, BMJ-BRIT MED J, V306, P13, DOI 10.1136/bmj.306.6869.13; MORLEY CJ, 1991, ARCH DIS CHILD, V66, P100, DOI 10.1136/adc.66.1.100; MOSKOWITZ WB, 1990, CIRCULATION, V81, P586, DOI 10.1161/01.CIR.81.2.586; RINTAHAKA RJ, 1986, FORENSIC SCI INT, V30, P219, DOI 10.1016/0379-0738(86)90017-4; ROTHMANK, 1986, MODERN EPIDEMIOLOGY; SHIONO PH, 1986, JAMA-J AM MED ASSOC, V255, P82; 1987, SAS USERS GUIDE STAT	29	227	231	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 20	1993	307	6915					1312	1318		10.1136/bmj.307.6915.1312	http://dx.doi.org/10.1136/bmj.307.6915.1312			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH556	8257885	Bronze, Green Published			2022-12-28	WOS:A1993MH55600019
J	BABUL, R; ADAM, S; KREMER, B; DUFRASNE, S; WIGGINS, S; HUGGINS, M; THEILMANN, J; BLOCH, M; HAYDEN, MR				BABUL, R; ADAM, S; KREMER, B; DUFRASNE, S; WIGGINS, S; HUGGINS, M; THEILMANN, J; BLOCH, M; HAYDEN, MR			ATTITUDES TOWARD DIRECT PREDICTIVE TESTING FOR THE HUNTINGTON DISEASE GENE - RELEVANCE FOR OTHER ADULT-ONSET DISORDERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LINKED DNA MARKERS; RISK; DIAGNOSIS	Objective.-To assess attitudes toward, and projected utilization of, direct mutation testing by individuals at risk for Huntington disease (HD). Design.-Prior to the cloning of the gene for HD, a questionnaire concerning the use of a definitive test was constructed and mailed to 354 participants in the Canadian Collaborative Study for HD. Completed questionnaires were received from 250 participants (response rate, 71%). Persons were asked to indicate whether they would participate in a new predictive test that was either 100% accurate (the definitive test, requiring blood only from the proband) or only 99% accurate. Results.-Most (72%) of the persons who had previously received a result in a predictive testing program said they would request testing in either situation. Significantly more persons would request the definitive test than the 99% accurate test (72% vs 58%; P<.02). Respondents for whom testing was uninformative in the linkage test program or who had previously received an increased-risk result were more likely to indicate they would use the test than those who received a decreased-risk result or chose not to have the original test (P=.0003). Less than half (46%) of the participants who initially chose not to have the linkage test said they would return for the new direct test. The major factor that has limited acceptance of predictive testing for this group is the concern about receiving an increased-risk result in the absence of any therapy to alter progression of the disease. Conclusions.-A direct mutation test for HD will most readily be accepted by persons who wanted but could not previously receive a result in the linkage test program and those who previously received an increased-risk result. In the absence of therapy, the majority of persons who previously chose not to have predictive testing are unlikely to participate in a new test despite improved accuracy. This has implications for the expected demands for testing services for other adult-onset genetic disorders.	UNIV BRITISH COLUMBIA, DEPT MED GENET, 416-2125 E MALL, VANCOUVER V6T 1Z4, BC, CANADA; MCGILL UNIV CLIN, ROYAL VICTORIA HOSP, MONTREAL H3A 2B4, QUEBEC, CANADA	University of British Columbia; McGill University; Royal Victoria Hospital			Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419; Adam, Shelin/0000-0002-4401-6157				ADAM S, 1993, J MED GENET, V30, P549, DOI 10.1136/jmg.30.7.549; ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; BLOCH M, 1992, AM J MED GENET, V42, P499, DOI 10.1002/ajmg.1320420416; BRANDT J, 1989, JAMA-J AM MED ASSOC, V261, P3108, DOI 10.1001/jama.261.21.3108; BREUNING MH, 1987, LANCET, V2, P1359; CRAUFURD D, 1989, LANCET, V2, P603; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; FLEISS JL, 1981, STAT METHODS RATES P, P119; FOX S, 1989, AM J MED GENET, V32, P211, DOI 10.1002/ajmg.1320320214; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HARPER PS, IN PRESS J MED GENET; HAYDEN MR, 1988, AM J HUM GENET, V43, P689; HUGGINS M, 1992, AM J MED GENET, V42, P508, DOI 10.1002/ajmg.1320420417; KAHNEMAN D, 1982, SCI AM, V246, P160, DOI 10.1038/scientificamerican0182-160; KESSLER S, 1987, AM J MED GENET, V26, P259, DOI 10.1002/ajmg.1320260204; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MARKEL DS, 1987, AM J MED GENET, V26, P295, DOI 10.1002/ajmg.1320260207; MASTROMAURO C, 1987, AM J MED GENET, V26, P271, DOI 10.1002/ajmg.1320260205; MEISSEN GJ, 1987, AM J MED GENET, V26, P283, DOI 10.1002/ajmg.1320260206; QUAID KA, 1993, AM J MED GENET, V45, P41, DOI 10.1002/ajmg.1320450112; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SKRAASTAD MI, 1991, AM J MED GENET, V39, P217, DOI 10.1002/ajmg.1320390221; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TVERSKY A, 1981, SCIENCE, V211, P453, DOI 10.1126/science.7455683; TYLER A, 1992, BRIT MED J, V304, P1593, DOI 10.1136/bmj.304.6842.1593; TYLER A, 1990, J MED GENET, V27, P488, DOI 10.1136/jmg.27.8.488; WASMUTH JJ, 1988, NATURE, V332, P734, DOI 10.1038/332734a0; WENT L, 1990, J MED GENET, V27, P34, DOI 10.1136/jmg.27.1.34; WEXLER NS, 1992, FASEB J, V6, P2820, DOI 10.1096/fasebj.6.10.1386047; WIGGINS S, 1992, NEW ENGL J MED, V327, P1401, DOI 10.1056/NEJM199211123272001	32	61	61	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1993	270	19					2321	2325		10.1001/jama.270.19.2321	http://dx.doi.org/10.1001/jama.270.19.2321			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF993	8230594				2022-12-28	WOS:A1993MF99300026
J	BREO, DL				BREO, DL			HUNTING DINO DNA - SCHWEITZER,MARY PUTS T-REX BONES UNDER THE MICROSCOPE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1993	270	19					2376	2377		10.1001/jama.270.19.2376	http://dx.doi.org/10.1001/jama.270.19.2376			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF993	8230604				2022-12-28	WOS:A1993MF99300036
J	ENGELHARDT, H; SCHUSTER, SC; BAEUERLEIN, E				ENGELHARDT, H; SCHUSTER, SC; BAEUERLEIN, E			AN ARCHIMEDEAN SPIRAL - THE BASAL DISK OF THE WOLINELLA FLAGELLAR MOTOR	SCIENCE			English	Article							CELL-ENVELOPE ASSOCIATIONS; SUCCINOGENES; APPARATUS; COMPLEXES	The motor that powers the rotation of the bacterial flagellum reaches through both membranes into the cytoplasm of Gram-negative bacteria. The flagellum is connected by a flexible link (hook) to the motor axis, which passes through the center of a structure called the basal disk. The basal disk functions with the L-P ring complex as a bushing, enabling the rotation of the motor in the cell wall. The protein subunits of the basal disk of Wolinella succinogenes form an Archimedian spiral. The polymerization of subunits from a nucleation point at the motor in the form of a spiral allows constant growth of the basal disk. The disk is thought to provide a reinforcement at the flagellar insertion at the cell pole and to disperse forces that are generated by the momentum of the flagellar rotation.	MAX PLANCK INST BIOCHEM,DEPT MEMBRANE BIOCHEM,D-82152 MARTINSRIED,GERMANY; MAX PLANCK INST BIOCHEM,DEPT STRUCT BIOL,D-82152 MARTINSRIED,GERMANY	Max Planck Society; Max Planck Society								AKIBA T, 1991, SCIENCE, V252, P1544, DOI 10.1126/science.2047860; BERG HC, 1973, NATURE, V245, P380, DOI 10.1038/245380a0; BRACEWELL RN, 1990, J OPT SOC AM A, V7, P21, DOI 10.1364/JOSAA.7.000021; CIRAGGS S, 1965, EXP CELL RES, V40, P658; COULTON JW, 1978, J BACTERIOL, V136, P1037, DOI 10.1128/JB.136.3.1037-1049.1978; DEPAMPHILIS ML, 1971, J BACTERIOL, V105, P110; ENGELHARDT H, UNPUB; FERRIS FG, 1984, CAN J MICROBIOL, V30, P322, DOI 10.1139/m84-048; GIBSON J, 1988, ELECTRON MICROSC REV, V1, P39; Grell K.G., 1973, PROTOZOOLOGY; JONES CJ, 1991, ADV MICROB PHYSL, V32, P110; JONES DM, 1985, J GEN MICROBIOL, V131, P2335; KUPPER J, 1989, J BACTERIOL, V171, P2803, DOI 10.1128/jb.171.5.2803-2810.1989; MACNAB RM, 1992, ANNU REV GENET, V26, P131, DOI 10.1146/annurev.ge.26.120192.001023; MOROOKA T, 1983, MICROBIOL IMMUNOL, V27, P655, DOI 10.1111/j.1348-0421.1983.tb00628.x; PATEL GB, 1986, CAN J MICROBIOL, V32, P623, DOI 10.1139/m86-117; SCHUSTER SC, 1992, J BACTERIOL, V174, P263, DOI 10.1128/jb.174.1.263-268.1992; SCHUSTER SC, UNPUB; THOMASHOW LS, 1985, J BACTERIOL, V163, P1038, DOI 10.1128/JB.163.3.1038-1046.1985; TICHENOR D, 1973, J OPT SOC AM, V63, P1620, DOI 10.1364/JOSA.63.001620; WOLIN MJ, 1961, J BACTERIOL, V81, P911, DOI 10.1128/JB.81.6.911-917.1961	21	15	15	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1046	1048		10.1126/science.8235620	http://dx.doi.org/10.1126/science.8235620			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	8235620				2022-12-28	WOS:A1993MG18700032
J	HOWARD, M; GRIMALDI, JC; BAZAN, JF; LUND, FE; SANTOSARGUMEDO, L; PARKHOUSE, RME; WALSETH, TF; LEE, HC				HOWARD, M; GRIMALDI, JC; BAZAN, JF; LUND, FE; SANTOSARGUMEDO, L; PARKHOUSE, RME; WALSETH, TF; LEE, HC			FORMATION AND HYDROLYSIS OF CYCLIC ADP RIBOSE CATALYZED BY LYMPHOCYTE ANTIGEN-CD38	SCIENCE			English	Article							CD38; DIFFERENTIATION; METABOLITE; MOLECULE; CYCLASE; RELEASE; ENZYME; NAD+	CD38 is a 42-kilodalton glycoprotein expressed extensively on B and T lymphocytes. CD38 exhibits a structural homology to Aplysia adenosine diphosphate (ADP)-ribosyl cyclase. This enzyme catalyzes the synthesis of cyclic ADP-ribose (cADPR), a metabolite of nicotinamide adenine dinucleotide (NAD+) with calcium-mobilizing activity. A complementary DNA encoding the extracellular domain of murine CD38 was constructed and expressed, and the resultant recombinant soluble CD38 was purified to homogeneity. Soluble CD38 catalyzed the formation and hydrolysis of cADPR when added to NAD+. Purified cADPR augmented the proliferative response of activated murine B cells, potentially implicating the enzymatic activity of CD38 in lymphocyte function.	INST ANIM HLTH,SURREY GU24 0NF,ENGLAND; UNIV MINNESOTA,DEPT PHARMACOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	HOWARD, M (corresponding author), DNAX RES INST MOLEC & CELLULAR BIOL INC,901 CALIFORNIA AVE,PALO ALTO,CA 94304, USA.		Bazan, J. Fernando/B-4562-2010; Walseth, Timothy F/F-9518-2010; Lee, Hon Cheung/C-4329-2009	Walseth, Timothy F/0000-0003-2558-7859; Santos-Argumedo, Leopoldo/0000-0002-4772-0713; Parkhouse, Michael/0000-0001-5967-3291	NICHD NIH HHS [HD17484] Funding Source: Medline; NIDA NIH HHS [DA05695] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA005695] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BENHAM CD, 1992, NATURE, V359, P103, DOI 10.1038/359103a0; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GLICK DL, 1991, CELL REGUL, V2, P212; HARADA N, 1993, J IMMUNOL, V151, P3111; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; HOWARD M, UNPUB; JACKSON DG, 1990, J IMMUNOL, V144, P2811; JOHNSON RL, 1992, J BIOL CHEM, V267, P4600; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, BIOCHIM BIOPHYS ACTA, V1164, P68, DOI 10.1016/0167-4838(93)90113-6; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LEE HC, 1993, J BIOL CHEM, V268, P293; MALAVASI F, 1992, INT J CLIN LAB RES, V22, P73, DOI 10.1007/BF02591400; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; SANTOSARGUMEDO L, 1993, J IMMUNOL, V151, P3119; SERVENTI IM, 1992, CURR TOP MICROBIOL, V175, P43; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; STRYER L, 1988, BIOCHEMISTRY-US, P191; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; WHITE AM, 1993, FEBS LETT, V318, P259, DOI 10.1016/0014-5793(93)80524-X; YAMADA H, 1993, J EXP MED, V177, P1614	28	681	712	2	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1056	1059		10.1126/science.8235624	http://dx.doi.org/10.1126/science.8235624			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	8235624				2022-12-28	WOS:A1993MG18700036
J	BAILEY, B; FARKAS, DL; TAYLOR, DL; LANNI, F				BAILEY, B; FARKAS, DL; TAYLOR, DL; LANNI, F			ENHANCEMENT OF AXIAL RESOLUTION IN FLUORESCENCE MICROSCOPY BY STANDING-WAVE EXCITATION	NATURE			English	Article							LEADING-EDGE; 3 DIMENSIONS; FIBROBLASTS; ACTIN; CELLS; ORGANIZATION; TRANSPORT	THE use of fluorescence microscopy for investigating the three-dimensional structure of cells and tissue is of growing importance in cell biology, biophysics and biomedicine. Three-dimensional data are obtained by recording a series of images of the specimen as it is stepped through the focal plane of the microscope1-3. Whether by direct imaging or by confocal scanning4,5, diffraction effects and noise generally limit axial resolution to about 0.5 mum. Here we describe a fluorescence microscope in which axial resolution is increased to better than 0.05 mum by using the principle of standing-wave excitation of fluorescence. Standing waves formed by interference in laser illumination create an excitation field with closely spaced nodes and antinodes, allowing optical sectioning of the specimen at very high resolution. We use this technique to obtain images of actin fibres and filaments in fixed cells, actin single filaments in vitro and myosin II in a living cell.	CARNEGIE MELLON UNIV, CTR LIGHT MICROSCOPE IMAGING & BIOTECHNOL, 4400 5TH AVE, PITTSBURGH, PA 15213 USA; CARNEGIE MELLON UNIV, DEPT BIOL SCI, PITTSBURGH, PA 15213 USA; CARNEGIE MELLON UNIV, DEPT PHYS, PITTSBURGH, PA 15213 USA	Carnegie Mellon University; Carnegie Mellon University; Carnegie Mellon University				Taylor, D. Lansing/0000-0001-6947-1343				AGARD DA, 1989, METHOD CELL BIOL, V30, P353; AGARD DA, 1984, ANNU REV BIOPHYS BIO, V13, P191; BEREITERHAHN J, 1979, J CELL BIOL, V82, P767, DOI 10.1083/jcb.82.3.767; BORN M, 1980, PRINCIPLES OPTICS, P439; BRAKENHOFF GJ, 1979, J MICROSC-OXFORD, V117, P219, DOI 10.1111/j.1365-2818.1979.tb01178.x; CARRINGTON WA, 1990, P SOC PHOTO-OPT INS, V1205, P72, DOI 10.1117/12.17785; CARTER KC, 1993, SCIENCE, V259, P1330, DOI 10.1126/science.8446902; DEBIASIO RL, 1988, J CELL BIOL, V107, P2631, DOI 10.1083/jcb.107.6.2631; FAN JH, 1993, J CELL BIOL, V121, P867, DOI 10.1083/jcb.121.4.867; FAY FS, 1983, J CELL BIOL, V96, P783, DOI 10.1083/jcb.96.3.783; FISHER GW, 1988, CELL MOTIL CYTOSKEL, V11, P235, DOI 10.1002/cm.970110403; GIULIANO KA, 1990, CELL MOTIL CYTOSKEL, V16, P14, DOI 10.1002/cm.970160104; HELL S, 1992, J OPT SOC AM A, V9, P2159, DOI 10.1364/JOSAA.9.002159; HOLMES TJ, 1988, J OPT SOC AM A, V5, P666, DOI 10.1364/JOSAA.5.000666; KOGELNIK H, 1966, PR INST ELECTR ELECT, V54, P1312, DOI 10.1109/PROC.1966.5119; KOSHY M, 1990, SOC PHOTO OPT INSTRU, V1205, P64; LANNI F, 1985, J CELL BIOL, V100, P1091, DOI 10.1083/jcb.100.4.1091; Lanni F., 1986, APPL FLUORESCENCE, P505; Lanni F., 1986, US Patent, Patent No. [4621911, 4,621,911]; Pawley J. B., 1989, HDB BIOL CONFOCAL MI; PODILCHUK CI, 1990, J OPT SOC AM A, V7, P517, DOI 10.1364/JOSAA.7.000517; PREZA C, 1992, J OPT SOC AM A, V9, P219, DOI 10.1364/JOSAA.9.000219; ROSS KFA, 1982, J MICROSC-OXFORD, V128, P7, DOI 10.1111/j.1365-2818.1982.tb00433.x; SHEPPARD CJR, 1977, OPT ACTA, V24, P1051, DOI 10.1080/713819421; SMALL JV, 1981, J CELL BIOL, V91, P695, DOI 10.1083/jcb.91.3.695; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597; Wilson T., 1984, THEORY PRACTICE SCAN	27	231	285	1	89	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	1993	366	6450					44	48		10.1038/366044a0	http://dx.doi.org/10.1038/366044a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF007	8232536				2022-12-28	WOS:A1993MF00700048
J	CARLIER, C; COSTE, J; ETCHEPARE, M; PERIQUET, B; AMEDEEMANESME, O				CARLIER, C; COSTE, J; ETCHEPARE, M; PERIQUET, B; AMEDEEMANESME, O			A RANDOMIZED CONTROLLED TRIAL TO TEST EQUIVALENCE BETWEEN RETINYL PALMITATE AND BETA-CAROTENE FOR VITAMIN-A-DEFICIENCY	BRITISH MEDICAL JOURNAL			English	Article							CONJUNCTIVAL IMPRESSION CYTOLOGY; ESTABLISH EQUIVALENCE; SENEGALESE CHILDREN; KAOLACK REGIONS; XEROPHTHALMIA; MALNUTRITION; PREVALENCE; MORTALITY; PRESCHOOL; DIOURBEL	Objectives-To determine whether beta carotene is therapeutically equivalent to retinyl palmitate in the formulation currently recommended by the World Health Organisation. Design-Randomised blind equivalence trial. Setting-Rural area in Senegal. Subjects-Children aged 2-15 years suffering from vitamin A deficiency as defined by abnormal results on eye cytology were randomly allocated treatment with retinyl palmitate (n=256) and beta carotene (n=254). Main outcome measure-Reversion to normal results on eye cytology as defined by the reappearance of goblet cells and normalisation of the epithelial cells. Results-Seven weeks after the supplement was given the percentages were 51.2% (124/242) children taking retinyl palmitate and 50.0% (123/246) of those taking beta carotene, who had reverted to normal eye cytology, a difference of 1.2% (95% confidence interval 0.8% to 1.6%). According to an equivalence testing procedure, the two treatments were statistically equivalent; the null hypothesis of non-equivalence was rejected (one tailed p value=0.03). Conclusions-Beta carotene supplementation seems to be a promising candidate for the alleviation of vitamin A deficiency. It could be given either as high dose capsule or through increased dietary intake. The challenge now is to improve dietary intake of vitamin A in programmes that are effective and sustainable at the community level.	INSERM,F-94276 LE KREMLIN BICETR,FRANCE; HOP COCHIN,DEPT BIOSTAT & INFORMAT MED,F-75674 PARIS 14,FRANCE; ORGANISME RECH ALIMENTAT & NUTR AFRICAINE,DAKAR,SENEGAMBIA; LAB BIOCHIM,SECTEUR CHROMATOG,F-31059 TOULOUSE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite								[Anonymous], 1982, WHO TECH REP SER, V672, P1; BENDICH A, 1991, P NUTR SOC, V50, P263, DOI 10.1079/PNS19910036; BLACKWELDER WC, 1982, CONTROL CLIN TRIALS, V3, P345, DOI 10.1016/0197-2456(82)90024-1; BRUBACHER GB, 1985, INT J VITAM NUTR RES, V55, P5; CARLIER C, 1991, AM J CLIN NUTR, V53, P74, DOI 10.1093/ajcn/53.1.74; CARLIER C, 1992, INT J VITAM NUTR RES, V62, P209; CARLIER C, 1992, BRIT J NUTR, V68, P529, DOI 10.1079/BJN19920110; CARLIER C, 1991, AM J CLIN NUTR, V53, P66, DOI 10.1093/ajcn/53.1.66; CARLIER C, 1992, INT J EPIDEMIOL, V21, P373, DOI 10.1093/ije/21.2.373; CARLIER C, 1992, INT J VITAM NUTR RES, V662, P216; DUNNETT CW, 1977, BIOMETRICS, V33, P593, DOI 10.2307/2529457; GLOVER J, 1976, INT J VITAM NUTR RES, V46, P239; GOODMAN DS, 1984, J NATL CANCER I, V73, P1375; HATHCOCK JN, 1990, AM J CLIN NUTR, V52, P183, DOI 10.1093/ajcn/52.2.183; LEFRANCOIS P, 1981, B OCCGE, V73, P50; MAKUCH R, 1978, CANCER TREAT REP, V62, P1037; MARIATH JGR, 1989, AM J CLIN NUTR, V49, P849, DOI 10.1093/ajcn/49.5.849; MELE L, 1991, AM J CLIN NUTR, V53, P1460, DOI 10.1093/ajcn/53.6.1460; METZLER CM, 1974, BIOMETRICS, V30, P309, DOI 10.2307/2529651; NATADISASTRA G, 1987, ARCH OPHTHALMOL-CHIC, V105, P1224; NATADISASTRA G, 1988, AM J CLIN NUTR, V48, P695, DOI 10.1093/ajcn/48.3.695; OLSON JA, 1987, AM J CLIN NUTR, V45, P704, DOI 10.1093/ajcn/45.4.704; OOMEN HAP, 1977, TROPICAL LEAF VEGETA; Pocock SJ., 2013, CLIN TRIALS PRACTICA; RAHMATHULLAH L, 1990, NEW ENGL J MED, V323, P929, DOI 10.1056/NEJM199010043231401; RAMSDEN DB, 1978, CLIN ENDOCRINOL, V8, P109, DOI 10.1111/j.1365-2265.1978.tb02159.x; RANKINS J, 1989, ECOL FOOD NUTR, V23, P131, DOI 10.1080/03670244.1989.9991095; REDDY V, 1989, AM J CLIN NUTR, V50, P814, DOI 10.1093/ajcn/50.4.814; RODARY C, 1989, STAT MED, V8, P593, DOI 10.1002/sim.4780080508; SEMBA RD, 1990, AM J OPHTHALMOL, V110, P416, DOI 10.1016/S0002-9394(14)77024-2; SMITH FR, 1973, AM J CLIN NUTR, V26, P973, DOI 10.1093/ajcn/26.9.973; SOMMER A, 1986, LANCET, V1, P1169; THATCHER RW, 1977, ARCH OPHTHALMOL-CHIC, V95, P678; THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477; TSOU SCS, 1984, HUMAN NUTRITION BETT; West Jr KP, 1984, PERIODIC LARGE ORAL; WITTPENN JR, 1986, ARCH OPHTHALMOL-CHIC, V104, P237; WIVAKUMAR B, 1972, ABSORPTION ORALLY AD; 1987, 1ST REPORT WORLD NUT, P36; 1992, LANCET, V339, P1514; 1988, VITAMIN A SUPPLEMENT; 1992, ANN TROP PAEDIATR, V12, P67; 1983, MEASURING CHANGE NUT	43	25	26	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1993	307	6912					1106	1110		10.1136/bmj.307.6912.1106	http://dx.doi.org/10.1136/bmj.307.6912.1106			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME918	8251808	Bronze, Green Published			2022-12-28	WOS:A1993ME91800016
J	MIMMS, LT; MOSLEY, JW; HOLLINGER, FB; AACH, RD; STEVENS, CE; CUNNINGHAM, M; VALLARI, DV; BARBOSA, LH; NEMO, GJ				MIMMS, LT; MOSLEY, JW; HOLLINGER, FB; AACH, RD; STEVENS, CE; CUNNINGHAM, M; VALLARI, DV; BARBOSA, LH; NEMO, GJ			EFFECT OF CONCURRENT ACUTE INFECTION WITH HEPATITIS-C VIRUS ON ACUTE HEPATITIS-B VIRUS-INFECTION	BRITISH MEDICAL JOURNAL			English	Article							TRANSFUSION-TRANSMITTED VIRUSES; NON-A-HEPATITIS; POSTTRANSFUSION HEPATITIS; RECIPIENTS; TRANSMISSION; ANTIBODY; DONORS; BLOOD; RISK	Objective-To investigate the possible interference with acute hepatitis B virus infection by coinfection with hepatitis C virus. Design-Analysis of stored sera collected for transfusion transmitted viruses study in 1970s. Setting-Four major medical centres in the United States. Patients-12 recipients of blood infected with hepatitis B virus. Main outcome measures-In 1970s, presence of antibodies in hepatitis B virus and raised serum alanine aminotransferase concentration; detection of antibodies to hepatitis C virus with new enzyme linked immunoassays. Results-Five of the 12 patients were coinfected with hepatitis C virus. Hepatitis B surface antigen was first detected at day 59 in patients infected with hepatitis B virus alone and at day 97 in those coinfected with hepatitis C virus (p=0.01); median durations of antigenaemia were 83 and 21 days respectively (p=0.05), and the antigen concentration was lower in the coinfected patients. Alanine aminotransferase patterns were uniphasic when hepatitis B virus infection occurred alone (range 479-2465 IU/l) and biphasic in patients with combined acute infection (no value >380 IU/l; p=0.0025). Four coinfected recipients developed chronic hepatitis C virus infection. The fifth patient was followed for only four months. Conclusions-Acute coinfection with hepatitis C virus and hepatitis B virus inhibits hepatitis B virus infection in humans, and onset of hepatitis B may reduce the severity of hepatitis C virus infection but not frequency of chronicity. Alanine aminotransferase concentration showed a biphasic pattern in dual infection.	UNIV SO CALIF,DEPT MED,LOS ANGELES,CA 90032; ABBOTT LABS,ABBOTT PK,IL; BAYLOR COLL MED,HOUSTON,TX 77030; MT SINAI MED CTR,CLEVELAND,OH 44106; NEW YORK BLOOD CTR,NEW YORK,NY 10021; NHLBI,TRANSFUS MED BRANCH,BETHESDA,MD 20892	University of Southern California; Abbott Laboratories; Baylor College of Medicine; New York Blood Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Hollinger, F Blaine/AAY-3323-2021		NHLBI NIH HHS [N01-HB-42972] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; AACH RD, 1981, NEW ENGL J MED, V304, P989, DOI 10.1056/NEJM198104233041701; BAGINSKI I, 1992, TRANSFUSION, V32, P215, DOI 10.1046/j.1537-2995.1992.32392213803.x; BAKH J, 1991, P NATL ACAD SCI USA, V89, P187; BROTMAN B, 1983, J MED VIROL, V11, P191, DOI 10.1002/jmv.1890110303; CONOVER WJ, 1980, PRACTICAL NONPARAMET, P224; EBLE K, 1991, J MED VIROL, V33, P139, DOI 10.1002/jmv.1890330302; GILLES PN, 1992, J VIROL, V66, P3955, DOI 10.1128/JVI.66.6.3955-3960.1992; HOLLINGER FB, 1984, J INFECT DIS, V150, P250, DOI 10.1093/infdis/150.2.250; MIMMS L, 1990, LANCET, V336, P1590, DOI 10.1016/0140-6736(90)93377-2; MOSLEY JW, 1990, JAMA-J AM MED ASSOC, V263, P77, DOI 10.1001/jama.263.1.77; STEVENS CE, 1984, ANN INTERN MED, V101, P733, DOI 10.7326/0003-4819-101-6-733; TATEDA A, 1979, J INFECT DIS, V139, P511, DOI 10.1093/infdis/139.5.511; TSIQUAYE KN, 1983, J MED VIROL, V11, P179, DOI 10.1002/jmv.1890110302; VALLARI DS, 1992, J CLIN MICROBIOL, V30, P552, DOI 10.1128/JCM.30.3.552-556.1992	15	99	100	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1993	307	6912					1095	1097		10.1136/bmj.307.6912.1095	http://dx.doi.org/10.1136/bmj.307.6912.1095			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME918	8251805	Bronze, Green Published			2022-12-28	WOS:A1993ME91800013
J	GRINDLEY, NDF				GRINDLEY, NDF			ANALYSIS OF A NUCLEOPROTEIN COMPLEX - THE SYNAPTOSOME OF GAMMA-DELTA RESOLVASE	SCIENCE			English	Article							SITE-SPECIFIC RECOMBINATION; MUTANTS; DOMAIN; TN3; RES	The gammadelta resolvase protein is one of a large family of transposon-encoded site-specific recombinases. It performs recombination in a DNA-protein complex that contains 12 resolvase protomers and two copies of the 120-base pair DNA substrate, res (each with three binding sites for a resolvase dimer). A derivative of resolvase with altered DNA binding specificity was used to show that the role of resolvase at site I, which contains the crossover point, differs from its role at the other two binding sites. The resolvase dimers that initially bind to site I are the only ones that require the residue Ser10, essential for catalysis of DNA breakage. In addition, these site I-bound dimers do not use a specific interaction between dimers that is required elsewhere in the complex for synapsis of the res sites.			GRINDLEY, NDF (corresponding author), YALE UNIV,BASS CTR MOLEC & STRUCT BIOL,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511, USA.							CRAIG NL, 1989, MOBILE DNA, P211; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; ELLEDGE SJ, 1989, GENE DEV, V3, P185, DOI 10.1101/gad.3.2.185; GRINDLEY NDF, 1982, CELL, V30, P19, DOI 10.1016/0092-8674(82)90007-1; HATFULL GF, 1987, CELL, V49, P103, DOI 10.1016/0092-8674(87)90760-4; HATFULL GF, 1986, P NATL ACAD SCI USA, V83, P5429, DOI 10.1073/pnas.83.15.5429; Hatfull GF, 1988, GENETIC RECOMBINATIO, P357; HEICHMAN KA, 1990, SCIENCE, V249, P511, DOI 10.1126/science.2166334; HUGHES RE, 1993, EMBO J, V12, P1447, DOI 10.1002/j.1460-2075.1993.tb05788.x; HUGHES RE, 1990, CELL, V63, P1331, DOI 10.1016/0092-8674(90)90428-H; HUGHES RK, UNPUB; Johnson RC, 1991, CURR OPIN GENET DEV, V1, P404, DOI 10.1016/S0959-437X(05)80307-7; KLIPPEL A, 1988, EMBO J, V7, P3983, DOI 10.1002/j.1460-2075.1988.tb03286.x; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; MAZZARELLI JM, 1993, BIOCHEMISTRY-US, V32, P2979, DOI 10.1021/bi00063a008; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; REED RR, 1981, CELL, V25, P713, DOI 10.1016/0092-8674(81)90178-1; RICE PR, UNPUB; RIMPHANITCHAYAKIT V, 1990, EMBO J, V9, P719, DOI 10.1002/j.1460-2075.1990.tb08165.x; SANDERSON MR, 1990, CELL, V63, P1323, DOI 10.1016/0092-8674(90)90427-G; STARK WM, 1989, TRENDS GENET, V5, P304, DOI 10.1016/0168-9525(89)90113-3; WASSERMAN SA, 1985, SCIENCE, V229, P171, DOI 10.1126/science.2990045	22	36	36	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 29	1993	262	5134					738	740		10.1126/science.8235593	http://dx.doi.org/10.1126/science.8235593			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	8235593				2022-12-28	WOS:A1993MD95200041
J	MARTIN, JB				MARTIN, JB			MOLECULAR-GENETICS OF NEUROLOGICAL DISEASES	SCIENCE			English	Editorial Material							FAMILIAL ALZHEIMERS-DISEASE; HYPERKALEMIC PERIODIC PARALYSIS; KALLMANNS SYNDROME; PROTEIN GENE; MUTATION; CHANNEL; CHROMOSOME-14; INSOMNIA; LINKAGE; REGION				MARTIN, JB (corresponding author), UNIV CALIF SAN FRANCISCO,513 PARNASSUS AVE,SAN FRANCISCO,CA 94143, USA.							ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BICK D, 1992, NEW ENGL J MED, V326, P1752, DOI 10.1056/NEJM199206253262606; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; DAVIES K, 1993, NATURE, V364, P88, DOI 10.1038/364088a0; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; GEORGE AL, 1993, NAT GENET, V3, P305, DOI 10.1038/ng0493-305; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; GUSELLA JF, 1993, NEW ENGL J MED, V329, P571, DOI 10.1056/NEJM199308193290811; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; LEDBETTER SA, 1992, AM J HUM GENET, V50, P182; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MARTIN JB, IN PRESS ANN NEUROL; MCCLATCHEY AI, 1992, CELL, V68, P769, DOI 10.1016/0092-8674(92)90151-2; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NATHANS J, 1992, ANNU REV GENET, V26, P403, DOI 10.1146/annurev.ge.26.120192.002155; NELSON DL, 1993, NAT GENET, V4, P107, DOI 10.1038/ng0693-107; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PRUSINER SB, 1992, BIOCHEMISTRY-US, V31, P12277, DOI 10.1021/bi00164a001; PTACEK LJ, 1991, CELL, V67, P1021; READ AP, 1993, NAT GENET, V4, P329, DOI 10.1038/ng0893-329; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; ROJAS CV, 1991, NATURE, V354, P387, DOI 10.1038/354387a0; RUGARLI EI, 1993, NAT GENET, V4, P19, DOI 10.1038/ng0593-19; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; STGEORGEHYSLOP P, 1992, NAT GENET, V2, P330, DOI 10.1038/ng1292-330; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; VANBROECKHOVEN C, 1992, NAT GENET, V2, P340; VERHEIJ C, 1993, NATURE, V363, P722, DOI 10.1038/363722a0; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0	37	41	41	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 29	1993	262	5134					674	676		10.1126/science.8235586	http://dx.doi.org/10.1126/science.8235586			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	8235586				2022-12-28	WOS:A1993MD95200027
J	PUTNEY, JW				PUTNEY, JW			EXCITEMENT ABOUT CALCIUM SIGNALING IN INEXCITABLE CELLS	SCIENCE			English	Article							PC12 CELLS; RELEASE; ENTRY; MECHANISMS; STORES; GENE				PUTNEY, JW (corresponding author), NIEHS,RES TRIANGLE PK,NC 27709, USA.		Putney, James W/F-7247-2019	Putney, James W/0000-0002-3379-4789				BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GS, 1992, J BIOL CHEM, V267, P18382; BIRD GS, 1993, J BIOL CHEM, V268, P21486; CLEMENTI E, 1992, J BIOL CHEM, V267, P2164; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FRIEL DD, 1992, NEURON, V8, P1109, DOI 10.1016/0896-6273(92)90132-W; GALIONE A, 1992, TRENDS PHARMACOL SCI, V13, P304, DOI 10.1016/0165-6147(92)90096-O; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GALIONE A, 1993, SCIENCE, V261, P352; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEREA LS, 1993, NEURON, V10, P31, DOI 10.1016/0896-6273(93)90239-N; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; Penner R, 1993, Curr Opin Neurobiol, V3, P368, DOI 10.1016/0959-4388(93)90130-Q; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; PUTNEY JW, 1981, PHILOS T ROY SOC B, V296, P37, DOI 10.1098/rstb.1981.0169; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; PUTNEY JW, IN PRESS ENDOCR REV; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; STAUDERMAN KA, 1989, J BIOL CHEM, V264, P18349; VOLPE P, 1988, P NATL ACAD SCI USA, V85, P1091, DOI 10.1073/pnas.85.4.1091; WHITE AM, 1993, FEBS LETT, V318, P259, DOI 10.1016/0014-5793(93)80524-X; WONG NS, 1988, BIOCHEM J, V252, P1; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	35	175	177	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 29	1993	262	5134					676	678		10.1126/science.8235587	http://dx.doi.org/10.1126/science.8235587			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	8235587				2022-12-28	WOS:A1993MD95200028
J	ROBINSON, R				ROBINSON, R			ECONOMIC-EVALUATION AND HEALTH-CARE - COST-BENEFIT-ANALYSIS .5.	BRITISH MEDICAL JOURNAL			English	Article							WILLINGNESS; PAY	Cost-benefit analysis is probably the most comprehensive method of economic evaluation available and it can be applied in two ways. The human capital approach means that the value of people's contributions is linked to what they are paid. The approach based on individuals' observed or stated preference means that their personal valuations are placed on an activity by assessing how much money they are prepared to accept for an increased risk or to pay for a particular service. Each method has its disadvantages and the most successful that has been devised so far is the ''willingness to pay'' (stated preference) approach, though the response to this is to a large extent dependent on the income of the person being questioned. There are still problems with its application, however, so its usefulness is limited.			ROBINSON, R (corresponding author), UNIV SOUTHAMPTON,FAC SOCIAL SCI,INST HLTH POLICY STUDIES,SOUTHAMPTON SO9 5NH,HANTS,ENGLAND.		Gutierrez, Alberto/B-7772-2011					Acton J., 1973, EVALUATING PUBLIC PR; DONALDSON C, 1990, J HEALTH ECON, V9, P103, DOI 10.1016/0167-6296(90)90043-3; JOHANNESSON M, 1991, HEALTH POLICY, V17, P1, DOI 10.1016/0168-8510(91)90114-D; Jones-Lee M, 1976, VALUE LIFE; Mitchell R.C., 1989, USING SURVEYS VALUE; MOONEY GH, 1977, VALUATION HUMAN LIFE; MOONEY GH, 1978, VALUATION SOCIAL COS; Morrison G C, 1992, Health Econ, V1, P233, DOI 10.1002/hec.4730010405; Pearce D.W., 1983, COST BENEFIT ANAL, Vsecond; Royal Commission into the Failure of West Gate Bridge, 1971, REPORT; THOMPSON MS, 1986, AM J PUBLIC HEALTH, V76, P392, DOI 10.2105/AJPH.76.4.392; WALSHE G, 1990, MANAGING COST BENEFI; [No title captured]	13	130	137	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1993	307	6909					924	926		10.1136/bmj.307.6909.924	http://dx.doi.org/10.1136/bmj.307.6909.924			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MB847	8241859	Bronze, Green Published			2022-12-28	WOS:A1993MB84700026
J	GARROW, J; SUMMERBELL, C				GARROW, J; SUMMERBELL, C			THE HAWKSLEY RANDOM ZERO SPHYGMOMANOMETER - REPEAT EXPERIMENT EXONERATES INSTRUMENT	BRITISH MEDICAL JOURNAL			English	Letter											GARROW, J (corresponding author), ST BARTHOLOMEWS HOSP,COLL MED,RANK DEPT HUMAN NUTR,LONDON EC1M 6BQ,ENGLAND.		Summerbell, Carolyn/AAC-3159-2019	Summerbell, Carolyn/0000-0003-1910-9383				CONROY RM, 1993, BRIT MED J, V306, P1319, DOI 10.1136/bmj.306.6888.1319; OBRIEN E, 1990, LANCET, V336, P1465, DOI 10.1016/0140-6736(90)93177-Q; ROSE GA, 1964, LANCET, V1, P296	3	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1993	307	6896					123	123		10.1136/bmj.307.6896.123-a	http://dx.doi.org/10.1136/bmj.307.6896.123-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM585	8240507	Green Published			2022-12-28	WOS:A1993LM58500046
J	SIMONS, AM; PHILLIPS, DH; COLEMAN, DV				SIMONS, AM; PHILLIPS, DH; COLEMAN, DV			DAMAGE TO DNA IN CERVICAL EPITHELIUM RELATED TO SMOKING TOBACCO	BRITISH MEDICAL JOURNAL			English	Article							CIGARETTE-SMOKING; UTERINE CERVIX; ADDUCTS; COTININE; SMOKERS; SENSITIVITY; NEOPLASIA; TISSUES; CANCER; CELLS	Objective-To determine whether tobacco smoking causes increased DNA modification (adducts) in human cervical epithelium. Design-Comparison of DNA adducts measured by the technique of postlabelling with phosphorus-32 in normal ectocervical epithelium of smokers and non-smokers. A questionnaire on smoking habit and a urinary cotinine assay were used to identify smokers and non-smokers. Setting-Cytology unit in large teaching hospital. Subjects-39 women (11 current smokers, seven former smokers, and 21 who had never smoked) undergoing gynaecological treatment (colposcopy or hysterectomy). Nineteen members of staff who did not smoke as controls. Interventions-Biopsy of normal ectocervical epithelium. Urine sample. Main outcome measures-Measurement of DNA adducts in cervical epithelial tissue of smokers and non-smokers. Smoking habit derived from results of questionnaire and urinary cotinine:creatinine ratio. Proportion of adducts in women with abnormal and normal results of cervical smear test. Results-DNA samples from smokers (identified from questionnaire) had significantly higher median proportions of DNA adducts that non-smokers (4.62 (95% confidence interval 4.04 to 7.74) v 3.47 (2.84 to 4.78) adducts/10(8) nucleotides; p=0.048). Exclusion of women whose urinary cotinine:creatinine ratio did not confirm their self reported smoking habit (smoker or non-smoker) increased this difference (4.7 (3.85 to 8.08) v 3.52 (2.32 to 4.95) adducts/10(8) nucleotides; p=0.03). Women who had abnormal results of cervical smear tests had significantly higher proportions of adducts than those with normal results (4.7 (3.90 to 8.13) v 3.47 (3.06 to 5.36) adducts/10(8) nucleotides; p=0.03). Conclusions-Tobacco smoking by women leads to increased modification of DNA in cervical epithelium, suggesting biochemical evidence consistent with smoking as a cause of cervical cancer.	ST MARYS HOSP,SCH MED,IMPERIAL COLL,FAC MED,CYTOL & CYTOGENET UNIT,LONDON W2 1PG,ENGLAND; INST CANC RES,HADDOW LABS,SUTTON SM2 5NG,SURREY,ENGLAND	Imperial College London; University of London; Institute of Cancer Research - UK				Phillips, David/0000-0001-8509-3485				BENOWITZ NL, 1983, CLIN PHARMACOL THER, V34, P604, DOI 10.1038/clpt.1983.222; BRISSON J, 1988, AM J EPIDEMIOL, V128, P337, DOI 10.1093/oxfordjournals.aje.a114973; CUZICK J, 1990, INT J CANCER, V45, P673, DOI 10.1002/ijc.2910450417; DUNN BP, 1991, INT J CANCER, V48, P485, DOI 10.1002/ijc.2910480403; FEYERABEND C, 1980, ANALYST, V105, P998, DOI 10.1039/an9800500998; GUPTA RC, 1982, CARCINOGENESIS, V3, P1081, DOI 10.1093/carcin/3.9.1081; GUPTA RC, 1985, CANCER RES, V45, P5656; HOFFMANN D, 1990, HDB EXPT PHARM, V94, P63; MCCANN MF, 1992, CANCER EPIDEM BIOMAR, V1, P125; MILLER EC, 1981, CANCER-AM CANCER SOC, V47, P2327, DOI 10.1002/1097-0142(19810515)47:10<2327::AID-CNCR2820471003>3.0.CO;2-Z; PHILLIPS DH, 1990, LANCET, V335, P417, DOI 10.1016/0140-6736(90)90257-6; PHILLIPS DH, 1988, NATURE, V336, P790, DOI 10.1038/336790a0; PHILLIPS DH, 1990, INT J CANCER, V46, P569, DOI 10.1002/ijc.2910460403; RANDERATH E, 1989, J NATL CANCER I, V81, P341, DOI 10.1093/jnci/81.5.341; REDDY MV, 1986, CARCINOGENESIS, V7, P1543, DOI 10.1093/carcin/7.9.1543; SASCO AJ, 1991, LANCET, V338, P123, DOI 10.1016/0140-6736(91)90119-A; SASSON IM, 1985, NEW ENGL J MED, V312, P315; SCHOKET B, 1990, J INVEST DERMATOL, V94, P241, DOI 10.1111/1523-1747.ep12874576; SILLETT RW, 1978, BRIT MED J, V2, P1185, DOI 10.1136/bmj.2.6146.1185; WILCOX RG, 1979, BRIT MED J, V2, P1026, DOI 10.1136/bmj.2.6197.1026; WINKELSTEIN W, 1990, AM J EPIDEMIOL, V131, P945, DOI 10.1093/oxfordjournals.aje.a115614; 1992, 5TH ROYAL COLL PHYS; 1986, MONOGRAPH EVALUATION, V38; 1986, TEENAGE GIRLS SMOKIN; 1991, OPCS MONITOR	25	92	95	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1993	306	6890					1444	1448		10.1136/bmj.306.6890.1444	http://dx.doi.org/10.1136/bmj.306.6890.1444			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE935	8257490	Green Published, Bronze			2022-12-28	WOS:A1993LE93500017
J	AUDET, AM; SCOTT, HD				AUDET, AM; SCOTT, HD			THE UNIFORM CLINICAL-DATA SET - AN EVALUATION OF THE PROPOSED NATIONAL DATABASE FOR MEDICARES QUALITY REVIEW PROGRAM	ANNALS OF INTERNAL MEDICINE			English	Article							CARE; IMPROVEMENT	The accuracy, reliability, and validity of the Medicare Peer Review Organization (PRO) review process have all been questioned. Evidence concerning the PRO program's effect on cost and quality of care remains lacking. The Health Care Financing Administration has thus committed itself to reform, and the uniform Clinical Data Set (UCDS) has been proposed as the national database for Medicare's quality review program. The UCDS is an automated, computerized data set designed to standardize the evaluation of quality. It should allow an objective, consistent, and efficient process for peer review, based on explicit decision criteria and on aggregated information about patterns of care and quality. But is this truly so? We review the existing evidence on the UCDS and compare it with the current PRO reviews of quality, concluding that although the UCDS can potentially improve the accuracy and the reliability of data abstraction and the validity of reviews, this remains to be shown. Preliminary data on the UCDS suggest that work is needed before it can meet appropriate expectations for a national database for quality assessments. We also propose a model for reviews of quality in which we show that reviews of care done in the context of internal quality improvement programs will differ in goals and intensity from reviews of care done at the national level. We suggest that the UCDS has a unique, but limited role-that of national surveillance of practice patterns. Detailed assessments of quality are more appropriately done at local or institutional levels.			AUDET, AM (corresponding author), AMER COLL PHYSICIANS, INDEPENDENCE MALL W, 6TH ST & RACE, PHILADELPHIA, PA 19106 USA.							ASH A, 1990, MED CARE, V28, P1025, DOI 10.1097/00005650-199011000-00005; Barnes C, 1988, Top Health Rec Manage, V9, P72; BROOK RH, 1991, ANN INTERN MED, V115, P486, DOI 10.7326/0003-4819-115-6-486; BROOK RH, 1973, NEW ENGL J MED, V288, P1323, DOI 10.1056/NEJM197306212882504; GOLDMAN RL, 1992, JAMA-J AM MED ASSOC, V267, P958, DOI 10.1001/jama.267.7.958; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; KELLIE SE, 1991, JAMA-J AM MED ASSOC, V265, P1265, DOI 10.1001/jama.265.10.1265; KRITCHEVSKY SB, 1991, JAMA-J AM MED ASSOC, V266, P1817, DOI 10.1001/jama.266.13.1817; LINTON AL, 1989, CAN MED ASSOC J, V141, P283; LOHR KN, 1992, I MED STRATEGY QUALI; NASH DB, 1992, JAMA-J AM MED ASSOC, V268, P917, DOI 10.1001/jama.268.7.917; OLEARY DS, 1991, JAMA-J AM MED ASSOC, V265, P1993, DOI 10.1001/jama.265.15.1993; Richardson F M, 1972, Med Care, V10, P29, DOI 10.1097/00005650-197201000-00004; RUBENSTEIN LV, 1991, RAND N3033HCFA; RUBIN HR, 1992, JAMA-J AM MED ASSOC, V267, P2349, DOI 10.1001/jama.267.17.2349; SANAZARO PJ, 1985, MED CARE, V23, P1097, DOI 10.1097/00005650-198509000-00007; SANAZARO PJ, 1991, JAMA-J AM MED ASSOC, V265, P1977, DOI 10.1001/jama.265.15.1977; SCHROEDER SA, 1991, JAMA-J AM MED ASSOC, V265, P1995; STRUMWASSER I, 1990, MED CARE, V28, P95, DOI 10.1097/00005650-199002000-00001; 1992, APR C PROF PHYS PAYM	20	24	25	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1993	119	12					1209	1213		10.7326/0003-4819-119-12-199312150-00008	http://dx.doi.org/10.7326/0003-4819-119-12-199312150-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM121	8239252				2022-12-28	WOS:A1993MM12100008
J	BROWN, EM; GAMBA, G; RICCARDI, D; LOMBARDI, M; BUTTERS, R; KIFOR, O; SUN, A; HEDIGER, MA; LYTTON, J; HEBERT, SC				BROWN, EM; GAMBA, G; RICCARDI, D; LOMBARDI, M; BUTTERS, R; KIFOR, O; SUN, A; HEDIGER, MA; LYTTON, J; HEBERT, SC			CLONING AND CHARACTERIZATION OF AN EXTRACELLULAR CA2+-SENSING RECEPTOR FROM BOVINE PARATHYROID	NATURE			English	Article							METABOTROPIC GLUTAMATE RECEPTOR; CALCIUM CONCENTRATIONS; DIVALENT-CATIONS; XENOPUS OOCYTES; CELLS; SEQUENCE; EXPRESSION; CA-2+; PROTEINS; HORMONE	MAINTENANCE of a stable internal environment within complex organisms requires specialized cells that sense changes in the extracellular concentration of specific ions (such as Ca2+). Although the molecular nature of such ion sensors is unknown, parathyroid cells possess a cell surface Ca2+-sensing mechanism that also recognizes trivalent and polyvalent cations (such as neomycin) and couples by changes in phosphoinositide turnover and cytosolic Ca2+ to regulation of parathyroid hormone secretion1-4. The latter restores normocalcaemia by acting on kidney and bone2. We now report the cloning of complementary DNA encoding an extracellular Ca2+-sensing receptor from bovine parathyroid with pharmacological and functional properties nearly identical to those of the native receptor. The novel approximately 120K receptor shares limited similarity with the metabotropic glutamate receptors5 and features a large extracellular domain, containing clusters of acidic amino-acid residues possibly involved in calcium binding, coupled to a seven-membrane-spanning domain like those in the G-protein-coupled receptor superfamily.	HARVARD UNIV,SCH MED,CTR STUDY KIDNEY DIS,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,MOLEC PHYSIOL & BIOPHYS LAB,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	BROWN, EM (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV ENDOCRINE HYPERTENS,BOSTON,MA 02115, USA.		Riccardi, Daniela/A-4674-2010; Centeno, Patricia Pacios/O-8368-2016; Gamba, Gerardo/P-4873-2016	Riccardi, Daniela/0000-0002-7322-3163; Gamba, Gerardo/0000-0002-4378-9043; Hediger, Matthias/0000-0003-1946-027X; Lytton, Jonathan/0000-0003-4770-2512				ABE T, 1992, J BIOL CHEM, V267, P13361; BAIMBRIDGE KG, 1992, TRENDS NEUROSCI, V15, P303, DOI 10.1016/0166-2236(92)90081-I; BROWN EM, 1991, ENDOCRINOLOGY, V128, P3047, DOI 10.1210/endo-128-6-3047; BROWN EM, 1991, J BONE MINER RES, V6, P1217; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; BROWN EM, 1990, ENDOCRINOLOGY, V127, P1064, DOI 10.1210/endo-127-3-1064; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HAWKINS D, 1989, ENDOCRINOLOGY, V124, P838, DOI 10.1210/endo-124-2-838; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; HUMES HD, 1986, KIDNEY, P1491; JUHLIN C, 1990, J BIOL CHEM, V265, P8275; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KEMP BE, 1992, METHOD ENZYMOL, V207, P121; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MORIARTY TM, 1989, J BIOL CHEM, V264, P13524; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NEMETH EF, 1986, FEBS LETT, V203, P15, DOI 10.1016/0014-5793(86)81427-2; NEMETH EF, 1990, CELL CALCIUM, V11, P323, DOI 10.1016/0143-4160(90)90033-Q; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; SHOBACK DM, 1988, ENDOCRINOLOGY, V123, P382, DOI 10.1210/endo-123-1-382; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	30	2172	2315	2	142	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 9	1993	366	6455					575	580		10.1038/366575a0	http://dx.doi.org/10.1038/366575a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	8255296				2022-12-28	WOS:A1993ML21800073
J	VAPORCIYAN, AA; DELISSER, HM; YAN, HC; MENDIGUREN, II; THOM, SR; JONES, ML; WARD, PA; ALBELDA, SM				VAPORCIYAN, AA; DELISSER, HM; YAN, HC; MENDIGUREN, II; THOM, SR; JONES, ML; WARD, PA; ALBELDA, SM			INVOLVEMENT OF PLATELET ENDOTHELIAL-CELL ADHESION MOLECULE-1 IN NEUTROPHIL RECRUITMENT IN-VIVO	SCIENCE			English	Article							BETA-2 INTEGRINS; INJURY; CD31; ROLES; LUNG	During inflammation, neutrophils migrate from the vascular lumen into extravascular sites. In vitro assays have suggested that platelet-endothelial cell adhesion molecule-1 [PECAM-1 (CD31)], a member of the immunoglobulin superfamily, is required for the transmigration of neutrophils across endothelial monolayers. Antibody to human PECAM-1, which cross-reacts with rat PECAM-1, was found to block not only in vivo accumulation of rat neutrophils into the peritoneal cavity and the alveolar compartment of the lung but also neutrophil accumulation in human skin grafts transplanted onto immunodeficient mice. On the basis of these findings in three different models of inflammation, it appears that PECAM-1 is required for neutrophil transmigration in vivo and may thus be a potential therapeutic target.	UNIV PENN,MED CTR,DEPT MED,DIV PULM & CRIT CARE,PHILADELPHIA,PA 19104; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV PENN,MED CTR,INST ENVIRONM MED,PHILADELPHIA,PA 19104	University of Pennsylvania; The Wistar Institute; University of Michigan System; University of Michigan; University of Pennsylvania			DeLisser, Horace/AFM-1942-2022		NHLBI NIH HHS [HL-31963, HL-430020-02, HL-46311] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL046311, R01HL046311, P01HL031963] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059; ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; DELISSER HM, 1993, J BIOL CHEM, V268, P16307; JOHNSON KJ, 1981, J IMMUNOL, V126, P2365; JOHNSON KJ, 1974, J CLIN INVEST, V54, P349, DOI 10.1172/JCI107770; MERWIN JR, UNPUB; MULLER WA, 1992, J EXP MED, V175, P1401, DOI 10.1084/jem.175.5.1401; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; MULLIGAN MS, 1992, J IMMUNOL, V148, P1847; MULLIGAN MS, 1991, J CLIN INVEST, V88, P1396, DOI 10.1172/JCI115446; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; OHTO H, 1985, BLOOD, V66, P873; STOCKINGER H, 1990, J IMMUNOL, V145, P3889; TAWIA SA, 1993, HUM REPROD, V8, P175; TRIPPESTAD A, 1971, CLIN EXP IMMUNOL, V8, P639; VARANI J, 1985, LAB INVEST, V53, P656; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; YAN HC, 1993, J CLIN INVEST, V91, P986, DOI 10.1172/JCI116320	19	425	436	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 3	1993	262	5139					1580	1582		10.1126/science.8248808	http://dx.doi.org/10.1126/science.8248808			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK329	8248808				2022-12-28	WOS:A1993MK32900043
J	EPSTEIN, AE; HALLSTROM, AP; ROGERS, WJ; LIEBSON, PR; SEALS, AA; ANDERSON, JL; COHEN, JD; CAPONE, RJ; WYSE, DG				EPSTEIN, AE; HALLSTROM, AP; ROGERS, WJ; LIEBSON, PR; SEALS, AA; ANDERSON, JL; COHEN, JD; CAPONE, RJ; WYSE, DG			MORTALITY FOLLOWING VENTRICULAR ARRHYTHMIA SUPPRESSION BY ENCAINIDE, FLECAINIDE, AND MORICIZINE AFTER MYOCARDIAL-INFARCTION - THE ORIGINAL DESIGN CONCEPT OF THE CARDIAC-ARRHYTHMIA SUPPRESSION TRIAL (CAST)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DRUG-THERAPY; DOUBLE-BLIND; SURVIVAL; MORBIDITY; PLACEBO; EVENTS; DEATH	Objective.-To test the hypothesis that in survivors of myocardial infarction, the suppression of ventricular premature depolarizations improves survival free of cardiac arrest and arrhythmic death. Design.-International, prospective, multicenter, randomized, placebo-controlled trial. Setting.-University and community hospitals. Patients.-A total of 3549 patients with myocardial infarction and left ventricular dysfunction. Intervention.-Administration of encainide, flecainide, moricizine, or placebo to suppress ventricular premature depolarizations. Main Outcome Measures.-Overall survival and survival free of cardiac arrest or arrhythmic death were compared in patients randomized to long-term, active antiarrhythmic drug therapy vs corresponding placebo, using the stratified log rank statistic. Results.-At 1 year from the time of randomization to blinded therapy, 95% of placebo-treated patients vs 90% of active drug-treated patients remained alive (P=.0006). Similarly, at 1 year, 96% of placebo-treated patients vs 93% of active drug-treated patients remained free of cardiac arrest or arrhythmic death (P=.003). Conclusions.-The suppression of asymptomatic or mildly symptomatic ventricular arrhythmias after myocardial infarction does not improve survival and can increase mortality. Treatment strategies designed solely to suppress these arrhythmias should no longer be followed.	UNIV ALABAMA, DEPT MED, DIV CARDIOVASC DIS, BIRMINGHAM, AL USA; UNIV WASHINGTON, CAST COORDINATING CTR, SEATTLE, WA 98195 USA; RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT MED, CARDIOL SECT, CHICAGO, IL 60612 USA; UNIV FLORIDA, DEPT MED, CARDIOL SECT, JACKSONVILLE, FL USA; LATTER DAY ST HOSP, DEPT MED, DIV CARDIOL, SALT LAKE CITY, UT 84143 USA; ST LOUIS UNIV, DEPT MED, DIV CARDIOL, ST LOUIS, MO 63103 USA; UNIV ROCHESTER, DEPT MED, CARDIOL UNIT, ROCHESTER, NY 14627 USA; UNIV CALGARY, DEPT MED, DIV CARDIOL, CALGARY T2N 1N4, ALBERTA, CANADA	University of Alabama System; University of Alabama Birmingham; University of Washington; University of Washington Seattle; Rush University; State University System of Florida; University of Florida; Saint Louis University; University of Rochester; University of Calgary								[Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1988, AM J CARDIOL, V61, P501; BURKART F, 1990, J AM COLL CARDIOL, V16, P1711, DOI 10.1016/0735-1097(90)90324-I; CAIRNS JA, 1991, CIRCULATION, V84, P550, DOI 10.1161/01.CIR.84.2.550; CEREMUZYNSKI L, 1992, J AM COLL CARDIOL, V20, P1056, DOI 10.1016/0735-1097(92)90357-S; CLYNE CA, 1992, NEW ENGL J MED, V327, P255; DELUNA AB, 1989, AM HEART J, V117, P151, DOI 10.1016/0002-8703(89)90670-4; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; EPSTEIN AE, 1991, J AM COLL CARDIOL, V18, P14, DOI 10.1016/S0735-1097(10)80210-4; GOLDSTEIN S, 1990, CIRCULATION, V82, P198; GREENE HL, 1992, J AM COLL CARDIOL, V19, P894, DOI 10.1016/0735-1097(92)90267-Q; HALLSTROM AP, 1988, AM J CARDIOL, V61, P704; HALLSTROM AP, 1991, STAT MED, V10, P1621, DOI 10.1002/sim.4780101013; KALBLFEISCH JP, 1980, STATISTICAL ANAL HEA; KANNEL WB, 1982, ANN NY ACAD SCI, V382, P3, DOI 10.1111/j.1749-6632.1982.tb55203.x; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; RODEN DM, 1986, AM HEART J, V111, P1088, DOI 10.1016/0002-8703(86)90010-4; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; STEINBECK G, 1992, NEW ENGL J MED, V327, P987, DOI 10.1056/NEJM199210013271404; TEO K, 1992, CIRCULATION, V86, P39; WILLIAMS EMV, 1984, J CLIN PHARMACOL, V24, P129, DOI 10.1002/j.1552-4604.1984.tb01822.x; WYSE DG, 1991, J AM COLL CARDIOL, V18, P20, DOI 10.1016/S0735-1097(10)80211-6; YUSEF S, 1985, PROG CARDIOVASC DIS, V77, P335; 1992, HEART STROKE FACTS, P11	24	131	134	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1993	270	20					2451	2455		10.1001/jama.270.20.2451	http://dx.doi.org/10.1001/jama.270.20.2451			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG671	8230622				2022-12-28	WOS:A1993MG67100026
J	MAYO, SL; BALDWIN, RL				MAYO, SL; BALDWIN, RL			GUANIDINIUM CHLORIDE INDUCTION OF PARTIAL UNFOLDING IN AMIDE PROTON-EXCHANGE IN RNASE-A	SCIENCE			English	Article							PANCREATIC RIBONUCLEASE-A; HYDROGEN-EXCHANGE; MAGNETIC-RESONANCE; FREE-ENERGY; PROTEIN; DENATURATION; TRANSITION; RATES; NMR	Amide (NH) proton exchange rates were measured in 0.0 to 0.7 M guanidinium chloride (GdmCl) for 23 slowly exchanging peptide NH protons of ribonuclease A (RNase A) at pH* 5.5 (uncorrected pH measured in D2O), 34-degrees-C. The purpose was to find out whether GdmCl induces exchange through binding to exchange intermediates that are partly or wholly unfolded. It was predicted that, when the logarithm of the exchange rate is plotted as a function of the molarity of GdmCl, the slope should be a measure of the amount of buried surface area exposed to GdmCl in the exchange intermediate. The results indicate that these concentrations of GdmCl do induce exchange by means of a partial unfolding mechanism for all 23 protons; this implies that exchange reactions can be used to study the unfolding and stability of local regions. Of the 23 protons, nine also show a second mechanism of exchange at lower concentrations of GdmCl, a mechanism that is nearly independent of GdmCl concentration and is termed ''limited structural fluctuation.''	STANFORD UNIV, MED CTR, SCH MED, DEPT BIOCHEM, STANFORD, CA 94305 USA	Stanford University					NIGMS NIH HHS [GM 19988] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019988, R37GM019988] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; COVINGTON AK, 1966, J PHYS CHEM-US, V70, P3820, DOI 10.1021/j100884a011; ENGLANDER JJ, 1979, ANAL BIOCHEM, V92, P517, DOI 10.1016/0003-2697(79)90693-6; ENGLANDER SW, 1992, SCIENCE, V256, P1684, DOI 10.1126/science.256.5064.1684; ENGLANDER SW, 1983, Q REV BIOPHYS, V16, P521, DOI 10.1017/S0033583500005217; HILTON BD, 1981, BIOCHEMISTRY-US, V20, P4697, DOI 10.1021/bi00519a027; JENG MF, 1990, BIOCHEMISTRY-US, V29, P10433, DOI 10.1021/bi00498a001; KIM KS, 1993, BIOCHEMISTRY-US, V32, P9609, DOI 10.1021/bi00088a013; KIM KS, 1993, BIOCHEMISTRY-US, V32, P9600, DOI 10.1021/bi00088a012; LOFTUS D, 1986, BIOCHEMISTRY-US, V25, P1428, DOI 10.1021/bi00354a036; MAYO SL, UNPUB; MOLDAY RS, 1972, BIOCHEMISTRY-US, V11, P150, DOI 10.1021/bi00752a003; Pace C N, 1986, Methods Enzymol, V131, P266; PACE CN, 1990, BIOCHEMISTRY-US, V29, P2564, DOI 10.1021/bi00462a019; PACE CN, 1975, CRC CRIT REV BIOCH, V31; RICHARDS FM, 1979, CARLSBERG RES COMMUN, V44, P47, DOI 10.1007/BF02906521; RICO M, 1989, EUR J BIOCHEM, V183, P623, DOI 10.1111/j.1432-1033.1989.tb21092.x; RICO M, COMMUNICATION; ROBERTSON AD, 1991, BIOCHEMISTRY-US, V30, P9907, DOI 10.1021/bi00105a014; ROBERTSON AD, 1989, BIOCHEMISTRY-US, V28, P5930, DOI 10.1021/bi00440a033; RODER H, 1989, METHOD ENZYMOL, V176, P446; SANTORO MM, 1992, BIOCHEMISTRY-US, V31, P4901, DOI 10.1021/bi00135a022; SCHELLMAN JA, 1987, BIOPOLYMERS, V26, P549, DOI 10.1002/bip.360260408; SEGAWA SI, 1984, BIOPOLYMERS, V23, P2473; SHAKHNOVICH EI, 1989, BIOPOLYMERS, V28, P1667, DOI 10.1002/bip.360281003; WAGNER G, 1979, J MOL BIOL, V130, P31, DOI 10.1016/0022-2836(79)90550-3; WESTMORELAND DG, 1975, J BIOL CHEM, V250, P7456; WLODAWER A, 1988, BIOCHEMISTRY-US, V27, P2705, DOI 10.1021/bi00408a010; WOODWARD C, 1982, MOL CELL BIOCHEM, V48, P135, DOI 10.1007/BF00421225	29	200	201	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	1993	262	5135					873	876		10.1126/science.8235609	http://dx.doi.org/10.1126/science.8235609			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	8235609				2022-12-28	WOS:A1993MF43800027
J	BARLOW, RB; BIRGE, RR; KAPLAN, E; TALLENT, JR				BARLOW, RB; BIRGE, RR; KAPLAN, E; TALLENT, JR			ON THE MOLECULAR-ORIGIN OF PHOTORECEPTOR NOISE	NATURE			English	Article							PRIMARY PHOTOCHEMICAL EVENTS; CIRCADIAN-RHYTHMS; EXTRACELLULAR PH; SCHIFF-BASE; RHODOPSIN; RETINA; TOAD; PERFORMANCE; SENSITIVITY; SYSTEM	RETINAL photoreceptors are noisy. They generate discrete electrical events in the dark indistinguishable from those evoked by light1,2 and thereby limit visual sensitivity at low levels of illumination3,4. The random spontaneous events are strongly temperature-dependent and have been attributed to thermal isomerizations of the vitamin A chromophore of rhodopsin, the light-sensitive molecule in photoreceptors1,5,6. But thermal generation of dark events in both vertebrate and invertebrate photoreceptors requires activation energies in the range of 23 to 27 kcal mol-1, which are significantly less than the energy barrier of 45 kcal mol-1 for photoisomerization of the chromophore of native rhodopsin7-9. We propose that photoreceptor noise results from the thermal isomerization of a relatively unstable form of rhodopsin, one in which the Schiff-base linkage between the chromophore and protein is unprotonated. This molecular mechanism is supported by both theoretical calculations of the properties of rhodopsin and experimental measurements of the properties of photoreceptor noise.	SYRACUSE UNIV,DEPT BIOENGN & NEUROSCI,SYRACUSE,NY 13244; SYRACUSE UNIV,DEPT CHEM,SYRACUSE,NY 13244; MARINE BIOL LAB,WOODS HOLE,MA 02543	Syracuse University; Syracuse University; Marine Biological Laboratory - Woods Hole	BARLOW, RB (corresponding author), SYRACUSE UNIV,INST SENSORY RES,SYRACUSE,NY 13244, USA.							AHO AC, 1988, NATURE, V334, P348, DOI 10.1038/334348a0; ASHMORE JF, 1977, J PHYSL, V332, P272; BARLOW HB, 1956, J OPT SOC AM, V46, P634, DOI 10.1364/JOSA.46.000634; BARLOW HB, 1988, NATURE, V334, P296, DOI 10.1038/334296a0; BARLOW RB, 1982, NATURE, V296, P65, DOI 10.1038/296065a0; BARLOW RB, 1983, J NEUROSCI, V3, P856; BARLOW RB, 1987, J GEN PHYSIOL, V89, P353, DOI 10.1085/jgp.89.3.353; BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; BAYLOR DA, 1980, J PHYSIOL-LONDON, V309, P591, DOI 10.1113/jphysiol.1980.sp013529; BIRGE RR, 1993, BIOPHYS J, V64, P1371, DOI 10.1016/S0006-3495(93)81501-7; BIRGE RR, 1990, BIOCHIM BIOPHYS ACTA, V1016, P293, DOI 10.1016/0005-2728(90)90163-X; BORGULA GA, 1989, VISION RES, V29, P1069, DOI 10.1016/0042-6989(89)90054-0; CHESLER M, 1987, AM J PHYSIOL, V253, pR666, DOI 10.1152/ajpregu.1987.253.4.R666; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; COPENHAGEN DR, 1987, J PHYSIOL-LONDON, V393, P667, DOI 10.1113/jphysiol.1987.sp016847; CORSON DW, 1980, BRAIN RES, V193, P558; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P9165, DOI 10.1021/bi00086a023; FAHRENBACH WH, 1969, Z ZELLFORSCH MIK ANA, V93, P451; HUBBARD R, 1966, J BIOL CHEM, V241, P1814; KAPLAN E, 1980, NATURE, V286, P393, DOI 10.1038/286393a0; KASS L, 1988, J COMP PHYSIOL A, V164, P95, DOI 10.1007/BF00612723; LILLYWHITE PG, 1977, J COMP PHYSIOL, V122, P189, DOI 10.1007/BF00611889; LISMAN JE, 1980, J GEN PHYSIOL, V73, P219; LONGSTAFF C, 1986, P NATL ACAD SCI USA, V83, P4209, DOI 10.1073/pnas.83.12.4209; OAKLEY B, 1989, J PHYSIOL-LONDON, V419, P353, DOI 10.1113/jphysiol.1989.sp017876; POWERS MK, 1991, VISUAL NEUROSCI, V7, P179, DOI 10.1017/S0952523800004016; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SCHICK GA, 1987, BIOCHEMISTRY-US, V26, P2556, DOI 10.1021/bi00383a022; SCHNEIDER M, 1987, Investigative Ophthalmology and Visual Science, V28, P186; SMITH WC, 1992, INVEST OPHTH VIS SCI, V32, P1004; TALLENT JR, 1992, J AM CHEM SOC, V114, P1581, DOI 10.1021/ja00031a007; Yeandle S., 1958, AM J OPHTHALMOL, V46, P82	32	104	105	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 4	1993	366	6450					64	66		10.1038/366064a0	http://dx.doi.org/10.1038/366064a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF007	8232538				2022-12-28	WOS:A1993MF00700054
J	TISCH, R; YANG, XD; SINGER, SM; LIBLAU, RS; FUGGER, L; MCDEVITT, HO				TISCH, R; YANG, XD; SINGER, SM; LIBLAU, RS; FUGGER, L; MCDEVITT, HO			IMMUNE-RESPONSE TO GLUTAMIC-ACID DECARBOXYLASE CORRELATES WITH INSULITIS IN NONOBESE DIABETIC MICE	NATURE			English	Article							MOUSE; IDENTIFICATION; AUTOANTIGEN; PRODUCTS; ANTIBODY; CLONING	KNOWING the autoantigen target(s) in an organ-specific autoimmune disease is essential to understanding its pathogenesis. Insulin-dependent diabetes mellitus (IDDM) is an autoimmune disease characterized by lymphocytic infiltration of the islets of Langerhans (insulitis) and destruction of insulin-secreting pancreatic beta-cells1. Several beta-cell proteins have been identified as autoantigens, but their importance in the diabetogenic process is not known2. The non-obese diabetic (NOD) mouse is a murine model for spontaneous IDDM3. Here we determine the temporal sequence of T-cell and antibody responses in NOD mice to a panel of five murine beta-cell antigens and find that antibody and T-cell responses specific for the two isoforms of glutamic acid decarboxylase (GAD) are first detected in 4-week-old NOD mice. This GAD-specific reactivity coincides with the earliest detectable response to an islet extract, and with the onset of insulitis. Furthermore, NOD mice receiving intrathymic injections of GAD65 exhibit markedly reduced T-cell proliferative responses to GAD and to the rest of the panel, in addition to remaining free of diabetes. These results indicate that the spontaneous response to beta-cell antigens arises very early in life and that the anti-GAD immune response has a critical role in the disease process during this period.	STANFORD UNIV,MED CTR,DEPT MED,STANFORD,CA 94305	Stanford University	TISCH, R (corresponding author), STANFORD UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305, USA.		Singer, Steven/V-7778-2019; Liblau, Roland/J-3530-2014	Singer, Steven/0000-0001-5719-7535; 				ATKINSON MA, 1992, LANCET, V339, P458, DOI 10.1016/0140-6736(92)91061-C; BAEKKESKOV S, 1982, NATURE, V298, P167, DOI 10.1038/298167a0; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BOITARD C, 1992, P NATL ACAD SCI USA, V89, P172, DOI 10.1073/pnas.89.1.172; CASTANO L, 1991, J CLIN ENDOCR METAB, V73, P1197, DOI 10.1210/jcem-73-6-1197; COFFMAN RL, 1988, IMMUNOL REV, V102, P5, DOI 10.1111/j.1600-065X.1988.tb00739.x; EISENBARTH GS, 1986, NEW ENGL J MED, V314, P1360; ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576; GERLING IC, 1992, DIABETES, V41, P1672, DOI 10.2337/diabetes.41.12.1672; HARRISON LC, 1992, IMMUNOL TODAY, V13, P348, DOI 10.1016/0167-5699(92)90170-C; HAYWARD AR, 1989, J IMMUNOL, V143, P1555; HONEYMAN MC, 1993, J EXP MED, V177, P535, DOI 10.1084/jem.177.2.535; LEFFERT JD, 1989, P NATL ACAD SCI USA, V86, P3127, DOI 10.1073/pnas.86.9.3127; MAKINO S, 1980, Experimental Animals (Tokyo), V29, P1; MILLER BJ, 1988, J IMMUNOL, V140, P52; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PROCHAZKA M, 1992, DIABETES, V41, P98, DOI 10.2337/diabetes.41.1.98; REICH EP, 1989, NATURE, V341, P326, DOI 10.1038/341326a0; SHIZURU JA, 1988, SCIENCE, V240, P659, DOI 10.1126/science.2966437	19	934	964	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 4	1993	366	6450					72	75		10.1038/366072a0	http://dx.doi.org/10.1038/366072a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF007	8232539				2022-12-28	WOS:A1993MF00700057
J	LYNN, JT				LYNN, JT			LAPHROAIG	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	1994	271	1					18	18						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN725	8258875				2022-12-28	WOS:A1994MN72500008
J	SEPKOWITZ, KA				SEPKOWITZ, KA			TUBERCULOSIS AND THE HEALTH-CARE WORKER - A HISTORICAL-PERSPECTIVE	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NOSOCOMIAL TRANSMISSION; HOSPITAL PERSONNEL; OUTBREAK; INFECTION; PHYSICIANS; RISK; EMPLOYEES; PATIENT	Many hospital outbreaks of tuberculosis have occurred in recent years in the United States, resulting in tuberculosis infection and disease among health care workers and patients. Several hospital workers have died of nosocomially acquired multidrug-resistant tuberculosis. Assuring the safety of the health care worker with respect to tuberculosis has become an urgent priority. A review of the medical literature of the past 100 years reveals that our current view of tuberculosis care as an occupational hazard emerged only in the 1950s, after a fierce and extensive debate. Many authorities had felt that care of the tuberculous patient conferred a health advantage to the care provider. This paper reviews this debate and considers steps taken decades ago, before our current environmental interventions were available to ensure the safety of the health care worker.			SEPKOWITZ, KA (corresponding author), CORNELL UNIV, MED CTR,NEW YORK HOSP, MEM SLOAN KETTERING CANC CTR,INFECT DIS SERV, 1275 YORK AVE, NEW YORK, NY 10021 USA.				NIAID NIH HHS [5 U01 AI27669-04] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027669] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRUZZI WA, 1953, NEW ENGL J MED, V248, P722, DOI 10.1056/NEJM195304232481705; AITKEN ML, 1987, AM REV RESPIR DIS, V136, P805, DOI 10.1164/ajrccm/136.4.805; ALARCON DG, 1946, DIS CHEST, V12, P336, DOI 10.1378/chest.12.4.336; ALPERT ME, 1965, NEW ENGL J MED, V272, P718, DOI 10.1056/NEJM196504082721404; Alt Howard L., 1941, AMER REV TUBERC, V44, P346; Amberson JB, 1936, ANN INTERN MED, V10, P156, DOI 10.7326/0003-4819-10-2-156; AMBERSON JB, 1942, TUBERCULOSIS IND, P296; AUFRECHT, 1915, AM MED, V21, P607; Badger TL, 1936, AM J NURS, V36, P1100, DOI 10.2307/3413842; BADGER TL, 1949, AM REV TUBERC PULM, V60, P305; Badger TL, 1937, NEW ENGL J MED, V217, P424, DOI DOI 10.1056/NEJM193709092171102; BAKER ALICE E., 1941, AMER REV TUBERC, V43, P288; BALDWIN ER, 1930, US VETERANS BUREAU M, V6, P1; BARRETTCONNOR E, 1979, JAMA-J AM MED ASSOC, V241, P33, DOI 10.1001/jama.241.1.33; BASS J, 1992, AM REV RESPIR DIS, V146, P1623; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; BELFIELD PW, 1984, BRIT J DIS CHEST, V78, P313; BIGGS HM, 1910, LANCET          0806, P371; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BOGEN E, 1959, AM J CLIN PATHOL, V31, P343; BOW MR, 1937, CAN PUBLIC HLTH J, V28, P63; BOYNTON RUTH E., 1939, AMER REV TUBERC, V39, P671; Brahdy L, 1940, J AMER MED ASSOC, V114, P102; BRAHDY L, 1940, NY STATE J MED, V40, P326; Brahdy L, 1941, AM J PUBLIC HEALTH N, V31, P1040, DOI 10.2105/AJPH.31.10.1040; BREAN HP, 1946, NEW ENGL J MED, V235, P315, DOI 10.1056/NEJM194609052351001; BRITTON JA, 1925, 21ST T ANN M NAT TUB, P442; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; BRUNON R, 1915, AM MED, V21, P607; CANNOR CA, 1940, DIPLOMATE, V12, P241; CATANZARO A, 1982, AM REV RESPIR DIS, V125, P559, DOI 10.1164/arrd.1982.125.5.559; CHILDRESS WG, 1951, JAMA-J AM MED ASSOC, V146, P1188, DOI 10.1001/jama.1951.03670130010004; CLAPP HC, 1881, IS CONSUMPTION CONTA; CLARK WR, 1924, PACIFIC COAST J NURS, V20, P97; COLLIN HC, 1988, LABORATORY ACQUIRED; CONNOLLY EC, 1950, TUBERCULOSIS AGING H; CRAVEN RB, 1975, ANN INTERN MED, V82, P628, DOI 10.7326/0003-4819-82-5-628; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DANIELS M, 1944, LANCET          0805, P165; DAUER CC, 1937, INT MED DIGEST, V30, P56; DICKIE HA, 1950, ANN INTERN MED, V33, P941, DOI 10.7326/0003-4819-33-4-941; DIEHL HS, 1948, JAMA-J AM MED ASSOC, V138, P8, DOI 10.1001/jama.1948.02900010010003; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; DUBLIN LI, 1914, J OUTDOOR LIFE   JUL, P204; DUBLIN LI, 1942, JUN S SAR LAB STUD T, P33; Dufault P, 1941, NEW ENGL J MED, V224, P711, DOI 10.1056/NEJM194104242241701; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; EHRENKRA.NJ, 1972, ANN INTERN MED, V77, P377, DOI 10.7326/0003-4819-77-3-377; ELLNER JJ, 1993, J INFECT DIS, V168, P537, DOI 10.1093/infdis/168.3.537; Emerson H, 1926, AM J PUBLIC HEALTH, V16, P1088, DOI 10.2105/AJPH.16.11.1088; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; Fishberg M, 1931, J AMER MED ASSOC, V97, P0661, DOI 10.1001/jama.1931.02730090075025; FISHBERG M, 1932, PULMONARY TUBERCULOS; FISHBERG M, 1916, NEW YORK J MED, V104, P1085; FISHBERG M, 1915, AM MED, V21, P607; Fishberg M., 1931, JAMA-J AM MED ASSOC, V97, P316; FITZ R, 1941, JAMA-J AM MED ASSOC, V117, P1125; FRAMPTON MW, 1992, ANN INTERN MED, V117, P312, DOI 10.7326/0003-4819-117-4-312; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GEER E. K., 1934, American Review of Tuberculosis and Pulmonary Diseases, V29, P88; Geer EK, 1932, ARCH INTERN MED, V49, P77, DOI 10.1001/archinte.1932.00150080080005; GEISELER PJ, 1986, AM REV RESPIR DIS, V133, P773; GEORGE RH, 1986, J HOSP INFECT, V8, P129, DOI 10.1016/0195-6701(86)90039-3; GOLDMAN KP, 1988, TUBERCLE, V69, P237, DOI 10.1016/0041-3879(88)90046-3; Gordon B, 1930, J AMER MED ASSOC, V94, P1643, DOI 10.1001/jama.1930.02710470007003; GREENBERG PD, 1991, AM REV RESPIR DIS, V143, P490, DOI 10.1164/ajrccm/143.3.490; GRIGG ERN, 1958, AM REV TUBERC PULM, V78, P151; GRIGG ERN, 1958, AM REV TUBERC PULM, V78, P426; GRIGG ERN, 1958, AM REV TUBERC PULM, V78, P583; HAHN RICHARD G., 1941, AMER REV TUBERC, V43, P600; HALEY CE, 1989, INFECT CONT HOSP EP, V10, P204, DOI 10.1086/646003; HASTINGS D. R., 1941, AMER REV TUBERC, V44, P681; HEDVALL ERIK, 1940, AMER REV TUBERC, V41, P770; HEIMBECK, 1947, JAMA-J AM MED ASSOC, V135, P934; Heimbeck J, 1928, ARCH INTERN MED, V41, P336, DOI 10.1001/archinte.1928.00130150043002; HEIMBECK J., 1936, Tubercle, V18, P97, DOI 10.1016/S0041-3879(36)80249-9; Heimbeck J, 1938, BRIT J TUBERCULOSIS, V32, P154, DOI [10.1016/S0366-0850(38)80144-7, DOI 10.1016/S0366-0850(38)80144-7]; HEIMBECK J, 1927, INT CLIN, V4, P6; Herman NB, 1932, B JOHNS HOPKINS HOSP, V51, P41; HERON GA, 1894, LANCET, V1, P1; HETHERINGTON DW, 1931, ARCH INTERN MED, V48, P734; Hetherington HW, 1935, ARCH INTERN MED, V55, P709, DOI 10.1001/archinte.1935.00160230002001; Hetherington HW, 1940, AM J HYG, V31, P45, DOI 10.1093/oxfordjournals.aje.a118608; Hodges FJ, 1936, ANN INTERN MED, V9, P1639, DOI 10.7326/0003-4819-9-12-1639; HUTTON MD, 1990, J INFECT DIS, V161, P286, DOI 10.1093/infdis/161.2.286; ISEMAN MD, 1992, ANN INTERN MED, V117, P251, DOI 10.7326/0003-4819-117-3-251; ISRAEL H. L., 1941, Journal of the American Medical Association, V117, P839; JACOBSON G, 1957, DIS CHEST, V32, P27, DOI 10.1378/chest.32.1.27; JENNINGS FL, 1938, MINN MED, V21, P102; JENNINGS FRANK L., 1935, AMER REV TUBERC, V32, P304; JEREB J, 1991, 31ST INT C ANT AG CH, P266; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; JEREB JA, 1992, 1992 WORLD C TUB BET, P51; JONES D. W. C., 1933, Tubercle, V15, P59; KANTOR HS, 1988, AM J MED, V84, P833, DOI 10.1016/0002-9343(88)90060-5; KARNS JR, 1959, AM REV TUBERC PULM, V79, P746; Katz J, 1951, PSYCHIAT QUART, V25, P500, DOI 10.1007/BF01584297; KELLER A. E., 1939, AMER REV TUBERC, V39, P657; Knopf SA, 1926, ARCH SURG-CHICAGO, V12, P320, DOI 10.1001/archsurg.1926.01130010324021; LEVINE I, 1968, ARCH INTERN MED, V121, P545, DOI 10.1001/archinte.121.6.545; LIMYUEN DM, 1946, AM REV TUBERC PULM, V54, P261; LINCOLN EDITH M., 1965, ADVANCES TUBERC RES, V14, P157; LOURIA MR, 1941, NY STATE J MED, V41, P1573; LUNDGREN R, 1987, TUBERCLE, V68, P147, DOI 10.1016/0041-3879(87)90032-8; MACKLIN MT, 1938, TUBERCLE, V19, P193; MALASKY C, 1990, AM REV RESPIR DIS, V142, P505, DOI 10.1164/ajrccm/142.3.505; MARIETTE ES, 1936, TUBERCLE, V36, P103; MARTIN D. C., 1934, American Review of Tuberculosis and Pulmonary Diseases, V29, P182; MEADE GM, 1948, AM REV TUBERC PULM, V58, P675; MEDLAR EM, 1948, AM REV TUBERC PULM, V58, P583; Meyer W, 1926, ARCH SURG-CHICAGO, V12, P311, DOI 10.1001/archsurg.1926.01130010315020; MIKOL EX, 1952, AM REV TUBERC PULM, V66, P16; MORRIS SI, 1946, AM REV TUBERC PULM, V54, P140; MUSCHENHEIM C, 1946, ANN INTERN MED, V24, P968, DOI 10.7326/0003-4819-24-6-968; Myers JA, 1930, AM J NURS, V30, P1361, DOI 10.2307/3411236; MYERS JA, 1966, DIS CHEST, V50, P120, DOI 10.1378/chest.50.2.120; Myers JA, 1931, J AMER MED ASSOC, V97, P0316, DOI 10.1001/jama.1931.02730050024010; MYERS JA, 1955, JAMA-J AM MED ASSOC, V158, P1; Myers JA, 1931, J AMER MED ASSOC, V97, P1093; MYERS JA, 1968, DIS CHEST, V53, P687; Myers JA, 1937, ARCH INTERN MED, V59, P1; MYERS JA, 1957, ANN INTERN MED, V46, P201, DOI 10.7326/0003-4819-46-2-201; Myers JA, 1940, ANN INTERN MED, V14, P873, DOI 10.7326/0003-4819-14-5-873; MYERS JA, 1934, ARCH INTERN MED, V102, P2086; MYERS JA, 1955, J DIS CHEST, V28, P610; MYERS JA, 1946, AM J NURS, V12, P354; NARDELL EA, 1990, AM REV RESPIR DIS, V142, P501, DOI 10.1164/ajrccm/142.3.501; NORRIS GW, 1941, NEW ENGL J MED, V224, P711; NORRIS GW, 1924, DISEASES CHEST; OATWAY WH, 1949, ARIZ MED, V6, P23; OPIE EL, 1931, JAMA-J AM MED ASSOC, V96, P2063; OSLER W, 1909, P ROY SOC MED, V3, P137; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; PIERCE JR, 1992, CHEST, V101, P581, DOI 10.1378/chest.101.2.581; PLUNKETT ROBERT E., 1940, AMER REV TUBERC, V41, P381; POLLAK BS, 1937, J MED SOC NJ, V36, P740; POLLINGER FM, 1910, BRIT MED J, V1, P1039; POLLOCK W. C., 1935, American Review of Tuberculosis and Pulmonary Diseases, V31, P203; REID ADA CHREE, 1940, JOUR INDUST HYG AND TOXICOL, V22, P408; RHOADS PAUL S., 1939, AMER REV TUBERC, V40, P444; RIGGINS HM, 1953, AM REV TUBERC PULM, V67, P74; RIGGINS HM, 1940, HOSPITALS, V14, P46; RILEY RL, 1967, AM REV RESPIR DIS, V96, P623; ROSE HG, 1953, NEW ENGL J MED, V248, P956; ROSENTHAL SR, 1948, JAMA-J AM MED ASSOC, V136, P73, DOI 10.1001/jama.1948.02890190001001; Ross EL, 1930, CAN MED ASSOC J, V22, P347; SAUGMAN C, 1915, AM MED, V21, P607; SCHEEL O, 1926, TUBERCLE, V7, P347; SCHUCK MH, 1950, DIS CHEST, V17, P442; Schwartz S, 1942, AM REV TUBERC, V47, P19; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SEPKOWITZ KA, 1994, IN PRESS CLIN INFECT; SHIPMAN S. J., 1933, American Review of Tuberculosis and Pulmonary Diseases, V27, P474; SOPER WILLARD B., 1939, AMER REV TUBERC, V39, P9; Springett V. H., 1948, TUBERCULOSIS YOUNG A; Squire J E, 1910, Br Med J, V1, P1039; STEAD WW, 1987, AM REV RESPIR DIS, V136, P803, DOI 10.1164/ajrccm/136.4.803; STEAD WW, 1967, AM REV RESPIR DIS, V95, P729; STEAD WW, 1967, NEW ENGL J MED, V277, P1008, DOI 10.1056/NEJM196711092771906; STEIDL J, 1932, AM REV TUBERC, V26, P98; STEIDL J, 1930, B HARVARD MED SCH AL, V5, P10; Stewart D. A., 1931, T AM HOSP ASS, P463; ULMAR D, 1936, Q B SEA VIEW HOSPITA, V2, P49; WALTERS FR, 1910, BRIT MED J, V1, P1039; WEBB GB, 1936, CLIO MED TUBERCULOSI; WEISS W, 1973, AM REV RESPIR DIS, V107, P136; WELBORN MB, 1938, J MED, V18, P563; WEST CW, 1942, MOD HOSP, V59, P75; Whitney JS, 1928, AM J NURS, V28, P768; Whitney JS, 1935, AM J NURS, V35, P367, DOI 10.2307/3411551; WHITNEY JS, 1941, TUBERCULOSIS NURSES; WHITNEY JS, 1931, FACTS FIGURES TUBERC; WHITNEY JS, 1940, DEATH RATES OCCUPATI; Williams CT, 1909, BRIT MED J, V1909, P433, DOI 10.1136/bmj.2.2538.433; WILLIAMS CT, 1882, BRIT MED J, V618, P21; Wright HP, 1941, CAN MED ASSOC J, V44, P44; ZAZA S, 1992, 1992 WORLD C TUB BET, P53; 1990, MMWR MORBID MORTAL W, V39, P1; 1991, MMWR MORBID MORTAL W, V40, P129; 1992, MMWR MORBID MORTAL W, V41, P1; 1990, MMWR MORBID MORTAL W, V39, P369; 1926, TUBERCLE, V7, P347; 1991, MMWR MORBID MORTAL W, V40, P585; 1993, MMWR MORBID MORTAL W, V42, P48; 1948, SAFER WAYS NURSING P	185	165	167	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1994	120	1					71	79		10.7326/0003-4819-120-1-199401010-00012	http://dx.doi.org/10.7326/0003-4819-120-1-199401010-00012			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP280	8250459				2022-12-28	WOS:A1994MP28000012
J	FREED, GL; KATZ, SL				FREED, GL; KATZ, SL			THE COMPREHENSIVE CHILDHOOD IMMUNIZATION ACT OF 1993 - TOWARD A MORE RATIONAL APPROACH	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CHILDREN; COUNTY		DUKE UNIV,MED CTR,DURHAM,NC 27710	Duke University	FREED, GL (corresponding author), UNIV N CAROLINA,CHAPEL HILL,NC 27599, USA.				AHRQ HHS [5-R01-HS07286-02] Funding Source: Medline; NICHD NIH HHS [1-R29-HD29555-01] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007286] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD029555] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BYRNE EB, 1970, J AMER MED ASSOC, V212, P770, DOI 10.1001/jama.212.5.770; CLINTON, 1993, NY TIMES        0504, P1; FOLEY JD, 1992, ERBI123 EMPL BEN RES; FREED GL, 1993, MILBANK Q, V71, P65, DOI 10.2307/3350275; HINMAN AR, 1991, AM J DIS CHILD, V145, P559, DOI 10.1001/archpedi.1991.02160050085023; Orenstein W A, 1990, J Health Care Poor Underserved, V1, P315; SCHULTE JM, 1991, PEDIATRICS, V87, P204; TOLLESTRUP K, 1991, AM J PREV MED, V7, P24, DOI 10.1016/S0749-3797(18)30961-9; YOKLEY JM, 1984, J APPL BEHAV ANAL, V17, P313, DOI 10.1901/jaba.1984.17-313; YOUNG SA, 1980, AM J PUBLIC HEALTH, V70, P422, DOI 10.2105/AJPH.70.4.422; YUDKOWSKY BK, 1990, PEDIATRICS, V85, P567; 1991, CHILDREN 1ST LEGISLA; 1993, NY TIMES        0213, P1; 1988, RES B PROFILE EMPLOY; 1993, AM ACADEMY PEDI 0820	15	18	18	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1993	329	26					1957	1960		10.1056/NEJM199312233292611	http://dx.doi.org/10.1056/NEJM199312233292611			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MM885	8247061				2022-12-28	WOS:A1993MM88500011
J	ROOME, AJ; WALSH, SJ; CARTTER, ML; HADLER, JL				ROOME, AJ; WALSH, SJ; CARTTER, ML; HADLER, JL			HEPATITIS-B VACCINE RESPONSIVENESS IN CONNECTICUT PUBLIC SAFETY PERSONNEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EFFICACY; IMMUNOGENICITY; EPIDEMIOLOGY; PREVENTION; SMOKING; VIRUS	Objective.-To determine the level and determinants of vaccine response in recently inoculated public safety personnel. Design.-Prevalence survey. Participants.-Public safety personnel who had completed vaccination 1 to 6 months prior to testing and had no serological evidence of previous exposure to hepatitis B virus. Main Outcome Measure.-An inadequate level of antibody to hepatitis B surface antigen was defined as less than 10 mIU/mL. Results.-All subjects in the study had been vaccinated using Recombivax HB, a recombinant hepatitis B vaccine. Of 528 individuals, 11.9% were found to have no or inadequate levels of antibody. The frequency of inadequate level of antibody increased significantly relative to age, from 2.8% among those younger than 30 years to 42.1% among those older than 60 years (P<.0001). Smoking (odds ratio [OR], 3.6; 95% confidence interval [CI], 2.0 to 6.4), extreme obesity (OR, 13.3; 95% CI, 3.8 to 49.1), and increasing time interval since completing the vaccine series (P<.01) were also associated with inadequate levels of antibody. These findings were confirmed by multivariate analysis using logistic regression. Conclusions.-Routine immunization of public safety personnel should include selective use of postvaccine testing. Postvaccination testing optimally should be performed in the 30- to 90-day interval after the last vaccine dose. New vaccination strategies are needed to improve response rates in persons with predictably poor response to hepatitis B vaccine.	CONNECTICUT DEPT HLTH & ADDICT SERV,EPIDEMIOL SECT,150 WASHINGTON ST,HARTFORD,CT 06106; UNIV CONNECTICUT,CTR HLTH,DEPT COMMUNITY MED,FARMINGTON,CT 06032	University of Connecticut								ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; ANDRE FE, 1989, AM J MED, V87, pS14, DOI 10.1016/0002-9343(89)90525-1; BLUMBERG BS, 1989, AM J MED, V87, pS2, DOI 10.1016/0002-9343(89)90522-6; HADLER SC, 1986, NEW ENGL J MED, V315, P209, DOI 10.1056/NEJM198607243150401; HOROWITZ MM, 1988, ANN INTERN MED, V108, P185, DOI 10.7326/0003-4819-108-2-185; JILG W, 1986, J HEPATOL, V3, P190, DOI 10.1016/S0168-8278(86)80025-3; MACKENZIE JS, 1976, J HYG-CAMBRIDGE, V77, P409, DOI 10.1017/S0022172400055790; MARGOLIS HS, 1991, SEMIN LIVER DIS, V11, P84, DOI 10.1055/s-2008-1040427; SHAW FE, 1989, VACCINE, V7, P425, DOI 10.1016/0264-410X(89)90157-6; STEVENS CE, 1987, JAMA-J AM MED ASSOC, V257, P2612, DOI 10.1001/jama.257.19.2612; WEBER DJ, 1985, JAMA-J AM MED ASSOC, V254, P3187, DOI 10.1001/jama.254.22.3187; WONG VCW, 1984, LANCET, V1, P921; 1991, MMWR MORB MORTAL WKL, V40, P1; 1991, JAMA-J AM MED ASSOC, V266, P1338; 1991, FED REGISTER, V56, P64004	15	156	166	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	1993	270	24					2931	2934		10.1001/jama.270.24.2931	http://dx.doi.org/10.1001/jama.270.24.2931			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM119	8254852				2022-12-28	WOS:A1993MM11900026
J	GULYAS, AI; MILES, R; SIK, A; TOTH, K; TAMAMAKI, N; FREUND, TF				GULYAS, AI; MILES, R; SIK, A; TOTH, K; TAMAMAKI, N; FREUND, TF			HIPPOCAMPAL PYRAMIDAL CELLS EXCITE INHIBITORY NEURONS THROUGH A SINGLE RELEASE SITE	NATURE			English	Article							MINIATURE SYNAPTIC CURRENTS; LONG-TERM POTENTIATION; PROTEIN PARVALBUMIN; RAT HIPPOCAMPUS; SLICES; CORTEX; IDENTIFICATION; TRANSMISSION; VARIABILITY; SYSTEM	MORPHOLOGICALLY a synapse consists of a presynaptic release site containing vesicles, a postsynaptic element with membrane specialization, and a synaptic cleft between them1. The number of release sites shapes the properties of synaptic transmission between neurons2-4. Although excitatory interactions between cortical neurons have been examined5-9, the number of release sites remains unknown. We have now recorded excitatory postsynaptic potentials evoked by single pyramidal cells in hippocampal interneurons and visualized both cells using biocytin injections. Light and electron microscopy showed that excitatory postsynaptic potentials were mediated by a single synapse. We also reconstructed the entire axon arborization of single pyramidal cells, filled in vivo, in sections counterstained for parvalbumin, which selectively marks basket and axo-axonic cells10,11. Single synaptic contacts between pyramidal cells and parvalbumin-containing neurons were dominant (>80%), providing evidence for high convergence and divergence in hippocampal networks12.	HUNGARIAN ACAD SCI,INST EXPTL MED,POB 67,H-1450 BUDAPEST,HUNGARY; INST PASTEUR,INSERM,U261,NEUROBIOL LAB,F-75264 PARIS 15,FRANCE; FUKUI MED SCH,DEPT ANAT,FUKUI 91011,JAPAN	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Fukui				Gulyas, Attila/0000-0003-4961-636X				BAIMBRIDGE KG, 1982, BRAIN RES, V239, P519, DOI 10.1016/0006-8993(82)90526-1; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BUSCH C, 1990, COLD SH Q B, V55, P69; BUZSAKI G, 1983, BRAIN RES REV, V6, P139, DOI 10.1016/0165-0173(83)90037-1; FREUND TF, 1985, J COMP NEUROL, V242, P275, DOI 10.1002/cne.902420209; HESTRIN S, 1992, NEURON, V9, P991, DOI 10.1016/0896-6273(92)90250-H; Heuser JE, 1977, HDB PHYSL, VI, P261; KAWAGUCHI Y, 1987, BRAIN RES, V416, P369, DOI 10.1016/0006-8993(87)90921-8; Korn H., 1987, SYNAPTIC FUNCTION, P57; KOSAKA T, 1987, BRAIN RES, V419, P119, DOI 10.1016/0006-8993(87)90575-0; LI XG, IN PRESS J COMP NEUR; LLINAS R, 1969, J NEUROPHYSIOL, V32, P847, DOI 10.1152/jn.1969.32.6.847; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; McClelland J. L., 1986, PARALLEL DISTRIBUTED, V2; MCNAUGHTON BL, 1987, TRENDS NEUROSCI, V10, P408, DOI 10.1016/0166-2236(87)90011-7; MILES R, 1990, J PHYSIOL-LONDON, V428, P61, DOI 10.1113/jphysiol.1990.sp018200; MILES R, 1986, J PHYSIOL-LONDON, V373, P397, DOI 10.1113/jphysiol.1986.sp016055; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; SAYER RJ, 1989, J NEUROSCI, V9, P840; SCHWARTZKROIN PA, 1978, BRAIN RES, V157, P1, DOI 10.1016/0006-8993(78)90991-5; SCHWARTZKROIN PA, 1993, BRAIN RES, V9, P991; SIK A, IN PRESS EUR J NEURO; SOMOGYI P, 1983, NEUROSCIENCE, V10, P261, DOI 10.1016/0306-4522(83)90133-1; STERN P, 1992, J PHYSIOL-LONDON, V449, P247, DOI 10.1113/jphysiol.1992.sp019085; STEVENS CF, 1993, NEURON S, V10, P55; TAMAMAKI N, 1984, BRAIN RES, V307, P336, DOI 10.1016/0006-8993(84)90489-X; Traub R.D., 1991, NEURONAL NETWORKS HI; WHITE EL, 1987, J COMP NEUROL, V262, P13, DOI 10.1002/cne.902620103	31	284	285	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 16	1993	366	6456					683	687		10.1038/366683a0	http://dx.doi.org/10.1038/366683a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM265	8259211				2022-12-28	WOS:A1993MM26500069
J	SERRANO, M; HANNON, GJ; BEACH, D				SERRANO, M; HANNON, GJ; BEACH, D			A NEW REGULATORY MOTIF IN CELL-CYCLE CONTROL CAUSING SPECIFIC-INHIBITION OF CYCLIN-D/CDK4	NATURE			English	Article							PROTEIN-KINASES	THE division cycle of eukaryotic cells is regulated by a family of protein kinases known as the cyclin-dependent kinases (CDKs)1,2. The sequential activation of individual members of this family and their consequent phosphorylation of critical substrates promotes orderly progression through the cell cycle3,4. The complexes formed by CDK4 and the D-type cyclins have been strongly implicated in the control of cell proliferation during the G1 phase3-6. CDK4 exists, in part, as a multi-protein complex with a D-type cyclin, proliferating cell nuclear antigen and a protein, p21 (refs 7-9). CDK4 associates separately with a protein of M(r) 16K, particularly in cells lacking a functional retinoblastoma protein9. Here we report the isolation of a human p16 complementary DNA and demonstrate that p16 binds to CDK4 and inhibits the catalytic activity of the CDK4/cyclin D enzymes. p16 seems to act in a regulatory feedback circuit with CDK4, D-type cyclins and retino-blastoma protein.	COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, POB 100, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute			Serrano, Manuel/H-2634-2015; Hannon, Gregory/AAB-3568-2019	Serrano, Manuel/0000-0001-7177-9312; 				CHEN XS, 1993, EUR J BIOCHEM, V214, P845, DOI 10.1111/j.1432-1033.1993.tb17988.x; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1988, ANTIBODIES LABORATOR; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; KATO J, 1993, GENE DEV, V7, P331; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LUKAS J, IN PRESS ONCOGENE; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SOLOMON M, 1993, J CURR OPIN CELL BIO, V5, P180; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHENG XF, 1993, CELL, V75, P155, DOI 10.1016/S0092-8674(05)80092-3; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	23	3369	3582	4	142	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1993	366	6456					704	707		10.1038/366704a0	http://dx.doi.org/10.1038/366704a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM265	8259215				2022-12-28	WOS:A1993MM26500075
J	BOUMPAS, DT; CHROUSOS, GP; WILDER, RL; CUPPS, TR; BALOW, JE				BOUMPAS, DT; CHROUSOS, GP; WILDER, RL; CUPPS, TR; BALOW, JE			GLUCOCORTICOID THERAPY FOR IMMUNE-MEDIATED DISEASES - BASIC AND CLINICAL CORRELATES	ANNALS OF INTERNAL MEDICINE			English	Article							RHEUMATOID-ARTHRITIS; INDUCED OSTEOPOROSIS; PULSE METHYLPREDNISOLONE; HUMAN-LYMPHOCYTES; NEGATIVE REGULATION; GENE-TRANSCRIPTION; ENDOTHELIAL-CELLS; MESSENGER-RNA; DNA-BINDING; C-JUN	Glucocorticoids are pleiotropic hormones that at pharmacologic doses prevent or suppress inflammation and other immunologically mediated processes. At the molecular level, glucocorticoids form complexes with specific receptors that migrate to the nucleus where they interact with selective regulatory sites within DNA; this results in positive and negative modulation of several genes involved in inflammatory and immune responses. At the cellular level, glucocorticoids inhibit the access of leukocytes to inflammatory sites; interfere with the functions of leukocytes, endothelial cells, and fibroblasts; and suppress the production and the effects of humoral factors involved in the inflammatory response. Clinically, several modes of glucocorticoid administration are used, depending on the disease process, the organ involved, and the extent of involvement. High doses of daily glucocorticoids are usually required in patients with severe diseases involving major organs, whereas alternate-day regimens may be used in patients with less aggressive diseases. Intravenous glucocorticoids (pulse therapy) are frequently used to initiate therapy in patients with rapidly progressive, immunologically mediated diseases. The benefits of glucocorticoid therapy can easily be offset by severe side effects; even with the greatest care, side effects may occur. Moreover, for certain complications (for example, infection diathesis, peptic ulcer, osteoporosis, avascular necrosis, and atherosclerosis), other drug toxicities and pathogenic factors overlap with glucocorticoid effects. Minimizing the incidence and severity of glucocorticoid-related side effects requires carefully decreasing the dose; using adjunctive disease-modifying immunosuppressive and anti-inflammatory agents; and taking general preventive measures.			BOUMPAS, DT (corresponding author), NIDDKD, KIDNEY DIS SECT, BLDG 10, ROOM 3N-112, BETHESDA, MD 20892 USA.							ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502; AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ALMAWI WY, 1991, J IMMUNOL, V146, P3523; ARYA SK, 1984, J IMMUNOL, V133, P273; AUSTIN HA, 1992, ANN INTERN MED, V116, P672, DOI 10.7326/0003-4819-116-8-672; AXELROD L, 1976, MEDICINE, V55, P39, DOI 10.1097/00005792-197601000-00003; BAILEY JM, 1991, BIOFACTORS, V3, P97; BARTON GJ, 1991, EUR J BIOCHEM, V198, P749, DOI 10.1111/j.1432-1033.1991.tb16076.x; Baxter J D, 1990, Adv Intern Med, V35, P173; Baxter J.D., 1979, GLUCOCORTICOID HORMO; BAXTER JD, 1992, HOSP PRACT, V27, P111; BOGGARAM V, 1991, MOL ENDOCRINOL, V5, P414, DOI 10.1210/mend-5-3-414; BOUMPAS DT, 1992, LANCET, V340, P741, DOI 10.1016/0140-6736(92)92292-N; BOUMPAS DT, 1991, J CLIN INVEST, V87, P1739, DOI 10.1172/JCI115192; BOUMPAS DT, 1991, CLIN EXP RHEUMATOL, V9, P413; BUTLER WT, 1973, J CLIN INVEST, V52, P2629, DOI 10.1172/JCI107455; CRONSTEIN BN, 1992, P NATL ACAD SCI USA, V89, P9991, DOI 10.1073/pnas.89.21.9991; CUPPS TR, 1985, J CLIN INVEST, V75, P754, DOI 10.1172/JCI111757; DALE DC, 1973, MED CLIN N AM, V57, P1277, DOI 10.1016/S0025-7125(16)32228-3; DALE DC, 1974, NEW ENGL J MED, V291, P1154, DOI 10.1056/NEJM197411282912203; DAVID DS, 1970, J CHRON DIS, V22, P637, DOI 10.1016/0021-9681(70)90078-0; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DROUIN J, 1992, MOL ENDOCRINOL, V6, P1299, DOI 10.1210/me.6.8.1299; ETTINGER WH, 1988, METABOLISM, V37, P1055, DOI 10.1016/0026-0495(88)90067-4; FAUCI AS, 1976, ANN INTERN MED, V84, P304, DOI 10.7326/0003-4819-84-3-304; FAUCI AS, 1974, J CLIN INVEST, V53, P240, DOI 10.1172/JCI107544; FAUCI AS, 1988, CURRENT THERAPY ALLE, V3, P149; GALILI N, 1980, CELL IMMUNOL, V50, P440, DOI 10.1016/0008-8749(80)90297-X; GOULDING NJ, 1992, IMMUNOL TODAY, V13, P295, DOI 10.1016/0167-5699(92)90040-E; GRAY RES, 1991, ARTHRITIS RHEUM-US, V34, P287, DOI 10.1002/art.1780340306; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KERN JA, 1988, J CLIN INVEST, V81, P237, DOI 10.1172/JCI113301; KERR DS, 1992, P NATL ACAD SCI USA, V89, P8527, DOI 10.1073/pnas.89.18.8527; KIMBERLY R P, 1992, Current Opinion in Rheumatology, V4, P325, DOI 10.1097/00002281-199206000-00007; KIMBERLY RP, 1988, RHEUM DIS CLIN N AM, V14, P203; KIMBERLY RP, 1982, CLIN RHEUM DIS, V8, P261; KLEIN A, 1990, J RHEUMATOL, V17, P30; LEWIS GP, 1971, LANCET, V2, P778; LIEBLING MR, 1981, ANN INTERN MED, V94, P21, DOI 10.7326/0003-4819-94-1-21; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; MANKIN HJ, 1992, NEW ENGL J MED, V326, P1473; MANOLIOS N, 1991, SEMIN ARTHRITIS RHEU, V20, P339, DOI 10.1016/0049-0172(91)90010-W; MASFERRER JL, 1992, P NATL ACAD SCI USA, V89, P3917, DOI 10.1073/pnas.89.9.3917; MEIKLE AW, 1977, AM J MED, V63, P200, DOI 10.1016/0002-9343(77)90233-9; MELBY JC, 1974, ANN INTERN MED, V81, P505, DOI 10.7326/0003-4819-81-4-505; MEUNIER PJ, 1993, NEW ENGL J MED, V328, P1781, DOI 10.1056/NEJM199306173282411; MUKHERJEE AB, 1992, DNA CELL BIOL, V11, P233, DOI 10.1089/dna.1992.11.233; NAPOLITANO LM, 1988, INT ANESTHESIOL CLIN, V26, P226, DOI 10.1097/00004311-198802630-00009; NASHEL DJ, 1986, AM J MED, V80, P925, DOI 10.1016/0002-9343(86)90639-X; NEUSTADT DH, 1988, DIAGNOSIS MANAGEMENT, P805; NIETO MA, 1992, CLIN EXP IMMUNOL, V88, P341; PALIOGIANNI F, 1993, J IMMUNOL, V151, P4081; PALIOGIANNI F, 1993, J CLIN INVEST, V91, P1481, DOI 10.1172/JCI116353; PALIOGIANNI F, 1993, ARTHRITIS RHEUM, V36, pS113; PETRI M, 1992, AM J MED, V93, P513, DOI 10.1016/0002-9343(92)90578-Y; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PIPER JM, 1991, ANN INTERN MED, V114, P735, DOI 10.7326/0003-4819-114-9-735; PODGORSKI MR, 1992, J RHEUMATOL, V19, P1668; REID IR, 1988, LANCET, V1, P143; REID IR, 1990, ARCH INTERN MED, V150, P2545, DOI 10.1001/archinte.150.12.2545; REID IR, 1993, NEW ENGL J MED, V328, P460, DOI 10.1056/NEJM199302183280702; RIGGS BL, 1992, NEW ENGL J MED, V327, P620; RINGE JD, 1987, EUR J CLIN PHARMACOL, V33, P35, DOI 10.1007/BF00610377; ROSE JQ, 1981, J PHARMACOKINET BIOP, V9, P389, DOI 10.1007/BF01060885; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SAMBROOK P, 1993, NEW ENGL J MED, V328, P1747, DOI 10.1056/NEJM199306173282404; SANO H, 1992, J CLIN INVEST, V89, P97, DOI 10.1172/JCI115591; SCHLAGHECKE R, 1992, NEW ENGL J MED, V326, P226, DOI 10.1056/NEJM199201233260403; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCUDELETTI M, 1990, ANN NY ACAD SCI, V595, P368, DOI 10.1111/j.1749-6632.1990.tb34310.x; SHARP PA, 1991, NATURE, V351, P16, DOI 10.1038/351016d0; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SILVERMAN SL, 1992, CALCIFIED TISSUE INT, V50, P101, DOI 10.1007/BF00298781; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; STERNBERG EM, 1992, ANN INTERN MED, V117, P854, DOI 10.7326/0003-4819-117-10-854; STERNBERG EM, 1993, ARTHRITIS ALLIED CON, P665; STRECK WF, 1979, AM J MED, V66, P910, DOI 10.1016/0002-9343(79)90444-3; STROM TB, 1993, DIS KIDNEY, P2879; STUCK AE, 1989, REV INFECT DIS, V11, P954; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; THORN GW, 1966, NEW ENGL J MED, V274, P775, DOI 10.1056/NEJM196604072741406; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; VACCA A, 1992, J EXP MED, V175, P637, DOI 10.1084/jem.175.3.637; VESELY DL, 1980, J PHARMACOL EXP THER, V214, P561; VILLAREAL DT, 1991, CALCIFIED TISSUE INT, V49, P141, DOI 10.1007/BF02565138; WILDER R L, 1990, Current Opinion in Rheumatology, V2, P436; WU CY, 1991, EUR J IMMUNOL, V21, P2645, DOI 10.1002/eji.1830211053; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2; ZIZIC T M, 1991, Current Opinion in Rheumatology, V3, P481, DOI 10.1097/00002281-199106000-00023	97	588	612	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1993	119	12					1198	1208		10.7326/0003-4819-119-12-199312150-00007	http://dx.doi.org/10.7326/0003-4819-119-12-199312150-00007			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM121	8239251				2022-12-28	WOS:A1993MM12100007
J	COUTAVAS, E; REN, MD; OPPENHEIM, JD; DEUSTACHIO, P; RUSH, MG				COUTAVAS, E; REN, MD; OPPENHEIM, JD; DEUSTACHIO, P; RUSH, MG			CHARACTERIZATION OF PROTEINS THAT INTERACT WITH THE CELL-CYCLE REGULATORY PROTEIN RAN/TC4	NATURE			English	Article							RCC1; POLYPEPTIDE; EXPRESSION; MITOSIS; GTPASE; GENES	THE human Ras-related nuclear protein Ran/TC4 (refs 1-4) is the prototype of a well conserved family of GTPases that can regulate both cell-cycle progression5-8 and messenger RNA transport9. Ran has been proposed to undergo tightly controlled cycles of GTP binding and hydrolysis, to operate as a GTPase switch10,11 whose GTP- and GDP-bound forms interact differentially with regulators and effectors. One known regulator, the protein RCC1 (refs 12, 13), interacts with Ran to catalyse guanine nucleotide exchange, and both RCC1 and Ran are components of an intrinsic checkpoint control that prevents the premature initiation of mitosis. To test and extend the GTPase-switch model, we searched for a Ran-specific GTPase-activating protein (GAP), and for putative effectors (proteins that interact specifically with Ran/TC4-GTP). We report here the identification of a Ran GAP and its use to characterize the GTP-hydrolysing properties of mutant Ran proteins, and the identification and cloning of a binding protein specific for Ran/TC4-GTP.	NYU MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016; NYU MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016; NYU MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016; NYU MED CTR,KAPLAN CTR,NEW YORK,NY 10016	New York University; New York University; New York University; New York University				Coutavas, Elias/0000-0003-4904-0081; Oppenheim, Joel/0000-0002-6920-5624; D'Eustachio, Peter/0000-0002-5494-626X				AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; Barbacid M., 1987, REV BIOCH, V56, P779; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1993, 13 WASH INT S; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRESSAN A, 1991, GENE, V103, P201, DOI 10.1016/0378-1119(91)90274-F; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; KADOWAKI T, 1992, P NATL ACAD SCI USA, V89, P2312, DOI 10.1073/pnas.89.6.2312; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MATSUMOTO T, 1993, MOL BIOL CELL, V4, P337, DOI 10.1091/mbc.4.3.337; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MCCORMICK F, 1992, PHILOS T ROY SOC B, V336, P43, DOI 10.1098/rstb.1992.0042; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; ROBERGE M, 1992, TRENDS CELL BIOL, V2, P177; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; UCHIDA S, 1990, MOL CELL BIOL, V10, P577, DOI 10.1128/MCB.10.2.577	23	246	250	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 9	1993	366	6455					585	587		10.1038/366585a0	http://dx.doi.org/10.1038/366585a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	8255297				2022-12-28	WOS:A1993ML21800076
J	MOLINA, CA; FOULKES, NS; LALLI, E; SASSONECORSI, P				MOLINA, CA; FOULKES, NS; LALLI, E; SASSONECORSI, P			INDUCIBILITY AND NEGATIVE AUTOREGULATION OF CREM - AN ALTERNATIVE PROMOTER DIRECTS THE EXPRESSION OF ICER, AN EARLY RESPONSE REPRESSOR	CELL			English	Article							CORTICOTROPIN-RELEASING FACTOR; DEPENDENT PROTEIN-KINASE; DNA-BINDING PROTEINS; NUCLEAR FACTOR CREB; CYCLIC-AMP; LEUCINE-ZIPPER; TRANSCRIPTION FACTORS; C-FOS; ELEMENT; GENE	cAMP-responsive element modulator (CREM) expression is tissue specific and developmentally regulated. Here we report that CREM is unique within the family of cAMP-responsive promoter element (CRE)-binding factors since it is inducible by activation of the cAMP signaling pathway. The kinetic of expression is characteristic of an early response gene. The induction is transient and cell specific, does not involve increased transcript stability, and does not require protein synthesis. Significantly, the subsequent decline in CREM expression requires de novo protein synthesis. The induced transcript encodes a novel repressor, inducible cAMP early repressor (ICER), and is generated from an alternative intronic promoter. A cluster of four CREs in this promoter directs cAMP inducibility. ICER binds to these elements and thereby represses the activity of its own promoter, thus constituting a negative autoregulatory loop.			MOLINA, CA (corresponding author), FAC MED STRASBOURG,INST CHIM BIOL,GENET MOLEC EUCARYOTES LAB,CNRS,INSERM,U184,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE.		Foulkes, Nicholas S/K-7003-2013; Lalli, Enzo/F-7052-2013	Foulkes, Nicholas S/0000-0002-1794-9891; Lalli, Enzo/0000-0002-0584-5681				AIBA H, 1983, CELL, V32, P141, DOI 10.1016/0092-8674(83)90504-4; AKERBLOM IE, 1990, MOL ENDOCRINOL, V4, P589, DOI 10.1210/mend-4-4-589; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BORRELLI E, 1992, Critical Reviews in Oncogenesis, V3, P321; BRAVO R, 1988, COLD SPRING HARB SYM, V53, P901, DOI 10.1101/SQB.1988.053.01.103; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; DELMAS V, 1993, MOL ENDOCRINOL, V10, P1502; DRUST DS, 1991, MOL ENDOCRINOL, V5, P1541, DOI 10.1210/mend-5-10-1541; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FLINT KJ, 1991, ONCOGENE, V6, P2019; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Maniatis T, 1989, DECONTAMINATION DILU; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MELLSTROM B, 1993, NEURON, V10, P655, DOI 10.1016/0896-6273(93)90167-P; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MYERS RM, 1981, CELL, V25, P373, DOI 10.1016/0092-8674(81)90056-8; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P893, DOI 10.1101/SQB.1988.053.01.102; NATT E, 1986, NUCLEIC ACIDS RES, V14, P7128; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; RIVIER C, 1983, ENDOCRINOLOGY, V113, P939, DOI 10.1210/endo-113-3-939; RIVIER J, 1984, SCIENCE, V224, P889, DOI 10.1126/science.6326264; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; SASSONECORSI P, 1990, PCR PROTOCOLS GUIDE, P84; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TEGTMEYER P, 1975, J VIROL, V16, P168, DOI 10.1128/JVI.16.1.168-178.1975; Treisman R, 1990, Semin Cancer Biol, V1, P47; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WILLIAMS JG, 1987, NUCL ACID HYBRIDISAT, P139; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	59	514	519	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 3	1993	75	5					875	886		10.1016/0092-8674(93)90532-U	http://dx.doi.org/10.1016/0092-8674(93)90532-U			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	8252624	Bronze			2022-12-28	WOS:A1993MK96600008
J	MITTLEMAN, MA; MACLURE, M; TOFLER, GH; SHERWOOD, JB; GOLDBERG, RJ; MULLER, JE				MITTLEMAN, MA; MACLURE, M; TOFLER, GH; SHERWOOD, JB; GOLDBERG, RJ; MULLER, JE			TRIGGERING OF ACUTE MYOCARDIAL-INFARCTION BY HEAVY PHYSICAL EXERTION - PROTECTION AGAINST TRIGGERING BY REGULAR EXERTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; ALL-CAUSE MORTALITY; COLLEGE ALUMNI; CARDIOVASCULAR-DISEASE; FIBRINOLYTIC-ACTIVITY; HEALTH-PROFESSIONALS; CIRCADIAN VARIATION; RISK; EXERCISE; ONSET	Background. Despite anecdotal evidence suggesting that heavy physical exertion can trigger the onset of acute myocardial infarction, there have been no controlled studies of the risk of myocardial infarction during and after heavy exertion, the length of time between heavy exertion and the onset of symptoms (induction time), and whether the risk can be modified by regular physical exertion. To address these questions, we collected data from patients with confirmed myocardial infarction on their activities one hour before the onset of myocardial infarction and during control periods. Methods. Interviews with 1228 patients conducted an average of four days after myocardial infarction provided data on their usual annual frequency of physical activity and the time, type, and intensity of physical exertion in the 26 hours before the onset of myocardial infarction. We compared the observed frequency of heavy exertion (6 or more metabolic equivalents) with the expected values using two types of self-matched analyses based on a new case-crossover study design. The low frequency of heavy exertion during the control periods was validated by data from a population-based control group of 218 subjects. Results. Of the patients, 4.4 percent reported heavy exertion within one hour before the onset of myocardial infarction. The estimated relative risk of myocardial infarction in the hour after heavy physical exertion, as compared with less strenuous physical exertion or none, was 5.9 (95 percent confidence interval, 4.6 to 7.7). Among people who usually exercised less than one, one to two, three to four, or five or more times per week, the respective relative risks were 107 (95 percent confidence interval, 67 to 171), 19.4 (9.9 to 38.1), 8.6 (3.6 to 20.5), and 2.4 (1.5 to 3.7). Thus, increasing levels of habitual physical activity were associated with progressively lower relative risks. The induction time from heavy exertion to the onset of myocardial infarction was less than one hour, and symptoms usually began during the activity. Conclusions. Heavy physical exertion can trigger the onset of acute myocardial infarction, particularly in people who are habitually sedentary. Improved understanding of the mechanisms by which heavy physical exertion triggers the onset of myocardial infarction and the manner in which regular exertion protects against it would facilitate the design of new preventive approaches.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; UNIV MASSACHUSETTS,SCH MED,DEPT MED,WORCESTER,MA 01605	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; University of Massachusetts System; University of Massachusetts Worcester	MITTLEMAN, MA (corresponding author), DEACONESS HOSP,INST PREVENT CARDIOVASC DIS,DIV CARDIOVASC,1 AUTUMN ST,5TH FL,BOSTON,MA 02215, USA.			Mittleman, Murray/0000-0001-9788-7274	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041016] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41016] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; Astrand P.O., 1986, TXB WORK PHYSL PHYSL; BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; COBB LA, 1986, J AM COLL CARDIOL, V7, P215, DOI 10.1016/S0735-1097(86)80284-4; CURFMAN GD, 1993, NEW ENGL J MED, V328, P574, DOI 10.1056/NEJM199302253280810; DAVIES MJ, 1985, BRIT HEART J, V53, P363; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; FLETCHER GF, 1992, CIRCULATION, V86, P340, DOI 10.1161/01.CIR.86.1.340; GREENLAND S, 1988, AM J EPIDEMIOL, V128, P1185, DOI 10.1093/oxfordjournals.aje.a115073; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HJALMARSON A, 1989, CIRCULATION, V80, P267, DOI 10.1161/01.CIR.80.2.267; JERN C, 1989, THROMB HAEMOSTASIS, V62, P767; KHANNA PK, 1975, BRIT HEART J, V37, P1273; KOHL HW, 1992, EPIDEMIOL REV, V14, P37, DOI 10.1093/oxfordjournals.epirev.a036091; LEE IM, 1992, AM J EPIDEMIOL, V135, P915, DOI 10.1093/oxfordjournals.aje.a116387; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; LEVINE SP, 1985, CIRCULATION, V71, P1129, DOI 10.1161/01.CIR.71.6.1129; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; MULLER JE, 1989, CIRCULATION, V79, P733, DOI 10.1161/01.CIR.79.4.733; MURRAY PM, 1993, ARCH INTERN MED, V153, P833, DOI 10.1001/archinte.153.7.833; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; ROSING DR, 1970, CIRC RES, V27, P171, DOI 10.1161/01.RES.27.2.171; Rothman K, 1986, MODERN EPIDEMIOLOGY; ROTHMAN KJ, 1981, AM J EPIDEMIOL, V114, P253, DOI 10.1093/oxfordjournals.aje.a113189; SALLIS JF, 1985, AM J EPIDEMIOL, V121, P91, DOI 10.1093/oxfordjournals.aje.a113987; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; SISCOVICK DS, 1984, NEW ENGL J MED, V311, P874, DOI 10.1056/NEJM198410043111402; SUMIYOSHI T, 1986, JPN CIRC J, V50, P164, DOI 10.1253/jcj.50.164; TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9; THOMPSON PD, 1982, JAMA-J AM MED ASSOC, V247, P2535, DOI 10.1001/jama.247.18.2535; TOFLER GH, 1990, AM J CARDIOL, V66, P22, DOI 10.1016/0002-9149(90)90729-K; TOFLER GH, 1992, J AM COLL CARDIOL, V20, P1049, DOI 10.1016/0735-1097(92)90356-R; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1019, DOI 10.1093/oxfordjournals.aje.a116396; WILLICH SN, 1989, CIRCULATION, V80, P853, DOI 10.1161/01.CIR.80.4.853; WILLICH SN, 1993, NEW ENGL J MED, V329, P1684, DOI 10.1056/NEJM199312023292302; 1992, HEART STROKE FACTS	42	1042	1060	1	29	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 2	1993	329	23					1677	1683		10.1056/NEJM199312023292301	http://dx.doi.org/10.1056/NEJM199312023292301			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ707	8232456				2022-12-28	WOS:A1993MJ70700001
J	LARSSON, K; OHLSEN, P; LARSSON, L; MALMBERG, P; RYDSTROM, PO; ULRIKSEN, H				LARSSON, K; OHLSEN, P; LARSSON, L; MALMBERG, P; RYDSTROM, PO; ULRIKSEN, H			HIGH PREVALENCE OF ASTHMA IN CROSS-COUNTRY SKIERS	BRITISH MEDICAL JOURNAL			English	Article							BRONCHIAL HYPERRESPONSIVENESS; SKELETAL-MUSCLE; COLD AIR; TERBUTALINE; SALBUTAMOL; EXERCISE; BRONCHODILATOR; RESPONSIVENESS; AGONIST; TESTS	Objectives-To study the prevalence of asthma (asthma symptoms and bronchial hyperresponsiveness) in Swedish cross country skiers compared with non-skiers and monitor changes in symptoms and bronchial hyperresponsiveness during the year. Design-Cross sectional study during the winter ski season and in the summer. Setting-Six ski clubs for elite skiers (total 47) in two different areas of Sweden. Subjects-42 elite cross country skiers and 29 non-skiing referents. Main outcome measures-Bronchial responsiveness, asthma symptoms, and lung function. Results-Bronchial responsiveness was significantly greater and asthma symptoms more prevalent in the skiers than in the referents. There was no difference in bronchial responsiveness within either group between winter and summer. 15 of the 42 skiers used antiasthmatic drugs regularly and 23 had a combination of asthma symptoms and hyperresponsive airways or physician diagnosed asthma, or both. Altogether 33 skiers had symptoms of asthma or bronchial hyperresponsiveness. One of the referents had symptoms of asthma and bronchial hyperresponsiveness, and none used antiasthmatic drugs regularly. Conclusions-Asthma, asthma-like symptoms, and bronchial hyperresponsiveness are much more common in cross country skiers than in the general population and non-skiers. Strenuous exercise at low temperatures entailing breathing large volumes of cold air is the most probable explanation of persistent asthma in skiers.	SWEDISH SKI ASSOC,CTR ATHLET,STOCKHOLM,SWEDEN; HOSP OSTERSUND,DEPT INTERNAL MED,OSTERSUND,SWEDEN		LARSSON, K (corresponding author), NATL INST OCCUPAT HLTH,IFL,DIV RESP,S-17184 SOLNA,SWEDEN.							AMARIV I, 1989, AM REV RESPIR DIS, V140, P1416; BEERMANN DH, 1987, J ANIM SCI, V65, P1514, DOI 10.2527/jas1987.6561514x; CHOO JJ, 1992, AM J PHYSIOL, V263, pE50, DOI 10.1152/ajpendo.1992.263.1.E50; DOSMAN JA, 1991, AM REV RESPIR DIS, V144, P45, DOI 10.1164/ajrccm/144.1.45; DROBNIC F, 1992, EUR RESPIR J S15, V5, pS456; FREEMAN W, 1989, THORAX, V44, P942, DOI 10.1136/thx.44.11.942; GOMES I, 1992, EUR RESPIR J S15, V5, pS455; HEDENSTROM H, 1985, B EUR PHYSIOPATH RES, V21, P551; HENDENSTROM H, 1986, UPPSALA MED SCI, V91, P299; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LARSSON K, 1992, CHEST, V101, P953, DOI 10.1378/chest.101.4.953; LARSSON K, 1987, RESPIRATION, V51, P214, DOI 10.1159/000195204; LARSSON L, 1993, EUR RESPIR J, V6, P198; LARSSON L, IN PRESS THORAX; LARSSON L, IN PRESS SCANDINAVIA; LITMANEN H, 1992, EUR RESPIR J S15, V5, pS445; LUNDBACK B, 1991, EUR RESPIR J, V4, P257; MALMBERG P, 1991, EUR RESPIR J, V4, P890; MARTINEAU L, 1992, CLIN SCI, V83, P615, DOI 10.1042/cs0830615; MARTINEZ JA, 1991, HORM METAB RES, V23, P590, DOI 10.1055/s-2007-1003762; MCKENZIE DC, 1993, MED SCI SPORTS EXERC, V15, P520; Morton AR, 1992, CLIN J SPORT MED, V2, P93; SIGNORILE JF, 1992, MED SCI SPORT EXER, V24, P638; STRAUSS RH, 1978, J CLIN INVEST, V61, P433, DOI 10.1172/JCI108954; STRAUSS RH, 1977, NEW ENGL J MED, V297, P743, DOI 10.1056/NEJM197710062971402; TOREN K, IN PRESS CHEST; VANSCHAYCK CP, 1990, J ALLERGY CLIN IMMUN, V86, P793, DOI 10.1016/S0091-6749(05)80185-X; VATHENEN AS, 1988, LANCET, V1, P554; VOY RO, 1984, MED SCI SPORTS EXERC, V18, P328; WEILER JM, 1986, CHEST, V90, P23, DOI 10.1378/chest.90.1.23	31	240	243	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1993	307	6915					1326	1329		10.1136/bmj.307.6915.1326	http://dx.doi.org/10.1136/bmj.307.6915.1326			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH556	8257888	Green Published, Bronze			2022-12-28	WOS:A1993MH55600022
J	ODDONE, EZ; COWPER, P; HAMILTON, JD; MATCHAR, DB; HARTIGAN, P; SAMSA, G; SIMBERKOFF, M; FEUSSNER, JR				ODDONE, EZ; COWPER, P; HAMILTON, JD; MATCHAR, DB; HARTIGAN, P; SAMSA, G; SIMBERKOFF, M; FEUSSNER, JR			COST-EFFECTIVENESS ANALYSIS OF EARLY ZIDOVUDINE TREATMENT OF HIV-INFECTED PATIENTS	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; AIDS; TRANSPLANTATION; EFFICACY; LEUKEMIA; THERAPY; AZT	Objective-To compare cost effectiveness of early and later treatment with zidovudine for patients infected with HIV. Design-Markov chain analysis of cost effectiveness based on results of use of health care and efficacy from a trial of zidovudine treatment. Setting-Seven Veterans Affairs medical centres in the United States. Subjects-338 patients with symptomatic HIV infection and a lymphocyte count of 200 x 10(6) to 500 x 10(6) CD4 cells/l. Interventions-Zidovudine 1500 mg/day started either at recruitment to the trial or when CD4 cell count fell below 200 x 10(6)/l. Main outcome measures-Health care costs and rates of disease progression between six clinical states of HIV infection. Results-Patients given early treatment with zidovudine remained without AIDS for an extra two months at a cost of $10 750 for each extra month without AIDS (at 1991 costs). Cost effectiveness ratio was most sensitive to the cost of zidovudine and to the quality of life of patients receiving early treatment. At treatment of 500 mg/day the cost effectiveness ratio for early treatment was $5432 for each extra month without AIDS. Patients given early treatment experienced more side effects, and if their quality of life was devalued by 8% compared with patients treated later the two treatments were equivalent in terms of quality adjusted months of life without AIDS. Conclusions-Early treatment with zidovudine is expensive and is very sensitive to the cost of zidovudine and to potential reductions in quality of life of patients who experience side effects. Doctors should reconsider early treatment with zidovudine for patients who experience side effects that substantially compromise their quality of life.	VET AFFAIRS MED CTR,ACQUIRED IMMUNODEFICIENCY SYNDROME & HIV INFECT RES CTR,DURHAM,NC; VET AFFAIRS COOPERAT STUDIES,W HAVEN,CT 06516; VET AFFAIRS MED CTR,DIV INFECT DIS,NEW YORK,NY 10032; DUKE UNIV,MED CTR,DEPT GEN INTERNAL MED,DURHAM,NC 27710; DUKE UNIV,CTR HLTH POLICY RES & EDUC,DURHAM,NC 27706	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; Duke University	ODDONE, EZ (corresponding author), VET AFFAIRS MED CTR,CTR HLTH SERV RES PRIMARY CARE,DURHAM,NC 27705, USA.		Matchar, David/M-3951-2019	Matchar, David/0000-0003-3020-2108				ABOULKER JP, 1993, LANCET, V341, P890; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; DRUMMOND MF, 1988, METHODS EC EVALATION, P81; EVANS RW, 1986, SURG CLIN N AM, V66, P603; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GARNER TI, 1987, MED CARE, V25, P25, DOI 10.1097/00005650-198701000-00004; GELBER RD, 1992, ANN INTERN MED, V116, P961, DOI 10.7326/0003-4819-116-12-961; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; KOCH MA, 1992, ARCH INTERN MED, V152, P2286, DOI 10.1001/archinte.152.11.2286; LUBECK DP, 1993, MED CARE, V31, P269, DOI 10.1097/00005650-199303000-00008; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; SCHULMAN KA, 1991, ANN INTERN MED, V114, P798, DOI 10.7326/0003-4819-114-9-798; SWANSON CE, 1990, AIDS, V4, P749, DOI 10.1097/00002030-199008000-00006; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WEEKS JC, 1991, NEW ENGL J MED, V325, P81, DOI 10.1056/NEJM199107113250202; WELCH HG, 1989, NEW ENGL J MED, V321, P807, DOI 10.1056/NEJM198909213211207; 1992, STATISTICAL ABSTRACT, P469; IN PRESS JAMA; 1991, RCS100141 VET AFF ME	22	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1993	307	6915					1322	1325		10.1136/bmj.307.6915.1322	http://dx.doi.org/10.1136/bmj.307.6915.1322			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH556	8257887	Green Published, Bronze			2022-12-28	WOS:A1993MH55600021
J	PORTER, JA; YU, MJ; DOBERSTEIN, SK; POLLARD, TD; MONTELL, C				PORTER, JA; YU, MJ; DOBERSTEIN, SK; POLLARD, TD; MONTELL, C			DEPENDENCE OF CALMODULIN LOCALIZATION IN THE RETINA ON THE NINAC UNCONVENTIONAL MYOSIN	SCIENCE			English	Article							ROD OUTER SEGMENTS; CA2+-DEPENDENT REGULATOR PROTEIN; INTEGRAL MEMBRANE-PROTEIN; INTESTINAL BRUSH-BORDER; BINDING-PROTEIN; DROSOPHILA-MELANOGASTER; GUANYLATE-CYCLASE; SACCHAROMYCES-CEREVISIAE; DICTYOSTELIUM-DISCOIDEUM; PHOTORECEPTOR CELLS	Calmodulin is a highly conserved regulatory protein found in all eukaryotic organisms which mediates a variety of calcium ion-dependent signaling pathways. In the Drosophila retina, calmodulin was concentrated in the photoreceptor cell microvillar structure, the rhabdomere, and was found in lower amounts in the sub-rhabdomeral cytoplasm. This calmodulin localization was dependent on the NINAC (neither inactivation nor afterpotential C) unconventional myosins. Mutant flies lacking the rhabdomere-specific p174 NINAC protein did not concentrate calmodulin in the rhabdomere, whereas flies lacking the sub-rhabdomeral p132 isoform had np detectable cytoplasmic calmodulin. Furthermore, a defect in vision resulted when calmodulin was not concentrated in the rhabdomeres, suggesting a role for calmodulin in the regulation of fly phototransduction. A general function of unconventional myosins may be to control the subcellular distribution of calmodulin.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University	PORTER, JA (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205, USA.		Montell, Craig/AAH-3357-2021	Montell, Craig/0000-0001-5637-1482	NATIONAL EYE INSTITUTE [R01EY008117] Funding Source: NIH RePORTER; NEI NIH HHS [EY08117] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ARIKAWA K, 1990, J CELL BIOL, V110, P1993, DOI 10.1083/jcb.110.6.1993; Blest A., 1988, ADV INSECT PHYSL, P1, DOI 10.1016/s0065-2806(08)60021-1; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BROCKERHOFF SE, 1992, J CELL BIOL, V118, P619, DOI 10.1083/jcb.118.3.619; BUCHNER E, 1991, J NEUROGENET, V7, P153, DOI 10.3109/01677069109167432; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; COLLINS JH, 1984, J BIOL CHEM, V259, P4128; DECOUET HG, 1989, CELL TISSUE RES, V244, P315; DEDMAN JR, 1977, J BIOL CHEM, V252, P8415; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; GLENNEY JR, 1984, CELL, V37, P743, DOI 10.1016/0092-8674(84)90410-0; GLENNEY JR, 1980, P NATL ACAD SCI-BIOL, V77, P6458, DOI 10.1073/pnas.77.11.6458; GLENNEY JR, 1980, J BIOL CHEM, V255, P551; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; HARDIE RC, 1983, PROGR SENSORY PHYSL, V5, P1; HEIZMANN CW, 1992, TRENDS NEUROSCI, V15, P259, DOI 10.1016/0166-2236(92)90067-I; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; HULEN D, 1991, CELL MOTIL CYTOSKEL, V18, P113, DOI 10.1002/cm.970180206; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KLEE CB, 1977, BIOCHEMISTRY-US, V16, P1017, DOI 10.1021/bi00624a033; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOHNKEN RE, 1981, J BIOL CHEM, V256, P2517; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; MATSUMOTO H, 1982, SCIENCE, V217, P839, DOI 10.1126/science.7100927; MATSUMOTO H, 1987, P NATL ACAD SCI USA, V84, P985, DOI 10.1073/pnas.84.4.985; MINKE B, 1992, NEUROMETHODS, P517; MISMER D, 1987, GENETICS, V116, P565; MONTELL C, 1987, J NEUROSCI, V7, P1558; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; NAGAO S, 1987, BIOCHEMISTRY-US, V26, P1659, DOI 10.1021/bi00380a026; NAGY K, 1991, Q REV BIOPHYS, V24, P165, DOI 10.1017/S0033583500003401; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; PORTER JA, 1992, J CELL BIOL, V116, P683, DOI 10.1083/jcb.116.3.683; PORTER JA, 1993, J CELL BIOL, V122, P601, DOI 10.1083/jcb.122.3.601; PORTER JW, UNPUB; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SEAMON KB, 1980, BIOCHEMISTRY-US, V19, P207, DOI 10.1021/bi00542a031; SMITH DP, 1991, ANNU REV CELL BIOL, V7, P161; SMITH VL, 1987, J MOL BIOL, V196, P471, DOI 10.1016/0022-2836(87)90025-8; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STEELE F, 1990, NEURON, V4, P883, DOI 10.1016/0896-6273(90)90141-2; STEELE FR, 1992, CELL, V69, P669, DOI 10.1016/0092-8674(92)90230-A; SUN GH, 1992, PROTOPLASMA, V166, P110, DOI 10.1007/BF01320150; SWANLJUNGCOLLINS H, 1992, J BIOL CHEM, V267, P3445; VANELDIK LJ, 1981, J BIOL CHEM, V256, P4205; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WOLFF DJ, 1977, J BIOL CHEM, V252, P4108; WONG F, 1989, NEURON, V3, P81, DOI 10.1016/0896-6273(89)90117-7; XIA ZG, 1993, J NEUROCHEM, V60, P305, DOI 10.1111/j.1471-4159.1993.tb05852.x; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; YAMANAKA MK, 1987, NUCLEIC ACIDS RES, V15, P3335, DOI 10.1093/nar/15.8.3335; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; ZHU QL, 1992, J CELL BIOL, V118, P347, DOI 10.1083/jcb.118.2.347; [No title captured]	62	124	125	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1038	1042		10.1126/science.8235618	http://dx.doi.org/10.1126/science.8235618			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	8235618				2022-12-28	WOS:A1993MG18700030
J	MULLER, M; BRISCOE, J; LAXTON, C; GUSCHIN, D; ZIEMIECKI, A; SILVENNOINEN, O; HARPUR, AG; BARBIERI, G; WITTHUHN, BA; SCHINDLER, C; PELLEGRINI, S; WILKS, AF; IHLE, JN; STARK, GR; KERR, IM				MULLER, M; BRISCOE, J; LAXTON, C; GUSCHIN, D; ZIEMIECKI, A; SILVENNOINEN, O; HARPUR, AG; BARBIERI, G; WITTHUHN, BA; SCHINDLER, C; PELLEGRINI, S; WILKS, AF; IHLE, JN; STARK, GR; KERR, IM			THE PROTEIN-TYROSINE KINASE JAK1 COMPLEMENTS DEFECTS IN INTERFERON-ALPHA/BETA AND INTERFERON-GAMMA SIGNAL-TRANSDUCTION	NATURE			English	Article							DNA-BINDING PROTEIN; TRANSCRIPTION FACTOR; STIMULATED TRANSCRIPTION; CYTOPLASMIC ACTIVATION; IFN-GAMMA; RECEPTOR; PHOSPHORYLATION; CLONING; CELLS; CDNA	We have produced a cell line which lacks the protein tyrosine kinase JAK1. and is completely, defective in interferon response. Complementation of this mutant with JAK1 restored the response, establishing the requirement for JAK1 in both the interferon-alpha/beta and -gamma signal transduction pathways. The reciprocal interdependence between JAK1 and Tyk2 activities in the interferon-alpha pathway, and between JAK1 and JAK2 in the interferon-gamma pathway, may reflect a requirement for these kinases in the correct assembly of interferon receptor complexes.	IMPERIAL CANC RES FUND, POB 124, 44 LINCOLNS FIELDS, LONDON WC2A 3PX, ENGLAND; UNIV BERN, INST CLIN & EXPTL CANC RES, CH-3004 BERN, SWITZERLAND; NYU MED CTR, NEW YORK, NY 10016 USA; LUDWIG INST CANC RES, MELBOURNE TUMOUR BIOL BRANCH, MELBOURNE, VIC 3050, AUSTRALIA; INST PASTEUR, INSERM, U276, F-75724 PARIS 15, FRANCE; ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38101 USA; COLUMBIA UNIV, MED CTR, DEPT MED, NEW YORK, NY 10032 USA; CLEVELAND CLIN FDN, RES INST, CLEVELAND, OH 44195 USA	Cancer Research UK; University of Bern; New York University; Ludwig Institute for Cancer Research; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; St Jude Children's Research Hospital; Columbia University; Cleveland Clinic Foundation			Guschin, Dmitry/U-3731-2019; Wilks, Andrew F/R-5542-2019; Barbieri, Giovanna/AAH-3645-2019; Pellegrini, Sandra -/G-5546-2015; Pellegrini, Sandra/Y-6351-2019; Guschin, Dmitry/O-7594-2018; witthuhn, bruce/GSE-3193-2022	Guschin, Dmitry/0000-0002-4184-0001; Pellegrini, Sandra -/0000-0001-5837-7589; Pellegrini, Sandra/0000-0001-5837-7589; Guschin, Dmitry/0000-0002-4184-0001; BARBIERI, GIOVANNA/0000-0002-5895-1795; Muller, Mathias/0000-0002-7879-3552; Briscoe, James/0000-0002-1020-5240				AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BEYERS A D, 1992, Trends in Cell Biology, V2, P253, DOI 10.1016/0962-8924(92)90190-X; BOLEN JB, 1993, ONCOGENE, V8, P2025; CLAESSON L, 1983, P NATL ACAD SCI-BIOL, V80, P7395, DOI 10.1073/pnas.80.24.7395; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DAVID M, 1993, J BIOL CHEM, V268, P6593; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; Demaeyer E., 1988, INTERFERONS OTHER RE; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; HARPUR AG, 1992, ONCOGENE, V7, P1347; HOWARD OMZ, 1992, ONCOGENE, V7, P895; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	51	721	737	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1993	366	6451					129	135		10.1038/366129a0	http://dx.doi.org/10.1038/366129a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG216	8232552				2022-12-28	WOS:A1993MG21600048
J	OBRIEN, TS; HANBURY, DC; CRANSTON, D				OBRIEN, TS; HANBURY, DC; CRANSTON, D			POSTRETIREMENT POLYDIPSIA MIMICKING PROSTATISM	BRITISH MEDICAL JOURNAL			English	Article											OBRIEN, TS (corresponding author), CHURCHILL HOSP,DEPT UROL,OXFORD OX3 7LJ,ENGLAND.		Cranston, David/K-7063-2019					DOLL HA, 1992, J UROLOGY, V147, P1566, DOI 10.1016/S0022-5347(17)37628-0; GERMAN K, 1993, BRIT MED J, V306, P429, DOI 10.1136/bmj.306.6875.429; MCKELVIE GB, 1993, BRIT J UROL, V71, P38, DOI 10.1111/j.1464-410X.1993.tb15877.x; POPE C, 1993, BRIT MED J, V306, P408, DOI 10.1136/bmj.306.6875.408	4	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1993	307	6911					1057	1057		10.1136/bmj.307.6911.1057	http://dx.doi.org/10.1136/bmj.307.6911.1057			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD556	8251785	Bronze, Green Published			2022-12-28	WOS:A1993MD55600028
J	STRAUS, WL; OSTROFF, SM; JERNIGAN, DB; KIEHN, TE; SORDILLO, EM; ARMSTRONG, D; BOONE, N; SCHNEIDER, N; KILBURN, JO; SILCOX, VA; LABOMBARDI, V; GOOD, RC				STRAUS, WL; OSTROFF, SM; JERNIGAN, DB; KIEHN, TE; SORDILLO, EM; ARMSTRONG, D; BOONE, N; SCHNEIDER, N; KILBURN, JO; SILCOX, VA; LABOMBARDI, V; GOOD, RC			CLINICAL AND EPIDEMIOLOGIC CHARACTERISTICS OF MYCOBACTERIUM-HAEMOPHILUM, AN EMERGING PATHOGEN IN IMMUNOCOMPROMISED PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; VIRUS INFECTION; CUTANEOUS MANIFESTATIONS; AIDS; LYMPHADENITIS; HEMOPHILUM	Objective:To describe 13 infections caused by Mycobacterium haemophilum. Design: Identification of patients by microbiologic record review, followed by medical record review and a case-control study. Setting: Seven metropolitan hospitals in New York. Patients: All patients with M. haemophilum infections diagnosed between January 1989 and September 1991 and followed through September 1992. Surviving patients were enrolled in the case-control study. Results: Infection with M. haemophilum causes disseminated cutaneous lesions, bacteremia, and diseases of the bones, joints, lymphatics, and the lungs. Improper culture techniques may delay laboratory diagnosis, and isolates may be identified incorrectly as other mycobacterial species. Persons with profound deficits in cell-mediated immunity have an increased risk for infection. These include persons with human immunodeficiency virus infection or lymphoma and those receiving medication to treat immunosuppression after organ transplant. Various antimycobacterial regimens have been used with apparent success to treat M. haemophilum infection. However, standards for defining antimicrobial susceptibility to the organism do not exist. Conclusions: Clinicians should consider this pathogen when evaluating an immunocompromised patient with cutaneous ulcerating lesions, joint effusions, or osteomyelitis. Microbiologists must be familiar with the fastidious growth requirements of this organism and screen appropriate specimens for mycobacteria using an acid-fast stain. If acid-fast bacilli are seen, M. haemophilum should be considered as the infecting organism as well as other mycobacteria, and appropriate media and incubation conditions should be used.	MEM SLOAN KETTERING CANC CTR, INFECT DIS SERV, NEW YORK, NY 10021 USA; ST LUKES ROOSEVELT HOSP, DEPT MICROBIOL, NEW YORK, NY 10025 USA; ST VINCENTS HOSP & MED CTR, DEPT MICROBIOL, NEW YORK, NY 10011 USA	Memorial Sloan Kettering Cancer Center; Mount Sinai St. Luke's; Mount Sinai West; Saint Vincents Hospital Manhattan	STRAUS, WL (corresponding author), CTR DIS CONTROL & PREVENT, DIV BACTERIAL & MYCOT DIS, MAILSTOP C-09, ATLANTA, GA 30333 USA.		Sordillo, Emilia Mia/AAF-3012-2021	Sordillo, Emilia Mia/0000-0001-7787-3051				ARMSTRONG KL, 1992, J PEDIATR-US, V121, P202, DOI 10.1016/S0022-3476(05)81188-6; ASCHOFF J, 1958, NATURWISSENSCHAFTEN, V45, P477, DOI 10.1007/BF00635546; BARBER TW, 1990, MEDICINE, V69, P375, DOI 10.1097/00005792-199011000-00005; BECHERER P, 1992, CLIN INFECT DIS, V14, P793, DOI 10.1093/clinids/14.3.793; BRANGER B, 1985, CLIN NEPHROL, V23, P46; BUTLER WR, 1992, 92ND GEN M AM SOC MI, P177; CLARK RP, 1985, MAN HIS THERMAL ENV, P1; DAVIS BR, 1982, ANN INTERN MED, V97, P723, DOI 10.7326/0003-4819-97-5-723; DAWSON DJ, 1981, MED J AUSTRALIA, V2, P289, DOI 10.5694/j.1326-5377.1981.tb128321.x; DAWSON DJ, 1980, J CLIN MICROBIOL, V11, P190, DOI 10.1128/JCM.11.2.190-192.1980; DEVER LL, 1992, CLIN INFECT DIS, V14, P1195, DOI 10.1093/clinids/14.6.1195; DOVER JS, 1991, ARCH DERMATOL, V127, P1383, DOI 10.1001/archderm.127.9.1383; DOVER JS, 1991, ARCH DERMATOL, V127, P1549, DOI 10.1001/archderm.127.10.1549; FELDMAN RA, 1974, ANN INTERN MED, V80, P445, DOI 10.7326/0003-4819-80-4-445; GOSLEE S, 1976, AM REV RESPIR DIS, V113, P287; GOUBY A, 1988, J MED MICROBIOL, V25, P299, DOI 10.1099/00222615-25-4-299; HAWKINS CC, 1986, ANN INTERN MED, V105, P184, DOI 10.7326/0003-4819-105-2-184; HOLTON J, 1991, J INFECTION, V23, P303, DOI 10.1016/0163-4453(91)93080-V; HOPEWELL PC, 1985, CHEST, V87, P104, DOI 10.1378/chest.87.1.104; HORSBURGH CR, 1991, NEW ENGL J MED, V324, P1332, DOI 10.1056/NEJM199105093241906; KAYE BR, 1989, ANN INTERN MED, V111, P158, DOI 10.7326/0003-4819-111-2-158; Kent PT, 1985, PUBLIC HLTH MYCOBACT, P1; KIEHN TE, 1993, EUR J CLIN MICROBIOL, V12, P114, DOI 10.1007/BF01967586; KRISTJANSSON M, 1991, REV INFECT DIS, V13, P906; MALES BM, 1987, J CLIN MICROBIOL, V25, P2367; MCBRIDE JA, 1992, AM J CLIN PATHOL, V98, P282; MEZO A, 1979, PATHOLOGY, V11, P377, DOI 10.3109/00313027909059014; MOULSDALE MT, 1983, TUBERCLE, V64, P29, DOI 10.1016/0041-3879(83)90047-8; RIES KM, 1990, NEW ENGL J MED, V322, P633; ROGERS PL, 1988, AM J MED, V84, P640, DOI 10.1016/0002-9343(88)90150-7; RYAN CG, 1983, J CLIN MICROBIOL, V18, P976, DOI 10.1128/JCM.18.4.976-977.1983; SAUBOLLE MA, 1991, 91ST ANN M AM SOC MI, P391; SOMPOLINSKY D, 1978, INT J SYST BACTERIOL, V28, P67, DOI 10.1099/00207713-28-1-67; THIBERT L, 1990, J CLIN MICROBIOL, V28, P621, DOI 10.1128/JCM.28.3.621-623.1990; Thibert L, 1988, Can Dis Wkly Rep, V14, P196; VADNEY FS, 1985, J CLIN MICROBIOL, V22, P884, DOI 10.1128/JCM.22.5.884-885.1985; WALDER BK, 1976, AUSTRALAS J DERMATOL, V17, P94, DOI 10.1111/j.1440-0960.1976.tb00798.x; WAYNE LG, 1992, CLIN MICROBIOL REV, V5, P1; WOLINSKY E, 1968, AM REV RESPIR DIS, V97, P1032; YARRISH RL, 1992, AIDS, V6, P557, DOI 10.1097/00002030-199206000-00006	40	87	87	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1994	120	2					118	125		10.7326/0003-4819-120-2-199401150-00004	http://dx.doi.org/10.7326/0003-4819-120-2-199401150-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ671	8256970				2022-12-28	WOS:A1994MQ67100004
J	BOJESTIG, M; ARNQVIST, HJ; HERMANSSON, G; KARLBERG, BE; LUDVIGSSON, J				BOJESTIG, M; ARNQVIST, HJ; HERMANSSON, G; KARLBERG, BE; LUDVIGSSON, J			DECLINING INCIDENCE OF NEPHROPATHY IN INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLOOD-GLUCOSE CONTROL; MICROVASCULAR COMPLICATIONS; GLYCEMIC CONTROL; KIDNEY-FUNCTION; MICROALBUMINURIA; PROTEINURIA; IDDM	Background. The high relative mortality among patients with insulin-dependent diabetes mellitus results mainly from diabetic nephropathy. The cumulative incidence of nephropathy of 25 to 30 percent among patients who had had diabetes for 25 years remained stable from 1950 to the early 1980s. In a population study, we assessed recent trends in the incidence of diabetic nephropathy. Methods. We studied all 213 patients in whom insulin-dependent diabetes mellitus was diagnosed before the age of 15 years between 1961 and 1980 in a district in southeastern Sweden. Ninety-two percent of the patients were followed from the onset of diabetes to 1991 or to death. Patients with persistent albuminuria (positive Albustix test) were considered to have diabetic nephropathy. Glycosylated hemoglobin was measured periodically in all patients, beginning in 1980. Results. The cumulative incidence of persistent albuminuria after 25 years of diabetes decreased from 30.0 percent among the patients in whom diabetes developed in the period 1961 to 1965 to 8.9 percent among those in whom it developed from 1966 to 1970 (P = 0.01). After 20 years of diabetes, the cumulative incidence decreased from 28.0 percent among the patients in whom diabetes developed from 1961 to 1965 to 5.8 percent among those in whom it developed from 1971 to 1975 (P = 0.01). Persistent albuminuria has not yet developed in any patient in whom diabetes was diagnosed in the period 1976 to 1980. The average glycosylated hemoglobin value decreased from 7.4 percent in the period 1980 to 1985 to 7.0 percent from 1986 to 1991 (P<0.001). The mean glycosylated hemoglobin value was higher in the patients with persistent albuminuria than the patients with no albuminuria (8.1 percent vs. 7.1 percent, P<0.001). Conclusions. During the past decade the cumulative incidence of diabetic nephropathy, as manifested by persistent albuminuria, among patients who have had diabetes for 25 years has decreased substantially, probably as a result of improved glycemic control.	EKSJO NASSJO HOSP,DEPT INTERNAL MED,EKSJO,SWEDEN; LINKOPING UNIV HOSP,DEPT INTERNAL MED,S-58185 LINKOPING,SWEDEN; LINKOPING UNIV HOSP,DEPT PEDIAT,S-58185 LINKOPING,SWEDEN	Linkoping University; Linkoping University			Ludvigsson, Johnny/AAI-2051-2020	Ludvigsson, Johnny/0000-0003-1695-5234				ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; BANGSTAD HJ, 1989, DIABETES RES CLIN EX, V12, P71; BORCHJOHNSEN K, 1985, DIABETOLOGIA, V28, P590, DOI 10.1007/BF00281993; BORCHJOHNSEN K, 1992, KIDNEY INT, V41, P719, DOI 10.1038/ki.1992.112; CHASE HP, 1989, JAMA-J AM MED ASSOC, V261, P1155, DOI 10.1001/jama.261.8.1155; DANTONIO JA, 1989, DIABETES CARE, V12, P694, DOI 10.2337/diacare.12.10.694; FELDTRASMUSSEN B, 1991, DIABETOLOGIA, V34, P164, DOI 10.1007/BF00418270; HANSSEN KF, 1992, DIABETIC MED, V9, P697, DOI 10.1111/j.1464-5491.1992.tb01876.x; KLEIN R, 1991, ARCH INTERN MED, V151, P1344, DOI 10.1001/archinte.151.7.1344; KOFOEDENEVOLDSEN A, 1987, DIABETES, V36, P205, DOI 10.2337/diabetes.36.2.205; KROLEWSKI AS, 1988, NEW ENGL J MED, V318, P140, DOI 10.1056/NEJM198801213180303; KROLEWSKI AS, 1987, NEW ENGL J MED, V317, P1390; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; Ludvigsson J., 1976, METABOLIC CONTROL JU; MARRE M, 1988, BMJ-BRIT MED J, V297, P1092, DOI 10.1136/bmj.297.6656.1092; MATHIESEN ER, 1989, DIABETOLOGIA, V32, P884, DOI 10.1007/BF00297455; MOGENSEN CE, 1987, KIDNEY INT, V31, P673, DOI 10.1038/ki.1987.50; NORGAARD K, 1989, DIABETIC MED, V6, P325, DOI 10.1111/j.1464-5491.1989.tb01173.x; ORCHARD TJ, 1990, DIABETES, V39, P1116, DOI 10.2337/diabetes.39.9.1116; PARVING HH, 1989, BMJ-BRIT MED J, V299, P533, DOI 10.1136/bmj.299.6698.533; REICHARD P, 1991, J INTERN MED, V230, P101, DOI 10.1111/j.1365-2796.1991.tb00415.x; VIBERTI GC, 1992, DIABETES CARE, V15, P1216, DOI 10.2337/diacare.15.9.1216; WANG PH, 1993, LANCET, V341, P1306, DOI 10.1016/0140-6736(93)90816-Y; 1990, SPSS MACINTOSH OPERA; 1990, AM J KIDNEY DIS S2, V16, P22	25	362	371	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 6	1994	330	1					15	18		10.1056/NEJM199401063300103	http://dx.doi.org/10.1056/NEJM199401063300103			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP649	8259139				2022-12-28	WOS:A1994MP64900003
J	BYRNE, C; VERNON, P; COHEN, JJ				BYRNE, C; VERNON, P; COHEN, JJ			EFFECT OF AGE AND DIAGNOSIS ON SURVIVAL OF OLDER PATIENTS BEGINNING CHRONIC DIALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To assess the survival of elderly patients in the United States beginning chronic dialysis for end-stage renal disease caused by diabetes mellitus, hypertension, glomerulonephritis, polycystic kidney disease, and other causes. Design.-A secondary analysis of data obtained from the Health Care Financing Administration. Patients.-All Medicare end-stage renal disease patients 55 years of age or older (n=95 394) who began chronic dialysis treatment in the US between 1982 and 1987. Main Outcome Measures.-The l-, 3-, and 5-year survival rates for each of six age strata and, within each strata, for each of the four most frequent causes of renal failure. Results.-Survival rates of dialysis patients fell precipitously, and much more rapidly for the study group than for the general population, as a function of advancing age. Older patients with diabetic nephropathy fared particularly badly, such that no patients with diabetic nephropathy aged 85 years or more survived 5 years. Conclusions.-Mortality rates of patients older than 55 years beginning chronic dialysis treatment increased dramatically as age at initiation of dialysis increased. Clinically meaningful survival data should prove useful to persons making decisions about the initiation of chronic dialysis.	SUNY STONY BROOK,SCH MED,STONY BROOK,NY 11794; NEW YORK STATE DEPT HLTH,STONY BROOK,NY	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook								BLAGG CR, 1991, AM J KIDNEY DIS, V17, P458, DOI 10.1016/S0272-6386(12)80641-X; Callahan D., 1987, MED GOALS AGEING SOC; CALLAHAN D, 1990, WHAT KIND LIFE LIMIT; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; INGLEHART JK, 1993, NEW ENGL J MED, V328, P366; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; LOWRANCE DC, 1993, AM J KIDNEY DIS, V21, P679; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; RETTIG RA, 1976, LAW CONTEMP PROBL, V40, P196, DOI 10.2307/1191314; RUBIN R, 1991, AM KIDNEY FUND NEWSL, V7, P1; RUBIN R, 1991, AM KIDNEY FUND NEWSL, V7, P3; SLEPIAN F, 1991, AM KIDNEY FUND NEWSL, V7, P1; 1988, PHS881104 US DEP HLT; 1993, USRDS1993 NIH NAT I; 1989, SAS SAT USERS GUIDE, V2; 1991, MONOGRAPH SERIES, V1	16	67	68	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	1994	271	1					34	36						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN725	8258884				2022-12-28	WOS:A1994MN72500027
J	BROSE, N				BROSE, N			MEMBRANE-FUSION TAKES EXCITATORY TURN - SYNTAXIN, VESICLE DOCKING PROTEIN, OR GLUTAMATE-RECEPTOR	CELL			English	Review							SYNAPTOTAGMIN; HPC-1		UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	BROSE, N (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.							BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BROSE N, 1993, J BIOL CHEM, V268, P22663; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; HIRAI Y, 1992, CELL, V69, P471, DOI 10.1016/0092-8674(92)90448-L; HOLLMANN M, 1994, IN PRESS ANN REV NEU; INOUE A, 1992, J BIOL CHEM, V267, P10613; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; NAKANISHI S, 1992, SCIENCE, V258, P579; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SIEGEL SJ, 1994, IN PRESS P NATL ACAD; SMIRNOVA T, 1993, SCIENCE, V262, P430, DOI 10.1126/science.8105537; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1993, CELL, V75, P1; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	21	12	13	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 17	1993	75	6					1043	1044		10.1016/0092-8674(93)90313-F	http://dx.doi.org/10.1016/0092-8674(93)90313-F			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	8261506				2022-12-28	WOS:A1993MM89300002
J	YU, YT; MARONEY, PA; NILSEN, TW				YU, YT; MARONEY, PA; NILSEN, TW			FUNCTIONAL RECONSTITUTION OF U6 SNRNA IN NEMATODE CIS-SPLICING AND TRANSSPLICING - U6 CAN SERVE AS BOTH A BRANCH ACCEPTOR AND A 5'-EXON	CELL			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR-RNA; SPLICEOSOME ASSEMBLY PATHWAY; BASE-PAIRING INTERACTION; YEAST; INVITRO; U2; SITE; RIBONUCLEOPROTEIN; U4	Maturation of nuclear pre-mRNAs in nematodes requires both cis- and trans-splicing. Both processing pathways involve analogous two-step phosphotransfer reactions and both are dependent upon the integrity of U6 snRNA. We have developed a functional reconstitution assay to assess the U6 snRNA sequence requirements for cis- and trans-splicing. Branch formation between the splicing substrates and U6 snRNA was observed. The frequency of this event was greatly enhanced when a highly conserved sequence in U6 snRNA was altered by mutation. In cis- and trans-splicing reactions reconstituted with this mutant U6 snRNA the liberated exon of U6 proceeded through the second step of splicing using the appropriate splice acceptor sites. These results demonstrate covalent interactions between a U snRNA required for splicing and a splicing substrate, and they provide evidence for an unexpected degree of catalytic flexibility within the spliceosome.			YU, YT (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,CTR MOLEC PARASITOL,DEPT MOLEC BIOL & MICROBIOL,CLEVELAND,OH 44106, USA.				NIAID NIH HHS [AI-28799] Funding Source: Medline; NIGMS NIH HHS [GM-31528] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031528] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baserga S., 1993, RNA WORLD, P359; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BROW DA, 1989, NATURE, V337, P14, DOI 10.1038/337014a0; DATTA B, 1993, MOL CELL BIOL, V13, P5377, DOI 10.1128/MCB.13.9.5377; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FABRIZIO P, 1989, GENE DEV, V3, P2137, DOI 10.1101/gad.3.12b.2137; FABRIZIO P, 1992, NUCLEIC ACIDS RES, V20, P3659, DOI 10.1093/nar/20.14.3659; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1989, AM ZOOL, V29, P557; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HANNON GJ, 1991, J BIOL CHEM, V266, P22792; HANNON GJ, 1990, CELL, V61, P1247, DOI 10.1016/0092-8674(90)90689-C; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; MARONEY PA, 1990, EMBO J, V9, P3667, DOI 10.1002/j.1460-2075.1990.tb07578.x; MICHAUD S, 1993, GENE DEV, V7, P1008, DOI 10.1101/gad.7.6.1008; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; Moore M., 1993, RNA WORLD, P303; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; NILSEN TW, 1993, ANNU REV MICROBIOL, V47, P413, DOI 10.1146/annurev.mi.47.100193.002213; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; TAKAHASHI Y, 1993, MOL CELL BIOL, V13, P5613, DOI 10.1128/MCB.13.9.5613; TANI T, 1991, GENE DEV, V5, P1022, DOI 10.1101/gad.5.6.1022; TANI T, 1989, NATURE, V337, P87, DOI 10.1038/337087a0; TSCHUDI C, 1990, CELL, V61, P459, DOI 10.1016/0092-8674(90)90527-L; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; VANKAN P, 1992, EMBO J, V11, P335, DOI 10.1002/j.1460-2075.1992.tb05056.x; VIERA J, 1987, METHOD ENZYMOL, V153, P3; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WEBER LA, 1978, METHOD CELL BIOL, V9, P215; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9; WOLFF T, 1992, EMBO J, V11, P345, DOI 10.1002/j.1460-2075.1992.tb05057.x; WOLFF T, 1993, GENE DEV, V7, P1377, DOI 10.1101/gad.7.7b.1377; WOLFF T, 1993, IN PRESS P NATL ACAD; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0	46	54	55	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 17	1993	75	6					1049	1059		10.1016/0092-8674(93)90315-H	http://dx.doi.org/10.1016/0092-8674(93)90315-H			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	8261508				2022-12-28	WOS:A1993MM89300004
J	IP, YT; REACH, M; ENGSTROM, Y; KADALAYIL, L; CAI, H; GONZALEZCRESPO, S; TATEI, K; LEVINE, M				IP, YT; REACH, M; ENGSTROM, Y; KADALAYIL, L; CAI, H; GONZALEZCRESPO, S; TATEI, K; LEVINE, M			DIF, A DORSAL-RELATED GENE THAT MEDIATES AN IMMUNE-RESPONSE IN DROSOPHILA	CELL			English	Article							NF-KAPPA-B; EMBRYONIC DORSOVENTRAL POLARITY; VENTRAL PATTERN-FORMATION; DNA-BINDING PROTEINS; ACUTE-PHASE RESPONSE; NUCLEAR-FACTOR; TRANSCRIPTION FACTORS; EXPRESSION; REL; TOLL	There are striking parallels between the regulation of gene expression along the dorsoventral (DV) axis of Drosophila embryos and lymphoid-restricted expression in the mammalian immune system. Both depend on regulatory factors containing rel domains (dorsal and NF-kappaB) that are controlled at the level of nuclear transport. A novel Rel-containing gene in Drosophila, Dif (dorsal-related immunity factor), provides a potential link between these seemingly disparate processes. Although Dif maps close to dorsal, it does not appear to participate in DV patterning, but instead mediates an immune response in Drosophila larvae. Dif is normally localized in the cytoplasm of the larval fat body, but quickly accumulates in the nucleus upon bacterial infection or injury. Evidence is presented that once in the nucleus, Dif binds to kappaB-like sequence motifs present in promoter regions of immunity genes. These results suggest that mammalian and insect immunity share a common evolutionary origin.	UNIV STOCKHOLM,ARRHENIUS LAB,DEPT MOLEC BIOL,S-10691 STOCKHOLM,SWEDEN	Stockholm University	IP, YT (corresponding author), UNIV CALIF SAN FRANCISCO,CTR MOLEC GENET,DEPT BIOL,SAN FRANCISCO,CA 94143, USA.			Kadalayil, Latha/0000-0002-3757-5487; Engstrom, Ylva/0000-0002-8731-4613; Levine, Michael/0000-0001-7629-0081	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046638, R37GM046638] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46638] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABASTADO JP, 1991, NEW BIOL, V3, P511; ABEL T, 1992, GENE DEV, V6, P466, DOI 10.1101/gad.6.3.466; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1991, HORMONAL CONTROL REG, P409; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BOMAN HG, 1991, EUR J BIOCHEM, V201, P23, DOI 10.1111/j.1432-1033.1991.tb16252.x; BOMAN HG, 1972, NATURE, V237, P232, DOI 10.1038/237232a0; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; EDBROOKE MR, 1991, CYTOKINE, V3, P380, DOI 10.1016/1043-4666(91)90041-B; ENGSTROM Y, 1993, J MOL BIOL, V232, P327, DOI 10.1006/jmbi.1993.1392; ENGSTROM Y, 1993, INSECT MOL SCI, P125; FALB D, 1992, GENE DEV, V6, P454, DOI 10.1101/gad.6.3.454; FREEDMAN AR, 1992, BIOCHEM J, V287, P645, DOI 10.1042/bj2870645; Gateff E., 1980, INVERTEBRATE SYSTEMS, P517; GAY NJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P290, DOI 10.1016/0167-4781(92)90163-T; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GERTTULA S, 1988, GENETICS, V119, P123; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOLDBERG DA, 1980, P NATL ACAD SCI-BIOL, V77, P5794, DOI 10.1073/pnas.77.10.5794; GONZALEZCRESPO S, 1993, GENE DEV, V7, P1703, DOI 10.1101/gad.7.9.1703; GORDON AH, 1985, RES MONOGRAPHS CELL, V10; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; GRANT PA, 1992, NUCLEIC ACIDS RES, V20, P4401, DOI 10.1093/nar/20.17.4401; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENTSCH B, 1992, NUCLEIC ACIDS RES, V20, P2657, DOI 10.1093/nar/20.11.2657; HULTMARK D, 1993, TRENDS GENET, V9, P178, DOI 10.1016/0168-9525(93)90165-E; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; IP YT, 1992, GENE DEV, V6, P1728, DOI 10.1101/gad.6.9.1728; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; IP YT, 1991, CELL, V64, P439; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; KAPPLER C, 1993, EMBO J, V12, P1561, DOI 10.1002/j.1460-2075.1993.tb05800.x; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOBAYASHI A, 1993, MOL CELL BIOL, V13, P4049, DOI 10.1128/MCB.13.7.4049; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; KYLSTEN P, 1990, EMBO J, V9, P217, DOI 10.1002/j.1460-2075.1990.tb08098.x; LANGERSAFER PR, 1982, P NATL ACAD SCI-BIOL, V79, P4381, DOI 10.1073/pnas.79.14.4381; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NONAKA M, 1990, MOL CELL BIOL, V10, P6283, DOI 10.1128/MCB.10.12.6283; REICHHART JM, 1992, EMBO J, V11, P1469, DOI 10.1002/j.1460-2075.1992.tb05191.x; RON D, 1990, MOL CELL ENDOCRINOL, V74, P97; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SAMAKOVLIS C, 1992, BIOCHEM BIOPH RES CO, V188, P1169, DOI 10.1016/0006-291X(92)91354-S; SAMAKOVLIS C, 1990, EMBO J, V9, P2969, DOI 10.1002/j.1460-2075.1990.tb07489.x; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P959, DOI 10.1128/MCB.9.3.959; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; SUN SC, 1991, EUR J BIOCHEM, V196, P247, DOI 10.1111/j.1432-1033.1991.tb15811.x; SUN SC, 1992, EUR J BIOCHEM, V204, P885, DOI 10.1111/j.1432-1033.1992.tb16708.x; TRYSELIUS Y, 1992, EUR J BIOCHEM, V204, P395, DOI 10.1111/j.1432-1033.1992.tb16648.x	69	380	391	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					753	763		10.1016/0092-8674(93)90495-C	http://dx.doi.org/10.1016/0092-8674(93)90495-C			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242747				2022-12-28	WOS:A1993MH74900020
J	MCDONALD, SJ; PRENDIVILLE, WJ; BLAIR, E				MCDONALD, SJ; PRENDIVILLE, WJ; BLAIR, E			RANDOMIZED CONTROLLED TRIAL OF OXYTOCIN ALONE VERSUS OXYTOCIN AND ERGOMETRINE IN ACTIVE MANAGEMENT OF 3RD STAGE OF LABOR	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective-To compare intramuscular oxytocin alone and intramuscular oxytocin with ergometrine (Syntometrine) for their effect in reducing the risk of postpartum haemorrhage when both are used as part of the active management of the third stage of labour. Design-Double blind, randomised controlled trial. Setting-Two metropolitan teaching hospitals in Perth, Western Australia. Subjects-All women who expected a vaginal birth during the period of the trial. Informed consent was obtained. Main outcome measures-Postpartum haemorrhage, nausea, vomiting, and increased blood pressure. Results-3497 women were randomly allocated to receive oxytocin-ergometrine (n=1730) or oxytocin (n=1753). Rates of postpartum haemorrhage (greater-than-or-equal-to 500 ml or greater-than-or-equal-to 1000 ml) were similar in both arms (odds ratio 0.90 (0.82); 95% confidence interval 0.75 to 1.07 (0.59 to 1.14) at 500 ml (1000 ml) threshold). The use of oxytocin-ergometrine was associated with nausea, vomiting, and increased blood pressure. Conclusions-There are few advantages but several disadvantages for the routine use of oxytoxin-ergometrine when prophylactic active management of the third stage of labour is practised. Further investigation of dose-response for oxytocin may be warranted.	COOMBE LYING IN HOSP, DEPT OBSTET & GYNAECOL, DUBLIN 8, IRELAND; WESTERN AUSTRALIAN RES INST CHILD HLTH, PERTH, WA 6001, AUSTRALIA	Trinity College Dublin; Telethon Kids Institute; University of Western Australia	MCDONALD, SJ (corresponding author), KING EDWARD MEM HOSP WOMEN, DELIVERY WARD, SUBIACO, WA 6008, AUSTRALIA.							BASKETT T, 1992, J SOC OBSTETRICI MAR, P61; Begley C M, 1990, Midwifery, V6, P3, DOI 10.1016/S0266-6138(05)80091-9; DOCHERTY PW, 1981, J OBSTET GYNAECOLOGY, V2, P60; Dumoulin JG., 1981, J OBSTET GYNAECOL, V1, P178, DOI [10.3109/01443618109067375, DOI 10.3109/01443618109067375]; ELBOURNE D, 1988, BRIT J OBSTET GYNAEC, V95, P17, DOI 10.1111/j.1471-0528.1988.tb06476.x; ELBOURNE DR, 1993, PREGNANCY CHILDBIRTH; Garcia J, 1987, Midwifery, V3, P2, DOI 10.1016/S0266-6138(87)80003-7; GILBERT L, 1987, BRIT J OBSTET GYNAEC, V94, P67, DOI 10.1111/j.1471-0528.1987.tb02255.x; Kwast B E, 1991, Midwifery, V7, P64, DOI 10.1016/S0266-6138(05)80229-3; MITCHELL GG, 1993, ONLINE J CURREN 0813; Nieminen U, 1963, ANN CHIR GYNAECOL, V53, P424; PRENDIVILLE W, 1988, BRIT J OBSTET GYNAEC, V95, P3, DOI 10.1111/j.1471-0528.1988.tb06475.x; PRENDIVILLE WJ, 1988, BMJ-BRIT MED J, V297, P1295, DOI 10.1136/bmj.297.6659.1295; PRENDVILLE W, 1988, EFFECTIVE CARE PREGN; Royston E, 1989, PREVENTING MATERNAL, P30; SYMES JB, 1984, J OBSTET GYNAECOL, V5, P36, DOI 10.3109/01443618409075741; Vaughan Williams C, 1974, J Obstet Gynaecol Br Commonw, V81, P596; 1990, WHOMCH907 REP TECHN	18	72	74	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 6	1993	307	6913					1167	1171		10.1136/bmj.307.6913.1167	http://dx.doi.org/10.1136/bmj.307.6913.1167			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF824	8251842	Bronze, Green Published			2022-12-28	WOS:A1993MF82400019
J	RAFTERY, J				RAFTERY, J			CAPITATION FUNDING - POPULATION, AGE, AND MORTALITY ADJUSTMENTS FOR REGIONAL AND DISTRICT HEALTH AUTHORITIES IN ENGLAND	BRITISH MEDICAL JOURNAL			English	Article								Objective-To assess the effect of each of the components of the national capitation funding formula-population projections and age and mortality weighting-at regional and district level. Design-Application of age-cost and mortality weights to the projected 1997 populations of regions and districts, based on the Department of Health public health common dataset. Setting-Regional and district health authorities in England. Results-The application of the age-cost and mortality weights to projected populations resulted in greater changes in the shares of weighted populations relative to the estimated 1991 population at district level (mean 0, range -17% to 28%) than at regional level (mean 0, range -9% to 6%). At district level mortality weights had less scope for influence (mean 0, range -9% to 14%) than population projections (mean 0, range -16% to 31%) or age weights (mean 0, range -20% to 30%). Conclusions-The adjustments to the 1991 population shares due to the application of the national capitation funding formula depend on the interaction of three elements: the projected population by age group, the age-cost weight, and the mortality weight. Since each is open to uncertainty, either in terms of measurement (projected population, particularly for births and the over 85s) or method (derivation of the age-cost and mortality weights), the formula should be implemented cautiously at district level. Ways should be considered of incorporating elements of uncertainty into the model. Further research is required on the elements and degree of uncertainty in each of these components, as well as on the relative health needs of different populations.			RAFTERY, J (corresponding author), WESSEX INST PUBL HLTH,WINCHESTER SO22 5DH,ENGLAND.							CARRHILL RA, 1990, J EPIDEMIOL COMMUN H, V44, P271, DOI 10.1136/jech.44.4.271; COOPER, 1988, INTEGRATED ANAL REV; COPAS JB, 1993, J ROY STAT SOC A STA, V156, P107, DOI 10.2307/2982863; Geary K, 1977, Br Med J, V1, P1367; MAYS N, 1987, RESOURCE ALLOCATION; PALMER SR, 1980, J EPIDEMIOL COMMUN H, V34, P212, DOI 10.1136/jech.34.3.212; Pinder D C, 1982, Community Med, V4, P188, DOI 10.1007/BF02548809; ROYSTON GHD, 1992, SOCIOECONOMIC PLANNI, V26, P168; SENN SJ, 1978, J EPIDEMIOL COMM HLT, V22, P32; SHELDON TA, 1993, BRIT MED J, V306, P835, DOI 10.1136/bmj.306.6881.835; SHELDON TA, 1992, J ROY STAT SOC A STA, V155, P403, DOI 10.2307/2982891; SNAITH AH, 1978, J EPIDEMIOL COMMUNIT, V22, P16; WINYARD PGA, 1981, BMJ, V286, P1112; 1993, DEP HLTH OFFICE POPU; 1992, PUBLIC HLTH COMMON D; 1976, RESOURCE ALLOCATION; 1987, REV RAWP; 1993, HOSPITAL COMMUNITY H; 1989, 2 WORK PAT WORK PAP	19	8	8	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1993	307	6912					1121	1124		10.1136/bmj.307.6912.1121	http://dx.doi.org/10.1136/bmj.307.6912.1121			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME918	8251813	Bronze, Green Published			2022-12-28	WOS:A1993ME91800022
J	NEWCOMB, PA; STORER, BE; LONGNECKER, MP; MITTENDORF, R; GREENBERG, ER; CLAPP, RW; BURKE, KP; WILLETT, WC; MACMAHON, B				NEWCOMB, PA; STORER, BE; LONGNECKER, MP; MITTENDORF, R; GREENBERG, ER; CLAPP, RW; BURKE, KP; WILLETT, WC; MACMAHON, B			LACTATION AND A REDUCED RISK OF PREMENOPAUSAL BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TERM FOLLOW-UP; UNITED-STATES; CHINESE-WOMEN; PREGNANCY; MOTHERS; AGE; ASSOCIATION; STILBESTROL; POPULATION; TRIAL	Background. The evidence of an association of lactation with a reduction in the risk of breast cancer among women has been limited and inconsistent. The effect of lactation appears to be confined to premenopausal women with a history of long lactation, but most studies of this relation have been limited in statistical power. We conducted a multicenter, population-based, case-control study with a sample large enough for us to describe more precisely the association between lactation and the risk of breast cancer. Methods. Patients less than 75 years old who had breast cancer were identified from statewide tumor registries in Wisconsin, Massachusetts, Maine, and New Hampshire. Controls were randomly selected from lists of licensed drivers if the case subjects were less than 65 years old, and from lists of Medicare beneficiaries if they were 65 through 74 years old. Information on lactation, reproductive history, and family and medical history was obtained by means of telephone interviews. After the exclusion of nulliparous women, 5878 case subjects and 8216 controls remained for analysis. Results. After adjustment for parity, age at first delivery, and other risk factors for breast cancer, lactation was associated with a slight reduction in the risk of breast cancer among premenopausal women, as compared with the risk among women who were parous but had never lactated (relative risk, 0.78; 95 percent confidence interval, 0.66 to 0.91); the relative risk of breast cancer among postmenopausal women who had lactated, as compared with those who had not, was 1.04 (95 percent confidence interval, 0.95 to 1.14). With an increasing cumulative duration of lactation, there was a decreasing risk of breast cancer among premenopausal women (P for trend <0.001) but not among postmenopausal, parous women (P for trend = 0.51). A younger age at first lactation was significantly associated with a reduction in the risk of premenopausal breast cancer (P for trend = 0.003). As compared with parous women who did not lactate, the relative risk of breast cancer among women who first lactated at less than 20 years of age and breast-fed their infants for a total of six months was 0.54 (95 percent confidence interval, 0.36 to 0.82). Conclusions. There is a reduction in the risk of breast cancer among premenopausal women who have lactated. No reduction in the risk of breast cancer occurred among postmenopausal women with a history of lactation.	MAINE BUR HLTH, DIV DIS CONTROL, AUGUSTA, ME USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT EPIDEMIOL, LOS ANGELES, CA 90024 USA; UNIV CHICAGO, PRITZKER SCH MED, DEPT OBSTET & GYNECOL, CHICAGO, IL 60637 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, DEPT COMMUNITY & FAMILY MED, HANOVER, NH 03756 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, DEPT MED, HANOVER, NH 03756 USA; HARVARD UNIV, SCH MED, CHANNING LAB, BOSTON, MA 02115 USA; MASSACHUSETTS DEPT PUBL HLTH, MASSACHUSETTS CANC REGISTRY, BOSTON, MA 02130 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA	University of California System; University of California Los Angeles; University of Chicago; Dartmouth College; Dartmouth College; Harvard University; Harvard Medical School; Massachusetts Department of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	NEWCOMB, PA (corresponding author), UNIV WISCONSIN, CTR COMPREHENS CANC, 1300 UNIV AVE, NO 4780, MADISON, WI 53706 USA.			Clapp, Richard/0000-0001-8174-0825; Longnecker, Matthew/0000-0001-6073-5322	NATIONAL CANCER INSTITUTE [R01CA047305, R01CA047147] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 47147, R01 CA 47305] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANERJEE MR, 1967, J CELL PHYSIOL, V69, P133, DOI 10.1002/jcp.1040690203; BERAL V, 1980, BRIT MED J, V281, P1098, DOI 10.1136/bmj.281.6248.1098; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; BRINTON LA, 1983, BRIT J CANCER, V47, P757, DOI 10.1038/bjc.1983.128; BYERS T, 1985, AM J EPIDEMIOL, V121, P664, DOI 10.1093/aje/121.5.664; DAO TL, 1960, J NATL CANCER I, V25, P991; DUFFY SW, 1983, J EPIDEMIOL COMMUN H, V37, P127, DOI 10.1136/jech.37.2.127; GREENBERG ER, 1984, NEW ENGL J MED, V311, P1393, DOI 10.1056/NEJM198411293112201; HADJIMICHAEL OC, 1984, J NATL CANCER I, V73, P831; HENDERSON BE, 1982, CANCER RES, V42, P3232; KALACHE A, 1980, BRIT MED J, V280, P223, DOI 10.1136/bmj.280.6209.223-a; KAMPERT JB, 1988, AM J EPIDEMIOL, V128, P962; KATSOUYANNI K, 1986, INT J CANCER, V38, P815, DOI 10.1002/ijc.2910380606; KURINIJ N, 1989, AM J PUBLIC HEALTH, V79, P1247, DOI 10.2105/AJPH.79.9.1247; KVALE G, 1988, J EPIDEMIOL COMMUN H, V42, P30, DOI 10.1136/jech.42.1.30; LAYDE PM, 1989, J CLIN EPIDEMIOL, V42, P963, DOI 10.1016/0895-4356(89)90161-3; LONDON SJ, 1990, AM J EPIDEMIOL, V132, P17, DOI 10.1093/oxfordjournals.aje.a115629; MACMAHON B, 1982, JNCI-J NATL CANCER I, V69, P1035; MACMAHON B, 1970, B WORLD HEALTH ORGAN, V42, P185; MARCHANT J, 1961, BRIT J CANCER, V15, P568, DOI 10.1038/bjc.1961.66; MCTIERNAN A, 1986, AM J EPIDEMIOL, V124, P353, DOI 10.1093/oxfordjournals.aje.a114405; NAGASAWA H, 1976, J ENDOCRINOL, V70, P389, DOI 10.1677/joe.0.0700389; PAGANINIHILL A, 1982, AM J EPIDEMIOL, V116, P114; PETRAKIS NL, 1987, INT J CANCER, V40, P587, DOI 10.1002/ijc.2910400502; ROSEROBIXBY L, 1987, INT J CANCER, V40, P747, DOI 10.1002/ijc.2910400606; RYAN AS, 1991, PEDIATRICS, V88, P719; SISKIND V, 1989, AM J EPIDEMIOL, V130, P229; TAO SC, 1988, INT J CANCER, V42, P495, DOI 10.1002/ijc.2910420404; THOMAS DB, 1983, ENVIRON HEALTH PERSP, V50, P209, DOI 10.2307/3429552; VESSEY MP, 1983, BRIT J OBSTET GYNAEC, V90, P1007, DOI 10.1111/j.1471-0528.1983.tb06438.x; WELSCH CW, 1977, CANCER RES, V37, P951; WYNDER EL, 1978, CANCER-AM CANCER SOC, V41, P2341, DOI 10.1002/1097-0142(197806)41:6<2341::AID-CNCR2820410637>3.0.CO;2-N; YOO KY, 1992, AM J EPIDEMIOL, V135, P726, DOI 10.1093/oxfordjournals.aje.a116359; YUAN JM, 1988, CANCER RES, V48, P1949; 1993, BMJ, V307, P17	35	361	372	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 13	1994	330	2					81	87		10.1056/NEJM199401133300201	http://dx.doi.org/10.1056/NEJM199401133300201			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ670	8259187				2022-12-28	WOS:A1994MQ67000001
J	POLLACK, SS; ROSENTHAL, MS				POLLACK, SS; ROSENTHAL, MS			IMAGES IN CLINICAL MEDICINE - DIAPER DIAGNOSIS OF PORPHYRIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									MT SINAI HOSP,NEW YORK,NY 10029	Icahn School of Medicine at Mount Sinai	POLLACK, SS (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,BRONX,NY 10461, USA.								0	6	6	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 13	1994	330	2					114	114						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ670	8259167				2022-12-28	WOS:A1994MQ67000006
J	CLERICI, M; LEVIN, JM; KESSLER, HA; HARRIS, A; BERZOFSKY, JA; LANDAY, AL; SHEARER, GM				CLERICI, M; LEVIN, JM; KESSLER, HA; HARRIS, A; BERZOFSKY, JA; LANDAY, AL; SHEARER, GM			HIV-SPECIFIC T-HELPER ACTIVITY IN SERONEGATIVE HEALTH-CARE WORKERS EXPOSED TO CONTAMINATED BLOOD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; CELL-MEDIATED-IMMUNITY; LYMPHOCYTES-T; SEROPOSITIVE INDIVIDUALS; INFECTED INDIVIDUALS; TYPE-1; SURVEILLANCE; RECOGNITION; RESPONSES	Objective.-To evaluate human immunodeficiency virus (HIV) type 1-specific cellular immune responses in HIV-seronegative health care workers with occupational high-risk exposures to HIV-infected (HIV-positive) patients. Design.-Peripheral blood mononuclear cells (PBMCs) were obtained after occupational exposures to HIV, and PBMCs from health care workers exposed to HIV-negative patients served as controls. The PBMCs were stimulated in vitro with HIV envelope synthetic peptides. Interleukin 2 (IL-2) production was measured in a bioassay. The HIV antibody status was determined by standard enzyme-linked immunosorbent assays. Exposed individuals were also evaluated for HIV proviral DNA by polymerase chain reaction techniques. Participants.-The PBMCs from eight health care workers with high-risk exposures and nine control health care workers were studied. Results.-The PBMCs from all individuals showed strong IL-2 production to control antigens, indicating intact T-helper function. Interleukin 2 production to HIV peptides was detected in PBMCs from six of eight HIV-exposed individuals, but in only one of the nine health care workers exposed to HIV-negative body fluids (P<.008). None of the HIV-exposed health care workers became infected as determined by negative HIV antibody and polymerase chain reaction analysis after follow-up evaluation that ranged from 8 to 64 weeks. Conclusion.-Human immunodeficiency virus-specific T-helper activity was detected in six (75%) of eight HIV-negative health care workers with exposure to HIV-positive body fluids. Potent HIV-specific T-helper activity was detectable 4 to 8 weeks after the exposure and was lost in individuals followed up for 8 to 64 weeks. Three health care workers remained responsive at 8, 19, and 24 weeks. Exposure to HIV without evidence of subsequent infection appears to result in activation of cellular immunity without activation of antibody production.	NCI, EXPTL IMMUNOL BRANCH, BLDG 10, ROOM 4B17, BETHESDA, MD 20892 USA; NCI, METAB BRANCH, BETHESDA, MD 20892 USA; RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT IMMUNOL MICROBIOL, CHICAGO, IL 60612 USA; RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT MED, CHICAGO, IL 60612 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Rush University; Rush University				Clerici, Mario/0000-0001-5920-6191				AHEARNE PM, 1988, AIDS RES HUM RETROV, V4, P259, DOI 10.1089/aid.1988.4.259; BELL DM, 1991, AM J MED, V91, pS294, DOI 10.1016/0002-9343(91)90385-B; BERZOFSKY JA, 1988, NATURE, V334, P706, DOI 10.1038/334706a0; BRETSCHER PA, 1974, CELL IMMUNOL, V13, P171, DOI 10.1016/0008-8749(74)90237-8; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; Butcher A., 1992, Clinical Immunology Newsletter, V12, P73, DOI 10.1016/0197-1859(92)90008-T; CEASE KB, 1987, P NATL ACAD SCI USA, V84, P4249, DOI 10.1073/pnas.84.12.4249; Centers for Disease Control (CDC), 1988, MMWR Morb Mortal Wkly Rep, V37, P229; CHAMBERLAND ME, 1991, JAMA-J AM MED ASSOC, V266, P3459, DOI 10.1001/jama.266.24.3459; CLERICI M, 1991, EUR J IMMUNOL, V21, P1345, DOI 10.1002/eji.1830210603; CLERICI M, 1989, NATURE, V339, P383, DOI 10.1038/339383a0; CLERICI M, 1991, J INFECT DIS, V164, P178, DOI 10.1093/infdis/164.1.178; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; COURGNAUD V, 1991, AIDS RES HUM RETROV, V7, P337, DOI 10.1089/aid.1991.7.337; DEROSSI A, 1991, AIDS, V5, P15, DOI 10.1097/00002030-199101000-00002; DOLIN R, 1991, ANN INTERN MED, V114, P119, DOI 10.7326/0003-4819-114-2-119; Hale P M, 1989, Int Immunol, V1, P409, DOI 10.1093/intimm/1.4.409; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; KUNDU SK, 1992, AIDS, V6, P643, DOI 10.1097/00002030-199207000-00005; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; PALTER F, 1989, IMMUNODEFIC REV, V1, P227; PARISH CR, 1972, TRANSPLANT REV-DENMA, V13, P35; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; RANKI A, 1989, AIDS, V3, P63, DOI 10.1097/00002030-198902000-00002; TACKET CO, 1990, AIDS RES HUM RETROV, V6, P535, DOI 10.1089/aid.1990.6.535; UCHIYAMA T, 1981, J IMMUNOL, V126, P1393; WAHREN B, 1989, J ACQ IMMUN DEF SYND, V2, P448; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WALKER BD, 1988, SCIENCE, V240, P64, DOI 10.1126/science.2451288; WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571; 1987, MMWR MORB MORTAL WKL, V36, P285; 1992, MMWR MORB MORTAL WKL, V41, P501; 1992, MMWR MORB MORTAL WKL, V41, P823	34	184	190	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	1994	271	1					42	46		10.1001/jama.271.1.42	http://dx.doi.org/10.1001/jama.271.1.42			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN725	8258885				2022-12-28	WOS:A1994MN72500029
J	HAMPSON, NB; KRAMER, CC; DUNFORD, RG; NORKOOL, DM				HAMPSON, NB; KRAMER, CC; DUNFORD, RG; NORKOOL, DM			CARBON-MONOXIDE POISONING FROM INDOOR BURNING OF CHARCOAL BRIQUETS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To describe the case characteristics of a series of patients poisoned with carbon monoxide (CO) resulting from indoor burning of charcoal briquets. Design.-Cases of patients with unintentional CO poisoning referred for treatment with hyperbaric oxygen were reviewed. Cases that occurred as the result of indoor burning of charcoal briquets were analyzed. Setting.-A private, urban, tertiary care center. Patients.-Seventy-nine patients ranging from 3 months to 87 years of age referred from 10 counties within the state of Washington between October 1982 and October 1993. Results.-Of 509 patients treated for acute unintentional CO poisoning, 79 cases occurred in 32 incidents as a result of indoor burning of charcoal briquets, for the purpose of either home heating or cooking. A majority of cases occurred in the months of October through January, commonly during power outages or when electricity was intentionally disconnected. Patients of minority races were disproportionately represented compared with the general population of the region. Conclusions.-Carbon monoxide poisoning is a significant hazard from indoor use of charcoal briquets. All cases are avoidable and public awareness of the risk should be enhanced.	VIRGINIA MASON RES CTR,DEPT HYPERBAR,SEATTLE,WA 98101; VIRGINIA MASON MED CTR,DEPT MED,SEATTLE,WA 98101	Virginia Mason Medical Center; Virginia Mason Medical Center								BARON RC, 1989, AM J PUBLIC HEALTH, V79, P1656, DOI 10.2105/AJPH.79.12.1656; BARRET L, 1985, CLIN TOXICOL, V23, P309; COBB N, 1991, JAMA-J AM MED ASSOC, V266, P659, DOI 10.1001/jama.266.5.659; FAIN DB, 1988, AM J FOREN MED PATH, V9, P301, DOI 10.1097/00000433-198812000-00006; FINCK PA, 1966, MIL MED, V131, P1513, DOI 10.1093/milmed/131.12.1513; GASMAN JD, 1990, WESTERN J MED, V153, P656; GEEHR EC, 1989, AM J EMERG MED, V7, P598, DOI 10.1016/0735-6757(89)90282-9; GRACE TW, 1981, JAMA-J AM MED ASSOC, V246, P1698; HAMPSON NB, 1992, JAMA-J AM MED ASSOC, V267, P538, DOI 10.1001/jama.267.4.538; KIM YS, 1985, J EPIDEMIOL COMMUN H, V39, P79, DOI 10.1136/jech.39.1.79; LIU KS, 1993, J EXPO ANAL ENV EPID, V3, P143; PIANTADOSI CA, 1990, UPDATE INTENSIVE CAR, V10, P460; RADFORD EP, 1982, PHS821250 US DEP HLT; STERNBACH G, 1991, WESTERN J MED, V154, P737; WILSON EF, 1972, J AMER MED ASSOC, V221, P405, DOI 10.1001/jama.221.4.405; YATES MW, 1967, J ENV HLTH, V29, P413; 1982, MMWR MORB MORTAL WKL, V31, P529; 1966, ANESTH ANALG, V45, P664; 1989, AIR CONTAMINANT 1910, P1000	19	42	43	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	1994	271	1					52	53		10.1001/jama.271.1.52	http://dx.doi.org/10.1001/jama.271.1.52			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN725	8258888				2022-12-28	WOS:A1994MN72500031
J	PHILLIPS, SP; SCHNEIDER, MS				PHILLIPS, SP; SCHNEIDER, MS			SEXUAL HARASSMENT OF FEMALE DOCTORS BY PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WORK	Background. Sexual harassment within the doctor-patient relationship is typically discussed in terms of male doctors harassing female patients. We investigated the sexual harassment of female doctors by patients. Methods. Surveys were mailed to a random sample of 599 of the 1064 licensed female family physicians in Ontario, Canada. Respondents were asked about their experiences of sexual harassment by either male or female patients and about the nature and frequency of harassing behavior. Suggestions for prevention were requested. Results. Seventy percent (422) of the questionnaires were completed and returned. More than 75 percent of the respondents reported some sexual harassment by a patient at some time during their careers. Physicians had been harassed most often in their own offices and by their own patients. However, in settings such as emergency rooms and clinics, unknown patients presented a proportionately higher risk. The physicians' perceptions of the seriousness of the problem varied with the frequency and severity ot the incidents. Conclusions. Sexual harassment of female doctors appears to occur frequently, and it is therefore an important topic to address in medical school and professional development.	ONTARIO INST STUDIES EDUC, DEPT APPL PSYCHOL, TORONTO M5S 1V6, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto	PHILLIPS, SP (corresponding author), QUEENS UNIV, DEPT FAMILY MED, 220 BAGOT ST, KINGSTON K7L 5E9, ON, CANADA.			Phillips, Susan/0000-0003-4798-1742				[Anonymous], J SEX RES; ESTRICH S, 1991, STANFORD LAW REV, V43, P813, DOI 10.2307/1228921; FISHER G, 1989, THESIS ONTARIO I STU; GRANT L, 1988, J AM MED WOMEN ASSOC, V43, P9; GRANT L, 1988, J AM MED WOMEN ASSOC, V43, P115; GRUBER JE, 1982, WORK OCCUPATION, V9, P271, DOI 10.1177/0730888482009003002; KARDENER SH, 1973, AM J PSYCHIAT, V130, P1077, DOI 10.1176/ajp.130.10.1077; KOMAROMY M, 1993, NEW ENGL J MED, V328, P322, DOI 10.1056/NEJM199302043280507; LAFONTAINE E, 1986, SEX ROLES, V15, P433, DOI 10.1007/BF00287982; MACKINNON CA, 1979, SEXUAL HARASSMENT WO, P27; MAYPOLE DE, 1986, SOC WORK, V31, P29; RICHMAN JA, 1992, JAMA-J AM MED ASSOC, V267, P692, DOI 10.1001/jama.267.5.692; Thorne-Finch R., 1992, ENDING SILENCE ORIGI; 1981, MERIT SYSTEMS PROTEC; 1980, FED REGISTER, V45, P25024; 1991, TASK FORCE SEXUAL AB	16	99	99	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1993	329	26					1936	1939		10.1056/NEJM199312233292607	http://dx.doi.org/10.1056/NEJM199312233292607			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM885	8247058				2022-12-28	WOS:A1993MM88500007
J	MAKKAR, RR; FROMM, BS; STEINMAN, RT; MEISSNER, MD; LEHMANN, MH				MAKKAR, RR; FROMM, BS; STEINMAN, RT; MEISSNER, MD; LEHMANN, MH			FEMALE GENDER AS A RISK FACTOR FOR TORSADES-DE-POINTES ASSOCIATED WITH CARDIOVASCULAR DRUGS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYMORPHOUS VENTRICULAR-TACHYCARDIA; LONG QT SYNDROME; AMIODARONE-INDUCED TORSADES; SOTALOL-INDUCED TORSADE; PRENYLAMINE-INDUCED TORSADE; CORONARY HEART-DISEASE; N-ACETYL PROCAINAMIDE; Q-T PROLONGATION; SUDDEN-DEATH; EARLY AFTERDEPOLARIZATIONS	Objective.-To test the hypothesis that female prevalence is greater than expected among reported cases of torsades de pointes associated with cardiovascular drugs that prolong cardiac repolarization. Data Sources.-A MEDLINE search of the English-language literature for the period of 1980 through 1992, using the terms torsade de pointes, polymorphic ventricular tachycardia, atypical ventricular tachycardia, proarrhythmia, and drug-induced ventricular tachycardia, supplemented by pertinent references (dating back to 1964) from the reviewed articles and by personal communications with researchers involved in this field. Study Selection.-Ninety-three articles were identified describing at least one case of polymorphic ventricular tachycardia (with gender specified) associated with quinidine, procainamide hydrochloride, disopyramide, amiodarone, sotalol hydrochloride, bepridil hydrochloride, or prenylamine. A total of 332 patients were included in the analysis following application of prospectively defined criteria (eg, corrected QT [QT(c)] interval of 0.45 second or greater while receiving drug). Data Extraction.-Clinical and electrocardiographic descriptors were extracted for analysis. Expected female prevalence for torsades de pointes associated with quinidine, procainamide, disopyramide, and amiodarone was conservatively estimated from gender-specific data reported for antiarrhythmic drug prescriptions in 1986, as derived from the National Disease and Therapeutic Index, a large pharmaceutical database; expected female prevalence for torsades de pointes associated with sotalol, bepridil, and prenylamine was assumed to be 50% or less since these agents are prescribed for male-predominant cardiovascular conditions. Results.-Women made up 70% (95% confidence interval, 64% to 75%) of the 332 reported cases of cardiovascular-drug-related torsades de pointes, and a female prevalence exceeding 50% was observed in 20 (83%) of 24 studies having at least four included cases. When analyzed according to various descriptors, women still constituted the majority (range, 51% to 94% of torsades de pointes cases), irrespective of the presence or absence of underlying coronary artery or rheumatic heart disease, left ventricular dysfunction, type of underlying arrhythmia, hypokalemia, hypomagnesemia, bradycardia, concomitant digoxin treatment, or level of QT(c) at baseline or while receiving drug. When cases of torsades de pointes were analyzed by individual drug, observed female prevalence was always greater than expected, representing a statistically significant difference (P<.05) for all agents except procainamide. Conclusions.-These findings strongly suggest that women are more prone than men to develop torsades de pointes during administration of cardiovascular drugs that prolong cardiac repolarization. The pathophysiological basis for, and therapeutic implications of, this gender disparity should be further investigated.	WAYNE STATE UNIV, HARPER HOSP, DEPT INTERNAL MED, DIV CARDIOL, DETROIT, MI 48202 USA	Wayne State University								ABINADER EG, 1983, CARDIOLOGY, V70, P37, DOI 10.1159/000173567; AKHTAR M, 1990, CIRCULATION, V82, P1561, DOI 10.1161/01.CIR.82.5.1561; ALGRA A, 1991, CIRCULATION, V83, P1888, DOI 10.1161/01.CIR.83.6.1888; ANDRIVET P, 1990, INTENS CARE MED, V16, P342, DOI 10.1007/BF01706367; ARSTALL MA, 1992, POSTGRAD MED J, V68, P289, DOI 10.1136/pgmj.68.798.289; BAGCHI N, 1990, ARCH INTERN MED, V150, P785, DOI 10.1001/archinte.150.4.785; BAJAJ BP, 1991, INT J CARDIOL, V33, P335, DOI 10.1016/0167-5273(91)90369-Z; BAUMAN JL, 1984, AM HEART J, V107, P425, DOI 10.1016/0002-8703(84)90081-4; BENDITT DG, 1991, J CARDIOVASC ELECT S, V2, pS221; BOCCARDO D, 1981, AM HEART J, V102, P797, DOI 10.1016/0002-8703(81)90112-5; BROWN MA, 1986, EUR HEART J, V7, P234, DOI 10.1093/oxfordjournals.eurheartj.a062057; Campbell W B, 1984, J Tenn Med Assoc, V77, P401; Centers for Disease Control (CDC), 1992, MMWR Morb Mortal Wkly Rep, V41, P526; CLELAND JGF, 1992, BRIT HEART J, V67, P1; COBB LA, 1992, CIRCULATION, V85, P98; COMMERFORD PJ, 1980, S AFR MED J, V58, P447; COUMEL P, 1992, AM J CARDIOL, V69, pD75; CRAMER G, 1968, ACTA MED SCAND S490, V184; DAVIES P, 1965, BRIT MED J, V2, P517, DOI 10.1136/bmj.2.5460.517; DELLABELLA P, 1990, EUR HEART J, V11, P1124; DELUNA AB, 1989, AM HEART J, V117, P151, DOI 10.1016/0002-8703(89)90670-4; DENES P, 1981, AM J CARDIOL, V48, P9, DOI 10.1016/0002-9149(81)90566-X; Dessertenne F, 1966, Arch Mal Coeur Vaiss, V59, P263; DHURANDHAR RW, 1978, HEART LUNG, V7, P783; DISEGNI E, 1980, ARCH INTERN MED, V140, P1036, DOI 10.1001/archinte.140.8.1036; EJVINSSON G, 1980, ACTA MED SCAND, V208, P445; ELSHERIF N, 1989, J AM COLL CARDIOL, V14, P252, DOI 10.1016/0735-1097(89)90082-X; FEILER HE, 1984, J AM OSTEOPATH ASSOC, V84, P276; FIELDS CD, 1988, CHEST, V94, P111, DOI 10.1378/chest.94.1.111; FONTAINE G, 1992, ANN NY ACAD SCI, V644, P157, DOI 10.1111/j.1749-6632.1992.tb31009.x; GEHLBACH SH, 1982, INTERPRETING MED LIT, P17; GRENADIER E, 1980, BRIT HEART J, V44, P330; HABBAB MA, 1990, AM J MED, V89, P241, DOI 10.1016/0002-9343(90)90307-Y; HABBAB MA, 1992, PACE, V15, P916, DOI 10.1111/j.1540-8159.1992.tb03082.x; HASHIBA K, 1978, JPN CIRC J, V42, P1133, DOI 10.1253/jcj.42.1133; HERRE JM, 1985, AM J CARDIOL, V55, P227, DOI 10.1016/0002-9149(85)90337-6; HII JTY, 1990, CIRCULATION, V82, P55; HII JTY, 1992, CIRCULATION, V86, P1376, DOI 10.1161/01.CIR.86.5.1376; HILLEMAN DE, 1992, CURR THER RES CLIN E, V51, P730; HINE LK, 1989, ARCH INTERN MED, V149, P1524, DOI 10.1001/archinte.149.7.1524; JACKMAN WM, 1988, PROG CARDIOVASC DIS, V31, P115, DOI 10.1016/0033-0620(88)90014-X; JENSEN G, 1975, CHEST, V67, P43, DOI 10.1378/chest.67.1.43; JENZER HR, 1976, EUR J CARDIOL, V4, P447; JORENS PG, 1989, ACTA CARDIOL, V44, P411; KADISH AH, 1990, CIRCULATION, V81, P14, DOI 10.1161/01.CIR.81.1.14; KADIWAR RM, 1990, IRISH MED J, V83, P163; KASANUKI H, 1992, ANN NY ACAD SCI, V644, P57, DOI 10.1111/j.1749-6632.1992.tb31002.x; KAY GN, 1983, J AM COLL CARDIOL, V2, P806; KEATING M, 1992, CIRCULATION, V85, P1973, DOI 10.1161/01.CIR.85.6.1973; KEMPF FC, 1984, AM J CARDIOL, V53, P1577, DOI 10.1016/0002-9149(84)90582-4; KEREN A, 1981, CIRCULATION, V64, P1167, DOI 10.1161/01.CIR.64.6.1167; KHAN MM, 1981, AM J CARDIOL, V47, P1301, DOI 10.1016/0002-9149(81)90263-0; KO PT, 1982, CAN MED ASSOC J, V127, P368; KOENIG W, 1983, AM HEART J, V105, P863, DOI 10.1016/0002-8703(83)90256-9; KONTOPOULOS A, 1981, POSTGRAD MED J, V57, P321, DOI 10.1136/pgmj.57.667.321; KOSTER RW, 1976, AM J CARDIOL, V38, P519, DOI 10.1016/0002-9149(76)90471-9; KRAPF R, 1985, BRIT MED J, V290, P1784, DOI 10.1136/bmj.290.6484.1784-a; KUCK KH, 1984, AM HEART J, V107, P179, DOI 10.1016/0002-8703(84)90158-3; KUMAR A, 1987, ANN INTERN MED, V106, P712, DOI 10.7326/0003-4819-106-5-712; KURITA T, 1992, AM J CARDIOL, V69, P628, DOI 10.1016/0002-9149(92)90154-Q; LARSEN PR, 1992, CECIL TXB MED, P1248; LECLERCQ JF, 1983, ARCH MAL COEUR VAISS, V76, P341; LECLERCQ JF, 1986, ARCH MAL COEUR VAISS, V79, P1024; LEENHARDT A, 1992, J CARDIOVASC ELECTR, V3, P281, DOI 10.1111/j.1540-8167.1992.tb00973.x; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; LEROY G, 1987, EUR HEART J, V8, P541, DOI 10.1093/oxfordjournals.eurheartj.a062315; LEVINE JH, 1989, CIRCULATION, V80, P1063, DOI 10.1161/01.CIR.80.4.1063; LEW W Y W, 1986, Canadian Journal of Cardiology, V2, P86; LEWIS BH, 1983, J AM COLL CARDIOL, V2, P426, DOI 10.1016/S0735-1097(83)80268-X; LOPEZ JA, 1987, AM J CARDIOL, V59, P376, DOI 10.1016/0002-9149(87)90824-1; LOWN B, 1971, CIRCULATION, V44, P130, DOI 10.1161/01.CIR.44.1.130; MACFARLANE PW, 1989, COMPREHENSIVE ELECTR, V1, P407; MANOUVRIER J, 1986, AM HEART J, V111, P1005, DOI 10.1016/0002-8703(86)90660-5; MARTINEZLOPEZ JI, 1988, J STATE MED SOC, V140, P11; MATTIONI TA, 1989, ANN INTERN MED, V111, P574, DOI 10.7326/0003-4819-111-7-574; MCKIBBIN JK, 1984, BRIT HEART J, V51, P157; MEANOCK CI, 1981, POSTGRAD MED J, V57, P381, DOI 10.1136/pgmj.57.668.381; MELTZER RS, 1978, AM J CARDIOL, V42, P1049; MERRI M, 1989, CIRCULATION, V80, P1301, DOI 10.1161/01.CIR.80.5.1301; MILLER DS, 1971, SOUTHERN MED J, V64, P597, DOI 10.1097/00007611-197105000-00019; MINARDO JD, 1988, NEW ENGL J MED, V319, P257, DOI 10.1056/NEJM198808043190501; MORO C, 1986, INT J CARDIOL, V13, P365, DOI 10.1016/0167-5273(86)90121-X; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; MOSS AJ, 1992, CIRCULATION, V85, P140; NATTEL S, 1990, AM J MED, V89, P235, DOI 10.1016/0002-9343(90)90305-W; NGUYEN KPV, 1986, ANN INTERN MED, V104, P283, DOI 10.7326/0003-4819-104-2-283_2; NGUYEN PT, 1979, AM J CARDIOL, V44, P339; NICHOLSON WJ, 1979, AM J CARDIOL, V43, P1053, DOI 10.1016/0002-9149(79)90374-6; NIKOLIC G, 1982, CIRCULATION, V66, P218, DOI 10.1161/01.CIR.66.1.218; OHE T, 1990, JPN CIRC J, V54, P1323, DOI 10.1253/jcj.54.10_1323; OLSHANSKY B, 1982, AM J CARDIOL, V50, P1439, DOI 10.1016/0002-9149(82)90489-1; ORAVETZ J, 1968, ARCH INTERN MED, V122, P63, DOI 10.1001/archinte.122.1.63; PANIDIS IP, 1983, J AM COLL CARDIOL, V2, P798, DOI 10.1016/S0735-1097(83)80225-3; PERTICONE F, 1986, AM HEART J, V112, P847, DOI 10.1016/0002-8703(86)90486-2; PRYSTOWSKY EN, 1985, AM J CARDIOL, V55, pC59, DOI 10.1016/0002-9149(85)90808-2; RADFORD MD, 1968, BRIT HEART J, V30, P91; RAKOVEC P, CATHET CARDIOVASC DI, V10, P167; RANKIN AC, 1990, AM HEART J, V119, P185, DOI 10.1016/S0002-8703(05)80099-7; REYNOLDS EW, 1976, MOD CONC CARDIOV DIS, V45, P117; RICCIONI N, 1980, CARDIOLOGY, V66, P199, DOI 10.1159/000170867; RICCIONI N, 1983, AM HEART J, V105, P870, DOI 10.1016/0002-8703(83)90259-4; RODEN DM, 1986, AM HEART J, V111, P1088, DOI 10.1016/0002-8703(86)90010-4; ROKSETH R, 1963, ARCH INTERN MED, V111, P184, DOI 10.1001/archinte.1963.03620260044008; ROTHMAN MT, 1980, BRIT MED J, V280, P922, DOI 10.1136/bmj.280.6218.922; SANTINELLI V, 1984, AM J CARDIOL, V53, P1462, DOI 10.1016/S0002-9149(84)91293-1; SARMIENTO JJ, 1985, AM HEART J, V109, P377, DOI 10.1016/0002-8703(85)90616-7; SCHATTNER A, 1989, POSTGRAD MED J, V65, P333, DOI 10.1136/pgmj.65.763.333; SCHIEMAN G, 1988, J ELECTROPHYSIOL, V2, P46; SCHWARTZ PJ, 1975, AM HEART J, V89, P378, DOI 10.1016/0002-8703(75)90089-7; SCHWEITZER P, 1982, MT SINAI J MED, V49, P110; SCLAROVKSY S, 1979, AM J CARDIOL, V44, P339, DOI 10.1016/0002-9149(79)90326-6; SCLAROVSKY S, 1983, AM HEART J, V105, P6, DOI 10.1016/0002-8703(83)90270-3; SELZER A, 1964, CIRCULATION, V30, P17, DOI 10.1161/01.CIR.30.1.17; SINGH BN, 1992, AM J CARDIOL, V69, pD68; SINGH SN, 1991, AM HEART J, V121, P601, DOI 10.1016/0002-8703(91)90735-Z; SMITH MS, 1987, AM J MED, V83, P971, DOI 10.1016/0002-9343(87)90662-0; SMITH WM, 1980, ANN INTERN MED, V93, P578, DOI 10.7326/0003-4819-93-4-578; SODERMARK T, 1975, BRIT HEART J, V37, P486; SOFFER J, 1982, AM J CARDIOL, V49, P2021, DOI 10.1016/0002-9149(82)90224-7; STEINBECK G, 1992, NEW ENGL J MED, V327, P987, DOI 10.1056/NEJM199210013271404; STEVENSON WG, 1985, PACE, V8, P528, DOI 10.1111/j.1540-8159.1985.tb05854.x; STRASBERG B, 1981, AM J CARDIOL, V47, P1309, DOI 10.1016/0002-9149(81)90264-2; STRATMANN HG, 1987, AM HEART J, V113, P1470, DOI 10.1016/0002-8703(87)90664-8; STRATMANN HG, 1985, AM HEART J, V109, P375, DOI 10.1016/0002-8703(85)90615-5; SURAWICZ B, 1989, J AM COLL CARDIOL, V14, P172, DOI 10.1016/0735-1097(89)90069-7; SWIRYN S, 1983, ARCH INTERN MED, V143, P314, DOI 10.1001/archinte.143.2.314; TARTINI R, 1982, LANCET, V1, P1327; THOMPSON KA, 1988, CLIN PHARMACOL THER, V43, P636, DOI 10.1038/clpt.1988.88; TRI TB, 1979, AM J CARDIOL, V44, P391, DOI 10.1016/0002-9149(79)90340-0; TZIVONI D, 1988, CIRCULATION, V77, P392, DOI 10.1161/01.CIR.77.2.392; TZIVONI D, 1983, AM J CARDIOL, V52, P639, DOI 10.1016/0002-9149(83)90043-7; WALD RW, 1981, J ELECTROCARDIOL, V14, P301, DOI 10.1016/S0022-0736(81)80013-1; WALDER LA, 1991, J AM COLL CARDIOL, V17, P1479, DOI 10.1016/0735-1097(91)90635-M; WANG T, 1986, AM J CARDIOL, V57, P1160, DOI 10.1016/0002-9149(86)90692-2; WARDEN T, 1989, AM J EMERG MED, V7, P126, DOI 10.1016/0735-6757(89)90118-6; WILBER DJ, 1988, NEW ENGL J MED, V318, P19, DOI 10.1056/NEJM198801073180105; WILT JL, 1993, ANN INTERN MED, V119, P391, DOI 10.7326/0003-4819-119-5-199309010-00007; WOOSLEY RL, 1993, JAMA-J AM MED ASSOC, V269, P1532, DOI 10.1001/jama.269.12.1532; Zar J.H., 1999, ZAR KUHR 5 2019, V4th; ZIPES DP, 1987, AM J CARDIOL, V59, pE26, DOI 10.1016/0002-9149(87)90198-6; 1982, ADV DATA VITAL HLTH, V84	141	683	693	1	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1993	270	21					2590	2597		10.1001/jama.270.21.2590	http://dx.doi.org/10.1001/jama.270.21.2590			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ266	8230644				2022-12-28	WOS:A1993MJ26600027
J	PETERSDORF, RG; GOITEIN, L				PETERSDORF, RG; GOITEIN, L			THE FUTURE OF INTERNAL-MEDICINE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material								Internal medicine may be in its twilight because it has failed to address the shortage of primary care physicians by training more general internists. Data from several sources indicate that progressively fewer persons are entering general internal medicine as opposed to its subspecialties. The reasons for this decline include adverse experiences in medical school, an unfavorable patient mix, declining incomes, and increasing hassles in caring for patients. A series of reforms, such as improving the teaching in medical school, strengthening divisions of general medicine, and establishing financial incentives, are proposed to reverse this trend. Other actions that must be taken include stopping the proliferation of subspecialty certificates, designating and accrediting primary care tracks, and cutting subspecialty positions. Internal medicine's fate is in its own hands, and the discipline must reorient itself to conform to societal needs.			PETERSDORF, RG (corresponding author), ASSOC AMER MED COLL, 2450 N ST NW, WASHINGTON, DC 20036 USA.							ANDERSEN RM, 1992, ANN INTERN MED, V117, P243, DOI 10.7326/0003-4819-117-3-243; BARONDESS JA, 1993, ANN INTERN MED, V119, P153, DOI 10.7326/0003-4819-119-2-199307150-00010; BLANK LL, 1992, ANN INTERN MED, V117, P778; DOLE E, 1993, ACP OBSERVER, V13, P13; HSIAO WC, 1993, NEW ENGL J MED, V328, P928, DOI 10.1056/NEJM199304013281306; KASSEBAUM DG, 1993, ACAD MED, V68, P278, DOI 10.1097/00001888-199304000-00014; KASSIRER JP, 1993, NEW ENGL J MED, V328, P648, DOI 10.1056/NEJM199303043280910; MORRIS TQ, 1993, TAKING CHARGE GRADUA, P35; PETERSDORF RG, 1989, J GEN INTERN MED, V4, P527, DOI 10.1007/BF02599554; PETERSDORF RG, 1993, ACAD MED, V68, P113, DOI 10.1097/00001888-199302000-00001; PETERSDORF RG, 1990, ACAD MED, V65, P96; SHULKIN DJ, 1989, JAMA-J AM MED ASSOC, V262, P1630, DOI 10.1001/jama.1989.03430120080019; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805; 1993, PHYSICIAN PAYMENT RE; 1992, IMPROVING ACCESS HLT; 1993, NRMP DATA; 1992, 1992 ANN GROUP PRACT; 1993, BLUEPRINT FUTURE REB; 1993, ACP OBSERVER, V13, P2; 1990, HASSLE FACTOR AM HLT; 1992, 1992 GRADUATING STUD; 1993, FISCAL YEAR 1994 BUD; 1993, ACAD MED, V68, P1; 1992, 1992 I GOALS RANK RE; 1992, RX HLTH FAMILY PHYSI	25	44	43	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1993	119	11					1130	1137		10.7326/0003-4819-119-11-199312010-00011	http://dx.doi.org/10.7326/0003-4819-119-11-199312010-00011			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ335	8239233				2022-12-28	WOS:A1993MJ33500011
J	ELDEIRY, WS; TOKINO, T; VELCULESCU, VE; LEVY, DB; PARSONS, R; TRENT, JM; LIN, D; MERCER, WE; KINZLER, KW; VOGELSTEIN, B				ELDEIRY, WS; TOKINO, T; VELCULESCU, VE; LEVY, DB; PARSONS, R; TRENT, JM; LIN, D; MERCER, WE; KINZLER, KW; VOGELSTEIN, B			WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION	CELL			English	Article							WILD-TYPE P53; DNA-BINDING SITE; CELL-LINE; COLORECTAL CARCINOMAS; ENHANCED EXPRESSION; GENE-EXPRESSION; GROWTH ARREST; PROTEIN; TRANSCRIPTION; CANCER	The ability of p53 to activate transcription from specific sequences suggests that genes induced by p53 may mediate its biological role as a tumor suppressor. Using a subtractive hybridization approach, we identified a gene, named WAF1, whose induction was associated with wild-type but not mutant p53 gene expression in a human brain tumor cell line. The WAF1 gene was localized to chromosome 6p21.2, and its sequence, structure, and activation by p53 was conserved in rodents. Introduction of WAF1 cDNA suppressed the growth of human brain, lung, and colon tumor cells in culture. Using a yeast enhancer trap, a p53-binding site was identified 2.4 kb upstream of WAF1 coding sequences. The WAF1 promoter, including this p53-binding site, conferred p53-dependent inducibility upon a heterologous reporter gene. These studies define a gene whose expression is directly induced by p53 and that could be an important mediator of p53-dependent tumor growth suppression.	JOHNS HOPKINS UNIV,SCH MED,PROGRAM HUMAN GENET & MOLEC BIOL,BALTIMORE,MD 21231; NATL CTR HUMAN GENOME RES,CANC GENET LAB,BETHESDA,MD 20892; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Jefferson University	ELDEIRY, WS (corresponding author), JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21231, USA.		Tokino, Takashi/AAI-9887-2021; Velculescu, Victor/ABF-4846-2020; El-Deiry, Wafik/AAJ-6080-2020	Velculescu, Victor/0000-0003-1195-438X; El-Deiry, Wafik/0000-0002-9577-8266; Parsons, Ramon/0000-0002-6656-3514	NATIONAL CANCER INSTITUTE [R01CA043460, R37CA043460, T32CA009071] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09071, CA-43460] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Battey, 1986, BASIC METHODS MOL BI; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; CALRKE AR, 1993, NATURE, V362, P849; CLIBY W, 1993, CANCER RES, V53, P2393; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HALEVY O, 1991, ONCOGENE, V6, P1593; HAMPSON IN, 1992, NUCLEIC ACIDS RES, V20, P2899, DOI 10.1093/nar/20.11.2899; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KERN SE, 1991, SCIENCE, V252, P1707; KINZLER KW, 1989, NUCLEIC ACIDS RES, V17, P3645, DOI 10.1093/nar/17.10.3645; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUKEIS R, 1990, GENE CHROMOSOME CANC, V2, P116, DOI 10.1002/gcc.2870020207; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MELTZER PS, 1992, NAT GENET, V1, P24, DOI 10.1038/ng0492-24; MERCER W E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P251; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORITA R, 1991, CANCER RES, V51, P820; MUNHOLLAND JM, 1992, EMBO J, V11, P177, DOI 10.1002/j.1460-2075.1992.tb05040.x; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RAEGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SATO T, 1991, CANCER RES, V51, P5118; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHERLEY JL, 1991, J BIOL CHEM, V266, P24815; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; STERNER DA, 1993, MOL CELL BIOL, V13, P2677, DOI 10.1128/MCB.13.5.2677; TRUNT R, 1993, J BIOL CHEM, V268, P2284; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	73	7732	7923	10	603	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					817	825		10.1016/0092-8674(93)90500-P	http://dx.doi.org/10.1016/0092-8674(93)90500-P			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	8242752	hybrid			2022-12-28	WOS:A1993MH74900025
J	HUGHES, KT; GILLEN, KL; SEMON, MJ; KARLINSEY, JE				HUGHES, KT; GILLEN, KL; SEMON, MJ; KARLINSEY, JE			SENSING STRUCTURAL INTERMEDIATES IN BACTERIAL FLAGELLAR ASSEMBLY BY EXPORT OF A NEGATIVE REGULATOR	SCIENCE			English	Article							HOOK-ASSOCIATED PROTEINS; SALMONELLA-TYPHIMURIUM; SIGMA FACTOR; GENE; MUTANTS; QUANTITIES; REGULON; ENCODES	The ability of a regulatory protein to sense the integrity of the bacterial flagellar structure was investigated. In response to a defective hook-basal body complex, the anti-sigma(28) FlgM protein inhibits flagellin transcription. In cells with a functional hook-basal body complex, the flagellin genes are transcribed normally and the FlgM protein is expelled into the growth medium. In strains with a defective hook-basal body structure, FlgM is absent from the media. The presence of flagellin protein in the media is substantially reduced in strains carrying a FlgM-LacZ protein fusion, suggesting that the fusion is blocking the flagellar export apparatus. These results suggest that the FlgM protein assesses the integrity of the flagellar hook-basal body complex by itself being a substrate for export by the flagellar-specific export apparatus.			HUGHES, KT (corresponding author), UNIV WASHINGTON,DEPT MICROBIOL,SC-42,SEATTLE,WA 98195, USA.			Karlinsey, Joyce E/0000-0002-3585-8301	NIGMS NIH HHS [GM43149, T32-GM07270] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043149, T32GM007270] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blair DF, 1992, CURR OPIN GENET DEV, V2, P756, DOI 10.1016/S0959-437X(05)80136-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CASTILHO BA, 1984, J BACTERIOL, V158, P488, DOI 10.1128/JB.158.2.488-495.1984; DAVIS RW, 1980, ADV BACTERIAL GENET, P207; GILLEN KL, 1991, J BACTERIOL, V173, P2301, DOI 10.1128/JB.173.7.2301-2310.1991; GILLEN KL, 1991, J BACTERIOL, V173, P6453, DOI 10.1128/jb.173.20.6453-6459.1991; GILLEN KL, UNPUB; HARLOW E, 1988, ANTIBODIES LAB MANUA, P519; HOMMA M, 1987, J BACTERIOL, V169, P3617, DOI 10.1128/jb.169.8.3617-3624.1987; HOMMA M, 1984, J BACTERIOL, V159, P1056, DOI 10.1128/JB.159.3.1056-1059.1984; IKEDA T, 1987, J BACTERIOL, V169, P1168, DOI 10.1128/jb.169.3.1168-1173.1987; JONES CJ, 1990, J BACTERIOL, V172, P1327, DOI 10.1128/jb.172.3.1327-1339.1990; KOMEDA Y, 1975, MOL GEN GENET, V142, P289, DOI 10.1007/BF00271253; KUTSUKAKE K, 1990, J BACTERIOL, V172, P741, DOI 10.1128/jb.172.2.741-747.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACNAB RM, 1992, ANNU REV GENET, V26, P131, DOI 10.1146/annurev.ge.26.120192.001023; MASSON D, 1987, CELL, V49, P679, DOI 10.1016/0092-8674(87)90544-7; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; OHNISHI K, 1990, MOL GEN GENET, V221, P139, DOI 10.1007/BF00261713; OHNISHI K, 1992, MOL MICROBIOL, V6, P3149, DOI 10.1111/j.1365-2958.1992.tb01771.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SILVERMA.M, 1973, J BACTERIOL, V113, P105, DOI 10.1128/JB.113.1.105-113.1973; STARNBACH M, COMMUNICATION; SUZUKI T, 1981, J BACTERIOL, V148, P973, DOI 10.1128/JB.148.3.973-979.1981; TRAXLER B, 1992, P NATL ACAD SCI USA, V89, P10852, DOI 10.1073/pnas.89.22.10852; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WAGENKNECHT T, 1982, J MOL BIOL, V162, P69, DOI 10.1016/0022-2836(82)90162-0; YOKATA T, 1970, J BACTERIOL, V103, P513	30	385	395	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1277	1280		10.1126/science.8235660	http://dx.doi.org/10.1126/science.8235660			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	8235660				2022-12-28	WOS:A1993MH32400043
J	CULLITON, BJ				CULLITON, BJ			HEALTH RESEARCH FEELS THE CHILL	NATURE			English	Editorial Material																			0	7	7	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 18	1993	366	6452					200	202		10.1038/366200a0	http://dx.doi.org/10.1038/366200a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH325	8232574				2022-12-28	WOS:A1993MH32500026
J	MORSY, MA; MITANI, K; CLEMENS, P; CASKEY, CT				MORSY, MA; MITANI, K; CLEMENS, P; CASKEY, CT			PROGRESS TOWARD HUMAN GENE-THERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; THYMIDINE KINASE GENE; HERPES-SIMPLEX VIRUS; CYSTIC-FIBROSIS GENE; SEVERE COMBINED IMMUNODEFICIENCY; HUMAN GLUCOCEREBROSIDASE GENE; HUMAN ADENOSINE-DEAMINASE; HEMATOPOIETIC STEM-CELLS; BONE-MARROW CELLS; ANIMAL-MODEL		BAYLOR COLL MED,INST MOLEC GENET,1 BAYLOR PLAZA,HOUSTON,TX 77030; HOWARD HUGHES MED INST,HOUSTON,TX	Baylor College of Medicine; Howard Hughes Medical Institute								ACSADI G, 1991, NATURE, V352, P815, DOI 10.1038/352815a0; ANDERSON DC, 1989, METABOLIC BASIS INHE, P2751; ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; Barranger J. A., 1989, METABOLIC BASIS INHE, P1677; BLAESE RM, 1993, PEDIATR RES, V33, P549; BODINE DM, 1990, P NATL ACAD SCI USA, V87, P3738, DOI 10.1073/pnas.87.10.3738; BORDIGNON C, 1989, P NATL ACAD SCI USA, V86, P6748, DOI 10.1073/pnas.86.17.6748; BORDIGNON C, 1993, HUM GENE THER, V4, P513, DOI 10.1089/hum.1993.4.4-513; BREAKEFIELD XO, 1991, NEW BIOL, V3, P203; BREAKEFIELD XO, 1993, NAT GENET, V3, P187, DOI 10.1038/ng0393-187; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; CARTER BJ, 1990, HDB PARVOVIRUSES, P155; CHAMBERLAIN JS, 1988, SCIENCE, V239, P1416, DOI 10.1126/science.3347839; CHAPMAN VM, 1989, P NATL ACAD SCI USA, V86, P1292, DOI 10.1073/pnas.86.4.1292; CHOWDHURY JR, 1991, SCIENCE, V254, P1802, DOI 10.1126/science.1722351; CLEMENS PR, 1992, CURRENT NEUROLOGY, P1; COLLEDGE WH, 1992, LANCET, V340, P680, DOI 10.1016/0140-6736(92)92223-3; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; CORRELL PH, 1992, BLOOD, V80, P331; COURNOYER D, 1993, ANNU REV IMMUNOL, V11, P297; COURNOYER D, 1991, HUM GENE THER, V2, P107; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; CRISTIANO RJ, 1993, P NATL ACAD SCI USA, V90, P2122, DOI 10.1073/pnas.90.6.2122; CULVER KW, 1991, HUM GENE THER, V2, P107, DOI 10.1089/hum.1991.2.2-107; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; DEMARS R, 1976, P NATL ACAD SCI USA, V73, P1693, DOI 10.1073/pnas.73.5.1693; DICKSON G, 1991, HUM GENET, V88, P53, DOI 10.1007/BF00204929; DOEHMER J, 1982, P NATL ACAD SCI-BIOL, V79, P2268, DOI 10.1073/pnas.79.7.2268; DONEHOWER LA, 1992, NATURE, V356, P212; DORIN JR, 1992, NATURE, V359, P211, DOI 10.1038/359211a0; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; ENGLAND SB, 1990, NATURE, V343, P180, DOI 10.1038/343180a0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FERRARI G, 1991, SCIENCE, V251, P1363, DOI 10.1126/science.1848369; FREESE E, 1972, PROSPECTS GENE THERA; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN MR, 1983, CELL, V35, P137, DOI 10.1016/0092-8674(83)90216-7; GUSSONI E, 1992, NATURE, V356, P435, DOI 10.1038/356435a0; HODGES PE, 1989, P NATL ACAD SCI USA, V86, P4142, DOI 10.1073/pnas.86.11.4142; HOFFMAN EP, 1988, NEURON, V1, P411, DOI 10.1016/0896-6273(88)90191-2; HOOGERBRUGGE PM, 1992, HUM GENE THER, V3, P553, DOI 10.1089/hum.1992.3.5-553; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HORWITZ M S, 1990, P1679; HWU P, 1993, J IMMUNOL, V150, P4104; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JONES SN, 1990, J BIOL CHEM, V265, P14684; KANTOFF PW, 1987, J EXP MED, V166, P219, DOI 10.1084/jem.166.1.219; KARLSSON S, 1991, BLOOD, V78, P2481; KARPATI G, 1993, ANN NEUROL, V34, P8, DOI 10.1002/ana.410340105; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KRAUSS JC, 1991, HUM GENE THER, V2, P221, DOI 10.1089/hum.1991.2.3-221; KREDICH NM, 1989, METABOLIC BASIS INHE, P1045; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; LAUTZ GE, 1993, P NATL ACAD SCI USA, V90, P4645; LEDLEY FD, 1991, HUM GENE THER, V2, P331, DOI 10.1089/hum.1991.2.4-331; LEE CC, 1991, NATURE, V349, P334, DOI 10.1038/349334a0; LEE CC, 1993, HUM GENE THER, V4, P159; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MANIATIS T, 1976, CELL, V8, P163, DOI 10.1016/0092-8674(76)90001-5; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MATSUMURA K, 1993, FEBS LETT, V320, P276, DOI 10.1016/0014-5793(93)80602-Q; MCDONALD JD, 1990, P NATL ACAD SCI USA, V87, P1965, DOI 10.1073/pnas.87.5.1965; MILLER AD, 1985, MOL CELL BIOL, V5, P431, DOI 10.1128/MCB.5.3.431; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MITANI K, 1993, HUM GENE THER, V4, P9, DOI 10.1089/hum.1993.4.1-9; MITANI K, 1993, PHILOS T ROY SOC B, V339, P217, DOI 10.1098/rstb.1993.0019; MORSY MA, 1993, J CLIN INVEST, V92, P1580, DOI 10.1172/JCI116739; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; MULLIGAN RC, 1981, MOL CELL BIOL, V1, P449, DOI 10.1128/MCB.1.5.449; MULLIGAN RC, 1991, NOBEL SYMP, V80, P143; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOLTA JA, 1992, J CLIN INVEST, V90, P342, DOI 10.1172/JCI115868; OHASHI T, 1992, P NATL ACAD SCI USA, V89, P11332, DOI 10.1073/pnas.89.23.11332; PARTRIDGE T, 1991, NEUROPATH APPL NEURO, V17, P353, DOI 10.1111/j.1365-2990.1991.tb00735.x; PONDER KP, 1991, P NATL ACAD SCI USA, V88, P1217, DOI 10.1073/pnas.88.4.1217; RAGOT T, 1993, NATURE, V361, P647, DOI 10.1038/361647a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; SAMBROOK J, 1968, P NATL ACAD SCI USA, V59, P1288; SAMULSKI RJ, 1991, EMBO J, V10, P3941, DOI 10.1002/j.1460-2075.1991.tb04964.x; SARVER N, 1993, AIDS RES HUM RETROV, V9, P483, DOI 10.1089/aid.1993.9.483; SHIMOTOHNO K, 1981, CELL, V26, P67, DOI 10.1016/0092-8674(81)90034-9; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; STEINBERG MH, 1991, AM J MED SCI, V302, P298, DOI 10.1097/00000441-199111000-00008; STRATFORDPERRICAUDET LD, 1990, HUM GENE THER, V1, P241, DOI 10.1089/hum.1990.1.3-241; TABIN CJ, 1982, MOL CELL BIOL, V2, P426, DOI 10.1128/MCB.2.4.426; Temin H. M., 1986, Gene transfer., P149; TEMIN HM, 1971, ANNU REV MICROBIOL, V25, P609, DOI 10.1146/annurev.mi.25.100171.003141; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; TYBULEWICZ VLJ, 1992, NATURE, V87, P439; VALENTINE BA, 1992, AM J MED GENET, V42, P352, DOI 10.1002/ajmg.1320420320; VANBEUSECHEM VW, 1992, P NATL ACAD SCI USA, V89, P7640, DOI 10.1073/pnas.89.16.7640; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934; WAKAMIYA M, 1993, AM J HUM GENET, V53, P1249; WEI CM, 1981, J VIROL, V39, P935, DOI 10.1128/JVI.39.3.935-944.1981; WELLS DJ, 1992, HUM MOL GENET, V1, P35; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WILLIAMS DA, 1990, HUM GENE THER, V1, P229, DOI 10.1089/hum.1990.1.3-229; WILSON JM, 1992, HUM GENE THER, V3, P179, DOI 10.1089/hum.1992.3.2-179; WILSON RW, 1993, HUM GENE THER, V4, P25, DOI 10.1089/hum.1993.4.1-25; WILSON RW, 1993, J IMMUNOL, V151, P1571; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; WU GY, 1991, J BIOL CHEM, V266, P14338; WU X, IN PRESS P NATL ACAD; YANG NS, 1990, P NATL ACAD SCI USA, V87, P9568, DOI 10.1073/pnas.87.24.9568	113	52	58	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1993	270	19					2338	2345		10.1001/jama.270.19.2338	http://dx.doi.org/10.1001/jama.270.19.2338			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF993	8230597				2022-12-28	WOS:A1993MF99300029
J	CHENG, H; LEDERER, WJ; CANNELL, MB				CHENG, H; LEDERER, WJ; CANNELL, MB			CALCIUM SPARKS - ELEMENTARY EVENTS UNDERLYING EXCITATION-CONTRACTION COUPLING IN HEART-MUSCLE	SCIENCE			English	Article							CA-2+ RELEASE CHANNEL; CARDIAC SARCOPLASMIC-RETICULUM; TRANSIENT INWARD CURRENT; RYANODINE RECEPTOR CHANNEL; SKELETAL-MUSCLE; INTRACELLULAR CALCIUM; PURKINJE-FIBERS; GUINEA-PIG; VENTRICULAR MYOCYTES; MOLECULAR-CLONING	Spontaneous local increases in the concentration of intracellular calcium, called ''calcium sparks,'' were detected in quiescent rat heart cells with a laser scanning confocal microscope and the fluorescent calcium indicator fluo-3. Estimates of calcium flux associated with the sparks suggest that calcium sparks result from spontaneous openings of single sarcoplasmic reticulum (SR) calcium-release channels, a finding supported by ryanodine-dependent changes of spark kinetics. At resting intracellular calcium concentrations, these SR calcium-release channels had a low rate of opening (approximately 0.0001 per second). An increase in the calcium content of the SR, however, was associated with a fourfold increase in opening rate and resulted in some sparks triggering propagating waves of increased intracellular calcium concentration. The calcium spark is the consequence of elementary events underlying excitation-contraction coupling and provides an explanation for both spontaneous and triggered changes in the intracellular calcium concentration in the mammalian heart.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,660 W REDWOOD ST,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,CTR MED BIOTECHNOL,BALTIMORE,MD 21201; ST GEORGE HOSP,SCH MED,DEPT PHARMACOL & CLIN PHARMACOL,LONDON SW17 0RE,ENGLAND	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; St Georges University London			Lederer, William/B-1285-2010; Heping, Cheng/AAE-2680-2019	Heping, Cheng/0000-0002-9604-6702				ARLOCK P, 1985, J PHYSIOL-LONDON, V360, P105, DOI 10.1113/jphysiol.1985.sp015606; BERLIN JR, 1987, AM J PHYSIOL, V253, pH1540, DOI 10.1152/ajpheart.1987.253.6.H1540; BERLIN JR, 1989, CIRC RES, V65, P115, DOI 10.1161/01.RES.65.1.115; BERS DM, 1993, AM J PHYSIOL, V264, pC1587, DOI 10.1152/ajpcell.1993.264.6.C1587; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BUCK E, 1992, J BIOL CHEM, V267, P23560; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; CANNELL MB, 1987, SCIENCE, V238, P1419, DOI 10.1126/science.2446391; CANNELL MB, 1985, FED PROC, V44, P2964; CHENG HY, UNPUB, P5019; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; FABIATO A, 1985, J GEN PHYSIOL, V85, P189, DOI 10.1085/jgp.85.2.189; FABIATO A, 1975, J PHYSIOL-LONDON, V249, P469, DOI 10.1113/jphysiol.1975.sp011026; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FILL M, 1988, TRENDS NEUROSCI, V11, P453, DOI 10.1016/0166-2236(88)90198-1; HUME JR, 1991, SCIENCE, V251, P1370, DOI 10.1126/science.251.4999.1370-a; INUI M, 1987, J BIOL CHEM, V262, P15637; INUI M, 1988, J BIOL CHEM, V263, P10843; KASS RS, 1978, J PHYSIOL-LONDON, V281, P187, DOI 10.1113/jphysiol.1978.sp012416; LAI FA, 1989, J BIOL CHEM, V264, P16776; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LEDERER WJ, 1990, SCIENCE, V248, P283, DOI 10.1126/science.2326638; LEDERER WJ, 1991, SCIENCE, V251, P1371, DOI 10.1126/science.251.4999.1371; LEVESQUE PC, 1991, ANN NY ACAD SCI, V639, P386, DOI 10.1111/j.1749-6632.1991.tb17327.x; LEW WYW, 1991, CIRC RES, V69, P1139, DOI 10.1161/01.RES.69.4.1139; LIPP P, 1988, J PHYSIOL-LONDON, V397, P601, DOI 10.1113/jphysiol.1988.sp017021; MARBAN E, 1985, CIRC RES, V56, P133, DOI 10.1161/01.RES.56.1.133; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MEISSNER G, 1992, MOL CELL BIOCHEM, V114, P119; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MEISSNER G, 1992, ADV EXP MED BIOL, V311, P277; MINTA A, 1989, J BIOL CHEM, V264, P8171; MITRA R, 1985, AM J PHYSIOL, V249, P1056, DOI 10.1152/ajpheart.1985.249.5.H1056; ONEILL SC, 1990, AM J PHYSIOL, V258, pC1165, DOI 10.1152/ajpcell.1990.258.6.C1165; PESSAH IN, 1991, MOL PHARMACOL, V39, P679; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; ROUSSEAU E, 1989, AM J PHYSIOL, V256, pH328, DOI 10.1152/ajpheart.1989.256.2.H328; SAH P, 1993, NEUROSCIENCE, V54, P157, DOI 10.1016/0306-4522(93)90391-R; SHAM JSK, 1992, SCIENCE, V255, P850, DOI 10.1126/science.1311127; SIPIDO KR, 1991, J PHYSIOL-LONDON, V435, P605, DOI 10.1113/jphysiol.1991.sp018528; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; SUTKO JL, 1985, FED PROC, V44, P2984; TAKAMATSU T, 1990, CELL CALCIUM, V11, P111, DOI 10.1016/0143-4160(90)90064-2; TINKER A, 1992, J GEN PHYSIOL, V100, P495, DOI 10.1085/jgp.100.3.495; VALDEOLMILLOS M, 1989, PFLUG ARCH EUR J PHY, V413, P676, DOI 10.1007/BF00581820; WIER WG, 1986, J PHYSIOL-LONDON, V376, P507, DOI 10.1113/jphysiol.1986.sp016167; WIER WG, 1987, SCIENCE, V235, P325, DOI 10.1126/science.3798114; WIER WG, 1985, FED PROC, V44, P2989; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	52	1590	1659	9	198	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 29	1993	262	5134					740	744		10.1126/science.8235594	http://dx.doi.org/10.1126/science.8235594			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	8235594				2022-12-28	WOS:A1993MD95200042
J	MCLAUGHLIN, JR; KING, WD; ANDERSON, TW; CLARKE, EA; ASHMORE, JP				MCLAUGHLIN, JR; KING, WD; ANDERSON, TW; CLARKE, EA; ASHMORE, JP			PATERNAL RADIATION EXPOSURE AND LEUKEMIA IN OFFSPRING - THE ONTARIO CASE-CONTROL STUDY	BRITISH MEDICAL JOURNAL			English	Article							SELLAFIELD NUCLEAR-PLANT; ATOMIC-BOMB SURVIVORS; WEST CUMBRIA; CHILDHOOD LEUKEMIA; DESCRIPTIVE EPIDEMIOLOGY; CHILDREN BORN; YOUNG-PEOPLE; LYMPHOMA; OCCUPATIONS; SEASCALE	Objectives-To test the hypothesis that there is an association between childhood leukaemia and the occupational exposure of fathers to ionising radiation before a child's conception. Design-Case-control study with eight matched controls per case. Setting-Regions of Ontario, Canada, with an operating nuclear facility. Subjects-Cases were children (age 0-14) who died from or were diagnosed as having leukaemia from 1950 to 1988 and were born to mothers living in the vicinity of an operating nuclear facility. Controls were identified from birth certificates, matched by date of birth and residence at birth. There were 112 cases and 890 controls. Main outcome measures-Paternal radiation exposure was determined by a record linkage to the Canadian National Dose Registry. Results-Six fathers of cases and 53 fathers of controls had had a total whole body dose >0.0 mSv before the child's conception, resulting in an odds ratio of 0.87 (95% confidence interval 0.32 to 2.34). There was no evidence of an increased leukaemia risk in relation to any exposure period (lifetime or six months or three months before conception) or exposure type (total whole body dose, external whole body dose, or tritium dose), except for radon exposure to uranium miners, which had a large odds ratio that was not significantly different from the null value. Conclusions-The findings of this study in Ontario did not support the hypothesis that childhood leukaemia is associated with the occupational exposure of fathers to ionising radiation before the child's conception.	ONTARIO CANC TREATMENT & RES FDN,DIV EPIDEMIOL & STAT,TORONTO M5G 2L7,ON,CANADA; UNIV BRITISH COLUMBIA,DEPT HLTH CARE & EPIDEMIOL,VANCOUVER V6M 1K6,BC,CANADA; HLTH & WELF CANADA,BUR RADIAT & MED DEVICES,OTTAWA K1A 0L2,ONTARIO,CANADA	University of British Columbia			McLaughlin, John R/E-4577-2013					ALEXANDER FE, 1992, BRIT MED J, V305, P715, DOI 10.1136/bmj.305.6855.715-a; ASHMORE JP, 1985, RADIAT PROT DOSIM, V11, P95; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P125; CLARKE EA, 1987, 20 YEARS CANCER INCI, P11; COUROT M, 1970, TESTIS, P390; CRAFT AW, 1984, LANCET, V2, P96; DOLL R, 1989, J ROY STAT SOC A STA, V152, P341, DOI 10.2307/2983131; GARDNER MJ, 1992, BRIT MED J, V305, P715, DOI 10.1136/bmj.305.6855.715; GARDNER MJ, 1987, BRIT MED J, V295, P819, DOI 10.1136/bmj.295.6602.819; GARDNER MJ, 1990, BRIT MED J, V300, P429, DOI 10.1136/bmj.300.6722.429; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GARDNER MJ, 1987, BRIT MED J, V295, P822, DOI 10.1136/bmj.295.6602.822; HENSHAW DL, 1990, LANCET, V335, P1008, DOI 10.1016/0140-6736(90)91071-H; KINLEN LJ, 1993, BRIT MED J, V306, P1153, DOI 10.1136/bmj.306.6886.1153; LINET MS, 1991, BRIT J CANCER, V63, P424, DOI 10.1038/bjc.1991.98; Little M. P., 1992, Journal of Radiological Protection, V12, P203, DOI 10.1088/0952-4746/12/4/001; LITTLE M P, 1991, Journal of Radiological Protection, V11, P231, DOI 10.1088/0952-4746/11/4/002; MCKINNEY PA, 1991, BRIT MED J, V302, P681, DOI 10.1136/bmj.302.6778.681; MCLAUGHLIN JR, 1993, CANCER CAUSE CONTROL, V4, P51, DOI 10.1007/BF00051714; MCLAUGHLIN JR, 1992, OCCUPATIONAL EXPOSUR; MULLER J, 1983, STUDY MORTALITY ONTA; ROBLES SC, 1988, J CLIN EPIDEMIOL, V41, P495, DOI 10.1016/0895-4356(88)90052-2; ROMAN E, 1993, BMJ-BRIT MED J, V306, P615, DOI 10.1136/bmj.306.6878.615; SORAHAN T, 1993, AM J IND MED, V23, P343, DOI 10.1002/ajim.4700230211; STILLER CA, 1985, LEUKEMIA RES, V9, P671, DOI 10.1016/0145-2126(85)90273-5; URQUHART JD, 1991, BRIT MED J, V302, P687, DOI 10.1136/bmj.302.6778.687; YOSHIMOTO Y, 1990, AM J HUM GENET, V46, P1041; YOSHIMOTO Y, 1990, JAMA-J AM MED ASSOC, V264, P596, DOI 10.1001/jama.264.5.596; 1988, HLTH RISKS RADON OTH, V4, P492; 1993, LOGXACT; 1986, CENSUS CANADA ONTA 2; 1975, MANUAL INT STATISTIC, V1; 1991, EGRET; 1980, NUCLEAR GENERATING D	34	70	72	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1993	307	6910					959	966		10.1136/bmj.307.6910.959	http://dx.doi.org/10.1136/bmj.307.6910.959			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC441	8241906	Bronze, Green Published			2022-12-28	WOS:A1993MC44100016
J	BARON, TH; RAMIREZ, B; RICHTER, JE				BARON, TH; RAMIREZ, B; RICHTER, JE			GASTROINTESTINAL MOTILITY DISORDERS DURING PREGNANCY	ANNALS OF INTERNAL MEDICINE			English	Review						GASTROINTESTINAL MOTILITY; PREGNANCY COMPLICATIONS; GASTROESOPHAGEAL REFLUX; NAUSEA; VOMITING	HUMAN CHORIONIC-GONADOTROPIN; HYPEREMESIS GRAVIDARUM; PLACENTAL-TRANSFER; NEONATAL EXPOSURE; ANOREXIA-NERVOSA; ESTRADIOL LEVELS; COLONIC TRANSIT; FETAL SHEEP; NAUSEA; METOCLOPRAMIDE	Purpose: To review the pathophysiology of gastrointestinal motility disorders during pregnancy, their clinical manifestations, and their management. Data Sources: Studies published from 1963 to 1992 identified by computerized literature searches of Index Medicus and MEDLINE; hand searches; contact with pharmaceutical representatives for information on drug therapy during pregnancy; and selected texts on drugs and obstetrics. Study Selection: Selected studies were those involving controlled design of physiology related to pregnancy or to hormonal effects on the gastrointestinal tract or both, and clinical studies or previous reviews that contributed to the understanding of the gastrointestinal effects of pregnancy. Data Extraction: Data concerning the epidemiology, causes, clinical manifestations, and complications of altered gastrointestinal motility during pregnancy as well as the strength of association between gastrointestinal disorders of pregnancy and hormonal changes were evaluated and used to develop a practical approach to evaluate and manage these patients. Results of Data Synthesis: Effects on the gastrointestinal tract during pregnancy are caused primarily by hormonal changes and not the physical effects of the gravid uterus. Motility changes occur throughout the gastrointestinal tract, including a reduction in lower esophageal sphincter pressure and its physiologic function with resulting gastroesophageal reflux and the risk for aspiration; alterations in gastric motor function associated with nausea and vomiting; and a decrease in the rate of small-bowel and colonic transit manifested primarily as abdominal bloating and constipation. These effects are mediated by progesterone, with estrogen probably acting as a primer. Conclusions: Given the large number of pregnancies each year complicated by gastrointestinal motility disorders, many physicians (including internists and gastroenterologists) must manage these problems. Knowledge of the underlying physiologic alterations in gastrointestinal motility during pregnancy and of safe treatment options is essential to the care of the pregnant patient.	UNIV ALABAMA, DIV GASTROENTEROL, UAB STN, UNIVERSITY, AL 35486 USA	University of Alabama System								ALBIBI R, 1983, ANN INTERN MED, V98, P86, DOI 10.7326/0003-4819-98-1-86; ANAND S, 1982, SCIENCE, V218, P493, DOI 10.1126/science.7123252; ANDERSON AS, 1984, HLTH VISITOR, V12, P363; ARMENTANO G, 1989, CLIN EXP OBSTET GYN, V4, P1306; ARVELA P, 1983, EUR J CLIN PHARMACOL, V24, P345, DOI 10.1007/BF00610052; BASSEY OO, 1977, BRIT J OBSTET GYNAEC, V84, P439, DOI 10.1111/j.1471-0528.1977.tb12619.x; BERKOWITZ RL, 1981, HDB PRESCRIBING MED; BOUILLON R, 1982, AM J OBSTET GYNECOL, V143, P922, DOI 10.1016/0002-9378(82)90475-6; BRAVERMAN DZ, 1988, J CLIN GASTROENTEROL, V10, P642, DOI 10.1097/00004836-198812000-00014; Briggs GG, 1983, DRUGS PREGNANCY LACT; BROCKUTNE JG, 1978, ANAESTH INTENS CARE, V6, P26, DOI 10.1177/0310057X7800600103; BRUCE LA, 1979, LIFE SCI, V25, P729, DOI 10.1016/0024-3205(79)90515-0; BYLSMAHOWELL M, 1983, CAN ANAESTH SOC J, V30, P487, DOI 10.1007/BF03007082; CASTRO LD, 1983, BR J CLIN PRACT, V37, P53; CHING MS, 1986, DEV PHARMACOL THERAP, V9, P323, DOI 10.1159/000457111; CHRISTOFIDES ND, 1982, BRIT MED J, V285, P1453, DOI 10.1136/bmj.285.6353.1453; CIPRIANI S, 1983, CLIN EUR, V22, P1; COLLINS E, 1978, OBSTET GYNECOL S5, V58, pS57; DATZ FL, 1987, J NUCL MED, V28, P1204; DAVISON J S, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P37; DEPUE RH, 1987, AM J OBSTET GYNECOL, V156, P1137, DOI 10.1016/0002-9378(87)90126-8; DUBOIS A, 1979, GASTROENTEROLOGY, V77, P319; FAIRWEATHER DV, 1968, AM J OBSTET GYNECOL, V102, P135, DOI 10.1016/0002-9378(68)90445-6; FELDMAN M, 1989, GASTROINTESTIONAL DI, P229; FILIPPONE M, 1983, CLIN RES, V31, pA282; FISHER RS, 1978, GASTROENTEROLOGY, V74, P1233; FISHER RS, 1978, AM J PHYSIOL, V234, pE243, DOI 10.1152/ajpendo.1978.234.3.E243; FITZGERALD CM, 1984, BRIT J MED PSYCHOL, V57, P159, DOI 10.1111/j.2044-8341.1984.tb01595.x; GILL RC, 1985, GASTROENTEROLOGY, V88, P1941, DOI 10.1016/0016-5085(85)90023-X; GREENHALF JO, 1973, PRACTITIONER, V210, P259; HARRINGTON RA, 1983, DRUGS, V25, P451, DOI 10.2165/00003495-198325050-00002; Heinonen OP, 1977, BIRTH DEFECTS DRUGS; HILL LM, 1984, MAYO CLIN PROC, V59, P707, DOI 10.1016/S0025-6196(12)62060-6; HILL LM, 1984, MAYO CLIN PROC, V59, P755, DOI 10.1016/S0025-6196(12)65586-4; HINDS JP, 1989, AM J GASTROENTEROL, V84, P123; HODGKINSON R, 1983, ANESTHESIOLOGY, V59, P86, DOI 10.1097/00000542-198308000-00003; HUTSON WR, 1989, GASTROENTEROLOGY, V96, P11, DOI 10.1016/0016-5085(89)90758-0; JARNFELTSAMSIOE A, 1983, GYNECOL OBSTET INVES, V16, P221; KAUPPILA A, 1979, BMJ-BRIT MED J, V1, P1670, DOI 10.1136/bmj.1.6179.1670; KLEBANOFF MA, 1986, BRIT MED J, V292, P724, DOI 10.1136/bmj.292.6522.724; KLEBANOFF MA, 1985, OBSTET GYNECOL, V66, P612; KOCH KL, 1990, DIGEST DIS SCI, V35, P961, DOI 10.1007/BF01537244; KUMAR D, 1962, AM J OBSTET GYNECOL, V84, P1300; LAWSON M, 1985, GASTROENTEROLOGY, V89, P996, DOI 10.1016/0016-5085(85)90199-4; LEVINE MG, 1988, OBSTET GYNECOL, V72, P102; LEVY N, 1971, DIGESTION, V4, P216, DOI 10.1159/000197122; LEWIS JH, 1985, AM J GASTROENTEROL, V80, P912; LEWIS RT, 1971, ARCH SURG-CHICAGO, V103, P335; MACMAHON B, 1981, JAMA-J AM MED ASSOC, V246, P371, DOI 10.1001/jama.246.4.371; MARCHAND P, 1955, BRIT J SURG, V42, P504, DOI 10.1002/bjs.18004217510; MARSHOOM R, 1974, ARZNEIMITTEL-FORSCH, V10, P1645; MASSON GM, 1985, BRIT J OBSTET GYNAEC, V92, P211, DOI 10.1111/j.1471-0528.1985.tb01084.x; MCCALLUM RW, 1985, DIGEST DIS SCI, V30, P713, DOI 10.1007/BF01320484; MIHALY GW, 1983, J PHARMACOL EXP THER, V227, P441; MOORE J, 1989, ANAESTHESIA, V44, P559, DOI 10.1111/j.1365-2044.1989.tb11441.x; NELSON MM, 1971, BRIT MED J, V1, P523, DOI 10.1136/bmj.1.5748.523; PARKER S, 1984, GASTROENTEROLOGY, V86, P675; Ranchet GGO., 1990, G ITAL OBSTET GINECO, P1; RILEY AJ, 1982, CLIN USE RANITIDINE, P78; RYAN JP, 1986, AM J PHYSIOL, V251, pG46, DOI 10.1152/ajpgi.1986.251.1.G46; SAHAKIAN V, 1991, OBSTET GYNECOL, V78, P33; SAMSIOE G, 1986, ACTA OBSTET GYN SCAN, V65, P427, DOI 10.3109/00016348609157377; SCHADE RR, 1984, GASTROENTEROLOGY, V86, P1234; SCHULZE K, 1977, GASTROENTEROLOGY, V73, P1082; SCOTT LD, 1982, DIGEST DIS SCI, V27, P660; SCOTT LD, 1983, GASTROENTEROLOGY, V84, P301; SCOTT LD, 1983, GASTROENTEROLOGY, V84, P1303; SEMMENS JP, 1971, OBSTET GYNECOL, V38, P555, DOI 10.1097/00006250-197110000-00009; SIDHU MS, 1970, P OBSTET GYNAECOL SO, V1, P43; SOULES MR, 1980, OBSTET GYNECOL, V55, P696; TAMURA J, 1983, Journal of Toxicological Sciences, V8, P141; TAYLOR G, 1966, LANCET, V1, P288; TIERSON FD, 1986, AM J OBSTET GYNECOL, V155, P1017, DOI 10.1016/0002-9378(86)90337-6; VANTHIEL DH, 1976, GASTROENTEROLOGY, V71, P232; VANTHIEL DH, 1977, GASTROENTEROLOGY, V72, P666; VANTHIEL DH, 1981, AM J OBSTET GYNECOL, V140, P420, DOI 10.1016/0002-9378(81)90037-5; WALD A, 1982, DIGEST DIS SCI, V27, P1015, DOI 10.1007/BF01391748; WILLIAMS M, 1971, BRIT J ANAESTH, V43, P783, DOI 10.1093/bja/43.8.783; WITTER FR, 1981, OBSTET GYNECOL, V58, pS79; 1976, B249 SMITHKL BEECH P; 1992, PHYSICIANS DESK REFE; 1974, 74SKF14227 SMITHKL B; 1974, B218 SMITHKL BEECH P; 1992, MONTHLY VITAL STATIS, V40, P1; 1984, COMPENDIUM DRUG THER	85	119	123	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1993	118	5					366	375		10.7326/0003-4819-118-5-199303010-00008	http://dx.doi.org/10.7326/0003-4819-118-5-199303010-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN688	8257464				2022-12-28	WOS:A1993KN68800008
J	STONE, R				STONE, R			INDUSTRIAL EFFORTS - PLENTY OF JOBS, LITTLE MINORITY SUPPORT IN BIOTECH	SCIENCE			English	Editorial Material																		1993, SCIENCE, V261, P1788	1	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1127	1127		10.1126/science.8235632	http://dx.doi.org/10.1126/science.8235632			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	8235632				2022-12-28	WOS:A1993MG18700064
